<SEC-DOCUMENT>0001628280-26-012804.txt : 20260227
<SEC-HEADER>0001628280-26-012804.hdr.sgml : 20260227
<ACCEPTANCE-DATETIME>20260227160743
ACCESSION NUMBER:		0001628280-26-012804
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260227
DATE AS OF CHANGE:		20260227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InfuSystem Holdings, Inc
		CENTRAL INDEX KEY:			0001337013
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				203341405
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35020
		FILM NUMBER:		26699724

	BUSINESS ADDRESS:	
		STREET 1:		3851 WEST HAMLIN ROAD
		CITY:			ROCHESTER HILLS
		STATE:			MI
		ZIP:			48309
		BUSINESS PHONE:		(248) 291-1210

	MAIL ADDRESS:	
		STREET 1:		3851 WEST HAMLIN ROAD
		CITY:			ROCHESTER HILLS
		STATE:			MI
		ZIP:			48309

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HAPC, Inc.
		DATE OF NAME CHANGE:	20060425

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Healthcare Acquisition Partners Corp.
		DATE OF NAME CHANGE:	20050824
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>infu-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:7814b130-9ea8-4497-bd4c-7510be4e72d5,g:0e5cd592-a670-4737-bede-9aef47e8c4b0,d:13594bbbfc1e4b049c5f01f53e10e953-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:infu="http://infusystem.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>infu-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0001337013</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-35">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" id="f-302">http://fasb.org/us-gaap/2025#Revenues</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList" id="f-303">http://fasb.org/us-gaap/2025#Revenues</ix:nonNumeric><ix:nonNumeric contextRef="c-31" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-316">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-32" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-318">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-34" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-322">P15Y</ix:nonNumeric><ix:nonNumeric contextRef="c-36" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-324">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-36" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-330">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-31" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="f-342">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-31" name="us-gaap:LessorOperatingLeaseRenewalTerm" format="ixt-sec:durday" id="f-371">7</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="infu-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="location"><xbrli:measure>infu:location</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>infu:segment</xbrli:measure></xbrli:unit><xbrli:unit id="financial_institution"><xbrli:measure>infu:financial_institution</xbrli:measure></xbrli:unit><xbrli:unit id="network"><xbrli:measure>infu:network</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:AmbulatoryPumpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">infu:SmithsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">infu:InformationTechnologySoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UnpatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-31</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">infu:ApolloMedicalSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:GA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:MI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="infu:LeaseClassificationAxis">infu:SalesTypeLeaseNetInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="infu:LeaseClassificationAxis">infu:SalesTypeLeaseNetInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-19</xbrli:startDate><xbrli:endDate>2018-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-15</xbrli:startDate><xbrli:endDate>2019-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">infu:ShareBasedPaymentArrangementAchievingMinimumThresholdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">infu:ShareBasedPaymentArrangementExceedingMinimumThresholdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-16</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001337013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-286 f-287" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/></ix:resources></ix:header></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C., 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:496.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:496.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">For the transition period from _________________ to ___________________</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-35020</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><img src="infu-20251231_g1.jpg" alt="InfuSystem_SAFE.SMART.TRUSTED._PMSC_Stacked_10-19.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:280px" id="i-1"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">INFUSYSTEM HOLDINGS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">20-3341405</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">3851 West Hamlin Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Rochester Hills</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Michigan</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">48309</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">s Telephone Number, including Area Code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">(248)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">291-1210</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Name of Each Exchange on which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">INFU</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">NYSE American LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Title of Class)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:22.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to  &#167;240.10D-1(b).  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate market value of the 19,594,074 shares of voting and non-voting equity of the registrant held by non-affiliates, computed by reference to the $6.24 closing price of the registrant's common stock on June 30, 2025,  the last business day of the registrants most recently completed second fiscal quarter, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">122,267,022</ix:nonFraction>. Aggregate market value excludes an aggregate of 831,890 shares of common stock held by officers and directors and by each person known by the registrant to own 10% or more of the outstanding common stock on such date. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The number of shares of the registrant&#8217;s common stock outstanding as of February&#160;25, 2026 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">20,215,159</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for its 2026 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_16">3</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_19">Item1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_19">9</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_22">20</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_25">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_25">21</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_28">22</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_31">22</a></span></div></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_34">22</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_40">23</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_43">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_43">24</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_46">25</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_73">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_73">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_73">34</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_76">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_76">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_76">36</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_154">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_154">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_154">72</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_157">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_157">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_157">72</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_160">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_160">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_160">73</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_163">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_163">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_163">74</a></span></div></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_166">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_169">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_169">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_169">75</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_172">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_172">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_172">75</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_175">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_175">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_175">75</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_178">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_178">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_178">76</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_181">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_181">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_181">76</a></span></div></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_184">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_187">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_187">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_187">77</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i13594bbbfc1e4b049c5f01f53e10e953_190">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_190">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_190">80</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References in this Form 10-K to</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">we</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">us</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, or the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">are to InfuSystem Holdings, Inc. (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">InfuSystem</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) and our wholly owned subsidiaries, as appropriate to the context.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement About Forward-Looking Statements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements contained in this Form 10-K are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;likely,&#8221; variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements necessarily are dependent on assumptions, data or methods that may be incorrect or imprecise. These forward-looking statements represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Many of the factors that will determine these items are beyond our ability to control or predict. In connection with the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from the forward-looking statements include, without limitation, those described in </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_19">Item 1A</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, and the including:</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in third-party reimbursement processes, rates, contractual relationships and payer mix;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on estimates of collectible revenue from third-party reimbursement;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the loss of a relationship with one or more third-party payers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with a federal government shutdown;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with payer concentration;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">physicians&#8217;&#160;acceptance of infusion pump therapy over alternative therapies and focus on early detection and diagnostics;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on our Medicare Supplier Number, which allows us to bill Medicare for services provided to Medicare patients;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of chemotherapy drugs used in our infusion pump systems;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future legislative and regulatory changes related to our business, such as  levels reimbursement received from Medicare and  Medicaid programs and the Center for Medicare and Medicaid Services (&#8220;CMS&#8221;) competitive bidding;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence upon our suppliers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">periodic reviews and billing audits from governmental and private payers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain controls and processes over billing and collection and the adequacy of our allowance for doubtful accounts and customer concessions;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with state licensure laws for Durable Medical Equipment suppliers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with our allowance for doubtful accounts and customer concessions;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to execute our business strategies to compete and grow our business, including our ability to</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">integrate artificial intelligence into our internal processes and introduce new products and services;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry competition;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with regulatory guidelines affecting our billing practices;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defective products manufactured by third-party suppliers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute on acquisition and joint-venture opportunities and integrate any acquired businesses;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain relationships with healthcare professionals and organizations;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with changing healthcare regulations;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to remain in compliance with our credit agreement or future debt agreements;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic uncertainty;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax laws or challenges to our tax positions;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the value of our net operating loss carryforwards may become impaired if we do not generate sufficient future taxable income required to utilize all or a portion of our net operating loss carryforwards prior to their expiration;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">volatility in the market price of our stock;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future price of our stock may be negatively affected by not paying dividends;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential dilution to current stockholders from the issuance of equity awards;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on net operating loss carryforwards and certain built-in losses following an ownership change;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain internal control over financial reporting;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation or other legal or regulatory proceedings in which we may be involved from time to time;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the collection of sales or consumption taxes;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement, both internally and externally, information technology improvements and to respond to technological changes, interruptions and security breaches;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, widespread public health emergencies such as pandemics, acts of war or terrorism and other external events affecting us, our customers or our suppliers; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire and retain key employees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These risks are not exhaustive. Other sections of this Annual Form 10-K include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements made in this Form 10-K speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You are cautioned to not rely upon forward-looking statements as predictions of future events. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, you should not rely on any of the forward-looking statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Market and Industry Data</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains market, industry and government data and forecasts obtained from publicly available information, various industry publications and surveys and other published industry sources such as consultant surveys and forecasts. Industry publications and surveys, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy and completeness of such information. We have not independently verified any of the data from third-party sources nor have we ascertained the underlying economic assumptions relied upon therein. Similarly, internal company surveys, industry forecasts and market research, which we believe to be reliable based upon management&#8217;s knowledge of the industry, have not been verified by any independent sources. None of the reports and other materials of third-party sources referred to in this Annual Report on Form 10-K were prepared for use in, or in connection with, this report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks and Trade Names</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of registered trademarks, including Ambulatory Infusion Made Easy&#174;, Biomed Made Easy&#174;, BlockPain Dashboard&#174;, EXPRESSTech&#174; and Infusion Made Easy&#174;. These and other trademarks of ours appearing in this report are our property. Solely for convenience, trademarks and trade names of ours referred to in this Form 10-K may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks and trade names. This report may contain additional trade names and trademarks of other companies. We do not intend our use or display of other companies' trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_16"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Background</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem Holdings, Inc. ("we," "us," "our" or the "Company") is a Delaware corporation. Formed in 2005, the Company operates through its subsidiary InfuSystem, Inc., a Delaware corporation ("InfuSystem" or "ISI"). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Business Concept and Strategy</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading national healthcare service provider, facilitating outpatient care for Durable Medical Equipment (DME) manufacturers and healthcare providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site healthcare providers. Our headquarters is in Rochester Hills, Michigan, and we operate our business from a total of seven locations in the United States ("U.S.") and Canada.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We provide our services under a two-platform model: Patient Services and Device Solutions.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our lead platform, Patient Services, provides last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex DME and related services. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Device Solutions platform compliments our Patient Services platform to enhance growth in existing markets. Device Solutions is strategically oriented with the Company's existing relationships with healthcare providers to incrementally capitalize on opportunities related to other services their practices offer or may plan to offer in the future.   </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our business strategy is focused on driving sustainable growth and innovation aligned with our mission to elevate the standard of care patients deserve. Over the last 30 plus years, we have developed a unique expertise and service offering that Durable Medical Equipment manufacturers and healthcare providers are using to reduce costs, improve service, and most importantly, provide welcome options for patients who want to continue their healthcare treatments from home. We have developed an exemplary Patient Services model in oncology and believe that we can extend this model into other Durable Medical Equipment therapies. The key is our ability to leverage the infrastructure of our existing platforms and  incrementally add to capabilities to our existing systems, such as, for example, sales, clinical, logistics, revenue cycle management, and biomedical services.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Patient Services provides turnkey solutions designed to be implemented without service disruptions, allowing our healthcare provider customers to focus on practicing medicine. InfuSystem provides the Durable Medical Equipment and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment, including, inspection, repair, certification and replacement. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Device Solutions are provided as a &#8220;concierge&#8221; offering, whereby InfuSystem leverages its strong service orientation to provide incremental services to our healthcare provider customers on a direct payer model. Device Solutions include equipment rental and sales, consumable sales, and biomedical support services.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem competes for and retains its business primarily on the basis of its longstanding participation and strong reputation in the Durable Medical Equipment space, its well established relationships with Durable Medical Equipment manufacturers and its healthcare provider customers, and the high levels of service it provides. Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract, which included nearly 840 t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hird-party payer</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> networks as of December&#160;31, 2025; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S. and Canada; (iv) our large pump fleet of ambulatory and large volume infusion pumps for rent and for sale, which may allow us to be more responsive to the needs of physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers and patients than a new market entrant; (v) seven geographic locations in the U.S. and Canada that allow for same-day or next-day delivery of pumps; (vi) our team of field-based and traveling biomedical technicians; and (vii) a wide array of pump repair and service capabilities. We do not perform any research and development on pumps, but we have made, and continue to make, investments in our information technology.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Services Segment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Services segment&#8217;s core purpose is to seek opportunities to grow our business by leveraging our unique know-how in clinic-to-home healthcare solutions involving Durable Medical Equipment, our logistics and billing capabilities, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our growing network of third-party payers under contract, and our clinical and biomedical capabilities. This leverage may take the form of new products or services, strategic alliances, joint ventures or acquisitions. The leading service within our Patient Services segment is supplying electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states (&#8220;Oncology Business&#8221;). Colorectal cancer is the third most prevalent form of cancer in the U.S., according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps. A goal for the Patient Services segment is to expand into treatment of other types of cancers. In 2025, our Oncology Business generated approximately 87% of our total Patient Services segment net revenues. In 2025, we generated approximately 43%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our total Patient Services segment net revenues from treatments for colorectal cancer and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our Patient Services segment net revenues from treatments for non-colorectal disease states. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of approved treatment protocols for pancreatic, head and neck, esophageal and other types of cancers, as well as other disease states which present opportunities for growth. There are also a number of other drugs currently approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), as well as agents in the pharmaceutical development pipeline, which we believe could potentially be used with continuous infusion protocols for the treatment of diseases other than colorectal cancer. Additional drugs or protocols currently in clinical trials may also obtain regulatory approval over the next several years. If these new drugs or protocols obtain regulatory approval for use with continuous infusion protocols, we expect pharmaceutical companies in this space to focus their sales and marketing efforts on promoting the new drugs and protocols to physicians.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Oncology Business focuses mainly on the continuous infusion of chemotherapy. Continuous infusion of chemotherapy can be described as the gradual administration of a drug via a small, lightweight, portable infusion pump over a prolonged period of time. A cancer patient can receive his or her medicine anywhere from one to 30 days per month depending on the chemotherapy regimen that is most appropriate to that individual&#8217;s health status and disease state. This may be followed by periods of rest and then repeated cycles with treatment goals of progression-free disease survival. This drug administration method has replaced intravenous push or bolus administration in specific circumstances. The advantages of slow continuous low doses of certain drugs are well documented. Clinical studies support the use of continuous infusion chemotherapy for decreased toxicity without loss of anti-tumor efficacy. The 2015 National Comprehensive Cancer Network (&#8220;NCCN&#8221;) Guidelines recommend the use of continuous infusion for treatment of numerous cancer diagnoses. We believe that the growth of continuous infusion therapy is driven by three factors: evidence of improved clinical outcomes; lower toxicity and side effects; and a favorable reimbursement environment.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Continuous infusion has demonstrated decreases in and alterations of the toxicity of a number of cytotoxic, or cell killing, agents. Higher doses of drugs can be administered over longer periods of time through continuous infusion, leading to improved tolerance and decreased toxicity. Nausea, vomiting, diarrhea and decreased white blood cell and platelet counts are all affected by duration of delivery. Continuous infusion can lead to improved tolerance and patient comfort while enhancing a patient&#8217;s ability to remain on a chemotherapy regimen. Additionally, the lower toxicity profile and resulting reduction in side effects enables patients undergoing continuous infusion therapy to continue a relatively normal lifestyle, which may include continuing to work, going shopping, and caring for family members. We believe that the partnering of physician management and patient autonomy provide for the highest quality of care with the greatest patient satisfaction.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that oncology practitioners have a heightened sensitivity to providing quality service and to their ability to obtain reimbursement for services they provide. Simultaneously, the CMS and private insurers continue to be focused on evidence-based medicine to inform their reimbursement decisions &#8212; that is, aligning reimbursement with clinical outcomes and adherence to standards of care. Continuous infusion therapy is a main component of the standard of care for certain types of cancer because clinical evidence demonstrates superior outcomes. Payers&#8217; recognition of this benefit is reflected in their relative reimbursement policies for clinical services related to the delivery of this care.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional areas of focus for our Patient Services segment are as follows:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Pain Management</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: providing our ambulatory pumps, products, and services for pain management in the area of post-surgical continuous peripheral nerve block.</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Wound Care</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: In 2020, we added Negative Pressure Wound Therapy ("NPWT") to our portfolio of DME devices offered to patients for home healthcare.  Similar to our capabilities surrounding infusion pumps, we offer these devices to patients for third party payer reimbursement and sales, rentals and leases of the equipment and related disposable supplies directly to other healthcare providers.  Our fleet off NPWT devices include devices manufactured by Smith and Nephew, Cork Medical LLC (&#8220;Cork&#8221;) and Genadyne Biotechnologies Inc.  In 2024, we added Advanced Wound Care dressings to our wound care product portfolio.   We take patient referrals for wound care disposable supplies directly and indirectly from wound care clinics and other sites of care.  The products are generally shipped directly from our suppliers to the patents and we receive reimbursement from the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">patient's health care plan carrier. During 2025, we added Pneumatic Compression Devices ("PCD") to our portfolio of DME devices offered to patients.</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: we believe there are opportunities to acquire smaller, regional healthcare service providers, in whole or in part that perform similar services to us but do not have the national market access, network of third-party payer contracts or operating economies of scale that we currently enjoy. We may also pursue acquisition opportunities of companies that perform similar services, but offer different therapies or utilize different devices.  In May 2025, we acquired the assets of Apollo Medical Supply (&#8220;Apollo&#8221;), a privately-held wound care service company based in Florida. As part of our Patient Services segment, this acquisition supplements our existing wound care business by providing access to an advanced patient service fulfillment know-how and software platform that we plan to integrate into our existing operations.</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Partnerships and Manufacturer Distribution Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We look to foster commercial relationships with various DME equipment manufactures and other health care providers where our services and capabilities create value in the healthcare supply chain.  In particular, our large portfolio of third-party payer contracts makes us an attractive distribution partner.  In November 2022, the Company established a partnership, SI Healthcare Technologies, LLC ("SI Healthcare"), with Sanara MedTech Inc. ("Sanara"). The partnership focuses on delivering DME products targeted at improving patient outcomes, lowering the cost of care, and increasing patient and provider satisfaction. The partnership enables us to offer innovative products such as Sanara&#8217;s advanced wound care product line to new customers through the jointly controlled entity.  In 2024, SI Healthcare entered into an exclusive distribution agreement with ChemoMouthpiece, LLC to market and sell a new product designed to reduce the incidence of Oral Mucositis in cancer patients. Oral mucositis is an inflammation of the mucous membranes in the mouth often caused by cancer treatments.  </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Information technology-based services</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: we also plan to continue to capitalize on key new information technology-based services such as EXPRESS, InfuBus or InfuConnect,&#160;DeviceHub, BlockPain Dashboard&#174; and Tracking Inhouse Management ("TIM").</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The payer environment within our Patient Services segment is in a constant state of change. We continue to extend our considerable breadth of payer networks under contract as patients move into different insurance coverage plans, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, due to a reduction in concessions. Consequently, we are increasingly focused on revenues net of concessions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Device Solutions Segment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Device Solutions segment&#8217;s core service is to: (i) sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; (ii) sell treatment-related consumables; and (iii) provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings, including hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others. We purchase new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service. Our 2021 acquisition of FilAMed, a privately-held biomedical services company has supplemented the Company&#8217;s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. Our 2021 acquisition of OB Healthcare Corporation (&#8220;OB Healthcare&#8221;), a privately-held biomedical services company further develops and expands InfuSystem&#8217;s Device Solutions segment by adding field service capabilities and complements the Company&#8217;s purchase of FilAMed.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Services</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Services Segment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our core service within our Patient Services segment is our Oncology Business. After delivering our ambulatory pumps to oncology offices, infusion clinics, and hospital and outpatient chemotherapy clinics, we then directly bill and collect payment from payers and patients for the use of these pumps. At any given time, our pumps are in the possession of these facilities, on a patient, in transit, or in our facilities for cleaning, calibration and storage as reserves for increased demand.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After a physician determines that a patient is eligible for ambulatory infusion pump therapy, the physician arranges for the patient to receive an infusion pump and provides the necessary chemotherapy drugs. The physician and nursing staff train the patient in the use of the pump and initiate service. The physician bills the payers, which may include Medicare, Medicaid, third-party payer companies or patients for the physician&#8217;s professional services associated with initiating and supervising the infusion pump administration, as well as the supply of drugs. We directly bill (i) payers, (ii) facilities of our Medicare patients, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and (iii) patients for the use of the pump and related disposable supplies. Billing to payers requires coordination with patients and physicians who initiate the service, as physicians&#8217; offices must provide us with appropriate documentation (patient&#8217;s insurance information, physician&#8217;s order, an acknowledgement of benefits that shows receipt of equipment by the patient, and, in some cases, physician&#8217;s progress notes) in order for us to submit a bill to the payers. We provide assistance to uninsured patients that cannot afford our pumps via our financial hardship program &#8211; a program that usually matches what our physician practices provide as long as the uninsured patients meet certain criteria. This billing process is handled from our Rochester Hills, Michigan location.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to providing high quality and convenient care, we believe that our business offers significant economic benefits for patients, providers and payers.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical support team employs oncology, pain, Intravenous Certified, and Oncology Certified registered nurses trained on ambulatory infusion pump equipment who staff our 24x7 customer service hotline to address questions that patients may have about their pump treatment, the infusion pumps or other medical or technical questions related to the pumps.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Physicians use our services to outsource the capital commitment, pump service, maintenance and billing and administrative burdens associated with pump ownership. Our services also allow the doctor to continue a direct relationship with the patient and to receive professional service fees for setting up the treatment and administering the drugs.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We provide methods for the physician offices to deliver the appropriate paperwork for billing through a number of electronic means including EXPRESS and InfuConnect reducing the required effort on the employees of the physician offices.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We believe our services are attractive to payers because such services are generally less expensive than hospitalization or standalone home healthcare.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Also, within Patient Services, we offer pain management services via electronic ambulatory infusion pumps for post-operative pain management using our pumps along with a numbing agent and a continuous nerve block catheter &#8211; continuous peripheral nerve block (&#8220;CPNB&#8221;). Using CPNB for the management of post-operative pain, which usually lasts two to three days after surgery, can result in reduced pain for the patient, increased satisfaction scores for the surgical center or hospital, and reduced need for post-operative opioid pain medication. These services include our patient care call center interaction offering support to patients and the review and collection of pain score patient outcome data for outpatient surgery centers using our proprietary BlockPain Dashboard&#174;.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Device Solutions Segment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other services we offer are classified under our Device Solutions segment and include the rental, sale or leasing and servicing of pole-mounted and ambulatory infusion pumps to oncology practices, hospitals and other clinical settings. These pumps are available for daily, weekly, monthly or annual rental periods. We also sell treatment consumables that can be used in conjunction with the pumps we sell and rent.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to sales, rental and leasing services, we also provide biomedical maintenance, repair and certification services for the devices we offer as well as for devices owned by customers but not acquired from us. We operate pump service and repair &#8220;Centers of Excellence&#8221; from all of our locations across the U.S. and Canada and employ a staff of highly-trained technicians to provide these services. Our main Center of Excellence for service is our Lenexa, Kansas facility.  In addition to the maintenance and repair services we perform at these facilities, we offer similar services that can be performed directly at our customer locations nation-wide through our team of field-based and traveling biomedical technicians. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, our rental fleet of pole-mounted pumps, ambulatory pumps and NPWT medical equipment for both our Patient Services and Device Solutions segments had a historical cost of $109.1 million, up from $107.0 million at the end of 2024, and included approximately 96 makes and models of equipment dedicated to our rental services. Additionally, as of December&#160;31, 2025 and 2024, we had a fleet of new and used pole-mounted pumps, ambulatory pumps and NPWT medical equipment with a historical cost of $4.6 million and $3.2 million, respectively, held for sale or for rental.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Information Technology</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Information Technology (&#8220;IT&#8221;) department is focused on not only supporting our internal IT infrastructure needs, but also supporting our revenue cycle management infrastructure, which includes our electronic medical record technology (&#8220;EMR&#8221;). Our EMR allows medical facilities to use our infusion pumps and services via our solutions such as EXPRESS and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuConnect. This focus has enabled current billing information to be transferred to us from participating facilities electronically and automatically. Our focus on IT solutions resulted in the development of EXPRESS, a product powered by our InfuBus data integration platform that provides for paperless delivery of the appropriate information for InfuSystem to bill payers that:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provides an enhanced visibility as a result of real time status and reporting;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduces risk of error;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">automates treatment logs, pump assignments, tracking and physician&#8217;s orders;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provides a secure scanner for easy pump assignment to patients; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">removes interruptions from physician practices&#8217;&#160;daily schedules, and standardizes data flow for clinics and hospitals with multiple locations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Relationships with Physician Offices</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had business relationships with clinical oncologists in approximately 2,100 outpatient oncology clinics. Although this represents a substantial number of the oncologists in the U.S., we believe that we can continue to expand our network to further penetrate the oncology market. Based on our retention rates and the positive results of our professional customer satisfaction research, we believe our relationships with physician offices are strong.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that, in general, we do not compete directly with hospitals and physician offices to treat patients. Rather, by providing products and services to hospitals and physician offices and other care facilities and providers, we believe that we assist other providers in meeting increasing patient demand and managing institutional constraints on capital and manpower due to the nature of limited resources in hospitals and physician offices.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Physician practices in the oncology field are following the overall healthcare practices trend to consolidate. However, for the period ended December&#160;31, 2025, the number of facility relationships we had remained relatively consistent. We expect this trend to continue for the foreseeable future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had 473 employees, including 461 full-time employees and 12 part-time or contract employees. None of our employees are unionized.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Material Suppliers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We supply a wide variety of pumps and associated equipment, as well as disposables and ancillary supplies. The majority of our pumps are electronic infusion pumps. ICU Medical, Inc. supplied approximately 60% of the ambulatory pumps purchased by us in 2025. The Company has a supply agreement in place with this supplier. Certain &#8220;spot&#8221; purchases are made on the open market subject to individual negotiation. We also supply NPWT medical equipment, as well as related disposables and ancillary supplies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues may be seasonal due to the impact of co-pays and deductibles for patients&#8217; insurance that traditionally reset each January. This has been further impacted by changes in the insurance industry as it responds to increased government regulation. Also, rental customers tend to make buy versus rent decisions late in the year as customer capital budgets are being finalized, impacting sales revenue in the second half of the year, predominantly in the fourth quarter. Furthermore, as the Company&#8217;s liquidity has increased, opportunistic pump purchases are made from time to time. These opportunistic pump purchases also allow for opportunistic pump sales, which could be material. The timing of such purchases and sales vary within the course of a year. Finally, certain of our annual operating expenses are incurred in higher amounts during the first quarter due to the timing of those expenses, such as fees for our annual audit, costs for our annual sales meeting and payroll taxes associated with the payment of our annual short-term incentive awards. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Laws</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with applicable federal, state and local environmental laws regulating the disposal of cleaning agents used in the process of cleaning medical equipment, as well as the disposal of sharps and blood products used in connection with the pumps and medical equipment. We do not believe that compliance with such laws has a material effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to providing our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site healthcare providers, we have sought to establish contracts with as many third-party payer organizations as commercially practicable in an effort to ensure that reimbursement is not a significant obstacle for providers recommending continuous infusion therapy and wish to utilize our services. A third-party payer organization is a healthcare payer or a group of medical services payers that contracts to provide a wide variety of healthcare services to enrolled members through participating providers such as us. A payer is any entity that pays on behalf of a member patient.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had contracts with nearly 840 third-party payer networks, an increase of 1% over the prior year period. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless we or the contracted payer elect not to renew. We also contract with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of net revenue in 2025 or 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Competitors</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our competition primarily consists of national, regional, and hospital-owned Durable Medical Equipment providers and service companies, physician providers and home care infusion providers and the competitive products and services they offer. An estimate of the number of competitors is not known or reasonably available, due to the wide variety in type and size of the market participants described below. We are not aware of any industry reports with respect to the competitive market described below. The description of market segments and business activities within those market segments is based on our experiences in the industry.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">National Durable Medical Equipment Providers and Service Companies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Other national providers and service companies have offerings similar to us. These products and service offerings include, but are not limited to, third-party reimbursement, direct rental and sale of infusion electronic and disposal pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, hospitals and other sites of care.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Regional Durable Medical Equipment Providers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Regional Durable Medical Equipment providers act as distributors for a variety of medical products. We believe regional Durable Medical Equipment provider sales forces generally consist of a relatively small number of salespeople, usually covering several states. Regional Durable Medical Equipment providers tend to carry a limited selection of infusion pumps and their salespeople generally have limited resources. Regional Durable Medical Equipment providers usually do not have 24x7 nursing services. We believe that Regional Durable Medical Equipment providers have relatively few third-party payer contracts, which may prevent these providers from being paid at acceptable levels and may also result in higher out-of-pocket costs for patients.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Hospital-Owned Durable Medical Equipment Providers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Many hospitals have in-house Durable Medical Equipment providers to supply basic equipment. In general, however, these providers have limited capital and tend to stock a small inventory of infusion pumps. We believe that hospital-owned providers have limited ability to grow because of limited patient populations. Growth from outside of the hospital may pose a challenge because hospitals typically will not provide referrals to competitors, instead preferring to offer patients a choice of non-hospital-affiliated Durable Medical Equipment providers.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Physician Providers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: A limited number of physicians maintain an inventory of their own infusion pumps and provide them to patients for a fee. However, we believe that pump utilization in this area tends to be low and the costs associated with ongoing supplies, preventative maintenance and repairs can be relatively high. Moreover, we believe that a high percentage of Durable Medical Equipment claims by doctors are rejected by payers upon first submission, requiring a physician&#8217;s staff to spend significant time and effort to resubmit claims and receive payment for treatment. The numerous service and technical questions from patients may present another significant cost to a physician provider&#8217;s staff.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Home Care Infusion Providers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Home care infusion providers provide chemotherapy drugs and services to allow for in-home patient treatment. We believe that home care infusion treatment can be very costly and that many patients do not carry insurance coverage that pay for home-based infusion services, resulting in larger out-of-pocket costs. Because home care treatments may take as long as six months, these costs can be high and can result in higher patient co-payments. We believe that home care providers may also be reluctant to offer 24x7 coverage or additional patient visits, due to capped fees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Regulation of Our Business</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to various regulations. Specifically, as a registered Medicare supplier of Durable Medical Equipment and related supplies, we must comply with supplier standards established by CMS regulating Medicare suppliers of Durable Medical Equipment, Prosthetics, Orthotics and Supplies (&#8220;DMEPOS Supplier Standards&#8221;). The DMEPOS Supplier Standards consist of 30 requirements that must be met in order for a DMEPOS supplier to be eligible to receive payment for a Medicare-covered item. Some of the more significant DMEPOS Supplier Standards require us to (i)&#160;advise Medicare beneficiaries of their option to purchase certain equipment, (ii)&#160;honor all warranties under state law and not charge Medicare beneficiaries for the repair or replacement of equipment or for services covered under warranty, (iii)&#160;permit CMS agents to conduct on-site inspections to ascertain compliance with the DMEPOS Supplier Standards, (iv)&#160;maintain liability insurance in prescribed amounts, (v)&#160;refrain from contacting Medicare beneficiaries by telephone, except in certain limited circumstances, (vi)&#160;answer questions and respond to complaints of beneficiaries regarding the supplied equipment, (vii)&#160;disclose the DMEPOS Supplier Standards to each Medicare beneficiary to whom we supply equipment, (viii)&#160;maintain a complaint resolution procedure and record certain information regarding each complaint, (ix)&#160;maintain accreditation from a CMS approved accreditation organization, and (x)&#160;meet certain specified surety bond requirements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the provisions of the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which are designed to protect the security and confidentiality of certain protected health information. Under HIPAA, we must provide patients access to certain records and must notify patients of our use of protected health information and patient privacy rights. Moreover, HIPAA sets limits on how we may use individually identifiable health information and prohibits the use of patient information for marketing purposes. The adoption of the American Recovery and Reinvestment Act of 2009 (&#8220;ARRA&#8221;) includes a new breach notification requirement that applies to breaches of unsecured health information occurring on or after September&#160;23, 2009. We are subject to regulations in the various states in which we operate. We believe we are in material compliance with all such regulations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our internet website address is </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.infusystem.com</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. On this website, we make available, free of charge, our Annual Reports on Form 10-K; our Quarterly Reports on Form 10-Q; our Current Reports on Form 8-K; our proxy statements related to our annual stockholders&#8217; meetings; and any amendments to those reports or statements filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the &#8220;Commission&#8221; or &#8220;SEC&#8221;) The charters of our audit, nominating and governance and compensation committees and our Code of Business Conduct and Ethics Policy are also available on our website and in print to any stockholder who requests them. We do not intend for information contained in on our website to be part of this Annual Report on Form 10-K.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_19"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. You should consider carefully all of the material risks described below, together with the other information contained in this Form 10-K. If any of the following events occur, our business, financial condition, results of operations and cash flows may be materially adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS RELATING TO OUR BUSINESS AND INDUSTRY </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any change in the overall healthcare reimbursement system may adversely impact our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are substantially dependent on third-party reimbursement. We are paid directly by private insurers and, in some cases, governmental agencies, often on a fixed fee basis, for the use of continuous infusion equipment and related disposable supplies provided to patients. If the average fees allowable by private insurers or governmental agencies were reduced, the negative impact on revenues could have a material effect on our business, financial condition, results of operations and cash flows. Also, if amounts owed to us by patients and insurers are reduced or not paid on a timely basis, our concessions may increase and/or revenues may decrease.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the healthcare reimbursement system often create financial incentives and disincentives that encourage or discourage the use of a particular type of product, therapy or clinical procedure. Such changes may be impacted by the growth in Accountable Care Organizations (&#8220;ACO&#8221;), reduction of providers by payers, the use of lower cost rental networks and other factors. Market acceptance of continuous infusion therapy may be adversely affected by changes or trends within the healthcare reimbursement system. Changes to the healthcare reimbursement system that favor other technologies or treatment regimens that reduce reimbursements to providers or treatment facilities, including increasing competitive pressures from home healthcare and other companies that use our services, may adversely affect our ability to market our services profitably. Overall, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such dependency and potential changes could materially and adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is substantially dependent on estimates of collectible revenue from third-party reimbursement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are substantially dependent on estimates of collectible revenue from third-party reimbursement. Due to the complex nature of third-party reimbursement for the use of continuous infusion equipment and related disposable supplies provided to patients, among other assumptions, we must estimate, based upon historical averages, the amount of collectible revenue that may be derived from each patient treatment. If average reimbursement rates diverge from historical levels, the estimates of such revenue may diverge from actual collections.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We utilize statistical methods and financial models to account for such changes, but there can be no assurance that the revenue reported in any period will ultimately be collected. Any recognized revenue related to third-party reimbursement from prior periods, which remains uncollected until written off from accounts receivable, will negatively impact revenues in the period in which it is written off. Thus, over time, recognized revenue net of concessions will approximate total collections.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of a relationship with one or more third-party payers could negatively impact our business.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our contracts for reimbursement with third-party payers are often for a term of one year, with automatic one-year renewals, unless we or the contracted payer elect not to renew. These evergreen contracts are subject to termination upon written notice. We may be unable to renew existing or obtain additional contract positions with third-party payers on favorable terms or at all. One or more terminations could have a material and adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any federal government shutdown may adversely impact our business.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our revenues are dependent on private insurers and governmental agencies. In the absence of any bipartisan agreement in the federal government with respect to payments from governmental agencies, our revenues could be reduced.  Government funding of government agencies or other activities that fund research and development is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies or notified bodies, including a prolonged government shutdown, may cause significant regulatory delays and, therefore, delay our efforts to seek clearances, approvals, or certifications. Future government shutdowns are beyond our control, and the ability of the FDA to review and approve or clear new products or to provide feedback on our programs, applications, and submissions can be affected by a variety of factors, including government budget and funding levels, reductions in workforce, ability to obtain and retain key personnel, and statutory, regulatory and policy changes. In addition, there may be delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel. Government shutdowns, if prolonged, can significantly impact the ability of government agencies upon which we rely. Further, any future government shutdown could impact our ability to access the public markets and obtain necessary capital to properly capitalize and continue our operations. Any of  which could have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payer concentration may adversely impact our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had contracts with nearly 840 third-party payer networks, an increase of 1% over the prior year period. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless we or the contracted payer elect not to renew. We also contract with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. No single payer represented more than 10% of net revenue in 2025 or 2024. To the extent such dependency was to occur, significant fluctuations in revenues, results of operations and liquidity could arise if any significant contracted payer reduces its reimbursement for the services we provide.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our billing process is dependent on meeting payer claims processing guidelines which are subject to change at the discretion of the payers. Such changes would materially impact our ability to bill and the timing of such billings, which could materially and adversely impact our net revenues and cash flows, which impact would be even greater if such changes are made by one of our larger payers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The continued consolidation of physician practices, outpatient infusion clinics, oncology clinics, homecare providers and hospitals, increases the concentration of decision makers who either choose to use our ambulatory electronic pumps within our Oncology Business or directly rent, lease or purchase pumps or supplies from us. While we make every effort to benefit from such concentration, it could materially and adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased focus on early detection and diagnostics may adversely affect our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An increased focus on lowering healthcare spending via improved diagnostic testing (i.e., defensive medicine) and patient monitoring could materially and negatively affect our business. A large portion of our ambulatory infusion pumps are dedicated to a specific form of cancer: colorectal cancer. As a result of rising healthcare costs, there may be a demand for more cost-effective approaches to disease management, specifically for colorectal cancer, as well as for emphasis on screening and accurate diagnostic testing to facilitate early detection of potentially costly, severe afflictions. Any change in the approach to treatment of colorectal cancer could have a material and adverse impact on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If future clinical studies demonstrate that oral medications or other therapies that do not use our electronic ambulatory pumps are at least as effective as continuous infusion therapy, our business could be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing clinical trials are currently evaluating and comparing the therapeutic benefits of current continuous infusion-based regimens with various oral medication regimens. If these clinical trials demonstrate that oral medications provide equal or greater therapeutic benefits and/or demonstrate reduced side effects compared to prior oral medication regimens, our revenues and overall business could be materially and adversely affected. Additionally, if new oral medications or other therapies that do not utilize our ambulatory electronic pumps are introduced to the market that are superior to existing oral therapies, physicians&#8217; willingness to prescribe continuous infusion-based regimens could decline, which would materially and adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is impacted by the availability of the chemotherapy drugs that are used in our continuous infusion pump systems.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We primarily derive our revenues from the rental of ambulatory infusion pumps to oncology patients through physicians&#8217; offices and chemotherapy clinics. A shortage in the availability of chemotherapy drugs that are used in the continuous infusion pump system, which has occurred in the past, could have a material and adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our Medicare Supplier Number.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are required to have a Medicare Supplier Number in order to have the ability to bill Medicare for services provided to Medicare patients. Furthermore, all third-party and Medicaid contracts require us to have a Medicare Supplier Number. We are required to comply with Medicare DMEPOS Supplier Standards in order to maintain our number. If we are unable to comply with the relevant standards, we could lose our Medicare Supplier Number. Without this number, we would be unable to continue our various third-party and Medicaid contracts. A significant portion of our revenues are dependent upon our Medicare Supplier Number, the loss of which would materially and adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The CMS requires that all Durable Medical Equipment providers must be accredited by a CMS-approved accreditation organization. We received accreditation from Community Health Accreditation Partner (&#8220;CHAP&#8221;) on February&#160;17, 2009 and we have remained accredited to date. If we lost our accredited status, our business, financial condition, revenues and results of operations would be materially and adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The impact of actual or perceived U.S. healthcare reform legislation on us remains uncertain.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The ACA has perpetuated the development of alternative provider payment models by CMS and the major national commercial payers. These payment models do not replace the current fee-for-service models nor replace current payer contracts, but rather provide additional financial incentives to certain &#8220;accountable&#8221; providers to improve quality and lower cost. The implications for us will come from the provider networks that are forming in order to integrate and coordinate care under these alternative models with CMS and the commercial payers. These provider networks include ACOs, patient-centered primary care medical homes, specialty medical homes, networks accepting bundled payment programs, and other &#8220;performance&#8221; networks that contract with CMS and commercial payers under alternative payment models that financially reward improved quality and lower medical cost. The relationship between us and our provider practices and facilities that are participating in these provider networks under alternative payment models will depend on (i) the extent to which these provider networks give priority to the medical cost associated with our Durable Medical Equipment services and (ii) whether our services are seen as part of a care delivery model that delivers higher value &#8211; higher quality at a lower cost.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The current U.S. administration has implemented a number of regulatory, policy, and personnel changes, including the elimination, downsizing, and reduced funding of certain government agencies and programs and the cancellation or delay of government contracts and research grants, each of which may be exacerbated by any future government shutdowns. The current </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">administration has also changed the composition of, and guidance from, advisory panels on healthcare practices and government enforcement.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Efforts to control healthcare costs, including limiting access to care, alternative delivery models, and changes in the methods used to determine reimbursement systems and rates, are ongoing at the U.S. federal and state levels. Future changes cannot be predicted with certainty, and may have an adverse effect on our industry and on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on independent suppliers for our products. Any delay or disruption in the supply of products, particularly our supply of electronic ambulatory pumps, may negatively impact our operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our infusion pumps and related consumables are obtained from outside vendors. The majority of our new pumps are electronic infusion pumps, which are supplied to us by one major supplier. Any loss or disruption of our relationships with outside vendors, including the supply of pumps, parts, or supply recall or pump end-of-life announcements or availability of related proprietary consumable supplies, could subject us to substantial delays in the delivery of pumps or services provided to customers. From time to time, we or our suppliers may experience supply chain disruptions or labor shortages due to circumstances beyond our or our suppliers&#8217; control. Significant delays in the delivery or service of pumps or related proprietary consumable supplies could result in possible cancellation of orders and the loss of customers. Our inability to provide pumps to meet delivery schedules could have a material adverse effect on our reputation in the industry, as well as on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face periodic reviews and billing audits from governmental and private payers and these audits could have adverse results that may negatively impact our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our participation in the Medicaid program and our registration in the Medicare program, we are subject to various governmental reviews and audits to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various government programs in which third-party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. Private pay sources also reserve the right to conduct audits. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all claims filed which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend reviews and audits may be significant and could have a material adverse effect on our business, financial condition, results of operations and cash flows. Moreover, an adverse review or audit could result in:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required refunding or retroactive adjustment of amounts we have been paid by governmental or private payers&#894;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state or Federal agencies imposing fines, penalties and other sanctions on us&#894;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of our right to participate in the Medicare program, state programs, or one or more private payer networks&#894; or</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our business and reputation in various markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any one of these results could have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to maintain controls and processes over billing and collecting could have a negative impact on our Consolidated Financial Statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The collection of accounts receivable is a significant challenge and requires constant focus and involvement by management and ongoing enhancements to information systems, billing center operating procedures and proper staffing levels. If we are unable to properly bill and collect our accounts receivable, our financial results could be materially and adversely affected. While management believes that our staffing, controls and processes are satisfactory, there can be no assurance that accounts receivable collectability will remain at current levels.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State licensure laws for Durable Medical Equipment suppliers are subject to change. If we fail to comply with any state laws, we will be unable to operate as a Durable Medical Equipment supplier in such state and our business operations will be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a Durable Medical Equipment supplier operating in all 50 states, we are subject to each state&#8217;s licensure laws regulating Durable Medical Equipment suppliers. State licensure laws for Durable Medical Equipment suppliers are subject to change and we must ensure that we are continually in compliance with the laws of all 50 states. In the event that we fail to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">comply with any state&#8217;s laws governing the licensing of Durable Medical Equipment suppliers, we will be unable to operate as a Durable Medical Equipment supplier in such state until we regain compliance. We may also be subject to certain fines and/or penalties and our business operations could be materially and adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our customer concessions may not be adequate to cover actual losses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party payer contracts do not guarantee annual inflationary increases, typical of the Durable Medical Equipment payer contracting environment. Contracted reimbursement rates are either subject to increases or decreases in CMS program rates or, if not indexed to government rates, are frozen until those payer contracts are reopened and renegotiated. While we monitor reimbursement levels to identify specific payer reimbursement rates that have eroded and renegotiate such rates, we may not be able to maintain or improve overall reimbursement levels, thereby compromising the adequacy of the predicted customer concessions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may also face reduced reimbursements from private third-party payers. In addition, our customers may be unable to make timely payments to us. Although we maintain allowances for estimated losses resulting from the inability of our customers to make required payments, we cannot guarantee that we will continue to experience the same loss rates that we have in the past. If we begin to experience an increase in our loss rates in excess of our allowances, it could materially and adversely impact our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth strategy includes expanding into treatment for cancers other than colorectal cancer. There can be no assurance that continuous infusion-based regimens for these other cancers will become standards of care for large numbers of patients or that we will be successful in penetrating these different markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An aspect of our growth strategy is to expand into the treatment of other cancers, such as pancreatic, head, neck and gastric cancers. This population of patients will expand only if clinical trial results for new drugs and new combinations of drugs demonstrate superior outcomes for regimens that include continuous infusion therapy relative to alternatives. No assurances can be given that these new drugs and drug combinations will be approved or will prove superior to oral medication or other treatment alternatives. In addition, no assurances can be given that we will be able to penetrate successfully any new markets that may develop in the future or manage the growth in additional resources that would be required.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The industry in which we operate is intensely competitive and ever-changing. If we are unable to successfully compete with our competitors, our business operations may suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The drug infusion industry is highly competitive. Some of our competitors and potential competitors, including some of the practices that we service, have significantly greater resources than we do for information technology, marketing and sales. As a result, they may be better able to compete for market share, even in areas in which our services may be superior. The industry is subject to technological changes and such changes may put our current fleet of pumps, smart pump licensing, our information technology solutions or our other technological-based solutions at a competitive disadvantage. Furthermore, the healthcare industry, in general, is experiencing market consolidation, reducing the number of decision makers. If we are unable to effectively compete in our market, our business, financial condition, results of operations and cash flows may be materially and adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our industry is dependent on regulatory guidelines that affect our billing practices. If our competitors do not comply with these regulatory guidelines, our business could be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggressive competitors may not fully comply with rules regarding CMS and other payers&#8217; billing and documentation requirements. Competitors who do not meet the same standards of compliance that we do with respect to billing regulations, may put us at a potential competitive disadvantage. We are a participating provider with Medicare and as of December&#160;31, 2025, we were under contract with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nearly </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">840 third-party payer networks, all of which have very stringent guidelines. If our competitors do not comply with these regulatory guidelines, we could be put at a potential competitive disadvantage and our business, financial condition, results of operations and cash flows could be material and adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we do not manufacture the products we distribute, if one of the products distributed by us proves to be defective or is misused by a healthcare practitioner or patient, we may be subject to liability that could adversely affect our financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not manufacture the pumps that we distribute, a defect in the design or manufacture of a pump distributed or serviced by us, or a failure of pumps distributed by us to perform for the use specified, could have a material and adverse effect on our reputation in the industry and subject us to claims of liability for injuries and otherwise. Misuse of the pumps distributed by us by a practitioner or patient that results in injury could similarly subject us to liability. Any substantial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">underinsured loss could have a material and adverse effect on our business, financial condition, results of operations and cash flows. Furthermore, any impairment of our reputation could have a material and adverse effect on our revenues and prospects for future business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in the past, and in the future intend to pursue growth opportunities through strategic alliances, joint ventures and strategic acquisitions, which may divert our management's attention, and we may be unable to achieve the expected benefits of such alliances, joint ventures or acquisitions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on the effective implementation and continued execution of our business and growth strategies. One of our growth strategies is to pursue opportunities for the further expansion of our business through strategic alliances, joint ventures or acquisitions. Any future strategic alliances, joint ventures or acquisitions will depend on our ability to identify suitable partners, negotiate acceptable terms for such transactions and, if necessary, obtain financing. The success of any strategic alliance, joint venture or acquisitions depends, in part, on our ability to successfully integrate the business and operations of the acquired companies. These investments require significant managerial attention, which may be diverted from our other operations. If we are not able to successfully integrate the operations of acquired businesses, we may not realize the anticipated benefits fully or at all, or it may take longer to realize than expected. There can be no assurance that any of the acquisitions we make will be successful or will be, or will remain, profitable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to support increased operations or personnel, our future growth and business could suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As we grow, the complexity of our operations increases, placing greater demands on our management. Our ability to manage our growth effectively depends on our ability to implement and improve our financial and management information systems on a timely basis and to effect other changes in our business including assimilating operations, technologies and products and services. In addition, we could have difficulty integrating or retaining personnel and maintaining employee morale as we take steps to combine the personnel and business cultures of separate organizations into one and to eliminate duplicate positions and functions. It may also be difficult for us to enter markets in which we have no or limited direct prior experience. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any one or more of these factors could disrupt our ongoing business, distract our management&#8217;s and employees&#8217; attention from our ongoing business operations, result in decreased operating performance and increase our expenses. Moreover, our profitability may suffer because of acquisition-related costs or amortization of intangible assets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to maintain adequate working relationships with healthcare professionals.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We seek to maintain close working relationships with respected physicians and medical personnel in hospitals and universities. We rely on these professionals to assist us in the development of proprietary service and improvements to complement and expand our existing service and product lines. If we are unable to maintain these relationships, our ability to market and sell new and improved products and services could decrease and future operating results could be unfavorably affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable governmental or accrediting bodies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal and state healthcare, and accreditation bodies&#8217; laws and regulations, including those pertaining to fraud and abuse and patients&#8217; rights, are applicable to our business. The laws that are applicable to our business include:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, soliciting, receiving or providing remuneration, directly or indirectly, to induce (i) the referral of an individual, for an item or service or (ii) the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, and which may apply to entities like us that promote medical devices, provide medical device management services and may provide coding and billing advice to customers;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the privacy and security of health information in certain circumstances, many of which differ in significant ways from state to state and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could materially and adversely affect our business, financial condition, results of operations and cash flows. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to protect our intellectual property could substantially harm our business and operating results.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect our trade secrets and other confidential information, we rely in part on confidentiality agreements with our employees, consultants and third parties with whom we have relationships. These agreements may not effectively prevent disclosure of trade secrets and other confidential information and may not provide an adequate remedy in the event of misappropriation of trade secrets or any unauthorized disclosure of trade secrets and other confidential information. In addition, others may independently discover our trade secrets and confidential information and, in such cases, we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce or determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. Failure to obtain or maintain trade secret protection, or our competitors' acquisition of our trade secrets, could materially and adversely affect our competitive business position.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covenants in our current and any future debt agreements restrict our business.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We finance our operations and capital expenditures with cash generated from operations and borrowings under our 2021 Credit Agreement. On April 26, 2023, we entered into a First Amendment to the 2021 Credit Agreement with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement. On July 15, 2025, we entered into a Second Amendment to the 2021 Credit Agreement with the Agent and the lenders party thereto, which further amended the 2021 Credit Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_124">Note </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_124">8</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_124"> (Debt)</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> in the notes to the accompanying consolidated financial statements for additional information regarding the 2021 Credit Agreement, as amended. Our 2021 Credit Agreement, as amended, contains and the agreements that govern our future indebtedness may contain, covenants that restrict our ability to and the ability of our subsidiaries to, among other things:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in a transaction that results in a change of control, as defined by the 2021 Credit Agreement;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create, incur, assume or suffer to exist any lien upon any of our property, assets or revenues;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments or acquisitions;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create, incur, assume or suffer to exist certain indebtedness;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">merge, dissolve, liquidate, consolidate or sell all or substantially all of our assets;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make any disposition or enter into any agreement to make any disposition;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repurchase outstanding stock from the open market; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declare or make, directly or indirectly, any dividend or other restricted payment, or incur any obligation (contingent or otherwise) to do so.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These covenants may restrict our ability to operate our business. Our failure to comply with these covenants could result in an event of default that, if not cured or waived, could result in reduced liquidity for us and could have a material and adverse effect on our ability to operate our business, financial condition, results of operations and cash flows. Additionally, our ability to pay interest and repay the principal for our indebtedness is dependent upon our ability to manage our business operations, generate sufficient cash flows to service such debt and the other factors discussed in this section. Our 2021 Credit Agreement, as amended, also contains certain financial covenants. As of December&#160;31, 2025, we were in compliance with all the covenants contained in the 2021 Credit Agreement, as amended, however, there can be no assurance that we will be able to manage any of the risks associated with debt agreements successfully.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Economic uncertainty or deterioration or geopolitical instability could adversely affect us.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The global economy has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. Although interest rates have recently been declining, the Federal Open Market Committee (&#8220;FOMC&#8221;) noted that further decreases to target rates may occur at a slower pace than the recent rate cuts, and it will continue to assess additional information and implications for monetary policy in determining future actions with respect to target rates. Future decreases in the policy rate will be dependent on trends in employment levels and inflation and financial and international developments. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Geopolitical uncertainties and international conflicts have increased negative pressure in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Further, the Trump administration has proposed or enacted tariffs and substantial changes to trade policies, which could adversely affect our business. For example, the Trump administration has imposed tariffs on certain foreign products, including most recently from Canada, Mexico and China, that in the past have resulted in and may result in future retaliatory tariffs on U.S. goods and products. We cannot predict whether these policies will continue, or if new policies will be enacted, or the impact, if any, that any policy changes could have on our business.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. We may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or challenges to our tax positions could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws, which changes may have retroactive application, could adversely affect our stockholders or us. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the United States enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks.  Such changes, among others, may adversely affect our effective tax rate, results of operation and general business condition. Also, on July 4, 2025, the U.S. One Big Beautiful Bill Act (the "OBBBA") was enacted, which includes permanent extensions of certain expiring provisions of the Tax Cuts and Jobs Act, among other tax and non-tax provisions. The legislation has multiple effective dates, with certain provisions effective beginning in fiscal year ended December 31, 2025 and others becoming effective through the fiscal year ended December 31, 2027. While we continue to evaluate the impact of the OBBBA, these legislative changes did not and are not expected to have a material impact on our results of operations and financial condition. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to audits by tax authorities from time to time in federal and state jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes and penalties. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision. However, there can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes of these audits could have a material impact on our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The value of our net operating loss carryforwards may become impaired if we do not generate sufficient future taxable income required to utilize all or a portion of our net operating loss carryforwards prior to their expiration.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. federal net operating loss carryforward for tax purposes was $5.8 million at December&#160;31, 2025, resulting in a federal deferred tax asset of $1.2 million, none of which expire. Our realization of our deferred tax assets including the loss carryforwards is dependent upon many factors, including our ability to generate sufficient taxable income in sufficient amounts. There can be no assurance that we will generate the required amounts of taxable income before the expiration dates are reached.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS RELATING TO OUR COMMON STOCK</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been, and is likely to remain, volatile, subject to low trading volume and may decline in value.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and may continue to be volatile. Market prices for securities of healthcare services companies, including ours, have historically been volatile, and the market has from time to time experienced significant price and volume fluctuations that appear unrelated to the operating performance of particular companies. The following factors, among others, can have a significant effect on the market price of our common stock:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations, new products, or clinical studies by others;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the coverage or reimbursement rates of private insurers and governmental agencies;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding new products or services;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements or speculation regarding strategic alliances, mergers, acquisitions or other transactions;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the liquidity of the market for our common stock;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">news of other healthcare events or announcements;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or perceived changes in healthcare policies in the U.S. or globally;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global financial conditions; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts and general market conditions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The actual or perceived realization of any risks described in these &#8220;Risk Factors&#8221; could also have a negative effect on the market price of our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not pay dividends and this may negatively affect the price of our stock.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our 2021 Credit Agreement, our ability to pay dividends on our common stock is limited and we do not anticipate paying dividends on our common stock in the foreseeable future. The future price of our common stock may be adversely impacted because we do not pay dividends.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock awards, performance-based restricted stock units and the exercise of stock options may depress our stock price and may result in dilution to our common stockholders.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are a significant number of shares of restricted stock awards (&#8220;RSUs&#8221;), performance-based restricted stock units (&#8220;PSUs&#8221;) and outstanding options to purchase our stock. If the market price of our common stock rises above the exercise price of outstanding options, holders of those securities may be likely to exercise their options and sell the common stock acquired upon exercise in the open market. Sales of a substantial number of shares of our common stock in the public market by holders of options may depress the prevailing market price for our common stock and could impair our ability to raise capital through the future sale of our equity securities. Additionally, if the holders of outstanding options exercise those options, our common stockholders will incur dilution in their relative percentage ownership.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, options to purchase 2,639,250 shares of common stock were outstanding, at a weighted average exercise price of $8.02 per share, of which 1,261,035 were exercisable at a weighted average exercise price of $9.42 per share. In addition, RSUs of 480,879 shares, with a weighted average grant date fair value of $7.31 per share, were outstanding and were issuable upon the vesting of certain time restrictions and PSUs of 382,802 shares, with a weighted average grant date fair value of $6.03 per share, were outstanding and were issuable upon meeting certain performance-based vesting criteria.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to limitations on net operating loss carryforwards and certain built-in losses following an ownership change.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we experience an ownership change, either via a major transaction or a series of trades where a substantial percentage of our ownership changes, which may be less than a majority of our ownership in certain cases, we may be limited in our ability to use our net operating loss carryforwards.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor shifts in past ownership (as defined under Section 382 of the Code). As of December&#160;31, 2025 our U.S. federal net operating loss carryforwards of approximately $5.8 million had an indefinite life. There can be no assurance that we will not experience an ownership change in the future, in which case we may be limited in our ability to use our deferred tax assets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A material weakness in our internal control over financial reporting could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial obligations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The Sarbanes-Oxley Act of 2002 requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Material weaknesses in our disclosure controls and procedures and internal control over financial reporting have been discovered in the past and may be discovered in the future. See Item 9A. &#8211; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further discussion. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot, however, guarantee that additional material weaknesses will not arise in the future. Such material weaknesses could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial obligations, which in turn could have a negative impact on our financial condition, results of operations or cash flows, restrict our ability to access the capital markets, require significant resources to correct the material weaknesses or deficiencies, subject us to fines, penalties or judgments, harm our reputation, or otherwise cause a decline in investor confidence and cause a decline in the market price of our stock. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any future pandemic, epidemic or outbreak of any highly infectious disease could cause disruptions in the U.S., regional and global economies and could materially and adversely impact our business, financial condition and results of operations and the business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the degree to which the effects of any future pandemic, epidemic or outbreak of any highly infectious disease may adversely affect our business, financial conditions and results of operations. Any future pandemic, epidemic or outbreak of any highly infectious disease could cause widespread disruptions to the U.S. and global economies and could contribute to significant volatility and negative pressure in financial markets. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to legal and regulatory proceedings that could have a material adverse impact on our business, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time and in the ordinary course of our business, we may become involved in various legal and regulatory proceedings. All such proceedings are inherently unpredictable and, regardless of the merits of the claims, litigation and regulatory proceedings may be expensive, time-consuming and disruptive to our operations and distracting to management. If resolved against us, such proceedings could result in excessive verdicts, injunctive relief or other equitable relief that may affect how we operate our business. Similarly, if we settle such proceedings, it may affect how we operate our business. Future court decisions, alternative dispute resolution awards, business expansion or legislative activity may increase our exposure to litigation and regulatory investigations. In some cases, substantial non-economic remedies or punitive damages may be sought. Although we maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular verdict, judgment or settlement that may be entered against us, that such coverage will prove to be adequate or that such coverage will continue to remain available on acceptable terms, if at all. If we incur liability that exceeds our insurance coverage or that is not within the scope of the coverage in proceedings brought against us, it could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not collect sales or consumption taxes in some jurisdictions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our core services are exempt from sales tax or its equivalent in many states. However, there are several states that consider pump rentals, sales and services taxable regardless of method of payment. We are collecting sales tax or its equivalent in numerous jurisdictions. A successful assertion by one or more states or localities requiring us to collect taxes where we currently do not, could result in substantial tax liabilities, including for past sales, as well as penalties and interest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unsuccessful in our efforts to implement and support information technology improvements or respond to technological changes, our growth, prospects and results of operations could be adversely affected.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To remain competitive, we must continue to enhance and improve the functionality and features of our technology solutions and services, including through the use of artificial intelligence (&#8220;AI&#8221;) technologies. We have implemented a service to support EMR technology with some of our outpatient infusion practices that enables billing information to be transferred between us and medical facilities electronically and automatically, thus eliminating the current use of mail, email and/or faxes. We have also implemented a web portal that supports our rental and service customers. We are currently engaged in a multi-year project to replace and upgrade multiple business applications, including our main enterprise resource planning system. If these efforts cease to be successful, our reputation and ability to attract and retain customers and contributors will be adversely affected. Furthermore, we are likely to incur expenses in connection with continually updating and improving our technology infrastructure and services. Without such improvements, our operations might suffer from unanticipated system disruptions, slow application performance or unreliable service levels, any of which could negatively affect our reputation and ability to attract and retain customers and contributors. We may face significant delays in introducing new services, products and enhancements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If competitors introduce new products and services using new technologies or if new industry standards and practices emerge, our existing technology and systems may become obsolete or less competitive, and our business may be harmed. In addition, the expansion and improvement of our systems and infrastructure will require us to commit substantial financial, operational and technical resources, with no assurance that our business will improve.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All of these factors could have a material adverse impact on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We also rely on our technology infrastructure to interact with customers and suppliers, fulfill orders and bill, collect and make payments, ship products, provide support to customers, fulfill contractual obligations and otherwise conduct business. Cyber incidents can result from deliberate attacks or unintentional events. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. The result of these incidents could include, but are not limited to, disrupted operations, misstated financial data, liability for stolen assets or information, increased cybersecurity protection costs, litigation and reputational damage adversely affecting customer or investor confidence. Additionally, following the onset of the COVID-19 pandemic, many employees transitioned to a remote or hybrid work environment, which has increased risks associated with our information technology systems and networks. These increased risks include cyber-attacks, computer viruses, disruptions, or shutdowns that could result in a failure to protect our information technology infrastructure and data integrity. We have implemented systems and processes to focus on identification, prevention, mitigation and resolution. However, these measures cannot provide absolute security, and our systems may be vulnerable to cybersecurity breaches such as viruses, hacking, and similar disruptions from unauthorized intrusions. Cyber-attacks continue to increase in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Such attacks are often carried out by motivated and highly skilled actors, who are increasingly well-resourced. Geopolitical events have also increased cybersecurity risks on a global basis. Further, use of AI by our employees, third-party service providers, strategic partners or other contractors or consultants, whether authorized or unauthorized, increases the risk that our intellectual property and other proprietary information will be unintentionally disclosed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third party service providers to supply and support certain aspects of our information technology systems. These vendors could become vulnerable to cyber-attacks, malicious intrusions, breakdowns, interference or other significant disruptions, and their systems may contain defects in design or manufacture or other problems that could result in system disruption or compromise the information security of our own systems. Any failure of our systems or third-party systems may compromise our sensitive information and/or personally identifiable information of our employees or patient health information subject to data privacy law protections. While we have secured cyber insurance to potentially cover certain risks associated with cyber incidents, there can be no assurance the insurance will be sufficient to cover any such liability.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The SEC has recently adopted rules that require us to provide greater disclosure regarding cybersecurity risk management, strategy and governance, as well as disclosure of material cybersecurity incidents. We cannot predict or estimate the amount of additional costs we will incur in order to comply with these rules or the timing of such costs. These rules may also require us to report a cybersecurity incident before we have been able to fully assess its impact or remediate the underlying issue. Efforts to comply with such reporting requirements could divert management's attention from our incident response and could potentially reveal system vulnerabilities to threat actors. Failure to timely report incidents under these or other similar rules could also result in monetary fines, sanctions or subject us to other forms of liability.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technological interruptions or the efficiency of our technology solutions could damage our reputation and brand and adversely affect our results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The satisfactory performance, security, reliability and availability of our network infrastructure are critical to our reputation, our ability to attract, communicate with and retain customers and our ability to maintain adequate customer service levels. Any system interruptions, outside intrusions, or security breaches could result in negative publicity, damage our reputation and brand or adversely affect our results of operations. We may experience temporary system interruptions for a variety of reasons, including security breaches and other security incidents, viruses, telecommunication and other network failures, power failures, software errors or data corruption. We rely upon third-party service providers, such as co-location and cloud service providers, for our data centers and application hosting, and we are dependent on these third parties to provide continuous power, cooling, internet connectivity and physical security for our servers. In the event that these third-party providers experience any interruption in operations or cease business for any reason, our business could be harmed. Although we operate two data centers in an active/standby configuration for geographic and vendor redundancy and even though we maintain a third disaster recovery facility to back up our content collection, a system disruption at the active data center could result in a noticeable disruption of our services. Because some of the causes of system interruptions may be outside of our control, we may not be able to remedy such interruptions in a timely manner, or at all. All of these factors could have a material adverse impact on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain the privacy and security of our customer, third-party payer, employee, supplier, or Company information could result in substantial costs or subject us to litigation, enforcement actions, and reputational damage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business, like that of most businesses in the healthcare and medical device industry, involves the receipt, storage, and transmission of customer information and payment and reimbursement information, as well as confidential information about third-party payers, our employees, our suppliers and us. State, federal and foreign laws, such as HIPAA, Section 5 of the FTC Act, or the California Consumer Privacy Act, as amended, and other similar state laws regulate the confidentiality of personal information, including sensitive information and the circumstances under which such information may be released. These measures may govern the disclosure and use of personal and patient medical record information and may require users of such information to implement specified security measures. Unauthorized access may trigger notification requirements, encourage actions by regulatory bodies, result in adverse publicity and lead to litigation. If we fail to monitor, maintain or protect our information technology systems and data integrity or fail to anticipate, plan for or manage significant disruptions to these systems, we could lose customers, be subject to fraud, breach our agreements with or duties toward customers, physicians, other parties, be subjected to regulatory sanctions or penalties, incur expenses or lose revenues, sustain damage to our reputation, or suffer other adverse consequences. Unauthorized tampering, adulteration or interference with our products may also create issues with product functionality that could result in a loss of data, risk to patient safety, and product recalls or field actions. Any of these events could have a material adverse effect on our business, reputation or financial condition.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology systems (including technology from third-party providers) to process, transmit, and store electronic information in our operations, including sensitive personal information and proprietary or confidential information. Our information systems are vulnerable to an increasing threat of continually evolving cybersecurity risks. Unauthorized parties may attempt to gain access to our systems or information through fraud or other means of deceiving our employees or third-party service providers. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information and device security. The methods used to obtain unauthorized access, disable or degrade service, or sabotage systems are also constantly changing and evolving, and may be difficult to anticipate or detect for long periods of time. We have implemented and regularly review and update processes and procedures to protect against unauthorized access to or use of secured data and to prevent data loss. However, the ever-evolving threats mean we must continually evaluate and adapt our systems and processes, and our efforts may not be adequate to safeguard against all data security breaches, misuse of data, or sabotage of our systems. Any future significant compromise or breach of our data security, whether external or internal, or misuse of customer, third-party payer, employee, supplier or Company data, could result in significant costs, lost sales, fines, lawsuits and damage to our reputation. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs. Specifically, as a result of the broad scale release and availability of emerging digital technologies, including AI technologies machine learning capabilities, there is a global trend towards more regulation to ensure the ethical use, privacy, and security of AI and the data that it processes. Compliance with such laws will likely be an increasing and substantial cost in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural disasters, pandemics, acts of war or terrorism and other external events could significantly impact our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters, including hurricanes, earthquakes, floods, excessive snowfall and other unfavorable weather conditions, widespread public health emergencies such as pandemics, acts of war or terrorism and other adverse external events may affect our operations. Such events may have a detrimental effect on our gross revenue, preventing many patients from visiting a facility to obtain our ambulatory infusion pumps or receive treatment. Similarly, such events could impact key suppliers or vendors, disrupting the services or materials they provide us. The severity of these occurrences, should they ever occur, will determine the extent to which and if our business, financial condition, results of operations and cash flows is materially and adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon executive officers and other key personnel. The loss of any of our executive officers or other key personnel could reduce our ability to manage our businesses and achieve our business plan, which could cause our sales to decline and our operating results and cash flows to suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success is substantially dependent on the continued services of our executive officers and other key personnel who generally have extensive experience in our industry. Our future success also will depend in large part upon our ability to identify, attract and retain other highly qualified executive officers, managerial, finance, technical, clinical, customer service and sales and marketing personnel. Competition for these individuals is intense, more so in the current labor market. The loss of the services of any executive officer or other key employee, or our failure to attract and retain other qualified and experienced personnel on acceptable terms, could have a material and adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_22"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1B.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Unresolved Staff Comments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1C.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity</span></div><div style="text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-36" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the critical importance of cybersecurity in safeguarding sensitive information, maintaining operational integrity, and ensuring the safety and efficacy of our medical devices. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-37" continuedAt="f-37-1">Our cybersecurity risk management program, which is based on recognized cybersecurity frameworks established by the National Institute of Standards and Technology ("NIST")</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"><ix:continuation id="f-37-1" continuedAt="f-37-2"> </ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-37-2">and led by our Chief Information Officer (CIO), is fully integrated into our overall enterprise risk management program, and shares common reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, operational and financial risk areas.</ix:continuation> We are dedicated to maintaining the highest standards of cybersecurity to protect our customers and stakeholders. We will continue to adapt to evolving threats and regulations to ensure the safety and security of our products and information.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Please see the Item 1A. Risk Factor above entitled "</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">" for more information regarding cybersecurity incident risks associated with InfuSystem.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-38" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risk Assessment</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We conduct regular risk assessments and penetration tests, leveraging AI-driven threat detection and continuous monitoring tools to identify vulnerabilities impacting confidentiality, integrity, and availability of systems and data. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Policies and Procedures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: InfuSystem has established and maintains cybersecurity policies and procedures that align with industry best practices and regulatory requirements. These policies address areas such as data protection, access control, incident response, and vulnerability management.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Training and Awareness</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We provide ongoing cybersecurity training and awareness programs to our employees and contractors, emphasizing the importance of their role in safeguarding sensitive information and reporting security incidents.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-39" continuedAt="f-39-1"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Use of Third-Parties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: InfuSystem works with a third-party Cybersecurity risk partner whose systems ingest information regarding the current state of the Company&#8217;s information and technology environment and using specialized algorithms provide assessments of the company&#8217;s Cybersecurity risk exposure as well as providing targeted advice to mitigate any risks identified.</span></ix:nonNumeric></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><ix:continuation id="f-39-1"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-40"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Third-Party Risk Management</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: InfuSystem evaluates the cybersecurity practices of third-party vendors and suppliers, ensuring that they meet our cybersecurity standards and pose no undue risk to our medical devices and data.</span></ix:nonNumeric></ix:continuation></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Incident Response Plan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We maintain a robust incident response plan that outlines the steps to be taken in the event of a cybersecurity incident. This plan includes procedures for reporting incidents, containing threats, and notifying affected parties as required by law.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Ongoing Efforts</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-41" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem is committed to continuous improvement in our cybersecurity risk management practices. In the coming fiscal year, we will focus on:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Enhancing our threat detection and monitoring capabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Conducting regular tabletop exercises to improve incident response readiness.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Staying abreast of emerging threats and adjusting our cybersecurity posture accordingly.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Collaborating with industry partners and regulatory authorities to enhance overall cybersecurity resilience in the medical device industry.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Governance</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-42" continuedAt="f-42-1" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem maintains a dedicated cybersecurity governance framework. While senior management is primarily responsible for assessing and managing our exposure to risk, our Board of Directors oversees our ERM, including cybersecurity risk management, and ultimately approves ERM policies and procedures. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-43" escape="true">Our Board conducts much of its risk oversight activities, including cybersecurity risk oversight, through our Audit Committee.</ix:nonNumeric> Given the ever-increasing volume of cyber </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-42-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">threats and the magnitude of a potential breach, cybersecurity is a standing topic for the Board of Directors and Audit Committee.</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-44" escape="true">As noted above, our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-45">CIO</ix:nonNumeric> leads our cybersecurity risk management program.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-46" escape="true">Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" continuedAt="f-47-1" escape="true">CIO has over a decade of executive-level experience managing information systems and cybersecurity programs in the healthcare industry. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-48" continuedAt="f-48-1" escape="true">The CIO serves as an Executive Officer who reports directly to senior management and, at least quarterly, makes reports to the Audit Committee.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><ix:continuation id="f-48-1"><ix:continuation id="f-47-1"> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-49">Senior management reports to the full Board of Directors with respect to cybersecurity matters on at least a quarterly basis.</ix:nonNumeric></ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-50">As of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to affect the Company, including our business strategy, results of operations or financial conditions.</ix:nonNumeric> </span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_28"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Properties.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not own any real property. We lease office and warehouse space at the following locations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">City</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State/Country</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rochester Hills</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Michigan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lenexa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kansas</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canton</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bakersfield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Santa Fe Springs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dallas</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Texas</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mississauga</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that such office and warehouse space is suitable and adequate for our business. All of our facilities are utilized to support both of our segments. </span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_31"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to certain claims and lawsuits in the ordinary course of business, the outcome of which cannot be determined at this time. In the opinion of management, any liability we might incur upon the resolution of these claims and lawsuits will not, in the aggregate, have a material adverse effect on our consolidated financial position or results of operations.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_34"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_40"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Market for Registrant</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the NYSE American under the symbol INFU. As of February&#160;25, 2026, we had approximately 222 stockholders of record of our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our purchases of our common stock during the three months ended December&#160;31, 2025 is as follows: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in thousands) (b)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2025 through October 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$10,327,463</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2025 through November 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51,908</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$9,827,463</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2025 through December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">85,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">85,986</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$9,028,153</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">145,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">137,894</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a) Of the 145,216 shares of common stock presented in the table above, 7,322 shares were originally granted to employees and non-employee directors as stock options and restricted stock awards under our equity compensation plans. Our equity compensation  plans allow for the withholding of shares to satisfy tax obligations due upon the exercise of stock options and vesting of restricted stock. Pursuant to our equity compensation plans, the 7,322 shares reflected above were relinquished by employees or non-employee directors in exchange for our agreement to pay U.S. federal, state and local tax withholding obligations resulting from the exercise of the Company's stock options and vesting of the Company's restricted stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b) On May 16, 2024, our Board of Directors approved a stock repurchase program (the "Share Repurchase Program") authorizing the Company to repurchase up to $20.0 million of the Company's outstanding common stock through June 30, 2026, which was announced on May 20, 2024. The Share Repurchase Program supersedes the previous authorization, which was set to expire on June 30, 2024. Repurchases under the Share Repurchase Program will be subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's existing credit agreement. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase Program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board. As of December&#160;31, 2025, the Company had repurchased approximately 1,498,376 shares under the Share Repurchase Program.  The Company had repurchased and retired approximately $6.2 million, or 553,149 shares under the previous authorization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have not declared or paid any dividends on our common stock. Under the terms of our 2021 Credit Agreement, as amended, our ability to pay dividends on our common stock is limited, and we do not anticipate paying dividends on our common stock in the foreseeable future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did not sell any unregistered securities during the fiscal year ended December&#160;31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Part III, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_175">Item 12</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to this Form 10-K for information relating to securities authorized for issuance under our equity compensation plans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, we are presenting the following on a voluntary basis. The following graph shows a comparison of cumulative total shareholder return to the Company's shareholders, the corresponding returns on the Russell 2000 Index during the five-year period ended December&#160;31, 2025 assuming $100 was invested on December&#160;31, 2020 with reinvestment of all dividends.</span></div><div style="margin-top:10pt;text-indent:27pt"><img src="infu-20251231_g2.jpg" alt="3175" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px" id="i-2"/></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">InfuSystem</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Russell 2000 Index</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_43"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;[Reserved]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Management</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The following discussion should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in this Form 10-K. The forward-looking statements included in this discussion and elsewhere in this Form 10-K involve risks and uncertainties, including those set forth under</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cautionary Statement About Forward-Looking Statements.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Actual results and experience could differ materially from the anticipated results and other expectations expressed in our forward-looking statements as a result of a number of factors, including but not limited to those discussed in this Item and in Item 1A -</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Risk Factors.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;</span></div><div><span><br/></span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_49"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> Overview</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading national healthcare service provider, facilitating outpatient care for Durable Medical Equipment (DME) manufacturers and healthcare providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site healthcare providers. Our headquarters is in Rochester Hills, Michigan, and we operate our business from a total of seven locations in the U.S. and Canada. We deliver local, field-based customer support as well as operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem is accredited in Michigan by the Community Health Accreditation Partner (CHAP) and is ISO 9001 certified at our Kansas, Michigan, Massachusetts, Canada and Santa Fe Springs, California locations as well as ISO 13485 certified at our Bakersfield, California location.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem competes for and retains its business primarily on the basis of its long participation and strong reputation in the DME space, its long-standing relationships with DME manufacturers and its healthcare provider customers, and the high levels of service it provides. Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract, which included </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nearly</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> 840 third-party payer networks as of December&#160;31, 2025; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S. and Canada; (iv) pump fleet of ambulatory and large volume infusion pumps for rent and for sale, which may allow us to be more responsive to the needs of physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers and patients than a new market entrant; (v) seven geographic locations in the U.S. and Canada that allow for same day or next day delivery of pumps; (vi) team of field-based and traveling biomedical technicians; and (vii) a wide array of pump repair and service capabilities. We do not perform any research and development on pumps, but we have made, and continue to make investments in our information technology.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Services Segment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Patient Services segment&#8217;s core purpose is to seek opportunities to leverage our unique know-how in clinic-to-home healthcare involving Durable Medical Equipment, our logistics and billing capabilities, our growing network of third-party payers under contract, and our clinical and biomedical capabilities. This leverage may take the form of new products and/or services, strategic alliances, joint ventures or acquisitions. The leading service within our Patient Services segment is our Oncology Business. Colorectal cancer is the third most prevalent form of cancer in the U.S., according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps. One of the goals for the Patient Services segment is to expand into treatment of other types of cancers. In 2025, our Oncology Business generated approximately 87% of our total Patient Services segment revenues. In 2025, we generated approximately 43% of our total Patient Services segment revenues from treatments for colorectal cancer and 44% of our Patient Services segment revenues from treatments for non-colorectal disease states. There are a number of approved treatment protocols for pancreatic, head and neck, esophageal and other types of cancers, as well as other disease states which present opportunities for growth. There are also a number of other drugs currently approved by the FDA, as well as agents in the pharmaceutical development pipeline, which we believe could potentially be used with continuous infusion protocols for the treatment of diseases other than colorectal cancer. Additional drugs or protocols currently in clinical trials may also obtain regulatory approval over the next several years. If these new drugs or protocols obtain regulatory approval for use with continuous infusion protocols, we expect the pharmaceutical companies to focus their sales and marketing efforts on promoting the new drugs and protocols to physicians.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our Oncology Business focuses mainly on the continuous infusion of chemotherapy. Continuous infusion of chemotherapy can be described as the gradual administration of a drug via a small, lightweight, portable infusion pump over a prolonged period of time. A cancer patient can receive his or her medicine anywhere from one to 30 days per month depending on the chemotherapy regimen that is most appropriate to that individual&#8217;s health status and disease state. This may be followed by periods of rest and then repeated cycles with treatment goals of progression-free disease survival. This drug administration method has replaced intravenous push or bolus administration in specific circumstances. The advantages of slow </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">continuous low doses of certain drugs are well documented. Clinical studies support the use of continuous infusion chemotherapy for decreased toxicity without loss of anti-tumor efficacy. The NCCN Guidelines recommend the use of continuous infusion for treatment of numerous cancer diagnoses. We believe that the growth of continuous infusion therapy is driven by three factors: evidence of improved clinical outcomes; lower toxicity and side effects; and a favorable reimbursement environment.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The use of continuous infusion has been demonstrated to decrease or alter the toxicity of a number of cytotoxic, or cell killing agents. Higher doses of drugs can be infused over longer periods of time, leading to improved tolerance and decreased toxicity. Nausea, vomiting, diarrhea and decreased white blood cell and platelet counts are all affected by duration of delivery. Continuous infusion can lead to improved tolerance and patient comfort while enhancing the patient&#8217;s ability to remain on the chemotherapy regimen. Additionally, the lower toxicity profile and resulting reduction in side effects enables patients undergoing continuous infusion therapy to continue a relatively normal lifestyle, which may include continuing to work, going shopping, and caring for family members. We believe that the partnering of physician management and patient autonomy provide for the highest quality of care with the greatest patient satisfaction.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that oncology practitioners have a heightened sensitivity to providing quality service and to their ability to obtain reimbursement for services they provide. Simultaneously, CMS and private insurers are increasingly focused on evidence-based medicine to inform their reimbursement decisions &#8212; that is, aligning reimbursement with clinical outcomes and adherence to standards of care. Continuous infusion therapy is a main component of the standard of care for certain types of cancers because clinical evidence demonstrates superior outcomes. Payers&#8217; recognition of this benefit is reflected in their relative reimbursement policies for clinical services related to the delivery of this care.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional areas of focus for our Patient Services segment are as follows:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Pain Management</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: providing our ambulatory pumps, products, and services for pain management in the area of post-surgical continuous peripheral nerve block.</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Wound Care</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: In 2020, we added Negative Pressure Wound Therapy ("NPWT") to our portfolio of DME devices offered to patients for home healthcare.  Similar to our capabilities surrounding infusion pumps, we offer these devices to patients for third party payer reimbursement and sales, rentals and leases of the equipment and related disposable supplies directly to other healthcare providers.  Our fleet off NPWT devices include devices manufactured by Smith and Nephew, Cork Medical LLC (&#8220;Cork&#8221;) and Genadyne Biotechnologies Inc.  In 2024, we added Advanced Wound Care dressings to our wound care product portfolio.   We take patient referrals for wound care disposable supplies directly and indirectly from wound care clinics and other sites of care.  The products are generally shipped directly from our suppliers to the patents and we receive reimbursement from the patient's health care plan carrier. During 2025, we added Pneumatic Compression Devices ("PCD") to our portfolio of DME devices offered to patients.</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: we believe there are opportunities to acquire smaller, regional healthcare service providers, in whole or in part that perform similar services to us but do not have the national market access, network of third-party payer contracts or operating economies of scale that we currently enjoy. We may also pursue acquisition opportunities of companies that perform similar services, but offer different therapies or utilize different devices.  In May 2025, we acquired the assets of Apollo Medical Supply (&#8220;Apollo&#8221;), a privately-held wound care service company based in Florida. As part of the Company&#8217;s Patient Services segment, this acquisition supplements the Company&#8217;s existing wound care business by providing access to an advanced patient service fulfillment know-how and software platform that the Company plans to integrate into its existing operations.</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Partnerships and Manufacturer Distribution Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We look to foster commercial relationships with various DME equipment manufactures and other health care providers where our services and capabilities create value in the healthcare supply chain.  In particular, our large portfolio of third-party payer contracts makes us an attractive distribution partner.  In November 2022, the Company established a partnership, SI Healthcare Technologies, LLC ("SI Healthcare"), with Sanara MedTech Inc. ("Sanara"). The partnership focuses on delivering DME products targeted at improving patient outcomes, lowering the cost of care, and increasing patient and provider satisfaction. The partnership enables InfuSystem to offer innovative products such as Sanara&#8217;s advanced wound care product line to new customers through the jointly controlled entity.  In 2024, SI Healchare entered into an exclusive distribution agreement with ChemoMouthpiece, LLC to market and sell a new product designed to reduce the incidence of Oral Mucositis in cancel patients.  Oral mucositis is an inflammation of the mucous membranes in the mouth often caused by cancer treatments.  </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Information technology-based services</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: we also plan to continue to capitalize on key new information technology-based services such as EXPRESS, InfuBus or InfuConnect,&#160;DeviceHub, BlockPain Dashboard&#174; and Tracking Inhouse Management ("TIM").</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The payer environment within our Patient Services segment is in a constant state of change. We continue to extend our considerable breadth of payer networks under contract as patients move into different insurance coverage plans, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, due to a reduction in concessions. Consequently, we are increasingly focused on net revenues less concessions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Device Solutions Segment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Device Solutions segment&#8217;s core service is to: (i) sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; (ii) sell treatment-related consumables; and (iii) provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings, including, home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others. We purchase new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service. Our acquisition of FilAMed, a privately-held biomedical services company, on January&#160;31, 2021 has supplemented the Company&#8217;s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings, including, home care and home infusion providers, skilled nursing facilities, pain centers and others. Our acquisition of OB Healthcare, a privately-held biomedical services company, on April&#160;18, 2021 further develops and expands InfuSystem&#8217;s Device Solutions segment by adding field service capabilities and complements the Company&#8217;s purchase of FilAMed.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_52"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Key Business Metrics</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management monitors a number of financial and non-financial measures and ratios on a regular basis in order to track the progress of our business and make adjustments as necessary. We believe that the most important of these measures and ratios include net revenues and our order-to-cash process, fleet utilization, operating margin, operating expenses, profitability, and debt levels including available credit and leverage ratios. These measures and ratios are compared to standards or objectives set by management, so that actions can be taken, as necessary, in order to achieve the standards and objectives.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">InfuSystem Holdings, Inc. Results of Operations for the year ended December&#160;31, 2025 compared to the year ended December&#160;31, 2024</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.768%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Patient Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Device Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">64,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: elimination of inter-segment revenues (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total Device Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">143,436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">134,861&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Patient Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Device Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">70,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Selling and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">63,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,623&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,657,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,271,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(613,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,097,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,707,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(609,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(a) Inter-segment revenues are for cleaning and repair services performed on medical equipment.</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for the year ended December&#160;31, 2025 were $143.4 million, an increase of $8.6 million, or 6.4%, compared to $134.9 million for the year ended December&#160;31, 2024. The increase included higher net revenues for both the Patient Services and Device Solutions segments.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Services</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services net revenue of $86.5 million increased $6.2 million, or 7.7%, during the year ended December&#160;31, 2025 as compared to the prior year. This increase was primarily attributable to additional treatment volume totaling $6.5 million offset partially by $0.3 million lower revenue from sales-type leases of NPWT pumps. The improved volume benefited Oncology revenue by $3.6 million or 5.0% and Wound Care revenue by $3.2 million, or 148.7%. Pain Management revenue decreased by $0.3 million, or 6.2%. Wound Care net revenues included first time sales of PCDs stemming from a new supplier relationship.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Device Solutions</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions net revenue of $56.9 million increased $2.4 million, or 4.4%, during 2025 as compared to the prior year. This increase included higher rental revenue totaling $1.0 million, or 4.9%, higher medical equipment sales, which increased by $0.5 million, or 7.3%, higher biomedical services revenue, which increased by $0.7 million, or 4%, and higher disposable medical supplies revenue, which increased by $0.2 million or 2.0%. The increase in rental revenue was mainly attributable to new customers added during and since the second quarter of 2024. Medical equipment sales increased due to higher than usual rental buyouts by existing rental customers in the current year. Biomedical services revenue included a non-recurring $0.6 million adjustment associated with a price increase agreed to by a large customer which was also effective for services already rendered but not fully invoiced based on the agreed billing structure.  The remaining increase in recurring biomedical services revenue was due to additional volume with other customers offset partially by lower devices under contract with our largest biomedical services customer,  GE Healthcare, and lower service repair volume associated with a contract with a device manufacturer to provide a one-time fleet wide software update.  During 2025, we restructured our biomedical services contract with GE Healthcare and, consequently, we are starting 2026 at a reduced revenue volume of $7.1 million, or 5.5% annually. This was a necessary change that will have an immediate favorable impact on our reported earnings and cash flows since we also expect an even larger reduction in our expenses.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The software update contract was performed in 2024 and 2025 with the greater amount of volume completed in 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Gross Profit</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the year ended December&#160;31, 2025 totaling $80.3 million increased $9.9 million, or 14.1%, from $70.4 million during the year ended December&#160;31, 2024. The increase was driven by the increase in net revenues and by higher gross profit as a percentage of net revenue (&#8220;gross margin&#8221;). Gross margin increased to 56.0% during 2025, as compared to 52.2% during the prior year period, an increase of 3.8%. Both operating segments contributed to the increase in gross profit during 2025 as compared to 2024.  Gross margin was lower for the Patient Services segment and was higher for the Devices Solutions segment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Services</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services gross profit was $55.4 million, during 2025, representing an increase of $2.5 million, or 4.8%, compared to the prior year. The improvement reflected increased net revenue offset partially by a lower gross margin, which decreased from the prior year by 1.8% to 64.0%. The decrease in gross margin reflected a change in product mix favoring lower gross margin revenues, offset partially by lower pump disposal expenses. The unfavorable gross margin mix was mainly related to the increase in revenue related to wound care treatments, which is a lower gross margin but less capital intensive business than other Patient Services revenue categories. Pump disposal expenses, which include retirements of damaged pumps and reserves for missing pumps, decreased by $0.2 million during 2025 compared to the prior year period.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Device Solutions</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions gross profit during 2025 was $24.9 million, representing an increase of $7.4 million, or 41.9%, over the prior year. The increase was partially due to the aforementioned non-recurring $0.6 million price increase adjustment agreed to by a large customer and to a $0.6&#160;million error correction during the prior year which did not repeat in the current year. The remaining $6.2 million improvement reflected increased net revenue. The Device Solutions gross margin was 43.8% during 2025, which was 11.6% higher than the prior year. This increase was partially due to the price increase adjustment which increased gross margin by 1.0% in the current year and the error correction in the prior year, which reduced gross margin during that period by 1.5%. The remaining 9.1% increase was attributable to improved procurement costs for materials, increased biomedical productivity and favorable product mix favoring higher gross margin revenues, such as rental revenue and sales of used equipment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets for the year ended December&#160;31, 2025 was $0.9 million which was a decrease of $0.1 million, or 7%  from the year ended December&#160;31, 2024 due to some intangible assets reaching the end of their amortization life. Based on the current amortization schedule and definite lived intangible assets existing as of December&#160;31, 2025, amortization expense is expected to decrease in 2026 and beyond.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selling and Marketing Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses for the year ended December&#160;31, 2025 were $10.5 million, a decrease of $0.8 million, compared to 2024. Selling and marketing expenses as a percentage of net revenues decreased to 7.3% compared to 8.4% in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024. This decrease reflected a reduction in sales team members, a shift in the mix of sales favoring revenue with lower commission rates and improved coverage of fixed costs from higher net revenues. Selling and marketing expenses consist of sales personnel salaries, commissions and associated fringe benefit and payroll-related items, marketing, travel and entertainment and other miscellaneous expenses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">G&amp;A</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">) Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expenses for the year ended December&#160;31, 2025 were $57.0 million, an increase of $5.8 million, or 11.2%, from $51.2 million for the year ended December&#160;31, 2024. G&amp;A expenses during these periods consisted primarily of accounting, administrative, third-party payer billing and contract services, customer service, nurses on staff, new product services, service center personnel salaries, fringe benefits and other payroll-related items, professional fees, legal fees, stock-based compensation, insurance and other miscellaneous items. Additionally, the amount for 2025 included a one-time accrued severance expense of $1.0 million for the Company's outgoing CEO, which was substantially in accordance with his employment agreement. This amount was higher than the total of one-time expenses in 2024 which included a $0.6 million payment to a former member of the board of directors related to a Cooperation Agreement and a one-time payment to the Company's former audit firm for services related to their consent to include their prior year audit report in our 2023 annual report totaling $0.3 million. The remaining increase, net of these amounts of $5.7 million, included $1.8 million of increased expenses related to information technology and business applications upgrades in 2025 as part of a project that began in the second half of 2024. Additional expenses above 2024 levels included personnel directly related to the increased net revenue including revenue cycle personnel and general business expenses totaling $3.5 million and $0.4 million increase in the company's bad debt reserve accrual which was a benefit in the prior year but an expense amount during 2025. G&amp;A expenses as a percentage of net revenues for 2025 increased to 39.7% compared to 38.0% for the prior year mainly reflecting the year-over-year increases offset partially by improved net revenue leverage of fixed costs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Income and Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, we incurred interest expense of $1.3 million, which was $0.5 million lower than interest expense during the year ended December&#160;31, 2024. This decrease was due to a decrease in outstanding borrowings on the 2021 Credit Agreement, as amended (defined below), revolving line of credit and lower average interest rates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Provision for/Benefit from Income Taxes</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company recorded a provision for income taxes of $4.0 million, representing an effective tax rate of 37.6% on pre-tax income totaling $10.6 million. During the year ended December&#160;31, 2024, the Company recorded a provision for income taxes of $2.7 million, representing an effective tax rate of 54% on pre-tax income totaling $5.1 million. The effective tax rate for both periods differed from the U.S. statutory rate mainly due to state, local and foreign taxes and permanent differences between expense recognized for book purposes versus tax purposes including differences associated in the amounts of equity compensation expense, limits on compensation for certain executive members of management and limitations on deductions for travel related meal expenses.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_67"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We finance our operations and capital expenditures with cash generated from operations and borrowings under our existing credit agreement. On February 5, 2021, we and certain of our subsidiaries, as borrowers, entered into a Credit Agreement (the &#8220;2021 Credit Agreement&#8221;) with JPMorgan Chase Bank, N.A., as administrative agent, sole bookrunner and sole lead arranger (the "Agent"), and the lenders party thereto. On April 26, 2023, the Company entered into a First Amendment to the 2021 Credit Agreement (the &#8220;First Amendment&#8221;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement. On July 15, 2025, the Company entered into a Second Amendment to the 2021 Credit Agreement (the &#8220;Second Amendment&#8221;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_124">Note </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_124">8</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_124"> (Debt)</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the notes to the accompanying consolidated financial statements for additional information regarding the 2021 Credit Agreement, as amended. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available liquidity (in millions):</span></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Revolving line of credit availability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">55.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">50.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Available liquidity</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58.2&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">51.4&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity and borrowing plans are established to align with our financial and strategic planning processes and ensure we have the necessary funding to meet our operating commitments, which primarily include the purchase of medical equipment, inventory, payroll and general expenses. We also take into consideration our overall capital allocation strategy which includes investment for future organic growth, potential acquisitions and repurchases of our common equity. We believe we have adequate sources of liquidity and funding available for at least the next year from the filing date of this report, as well as for our currently anticipated long-term needs. However, any projections of future earnings and cash flows are subject to substantial uncertainty, including factors such as the successful execution of our business plan and general economic conditions. We may need to access debt and equity markets in the future if unforeseen costs or opportunities arise, to meet working capital requirements, fund acquisitions or investments or repay indebtedness under the 2021 Credit Agreement. If we need to obtain new debt or equity financing in the future, the terms and availability of such financing may be impacted by economic and financial market conditions as well as our financial condition and results of operations at the time we seek additional financing. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt Activities:</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement provides for a revolving credit facility (the &#8220;Revolving Facility&#8221;) of $75.0 million, maturing on July 15, 2030. The Revolving Facility may be increased by $35&#160;million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7.0 million in letters of credit subject to the satisfaction of certain conditions. On February&#160;5, 2021, the Borrowers made an initial borrowing of $30.0 million under the Revolving Facility. Proceeds from the loan, along with approximately $8.2 million in cash, were used to repay all amounts due under the Company&#8217;s then existing credit agreement.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement has customary representations and warranties. The ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement includes customary events of default. The occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company entered into the First Amendment  with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things: (i) an extension of the maturity date for the 2021 Credit Agreement to April 26, 2028, (ii) the replacement of London Interbank Offered Rate (&#8220;LIBOR&#8221;) with Adjusted Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as a benchmark interest rate, and (iii) an increase of the maximum dollar amount of incremental revolving loans from $25&#160;million to $35&#160;million. Incremental revolving loans continue to be subject to certain conditions, including the consent of the Agent and obtaining necessary commitments.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2025, the Company entered into the Second Amendment with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things: (i) an extension of the maturity date for the 2021 Credit Agreement to July 15, 2030, and (ii) a 0.05% decrease in the Alternative Base Rate and the Adjusted Term SOFR rates.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement, First Amendment and Second Amendment were accounted for as debt modifications that resulted in small increases to deferred debt issuance costs. As of December&#160;31, 2025, the Company was in compliance with all </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">debt-related covenants under the 2021 Credit Agreement, as amended. Considering our current liquidity position and short-term financial forecasts, we expect to continue to be in compliance with our financial covenants at the end of our fiscal year ending December 31, 2026.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revolver:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross availability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding draws</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(20,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(24,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Availability on Revolver</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50,876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement, as amended, bear interest at a variable rate equal to, at the Company&#8217;s election, Adjusted Term SOFR for Term Benchmark loans or an Alternative Base Rate for ABR loans, as defined by the Second Amendment, plus a spread that will vary depending upon the Company&#8217;s leverage ratio. The spread ranges from 2.05% to 3.05% for Term Benchmark Loans and 1.05% to 2.05% for base rate loans. The weighted-average Term Benchmark loan rate at December&#160;31, 2025 was 5.83% (Adjusted Term SOFR of 3.78% plus 2.05%). The actual ABR loan rate at December&#160;31, 2025 was 7.80% (lender&#8217;s prime rate of 6.75% plus 1.05%).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2024, our Board of Directors approved a stock repurchase program (the "Share Repurchase Program") that authorizes the Company to repurchase up to $20.0 million of the Company's outstanding common stock through June 30, 2026. The Share Repurchase Program supersedes the previous authorization, which was set to expire on June 30, 2024. Repurchases under the Share Repurchase Program are subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's existing credit agreement. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had repurchased and retired approximately $11.0 million, or 1,498,376 shares, of the Company's outstanding common stock under the Share Repurchase Program. The Company had repurchased and retired approximately $6.2 million, or 553,149 shares under the previous authorization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows:</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Years Ended December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">In millions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">2025 vs. 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Cash Flow</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; Net cash provided by operating activities for the year ended December&#160;31, 2025 was $24.4 million compared to $20.5 million for the year ended December&#160;31, 2024. This $3.9 million, or 19.3%, increase was attributable to an increase in net income adjusted for non-cash items, which was $24.5 million during the 2025 compared to $19.8 million during 2024, an increase of $4.7 million.  The adjusted net income benefit was partially offset by a swing in cash flows related to working capital which was a $0.1 million use of cash during 2025 and a $0.7 million source of cash during 2024, a change unfavorable to operating cash flow totaling $0.7 million. The increase in net income adjusted for non-cash items was primarily attributable to the aforementioned higher revenue, increase in gross margin and lower selling and marketing expenses in 2025.  These benefits were partially offset by the increased general and administrative expenses described above. The use of cash for working capital items during the 2025 was primarily driven by an increase in other current assets of $0.9 million and a decrease in  accounts payable and other liabilities of $0.7 million.  These were partially offset by a decrease in inventories of $1.1 million. The increase in other current assets was primarily related to an increase in a contract asset associated with a customer price increase.  The decrease in inventories during 2025 reflected better management of inventory levels held to support recurring revenue including an increased percentage of product being shipped directly from suppliers to customers.  The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">decrease in accounts payable and other liabilities was primarily driven by the lower amount of inventory and variations in timing of the receipt of goods and services and payments.  Increases in accounts receivable and inventory during 2024 reflected the higher revenue during the period. The decrease in other assets reflected repayments on Sales-Type leases that exceeded the amount of new Sales-Type leases entered into during 2025. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Cash Flow.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Net cash used in investing activities was $6.8 million for the year ended December&#160;31, 2025 compared to $13.2 million for the year ended December&#160;31, 2024. This $6.4 million decrease in net cash used was primarily due to a $8.6 million decrease in purchases of medical equipment. Purchases of medical equipment was higher in 2024 due to increased volume in our rental business, during that period, which required us to purchase additional pumps. Our revenue growth in 2025 was more weighted to service lines that do not require the purchase of capital equipment such as the Wound Care category in the Patient Services segment.  This decrease was partially offset by cash used in 2025 to acquire certain assets of Apollo Medical Supply (&#8220;Apollo&#8221;), a privately-held wound care service company totaling $1.4 million.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Cash Flow.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160; Net cash used in financing activities for the year ended December&#160;31, 2025 was $15.0 million compared to $6.9 million for the year ended December&#160;31, 2024. The use of cash during 2025 primarily included net revolving line of credit repayments under the 2021 Credit Agreement totaling $4.1 million and the repurchase of common stock totaling $9.9 million. During 2024, net revolving line of credit repayments totaled $5.3 million and the use of cash for repurchase of common stock totaled $1.2 million.</span></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_70"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. We consider critical accounting policies to be those that require more significant judgments and estimates in the preparation of our consolidated financial statements, including the following: revenue recognition and reserve for missing medical equipment. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management believes its application of accounting policies, and the estimates inherently required therein, are reasonable. These accounting policies and estimates are periodically reevaluated, and adjustments are made when facts and circumstances dictate a change.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are more fully described under the heading &#8220;Summary of Significant Accounting Policies&#8221; in </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_106">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our Consolidated Financial Statements included in this Form 10-K. We believe the following critical accounting estimates are the most significant to the presentation of our financial statements and require the most difficult, subjective and complex judgments:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from multiple sources including from the sale and rental of our products as well as service contracts. Due to the various types and complexity of these arrangements, we consider the application of the accounting policies that govern revenue recognition and the determination of the net realizable value of revenues and accounts receivable to be critical in relation to our consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606 - Revenue from Contracts with Customers ("ASC 606") stipulates revenue recognition at the time and in an amount that reflects the consideration expected to be entitled for the performance obligations that have been provided. ASC 606 defines contracts as creating enforceable rights and may be established through written contracts, oral agreements and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three separate and distinct performance obligations offered to its customers: a rental service performance obligation, a product sale performance obligation and a service performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. These performance obligations are related to separate revenue streams and at no point are they combined into a single transaction. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial payers, government insurance payers, medical facilities and patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates a significant amount of its revenues that are accounted for under ASC 606 from the rental service of infusion pumps to its customers with the remainder of this revenue being derived from product sales and services. For the rental service performance obligation, revenue is based on its estimated standalone price, determined using reimbursement rates established by third-party payer or other contracts. Revenue is recognized over the contract term in which the related performance obligation is satisfied. The Company&#8217;s revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms, or when the customer uses the products in the case of when our products are stored at a customer's location. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products. The Company's revenues related to services are recognized as the service work is completed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and product performance obligations. These judgments include, among others, the estimation of variable consideration. The Company allocates variable consideration using standalone selling price when appropriate and available. When an appropriate standalone selling price is not available, the Company allocates based on a best estimate approach using the relative fair market value. Variable factors include differences in transaction price and changes in the expected total volume of services during the contract period.  In calculating the variable amount of revenue for these performance obligations, variable consideration is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions and by forecasting total revenue volume for the contract period. The contract period starts at contract inception and typically extends 30 days past the end of each reporting period representing the non-cancelable period of each agreement.  These estimates for variable consideration are based on historical service volumes with our customers and prices with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn&#8217;t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of consideration that is expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the components of variable consideration.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as changes in volume and actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer&#8217;s ability to pay are recorded as an adjustment to the allowance for credit losses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserve for Missing Medical Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment in rental service consists of equipment that the Company purchases from third-parties and is (1) for sale or rent, and (2) used in service to generate rental revenue. The Company periodically performs an analysis to identify potentially missing medical equipment and records a reserve equal to the underlying net book value. The Company determines the need for a reserve based upon the length of time a pump has been in the field without evidence of existence. The Company's basis for determining the need for a reserve is based upon historical experience and other meaningful observable information. The reserve is equal to the underlying net book value of the medical equipment considered missing, which was $2.7 million and $2.5 million as of December&#160;31, 2025 and 2024, respectively. The expense related to adjustments in the reserve is recorded to cost of revenues on the Consolidated Statements of Operations and Comprehensive Income.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_73"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosure About Market Risk.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from changes in foreign currency exchange rates and short-term interest rates. Market risks for changes in interest rates relate primarily to our debt obligations under our 2021 Credit Agreement, as amended. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in our functional currency which is the U.S. Dollar ("USD") and include exposures primarily to the Canadian Dollar.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. We did not have any foreign currency derivative contracts outstanding at any time during the three-year period ended December&#160;31, 2025. The maximum length of time over which we hedge our exposure to short-term interest rate risk is equal to the remaining term for the debt obligation being hedged. We had interest rate derivative contracts with a notional value of $20.0 million as of December&#160;31, 2025 and 2024, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not enter into derivative financial instruments for speculative or trading purposes. Our hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to accumulated other comprehensive loss in the Company's consolidated balance sheets.&#160;When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive income is recorded in earnings in the consolidated statement of income on the same line as the gain or loss on the hedged item attributable to the hedged risk.&#160;We record the ineffective portion of interest rate hedging instruments, if any, to interest expense in the consolidated statement of operations and comprehensive income. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_127">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements for information related to the fair values of derivative instruments in our consolidated balance sheets as of December&#160;31, 2025 and 2024 and information related to the effect of derivative instruments included in our Consolidated statement of operations and comprehensive income including the amount of unrealized gain associated with our interest rate derivatives reported in accumulated other comprehensive income that was reclassified into earnings during 2025 and 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounts such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument&#8217;s full term.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company amended its 2021 Credit Agreement with the First Amendment, discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_124">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements, to provide for the replacement of USD LIBOR with Term SOFR as a benchmark interest rate indexed to revolving loans. On May 11, 2023, the Company settled its two outstanding interest rate swap agreements, which were indexed to USD LIBOR, and entered into a new interest rate swap agreement indexed to SOFR to coincide with the index change in the 2021 Credit Agreement, as amended. The swap agreement has a notional value of $20.0 million, which is equal to the combined notional value of the two settled swap agreements. The term of the swap agreement, which matches the April 26, 2028 expiration date of the 2021 Credit Agreement, as amended, extends past the term of the settled swap agreements by approximately 26 months. Because of the hedging relationships, a change of 50% in the market rate of SOFR would not have a material impact on our financial results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Index to Financial Statements</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:91.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_82">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> (Deloitte &amp; Touche LLP; Detroit, MI; PCAOB ID# <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-51">34</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_79">37</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_88">Consolidated Balance Sheets as of December&#160;31, </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_88">20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_88">25</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_88"> and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_88">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_91">Consolidated Statements of Operations and Comprehensive Income for the years ended December&#160;31, </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_91">2025</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_91"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_91">24</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_91">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_94">Consolidated Statements of Stockholders&#8217;&#160;Equity for the years ended December&#160;31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_94">25</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_94"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_94">24</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_94">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_97">Consolidated Statements of Cash Flows for the years ended December&#160;31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_97">25</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_97"> and </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_97">202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_97">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_97">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_100">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_100">44</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of InfuSystem Holdings, Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of InfuSystem Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2025 and 2024, the related consolidated statements of operations and comprehensive income, stockholders&#8217; equity, and cash flows, for each of the two years in the period ended December&#160;31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2025, and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December&#160;31, 2025, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February&#160;27, 2026, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net and Net Revenues - Third-Party Payer Rental Accounts Receivable and Revenue Price Concessions - Refer to Notes 2 and 4 to the Financial Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management records third-party payer rental accounts receivable and related revenue for medical equipment and certain related disposable supplies at their net realizable values. Due to the nature of the industry and the reimbursement environment in which the Company operates, the Company estimates price concessions, which represent variable consideration resulting from differences between the rates charged and expected reimbursements, in order to record third-party payer rental accounts receivable and related revenues at their net realizable values. These price concessions are based on historical collection trends of third-party payer rental accounts receivable and revenue. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We identified the estimate of third-party payer rental accounts receivable and related revenue price concessions as a critical audit matter because of the significant judgments made by management to reduce third-party payer rental accounts receivable and revenue to their net realizable value. A high degree of auditor judgment and an increased extent of effort was required when performing audit procedures to evaluate management's estimate of price concessions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to management's estimate of price concessions recorded to reduce third-party payer rental accounts receivable and revenues to their net realizable value included the following, among others:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating the methodology and assumptions used by management in determining the estimated price concessions.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing the source information used by management in determining the estimated price concessions.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing the mathematical accuracy of management's calculation of the estimated price concessions.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating management's ability to accurately estimate price concessions by comparing prior year estimates to actual collection results.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-52">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-53">Detroit, Michigan</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;27, 2026</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except par value and share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-54">3,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="f-55">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">22,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">21,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-58">5,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-59">6,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">4,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">3,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">36,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">32,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Medical equipment for sale or rental</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRental" format="ixt:num-dot-decimal" scale="3" id="f-64">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRental" format="ixt:num-dot-decimal" scale="3" id="f-65">3,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Medical equipment in rental service, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-66">34,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-67">39,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property &amp; equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-68">3,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-69">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-70">3,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-71">3,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-72">6,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-73">6,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-74">4,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-75">5,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-76">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-77">7,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" scale="3" id="f-78">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-81">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-82">100,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-83">103,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">LIABILITIES AND STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"> EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">10,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">9,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">9,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">7,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">20,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">17,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Long-term debt, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">19,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">23,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">3,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">4,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-94">43,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-95">46,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-97">0.0001</ix:nonFraction></ix:nonFraction> par value: authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-99">1,000,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-101">none</ix:nonFraction></ix:nonFraction> issued</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-104"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-105">0.0001</ix:nonFraction></ix:nonFraction> par value: authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-107">200,000,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-109">20,209,636</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-111">21,272,351</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-112">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-113">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-114">117,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-115">113,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-116">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-117">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Retained deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-118">60,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-119">57,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-120">57,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-121">57,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">100,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">103,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-124">143,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-125">134,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-126">63,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-127">64,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-128">80,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-129">70,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Selling, general and administrative expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-130">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-131">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Selling and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">10,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">11,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">56,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">51,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-136">68,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-137">63,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">11,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">6,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-140">1,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-141">1,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-142">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-143">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-144">10,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-145">5,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-146">3,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-147">2,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">6,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-151">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-152">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-154">20,657,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-155">21,271,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-156">21,097,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157">21,707,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-158">6,627</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">2,345</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain (loss) on hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" scale="3" id="f-160">733</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" scale="3" id="f-161">40</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Provision for) benefit from income tax on unrealized hedge gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" scale="3" id="f-162">179</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" scale="3" id="f-163">9</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-164">554</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-165">31</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-166">6,073</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-167">2,376</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EQUITY</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.686%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.150%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Par Value<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Retained <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-168">21,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">109,837</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">58,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">1,088</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">52,302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued upon restricted stock vesting and option exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="f-174">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="f-175">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="f-176">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-177">4,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-178">4,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-179">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="f-180">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="f-181">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock repurchased as part of share repurchase program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="3" id="f-182">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-183">1,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-184">1,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-185">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-186">816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-187">816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-188">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-189">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-192">21,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-193">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">113,868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">57,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">1,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">57,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued upon restricted stock vesting and option exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="f-198">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="f-199">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="f-200">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-201">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-202">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-203">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="f-204">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="f-205">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock repurchased as part of share repurchase program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="f-206">1,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-207">9,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-208">9,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-209">133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-210">1,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-211">1,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-212">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-213">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">6,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">6,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-216">20,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-217">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">117,461</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">60,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-220">565</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">57,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-222">6,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-223">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Provision for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-224">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-225">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-226">12,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-227">11,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss on disposal of and reserve adjustments for medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="f-228">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="f-229">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Gain on sale of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="f-230">3,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="f-231">2,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-232">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-233">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of deferred debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-234">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-235">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-236">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-237">4,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-238">2,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-239">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Changes in assets - (increase)/decrease:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-240">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-241">701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-242">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-243">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-244">903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-245">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-246">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-247">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Changes in liabilities - (decrease)/increase:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="f-248">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="f-249">676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-250">24,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-251">20,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of business</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-252">1,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Purchase of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-254">8,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-255">16,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-256">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-257">1,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds from sale of medical equipment, property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-258">3,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-259">4,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">NET CASH USED IN INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-260">6,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-261">13,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Principal payments on long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="3" id="f-262">52,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="3" id="f-263">56,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash proceeds from long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-264">48,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-265">50,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-266">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock repurchased as part of share repurchase program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-268">9,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-269">1,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 35.57pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-270">1,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-271">816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash proceeds from exercise of options and ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-272">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-273">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">NET CASH USED IN FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-274">14,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-275">6,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-276">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-277">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-278">527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-279">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-280">3,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-281">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain supplementary cash flow information:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-282">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-283">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-284">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-285">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">NON-CASH TRANSACTIONS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions to medical equipment and property (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-286">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-287">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a) <ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Amounts consist of current liabilities for medical equipment and property that have not been included in investing activities. These amounts have not been paid for as of December 31, 2025 and 2024, respectively, but will be included as a cash outflow from investing activities for purchases of medical equipment and property when paid.</ix:footnote></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_103"></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccounting" id="f-288" continuedAt="f-288-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt">Basis of Presentation and Nature of Operations</span></ix:nonNumeric></div><ix:continuation id="f-288-1"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem Holdings, Inc. and its consolidated subsidiaries (collectively, the &#8220;Company&#8221;) are a leading national provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from <ix:nonFraction unitRef="location" contextRef="c-1" decimals="INF" name="infu:NumberOfLocations" format="ixt-sec:numwordsen" scale="0" id="f-289">seven</ix:nonFraction> locations in the United States ("U.S.") and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site healthcare providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem, Inc. is the operating subsidiary of the Company. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s core service is supplying electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company&#8217;s pumps are electronic infusion pumps. ICU Medical, Inc. supplied approximately <ix:nonFraction unitRef="number" contextRef="c-28" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-290">60</ix:nonFraction>% of the ambulatory pumps purchased by the Company in 2025. The Company has a supply agreement in place with this supplier. Certain &#8220;spot&#8221; purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (&#8220;NPWT&#8221;) medical equipment, as well as related disposables and ancillary supplies.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company&#8217;s ambulatory infusion pump management service.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_106"></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-291" continuedAt="f-291-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt">Summary of Significant Accounting Policies</span></ix:nonNumeric></div><ix:continuation id="f-291-1" continuedAt="f-291-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-292" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-293" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-294">two</ix:nonFraction> reportable segments, Patient Services and Device Solutions based on management's view of its business for purpose of evaluating performance and making operating decisions. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company&#8217;s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker ("CODM"), reviews segment financial information. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_142">Note 14</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for segment disclosures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-295" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-296" continuedAt="f-296-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-2" continuedAt="f-291-3"><ix:continuation id="f-296-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions.  For intangible assets, the Company typically uses the income approach to determine their estimated fair values. Key estimates and assumptions in that approach include the amount and timing of projected future cash flow, the discount rate selected to measure the risks inherent in those cash flows and the assessment of the asset's useful life. Initial purchase price allocations are subject to revision within the measurement period, not to exceed one year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-297" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains substantially all of its cash and cash equivalents primarily with <ix:nonFraction unitRef="financial_institution" contextRef="c-4" decimals="INF" name="infu:NumberOfFinancialInstitutions" format="ixt-sec:numwordsen" scale="0" id="f-298">two</ix:nonFraction> financial institutions that are insured with the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits. Accounts at banks with an aggregate excess of the amount of outstanding checks over the cash balances are included in accounts payable in current liabilities in the consolidated balance sheet. At December&#160;31, 2025, and 2024, the Company did not have any cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-299" continuedAt="f-299-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from multiple sources including from the sale and rental of our products as well as service contracts. Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") stipulates revenue recognition at the time and in an amount that reflects the consideration expected to be entitled for the performance obligations that have been provided. ASC 606 defines contracts as creating enforceable rights and may be established through written contracts, oral agreements and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three separate and distinct performance obligations offered to its customers: a rental service performance obligation, a product sale performance obligation and a service performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial payers, government insurance payers, medical facilities and patients.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates a significant amount of its revenues that are accounted for under ASC 606 from the rental service of infusion pumps to its customers and the remainder of its revenue from product sales and services. For the rental service performance obligation revenue is based on its standalone price, determined using reimbursement rates established by third-party payer or other contracts. Revenue is recognized over the contract term in the period in which the related performance obligation is satisfied. The Company&#8217;s revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms, or when the customer uses the products in the case of when our products are stored at a customer's location. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products. The Company's revenues related to services are recognized as the service work is completed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and product performance obligations. These judgments include, among others, the estimation of variable consideration. The Company allocates variable consideration using standalone selling price when appropriate and available. When an appropriate standalone selling price is not available, the Company allocates based on a best estimate approach using the relative fair market value. Variable factors include differences in transaction price and changes in the expected total volume of services during the contract period.  In calculating the variable amount of revenue for these performance obligations, variable consideration is estimated as price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other customer concessions. The contract period starts at contract inception and typically extends 30 days past the end of each reporting period representing the non-cancelable period of each agreement.  These estimates for variable consideration are based on historical service volumes with our customers and prices with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn&#8217;t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that is expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the components of variable consideration.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-3" continuedAt="f-291-4"><ix:continuation id="f-299-1"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as changes in volume and actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer&#8217;s ability to pay are recorded as an adjustment to the allowance for credit losses.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LessorLeasesPolicyTextBlock" id="f-300" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Arrangements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generates its revenues from the rental of infusion pumps to its customers as leases. Under Accounting Standards Codification Topic 842, "Leases" ("ASC 842"), leases may be classified as either financing, sales-type, or operating, and the Company is required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition and classification within the statement of operations. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient for all qualifying non-lease components. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial insurance payers, government insurance payers, medical facilities and patients.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily participates in operating leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. The Company&#8217;s operating leases are primarily for medical equipment under operating lease arrangements that expire at various dates over the next twelve months. The Company&#8217;s leases do not contain any restrictive covenants. Most of the Company&#8217;s equipment leases do not contain any material residual value guarantees. For the agreements that have guarantees, the residual value reflects management's best estimate of the expected sales price for the equipment at lease termination based on sales history adjusted for recent trends in the expected exit markets. The Company&#8217;s equipment leases may contain renewal options which range from one week to <ix:nonNumeric contextRef="c-29" name="us-gaap:LessorOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-301">one year</ix:nonNumeric>. Lease payments receivable reflect contractual lease payments adjusted for renewal or termination options that the Company believe the customer is reasonably certain to exercise. As of December&#160;31, 2025, the Company did not have any operating leases that contained renewal options with increasing rental amounts. Many of the Company's leases allow the customer to extend the lease at prevailing market terms. The Company's operating leased assets are not protected against casualty loss through third-party insurance.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates, including management's assessment of probability of collection, are required to record revenue and accounts receivable at their net realizable values, otherwise, if probability of collection is not met, the Company records revenue for such leases on a cash basis. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in variable lease payments that require adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. The Company adjusts revenue for historical trends on revenue adjustments due to timely filings, deaths, and other types of analyzable adjustments on a monthly basis to record rental revenue at the expected collectible amounts. Consistent with Accounting Standards Codification Topic 450, "Contingencies", for contracts where collection is considered probable, accounts receivable is reduced by an allowance for credit losses which provides for those accounts from which payment is not expected to be received although product was delivered and revenue was earned. The Company records an allowance for credit losses based upon an analysis of historical collections. The Company has elected to record the adjustments to accounts receivables in net revenues on the <span style="-sec-ix-hidden:f-302"><span style="-sec-ix-hidden:f-303">Consolidated Statements of Operations and Comprehensive Income</span></span>. The determination that an account is uncollectible, and the ultimate write-off of that account occurs once collection is considered to be highly unlikely, and it is written-off and charged to the allowance at that time.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also participates in sales-type leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. In a sales-type lease, lessors are required to recognize a lease receivable, selling profit, initial indirect costs, and residual asset values for all of these types of leases, and to disclose key information about leasing arrangements. The Company&#8217;s sales-type leases are primarily for medical equipment under sales-type lease arrangements that expire at various dates over the next <ix:nonNumeric contextRef="c-4" name="us-gaap:LessorSalesTypeLeaseTermOfContract1" format="ixt-sec:durwordsen" id="f-304">three years</ix:nonNumeric>. The Company&#8217;s leases do not contain any restrictive covenants. The Company&#8217;s equipment leases do not contain any material residual value guarantees or renewal options.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease revenue for leased assets is recognized in net revenue. The Company further recognizes any variable lease payments that are not included in the net investment in the lease as income in profit or loss in the period when the changes in facts and circumstances on which the variable lease payments are based occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-305" continuedAt="f-305-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowance for Credit Losses, and Contingencies</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts billed that have not yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at net </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-4" continuedAt="f-291-5"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-305-1">realizable value, inclusive of adjustments for variable consideration. These adjustments reflect the amounts expected to be collected from payers based on an analysis of historical collections. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for credit losses, and contingencies, is established as a result of an adverse change in the Company&#8217;s payers&#8217; ability to pay outstanding billings.</ix:continuation> The allowance for credit losses was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-306">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-307">0.2</ix:nonFraction> million as of December&#160;31, 2025 and 2024, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-308" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (first-in, first-out basis) or net realizable value. Cost primarily represents the purchase price paid for the items on hand. The Company periodically performs an analysis of slow-moving inventory and records an adjustment to reflect the recoverable amount.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="infu:MedicalEquipmentPolicyTextBlock" id="f-309" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment (&#8220;Equipment&#8221;) consists of equipment that the Company purchases from third-parties and is (1) held for sale or rent, and (2) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically <ix:nonNumeric contextRef="c-1" name="infu:MedicalEquipmentInRentalServicesUsefulLife" format="ixt-sec:durwordsen" id="f-310">seven years</ix:nonNumeric>. The Company does not depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a gain or loss is recorded in the current period. The Company periodically performs an analysis to identify potentially missing Equipment and records a reserve equal to the underlying net book value, which was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="infu:MedicalEquipmentInRentalServicesReserve" scale="6" id="f-311">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="infu:MedicalEquipmentInRentalServicesReserve" scale="6" id="f-312">2.5</ix:nonFraction> million as of December&#160;31, 2025 and 2024, respectively. This amount approximates the accelerated depreciation the Company would recognize over the remaining useful lives of the assets determined to be missing. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="infu:MedicalEquipmentHeldForSaleOrRentalReserve" scale="6" id="f-313"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="infu:MedicalEquipmentHeldForSaleOrRentalReserve" scale="6" id="f-314">0.1</ix:nonFraction></ix:nonFraction> million as of both December&#160;31, 2025 and 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Medical Equipment in the Consolidated Statements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (&#8220;Unallocated Assets&#8221;). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its two primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-315" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from <span style="-sec-ix-hidden:f-316">three</span> to <ix:nonNumeric contextRef="c-29" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-317">seven years</ix:nonNumeric>. Externally purchased information technology software and hardware are depreciated over <span style="-sec-ix-hidden:f-318">three</span> and <ix:nonNumeric contextRef="c-33" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-319">five years</ix:nonNumeric>, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are expensed to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-320" continuedAt="f-320-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-320-1">Goodwill is tested for impairment annually or more frequently when certain events or circumstances trigger a review. Management has the option to first assess qualitative factors such as current performance and overall economic conditions to determine whether or not it is necessary to perform a quantitative goodwill impairment test. If the Company chooses that option, then the Company would not be required to perform a quantitative goodwill impairment test unless the Company determines that, based on a qualitative assessment, it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines that an impairment is more likely than not, or if the Company chooses not to perform a qualitative assessment, the Company will then proceed with the quantitative assessment. Under the quantitative test, if the fair value of a reporting unit exceeds its carrying amount, then goodwill of the reporting unit is considered to not be impaired. If the carrying amount of the reporting unit exceeds its fair value, then an impairment loss is recognized in an amount equal to the excess, up to the value of the goodwill. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that there was no impairment.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-5" continuedAt="f-291-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-321" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of trade names, physician and customer relationships, unpatented technology, non-competition agreements and software. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from <span style="-sec-ix-hidden:f-322">fifteen</span> to <ix:nonNumeric contextRef="c-35" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-323">twenty years</ix:nonNumeric>. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others. The useful lives of these relationships are based on the expected attrition rates. Acquired software is amortized on a straight-line basis over the period of expected benefit, which ranges from <span style="-sec-ix-hidden:f-324">three</span> to <ix:nonNumeric contextRef="c-37" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-325">five years</ix:nonNumeric>. Acquired unpatented technology arose from recent acquisitions and is amortized on a straight-line basis over the period of expected benefit, which is <ix:nonNumeric contextRef="c-38" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-326">seven years</ix:nonNumeric>. This asset represents acquired knowledge of repair solutions that will be leveraged into opportunities into the acute care market. The non-competition agreements arose from recent acquisitions and are amortized on a straight-line basis over the terms of the agreements, which is <ix:nonNumeric contextRef="c-39" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-327">five years</ix:nonNumeric>. Trade names associated with the original acquisition of InfuSystem are not amortized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. Management has the option of first performing the impairment test for intangible assets with indefinite lives on a qualitative basis, by evaluating factors to determine whether it is more likely than not that an impairment exists. If it is more likely than not that an impairment exists, or if the Company chooses not to perform a qualitative assessment, then a quantitative impairment test is performed. Impairment exists when the carrying amount of the intangible asset exceeds its fair value. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in <ix:nonFraction unitRef="usd" contextRef="c-40" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-328">no</ix:nonFraction> impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CapitalizationOfInternalCostsPolicy" id="f-329" continuedAt="f-329-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization and Depreciation</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-329-1">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of <span style="-sec-ix-hidden:f-330">three</span> to <ix:nonNumeric contextRef="c-37" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-331">five years</ix:nonNumeric>. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred.</ix:continuation> The Company did <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:fixed-zero" scale="0" id="f-332"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:fixed-zero" scale="0" id="f-333">not</ix:nonFraction></ix:nonFraction> capitalize any internal-use software for the year ended December&#160;31, 2025, and 2024. Amortization expense for capitalized software was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="f-334"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="f-335">0.1</ix:nonFraction></ix:nonFraction> million as of both December&#160;31, 2025 and 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. For the year ended December&#160;31, 2025, the Company assessed the impairment indicators and found <ix:nonFraction unitRef="usd" contextRef="c-41" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-336">none</ix:nonFraction> to be present.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-337" continuedAt="f-337-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-337-1">Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value may not be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management&#8217;s best estimates, appropriate assumptions and projections at the time. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.</ix:continuation> For the years ended December&#160;31, 2025 and 2024, respectively, the Company assessed the impairment indicators and found <ix:nonFraction unitRef="usd" contextRef="c-41" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-338"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-339">none</ix:nonFraction></ix:nonFraction> to be present.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-340" continuedAt="f-340-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For policies related to the Company acting as a lessor, refer to the "Lease Arrangements" policy section above.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the policies related to the Company as lessee, under ASC 842, lessees are required to recognize a lease liability and right-of-use asset (&#8220;ROU asset&#8221;) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-6" continuedAt="f-291-7"><ix:continuation id="f-340-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than twelve months.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient. The company also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did not recognize ROU assets and lease liabilities for these leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In adopting ASC 842, the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company&#8217;s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-341">seven years</ix:nonNumeric>. The Company&#8217;s leases do not contain any restrictive covenants. The Company&#8217;s office leases generally contain renewal options for periods ranging from <span style="-sec-ix-hidden:f-342">one</span> to <ix:nonNumeric contextRef="c-29" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-343">five years</ix:nonNumeric>. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company&#8217;s office leases do not contain any material residual value guarantees. The Company&#8217;s equipment leases generally do not contain renewal options. The Company is not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company&#8217;s office leases, the implicit rate is typically not available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments due under the Company&#8217;s operating leases include fixed payments as well as variable payments. For the Company&#8217;s office leases, variable payments include amounts for the Company&#8217;s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company&#8217;s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="infu:RevenueRecognitionCostOfRevenuePolicyTextBlock" id="f-344" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues include the costs of servicing and maintaining pumps, products and services sold, shipping, depreciation of medical equipment, and other direct and indirect costs related to net revenues, and these expenses are expensed as incurred. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-345" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and 2024, the Company had contracts with nearly <ix:nonFraction unitRef="network" contextRef="c-4" decimals="0" name="infu:NumberOfContractsWithThirdParties" scale="0" id="f-346">840</ix:nonFraction> and <ix:nonFraction unitRef="network" contextRef="c-5" decimals="0" name="infu:NumberOfContractsWithThirdParties" scale="0" id="f-347">835</ix:nonFraction> third-party payer networks, respectively. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of <ix:nonNumeric contextRef="c-1" name="infu:TermOfContract" format="ixt-sec:durwordsen" id="f-348">one year</ix:nonNumeric>, with automatic <ix:nonNumeric contextRef="c-1" name="infu:TermOfRenewal" format="ixt-sec:durwordsen" id="f-349">one-year</ix:nonNumeric> renewals, unless the Company or the contracted payer elect not to renew. The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of its Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of the Company's net revenue in 2025 or 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-350" continuedAt="f-350-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred&#160;income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all of any deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities.&#160;Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a two-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-not that the position will be </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-7" continuedAt="f-291-8"><ix:continuation id="f-350-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sustained upon examination. Second, for positions that are determined are more-likely-than-not to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than 50% likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="infu:TreasuryStockPolicyPolicyTextBlock" id="f-351" continuedAt="f-351-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-351-1">The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which may include open market transactions or privately negotiated transactions and may be made under a Rule 10b5-1 plan, or in targeted stock purchase agreements approved by the Board. Treasury stock is accounted for using the par value method.</ix:continuation> As of December&#160;31, 2025 and 2024, respectively, the Company did <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:TreasuryStockSharesRetired" format="ixt:fixed-zero" scale="0" id="f-352"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:TreasuryStockSharesRetired" format="ixt:fixed-zero" scale="0" id="f-353">not</ix:nonFraction></ix:nonFraction> have any shares being held in treasury.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-354" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, &#8220;Share-Based Awards&#8221;) on the date of grant using either the grant date price of the Company's common stock or option-pricing models which are affected by the Company&#8217;s stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company&#8217;s expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company&#8217;s stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. Forfeitures are recognized as they occur. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company also determines the fair value of performance-based restricted stock units (&#8220;PSUs&#8221;) based upon the type of performance measure. These awards typically vest after the Company&#8217;s achievement of either a specific Company performance metric or when the market value of the Company&#8217;s stock meets a specific metric such as when the closing price of the Company's stock reaches a target value for a minimum number of consecutive trading days. Under FASB Accounting Standards Codification Topic 718, "Compensation: Stock Compensation", the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A third-party valuation expert was engaged to prepare a &#8220;Monte Carlo simulation&#8221; to account for the market condition to assist management in its conclusion of fair value. That simulation takes into account the beginning stock price of the Company&#8217;s common stock, the expected volatilities for the Company&#8217;s stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. Compensation costs are accelerated if the market condition is satisfied prior to the end of the service period derived under the Monte Carlo simulation. The grant date fair value of the other PSUs is calculated as the closing price of the Company&#8217;s common stock on the grant date multiplied by the number of shares estimated to be delivered subject to the award terms. Company performance measure goals are considered a performance condition and the timing and amount of compensation cost for those PSUs corresponds with management&#8217;s expectation of the probable outcome of the performance conditions as of the grant date and during the vesting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredChargesPolicyTextBlock" id="f-355" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Debt Issuance Costs</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized debt issuance costs as of December&#160;31, 2025 and 2024 relate to the Company&#8217;s credit facility. The costs related to the agreement are netted against current and non-current debt and is recognized in Interest expense. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-356" continuedAt="f-356-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its earnings per share which includes the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the 2014 and 2021 stock incentive plans. Anti-dilutive stock awards are comprised of stock options and unvested </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-8" continuedAt="f-291-9"><ix:continuation id="f-356-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method. In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-357" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Numerator (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-358">6,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-359">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-360">20,657,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-361">21,271,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-362">439,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-363">435,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-364">21,097,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-365">21,707,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options of <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-366">2,072,460</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-367">1,950,403</ix:nonFraction> shares were not included in the calculation for the years ended December&#160;31, 2025 and 2024, respectively, because they would have an anti-dilutive effect.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-368" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company&#8217;s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (&#8220;AOCI&#8221;) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s derivative financial instruments are categorized as Level II of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-369" continuedAt="f-369-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets as of December&#160;31, 2025 and 2024 for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company&#8217;s long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted Accounting Standards Codification Topic 820, "Fair Value Measurement", which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;quoted prices in active markets for identical instruments;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level II</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-9"><ix:continuation id="f-369-1"><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level III</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;significant inputs to the valuation model are unobservable.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-370" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements and Developments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#8221; (&#8220;ASU 2023-09&#8221;). ASU 2023-09 enhances existing income tax disclosures primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments in this ASU require public entities to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. Public entities are also required to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes and also disaggregated by individual jurisdictions. The Company adopted the standard on January 1, 2025.  Because the ASU affects disclosure requirements only, adoption did not impact the Company's consolidated financial position, results of operations, or cash flows.  See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which reflects the expanded disclosures required under the amended guidance.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued Accounting Standards Update 2024-03, &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221; (&#8220;ASU 2024-03&#8221;), which requires disclosures, in the notes to the financial statements, about the types of expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In July 2025, the FASB issued Accounting Standards Update 2025-05, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&#8221; (&#8220;ASU 2025-05&#8221;), which provides a practical expedient election that assumes current conditions as of the balance sheet date remain unchanged when developing forecasts for estimating expected credit losses. ASU 2025-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2025, with early adoption permitted.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently evaluating the impact of ASU 2025-05 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">n September 2025, the FASB issued Accounting Standards Update 2025-06, &#8220;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), Targeted improvements to the Accounting for Internal-Use Software&#8221; (&#8220;ASU 2025-06&#8221;), to update accounting for software costs that are accounted for under Subtopic 350-40. The ASU 2025-06 removes all references to prescriptive and sequential software development stages throughout Subtopic 350-40. The amendments in ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company&#8217;s project to replace its enterprise resource planning application is expected to be completed prior to the required adoption period. The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">n December 2025, the FASB issued Accounting Standards Update 2025-09, "Derivatives and Hedging (Topic 815): Hedge Accounting Improvements" ("ASU 2025-09"), which provides clarifications to certain hedge accounting requirements.  The amendments are intended to improve consistency in the application of hedge effectiveness and related disclosures.  The standard is effective for fiscal years beginning after December 15, 2026.  The Company is currently evaluating the impact of ASU 2025-09 on its consolidated financial statements and disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_109"></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-372" continuedAt="f-372-1" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="f-372-1" continuedAt="f-372-2"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions Accounted for Using the Purchase Method</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company acquired certain assets of Apollo Medical Supply (&#8220;Apollo&#8221;), a privately-held wound care service company based in Florida. As part of the Company&#8217;s Patient Services segment, this acquisition supplements the Company&#8217;s existing wound care business by providing access to an advanced patient service fulfillment know-how and software platform that the Company plans to integrate into its existing operations. Apollo&#8217;s results of operation are included in the Company&#8217;s consolidated statements of operations and comprehensive income since the Closing Date.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, &#8220;Business Combinations,&#8221; the purchase price for the acquisition was allocated to the assets acquired and liabilities assumed based upon their estimated fair values as of the respective acquisition date. The preliminary purchase price allocation was primarily based upon a valuation using </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-372-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s estimates and assumptions. Upon completion of the final purchase price allocation, the Company expects to specifically identify intangible assets and allocate the excess of the purchase price over the net assets to goodwill, if any. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-373" continuedAt="f-373-1" escape="true">The preliminary allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-373-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.252%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Apollo</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="f-374">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" id="f-375">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-376">1,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="f-377">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-378">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company updated the valuation of Apollo with immaterial changes in accounts receivable, intangible assets and other liabilities. As the amounts are immaterial, the unaudited pro forma financial information has not been presented.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-379" continuedAt="f-379-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-379-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-380" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s disaggregated revenue by offering type (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services revenue recognized at a point in time:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-381">2,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-47" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-382">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-383">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-49" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-384">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third-Party Payer products</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-385">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-51" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-386">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-387">15,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-53" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-388">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services revenue recognized over time:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct rental services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-389">7,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-55" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-390">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-391">7,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-57" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-392">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third-Party Payer rental services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-393">50,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-394">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-395">47,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-61" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-396">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Patient Services accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-397">78,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-398">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-399">72,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-400">53.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions revenue recognized at a point in time:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-401">17,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-402">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-403">16,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-404">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-405">11,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-406">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-407">8,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-408">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions revenue recognized over time:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-409">5,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-410">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-411">8,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-412">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Device Solutions accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-413">34,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-414">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-415">33,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-416">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue Accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-417">113,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-418">78.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-419">106,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-420">78.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services Lease Revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-421">8,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-422">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-423">7,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-424">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions Lease Revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-425">22,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-426">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-427">20,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-428">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue accounted for under ASC 842</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-429">30,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-430">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-431">28,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-432">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Revenue</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-433">143,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-434">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-435">134,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-436">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-437" escape="true"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.668%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Change in 2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-438">22,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-439">21,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-440">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:ContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-441">1,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:ContractAssets" scale="3" id="f-442">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="infu:ContractAssets" scale="3" id="f-443">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:ContractLiabilities" scale="3" id="f-444">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:ContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="infu:ContractLiabilities" scale="3" id="f-446">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The change in contract assets during the fiscal year ended December&#160;31, 2025 was mainly due to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="infu:ContractAssetsRevenuePartiallyOffsetAmount" scale="6" id="f-447">8.7</ix:nonFraction> million of contract assets reclassified to accounts receivable as our right to consideration for these contract assets became unconditional, partially offset by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="infu:ContractAssetsRevenueRecognized" scale="6" id="f-448">9.4</ix:nonFraction> million of revenue recognized for which the payment is subject to conditions other than the passage of time. Contract assets are included in other current assets on the Company's consolidated balance sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="infu:MedicalEquipmentAndPropertyDisclosureTextBlock" id="f-449" continuedAt="f-449-1" escape="true">Medical Equipment</ix:nonNumeric></span></div><ix:continuation id="f-449-1"><ix:nonNumeric contextRef="c-1" name="infu:ScheduleOfMedicalEquipmentTableTextBlock" id="f-450" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRentalGross" format="ixt:num-dot-decimal" scale="3" id="f-451">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRentalGross" format="ixt:num-dot-decimal" scale="3" id="f-452">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental - pump reserve</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRentalReserve" scale="3" id="f-453">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRentalReserve" scale="3" id="f-454">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental - net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRental" format="ixt:num-dot-decimal" scale="3" id="f-455">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentHeldForSaleOrRental" format="ixt:num-dot-decimal" scale="3" id="f-456">3,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentInRentalServicesGross" format="ixt:num-dot-decimal" scale="3" id="f-457">109,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentInRentalServicesGross" format="ixt:num-dot-decimal" scale="3" id="f-458">107,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service - pump reserve</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentInRentalServicesReserve" format="ixt:num-dot-decimal" scale="3" id="f-459">2,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentInRentalServicesReserve" format="ixt:num-dot-decimal" scale="3" id="f-460">2,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentInRentalServicesAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-461">71,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentInRentalServicesAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-462">65,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service - net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-463">34,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-464">39,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:MedicalEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-465">39,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:MedicalEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-466">42,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for medical equipment for the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="infu:DepreciationExpenseRelatedToMedicalEquipment" scale="6" id="f-467">11.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="infu:DepreciationExpenseRelatedToMedicalEquipment" scale="6" id="f-468">10.2</ix:nonFraction> million, respectively, which were recorded in &#8220;cost of revenues&#8221; for each period. The pump reserve for medical equipment in rental service represents an estimate for medical equipment that is considered to be missing. The reserve calculated is equal to the net book value of assets that have not returned from the field within a certain timeframe. Sales of the Company's medical equipment are included in net revenue.</span></div></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_118"></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-469" continuedAt="f-469-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-469-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-470" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-471">6,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-472">5,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-473">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-474">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-475">4,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-476">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Automobiles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-477">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-478">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-480">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-481">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-483">5,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-484">3,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-485">2,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-486">4,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-487">2,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-488">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-489">11,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-490">8,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-491">3,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-492">11,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-493">7,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-494">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property and equipment for each of the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationNonproduction" scale="6" id="f-495">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DepreciationNonproduction" scale="6" id="f-496">1.3</ix:nonFraction> million, respectively. This expense was recorded in &#8220;general and administrative expenses&#8221; for each period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-497" continuedAt="f-497-1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="f-497-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-498" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying value of goodwill by segment are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Device Solutions (a)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-499">3,710</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of December 31, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-501">3,710</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(a) The Patient Services segment has <ix:nonFraction unitRef="usd" contextRef="c-105" decimals="INF" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-502">no</ix:nonFraction> recorded goodwill. </span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="infu:CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" id="f-503" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nonamortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade names</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-504">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-505">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-506">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-507">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade names</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-508">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-509">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-511">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-512">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Physician and customer relationships</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-514">40,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-515">35,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-516">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-517">38,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-518">34,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-519">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unpatented technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-520">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-521">662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-522">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-523">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-524">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-525">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-competition agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-526">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-527">444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-528">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-529">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-530">349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-531">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-532">10,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-533">10,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-534">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-535">10,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-536">10,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-537">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total nonamortizable and amortizable intangible assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-538">53,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-539">47,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-540">6,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-541">52,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-542">46,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-543">6,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets for the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-544">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-545">1.0</ix:nonFraction> million, respectively, which was recorded in "amortization of intangibles expenses" for each period. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-546" continuedAt="f-546-1" escape="true">Expected remaining annual amortization expense for the next five years for intangible assets recorded as of December&#160;31, 2025 is as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-546-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2031 and <br/>thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="f-547">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="f-548">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="f-549">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-550">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="f-551">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-552">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_124"></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-553" continuedAt="f-553-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-553-1" continuedAt="f-553-2"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;5, 2021</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the Company entered into a Credit Agreement (the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2021 Credit Agreement&#8221;) with JPMorgan Chase Bank, N.A., as administrative agent (the &#8220;Agent&#8221;), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the 2021 Credit Agreement are InfuSystem Holdings, Inc. and its subsidiaries (collectively, the &#8220;Borrowers&#8221;).</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement provides for a revolving credit facility (the &#8220;Revolving Facility&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-554">75.0</ix:nonFraction> million. The Revolving Facility may be increased by $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" scale="6" id="f-555">25.0</ix:nonFraction> million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-556">7.0</ix:nonFraction> million in letters of credit subject to the satisfaction of certain conditions. The 2021 Credit Agreement has customary representations and warranties. The ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less <ix:nonFraction unitRef="number" contextRef="c-117" decimals="INF" name="infu:PercentageOfTotalDepreciationExpense" scale="-2" id="f-557">50</ix:nonFraction>% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of <ix:nonFraction unitRef="number" contextRef="c-118" decimals="INF" name="infu:DebtInstrumentCovenantMinimumFixedCoverageRatio" scale="0" id="f-558">1.20</ix:nonFraction> to 1.00; and</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-553-2" continuedAt="f-553-3"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of <ix:nonFraction unitRef="number" contextRef="c-118" decimals="INF" name="infu:DebtInstrumentCovenantMaximumLeverageRatio" scale="0" id="f-559">3.50</ix:nonFraction> to 1.00.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement includes customary events of default. The occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder. Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company entered into a First Amendment to the 2021 Credit Agreement (the &#8220;First Amendment&#8221;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things: (i) an extension of the maturity date for the 2021 Credit Agreement to April 26, 2028, (ii) the replacement of London Interbank Offered Rate with Adjusted Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as a benchmark interest rate, and (iii) an increase of the maximum dollar amount of incremental revolving loans from $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" scale="6" id="f-560">25</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" scale="6" id="f-561">35</ix:nonFraction>&#160;million. Incremental revolving loans continue to be subject to certain conditions, including the consent of the Agent and obtaining necessary commitments.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2025, the Company entered into a Second Amendment to the 2021 Credit Agreement (the &#8220;Second Amendment&#8221;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things, an extension of the maturity date for the 2021 Credit Agreement to July 15, 2030.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The First Amendment and Second Amendment were accounted for as debt modifications. As of December&#160;31, 2025, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement, as amended</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="f-562" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands):</span></div><div style="margin-top:10pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross availability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-563">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-564">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding draws</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-565">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-566">24,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Availability on Revolving Facility</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-567">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-568">50,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-569" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had future maturities of its long-term debt as of December&#160;31, 2025 as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2031 and <br/>thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="f-574">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-576">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="f-581">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-583">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-584" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a breakdown of the Company&#8217;s current and long-term debt (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Current<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Current<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="infu:LongTermDebtGrossCurrent" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="infu:LongTermDebtGrossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-586">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-587">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="infu:LongTermDebtGrossCurrent" format="ixt:fixed-zero" scale="3" id="f-588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="infu:LongTermDebtGrossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-589">24,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-590">24,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized value of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:UnamortizedDebtIssuanceExpenseCurrent" format="ixt:fixed-zero" scale="3" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:UnamortizedDebtIssuanceExpenseNoncurrent" scale="3" id="f-592">375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="f-593">375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:UnamortizedDebtIssuanceExpenseCurrent" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:UnamortizedDebtIssuanceExpenseNoncurrent" scale="3" id="f-595">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="f-596">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-598">19,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-599">19,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-601">23,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-602">23,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement, as amended, bear interest at a variable rate equal to, at the Company&#8217;s election, Adjusted Term SOFR for Term Benchmark loans or an Alternative Base Rate for ABR loans, as defined by the Second Amendment, plus a spread that will vary depending </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-553-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">upon the Company&#8217;s leverage ratio. The spread ranges from <ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-603">2.05</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-124" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-604">3.05</ix:nonFraction>% for Term Benchmark Loans and <ix:nonFraction unitRef="number" contextRef="c-125" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-605">1.05</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-126" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-606">2.05</ix:nonFraction>% for base rate loans. The weighted-average Term Benchmark loan rate at December&#160;31, 2025 was <ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-607">5.83</ix:nonFraction>% (Adjusted Term SOFR of <ix:nonFraction unitRef="number" contextRef="c-128" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-608">3.78</ix:nonFraction>% plus <ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-609">2.05</ix:nonFraction>%). The actual ABR loan rate at December&#160;31, 2025 was <ix:nonFraction unitRef="number" contextRef="c-130" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-610">7.80</ix:nonFraction>% (lender&#8217;s prime rate of <ix:nonFraction unitRef="number" contextRef="c-131" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-611">6.75</ix:nonFraction>% plus <ix:nonFraction unitRef="number" contextRef="c-132" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-612">1.05</ix:nonFraction>%).</span></div></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_127"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-613" continuedAt="f-613-1" escape="true">Derivative Financial Instruments and Hedging Activities</ix:nonNumeric></span></div><ix:continuation id="f-613-1" continuedAt="f-613-2"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a derivative investment policy which provides guidelines and objectives related to managing financial and operational exposures arising from market changes in short term interest rates. In accordance with this policy, the Company can enter into interest rate swaps or similar instruments, will endeavor to evaluate all the risks inherent in a transaction before entering into a derivative financial instrument and will not enter into derivative financial instruments for speculative or trading purposes. Hedging relationships are formally documented at the inception of the hedge and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 Credit Agreement. The Company uses an interest rate swap agreement to manage exposure arising from this risk.  The swap has a constant notional amount over a <ix:nonNumeric contextRef="c-133" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="f-614">five-year</ix:nonNumeric> term that ends on April 26, 2028. The agreement pays the Company 30-day SOFR on the notional amount and the Company pays a fixed rate of interest equal to <ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-615">1.74</ix:nonFraction>%. The Company does not have any other derivative financial instruments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-613-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-616" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Notional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Fair Value Derivative Assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-617">20,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" scale="3" id="f-618">748</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="21" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:40.57pt"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Notional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Fair Value Derivative Assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-619">20,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-620">1,481</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="21" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:40.57pt"><span><br/></span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-621" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.102%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Gain on cash flow hedges - interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-622">1,119</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-623">1,088</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="3" id="f-624">227</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="3" id="f-625">734</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amounts reclassified to interest expense (a)(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="f-626">506</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="f-627">694</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="3" id="f-628">179</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="3" id="f-629">9</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-630">565</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-631">1,119</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(a) Negative amounts represent interest income and positive amounts represent interest expense. Interest expense as presented in the consolidated statement of operations for the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-632">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-633">1.8</ix:nonFraction> million, respectively.</span></div></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(b) As of December&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" scale="6" id="f-634">0.3</ix:nonFraction> million of income is expected to be reclassified into earnings within the next 12 months.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" format="ixt:fixed-zero" scale="3" id="f-635"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="INF" name="us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" format="ixt:fixed-zero" scale="3" id="f-636">not</ix:nonFraction></ix:nonFraction> incur any hedge ineffectiveness during the years ended December&#160;31, 2025 and 2024, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-637" continuedAt="f-637-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-637-1" continuedAt="f-637-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, U.S. Congress enacted the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;), which included significant provisions modifying the U.S. tax framework. While the Company continues to evaluate the impact of OBBBA, these legislative changes did not and are not expected to have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-638" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s income before income taxes (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-639">9,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-640">3,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-641">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-642">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-643">10,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-644">5,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-645" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s components of the consolidated provision for income taxes (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S Federal income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-646">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-648">2,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-649">1,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. Federal income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-650">2,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-651">1,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-652">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-653">488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-654">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-655">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total state and local income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="f-656">982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="f-657">733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-658">513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-659">308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-660">3,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-661">2,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-662" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a reconciliation of the Company&#8217;s income tax (expense) benefit from the effective income tax rate to the U.S. federal statutory rate (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">% of Pretax Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">% of Pretax Income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at the statutory rate</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-663">2,231</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-664">21.0</ix:nonFraction></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-665">1,062</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-666">21.0</ix:nonFraction></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax expense, net of federal income tax effect</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-667">776</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-668">7.3</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-669">579</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-670">11.4</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Meals and Entertainment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-671">127</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="f-672">1.2</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-673">124</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="f-674">2.5</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="f-676">&#8212;</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-677">471</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-678">9.3</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-deductible Officer's Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" scale="3" id="f-679">491</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" scale="-2" id="f-680">4.6</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" scale="3" id="f-681">153</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" scale="-2" id="f-682">3.0</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Income for Canada Disregarded Entity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" scale="3" id="f-683">165</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" scale="-2" id="f-684">1.6</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" scale="3" id="f-685">171</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" scale="-2" id="f-686">3.4</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-687">34</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-688">0.3</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-689">2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" format="ixt:fixed-zero" scale="-2" id="f-690">&#8212;</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" format="ixt:fixed-zero" scale="3" id="f-691">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" format="ixt:fixed-zero" scale="-2" id="f-692">&#8212;</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" scale="3" id="f-693">78</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" scale="-2" id="f-694">1.6</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Tax Effects</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-695">240</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-696">2.3</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-697">72</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-698">1.4</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciling Adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="3" id="f-699">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-700">&#8212;</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="3" id="f-701">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-702">&#8212;</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit at effective income tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-703">3,996</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-704">37.6</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-705">2,714</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-706">53.6</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-637-2" continuedAt="f-637-3"><div style="margin-top:14pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> During 2025, state and local taxes in California, Kansas, Michigan, and Texas comprised the majority of the state and local income taxes, net of federal effect category.  During 2024, state and local taxes in Texas, Michigan, Kansas, Illinois, and New York comprised the majority of the state and local income taxes, net of federal effect category</span></div><div style="margin-top:14pt;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-707" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">The following table illustrates incomes taxes paid by jurisdiction (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" format="ixt:fixed-zero" scale="3" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" format="ixt:fixed-zero" scale="3" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S State and local</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Florida</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-710">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-711">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Georgia</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-712">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Illinois</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-713">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michigan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-714">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;New York</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-715">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pennsylvania</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-716">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Texas</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-717">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-718">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-719">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-720">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-721">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-722">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Canada</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxPaidForeignAfterRefundReceived" scale="3" id="f-723">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxPaidForeignAfterRefundReceived" scale="3" id="f-724">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-725">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-726">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a) The amount of income taxes paid during the year does not meet the 5% disaggregation threshold and is included in other.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-727" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Federal, state and local tax assets &#8211;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-728">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-729">4,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-730">2,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-731">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss (a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-732">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-733">3,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-734">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-735">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-736">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="f-737">801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="f-738">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="f-739">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-740">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-741">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="3" id="f-742">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="3" id="f-743">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-744">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-745">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred Federal, state and local tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-746">13,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-747">14,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Federal, state and local tax liabilities &#8211;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and asset basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-748">6,502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-749">4,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="3" id="f-750">731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="3" id="f-751">737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="infu:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-752">1,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="infu:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-753">1,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="3" id="f-754">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="3" id="f-755">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred Federal, state and local tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-756">8,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-757">7,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-758">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-759">7,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) At December&#160;31, 2025 and 2024, this includes state and local net operating losses of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-760">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-761">0.4</ix:nonFraction> million, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-637-3"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. federal net operating loss carryforward for tax purposes was $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-762">5.8</ix:nonFraction> million at December&#160;31, 2025, resulting in a federal deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-763">1.2</ix:nonFraction> million; such net operating loss carryforwards have an indefinite life. The Company&#8217;s state net operating loss carryforward of approximately $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-764">0.2</ix:nonFraction> million is comprised of various jurisdictions. These state net operating losses can be used for a period of <ix:nonNumeric contextRef="c-156" name="infu:OperatingLossCarryforwardsExpirationPeriods" format="ixt-sec:duryear" id="f-765">5</ix:nonNumeric> to <ix:nonNumeric contextRef="c-157" name="infu:OperatingLossCarryforwardsExpirationPeriods" format="ixt-sec:duryear" id="f-766">20</ix:nonNumeric> years and vary by state, and if unused, begin to expire in 2026, though a substantial portion expires beyond 2026. Approximately less than $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="infu:OperatingLossCarryforwardsWithADefiniteLife" scale="6" id="f-767">0.1</ix:nonFraction> million of the state net operating loss carryforwards have an indefinite life. Tax benefits of operating loss and tax credit carryforwards are evaluated on an ongoing basis, including a review of historical and projected future operating results, the eligible carryforward period, and other circumstances.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor shifts in past ownership (as defined under Section 382 of the Code).  The Company had <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-768"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-769">no</ix:nonFraction></ix:nonFraction> uncertain tax positions for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation for Federal and various state jurisdictions in the U.S. and Canada. The Federal income tax returns of the Company for the years 2022 through 2025 are open to examination by the Internal Revenue Service. The state income tax returns and other state tax filings of the Company are subject to examination by the state taxing authorities, for various periods generally up to four years after they are filed. Canadian income tax returns of the Company for the years 2020 through 2025 are subject to examination by the Canada Revenue Agency.</span></div></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_133"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-770" continuedAt="f-770-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-770-1"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time in the ordinary course of its business, the Company may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not at this time involved in any proceedings that the Company currently believes could have a material effect on the Company&#8217;s financial condition, results of operations or cash flows.</span></div></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_136"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="f-772" continuedAt="f-772-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-771" continuedAt="f-771-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-772-1" continuedAt="f-772-2"><ix:continuation id="f-771-1" continuedAt="f-771-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As Lessee:</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-773" continuedAt="f-773-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s operating lease costs consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-774">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-775">1,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-776">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-777">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-778">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-779">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs for the years ended December&#160;31, 2025 and 2024 of approximately $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-780">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-781">2.3</ix:nonFraction> million, respectively, were recorded to G&amp;A expenses. Expense related to short-term leases, which are not recorded on the Company's consolidated balance sheets, was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShortTermLeasePayments" scale="6" id="f-782">0.8</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:ShortTermLeasePayments" format="ixt-sec:numwordsen" scale="0" id="f-783">nil</ix:nonFraction> for the fiscal years ended December&#160;31, 2025, and 2024, respectively.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-772-2" continuedAt="f-772-3"><ix:continuation id="f-771-2" continuedAt="f-771-3"><ix:continuation id="f-773-1"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to the Company&#8217;s leases are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities and right of use assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-784">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-785">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-786">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-787">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increases to right of use assets resulting from lease modifications:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:IncreasesToRightOfUseAssetsResultingFromLeaseModifications" scale="3" id="f-788">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="infu:IncreasesToRightOfUseAssetsResultingFromLeaseModifications" format="ixt:fixed-zero" scale="3" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for the Company&#8217;s operating leases are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-790">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-791">5.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-792">7.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-793">7.9</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-794" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of December&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-795">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-796">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-797">1,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-798">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-799">818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="f-800">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-801">7,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-802">2,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-803">4,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The long-term portion of the lease liabilities included in the amounts above is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-804">3.4</ix:nonFraction> million with the remainder included in other current liabilities in the Consolidated Balance Sheets. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As Lessor</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient for all qualifying non-lease components.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="f-805" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s lease revenues consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-806">30,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-807">27,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseIncome" scale="3" id="f-808">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseIncome" scale="3" id="f-809">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-810">30,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-811">28,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-772-3"><ix:continuation id="f-771-3"><ix:nonNumeric contextRef="c-1" name="infu:NetInvestmentInSalesTypeLeasesTableTextBlock" id="f-812" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of our net investment in sales-type leases as of December&#160;31, 2025 and 2024 were (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseReceivable" format="ixt:num-dot-decimal" scale="3" id="f-813">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseReceivable" format="ixt:num-dot-decimal" scale="3" id="f-814">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" format="ixt:num-dot-decimal" scale="3" id="f-815">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" format="ixt:num-dot-decimal" scale="3" id="f-816">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December&#160;31, 2025 and 2024 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="f-817">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-818">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-819">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-820">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-821">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-822">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="f-823" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of sales-type leases as of December&#160;31, 2025 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sales-Type Leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" scale="3" id="f-824">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" scale="3" id="f-825">658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" scale="3" id="f-826">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" scale="3" id="f-827">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="f-828">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" scale="3" id="f-829">530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivable" format="ixt:num-dot-decimal" scale="3" id="f-830">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_139"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-831" continuedAt="f-831-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-831-1" continuedAt="f-831-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various stock option and stock-based incentive plans and agreements whereby equity based awards are granted to certain employees, directors and others approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or Compensation Committee. Grants may be made in the form of stock options, restricted stock awards ("RSUs" or "RSAs"), performance-based restricted stock units ("PSU's), unrestricted common stock in addition to other award types. Stock options are granted with an exercise price at, or above, fair market value on the date of grant, generally expire in <ix:nonNumeric contextRef="c-162" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-832">5</ix:nonNumeric> to <ix:nonNumeric contextRef="c-163" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-833">10</ix:nonNumeric> years from the grant date and generally become exercisable over a period of up to <ix:nonNumeric contextRef="c-164" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" format="ixt-sec:duryear" id="f-834">3</ix:nonNumeric> years. RSUs generally become vested over a period of up to <ix:nonNumeric contextRef="c-165" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-835">three years</ix:nonNumeric>. PSUs generally become vested over a period of up to <ix:nonNumeric contextRef="c-166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-836">three years</ix:nonNumeric> based on the performance of a specific achievement. Awards typically vest and are issued only if the participants remain employed by the Company through the vesting date. Common stock issued under these awards is issued from shares reserved under the Company&#8217;s plan described below. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2021, the Company&#8217;s Board adopted the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan was approved by the Company&#8217;s shareholders at the 2021 Annual Meeting on May 18, 2021 and became effective at that time. The 2021 plan supersedes the 2014 Amended and Restated Stock Incentive Plan (the "2014 Plan"). The 2021 Plan provided for the issuance of a maximum of <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-837">2,500,000</ix:nonFraction> shares of common stock in connection with the grant of stock-based or stock-denominated awards, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan, which as of December 31, 2025 totaled <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-838">428,067</ix:nonFraction>. On May 16, 2023 at the 2023 Annual Meeting, the Company's shareholders approved the First Amendment (the "First Amendment") to the 2021 Plan. The First Amendment increased the maximum number of shares of the Company's common stock reserved for issuance under the 2021 Plan by <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-839">2,500,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-840">5,000,000</ix:nonFraction> shares, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan. On May 15, 2025 at the 2025 Annual Meeting, the Company's shareholders approved the Second Amendment (the "Second Amendment") to the 2021 Plan. The Second Amendment increased the maximum number of shares of the Company's common stock reserved for issuance under the 2021 Plan by <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-841">1,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-842">6,000,000</ix:nonFraction> shares, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-831-2" continuedAt="f-831-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reductions in the available share limit associated with these grants are based on a fungible ratio of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" scale="0" id="f-843">1</ix:nonFraction>:1 for stock options and stock appreciation rights and <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" scale="0" id="f-844">2</ix:nonFraction>:1 for all other types of awards. Any shares subject to an award that expires or is cancelled, forfeited, or terminated without issuance of the full number of shares of stock to which the award related again become available for issuance under the limit. As of December&#160;31, 2025, a total of <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-845">639,308</ix:nonFraction> common shares remained available for future grant under the 2021 Plan. This amount reflects reductions from the original limit for grants reflective of the respective fungible ratios. The available amount also reflects the maximum potential share issuance potential in the case of performance grants that provide for variable share payouts.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On April 23, 2014, the Company&#8217;s Board adopted the 2014 Plan. The 2014 Plan was approved by the Company&#8217;s shareholders at the 2014 Annual Meeting and became effective as of the date it was adopted by the Board of Directors. The 2014 Plan provided for the issuance of a maximum of <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-846">2,000,000</ix:nonFraction> shares of common stock in connection with the grant of stock-based or stock-denominated awards. On July 19, 2018, the Company&#8217;s stockholders approved the reservation of an additional <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-847">1,000,000</ix:nonFraction> shares to be issued under the 2014 Plan. On May 15, 2019, the Company&#8217;s stockholders approved the reservation of an additional <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-848">1,000,000</ix:nonFraction> shares to be issued under the 2014 Plan. The 2021 Plan replaced and superseded the 2014 Plan, so as of the adoption date of the 2021 Plan, no common shares remained available for future grant under the 2014 Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All stock option awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-849" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestrictedStockExpense" format="ixt:num-dot-decimal" scale="3" id="f-850">2,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedStockExpense" format="ixt:num-dot-decimal" scale="3" id="f-851">2,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock option expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockOptionPlanExpense" format="ixt:num-dot-decimal" scale="3" id="f-852">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockOptionPlanExpense" format="ixt:num-dot-decimal" scale="3" id="f-853">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-854">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-855">4,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="3" id="f-856">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="3" id="f-857">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shares Forgone to Satisfy Minimum Statutory Withholdings</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025 and 2024, shares of common stock were issued to employees and directors as their restricted stock awards vested or stock options were exercised. Under the terms of the Company&#8217;s stock plans, at the election of each employee, the Company can authorize a net settlement of distributable shares to employees in order to satisfy an individual employees' tax withholding obligations. For the years ended December&#160;31, 2025 and 2024 the Company received <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-858">132,909</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-859">108,607</ix:nonFraction> shares, respectively, from employees for tax withholding obligations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards entitle the holder to receive, upon meeting certain time-based vesting criteria, a specified number of shares of the Company&#8217;s common stock. Stock-based compensation cost of restricted stock awards is measured by the market value of the Company&#8217;s common stock on the date of grant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-831-3" continuedAt="f-831-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-860" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted share activity, excluding the Company&#8217;s employee stock purchase plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant<br/>date fair<br/>value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-861">503,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-862">8.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-863">228,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-864">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-865">110,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-866">9.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested shares forgone to satisfy minimum statutory withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-867">65,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" scale="0" id="f-868">9.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-869">75,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-870">7.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-871">480,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-178" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-872">7.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of awards granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-873">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-179" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-874">7.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="0" id="f-875">824,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="0" id="f-876">1,122,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares forgone to satisfy minimum statutory withholding</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="0" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" format="ixt:num-dot-decimal" scale="0" id="f-877">493,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="0" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" format="ixt:num-dot-decimal" scale="0" id="f-878">651,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-879">1.3</ix:nonFraction> million of pre-tax total unrecognized compensation cost related to non-vested restricted stock awards, which will be adjusted for future forfeitures, if any. The Company expects to recognize such cost over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-880">one year</ix:nonNumeric>.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company granted approximately <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-881">364,905</ix:nonFraction> PSUs and during the year ended December&#160;31, 2024, the Company granted approximately <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-882">117,582</ix:nonFraction> PSUs. PSUs entitle the holder to receive, upon meeting certain performance-based vesting criteria, a specified number of shares of the Company&#8217;s common stock. These market-based awards vest after the Company&#8217;s achievement of either a specified trading price metric of the Company&#8217;s stock, such as when the trading price reaches a target value for a minimum number of consecutive trading days, or after an attainment of total shareholder return ("TSR") metric relative to a TSR for a benchmark group of other companies. In the case of the awards having a trading price metric, awards are paid in stock either immediately upon achievement of the performance condition or expire without any payment after the third anniversary of the grant date. In the case of the awards having a TSR metric, awards can be earned at an amount of <ix:nonFraction unitRef="number" contextRef="c-182" decimals="2" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" scale="-2" id="f-883">50</ix:nonFraction>% of the target number of shares for achieving a minimum threshold below the target or up to <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" scale="-2" id="f-884">200</ix:nonFraction>% of the target number of shares for exceeding the target, with a linear adjustment between the threshold and target or between target and maximum performance achievement. The TSR awards also have a time-based vesting criteria. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-885" continuedAt="f-885-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s PSU activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>grant <br/>date fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-886">189,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-887">7.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-888">364,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-889">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-890">30,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-891">3.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested shares forgone to satisfy minimum statutory withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" format="ixt:num-dot-decimal" scale="0" id="f-892">19,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" scale="0" id="f-893">3.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-894">121,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-895">9.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-896">382,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-897">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-831-4" continuedAt="f-831-5"><ix:continuation id="f-885-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of awards granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-898">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-181" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-899">5.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="0" id="f-900">309,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="0" id="f-901">83,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares forgone to satisfy minimum statutory withholding</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="0" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" format="ixt:num-dot-decimal" scale="0" id="f-902">201,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="0" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" format="ixt:num-dot-decimal" scale="0" id="f-903">67,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-904">1.5</ix:nonFraction> million of pre-tax total unrecognized compensation cost related to non-vested PSUs, which will be adjusted for changes to management&#8217;s expectations of the probable outcomes of the performance conditions, if any. The Company expects to recognize such cost over a weighted average period of <ix:nonNumeric contextRef="c-180" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-905">one year</ix:nonNumeric>.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">At the 2023 Annual Meeting of Stockholders held on May 16, 2023, the Company's stockholders approved the InfuSystem Holdings, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP"), which was previously approved by the Company's Board.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the adoption of the 2023 ESPP, the Company's Board terminated the InfuSystem Holdings, Inc. Employee Stock Purchase Plan (the "Original ESPP").</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Following termination of the Original ESPP, all rights the Company intends to grant under an "employee stock purchase plan" as such term is defined in section 423 of the Internal Revenue Code of 1986, as amended, will be granted under the 2023 ESPP.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The 2023 ESPP provides that a maximum of <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP" format="ixt:num-dot-decimal" scale="0" id="f-906">300,000</ix:nonFraction> shares of Common Stock, plus any shares remaining under the Original ESPP after the close of its final offering period, are available for sale under the 2023 ESPP.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The terms of the 2023 ESPP provides eligible participants electing to participate in the plan with an option to acquire shares of Common Stock during specified offering periods.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The per share option exercise price at which shares of Common Stock will be sold under the 2023 ESPP will be equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-186" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-907">85</ix:nonFraction>% of the closing price of a share of Common Stock on the NYSE American (or such other exchange on which the shares of Common Stock are traded) on the first day of an offering period or (ii) <ix:nonFraction unitRef="number" contextRef="c-186" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-908">85</ix:nonFraction>% of the closing price of a share of Common Stock on the purchase date.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">No employee may purchase more than $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="infu:EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" format="ixt:num-dot-decimal" scale="0" id="f-909">25,000</ix:nonFraction> worth of fair market value shares in any calendar year. As allowed under the 2023 ESPP, a participant may elect to withdraw from the plan, effective for the purchase period in progress at the time of the election with all accumulated payroll deductions returned to the participant at the time of withdrawal. The 2023 ESPP is administered by the Board's Compensation Committee.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Eligible participants under the plan include all full-time employees and certain part-time employees of the Company who meet certain eligibility requirements set forth in the 2023 ESPP.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Participation in the 2023 ESPP for any eligible employee is voluntary.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="infu:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-910">209,321</ix:nonFraction> shares remaining available for future issuance. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="f-911" continuedAt="f-911-1" escape="true">The following table summarizes the activity relating to the Company&#8217;s ESPP program:</ix:nonNumeric></span></div><ix:continuation id="f-911-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-912">139,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-913">93,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares of stock sold to employees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-914">61,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-915">52,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per ESPP award</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="infu:EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" scale="0" id="f-916">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="infu:EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" scale="0" id="f-917">9.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value of stock option awards using the Black-Scholes option pricing model, which incorporates various assumptions including volatility, expected term, risk-free interest rates and dividend yields. The expected volatility assumption is based on historical volatility of the Company&#8217;s common stock over the most recent period commensurate with the expected life of the stock option granted. The Company uses historical volatility because management believes such volatility is representative of prospective trends. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the stock option awarded. The Company uses historical exercise data to determine the expected lives. Dividend yields have not been a factor in determining fair value of stock options granted as the Company has never issued cash dividends and does not anticipate issuing cash dividends in the future.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-831-5" continuedAt="f-831-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-918" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables detail the various stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:44.061%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2014 Plan (Options)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number<br/>of Authorized<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-919">535,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-920">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-188" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-921">3.57</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-922">1,588,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-923">49,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-924">2.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised shares forgone to satisfy minimum statutory withholding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-925">32,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-926">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares tendered for cashless exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-927">27,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-928">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and expirations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-929">75,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-930">8.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-931">349,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-190" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-932">8.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-189" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-933">3.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-934">960,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-935">349,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-190" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-936">8.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-189" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-937">3.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-938">960,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:44.061%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2021 Plan (Options)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number<br/>of Authorized<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-939">1,840,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-191" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-940">8.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-192" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-941">8.54</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-942">1,504,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-943">889,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-944">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-945">12,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-946">8.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised shares forgone to satisfy minimum statutory withholding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-947">14,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-948">7.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cashless exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-949">177,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-950">8.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and expirations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-951">236,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-952">8.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-953">2,289,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-954">8.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-193" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-955">8.15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-956">3,888,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-957">911,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-958">9.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-193" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-959">7.22</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-960">729,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-961" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-962">46</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-963">57</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-964">46</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-194" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-965">51</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-966">3.56</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-164" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-967">4.01</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-968">4.22</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-969">4.60</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected lives at date of grant (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-970">4.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-194" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-971">4.08</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-972">2.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-973">2.97</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-974">926,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-975">322,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-831-6"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2024, our Board of Directors approved a stock repurchase program (the "Share Repurchase Program") that authorizes the Company to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-976">20.0</ix:nonFraction> million of the Company's outstanding common stock through June 30, 2026. The Share Repurchase Program supersedes the previous authorization, which was set to expire on June 30, 2024. Repurchases under the Share Repurchase Program are subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's existing credit agreement. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had repurchased and retired approximately $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-977">11.0</ix:nonFraction> million, or <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="0" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-978">1,498,376</ix:nonFraction> shares, of the Company's outstanding common stock under the Share Repurchase Program. The Company had repurchased and retired approximately $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-979">6.2</ix:nonFraction> million, or <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="0" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-980">553,149</ix:nonFraction> shares under the previous authorization.</span></div></ix:continuation><div id="i13594bbbfc1e4b049c5f01f53e10e953_142"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-981" continuedAt="f-981-1" escape="true">Business Segment Information</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><ix:continuation id="f-981-1" continuedAt="f-981-2"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s reportable segments are organized based on service platforms, with the Patient Services segment reflecting higher margin rental revenues that generally include payments made by third-party and direct payers and the Device Solutions segment reflecting lower margin product sales, direct payer rental and services revenues. Resources are allocated and performance is assessed for these segments by the Company&#8217;s Chief Executive Officer, whom the Company has determined to be its CODM. The CODM uses gross profit for each segment predominantly in the annual budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making operating and capital resource allocation decisions among each segment.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-982" continuedAt="f-982-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial information summarized below is presented by reportable segment:&#160;</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-982-1" continuedAt="f-982-2"><ix:continuation id="f-981-2" continuedAt="f-981-3"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Patient Services</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Device Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - external</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:num-dot-decimal" scale="3" id="f-983">86,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:num-dot-decimal" scale="3" id="f-984">56,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:fixed-zero" scale="3" id="f-985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:num-dot-decimal" scale="3" id="f-986">143,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - internal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="infu:NetRevenuesInternal" format="ixt:fixed-zero" scale="3" id="f-987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="infu:NetRevenuesInternal" format="ixt:num-dot-decimal" scale="3" id="f-988">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="infu:NetRevenuesInternal" format="ixt:num-dot-decimal" scale="3" id="f-989">7,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:NetRevenuesInternal" format="ixt:fixed-zero" scale="3" id="f-990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-991">86,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-992">64,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-993">7,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-994">143,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant Segment Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and material costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-995">23,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-996">18,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-997">7,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-998">35,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="3" id="f-999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1000">16,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="3" id="f-1001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1002">16,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1003">7,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1004">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:fixed-zero" scale="3" id="f-1005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1006">11,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-1007">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-1008">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:fixed-zero" scale="3" id="f-1009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-1010">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1011">55,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1012">24,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-1013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1014">80,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1015">68,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1016">1,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1017">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1018">10,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1019">53,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1020">45,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1021">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1022">100,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1023">4,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1024">3,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:fixed-zero" scale="3" id="f-1025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1026">8,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1027">8,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1028">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1030">13,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="f-982-2"><ix:continuation id="f-981-3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Patient Services</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Device Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - external</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:num-dot-decimal" scale="3" id="f-1031">80,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:num-dot-decimal" scale="3" id="f-1032">54,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:fixed-zero" scale="3" id="f-1033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="infu:NetRevenuesExternal" format="ixt:num-dot-decimal" scale="3" id="f-1034">134,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - internal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="infu:NetRevenuesInternal" format="ixt:fixed-zero" scale="3" id="f-1035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="infu:NetRevenuesInternal" format="ixt:num-dot-decimal" scale="3" id="f-1036">7,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" sign="-" name="infu:NetRevenuesInternal" format="ixt:num-dot-decimal" scale="3" id="f-1037">7,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="infu:NetRevenuesInternal" format="ixt:fixed-zero" scale="3" id="f-1038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1039">80,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1040">61,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1041">7,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1042">134,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant Segment Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and material costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1043">20,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1044">21,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" sign="-" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1045">7,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1046">34,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="3" id="f-1047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1048">18,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="3" id="f-1049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1050">18,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1051">6,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1052">3,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:fixed-zero" scale="3" id="f-1053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1054">10,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-1055">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-1056">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:fixed-zero" scale="3" id="f-1057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-1058">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1059">52,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1060">17,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-1061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1062">70,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1063">63,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1064">1,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1065">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1066">5,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1067">54,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1068">47,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1069">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1070">103,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1071">6,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1072">10,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:fixed-zero" scale="3" id="f-1073">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="infu:PaymentsToAcquireMedicalEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1074">16,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1075">7,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1076">4,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1078">12,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.</span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_148"></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1079" continuedAt="f-1079-1" escape="true">Employee Benefit Plans and Other</ix:nonNumeric></span><ix:continuation id="f-1079-1" continuedAt="f-1079-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:continuation></div><ix:continuation id="f-1079-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution plan in which the Company makes discretionary matching contributions for a certain percentage of employee contributions.  For the years ended December&#160;31, 2025 and 2024, the Company&#8217;s matching contributions was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1080">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1081">1.3</ix:nonFraction> million, respectively.   The Company does not provide other post-retirement or post-employment benefits to its employees. As of December&#160;31, 2025 and 2024, accrued payroll liabilities included in Other current liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1082">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1083">4.8</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_157"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9A.&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management, with the participation of our Chief Executive Officer (&#8220;CEO&#8221;) and our Chief Financial Officer (&#8220;CFO&#8221;), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Such information is accumulated and communicated to the company&#8217;s management, including its CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our CEO and CFO determined that the Company's disclosure controls and procedures were effective as of December&#160;31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">s Report on Internal Controls Over Financial Reporting</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Management, with the participation of our CEO and CFO, has conducted an evaluation of the effectiveness of the Company's internal control over financial reporting, based on the framework set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on this assessment, management has concluded that the Company's internal control over financial reporting was effective as of December&#160;31, 2025. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The effectiveness of our internal control over financial reporting as of December 31, 2025 has been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in its report, which is included below.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Changes in Internal Control over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), during the quarter ended December&#160;31, 2025, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations over Internal Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A company's internal control over financial reporting is a process designed by, or under the supervision of, its principle executive and principal financial officers, and effected by such company's board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with US GAAP and includes those policies and procedures that:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with US GAAP, and that the receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving their objectives. Further, the design of a control system must reflect that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements or fraud. Also, projections of any evaluation of effectiveness of controls in future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of InfuSystem Holdings, Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of InfuSystem Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">issued by COSO.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December&#160;31, 2025, of the Company and our report dated February&#160;27, 2026, expressed an unqualified opinion on those financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Detroit, Michigan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;27, 2026</span></div><div style="margin-top:10pt"><span><br/></span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_160"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9B.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other Information.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2025, no director or officer of the Company, as defined in Rule 16a-1(f) of the Exchange Act, <ix:nonNumeric contextRef="c-212" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1084"><ix:nonNumeric contextRef="c-212" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1085">adopted</ix:nonNumeric></ix:nonNumeric>, modified, or <ix:nonNumeric contextRef="c-212" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1086"><ix:nonNumeric contextRef="c-212" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1087">terminated</ix:nonNumeric></ix:nonNumeric> any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9C.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_169"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Part III, Item&#160;10 is incorporated herein by reference to the sections titled &#8220;Election of Directors,&#8221; &#8220;Board of Directors and Committees of the Board of Directors,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our definitive proxy statement relating to the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Insider Trading Policy</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted insider trading policies and procedures applicable to its directors, officers and employees, as well as to the Company itself, governing the purchase, sale and other dispositions of the Company's securities (the "Insider Trading Policy"). The Company believes that the Insider Trading Policy is reasonably designed to promote compliance with applicable U.S. federal securities laws, rules, and regulations, and the listing standards of the NYSE American. A copy of the Insider Trading Policy is filed as </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx191.htm">Exhibit 19.1</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to this Form 10-K.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_172"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Part III, Item&#160;11 is incorporated herein by reference to the sections titled &#8220;Advisory Vote Regarding Executive Compensation,&#8221; &#8220;Executive Compensation,&#8221; and &#8220;Policies and Practices Related to the Grant of Certain Equity Awards&#8221; in our definitive proxy statement relating to the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_175"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information as of December&#160;31, 2025 with respect to compensation plans, including individual compensation arrangements, under which our equity securities are authorized for issuance:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities to be issued upon<br/>&#160;exercise of outstanding options and rights<br/>( a ) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price of options<br/>&#160;and rights<br/>( b ) (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities remaining available <br/>for future issuance under equity<br/>&#160;compensation plans (excluding securities reflected in column (a)) (3)<br/>( c )</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Plan Category:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2014 Plan *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2021 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,153,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">639,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,502,931&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">639,308&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">* As of December&#160;31, 2025, this plan is no longer in effect other than for stock options and rights that were previously granted and remain outstanding.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1) This amount includes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">863,681</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> shares of common stock issuable upon the vesting of certain restricted stock awards and performance-based restricted stock units and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,639,250</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> shares of common stock issuable upon the exercise of vested stock option awards.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2) Excludes RSUs and PSUs, which have no exercise price.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3) Includes 2,500,000 shares authorized as part of our 2021 Annual Meeting of Stockholders held in May 2021, plus 2,500,000 shares authorized as part of our 2023 Annual Meeting of Stockholders held in May 2023, plus 1,000,000 shares authorized as part of our 2025 Annual Meeting of Stockholders held in May 2025, plus 428,067 shares granted under the 2014 Plan that expired or were cancelled, forfeited, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">or terminated under the terms of the 2014 Plan and thus eligible to be added to the 2021 Plan, less 5,788,759 shares that were made available to certain employees, directors and others.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The other information required by Part III, Item&#160;12 is incorporated herein by reference to the section titled &#8220;Security Ownership of certain Beneficial Owners and Management&#8221; in our definitive proxy statement relating to the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_178"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Part III, Item&#160;13 is incorporated herein by reference to the sections titled &#8220;Election of Directors &#8211; Director Independence&#8221; and &#8220;Certain Relationships and Related Party Transactions&#8221; in our definitive proxy statement relating to the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_181"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Part III, Item&#160;14 is incorporated herein by reference to the sections titled &#8220;Ratification of Independent Registered Public Accounting Firm&#8221; and &#8220;Independent Auditor&#8217;s Fees&#8221; in our definitive proxy statement relating to the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_187"></div><div style="-sec-extract:summary;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed or furnished as part of this Form 10-K:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statements</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the Index to Financial Statements under Item 8, Part II hereof.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#160;Financial Statement Schedules</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Statement Schedules have been omitted either because they are not required or because the information has been included in the financial statements or the notes thereto included in this Annual Report on Form 10-K.&#160;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the accompanying Exhibit Index set forth below. Pursuant to the rules and regulations of the Securities and Exchange Commission, the Company has filed, furnished or incorporated by reference the documents referenced in the Exhibit Index as exhibits to this Form 10-K. The documents include agreements to which the Company is a party or has a beneficial interest. The agreements have been filed to provide investors with information regarding their respective terms. The agreements are not intended to provide any other factual information about the Company or its business or operations. In particular, the assertions embodied in any representations, warranties and covenants contained in the agreements may be subject to qualifications with respect to knowledge and materiality different from those applicable to investors and may be qualified by information in confidential disclosure schedules not included with the exhibits. These disclosure schedules may contain information that modifies, qualifies and creates exceptions to the representations, warranties and covenants set forth in the agreements. Moreover, certain representations, warranties and covenants in the agreements may have been used for the purpose of allocating risk between the parties, rather than establishing matters as facts. In addition, information concerning the subject matter of the representations, warranties and covenants may have changed after the date of the respective agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures. Accordingly, investors should not rely on the representations, warranties and covenants in the agreements as characterizations of the actual state of facts about the Company or its business or operations on the date hereof. The Company will furnish to any stockholder, upon written request, any exhibit listed in the Exhibit Index upon payment by such stockholder of the Company's reasonable expenses in furnishing any such exhibit.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Description of Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828025029052/infu20250520-exx31xseconda.htm">Second Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s current report on Form 8-K (File No. 1-35020) filed on June 3, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774918013086/ex_117488.htm">Amended and Restated By-Laws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on July 9, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000119312506045150/dex42.htm">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-129035) filed on March 3, 2006).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774920006370/ex_178388.htm">Description of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K (File No. 1-35020) filed on March 30, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000119312508074068/dex41.htm">InfuSystem Holdings, Inc. 2007 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-150066) filed on April 3, 2008).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000119312514404525/d810092dex101.htm">Form of Stock Option Award Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 1-35020) filed on November 10, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.3**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000119312515183952/d922316dex104.htm">Form of Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 12, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Description of Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.4**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000119312517347899/d497820dex102.htm">Stock Option Award Agreement by and between InfuSystem Holdings, Inc. and Richard DiIorio, dated as of November 15, 2017 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on November 20, 2017).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.5**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000119312517347899/d497820dex103.htm">Stock Appreciation Right Award Agreement by and between InfuSystem Holdings, Inc. and Richard DiIorio, dated as of November 15, 2017 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on November 20, 2017).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.6**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774919010376/ex_145338.htm">InfuSystem Holdings, Inc. 2014 Equity Plan (as amended through May 15, 2019) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 17, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.7**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774920011856/ex_188152.htm">Form of Performance Unit Award Agreement under the 2014 Equity Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 27, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.8**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774920023787/ex_212648.htm">Composite Copy of InfuSystem Holdings, Inc. Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 1-35020) filed on November 13, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774920018661/ex_201351.htm">Restricted Stock Unit Agreement (Service-Based), dated August 24, 2020, between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on August 25, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.10**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774920018661/ex_201352.htm">Restricted Stock Unit Agreement (Performance-Based), dated August 24, 2020, between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on August 25, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921002490/ex_225362.htm">Credit Agreement dated as of February 5, 2021 among InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc., IFC LLC, the other Loan Parties thereto, and JPMorgan Chase Bank, N.A. as Administrative Agent, Sole Bookrunner and Sole Lead Arranger (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on February 11, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921002490/ex_225361.htm">Pledge and Security Agreement entered into as of February 5, 2021 by and among InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc. and IFC LLC, and JPMorgan Chase Bank, N.A., in its capacity as administrative agent for the other lenders party to the Credit Agreement (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on February 11, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.13**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921004662/ex_231141.htm">Restricted Stock Unit Agreement (Service-Based), dated March 1, 2021, between the Company and Carrie Lachance (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on March 2, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.14**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921012599/ex_250181.htm">InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-256231) filed on May 18, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.15**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921013182/ex_252604.htm">Form of Nonqualified Stock Option Agreement (Non-employee Directors) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.16**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921013182/ex_252605.htm">Form of Nonqualified Stock Option Agreement (Employees) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.17**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921013182/ex_252606.htm">Form of Restricted Stock Unit Agreement (Time-based Vesting) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Description of Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.18**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921013182/ex_252607.htm">Form of Restricted Stock Unit Agreement (Performance-based Vesting) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.19**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921013182/ex_252608.htm">First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.20**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921013182/ex_252609.htm">First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Barry Steele (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.21**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1337013/000143774921013182/ex_252610.htm">First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Carrie Lachance (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.22**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828022021154/infu-20220630xexx1011.htm">Form of Restricted Stock Unit Agreement (Performance-based Vesting) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on August 4, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828023014923/exhibit10104-26x2023firsta.htm">First Amendment to Credit Agreement dated as of April 21, 2023 by and among InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc., IFC LLC, the lenders party thereto and JPMorgan Chase Bank, N.A. as administrative agent for the lenders (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 2, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.24**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828023019625/infu-20230516xexx101x2021e.htm">First Amendment to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 25, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.25**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828023019625/infu-20230516xexx102x2023e.htm">InfuSystem Holdings, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 1-35020) filed on May 25, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828023016802/infu-20230331xexx10111.htm">Non-Disclosure Agreement for Potential Director Candidate, dated August 4, 2022, by and between the Company and R. Rimmy Malhotra (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 9, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828024010047/exhibit99103-08x24xmalhotr.htm">Cooperation Agreement, dated as of March 8, 2024, among InfuSystem Holdings, Inc., R. Rimmy Malhotra and Nicoya Capital LLC. (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K (File No. 1-35020) filed on March 8, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828025035245/exhibit1017-15x252ndamendm.htm">Second Amendment to Credit Agreement, dated July 15, 2025, by and among InfuSystem Holdings, Inc., InfuSystem, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A. as administrative agent for the lenders (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-35020) filed on July 17, 2025)</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.29**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828025029052/infu20250529-exx101xsecond.htm">Second Amended and Restated Employment Agreement, dated May 29, 2025, by and between the Company and Carrie Lachance (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-35020) filed on June 3, 2025)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828025029052/infu20250529-exx101xsecond.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.30**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828025015754/exhibit101separationagreem.htm">Separation Agreement, dated March 31, 2025, by and between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-35020) filed on April 1, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.31**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1337013/000162828025026831/infu20250515-exx101x2021eq.htm">Second Amendment to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-35020) filed on May 20, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx191.htm">19.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx191.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1088">InfuSystem Holdings, Inc. Insider Trading Policy</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Description of Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx211.htm">21.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx211.htm">Subsidiaries of InfuSystem Holdings, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="infu-20251231xexx231.htm">23.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="infu-20251231xexx231.htm">Consent of DELOITTE &amp; TOUCHE LLP</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="infu-20251231xexx311.htm">31.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="infu-20251231xexx311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx312.htm">31.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx312.htm">Certification of&#160;Principal Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx321.htm">32.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx321.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx322.htm">32.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx322.htm">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="infu-20251231xexx971former.htm">97.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="infu-20251231xexx971former.htm">InfuSystem Holdings, Inc. Policy for the Recovery of Erroneously Awarded Compensation, dated as of October 2, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Management contract or compensatory plan, contract or arrangement.</span></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_190"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;10-K Summary</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i13594bbbfc1e4b049c5f01f53e10e953_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i13594bbbfc1e4b049c5f01f53e10e953_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">INFUSYSTEM HOLDINGS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;CARRIE LACHANCE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Carrie Lachance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacity and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;CARRIE LACHANCE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Carrie Lachance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;BARRY STEELE </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Barry Steele</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Principal Accounting and Financial Officer)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SCOTT SHUDA </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Scott Shuda</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chairman of the Board<br/>Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;KENNETH EICHENBAUM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth Eichenbaum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PAUL GENDRON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Paul Gendron</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;BEVERLY HUSS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Beverly Huss</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;RONALD HUNDZINSKI</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Ronald Hundzinski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DR. JOHN J. SVIOKLA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Dr. John J. Sviokla</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>infu-20251231xexx191.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i819c2dec3bcd44e7ad5425bf8e429099_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 19.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFUSYSTEM HOLDINGS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">INSIDER TRADING AND INFORMATION DISCLOSURE POLICY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">AS AMENDED AND RESTATED ON JANUARY 19, 2024</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTRODUCTION </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Policy explains the requirements and procedures to be followed by employees, officers, and directors of InfuSystem Holdings, Inc. and its subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InfuSystem</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) when trading in InfuSystem securities (and, in some cases, the securities of other companies) and in responding to questions about, and requests for, confidential information about InfuSystem&#8217;s business and affairs.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem&#8217;s Chief Financial Officer or another employee designated by InfuSystem&#8217;s Board of Directors from time to time shall serve as the compliance officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for purposes of this Policy and shall be responsible for administration of this Policy.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contact the Compliance Officer if you ever have questions about this Policy or its application to any situation in which you wish to trade InfuSystem securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">APPLICABILITY OF POLICY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Policy applies to all transactions in InfuSystem&#8217;s securities, including common stock, options for common stock and any other securities InfuSystem may issue from time to time, such as preferred stock, warrants and convertible debentures, as well as to derivative securities relating to InfuSystem&#8217;s stock.  It applies to all officers of InfuSystem, all members of InfuSystem&#8217;s Board of Directors, and all employees, consultants and contractors of InfuSystem who receive or have access to Inside Information (as defined below) regarding InfuSystem.  This group of people, members of their immediate families, members of their households, and entities that they control are sometimes referred to in this Policy as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insiders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;  This Policy also applies to any person who receives Inside Information from any Insider.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any person who possesses Inside Information regarding InfuSystem is an Insider for so long as the information is not publicly known.  Any employee can be an Insider from time to time, and would at those times be subject to this Policy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to this Policy, InfuSystem will comply with all applicable insider trading laws, rules, regulations and listing standards, including those governing its purchase, sale or other disposition of InfuSystem securities&#59; provided that InfuSystem shall not be subject to the other provisions of this Policy in purchasing, selling or otherwise  disposing of InfuSystem securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INSIDER TRADING AND TIPPING</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state securities laws prohibit&#58; (a) the purchase or sale of securities while in possession of material non-public information (&#8220;Inside Information&#8221;)&#59; or (b) the selective disclosure of Inside Information to others who then trade in securities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tip</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tipping</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INFUSYSTEM POLICY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No InfuSystem Insider shall&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Buy or sell InfuSystem securities or the securities of other companies with which InfuSystem does business, including customers and suppliers, during any period commencing with the date that he or she possesses Inside Information and ending 24 hours after such information is publicly disclosed.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Tip Inside Information to outsiders, including family members and others.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Answer questions or provide information, including Inside Information, about InfuSystem and its affairs to outsiders unless specifically authorized to do so. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are no exceptions or waivers to this policy, even for transactions that seem necessary or justifiable (such as the need to raise money for a personal financial emergency).  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">MATERIAL NON-PUBLIC INFORMATION (INSIDE INFORMATION)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inside Information is material non-public information.  Under applicable securities laws, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">material</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; information is any information that a reasonable investor would likely consider important in deciding whether to buy, sell, or hold stock. Any information that could be expected to affect a company&#8217;s stock price, whether it is positive or negative, should be considered material.  There is no bright-line standard for assessing materiality&#59; rather, materiality is based on an assessment of all the facts and circumstances, and is often evaluated by enforcement authorities with the benefit of hindsight.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-public</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; information is any information that has not been disclosed generally to the marketplace.  Effective disclosure of such information comes through public filings with the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and other regulatory bodies, press releases and public meetings with analysts and the press. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All information that you learn about InfuSystem or its business plans is potentially Inside Information until InfuSystem publicly discloses it.  Similarly, information received about any other company with which InfuSystem does business, including customers, vendors and suppliers, that is not yet in general circulation is also potentially Inside Information.  Rumor and speculation in the public or media about material information, absent official statement, is not a sufficient basis to trade on Inside Information.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible to define all categories of Inside Information, examples of information that would be regarded as Inside Information include, but are not limited to, information relating to&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;InfuSystem&#8217;s historical or projected financial results, sales results, earnings, losses, liquidity and other similar financial information. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Possible action related to stock, such as a dividend declaration, stock split, stock repurchases, or anticipated public or private offerings of InfuSystem securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The fact that InfuSystem is evaluating or considering an acquisition candidate, business unit divestiture, joint venture, tender offer, or restructuring activity, that discussions or negotiations are in progress, or that such a transaction is being undertaken.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;News of significant changes in products or services, the gain or loss of a significant customer or supplier, and other major marketing changes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Changes in management or control. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Any significant actual or threatened litigation, dispute, or government investigation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;News regarding actual or potential reductions in force.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TIPPING</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Insiders, in addition to being forbidden from using Inside Information to trade in securities for their own advantage, are also prohibited from Tipping Inside Information to an outsider.  An outsider is any person other than an InfuSystem employee, officer, or director, and includes, but is not limited to, friends, business associates, spouses, or family members.  Under the securities laws, both the discloser and recipient of Inside Information are liable for violations and you will be held accountable for trading by your immediate family and others living in your household. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inside Information must be protected.  Common sense applies.  Avoid inadvertent communication.  For example&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Do not discuss new developments, which could constitute Inside Information, in public places such as elevators, hallways, restaurants, airplanes, taxicabs, or any place where you can be overheard.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Do not gossip or speculate with other employees or non-employees regarding any Inside Information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Do not read documents with Inside Information in public places or discard them where others can retrieve them.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Do not carry documents with Inside Information in public places in an exposed manner.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Cover documents with Inside Information on your desk before you leave your office or room and do not leave them where visitors can read them.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Do not copy documents with Inside Information for personal use, without the express consent of a supervisor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If documents containing Inside Information are to be disposed of, they should be securely shredded or otherwise destroyed.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">POTENTIAL CRIMINAL AND CIVIL LIABILITY AND&#47;OR DISCIPLINARY ACTION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. Liability for Insider Trading. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to federal and state securities laws, Insiders may be subject to criminal and civil fines and penalties as well as imprisonment for engaging in transactions in InfuSystem&#8217;s securities at a time when they have knowledge of Inside Information regarding InfuSystem.  While the regulatory authorities concentrate their efforts on individuals who trade, or who tip inside information to others who trade, the federal securities laws also impose potential liability on InfuSystem and other &#8220;controlling persons&#8221; if they fail to take reasonable steps to prevent insider trading by InfuSystem Insiders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. Liability for Tipping. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Insiders may also be liable for improper transactions by any person (commonly referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">tippee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to whom they have disclosed Inside Information regarding InfuSystem or to whom they have made recommendations or expressed opinions on the basis of such information as to trading in InfuSystem&#8217;s securities. The SEC has imposed large penalties even when the disclosing person did not profit from the trading. The SEC, the stock exchanges and Financial Industry Regulatory Authority use sophisticated electronic surveillance techniques to uncover insider trading.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. Possible Disciplinary Actions. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employees who violate this Policy shall be subject to disciplinary action, which may include ineligibility for future participation in InfuSystem&#8217;s equity incentive plans or termination of employment, and may also be reported to enforcement authorities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RECOMMENDED GUIDELINES&#58;  TIMING OF SECURITIES TRADING AND WINDOW PERIODS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investment by InfuSystem employees and directors in InfuSystem securities is encouraged.  However, there are restrictions regarding the timing of trading in InfuSystem securities.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Closed Window Period.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To ensure compliance with this Policy and applicable securities laws, all officers of InfuSystem, all members of InfuSystem&#8217;s Board of Directors and all other persons designated by the Compliance Officer, as well as members of their immediate families, members of their households, and entities that they control, should refrain from conducting any transactions in InfuSystem&#8217;s securities (a) during the period beginning the day after the last day of each of the first three fiscal quarters and continuing for 24 hours after the public release of the financial results for such quarter and (b) during the 14-days inclusive prior to the ending of each annual year (i.e., December 17th) and continuing for 24 hours after the public release of the financial results for such year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Closed Window Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to SEC rules, directors and executive officers are prohibited from trading in InfuSystem&#8217;s equity securities during any period of three or more consecutive days during which at least 50% of the participants or beneficiaries in an &#8220;individual account&#8221; retirement plan of InfuSystem or its subsidiaries are unable to purchase, sell, or otherwise acquire or transfer an interest in the equity of InfuSystem held in such plan due to a temporary suspension by InfuSystem or a fiduciary.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Individual account</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; plans include, without limitation, defined contribution plans such as broad-based tax-qualified 401(k) plans and profit sharing plans, stock bonus plans, and certain nonqualified deferred compensation arrangements.  There are limited exceptions to this rule, and Insiders should consult with InfuSystem&#8217;s Compliance Officer prior to attempting a stock transaction during any such Closed Window Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, an event may occur that is material to InfuSystem and is known by only a few Insiders. So long as the event remains material and nonpublic, the persons designated by the Compliance</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Officer may not trade InfuSystem securities. In addition, the InfuSystem&#8217;s financial results may be sufficiently material in a particular fiscal quarter that, in the judgment of the Compliance</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Officer, designated persons should refrain from trading in InfuSystem securities even sooner than the typical Closed Window Period described above. In that situation, the Compliance Officer may notify these persons that they should not trade in the InfuSystem&#8217;s securities, without disclosing the reason for the restriction. The existence of an event-specific trading restriction period or extension of a Closed Window Period will not be announced to the company as a whole, and should not be communicated to any other person. Even if the Compliance Officer has not designated you as a person who should not trade due to an event-specific restriction, you should not trade while aware of material nonpublic information. Exceptions will not be granted during an event-specific trading restriction period.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Open Window Period.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The safest period for trading in InfuSystem&#8217;s securities, assuming the absence of Inside Information, is generally the first few days following the opening of the trading window, which shall open 24 hours after the public release of the financial results for all quarterly periods (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Window Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Trading in InfuSystem&#8217;s securities during an Open Window Period should not be considered a &#8220;safe harbor&#8221; if an Insider is in possession of Inside Information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even after Inside Information is disclosed by InfuSystem in connection with a quarterly earnings release, for example, sufficient time must pass to permit the market and outside investors to digest the information and make investment decisions before Insiders can trade in InfuSystem&#8217;s securities.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities scrutinize securities trading with hindsight.  Consequently, before trading in InfuSystem securities, you should carefully consider how the authorities, in the future, might view your trading with the benefit of hindsight.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Every Insider has the individual responsibility to comply with this Policy against insider trading, regardless of whether InfuSystem has recommended an Open Window Period to that Insider or any other Insiders of InfuSystem.  The guidelines set forth in this Policy are guidelines only, and appropriate judgment should be exercised in connection with any trade in InfuSystem&#8217;s securities.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An Insider may, from time to time, have to forego a proposed transaction in InfuSystem&#8217;s securities even if he or she planned to make the transaction before learning of the Inside Information and even though the Insider believes he or she may suffer an economic loss or forgo anticipated profit by waiting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRE-CLEARANCE OF TRADES BY DIRECTORS, OFFICERS, AND CERTAIN OTHER EMPLOYEES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To prevent inadvertent violations and avoid even the appearance of an improper transaction (e.g., when an officer trades while unaware of a pending major development) and to ensure the proper filing of SEC reports, the following procedure must be followed&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">All transactions in InfuSystem securities (acquisitions, dispositions, gifts, transfers, etc.) by all officers of InfuSystem, all members of InfuSystem&#8217;s Board of Directors and all other persons designated by the Compliance Officer, as well as members of their immediate families, members of their households, and entities that they control, must (a) be pre-cleared by the Compliance Officer and (b) in the case of officers of InfuSystem and member of InfuSystem's Board of Directors, provide timely notice to the Chairman of the Board of Directors or the Chairman of the Audit Committee on the anticipated timing of such transactions.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If you contemplate trading, contact the Compliance Officer in advance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If you believe that you may be in possession of Inside Information, do not disclose that information without discussing the same with the Compliance Officer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">LIABILITY OF SUPERVISORY PERSONS FOR TRADING BY SUBORDINATES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under securities laws, InfuSystem and its directors, officers, or supervising employees may be liable for significant penalties if they do not take appropriate action to prevent a person directly or indirectly under their control from trading in securities on the basis of Inside Information &#8211; or if they recklessly disregard the likelihood that such trading would take place.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If Inside Information is inadvertently disclosed, no matter what the circumstances, the person making or discovering that disclosure should immediately report the facts to InfuSystem&#8217;s Compliance Officer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTAIN EXCEPTIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Policy does not apply in the case of certain transactions as described herein, except as specifically noted&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. Stock Option Exercises.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  This Policy does not apply to the exercise of an employee stock option acquired pursuant to InfuSystem&#8217;s equity compensation plans or to the exercise of a tax withholding right pursuant to which an employee has elected to have InfuSystem withhold shares subject to an option in order to satisfy any tax withholding obligations.  However, this Policy </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">does apply</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to any sale of stock as part of a broker-assisted &#8220;cashless exercise&#8221; of an option, or any other open market sale for the purpose of generating cash needed to pay the exercise price of an option.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2.  Restricted Stock Awards.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  This Policy does not apply to the vesting of restricted stock, or the exercise of a tax withholding right pursuant to which an employee elects to have InfuSystem withhold shares of stock in order to satisfy any tax withholding obligations.  However, this Policy </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">does apply</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to any market sale of restricted stock once vested.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. Employee Stock Purchase Plan.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> This Policy does not apply to purchases of InfuSystem securities in the employee stock purchase plan resulting from your periodic contribution of money to the plan pursuant to the election you made at the time of your enrollment in the plan. This Policy also does not apply to purchases of InfuSystem securities resulting from lump sum contributions to the plan, provided that you elected to participate by lump sum payment at the beginning of the applicable enrollment period. This Policy </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">does apply</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, however, to your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">election to participate in the plan for any enrollment period, and to your sales of InfuSystem securities purchased pursuant to the plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4.  Other Similar Transactions.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  Any other purchase of InfuSystem securities directly from InfuSystem or sales of InfuSystem securities directly to InfuSystem are not subject to this Policy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. Gifts.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  InfuSystem may permit bona fide gifts of stock during periods when trading is restricted, as determined by the Compliance Officer. Whether a gift is bona fide will depend on the circumstances surrounding the gift, such as whether the gift is made to a charity or to a relative or friend of the donor and whether the shares are to be sold immediately thereafter. If you intend to make a gift during periods when trading is restricted, you must have the gift transaction approved by the Compliance Officer prior to making the gift.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SPECIAL AND PROHIBITED TRANSACTIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem has determined that there is a heightened legal risk and&#47;or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions. It therefore is InfuSystem&#8217;s policy that any persons covered by this Policy may not engage in any of the following transactions, or should otherwise consider InfuSystem&#8217;s preferences as described below&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. Short-Term Trading.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term trading of InfuSystem securities may be distracting to the person and may unduly focus the person on InfuSystem&#8217;s short-term stock market performance instead of InfuSystem&#8217;s long-term business objectives. For these reasons, any director, officer or other employee of InfuSystem who purchases InfuSystem securities in the open market may not sell any InfuSystem securities of the same class during the six months following the purchase (or vice versa).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. Short Sales.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Short sales of InfuSystem securities (i.e., the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have the potential to signal to the market that the seller lacks confidence in InfuSystem&#8217;s prospects. In addition, short sales may reduce a seller&#8217;s incentive to seek to improve InfuSystem&#8217;s performance. For these reasons, short sales of InfuSystem securities are prohibited. In addition, Section 16(c) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), prohibits officers and directors from engaging in short sales. (Short sales arising from certain types of hedging transactions are governed by the paragraph below captioned &#8220;Hedging Transactions.&#8221;)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. Publicly-Traded Options.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Given the relatively short term of publicly-traded options, transactions in options may create the appearance that a director, officer or employee is trading based on material nonpublic information and focus a director&#8217;s, officer&#8217;s or other employee&#8217;s attention on short-term performance at the expense of InfuSystem&#8217;s long-term objectives. Accordingly, transactions in put options, call options or other derivative securities, on an exchange or in any other organized market, are prohibited by this Policy. (Option positions arising from certain types of hedging transactions are governed by the next paragraph below.)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. Hedging Transactions.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such transactions may permit a director, officer or employee to continue to own InfuSystem securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the director, officer or employee may no longer have the same objectives as InfuSystem&#8217;s other shareholders. Therefore, InfuSystem strongly discourages you from engaging in such transactions. Any person wishing to enter into such an arrangement must first submit the proposed transaction for approval by the Compliance Officer. Any request for pre-clearance of a hedging or similar arrangement must be submitted to the Compliance Officer at least two weeks prior to the proposed execution of documents evidencing the proposed transaction and must set forth a justification for the proposed transaction.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. Margin Accounts and Pledged Securities.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&#8217;s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in InfuSystem securities, directors, officers and other employees are prohibited from holding InfuSystem securities in a margin account or otherwise pledging InfuSystem securities as collateral for a loan. (Pledges of InfuSystem securities arising from certain types of hedging transactions are governed by the paragraph above captioned &#8220;Hedging Transactions.&#8221;)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. Standing and Limit Orders.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Standing and limit orders (except standing and limit orders under approved Rule 10b5-1 Plans, as described below) create heightened risks for insider trading violations similar to the use of margin accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when a director, officer or other employee is in possession of material nonpublic information. InfuSystem therefore discourages placing standing or limit orders on InfuSystem securities. If a person subject to this Policy determines that they must use a standing order or limit order, the order should be limited to short duration and should otherwise comply with the restrictions and procedures set forth in this Policy.  Persons subject to the pre-clearance provisions of this Policy are prohibited from placing standing or limit orders on InfuSystem securities other than in connection with approved 10b5-1 programs, which are discussed in the following section.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">10b5-1 PROGRAMS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to SEC Rule 10b5-1, directors, officers and employees of InfuSystem may establish during Open Window Periods written programs which permit (i) automatic trading of InfuSystem stock through a third-party broker or (ii) trading of InfuSystem&#8217;s stock by an independent person (e.g., an investment banker) who is not aware of material nonpublic information at the time of a trade.  All programs shall be subject to the restrictions and limitations set forth in Exhibit A, attached hereto, which shall be updated from time to time by InfuSystem&#8217;s Compliance Officer to conform any changes to SEC Rule 10b5-1 or the practices thereunder.  Once a program is implemented in accordance with this Policy and such Exhibit, trades pursuant to such program shall not be subject to the limitations and restrictions set forth in other sections of this Policy.  Trading pursuant to a program may occur even at a time outside of an Open Window Period or when the person on whose behalf such trade is made is aware of material nonpublic information.  Each program (or the form of program established by an investment bank or other third party) must be reviewed by InfuSystem&#8217;s Compliance Officer prior to establishment, amendment or termination, to confirm compliance with this Policy and all applicable securities laws. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ADDITIONAL INFORMATION &#8211; DIRECTORS AND OFFICERS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Directors and officers of InfuSystem must also comply with the reporting obligations and limitations on short-swing transactions set forth in Section 16 of the Exchange Act.  The practical effect of these provisions is that officers and directors who purchase and sell InfuSystem&#8217;s securities within a six-month period must disgorge all profits to InfuSystem whether or not they had knowledge of any Inside Information.  Under these provisions, and so long as certain other criteria are met, neither the receipt of an option under InfuSystem&#8217;s option plans, nor the exercise of that option is deemed a purchase under Section 16&#59; however, the sale of any such shares is a sale under Section 16.  Moreover, no officer or director may ever make a short sale of InfuSystem stock.  InfuSystem has provided or will provide separate memoranda and other appropriate materials to its officers and directors regarding compliance with Section 16 and its related rules and is ready to assist directors and officers in preparing and filing the required forms.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DISCLOSURE OF INFORMATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem has developed and continues to develop proprietary, confidential and non-public information.  In the course of business operations, you may become aware of such information.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">You may not disclose or otherwise use any proprietary, confidential or nonpublic information of any kind acquired as a result of your association with InfuSystem except, of course, for or on behalf of InfuSystem.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  This obligation applies whether that information relates to InfuSystem or another organization (such as a customer or supplier) and continues even after you are no longer associated with InfuSystem.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event any officer, director or employee receives any inquiry from outside of InfuSystem, such as a stock analyst, for information (particularly financial results and&#47;or projections) that may be Inside Information, the inquiry should be referred to InfuSystem&#8217;s Chief Financial Officer, who is responsible for coordinating and overseeing the release of such information to the investing public, analysts and others in compliance with applicable laws and regulations.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If you have a question as to whether information is proprietary, confidential or nonpublic, you should contact the Compliance Officer.  You must abstain from disclosing or otherwise using such information until you are informed that its disclosure or other use is permitted.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, do not answer questions from news media reporters, securities analysts, or stockholders about InfuSystem business, policies, or practices, either directly or through another person.  Instead, refer such inquiries to the Chief Executive Officer, Chairman or Vice Chairman of the Board of Directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trading programs established pursuant to the section entitled &#8220;10b5-1 Programs&#8221; of InfuSystem&#8217;s Insider Trading and Information Disclosure Policy Statement (each a &#8220;Program&#8221;) are limited to the following two types&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;A written Program which permits automatic trading of InfuSystem&#8217;s stock through a third party broker (an &#8220;Automatic Trading Program&#8221;) established by a director, officer or employee of InfuSystem (a &#8220;Program Eligible Person&#8221;) during an Open Window Period and at a time when the Program Eligible Person is not aware of material nonpublic information.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  The Automatic Trading Program document must specify the number of shares to be purchased or sold, the price(s) at which transaction are to take place, and the date(s) on which transactions are to take place.  Alternatively, the Automatic Trading Program may establish an objective formula for any or all of these criteria (e.g., the number of shares could be specified as a percentage of the holdings of the Program Eligible Person)&#59; or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;A Program where transactions in InfuSystem&#8217;s stock initiated by the trustee of a so-called &#8220;blind&#8221; trust, provided the Program is established by a Program Eligible Person during an Open Window Period and at a time when the Program Eligible Person is not aware of material nonpublic information.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  A &#8220;blind&#8221; trust is a trust established by a Program Eligible Person.  The investment and disposition decisions must be made by an independent trustee without any involvement or even knowledge of the Program Eligible Person.  The trustee should be a recognized financial institution possessing trust powers.  Under this type of Program, the Program Eligible Person cannot exert any influence over, or even communicate with, the trustee regarding specific investments.  If the trustee becomes aware of material nonpublic information regarding InfuSystem, whether from the Program Eligible Person or otherwise, the trustee may not engage in a purchase or sale of InfuSystem&#8217;s stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Program Restrictions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  All Programs shall also be subject to the following restrictions and limitations to the extent then provided in Rule 10b5-1 or required by the Compliance Officer.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Program must be in writing and approved in advance by the Compliance Officer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Program must comply with and be adopted in accordance with the provisions of Rule 10b5-1.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Program Eligible Person cannot engage in any separate transaction (e.g., a hedging transaction) which directly or indirectly alters or offsets an authorized transaction made under the Program. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any Program Eligible Person preparing such a Program must allow for the cancellation of a transaction and&#47;or suspension of a Program upon notice and request by InfuSystem to the extent the Program or any proposed trade (i) fails to comply with applicable law (e.g., exceeding the number of shares which the Program Eligible Person may sell under Rule 144 in a rolling three-month period), or (ii) would </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">create material adverse consequences for InfuSystem (e.g., due to the imposition of lock-up agreements on InfuSystem&#8217;s officers).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;No Program may be established during a Closed Window Period or at a time when the Program Eligible Person is aware of material nonpublic information.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Once a Program is prepared, it cannot be changed, modified or terminated, except (i) with notice to InfuSystem&#8217;s Compliance Officer and (ii) at a time when the Program Eligible Person is permitted to trade in InfuSystem&#8217;s stock under this Policy (i.e., during the Open Window Period when the Program Eligible Person is not otherwise blocked from trading and when the Program Eligible Person is not aware of material nonpublic information). Any cancellation of trades under a Program is considered an amendment of the Program.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;All Programs must be entered into in good faith and not as part of a plan or scheme to evade the prohibitions of the securities laws (including, without limitation, Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended) and the Program Eligible Person must act in good faith with respect to the Program throughout the duration of the Program.   InfuSystem may immediately terminate any Program that it determines was put in place either (i) not in good faith or (ii) as part of a plan or scheme to evade the prohibitions of the securities laws.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Other than for an issuer, Rule 10b5-1 requires a cooling-off period between the establishment of a Program, or any specified modification of a Program, and the commencement of sales thereafter.</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;For directors and officers of InfuSystem subject to Section 16 of the Exchange Act, the cooling-off period extends until the later of&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;90 days after the adoption (or modification) of the Program&#59; and</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;two business days following the disclosure of InfuSystem&#8217;s financial results in a periodic report on Form 10-K or Form 10-Q for the fiscal quarter in which the Program was adopted or modified&#59; provided that the cooling-off period is not required to exceed 120 days.</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2)&#160;&#160;&#160;&#160;For other Program Eligible Persons, the cooling-off period extends until 30 days after the adoption (or modification) of the Program.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;For directors and officers of InfuSystem subject to Section 16 of the Exchange Act, the Program must include a certification by the director or officer stating that, on the date of the adoption of the Program, he or she is&#58; (i) not aware of any material non-public information about InfuSystem or its securities&#59; and (ii) adopting the Program in good faith and not as a part of a plan or scheme to evade the prohibitions of Rule 10b-5.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;A Program Eligible Person may not have in place more than one Program at a time other than as permitted by applicable law and approved by the Compliance Officer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;A Program Eligible Person may not enter into more than one single-trade plan during any consecutive 12-month period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;A Program Eligible Person or his or her broker must inform the Compliance Officer of each transaction under the Program so that InfuSystem may monitor compliance with the filing obligations of Section 16 of the Exchange Act and Rule 144 of the Securities Act of 1933, as amended.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;The Program must comply with and be adopted in accordance with the such other requirements as may be directed by the Compliance Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;InfuSystem will publicly disclose the adoption or termination of a Program by a Program Eligible Person, and will include disclosure regarding the material terms of any such Program in its filings with the SEC, in each case to the extent required by applicable law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The key terms of InfuSystem Policy and Programs established pursuant to it (and trades made pursuant thereto) may be disclosed to the public through a press release, by placement on InfuSystem&#8217;s Website or through other means to be determined by InfuSystem in its discretion. InfuSystem shall not have any liability to any Program Eligible Person as a result of the establishment of a Program, any InfuSystem disclosure with respect thereto, or any cancellation or transactions and&#47;or suspension of a Program as discussed above.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated by the Board of Directors on January 19, 2024.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>infu-20251231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if2e76dabec524a138bb03b01a2902893_1"></div><div style="min-height:49.96pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 21.1</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries of the Registrant</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.279%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction&#160;of&#160;Organization</font></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">InfuSystem, Inc.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:61.61pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>infu-20251231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i08746c32131144248ec6f134eac98e08_1"></div><div style="min-height:49.96pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 23.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in the Registration Statement Nos. 333-195929, 333-195930, 333-217090, 333-226872, 333-232146, 333-256231, 333-272459, 333-272461 and 333-287988 on Form S-8 of our reports dated February&#160;27, 2026</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> relating to the financial statements of InfuSystem Holdings, Inc. and the effectiveness of InfuSystem Holdings, Inc.&#8217;s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December&#160;31, 2025.</font></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; DELOITTE &#38; TOUCHE LLP </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Detroit, Michigan </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;27, 2026</font></div><div><font><br></font></div><div style="height:61.61pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>infu-20251231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if27968bccbb44396b5d4c5c135c3278b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY OFFICER</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard DiIorio, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Form 10-K for the year ended December&#160;31, 2025 of InfuSystem Holdings, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-9pt"><font><br></font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-9pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 27, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; CARRIE LACHANCE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Carrie Lachance</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>infu-20251231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i8fe91132162b44359ff7e590756e2f81_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY OFFICER</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Barry Steele, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Form 10-K for the year ended December&#160;31, 2025 of InfuSystem Holdings, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-9pt"><font><br></font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-9pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 27, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BARRY STEELE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Barry Steele</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>infu-20251231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i171ffd7428ff4e1eaa381deb8509fa47_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Form 10-K for the year ended December&#160;31, 2025 (the &#8220;Report&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt;text-indent:27pt"><font><br></font></div><div style="margin-top:10pt;text-indent:27pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 27, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; CARRIE LACHANCE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Carrie Lachance</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>infu-20251231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i7c5b2fc57d3944dcb167625815639930_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Form 10-K for the year ended December 31, 2024 (the &#8220;Report&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt;text-indent:27pt"><font><br></font></div><div style="margin-top:10pt;text-indent:27pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 27, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BARRY STEELE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Barry Steele</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>infu-20251231xexx971former.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib67802a5cc854a828b5c051f66de8526_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 97.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFUSYSTEM HOLDINGS, INC.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Purpose</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of this Policy is to describe certain circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to the Company Group. Each Executive Officer must sign an acknowledgement or other agreement pursuant to which such Executive Officer will agree to be bound by, and comply with, this Policy.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This Policy will be administered by the Committee. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. Notwithstanding the foregoing, it is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Securities Exchange Act of 1934, as amended, and any applicable rules or standards adopted by the SEC or the NYSE, and, to the extent this Policy is in any manner deemed inconsistent with such rules or standards, this Policy will be treated as retroactively amended to be compliant with such rules or standards. Any determinations made by the Committee will be final and binding on all affected individuals and need not be uniform with respect to each individual covered by this Policy. In the administration of this Policy, the Committee is authorized and directed to consult with the full Board or such other committees of the Board, such as the Audit Committee, as may be necessary or appropriate as to matters within the scope of such other committee's responsibility and authority. Subject to any limitation at applicable law, the Committee may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. For purposes of this Policy, the following capitalized terms have the meanings set forth below.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. For the avoidance of doubt, an out-of-period adjustment, in which an error is immaterial to the previously issued financial statements and the correction of the error is also immaterial to the current period, will not constitute an Accounting Restatement.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means the Board of Directors of the Company.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback Eligible Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means, in connection with an Accounting Restatement and with respect to each individual who served as an Executive Officer at any time during the applicable performance period for any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company Group), all Incentive-based Compensation Received by such Executive Officer (1) on or after the Effective Date, (2) after beginning service as an Executive Officer, (3) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (4) during the applicable Clawback Period.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date and any transition period (that results from a change in the Company's fiscal year) of less than nine months within or immediately following those three completed fiscal years. For purposes of this Policy, a transition period between the last day of the Company's previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to twelve months will be deemed a completed fiscal year.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means the Compensation Committee of the Board.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means InfuSystem Holdings, Inc., a Delaware corporation.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company Group</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means the Company, together with each of its direct and indirect subsidiaries.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means October 2, 2023.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid. By way of example, with respect to any compensation plans or programs that take into account or relate to Incentive-based Compensation, the amount of Erroneously Awarded Compensation subject to recovery under this Policy includes the amount contributed to any notional account based on Erroneously Awarded Compensation and any earnings accrued to date on that notional amount.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means (1) each individual who is or was designated as an &#34;officer&#34; of the Company in accordance with 17 C.F.R. 240.16a-1(f) and (2) such additional members of the Company's senior leadership team as may be designated by the Committee. Executive Officer for purposes of this Policy includes, at a minimum, executive officers identified pursuant to 17 C.F.R. 229.401(b). Subsequent changes in an Executive Officer's employment status, including retirement or termination of employment, do not affect the Company's rights to recover Erroneously Awarded Compensation pursuant to this Policy.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Measure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and any other measure that is derived wholly or in part from such measure. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company's financial statements or included in a filing with the SEC. Stock price and total shareholder return will, for purposes of this Policy, each be considered a Financial Reporting Measure.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive-based Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"> &#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NYSE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means NYSE American LLC.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means this Policy for the Recovery of Erroneously Awarded Compensation, as the same may be amended or restated from time to time.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">o.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Received</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means actual or deemed receipt, and Incentive-based Compensation will be deemed received in the Company's fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if payment or grant of the Incentive-based Compensation occurs after the end of that period. For the avoidance of doubt, Incentive-based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition will be considered Received when the relevant Financial Reporting Measure is achieved, even if the Incentive-based Compensation continues to be subject to the service-based vesting condition which is later satisfied.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">p.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means the earlier to occur of (1) the date the Board, a committee of the Board, or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement or (2) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement, in each case regardless of if or when the restated financial statements are filed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">q.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Repayment of Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">If an Accounting Restatement occurs, the Committee will reasonably promptly determine the amount of any Erroneously Awarded Compensation for each Executive Officer in connection with such Accounting Restatement and will reasonably promptly thereafter provide each Executive Officer with a written notice containing the amount of Erroneously Awarded Compensation and a demand for repayment or return, as applicable. For Incentive-based Compensation based on (or derived from) stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount will be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-based Compensation was Received (in which case, the Company will maintain documentation of such determination of that reasonable estimate and provide such documentation to the NYSE).</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Committee has broad discretion to determine the appropriate means of recovery of Erroneously Awarded Compensation based on all applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery, which methods of recovery need not be applied on a consistent basis&#59; provided in any case that any such method provides for reasonably prompt recovery and otherwise complies with any requirements of the NYSE. To the extent that the Committee determines that any method of recovery (other than repayment by the Executive Officer in a lump sum in cash or property) is appropriate, the Company will offer to enter into a repayment agreement (in a form reasonable acceptable to the Committee) with the Executive Officer. If the Executive Officer fails to sign the repayment agreement within 30 days after such offer is extended, the Executive Officer will be required to repay the Erroneously Awarded Compensation in a lump sum in cash. For the avoidance of doubt, except as set forth in Section 4(e) below, in no event may the Company Group accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer's obligations hereunder.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">To the extent that an Executive Officer fails to repay all Erroneously Awarded Compensation to the Company Group when due, the Company will, or will cause one or more other members of the Company Group to, take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer, which may include, by way of example, the forfeiture of unvested Incentive-based Compensation, the forfeiture of unvested time-based equity or cash incentive compensation awards, the forfeiture of benefits under a nonqualified deferred compensation plan, withholding of dividends and the offset of all or a portion of the amount of the Erroneously Awarded Compensation against other compensation payable to the Executive Officer. </font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The applicable Executive Officer must reimburse the Company Group for any and all expenses reasonably incurred (including legal fees) by members of the Company Group in recovering such Erroneously Awarded Compensation in accordance with the terms of this Policy.</font></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Notwithstanding anything herein to the contrary, the Company will not be required to take the actions contemplated by this Section 4 if the following conditions are met and the Committee determines that recovery would be impracticable&#58;</font></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-23.27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">The direct expenses paid to a third party to assist in enforcing the Policy against an Executive Officer would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously Awarded Compensation, documented such attempts, and provided such documentation to the NYSE&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-26.04pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Recovery would violate home country law where that law was adopted prior to November 28, 2022&#59; provided that, before determining that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such a violation, and a copy of the opinion has been provided to the NYSE&#59; or</font></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-28.81pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Reporting and Disclosure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required by applicable SEC filings.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Indemnification Prohibition</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. No member of the Company Group will indemnify any Executive Officer (including for the avoidance of doubt any former Executive Officer) against (a) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (b) any claims relating to the enforcement by any member of the Company Group of its rights under this Policy. Further, the members of the Company Group are prohibited from paying or reimbursing an Executive Officer (including for the avoidance of doubt any former Executive Officer) for the cost of purchasing insurance to cover any such loss. No member of the Company Group will enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the right of any member of the Company Group to recovery of any Erroneously Awarded Compensation and this Policy will supersede any such agreement (whether entered into before, on or after the Effective Date).</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Administrator Indemnification</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Any members of the Committee, and any other members of the Board who assist in the administration of this Policy, will not be personally liable for any action, determination or interpretation made with respect to this Policy and will be fully indemnified by the Company to the fullest extent under applicable law and Company policy or applicable indemnification agreement with respect to any such action, determination or interpretation. The foregoing sentence will not limit any other rights to indemnification of the members of the Board under applicable law or Company policy or applicable indemnification agreement.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This Policy is effective as of the Effective Date.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Committee may unilaterally amend this Policy from time to time in its discretion and will amend this Policy as it deems necessary, including as and when it determines that it is legally required by any federal securities laws, SEC rule, or the rules of any national securities exchange or national securities association on which the Company's securities are listed. The Committee may terminate this Policy at any time. Notwithstanding anything in this Section 9 to the contrary, no amendment or termination of this Policy will be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule, or the rules of any national securities exchange or national securities association on which the Company's securities are listed.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Other Recoupment Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">No Additional Payments&#59; Company Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Committee intends that this Policy will be applied to the fullest extent of the law. The Committee may require that any employment agreement, equity award agreement, or any other agreement entered into on or after the Effective Date will, as a condition to the grant of any benefit thereunder, require an employee to agree to abide by the terms of this Policy to the extent applicable, and any employment agreement, equity award agreement, or any other agreement entered into with an employee of any member of the Company Group before, on or after the Effective Date may be unilaterally amended by any member of the Company Group to comply with this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to any member of the Company Group under applicable law, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulation or rule or pursuant to the terms of any similar policy or provision in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the members of the Company Group. Nothing contained in this Policy, and no recoupment or recovery as contemplated by this Policy, will limit any claims, damages or other legal remedies the members of the Company Group or any of their respective affiliates may have against an Executive Officer arising out of or resulting from any actions or omissions by the Executive Officer.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Successors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This Policy will be binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The provisions of this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and will automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Governing Law&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Except to the extent preempted by federal law, the laws of the State of Delaware, as amended from time to time, will govern the construction and application of this Policy. Words used in the singular include the plural, as appropriate. The words &#34;herein,&#34; &#34;hereunder,&#34; and other similar compounds of the word &#34;here&#34; refer to this entire Policy, not to a particular section. Any mention of &#34;Sections&#34;, unless stated specifically to the contrary, refers to a section in this Policy. All references to statutory sections or rules or standards of any governmental authority, national securities exchange or national securities association include the section, rule or standard so identified, as amended from time to time, or any other applicable statute, rule or standard of similar import and in the case of any statute, all applicable rule and regulations promulgated thereunder. The word &#34;including&#34; (in its various forms) means &#34;including without limitation.&#34;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>infu-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:7814b130-9ea8-4497-bd4c-7510be4e72d5,g:0e5cd592-a670-4737-bede-9aef47e8c4b0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:infu="http://infusystem.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://infusystem.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="infu-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="infu-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="infu-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="infu-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://infusystem.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://infusystem.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandNatureofOperations" roleURI="http://infusystem.com/role/BasisofPresentationandNatureofOperations">
        <link:definition>9952156 - Disclosure - Basis of Presentation and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://infusystem.com/role/BusinessCombinations">
        <link:definition>9952158 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://infusystem.com/role/Revenue">
        <link:definition>9952159 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalEquipment" roleURI="http://infusystem.com/role/MedicalEquipment">
        <link:definition>9952160 - Disclosure - Medical Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://infusystem.com/role/PropertyandEquipment">
        <link:definition>9952161 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://infusystem.com/role/GoodwillandIntangibleAssets">
        <link:definition>9952162 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://infusystem.com/role/Debt">
        <link:definition>9952163 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsandHedgingActivities" roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivities">
        <link:definition>9952164 - Disclosure - Derivative Financial Instruments and Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://infusystem.com/role/IncomeTaxes">
        <link:definition>9952165 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://infusystem.com/role/CommitmentsandContingencies">
        <link:definition>9952166 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://infusystem.com/role/Leases">
        <link:definition>9952167 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://infusystem.com/role/ShareBasedCompensation">
        <link:definition>9952168 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentInformation" roleURI="http://infusystem.com/role/BusinessSegmentInformation">
        <link:definition>9952169 - Disclosure - Business Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandOther" roleURI="http://infusystem.com/role/EmployeeBenefitPlansandOther">
        <link:definition>9952170 - Disclosure - Employee Benefit Plans and Other</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEarningsPerShareTables" roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesEarningsPerShareTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://infusystem.com/role/BusinessCombinationsTables">
        <link:definition>9955513 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://infusystem.com/role/RevenueTables">
        <link:definition>9955514 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalEquipmentTables" roleURI="http://infusystem.com/role/MedicalEquipmentTables">
        <link:definition>9955515 - Disclosure - Medical Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://infusystem.com/role/PropertyandEquipmentTables">
        <link:definition>9955516 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>9955517 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://infusystem.com/role/DebtTables">
        <link:definition>9955518 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsandHedgingActivitiesTables" roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables">
        <link:definition>9955519 - Disclosure - Derivative Financial Instruments and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://infusystem.com/role/IncomeTaxesTables">
        <link:definition>9955520 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://infusystem.com/role/LeasesTables">
        <link:definition>9955521 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://infusystem.com/role/ShareBasedCompensationTables">
        <link:definition>9955522 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentInformationTables" roleURI="http://infusystem.com/role/BusinessSegmentInformationTables">
        <link:definition>9955523 - Disclosure - Business Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandNatureofOperationsDetails" roleURI="http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails">
        <link:definition>9955524 - Disclosure - Basis of Presentation and Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>9955526 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>9955527 - Disclosure - Business Combinations - Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofDisaggregationofRevenueDetails" roleURI="http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails">
        <link:definition>9955528 - Disclosure - Revenue - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractBalancesDetails" roleURI="http://infusystem.com/role/RevenueContractBalancesDetails">
        <link:definition>9955529 - Disclosure - Revenue - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://infusystem.com/role/RevenueNarrativeDetails">
        <link:definition>9955530 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalEquipmentScheduleofMedicalEquipmentDetails" roleURI="http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails">
        <link:definition>9955531 - Disclosure - Medical Equipment - Schedule of Medical Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalEquipmentNarrativeDetails" roleURI="http://infusystem.com/role/MedicalEquipmentNarrativeDetails">
        <link:definition>9955532 - Disclosure - Medical Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>9955533 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://infusystem.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>9955534 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofGoodwillDetails" roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails">
        <link:definition>9955535 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails" roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails">
        <link:definition>9955536 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1" roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1">
        <link:definition>9955536 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>9955537 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>9955538 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://infusystem.com/role/DebtNarrativeDetails">
        <link:definition>9955539 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLineofCreditFacilitiesDetails" roleURI="http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails">
        <link:definition>9955540 - Disclosure - Debt - Schedule of Line of Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofMaturitiesofLongtermDebtDetails" roleURI="http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails">
        <link:definition>9955541 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofDebtDetails" roleURI="http://infusystem.com/role/DebtScheduleofDebtDetails">
        <link:definition>9955542 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofDebtDetails_1" roleURI="http://infusystem.com/role/DebtScheduleofDebtDetails_1">
        <link:definition>9955542 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails">
        <link:definition>9955543 - Disclosure - Derivative Financial Instruments and Hedging Activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails">
        <link:definition>9955544 - Disclosure - Derivative Financial Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails" roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails">
        <link:definition>9955545 - Disclosure - Derivative Financial Instruments and Hedging Activities - Schedule of Designated as Hedging Instruments in AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails" roleURI="http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails">
        <link:definition>9955546 - Disclosure - Income Taxes - Schedule of Income Before Income Tax, Domestic and Foreign (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9955547 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955548 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails" roleURI="http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails">
        <link:definition>9955549 - Disclosure - Income Taxes - Schedule of Income Taxes Paid Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://infusystem.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955550 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesCarryForwardsDetails" roleURI="http://infusystem.com/role/IncomeTaxesCarryForwardsDetails">
        <link:definition>9955551 - Disclosure - Income Taxes - Carry Forwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostDetails" roleURI="http://infusystem.com/role/LeasesLeaseCostDetails">
        <link:definition>9955552 - Disclosure - Leases - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://infusystem.com/role/LeasesNarrativeDetails">
        <link:definition>9955553 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowDetails" roleURI="http://infusystem.com/role/LeasesSupplementalCashFlowDetails">
        <link:definition>9955554 - Disclosure - Leases - Supplemental Cash Flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedAverageTableDetails" roleURI="http://infusystem.com/role/LeasesWeightedAverageTableDetails">
        <link:definition>9955555 - Disclosure - Leases - Weighted Average Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9955556 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9955556 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseRevenueDetails" roleURI="http://infusystem.com/role/LeasesLeaseRevenueDetails">
        <link:definition>9955557 - Disclosure - Leases - Lease Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNetInvestmentinSalesTypeLeasesDetails" roleURI="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails">
        <link:definition>9955558 - Disclosure - Leases - Net Investment in Sales-Type Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails" roleURI="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails">
        <link:definition>9955559 - Disclosure - Leases - Net Investment in Sales-Type Leases in Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofSaleTypeLeasesDetails" roleURI="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails">
        <link:definition>9955560 - Disclosure - Leases - Maturities of Sale-Type Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofSaleTypeLeasesDetails_1" roleURI="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails_1">
        <link:definition>9955560 - Disclosure - Leases - Maturities of Sale-Type Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://infusystem.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>9955561 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockbasedCompensationDetails" roleURI="http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails">
        <link:definition>9955562 - Disclosure - Share-Based Compensation - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails" roleURI="http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails">
        <link:definition>9955563 - Disclosure - Share-Based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPSUActivityDetails" roleURI="http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails">
        <link:definition>9955564 - Disclosure - Share-Based Compensation - PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails" roleURI="http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails">
        <link:definition>9955565 - Disclosure - Share-Based Compensation - Summary of Activity Relating to Company's ESPP Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2014and2021PlanActivityDetails" roleURI="http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails">
        <link:definition>9955566 - Disclosure - Share-Based Compensation - 2014 and 2021 Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails" roleURI="http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails">
        <link:definition>9955567 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentInformationDetails" roleURI="http://infusystem.com/role/BusinessSegmentInformationDetails">
        <link:definition>9955568 - Disclosure - Business Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandOtherDetails" roleURI="http://infusystem.com/role/EmployeeBenefitPlansandOtherDetails">
        <link:definition>9955569 - Disclosure - Employee Benefit Plans and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="infu_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="infu_MedicalEquipmentHeldForSaleOrRental" abstract="false" name="MedicalEquipmentHeldForSaleOrRental" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" abstract="false" name="MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_PaymentsToAcquireMedicalEquipment" abstract="false" name="PaymentsToAcquireMedicalEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_MedicalEquipmentAbstract" abstract="true" name="MedicalEquipmentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="infu_MedicalEquipmentAndPropertyDisclosureTextBlock" abstract="false" name="MedicalEquipmentAndPropertyDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="infu_MedicalEquipmentPolicyTextBlock" abstract="false" name="MedicalEquipmentPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="infu_RevenueRecognitionCostOfRevenuePolicyTextBlock" abstract="false" name="RevenueRecognitionCostOfRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="infu_TreasuryStockPolicyPolicyTextBlock" abstract="false" name="TreasuryStockPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="infu_ScheduleOfMedicalEquipmentTableTextBlock" abstract="false" name="ScheduleOfMedicalEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" abstract="false" name="CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="infu_NetInvestmentInSalesTypeLeasesTableTextBlock" abstract="false" name="NetInvestmentInSalesTypeLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="infu_AmbulatoryPumpsMember" abstract="true" name="AmbulatoryPumpsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_SmithsMedicalIncMember" abstract="true" name="SmithsMedicalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_NumberOfLocations" abstract="false" name="NumberOfLocations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="infu_InformationTechnologySoftwareMember" abstract="true" name="InformationTechnologySoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_PhysicianAndCustomerRelationshipsMember" abstract="true" name="PhysicianAndCustomerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_NumberOfFinancialInstitutions" abstract="false" name="NumberOfFinancialInstitutions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="infu_MedicalEquipmentInRentalServicesUsefulLife" abstract="false" name="MedicalEquipmentInRentalServicesUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="infu_MedicalEquipmentInRentalServicesReserve" abstract="false" name="MedicalEquipmentInRentalServicesReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_MedicalEquipmentHeldForSaleOrRentalReserve" abstract="false" name="MedicalEquipmentHeldForSaleOrRentalReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_NumberOfContractsWithThirdParties" abstract="false" name="NumberOfContractsWithThirdParties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="infu_TermOfContract" abstract="false" name="TermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="infu_TermOfRenewal" abstract="false" name="TermOfRenewal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="infu_ApolloMedicalSupplyMember" abstract="true" name="ApolloMedicalSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_ThirdPartyPayerRentalsMember" abstract="true" name="ThirdPartyPayerRentalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_DirectPayerRentalsMember" abstract="true" name="DirectPayerRentalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_PatientServicesAndDeviceSolutionsMember" abstract="true" name="PatientServicesAndDeviceSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_PatientServicesMember" abstract="true" name="PatientServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_DeviceSolutionsMember" abstract="true" name="DeviceSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_ContractAssets" abstract="false" name="ContractAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_ContractLiabilities" abstract="false" name="ContractLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_ContractAssetsRevenuePartiallyOffsetAmount" abstract="false" name="ContractAssetsRevenuePartiallyOffsetAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_ContractAssetsRevenueRecognized" abstract="false" name="ContractAssetsRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_MedicalEquipmentHeldForSaleOrRentalGross" abstract="false" name="MedicalEquipmentHeldForSaleOrRentalGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_MedicalEquipmentInRentalServicesGross" abstract="false" name="MedicalEquipmentInRentalServicesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation" abstract="false" name="MedicalEquipmentInRentalServicesAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_MedicalEquipmentNet" abstract="false" name="MedicalEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_DepreciationExpenseRelatedToMedicalEquipment" abstract="false" name="DepreciationExpenseRelatedToMedicalEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_The2021CreditAgreementMember" abstract="true" name="The2021CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_TermBenchmarkLoansMember" abstract="true" name="TermBenchmarkLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_ABRLoansMember" abstract="true" name="ABRLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_PercentageOfTotalDepreciationExpense" abstract="false" name="PercentageOfTotalDepreciationExpense" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="infu_DebtInstrumentCovenantMinimumFixedCoverageRatio" abstract="false" name="DebtInstrumentCovenantMinimumFixedCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="infu_DebtInstrumentCovenantMaximumLeverageRatio" abstract="false" name="DebtInstrumentCovenantMaximumLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="infu_LongTermDebtGrossCurrent" abstract="false" name="LongTermDebtGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_LongTermDebtGrossNoncurrent" abstract="false" name="LongTermDebtGrossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_UnamortizedDebtIssuanceExpenseCurrent" abstract="false" name="UnamortizedDebtIssuanceExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_UnamortizedDebtIssuanceExpenseNoncurrent" abstract="false" name="UnamortizedDebtIssuanceExpenseNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="infu_OperatingLossCarryforwardsWithADefiniteLife" abstract="false" name="OperatingLossCarryforwardsWithADefiniteLife" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_OperatingLossCarryforwardsExpirationPeriods" abstract="false" name="OperatingLossCarryforwardsExpirationPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="infu_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications" abstract="false" name="IncreasesToRightOfUseAssetsResultingFromLeaseModifications" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_SalesTypeLeaseNetInvestmentInLeaseTable" abstract="true" name="SalesTypeLeaseNetInvestmentInLeaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="infu_LeaseClassificationAxis" abstract="true" name="LeaseClassificationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="infu_LeaseClassificationDomain" abstract="true" name="LeaseClassificationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_SalesTypeLeaseNetInvestmentMember" abstract="true" name="SalesTypeLeaseNetInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_SalesTypeLeaseNetInvestmentInLeaseLineItems" abstract="true" name="SalesTypeLeaseNetInvestmentInLeaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember" abstract="true" name="ShareBasedPaymentArrangementExceedingMinimumThresholdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember" abstract="true" name="ShareBasedPaymentArrangementAchievingMinimumThresholdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_A2021EquityIncentivePlanMember" abstract="true" name="A2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_A2014EquityIncentivePlanMember" abstract="true" name="A2014EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" abstract="false" name="EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" abstract="false" name="StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" abstract="false" name="EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="infu_CorporateAndEliminationsMember" abstract="true" name="CorporateAndEliminationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="infu_NetRevenuesExternal" abstract="false" name="NetRevenuesExternal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="infu_NetRevenuesInternal" abstract="false" name="NetRevenuesInternal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>infu-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:7814b130-9ea8-4497-bd4c-7510be4e72d5,g:0e5cd592-a670-4737-bede-9aef47e8c4b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_541b632c-2f99-4799-9194-dfc0ce32b677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ae354812-8ec4-4ec8-9be0-fb4a6839dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_541b632c-2f99-4799-9194-dfc0ce32b677" xlink:to="loc_us-gaap_StockholdersEquity_ae354812-8ec4-4ec8-9be0-fb4a6839dd42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7725fc58-ebc1-430b-a911-a2726e5455c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_541b632c-2f99-4799-9194-dfc0ce32b677" xlink:to="loc_us-gaap_Liabilities_7725fc58-ebc1-430b-a911-a2726e5455c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a733fa8f-8956-4a0d-a4f9-fe6aae484b72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ba5c8370-183a-4e25-a0c1-7c1691a10bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a733fa8f-8956-4a0d-a4f9-fe6aae484b72" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ba5c8370-183a-4e25-a0c1-7c1691a10bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5b053b23-c5e5-4195-9fe4-c9aa7cebcbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a733fa8f-8956-4a0d-a4f9-fe6aae484b72" xlink:to="loc_us-gaap_AccountsPayableCurrent_5b053b23-c5e5-4195-9fe4-c9aa7cebcbb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2a7b855d-cad0-458d-9816-a7bddadfabb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_31d8476e-74e1-49bc-bda6-1b5c508a40d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2a7b855d-cad0-458d-9816-a7bddadfabb9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_31d8476e-74e1-49bc-bda6-1b5c508a40d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_018c8abb-ada2-41ed-b016-ae7972ec4d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2a7b855d-cad0-458d-9816-a7bddadfabb9" xlink:to="loc_us-gaap_LiabilitiesCurrent_018c8abb-ada2-41ed-b016-ae7972ec4d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_876fabc5-c25e-4947-a51f-52a68011041a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2a7b855d-cad0-458d-9816-a7bddadfabb9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_876fabc5-c25e-4947-a51f-52a68011041a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7f74f872-5b21-4b50-b2a9-60df281a0597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7f74f872-5b21-4b50-b2a9-60df281a0597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_16eb7729-2f66-4e09-a665-582c2d61e358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_16eb7729-2f66-4e09-a665-582c2d61e358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ae6cf117-9743-4b44-9f89-39dcdb0854b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ae6cf117-9743-4b44-9f89-39dcdb0854b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1c821cb-d450-4db3-8b61-bbf9d9d2548a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1c821cb-d450-4db3-8b61-bbf9d9d2548a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_b59bf779-b73e-4858-8488-3403e1e236d0" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_b59bf779-b73e-4858-8488-3403e1e236d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c332862-cc4f-47b7-a2d1-7dd79d57ac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c332862-cc4f-47b7-a2d1-7dd79d57ac3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5d07bf93-ed49-4fd6-b2b8-2a88a4f881e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_AssetsCurrent_5d07bf93-ed49-4fd6-b2b8-2a88a4f881e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRental_fc3ae213-e729-4753-b6bf-0eb390d08b49" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRental"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRental_fc3ae213-e729-4753-b6bf-0eb390d08b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_07d84aad-2487-4477-ac51-17952a018c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_Goodwill_07d84aad-2487-4477-ac51-17952a018c0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_6a3ccecb-1766-49fd-bbc9-80fe3ad1802e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f51c4f92-ca10-4be7-9dfa-4e1ae43e5382" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_6a3ccecb-1766-49fd-bbc9-80fe3ad1802e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7f7669e-f0b1-478e-a200-75712b4b2ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4db5c1cf-d0e4-4518-af85-f06947a0cd89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b7f7669e-f0b1-478e-a200-75712b4b2ed9" xlink:to="loc_us-gaap_CommonStockValue_4db5c1cf-d0e4-4518-af85-f06947a0cd89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_55156f4e-ca5a-4207-91b9-5b6e25969ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b7f7669e-f0b1-478e-a200-75712b4b2ed9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_55156f4e-ca5a-4207-91b9-5b6e25969ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b7cb768-db95-407c-bad0-3086580b3d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b7f7669e-f0b1-478e-a200-75712b4b2ed9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b7cb768-db95-407c-bad0-3086580b3d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_611a716e-4634-4af8-b873-a33cb1e658ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b7f7669e-f0b1-478e-a200-75712b4b2ed9" xlink:to="loc_us-gaap_PreferredStockValue_611a716e-4634-4af8-b873-a33cb1e658ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0857dcdc-49ce-48cf-bb46-eebe4854dc53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b7f7669e-f0b1-478e-a200-75712b4b2ed9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0857dcdc-49ce-48cf-bb46-eebe4854dc53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c5969cdb-0291-45f3-8ca5-e35c541b9508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f8f390e2-2b5b-4f3f-84bb-247d5fff8516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5969cdb-0291-45f3-8ca5-e35c541b9508" xlink:to="loc_us-gaap_InventoryNet_f8f390e2-2b5b-4f3f-84bb-247d5fff8516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_88aafe65-693f-4621-a71d-5b7f0b40b61f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5969cdb-0291-45f3-8ca5-e35c541b9508" xlink:to="loc_us-gaap_OtherAssetsCurrent_88aafe65-693f-4621-a71d-5b7f0b40b61f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f36b21e0-75cf-49a7-a989-4e7684efd303" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5969cdb-0291-45f3-8ca5-e35c541b9508" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f36b21e0-75cf-49a7-a989-4e7684efd303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5c864235-80dd-4a50-a262-f6d0bf28cc86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5969cdb-0291-45f3-8ca5-e35c541b9508" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5c864235-80dd-4a50-a262-f6d0bf28cc86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8fe4cf31-5b2d-49d5-bdf7-79a94e09bc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c534710-96db-403f-97a0-c18a828e53ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8fe4cf31-5b2d-49d5-bdf7-79a94e09bc8a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c534710-96db-403f-97a0-c18a828e53ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0f6d465d-adb8-4ef0-8586-57832f5c1460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8fe4cf31-5b2d-49d5-bdf7-79a94e09bc8a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0f6d465d-adb8-4ef0-8586-57832f5c1460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4a2be56f-db26-4fdb-ae69-69c7c6b2027e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5bf8726f-c7e9-4a86-9f17-69fa5458e1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4a2be56f-db26-4fdb-ae69-69c7c6b2027e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5bf8726f-c7e9-4a86-9f17-69fa5458e1ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_57203465-2c8a-4b3b-a7f5-4a81cfa4156c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4a2be56f-db26-4fdb-ae69-69c7c6b2027e" xlink:to="loc_us-gaap_NetIncomeLoss_57203465-2c8a-4b3b-a7f5-4a81cfa4156c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c29c7399-3d61-4858-975c-4fd6d6adb27b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_3632c8bf-33b4-4a4c-98a9-1658f2411336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c29c7399-3d61-4858-975c-4fd6d6adb27b" xlink:to="loc_us-gaap_InterestExpenseNonoperating_3632c8bf-33b4-4a4c-98a9-1658f2411336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_548f7d93-957b-49e7-8cec-33cbad980270" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c29c7399-3d61-4858-975c-4fd6d6adb27b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_548f7d93-957b-49e7-8cec-33cbad980270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_efa605c9-eb98-4528-9373-acaa95a2e127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c29c7399-3d61-4858-975c-4fd6d6adb27b" xlink:to="loc_us-gaap_OperatingIncomeLoss_efa605c9-eb98-4528-9373-acaa95a2e127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2a7483c1-af80-4aed-bcb0-dcfbc3e39249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f760fd52-cbdb-464c-9b8b-67723690fd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a7483c1-af80-4aed-bcb0-dcfbc3e39249" xlink:to="loc_us-gaap_OperatingExpenses_f760fd52-cbdb-464c-9b8b-67723690fd4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fe5d4782-2c75-45aa-b78a-50b68de849d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a7483c1-af80-4aed-bcb0-dcfbc3e39249" xlink:to="loc_us-gaap_GrossProfit_fe5d4782-2c75-45aa-b78a-50b68de849d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_88e28b22-02c2-47a8-a748-9a16938520d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c5903c5f-5b63-416b-9933-cc1caa0de3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_88e28b22-02c2-47a8-a748-9a16938520d5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c5903c5f-5b63-416b-9933-cc1caa0de3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_264ddfa4-66ff-4282-9f24-39e1abb85c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_88e28b22-02c2-47a8-a748-9a16938520d5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_264ddfa4-66ff-4282-9f24-39e1abb85c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_cefa0d17-2a10-4f57-b409-983b0923423c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_88e28b22-02c2-47a8-a748-9a16938520d5" xlink:to="loc_us-gaap_SellingAndMarketingExpense_cefa0d17-2a10-4f57-b409-983b0923423c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fabafea3-dca3-471a-b7af-c2b1753e6e79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_817d4266-3d43-412f-a631-5b1272afbc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fabafea3-dca3-471a-b7af-c2b1753e6e79" xlink:to="loc_us-gaap_Revenues_817d4266-3d43-412f-a631-5b1272afbc5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a17cd2dc-9478-40b0-bff6-c60b8cb07f70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fabafea3-dca3-471a-b7af-c2b1753e6e79" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a17cd2dc-9478-40b0-bff6-c60b8cb07f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a1ec7dcb-8306-4a2b-a7ea-0fd5ade2443d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_6a58682f-7842-4e62-8982-c7b1df20c135" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a1ec7dcb-8306-4a2b-a7ea-0fd5ade2443d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_6a58682f-7842-4e62-8982-c7b1df20c135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_57eb3e39-8bc0-4e29-b1e7-3d5a2d77981d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a1ec7dcb-8306-4a2b-a7ea-0fd5ade2443d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_57eb3e39-8bc0-4e29-b1e7-3d5a2d77981d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344d09a7-8df9-47cf-bde0-65bb0c0cff5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23593ffe-a8a9-47f8-b710-660bb4498f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344d09a7-8df9-47cf-bde0-65bb0c0cff5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23593ffe-a8a9-47f8-b710-660bb4498f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_040af518-69c8-493f-9a7d-3522fb9603a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344d09a7-8df9-47cf-bde0-65bb0c0cff5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_040af518-69c8-493f-9a7d-3522fb9603a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3bc55a56-b9b3-4b3b-a8a2-a25a6773381d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344d09a7-8df9-47cf-bde0-65bb0c0cff5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3bc55a56-b9b3-4b3b-a8a2-a25a6773381d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd31cef7-defb-4b6d-8a6a-b042bea8ce38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f4ea8ece-6ba0-43d4-b1f3-848fe0aa83a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd31cef7-defb-4b6d-8a6a-b042bea8ce38" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f4ea8ece-6ba0-43d4-b1f3-848fe0aa83a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PaymentsToAcquireMedicalEquipment_05c7c7bf-a825-45fd-a323-d596fa882534" xlink:href="infu-20251231.xsd#infu_PaymentsToAcquireMedicalEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd31cef7-defb-4b6d-8a6a-b042bea8ce38" xlink:to="loc_infu_PaymentsToAcquireMedicalEquipment_05c7c7bf-a825-45fd-a323-d596fa882534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4459f62e-f146-4951-88e4-a5d13f42e696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd31cef7-defb-4b6d-8a6a-b042bea8ce38" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4459f62e-f146-4951-88e4-a5d13f42e696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_019c4c04-072e-72c2-8ae4-f38d92e1cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd31cef7-defb-4b6d-8a6a-b042bea8ce38" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_019c4c04-072e-72c2-8ae4-f38d92e1cc1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47cab210-8d60-4848-9f9e-73aff44a1c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_38dd4a00-81cd-40b7-bd18-32e6a9952824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47cab210-8d60-4848-9f9e-73aff44a1c8b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_38dd4a00-81cd-40b7-bd18-32e6a9952824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6d3cf535-7a27-463a-8437-8774ceb49fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47cab210-8d60-4848-9f9e-73aff44a1c8b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6d3cf535-7a27-463a-8437-8774ceb49fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_030ce9ce-edd8-44db-a143-ef81e49488c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47cab210-8d60-4848-9f9e-73aff44a1c8b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_030ce9ce-edd8-44db-a143-ef81e49488c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0eaa0377-ffef-4d4e-bd05-d93815bc6b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47cab210-8d60-4848-9f9e-73aff44a1c8b" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0eaa0377-ffef-4d4e-bd05-d93815bc6b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8cc37c8e-abd2-4f2a-b0c5-e999173787b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47cab210-8d60-4848-9f9e-73aff44a1c8b" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8cc37c8e-abd2-4f2a-b0c5-e999173787b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_4b6b3ea0-d2ef-423e-940d-33ef71906ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47cab210-8d60-4848-9f9e-73aff44a1c8b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_4b6b3ea0-d2ef-423e-940d-33ef71906ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_25c66467-8aa2-4b8e-9044-d5a75aa6a113" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_25c66467-8aa2-4b8e-9044-d5a75aa6a113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ae5ff61-72fa-41d1-8f25-99249d1c5d39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ae5ff61-72fa-41d1-8f25-99249d1c5d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ca36f6c9-2189-4065-a2ca-51ad2173925b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ca36f6c9-2189-4065-a2ca-51ad2173925b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_2599f40d-509c-410c-b7ed-e58be0cc3288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_2599f40d-509c-410c-b7ed-e58be0cc3288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5cd530c6-fcc8-4fb6-8dfc-2e0b20f88714" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5cd530c6-fcc8-4fb6-8dfc-2e0b20f88714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_63885716-4fcc-4916-a789-1bcc36beb014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_Depreciation_63885716-4fcc-4916-a789-1bcc36beb014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b329bbe4-3545-4ccb-8f21-e6c26b7685b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_ShareBasedCompensation_b329bbe4-3545-4ccb-8f21-e6c26b7685b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_293d1b72-1ace-46e7-872c-2fc9ec021ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_293d1b72-1ace-46e7-872c-2fc9ec021ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ea6ef1a-9407-469a-82d4-cc74dc6814c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_NetIncomeLoss_0ea6ef1a-9407-469a-82d4-cc74dc6814c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a7f4e02f-1bd7-42b4-9d90-df946cfe457e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a7f4e02f-1bd7-42b4-9d90-df946cfe457e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9deb6d38-adf3-4ea6-bf6c-b6bcfbbda314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9deb6d38-adf3-4ea6-bf6c-b6bcfbbda314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56af5eb3-710f-448d-aee8-613480651920" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56af5eb3-710f-448d-aee8-613480651920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_138afbc6-862a-4a26-976a-dacbab0412e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_138afbc6-862a-4a26-976a-dacbab0412e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f3315f46-564a-474b-8dfa-8a3b16407d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42b235eb-4547-4822-b333-a794a70b53f3" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f3315f46-564a-474b-8dfa-8a3b16407d2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aef5292f-2780-498d-a9b3-726f9b10bde1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e9f5141-a140-4d1c-b7a7-b20d9559fa61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aef5292f-2780-498d-a9b3-726f9b10bde1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e9f5141-a140-4d1c-b7a7-b20d9559fa61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4420efe2-2254-4ec0-b17a-ee1994e1ddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aef5292f-2780-498d-a9b3-726f9b10bde1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4420efe2-2254-4ec0-b17a-ee1994e1ddb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_019b0209-c3a4-75a9-9e64-2b50ea69bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_019b0209-c3a4-7152-8318-5c25d76a2087" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_019b0209-c3a4-75a9-9e64-2b50ea69bfd3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_019b0209-c3a4-7152-8318-5c25d76a2087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_019b0209-c3a4-76d3-b672-b75c7a9e0a70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_019b0209-c3a4-75a9-9e64-2b50ea69bfd3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_019b0209-c3a4-76d3-b672-b75c7a9e0a70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_019b0209-c3a4-79f6-bcd5-b1aa7d5f9da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_019b0209-c3a4-75a9-9e64-2b50ea69bfd3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_019b0209-c3a4-79f6-bcd5-b1aa7d5f9da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_019b0209-c3a4-7847-be56-cea10c4e34ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_019b0209-c3a4-75a9-9e64-2b50ea69bfd3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_019b0209-c3a4-7847-be56-cea10c4e34ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#RevenueScheduleofDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e81a148f-d5b3-4391-b49e-f62cb04d6d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncome_72f492d1-2ba2-4309-9ee7-7cfdea48f64e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_e81a148f-d5b3-4391-b49e-f62cb04d6d89" xlink:to="loc_us-gaap_LeaseIncome_72f492d1-2ba2-4309-9ee7-7cfdea48f64e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_deafcea6-6479-4169-b424-7471e7002a59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_e81a148f-d5b3-4391-b49e-f62cb04d6d89" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_deafcea6-6479-4169-b424-7471e7002a59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#MedicalEquipmentScheduleofMedicalEquipmentDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRental_084fe026-a1af-412f-87c4-d1f171f22697" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRental"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_b57cd4ee-5d5d-4dc9-adef-d76964d90d34" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalReserve"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_infu_MedicalEquipmentHeldForSaleOrRental_084fe026-a1af-412f-87c4-d1f171f22697" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_b57cd4ee-5d5d-4dc9-adef-d76964d90d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalGross_bca157d4-87f3-4554-8a30-e128f93ee5e2" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_infu_MedicalEquipmentHeldForSaleOrRental_084fe026-a1af-412f-87c4-d1f171f22697" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRentalGross_bca157d4-87f3-4554-8a30-e128f93ee5e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentNet_70115f87-290a-4a7b-952b-09a9070fc0f3" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_eaad82e6-252b-4b38-95e6-4f81da036ac5" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_infu_MedicalEquipmentNet_70115f87-290a-4a7b-952b-09a9070fc0f3" xlink:to="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_eaad82e6-252b-4b38-95e6-4f81da036ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRental_3b4b5d85-9f29-471b-b8f9-426008499ecb" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRental"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_infu_MedicalEquipmentNet_70115f87-290a-4a7b-952b-09a9070fc0f3" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRental_3b4b5d85-9f29-471b-b8f9-426008499ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_1199ae28-9c7b-442c-9f44-54140514d879" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation_194b68e5-dcd1-44ad-ac8b-c3165082dc45" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_1199ae28-9c7b-442c-9f44-54140514d879" xlink:to="loc_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation_194b68e5-dcd1-44ad-ac8b-c3165082dc45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesReserve_dc465d41-a699-4311-aeb9-048c6d7b837c" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesReserve"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_1199ae28-9c7b-442c-9f44-54140514d879" xlink:to="loc_infu_MedicalEquipmentInRentalServicesReserve_dc465d41-a699-4311-aeb9-048c6d7b837c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesGross_c4396881-4e2d-4277-870f-eb2d80b32b99" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_1199ae28-9c7b-442c-9f44-54140514d879" xlink:to="loc_infu_MedicalEquipmentInRentalServicesGross_c4396881-4e2d-4277-870f-eb2d80b32b99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_651da3d1-6606-41b5-a6d9-3fbcdf92b263" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9bf3ded3-bb62-4a75-a44b-a6b12c07a877" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_651da3d1-6606-41b5-a6d9-3fbcdf92b263" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9bf3ded3-bb62-4a75-a44b-a6b12c07a877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_25a0ca80-e757-49d9-a9f6-c9822bc4d813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_651da3d1-6606-41b5-a6d9-3fbcdf92b263" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_25a0ca80-e757-49d9-a9f6-c9822bc4d813" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b18bdeb5-4fd5-4a39-b7ce-a7defec53f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_26afae36-e7ac-4703-ba74-b3310b3236b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b18bdeb5-4fd5-4a39-b7ce-a7defec53f6d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_26afae36-e7ac-4703-ba74-b3310b3236b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f32b9b60-c48b-4111-bedb-d1c9b622f07d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b18bdeb5-4fd5-4a39-b7ce-a7defec53f6d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f32b9b60-c48b-4111-bedb-d1c9b622f07d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9edab0d3-63d9-410d-8b2f-5527aa5d401c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b9243ea8-5eff-4863-bf73-f025321f15f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9edab0d3-63d9-410d-8b2f-5527aa5d401c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b9243ea8-5eff-4863-bf73-f025321f15f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_26f522a8-9b39-4f75-aee1-a4ec8bde282b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9edab0d3-63d9-410d-8b2f-5527aa5d401c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_26f522a8-9b39-4f75-aee1-a4ec8bde282b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9cad13cd-0891-4d5c-a282-54ffe5667038" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_183b0945-dbef-42c5-93df-8955e050f5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9cad13cd-0891-4d5c-a282-54ffe5667038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_183b0945-dbef-42c5-93df-8955e050f5ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3eacb0f3-6594-4a3f-b2f5-a067c384b95c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9cad13cd-0891-4d5c-a282-54ffe5667038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3eacb0f3-6594-4a3f-b2f5-a067c384b95c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c9f3177c-b8c9-481c-bd25-448a063aab71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0e86999d-63ea-4427-8d48-7f1a7ecc6244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c9f3177c-b8c9-481c-bd25-448a063aab71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0e86999d-63ea-4427-8d48-7f1a7ecc6244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d621d395-ed4c-40b2-8acc-c8b3ec78b844" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c9f3177c-b8c9-481c-bd25-448a063aab71" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d621d395-ed4c-40b2-8acc-c8b3ec78b844" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofLineofCreditFacilitiesDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_f0e15773-df4c-4f34-ae63-cd98663a4b69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_66a92129-a502-480c-80c7-4beccdd0ab34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_f0e15773-df4c-4f34-ae63-cd98663a4b69" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_66a92129-a502-480c-80c7-4beccdd0ab34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_499d07c0-2efa-4c05-bbde-4443d192929d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_f0e15773-df4c-4f34-ae63-cd98663a4b69" xlink:to="loc_us-gaap_LineOfCredit_499d07c0-2efa-4c05-bbde-4443d192929d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofMaturitiesofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f9f4193d-155c-45ba-983f-889f2b2aa746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_743ead41-d99f-4714-a2bb-1631355f3d01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f9f4193d-155c-45ba-983f-889f2b2aa746" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_743ead41-d99f-4714-a2bb-1631355f3d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a1b067d5-00cf-4f1f-9bcd-91f06fcdc136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f9f4193d-155c-45ba-983f-889f2b2aa746" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a1b067d5-00cf-4f1f-9bcd-91f06fcdc136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_88901c96-cb41-454f-9ecb-ac2f2c025043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f9f4193d-155c-45ba-983f-889f2b2aa746" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_88901c96-cb41-454f-9ecb-ac2f2c025043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5ceb177f-53ed-4a01-81a8-64ba83b187ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f9f4193d-155c-45ba-983f-889f2b2aa746" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5ceb177f-53ed-4a01-81a8-64ba83b187ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47fa33dd-df29-47c0-8867-bd9cbc756736" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f9f4193d-155c-45ba-983f-889f2b2aa746" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47fa33dd-df29-47c0-8867-bd9cbc756736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_16cadddb-5eb2-47af-bf39-08f727c241ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f9f4193d-155c-45ba-983f-889f2b2aa746" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_16cadddb-5eb2-47af-bf39-08f727c241ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_49772744-4ba5-4f83-add7-2e91df420ded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_58a75a7b-2244-4a68-b9af-816f21a98ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_49772744-4ba5-4f83-add7-2e91df420ded" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_58a75a7b-2244-4a68-b9af-816f21a98ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_eedf93d0-47ac-49b0-b903-38fbf8e2b489" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_49772744-4ba5-4f83-add7-2e91df420ded" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_eedf93d0-47ac-49b0-b903-38fbf8e2b489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e3a81b32-6a29-479a-9cfa-45f30c1ed1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossNoncurrent_93c5cbe4-167f-4c24-bb5a-4c1f0ef31c9c" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_e3a81b32-6a29-479a-9cfa-45f30c1ed1cb" xlink:to="loc_infu_LongTermDebtGrossNoncurrent_93c5cbe4-167f-4c24-bb5a-4c1f0ef31c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_bcef5c5f-0c2c-40b8-8ad3-f98c6e861bca" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_e3a81b32-6a29-479a-9cfa-45f30c1ed1cb" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_bcef5c5f-0c2c-40b8-8ad3-f98c6e861bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_fbc3a6be-cd84-420e-a8d1-0b86a9911301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_04993092-f21b-4eb1-9bde-94da7b01f5ad" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_fbc3a6be-cd84-420e-a8d1-0b86a9911301" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_04993092-f21b-4eb1-9bde-94da7b01f5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_0b4cdb0d-6b18-4df5-ae32-05a158df8b8a" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_fbc3a6be-cd84-420e-a8d1-0b86a9911301" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_0b4cdb0d-6b18-4df5-ae32-05a158df8b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2e520ead-7271-4bf3-8e9b-62e2f289f8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossCurrent_6871dad1-be76-4806-8f56-2441397383fd" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2e520ead-7271-4bf3-8e9b-62e2f289f8bb" xlink:to="loc_infu_LongTermDebtGrossCurrent_6871dad1-be76-4806-8f56-2441397383fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossNoncurrent_e7823f3d-f084-4edc-aa06-7ab6d58c935a" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2e520ead-7271-4bf3-8e9b-62e2f289f8bb" xlink:to="loc_infu_LongTermDebtGrossNoncurrent_e7823f3d-f084-4edc-aa06-7ab6d58c935a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3a103b9c-737e-4e5c-ab14-e488120def37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossCurrent_f5e4f9f1-6de7-422f-8843-21afea24a4ee" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtCurrent_3a103b9c-737e-4e5c-ab14-e488120def37" xlink:to="loc_infu_LongTermDebtGrossCurrent_f5e4f9f1-6de7-422f-8843-21afea24a4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_bcf1b6f1-fe11-4c1d-a78c-6d4699762b47" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtCurrent_3a103b9c-737e-4e5c-ab14-e488120def37" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_bcf1b6f1-fe11-4c1d-a78c-6d4699762b47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofDebtDetails_1" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/DebtScheduleofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_165f108c-fd89-41a8-bed2-2779ea6cf670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_660ec153-795f-40fd-8085-c945d3b03d78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_165f108c-fd89-41a8-bed2-2779ea6cf670" xlink:to="loc_us-gaap_LongTermDebtCurrent_660ec153-795f-40fd-8085-c945d3b03d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a73a4e73-b0ed-4d65-84ed-3ec45eb16aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_165f108c-fd89-41a8-bed2-2779ea6cf670" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a73a4e73-b0ed-4d65-84ed-3ec45eb16aa7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f60bacc3-820e-4dae-99d4-6041d8618fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fcd91397-7c90-41bb-81ee-9e30066e2a08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f60bacc3-820e-4dae-99d4-6041d8618fd0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fcd91397-7c90-41bb-81ee-9e30066e2a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0c4bcaad-2330-4f57-b82f-c168ace0702c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f60bacc3-820e-4dae-99d4-6041d8618fd0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0c4bcaad-2330-4f57-b82f-c168ace0702c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1c30827b-d2ce-40ae-9ca4-5155aa0454ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_a62e2112-5bfe-4e92-ac9e-10729ec822b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1c30827b-d2ce-40ae-9ca4-5155aa0454ca" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_a62e2112-5bfe-4e92-ac9e-10729ec822b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a10831c0-849a-459f-8e8c-86adfd7a11d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1c30827b-d2ce-40ae-9ca4-5155aa0454ca" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a10831c0-849a-459f-8e8c-86adfd7a11d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_8210940e-d1c8-4321-b19e-6e8beb774e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1c30827b-d2ce-40ae-9ca4-5155aa0454ca" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_8210940e-d1c8-4321-b19e-6e8beb774e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_5a531c02-aafb-440d-99c8-f25f2244fc86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2bd15d26-5fbf-48e0-ae35-987d7306f812" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_5a531c02-aafb-440d-99c8-f25f2244fc86" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2bd15d26-5fbf-48e0-ae35-987d7306f812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e5ffbbe0-33dd-4121-8568-4eef6e808ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_5a531c02-aafb-440d-99c8-f25f2244fc86" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e5ffbbe0-33dd-4121-8568-4eef6e808ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_50cc9324-f724-40a3-9414-65f920721366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6f0a515d-f229-4ae2-b53a-3f0702ad9d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_50cc9324-f724-40a3-9414-65f920721366" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6f0a515d-f229-4ae2-b53a-3f0702ad9d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d51dd6e2-68cd-4fba-ad6c-2dc7b9c3d1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_50cc9324-f724-40a3-9414-65f920721366" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d51dd6e2-68cd-4fba-ad6c-2dc7b9c3d1a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019b7424-209e-79c9-b32a-d14d98203ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019b7424-209e-79c9-b32a-d14d98203ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019b7424-209e-7460-9329-48501520d5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019b7424-209e-7460-9329-48501520d5d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_019b7424-209e-7e5f-ad34-1930c1811675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_019b7424-209e-7e5f-ad34-1930c1811675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019b7424-209e-7c41-94e7-80622e305c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019b7424-209e-7c41-94e7-80622e305c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount_019b7424-209e-7392-a8ad-db57b9c2c6a0" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount_019b7424-209e-7392-a8ad-db57b9c2c6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount_019b7424-209e-7207-8c3f-f46f55483314" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount_019b7424-209e-7207-8c3f-f46f55483314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019b7424-209e-75ec-96e4-d7b52c214065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019b7424-209e-75ec-96e4-d7b52c214065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount_019c4840-0c1f-71fe-9996-54eed779c877" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount_019c4840-0c1f-71fe-9996-54eed779c877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c4840-0c1f-7bf7-bab4-d27d6d2b96fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c4840-0c1f-7bf7-bab4-d27d6d2b96fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c4840-0c1f-7274-a1d7-ef8301e2629c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b7424-209e-7b07-9bf4-c052fb1db25b" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c4840-0c1f-7274-a1d7-ef8301e2629c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b7424-b272-7d1e-8060-78afb56494e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b7424-b272-7d1e-8060-78afb56494e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b7424-b272-7142-a759-dfb097017f59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b7424-b272-7142-a759-dfb097017f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_019b7424-b272-7739-927e-6d6d567e4d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_019b7424-b272-7739-927e-6d6d567e4d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019b7424-b272-7f3c-93d0-417e675321ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019b7424-b272-7f3c-93d0-417e675321ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent_019b7424-b272-7f4d-a280-4eb19d84c90b" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent_019b7424-b272-7f4d-a280-4eb19d84c90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent_019b7424-b272-7dae-b6d5-6c9113d33a34" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent_019b7424-b272-7dae-b6d5-6c9113d33a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019b7424-b272-72fa-b6f1-9a7d2a682315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019b7424-b272-72fa-b6f1-9a7d2a682315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent_019c4840-31b6-7df1-b0f6-77d3915ec4a6" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent_019c4840-31b6-7df1-b0f6-77d3915ec4a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c4840-31b6-7d4f-b1a9-52e5cf532152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c4840-31b6-7d4f-b1a9-52e5cf532152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c4840-31b6-7bb5-899f-90c866831963" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b7424-b272-7177-83bd-a729e8a27d66" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c4840-31b6-7bb5-899f-90c866831963" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019b7422-a2f1-78ce-9c06-db56956e12ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019b7422-a2f1-72e6-ade0-73e9e84b0db7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019b7422-a2f1-78ce-9c06-db56956e12ce" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019b7422-a2f1-72e6-ade0-73e9e84b0db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019b7422-a2f1-7b8d-9d75-442e573e7952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019b7422-a2f1-78ce-9c06-db56956e12ce" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019b7422-a2f1-7b8d-9d75-442e573e7952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019b7422-a2f1-7f5f-a152-60e561d93d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019b7422-a2f1-78ce-9c06-db56956e12ce" xlink:to="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019b7422-a2f1-7f5f-a152-60e561d93d6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesCarryForwardsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesCarryForwardsDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/IncomeTaxesCarryForwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_22e9f792-bcf1-4e35-8322-ba83eaa7b9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_22e9f792-bcf1-4e35-8322-ba83eaa7b9c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_f70a1747-9901-4f86-9813-a665c0a1a3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_f70a1747-9901-4f86-9813-a665c0a1a3f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9a28907b-485c-4f62-996f-84a373ae7734" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9a28907b-485c-4f62-996f-84a373ae7734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c4bc4486-f1d1-47c6-a689-e60a5fdfa3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c4bc4486-f1d1-47c6-a689-e60a5fdfa3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_d96201ff-904d-4ecb-aadd-55e6aa7069ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_d96201ff-904d-4ecb-aadd-55e6aa7069ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_aa517859-6296-4963-895b-29ba756215d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_aa517859-6296-4963-895b-29ba756215d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4dae1b42-95dd-4355-ba5f-19114d5321e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4dae1b42-95dd-4355-ba5f-19114d5321e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities_ec98d8c8-0e8a-48ed-bee6-e916b2ef1e7c" xlink:href="infu-20251231.xsd#infu_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities_ec98d8c8-0e8a-48ed-bee6-e916b2ef1e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_d150f43e-85b2-48cd-bd36-53727ad0cb15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318c0f9-b28d-46bd-ab11-62893752e06e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_d150f43e-85b2-48cd-bd36-53727ad0cb15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f59ef1af-66c5-4641-befb-3724fb49b68b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b9e31767-2a96-4376-ae51-1a807e26b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f59ef1af-66c5-4641-befb-3724fb49b68b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b9e31767-2a96-4376-ae51-1a807e26b68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_900b1a03-1f19-480c-b6ec-e975db1f5249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f59ef1af-66c5-4641-befb-3724fb49b68b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_900b1a03-1f19-480c-b6ec-e975db1f5249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets_4be8c244-3574-4929-87ec-35338a7753c4" xlink:href="infu-20251231.xsd#infu_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f59ef1af-66c5-4641-befb-3724fb49b68b" xlink:to="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets_4be8c244-3574-4929-87ec-35338a7753c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_3fc84476-2b19-4564-8ef8-4fe7e819aa34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f59ef1af-66c5-4641-befb-3724fb49b68b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_3fc84476-2b19-4564-8ef8-4fe7e819aa34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9d4a132c-d372-45a0-bfbf-1b56c9cac50b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0dc825ed-c062-4ea0-bf4c-865a1b68c3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9d4a132c-d372-45a0-bfbf-1b56c9cac50b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0dc825ed-c062-4ea0-bf4c-865a1b68c3b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1df1c042-d1ef-4954-831d-6373ca28f091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9d4a132c-d372-45a0-bfbf-1b56c9cac50b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1df1c042-d1ef-4954-831d-6373ca28f091" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_19847e1b-06e6-4185-aa48-739f98c0cc82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cab69ae3-dd59-4dca-957c-4650c033abab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_19847e1b-06e6-4185-aa48-739f98c0cc82" xlink:to="loc_us-gaap_OperatingLeaseCost_cab69ae3-dd59-4dca-957c-4650c033abab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0fd1bf22-bd8a-41e6-8702-05610373b817" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_19847e1b-06e6-4185-aa48-739f98c0cc82" xlink:to="loc_us-gaap_VariableLeaseCost_0fd1bf22-bd8a-41e6-8702-05610373b817" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56ee59f2-936b-45b2-a3a8-8d1f5dcedbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3b6f875a-7bf7-4eed-b602-e2d41e8fc907" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56ee59f2-936b-45b2-a3a8-8d1f5dcedbfc" xlink:to="loc_us-gaap_OperatingLeaseLiability_3b6f875a-7bf7-4eed-b602-e2d41e8fc907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_09242fab-b1f5-4b0a-b1e7-bd6342cfb084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56ee59f2-936b-45b2-a3a8-8d1f5dcedbfc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_09242fab-b1f5-4b0a-b1e7-bd6342cfb084" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ffed113-bf8a-4d34-899e-50aedd3d47c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77faa40e-733b-47a8-8a7e-6714aed658b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ffed113-bf8a-4d34-899e-50aedd3d47c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77faa40e-733b-47a8-8a7e-6714aed658b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bae73cf4-b1d4-4597-871d-9464d2081b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ffed113-bf8a-4d34-899e-50aedd3d47c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bae73cf4-b1d4-4597-871d-9464d2081b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4ee5b63b-a9fe-44c8-b6f1-6af0c2293e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ffed113-bf8a-4d34-899e-50aedd3d47c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4ee5b63b-a9fe-44c8-b6f1-6af0c2293e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_758d4f43-25fb-4bfb-894c-cfa5b9fa3b32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ffed113-bf8a-4d34-899e-50aedd3d47c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_758d4f43-25fb-4bfb-894c-cfa5b9fa3b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_24b13e01-bbf0-4ac8-ab0c-6af000a37710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ffed113-bf8a-4d34-899e-50aedd3d47c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_24b13e01-bbf0-4ac8-ab0c-6af000a37710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b3f18b95-fe16-42b9-b1f3-5b252969e532" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ffed113-bf8a-4d34-899e-50aedd3d47c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b3f18b95-fe16-42b9-b1f3-5b252969e532" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesLeaseRevenueDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesLeaseRevenueDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesLeaseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncome_944c1ca9-cac8-47b1-8520-0956b4cbbc30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_7e6550af-ee3a-45a0-a7fa-ab569346259e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseIncome_944c1ca9-cac8-47b1-8520-0956b4cbbc30" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_7e6550af-ee3a-45a0-a7fa-ab569346259e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome_c4e7ff34-d0f7-4206-bec1-55250f4ee22c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseIncome_944c1ca9-cac8-47b1-8520-0956b4cbbc30" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseIncome_c4e7ff34-d0f7-4206-bec1-55250f4ee22c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesNetInvestmentinSalesTypeLeasesDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_f3b06a2b-9b06-4bf3-ab10-f5f97c262218" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_27e1528c-b873-405e-9419-7b42d7dd0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_f3b06a2b-9b06-4bf3-ab10-f5f97c262218" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_27e1528c-b873-405e-9419-7b42d7dd0a03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8dfc5a40-6ebf-436d-aac7-fb381b794470" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_24f55bd0-fe65-41ca-ab77-61043dc4bc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfc5a40-6ebf-436d-aac7-fb381b794470" xlink:to="loc_us-gaap_OtherAssets_24f55bd0-fe65-41ca-ab77-61043dc4bc2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_a6824c9a-1659-4b27-a56a-3caef6019964" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfc5a40-6ebf-436d-aac7-fb381b794470" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_a6824c9a-1659-4b27-a56a-3caef6019964" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesMaturitiesofSaleTypeLeasesDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_ba5abd07-12ab-4ed0-bba8-3267cbc943b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_64bb2ee4-90a6-41b3-a11b-083ff5da18a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_ba5abd07-12ab-4ed0-bba8-3267cbc943b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_64bb2ee4-90a6-41b3-a11b-083ff5da18a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_259e2ab1-733e-4b4d-85fd-73287d88d885" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_ba5abd07-12ab-4ed0-bba8-3267cbc943b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_259e2ab1-733e-4b4d-85fd-73287d88d885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_25b81dc5-02f2-4d0b-98e8-bab306fa0f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_ba5abd07-12ab-4ed0-bba8-3267cbc943b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_25b81dc5-02f2-4d0b-98e8-bab306fa0f53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_019c4851-fe0e-700e-bf1b-956aca45d03b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_ba5abd07-12ab-4ed0-bba8-3267cbc943b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_019c4851-fe0e-700e-bf1b-956aca45d03b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails_1" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesMaturitiesofSaleTypeLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_26caf713-7fe6-4372-a139-33311bdd7eac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_5dd8a277-dd46-43fe-bcf9-e0692803f077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_26caf713-7fe6-4372-a139-33311bdd7eac" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_5dd8a277-dd46-43fe-bcf9-e0692803f077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_347a1ca1-a9f8-48bb-a6ab-846d71528e27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_26caf713-7fe6-4372-a139-33311bdd7eac" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_347a1ca1-a9f8-48bb-a6ab-846d71528e27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationStockbasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e6e85b48-17a0-4d3d-9879-1fefa9e53b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_839d33c7-cf6c-4cee-9a1e-9625c42ce502" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_e6e85b48-17a0-4d3d-9879-1fefa9e53b6a" xlink:to="loc_us-gaap_StockOptionPlanExpense_839d33c7-cf6c-4cee-9a1e-9625c42ce502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_7ec4dbaf-9aca-4c99-b535-87dae8a90946" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_e6e85b48-17a0-4d3d-9879-1fefa9e53b6a" xlink:to="loc_us-gaap_RestrictedStockExpense_7ec4dbaf-9aca-4c99-b535-87dae8a90946" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessSegmentInformationDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessSegmentInformationDetails"/>
  <link:calculationLink xlink:role="http://infusystem.com/role/BusinessSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_62b606b7-0869-4a9f-a6f3-e9e5e1e00445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_c1a5e26f-0037-400a-871f-4f56f95c770d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_62b606b7-0869-4a9f-a6f3-e9e5e1e00445" xlink:to="loc_us-gaap_LaborAndRelatedExpense_c1a5e26f-0037-400a-871f-4f56f95c770d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0824ac5e-23d9-4db4-a246-73c39fff979d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_62b606b7-0869-4a9f-a6f3-e9e5e1e00445" xlink:to="loc_us-gaap_Revenues_0824ac5e-23d9-4db4-a246-73c39fff979d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_cf608f76-7d57-40a7-8518-fecad3b056d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_62b606b7-0869-4a9f-a6f3-e9e5e1e00445" xlink:to="loc_us-gaap_SuppliesExpense_cf608f76-7d57-40a7-8518-fecad3b056d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_e4f46938-b2ef-4a59-b5d1-5a75457cbf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_62b606b7-0869-4a9f-a6f3-e9e5e1e00445" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_e4f46938-b2ef-4a59-b5d1-5a75457cbf5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_fe3b2816-98e4-4474-88a2-86dd4c48da6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_62b606b7-0869-4a9f-a6f3-e9e5e1e00445" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_fe3b2816-98e4-4474-88a2-86dd4c48da6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_53842906-6762-4f0b-8ada-b9e25173772d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesInternal_63ad3f68-3498-4e46-b1c1-61147060665c" xlink:href="infu-20251231.xsd#infu_NetRevenuesInternal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_53842906-6762-4f0b-8ada-b9e25173772d" xlink:to="loc_infu_NetRevenuesInternal_63ad3f68-3498-4e46-b1c1-61147060665c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesExternal_0cfc539b-67ed-4ea0-8073-810cb4720961" xlink:href="infu-20251231.xsd#infu_NetRevenuesExternal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_53842906-6762-4f0b-8ada-b9e25173772d" xlink:to="loc_infu_NetRevenuesExternal_0cfc539b-67ed-4ea0-8073-810cb4720961" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>infu-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:7814b130-9ea8-4497-bd4c-7510be4e72d5,g:0e5cd592-a670-4737-bede-9aef47e8c4b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fcd87e0a-bc2f-4c42-bd76-b545eb4bc9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d00c6672-aeaa-4813-8802-94ea3d414e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fcd87e0a-bc2f-4c42-bd76-b545eb4bc9eb" xlink:to="loc_us-gaap_StatementTable_d00c6672-aeaa-4813-8802-94ea3d414e71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ffcff50f-94b8-436d-b5f1-0d24c0d13c84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d00c6672-aeaa-4813-8802-94ea3d414e71" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ffcff50f-94b8-436d-b5f1-0d24c0d13c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ffcff50f-94b8-436d-b5f1-0d24c0d13c84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ffcff50f-94b8-436d-b5f1-0d24c0d13c84" xlink:to="loc_us-gaap_EquityComponentDomain_ffcff50f-94b8-436d-b5f1-0d24c0d13c84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ffcff50f-94b8-436d-b5f1-0d24c0d13c84" xlink:to="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_285aef99-1e43-4899-92c5-3a601643baec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_CommonStockMember_285aef99-1e43-4899-92c5-3a601643baec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_86e34e46-f3b3-4b77-9d88-13f931b644dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_86e34e46-f3b3-4b77-9d88-13f931b644dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_edb647d1-f315-4b3a-808f-5d6045e6e517" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_RetainedEarningsMember_edb647d1-f315-4b3a-808f-5d6045e6e517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30b3b9a8-b6b8-4040-a3ea-ef101bf03045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30b3b9a8-b6b8-4040-a3ea-ef101bf03045" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fcd87e0a-bc2f-4c42-bd76-b545eb4bc9eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_66ccd32e-81ff-4f1d-b699-1a090c1962c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_66ccd32e-81ff-4f1d-b699-1a090c1962c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36d19c19-a80a-4b99-a9ea-ea0409a6e8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockholdersEquity_36d19c19-a80a-4b99-a9ea-ea0409a6e8a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_740e69b9-f8e4-41b6-a408-8a2e17ca2fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_740e69b9-f8e4-41b6-a408-8a2e17ca2fe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_d9780841-2358-4594-bde4-baea8fb2dbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_d9780841-2358-4594-bde4-baea8fb2dbd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fb5eb25-c958-42d1-84ab-1bcfa1b84dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fb5eb25-c958-42d1-84ab-1bcfa1b84dcd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bf7d1704-332c-444f-9871-746188363c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bf7d1704-332c-444f-9871-746188363c8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_3257a42d-bcb9-4380-8fd3-e40112518494" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_3257a42d-bcb9-4380-8fd3-e40112518494" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c54ede72-60af-4211-84f4-7d8046e6ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c54ede72-60af-4211-84f4-7d8046e6ec46" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1923f6ff-893c-48c2-b3dd-1e54f233e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1923f6ff-893c-48c2-b3dd-1e54f233e80f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8d82c95a-ed1c-4a45-b3fc-8e15323cac9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8d82c95a-ed1c-4a45-b3fc-8e15323cac9b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b0e47006-c7c4-490a-b2c4-1f90c7a65c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b0e47006-c7c4-490a-b2c4-1f90c7a65c4e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e063f78-5b30-42eb-a155-5fdcd77654b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e063f78-5b30-42eb-a155-5fdcd77654b8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0bb0fc48-6def-440b-bb3a-b2968529c495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_NetIncomeLoss_0bb0fc48-6def-440b-bb3a-b2968529c495" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_255c564d-06ed-4305-9adf-02c0b84e3dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_86231e23-6557-4f26-9f40-cbeef3619c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BasisofPresentationandNatureofOperationsDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cfb080f7-0e86-449b-bc03-aba52b8068c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_srt_ProductOrServiceAxis_cfb080f7-0e86-449b-bc03-aba52b8068c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfb080f7-0e86-449b-bc03-aba52b8068c8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cfb080f7-0e86-449b-bc03-aba52b8068c8" xlink:to="loc_srt_ProductsAndServicesDomain_cfb080f7-0e86-449b-bc03-aba52b8068c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9200fcef-9e39-4516-a2d9-729db9ab1dd2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cfb080f7-0e86-449b-bc03-aba52b8068c8" xlink:to="loc_srt_ProductsAndServicesDomain_9200fcef-9e39-4516-a2d9-729db9ab1dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_AmbulatoryPumpsMember_6cf3d25d-9bcf-477c-9998-8f4265b735f3" xlink:href="infu-20251231.xsd#infu_AmbulatoryPumpsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9200fcef-9e39-4516-a2d9-729db9ab1dd2" xlink:to="loc_infu_AmbulatoryPumpsMember_6cf3d25d-9bcf-477c-9998-8f4265b735f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c6935fa-58ce-4539-9838-611113798d88" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_srt_RangeAxis_0c6935fa-58ce-4539-9838-611113798d88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c6935fa-58ce-4539-9838-611113798d88_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c6935fa-58ce-4539-9838-611113798d88" xlink:to="loc_srt_RangeMember_0c6935fa-58ce-4539-9838-611113798d88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48e3d128-fef8-40b6-b14a-0a743a282547" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c6935fa-58ce-4539-9838-611113798d88" xlink:to="loc_srt_RangeMember_48e3d128-fef8-40b6-b14a-0a743a282547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_293c3021-933a-4bdf-9b39-52c24f9ea4f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48e3d128-fef8-40b6-b14a-0a743a282547" xlink:to="loc_srt_MinimumMember_293c3021-933a-4bdf-9b39-52c24f9ea4f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_100b8fc0-15fe-4351-8aeb-808ec0880981" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_100b8fc0-15fe-4351-8aeb-808ec0880981" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_100b8fc0-15fe-4351-8aeb-808ec0880981_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_100b8fc0-15fe-4351-8aeb-808ec0880981" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_100b8fc0-15fe-4351-8aeb-808ec0880981_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9c39ff4-9624-4551-bc12-aa17545b1760" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_100b8fc0-15fe-4351-8aeb-808ec0880981" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9c39ff4-9624-4551-bc12-aa17545b1760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember_1215f14c-62ec-4341-9e30-8b4b557894ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9c39ff4-9624-4551-bc12-aa17545b1760" xlink:to="loc_us-gaap_CostOfGoodsProductLineMember_1215f14c-62ec-4341-9e30-8b4b557894ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_86876c9c-7a74-4a67-a634-91e63068c813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_86876c9c-7a74-4a67-a634-91e63068c813" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_86876c9c-7a74-4a67-a634-91e63068c813_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_86876c9c-7a74-4a67-a634-91e63068c813" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_86876c9c-7a74-4a67-a634-91e63068c813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1a001bd0-46fd-4de1-9272-6045096ac431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_86876c9c-7a74-4a67-a634-91e63068c813" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1a001bd0-46fd-4de1-9272-6045096ac431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_b0f30f2d-ad73-4f57-a6ab-8cebe246e98d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1a001bd0-46fd-4de1-9272-6045096ac431" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_b0f30f2d-ad73-4f57-a6ab-8cebe246e98d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_40222855-a18f-417f-a6c0-b0ef934fc1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_40222855-a18f-417f-a6c0-b0ef934fc1e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_40222855-a18f-417f-a6c0-b0ef934fc1e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_40222855-a18f-417f-a6c0-b0ef934fc1e5" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_40222855-a18f-417f-a6c0-b0ef934fc1e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e2cad09d-9cb9-4fdc-9357-bb8d4946f858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_40222855-a18f-417f-a6c0-b0ef934fc1e5" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e2cad09d-9cb9-4fdc-9357-bb8d4946f858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SmithsMedicalIncMember_84fce0a9-5b84-4ee5-8400-42ad34f4dc54" xlink:href="infu-20251231.xsd#infu_SmithsMedicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e2cad09d-9cb9-4fdc-9357-bb8d4946f858" xlink:to="loc_infu_SmithsMedicalIncMember_84fce0a9-5b84-4ee5-8400-42ad34f4dc54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfLocations_34a6edd5-fd74-441e-be87-ec41b9a72838" xlink:href="infu-20251231.xsd#infu_NumberOfLocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:to="loc_infu_NumberOfLocations_34a6edd5-fd74-441e-be87-ec41b9a72838" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b057a085-02a0-480b-954c-772573e2b43d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b057a085-02a0-480b-954c-772573e2b43d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_srt_RangeAxis_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4" xlink:to="loc_srt_RangeMember_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4" xlink:to="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16522454-3525-4336-b5cf-18e5a2b79c67" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:to="loc_srt_MinimumMember_16522454-3525-4336-b5cf-18e5a2b79c67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff4fd19d-8611-4b97-8118-b3990c47e003" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:to="loc_srt_MaximumMember_ff4fd19d-8611-4b97-8118-b3990c47e003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_InformationTechnologySoftwareMember_fea49eca-d7a3-46b9-a96e-ca3fb543f5ef" xlink:href="infu-20251231.xsd#infu_InformationTechnologySoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:to="loc_infu_InformationTechnologySoftwareMember_fea49eca-d7a3-46b9-a96e-ca3fb543f5ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d174b346-4fe5-496d-b13e-f008cfd07756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:to="loc_us-gaap_ComputerEquipmentMember_d174b346-4fe5-496d-b13e-f008cfd07756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_598f1245-69c2-4ca0-999e-6f66d3984f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_598f1245-69c2-4ca0-999e-6f66d3984f9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_598f1245-69c2-4ca0-999e-6f66d3984f9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_598f1245-69c2-4ca0-999e-6f66d3984f9f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_598f1245-69c2-4ca0-999e-6f66d3984f9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_598f1245-69c2-4ca0-999e-6f66d3984f9f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PhysicianAndCustomerRelationshipsMember_06bfb9bc-06ad-4e24-8582-1d8bb2628746" xlink:href="infu-20251231.xsd#infu_PhysicianAndCustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_infu_PhysicianAndCustomerRelationshipsMember_06bfb9bc-06ad-4e24-8582-1d8bb2628746" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1d6fa5ab-67b0-4dc3-923e-cc6ab824133a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1d6fa5ab-67b0-4dc3-923e-cc6ab824133a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpatentedTechnologyMember_51a8f16b-9462-4e96-bf6c-31f602bd8b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnpatentedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_us-gaap_UnpatentedTechnologyMember_51a8f16b-9462-4e96-bf6c-31f602bd8b5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b3b67974-c246-4c6b-a806-5053a0f600f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b3b67974-c246-4c6b-a806-5053a0f600f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c53718d-b840-4bb9-a225-aeca80b5c701" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c53718d-b840-4bb9-a225-aeca80b5c701" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9c53718d-b840-4bb9-a225-aeca80b5c701_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c53718d-b840-4bb9-a225-aeca80b5c701" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9c53718d-b840-4bb9-a225-aeca80b5c701_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6bb2304-5ac3-4baf-bc81-267775656414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c53718d-b840-4bb9-a225-aeca80b5c701" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6bb2304-5ac3-4baf-bc81-267775656414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1cdbafe9-f966-4309-9163-55b0691b360e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6bb2304-5ac3-4baf-bc81-267775656414" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1cdbafe9-f966-4309-9163-55b0691b360e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2ec45ced-f44c-4215-b970-1b660d218c56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_NumberOfReportableSegments_2ec45ced-f44c-4215-b970-1b660d218c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfFinancialInstitutions_49b1c13b-23e0-4c05-8a71-33fd3c92c3c2" xlink:href="infu-20251231.xsd#infu_NumberOfFinancialInstitutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_NumberOfFinancialInstitutions_49b1c13b-23e0-4c05-8a71-33fd3c92c3c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_1f61a777-934c-4c1f-87d8-bd31cad2c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_1f61a777-934c-4c1f-87d8-bd31cad2c5e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_a74552fb-ef6a-4eff-885e-6b72f8d2506a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_a74552fb-ef6a-4eff-885e-6b72f8d2506a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_019c8dae-2b93-776a-a9d7-888333c64640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_019c8dae-2b93-776a-a9d7-888333c64640" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_019c8db0-5845-7c76-8d68-be34f56ae82f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorSalesTypeLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_019c8db0-5845-7c76-8d68-be34f56ae82f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bdb6cc99-b9b9-44e0-acc9-10005265dc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bdb6cc99-b9b9-44e0-acc9-10005265dc6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesUsefulLife_86706785-93f1-4db3-88c0-1f82d3ae862c" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_MedicalEquipmentInRentalServicesUsefulLife_86706785-93f1-4db3-88c0-1f82d3ae862c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesReserve_5e9071d6-4975-4e55-b55a-06b0d0ef5be2" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_MedicalEquipmentInRentalServicesReserve_5e9071d6-4975-4e55-b55a-06b0d0ef5be2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_be315439-65dd-4053-85f9-bfa0af51061d" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_be315439-65dd-4053-85f9-bfa0af51061d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_77d0098b-aa69-4b9d-b128-ae3375e800c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_77d0098b-aa69-4b9d-b128-ae3375e800c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52b81d7e-9970-41d9-bcfe-b05b9e748286" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52b81d7e-9970-41d9-bcfe-b05b9e748286" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_6cbaab59-cfe6-4857-8801-a7125e3f61e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_6cbaab59-cfe6-4857-8801-a7125e3f61e0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9056484a-5a3b-433a-9c08-be746449af3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9056484a-5a3b-433a-9c08-be746449af3a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c546883-e9c6-4875-bd1e-c9c953623ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c546883-e9c6-4875-bd1e-c9c953623ba8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ff7be99-cbbc-41f0-905c-8259d02ac63d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ff7be99-cbbc-41f0-905c-8259d02ac63d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b8c298c-5357-4b83-9005-30b598053789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b8c298c-5357-4b83-9005-30b598053789" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfContractsWithThirdParties_3e1eeb7c-44c5-40e7-b817-e4038f00a7cd" xlink:href="infu-20251231.xsd#infu_NumberOfContractsWithThirdParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_NumberOfContractsWithThirdParties_3e1eeb7c-44c5-40e7-b817-e4038f00a7cd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermOfContract_e541561e-9b12-4115-ab09-168697228536" xlink:href="infu-20251231.xsd#infu_TermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_TermOfContract_e541561e-9b12-4115-ab09-168697228536" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermOfRenewal_07553f6d-9e9f-4456-b1f6-38ab6c56900e" xlink:href="infu-20251231.xsd#infu_TermOfRenewal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_TermOfRenewal_07553f6d-9e9f-4456-b1f6-38ab6c56900e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_1654e431-7c4c-4803-82fc-1b85adbf9620" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_1654e431-7c4c-4803-82fc-1b85adbf9620" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4fab4155-02cb-4a1d-b718-95d4224bdbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4fab4155-02cb-4a1d-b718-95d4224bdbe9" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_1b5823bc-4aa6-4474-8896-f40702bb7bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_1b5823bc-4aa6-4474-8896-f40702bb7bf1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019b020b-8436-7969-880b-60cdcde38596" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_1b5823bc-4aa6-4474-8896-f40702bb7bf1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019b020b-8436-7969-880b-60cdcde38596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7969-880b-60cdcde38596_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019b020b-8436-7969-880b-60cdcde38596" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7969-880b-60cdcde38596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7be2-b1ac-aed6afa0cfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019b020b-8436-7969-880b-60cdcde38596" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7be2-b1ac-aed6afa0cfbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ApolloMedicalSupplyMember_019b020b-8436-7663-a041-aa6f8d8d7be9" xlink:href="infu-20251231.xsd#infu_ApolloMedicalSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7be2-b1ac-aed6afa0cfbb" xlink:to="loc_infu_ApolloMedicalSupplyMember_019b020b-8436-7663-a041-aa6f8d8d7be9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b65a46b2-e0cc-4f84-9a57-3cd65d463b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b65a46b2-e0cc-4f84-9a57-3cd65d463b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ae7d408d-fa24-4e99-8c08-27c7d825efec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ae7d408d-fa24-4e99-8c08-27c7d825efec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e03d46a2-4045-4ecb-825d-254b24188f40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e03d46a2-4045-4ecb-825d-254b24188f40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_019b0207-1e33-72b2-96f4-feaf06cb448b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_019b0207-1e33-72b2-96f4-feaf06cb448b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5d82bf16-8999-4317-92fe-92f16af00643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5d82bf16-8999-4317-92fe-92f16af00643" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#RevenueScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f3bea834-a72c-4284-a906-e24dd238f90f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f3bea834-a72c-4284-a906-e24dd238f90f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4a842eef-9093-4cd4-963b-9a4164fdfe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:to="loc_us-gaap_SalesRevenueNetMember_4a842eef-9093-4cd4-963b-9a4164fdfe2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_076dd58e-cb71-4add-bf17-51d25f896eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_076dd58e-cb71-4add-bf17-51d25f896eba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_076dd58e-cb71-4add-bf17-51d25f896eba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_076dd58e-cb71-4add-bf17-51d25f896eba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_076dd58e-cb71-4add-bf17-51d25f896eba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_242a60f9-fc9e-48c4-bb86-022671406e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_076dd58e-cb71-4add-bf17-51d25f896eba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_242a60f9-fc9e-48c4-bb86-022671406e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ad0bae65-1969-465a-818c-2bacf4220f98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_242a60f9-fc9e-48c4-bb86-022671406e5c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ad0bae65-1969-465a-818c-2bacf4220f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_srt_ProductOrServiceAxis_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072" xlink:to="loc_srt_ProductsAndServicesDomain_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072" xlink:to="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ThirdPartyPayerRentalsMember_47dc330f-ed94-4a6f-b149-d251a64153b8" xlink:href="infu-20251231.xsd#infu_ThirdPartyPayerRentalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_infu_ThirdPartyPayerRentalsMember_47dc330f-ed94-4a6f-b149-d251a64153b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DirectPayerRentalsMember_fc467cf9-2fb6-4ff7-87c5-e9f72b5a0b94" xlink:href="infu-20251231.xsd#infu_DirectPayerRentalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_infu_DirectPayerRentalsMember_fc467cf9-2fb6-4ff7-87c5-e9f72b5a0b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_61babb9d-a892-4f06-8f69-6126ada8b6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_us-gaap_ProductMember_61babb9d-a892-4f06-8f69-6126ada8b6c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_748a2707-598d-4455-bd03-4f6135086472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_us-gaap_ServiceMember_748a2707-598d-4455-bd03-4f6135086472" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_810ffb4a-01b2-419d-b8fc-f50cf6a65582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_810ffb4a-01b2-419d-b8fc-f50cf6a65582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_810ffb4a-01b2-419d-b8fc-f50cf6a65582_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_810ffb4a-01b2-419d-b8fc-f50cf6a65582" xlink:to="loc_us-gaap_SegmentDomain_810ffb4a-01b2-419d-b8fc-f50cf6a65582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f26f3ba6-0c0f-4f6d-8559-527931275da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_810ffb4a-01b2-419d-b8fc-f50cf6a65582" xlink:to="loc_us-gaap_SegmentDomain_f26f3ba6-0c0f-4f6d-8559-527931275da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:href="infu-20251231.xsd#infu_PatientServicesAndDeviceSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f26f3ba6-0c0f-4f6d-8559-527931275da1" xlink:to="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesMember_cbbe1602-20f3-4d5c-82a8-27befd64714b" xlink:href="infu-20251231.xsd#infu_PatientServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:to="loc_infu_PatientServicesMember_cbbe1602-20f3-4d5c-82a8-27befd64714b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeviceSolutionsMember_d51fff3c-11b3-417e-b316-8db87cda638c" xlink:href="infu-20251231.xsd#infu_DeviceSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:to="loc_infu_DeviceSolutionsMember_d51fff3c-11b3-417e-b316-8db87cda638c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_b330de81-58fd-4755-a1d5-2d9214702f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_b330de81-58fd-4755-a1d5-2d9214702f43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_52a2c003-afcd-4b15-b05a-c11fba05243f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:to="loc_us-gaap_TransferredOverTimeMember_52a2c003-afcd-4b15-b05a-c11fba05243f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_498574dc-801f-42e5-aa7e-d2ba8e014a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_498574dc-801f-42e5-aa7e-d2ba8e014a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncome_47b07a5c-1cd9-4231-b2ba-046474f46837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_LeaseIncome_47b07a5c-1cd9-4231-b2ba-046474f46837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_99734620-ea2d-417a-8e75-5adbdb4fcce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_Revenues_99734620-ea2d-417a-8e75-5adbdb4fcce4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6728d43d-5f13-489f-91e9-5eeedf1ed857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6728d43d-5f13-489f-91e9-5eeedf1ed857" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/RevenueContractBalancesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#RevenueContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/RevenueContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_19be36ff-dac9-4ca0-8a12-8726230384c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_19be36ff-dac9-4ca0-8a12-8726230384c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_793efb1c-7cf2-4d92-8149-0dcf0e222619" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_19be36ff-dac9-4ca0-8a12-8726230384c3" xlink:to="loc_srt_RestatementAxis_793efb1c-7cf2-4d92-8149-0dcf0e222619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_793efb1c-7cf2-4d92-8149-0dcf0e222619_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_793efb1c-7cf2-4d92-8149-0dcf0e222619" xlink:to="loc_srt_RestatementDomain_793efb1c-7cf2-4d92-8149-0dcf0e222619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_883741d0-0a19-4bd7-ba9c-76a75824e10f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_793efb1c-7cf2-4d92-8149-0dcf0e222619" xlink:to="loc_srt_RestatementDomain_883741d0-0a19-4bd7-ba9c-76a75824e10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_348ea66c-7220-4144-b89f-b2bf43e39012" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_883741d0-0a19-4bd7-ba9c-76a75824e10f" xlink:to="loc_srt_RestatementAdjustmentMember_348ea66c-7220-4144-b89f-b2bf43e39012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4e6e6680-a81c-4d83-bcfa-82c1c8bb4eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4e6e6680-a81c-4d83-bcfa-82c1c8bb4eb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractAssets_9baf49c9-d8b4-44b9-ad9a-1f563dafac4d" xlink:href="infu-20251231.xsd#infu_ContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:to="loc_infu_ContractAssets_9baf49c9-d8b4-44b9-ad9a-1f563dafac4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractLiabilities_019bf9a3-75dc-7d05-b692-db82e665aaa0" xlink:href="infu-20251231.xsd#infu_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:to="loc_infu_ContractLiabilities_019bf9a3-75dc-7d05-b692-db82e665aaa0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a3a2cbd8-7dae-4ea6-8d2a-cdab5959c095" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a3a2cbd8-7dae-4ea6-8d2a-cdab5959c095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3bbd9770-276b-40fa-b566-635f230c8103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a3a2cbd8-7dae-4ea6-8d2a-cdab5959c095" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3bbd9770-276b-40fa-b566-635f230c8103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3bbd9770-276b-40fa-b566-635f230c8103_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3bbd9770-276b-40fa-b566-635f230c8103" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3bbd9770-276b-40fa-b566-635f230c8103_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3bbd9770-276b-40fa-b566-635f230c8103" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_277a7958-6da5-499e-a354-d150392e7403" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_277a7958-6da5-499e-a354-d150392e7403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AutomobilesMember_a1e42440-04f5-41f2-9360-3f60f6c94012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AutomobilesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:to="loc_us-gaap_AutomobilesMember_a1e42440-04f5-41f2-9360-3f60f6c94012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff7b8219-abe1-429c-b55e-824b672e36d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff7b8219-abe1-429c-b55e-824b672e36d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8e825376-2a4c-45e3-b3e0-7dbdfffb052a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8e825376-2a4c-45e3-b3e0-7dbdfffb052a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_005baf5f-fb47-4d7b-8cfc-e5472dcb5b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_005baf5f-fb47-4d7b-8cfc-e5472dcb5b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_74eaebcd-57c1-40a6-adbc-8e51fd2da40e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_74eaebcd-57c1-40a6-adbc-8e51fd2da40e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_68318338-a4d3-430d-b425-7ea83bad4f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a3cf4418-506c-4145-a221-2bb4122ada8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_68318338-a4d3-430d-b425-7ea83bad4f8a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a3cf4418-506c-4145-a221-2bb4122ada8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_47929f40-6ed9-4171-bec2-a66c9419aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a3cf4418-506c-4145-a221-2bb4122ada8f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_47929f40-6ed9-4171-bec2-a66c9419aa4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_47929f40-6ed9-4171-bec2-a66c9419aa4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_47929f40-6ed9-4171-bec2-a66c9419aa4a" xlink:to="loc_us-gaap_SegmentDomain_47929f40-6ed9-4171-bec2-a66c9419aa4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_47929f40-6ed9-4171-bec2-a66c9419aa4a" xlink:to="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeviceSolutionsMember_3946c975-2f90-4497-a394-1eb130b11bcb" xlink:href="infu-20251231.xsd#infu_DeviceSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:to="loc_infu_DeviceSolutionsMember_3946c975-2f90-4497-a394-1eb130b11bcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesMember_e605265a-1c36-4d96-bd48-83ca155b37ea" xlink:href="infu-20251231.xsd#infu_PatientServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:to="loc_infu_PatientServicesMember_e605265a-1c36-4d96-bd48-83ca155b37ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_68318338-a4d3-430d-b425-7ea83bad4f8a" xlink:to="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31fca48b-cde0-476c-82a2-01e3bbcf4869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:to="loc_us-gaap_Goodwill_31fca48b-cde0-476c-82a2-01e3bbcf4869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0409d738-d56d-4d61-b0b3-2eed4b2bc47b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0409d738-d56d-4d61-b0b3-2eed4b2bc47b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b150e68e-3747-4432-a0bb-d80314084f31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92869777-c52b-42dc-b1b4-41169f5feb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92869777-c52b-42dc-b1b4-41169f5feb4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8bb31363-fc51-4d46-b190-f6d279572562" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92869777-c52b-42dc-b1b4-41169f5feb4c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8bb31363-fc51-4d46-b190-f6d279572562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bb31363-fc51-4d46-b190-f6d279572562_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8bb31363-fc51-4d46-b190-f6d279572562" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bb31363-fc51-4d46-b190-f6d279572562_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8bb31363-fc51-4d46-b190-f6d279572562" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2bfd2844-a9c5-4208-ac1a-7ec12375cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_TradeNamesMember_2bfd2844-a9c5-4208-ac1a-7ec12375cc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PhysicianAndCustomerRelationshipsMember_34906375-5f5a-41cc-9983-58bd9e347fbc" xlink:href="infu-20251231.xsd#infu_PhysicianAndCustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_infu_PhysicianAndCustomerRelationshipsMember_34906375-5f5a-41cc-9983-58bd9e347fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_cdca3f59-9876-42ab-8536-14d7bcbd17bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_cdca3f59-9876-42ab-8536-14d7bcbd17bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_f22bd402-f966-4a88-acb3-4b4adc658ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_f22bd402-f966-4a88-acb3-4b4adc658ab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5fe5ad8b-f3c8-4a7c-983f-7053b1440105" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5fe5ad8b-f3c8-4a7c-983f-7053b1440105" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_048a83e2-5098-4419-b90c-cbca8c6a570c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_048a83e2-5098-4419-b90c-cbca8c6a570c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2d7161b6-2bee-45d9-a166-ae99a5aa45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2d7161b6-2bee-45d9-a166-ae99a5aa45eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d5620e7-bd4b-4667-a159-fcb294e26482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d5620e7-bd4b-4667-a159-fcb294e26482" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e84a42c8-4cae-46af-8765-dbf09ad9c6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e84a42c8-4cae-46af-8765-dbf09ad9c6eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_617f3efb-a08a-4a0b-8a94-5b9a42a8c038" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_617f3efb-a08a-4a0b-8a94-5b9a42a8c038" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0742ddef-c5e6-4446-bbeb-b916aa0b7247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0742ddef-c5e6-4446-bbeb-b916aa0b7247" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c11ff90c-2c85-453a-a948-4f19c7d12b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_DebtInstrumentAxis_c11ff90c-2c85-453a-a948-4f19c7d12b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c11ff90c-2c85-453a-a948-4f19c7d12b21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c11ff90c-2c85-453a-a948-4f19c7d12b21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c11ff90c-2c85-453a-a948-4f19c7d12b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_76bbe60c-cf9b-4c42-95ef-947f943f7883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c11ff90c-2c85-453a-a948-4f19c7d12b21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_76bbe60c-cf9b-4c42-95ef-947f943f7883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_The2021CreditAgreementMember_47759b47-fb51-4f6b-96b5-2b929ba9e8fa" xlink:href="infu-20251231.xsd#infu_The2021CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_76bbe60c-cf9b-4c42-95ef-947f943f7883" xlink:to="loc_infu_The2021CreditAgreementMember_47759b47-fb51-4f6b-96b5-2b929ba9e8fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e4f84e85-f522-4676-9057-5478ef1df364" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_CreditFacilityAxis_e4f84e85-f522-4676-9057-5478ef1df364" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e4f84e85-f522-4676-9057-5478ef1df364_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e4f84e85-f522-4676-9057-5478ef1df364" xlink:to="loc_us-gaap_CreditFacilityDomain_e4f84e85-f522-4676-9057-5478ef1df364_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e4f84e85-f522-4676-9057-5478ef1df364" xlink:to="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_71b7fd34-5b43-4829-9d78-a53dfc4e0b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_71b7fd34-5b43-4829-9d78-a53dfc4e0b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_05cd4b83-34a4-4e0e-b07c-caa276eb30fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:to="loc_us-gaap_LetterOfCreditMember_05cd4b83-34a4-4e0e-b07c-caa276eb30fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e86a1d3-c9e9-4abd-88f6-08408ff40670" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_srt_RangeAxis_4e86a1d3-c9e9-4abd-88f6-08408ff40670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e86a1d3-c9e9-4abd-88f6-08408ff40670_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4e86a1d3-c9e9-4abd-88f6-08408ff40670" xlink:to="loc_srt_RangeMember_4e86a1d3-c9e9-4abd-88f6-08408ff40670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4e86a1d3-c9e9-4abd-88f6-08408ff40670" xlink:to="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_42150289-7ccf-426b-85bf-abb6ec82dbe0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:to="loc_srt_MinimumMember_42150289-7ccf-426b-85bf-abb6ec82dbe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33d7676d-9fec-4d9e-84aa-8e6a952af23a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:to="loc_srt_MaximumMember_33d7676d-9fec-4d9e-84aa-8e6a952af23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_VariableRateAxis_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c" xlink:to="loc_us-gaap_VariableRateDomain_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c" xlink:to="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_3af647a5-127f-45f1-a720-aafbdc334305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_3af647a5-127f-45f1-a720-aafbdc334305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_4ddc51df-406d-4c70-be6e-50fdb47f81e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:to="loc_us-gaap_BaseRateMember_4ddc51df-406d-4c70-be6e-50fdb47f81e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_649201fb-da9e-4bff-8e11-c2f4b0957a84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:to="loc_us-gaap_PrimeRateMember_649201fb-da9e-4bff-8e11-c2f4b0957a84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94b08f2f-e0bc-4cac-a385-11206647acc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94b08f2f-e0bc-4cac-a385-11206647acc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94b08f2f-e0bc-4cac-a385-11206647acc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94b08f2f-e0bc-4cac-a385-11206647acc9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94b08f2f-e0bc-4cac-a385-11206647acc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94b08f2f-e0bc-4cac-a385-11206647acc9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermBenchmarkLoansMember_bafe0faa-494d-4944-bd7b-21200ea502dc" xlink:href="infu-20251231.xsd#infu_TermBenchmarkLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:to="loc_infu_TermBenchmarkLoansMember_bafe0faa-494d-4944-bd7b-21200ea502dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ABRLoansMember_4998f977-9c79-4492-bbe1-dce6b6471968" xlink:href="infu-20251231.xsd#infu_ABRLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:to="loc_infu_ABRLoansMember_4998f977-9c79-4492-bbe1-dce6b6471968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d869645-5699-4f19-82bd-045d07c60ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d869645-5699-4f19-82bd-045d07c60ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions_2a0aa57b-a7a4-429b-b0c3-3175c5f18fcf" xlink:href="infu-20251231.xsd#infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions_2a0aa57b-a7a4-429b-b0c3-3175c5f18fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PercentageOfTotalDepreciationExpense_6db870be-9724-4008-9783-5d6b5d91c0e7" xlink:href="infu-20251231.xsd#infu_PercentageOfTotalDepreciationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_PercentageOfTotalDepreciationExpense_6db870be-9724-4008-9783-5d6b5d91c0e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio_7a06fb7a-b5df-41f3-bd0f-941952a019cd" xlink:href="infu-20251231.xsd#infu_DebtInstrumentCovenantMinimumFixedCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio_7a06fb7a-b5df-41f3-bd0f-941952a019cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DebtInstrumentCovenantMaximumLeverageRatio_ccd46779-e7d3-4438-aee1-d821ea086033" xlink:href="infu-20251231.xsd#infu_DebtInstrumentCovenantMaximumLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_DebtInstrumentCovenantMaximumLeverageRatio_ccd46779-e7d3-4438-aee1-d821ea086033" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9308e31f-b52d-4dd4-9aa1-29f8ad23c14c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9308e31f-b52d-4dd4-9aa1-29f8ad23c14c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45804ce7-b19b-40ed-8f79-ec31017de81b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45804ce7-b19b-40ed-8f79-ec31017de81b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofLineofCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7832a957-11fc-4bd6-8905-6a90ae32c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:to="loc_us-gaap_DebtInstrumentTable_7832a957-11fc-4bd6-8905-6a90ae32c8f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_064aa6b0-8565-4e91-a0f3-239577a77587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7832a957-11fc-4bd6-8905-6a90ae32c8f3" xlink:to="loc_us-gaap_CreditFacilityAxis_064aa6b0-8565-4e91-a0f3-239577a77587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_064aa6b0-8565-4e91-a0f3-239577a77587_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_064aa6b0-8565-4e91-a0f3-239577a77587" xlink:to="loc_us-gaap_CreditFacilityDomain_064aa6b0-8565-4e91-a0f3-239577a77587_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_734e414c-86ff-49f2-b51f-84974f63c2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_064aa6b0-8565-4e91-a0f3-239577a77587" xlink:to="loc_us-gaap_CreditFacilityDomain_734e414c-86ff-49f2-b51f-84974f63c2b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1a04a063-421c-459d-889b-a75bc16668fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_734e414c-86ff-49f2-b51f-84974f63c2b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1a04a063-421c-459d-889b-a75bc16668fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_fe0b9b8f-5358-4a82-8c7f-3adae3157848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_fe0b9b8f-5358-4a82-8c7f-3adae3157848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_645fbe70-c96d-4339-9ec8-4e56c083404c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:to="loc_us-gaap_LineOfCredit_645fbe70-c96d-4339-9ec8-4e56c083404c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ed586f34-bd67-4bdf-877a-c4d4dcd23bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ed586f34-bd67-4bdf-877a-c4d4dcd23bbe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofMaturitiesofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8af0f914-5130-4a25-ba80-8a9ca4fa3691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_DebtInstrumentTable_8af0f914-5130-4a25-ba80-8a9ca4fa3691" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2bb4f96c-6036-4904-924f-15801f6a6fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8af0f914-5130-4a25-ba80-8a9ca4fa3691" xlink:to="loc_us-gaap_CreditFacilityAxis_2bb4f96c-6036-4904-924f-15801f6a6fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2bb4f96c-6036-4904-924f-15801f6a6fcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2bb4f96c-6036-4904-924f-15801f6a6fcd" xlink:to="loc_us-gaap_CreditFacilityDomain_2bb4f96c-6036-4904-924f-15801f6a6fcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4ba3faa0-4fbb-4efb-97d7-bacc51782863" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2bb4f96c-6036-4904-924f-15801f6a6fcd" xlink:to="loc_us-gaap_CreditFacilityDomain_4ba3faa0-4fbb-4efb-97d7-bacc51782863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a82a15b2-1df2-4109-a1d6-3d6bd592deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4ba3faa0-4fbb-4efb-97d7-bacc51782863" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a82a15b2-1df2-4109-a1d6-3d6bd592deb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2cab1e36-5e20-43c5-8e79-b7338ac2300e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2cab1e36-5e20-43c5-8e79-b7338ac2300e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4c8bbb33-69cf-49de-9739-6190bb44c84a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4c8bbb33-69cf-49de-9739-6190bb44c84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9d33f312-8719-4255-a1f3-9069dfcf1283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9d33f312-8719-4255-a1f3-9069dfcf1283" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_af16bbed-fba1-4c6a-8e14-e140856fc7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_af16bbed-fba1-4c6a-8e14-e140856fc7c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_88ce9afa-b58c-4165-bdc6-6adefcf01c05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_88ce9afa-b58c-4165-bdc6-6adefcf01c05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7eae2c27-740e-4fe3-8cd9-f0e9c92e1f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7eae2c27-740e-4fe3-8cd9-f0e9c92e1f53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_52e5577e-3ae9-4831-86a2-d2ca5d56b3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_52e5577e-3ae9-4831-86a2-d2ca5d56b3fe" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4c7a4353-d6a8-4b5c-9937-f109f3bdd482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_DebtInstrumentTable_4c7a4353-d6a8-4b5c-9937-f109f3bdd482" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b89bf37d-9591-4eb9-9dd1-721977ee7090" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c7a4353-d6a8-4b5c-9937-f109f3bdd482" xlink:to="loc_us-gaap_CreditFacilityAxis_b89bf37d-9591-4eb9-9dd1-721977ee7090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b89bf37d-9591-4eb9-9dd1-721977ee7090_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b89bf37d-9591-4eb9-9dd1-721977ee7090" xlink:to="loc_us-gaap_CreditFacilityDomain_b89bf37d-9591-4eb9-9dd1-721977ee7090_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9e1ca486-8d9f-432b-9209-560b25b17a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b89bf37d-9591-4eb9-9dd1-721977ee7090" xlink:to="loc_us-gaap_CreditFacilityDomain_9e1ca486-8d9f-432b-9209-560b25b17a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e3f7edf5-2f1b-4e95-89fc-da31961aa582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9e1ca486-8d9f-432b-9209-560b25b17a68" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e3f7edf5-2f1b-4e95-89fc-da31961aa582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossCurrent_3746e634-a6ad-440a-830b-924f311a675a" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_LongTermDebtGrossCurrent_3746e634-a6ad-440a-830b-924f311a675a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossNoncurrent_64810c2f-2e43-404c-b7a5-eaa5beef76c3" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_LongTermDebtGrossNoncurrent_64810c2f-2e43-404c-b7a5-eaa5beef76c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7f86e538-beb6-43f7-9794-d1fcd0d3e2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7f86e538-beb6-43f7-9794-d1fcd0d3e2cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_d5f466ec-be7b-4b76-af67-5e8bcbad4986" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_d5f466ec-be7b-4b76-af67-5e8bcbad4986" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_4f0c0b11-5dac-4d83-9cd0-5981ebffdf9e" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_4f0c0b11-5dac-4d83-9cd0-5981ebffdf9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_08c4c251-36b3-416b-b432-f6cc8309669f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_08c4c251-36b3-416b-b432-f6cc8309669f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8e373018-9c8c-42e6-813a-8c5270b103c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_LongTermDebtCurrent_8e373018-9c8c-42e6-813a-8c5270b103c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4ad518d4-9a40-4317-be81-487d780560d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4ad518d4-9a40-4317-be81-487d780560d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_266e4c0a-8692-4906-8f07-6d6861a872ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_LongTermDebt_266e4c0a-8692-4906-8f07-6d6861a872ea" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:to="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a4338942-2d4d-4d55-8b98-6f759bbb0af9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a4338942-2d4d-4d55-8b98-6f759bbb0af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_62f18f15-b465-4972-b673-cc9e6c1aad97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a4338942-2d4d-4d55-8b98-6f759bbb0af9" xlink:to="loc_us-gaap_InterestRateSwapMember_62f18f15-b465-4972-b673-cc9e6c1aad97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3de362d2-35f4-423b-ad5e-020045e8c256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:to="loc_us-gaap_HedgingDesignationAxis_3de362d2-35f4-423b-ad5e-020045e8c256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3de362d2-35f4-423b-ad5e-020045e8c256_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_3de362d2-35f4-423b-ad5e-020045e8c256" xlink:to="loc_us-gaap_HedgingDesignationDomain_3de362d2-35f4-423b-ad5e-020045e8c256_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e210ada7-3669-42c2-bf93-729f4e5af548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_3de362d2-35f4-423b-ad5e-020045e8c256" xlink:to="loc_us-gaap_HedgingDesignationDomain_e210ada7-3669-42c2-bf93-729f4e5af548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c0b44d3-4cdc-4ff5-8f29-d1b3710bdaad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e210ada7-3669-42c2-bf93-729f4e5af548" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c0b44d3-4cdc-4ff5-8f29-d1b3710bdaad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_53cae4a2-e37f-48be-b782-3dabc9a99411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_53cae4a2-e37f-48be-b782-3dabc9a99411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_53cae4a2-e37f-48be-b782-3dabc9a99411_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_53cae4a2-e37f-48be-b782-3dabc9a99411" xlink:to="loc_us-gaap_HedgingRelationshipDomain_53cae4a2-e37f-48be-b782-3dabc9a99411_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0dd832cb-e13c-414e-a599-14a63f3265cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_53cae4a2-e37f-48be-b782-3dabc9a99411" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0dd832cb-e13c-414e-a599-14a63f3265cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_873b22c5-3da2-435d-8bb3-caa09697b306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0dd832cb-e13c-414e-a599-14a63f3265cf" xlink:to="loc_us-gaap_CashFlowHedgingMember_873b22c5-3da2-435d-8bb3-caa09697b306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_f4b0846a-66a0-4d3c-a14c-e2ca8077ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:to="loc_us-gaap_DerivativeTermOfContract_f4b0846a-66a0-4d3c-a14c-e2ca8077ebec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_6257fbad-000e-45ac-bb27-c1c36b301e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_6257fbad-000e-45ac-bb27-c1c36b301e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_fb58e0a9-344b-4603-a033-b3fbe87b7565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:to="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_fb58e0a9-344b-4603-a033-b3fbe87b7565" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:to="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4c270e00-3c9d-425c-83d1-656cf332792f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4c270e00-3c9d-425c-83d1-656cf332792f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4c270e00-3c9d-425c-83d1-656cf332792f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4c270e00-3c9d-425c-83d1-656cf332792f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4c270e00-3c9d-425c-83d1-656cf332792f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_95c92f36-163b-4eb4-9527-7ef04c5c8237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4c270e00-3c9d-425c-83d1-656cf332792f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_95c92f36-163b-4eb4-9527-7ef04c5c8237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_5c59e356-8575-4c15-a098-6f38f9a85352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_95c92f36-163b-4eb4-9527-7ef04c5c8237" xlink:to="loc_us-gaap_CashFlowHedgingMember_5c59e356-8575-4c15-a098-6f38f9a85352" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f9cfe0e3-4867-47f4-a696-6431d5df72d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f9cfe0e3-4867-47f4-a696-6431d5df72d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_59d73874-59bc-4afe-b8fd-dacf6f0cda59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f9cfe0e3-4867-47f4-a696-6431d5df72d5" xlink:to="loc_us-gaap_InterestRateSwapMember_59d73874-59bc-4afe-b8fd-dacf6f0cda59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4ec4163f-6ebd-4e76-89fc-ae0164cd860f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:to="loc_us-gaap_HedgingDesignationAxis_4ec4163f-6ebd-4e76-89fc-ae0164cd860f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4ec4163f-6ebd-4e76-89fc-ae0164cd860f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4ec4163f-6ebd-4e76-89fc-ae0164cd860f" xlink:to="loc_us-gaap_HedgingDesignationDomain_4ec4163f-6ebd-4e76-89fc-ae0164cd860f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_acb10541-9a7d-4b9d-a3f6-bf3a65241173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4ec4163f-6ebd-4e76-89fc-ae0164cd860f" xlink:to="loc_us-gaap_HedgingDesignationDomain_acb10541-9a7d-4b9d-a3f6-bf3a65241173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7c0021c-a3a0-45d9-bcb4-eadd60d5815c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_acb10541-9a7d-4b9d-a3f6-bf3a65241173" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7c0021c-a3a0-45d9-bcb4-eadd60d5815c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_17b96af5-435d-4b58-a712-c740b2574ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_17b96af5-435d-4b58-a712-c740b2574ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_0f412363-2db4-4bb5-ac76-81edb682f728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_0f412363-2db4-4bb5-ac76-81edb682f728" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:to="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd2d72f1-be01-4461-9d47-e6017967af8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd2d72f1-be01-4461-9d47-e6017967af8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd2d72f1-be01-4461-9d47-e6017967af8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd2d72f1-be01-4461-9d47-e6017967af8a" xlink:to="loc_us-gaap_EquityComponentDomain_bd2d72f1-be01-4461-9d47-e6017967af8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_171fb240-b0ab-4a6d-986f-821cd63df94b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd2d72f1-be01-4461-9d47-e6017967af8a" xlink:to="loc_us-gaap_EquityComponentDomain_171fb240-b0ab-4a6d-986f-821cd63df94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c655a93b-fd2d-4651-b5cb-3688f108759a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_171fb240-b0ab-4a6d-986f-821cd63df94b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c655a93b-fd2d-4651-b5cb-3688f108759a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d895d255-a95d-4fef-95f2-ad3c75c3ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d895d255-a95d-4fef-95f2-ad3c75c3ce8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d895d255-a95d-4fef-95f2-ad3c75c3ce8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d895d255-a95d-4fef-95f2-ad3c75c3ce8f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d895d255-a95d-4fef-95f2-ad3c75c3ce8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_143d4f51-9c05-490b-a7c4-aa4400670bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d895d255-a95d-4fef-95f2-ad3c75c3ce8f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_143d4f51-9c05-490b-a7c4-aa4400670bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d393f23c-c86f-4bdc-84aa-9508d7493615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_143d4f51-9c05-490b-a7c4-aa4400670bd3" xlink:to="loc_us-gaap_InterestRateSwapMember_d393f23c-c86f-4bdc-84aa-9508d7493615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_589d6de9-4e0e-478a-b500-ce494f14fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_589d6de9-4e0e-478a-b500-ce494f14fd23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_589d6de9-4e0e-478a-b500-ce494f14fd23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_589d6de9-4e0e-478a-b500-ce494f14fd23" xlink:to="loc_us-gaap_HedgingRelationshipDomain_589d6de9-4e0e-478a-b500-ce494f14fd23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_84c4efb7-1f8e-4666-8e37-33ddb15fd99b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_589d6de9-4e0e-478a-b500-ce494f14fd23" xlink:to="loc_us-gaap_HedgingRelationshipDomain_84c4efb7-1f8e-4666-8e37-33ddb15fd99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_f45e9b08-e62d-499c-be84-0a7c2c0aadfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_84c4efb7-1f8e-4666-8e37-33ddb15fd99b" xlink:to="loc_us-gaap_CashFlowHedgingMember_f45e9b08-e62d-499c-be84-0a7c2c0aadfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_46ea9b67-38c6-427f-9c01-50edcc88d055" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_HedgingDesignationAxis_46ea9b67-38c6-427f-9c01-50edcc88d055" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_46ea9b67-38c6-427f-9c01-50edcc88d055_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_46ea9b67-38c6-427f-9c01-50edcc88d055" xlink:to="loc_us-gaap_HedgingDesignationDomain_46ea9b67-38c6-427f-9c01-50edcc88d055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0ba82872-2464-4c02-b808-dd6bb48f3f39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_46ea9b67-38c6-427f-9c01-50edcc88d055" xlink:to="loc_us-gaap_HedgingDesignationDomain_0ba82872-2464-4c02-b808-dd6bb48f3f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db27e21f-35ad-43ba-b81d-e09cc0aaf6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0ba82872-2464-4c02-b808-dd6bb48f3f39" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db27e21f-35ad-43ba-b81d-e09cc0aaf6ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d07fa8a-4efb-407c-9637-c8163fb494cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_StockholdersEquity_3d07fa8a-4efb-407c-9637-c8163fb494cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_8f915d20-e56d-4e19-910a-06b24a4a26ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_8f915d20-e56d-4e19-910a-06b24a4a26ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_6b43d35c-8844-48f1-8aad-ddc7140a2e67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_6b43d35c-8844-48f1-8aad-ddc7140a2e67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_0a3791de-8c81-4374-ae31-b8c09eeb8c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_0a3791de-8c81-4374-ae31-b8c09eeb8c8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e81e5f97-1e46-4c00-91e0-902aa1c1110a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_35b47c3e-e153-4da7-acbe-029e16455f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:to="loc_us-gaap_InterestExpenseNonoperating_35b47c3e-e153-4da7-acbe-029e16455f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_2323aacc-2430-42d2-ad02-9deeb0d3adf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_2323aacc-2430-42d2-ad02-9deeb0d3adf8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_019b0311-3462-7066-b3fa-2db446e9b8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_019b0311-3462-7066-b3fa-2db446e9b8d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019b0311-3462-7323-a245-373e1114396d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_019b0311-3462-7066-b3fa-2db446e9b8d1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019b0311-3462-7323-a245-373e1114396d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7323-a245-373e1114396d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b0311-3462-7323-a245-373e1114396d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7323-a245-373e1114396d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7ebf-9417-e393d208a8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b0311-3462-7323-a245-373e1114396d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7ebf-9417-e393d208a8cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7ebf-9417-e393d208a8cf" xlink:to="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_019b0311-3462-7c77-93bd-034015d76b02" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_FL_019b0311-3462-7c77-93bd-034015d76b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_019b5126-96aa-79c7-b406-257d46d89dc6" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_GA_019b5126-96aa-79c7-b406-257d46d89dc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_019b5126-4ef6-7d01-81bc-a4c7d72dbb90" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_IL_019b5126-4ef6-7d01-81bc-a4c7d72dbb90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI_019b0311-3462-7cee-a24d-445d34114dc1" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_MI_019b0311-3462-7cee-a24d-445d34114dc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_019c4844-b6bc-78b7-8d54-c9201c5211f9" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_NY_019c4844-b6bc-78b7-8d54-c9201c5211f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_019b0311-3462-71dd-b2c3-ecededc55851" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_PA_019b0311-3462-71dd-b2c3-ecededc55851" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_019b5126-dd0e-7343-9df1-9873ef01fbfe" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_TX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_TX_019b5126-dd0e-7343-9df1-9873ef01fbfe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019b0311-3462-77f1-89be-e9542bf44574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019b0311-3462-77f1-89be-e9542bf44574" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019b0311-3462-717f-80c0-17ea33e456db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019b0311-3462-717f-80c0-17ea33e456db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019b0311-3462-764b-9893-17aa82caf7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019b0311-3462-764b-9893-17aa82caf7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019b0311-3462-73ea-a345-b931e63c448e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019b0311-3462-73ea-a345-b931e63c448e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019b0311-3462-79d1-a13a-5701575bc6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019b0311-3462-79d1-a13a-5701575bc6b9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c50d683d-a101-45ea-8480-e19762e3f1cd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:to="loc_srt_RangeAxis_c50d683d-a101-45ea-8480-e19762e3f1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c50d683d-a101-45ea-8480-e19762e3f1cd_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c50d683d-a101-45ea-8480-e19762e3f1cd" xlink:to="loc_srt_RangeMember_c50d683d-a101-45ea-8480-e19762e3f1cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c50d683d-a101-45ea-8480-e19762e3f1cd" xlink:to="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f33e9849-41ae-4f7e-9354-70d1ae798cce" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:to="loc_srt_MinimumMember_f33e9849-41ae-4f7e-9354-70d1ae798cce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_370980d3-2703-4fd7-abfc-06d7fe74ccfd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:to="loc_srt_MaximumMember_370980d3-2703-4fd7-abfc-06d7fe74ccfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8ac9d8af-6e90-4860-9676-028332f09d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8ac9d8af-6e90-4860-9676-028332f09d6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ac9d8af-6e90-4860-9676-028332f09d6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ac9d8af-6e90-4860-9676-028332f09d6b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ac9d8af-6e90-4860-9676-028332f09d6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ac9d8af-6e90-4860-9676-028332f09d6b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f568563c-acaf-45f0-9f6f-f92a303dbc42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:to="loc_us-gaap_DomesticCountryMember_f568563c-acaf-45f0-9f6f-f92a303dbc42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3de533ec-64b7-4824-aadb-874b3955014b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3de533ec-64b7-4824-aadb-874b3955014b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0631f9de-4d34-413d-92f9-e91ac69284a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0631f9de-4d34-413d-92f9-e91ac69284a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8e55fc11-b2d0-46b1-a32c-5d827c9d46ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8e55fc11-b2d0-46b1-a32c-5d827c9d46ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_OperatingLossCarryforwardsWithADefiniteLife_f009c396-08c8-4a22-be82-117d52261843" xlink:href="infu-20251231.xsd#infu_OperatingLossCarryforwardsWithADefiniteLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_infu_OperatingLossCarryforwardsWithADefiniteLife_f009c396-08c8-4a22-be82-117d52261843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_OperatingLossCarryforwardsExpirationPeriods_52438caf-14d3-43ee-b8fc-724bad19e92b" xlink:href="infu-20251231.xsd#infu_OperatingLossCarryforwardsExpirationPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_infu_OperatingLossCarryforwardsExpirationPeriods_52438caf-14d3-43ee-b8fc-724bad19e92b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d462d7d9-2b47-4f6a-8607-b1404c04860f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d462d7d9-2b47-4f6a-8607-b1404c04860f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesCarryForwardsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesCarryForwardsDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/IncomeTaxesCarryForwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_75f8e70a-de3b-40ef-a546-fbbb0cf6896f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_75f8e70a-de3b-40ef-a546-fbbb0cf6896f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_383b7f87-cdc1-42b2-aa98-86d70bcc309a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_75f8e70a-de3b-40ef-a546-fbbb0cf6896f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_383b7f87-cdc1-42b2-aa98-86d70bcc309a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_383b7f87-cdc1-42b2-aa98-86d70bcc309a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_383b7f87-cdc1-42b2-aa98-86d70bcc309a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_383b7f87-cdc1-42b2-aa98-86d70bcc309a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6b724a9a-1cea-462f-bb11-c13fa97d49ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_383b7f87-cdc1-42b2-aa98-86d70bcc309a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6b724a9a-1cea-462f-bb11-c13fa97d49ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d4aabec5-1c6b-4e37-bfe8-6c622af197f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6b724a9a-1cea-462f-bb11-c13fa97d49ca" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d4aabec5-1c6b-4e37-bfe8-6c622af197f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_302276c1-85ee-48e7-8cca-7ec1875cfbec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_302276c1-85ee-48e7-8cca-7ec1875cfbec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ca27202-242a-48bc-92ab-e930bafd6b36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ca27202-242a-48bc-92ab-e930bafd6b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_964067fe-479f-4f8a-a4e7-ef7140575e46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_964067fe-479f-4f8a-a4e7-ef7140575e46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities_f292ba0f-cd47-4710-be89-f5e99ef4b54c" xlink:href="infu-20251231.xsd#infu_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities_f292ba0f-cd47-4710-be89-f5e99ef4b54c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e822a8bf-6882-46be-9a21-05307c622639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e822a8bf-6882-46be-9a21-05307c622639" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_8d9a8149-0687-4d27-a297-665b9062add3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_8d9a8149-0687-4d27-a297-665b9062add3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_52c95b9a-3e21-481f-b0fc-4e8cd170c021" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_52c95b9a-3e21-481f-b0fc-4e8cd170c021" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_6526d2e8-dc89-48d9-aa8d-b4c15cd43075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_6526d2e8-dc89-48d9-aa8d-b4c15cd43075" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_761e4a30-07de-4ca9-98ba-0006d7fe0298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_761e4a30-07de-4ca9-98ba-0006d7fe0298" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_de0f5c37-ab71-4947-b636-6cb0d34f0f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_de0f5c37-ab71-4947-b636-6cb0d34f0f45" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cc84e341-4455-4d18-b3d1-7a7165c00144" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cc84e341-4455-4d18-b3d1-7a7165c00144" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_5e080af9-737a-413f-a318-878aef003507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_5e080af9-737a-413f-a318-878aef003507" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets_1a53ffd4-f55d-4d3f-a43f-5f7a1b7cc65d" xlink:href="infu-20251231.xsd#infu_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets_1a53ffd4-f55d-4d3f-a43f-5f7a1b7cc65d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_746b3eba-2dc7-490f-ad22-c70d5d2ca792" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_746b3eba-2dc7-490f-ad22-c70d5d2ca792" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8c11fb3b-9822-4ea0-96cf-4e6549d07d69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8c11fb3b-9822-4ea0-96cf-4e6549d07d69" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2b94f485-dad2-446d-b858-52e202ec7a31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2b94f485-dad2-446d-b858-52e202ec7a31" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e0777363-d600-4e63-a7d9-ec5ecef5bca3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e0777363-d600-4e63-a7d9-ec5ecef5bca3" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_16d144c8-9357-47a4-96a5-8d3e42f9853f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_16d144c8-9357-47a4-96a5-8d3e42f9853f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f4cf8981-20df-4923-b72f-105cc63f40d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_16d144c8-9357-47a4-96a5-8d3e42f9853f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f4cf8981-20df-4923-b72f-105cc63f40d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f4cf8981-20df-4923-b72f-105cc63f40d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f4cf8981-20df-4923-b72f-105cc63f40d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f4cf8981-20df-4923-b72f-105cc63f40d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70b50746-4c10-4cca-8fa8-bab30876fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f4cf8981-20df-4923-b72f-105cc63f40d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70b50746-4c10-4cca-8fa8-bab30876fa98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c15601eb-be97-423c-b493-ed0b9aff4730" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70b50746-4c10-4cca-8fa8-bab30876fa98" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c15601eb-be97-423c-b493-ed0b9aff4730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fb04639d-37b7-4ca0-85ca-867375735ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:to="loc_us-gaap_LeaseCost_fb04639d-37b7-4ca0-85ca-867375735ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeasePayments_019c4850-a9ab-7226-986b-836867244cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:to="loc_us-gaap_ShortTermLeasePayments_019c4850-a9ab-7226-986b-836867244cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8dc1ab15-e366-4ee1-a105-ea5a4f670102" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8dc1ab15-e366-4ee1-a105-ea5a4f670102" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentInLeaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable_776bcb1f-e43e-4b74-a811-74f70ba11c89" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentInLeaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:to="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable_776bcb1f-e43e-4b74-a811-74f70ba11c89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LeaseClassificationAxis_139db6fd-b329-490f-809b-f55260abb703" xlink:href="infu-20251231.xsd#infu_LeaseClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable_776bcb1f-e43e-4b74-a811-74f70ba11c89" xlink:to="loc_infu_LeaseClassificationAxis_139db6fd-b329-490f-809b-f55260abb703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LeaseClassificationDomain_139db6fd-b329-490f-809b-f55260abb703_default" xlink:href="infu-20251231.xsd#infu_LeaseClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_infu_LeaseClassificationAxis_139db6fd-b329-490f-809b-f55260abb703" xlink:to="loc_infu_LeaseClassificationDomain_139db6fd-b329-490f-809b-f55260abb703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LeaseClassificationDomain_220020b6-afec-4713-8e37-38c928ef1a4b" xlink:href="infu-20251231.xsd#infu_LeaseClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_infu_LeaseClassificationAxis_139db6fd-b329-490f-809b-f55260abb703" xlink:to="loc_infu_LeaseClassificationDomain_220020b6-afec-4713-8e37-38c928ef1a4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentMember_97fcc8a6-f873-4238-be98-a9fbba011fa3" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_infu_LeaseClassificationDomain_220020b6-afec-4713-8e37-38c928ef1a4b" xlink:to="loc_infu_SalesTypeLeaseNetInvestmentMember_97fcc8a6-f873-4238-be98-a9fbba011fa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_11d128cc-2a10-48df-949a-fdd1100e3841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_11d128cc-2a10-48df-949a-fdd1100e3841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_259d61c9-9251-43cb-bbef-0db87ac80f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:to="loc_us-gaap_OtherAssets_259d61c9-9251-43cb-bbef-0db87ac80f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7331c40f-97e0-4469-b10d-eef7bca8685e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:to="loc_us-gaap_Assets_7331c40f-97e0-4469-b10d-eef7bca8685e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f8cafd1-ca9c-458c-855e-f0e233533474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_us-gaap_AwardTypeAxis_0f8cafd1-ca9c-458c-855e-f0e233533474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8cafd1-ca9c-458c-855e-f0e233533474_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0f8cafd1-ca9c-458c-855e-f0e233533474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8cafd1-ca9c-458c-855e-f0e233533474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0f8cafd1-ca9c-458c-855e-f0e233533474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ba5b55e-0772-4457-8ac7-2388b04bcab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ba5b55e-0772-4457-8ac7-2388b04bcab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_26071ef0-89db-4852-9876-0eb0acfd0538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_RestrictedStockMember_26071ef0-89db-4852-9876-0eb0acfd0538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_746bba8d-db0c-4e46-a8d6-1aa5f6faa2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_PerformanceSharesMember_746bba8d-db0c-4e46-a8d6-1aa5f6faa2ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_60e7073e-0dc1-4de9-b0c6-112535a4f2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_EmployeeStockMember_60e7073e-0dc1-4de9-b0c6-112535a4f2c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_549c82ca-709d-4b1d-9ede-d8e57def1195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_us-gaap_VestingAxis_549c82ca-709d-4b1d-9ede-d8e57def1195" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_549c82ca-709d-4b1d-9ede-d8e57def1195_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_549c82ca-709d-4b1d-9ede-d8e57def1195" xlink:to="loc_us-gaap_VestingDomain_549c82ca-709d-4b1d-9ede-d8e57def1195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_549c82ca-709d-4b1d-9ede-d8e57def1195" xlink:to="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember_c4773790-d16f-4d35-80d6-e56b3de78984" xlink:href="infu-20251231.xsd#infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:to="loc_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember_c4773790-d16f-4d35-80d6-e56b3de78984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember_ccf8c2e3-2b2f-499b-82af-cf8c0ba161a6" xlink:href="infu-20251231.xsd#infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:to="loc_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember_ccf8c2e3-2b2f-499b-82af-cf8c0ba161a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_21599de8-93f3-4f16-a0cd-45d0cd421a27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_us-gaap_PlanNameAxis_21599de8-93f3-4f16-a0cd-45d0cd421a27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_21599de8-93f3-4f16-a0cd-45d0cd421a27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_21599de8-93f3-4f16-a0cd-45d0cd421a27" xlink:to="loc_us-gaap_PlanNameDomain_21599de8-93f3-4f16-a0cd-45d0cd421a27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_21599de8-93f3-4f16-a0cd-45d0cd421a27" xlink:to="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2021EquityIncentivePlanMember_a0cd3769-10f0-4ff2-9685-222abee01b9d" xlink:href="infu-20251231.xsd#infu_A2021EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:to="loc_infu_A2021EquityIncentivePlanMember_a0cd3769-10f0-4ff2-9685-222abee01b9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2014EquityIncentivePlanMember_987e5e34-c8d9-4e2c-91fb-a47fd3f61d09" xlink:href="infu-20251231.xsd#infu_A2014EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:to="loc_infu_A2014EquityIncentivePlanMember_987e5e34-c8d9-4e2c-91fb-a47fd3f61d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c387249-8179-4348-9167-26d52cd753ec" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_srt_RangeAxis_7c387249-8179-4348-9167-26d52cd753ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c387249-8179-4348-9167-26d52cd753ec_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7c387249-8179-4348-9167-26d52cd753ec" xlink:to="loc_srt_RangeMember_7c387249-8179-4348-9167-26d52cd753ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7c387249-8179-4348-9167-26d52cd753ec" xlink:to="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a4c1dfc-ab87-41f6-9fb5-cb2f82faa50a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:to="loc_srt_MinimumMember_5a4c1dfc-ab87-41f6-9fb5-cb2f82faa50a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a80c3e74-573f-459c-a1ab-ce0d78f1cde3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:to="loc_srt_MaximumMember_a80c3e74-573f-459c-a1ab-ce0d78f1cde3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7886f9d8-ba3d-49ad-9ed9-ca649dd51025" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7886f9d8-ba3d-49ad-9ed9-ca649dd51025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod_fb49ff65-d999-414e-98d7-c771a4058d0e" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod_fb49ff65-d999-414e-98d7-c771a4058d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3ad23fd-872a-4ab2-985d-f55fe23fdd79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3ad23fd-872a-4ab2-985d-f55fe23fdd79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b45e93d2-9b95-422c-b6fd-34de699d0143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b45e93d2-9b95-422c-b6fd-34de699d0143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_43dfa4e3-051b-4821-912f-cee5a1dac889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_43dfa4e3-051b-4821-912f-cee5a1dac889" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio_fdf11354-3a00-475a-8a4a-1fa82cd96d1f" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio_fdf11354-3a00-475a-8a4a-1fa82cd96d1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio_17a43ae1-ab0a-477e-8046-aa2fbd8b0e76" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio_17a43ae1-ab0a-477e-8046-aa2fbd8b0e76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_138dea27-d959-4553-b717-43f8ed87c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_138dea27-d959-4553-b717-43f8ed87c9a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbc55c-6915-4ed3-91e4-c60e6c535d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbc55c-6915-4ed3-91e4-c60e6c535d7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_73e603a8-e79e-4f7d-90da-62a820bacc66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_73e603a8-e79e-4f7d-90da-62a820bacc66" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46f064da-dbdb-4900-81a4-b86fe4c61e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46f064da-dbdb-4900-81a4-b86fe4c61e34" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a353cbda-715d-4c5b-b911-295f07dfd8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a353cbda-715d-4c5b-b911-295f07dfd8a4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f16a782-d879-46b1-9f46-d423f77a1854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f16a782-d879-46b1-9f46-d423f77a1854" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned_8db9ebad-0216-4bee-ba98-63d41d1a1308" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned_8db9ebad-0216-4bee-ba98-63d41d1a1308" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_3395637a-447f-4b08-a9df-0a62008c3493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_3395637a-447f-4b08-a9df-0a62008c3493" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6dd87dcb-fd8c-49b1-b843-b49ed1f4b04b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6dd87dcb-fd8c-49b1-b843-b49ed1f4b04b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum_3a4ea7d1-c8e4-4a33-b930-7ed35c609609" xlink:href="infu-20251231.xsd#infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum_3a4ea7d1-c8e4-4a33-b930-7ed35c609609" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance_d096c99f-0a6a-478e-b3b4-9e2b30893e29" xlink:href="infu-20251231.xsd#infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance_d096c99f-0a6a-478e-b3b4-9e2b30893e29" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_dc81f124-b890-47fa-861f-b647e2e18138" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_dc81f124-b890-47fa-861f-b647e2e18138" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_9625d7a5-dc2c-49fe-887f-5f2c87f07f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_9625d7a5-dc2c-49fe-887f-5f2c87f07f2a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1c879794-23c9-4a4e-a69d-3cf38204f9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1c879794-23c9-4a4e-a69d-3cf38204f9e9" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5dca62e1-b617-4496-827e-b272f5c8cad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5dca62e1-b617-4496-827e-b272f5c8cad3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e760def8-70fa-437b-a76f-d815d1886089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5dca62e1-b617-4496-827e-b272f5c8cad3" xlink:to="loc_us-gaap_AwardTypeAxis_e760def8-70fa-437b-a76f-d815d1886089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e760def8-70fa-437b-a76f-d815d1886089_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e760def8-70fa-437b-a76f-d815d1886089" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e760def8-70fa-437b-a76f-d815d1886089_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d6e7d-b7a4-4619-9acf-0bee5bd4acaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e760def8-70fa-437b-a76f-d815d1886089" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d6e7d-b7a4-4619-9acf-0bee5bd4acaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e3be6d89-39f2-4b02-9f21-741a7f12bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d6e7d-b7a4-4619-9acf-0bee5bd4acaa" xlink:to="loc_us-gaap_RestrictedStockMember_e3be6d89-39f2-4b02-9f21-741a7f12bce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_486462de-f1df-4ad7-94cd-06335b5dc954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_486462de-f1df-4ad7-94cd-06335b5dc954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14ce0184-5717-4152-825c-68c8abf92648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14ce0184-5717-4152-825c-68c8abf92648" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6294f7bc-84d9-42d7-84d6-07200104710b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6294f7bc-84d9-42d7-84d6-07200104710b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_9aa5ffa0-2d2e-4351-9598-f2d12c4b4ed4" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_9aa5ffa0-2d2e-4351-9598-f2d12c4b4ed4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0beff3f8-ae64-469c-bb1f-0c79bae0d669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0beff3f8-ae64-469c-bb1f-0c79bae0d669" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b62a45f-192f-4375-bfdc-eb806b46c157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3fe1a5f-846e-427e-97fa-2e828f219d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3fe1a5f-846e-427e-97fa-2e828f219d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb7bbd-c35e-49b6-bc28-138a9c15340b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb7bbd-c35e-49b6-bc28-138a9c15340b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ca85108f-6097-4e4d-9374-18da3cba2fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ca85108f-6097-4e4d-9374-18da3cba2fd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_b8b135a4-be3d-4d78-bc0b-5524b30da298" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_b8b135a4-be3d-4d78-bc0b-5524b30da298" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435711eb-42eb-4d1a-9d51-0909d6af1fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435711eb-42eb-4d1a-9d51-0909d6af1fc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36fe559f-c124-4db3-9fc3-599487c5c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_af75649e-884d-4af2-b3d5-0bae08fbf338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_af75649e-884d-4af2-b3d5-0bae08fbf338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue_8fa49885-f4b5-45a7-98da-55dd9e0300bf" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue_8fa49885-f4b5-45a7-98da-55dd9e0300bf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e77612f-c5b0-4555-9ea7-760dcf885122" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e77612f-c5b0-4555-9ea7-760dcf885122" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47972337-fd7f-4a5b-a82d-5030af330b91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e77612f-c5b0-4555-9ea7-760dcf885122" xlink:to="loc_us-gaap_AwardTypeAxis_47972337-fd7f-4a5b-a82d-5030af330b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47972337-fd7f-4a5b-a82d-5030af330b91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_47972337-fd7f-4a5b-a82d-5030af330b91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47972337-fd7f-4a5b-a82d-5030af330b91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdc2afe5-4b27-40e6-870a-ae32488ce2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_47972337-fd7f-4a5b-a82d-5030af330b91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdc2afe5-4b27-40e6-870a-ae32488ce2bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_614df6ba-44b7-470f-b255-c24b67f92dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdc2afe5-4b27-40e6-870a-ae32488ce2bc" xlink:to="loc_us-gaap_PerformanceSharesMember_614df6ba-44b7-470f-b255-c24b67f92dc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b891e498-5ead-47b5-9ea8-a65a6ae4f035" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b891e498-5ead-47b5-9ea8-a65a6ae4f035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c7d932bd-fcbf-4ff6-984d-6b491902e3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c7d932bd-fcbf-4ff6-984d-6b491902e3cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e4cf8e38-4c1e-4b7d-98f9-b57e17eab557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e4cf8e38-4c1e-4b7d-98f9-b57e17eab557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone_e6a7aa5e-05d0-407f-9cb7-389b6434a2b8" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone_e6a7aa5e-05d0-407f-9cb7-389b6434a2b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019be390-a27b-7c56-8422-21d49e700daa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019be390-a27b-7c56-8422-21d49e700daa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee18f2a5-29f7-48bb-821d-6d31d6f0d247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5f7d08b-2a39-4bae-91f5-8d9f1f9fb14a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5f7d08b-2a39-4bae-91f5-8d9f1f9fb14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58119c28-2d69-4c65-af66-95f202ca14ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58119c28-2d69-4c65-af66-95f202ca14ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_476d40ac-520c-41ea-b9af-7b2f3d8cb4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_476d40ac-520c-41ea-b9af-7b2f3d8cb4b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue_64297fa4-aa81-44b0-82e3-78d6af296743" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue_64297fa4-aa81-44b0-82e3-78d6af296743" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019be390-a27b-7b72-87c0-d2e88d611e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019be390-a27b-7b72-87c0-d2e88d611e2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b823f37-bd35-462c-bf0d-afb102ac377d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ad028d5d-fd29-45ce-b2fd-a6d50bb75fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ad028d5d-fd29-45ce-b2fd-a6d50bb75fdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue_f7c4e0be-0011-4679-89da-2b55cf539cb2" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue_f7c4e0be-0011-4679-89da-2b55cf539cb2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensation2014and2021PlanActivityDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9a9c0cf-272c-4229-8d9c-ae68b4d9da97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9a9c0cf-272c-4229-8d9c-ae68b4d9da97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e352a853-09bb-4312-a4cc-aae28565a37a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9a9c0cf-272c-4229-8d9c-ae68b4d9da97" xlink:to="loc_us-gaap_PlanNameAxis_e352a853-09bb-4312-a4cc-aae28565a37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e352a853-09bb-4312-a4cc-aae28565a37a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e352a853-09bb-4312-a4cc-aae28565a37a" xlink:to="loc_us-gaap_PlanNameDomain_e352a853-09bb-4312-a4cc-aae28565a37a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e352a853-09bb-4312-a4cc-aae28565a37a" xlink:to="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2014EquityIncentivePlanMember_42f23194-69db-4a10-9dd9-e08abcb5f1d8" xlink:href="infu-20251231.xsd#infu_A2014EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:to="loc_infu_A2014EquityIncentivePlanMember_42f23194-69db-4a10-9dd9-e08abcb5f1d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2021EquityIncentivePlanMember_5f8ae7e4-926d-41b0-b639-90625dda1175" xlink:href="infu-20251231.xsd#infu_A2021EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:to="loc_infu_A2021EquityIncentivePlanMember_5f8ae7e4-926d-41b0-b639-90625dda1175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16d7f197-bcd3-4cb7-98b2-88e7a719ed7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16d7f197-bcd3-4cb7-98b2-88e7a719ed7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2e0df83b-aa3e-477b-827c-730aa24e9b38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2e0df83b-aa3e-477b-827c-730aa24e9b38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77526338-42f9-4bbf-b7ea-a69a0ddb35ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77526338-42f9-4bbf-b7ea-a69a0ddb35ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9b799676-8538-4a6f-9414-8d12f9745802" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9b799676-8538-4a6f-9414-8d12f9745802" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_7221e7f6-e85f-4941-8858-b25c265112ac" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_7221e7f6-e85f-4941-8858-b25c265112ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019c20f9-0ba8-7c53-9d7d-9c37b73015f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019c20f9-0ba8-7c53-9d7d-9c37b73015f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18322358-60b1-493e-a254-85ba843f97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a7aece3b-56f9-403e-8bca-6b2961cd9523" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a7aece3b-56f9-403e-8bca-6b2961cd9523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d1465cba-04b3-4071-9d9a-ae504410151d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d1465cba-04b3-4071-9d9a-ae504410151d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab6c1b72-de80-4505-8e55-28080bcc3ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab6c1b72-de80-4505-8e55-28080bcc3ae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_120ed536-80bc-44e6-ba6f-7ef418081117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_120ed536-80bc-44e6-ba6f-7ef418081117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15a68338-d779-4615-bf39-e5060dacd712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15a68338-d779-4615-bf39-e5060dacd712" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice_2d301b0f-6ff5-4229-9667-2618ae5df966" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice_2d301b0f-6ff5-4229-9667-2618ae5df966" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_355e1d20-6db2-4752-b36f-64b305c1ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_355e1d20-6db2-4752-b36f-64b305c1ca6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d20a3353-31e7-492e-8de7-6afbaa5757c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_002c2a86-66c8-4f73-855b-d77247b1bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_002c2a86-66c8-4f73-855b-d77247b1bb96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_85770f31-c35e-4b3a-9fdf-7046806e74bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_85770f31-c35e-4b3a-9fdf-7046806e74bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_54d1895e-6ff5-48e4-809a-815a651b3396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_54d1895e-6ff5-48e4-809a-815a651b3396" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e42ce06-b48d-4714-8ee8-908ea0fccb93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e42ce06-b48d-4714-8ee8-908ea0fccb93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c34f5c13-a7d1-411a-aa8a-d9219e68743b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c34f5c13-a7d1-411a-aa8a-d9219e68743b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08e65345-dbdc-4b5a-84ac-5235831e1116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08e65345-dbdc-4b5a-84ac-5235831e1116" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9c9ff705-94b8-47cd-b66a-b26d508883d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08e65345-dbdc-4b5a-84ac-5235831e1116" xlink:to="loc_us-gaap_AwardTypeAxis_9c9ff705-94b8-47cd-b66a-b26d508883d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c9ff705-94b8-47cd-b66a-b26d508883d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9c9ff705-94b8-47cd-b66a-b26d508883d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c9ff705-94b8-47cd-b66a-b26d508883d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c1771af-03da-4f81-943c-503a4e2f0ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9c9ff705-94b8-47cd-b66a-b26d508883d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c1771af-03da-4f81-943c-503a4e2f0ffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93694703-efd5-42eb-a42e-246098f00b14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c1771af-03da-4f81-943c-503a4e2f0ffc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93694703-efd5-42eb-a42e-246098f00b14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d5b7624f-69f1-4f28-a2ff-b5231aa2c2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d5b7624f-69f1-4f28-a2ff-b5231aa2c2d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7c2ec54e-8b11-4fd5-93a2-aa31e114a460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7c2ec54e-8b11-4fd5-93a2-aa31e114a460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1775ba2b-7e9a-4017-a581-c1d0436cb03a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1775ba2b-7e9a-4017-a581-c1d0436cb03a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12d96ce4-07c3-459c-a956-55d780547261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12d96ce4-07c3-459c-a956-55d780547261" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b40e2160-2fae-4e5c-85fa-063c49579ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b40e2160-2fae-4e5c-85fa-063c49579ff8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bb09fb89-e791-48ab-9ffb-2df158083584" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bb09fb89-e791-48ab-9ffb-2df158083584" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e5147-0be7-4b06-b555-0dde1488f0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e5147-0be7-4b06-b555-0dde1488f0ad" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessSegmentInformationDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://infusystem.com/role/BusinessSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d8e3cb59-a473-41cb-9e2e-24cee2977f97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d8e3cb59-a473-41cb-9e2e-24cee2977f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8e3cb59-a473-41cb-9e2e-24cee2977f97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8e3cb59-a473-41cb-9e2e-24cee2977f97" xlink:to="loc_us-gaap_SegmentDomain_d8e3cb59-a473-41cb-9e2e-24cee2977f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8e3cb59-a473-41cb-9e2e-24cee2977f97" xlink:to="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesMember_d07c997a-0367-437a-8c20-88e08af9c23d" xlink:href="infu-20251231.xsd#infu_PatientServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:to="loc_infu_PatientServicesMember_d07c997a-0367-437a-8c20-88e08af9c23d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeviceSolutionsMember_6df30fee-ab75-44be-b63e-3a2d6c6ff9a3" xlink:href="infu-20251231.xsd#infu_DeviceSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:to="loc_infu_DeviceSolutionsMember_6df30fee-ab75-44be-b63e-3a2d6c6ff9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2a3d563a-7046-4750-a83b-3329a7e11d15" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:to="loc_srt_ConsolidationItemsAxis_2a3d563a-7046-4750-a83b-3329a7e11d15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2a3d563a-7046-4750-a83b-3329a7e11d15_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2a3d563a-7046-4750-a83b-3329a7e11d15" xlink:to="loc_srt_ConsolidationItemsDomain_2a3d563a-7046-4750-a83b-3329a7e11d15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2a3d563a-7046-4750-a83b-3329a7e11d15" xlink:to="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ceb04209-a419-4fdb-a0dd-447a4155bb79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:to="loc_us-gaap_OperatingSegmentsMember_ceb04209-a419-4fdb-a0dd-447a4155bb79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_CorporateAndEliminationsMember_0e114ea4-a9e7-4046-9b68-e02806c93b32" xlink:href="infu-20251231.xsd#infu_CorporateAndEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:to="loc_infu_CorporateAndEliminationsMember_0e114ea4-a9e7-4046-9b68-e02806c93b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesExternal_d1891545-3d64-44dc-827d-33af8516080c" xlink:href="infu-20251231.xsd#infu_NetRevenuesExternal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_infu_NetRevenuesExternal_d1891545-3d64-44dc-827d-33af8516080c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesInternal_a75b47b4-4f78-457a-bb3b-0d68ead2da97" xlink:href="infu-20251231.xsd#infu_NetRevenuesInternal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_infu_NetRevenuesInternal_a75b47b4-4f78-457a-bb3b-0d68ead2da97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f24c2e39-e40c-470e-8248-edf9d0297496" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_Revenues_f24c2e39-e40c-470e-8248-edf9d0297496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_98666ce8-aa74-4d3b-a909-854a9342b59b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_SuppliesExpense_98666ce8-aa74-4d3b-a909-854a9342b59b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_2d62d42b-0e60-4731-8437-0eaa054f3283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_LaborAndRelatedExpense_2d62d42b-0e60-4731-8437-0eaa054f3283" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_732c30eb-73ea-403b-9d01-8c34d9b0588d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_732c30eb-73ea-403b-9d01-8c34d9b0588d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_183be89b-1803-4a67-b532-ae5455e722af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_183be89b-1803-4a67-b532-ae5455e722af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a186535d-3518-478e-b6f7-5a44b5371772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_GrossProfit_a186535d-3518-478e-b6f7-5a44b5371772" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d6d2bd8d-9649-4dad-a78d-2cc8a0f8813b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_OperatingExpenses_d6d2bd8d-9649-4dad-a78d-2cc8a0f8813b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_9cd11a24-0993-4b8f-8c31-3516d101d5af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_InterestExpenseNonoperating_9cd11a24-0993-4b8f-8c31-3516d101d5af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c8a8cdcd-2b83-4dad-8e40-a50d659b8196" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c8a8cdcd-2b83-4dad-8e40-a50d659b8196" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7910595-d67e-489b-be62-7df1df747167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7910595-d67e-489b-be62-7df1df747167" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_46ed262d-3eb2-4f62-9352-bed37d37c938" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_Assets_46ed262d-3eb2-4f62-9352-bed37d37c938" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PaymentsToAcquireMedicalEquipment_bd0b2caf-4f37-4931-9291-e462aaf785d6" xlink:href="infu-20251231.xsd#infu_PaymentsToAcquireMedicalEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_infu_PaymentsToAcquireMedicalEquipment_bd0b2caf-4f37-4931-9291-e462aaf785d6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_45596180-22fd-452c-9ff8-e136277c5900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_DepreciationAndAmortization_45596180-22fd-452c-9ff8-e136277c5900" xlink:type="arc" order="11"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>infu-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:7814b130-9ea8-4497-bd4c-7510be4e72d5,g:0e5cd592-a670-4737-bede-9aef47e8c4b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_36a4983b-4871-4187-be4e-d846965915af_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_96fcb12e-a013-4a0a-a07f-d33498ddfa4a_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_831d8941-cbd8-414d-b834-208370dd2607_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_066ea93e-6228-403b-925f-3fee5bd2a93e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c530ed85-295c-4696-8cf0-18f09d113f54_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_019c8dae-2b93-7387-8bdd-3c6e32f3c3a3_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LessorOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum_c14017dc-91e3-4c52-b5a5-14b159046b4e_terseLabel_en-US" xlink:label="lab_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESOP purchase per employee maximum</link:label>
    <link:label id="lab_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum_label_en-US" xlink:label="lab_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan ESPP Purchase Per Employee Maximum</link:label>
    <link:label id="lab_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum_documentation_en-US" xlink:label="lab_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum threshold, per employee, of purchases made in the employee stock ownership plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" xlink:href="infu-20251231.xsd#infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" xlink:to="lab_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9ad24474-6d3e-4081-a6f9-dd817a4caa30_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total nonamortizable and amortizable intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_908e155c-cfd0-4720-9910-a755c281f3f2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ScheduleOfMedicalEquipmentTableTextBlock_240935b5-c401-447e-85a3-364c5ff566f9_terseLabel_en-US" xlink:label="lab_infu_ScheduleOfMedicalEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Medical Equipment</link:label>
    <link:label id="lab_infu_ScheduleOfMedicalEquipmentTableTextBlock_label_en-US" xlink:label="lab_infu_ScheduleOfMedicalEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Medical Equipment [Table Text Block]</link:label>
    <link:label id="lab_infu_ScheduleOfMedicalEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_infu_ScheduleOfMedicalEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of medical equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ScheduleOfMedicalEquipmentTableTextBlock" xlink:href="infu-20251231.xsd#infu_ScheduleOfMedicalEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ScheduleOfMedicalEquipmentTableTextBlock" xlink:to="lab_infu_ScheduleOfMedicalEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a1abb6b5-ec8c-4ce4-aa35-b1ed6e384b38_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_47eb36f1-c7e5-4702-bfe4-605a0d987129_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bc9eb669-709d-431e-8995-0ebd25eeaa2c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_OperatingLossCarryforwardsWithADefiniteLife_a85e1310-3a45-4568-aaae-516be35425fb_terseLabel_en-US" xlink:label="lab_infu_OperatingLossCarryforwardsWithADefiniteLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards with a definite life</link:label>
    <link:label id="lab_infu_OperatingLossCarryforwardsWithADefiniteLife_label_en-US" xlink:label="lab_infu_OperatingLossCarryforwardsWithADefiniteLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards With A Definite Life</link:label>
    <link:label id="lab_infu_OperatingLossCarryforwardsWithADefiniteLife_documentation_en-US" xlink:label="lab_infu_OperatingLossCarryforwardsWithADefiniteLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of operating loss carryforwards that have an indefinite life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_OperatingLossCarryforwardsWithADefiniteLife" xlink:href="infu-20251231.xsd#infu_OperatingLossCarryforwardsWithADefiniteLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_OperatingLossCarryforwardsWithADefiniteLife" xlink:to="lab_infu_OperatingLossCarryforwardsWithADefiniteLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c8c311c6-bed0-4a56-8720-360dbd4bd94e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements and Developments</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockExpense_cec10937-1170-4383-beab-aeb9080e3788_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share expense</link:label>
    <link:label id="lab_us-gaap_RestrictedStockExpense_label_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense" xlink:to="lab_us-gaap_RestrictedStockExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_0f947154-ce6c-40ce-85b9-e09736321693_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_77f766ab-df56-4985-b661-1844e08a9c34_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5a91292a-8d6d-485e-af47-3ece0b0c0a59_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_TermBenchmarkLoansMember_b6801c27-374b-4d40-a2d6-780b3d7b2b7c_terseLabel_en-US" xlink:label="lab_infu_TermBenchmarkLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Benchmark Loans</link:label>
    <link:label id="lab_infu_TermBenchmarkLoansMember_label_en-US" xlink:label="lab_infu_TermBenchmarkLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Benchmark Loans [Member]</link:label>
    <link:label id="lab_infu_TermBenchmarkLoansMember_documentation_en-US" xlink:label="lab_infu_TermBenchmarkLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Benchmark Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermBenchmarkLoansMember" xlink:href="infu-20251231.xsd#infu_TermBenchmarkLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_TermBenchmarkLoansMember" xlink:to="lab_infu_TermBenchmarkLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_caef7618-e03d-4435-857e-9a9b53a1fc73_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_4b6230fd-ba67-44b4-8c6d-1fbe2ecd86ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c7b845fc-ac81-4fb6-903f-322e8154df40_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award, shares allowed for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_48a296ce-ca67-46c8-a367-0f602e862612_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_a2707430-fc32-4f22-87af-d0a0666ea7f4_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplies and material costs</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9975a132-64c9-4edc-9467-e4377ca8ca06_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9328f788-09b7-49e0-bdc4-6e73f8a5da17_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred Federal, state and local tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7d288e69-634b-45f5-b378-72db7abf4a54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cc1bf502-6c5b-44db-abd5-3af5e0f33035_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_92a0a146-d5b9-4aa9-bb80-6860074b15af_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of stock sold to employees (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_af363cb4-664f-41eb-a8ce-fda6740a1c4b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_ddcbd4b4-3fa4-4860-815d-ce5b6f053b79_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">% of Total Net Revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b2d64189-f732-4a55-bf91-9c2b8db8656b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_51f577a7-0e77-4b4a-ba04-c3f0a74f7e06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_866f7139-73ea-40c2-944e-058ea50f0b3a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_9db90dd7-7847-4bf6-87fd-d4e758270ce5_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total U.S. Federal income tax expense</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_49f81cf5-eb66-4580-9005-893a7855393c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_NumberOfLocations_55b1793b-73c3-45eb-94b3-6fbcfad9c0e9_terseLabel_en-US" xlink:label="lab_infu_NumberOfLocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of locations</link:label>
    <link:label id="lab_infu_NumberOfLocations_label_en-US" xlink:label="lab_infu_NumberOfLocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Locations</link:label>
    <link:label id="lab_infu_NumberOfLocations_documentation_en-US" xlink:label="lab_infu_NumberOfLocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Locations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfLocations" xlink:href="infu-20251231.xsd#infu_NumberOfLocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_NumberOfLocations" xlink:to="lab_infu_NumberOfLocations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6704c14-e78c-4aa2-b5a7-847bb98e136a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_ef7cbfb5-ec3c-48a7-8f21-dd48050f18b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of medical equipment, property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a6671ac9-7a13-4614-a515-35c238468cc6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_7b412459-69ca-4eb2-a0b1-41b3b619e69f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-7b42-abd2-648502c68832_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">% of Pretax Income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeasePayments_019c4850-a9ab-7b8c-9c3a-b266684dedda_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Lease Payments</link:label>
    <link:label id="lab_us-gaap_ShortTermLeasePayments_label_en-US" xlink:label="lab_us-gaap_ShortTermLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeasePayments" xlink:to="lab_us-gaap_ShortTermLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d587a5ea-3155-434b-9b1e-a4dfb8763ae6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_bfd9f2f3-a035-4644-87e5-8aa48fd4d168_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon restricted stock vesting and option exercise</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3f047e35-07eb-415a-bb70-864e5f08896f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_78ca6704-783d-4227-b2ce-618b1eeb1786_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0f7b0ddd-1514-45b2-ab55-60dc0db106c7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_394d9e45-10e3-4f0a-9acf-b3abbe727f56_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_019c4844-b6bc-7de7-9627-9adb7df2ea0f_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d8eafa18-715b-4336-aaca-4ab2b9686d6f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_886c6d7a-4e29-41d9-b813-ee64444e93ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock,, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_400df40c-4307-4a20-9d10-6ab602b8195e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1453507e-1afa-4880-af71-d25aad11be0e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3132aef8-4655-459a-8e16-1b6fdf70c594_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_SmithsMedicalIncMember_c2d9d675-8481-4359-a61e-ab8525ca12ae_terseLabel_en-US" xlink:label="lab_infu_SmithsMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Smiths Medical, Inc.</link:label>
    <link:label id="lab_infu_SmithsMedicalIncMember_label_en-US" xlink:label="lab_infu_SmithsMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Smiths Medical, Inc. [Member]</link:label>
    <link:label id="lab_infu_SmithsMedicalIncMember_documentation_en-US" xlink:label="lab_infu_SmithsMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Smiths Medical, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SmithsMedicalIncMember" xlink:href="infu-20251231.xsd#infu_SmithsMedicalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_SmithsMedicalIncMember" xlink:to="lab_infu_SmithsMedicalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd7565-b954-44aa-b24f-a9d48e5d29b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Authorized Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_70d1c979-bd96-4c77-ab23-d54fa83a4cee_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_202b5f54-2c75-4422-b209-c8add24ccb15_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_e4df86d7-9f20-4cdd-be10-446585391ded_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dee299da-093a-45d5-bfd4-ea9a3de619f8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_37c68f07-6660-4068-8cf5-0b9896e0446e_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_77ee4b1f-903d-44f0-bae9-359777fa9af7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_057ddd85-7647-4094-8a71-d7800ec12a80_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30be1d56-cf04-46bf-a6aa-a77e803fd920_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_04262eed-8816-4646-8500-580298bccd9f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1ae014b0-3334-4cd4-969a-ddae72875528_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d9047e51-cb19-477b-8bfe-9e6b958e3742_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_6ac1513e-d39c-4a3d-9371-1c575e0c1683_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon restricted stock vesting and option exercise (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_019b7402-4b7e-787c-82ef-5ef5c3a915ab_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4047cf4a-6983-4dac-ab23-7b2171c5d095_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e8b542b2-1397-42c7-9053-036c849557cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_21350f08-106a-4b07-93d4-c6c2d75cb330_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_aca2f63b-4cba-4a29-9879-c61368e6291b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5dd8dd5d-bd90-4392-a282-2c9bc70ef5f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_94dbf2aa-47db-462c-b220-893af35e3429_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7a890e2-8b66-45d5-ba4c-6eca69a19276_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_5b206082-6a48-4a2b-bb17-96b440470b63_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of medical equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_69d01fb3-bfb7-43ec-8536-1c32c7413727_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent_019c4837-8831-7d46-95aa-881c2373466a_terseLabel_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income for Canada Disregarded Entity</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent_label_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Percent</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent_documentation_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" xlink:to="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_019c4841-484a-713d-a378-c55e20540bdf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Meals and Entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8a06c6e0-b8ec-4d61-b282-15409e020d7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_fd4e27a2-0f56-4b89-9eb5-a6d4a3740410_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_95e61e2f-0ad6-40c9-b940-bd7caf606bbf_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_NumberOfContractsWithThirdParties_27cfa65f-9d9a-44fa-a8b3-4bb70b087cd1_terseLabel_en-US" xlink:label="lab_infu_NumberOfContractsWithThirdParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of contracts with third parties</link:label>
    <link:label id="lab_infu_NumberOfContractsWithThirdParties_label_en-US" xlink:label="lab_infu_NumberOfContractsWithThirdParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Contracts With Third Parties</link:label>
    <link:label id="lab_infu_NumberOfContractsWithThirdParties_documentation_en-US" xlink:label="lab_infu_NumberOfContractsWithThirdParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Contracts With Third Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfContractsWithThirdParties" xlink:href="infu-20251231.xsd#infu_NumberOfContractsWithThirdParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_NumberOfContractsWithThirdParties" xlink:to="lab_infu_NumberOfContractsWithThirdParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_062515ab-b8a6-423d-a8e2-797702b844a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses and Interest in Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef526da9-b090-4178-aab7-180694dd7f02_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_05bbb8d9-68c8-4c70-8def-73fede435d2a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember_b2ebae2b-0868-4c1b-a346-ac82800e0335_terseLabel_en-US" xlink:label="lab_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Exceeding Minimum Threshold</link:label>
    <link:label id="lab_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember_label_en-US" xlink:label="lab_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Exceeding Minimum Threshold [Member]</link:label>
    <link:label id="lab_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember_documentation_en-US" xlink:label="lab_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to exceeding the minimum threshold under the share-based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember" xlink:href="infu-20251231.xsd#infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember" xlink:to="lab_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3e63b3f3-86f2-4fd0-a0e5-79e6b2f7034f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_db7d2ffc-470f-4e18-b0af-8613538a4ac2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_8fa98bf2-c182-46f9-946f-f6206cb2bde0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_908c0e4c-715c-4746-8c47-e785c5ea9e70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of PSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019b5905-ef9b-7067-b0f0-1e1f3b36803e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e7a91d3e-b057-4f98-bd6a-749654ac2acb_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_584fd10a-7498-43b2-aa4a-5601a9199ffd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_085996ad-2cf9-455e-8bda-b876391b4f62_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions by employer</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_47ea4691-da39-4f2d-b916-9fe5a299889f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_024c1790-6944-4d47-8a62-97e63044f990_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88bdf4fd-0eef-4f05-ab0d-8b1d01a87944_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised shares forgone to satisfy minimum statutory withholding, weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentMember_568639cd-6121-4896-b54c-caf646ab25d6_terseLabel_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment</link:label>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentMember_label_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment [Member]</link:label>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentMember_documentation_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentMember" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentMember" xlink:to="lab_infu_SalesTypeLeaseNetInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ab2cb58c-4d1c-4ff2-803b-a886f2e2ca1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_5d0b7b1d-9de3-495e-873f-6db456266a52_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TX_019b7403-8158-7166-992c-17e45ac72fe9_terseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Texas</link:label>
    <link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TEXAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_TX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9a8b133a-5824-4279-8e5f-c52bbf7e3b60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4ed85382-1d18-473e-a3a3-c6e5291836f5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_PatientServicesAndDeviceSolutionsMember_a437139a-ac8b-43d6-98b1-102293d06891_terseLabel_en-US" xlink:label="lab_infu_PatientServicesAndDeviceSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient Services and Device Solutions</link:label>
    <link:label id="lab_infu_PatientServicesAndDeviceSolutionsMember_label_en-US" xlink:label="lab_infu_PatientServicesAndDeviceSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patient Services And Device Solutions [Member]</link:label>
    <link:label id="lab_infu_PatientServicesAndDeviceSolutionsMember_documentation_en-US" xlink:label="lab_infu_PatientServicesAndDeviceSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient Services And Device Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesAndDeviceSolutionsMember" xlink:href="infu-20251231.xsd#infu_PatientServicesAndDeviceSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_PatientServicesAndDeviceSolutionsMember" xlink:to="lab_infu_PatientServicesAndDeviceSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased_2b561ef5-0290-47e7-a729-15616cd4556a_terseLabel_en-US" xlink:label="lab_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value per ESPP award (usd per share)</link:label>
    <link:label id="lab_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased_label_en-US" xlink:label="lab_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value per ESPP award (in dollars per share)</link:label>
    <link:label id="lab_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased_documentation_en-US" xlink:label="lab_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average purchase price of shares purchased under the employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="infu-20251231.xsd#infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="lab_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_ab5e2ab3-ef11-4438-b68b-db741ba0f11a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures, and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ed48d073-4e94-41e1-a44f-35856376089e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_69e514b1-2d96-4fad-afb1-f045f39ef443_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type and Direct Financing Leases, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_c46b5f55-b40a-4ac5-b14f-0c609bf4bb19_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_6ec1b781-3614-433f-abe9-91cb1c8c5761_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_54cdf97f-21dc-4351-a496-d5f44fe9cd62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_99886ab9-8ac3-43af-b457-4d51cf8184ab_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_75aa472b-601a-412e-96c0-67253aa360a8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_f4186a5b-0543-4b79-bc18-ad56ec4755b6_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_756a7445-ce4f-4763-93db-04e921f4fb70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c1b5f8b-c168-430e-bbb2-8a96c44fdc68_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3ba4c41e-5840-4cb4-adcb-6e69e3dd2fda_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_35648644-0b8b-42d5-9e48-758d9b24804e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_edc9396e-281d-4728-9a82-37cb72009ad7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1f511b34-705f-4544-a11f-65df5e8ca8b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_83c616c8-0d3e-4b82-86b1-611d81de0e05_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment in rental service, net of accumulated depreciation</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_dd301fed-e7fd-4c90-a45e-2069e33f7416_totalLabel_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment in rental service - net</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_label_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment In Rental Service, Net Of Accumulated Depreciation</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents medical equipment in rental service, net of accumulated depreciation, as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" xlink:to="lab_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_f5490580-5060-4a9b-b466-5d9849dd228a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_126b5d9a-b449-4f62-b47b-c41b2cab0071_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_14068807-bfd4-41a1-9b65-d45019a43fde_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_af318bf4-4298-4432-b131-e0c0d2065908_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_e379d878-41e4-403d-ab96-45869ccf002d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_40e15058-4114-49fe-af3d-0990de384f06_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a7493255-8597-479d-81d9-65c3c36a74be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve_4fdb053b-5ef5-42b2-93a4-fa229c8cc313_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment for sale or rental, reserve</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve_0ce0238a-5329-4f18-8b56-57beac0fa9a9_negatedTerseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment for sale or rental - pump reserve</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve_label_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment Held For Sale Or Rental, Reserve</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of reserve associated with medical equipment for sale or rental, as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve" xlink:to="lab_infu_MedicalEquipmentHeldForSaleOrRentalReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3362e164-9a2c-4a85-ac75-9cd7320c7fd4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a35eba31-6ece-42d8-a85a-bd08cf00e3a4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent_019c4834-821f-77bc-bf71-d8778de847a0_terseLabel_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible Officer's Compensation</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent_label_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Percent</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent_documentation_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" xlink:to="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d9a9f4da-2b58-437a-9092-8729a4008f89_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c82c2c41-2747-4780-9f82-5027cde54649_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets held-for-use</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c0ad248f-b0d6-4849-9e2b-f177df8b3aa7_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_DeviceSolutionsMember_0da79fc7-1992-4a20-bc3b-812356cf21dd_terseLabel_en-US" xlink:label="lab_infu_DeviceSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Device Solutions</link:label>
    <link:label id="lab_infu_DeviceSolutionsMember_label_en-US" xlink:label="lab_infu_DeviceSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Device Solutions [Member]</link:label>
    <link:label id="lab_infu_DeviceSolutionsMember_documentation_en-US" xlink:label="lab_infu_DeviceSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Device Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeviceSolutionsMember" xlink:href="infu-20251231.xsd#infu_DeviceSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_DeviceSolutionsMember" xlink:to="lab_infu_DeviceSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_f7d99a44-d8d2-446e-8263-93380fd8d409_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets - (increase)/decrease:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_76954706-db55-4c6f-afcb-8439315475d4_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3131660b-ffed-477f-8eda-d99645df16a4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number of authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad52ef0c-223d-446e-a3e8-7ba466f11e9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number of authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_UnamortizedDebtIssuanceExpenseCurrent_499231e9-4060-4a2a-b779-f04348d3083c_negatedTerseLabel_en-US" xlink:label="lab_infu_UnamortizedDebtIssuanceExpenseCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized value of debt issuance costs</link:label>
    <link:label id="lab_infu_UnamortizedDebtIssuanceExpenseCurrent_label_en-US" xlink:label="lab_infu_UnamortizedDebtIssuanceExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense Current</link:label>
    <link:label id="lab_infu_UnamortizedDebtIssuanceExpenseCurrent_documentation_en-US" xlink:label="lab_infu_UnamortizedDebtIssuanceExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The current portion of unamortized debt issuance expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseCurrent" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_UnamortizedDebtIssuanceExpenseCurrent" xlink:to="lab_infu_UnamortizedDebtIssuanceExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_5cf7e66f-24f3-42d3-86de-b02dec300f33_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ac38d8ac-0dc2-4092-af5e-cbaf71a95741_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax expense, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0d467fd9-b426-49ce-a21a-0367329457e7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_eb1cea96-9da4-4658-a3d3-9752fb410d0b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_8cdd9f89-fec2-4277-9af2-42b67a2b8306_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio_36e71992-f437-4d86-a70d-f034a6fb2ac5_terseLabel_en-US" xlink:label="lab_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, minimum fixed coverage ratio</link:label>
    <link:label id="lab_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio_label_en-US" xlink:label="lab_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Covenant Minimum Fixed Coverage Ratio</link:label>
    <link:label id="lab_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio_documentation_en-US" xlink:label="lab_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum fixed coverage ratio required by the debt agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio" xlink:href="infu-20251231.xsd#infu_DebtInstrumentCovenantMinimumFixedCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio" xlink:to="lab_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2b0df15c-29e0-43b7-a7c3-ba8ff988223f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b1f34b2f-59a2-4195-a3bd-135b6da7ca7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e6842ad5-3a35-4e40-8a20-72540ba9b071_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_8ed0582f-85e3-429c-8f6a-e2fc4d64bbf3_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d457c1da-44dc-403a-a1d7-e249867a26ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_641425c3-f6e5-4f0c-86f5-a855821c4ff8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bad debt reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ba16963a-48e5-4444-ae47-4b8a12846de1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6ad5a0e5-bb24-4240-93cb-f47d4aa667de_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsProductLineMember_a9a151c1-ae4b-4550-ad97-a3e9d135a1a0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsProductLineMember_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsProductLineMember" xlink:to="lab_us-gaap_CostOfGoodsProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4df9142f-8124-4c79-9d91-8a011c0a8507_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod_13ebf8f3-bef7-4b1a-8e5c-b6248fc88b76_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable period</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Exercisable Period</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Exercisable Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_b88e0aed-c4e8-49b6-a9af-48ebc002791d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_41c7a563-2f33-4aeb-bf76-4421e94bf2d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and asset basis differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_55697dbc-2e15-47c9-b865-3242dcd3374e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a16391db-d808-4a79-ac4c-71113a0bfd80_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3bc18002-c51d-4112-b2b0-51def2df436e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_LongTermDebtGrossCurrent_6cf9db93-e15d-40ef-b05f-a03eeed74161_verboseLabel_en-US" xlink:label="lab_infu_LongTermDebtGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Portion</link:label>
    <link:label id="lab_infu_LongTermDebtGrossCurrent_label_en-US" xlink:label="lab_infu_LongTermDebtGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross, Current</link:label>
    <link:label id="lab_infu_LongTermDebtGrossCurrent_documentation_en-US" xlink:label="lab_infu_LongTermDebtGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before unamortized (discount) premium and debt issuance costs, of the current portion of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossCurrent" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_LongTermDebtGrossCurrent" xlink:to="lab_infu_LongTermDebtGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0e1766d7-41e4-49b2-bd3d-db6185811ac4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_32b288b5-b348-4e95-b7d5-f13f3a7273e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c77f961c-26a6-40b7-bd67-871e9a4d8993_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79d581d3-14a3-45e9-988a-991733c75772_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5680b4a-a0c1-4e7a-86b9-b4e62566a465_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fd5c0657-d865-424b-af93-faf079116538_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b7a89160-a8f5-4c15-9bad-668d01f1bc56_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4dfaa94d-b035-4a1a-841b-7d013247120a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Income tax (expense) benefit at effective income tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_d1a99610-f13a-4818-8f7c-c03db1074fa5_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e34b70be-22d9-407c-b918-89deef88abc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_6455bfd6-513f-451c-a857-0cf769197e05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance_18c51dbc-77ef-4a47-b294-70d40c784c31_terseLabel_en-US" xlink:label="lab_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period shares employee stock ownership plan number of remaining shares available for future issuance (in shares)</link:label>
    <link:label id="lab_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance_label_en-US" xlink:label="lab_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance</link:label>
    <link:label id="lab_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period shares employee stock ownership plan number of remaining shares available for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" xlink:href="infu-20251231.xsd#infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" xlink:to="lab_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_c4e43a81-0a94-4c59-9100-a50628477b23_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_985f03d8-2325-4a3d-8962-91dd67f84c9e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8163edfe-1a50-4f8b-8674-b4ea4c66f0cd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3538814a-51a9-4268-a16f-a7bf61f6bb8f_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total nonamortizable and amortizable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1b0e16d4-0334-4887-bed3-230fbe64e2cc_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock_93e8221e-46aa-441b-88cf-1c3fc5091619_terseLabel_en-US" xlink:label="lab_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets</link:label>
    <link:label id="lab_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the carrying amount and accumulated amortization of identifiable intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" xlink:href="infu-20251231.xsd#infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" xlink:to="lab_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c046c124-aa88-456a-b498-6216bd21f677_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_4c1c2c21-a027-4e94-85e6-f017fc1a8527_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b51602a-717e-4ab2-b983-6c30540fd065_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_aa52d07a-8c93-4166-9351-395be1a12475_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_fc865876-4db4-4991-8735-5e782bb51eba_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type and Direct Financing Leases, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_8f46c66a-211f-4f68-9849-4c2891f156e0_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_DirectPayerRentalsMember_ae68b650-25a5-414d-a9c0-b9156a41c272_terseLabel_en-US" xlink:label="lab_infu_DirectPayerRentalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct Payer Rentals</link:label>
    <link:label id="lab_infu_DirectPayerRentalsMember_label_en-US" xlink:label="lab_infu_DirectPayerRentalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Payer Rentals [Member]</link:label>
    <link:label id="lab_infu_DirectPayerRentalsMember_documentation_en-US" xlink:label="lab_infu_DirectPayerRentalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Payer Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DirectPayerRentalsMember" xlink:href="infu-20251231.xsd#infu_DirectPayerRentalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_DirectPayerRentalsMember" xlink:to="lab_infu_DirectPayerRentalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_The2021CreditAgreementMember_191662e8-a6f5-47a2-aa2e-23fbb824e068_terseLabel_en-US" xlink:label="lab_infu_The2021CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The 2021 Credit Agreement</link:label>
    <link:label id="lab_infu_The2021CreditAgreementMember_label_en-US" xlink:label="lab_infu_The2021CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 Credit Agreement [Member]</link:label>
    <link:label id="lab_infu_The2021CreditAgreementMember_documentation_en-US" xlink:label="lab_infu_The2021CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the "2021 Credit Agreement".</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_The2021CreditAgreementMember" xlink:href="infu-20251231.xsd#infu_The2021CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_The2021CreditAgreementMember" xlink:to="lab_infu_The2021CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_131e2b4f-eaa7-4d2b-8c7b-a7c0689e69cb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b88316bf-87c4-47d6-81f2-2a57ed9ea6ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5ec4b14f-633a-4585-85bc-6f516e2e7be7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_471ad17c-6528-4fe5-a755-8dda929b95ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_c030b87f-0a0e-4242-8620-12d1b0f85b1c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Provision for) benefit from income tax on unrealized hedge gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_e7e5a2ca-f291-475a-b29f-9fb509cb7b09_totalLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type and Direct Financing Leases, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_47ad1d4b-6c51-49bb-8c4f-0d57596501f9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_PhysicianAndCustomerRelationshipsMember_f0941125-3ce9-4741-9cf1-769485c3c2fa_terseLabel_en-US" xlink:label="lab_infu_PhysicianAndCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Physician and customer relationships</link:label>
    <link:label id="lab_infu_PhysicianAndCustomerRelationshipsMember_label_en-US" xlink:label="lab_infu_PhysicianAndCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Physician and Customer Relationships [Member]</link:label>
    <link:label id="lab_infu_PhysicianAndCustomerRelationshipsMember_documentation_en-US" xlink:label="lab_infu_PhysicianAndCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to physician and customer relationships.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PhysicianAndCustomerRelationshipsMember" xlink:href="infu-20251231.xsd#infu_PhysicianAndCustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_PhysicianAndCustomerRelationshipsMember" xlink:to="lab_infu_PhysicianAndCustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019b0311-3462-7f41-9b66-a56525bd3b14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, Federal, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_AmbulatoryPumpsMember_a60debf1-f094-4872-91ca-2e7a0d53c9b7_terseLabel_en-US" xlink:label="lab_infu_AmbulatoryPumpsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ambulatory Pumps</link:label>
    <link:label id="lab_infu_AmbulatoryPumpsMember_label_en-US" xlink:label="lab_infu_AmbulatoryPumpsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ambulatory Pumps [Member]</link:label>
    <link:label id="lab_infu_AmbulatoryPumpsMember_documentation_en-US" xlink:label="lab_infu_AmbulatoryPumpsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the ambulatory pumps.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_AmbulatoryPumpsMember" xlink:href="infu-20251231.xsd#infu_AmbulatoryPumpsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_AmbulatoryPumpsMember" xlink:to="lab_infu_AmbulatoryPumpsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_0f6d4702-9c58-49a1-b568-f54827d74b52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reconciling Adjustment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_66047ae0-551d-4faf-a3d8-3576f04d42b7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03378051-6a1c-4298-839c-305677732d0e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentNet_58a3475d-9465-4a75-b0f2-89516e4f63ee_totalLabel_en-US" xlink:label="lab_infu_MedicalEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_infu_MedicalEquipmentNet_label_en-US" xlink:label="lab_infu_MedicalEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment, Net</link:label>
    <link:label id="lab_infu_MedicalEquipmentNet_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the net amount of medical equipment, as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentNet" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentNet" xlink:to="lab_infu_MedicalEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ee7adaa9-897f-4a03-9a65-e94a3e4160aa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c0637ba3-e5f9-4217-8b6f-3adc648c4dea_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_71a8ff3e-ff07-48e7-a4f5-a51ddeababf8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH PROVIDED BY OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d381761-8f06-4a6a-8cf2-d4906fd8002b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f5c0a09-7100-4b9e-ae3a-932c391bda61_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S Federal income tax expense</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_InformationTechnologySoftwareMember_cafb7c8d-6411-4128-becc-1b53916e4274_terseLabel_en-US" xlink:label="lab_infu_InformationTechnologySoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information Technology Software</link:label>
    <link:label id="lab_infu_InformationTechnologySoftwareMember_label_en-US" xlink:label="lab_infu_InformationTechnologySoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Information Technology Software [Member]</link:label>
    <link:label id="lab_infu_InformationTechnologySoftwareMember_documentation_en-US" xlink:label="lab_infu_InformationTechnologySoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the external information technology software used.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_InformationTechnologySoftwareMember" xlink:href="infu-20251231.xsd#infu_InformationTechnologySoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_InformationTechnologySoftwareMember" xlink:to="lab_infu_InformationTechnologySoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_60f380bc-a9ef-4439-ad50-d12630d58c21_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d90723db-9a90-41d8-a173-3ee7c8ae76b8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_03113c67-1a50-4a93-9b6a-d96a4358b69a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7fa59bf1-e1b2-44d0-b41c-a410d53f3fc1_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_ba83233f-7402-4719-bcf3-720c62a0b7a9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost, total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_3dd5683c-d7d7-4ac5-9715-7a44cab5da4c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AutomobilesMember_efff96c0-18e1-4a5d-93d8-312af3e5b248_terseLabel_en-US" xlink:label="lab_us-gaap_AutomobilesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automobiles</link:label>
    <link:label id="lab_us-gaap_AutomobilesMember_label_en-US" xlink:label="lab_us-gaap_AutomobilesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Automobiles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AutomobilesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AutomobilesMember" xlink:to="lab_us-gaap_AutomobilesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_532bf63a-ef8d-4995-a553-7f52a188c2a1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_1cc66b95-9f88-4a39-b020-d2bb6b8e374c_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_857ba4eb-ad1f-423c-86a8-433a3ad74e6c_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_81971bb4-96c9-4e47-ac70-6d5a4e87df53_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Components of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b2c028c7-ca9c-483e-a09f-953080b66706_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3956bb42-b8e6-40ee-8585-288c1eb5eac1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f7598111-e62d-441e-97a3-95fd1532590d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fcfe3424-0b89-46ea-a9d7-1ae279451e4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_442154ef-dc77-48cd-a337-e5e21bc94f4c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_ebcd6942-e61e-4fc2-88e1-c02f98ea522e_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_PatientServicesMember_0e444555-c527-46fe-b9d5-ab54fd9ea1a2_terseLabel_en-US" xlink:label="lab_infu_PatientServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient Services</link:label>
    <link:label id="lab_infu_PatientServicesMember_label_en-US" xlink:label="lab_infu_PatientServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patient Services [Member]</link:label>
    <link:label id="lab_infu_PatientServicesMember_documentation_en-US" xlink:label="lab_infu_PatientServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesMember" xlink:href="infu-20251231.xsd#infu_PatientServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_PatientServicesMember" xlink:to="lab_infu_PatientServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_afa75224-e280-4dc4-bb63-3d43487936a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_bcfc77bc-c9e3-4df7-938c-c69b171c067e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5955e293-5284-4180-b2b5-d76bb8f39aa9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised shares forgone to satisfy minimum statutory withholding, number of authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3e27a674-fb90-47ab-a458-2ee30dc243d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f776ab39-2a59-42d0-8afe-3f8e9509ab8d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_019b0204-91b4-7f3b-90d6-8166ef750860_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67ab53f9-a639-4114-98dc-3389d6982695_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_c1274997-c607-4f96-bf2b-0f2ab615f7cf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e892a838-fea3-4217-8ba5-525bab56c462_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_52b6fba5-8434-44f6-ac59-07edf73c7769_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-7f0f-b3ef-4064202e32d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_953238c3-2bae-4a9c-8f01-986d55f7952b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign income tax expense</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentAndPropertyDisclosureTextBlock_3aa630dd-7ace-4346-bc11-d462ae803782_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentAndPropertyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment</link:label>
    <link:label id="lab_infu_MedicalEquipmentAndPropertyDisclosureTextBlock_label_en-US" xlink:label="lab_infu_MedicalEquipmentAndPropertyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment and Property Disclosure [Text Block]</link:label>
    <link:label id="lab_infu_MedicalEquipmentAndPropertyDisclosureTextBlock_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentAndPropertyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for medical equipment and property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentAndPropertyDisclosureTextBlock" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentAndPropertyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentAndPropertyDisclosureTextBlock" xlink:to="lab_infu_MedicalEquipmentAndPropertyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_c2cc222c-1c9c-4805-af9f-7edf59b0c3a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_e4718436-a609-4e26-97c4-6a8a0e5779cc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ec4c50a0-a6d0-486d-ac0a-1e4c22f98f9a_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_TermOfRenewal_1ff5cdc6-9a23-4679-b95c-36d98ace5891_terseLabel_en-US" xlink:label="lab_infu_TermOfRenewal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of renewal</link:label>
    <link:label id="lab_infu_TermOfRenewal_label_en-US" xlink:label="lab_infu_TermOfRenewal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Renewal</link:label>
    <link:label id="lab_infu_TermOfRenewal_documentation_en-US" xlink:label="lab_infu_TermOfRenewal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Renewal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermOfRenewal" xlink:href="infu-20251231.xsd#infu_TermOfRenewal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_TermOfRenewal" xlink:to="lab_infu_TermOfRenewal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3b230396-e7f6-4d22-b644-2eee521efdac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_0dbef24b-f6ff-47ef-bece-a6a6afbb801e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_944b7492-b5f4-43f0-bd15-a8e9f39c377f_negatedTerseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested shares forgone to satisfy minimum statutory withholding, number of shares (in shares)</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expirations In Period</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_32710621-d554-48db-a3b0-09d18118fc69_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_8d0f7473-e6de-4cd6-ac51-9f70ef80d3b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_320296de-8fbd-4333-a06c-bf6aae838174_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_78c66ad1-461e-4829-be92-4167797ac765_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_94bd92f6-7a94-4f68-b533-b1da049a6561_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_9aeae69a-f784-49e3-8f34-9f393c3f2cac_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3f0ef71c-9de2-4080-8608-752dbb72f47f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3d36178d-e6a7-40c7-9826-a93ded76e943_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fc565b38-1f2a-46e1-9e36-a0afa7cf484b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1b4b10cc-c816-48b6-8809-cc4fccaee011_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax (expense) benefit at effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e02f48f2-1312-481c-a002-17ce5559fb07_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d8b7177f-167d-4419-b969-15f9533b95aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_DepreciationExpenseRelatedToMedicalEquipment_aa785e72-8e9e-4be4-a627-f6ae42170187_terseLabel_en-US" xlink:label="lab_infu_DepreciationExpenseRelatedToMedicalEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense related to medical equipment</link:label>
    <link:label id="lab_infu_DepreciationExpenseRelatedToMedicalEquipment_label_en-US" xlink:label="lab_infu_DepreciationExpenseRelatedToMedicalEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation Expense Related To Medical Equipment</link:label>
    <link:label id="lab_infu_DepreciationExpenseRelatedToMedicalEquipment_documentation_en-US" xlink:label="lab_infu_DepreciationExpenseRelatedToMedicalEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of depreciation expense related to medical equipment recorded during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DepreciationExpenseRelatedToMedicalEquipment" xlink:href="infu-20251231.xsd#infu_DepreciationExpenseRelatedToMedicalEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_DepreciationExpenseRelatedToMedicalEquipment" xlink:to="lab_infu_DepreciationExpenseRelatedToMedicalEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_17da40f0-b3d2-4af7-8929-72d7b2086518_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_a42af83f-88d3-4bfe-943d-819450b581fe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:to="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_746daf67-5237-45d6-a10c-8c1df265e707_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_128cad1a-2a8c-4885-9661-1e6e7f55ed57_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesReserve_e7d91fa1-46c5-4ab1-9e70-6586b5e31d63_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment in rental services reserve</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesReserve_3ec85a7a-4d9c-45cd-9067-f2d8eda43eb5_negatedTerseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesReserve" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment in rental service - pump reserve</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesReserve_label_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment In Rental Services, Reserve</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesReserve_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of medical equipment in rental services reserve, as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesReserve" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentInRentalServicesReserve" xlink:to="lab_infu_MedicalEquipmentInRentalServicesReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3f72de62-aafa-4af8-a501-ba4c0a644a69_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, number of authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_LeaseClassificationDomain_c88ce3ef-7a22-4d9e-ac77-a1ef6f0838d6_terseLabel_en-US" xlink:label="lab_infu_LeaseClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Classification [Domain]</link:label>
    <link:label id="lab_infu_LeaseClassificationDomain_label_en-US" xlink:label="lab_infu_LeaseClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Classification [Domain]</link:label>
    <link:label id="lab_infu_LeaseClassificationDomain_documentation_en-US" xlink:label="lab_infu_LeaseClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LeaseClassificationDomain" xlink:href="infu-20251231.xsd#infu_LeaseClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_LeaseClassificationDomain" xlink:to="lab_infu_LeaseClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount_a4f671e9-3cb9-4b13-afca-c6881ab20730_terseLabel_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount_label_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Amount</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount_documentation_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" xlink:to="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2e55e955-3f95-4976-911f-3eadc60d1043_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7cd7ce70-b435-4b98-b612-573d907d68d1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6b8b4de6-1413-4865-9611-d80be60c7067_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRental_1067e92e-4e1b-4507-83f7-66f34cfcd714_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRental" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment for sale or rental</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRental_138a95ba-60e9-4a33-8fe1-ae2b52f2e010_totalLabel_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRental" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment for sale or rental - net</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRental_label_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRental" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment Held For Sale Or Rental</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRental_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRental" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents medical equipment held for sale or rental as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRental" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRental"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentHeldForSaleOrRental" xlink:to="lab_infu_MedicalEquipmentHeldForSaleOrRental" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5ba04231-6c38-4dde-a271-68d11c9d1e33_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_17fd74bb-2667-4eec-8509-b23d21d1bb15_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Segment Expenses:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_7468205f-a1e6-4e77-b3bd-bfb0b6e36f58_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_c11cdf60-339c-4d8f-b333-028dafc86e96_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_1da31421-29ed-4046-af75-5223f99c5284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio_1e4311aa-659c-4d53-976e-66dc1d35db93_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other types of awards, reduction ratio</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Reduction Ratio</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Reduction Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_994996ff-278f-4f23-ac24-dee8f7f9395a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3941f207-72e4-49eb-8c58-9eb120a8ebea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_e8705402-6ffe-43f8-828a-ec9e7d5cecfb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2aa3133-7d4e-48b4-9942-7592cddcbc2c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e70cf88-f764-407e-8a63-8fea419fd5ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_773c0713-e1ed-440c-ad0e-f999133c9057_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_f2117288-e758-40af-b010-d2630080e84d_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Maturities of Sales-type Leases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1695c449-8677-4731-b743-172ed0947edf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b35ed4a3-1acc-4e8f-bda4-9a2fd5bd0b6b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ec26d413-d6fc-41f7-b36d-ef0333411c13_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_A2014EquityIncentivePlanMember_fb901167-25b6-474b-b31d-4cabdc90bbd2_terseLabel_en-US" xlink:label="lab_infu_A2014EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_infu_A2014EquityIncentivePlanMember_label_en-US" xlink:label="lab_infu_A2014EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2014 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_infu_A2014EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_infu_A2014EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2014EquityIncentivePlanMember" xlink:href="infu-20251231.xsd#infu_A2014EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_A2014EquityIncentivePlanMember" xlink:to="lab_infu_A2014EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6641c98e-6a1c-4c97-89c8-576d0b9d3cd3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_22830d22-f841-4ac7-a1b9-b74cfa455750_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a73da7bf-8b9a-4ebb-9e27-433d501ad933_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d5b744f1-6253-4ec5-b811-b6be3c58f2ce_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a8b19edb-1ddc-4497-bd71-e9630b87bdcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_93860f3f-65bf-40ec-88f7-295cbb9f05e3_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_cee5e190-d4e1-484e-8aaa-2443b0849619_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease_0192d54c-0c58-425f-bdd4-5df2daaf40da_totalLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net investment in leases</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_21251653-d330-4384-ab17-613391905d2e_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_26997e9b-07a9-4530-93b4-882ea619f6a8_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses, and Contingencies</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_bdb3f6ef-79cf-4230-91d3-767234555114_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total state and local income tax expense</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_TermOfContract_7f399764-8f99-489d-9db4-653743cbb204_terseLabel_en-US" xlink:label="lab_infu_TermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_infu_TermOfContract_label_en-US" xlink:label="lab_infu_TermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Contract</link:label>
    <link:label id="lab_infu_TermOfContract_documentation_en-US" xlink:label="lab_infu_TermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermOfContract" xlink:href="infu-20251231.xsd#infu_TermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_TermOfContract" xlink:to="lab_infu_TermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b27fb60e-a207-4ecc-b129-50aba33252a3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a13382b9-e170-48aa-9ab0-8bf72b186b3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign income tax (Canada)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_50bd4a99-d324-4a50-ba18-8148e3ae42e4_terseLabel_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment In Lease [Line Items]</link:label>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_label_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment In Lease [Line Items]</link:label>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_documentation_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment In Lease [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentInLeaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems" xlink:to="lab_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6b66a9f0-3023-4b6f-bdab-09d547e68dcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_023fc231-60eb-4509-856c-3116ab01c078_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_d66c0211-052b-4def-b7c9-d36115104c3a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3eb23505-0be4-4711-8a99-a1d0b71464bf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1499a304-5bff-4293-945b-b60913d00678_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_AuditInformationAbstract_label_en-US" xlink:label="lab_infu_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_infu_AuditInformationAbstract_documentation_en-US" xlink:label="lab_infu_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_AuditInformationAbstract" xlink:href="infu-20251231.xsd#infu_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_AuditInformationAbstract" xlink:to="lab_infu_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_043a2c9a-713a-4665-a780-252c87395bfe_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_66f2a28a-ce66-4409-a907-73e4d1c03d35_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_82346194-98f6-4bde-a81d-e64cac64f241_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonvested award, excluding option, cost not yet recognized, amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent_019c8dab-5507-7a31-b366-5521ef8f45f5_negatedLabel_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent_label_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Percent</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent_documentation_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" xlink:to="lab_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b025f-65a5-710a-a3f9-c78cd75e5cb7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense at the statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_96998d2e-c657-4dcb-8373-409c79a46df1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2031 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d4ba74c5-98d0-4b84-be94-3a513ba5ffae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRentalGross_850bdac8-f0ee-4fc7-8ab4-42a0c9ea3e8a_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRentalGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment for sale or rental</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRentalGross_label_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRentalGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment Held For Sale Or Rental, Gross</link:label>
    <link:label id="lab_infu_MedicalEquipmentHeldForSaleOrRentalGross_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentHeldForSaleOrRentalGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents medical equipment held for sale or rental as of the balance sheet date, before reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalGross" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentHeldForSaleOrRentalGross" xlink:to="lab_infu_MedicalEquipmentHeldForSaleOrRentalGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fbd22c9a-3008-40f0-abfd-cdb7d4ec7dd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchased as part of share repurchase program (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_18840087-1e6d-4a69-9c2b-7c88b6d5be20_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased and retired during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fac7984e-ef4c-4e6a-baa7-d092c0fd11a0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_fe968efe-788d-4ab5-8099-2939c0751c57_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_ffd7cd5a-8459-4d2d-8f44-22ece47722e4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6f3f5263-5236-4718-a5d1-fb3b7761b9c2_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_3ad85672-286d-4690-8958-42fd5acfcf01_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9d2d65fb-2606-459b-9461-b2d809f75d9b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_fc68a298-7b6e-43ac-ad03-248936d95ac7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_54bed704-fa09-4915-a40b-41a12e7eea2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bfe3572a-5eb3-47c9-ae46-90b269d0d965_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_bbdd449d-877a-45ce-87a1-8091076c1e55_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans and Other</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_09b9dcfa-0731-4755-a420-e38fa48e9b10_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_59bda5f0-b7d9-4aec-b63a-bcf9289d79c4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a3cb0e7e-3e7f-44ae-b007-84e98a99a324_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_35cac3dd-b90e-45d3-9365-c16de6a7a4ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d2881c90-3ae0-49e6-8ac1-cf4a5708fdb1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock_2e62545f-bec2-4bbe-b8ad-adbc18ca092f_terseLabel_en-US" xlink:label="lab_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Revenues</link:label>
    <link:label id="lab_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock_label_en-US" xlink:label="lab_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Cost of Revenue [Policy Text Block]</link:label>
    <link:label id="lab_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock_documentation_en-US" xlink:label="lab_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for the cost of revenue for servicing and maintaining products sold including shipping and handling costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock" xlink:href="infu-20251231.xsd#infu_RevenueRecognitionCostOfRevenuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock" xlink:to="lab_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications_abe7ed0d-fd03-492e-aa73-6c040dd53707_terseLabel_en-US" xlink:label="lab_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications_label_en-US" xlink:label="lab_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increases to Right of Use Assets Resulting From Lease Modifications</link:label>
    <link:label id="lab_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications_documentation_en-US" xlink:label="lab_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increases to Right of Use Assets Resulting From Lease Modifications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications" xlink:href="infu-20251231.xsd#infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications" xlink:to="lab_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40e368d4-aed6-483c-abfb-8407c23b1acd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_91f1c06f-0fdc-4423-a888-4706bf9ab1ce_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_7174eda0-0700-4c05-afff-d95526c397a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_019c482b-22a3-7e7f-a63c-ddea83ef3a75_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meals and Entertainment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2a1ffda2-443d-4f80-9a05-699a7c3f080b_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3f67c116-6fbf-473a-a78a-d09128c4a609_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares withheld for tax withholding obligation (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_924768ef-3e49-4f26-8f2b-c710e9e50b66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7c5616df-3110-4829-8842-6e3185cf69db_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount_019c4841-6671-7fb5-870a-077228856905_negatedTerseLabel_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income for Canada Disregarded Entity</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount_label_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Amount</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount_documentation_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" xlink:to="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_52dbf973-9726-4ff8-aa7c-98133846bfe8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice_202d502a-ce08-4bfe-afc6-934f8231182f_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise, weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cashless Exercises In Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average exercise price of awarded shares exercised in the period in a cashless transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_78c6d4ea-afee-4f05-9c8d-efeed7cd437d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_a68a677a-35fb-4a14-9f46-1b6d2d3c8e65_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedge gain (loss) to be reclassified within 12 months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0b954349-c116-498d-b642-f421f31a9332_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0ccea8c4-b1f6-4afc-a947-eac6141d8708_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, total</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ContractAssetsRevenuePartiallyOffsetAmount_9677f4da-b95f-4144-a38c-780282b6a9aa_terseLabel_en-US" xlink:label="lab_infu_ContractAssetsRevenuePartiallyOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets partially offset amount</link:label>
    <link:label id="lab_infu_ContractAssetsRevenuePartiallyOffsetAmount_label_en-US" xlink:label="lab_infu_ContractAssetsRevenuePartiallyOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Assets, Revenue, Partially Offset Amount</link:label>
    <link:label id="lab_infu_ContractAssetsRevenuePartiallyOffsetAmount_documentation_en-US" xlink:label="lab_infu_ContractAssetsRevenuePartiallyOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Assets, Revenue, Partially Offset Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractAssetsRevenuePartiallyOffsetAmount" xlink:href="infu-20251231.xsd#infu_ContractAssetsRevenuePartiallyOffsetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ContractAssetsRevenuePartiallyOffsetAmount" xlink:to="lab_infu_ContractAssetsRevenuePartiallyOffsetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesUsefulLife_cd34d7f5-d61f-4efd-a951-727a25f6d5f3_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment in rental services, useful life</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesUsefulLife_label_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment In Rental Services Useful Life</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesUsefulLife_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the useful life of medical equipment in rental services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesUsefulLife" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentInRentalServicesUsefulLife" xlink:to="lab_infu_MedicalEquipmentInRentalServicesUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_8e07fbef-3fac-41da-a62c-680942440161_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related expenses</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_LongTermDebtGrossNoncurrent_622136ff-6581-4263-b405-c9fc4de6e9ec_verboseLabel_en-US" xlink:label="lab_infu_LongTermDebtGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Portion</link:label>
    <link:label id="lab_infu_LongTermDebtGrossNoncurrent_label_en-US" xlink:label="lab_infu_LongTermDebtGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross, Noncurrent</link:label>
    <link:label id="lab_infu_LongTermDebtGrossNoncurrent_documentation_en-US" xlink:label="lab_infu_LongTermDebtGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, excluding the current portion. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossNoncurrent" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_LongTermDebtGrossNoncurrent" xlink:to="lab_infu_LongTermDebtGrossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_90d96bed-f0db-4d3e-8062-8dafabfedfbc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationNonproduction_8f02ce9d-9c86-4921-8ed1-adbcaeec4df6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, nonproduction</link:label>
    <link:label id="lab_us-gaap_DepreciationNonproduction_label_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationNonproduction" xlink:to="lab_us-gaap_DepreciationNonproduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_45371712-f22d-4e41-b947-f365f2757f94_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of common stock equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e793707f-9960-4263-bc71-51dce58d4c20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement, equity instruments other than options, grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_434b1886-3106-406d-90ef-0fef45ea630d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1114f177-9838-4348-b1f2-b6295de1d9ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019b7400-1d4f-7db1-b8eb-ab3432860556_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Tax Jurisdiction, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:to="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_9ee4de88-3551-4d00-b03e-cb27a00ffd8c_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_c9a03c04-970f-410f-994a-a566d0f546d4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_61ea1940-c9d1-4088-b5f0-2caff6e2d210_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d94e4fbd-c4c4-4c58-8639-7e1e42dc0474_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_2430aae7-777d-4bec-9c84-11ad4ed7ceb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_97e1b64b-f5dc-4122-93cc-e0c5ed0d0014_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_25c9c8d6-56f1-4681-ad0f-29b1f4a08f00_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0b2e1b71-566e-4492-bedd-cee46c67162d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of and reserve adjustments for medical equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_CorporateAndEliminationsMember_ae1c2af1-879f-454c-b0ac-2d938cc3a91b_terseLabel_en-US" xlink:label="lab_infu_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate/Eliminations</link:label>
    <link:label id="lab_infu_CorporateAndEliminationsMember_label_en-US" xlink:label="lab_infu_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate and Eliminations [Member]</link:label>
    <link:label id="lab_infu_CorporateAndEliminationsMember_documentation_en-US" xlink:label="lab_infu_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding corporate and eliminations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_CorporateAndEliminationsMember" xlink:href="infu-20251231.xsd#infu_CorporateAndEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_CorporateAndEliminationsMember" xlink:to="lab_infu_CorporateAndEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_542d5572-fe81-48ed-ad44-ab707d74023a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_998028bb-ead7-4057-975b-c5242f68f918_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payment for) Other Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_TreasuryStockPolicyPolicyTextBlock_0b3f91bf-fd46-4916-bcfd-84eaec3c9d68_terseLabel_en-US" xlink:label="lab_infu_TreasuryStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_infu_TreasuryStockPolicyPolicyTextBlock_label_en-US" xlink:label="lab_infu_TreasuryStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Policy [Policy Text Block]</link:label>
    <link:label id="lab_infu_TreasuryStockPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_infu_TreasuryStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for policy of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TreasuryStockPolicyPolicyTextBlock" xlink:href="infu-20251231.xsd#infu_TreasuryStockPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_TreasuryStockPolicyPolicyTextBlock" xlink:to="lab_infu_TreasuryStockPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_NetRevenuesExternal_a5dcf69f-6b51-437a-b026-347da65f4d9c_terseLabel_en-US" xlink:label="lab_infu_NetRevenuesExternal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenues - external</link:label>
    <link:label id="lab_infu_NetRevenuesExternal_label_en-US" xlink:label="lab_infu_NetRevenuesExternal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Revenues, External</link:label>
    <link:label id="lab_infu_NetRevenuesExternal_documentation_en-US" xlink:label="lab_infu_NetRevenuesExternal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of external net revenues recognized during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesExternal" xlink:href="infu-20251231.xsd#infu_NetRevenuesExternal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_NetRevenuesExternal" xlink:to="lab_infu_NetRevenuesExternal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce611fb6-8308-44f9-bd69-d22b75717962_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_DeferredTaxLiabilitiesRightOfUseAssets_df25b69c-4d2e-4c0f-a80f-826a059b6f53_negatedTerseLabel_en-US" xlink:label="lab_infu_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_infu_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_infu_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:label id="lab_infu_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_infu_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="infu-20251231.xsd#infu_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_infu_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_45e654d3-77d0-4688-95d3-da66f1d35a3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_84ef1875-08a9-4a7b-b645-c8d3acd72fdd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_85fd0b62-1281-44a7-863e-4a18d2dedc68_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3c5342a3-00da-45b7-92c8-ec4bd51c6b55_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ContractAssets_bac3c9f4-3901-4ee8-8ec5-07aa03d91b7f_terseLabel_en-US" xlink:label="lab_infu_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_infu_ContractAssets_label_en-US" xlink:label="lab_infu_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Assets</link:label>
    <link:label id="lab_infu_ContractAssets_documentation_en-US" xlink:label="lab_infu_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractAssets" xlink:href="infu-20251231.xsd#infu_ContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ContractAssets" xlink:to="lab_infu_ContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019b0260-4de2-7155-a2e3-2a38ac8970a9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign income tax (Canada)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_239444e4-e387-461b-8f84-799101f1a981_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_dba03505-0ff4-4657-a8b4-7571f7709367_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_50c3765c-a4fb-4732-bc40-66a153e01acc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_ecba96ee-cbfe-45ac-a310-4d7ecda77e97_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_955feebc-19d0-44da-92ab-87ae0d3ead0a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_12fbb0d0-cdd2-40ca-aa9d-8cb6057215a6_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db80b214-bc34-4143-9722-d1a6afc49560_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4a0dc850-d881-464f-86bb-833ec0c029e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_a3e16821-1b0a-4e95-90e6-a00a79cd5430_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_cd08d272-cfd7-4156-be05-2ed887e01541_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_415b558e-218b-4b99-8330-0bd6c46163db_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred Federal, state and local tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_a42fc8c0-79a2-421c-9a0d-3200407868e2_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_54d6790b-7815-4659-95fb-2f1845feaca9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a7d9bf9b-a17f-40d0-8aac-0fb26396395f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Designated as Hedging Instruments in AOCI</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_04ff0543-f87f-42f7-a884-b57e8325f0ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1992139a-7f4b-4ce5-bddb-8a9c658ed589_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_de203837-2841-449d-ab7f-8cd4a72bcbce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_ab18cddd-d70a-4302-ac14-ba69fc3dc4ef_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_de858d55-8065-4840-a9f5-f625f5c7b61e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Availability on Revolving Facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnpatentedTechnologyMember_9a97b75d-958a-46d2-8933-78820d9950dd_terseLabel_en-US" xlink:label="lab_us-gaap_UnpatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpatented Technology</link:label>
    <link:label id="lab_us-gaap_UnpatentedTechnologyMember_label_en-US" xlink:label="lab_us-gaap_UnpatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unpatented Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpatentedTechnologyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnpatentedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnpatentedTechnologyMember" xlink:to="lab_us-gaap_UnpatentedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019b73e6-df2f-7e89-aa9d-be474750e8b8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_543163f4-8a10-4932-8d5d-7a75f16e5548_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0a5a39ab-d9ae-464c-a318-299861052ace_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0a8e1187-30ea-4b2d-aaa6-f7357d80c3f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_019c4851-79d4-7847-850e-335e39fe389a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type and Direct Financing Leases, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f4f2abca-568e-4080-81bb-c730ea015170_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_83a3b16e-c1d2-4992-9250-d60719bcc0b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7491b95f-1a96-42c4-9f12-fd49e384eb91_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a80dd8d3-5571-4b7e-b00a-6a14eac3bcfc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0c2f1dcf-e11d-4167-bcc1-4bc427956596_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b9779835-e423-40a3-8400-f265b143b788_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_700a2868-87b6-4de7-b494-355efeb0e207_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_208c5fe7-c87d-4bc5-abc3-5098fcc9b659_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from exercise of options and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3e3f62ef-3713-47fb-9054-b1505f6d7bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_aeae62b6-18ff-47ea-9d60-a6e1cb841695_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value: authorized 200,000,000 shares; 20,209,636 shares issued and outstanding as of December&#160;31, 2025 and 21,272,351 shares issued and outstanding as of December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_95bf2728-37d7-471d-8fc4-68b74a509178_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d95512bc-8118-4d51-9d0b-8965fae54dc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_b3fe5ae7-b154-4cb8-8eb7-54aa405dbded_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_46ba58ed-2ea7-4684-a803-235761999680_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2ad4f26c-7ea9-4cca-824e-344011de211a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6695ce4c-5dd4-4c38-a536-6b18674c4c65_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f6cf95fc-900f-4288-93d1-bc968cce2779_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_86037a65-fd31-4811-9373-facc31c45d95_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_3e10b1be-4349-461b-b26f-bdd71a0ab138_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in liabilities - (decrease)/increase:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_f53ebd2b-65b5-4f5a-870a-a6ed92cb90eb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_9e7f41a3-dfb5-4d7b-a6ed-5a1f06e2aa66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_198508fe-ad36-4e69-9279-63a34603ee43_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_06062a60-3849-4f35-9ee9-067648b46626_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized computer software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3279dfaa-f0f6-4391-9ec7-a900e0a14b7b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ContractAssetsRevenueRecognized_be73036d-d57f-442d-b9c8-c61da253f7a5_terseLabel_en-US" xlink:label="lab_infu_ContractAssetsRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets, revenue recognized</link:label>
    <link:label id="lab_infu_ContractAssetsRevenueRecognized_label_en-US" xlink:label="lab_infu_ContractAssetsRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Assets, Revenue Recognized</link:label>
    <link:label id="lab_infu_ContractAssetsRevenueRecognized_documentation_en-US" xlink:label="lab_infu_ContractAssetsRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Assets, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractAssetsRevenueRecognized" xlink:href="infu-20251231.xsd#infu_ContractAssetsRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ContractAssetsRevenueRecognized" xlink:to="lab_infu_ContractAssetsRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_DeferredTaxAssetsOperatingLeaseLiabilities_07648afd-0697-42ee-bed8-e6c7c41d73d8_terseLabel_en-US" xlink:label="lab_infu_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_infu_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_infu_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_infu_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_infu_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="infu-20251231.xsd#infu_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_infu_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_111b8f37-2e05-45f4-ab4a-92a4c116622f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_29b847d6-8f25-47cc-9e13-b0edf720c620_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount_019c4841-5946-7980-817f-255c3c78e531_negatedTerseLabel_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible Officer's Compensation</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount_label_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Amount</link:label>
    <link:label id="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount_documentation_en-US" xlink:label="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" xlink:to="lab_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_82890d11-702e-4c63-8d49-af973bc93bc9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a224cafb-ed57-4ea5-8bbf-1decc020bee4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_41cdbd40-8ca1-4454-80d6-95aab623128b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019c20f9-4624-74a5-a208-2104613766da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited and expirations, number of authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_86150823-47ff-4ce2-8f67-58c493ed22bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_533897fb-45d0-4b84-b205-dcfe6c1a0f20_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b0172238-8b78-44fc-b0b6-c1c715d4a485_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0920e2c8-f86b-480b-84f7-41b77d4f09ff_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_bb02cdae-8e95-478d-99f1-4eaaff8817ac_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_deeafa38-46e4-4e34-b0a4-be9c2a184bb7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_11f684b1-5fe5-47a1-8ec3-1080f5f08c38_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a1e84ec7-5159-4f70-901c-a82c3aaf4ebc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_537f0da9-fab0-4dec-9e53-a71fa4e8bb52_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b8561f71-bb34-48a9-9751-4141a1ba3b60_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f526455a-ab8f-48ef-bda6-c18bde748f85_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_a17d0242-7e1d-4d03-af53-4fef41d2d12a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_PercentageOfTotalDepreciationExpense_18dfb5a7-0aac-4163-bb9a-cd2fb51559c8_terseLabel_en-US" xlink:label="lab_infu_PercentageOfTotalDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total depreciation expense (as a percent)</link:label>
    <link:label id="lab_infu_PercentageOfTotalDepreciationExpense_label_en-US" xlink:label="lab_infu_PercentageOfTotalDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Total Depreciation Expense</link:label>
    <link:label id="lab_infu_PercentageOfTotalDepreciationExpense_documentation_en-US" xlink:label="lab_infu_PercentageOfTotalDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of total depreciation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PercentageOfTotalDepreciationExpense" xlink:href="infu-20251231.xsd#infu_PercentageOfTotalDepreciationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_PercentageOfTotalDepreciationExpense" xlink:to="lab_infu_PercentageOfTotalDepreciationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_f289d32e-4845-48b7-bdf0-98b313988712_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc0f8adb-e0ca-4105-88d5-3061ed21bda7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_036ef3a4-4cd4-416c-8ceb-4b3df7950f32_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01b7f3bb-c5f0-4f87-9703-6cee9d7578f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a07932cf-4998-41f4-a6b0-a7919e7c446b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4a028f04-b534-4a3d-b414-9f524550c657_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_ff705cca-d59a-42f8-a126-1e77b15bad3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock ownership plan (ESOP) (in shares)</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Shares Contributed to ESOP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019c20f9-9bf7-7843-9a81-a077050dae44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures and expirations (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_1b0be3b6-74ea-45ae-95fa-742dcdaca972_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_29f37690-ad41-491f-b8d3-b47ceb7bdc43_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_20aebd38-c171-4081-a2c9-6ab80114feff_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b5fb5ee7-f8c4-4119-8d58-9de14b97728a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9d0faab6-fa07-461e-a2ac-35e1a3cce54e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentAbstract_label_en-US" xlink:label="lab_infu_MedicalEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment [Abstract]</link:label>
    <link:label id="lab_infu_MedicalEquipmentAbstract_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentAbstract" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentAbstract" xlink:to="lab_infu_MedicalEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_145944ae-2e85-4d79-92a5-02008dea68db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c4841bef-a120-4715-a150-fe9f5ab8253b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_1b11f0ee-535e-4c6c-8d87-e1162183d64d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Goodwill, Reportable Segment Assignment [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Goodwill, Reportable Segment Assignment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_32e48212-7192-454c-aa7e-f4c1cf3e5808_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_f32f8d86-d560-4075-ab91-c4acffabacc9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio_a5834990-4da5-424d-8cc2-730775414c84_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, reduction ratio</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Reduction Ratio</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Reduction Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_897b9e62-0215-4691-9557-18535393274d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ca5fadc4-b343-4a8d-b840-9d736fdb7f9e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6e97d505-a5b3-4ede-9244-849634940a03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dc40ff62-3371-4463-9fac-466f8343f7db_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d21a5bb9-efda-407a-bce4-0ace895df196_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d18fa2a5-f31a-4b17-a143-1d29db083b42_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research &amp; development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_36b51e70-ef85-4955-8dad-7e2041df6af7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c5e533b6-471a-4020-a07f-3683a31369ea_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_1957b9f6-1c89-460a-b52b-74710d615e33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_03107292-c7df-4203-967d-956fba1d74bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_1bca0180-02d9-40b4-a209-258632e15c09_negatedLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Outstanding draws</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_142f9430-0337-404f-be16-3513db79f33d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_PaymentsToAcquireMedicalEquipment_099fd634-7717-4249-9e72-66372d9b2034_negatedLabel_en-US" xlink:label="lab_infu_PaymentsToAcquireMedicalEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of medical equipment</link:label>
    <link:label id="lab_infu_PaymentsToAcquireMedicalEquipment_5d49c54a-c9bc-4d2c-aa4f-e8a5ff7c9389_terseLabel_en-US" xlink:label="lab_infu_PaymentsToAcquireMedicalEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of medical equipment</link:label>
    <link:label id="lab_infu_PaymentsToAcquireMedicalEquipment_label_en-US" xlink:label="lab_infu_PaymentsToAcquireMedicalEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Medical Equipment</link:label>
    <link:label id="lab_infu_PaymentsToAcquireMedicalEquipment_documentation_en-US" xlink:label="lab_infu_PaymentsToAcquireMedicalEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of cash paid during the period to acquire medical equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PaymentsToAcquireMedicalEquipment" xlink:href="infu-20251231.xsd#infu_PaymentsToAcquireMedicalEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_PaymentsToAcquireMedicalEquipment" xlink:to="lab_infu_PaymentsToAcquireMedicalEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_UnamortizedDebtIssuanceExpenseNoncurrent_3a99b521-3bec-4140-8e7e-4cf0be97e649_negatedTerseLabel_en-US" xlink:label="lab_infu_UnamortizedDebtIssuanceExpenseNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized value of the debt issuance costs, long-term debt</link:label>
    <link:label id="lab_infu_UnamortizedDebtIssuanceExpenseNoncurrent_label_en-US" xlink:label="lab_infu_UnamortizedDebtIssuanceExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense Noncurrent</link:label>
    <link:label id="lab_infu_UnamortizedDebtIssuanceExpenseNoncurrent_documentation_en-US" xlink:label="lab_infu_UnamortizedDebtIssuanceExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncurrent portion of unamortized debt issuance expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent" xlink:to="lab_infu_UnamortizedDebtIssuanceExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_019b0207-1e33-7396-b7d5-c50d20f0e609_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Liability Assumed, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5a365d6f-f66d-432f-816a-290410b024bb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue_411f8c83-713a-44ed-a3b7-1bb6309a32b8_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested shares forgone to satisfy minimum statutory withholding (usd per share)</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3aa1daca-a7f5-4d8f-af0f-e0ceaaa1452d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_63214e3c-684c-449d-ab62-64213564ca4a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_49ce2611-f36b-4375-a333-3ef0a9ea93c9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_534bf4fe-ebf0-457e-b624-9b2be6c8421c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cd0be378-98db-4cdc-aa55-d3d5907da43c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CASH TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_A2021EquityIncentivePlanMember_97410772-3d2d-4cd3-a085-5b246017981b_terseLabel_en-US" xlink:label="lab_infu_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:label id="lab_infu_A2021EquityIncentivePlanMember_label_en-US" xlink:label="lab_infu_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_infu_A2021EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_infu_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2021EquityIncentivePlanMember" xlink:href="infu-20251231.xsd#infu_A2021EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_A2021EquityIncentivePlanMember" xlink:to="lab_infu_A2021EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8b0b69df-4fa5-40e7-8139-acfb7f5d7787_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019b0311-3462-7d6a-8fe4-f7c55fc338cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S State and local</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, State and Local, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_822296e4-6523-492b-88b0-da239535e3de_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-competition agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_3b2d325e-1c6e-4358-8529-28d2635a2a27_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentPolicyTextBlock_0a2b8374-5b54-429f-bee0-e49d4e9520d2_terseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment</link:label>
    <link:label id="lab_infu_MedicalEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_infu_MedicalEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment [Policy Text Block]</link:label>
    <link:label id="lab_infu_MedicalEquipmentPolicyTextBlock_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for medical equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentPolicyTextBlock" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentPolicyTextBlock" xlink:to="lab_infu_MedicalEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_4d01ac63-96c2-4303-9a7b-043548dde2b5_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1_019c8db0-5845-754a-9281-3b5f35aa94e2_terseLabel_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-type lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Sales-type Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorSalesTypeLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:to="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_9e1e5058-62c3-4063-b27a-936018ea9dbd_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_OperatingLossCarryforwardsExpirationPeriods_e4d06763-325a-4ebc-86c8-df4ab576f959_terseLabel_en-US" xlink:label="lab_infu_OperatingLossCarryforwardsExpirationPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards expiration periods</link:label>
    <link:label id="lab_infu_OperatingLossCarryforwardsExpirationPeriods_label_en-US" xlink:label="lab_infu_OperatingLossCarryforwardsExpirationPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Expiration Periods</link:label>
    <link:label id="lab_infu_OperatingLossCarryforwardsExpirationPeriods_documentation_en-US" xlink:label="lab_infu_OperatingLossCarryforwardsExpirationPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The duration of operating loss carryforwards before expiration begins.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_OperatingLossCarryforwardsExpirationPeriods" xlink:href="infu-20251231.xsd#infu_OperatingLossCarryforwardsExpirationPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_OperatingLossCarryforwardsExpirationPeriods" xlink:to="lab_infu_OperatingLossCarryforwardsExpirationPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_69b2388b-11de-4fa9-9b0c-adf8adf91d3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchased as part of share repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_659dc328-a71d-48fe-a943-d2cb992d9dfc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased and retired during period</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_e838d829-0af2-40ff-b60d-a507e375f3b6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8b96c3b4-ec33-40be-9764-f96da9c99a65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ce8aaaac-b844-4093-9cf9-b128d7d61a8b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_019b7422-a2f1-7979-bf3f-87ce610554f2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019b5104-f323-719b-a167-fe51bdf1a010_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fa9e3098-71d3-4b1a-9d4a-6c576a0bda30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ea699a0e-5d1a-4f9b-8339-0e59950a5943_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7c661203-8516-40f9-9ed3-bc5c69bf5c2b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_d69e19b7-463f-4715-a07c-4a3cfcb1db10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_227f920a-faf2-480b-be7d-a1e3c7385328_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_adfcc079-97e0-4381-840a-2324f55703e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e76cb6dc-dc5e-41d1-ab2f-5ef2d1a56d6b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_81db7bf6-225b-4626-aa2e-ed331d94f6f9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related liabilities, current</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizationOfInternalCostsPolicy_237305c7-01ad-4502-ab68-b121a58798e3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software Capitalization and Depreciation</link:label>
    <link:label id="lab_us-gaap_CapitalizationOfInternalCostsPolicy_label_en-US" xlink:label="lab_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oil and Gas, Internal Cost Capitalization [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfInternalCostsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:to="lab_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_311313ff-5c57-40bc-a2d9-43c7192868c9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81f40869-6e14-4edf-841d-c20e06c1be31_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_feedcb2c-4ec9-43c9-ae1e-bf734d82e617_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_LeaseClassificationAxis_181d2cea-9b77-40b9-874b-7efa678e508d_terseLabel_en-US" xlink:label="lab_infu_LeaseClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Classification [Axis]</link:label>
    <link:label id="lab_infu_LeaseClassificationAxis_label_en-US" xlink:label="lab_infu_LeaseClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Classification [Axis]</link:label>
    <link:label id="lab_infu_LeaseClassificationAxis_documentation_en-US" xlink:label="lab_infu_LeaseClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Classification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LeaseClassificationAxis" xlink:href="infu-20251231.xsd#infu_LeaseClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_LeaseClassificationAxis" xlink:to="lab_infu_LeaseClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_NetInvestmentInSalesTypeLeasesTableTextBlock_f3a9c180-ab12-44cc-9ea8-1c3c8b71a113_terseLabel_en-US" xlink:label="lab_infu_NetInvestmentInSalesTypeLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment in Sales-type Leases</link:label>
    <link:label id="lab_infu_NetInvestmentInSalesTypeLeasesTableTextBlock_label_en-US" xlink:label="lab_infu_NetInvestmentInSalesTypeLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment In Sales-Type Leases [Table Text Block]</link:label>
    <link:label id="lab_infu_NetInvestmentInSalesTypeLeasesTableTextBlock_documentation_en-US" xlink:label="lab_infu_NetInvestmentInSalesTypeLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Investment In Sales-Type Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetInvestmentInSalesTypeLeasesTableTextBlock" xlink:href="infu-20251231.xsd#infu_NetInvestmentInSalesTypeLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_NetInvestmentInSalesTypeLeasesTableTextBlock" xlink:to="lab_infu_NetInvestmentInSalesTypeLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_894dc210-077d-4350-bc45-4c3ed59b4d01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_519898f7-4347-47d8-ab74-19324ec28b7b_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_fb5ea41e-6e8d-490d-a610-f1165f799cc1_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_019b7402-be2e-7c98-9e00-2c10ca11823a_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Illinois</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_16862f36-3e4d-4b7c-94d6-e72ec0047d71_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1b102ae8-a0aa-41b6-99d1-3af2c9296320_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_80379a01-8351-4c6b-bc9a-a11b804edfa0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_5445461d-b225-487a-8536-7e4dcb6aa588_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Leases Revenues</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_DebtInstrumentCovenantMaximumLeverageRatio_47281374-61be-44b0-9043-5a0834f63df5_terseLabel_en-US" xlink:label="lab_infu_DebtInstrumentCovenantMaximumLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, maximum leverage ratio</link:label>
    <link:label id="lab_infu_DebtInstrumentCovenantMaximumLeverageRatio_label_en-US" xlink:label="lab_infu_DebtInstrumentCovenantMaximumLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Covenant Maximum Leverage Ratio</link:label>
    <link:label id="lab_infu_DebtInstrumentCovenantMaximumLeverageRatio_documentation_en-US" xlink:label="lab_infu_DebtInstrumentCovenantMaximumLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum leverage ratio required by the debt agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DebtInstrumentCovenantMaximumLeverageRatio" xlink:href="infu-20251231.xsd#infu_DebtInstrumentCovenantMaximumLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_DebtInstrumentCovenantMaximumLeverageRatio" xlink:to="lab_infu_DebtInstrumentCovenantMaximumLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2e21d65f-8101-4873-aa0f-265622a1f079_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_019b7403-358b-717b-911f-626b731ea13d_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Georgia</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_680fc08b-199d-4966-9572-40790422d5ba_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6a895b9a-5c73-44eb-8f4e-c527aec79adc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff2a6307-b7a1-4025-89d8-bda185b9b1fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_19402af1-10e9-4a11-a10a-6e98ba0c62e3_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019b0262-ec5b-7ea5-9054-8c85b7636b76_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciling Adjustment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncome_e8946351-eb8a-4717-895d-8758fa6ffb51_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-type lease revenue</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-type Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseLeaseIncome" xlink:to="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b1b9762e-c151-4056-bc4a-4cf9428edd80_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property &amp; equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6b5a56bc-c4d5-43a4-9891-b8425083ada5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_a5c17059-cb3c-4a64-aa19-4b95701581f7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6ccf21b0-943f-449b-b0ed-658328d6be75_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_650c00e8-b5bd-45ed-9826-0e1118030777_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax expense</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_19d42e01-0d54-4bd4-8117-928b870743be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchased as part of share repurchase program</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_ca773b7d-3a2d-4479-9e19-7fc619b3da35_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions_b9037a8f-8078-4ead-ba2a-1880c9e4569c_terseLabel_en-US" xlink:label="lab_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions_label_en-US" xlink:label="lab_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity Subject To Certain Conditions</link:label>
    <link:label id="lab_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions_documentation_en-US" xlink:label="lab_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional borrowing capacity under the credit facility subject to certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" xlink:href="infu-20251231.xsd#infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" xlink:to="lab_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_339b61f5-4573-446f-bd9f-c735359ddb13_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_8f7b31cd-4377-451a-bdde-cd8cf04d0fc6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_NumberOfFinancialInstitutions_44db65f3-a7aa-4d65-b92e-9159f940d00a_terseLabel_en-US" xlink:label="lab_infu_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of financial institutions</link:label>
    <link:label id="lab_infu_NumberOfFinancialInstitutions_label_en-US" xlink:label="lab_infu_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions</link:label>
    <link:label id="lab_infu_NumberOfFinancialInstitutions_documentation_en-US" xlink:label="lab_infu_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of financial institutions where the entity maintains its cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfFinancialInstitutions" xlink:href="infu-20251231.xsd#infu_NumberOfFinancialInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_NumberOfFinancialInstitutions" xlink:to="lab_infu_NumberOfFinancialInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_608058c7-eec2-4655-a0e5-6eca1d46b9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award, increase in shares allowed for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e2e06877-8289-4979-b121-311be041ff7b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_0025c143-4d69-4c77-b27a-0c90fcbe886b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6f5f1790-4d61-41ad-ad75-08e36d121600_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, expiration</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_fecc0f01-1451-4271-8366-dfce35144fa0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_14ab84e3-7727-4607-bf3b-7813900aeb6e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_019b7400-acf6-7e68-b7cc-fa38c2f9a187_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_255c7dfa-dfa2-49c0-8b07-451d7cf5f85e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentInLeaseTable_29627213-8b99-4f96-9a98-f83419d81759_terseLabel_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentInLeaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment In Lease [Table]</link:label>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentInLeaseTable_label_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentInLeaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment In Lease [Table]</link:label>
    <link:label id="lab_infu_SalesTypeLeaseNetInvestmentInLeaseTable_documentation_en-US" xlink:label="lab_infu_SalesTypeLeaseNetInvestmentInLeaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Net Investment In Lease [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentInLeaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable" xlink:to="lab_infu_SalesTypeLeaseNetInvestmentInLeaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_abbc470b-b216-4fcb-9582-7c18f6e981ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense at the statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_dbeab6ee-3e06-404b-bcbd-64c399eb0d9a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ApolloMedicalSupplyMember_019b020b-8436-79d8-85cd-8f3045d0fe25_terseLabel_en-US" xlink:label="lab_infu_ApolloMedicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apollo</link:label>
    <link:label id="lab_infu_ApolloMedicalSupplyMember_label_en-US" xlink:label="lab_infu_ApolloMedicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apollo Medical Supply [Member]</link:label>
    <link:label id="lab_infu_ApolloMedicalSupplyMember_documentation_en-US" xlink:label="lab_infu_ApolloMedicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apollo Medical Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ApolloMedicalSupplyMember" xlink:href="infu-20251231.xsd#infu_ApolloMedicalSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ApolloMedicalSupplyMember" xlink:to="lab_infu_ApolloMedicalSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0431b381-4671-4873-912b-9ef774d4db8b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone_93b5ebe6-ef4b-47e7-9759-f713f6fad377_negatedTerseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested shares forgone to satisfy minimum statutory withholding (in shares)</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_df81e11a-02ef-479f-8fd0-9ecb5d0dbb75_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_09cb82b0-cf62-48f1-b126-daf02cbcfa01_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019b0260-8a18-7a27-b278-51636b592df1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_217355a3-749a-4d89-bc51-e1fd3dbd9fef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b0260-13e4-7669-8f2d-63f6de58e497_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax expense, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_22a4710a-66d4-4888-b07c-681b4ae81dad_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_f7766adc-d191-441c-bb69-8f3bca500941_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpatented technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e75cdd20-8349-413a-ae64-dc90097b29d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/(Loss) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_e013de3d-a131-43ff-bd3e-ab3ff7853b59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eec52ca9-a99e-4dd9-bb04-fbf8ca2f1595_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lives at date of grant (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304dd9c1-c793-4cef-9573-230bbadfbaab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned_df5ce75d-6340-4b4b-bf58-1ce8c42d5b3c_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award percentage of target number of shares to be earned</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Target Number Of Shares To Be Earned</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of target number of shares to be earned under share based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7b6cdb8e-47ac-430d-bd60-c136034b0fed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8bf0dada-6ed3-4455-bc23-e0ee2c5f0223_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d0479396-4a28-4464-b531-3c2c919e328d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_21d43298-fed9-4eee-818a-79f4d8c518de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ecc506fc-d8ca-4a62-86e4-799f18c574dd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_54fe58be-1196-4944-bdc9-c8a888e5df70_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_3fa2b56e-e9e2-4252-a313-a17c6dd2837c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_210f729e-a44e-4fc1-90e7-da47e4c9a89d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42e6c117-ff69-4e11-89d8-9181cdc42517_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bc8af0b-2736-4f37-983a-ccf67af3f9a8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_1e9395c8-c7d9-4aac-9157-f4546dfac1f7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ABRLoansMember_1d935fcd-53ad-4b78-b8c3-79af7c51f134_terseLabel_en-US" xlink:label="lab_infu_ABRLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ABR Loans</link:label>
    <link:label id="lab_infu_ABRLoansMember_label_en-US" xlink:label="lab_infu_ABRLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ABR Loans [Member]</link:label>
    <link:label id="lab_infu_ABRLoansMember_documentation_en-US" xlink:label="lab_infu_ABRLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the ABR loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ABRLoansMember" xlink:href="infu-20251231.xsd#infu_ABRLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ABRLoansMember" xlink:to="lab_infu_ABRLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_de395378-a168-4c4d-a29f-c0e53ce7a420_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_41bf0a57-d906-435c-925f-08908108351d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MI_019b7401-3c81-7340-ae02-84d79e604f0b_terseLabel_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Michigan</link:label>
    <link:label id="lab_stpr_MI_label_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MICHIGAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MI" xlink:to="lab_stpr_MI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f3291dd3-ba3f-46e2-bcef-53daf15b0bfb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ContractLiabilities_019bf9a3-75dc-736d-8323-a348825be1bc_terseLabel_en-US" xlink:label="lab_infu_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_infu_ContractLiabilities_label_en-US" xlink:label="lab_infu_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liabilities</link:label>
    <link:label id="lab_infu_ContractLiabilities_documentation_en-US" xlink:label="lab_infu_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractLiabilities" xlink:href="infu-20251231.xsd#infu_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ContractLiabilities" xlink:to="lab_infu_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ThirdPartyPayerRentalsMember_25dc6470-3350-48e3-9d2f-0aebe8131923_terseLabel_en-US" xlink:label="lab_infu_ThirdPartyPayerRentalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third-Party Payer Rentals</link:label>
    <link:label id="lab_infu_ThirdPartyPayerRentalsMember_label_en-US" xlink:label="lab_infu_ThirdPartyPayerRentalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third-Party Payer Rentals [Member]</link:label>
    <link:label id="lab_infu_ThirdPartyPayerRentalsMember_documentation_en-US" xlink:label="lab_infu_ThirdPartyPayerRentalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents third-party payor rental.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ThirdPartyPayerRentalsMember" xlink:href="infu-20251231.xsd#infu_ThirdPartyPayerRentalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ThirdPartyPayerRentalsMember" xlink:to="lab_infu_ThirdPartyPayerRentalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_b56be79b-b462-4eac-b102-87624d95cd76_terseLabel_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangements</link:label>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue_67537afb-e402-418f-b163-c051d0791bc0_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares forgone to satisfy minimum statutory withholding</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Shares Forgone, Fair Value</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Shares Forgone, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ef70317b-3984-484f-9b67-d107ef44ea69_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5eca2c60-12f3-4a0a-ada8-58342fda35a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c9ef3bdb-30db-4d5c-8629-1af50373bede_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ee08d961-85fc-488e-95a5-731b06e21280_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_ba445cfe-d3d6-44f9-a430-166853d9a96b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares, retired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_51602f50-566e-4536-949f-f04499c51c27_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_7f8588f8-a526-44c7-a5a8-fbf12fae443d_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested shares forgone to satisfy minimum statutory withholding, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Expirations, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average fair value at grant date for nonvested equity-based awards expired during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_8348fc4f-be3d-4756-b0e0-062c92429b62_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e16f9c83-7d35-45b4-9112-d67144f1fc0d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_cf5e6722-79bf-424d-a393-c2b432fbddc7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Type and Direct Financing Leases, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_5fdd994d-3e3d-4c59-b2be-6a27ee8d9c90_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec9e68d1-bcd1-40c6-9f88-f515bcb76148_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH USED IN FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation_236a651c-c787-4af1-adc1-66fe81258f6d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_51b1375a-1998-4930-9285-ac1f7387d396_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue_d08e2f19-6ab7-46fe-a2c8-f90af249a2b9_terseLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares forgone to satisfy minimum statutory withholding</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options, Expiration In Period Fair Value</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of share-based awards expired during the period, to receive or retain shares or units, other instruments, or cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4f8f17d1-0406-45f2-a64c-0de6106e5aba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2031 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa766a5d-4425-421e-9a93-7bb8478dd79f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dd07d9da-4560-40d1-bebd-76dfd327249f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a96828a7-cc23-4adf-8e4a-720c94b2b745_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e02797c4-10bf-40ae-88ba-ed2ed5bb1d04_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseReceivable_14cd9754-0a28-4a50-9b89-77f9875bc74b_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease receivable</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseReceivable_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-type Lease, Lease Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:to="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5fde95c5-6d95-4155-ae3e-40b71d895df2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9b99c6ae-1ec4-4a65-be60-6e782606104e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_324e5ca5-65a1-4453-8153-53c221aa8f23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_9c34b916-d2eb-4dfe-b852-8f89a5b740b8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_NetRevenuesInternal_a4ae4c4d-e73b-4e69-a730-6bc7b4b491f9_terseLabel_en-US" xlink:label="lab_infu_NetRevenuesInternal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenues - internal</link:label>
    <link:label id="lab_infu_NetRevenuesInternal_label_en-US" xlink:label="lab_infu_NetRevenuesInternal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Revenues, Internal</link:label>
    <link:label id="lab_infu_NetRevenuesInternal_documentation_en-US" xlink:label="lab_infu_NetRevenuesInternal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of internal net revenues recognized during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesInternal" xlink:href="infu-20251231.xsd#infu_NetRevenuesInternal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_NetRevenuesInternal" xlink:to="lab_infu_NetRevenuesInternal" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_9079edb5-cdf2-4b69-b317-46330180d8aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_65295630-dcd7-427c-b28c-5b9add8c5aed_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_7875fd30-a6c7-4090-8b48-d33a99b042d3_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1814c540-4a5c-4fbb-8f93-c194e75d8a2a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_f73aa842-9ed2-4731-aef4-7b751c1aead1_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified to interest expense</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0aa0a919-0d21-4407-a04f-12e93b6fc1e3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_801a1818-77d5-40a2-b9fd-4b05a14bbccf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd5918be-dfec-44ba-bcfb-06f53d7bd159_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_52ff6efb-4534-4fc8-a276-621205d8b3a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_72f40ef7-c419-45f8-82ce-33ab08f9bb3e_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option expense</link:label>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_label_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock or Unit Option Plan Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense" xlink:to="lab_us-gaap_StockOptionPlanExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_deaf0035-5b63-4c4d-b918-39f320d76547_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ecac3a73-56bd-4830-93d7-d29155ef3f1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73daa226-ced6-4681-ac16-71b4d68f5846_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a43bdb5d-85d3-4b5c-afdb-8eb486d2a55b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e1c19e6b-354c-4145-a4c7-ed823bbef2c3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fe63f5aa-11cd-42cd-a3dc-300d8d5305fa_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a7b89d7c-f392-4d83-9ab9-27490f970989_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_064e7fcf-dea9-4bb1-ba86-c6cf9e40f3cc_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_789ef148-20dc-407d-8a24-d045fe5aa74a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_db384d33-1a34-4d34-bb0c-46cb73eb66d4_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_a958ffb8-d07d-4bbc-9070-5ebb934175b5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_e0240f48-050d-43c9-8a93-2032b5b16c80_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease receivables</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-type and Direct Financing Leases, Lease Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation_f2f4a85f-3c54-450b-bf0e-b858b8edf08b_negatedTerseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation_label_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment In Rental Services, Accumulated Depreciation</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accumulated depreciation related to medical equipment in rental services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation" xlink:to="lab_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_66c1cc80-9c34-436b-978d-80273affeada_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating lease revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_b0d721e9-a01c-42f1-b907-b54ea9f21bfa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesGross_3151bae4-c294-4cb4-bd38-0364099489a0_verboseLabel_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment in rental service</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesGross_label_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment In Rental Services, Gross</link:label>
    <link:label id="lab_infu_MedicalEquipmentInRentalServicesGross_documentation_en-US" xlink:label="lab_infu_MedicalEquipmentInRentalServicesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the gross amount of medical equipment in rental services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesGross" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_MedicalEquipmentInRentalServicesGross" xlink:to="lab_infu_MedicalEquipmentInRentalServicesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_90c950df-8e52-4bab-8b9e-a6292094dded_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_15836241-a0fc-46a5-8114-4e8721bb3737_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019b0311-3462-7cb1-ab8b-69677b8478b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, Foreign, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseIncome_def41e90-c006-41a8-b258-9fc3300067e4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease revenue</link:label>
    <link:label id="lab_us-gaap_LeaseIncome_07d7c8fd-2f7b-4930-86a8-5ed3877f4627_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease revenue</link:label>
    <link:label id="lab_us-gaap_LeaseIncome_label_en-US" xlink:label="lab_us-gaap_LeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseIncome" xlink:to="lab_us-gaap_LeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1fe13c9e-7a96-4499-9a20-36f2df818832_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77378c70-ddd5-46eb-b43e-b989701212d7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember_b352df5c-77c3-4c2e-8281-e46230de4ef8_terseLabel_en-US" xlink:label="lab_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Achieving Minimum Threshold</link:label>
    <link:label id="lab_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember_label_en-US" xlink:label="lab_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Achieving Minimum Threshold [Member]</link:label>
    <link:label id="lab_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember_documentation_en-US" xlink:label="lab_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to the achievement of minimum threshold under the share-based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember" xlink:href="infu-20251231.xsd#infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember" xlink:to="lab_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0cf7a8fe-1fbc-440a-89da-fc807409774c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to medical equipment and property</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2343d652-b8f5-437f-b1ee-cc7f2b43497c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_42770c72-4fb8-4c97-b3a0-62a40f75a36a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_128f2991-fc2c-4312-aebb-f9d5629153e1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_8e5c65ef-088e-448b-9e5e-e0e6bd765f35_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_ecdb7d29-c3ea-46f9-900d-828426a75049_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Unamortized value of the debt issuance costs, total</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_e087a385-0d67-42e6-8e35-4543fe497b46_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e04d837-9a2f-48da-9386-00282689ac75_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_38817059-2f6a-4c29-a666-e3bea5da727f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b119d1b7-c679-4661-a23a-1449daff8f58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_62a2200d-1e1b-40d1-bf64-d52f507866a0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4845dfba-8282-459c-80d3-27e7e7ce0154_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff1ec4e8-9358-43eb-af3a-86ddcf84aee9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1686f030-881d-43b4-8c0c-fcaccf18ac73_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_628359ab-ff93-421c-ac81-c60b22d60b00_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_01a2ce26-4c0c-4594-b884-0b11d61f8892_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_a72902be-3206-4f0b-a432-255a14c0de68_negatedLabel_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise, number of authorized shares (in shares)</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_label_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cashless Exercises In Period</link:label>
    <link:label id="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_documentation_en-US" xlink:label="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares exercised in a cashless transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:to="lab_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>infu-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:7814b130-9ea8-4497-bd4c-7510be4e72d5,g:0e5cd592-a670-4737-bede-9aef47e8c4b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://infusystem.com/role/Cover" xlink:type="simple" xlink:href="infu-20251231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7ad23edf-aa77-44ee-9d24-1067e83001bd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentType_7ad23edf-aa77-44ee-9d24-1067e83001bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0b2b6c78-cef3-4edf-b36c-fcdce968e87c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentAnnualReport_0b2b6c78-cef3-4edf-b36c-fcdce968e87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fc2c460a-5148-4f32-98b0-239f6aa2648c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentPeriodEndDate_fc2c460a-5148-4f32-98b0-239f6aa2648c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9b8edc6b-feb6-4e9b-8fba-10b40d483797" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_CurrentFiscalYearEndDate_9b8edc6b-feb6-4e9b-8fba-10b40d483797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7d155fc6-d837-4e50-bcfd-45a796b5d7a3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentTransitionReport_7d155fc6-d837-4e50-bcfd-45a796b5d7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4b155453-c256-42fe-9d9a-c4daff60cc51" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityFileNumber_4b155453-c256-42fe-9d9a-c4daff60cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ac5b4419-363c-465d-9d2c-1d355d056591" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityRegistrantName_ac5b4419-363c-465d-9d2c-1d355d056591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_000d78df-b467-4f86-bd77-236780a918d9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_000d78df-b467-4f86-bd77-236780a918d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9e91074b-eb1a-44b4-92c4-46cc68194810" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityTaxIdentificationNumber_9e91074b-eb1a-44b4-92c4-46cc68194810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_656d8bf1-7d4e-43e9-a89b-02e22bfc8cfa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityAddressAddressLine1_656d8bf1-7d4e-43e9-a89b-02e22bfc8cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6050fc44-e4a0-4150-b560-0f7b0b9728af" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityAddressCityOrTown_6050fc44-e4a0-4150-b560-0f7b0b9728af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0db7a200-9e73-45c1-b8e6-768154b25568" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityAddressStateOrProvince_0db7a200-9e73-45c1-b8e6-768154b25568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a6400ba4-661f-4f47-a30a-da81f8cf7dda" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityAddressPostalZipCode_a6400ba4-661f-4f47-a30a-da81f8cf7dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c5a41684-f277-4204-b8a4-995aa62f061a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_CityAreaCode_c5a41684-f277-4204-b8a4-995aa62f061a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_626541c7-4bcd-4f18-9e06-faab15db0c3e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_LocalPhoneNumber_626541c7-4bcd-4f18-9e06-faab15db0c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f17f529c-7ef7-4a22-9cf4-be4d55ac08d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_Security12bTitle_f17f529c-7ef7-4a22-9cf4-be4d55ac08d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f831745b-7633-443f-b5aa-254bfce33c37" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_TradingSymbol_f831745b-7633-443f-b5aa-254bfce33c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7c48eecf-f174-489a-a3e5-d538e7a28824" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_SecurityExchangeName_7c48eecf-f174-489a-a3e5-d538e7a28824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b8903903-477f-416b-8bbf-5ec680a1679a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b8903903-477f-416b-8bbf-5ec680a1679a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_0e1aff2e-6315-4154-ab6f-bc97c7d852ed" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityVoluntaryFilers_0e1aff2e-6315-4154-ab6f-bc97c7d852ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_066d5b80-9959-479a-974a-945f735cd358" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityCurrentReportingStatus_066d5b80-9959-479a-974a-945f735cd358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d634e1e0-485b-41a5-aab7-679ae9873195" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityInteractiveDataCurrent_d634e1e0-485b-41a5-aab7-679ae9873195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0377f38f-9aec-482f-af01-b344821f8db2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityFilerCategory_0377f38f-9aec-482f-af01-b344821f8db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_814dc3f9-20b7-4a92-a4d1-5944fcb8ab64" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntitySmallBusiness_814dc3f9-20b7-4a92-a4d1-5944fcb8ab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a5bd8c91-b3ff-4027-a878-03c0f1f18da8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityEmergingGrowthCompany_a5bd8c91-b3ff-4027-a878-03c0f1f18da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c00d3d27-9817-4452-bdf6-a5842e8198c1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c00d3d27-9817-4452-bdf6-a5842e8198c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_420ccc43-443c-4781-a643-9d081ce12c91" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_420ccc43-443c-4781-a643-9d081ce12c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e7aca7f8-ec5e-47e8-bcb1-0f7202f97aa4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityShellCompany_e7aca7f8-ec5e-47e8-bcb1-0f7202f97aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_49b40c25-683a-4216-85ce-14ef3b7ae38a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityPublicFloat_49b40c25-683a-4216-85ce-14ef3b7ae38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fa733c36-2943-459f-85f2-b351d5c6e853" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fa733c36-2943-459f-85f2-b351d5c6e853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9b32e99a-0c50-41df-875b-84dc8ada380e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9b32e99a-0c50-41df-875b-84dc8ada380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3eceb15c-9b68-4d59-9ef0-c476074a965c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_EntityCentralIndexKey_3eceb15c-9b68-4d59-9ef0-c476074a965c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_18688692-24c5-47b7-9bb6-ba2800a04d9b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentFiscalYearFocus_18688692-24c5-47b7-9bb6-ba2800a04d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_72ad0a91-abc2-469a-9b8c-eebdf02f40c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_72ad0a91-abc2-469a-9b8c-eebdf02f40c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_10fbb6e7-2a11-45ae-ae6d-66ac7ea28adc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a11a94e-d23a-4394-9cf9-423974e188a5" xlink:to="loc_dei_AmendmentFlag_10fbb6e7-2a11-45ae-ae6d-66ac7ea28adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/AuditInformation" xlink:type="simple" xlink:href="infu-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_infu_AuditInformationAbstract_695205f9-5a60-4ff8-936b-3130fff56a1d" xlink:href="infu-20251231.xsd#infu_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_206067f3-e969-460d-adfe-e8098d81876b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_AuditInformationAbstract_695205f9-5a60-4ff8-936b-3130fff56a1d" xlink:to="loc_dei_AuditorFirmId_206067f3-e969-460d-adfe-e8098d81876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_56e0fcba-6e84-4293-8848-083f1d72d29b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_AuditInformationAbstract_695205f9-5a60-4ff8-936b-3130fff56a1d" xlink:to="loc_dei_AuditorName_56e0fcba-6e84-4293-8848-083f1d72d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b8a1685c-f2a6-4373-9e9e-1c1e2a234d1f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_AuditInformationAbstract_695205f9-5a60-4ff8-936b-3130fff56a1d" xlink:to="loc_dei_AuditorLocation_b8a1685c-f2a6-4373-9e9e-1c1e2a234d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c7fe0a7a-cb79-4400-92e8-1524e2b30a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7fe0a7a-cb79-4400-92e8-1524e2b30a7f" xlink:to="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_68bc86ba-ef36-41dc-b4d2-80bcab130e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_68bc86ba-ef36-41dc-b4d2-80bcab130e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2661c886-988b-4507-8112-aa32669a0ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68bc86ba-ef36-41dc-b4d2-80bcab130e76" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2661c886-988b-4507-8112-aa32669a0ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6b37c591-fa5a-44ab-bdd4-d06d296a6a87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68bc86ba-ef36-41dc-b4d2-80bcab130e76" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6b37c591-fa5a-44ab-bdd4-d06d296a6a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e6b990a7-4a0e-4358-b874-a45541f0d171" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68bc86ba-ef36-41dc-b4d2-80bcab130e76" xlink:to="loc_us-gaap_InventoryNet_e6b990a7-4a0e-4358-b874-a45541f0d171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3cd17e16-8dc2-4057-9c19-5631cfd2175b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68bc86ba-ef36-41dc-b4d2-80bcab130e76" xlink:to="loc_us-gaap_OtherAssetsCurrent_3cd17e16-8dc2-4057-9c19-5631cfd2175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7407fcde-7532-450c-9944-c5a121095d56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68bc86ba-ef36-41dc-b4d2-80bcab130e76" xlink:to="loc_us-gaap_AssetsCurrent_7407fcde-7532-450c-9944-c5a121095d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRental_73009e68-4d36-4067-b540-bff9d7fca579" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRental"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRental_73009e68-4d36-4067-b540-bff9d7fca579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_bfeecd22-0f0d-4a63-b85a-4c0ac578790a" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_bfeecd22-0f0d-4a63-b85a-4c0ac578790a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52a62b77-e826-49d2-8af8-36fd0da57c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52a62b77-e826-49d2-8af8-36fd0da57c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46d77823-9090-49bc-a520-528b4ec1f3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_Goodwill_46d77823-9090-49bc-a520-528b4ec1f3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f0002642-73c1-4531-923a-7baf7e132f66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f0002642-73c1-4531-923a-7baf7e132f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5bf8b98-51a4-4bce-997c-de1781fee3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5bf8b98-51a4-4bce-997c-de1781fee3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_13d07c6b-e576-40d3-8c33-eceee9c6232a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_13d07c6b-e576-40d3-8c33-eceee9c6232a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_3d326de0-ecda-4cdd-98bc-71bb07d9999c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_3d326de0-ecda-4cdd-98bc-71bb07d9999c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_398d5aad-6546-4a7f-88ba-ba90f5c18d48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_398d5aad-6546-4a7f-88ba-ba90f5c18d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c658dddb-6ed1-4e53-99fc-a47e20371b35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eed6823-7987-4e94-9d1f-306789ded6f9" xlink:to="loc_us-gaap_Assets_c658dddb-6ed1-4e53-99fc-a47e20371b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7fe0a7a-cb79-4400-92e8-1524e2b30a7f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8a7971a8-9663-484d-bb94-630cf60682cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8a7971a8-9663-484d-bb94-630cf60682cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_af26b276-c612-4f8a-921b-ca7039605a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a7971a8-9663-484d-bb94-630cf60682cc" xlink:to="loc_us-gaap_AccountsPayableCurrent_af26b276-c612-4f8a-921b-ca7039605a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2e5bc38d-3983-402b-9eed-0ee8d574894f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a7971a8-9663-484d-bb94-630cf60682cc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2e5bc38d-3983-402b-9eed-0ee8d574894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7e3ed0a8-6829-4a4d-a36c-3d076c667011" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a7971a8-9663-484d-bb94-630cf60682cc" xlink:to="loc_us-gaap_LiabilitiesCurrent_7e3ed0a8-6829-4a4d-a36c-3d076c667011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b510bcd7-88eb-4182-8709-4377a3dff42c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b510bcd7-88eb-4182-8709-4377a3dff42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eba3a07e-f2e5-4c20-8ca9-8c7c2d2d862d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eba3a07e-f2e5-4c20-8ca9-8c7c2d2d862d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3823fcd7-84f4-4ec8-be51-a622acc55de2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:to="loc_us-gaap_Liabilities_3823fcd7-84f4-4ec8-be51-a622acc55de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:to="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9899a02f-1901-48df-851f-839192d41b16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:to="loc_us-gaap_PreferredStockValue_9899a02f-1901-48df-851f-839192d41b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d1fa9465-122a-4c35-a9a5-4c2a4dd538b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:to="loc_us-gaap_CommonStockValue_d1fa9465-122a-4c35-a9a5-4c2a4dd538b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6ef0e7e7-7452-416a-8724-7127ae4562c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6ef0e7e7-7452-416a-8724-7127ae4562c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d7e5992-70cd-4054-bbe0-3320ceaf5348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d7e5992-70cd-4054-bbe0-3320ceaf5348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_95df276b-31fe-4ab9-b394-50412e6bcef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_95df276b-31fe-4ab9-b394-50412e6bcef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_463cceda-c8d9-4d5c-97c0-16c1b5882e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97d27244-6850-4f70-bdf7-deb696ad200f" xlink:to="loc_us-gaap_StockholdersEquity_463cceda-c8d9-4d5c-97c0-16c1b5882e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_699cdc93-9440-4011-ade7-f5aa8f76a218" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23067f76-aa41-43c3-b8df-0ea99082dc51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_699cdc93-9440-4011-ade7-f5aa8f76a218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_43ce6044-c7fa-400d-b6d7-9d6e0c8c085a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_43ce6044-c7fa-400d-b6d7-9d6e0c8c085a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e0f4ebb6-00bd-4498-8164-738ecbc962c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e0f4ebb6-00bd-4498-8164-738ecbc962c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e8f6c969-02b9-4134-ad8a-9157711aa249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e8f6c969-02b9-4134-ad8a-9157711aa249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3c5f4b2-8ddb-4379-8b7b-d8db18c5d4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3c5f4b2-8ddb-4379-8b7b-d8db18c5d4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4c0c262d-4362-4820-8211-f8b9050a5d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4c0c262d-4362-4820-8211-f8b9050a5d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0dd5b510-2613-4f06-9e3a-3640410d8ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:to="loc_us-gaap_CommonStockSharesIssued_0dd5b510-2613-4f06-9e3a-3640410d8ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_61e4d55e-9173-45bc-887d-abbb1f152e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_795cc9c3-1587-4c7d-bf9c-0b04613c5a31" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_61e4d55e-9173-45bc-887d-abbb1f152e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a6fe471c-188a-4365-983f-e1aea4d8cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_Revenues_a6fe471c-188a-4365-983f-e1aea4d8cba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cccc4b3a-b2be-467d-9184-15517eebf0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cccc4b3a-b2be-467d-9184-15517eebf0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_3b3495c7-a05e-4890-8390-eb35e04ff6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_GrossProfit_3b3495c7-a05e-4890-8390-eb35e04ff6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_f3fd209f-7637-4b48-bc44-8a73ac415357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_f3fd209f-7637-4b48-bc44-8a73ac415357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_599f42b2-9468-47b2-b2c4-b7964d0e126d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_f3fd209f-7637-4b48-bc44-8a73ac415357" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_599f42b2-9468-47b2-b2c4-b7964d0e126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_4f1d6c00-b639-41ee-8aa4-601c6efdae70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_f3fd209f-7637-4b48-bc44-8a73ac415357" xlink:to="loc_us-gaap_SellingAndMarketingExpense_4f1d6c00-b639-41ee-8aa4-601c6efdae70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6aa05513-8169-416f-9485-3450a75b02d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_f3fd209f-7637-4b48-bc44-8a73ac415357" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6aa05513-8169-416f-9485-3450a75b02d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_90b3c055-a9a0-40c6-9a3c-d67687c19208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_f3fd209f-7637-4b48-bc44-8a73ac415357" xlink:to="loc_us-gaap_OperatingExpenses_90b3c055-a9a0-40c6-9a3c-d67687c19208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2801319c-3b40-4bd0-ba3c-41fa4423f48e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_OperatingIncomeLoss_2801319c-3b40-4bd0-ba3c-41fa4423f48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a56bd2d-4e18-4dd5-8a7c-2042d9e1ae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a56bd2d-4e18-4dd5-8a7c-2042d9e1ae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_e5e6958c-def7-4252-81fb-2a570a3c66af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a56bd2d-4e18-4dd5-8a7c-2042d9e1ae6f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_e5e6958c-def7-4252-81fb-2a570a3c66af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_07623a00-c815-4643-b38c-6e8cd9382fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a56bd2d-4e18-4dd5-8a7c-2042d9e1ae6f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_07623a00-c815-4643-b38c-6e8cd9382fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fde2a930-7741-4763-9e08-316c554d8b41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fde2a930-7741-4763-9e08-316c554d8b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4b08184-908f-4cce-8b0f-fd9f3b6d774a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b4b08184-908f-4cce-8b0f-fd9f3b6d774a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94f2712d-f232-4596-a7bc-bbd9a1d34678" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_NetIncomeLoss_94f2712d-f232-4596-a7bc-bbd9a1d34678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_c8feedb8-4a2b-4ca0-a0d8-79906bdfbf86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_c8feedb8-4a2b-4ca0-a0d8-79906bdfbf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5e29f36a-2c58-4180-9934-2940ad0c470c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c8feedb8-4a2b-4ca0-a0d8-79906bdfbf86" xlink:to="loc_us-gaap_EarningsPerShareBasic_5e29f36a-2c58-4180-9934-2940ad0c470c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7e410224-be78-4aeb-9123-42f3a0e1b377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c8feedb8-4a2b-4ca0-a0d8-79906bdfbf86" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7e410224-be78-4aeb-9123-42f3a0e1b377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ddc3cef9-c659-493a-8aad-04af3a2b891f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ddc3cef9-c659-493a-8aad-04af3a2b891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8dabf954-256b-43f6-b2d6-7c4e55c268ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ddc3cef9-c659-493a-8aad-04af3a2b891f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8dabf954-256b-43f6-b2d6-7c4e55c268ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fbfd3c7-4e47-4f6b-84bf-fffb965b8a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ddc3cef9-c659-493a-8aad-04af3a2b891f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fbfd3c7-4e47-4f6b-84bf-fffb965b8a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ff66edd7-0d58-4eed-8f52-4b24af535d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7fcc8925-dad4-47dd-8d30-b71e62d134fa" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ff66edd7-0d58-4eed-8f52-4b24af535d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aea1d32d-7685-4b63-a314-6304ffcec7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ff66edd7-0d58-4eed-8f52-4b24af535d67" xlink:to="loc_us-gaap_NetIncomeLoss_aea1d32d-7685-4b63-a314-6304ffcec7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_9759d7dc-68ce-43c8-bfaa-2c207f9ea49f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ff66edd7-0d58-4eed-8f52-4b24af535d67" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_9759d7dc-68ce-43c8-bfaa-2c207f9ea49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_ad021474-6bdf-4360-bb2c-095cce604736" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_9759d7dc-68ce-43c8-bfaa-2c207f9ea49f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_ad021474-6bdf-4360-bb2c-095cce604736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_f994d31f-5a8c-4928-859d-15859d425efe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_9759d7dc-68ce-43c8-bfaa-2c207f9ea49f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_f994d31f-5a8c-4928-859d-15859d425efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6bdab02b-8298-4cfd-8fba-34cab8ee6683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_9759d7dc-68ce-43c8-bfaa-2c207f9ea49f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6bdab02b-8298-4cfd-8fba-34cab8ee6683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5be0b955-256b-48f7-8f26-56c81651759c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ff66edd7-0d58-4eed-8f52-4b24af535d67" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5be0b955-256b-48f7-8f26-56c81651759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7c6ed25-f47d-49b8-8eaa-01d609163419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d00c6672-aeaa-4813-8802-94ea3d414e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7c6ed25-f47d-49b8-8eaa-01d609163419" xlink:to="loc_us-gaap_StatementTable_d00c6672-aeaa-4813-8802-94ea3d414e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ffcff50f-94b8-436d-b5f1-0d24c0d13c84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d00c6672-aeaa-4813-8802-94ea3d414e71" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ffcff50f-94b8-436d-b5f1-0d24c0d13c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ffcff50f-94b8-436d-b5f1-0d24c0d13c84" xlink:to="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_285aef99-1e43-4899-92c5-3a601643baec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_CommonStockMember_285aef99-1e43-4899-92c5-3a601643baec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_86e34e46-f3b3-4b77-9d88-13f931b644dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_86e34e46-f3b3-4b77-9d88-13f931b644dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_edb647d1-f315-4b3a-808f-5d6045e6e517" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_RetainedEarningsMember_edb647d1-f315-4b3a-808f-5d6045e6e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30b3b9a8-b6b8-4040-a3ea-ef101bf03045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_048292e6-da35-43d2-a92a-3fc7cdc38d44" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30b3b9a8-b6b8-4040-a3ea-ef101bf03045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fcd87e0a-bc2f-4c42-bd76-b545eb4bc9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d00c6672-aeaa-4813-8802-94ea3d414e71" xlink:to="loc_us-gaap_StatementLineItems_fcd87e0a-bc2f-4c42-bd76-b545eb4bc9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fcd87e0a-bc2f-4c42-bd76-b545eb4bc9eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_66ccd32e-81ff-4f1d-b699-1a090c1962c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_66ccd32e-81ff-4f1d-b699-1a090c1962c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36d19c19-a80a-4b99-a9ea-ea0409a6e8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockholdersEquity_36d19c19-a80a-4b99-a9ea-ea0409a6e8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_740e69b9-f8e4-41b6-a408-8a2e17ca2fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_740e69b9-f8e4-41b6-a408-8a2e17ca2fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_d9780841-2358-4594-bde4-baea8fb2dbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_d9780841-2358-4594-bde4-baea8fb2dbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fb5eb25-c958-42d1-84ab-1bcfa1b84dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fb5eb25-c958-42d1-84ab-1bcfa1b84dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bf7d1704-332c-444f-9871-746188363c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bf7d1704-332c-444f-9871-746188363c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_3257a42d-bcb9-4380-8fd3-e40112518494" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_3257a42d-bcb9-4380-8fd3-e40112518494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c54ede72-60af-4211-84f4-7d8046e6ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c54ede72-60af-4211-84f4-7d8046e6ec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1923f6ff-893c-48c2-b3dd-1e54f233e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1923f6ff-893c-48c2-b3dd-1e54f233e80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8d82c95a-ed1c-4a45-b3fc-8e15323cac9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8d82c95a-ed1c-4a45-b3fc-8e15323cac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b0e47006-c7c4-490a-b2c4-1f90c7a65c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b0e47006-c7c4-490a-b2c4-1f90c7a65c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e063f78-5b30-42eb-a155-5fdcd77654b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e063f78-5b30-42eb-a155-5fdcd77654b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0bb0fc48-6def-440b-bb3a-b2968529c495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_NetIncomeLoss_0bb0fc48-6def-440b-bb3a-b2968529c495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_255c564d-06ed-4305-9adf-02c0b84e3dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_255c564d-06ed-4305-9adf-02c0b84e3dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_86231e23-6557-4f26-9f40-cbeef3619c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77065336-f0bf-4b48-af42-77ce5dd2b327" xlink:to="loc_us-gaap_StockholdersEquity_86231e23-6557-4f26-9f40-cbeef3619c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="infu-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7022d056-732f-411a-84f5-c07ee32dd8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7022d056-732f-411a-84f5-c07ee32dd8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7486d583-c8ae-4130-a709-333f82aa3149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7022d056-732f-411a-84f5-c07ee32dd8df" xlink:to="loc_us-gaap_NetIncomeLoss_7486d583-c8ae-4130-a709-333f82aa3149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7022d056-732f-411a-84f5-c07ee32dd8df" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_af93ab98-d6d6-4c92-b042-6ce78a3cb710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_af93ab98-d6d6-4c92-b042-6ce78a3cb710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7a41736e-095e-4f7b-8f31-b6c76993d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_Depreciation_7a41736e-095e-4f7b-8f31-b6c76993d1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_e6f31eb5-86b4-4cfa-8016-882bac0d31a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_e6f31eb5-86b4-4cfa-8016-882bac0d31a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_02306f1d-25c2-43b5-b553-e3053cc386ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_02306f1d-25c2-43b5-b553-e3053cc386ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ad84195b-07df-46f7-9f11-11f4aedd32b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ad84195b-07df-46f7-9f11-11f4aedd32b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b726c1cd-b207-408b-bf79-bbd10a36170f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b726c1cd-b207-408b-bf79-bbd10a36170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1cdaf274-6217-4c41-9171-3f8a489e072b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_ShareBasedCompensation_1cdaf274-6217-4c41-9171-3f8a489e072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8625f27b-a82c-40ab-84a3-89632686830d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac9a553-84a2-4fe6-80b6-38fd7a56aa3d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8625f27b-a82c-40ab-84a3-89632686830d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4aa713d1-2815-426d-864a-cb9577198419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7022d056-732f-411a-84f5-c07ee32dd8df" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4aa713d1-2815-426d-864a-cb9577198419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f503afea-5797-4cf7-96a5-1d52837a853f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4aa713d1-2815-426d-864a-cb9577198419" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f503afea-5797-4cf7-96a5-1d52837a853f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8b7ea972-5ab9-41fa-82da-c67e3ce7ae8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4aa713d1-2815-426d-864a-cb9577198419" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8b7ea972-5ab9-41fa-82da-c67e3ce7ae8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1a796afc-ffb1-47bd-9b00-11e6b98a31a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4aa713d1-2815-426d-864a-cb9577198419" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1a796afc-ffb1-47bd-9b00-11e6b98a31a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_79aab010-f0de-43b1-a8e1-429aea46675b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4aa713d1-2815-426d-864a-cb9577198419" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_79aab010-f0de-43b1-a8e1-429aea46675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_cd4c59ce-82a2-43ad-ad10-2e124bcb1591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7022d056-732f-411a-84f5-c07ee32dd8df" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_cd4c59ce-82a2-43ad-ad10-2e124bcb1591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_150136f3-c7d5-4177-87eb-012ed5bc36d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_cd4c59ce-82a2-43ad-ad10-2e124bcb1591" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_150136f3-c7d5-4177-87eb-012ed5bc36d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b9bfef4e-217f-4e39-9751-b231a266b190" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7022d056-732f-411a-84f5-c07ee32dd8df" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b9bfef4e-217f-4e39-9751-b231a266b190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5400d696-a9b7-4503-9d6f-84f1f3d5bee3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5400d696-a9b7-4503-9d6f-84f1f3d5bee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_019c485f-932d-7873-ad79-14c1d57fe5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5400d696-a9b7-4503-9d6f-84f1f3d5bee3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_019c485f-932d-7873-ad79-14c1d57fe5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PaymentsToAcquireMedicalEquipment_d1d30c57-4fa7-47f9-a25a-f645abcee34f" xlink:href="infu-20251231.xsd#infu_PaymentsToAcquireMedicalEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5400d696-a9b7-4503-9d6f-84f1f3d5bee3" xlink:to="loc_infu_PaymentsToAcquireMedicalEquipment_d1d30c57-4fa7-47f9-a25a-f645abcee34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ebf9c74d-f18a-4b58-b39a-80617fe06b75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5400d696-a9b7-4503-9d6f-84f1f3d5bee3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ebf9c74d-f18a-4b58-b39a-80617fe06b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_efcc8682-0e83-4b95-adc8-0f77efe9db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5400d696-a9b7-4503-9d6f-84f1f3d5bee3" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_efcc8682-0e83-4b95-adc8-0f77efe9db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30bacd8b-e134-4955-b14c-0ef9f58518f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5400d696-a9b7-4503-9d6f-84f1f3d5bee3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30bacd8b-e134-4955-b14c-0ef9f58518f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_8e16d6db-5011-4653-91d6-47c1202f8302" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_8e16d6db-5011-4653-91d6-47c1202f8302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_57849a54-a7c8-4771-b8aa-b04614c00ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_57849a54-a7c8-4771-b8aa-b04614c00ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2466e424-c02f-47e7-bf9c-fdc152bdfba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2466e424-c02f-47e7-bf9c-fdc152bdfba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f1e033c3-0a49-4863-96f1-98e3a3ed13d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f1e033c3-0a49-4863-96f1-98e3a3ed13d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_98e54cdf-5111-429d-abe6-2facc05711ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_98e54cdf-5111-429d-abe6-2facc05711ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_57081f83-c7f2-45f9-93af-275275fdb9af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:to="loc_us-gaap_ProceedsFromStockPlans_57081f83-c7f2-45f9-93af-275275fdb9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e6ed683-71f1-4950-857b-625e615300c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b344c94b-af89-4f58-827c-6712ca42151c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e6ed683-71f1-4950-857b-625e615300c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_145f8630-fb51-48ba-ab5d-f7208bbadc23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_145f8630-fb51-48ba-ab5d-f7208bbadc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ed53eae-9ca4-4014-8ac8-e927f0835877" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ed53eae-9ca4-4014-8ac8-e927f0835877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d332327-0d40-43ff-86de-58983a1b1235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d332327-0d40-43ff-86de-58983a1b1235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4eb81c9c-89e4-4649-89fb-f282e99e8fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4eb81c9c-89e4-4649-89fb-f282e99e8fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_52254502-f2cc-4a99-962a-b0824547764e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4eb81c9c-89e4-4649-89fb-f282e99e8fe1" xlink:to="loc_us-gaap_InterestPaidNet_52254502-f2cc-4a99-962a-b0824547764e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_c182d9ac-d53e-441d-8633-9886e05bfc51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4eb81c9c-89e4-4649-89fb-f282e99e8fe1" xlink:to="loc_us-gaap_IncomeTaxesPaid_c182d9ac-d53e-441d-8633-9886e05bfc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d998d93-1ae8-4c28-82b2-98bcb6ff30cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32915b10-126f-43ac-8b1c-7f00facc78b4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d998d93-1ae8-4c28-82b2-98bcb6ff30cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6a040ea8-6ac4-4800-b9f8-af89301d02bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d998d93-1ae8-4c28-82b2-98bcb6ff30cf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6a040ea8-6ac4-4800-b9f8-af89301d02bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BasisofPresentationandNatureofOperations" xlink:type="simple" xlink:href="infu-20251231.xsd#BasisofPresentationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BasisofPresentationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5b988c55-96ce-43c9-88cd-3e279f44ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_9c8db2d3-3d4b-4c86-b2ec-91941317b324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5b988c55-96ce-43c9-88cd-3e279f44ee2b" xlink:to="loc_us-gaap_BasisOfAccounting_9c8db2d3-3d4b-4c86-b2ec-91941317b324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="infu-20251231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4b15792a-ddb2-4210-9bc4-2eda6240e76e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_64471276-a1f6-47e5-90e2-f4564499abd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15792a-ddb2-4210-9bc4-2eda6240e76e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_64471276-a1f6-47e5-90e2-f4564499abd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessCombinations" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_78308c32-7fa9-4335-b139-e64f8481bc39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_03f866ba-1d47-4b89-8962-d7dca7606d91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_78308c32-7fa9-4335-b139-e64f8481bc39" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_03f866ba-1d47-4b89-8962-d7dca7606d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/Revenue" xlink:type="simple" xlink:href="infu-20251231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_a6598c97-dad1-4955-837e-c4edfb02caee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9e14901d-304f-4ad3-b5eb-715dc601732b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_a6598c97-dad1-4955-837e-c4edfb02caee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9e14901d-304f-4ad3-b5eb-715dc601732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/MedicalEquipment" xlink:type="simple" xlink:href="infu-20251231.xsd#MedicalEquipment"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/MedicalEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentAbstract_ef0de23f-ae59-4e67-a586-8d6b69126791" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentAndPropertyDisclosureTextBlock_de8c6a69-0f5f-49b0-90cb-4ca028e3beb6" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentAndPropertyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_ef0de23f-ae59-4e67-a586-8d6b69126791" xlink:to="loc_infu_MedicalEquipmentAndPropertyDisclosureTextBlock_de8c6a69-0f5f-49b0-90cb-4ca028e3beb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="infu-20251231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f9e6760-451e-4937-95f8-9dbfc6cb3486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f847f55d-2fee-43e9-9746-4beaf40dc449" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f9e6760-451e-4937-95f8-9dbfc6cb3486" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f847f55d-2fee-43e9-9746-4beaf40dc449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af5496d7-b114-47de-a369-5f62b53236aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_44cdeda5-0ff6-478c-9324-04d83987216e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af5496d7-b114-47de-a369-5f62b53236aa" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_44cdeda5-0ff6-478c-9324-04d83987216e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/Debt" xlink:type="simple" xlink:href="infu-20251231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e0b2c9f9-ff90-4c53-a8b0-393dc4e00572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5aa69a4e-2565-44d8-9b75-9f1ed9e31960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0b2c9f9-ff90-4c53-a8b0-393dc4e00572" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5aa69a4e-2565-44d8-9b75-9f1ed9e31960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivities" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivities"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_87e033df-529e-465d-9bcf-f9a962b0b29b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1e8f957a-acb0-45f4-87b4-6a67cc0eddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_87e033df-529e-465d-9bcf-f9a962b0b29b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1e8f957a-acb0-45f4-87b4-6a67cc0eddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxes" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_37911b12-ef38-4b27-997e-b36bb576ee83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cb72c026-5f68-406a-acf1-9f2b634d694a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_37911b12-ef38-4b27-997e-b36bb576ee83" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cb72c026-5f68-406a-acf1-9f2b634d694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="infu-20251231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1f99692-ff37-4223-8a5d-860cea01775d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a67e2679-ff7d-4e94-b1a3-5007251edc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1f99692-ff37-4223-8a5d-860cea01775d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a67e2679-ff7d-4e94-b1a3-5007251edc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/Leases" xlink:type="simple" xlink:href="infu-20251231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8db82938-9b65-42d8-9c40-c359c8749a38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1024d4ed-c3d1-4fff-b505-bf45eb1d0d05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8db82938-9b65-42d8-9c40-c359c8749a38" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1024d4ed-c3d1-4fff-b505-bf45eb1d0d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_cc802ac6-50b6-46a6-a42a-54ca82e0aafa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8db82938-9b65-42d8-9c40-c359c8749a38" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_cc802ac6-50b6-46a6-a42a-54ca82e0aafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf5cd44f-1a0d-4a0f-9a51-3372553a81ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cb121ad1-4a1a-4b35-9eaf-039e4139da15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf5cd44f-1a0d-4a0f-9a51-3372553a81ab" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cb121ad1-4a1a-4b35-9eaf-039e4139da15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessSegmentInformation" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessSegmentInformation"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BusinessSegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bc383b54-6da8-476f-a10b-0e4c26f7a714" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_d8737850-3f02-4176-bf67-0d13c4eb67f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bc383b54-6da8-476f-a10b-0e4c26f7a714" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_d8737850-3f02-4176-bf67-0d13c4eb67f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/EmployeeBenefitPlansandOther" xlink:type="simple" xlink:href="infu-20251231.xsd#EmployeeBenefitPlansandOther"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/EmployeeBenefitPlansandOther" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5c31d47d-4d0c-491d-af86-e91e5a9982ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b6e96944-4f17-4c8c-a23d-5045d913cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5c31d47d-4d0c-491d-af86-e91e5a9982ea" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b6e96944-4f17-4c8c-a23d-5045d913cd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="infu-20251231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7865b29b-d860-4a03-888e-e76d77e320c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7865b29b-d860-4a03-888e-e76d77e320c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_64af983a-9648-4359-9bf4-cea05ec41e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_64af983a-9648-4359-9bf4-cea05ec41e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_62f9f590-bc21-45ef-b2ff-7e1188c76124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_UseOfEstimates_62f9f590-bc21-45ef-b2ff-7e1188c76124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_9d33c239-364a-4ad2-847d-7ad718077963" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_9d33c239-364a-4ad2-847d-7ad718077963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_65cd9d60-2775-48aa-a27e-a7abd99b2978" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_65cd9d60-2775-48aa-a27e-a7abd99b2978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fcb66370-3aad-465e-875c-1b1fd2515db6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fcb66370-3aad-465e-875c-1b1fd2515db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock_05d4153d-ed7f-4e57-a4e8-8b9f335ce20a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_LessorLeasesPolicyTextBlock_05d4153d-ed7f-4e57-a4e8-8b9f335ce20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_e38b7078-b53e-4c68-a9c5-a53fd06ce1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_e38b7078-b53e-4c68-a9c5-a53fd06ce1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_582bbc0e-f66d-4019-bf28-a9db61b477eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_582bbc0e-f66d-4019-bf28-a9db61b477eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentPolicyTextBlock_100f07cf-0db9-4070-b8ca-0c104eb90fa8" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_infu_MedicalEquipmentPolicyTextBlock_100f07cf-0db9-4070-b8ca-0c104eb90fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_78c53f1d-d43f-4a70-a759-1c1df48fdd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_78c53f1d-d43f-4a70-a759-1c1df48fdd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_669955cb-82e3-4554-8c73-09692fe9035d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_669955cb-82e3-4554-8c73-09692fe9035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_f339ff71-7345-488e-b035-6029eab645b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_f339ff71-7345-488e-b035-6029eab645b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationOfInternalCostsPolicy_8e73734f-c32d-41bc-b1a2-e5933d705042" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfInternalCostsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_CapitalizationOfInternalCostsPolicy_8e73734f-c32d-41bc-b1a2-e5933d705042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1a3c539e-60d5-4fde-ae6e-ddfb53d624e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1a3c539e-60d5-4fde-ae6e-ddfb53d624e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_75dde092-67aa-478d-b340-e89465ee3974" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_75dde092-67aa-478d-b340-e89465ee3974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock_97b4b6b6-770c-4a3c-a690-7da50a905aa0" xlink:href="infu-20251231.xsd#infu_RevenueRecognitionCostOfRevenuePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock_97b4b6b6-770c-4a3c-a690-7da50a905aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_35411bf6-66a0-4917-ba0d-1e77d91c35ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_35411bf6-66a0-4917-ba0d-1e77d91c35ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_43d336f4-7883-4cf5-b3eb-9c1781bad9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_43d336f4-7883-4cf5-b3eb-9c1781bad9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TreasuryStockPolicyPolicyTextBlock_6e3fe537-602d-4681-8e86-8d19ec175238" xlink:href="infu-20251231.xsd#infu_TreasuryStockPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_infu_TreasuryStockPolicyPolicyTextBlock_6e3fe537-602d-4681-8e86-8d19ec175238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_20793483-a96a-4823-afce-6c905c71f56a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_20793483-a96a-4823-afce-6c905c71f56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_bcb0ef40-be41-4880-add9-11d9abb5b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_bcb0ef40-be41-4880-add9-11d9abb5b8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c369bfc6-ca9e-4574-b906-40d91947cff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c369bfc6-ca9e-4574-b906-40d91947cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_2e798033-54fa-4bf7-8174-29d3c1e44250" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_2e798033-54fa-4bf7-8174-29d3c1e44250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_766cbc2c-eb8d-4a22-8ade-5a4064101a19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_766cbc2c-eb8d-4a22-8ade-5a4064101a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9dfe5b01-e1d0-4a36-b373-3e9745a34fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f2bdc909-1b83-44de-8f74-320142a0648a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9dfe5b01-e1d0-4a36-b373-3e9745a34fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesEarningsPerShareTables" xlink:type="simple" xlink:href="infu-20251231.xsd#SummaryofSignificantAccountingPoliciesEarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesEarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f4261ee9-15e4-4c07-ad6b-e993723b4a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3c1a352d-c710-4106-93fe-d16a382ccb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4261ee9-15e4-4c07-ad6b-e993723b4a64" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3c1a352d-c710-4106-93fe-d16a382ccb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7f8689c6-369a-4c8b-8153-a1a4b472f246" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_713ee35a-90d7-43aa-9b9f-7785cf8acb27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7f8689c6-369a-4c8b-8153-a1a4b472f246" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_713ee35a-90d7-43aa-9b9f-7785cf8acb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/RevenueTables" xlink:type="simple" xlink:href="infu-20251231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_e3cebe1d-958c-41d3-822b-e6bed1664dee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_abc486c7-6d30-4db5-b4f1-dd0b35125b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_e3cebe1d-958c-41d3-822b-e6bed1664dee" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_abc486c7-6d30-4db5-b4f1-dd0b35125b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_ca8e830a-e58f-4c30-a68c-c6513a6343d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_e3cebe1d-958c-41d3-822b-e6bed1664dee" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_ca8e830a-e58f-4c30-a68c-c6513a6343d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/MedicalEquipmentTables" xlink:type="simple" xlink:href="infu-20251231.xsd#MedicalEquipmentTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/MedicalEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentAbstract_b405ee78-ec9b-4c5b-99f4-d8b5139d657a" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ScheduleOfMedicalEquipmentTableTextBlock_53fb1ea8-f410-4130-8647-1eecb315258b" xlink:href="infu-20251231.xsd#infu_ScheduleOfMedicalEquipmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_b405ee78-ec9b-4c5b-99f4-d8b5139d657a" xlink:to="loc_infu_ScheduleOfMedicalEquipmentTableTextBlock_53fb1ea8-f410-4130-8647-1eecb315258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="infu-20251231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cb2e024e-fcce-4753-ab92-b8ead10aa457" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_864f4797-f1dd-4324-8ea7-b1a7e2551ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cb2e024e-fcce-4753-ab92-b8ead10aa457" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_864f4797-f1dd-4324-8ea7-b1a7e2551ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b1e6280-a79b-433e-bf52-bbeb0470cb92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e0dc2800-b57f-463d-8af1-dd380e5fbfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b1e6280-a79b-433e-bf52-bbeb0470cb92" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e0dc2800-b57f-463d-8af1-dd380e5fbfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock_3fe62dcb-7511-46d2-b8a6-47bbd3278893" xlink:href="infu-20251231.xsd#infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b1e6280-a79b-433e-bf52-bbeb0470cb92" xlink:to="loc_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock_3fe62dcb-7511-46d2-b8a6-47bbd3278893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3ee804d4-f860-4453-8263-691dc1e1ca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b1e6280-a79b-433e-bf52-bbeb0470cb92" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3ee804d4-f860-4453-8263-691dc1e1ca8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtTables" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_97656460-399a-4b57-9e19-a471037b5da2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_208e2f52-231d-4eeb-9053-73b3237767e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97656460-399a-4b57-9e19-a471037b5da2" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_208e2f52-231d-4eeb-9053-73b3237767e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_78e65d08-b69f-4fd8-bf48-6241cd938805" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97656460-399a-4b57-9e19-a471037b5da2" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_78e65d08-b69f-4fd8-bf48-6241cd938805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_ddd60abf-f073-4006-aec2-bc59153c7fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97656460-399a-4b57-9e19-a471037b5da2" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_ddd60abf-f073-4006-aec2-bc59153c7fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9801b023-8a23-45d0-bc0f-fbdcf241cfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6cb3dd8e-113b-4e62-abf0-0d142ad1556e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9801b023-8a23-45d0-bc0f-fbdcf241cfc7" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6cb3dd8e-113b-4e62-abf0-0d142ad1556e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_40e68031-0bfa-410a-a389-8ccc17c2ce40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9801b023-8a23-45d0-bc0f-fbdcf241cfc7" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_40e68031-0bfa-410a-a389-8ccc17c2ce40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_954cfed7-06c2-43df-a6d0-2bc27a6eb47b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_681fd572-8e09-4210-b13a-ffde7be0e31d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_954cfed7-06c2-43df-a6d0-2bc27a6eb47b" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_681fd572-8e09-4210-b13a-ffde7be0e31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a5fcff00-5861-4d4e-9d3c-f5fdca6425da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_954cfed7-06c2-43df-a6d0-2bc27a6eb47b" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a5fcff00-5861-4d4e-9d3c-f5fdca6425da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_56c59c7a-01bd-442d-bc6c-a8f785cc894f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_954cfed7-06c2-43df-a6d0-2bc27a6eb47b" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_56c59c7a-01bd-442d-bc6c-a8f785cc894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019b5905-ef9b-7744-a583-191b908cc472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_954cfed7-06c2-43df-a6d0-2bc27a6eb47b" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019b5905-ef9b-7744-a583-191b908cc472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_12dea540-6a16-4815-8e33-e63107150718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_954cfed7-06c2-43df-a6d0-2bc27a6eb47b" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_12dea540-6a16-4815-8e33-e63107150718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesTables" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_caf113ed-9f19-490d-b067-23821d9c86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b3d4a59d-37b2-47f5-b549-2cb3378c1c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_caf113ed-9f19-490d-b067-23821d9c86f2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b3d4a59d-37b2-47f5-b549-2cb3378c1c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3ce4481f-251e-40bc-9e3b-6be2e6b1aee9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_caf113ed-9f19-490d-b067-23821d9c86f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3ce4481f-251e-40bc-9e3b-6be2e6b1aee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_7b9fafce-c202-4498-9e81-b75f657a3e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_caf113ed-9f19-490d-b067-23821d9c86f2" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_7b9fafce-c202-4498-9e81-b75f657a3e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetInvestmentInSalesTypeLeasesTableTextBlock_c322be4f-07fd-4c0b-b730-158f2810aa86" xlink:href="infu-20251231.xsd#infu_NetInvestmentInSalesTypeLeasesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_caf113ed-9f19-490d-b067-23821d9c86f2" xlink:to="loc_infu_NetInvestmentInSalesTypeLeasesTableTextBlock_c322be4f-07fd-4c0b-b730-158f2810aa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_11dd0bf3-47d4-4aba-a585-4a56428b485f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_caf113ed-9f19-490d-b067-23821d9c86f2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_11dd0bf3-47d4-4aba-a585-4a56428b485f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52268184-62ef-4553-9a79-4811bb078d29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9b0131c4-d1e6-444f-ab2e-581701221465" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52268184-62ef-4553-9a79-4811bb078d29" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9b0131c4-d1e6-444f-ab2e-581701221465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6cadee2e-c306-4dda-a5d9-b71c474f09ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52268184-62ef-4553-9a79-4811bb078d29" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6cadee2e-c306-4dda-a5d9-b71c474f09ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_f2669709-3df6-45d6-afcb-d33156dfe93a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52268184-62ef-4553-9a79-4811bb078d29" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_f2669709-3df6-45d6-afcb-d33156dfe93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_6b7b981c-ca43-47f7-a1b9-6092c5a8b637" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52268184-62ef-4553-9a79-4811bb078d29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_6b7b981c-ca43-47f7-a1b9-6092c5a8b637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b21098d8-511a-4d6a-afaa-b7799a942b68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52268184-62ef-4553-9a79-4811bb078d29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b21098d8-511a-4d6a-afaa-b7799a942b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7d565b82-c09f-4ff2-9e63-aa4c4eafaec0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52268184-62ef-4553-9a79-4811bb078d29" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7d565b82-c09f-4ff2-9e63-aa4c4eafaec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessSegmentInformationTables" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessSegmentInformationTables"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BusinessSegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3bdbdaf5-aec2-4fee-bb58-dcc3af736475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b8c661d4-257e-4fca-9a8d-102d77fef352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3bdbdaf5-aec2-4fee-bb58-dcc3af736475" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b8c661d4-257e-4fca-9a8d-102d77fef352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BasisofPresentationandNatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d715142-7805-4110-807f-840ac261c523" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d715142-7805-4110-807f-840ac261c523" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cfb080f7-0e86-449b-bc03-aba52b8068c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_srt_ProductOrServiceAxis_cfb080f7-0e86-449b-bc03-aba52b8068c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9200fcef-9e39-4516-a2d9-729db9ab1dd2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cfb080f7-0e86-449b-bc03-aba52b8068c8" xlink:to="loc_srt_ProductsAndServicesDomain_9200fcef-9e39-4516-a2d9-729db9ab1dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_AmbulatoryPumpsMember_6cf3d25d-9bcf-477c-9998-8f4265b735f3" xlink:href="infu-20251231.xsd#infu_AmbulatoryPumpsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9200fcef-9e39-4516-a2d9-729db9ab1dd2" xlink:to="loc_infu_AmbulatoryPumpsMember_6cf3d25d-9bcf-477c-9998-8f4265b735f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c6935fa-58ce-4539-9838-611113798d88" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_srt_RangeAxis_0c6935fa-58ce-4539-9838-611113798d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48e3d128-fef8-40b6-b14a-0a743a282547" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c6935fa-58ce-4539-9838-611113798d88" xlink:to="loc_srt_RangeMember_48e3d128-fef8-40b6-b14a-0a743a282547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_293c3021-933a-4bdf-9b39-52c24f9ea4f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48e3d128-fef8-40b6-b14a-0a743a282547" xlink:to="loc_srt_MinimumMember_293c3021-933a-4bdf-9b39-52c24f9ea4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_100b8fc0-15fe-4351-8aeb-808ec0880981" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_100b8fc0-15fe-4351-8aeb-808ec0880981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9c39ff4-9624-4551-bc12-aa17545b1760" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_100b8fc0-15fe-4351-8aeb-808ec0880981" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9c39ff4-9624-4551-bc12-aa17545b1760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember_1215f14c-62ec-4341-9e30-8b4b557894ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9c39ff4-9624-4551-bc12-aa17545b1760" xlink:to="loc_us-gaap_CostOfGoodsProductLineMember_1215f14c-62ec-4341-9e30-8b4b557894ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_86876c9c-7a74-4a67-a634-91e63068c813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_86876c9c-7a74-4a67-a634-91e63068c813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1a001bd0-46fd-4de1-9272-6045096ac431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_86876c9c-7a74-4a67-a634-91e63068c813" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1a001bd0-46fd-4de1-9272-6045096ac431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_b0f30f2d-ad73-4f57-a6ab-8cebe246e98d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1a001bd0-46fd-4de1-9272-6045096ac431" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_b0f30f2d-ad73-4f57-a6ab-8cebe246e98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_40222855-a18f-417f-a6c0-b0ef934fc1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_40222855-a18f-417f-a6c0-b0ef934fc1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e2cad09d-9cb9-4fdc-9357-bb8d4946f858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_40222855-a18f-417f-a6c0-b0ef934fc1e5" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e2cad09d-9cb9-4fdc-9357-bb8d4946f858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SmithsMedicalIncMember_84fce0a9-5b84-4ee5-8400-42ad34f4dc54" xlink:href="infu-20251231.xsd#infu_SmithsMedicalIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e2cad09d-9cb9-4fdc-9357-bb8d4946f858" xlink:to="loc_infu_SmithsMedicalIncMember_84fce0a9-5b84-4ee5-8400-42ad34f4dc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_44728a05-fabb-46c5-b06b-6ad53890397a" xlink:to="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfLocations_34a6edd5-fd74-441e-be87-ec41b9a72838" xlink:href="infu-20251231.xsd#infu_NumberOfLocations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:to="loc_infu_NumberOfLocations_34a6edd5-fd74-441e-be87-ec41b9a72838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b057a085-02a0-480b-954c-772573e2b43d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_897f6121-9f88-43b2-afc6-cf2de7678ef3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b057a085-02a0-480b-954c-772573e2b43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f348f412-a6b3-4f91-bc5d-eab42bef4138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f348f412-a6b3-4f91-bc5d-eab42bef4138" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_srt_RangeAxis_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bc2e7fc9-7749-4db7-ba3e-2a7e697db2b4" xlink:to="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16522454-3525-4336-b5cf-18e5a2b79c67" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:to="loc_srt_MinimumMember_16522454-3525-4336-b5cf-18e5a2b79c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff4fd19d-8611-4b97-8118-b3990c47e003" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a597513a-11ff-4a9f-8776-ebe25834a7e2" xlink:to="loc_srt_MaximumMember_ff4fd19d-8611-4b97-8118-b3990c47e003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22b11fc4-83a6-46f3-92bf-ccc1ec667e9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_InformationTechnologySoftwareMember_fea49eca-d7a3-46b9-a96e-ca3fb543f5ef" xlink:href="infu-20251231.xsd#infu_InformationTechnologySoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:to="loc_infu_InformationTechnologySoftwareMember_fea49eca-d7a3-46b9-a96e-ca3fb543f5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d174b346-4fe5-496d-b13e-f008cfd07756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d7278d5-c268-4a7b-9e55-7f90fb2bd4f9" xlink:to="loc_us-gaap_ComputerEquipmentMember_d174b346-4fe5-496d-b13e-f008cfd07756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_598f1245-69c2-4ca0-999e-6f66d3984f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_598f1245-69c2-4ca0-999e-6f66d3984f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_598f1245-69c2-4ca0-999e-6f66d3984f9f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PhysicianAndCustomerRelationshipsMember_06bfb9bc-06ad-4e24-8582-1d8bb2628746" xlink:href="infu-20251231.xsd#infu_PhysicianAndCustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_infu_PhysicianAndCustomerRelationshipsMember_06bfb9bc-06ad-4e24-8582-1d8bb2628746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1d6fa5ab-67b0-4dc3-923e-cc6ab824133a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1d6fa5ab-67b0-4dc3-923e-cc6ab824133a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpatentedTechnologyMember_51a8f16b-9462-4e96-bf6c-31f602bd8b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnpatentedTechnologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_us-gaap_UnpatentedTechnologyMember_51a8f16b-9462-4e96-bf6c-31f602bd8b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b3b67974-c246-4c6b-a806-5053a0f600f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_429497fe-f8b5-4f06-854f-832742a4ab6f" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b3b67974-c246-4c6b-a806-5053a0f600f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c53718d-b840-4bb9-a225-aeca80b5c701" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c53718d-b840-4bb9-a225-aeca80b5c701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6bb2304-5ac3-4baf-bc81-267775656414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c53718d-b840-4bb9-a225-aeca80b5c701" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6bb2304-5ac3-4baf-bc81-267775656414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1cdbafe9-f966-4309-9163-55b0691b360e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6bb2304-5ac3-4baf-bc81-267775656414" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1cdbafe9-f966-4309-9163-55b0691b360e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_056f6286-aa8a-4709-bd3e-ded32583fdc1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2ec45ced-f44c-4215-b970-1b660d218c56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_NumberOfReportableSegments_2ec45ced-f44c-4215-b970-1b660d218c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfFinancialInstitutions_49b1c13b-23e0-4c05-8a71-33fd3c92c3c2" xlink:href="infu-20251231.xsd#infu_NumberOfFinancialInstitutions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_NumberOfFinancialInstitutions_49b1c13b-23e0-4c05-8a71-33fd3c92c3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_1f61a777-934c-4c1f-87d8-bd31cad2c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_1f61a777-934c-4c1f-87d8-bd31cad2c5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_a74552fb-ef6a-4eff-885e-6b72f8d2506a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_a74552fb-ef6a-4eff-885e-6b72f8d2506a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_019c8dae-2b93-776a-a9d7-888333c64640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_019c8dae-2b93-776a-a9d7-888333c64640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_019c8db0-5845-7c76-8d68-be34f56ae82f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorSalesTypeLeaseTermOfContract1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_019c8db0-5845-7c76-8d68-be34f56ae82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bdb6cc99-b9b9-44e0-acc9-10005265dc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bdb6cc99-b9b9-44e0-acc9-10005265dc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesUsefulLife_86706785-93f1-4db3-88c0-1f82d3ae862c" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_MedicalEquipmentInRentalServicesUsefulLife_86706785-93f1-4db3-88c0-1f82d3ae862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesReserve_5e9071d6-4975-4e55-b55a-06b0d0ef5be2" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesReserve"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_MedicalEquipmentInRentalServicesReserve_5e9071d6-4975-4e55-b55a-06b0d0ef5be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_be315439-65dd-4053-85f9-bfa0af51061d" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalReserve"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_be315439-65dd-4053-85f9-bfa0af51061d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_77d0098b-aa69-4b9d-b128-ae3375e800c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_77d0098b-aa69-4b9d-b128-ae3375e800c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52b81d7e-9970-41d9-bcfe-b05b9e748286" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52b81d7e-9970-41d9-bcfe-b05b9e748286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_6cbaab59-cfe6-4857-8801-a7125e3f61e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_6cbaab59-cfe6-4857-8801-a7125e3f61e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9056484a-5a3b-433a-9c08-be746449af3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9056484a-5a3b-433a-9c08-be746449af3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c546883-e9c6-4875-bd1e-c9c953623ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c546883-e9c6-4875-bd1e-c9c953623ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ff7be99-cbbc-41f0-905c-8259d02ac63d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ff7be99-cbbc-41f0-905c-8259d02ac63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b8c298c-5357-4b83-9005-30b598053789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b8c298c-5357-4b83-9005-30b598053789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NumberOfContractsWithThirdParties_3e1eeb7c-44c5-40e7-b817-e4038f00a7cd" xlink:href="infu-20251231.xsd#infu_NumberOfContractsWithThirdParties"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_NumberOfContractsWithThirdParties_3e1eeb7c-44c5-40e7-b817-e4038f00a7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermOfContract_e541561e-9b12-4115-ab09-168697228536" xlink:href="infu-20251231.xsd#infu_TermOfContract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_TermOfContract_e541561e-9b12-4115-ab09-168697228536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermOfRenewal_07553f6d-9e9f-4456-b1f6-38ab6c56900e" xlink:href="infu-20251231.xsd#infu_TermOfRenewal"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_infu_TermOfRenewal_07553f6d-9e9f-4456-b1f6-38ab6c56900e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_1654e431-7c4c-4803-82fc-1b85adbf9620" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_1654e431-7c4c-4803-82fc-1b85adbf9620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4fab4155-02cb-4a1d-b718-95d4224bdbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cadbfe0e-fa6e-4ec7-bc90-b7c700e87a76" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4fab4155-02cb-4a1d-b718-95d4224bdbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6910542b-904f-4683-8cb8-e1fc685824b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d3ead25-4789-4e03-ac79-962509d3554d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6910542b-904f-4683-8cb8-e1fc685824b7" xlink:to="loc_us-gaap_NetIncomeLoss_5d3ead25-4789-4e03-ac79-962509d3554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cb0708be-dcc8-4263-bcca-06efbd5bb94d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6910542b-904f-4683-8cb8-e1fc685824b7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cb0708be-dcc8-4263-bcca-06efbd5bb94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81ca7bb0-4581-458f-b8e7-5f74e084cfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cb0708be-dcc8-4263-bcca-06efbd5bb94d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81ca7bb0-4581-458f-b8e7-5f74e084cfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9d248da7-7575-4f1e-8013-008b7636d6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cb0708be-dcc8-4263-bcca-06efbd5bb94d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9d248da7-7575-4f1e-8013-008b7636d6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c36574ac-fe63-49e5-9769-0b629c7ba4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cb0708be-dcc8-4263-bcca-06efbd5bb94d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c36574ac-fe63-49e5-9769-0b629c7ba4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a02910ce-414e-4256-94ee-e3fd1e991b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_1b5823bc-4aa6-4474-8896-f40702bb7bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSegmentAllocationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a02910ce-414e-4256-94ee-e3fd1e991b9d" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_1b5823bc-4aa6-4474-8896-f40702bb7bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019b020b-8436-7969-880b-60cdcde38596" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_1b5823bc-4aa6-4474-8896-f40702bb7bf1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019b020b-8436-7969-880b-60cdcde38596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7be2-b1ac-aed6afa0cfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019b020b-8436-7969-880b-60cdcde38596" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7be2-b1ac-aed6afa0cfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ApolloMedicalSupplyMember_019b020b-8436-7663-a041-aa6f8d8d7be9" xlink:href="infu-20251231.xsd#infu_ApolloMedicalSupplyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b020b-8436-7be2-b1ac-aed6afa0cfbb" xlink:to="loc_infu_ApolloMedicalSupplyMember_019b020b-8436-7663-a041-aa6f8d8d7be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_1b5823bc-4aa6-4474-8896-f40702bb7bf1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b65a46b2-e0cc-4f84-9a57-3cd65d463b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b65a46b2-e0cc-4f84-9a57-3cd65d463b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ae7d408d-fa24-4e99-8c08-27c7d825efec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ae7d408d-fa24-4e99-8c08-27c7d825efec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e03d46a2-4045-4ecb-825d-254b24188f40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e03d46a2-4045-4ecb-825d-254b24188f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_019b0207-1e33-72b2-96f4-feaf06cb448b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_019b0207-1e33-72b2-96f4-feaf06cb448b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5d82bf16-8999-4317-92fe-92f16af00643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4901fdb6-271b-4df5-bb5c-d7a356566939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5d82bf16-8999-4317-92fe-92f16af00643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#RevenueScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_7e80d60a-8a4c-4c56-b4bb-0432ed6e219c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_7e80d60a-8a4c-4c56-b4bb-0432ed6e219c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0cd3d20c-f7b5-40ac-aa02-a2baf00977ad" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f3bea834-a72c-4284-a906-e24dd238f90f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f3bea834-a72c-4284-a906-e24dd238f90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4a842eef-9093-4cd4-963b-9a4164fdfe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_249de48a-055e-486b-96d2-ebdcf3305b7c" xlink:to="loc_us-gaap_SalesRevenueNetMember_4a842eef-9093-4cd4-963b-9a4164fdfe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_076dd58e-cb71-4add-bf17-51d25f896eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_076dd58e-cb71-4add-bf17-51d25f896eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_242a60f9-fc9e-48c4-bb86-022671406e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_076dd58e-cb71-4add-bf17-51d25f896eba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_242a60f9-fc9e-48c4-bb86-022671406e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ad0bae65-1969-465a-818c-2bacf4220f98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_242a60f9-fc9e-48c4-bb86-022671406e5c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ad0bae65-1969-465a-818c-2bacf4220f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_srt_ProductOrServiceAxis_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f5d9a0ab-acdd-4be1-bb3a-7abeb640d072" xlink:to="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ThirdPartyPayerRentalsMember_47dc330f-ed94-4a6f-b149-d251a64153b8" xlink:href="infu-20251231.xsd#infu_ThirdPartyPayerRentalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_infu_ThirdPartyPayerRentalsMember_47dc330f-ed94-4a6f-b149-d251a64153b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DirectPayerRentalsMember_fc467cf9-2fb6-4ff7-87c5-e9f72b5a0b94" xlink:href="infu-20251231.xsd#infu_DirectPayerRentalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_infu_DirectPayerRentalsMember_fc467cf9-2fb6-4ff7-87c5-e9f72b5a0b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_61babb9d-a892-4f06-8f69-6126ada8b6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_us-gaap_ProductMember_61babb9d-a892-4f06-8f69-6126ada8b6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_748a2707-598d-4455-bd03-4f6135086472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3fc95e8f-8ce3-42f2-a7c6-f9344aaaee29" xlink:to="loc_us-gaap_ServiceMember_748a2707-598d-4455-bd03-4f6135086472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_810ffb4a-01b2-419d-b8fc-f50cf6a65582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_810ffb4a-01b2-419d-b8fc-f50cf6a65582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f26f3ba6-0c0f-4f6d-8559-527931275da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_810ffb4a-01b2-419d-b8fc-f50cf6a65582" xlink:to="loc_us-gaap_SegmentDomain_f26f3ba6-0c0f-4f6d-8559-527931275da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:href="infu-20251231.xsd#infu_PatientServicesAndDeviceSolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f26f3ba6-0c0f-4f6d-8559-527931275da1" xlink:to="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesMember_cbbe1602-20f3-4d5c-82a8-27befd64714b" xlink:href="infu-20251231.xsd#infu_PatientServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:to="loc_infu_PatientServicesMember_cbbe1602-20f3-4d5c-82a8-27befd64714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeviceSolutionsMember_d51fff3c-11b3-417e-b316-8db87cda638c" xlink:href="infu-20251231.xsd#infu_DeviceSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_PatientServicesAndDeviceSolutionsMember_0b15078e-ea55-496d-b027-bec0f4dee3ff" xlink:to="loc_infu_DeviceSolutionsMember_d51fff3c-11b3-417e-b316-8db87cda638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_37d4bd97-af0b-4c60-9b26-cc6c5f6a75b7" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_b330de81-58fd-4755-a1d5-2d9214702f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_b330de81-58fd-4755-a1d5-2d9214702f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_52a2c003-afcd-4b15-b05a-c11fba05243f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_303ffa92-78ef-402a-94b7-fd80010e7df1" xlink:to="loc_us-gaap_TransferredOverTimeMember_52a2c003-afcd-4b15-b05a-c11fba05243f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fee86243-2fd9-42f6-82f9-1833b74fa145" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_498574dc-801f-42e5-aa7e-d2ba8e014a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_498574dc-801f-42e5-aa7e-d2ba8e014a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncome_47b07a5c-1cd9-4231-b2ba-046474f46837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_LeaseIncome_47b07a5c-1cd9-4231-b2ba-046474f46837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_99734620-ea2d-417a-8e75-5adbdb4fcce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_Revenues_99734620-ea2d-417a-8e75-5adbdb4fcce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6728d43d-5f13-489f-91e9-5eeedf1ed857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0b962e32-f0ac-4de9-9d2d-3931a47aa814" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6728d43d-5f13-489f-91e9-5eeedf1ed857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/RevenueContractBalancesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#RevenueContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/RevenueContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_6748ad8c-5e9e-4d31-a041-4564dc229841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_19be36ff-dac9-4ca0-8a12-8726230384c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_6748ad8c-5e9e-4d31-a041-4564dc229841" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_19be36ff-dac9-4ca0-8a12-8726230384c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_793efb1c-7cf2-4d92-8149-0dcf0e222619" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_19be36ff-dac9-4ca0-8a12-8726230384c3" xlink:to="loc_srt_RestatementAxis_793efb1c-7cf2-4d92-8149-0dcf0e222619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_883741d0-0a19-4bd7-ba9c-76a75824e10f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_793efb1c-7cf2-4d92-8149-0dcf0e222619" xlink:to="loc_srt_RestatementDomain_883741d0-0a19-4bd7-ba9c-76a75824e10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_348ea66c-7220-4144-b89f-b2bf43e39012" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_883741d0-0a19-4bd7-ba9c-76a75824e10f" xlink:to="loc_srt_RestatementAdjustmentMember_348ea66c-7220-4144-b89f-b2bf43e39012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_19be36ff-dac9-4ca0-8a12-8726230384c3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4e6e6680-a81c-4d83-bcfa-82c1c8bb4eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4e6e6680-a81c-4d83-bcfa-82c1c8bb4eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractAssets_9baf49c9-d8b4-44b9-ad9a-1f563dafac4d" xlink:href="infu-20251231.xsd#infu_ContractAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:to="loc_infu_ContractAssets_9baf49c9-d8b4-44b9-ad9a-1f563dafac4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractLiabilities_019bf9a3-75dc-7d05-b692-db82e665aaa0" xlink:href="infu-20251231.xsd#infu_ContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d326a2b8-da60-4e6c-a49f-eceea8d84efd" xlink:to="loc_infu_ContractLiabilities_019bf9a3-75dc-7d05-b692-db82e665aaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_fbf71cf0-effe-4c95-9898-339ef155835d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractAssetsRevenuePartiallyOffsetAmount_0fa25460-02bf-4ba7-b23a-76a3044130b1" xlink:href="infu-20251231.xsd#infu_ContractAssetsRevenuePartiallyOffsetAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_fbf71cf0-effe-4c95-9898-339ef155835d" xlink:to="loc_infu_ContractAssetsRevenuePartiallyOffsetAmount_0fa25460-02bf-4ba7-b23a-76a3044130b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ContractAssetsRevenueRecognized_e14dc6dd-58e8-4053-9aca-c76540c01633" xlink:href="infu-20251231.xsd#infu_ContractAssetsRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_fbf71cf0-effe-4c95-9898-339ef155835d" xlink:to="loc_infu_ContractAssetsRevenueRecognized_e14dc6dd-58e8-4053-9aca-c76540c01633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#MedicalEquipmentScheduleofMedicalEquipmentDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalGross_d92f0d0a-2851-4e06-b942-cfc41be171b7" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRentalGross_d92f0d0a-2851-4e06-b942-cfc41be171b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_7b263804-0a87-4740-acbe-0f90bf031e75" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRentalReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRentalReserve_7b263804-0a87-4740-acbe-0f90bf031e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentHeldForSaleOrRental_0b34d8ee-ccee-440b-8e63-4d8061decd63" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentHeldForSaleOrRental"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentHeldForSaleOrRental_0b34d8ee-ccee-440b-8e63-4d8061decd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesGross_87977c17-b924-4a12-a824-cc9c57b44fd1" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentInRentalServicesGross_87977c17-b924-4a12-a824-cc9c57b44fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesReserve_fc9620a0-d2dd-4e7d-b25e-7a0b2354587c" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentInRentalServicesReserve_fc9620a0-d2dd-4e7d-b25e-7a0b2354587c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation_4a9d39f5-6f5f-4bb9-b3b4-a542cfa6d713" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation_4a9d39f5-6f5f-4bb9-b3b4-a542cfa6d713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_bced6eeb-df85-4d8a-9317-ca4de42335a1" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation_bced6eeb-df85-4d8a-9317-ca4de42335a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentNet_afa713aa-faaa-4825-9d38-018d8d3e37b6" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_82e9cb81-bbb8-4917-8ba5-5660d106f156" xlink:to="loc_infu_MedicalEquipmentNet_afa713aa-faaa-4825-9d38-018d8d3e37b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/MedicalEquipmentNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#MedicalEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/MedicalEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_infu_MedicalEquipmentAbstract_31d78910-4523-4e34-871c-4b7bf3c0cf04" xlink:href="infu-20251231.xsd#infu_MedicalEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DepreciationExpenseRelatedToMedicalEquipment_86f7ed0b-3f6d-4d67-a25e-738636da059b" xlink:href="infu-20251231.xsd#infu_DepreciationExpenseRelatedToMedicalEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_MedicalEquipmentAbstract_31d78910-4523-4e34-871c-4b7bf3c0cf04" xlink:to="loc_infu_DepreciationExpenseRelatedToMedicalEquipment_86f7ed0b-3f6d-4d67-a25e-738636da059b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0dd5408-0119-4473-8838-610dae9cb560" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a3a2cbd8-7dae-4ea6-8d2a-cdab5959c095" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0dd5408-0119-4473-8838-610dae9cb560" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a3a2cbd8-7dae-4ea6-8d2a-cdab5959c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3bbd9770-276b-40fa-b566-635f230c8103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a3a2cbd8-7dae-4ea6-8d2a-cdab5959c095" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3bbd9770-276b-40fa-b566-635f230c8103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3bbd9770-276b-40fa-b566-635f230c8103" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_277a7958-6da5-499e-a354-d150392e7403" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_277a7958-6da5-499e-a354-d150392e7403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AutomobilesMember_a1e42440-04f5-41f2-9360-3f60f6c94012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AutomobilesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:to="loc_us-gaap_AutomobilesMember_a1e42440-04f5-41f2-9360-3f60f6c94012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff7b8219-abe1-429c-b55e-824b672e36d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ed17824-d008-44b8-896c-cfd28077af70" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff7b8219-abe1-429c-b55e-824b672e36d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a3a2cbd8-7dae-4ea6-8d2a-cdab5959c095" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8e825376-2a4c-45e3-b3e0-7dbdfffb052a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8e825376-2a4c-45e3-b3e0-7dbdfffb052a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_005baf5f-fb47-4d7b-8cfc-e5472dcb5b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_005baf5f-fb47-4d7b-8cfc-e5472dcb5b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_74eaebcd-57c1-40a6-adbc-8e51fd2da40e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4d7adff0-0db0-4c78-ba8e-fd698e3dadea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_74eaebcd-57c1-40a6-adbc-8e51fd2da40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c0718a-b9e7-4058-a13c-f12cfef5233a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction_8ec6a49f-cadb-4a59-96b6-b7f7be312c74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c0718a-b9e7-4058-a13c-f12cfef5233a" xlink:to="loc_us-gaap_DepreciationNonproduction_8ec6a49f-cadb-4a59-96b6-b7f7be312c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8af20c3c-e433-4bcf-a570-441a13393e33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a3cf4418-506c-4145-a221-2bb4122ada8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8af20c3c-e433-4bcf-a570-441a13393e33" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a3cf4418-506c-4145-a221-2bb4122ada8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_47929f40-6ed9-4171-bec2-a66c9419aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a3cf4418-506c-4145-a221-2bb4122ada8f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_47929f40-6ed9-4171-bec2-a66c9419aa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_47929f40-6ed9-4171-bec2-a66c9419aa4a" xlink:to="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeviceSolutionsMember_3946c975-2f90-4497-a394-1eb130b11bcb" xlink:href="infu-20251231.xsd#infu_DeviceSolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:to="loc_infu_DeviceSolutionsMember_3946c975-2f90-4497-a394-1eb130b11bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesMember_e605265a-1c36-4d96-bd48-83ca155b37ea" xlink:href="infu-20251231.xsd#infu_PatientServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3b024616-49ea-4fc4-b396-cff465e76d09" xlink:to="loc_infu_PatientServicesMember_e605265a-1c36-4d96-bd48-83ca155b37ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_68318338-a4d3-430d-b425-7ea83bad4f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a3cf4418-506c-4145-a221-2bb4122ada8f" xlink:to="loc_us-gaap_GoodwillLineItems_68318338-a4d3-430d-b425-7ea83bad4f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_68318338-a4d3-430d-b425-7ea83bad4f8a" xlink:to="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31fca48b-cde0-476c-82a2-01e3bbcf4869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:to="loc_us-gaap_Goodwill_31fca48b-cde0-476c-82a2-01e3bbcf4869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0409d738-d56d-4d61-b0b3-2eed4b2bc47b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0409d738-d56d-4d61-b0b3-2eed4b2bc47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b150e68e-3747-4432-a0bb-d80314084f31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f84ad78a-c1bb-4461-9bfd-2578669dde74" xlink:to="loc_us-gaap_Goodwill_b150e68e-3747-4432-a0bb-d80314084f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_484f0bfb-291a-413b-ab1e-ae32f15dfe07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92869777-c52b-42dc-b1b4-41169f5feb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_484f0bfb-291a-413b-ab1e-ae32f15dfe07" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92869777-c52b-42dc-b1b4-41169f5feb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8bb31363-fc51-4d46-b190-f6d279572562" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92869777-c52b-42dc-b1b4-41169f5feb4c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8bb31363-fc51-4d46-b190-f6d279572562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8bb31363-fc51-4d46-b190-f6d279572562" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2bfd2844-a9c5-4208-ac1a-7ec12375cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_TradeNamesMember_2bfd2844-a9c5-4208-ac1a-7ec12375cc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PhysicianAndCustomerRelationshipsMember_34906375-5f5a-41cc-9983-58bd9e347fbc" xlink:href="infu-20251231.xsd#infu_PhysicianAndCustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_infu_PhysicianAndCustomerRelationshipsMember_34906375-5f5a-41cc-9983-58bd9e347fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_cdca3f59-9876-42ab-8536-14d7bcbd17bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_cdca3f59-9876-42ab-8536-14d7bcbd17bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_f22bd402-f966-4a88-acb3-4b4adc658ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_f22bd402-f966-4a88-acb3-4b4adc658ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5fe5ad8b-f3c8-4a7c-983f-7053b1440105" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448762b-a18a-441b-b9a7-6ae74e07579c" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5fe5ad8b-f3c8-4a7c-983f-7053b1440105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92869777-c52b-42dc-b1b4-41169f5feb4c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_048a83e2-5098-4419-b90c-cbca8c6a570c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_048a83e2-5098-4419-b90c-cbca8c6a570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2d7161b6-2bee-45d9-a166-ae99a5aa45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2d7161b6-2bee-45d9-a166-ae99a5aa45eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d5620e7-bd4b-4667-a159-fcb294e26482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d5620e7-bd4b-4667-a159-fcb294e26482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e84a42c8-4cae-46af-8765-dbf09ad9c6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e84a42c8-4cae-46af-8765-dbf09ad9c6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_617f3efb-a08a-4a0b-8a94-5b9a42a8c038" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_617f3efb-a08a-4a0b-8a94-5b9a42a8c038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0742ddef-c5e6-4446-bbeb-b916aa0b7247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e2e74174-fdf7-4322-a95b-964145741f40" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0742ddef-c5e6-4446-bbeb-b916aa0b7247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c143659c-69f4-44b1-bd24-f341914a36fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1471cf3d-795b-4f36-af33-e7780a2342fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c143659c-69f4-44b1-bd24-f341914a36fa" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1471cf3d-795b-4f36-af33-e7780a2342fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24d19b61-9307-4913-a914-94f78a15fd91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_241d5a36-de0f-4c34-a9d9-2503ffc53392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24d19b61-9307-4913-a914-94f78a15fd91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_241d5a36-de0f-4c34-a9d9-2503ffc53392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_728e2eca-a14a-493b-a688-d4f5e1bcc5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24d19b61-9307-4913-a914-94f78a15fd91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_728e2eca-a14a-493b-a688-d4f5e1bcc5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b761aa7a-f424-4762-8020-656de6ff928f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24d19b61-9307-4913-a914-94f78a15fd91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b761aa7a-f424-4762-8020-656de6ff928f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3696237a-f0a2-40a1-9883-1180cb45bf38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24d19b61-9307-4913-a914-94f78a15fd91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3696237a-f0a2-40a1-9883-1180cb45bf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e6984b61-3b67-4a08-a4f2-f8acdc812bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24d19b61-9307-4913-a914-94f78a15fd91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e6984b61-3b67-4a08-a4f2-f8acdc812bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f8f9c78d-4a64-4f9f-9004-9b977065d5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24d19b61-9307-4913-a914-94f78a15fd91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f8f9c78d-4a64-4f9f-9004-9b977065d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_76a9b53e-a6ab-4015-8ae9-005a6bb8a8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_76a9b53e-a6ab-4015-8ae9-005a6bb8a8a1" xlink:to="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c11ff90c-2c85-453a-a948-4f19c7d12b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_DebtInstrumentAxis_c11ff90c-2c85-453a-a948-4f19c7d12b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_76bbe60c-cf9b-4c42-95ef-947f943f7883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c11ff90c-2c85-453a-a948-4f19c7d12b21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_76bbe60c-cf9b-4c42-95ef-947f943f7883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_The2021CreditAgreementMember_47759b47-fb51-4f6b-96b5-2b929ba9e8fa" xlink:href="infu-20251231.xsd#infu_The2021CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_76bbe60c-cf9b-4c42-95ef-947f943f7883" xlink:to="loc_infu_The2021CreditAgreementMember_47759b47-fb51-4f6b-96b5-2b929ba9e8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e4f84e85-f522-4676-9057-5478ef1df364" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_CreditFacilityAxis_e4f84e85-f522-4676-9057-5478ef1df364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e4f84e85-f522-4676-9057-5478ef1df364" xlink:to="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_71b7fd34-5b43-4829-9d78-a53dfc4e0b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_71b7fd34-5b43-4829-9d78-a53dfc4e0b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_05cd4b83-34a4-4e0e-b07c-caa276eb30fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_950d8955-0c10-40d0-8086-cc0cd231dbb5" xlink:to="loc_us-gaap_LetterOfCreditMember_05cd4b83-34a4-4e0e-b07c-caa276eb30fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e86a1d3-c9e9-4abd-88f6-08408ff40670" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_srt_RangeAxis_4e86a1d3-c9e9-4abd-88f6-08408ff40670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4e86a1d3-c9e9-4abd-88f6-08408ff40670" xlink:to="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_42150289-7ccf-426b-85bf-abb6ec82dbe0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:to="loc_srt_MinimumMember_42150289-7ccf-426b-85bf-abb6ec82dbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33d7676d-9fec-4d9e-84aa-8e6a952af23a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c4ea71e-ec96-4807-9351-3c217291c0c6" xlink:to="loc_srt_MaximumMember_33d7676d-9fec-4d9e-84aa-8e6a952af23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_VariableRateAxis_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_fd3aee15-51c7-4fa1-b38b-b28e22ccd66c" xlink:to="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_3af647a5-127f-45f1-a720-aafbdc334305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_3af647a5-127f-45f1-a720-aafbdc334305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_4ddc51df-406d-4c70-be6e-50fdb47f81e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:to="loc_us-gaap_BaseRateMember_4ddc51df-406d-4c70-be6e-50fdb47f81e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_649201fb-da9e-4bff-8e11-c2f4b0957a84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca36db52-2229-47f7-a98a-b0d981be23c0" xlink:to="loc_us-gaap_PrimeRateMember_649201fb-da9e-4bff-8e11-c2f4b0957a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94b08f2f-e0bc-4cac-a385-11206647acc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94b08f2f-e0bc-4cac-a385-11206647acc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94b08f2f-e0bc-4cac-a385-11206647acc9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_TermBenchmarkLoansMember_bafe0faa-494d-4944-bd7b-21200ea502dc" xlink:href="infu-20251231.xsd#infu_TermBenchmarkLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:to="loc_infu_TermBenchmarkLoansMember_bafe0faa-494d-4944-bd7b-21200ea502dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ABRLoansMember_4998f977-9c79-4492-bbe1-dce6b6471968" xlink:href="infu-20251231.xsd#infu_ABRLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e63b043-5d1b-422f-831c-bf795150602f" xlink:to="loc_infu_ABRLoansMember_4998f977-9c79-4492-bbe1-dce6b6471968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b5da0ff-3b04-499c-a752-dac5f2925f53" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d869645-5699-4f19-82bd-045d07c60ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d869645-5699-4f19-82bd-045d07c60ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions_2a0aa57b-a7a4-429b-b0c3-3175c5f18fcf" xlink:href="infu-20251231.xsd#infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions_2a0aa57b-a7a4-429b-b0c3-3175c5f18fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PercentageOfTotalDepreciationExpense_6db870be-9724-4008-9783-5d6b5d91c0e7" xlink:href="infu-20251231.xsd#infu_PercentageOfTotalDepreciationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_PercentageOfTotalDepreciationExpense_6db870be-9724-4008-9783-5d6b5d91c0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio_7a06fb7a-b5df-41f3-bd0f-941952a019cd" xlink:href="infu-20251231.xsd#infu_DebtInstrumentCovenantMinimumFixedCoverageRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio_7a06fb7a-b5df-41f3-bd0f-941952a019cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DebtInstrumentCovenantMaximumLeverageRatio_ccd46779-e7d3-4438-aee1-d821ea086033" xlink:href="infu-20251231.xsd#infu_DebtInstrumentCovenantMaximumLeverageRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_infu_DebtInstrumentCovenantMaximumLeverageRatio_ccd46779-e7d3-4438-aee1-d821ea086033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9308e31f-b52d-4dd4-9aa1-29f8ad23c14c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9308e31f-b52d-4dd4-9aa1-29f8ad23c14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45804ce7-b19b-40ed-8f79-ec31017de81b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cbaafff-d09c-4da6-afcd-13ac66ad465e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45804ce7-b19b-40ed-8f79-ec31017de81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofLineofCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_80bb5def-8a45-4df9-b858-fa60b75ad92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7832a957-11fc-4bd6-8905-6a90ae32c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80bb5def-8a45-4df9-b858-fa60b75ad92a" xlink:to="loc_us-gaap_DebtInstrumentTable_7832a957-11fc-4bd6-8905-6a90ae32c8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_064aa6b0-8565-4e91-a0f3-239577a77587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7832a957-11fc-4bd6-8905-6a90ae32c8f3" xlink:to="loc_us-gaap_CreditFacilityAxis_064aa6b0-8565-4e91-a0f3-239577a77587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_734e414c-86ff-49f2-b51f-84974f63c2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_064aa6b0-8565-4e91-a0f3-239577a77587" xlink:to="loc_us-gaap_CreditFacilityDomain_734e414c-86ff-49f2-b51f-84974f63c2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1a04a063-421c-459d-889b-a75bc16668fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_734e414c-86ff-49f2-b51f-84974f63c2b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1a04a063-421c-459d-889b-a75bc16668fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7832a957-11fc-4bd6-8905-6a90ae32c8f3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_fe0b9b8f-5358-4a82-8c7f-3adae3157848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_fe0b9b8f-5358-4a82-8c7f-3adae3157848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_645fbe70-c96d-4339-9ec8-4e56c083404c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:to="loc_us-gaap_LineOfCredit_645fbe70-c96d-4339-9ec8-4e56c083404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ed586f34-bd67-4bdf-877a-c4d4dcd23bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bfcfbd99-2881-40d1-bc0e-76f85e1c007d" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ed586f34-bd67-4bdf-877a-c4d4dcd23bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_26175a46-3dd6-44f9-8d0e-e39be6551154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8af0f914-5130-4a25-ba80-8a9ca4fa3691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26175a46-3dd6-44f9-8d0e-e39be6551154" xlink:to="loc_us-gaap_DebtInstrumentTable_8af0f914-5130-4a25-ba80-8a9ca4fa3691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2bb4f96c-6036-4904-924f-15801f6a6fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8af0f914-5130-4a25-ba80-8a9ca4fa3691" xlink:to="loc_us-gaap_CreditFacilityAxis_2bb4f96c-6036-4904-924f-15801f6a6fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4ba3faa0-4fbb-4efb-97d7-bacc51782863" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2bb4f96c-6036-4904-924f-15801f6a6fcd" xlink:to="loc_us-gaap_CreditFacilityDomain_4ba3faa0-4fbb-4efb-97d7-bacc51782863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a82a15b2-1df2-4109-a1d6-3d6bd592deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4ba3faa0-4fbb-4efb-97d7-bacc51782863" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a82a15b2-1df2-4109-a1d6-3d6bd592deb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8af0f914-5130-4a25-ba80-8a9ca4fa3691" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2cab1e36-5e20-43c5-8e79-b7338ac2300e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2cab1e36-5e20-43c5-8e79-b7338ac2300e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4c8bbb33-69cf-49de-9739-6190bb44c84a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4c8bbb33-69cf-49de-9739-6190bb44c84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9d33f312-8719-4255-a1f3-9069dfcf1283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9d33f312-8719-4255-a1f3-9069dfcf1283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_af16bbed-fba1-4c6a-8e14-e140856fc7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_af16bbed-fba1-4c6a-8e14-e140856fc7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_88ce9afa-b58c-4165-bdc6-6adefcf01c05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_88ce9afa-b58c-4165-bdc6-6adefcf01c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7eae2c27-740e-4fe3-8cd9-f0e9c92e1f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7eae2c27-740e-4fe3-8cd9-f0e9c92e1f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_52e5577e-3ae9-4831-86a2-d2ca5d56b3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4acc1eaf-5bce-4e96-a839-c7b8228a143c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_52e5577e-3ae9-4831-86a2-d2ca5d56b3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DebtScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_32ca38b9-f96c-45d0-b69f-02cafc986b76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4c7a4353-d6a8-4b5c-9937-f109f3bdd482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_32ca38b9-f96c-45d0-b69f-02cafc986b76" xlink:to="loc_us-gaap_DebtInstrumentTable_4c7a4353-d6a8-4b5c-9937-f109f3bdd482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b89bf37d-9591-4eb9-9dd1-721977ee7090" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c7a4353-d6a8-4b5c-9937-f109f3bdd482" xlink:to="loc_us-gaap_CreditFacilityAxis_b89bf37d-9591-4eb9-9dd1-721977ee7090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9e1ca486-8d9f-432b-9209-560b25b17a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b89bf37d-9591-4eb9-9dd1-721977ee7090" xlink:to="loc_us-gaap_CreditFacilityDomain_9e1ca486-8d9f-432b-9209-560b25b17a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e3f7edf5-2f1b-4e95-89fc-da31961aa582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9e1ca486-8d9f-432b-9209-560b25b17a68" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e3f7edf5-2f1b-4e95-89fc-da31961aa582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c7a4353-d6a8-4b5c-9937-f109f3bdd482" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossCurrent_3746e634-a6ad-440a-830b-924f311a675a" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_LongTermDebtGrossCurrent_3746e634-a6ad-440a-830b-924f311a675a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LongTermDebtGrossNoncurrent_64810c2f-2e43-404c-b7a5-eaa5beef76c3" xlink:href="infu-20251231.xsd#infu_LongTermDebtGrossNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_LongTermDebtGrossNoncurrent_64810c2f-2e43-404c-b7a5-eaa5beef76c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7f86e538-beb6-43f7-9794-d1fcd0d3e2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7f86e538-beb6-43f7-9794-d1fcd0d3e2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_d5f466ec-be7b-4b76-af67-5e8bcbad4986" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseCurrent_d5f466ec-be7b-4b76-af67-5e8bcbad4986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_4f0c0b11-5dac-4d83-9cd0-5981ebffdf9e" xlink:href="infu-20251231.xsd#infu_UnamortizedDebtIssuanceExpenseNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_infu_UnamortizedDebtIssuanceExpenseNoncurrent_4f0c0b11-5dac-4d83-9cd0-5981ebffdf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_08c4c251-36b3-416b-b432-f6cc8309669f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_08c4c251-36b3-416b-b432-f6cc8309669f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8e373018-9c8c-42e6-813a-8c5270b103c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_LongTermDebtCurrent_8e373018-9c8c-42e6-813a-8c5270b103c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4ad518d4-9a40-4317-be81-487d780560d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4ad518d4-9a40-4317-be81-487d780560d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_266e4c0a-8692-4906-8f07-6d6861a872ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a895d7fe-a800-4419-a611-b8ccddf03411" xlink:to="loc_us-gaap_LongTermDebt_266e4c0a-8692-4906-8f07-6d6861a872ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2f8d4e1a-b268-44d3-a6fd-c83ea5eee5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2f8d4e1a-b268-44d3-a6fd-c83ea5eee5f0" xlink:to="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a4338942-2d4d-4d55-8b98-6f759bbb0af9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5d8b86c8-9a90-430b-8be3-23fd9c1a3f23" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a4338942-2d4d-4d55-8b98-6f759bbb0af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_62f18f15-b465-4972-b673-cc9e6c1aad97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a4338942-2d4d-4d55-8b98-6f759bbb0af9" xlink:to="loc_us-gaap_InterestRateSwapMember_62f18f15-b465-4972-b673-cc9e6c1aad97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3de362d2-35f4-423b-ad5e-020045e8c256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:to="loc_us-gaap_HedgingDesignationAxis_3de362d2-35f4-423b-ad5e-020045e8c256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e210ada7-3669-42c2-bf93-729f4e5af548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_3de362d2-35f4-423b-ad5e-020045e8c256" xlink:to="loc_us-gaap_HedgingDesignationDomain_e210ada7-3669-42c2-bf93-729f4e5af548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c0b44d3-4cdc-4ff5-8f29-d1b3710bdaad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e210ada7-3669-42c2-bf93-729f4e5af548" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c0b44d3-4cdc-4ff5-8f29-d1b3710bdaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_53cae4a2-e37f-48be-b782-3dabc9a99411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_53cae4a2-e37f-48be-b782-3dabc9a99411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0dd832cb-e13c-414e-a599-14a63f3265cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_53cae4a2-e37f-48be-b782-3dabc9a99411" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0dd832cb-e13c-414e-a599-14a63f3265cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_873b22c5-3da2-435d-8bb3-caa09697b306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0dd832cb-e13c-414e-a599-14a63f3265cf" xlink:to="loc_us-gaap_CashFlowHedgingMember_873b22c5-3da2-435d-8bb3-caa09697b306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a371586-80a8-4d5d-9434-22d515ce7ac3" xlink:to="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_f4b0846a-66a0-4d3c-a14c-e2ca8077ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:to="loc_us-gaap_DerivativeTermOfContract_f4b0846a-66a0-4d3c-a14c-e2ca8077ebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_6257fbad-000e-45ac-bb27-c1c36b301e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_6257fbad-000e-45ac-bb27-c1c36b301e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_fb58e0a9-344b-4603-a033-b3fbe87b7565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4d95f1dc-b9ab-464b-bd47-31b238358fb3" xlink:to="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_fb58e0a9-344b-4603-a033-b3fbe87b7565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ffcf44cf-06be-4bbd-b88d-9f47c2964739" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ffcf44cf-06be-4bbd-b88d-9f47c2964739" xlink:to="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4c270e00-3c9d-425c-83d1-656cf332792f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4c270e00-3c9d-425c-83d1-656cf332792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_95c92f36-163b-4eb4-9527-7ef04c5c8237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4c270e00-3c9d-425c-83d1-656cf332792f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_95c92f36-163b-4eb4-9527-7ef04c5c8237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_5c59e356-8575-4c15-a098-6f38f9a85352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_95c92f36-163b-4eb4-9527-7ef04c5c8237" xlink:to="loc_us-gaap_CashFlowHedgingMember_5c59e356-8575-4c15-a098-6f38f9a85352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f9cfe0e3-4867-47f4-a696-6431d5df72d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c30eeedf-e020-4bd6-9d2f-b3d95450ee5d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f9cfe0e3-4867-47f4-a696-6431d5df72d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_59d73874-59bc-4afe-b8fd-dacf6f0cda59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f9cfe0e3-4867-47f4-a696-6431d5df72d5" xlink:to="loc_us-gaap_InterestRateSwapMember_59d73874-59bc-4afe-b8fd-dacf6f0cda59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4ec4163f-6ebd-4e76-89fc-ae0164cd860f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:to="loc_us-gaap_HedgingDesignationAxis_4ec4163f-6ebd-4e76-89fc-ae0164cd860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_acb10541-9a7d-4b9d-a3f6-bf3a65241173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4ec4163f-6ebd-4e76-89fc-ae0164cd860f" xlink:to="loc_us-gaap_HedgingDesignationDomain_acb10541-9a7d-4b9d-a3f6-bf3a65241173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7c0021c-a3a0-45d9-bcb4-eadd60d5815c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_acb10541-9a7d-4b9d-a3f6-bf3a65241173" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7c0021c-a3a0-45d9-bcb4-eadd60d5815c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3a37bc6c-a9b1-4bd9-821d-79a3458cbc26" xlink:to="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_17b96af5-435d-4b58-a712-c740b2574ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_17b96af5-435d-4b58-a712-c740b2574ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_0f412363-2db4-4bb5-ac76-81edb682f728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_13b03c3e-db51-4eaf-a804-2a3c4f70eae0" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_0f412363-2db4-4bb5-ac76-81edb682f728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5222d6a6-aa6e-4f2d-b484-4fd8192ecc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5222d6a6-aa6e-4f2d-b484-4fd8192ecc2e" xlink:to="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd2d72f1-be01-4461-9d47-e6017967af8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd2d72f1-be01-4461-9d47-e6017967af8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_171fb240-b0ab-4a6d-986f-821cd63df94b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd2d72f1-be01-4461-9d47-e6017967af8a" xlink:to="loc_us-gaap_EquityComponentDomain_171fb240-b0ab-4a6d-986f-821cd63df94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c655a93b-fd2d-4651-b5cb-3688f108759a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_171fb240-b0ab-4a6d-986f-821cd63df94b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c655a93b-fd2d-4651-b5cb-3688f108759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d895d255-a95d-4fef-95f2-ad3c75c3ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d895d255-a95d-4fef-95f2-ad3c75c3ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_143d4f51-9c05-490b-a7c4-aa4400670bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d895d255-a95d-4fef-95f2-ad3c75c3ce8f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_143d4f51-9c05-490b-a7c4-aa4400670bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d393f23c-c86f-4bdc-84aa-9508d7493615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_143d4f51-9c05-490b-a7c4-aa4400670bd3" xlink:to="loc_us-gaap_InterestRateSwapMember_d393f23c-c86f-4bdc-84aa-9508d7493615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_589d6de9-4e0e-478a-b500-ce494f14fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_589d6de9-4e0e-478a-b500-ce494f14fd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_84c4efb7-1f8e-4666-8e37-33ddb15fd99b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_589d6de9-4e0e-478a-b500-ce494f14fd23" xlink:to="loc_us-gaap_HedgingRelationshipDomain_84c4efb7-1f8e-4666-8e37-33ddb15fd99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_f45e9b08-e62d-499c-be84-0a7c2c0aadfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_84c4efb7-1f8e-4666-8e37-33ddb15fd99b" xlink:to="loc_us-gaap_CashFlowHedgingMember_f45e9b08-e62d-499c-be84-0a7c2c0aadfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_46ea9b67-38c6-427f-9c01-50edcc88d055" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_HedgingDesignationAxis_46ea9b67-38c6-427f-9c01-50edcc88d055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0ba82872-2464-4c02-b808-dd6bb48f3f39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_46ea9b67-38c6-427f-9c01-50edcc88d055" xlink:to="loc_us-gaap_HedgingDesignationDomain_0ba82872-2464-4c02-b808-dd6bb48f3f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db27e21f-35ad-43ba-b81d-e09cc0aaf6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0ba82872-2464-4c02-b808-dd6bb48f3f39" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db27e21f-35ad-43ba-b81d-e09cc0aaf6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dd1746bd-089d-463c-82c2-0b51b094b264" xlink:to="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d07fa8a-4efb-407c-9637-c8163fb494cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_StockholdersEquity_3d07fa8a-4efb-407c-9637-c8163fb494cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_8f915d20-e56d-4e19-910a-06b24a4a26ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_8f915d20-e56d-4e19-910a-06b24a4a26ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_6b43d35c-8844-48f1-8aad-ddc7140a2e67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_6b43d35c-8844-48f1-8aad-ddc7140a2e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_0a3791de-8c81-4374-ae31-b8c09eeb8c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_0a3791de-8c81-4374-ae31-b8c09eeb8c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e81e5f97-1e46-4c00-91e0-902aa1c1110a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9848ce43-6c00-42f8-b65d-ea5254a225a9" xlink:to="loc_us-gaap_StockholdersEquity_e81e5f97-1e46-4c00-91e0-902aa1c1110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_35b47c3e-e153-4da7-acbe-029e16455f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:to="loc_us-gaap_InterestExpenseNonoperating_35b47c3e-e153-4da7-acbe-029e16455f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_2323aacc-2430-42d2-ad02-9deeb0d3adf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5192f25e-f858-4571-b4c0-763c4cd461c5" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_2323aacc-2430-42d2-ad02-9deeb0d3adf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_66ef1df7-a457-4674-9a87-62fc9d6b6d09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_da9a44d7-9902-451c-ae28-a6983c0f3578" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66ef1df7-a457-4674-9a87-62fc9d6b6d09" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_da9a44d7-9902-451c-ae28-a6983c0f3578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6f08e8b4-d1de-4776-8cdf-e64697ecc66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66ef1df7-a457-4674-9a87-62fc9d6b6d09" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6f08e8b4-d1de-4776-8cdf-e64697ecc66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fea7fa8e-f280-419c-96e9-af6ad8ef82d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66ef1df7-a457-4674-9a87-62fc9d6b6d09" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fea7fa8e-f280-419c-96e9-af6ad8ef82d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f98a1782-6f5a-4a53-95a7-e6f07d1be949" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3200fcc6-45f5-48b5-843e-37fdb3919e65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f98a1782-6f5a-4a53-95a7-e6f07d1be949" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3200fcc6-45f5-48b5-843e-37fdb3919e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ad931e72-c624-40c1-8f07-cdaa02ebfd87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3200fcc6-45f5-48b5-843e-37fdb3919e65" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ad931e72-c624-40c1-8f07-cdaa02ebfd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_04b4ab09-21ee-476a-a98d-423566297786" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3200fcc6-45f5-48b5-843e-37fdb3919e65" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_04b4ab09-21ee-476a-a98d-423566297786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_dfcb7518-c8ee-4b40-ad79-d7a564b2e8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3200fcc6-45f5-48b5-843e-37fdb3919e65" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_dfcb7518-c8ee-4b40-ad79-d7a564b2e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_c870c09a-d2d4-44cf-82d6-3d70ae90b1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f98a1782-6f5a-4a53-95a7-e6f07d1be949" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_c870c09a-d2d4-44cf-82d6-3d70ae90b1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cadd636f-f658-427f-bbf3-0c1b9efacaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_c870c09a-d2d4-44cf-82d6-3d70ae90b1e4" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cadd636f-f658-427f-bbf3-0c1b9efacaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c86e7593-1ee3-4ee8-ae98-3480bfc4b232" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_c870c09a-d2d4-44cf-82d6-3d70ae90b1e4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c86e7593-1ee3-4ee8-ae98-3480bfc4b232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_649a3ff5-fde6-4086-9b25-88f58b70fbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_c870c09a-d2d4-44cf-82d6-3d70ae90b1e4" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_649a3ff5-fde6-4086-9b25-88f58b70fbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_4f49f075-1f22-4865-8607-5830197b6a22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f98a1782-6f5a-4a53-95a7-e6f07d1be949" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_4f49f075-1f22-4865-8607-5830197b6a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_40c5f24b-d975-40f3-8d5c-b8ee751e49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_4f49f075-1f22-4865-8607-5830197b6a22" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_40c5f24b-d975-40f3-8d5c-b8ee751e49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68e8f086-6215-4762-97e3-d7b7d2c85a26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f98a1782-6f5a-4a53-95a7-e6f07d1be949" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68e8f086-6215-4762-97e3-d7b7d2c85a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_297353f0-e7ea-49aa-87a8-ae107bdb6e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_297353f0-e7ea-49aa-87a8-ae107bdb6e9b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e3bde263-0e91-4040-b392-4877821e0b13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e3bde263-0e91-4040-b392-4877821e0b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fecb2c14-9ec1-4f65-b1d5-a4e8bbd92256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fecb2c14-9ec1-4f65-b1d5-a4e8bbd92256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_019c482a-f943-77d8-9d06-4ad42c331431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_019c482a-f943-77d8-9d06-4ad42c331431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_aca5e58c-5641-4571-b245-e6fe19f0378b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_aca5e58c-5641-4571-b245-e6fe19f0378b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount_019c4830-a3e5-7407-8dbd-a156835d824b" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount_019c4830-a3e5-7407-8dbd-a156835d824b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount_019c4839-d267-708d-999d-e69b63a2ee08" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount_019c4839-d267-708d-999d-e69b63a2ee08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019b73e4-11c5-70c8-86a2-7afa781ce0be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019b73e4-11c5-70c8-86a2-7afa781ce0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount_392a3480-0a01-4fd5-9758-58e25937c1ad" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount_392a3480-0a01-4fd5-9758-58e25937c1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7856533e-0384-473b-af58-c6162e5cd1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7856533e-0384-473b-af58-c6162e5cd1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_91058568-ab7e-4a65-af21-b695a849e720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_91058568-ab7e-4a65-af21-b695a849e720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_99ee2573-0d35-48c6-a0fd-f5112c9e68b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019b0265-997b-704c-8753-30009684c6c6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_99ee2573-0d35-48c6-a0fd-f5112c9e68b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_297353f0-e7ea-49aa-87a8-ae107bdb6e9b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b025f-65a5-78d4-8bb8-ebca611a25ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b025f-65a5-78d4-8bb8-ebca611a25ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b0260-13e4-7901-8e5f-c1bce5199ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b0260-13e4-7901-8e5f-c1bce5199ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_019c482b-22a3-7451-a6f7-6be71f6f284d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_019c482b-22a3-7451-a6f7-6be71f6f284d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019b0260-8a18-72e4-b11b-61de96ecab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019b0260-8a18-72e4-b11b-61de96ecab1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent_019c4834-821f-762e-a204-d9a2bbfe1f69" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent_019c4834-821f-762e-a204-d9a2bbfe1f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent_019c4837-8831-7805-b3c5-3f694df73409" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent_019c4837-8831-7805-b3c5-3f694df73409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019b73f0-8aa3-7c59-93e4-b014be91b9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019b73f0-8aa3-7c59-93e4-b014be91b9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent_019b0260-f3d9-7849-bdbb-bcb6a4891b95" xlink:href="infu-20251231.xsd#infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent_019b0260-f3d9-7849-bdbb-bcb6a4891b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019b0260-4de2-7263-b0b0-9a806db18991" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019b0260-4de2-7263-b0b0-9a806db18991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019b0262-ec5b-7442-9926-57ed5135e4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019b0262-ec5b-7442-9926-57ed5135e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b0263-43f7-7ad4-95f9-987fc35f1d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b0266-faf9-73b6-816c-7d7c6d1b9396" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b0263-43f7-7ad4-95f9-987fc35f1d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b030e-e7a0-7d6e-8557-5aeb6e994d85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_019b0311-3462-7066-b3fa-2db446e9b8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b030e-e7a0-7d6e-8557-5aeb6e994d85" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_019b0311-3462-7066-b3fa-2db446e9b8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019b0311-3462-7323-a245-373e1114396d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_019b0311-3462-7066-b3fa-2db446e9b8d1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019b0311-3462-7323-a245-373e1114396d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7ebf-9417-e393d208a8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b0311-3462-7323-a245-373e1114396d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7ebf-9417-e393d208a8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b0311-3462-7ebf-9417-e393d208a8cf" xlink:to="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_019b0311-3462-7c77-93bd-034015d76b02" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_FL"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_FL_019b0311-3462-7c77-93bd-034015d76b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_019b5126-96aa-79c7-b406-257d46d89dc6" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_GA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_GA_019b5126-96aa-79c7-b406-257d46d89dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_019b5126-4ef6-7d01-81bc-a4c7d72dbb90" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_IL"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_IL_019b5126-4ef6-7d01-81bc-a4c7d72dbb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI_019b0311-3462-7cee-a24d-445d34114dc1" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MI"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_MI_019b0311-3462-7cee-a24d-445d34114dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_019c4844-b6bc-78b7-8d54-c9201c5211f9" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_NY_019c4844-b6bc-78b7-8d54-c9201c5211f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_019b0311-3462-71dd-b2c3-ecededc55851" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_PA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_PA_019b0311-3462-71dd-b2c3-ecededc55851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_019b5126-dd0e-7343-9df1-9873ef01fbfe" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_TX"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_stpr_TX_019b5126-dd0e-7343-9df1-9873ef01fbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019b0311-3462-77f1-89be-e9542bf44574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c4f0e-b28b-7a20-8b8b-eadf638c58fd" xlink:to="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019b0311-3462-77f1-89be-e9542bf44574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_019b0311-3462-7066-b3fa-2db446e9b8d1" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019b0311-3462-717f-80c0-17ea33e456db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019b0311-3462-717f-80c0-17ea33e456db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019b0311-3462-764b-9893-17aa82caf7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019b0311-3462-764b-9893-17aa82caf7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019b0311-3462-73ea-a345-b931e63c448e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019b0311-3462-73ea-a345-b931e63c448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019b0311-3462-79d1-a13a-5701575bc6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019b0311-3462-796d-8577-5939299d5499" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019b0311-3462-79d1-a13a-5701575bc6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a6227b82-8b1f-404c-9181-7cde67342d59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a6227b82-8b1f-404c-9181-7cde67342d59" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c50d683d-a101-45ea-8480-e19762e3f1cd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:to="loc_srt_RangeAxis_c50d683d-a101-45ea-8480-e19762e3f1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c50d683d-a101-45ea-8480-e19762e3f1cd" xlink:to="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f33e9849-41ae-4f7e-9354-70d1ae798cce" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:to="loc_srt_MinimumMember_f33e9849-41ae-4f7e-9354-70d1ae798cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_370980d3-2703-4fd7-abfc-06d7fe74ccfd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60f15f24-78e9-4dc0-9995-3f7da71134c5" xlink:to="loc_srt_MaximumMember_370980d3-2703-4fd7-abfc-06d7fe74ccfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8ac9d8af-6e90-4860-9676-028332f09d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8ac9d8af-6e90-4860-9676-028332f09d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ac9d8af-6e90-4860-9676-028332f09d6b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f568563c-acaf-45f0-9f6f-f92a303dbc42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:to="loc_us-gaap_DomesticCountryMember_f568563c-acaf-45f0-9f6f-f92a303dbc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3de533ec-64b7-4824-aadb-874b3955014b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7850cb2e-0ec0-4115-91db-b305a7243e40" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3de533ec-64b7-4824-aadb-874b3955014b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_806c837c-c860-43b3-ab77-36a7ce196933" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0631f9de-4d34-413d-92f9-e91ac69284a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0631f9de-4d34-413d-92f9-e91ac69284a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8e55fc11-b2d0-46b1-a32c-5d827c9d46ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8e55fc11-b2d0-46b1-a32c-5d827c9d46ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_OperatingLossCarryforwardsWithADefiniteLife_f009c396-08c8-4a22-be82-117d52261843" xlink:href="infu-20251231.xsd#infu_OperatingLossCarryforwardsWithADefiniteLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_infu_OperatingLossCarryforwardsWithADefiniteLife_f009c396-08c8-4a22-be82-117d52261843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_OperatingLossCarryforwardsExpirationPeriods_52438caf-14d3-43ee-b8fc-724bad19e92b" xlink:href="infu-20251231.xsd#infu_OperatingLossCarryforwardsExpirationPeriods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_infu_OperatingLossCarryforwardsExpirationPeriods_52438caf-14d3-43ee-b8fc-724bad19e92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d462d7d9-2b47-4f6a-8607-b1404c04860f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b49245ed-a901-42be-8803-91a42bd604de" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d462d7d9-2b47-4f6a-8607-b1404c04860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/IncomeTaxesCarryForwardsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#IncomeTaxesCarryForwardsDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/IncomeTaxesCarryForwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3236708d-a029-4c83-837c-75c734a2e6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_75f8e70a-de3b-40ef-a546-fbbb0cf6896f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3236708d-a029-4c83-837c-75c734a2e6eb" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_75f8e70a-de3b-40ef-a546-fbbb0cf6896f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_383b7f87-cdc1-42b2-aa98-86d70bcc309a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_75f8e70a-de3b-40ef-a546-fbbb0cf6896f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_383b7f87-cdc1-42b2-aa98-86d70bcc309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6b724a9a-1cea-462f-bb11-c13fa97d49ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_383b7f87-cdc1-42b2-aa98-86d70bcc309a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6b724a9a-1cea-462f-bb11-c13fa97d49ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d4aabec5-1c6b-4e37-bfe8-6c622af197f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6b724a9a-1cea-462f-bb11-c13fa97d49ca" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d4aabec5-1c6b-4e37-bfe8-6c622af197f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_75f8e70a-de3b-40ef-a546-fbbb0cf6896f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_302276c1-85ee-48e7-8cca-7ec1875cfbec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_302276c1-85ee-48e7-8cca-7ec1875cfbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ca27202-242a-48bc-92ab-e930bafd6b36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ca27202-242a-48bc-92ab-e930bafd6b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_964067fe-479f-4f8a-a4e7-ef7140575e46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_964067fe-479f-4f8a-a4e7-ef7140575e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities_f292ba0f-cd47-4710-be89-f5e99ef4b54c" xlink:href="infu-20251231.xsd#infu_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_infu_DeferredTaxAssetsOperatingLeaseLiabilities_f292ba0f-cd47-4710-be89-f5e99ef4b54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e822a8bf-6882-46be-9a21-05307c622639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e822a8bf-6882-46be-9a21-05307c622639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_8d9a8149-0687-4d27-a297-665b9062add3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_8d9a8149-0687-4d27-a297-665b9062add3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_52c95b9a-3e21-481f-b0fc-4e8cd170c021" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_52c95b9a-3e21-481f-b0fc-4e8cd170c021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_6526d2e8-dc89-48d9-aa8d-b4c15cd43075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_6526d2e8-dc89-48d9-aa8d-b4c15cd43075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_761e4a30-07de-4ca9-98ba-0006d7fe0298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_761e4a30-07de-4ca9-98ba-0006d7fe0298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_de0f5c37-ab71-4947-b636-6cb0d34f0f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_de0f5c37-ab71-4947-b636-6cb0d34f0f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cc84e341-4455-4d18-b3d1-7a7165c00144" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cc84e341-4455-4d18-b3d1-7a7165c00144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_5e080af9-737a-413f-a318-878aef003507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_5e080af9-737a-413f-a318-878aef003507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets_1a53ffd4-f55d-4d3f-a43f-5f7a1b7cc65d" xlink:href="infu-20251231.xsd#infu_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_infu_DeferredTaxLiabilitiesRightOfUseAssets_1a53ffd4-f55d-4d3f-a43f-5f7a1b7cc65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_746b3eba-2dc7-490f-ad22-c70d5d2ca792" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_746b3eba-2dc7-490f-ad22-c70d5d2ca792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8c11fb3b-9822-4ea0-96cf-4e6549d07d69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8c11fb3b-9822-4ea0-96cf-4e6549d07d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2b94f485-dad2-446d-b858-52e202ec7a31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2b94f485-dad2-446d-b858-52e202ec7a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e0777363-d600-4e63-a7d9-ec5ecef5bca3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_52cab4ea-44bf-4c4c-9652-9fa2f5defdc6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e0777363-d600-4e63-a7d9-ec5ecef5bca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_39fed3c2-3671-4667-8143-30bee20b8540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bfc614e5-6b4c-4484-a3b4-98d4d64df10e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39fed3c2-3671-4667-8143-30bee20b8540" xlink:to="loc_us-gaap_OperatingLeaseCost_bfc614e5-6b4c-4484-a3b4-98d4d64df10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_93b04e52-2b90-4626-9247-9a7377abe28e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39fed3c2-3671-4667-8143-30bee20b8540" xlink:to="loc_us-gaap_VariableLeaseCost_93b04e52-2b90-4626-9247-9a7377abe28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a7eb6e5d-99b8-40d5-9275-bf4257c2557c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39fed3c2-3671-4667-8143-30bee20b8540" xlink:to="loc_us-gaap_LeaseCost_a7eb6e5d-99b8-40d5-9275-bf4257c2557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bb0d3d7d-ffa7-4dd6-a337-c49f88c76ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_16d144c8-9357-47a4-96a5-8d3e42f9853f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bb0d3d7d-ffa7-4dd6-a337-c49f88c76ef7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_16d144c8-9357-47a4-96a5-8d3e42f9853f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f4cf8981-20df-4923-b72f-105cc63f40d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_16d144c8-9357-47a4-96a5-8d3e42f9853f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f4cf8981-20df-4923-b72f-105cc63f40d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70b50746-4c10-4cca-8fa8-bab30876fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f4cf8981-20df-4923-b72f-105cc63f40d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70b50746-4c10-4cca-8fa8-bab30876fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c15601eb-be97-423c-b493-ed0b9aff4730" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70b50746-4c10-4cca-8fa8-bab30876fa98" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c15601eb-be97-423c-b493-ed0b9aff4730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_16d144c8-9357-47a4-96a5-8d3e42f9853f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fb04639d-37b7-4ca0-85ca-867375735ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:to="loc_us-gaap_LeaseCost_fb04639d-37b7-4ca0-85ca-867375735ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeasePayments_019c4850-a9ab-7226-986b-836867244cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:to="loc_us-gaap_ShortTermLeasePayments_019c4850-a9ab-7226-986b-836867244cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8dc1ab15-e366-4ee1-a105-ea5a4f670102" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ead2c04-6a8d-4a22-8843-5584f3bb4a9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8dc1ab15-e366-4ee1-a105-ea5a4f670102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesSupplementalCashFlowDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesSupplementalCashFlowDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesSupplementalCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_37a0a904-a48f-4731-bac2-930851c0691e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3ee9fb5a-45ee-4ca4-b13a-257130bb84a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37a0a904-a48f-4731-bac2-930851c0691e" xlink:to="loc_us-gaap_OperatingLeasePayments_3ee9fb5a-45ee-4ca4-b13a-257130bb84a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_afa22e4f-45d0-4684-a722-293d4804e692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37a0a904-a48f-4731-bac2-930851c0691e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_afa22e4f-45d0-4684-a722-293d4804e692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications_23c5bbbe-53b5-4764-b3f6-74183d477eb6" xlink:href="infu-20251231.xsd#infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37a0a904-a48f-4731-bac2-930851c0691e" xlink:to="loc_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications_23c5bbbe-53b5-4764-b3f6-74183d477eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesWeightedAverageTableDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesWeightedAverageTableDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesWeightedAverageTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cac665fa-5b6f-4006-a25e-c696ea0fcd36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1709b251-b905-4387-ac1d-a6afb722ca20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cac665fa-5b6f-4006-a25e-c696ea0fcd36" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1709b251-b905-4387-ac1d-a6afb722ca20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0450be18-c4e1-4f12-b26e-94631596fb64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cac665fa-5b6f-4006-a25e-c696ea0fcd36" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0450be18-c4e1-4f12-b26e-94631596fb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_be7c5565-2263-4d24-829f-7f3f1933e234" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_be7c5565-2263-4d24-829f-7f3f1933e234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4277b52b-35f7-4234-bac2-49ea956cecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4277b52b-35f7-4234-bac2-49ea956cecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6d9aca35-c530-43c2-940f-6e1468288324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6d9aca35-c530-43c2-940f-6e1468288324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9bf7c81d-ec03-4e63-b622-cd5601567563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9bf7c81d-ec03-4e63-b622-cd5601567563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5af700da-bc10-4a0b-b582-f2b093e8c21f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5af700da-bc10-4a0b-b582-f2b093e8c21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a571aeb5-1bea-456f-823e-198d5e04d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a571aeb5-1bea-456f-823e-198d5e04d26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c72cf36-0799-43fa-b4c6-434267b9cefa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c72cf36-0799-43fa-b4c6-434267b9cefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff8a36ac-0651-4f32-84fb-e2d056be906a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff8a36ac-0651-4f32-84fb-e2d056be906a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_80d573dc-2bf7-49bb-a81d-72120c5e25ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f5b1bbe-b3ec-4d3a-9076-2f471f54cf82" xlink:to="loc_us-gaap_OperatingLeaseLiability_80d573dc-2bf7-49bb-a81d-72120c5e25ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesLeaseRevenueDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesLeaseRevenueDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesLeaseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bdbc0c3c-da6c-423a-bebe-78398a0b30ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_096cfa61-b925-459a-8e31-80564ed668bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bdbc0c3c-da6c-423a-bebe-78398a0b30ae" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_096cfa61-b925-459a-8e31-80564ed668bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome_2df5625e-bbfd-4031-93ae-3622ef1a021c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bdbc0c3c-da6c-423a-bebe-78398a0b30ae" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseIncome_2df5625e-bbfd-4031-93ae-3622ef1a021c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncome_e216edd5-f5ca-49ee-8144-031418d68650" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bdbc0c3c-da6c-423a-bebe-78398a0b30ae" xlink:to="loc_us-gaap_LeaseIncome_e216edd5-f5ca-49ee-8144-031418d68650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesNetInvestmentinSalesTypeLeasesDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5bd9c030-ebc1-4739-a99b-444f004ad8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_9d20f6d9-0f83-4bda-a6e4-0b749df30ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5bd9c030-ebc1-4739-a99b-444f004ad8fd" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_9d20f6d9-0f83-4bda-a6e4-0b749df30ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_d5ca5050-7eea-4cbd-ade4-9fcd2c423727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5bd9c030-ebc1-4739-a99b-444f004ad8fd" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_d5ca5050-7eea-4cbd-ade4-9fcd2c423727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dc8cc373-1486-4ad0-8dc1-3aa281ef02c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable_776bcb1f-e43e-4b74-a811-74f70ba11c89" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentInLeaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dc8cc373-1486-4ad0-8dc1-3aa281ef02c4" xlink:to="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable_776bcb1f-e43e-4b74-a811-74f70ba11c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LeaseClassificationAxis_139db6fd-b329-490f-809b-f55260abb703" xlink:href="infu-20251231.xsd#infu_LeaseClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable_776bcb1f-e43e-4b74-a811-74f70ba11c89" xlink:to="loc_infu_LeaseClassificationAxis_139db6fd-b329-490f-809b-f55260abb703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_LeaseClassificationDomain_220020b6-afec-4713-8e37-38c928ef1a4b" xlink:href="infu-20251231.xsd#infu_LeaseClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_LeaseClassificationAxis_139db6fd-b329-490f-809b-f55260abb703" xlink:to="loc_infu_LeaseClassificationDomain_220020b6-afec-4713-8e37-38c928ef1a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentMember_97fcc8a6-f873-4238-be98-a9fbba011fa3" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_LeaseClassificationDomain_220020b6-afec-4713-8e37-38c928ef1a4b" xlink:to="loc_infu_SalesTypeLeaseNetInvestmentMember_97fcc8a6-f873-4238-be98-a9fbba011fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:href="infu-20251231.xsd#infu_SalesTypeLeaseNetInvestmentInLeaseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseTable_776bcb1f-e43e-4b74-a811-74f70ba11c89" xlink:to="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_11d128cc-2a10-48df-949a-fdd1100e3841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_11d128cc-2a10-48df-949a-fdd1100e3841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_259d61c9-9251-43cb-bbef-0db87ac80f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:to="loc_us-gaap_OtherAssets_259d61c9-9251-43cb-bbef-0db87ac80f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7331c40f-97e0-4469-b10d-eef7bca8685e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems_8b2385ce-59ba-4197-85b4-515182064490" xlink:to="loc_us-gaap_Assets_7331c40f-97e0-4469-b10d-eef7bca8685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#LeasesMaturitiesofSaleTypeLeasesDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_64341cd1-dc7c-4339-b8cf-0ee144710a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_64341cd1-dc7c-4339-b8cf-0ee144710a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_62147ee8-7ca2-4004-be7e-0ab0ff0581c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_62147ee8-7ca2-4004-be7e-0ab0ff0581c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_8f298e7f-1c90-4fe4-9d79-eeee09a875cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_8f298e7f-1c90-4fe4-9d79-eeee09a875cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_019c4851-79d4-7aee-b97b-1f51e07669a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_019c4851-79d4-7aee-b97b-1f51e07669a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_69f89394-d14b-4720-b69f-7b8de1aa75b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_69f89394-d14b-4720-b69f-7b8de1aa75b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_db17a2dd-196e-4a4b-94be-aac6933bd984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_db17a2dd-196e-4a4b-94be-aac6933bd984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_bd89b0bb-eece-403f-a956-d51acb0fd700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ccbee08-988b-43c5-beae-045c1c4a69b6" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_bd89b0bb-eece-403f-a956-d51acb0fd700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_590240ae-59e8-4335-a06e-fdd120b34a91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_590240ae-59e8-4335-a06e-fdd120b34a91" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f8cafd1-ca9c-458c-855e-f0e233533474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_us-gaap_AwardTypeAxis_0f8cafd1-ca9c-458c-855e-f0e233533474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0f8cafd1-ca9c-458c-855e-f0e233533474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ba5b55e-0772-4457-8ac7-2388b04bcab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ba5b55e-0772-4457-8ac7-2388b04bcab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_26071ef0-89db-4852-9876-0eb0acfd0538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_RestrictedStockMember_26071ef0-89db-4852-9876-0eb0acfd0538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_746bba8d-db0c-4e46-a8d6-1aa5f6faa2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_PerformanceSharesMember_746bba8d-db0c-4e46-a8d6-1aa5f6faa2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_60e7073e-0dc1-4de9-b0c6-112535a4f2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cd5533-c8ae-4c78-9037-1557aa4b9fc4" xlink:to="loc_us-gaap_EmployeeStockMember_60e7073e-0dc1-4de9-b0c6-112535a4f2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_549c82ca-709d-4b1d-9ede-d8e57def1195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_us-gaap_VestingAxis_549c82ca-709d-4b1d-9ede-d8e57def1195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_549c82ca-709d-4b1d-9ede-d8e57def1195" xlink:to="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember_c4773790-d16f-4d35-80d6-e56b3de78984" xlink:href="infu-20251231.xsd#infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:to="loc_infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember_c4773790-d16f-4d35-80d6-e56b3de78984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember_ccf8c2e3-2b2f-499b-82af-cf8c0ba161a6" xlink:href="infu-20251231.xsd#infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6727e1ec-d22a-4915-b75a-e273d025107d" xlink:to="loc_infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember_ccf8c2e3-2b2f-499b-82af-cf8c0ba161a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_21599de8-93f3-4f16-a0cd-45d0cd421a27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_us-gaap_PlanNameAxis_21599de8-93f3-4f16-a0cd-45d0cd421a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_21599de8-93f3-4f16-a0cd-45d0cd421a27" xlink:to="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2021EquityIncentivePlanMember_a0cd3769-10f0-4ff2-9685-222abee01b9d" xlink:href="infu-20251231.xsd#infu_A2021EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:to="loc_infu_A2021EquityIncentivePlanMember_a0cd3769-10f0-4ff2-9685-222abee01b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2014EquityIncentivePlanMember_987e5e34-c8d9-4e2c-91fb-a47fd3f61d09" xlink:href="infu-20251231.xsd#infu_A2014EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_06d66da6-b760-4574-a01c-5028cd2182d2" xlink:to="loc_infu_A2014EquityIncentivePlanMember_987e5e34-c8d9-4e2c-91fb-a47fd3f61d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c387249-8179-4348-9167-26d52cd753ec" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_srt_RangeAxis_7c387249-8179-4348-9167-26d52cd753ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7c387249-8179-4348-9167-26d52cd753ec" xlink:to="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a4c1dfc-ab87-41f6-9fb5-cb2f82faa50a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:to="loc_srt_MinimumMember_5a4c1dfc-ab87-41f6-9fb5-cb2f82faa50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a80c3e74-573f-459c-a1ab-ce0d78f1cde3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_350a026a-884d-41e0-8560-e480fc17af2b" xlink:to="loc_srt_MaximumMember_a80c3e74-573f-459c-a1ab-ce0d78f1cde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_743462d8-4748-4c6a-bd44-ce3168ed9a9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7886f9d8-ba3d-49ad-9ed9-ca649dd51025" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7886f9d8-ba3d-49ad-9ed9-ca649dd51025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod_fb49ff65-d999-414e-98d7-c771a4058d0e" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod_fb49ff65-d999-414e-98d7-c771a4058d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3ad23fd-872a-4ab2-985d-f55fe23fdd79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3ad23fd-872a-4ab2-985d-f55fe23fdd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b45e93d2-9b95-422c-b6fd-34de699d0143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b45e93d2-9b95-422c-b6fd-34de699d0143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_43dfa4e3-051b-4821-912f-cee5a1dac889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_43dfa4e3-051b-4821-912f-cee5a1dac889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio_fdf11354-3a00-475a-8a4a-1fa82cd96d1f" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio_fdf11354-3a00-475a-8a4a-1fa82cd96d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio_17a43ae1-ab0a-477e-8046-aa2fbd8b0e76" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio_17a43ae1-ab0a-477e-8046-aa2fbd8b0e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_138dea27-d959-4553-b717-43f8ed87c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_138dea27-d959-4553-b717-43f8ed87c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbc55c-6915-4ed3-91e4-c60e6c535d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbc55c-6915-4ed3-91e4-c60e6c535d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_73e603a8-e79e-4f7d-90da-62a820bacc66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_73e603a8-e79e-4f7d-90da-62a820bacc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46f064da-dbdb-4900-81a4-b86fe4c61e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46f064da-dbdb-4900-81a4-b86fe4c61e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a353cbda-715d-4c5b-b911-295f07dfd8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a353cbda-715d-4c5b-b911-295f07dfd8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f16a782-d879-46b1-9f46-d423f77a1854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f16a782-d879-46b1-9f46-d423f77a1854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned_8db9ebad-0216-4bee-ba98-63d41d1a1308" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned_8db9ebad-0216-4bee-ba98-63d41d1a1308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_3395637a-447f-4b08-a9df-0a62008c3493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_3395637a-447f-4b08-a9df-0a62008c3493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6dd87dcb-fd8c-49b1-b843-b49ed1f4b04b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6dd87dcb-fd8c-49b1-b843-b49ed1f4b04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum_3a4ea7d1-c8e4-4a33-b930-7ed35c609609" xlink:href="infu-20251231.xsd#infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum_3a4ea7d1-c8e4-4a33-b930-7ed35c609609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance_d096c99f-0a6a-478e-b3b4-9e2b30893e29" xlink:href="infu-20251231.xsd#infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance_d096c99f-0a6a-478e-b3b4-9e2b30893e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_dc81f124-b890-47fa-861f-b647e2e18138" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_dc81f124-b890-47fa-861f-b647e2e18138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_9625d7a5-dc2c-49fe-887f-5f2c87f07f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_9625d7a5-dc2c-49fe-887f-5f2c87f07f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1c879794-23c9-4a4e-a69d-3cf38204f9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bb604e2-07f5-432b-b8d5-2924d1ba69cb" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1c879794-23c9-4a4e-a69d-3cf38204f9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5a3e2f4-0e7f-4b55-89b1-c08402dc3ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_f86a0958-c84e-4d10-b694-c41b9f14597f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5a3e2f4-0e7f-4b55-89b1-c08402dc3ac7" xlink:to="loc_us-gaap_RestrictedStockExpense_f86a0958-c84e-4d10-b694-c41b9f14597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_d6849bce-e7cf-478e-bbae-70777d17432a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5a3e2f4-0e7f-4b55-89b1-c08402dc3ac7" xlink:to="loc_us-gaap_StockOptionPlanExpense_d6849bce-e7cf-478e-bbae-70777d17432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d30c9e07-6ce2-4333-9f8b-419b7b303979" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5a3e2f4-0e7f-4b55-89b1-c08402dc3ac7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d30c9e07-6ce2-4333-9f8b-419b7b303979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_037beead-a62d-42c7-be1d-58d59ae79e36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5a3e2f4-0e7f-4b55-89b1-c08402dc3ac7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_037beead-a62d-42c7-be1d-58d59ae79e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ec2c3e0-3b60-4756-ac74-59d8d49c9f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5dca62e1-b617-4496-827e-b272f5c8cad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ec2c3e0-3b60-4756-ac74-59d8d49c9f3e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5dca62e1-b617-4496-827e-b272f5c8cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e760def8-70fa-437b-a76f-d815d1886089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5dca62e1-b617-4496-827e-b272f5c8cad3" xlink:to="loc_us-gaap_AwardTypeAxis_e760def8-70fa-437b-a76f-d815d1886089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d6e7d-b7a4-4619-9acf-0bee5bd4acaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e760def8-70fa-437b-a76f-d815d1886089" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d6e7d-b7a4-4619-9acf-0bee5bd4acaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e3be6d89-39f2-4b02-9f21-741a7f12bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d6e7d-b7a4-4619-9acf-0bee5bd4acaa" xlink:to="loc_us-gaap_RestrictedStockMember_e3be6d89-39f2-4b02-9f21-741a7f12bce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5dca62e1-b617-4496-827e-b272f5c8cad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_486462de-f1df-4ad7-94cd-06335b5dc954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_486462de-f1df-4ad7-94cd-06335b5dc954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14ce0184-5717-4152-825c-68c8abf92648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14ce0184-5717-4152-825c-68c8abf92648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6294f7bc-84d9-42d7-84d6-07200104710b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6294f7bc-84d9-42d7-84d6-07200104710b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_9aa5ffa0-2d2e-4351-9598-f2d12c4b4ed4" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_9aa5ffa0-2d2e-4351-9598-f2d12c4b4ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0beff3f8-ae64-469c-bb1f-0c79bae0d669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0beff3f8-ae64-469c-bb1f-0c79bae0d669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b62a45f-192f-4375-bfdc-eb806b46c157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_79fcd418-17ec-4c37-89e5-e1bbea969f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b62a45f-192f-4375-bfdc-eb806b46c157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3fe1a5f-846e-427e-97fa-2e828f219d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3fe1a5f-846e-427e-97fa-2e828f219d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb7bbd-c35e-49b6-bc28-138a9c15340b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cbcb7bbd-c35e-49b6-bc28-138a9c15340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ca85108f-6097-4e4d-9374-18da3cba2fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ca85108f-6097-4e4d-9374-18da3cba2fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_b8b135a4-be3d-4d78-bc0b-5524b30da298" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_b8b135a4-be3d-4d78-bc0b-5524b30da298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435711eb-42eb-4d1a-9d51-0909d6af1fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435711eb-42eb-4d1a-9d51-0909d6af1fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36fe559f-c124-4db3-9fc3-599487c5c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c25c861-edc0-4153-bc50-20abe039a735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36fe559f-c124-4db3-9fc3-599487c5c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_af75649e-884d-4af2-b3d5-0bae08fbf338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_af75649e-884d-4af2-b3d5-0bae08fbf338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue_8fa49885-f4b5-45a7-98da-55dd9e0300bf" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_597f2938-6fd0-48d4-8914-d9d6cfdf650e" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue_8fa49885-f4b5-45a7-98da-55dd9e0300bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af1c9770-3488-4ca5-91b6-de725324471c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e77612f-c5b0-4555-9ea7-760dcf885122" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af1c9770-3488-4ca5-91b6-de725324471c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e77612f-c5b0-4555-9ea7-760dcf885122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47972337-fd7f-4a5b-a82d-5030af330b91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e77612f-c5b0-4555-9ea7-760dcf885122" xlink:to="loc_us-gaap_AwardTypeAxis_47972337-fd7f-4a5b-a82d-5030af330b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdc2afe5-4b27-40e6-870a-ae32488ce2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_47972337-fd7f-4a5b-a82d-5030af330b91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdc2afe5-4b27-40e6-870a-ae32488ce2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_614df6ba-44b7-470f-b255-c24b67f92dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdc2afe5-4b27-40e6-870a-ae32488ce2bc" xlink:to="loc_us-gaap_PerformanceSharesMember_614df6ba-44b7-470f-b255-c24b67f92dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e77612f-c5b0-4555-9ea7-760dcf885122" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b891e498-5ead-47b5-9ea8-a65a6ae4f035" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b891e498-5ead-47b5-9ea8-a65a6ae4f035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c7d932bd-fcbf-4ff6-984d-6b491902e3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c7d932bd-fcbf-4ff6-984d-6b491902e3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e4cf8e38-4c1e-4b7d-98f9-b57e17eab557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e4cf8e38-4c1e-4b7d-98f9-b57e17eab557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone_e6a7aa5e-05d0-407f-9cb7-389b6434a2b8" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone_e6a7aa5e-05d0-407f-9cb7-389b6434a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019be390-a27b-7c56-8422-21d49e700daa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019be390-a27b-7c56-8422-21d49e700daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee18f2a5-29f7-48bb-821d-6d31d6f0d247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f66668f6-44c2-4dd6-a717-a389f7a62349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee18f2a5-29f7-48bb-821d-6d31d6f0d247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5f7d08b-2a39-4bae-91f5-8d9f1f9fb14a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5f7d08b-2a39-4bae-91f5-8d9f1f9fb14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58119c28-2d69-4c65-af66-95f202ca14ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58119c28-2d69-4c65-af66-95f202ca14ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_476d40ac-520c-41ea-b9af-7b2f3d8cb4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_476d40ac-520c-41ea-b9af-7b2f3d8cb4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue_64297fa4-aa81-44b0-82e3-78d6af296743" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue_64297fa4-aa81-44b0-82e3-78d6af296743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019be390-a27b-7b72-87c0-d2e88d611e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019be390-a27b-7b72-87c0-d2e88d611e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b823f37-bd35-462c-bf0d-afb102ac377d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3fc215df-a723-4f36-b45d-d1575b54cf30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b823f37-bd35-462c-bf0d-afb102ac377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ad028d5d-fd29-45ce-b2fd-a6d50bb75fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ad028d5d-fd29-45ce-b2fd-a6d50bb75fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue_f7c4e0be-0011-4679-89da-2b55cf539cb2" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cf46ce7-5c58-4c80-a1ec-b1a8269c4017" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue_f7c4e0be-0011-4679-89da-2b55cf539cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13ced0c0-7a70-4fc4-8d2a-0893dbd18c13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_c592fbaf-821e-47c3-88d0-1ec8302579ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13ced0c0-7a70-4fc4-8d2a-0893dbd18c13" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_c592fbaf-821e-47c3-88d0-1ec8302579ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b1b8d4a2-2728-4549-adbc-0478fb9872a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13ced0c0-7a70-4fc4-8d2a-0893dbd18c13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b1b8d4a2-2728-4549-adbc-0478fb9872a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased_cf000731-4cfc-4689-960b-05c07fc776b8" xlink:href="infu-20251231.xsd#infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13ced0c0-7a70-4fc4-8d2a-0893dbd18c13" xlink:to="loc_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased_cf000731-4cfc-4689-960b-05c07fc776b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensation2014and2021PlanActivityDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1143d41d-072f-439d-9770-8511b8c855a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9a9c0cf-272c-4229-8d9c-ae68b4d9da97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1143d41d-072f-439d-9770-8511b8c855a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9a9c0cf-272c-4229-8d9c-ae68b4d9da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e352a853-09bb-4312-a4cc-aae28565a37a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9a9c0cf-272c-4229-8d9c-ae68b4d9da97" xlink:to="loc_us-gaap_PlanNameAxis_e352a853-09bb-4312-a4cc-aae28565a37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e352a853-09bb-4312-a4cc-aae28565a37a" xlink:to="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2014EquityIncentivePlanMember_42f23194-69db-4a10-9dd9-e08abcb5f1d8" xlink:href="infu-20251231.xsd#infu_A2014EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:to="loc_infu_A2014EquityIncentivePlanMember_42f23194-69db-4a10-9dd9-e08abcb5f1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_A2021EquityIncentivePlanMember_5f8ae7e4-926d-41b0-b639-90625dda1175" xlink:href="infu-20251231.xsd#infu_A2021EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_47f38c43-4170-4904-a873-947b016cfb96" xlink:to="loc_infu_A2021EquityIncentivePlanMember_5f8ae7e4-926d-41b0-b639-90625dda1175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9a9c0cf-272c-4229-8d9c-ae68b4d9da97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16d7f197-bcd3-4cb7-98b2-88e7a719ed7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16d7f197-bcd3-4cb7-98b2-88e7a719ed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2e0df83b-aa3e-477b-827c-730aa24e9b38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2e0df83b-aa3e-477b-827c-730aa24e9b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77526338-42f9-4bbf-b7ea-a69a0ddb35ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77526338-42f9-4bbf-b7ea-a69a0ddb35ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9b799676-8538-4a6f-9414-8d12f9745802" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9b799676-8538-4a6f-9414-8d12f9745802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_7221e7f6-e85f-4941-8858-b25c265112ac" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_7221e7f6-e85f-4941-8858-b25c265112ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019c20f9-0ba8-7c53-9d7d-9c37b73015f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019c20f9-0ba8-7c53-9d7d-9c37b73015f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18322358-60b1-493e-a254-85ba843f97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d32a6ee8-6e39-4af1-a565-5a6a001bba8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18322358-60b1-493e-a254-85ba843f97ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a7aece3b-56f9-403e-8bca-6b2961cd9523" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a7aece3b-56f9-403e-8bca-6b2961cd9523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d1465cba-04b3-4071-9d9a-ae504410151d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d1465cba-04b3-4071-9d9a-ae504410151d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab6c1b72-de80-4505-8e55-28080bcc3ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab6c1b72-de80-4505-8e55-28080bcc3ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_120ed536-80bc-44e6-ba6f-7ef418081117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_120ed536-80bc-44e6-ba6f-7ef418081117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15a68338-d779-4615-bf39-e5060dacd712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15a68338-d779-4615-bf39-e5060dacd712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice_2d301b0f-6ff5-4229-9667-2618ae5df966" xlink:href="infu-20251231.xsd#infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice_2d301b0f-6ff5-4229-9667-2618ae5df966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_355e1d20-6db2-4752-b36f-64b305c1ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_355e1d20-6db2-4752-b36f-64b305c1ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d20a3353-31e7-492e-8de7-6afbaa5757c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d6a37191-b401-4757-9b6f-cdf401eac6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d20a3353-31e7-492e-8de7-6afbaa5757c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_002c2a86-66c8-4f73-855b-d77247b1bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_002c2a86-66c8-4f73-855b-d77247b1bb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87a5debe-751d-4dcf-a1d6-2f7593f6eb46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_85770f31-c35e-4b3a-9fdf-7046806e74bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_85770f31-c35e-4b3a-9fdf-7046806e74bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_54d1895e-6ff5-48e4-809a-815a651b3396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_54d1895e-6ff5-48e4-809a-815a651b3396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e42ce06-b48d-4714-8ee8-908ea0fccb93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e42ce06-b48d-4714-8ee8-908ea0fccb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c34f5c13-a7d1-411a-aa8a-d9219e68743b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1aca4b31-09e2-4dc1-b495-df11fff25314" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c34f5c13-a7d1-411a-aa8a-d9219e68743b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ebf249fc-e3dc-452c-a357-034da92ae4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08e65345-dbdc-4b5a-84ac-5235831e1116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ebf249fc-e3dc-452c-a357-034da92ae4d2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08e65345-dbdc-4b5a-84ac-5235831e1116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9c9ff705-94b8-47cd-b66a-b26d508883d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08e65345-dbdc-4b5a-84ac-5235831e1116" xlink:to="loc_us-gaap_AwardTypeAxis_9c9ff705-94b8-47cd-b66a-b26d508883d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c1771af-03da-4f81-943c-503a4e2f0ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9c9ff705-94b8-47cd-b66a-b26d508883d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c1771af-03da-4f81-943c-503a4e2f0ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93694703-efd5-42eb-a42e-246098f00b14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c1771af-03da-4f81-943c-503a4e2f0ffc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93694703-efd5-42eb-a42e-246098f00b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08e65345-dbdc-4b5a-84ac-5235831e1116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d5b7624f-69f1-4f28-a2ff-b5231aa2c2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d5b7624f-69f1-4f28-a2ff-b5231aa2c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7c2ec54e-8b11-4fd5-93a2-aa31e114a460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7c2ec54e-8b11-4fd5-93a2-aa31e114a460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1775ba2b-7e9a-4017-a581-c1d0436cb03a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1775ba2b-7e9a-4017-a581-c1d0436cb03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12d96ce4-07c3-459c-a956-55d780547261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12d96ce4-07c3-459c-a956-55d780547261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b40e2160-2fae-4e5c-85fa-063c49579ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b40e2160-2fae-4e5c-85fa-063c49579ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bb09fb89-e791-48ab-9ffb-2df158083584" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bb09fb89-e791-48ab-9ffb-2df158083584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e5147-0be7-4b06-b555-0dde1488f0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c4d78d5-2894-4a5a-846f-3d568f3114bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e5147-0be7-4b06-b555-0dde1488f0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/BusinessSegmentInformationDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#BusinessSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/BusinessSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ef13c4ff-e736-480f-bb78-14bcbf14f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ef13c4ff-e736-480f-bb78-14bcbf14f0f5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d8e3cb59-a473-41cb-9e2e-24cee2977f97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d8e3cb59-a473-41cb-9e2e-24cee2977f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8e3cb59-a473-41cb-9e2e-24cee2977f97" xlink:to="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PatientServicesMember_d07c997a-0367-437a-8c20-88e08af9c23d" xlink:href="infu-20251231.xsd#infu_PatientServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:to="loc_infu_PatientServicesMember_d07c997a-0367-437a-8c20-88e08af9c23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_DeviceSolutionsMember_6df30fee-ab75-44be-b63e-3a2d6c6ff9a3" xlink:href="infu-20251231.xsd#infu_DeviceSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bea5d9ec-b342-43ac-a10e-72509c3e83e9" xlink:to="loc_infu_DeviceSolutionsMember_6df30fee-ab75-44be-b63e-3a2d6c6ff9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2a3d563a-7046-4750-a83b-3329a7e11d15" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:to="loc_srt_ConsolidationItemsAxis_2a3d563a-7046-4750-a83b-3329a7e11d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2a3d563a-7046-4750-a83b-3329a7e11d15" xlink:to="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ceb04209-a419-4fdb-a0dd-447a4155bb79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:to="loc_us-gaap_OperatingSegmentsMember_ceb04209-a419-4fdb-a0dd-447a4155bb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_CorporateAndEliminationsMember_0e114ea4-a9e7-4046-9b68-e02806c93b32" xlink:href="infu-20251231.xsd#infu_CorporateAndEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_06398402-9534-4517-88c0-a8cf817f6750" xlink:to="loc_infu_CorporateAndEliminationsMember_0e114ea4-a9e7-4046-9b68-e02806c93b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c28e7f98-29dd-405d-ba53-f7a9e01f68ae" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesExternal_d1891545-3d64-44dc-827d-33af8516080c" xlink:href="infu-20251231.xsd#infu_NetRevenuesExternal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_infu_NetRevenuesExternal_d1891545-3d64-44dc-827d-33af8516080c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_NetRevenuesInternal_a75b47b4-4f78-457a-bb3b-0d68ead2da97" xlink:href="infu-20251231.xsd#infu_NetRevenuesInternal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_infu_NetRevenuesInternal_a75b47b4-4f78-457a-bb3b-0d68ead2da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f24c2e39-e40c-470e-8248-edf9d0297496" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_Revenues_f24c2e39-e40c-470e-8248-edf9d0297496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_98666ce8-aa74-4d3b-a909-854a9342b59b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_SuppliesExpense_98666ce8-aa74-4d3b-a909-854a9342b59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_2d62d42b-0e60-4731-8437-0eaa054f3283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_LaborAndRelatedExpense_2d62d42b-0e60-4731-8437-0eaa054f3283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_732c30eb-73ea-403b-9d01-8c34d9b0588d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_732c30eb-73ea-403b-9d01-8c34d9b0588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_183be89b-1803-4a67-b532-ae5455e722af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_a94062e1-b3de-4553-916c-eb10a98ea5ca" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_183be89b-1803-4a67-b532-ae5455e722af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a186535d-3518-478e-b6f7-5a44b5371772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_GrossProfit_a186535d-3518-478e-b6f7-5a44b5371772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d6d2bd8d-9649-4dad-a78d-2cc8a0f8813b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_OperatingExpenses_d6d2bd8d-9649-4dad-a78d-2cc8a0f8813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_9cd11a24-0993-4b8f-8c31-3516d101d5af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_InterestExpenseNonoperating_9cd11a24-0993-4b8f-8c31-3516d101d5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c8a8cdcd-2b83-4dad-8e40-a50d659b8196" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c8a8cdcd-2b83-4dad-8e40-a50d659b8196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7910595-d67e-489b-be62-7df1df747167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7910595-d67e-489b-be62-7df1df747167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_46ed262d-3eb2-4f62-9352-bed37d37c938" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_Assets_46ed262d-3eb2-4f62-9352-bed37d37c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_infu_PaymentsToAcquireMedicalEquipment_bd0b2caf-4f37-4931-9291-e462aaf785d6" xlink:href="infu-20251231.xsd#infu_PaymentsToAcquireMedicalEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_infu_PaymentsToAcquireMedicalEquipment_bd0b2caf-4f37-4931-9291-e462aaf785d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_45596180-22fd-452c-9ff8-e136277c5900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e839eb24-10cf-4701-b88c-ca1b7715f02b" xlink:to="loc_us-gaap_DepreciationAndAmortization_45596180-22fd-452c-9ff8-e136277c5900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://infusystem.com/role/EmployeeBenefitPlansandOtherDetails" xlink:type="simple" xlink:href="infu-20251231.xsd#EmployeeBenefitPlansandOtherDetails"/>
  <link:presentationLink xlink:role="http://infusystem.com/role/EmployeeBenefitPlansandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6229d942-38ea-46ec-a6e3-903e1b33f701" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_a0e7bb4a-d3d2-4bc4-bc24-569c3aa46d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6229d942-38ea-46ec-a6e3-903e1b33f701" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_a0e7bb4a-d3d2-4bc4-bc24-569c3aa46d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_47e97279-f454-4e2b-9c7f-ffa0d6e759fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6229d942-38ea-46ec-a6e3-903e1b33f701" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_47e97279-f454-4e2b-9c7f-ffa0d6e759fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>infu-20251231_g1.jpg
<TEXT>
begin 644 infu-20251231_g1.jpg
M_]C_X1$817AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S:"D ,C Q.3HQ,#HP-" P.3HR.3HU
M-      #H $  P    '__P  H ( !     $   <7H , !     $   (]
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #]H         2     $
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M<W'J]M&740W_ (JP[W!O_%/993_Q:VFX^%TOZIQU&HV"\"RRL2";;(=4W?\
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M.$))300Z      $/    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    6 $@ 4  @
M $\ 9@!F &D 8P!E &H 90!T "  4 !R &\ (  X #8 ,0 P       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! !+     $  0$L     0 !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$         @  .$))300"
M   "   X0DE-!#        $! #A"24T$+0      !@ !     CA"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  .7    !@             "/0  !Q<    Q $D ;@!F '4 4P!Y ', = !E
M &T 7P!3 $$ 1@!% "X 4P!- $$ 4@!4 "X 5 !2 %4 4P!4 $4 1  N %\
M4 !- %, 0P!? %, = !A &, :P!E &0 7P Q #  +0 Q #D    !
M                  $             !Q<   (]
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   (]     %)G:'1L;VYG   '
M%P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "/0    !29VAT;&]N9P  !Q<    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
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MP  1"  S * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$
M 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$
M P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#N
M?K/]:,?H5(8UHNSK@3523  X]:[]VK=_V]_VY97C?5?J?UGZQGN=G!S^EVL=
MO=L])@_T?V6VL,M>[=[?YRS]&M#IOU>JSNIY/7>JL%S[;7C#H>/:RJLFFBQ]
M;O:ZRQC/49^Y_.?SRWLW(^RX=^5MW^A6^S9,3L:7[=VNW=M5DRQPA[<8">26
MDIR_1EVA_=8.')*?'*9A"/RXX_I#][)_WKA=5Z-U'!:[-Z/EY %?N?BNL=9H
M.75"XV;]O^AL_P"M_P"C1OJ[]9/VB?LN4&MR@W<Q[=&V-'):W\VQOY[/^N?\
M7+ZL?67]OLR'?9OLWV<L$;_4W;PX_N5[=NU&QOJW@8W5#U*ISVNESF4Z>FUS
MP6V.;[=WYSO9N4,X2@3"8J0982C,"43<2ZR28D-!<= -25P6)]:?K;UK,>>D
MT,&/6YKG5AK26UN=[?5LN>S?8Y@=_-)V+#+()$$ 1^:4CPC5;DRQ@8@V3/2(
MB.(Z;O?)))*)D4DN:ZC]<ZJ+W485(R-AVFUSMK2X?2%36M>ZS^NK/0OK([JU
MSJ'8KJW,;N=:QV^L>5A(8ZM[OS&HT46'<22202I))5,[JG3^G!AS;A3ZD[)!
M,[8W_1!_>24VTE%CVO8U[#+7 %I\05))2DDDDE*2232$E/\ _]#I>EY^<SZU
MV49%[W,MMNJ=6YQ+(&^RC8QWM9[6-V;5T?6?^1\[_P +6_\ 4.67]8>AY-F0
MSJW3!.926N?5^_L^@]O_  C?H/9_A:O^G:R>HT9_U?SK636]N-:+J7@M?6_T
MW;J[6.VN:GQ^:/F%IVEY%X_ZI9E^#T#K>7C$-NI;4YA<)$P_\U&I^LOUSZAT
M^R_"K::\4N.3DL8SPW^FRNT^[TZ_<_TV6V*E]7W-_P":OU@U&E=7?R>M[ZBD
M'ZKYI!!BZ[_SW6M#-PQ.69A&<ADC'U#O"+0P<<AAQB<H1..1/#W$D&#]9/K'
MU?HC_L%==O4,:YK<@PP-=COKL<+=MSV,]3U6;7;%D?4A_7&YCATJMK\9UF.,
M]SMLMJW/U;ZCV._F_7_F]ZT/\6Y!QNK01_-T_P#4Y"G_ (KR#^T8,^W'_P#=
MA+)PXX\S&,(U$PZ?O]_[OZ"(<627*RE*5R$[_P #_O\ ]-O?5/ZQ=4ZIU?+Q
M<M['4TL<ZL-9M,BS8W7^HFQ/K%U6[ZXV='?8S[&U]K0T, =#:R]GZ3^LN>Z-
MU:OZL_6#.^WU/</TE+VL W@[_4KL#;'5M=6]O\I%Z!F_:?KO]MLK=4;C=:*B
M"7AIJ<^OV#W/<ZK:[VH3P1!RR$!P>U<#_6K>*Z.>1&./$>/W>&8_JW+0MS"N
MS/JSGN^U8V_V^EN=[0X R+,>_:YOO_.9_GK?KZW5GX.6_I ^S]28WUG56,&Y
M^W:''V2V[<P>CNW?Z-4V?76BPWUY6(74DD5M&TNV\;,FJTM:VS][_,57ZK4/
MRNMOS:*O1Q:O4)#=6M]3VUX['?G;=V[_ %8L_P V]Y.S]6^NOS\*]^8]OJXQ
MW/>!M'I.&]CX_LV-_L++Q?K1U5V/EY]NQU->UE%.W;^DM=^BWV?NT4M_2?OJ
MAU:FSHW4<W'J]M&740W_ (JP[W!O_%/993_Q:VFX^%TOZIQU&HV"\"RRL2";
M;(=4W?\ X+TXK9ZGYGII:?:G]C6P>H?6_+%>3CNINJL?MVD,#6ZZNN:S]/6S
M^V^Q5/K6[J9RHSVAN*'6?8W#;)9#-^[8YSO\]JSLIW3*S5=TN[(;>>6O #VG
M\WTKJ=KK';OS?>MKZW-RG].Z9;DB+-CFWNB +7LK.TQ[6^YEB75'1NX74^L=
M/P;\KJ]3?L]==8Q&LV O<Z6AGL>__@_I*H.I?6W(Q'=3J-5>*T%XK:&DEC9W
MO:VS=8YK=O\ I*]_^#8I9.:SK_17XN%79]IP6U6OK('NC<QS*MKO?[6V;/:L
M/'_8'V5S\O[3]L9/LK+ QQ'T?<]A=3_PGJ)*>AO^LV5;T$9V/MJRF7-IN$;F
MR1NW,!/T+&[52LZ[]9WX3,Y@%>(R&/N#&$/?.QSRUYW^GZGZ/V-_ZXAY./A5
M?5C[3C"ZMN3D5%S<@B06@L_1N:VO?4[\RS\]72YO_,*9$;1KV_GTOXJ_@BM^
ML'UCS,8Y>'4*<?&;&3:P-?+P-UCVB[W>DUOYC&/]/_"6K1Z-<>N4TYF2=F3@
MV%CMFC7:-<U^W\W<QW_;BJ]%<#]3\X@B-N3K_9<B?48@X65!!_3#C^HQ!(?_
MT?55%S&.!#F@APVN!$R/W2I))*0MP\1C'5LHK:RS1[0T .C]YL>Y2KHIJ865
M5M8PZEK0 "3Y!9_4.MC"ZEBX!H<XY,1:Y[*V:N%7IU.N<W[1D-GU'8[/TOI(
MN1UC'Q^J8_37M<7Y#9]0?083O]!ECC^=D^AD^C_Q"?P3-;ZCB^D>JWBC]AK[
M6U5C8U((IJ96'0'!C0V8XG:GIQL>B?0J95NB=C0V8XG:LT=>8>NNZ,*AO9$V
M.MK:3-?VB:L=SO7N:WZ+_3:ET[KS,_J63@LJ#/LKK&.<;:R\FIXIW?9FN]=E
M;]WLL<U$X\E$GL)G7]$_*KCC=>)C]6_?@8.18VW(QZKK&?0?8QKG#O[7.!4A
MC8XM]<5,]8_X3:-W&WZ?TOHI\B[T*++MC[/28Y_IUC<]VT;ME;/S['?F-633
M]966=$OZN<<[:#'HUV,L<XG9#/T;OT=WZ78^BW9;ZB$8SD-+(OAW_>Z*)B#K
MY_8Z5W3\#(?ZE^-5:_\ >>QKC_G."62\86!=9CU _9ZGOKI:(!+07AC0P?G?
MU55Z;U["ZGF78V)+V4UUV>MPUWJ;I8S\[=3MVW?N6_HOYRM1P>OXN=C9>14Q
MX&&7':8FRL#U*<FK_@<EH_0I'',7<3I5_P"%\JN*.E$:W7T>?:SJ/UCZO1;D
MXKJ,6F-X+7!@8T^H]N^P5^I9>[;7[/\ !KLR 001(.A!6/TGZQ_M7%R+<;%<
MZVAC'MJ;96YK_4#G,J]=CS75>W9^FIM_F?T?^D5KHW4W]4P_M9QW8U;W$5!S
MFN+FC0O_ $9=M]^]B4L<HW8KAT.H_25&435&^+79L58.%2_U*<>JM_[[&-:?
M\YH17ULL866-#V.T<UPD'X@JAUCJM_36TNKQ'98O>*AM>QD6/+:Z&?I2W^=>
M_P#ZVJO5?K/7TO*JQKL9SWV5-M<&OK#O<[TO2IJ>YKLJ]KO\%0E'%.54+NZU
M'Z*C.(NSMX=W6HQ,7&G[/373N^EZ;0V8\=@"C9@X5MGJVX]3[/WW,:7:?RB-
MRI]1ZY7@'*#J7V?9*J+G;2!(OLLQVM&[]ST=Z63UL4=7IZ7Z!)M /JN>RL'=
MN_F&6N:[*]+9^G;3^DKWUI#',ZUTO[/5_P!THR'?^1=&RNNUNVQC7MYAP!$_
M--Z-/I^CZ;?2_P!' V^/T?HJA3U7*LZM9TYV"]C:@'NR#966^F\V-HL]-KO4
M_3/HL;L_P?\ A$+I?U@9U&S):VD5LQ=VX^K6Y\L>^KWT,=ZM.[TMS/42]N=$
MUL =Q^E\JN..W>QMV=1M-+6&MK&MK,RP  &?I>U*NFJH$5,;6#J0T :_V5E=
M-^L)SJW3AV4Y!QFYF/2YS'>K4\?HW5V5N<UK]WL?7;LV;UI8MUM]6^ZAV,Z2
M/3>6DQV=^B<]ON0E"4;O2O%(D#L__]+U5)?*J22GZ-^L7V/U*O5GUM]'I^K]
MI^R?SS8^U_9?U/=N_HWVG_#^G_@EE]7^R_\ .%^_]G_S^+ZGK?:/M^Z:O3^P
M^E_8]/[+^@_G/M7^'7@R2L0VC_.['Y?./R_U6*77Y-Q\W[7Z8Z?Z7[7ZKL]/
M?OI]39ZF_P#FF[?6]7]!]'Z'V;\S^=_2JATW]G>KU&/6]3U,KU?0^V^A&\^I
MLW?JWV[]_P"Q?I?5]3[,OG9)-'7^<VCMY?I?U?\ -I[?+O+^7_?OU!^A_9FF
M_P!'T/SO4]3;L_.G]<]3;_Z$_P#75SY^P_LSJFS9Z'VG'G[5]L]>?U6/M_K?
MK_J?0^R^G^B]'T=_^&7S^DE#K\_S#Y/[W_33+_!V/S?R^5^B*OLWV_.W_9]W
MV2_?]E]??L^TY?TO1_1^K_W(^S_KOV_[3_P:S_J]]E]+._Y.G["W_D[[1Z7I
MQ;_3_P WUOW/^]#9ZR\'23AL?YWI_=_PO^Y6]1\G7^]]/^Z?H_ZM?9_T_H^G
M/IXL^AZ^S;]GJ]+?]J]OK?U/T_V3[']K]Z;H?V3[#TO9_P -Z/V?[3Z'+_4W
M^M_T?M_^$_HR^<4DV6\OYSIO_<E\_P#+^;2/T?D_E*/ROTQUSTO2Q/5]./MN
M-M]7U(W>HW9L^S_X;_1>K^K_ .G_ $:S^N?9/VC9ZWISZ&-N_I/K;?M;8]'[
M)[?4W_T/TOUG[7]/] OG=)#'^C\_^!]/E3+K\O\ A?M?H/ZQ_9/VB/6]#U?3
MQ_3]7[3LG[0[_E+[)^J_9-W]"^U_]J_4_P &K'6OL?[5P]_](]>C;Z_VG[/&
MYWT/2_R?]O\ ^XGJ_P"$_P"M+YT23AM'^<^66W_<?U?WD'<_)N/Y2_[E^FZO
M3_;F5&SU/LN/NC?ZFWU,O;OW?J_I_3]/T_TW\[ZW^ 6?T+[#Z.1Z&_U)O]2/
MMGV3^=LW>C]L_5O4W?S_ -F_PGK>G^C7SHDFC:7S[1_N_P"%_P"HTG<?+U\_
M\'_NGW[H?[.](^E'I?9\+=Z?VWU]V_V>A]I_6?V3N_HWH_H?Y[[1^B]1=8OE
M5)+-\WZ>_P#E/FZ)A\H^7_!V?__9.$))300A      !=     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    %P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 0P @ #( ,  Q #<    ! #A"24T$!@
M    !P ( 0$  0$ _^% J&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M  $  /;6  $     TRU!1$)%
M                           *9&5S8P   /P   !T8W!R=    7     K
M=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&03)",0  H[@
M *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M=  '
M[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V,@
M
M                                          !T97AT     $-O<'ER
M:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U6@
MO&<  )(P;69T,@     $ PD   $                    !
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MXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-4\: "*A6-TV
M"J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z $KIZ;-5_W[3-
M4SQ_NK!(-M%_O*40$"I_](KNW3R287R8QVN0>GQ#L5:.LGP0FL>-&GP1@Y>+
MMWQ):YZ*@GRQ4G6)B'TR-HZ))WX!$3*+UG_>VT:1+8;+Q@6/0H6$L"J-@X1O
MF;*+_(.0@H.*K8+R:HR)C8*(45Z(HX) -7J(28)@$ 2*F(.&V;.0 )$DQ)V.
M(H[MKOV,8XS?F("*\8LF@56)LXFR:6J(IHA\4$J'RX=V-':'>8<%#OJ)5H:[
MV$>/")N2PRZ-,IA[K8&+AI67EQZ*$Y+]@!>(Z)"^:%.'YHZ\3UN'$XS_,YV&
MPHP=#A2(*(F$UNF.2J85P=&,>*(FK"2*U)YSE=*):)L*?N:(,I?J9TN'/I4M
M3GV&;Y+,,MF&')'!#4Z')8C_U:>-L;#'P)N+XJP JO:*/J=WE+2(UJ-!?>*'
MI)]<9EB&IYO:3;6%W9CY,BR%BI?R#*B&2XB/U)"-,[NEOY*+9[8%J?*)PK"F
MD[Z(6ZND?0J',*<(99Z&-J+G30R%7Y^O,9V%"YT_#!Z%EX@QTZ.,R\;'OK.+
M \!)J1:)7KH4DN>']+1)?$*&S*\$9/:%W*IW3(>%!:=E,22$HJ$Z"ZZ%!(?F
MTN",<M)7O?N*L,KQJ%V)#</ADC&'H[U3>YV&>K=\9&F%B[+'3 V$O:YG,+>$
M7*#P"U6$CH>IS/N;\GM;N).91WLAH_:6N'L)CMZ48'LF>16217MX8FF097OY
M2G*.VGR3+V..-7U^"GZ0'W_ RSJ:XH3]MV:8(X/GHP&5F8+\C?J338)+>"N1
M0X'887R/=8&:27Z-]X&!+GF-5X'C"<^.FX,(R=.9WXZMMAR7)8S"H>64F(KX
MC.&26XF)=R&07HA48(..GH=>2)B-*H:@+:>,C(:="36-1X7HR*B8YYB.M..6
M/97.H*>3O9,TB[N1<I#M=@./AH[_7W^-THU21[&,9HO[+-Z+S(O-"*^,'X7?
MQWR8+**&L\:5A)[ZGWN3"YNLBH20TIBJ=.R.V97T7H^-,9.@1NZ+Q9'$+#N+
M)Y&^"#R+(861QE^7FZRELK*4]:A9GFR2?J1*B8202J"-= &.4YTC7;B,G9HG
M1D&+-)?W*ZZ*E)<[!]N*3(50Q6:7)K;LL<F4@+'>G8F2"*T.B*J/U:B:<T"-
MY:2/71.,,*$31;&*M)[3*SJ*$IO(!XN)FX4:Q)*6P\%XL0>4'KNEG,F1I[86
MA^Z/<K#N<H^-A:Q57'V+VJB913Z*7*9!*MF)J)SY!TJ)"X3NP^*6;LQYL&>3
MRL78G"B15K^%ATZ/([FS<?Z--K2J7 .+C;$31-6*&JQ"*GR):9RZ!Q:(F83+
MO3^ET'IZJARB:'I-EM&?''I%@Q2<"'IR;IV9.'K462R6LGMD0E.4HGP*)_.3
M\WS]!*J3?W^FN[.DXH.4J2JA6H*<EA6>"H'0@F":_8$^;=N8.H#K6&.5PH#.
M08*3O(#;)S23"X%U!&B2 X*:NHBCZXS"J!>@:(L!E22=%8EN@6N:%X@I;/&7
M78<G5XJ4[X9F0+R2[H7H)HZ2.(9;!"^0M(+4N7RC&Y7UIOV?HY-ZD_^<69$Y
M@%^93H\S:_66G8V15JV4-(PQ0 *2-(LY)?F1=XO9 _V/DH*RN):B59]HI@J>
MZ9PSDOZ;JID_?U:8II:+:P25V)0N5=F3?)(_/U*1?I#L)6Z0OY%6 ]..F8*6
MMZ.AR*D"I36>5:45DBZ;$:%K?H*8$9X9:CF55ILB52*2ZYBL/L.0[)<_)0&0
M)Y8+ Z^-R()]MLNA5[*]I&V=X:X>D6R:G:G&?<J7H*71:9:4ZZ)25):2@)^#
M/D^0;)Y4)*R/H)C, Y&-&H)IM@^@_KRVH\:=@K=AD,J:/;)<?2R7/ZW,:0&4
MCJG@5!>2+:<-/>^0$J3#)&6/,)B; WF,C8)9M7&@K\<LHSR=+<$7D$&9ZKM?
M?*66\+8_:(B40+(24[.1X*]'/9N/TJFH)!^.])AL V6,'8),KAZO_GGDG"FK
MWGFVBA"GWGFR=XJD%WGF9$>@F'I03_F=<WKF.A^:]GN-("F:F'QQ  "5TW_*
MK,ZO*(*#FVBJY(&9B7ZFVH#@=ONC$X!C8ZB?FX F3U.<?X C.72:!8!,'Z&9
MEH$7  "4CH  J]^N/8LNFHJI_HF-B+VE[8@:=C&B,(;[8N2>O(8@3I^;IH6.
M.-69+(5+'RZ8JX9&  "3<(  JQ*M:I/GF:JI-Y&:A\RE,(^$=5"A:(V]8A*=
M_(Q13>B:Z(LX.$&8:HJB'LJ7UXNS  "2>(  JD&LRIRTF-JHF)G"AO.DE)<7
M='6@SY3 84V=2Y*P34*:/9$H-[^7N)!K'G67%)!A  N1DH 'J9"L+*7,F"^G
M_*(QADBC^9[B<\J@-9OO8*J<LIE<3*^9CY=K-TV7"I;E'BB67Y18 !N0Q( 2
MJ.*KN:\#EZ*G?:JXA<*C<J;#<T"?K*-#8"F<-J!/3$&9')X[-O:6@)U]'?.5
MR)1  "B0&8 ;J$*K8;ATEQFG&[-[A4.C#:[G<LB?2*KD7[N;UJ>I2^&8Q:7C
M-K"6(Z+K'<R53Y0F #./CX BI[FK%<)>EJ:FQ+RKA-:BMK=Q<F*>]K+Z7V.;
MAJ^Z2YR8=:T?-GN5W:36':>5"90- #R/(( HG["ZA'ETCM6UJWDZ?=&P_'DR
M;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(  GJ:YMH&DCD*T
MPH"]?6*P!8 -:_.KC'^>6;BG9']R1FRCKG^#,6R@WG_!%["A.X"Z  "0;H
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M1*>E>IBL@J03:2^H!*$%5R6CU)Z71#F@")U)+\2<\)PG%Q6<J(^;  "."H
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M"(<G<5ZXGH7<8-NS=83S3Z&NGX19/5*J6H09*2.G2H1.#Z^H3X3N  ",P8
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MH:R3;_:U'ZC+7XVOXZ783G>K":0:/&^FO*+_*+.C4YN%$&RC1(L;  "+_X
MCM2_\+G)?ZZZ+;2;;^VTF[ M7X>O4:SZ3GNJ<*M</("F(*?U*-RBR)N@$+"B
MN(M(  "+ZX  A+30GWCS==?*67B#9J[$;WA;5Q&^UGA]1K.YDWC:-0>U"'E8
M(/:R=WFN!^NRV7M%  ")^8  A&+/GX!N=9O)?G]G9G##C'ZM5LZ]UGY$1G&X
M='XI--FSS'Y0(/:P_GZ?"&>PZG_G  "*%H  A$K.A8?%=6_(?(9!9D/"A83Z
M5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X  A$;-?(\6=5_'
M;(T99B#!<HMG5G:[FXH:1B2V*(E(-+6Q9HC^(2RN28GD"5VMFX95  "*18
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MQ;#J9F2]DZSR5O*WHZIF1L*R):C?-8BM5J0R(F6IVY=!"T>HL(>@  "*B(
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M-92:?ZF?PI)_;@*<B)"?6YR9B8[V2"R6_8V_,R:5 HTO&<B5+8SM  ")KX
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MN'0W=I"LHG3"9>^HQ75L5&>E*W8Q0:*B"'<#+/"?^'>L$FZB''>L  ")?H
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M9II+<]2H.)?58R^D096M4<Z@E)/E/V:=69+#*T";"Y,3$A";\HPV  "&LX
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M"'K4:JZU/'JL6O2PJWJV2D^L;GKN.%^HU7M#)#2FQWN!"I^H+GQB  "%MH
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MVI]D:/6P[YRN63FL/IIK2,*G[)C;-SFD+)BJ([JAF):C"YRAE(?9  "$FH
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MGH#87T>^/8 /4$ZY"W^@0'VT.G]M+U"P1W]W&WVNDG^K!)>L28!U  "#(8
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M6Z/]7ORYP:$L4!:T89\40&>O=9Y9+XVK5IS3''BHX)- !H>EZX1J  "#'(
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MUA5_#G&VP>5_$'+*K/1_'7//EQ]_-731@'5_5G7=:.Y_B';V4#%_SW@(-)J
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M"8#*A>F3VX!E<^V1Y8 <8060'7_Q30&.F'_?-V.-@7_6'7>-_G_S  "'<H
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M,:P+@:N0!ZA&;\>.!*2G72V,1*&*2::*SY]D-+2)F)W9&XN)AY*?  ""_8
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M8X=$>1B;AH93:$Z8V86$5H"6<X3C0Y.49(1J+MZ2_X0K%0>4/H2   "#*(
MEWZ@?)#=B$.=?(]">$>:H8V]9W27]XQ85=&5@8L:0OR3>XHU+FR2#(G1%,J3
M&XE   "";(  EM>?L)FKAY><N9=Z=Y>9WY579LF7+Y-352^4MY&-0GN2FY!
M+@R1)Y .%)*2%(U&  "!SH  ED:?'**/AQB<*)_/=Q691)T-9CF6BIIT5)V4
M%9A!0?^1_);)+;20;9:%%&&1.(W(  "!2X  E<Z>L:N7AIV;O:A.=I*8TJ3Y
M9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  " X(  E76>8K3PACN;
M:[$I=B*8>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV% *0#(V'  " BX
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M38T-;1ZCP8NT74&@8HJ!3(F=3(F).HV:P8CL)I29,8C_#3^:7(<]  " &H
MBA"J09;$>ZZFEI3-;)BC!9+L7+J?H9$Y3 F<A8_1.C*9W8[T)EN8/X];#4*9
M)XCW  "  (  B:BIGI\@>T"E^)RK;":B9)I&7$B>_9@82Z&;WI9<.>.9+I6&
M)C:77I3<#4J8$8C\  "  (  B4NI-*>G>P6EBJ2]:^>AY*'.6_B>8I\C2TJ;
M.9TY.8J8F9RL)?.6RYER#4J7.8C\  "  (  B0.HZ+"">KRE,ZTJ:Y6A@JG
M6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (  ?W*Y_VUL<>&U
MP&YI8[&QO6]Q5*NMZ7" 1)FJ8'&-,P&GDW)X'KNFT7+!!;VG/W-M  "  (
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MK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>HX32  "  (
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ML72+6#J[!'352?&VAG5 .I:R=G6_*8VO?W8A%16OQ'6[  ^IZ7CG  "  (
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M8I;@5ZZU?Y4*26.PSY.-.C^LD)+"*;:I.),'%F"H+8\A D>AM(&*  "  (
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M^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!6(W=  " ((
MIN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z'E&
M;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%. .9S9
M-S=_WYNU'?A_IY1$  "  (  I>.#+;<:E:2"8+,SA%Z!?*[K<CR J:J@7WR
M$*;O2]=_KZ1Z-LU_6*%Y'9Y_#90'  "  (  GJ:5'FE.C]23)FLC?^Z1>6S4
M;LR0 VYJ7(V.L&_V20^-G7%T,]:-$'*R&8>.HG+V  "#%GJ\G>R3E'):CQ:1
MR'--?Q20)W0S;?J.K'446\2-6'7Y2%6,17;9,RB+K7>*&/V- '>#  "!H7X?
MG1B2$WM.CA"08GM]?B&.QGNG;0"-6'O86N",#7P81XZ+ 7Q?,GZ*8WR1&'Z+
M?'QL  " 6H  G!F0MX0KC/V/"X.S?/:-?H,U; F,$(*X6?J*UH)81LZ)TX()
M,>6),('-&!&*$H'9  "  (  FR:/A(TLC "-XHP0>_B,7HKI:PB*]HF_62V)
MM8BR1AR(OH?<,5F(%X=0%["(QH=8  "  (  FE*.H)91BS^-!I28>S>+?I+$
M:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "  (  F:2-[Y^"BH>,
M6ITP>GF*S9JU:7J)7I@]5ZV((98*1-6'')1;,%Z&5Y/T%O^&LH^-  "  (
MF1R-:*C,B?6+V*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&BYM)+^:%O9HI%KZ%
MX8]A  "  (  F+V-"+)6B82+>Z[Q>5:)W*LY:$Z(4J>05I&'!J240]6&!*+V
M+X:%.)\=%FN%2(\H  "  (  D-B>X6C,@M><3&J-<]^: FPT8\27[VW%4H>6
M"V])/^R4AG"Q*TJ3Z'&S$&R6WG$O  "  'W0D$"=C7%C@DB;$')1<SR8PW,Z
M8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (  CYB<(7G9@769
MNGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3+WLE  "  (
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M4J)#;P"3 Y^37O:0S9SQ3AV.W)K4/":-3YG<*&N,.)@:#TN,K(I7  "  (
MC &7/:W$?<.4]*K<;I&2FJ>H7H*05J213;2.6Z)1.\^,QJ#U*!^+KYLA#QR+
M^8HW  "  (  @XFI$V@W=CRE]FG@:!6C'FMX6.*@>&S^2(N>#FYR-K*<-6^W
M(EZ;XW!:"%B=KW @  "  (  @Q*G\G!G==ZDUG%'9ZVAYW(L6(&?)W,62#"<
MJW/^-F>:PW3+(BN:1W4>"(";='4Q  "  (  @I:FEGAH=3^CB'BB9R*@DWCE
M5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "  (  @@"E0H!0=)"B
M.H  9E^?3G^V5TZ<C'^"1QR:&']I-8N8*7]?(:&7=7]8"*Z7BW^3  "  (
M@62D)8A'<_"A)(=X9;6>/(:M5I^;>87Q1I:8^H5<-1N7#X4"(5J60H44"+R5
MWX/1  "  (  @-BC2Y!?<VB@3H\992Z=88W+5A6:F(R/1A.8$HN(-,B6!XKQ
M(2N5)(MB",R48(7S  "  (  @&VBD)B'<O>?F9;.9+B<J)4"59V9VI--1::7
M49'R-'>5/)%;(164'I#H".*3#H8"  "  (  @!2B%*#3<L.?&YZY9'Z<%YQM
M55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (  ?]&AO*E<<GV>
MMZ;L9"Z;IJ0R5/J8K:&E10*6#: M,]F3_)Y\()F2V)8*"..1.X8"  "  (
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M6(4N6P6GSX2'3+>D;8/S/7*A9(./+)"?,H-K&-F>]X._ NV:.X'[  "  (
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M0&@.4..WEFEP0R.T!6K&-"JPZ&OT(Q^O/FRB#B&Q2&OC  "?!'.P  "  (
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M'(G)4$2Q (C<0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(    "  (
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M-<""?74X&\B#;W5F  "  'JYH(N!V7;5D6:!B'>+@5V!.W@K<!*! WC 7<"
MWGE52CB UWGD-06 \WI/&S>!FGHL  "  'XZGV: &8 ED#-_W8 B@!=_IX #
M;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (  GCM^L(E]CR1^
M?8C/?P=^4(?_;>1^*X<=6]9^'H9*2)%^,H69,[)^0H4-&CE^684,  "  (
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MG67Q=_",>6@@9Y^+B6HG5AN*NVP50SV**FWA+G:**6]'$\B,FV\4  "  'I
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M2HZR<T.%8(UW8R*$A8PG4B2#S(KP/_*#1(H *]*"_8F>$A^#9X@Z  "  (
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M'VT":YF3:6YG7$61VV^_2[R0>W$&.;Z/@7(G)7B/=G+("RZ1&')%  "  (
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MW9/P9[R-.Y)B6(:+J)#%2&N*38]H-Q2)0HZ8(YZ(LH[&"L:('8=)  "  (
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M0G,A7YV:]'/F42&8T72L08*6\G5H,$25L77^'#:6!77[!%*3Q7=-  "  (
M>,2>$'H=;#*;NWIA7LV9>'J<4'R76'K<0.R5@7L=+].4/'M/&_>49WLQ!'21
MP'Q,  "  (  >!N<OX'O:XB:<H&Y7AZ8-8%V3\B6$X$M0&B4-(#X+V22[X#<
M&[62]8#8!(Z/_8"=  "  (  =X:;NHG?:OJ9<XDX79.7,(AU3SJ5"8>M/^*3
M(H<'+QF1N8:Q&X^1G8<6!*B.=H,F  "  (  =Q&:W9'7:H"8GI#$71666(^&
M3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "  (  =K.:19GK:DN8
M!IB#7-V5KI;+3G.3894,/QZ199/6+F./^Y/2&S"/C)$]!-6,'(-%  "  (
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M WA34_VC+'B<1FJ@>GCO-XF>,WE!)MV<W'EL$I>>,GCU  "4,'QC  "  (
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MI)RH4IF>F)KW1-B;HIE6-C.9%YC/)?R7:I;G$JJ7J8R>  N/BH (  "  (
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MK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".P8    "  (
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MXZ!7?EAM!9V1;35N'9J\6S9O0I@K2#!P4I89,]%PU)4?&SIO-9%Z  "  (
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M*GIR=Y=YA7K;9WEYX7LY5A!Z3GN.0W%ZP'O<+PE[&WP*%69['7NF  "  (
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MCZ6*<WUS]**38U5T49^/4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "  (
MBRR(?EWP?A&'K6#';].''6-J8$>&N&7;3W2&<6@G/2N&9FH[*+R&[6NY#@:(
M_FM'  "  'G3BE&&-&:M?3J%I&BU;NR%+6J:7W.$SFQB3KJ$BFX//(^$?&^/
M*$"$WW"/#=>&26_U  "  'U8B5Z$!V]3?!V#I'"C;>V#0G';7G>"\W+Z3=^"
MNW0+.]B"L73Z)[."]W6'#9Z#YW3O  "  (  B$^"%'?H>OJ!Q7B7;+B!>'DJ
M782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (  ATJ 5H"+>?V
M&X"C:\)_WX"67(M_IH!N3&=_>X!).JA_?8 M)MQ_CH 0#5)__G_H  "  (
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M%H7[8%Z'*H6'4@N&0H3X0KJ%?(1Q,?*$]X0@'FZ$^80[!I&$/(+;  "  (
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M1V9O6+26HFA 2N&5(VGX.[:3ZFN#*J^3;FRK%C"5%VR4 "^0OFZV  "  (
M<$^8$VQ"9**6:FV.6 Z4RV[,2C^336_[.S22$7$)*E:1@G'*%A62W'&% '..
M<'0S  "  (  ;Y.6,7/C8]&4EG2M5RN3!W5E28V1CW82.IF06W:H*>6/P7<)
M%=Z0V7:M **,:WE$  "  (  ;M>4FWN08Q>3#'OB5G&1@GP=2-"0"7Q#.A*.
MSWQG*76.,7Q\%9R/#GPZ ,.*JGVF  "  (  ;C*36X-:8GR1UH,^5=R02(+[
M2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (  ;:R23XLG8?60
MU8JA552/18GD1[.-OXD5.0:,=HAV*,^+G8A1%76+XX@$ 0.'WX"O  "  (
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MN&NX31F>E&SQ/_B<FFX>,7^;$6\:(-":P6^5#'V<;&\&  "*>W>B  "  (
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M2HZ;2M.8'(V^/=B5_8S;+ZZ41(QV'XN3?HRO#(F3)8AZ  "%(8    "  (
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M)F_]05>GJ'"Y-.>E57%M)M^CO''L%@JD3G&K!(2A7'+\  "%07Z*  "  (
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M>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD!6J8<(.I  "!@(    "  (
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M9I#8=D9F-H]F9B%G[8WB50UIDHQ]0M9J](M6+Q5K:HJL%IUK(XG'  "  (
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M6)9$:Y5L?)2!7%UMB9*I3"-NCI$/.JIO6X_V)X!O)X_L#P!Q4(HE  "  (
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M#7+W9)9Z:'0%5BYZNW3W1EM[('73-1=[AW:((71[U';0"+)]<'<+  "  (
M?8!WB7I+</EX"WK<8XQX>7M)52QXVGN91;1Y/WOA-(MYJ7P;(1EYP'P@"*I[
MH7R6  "  (  ?(]UUX+><"QV:X+?8LUVX8*M5%]W1H)<1.5WK((0,_)X H'?
M()]WXX'5"(-Z'X%<  "  (  >\MT<8MJ;V9U$(K>8@QUB8H04Z5U\8DH1#1V
M6(A=,UQVH(?9($IV.X@/"')XV(55  "  (  >S%S4I/P;LYS^Y+@87-T<Y%_
M4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (  >KYR>)Q\;E=S
M)YK]8/-SFYD04I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW"H6&  "  (
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M'7B160Z ZGDB2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O   "  (
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M,'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PN'$GVU  " &X    "  (
M9%J(B(2+65*'YH1W36B'((0O0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "
M (    "  (  8]Z'@(Q%60V&[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!
M#N6#H(?R  "  (    "  (  8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#
M<Y!N(@*"[9 J#MN"78H+  "  (    "  (  7.">\57?4D*=65B?1L"<"%M%
M.?F:^UVX*XF:?5^^&DF;S6"X!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;
M65]51C>9]&%Y.968P&-R*U&8%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (
M6U^:A61#4/69&V7\19^7O6>B.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  "
MEW<4  "  (  6K:80&M:4#B6YVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.
M!RZ2L7 C  "  'ME  "  (  6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1
MJW4M&922''4A!S&0*G7>  "  '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5
M-U&0Z7K#*9B0!'K?&7&0+7K,!SN-^'O1  "  (    "  (  6/"3:X$33I:2
M/H$[0TR0ZH$C-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@  "  (    "  (
M6(B27(A@3B^1.H@[0N>/YH?$-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "
M (    "  (  6#>1CH_E3@F0<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA
M!W*)5(4)  "  (    "  (  4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:E
MV5SW#I>HHUT(  "@"&!\  "  '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R
M+H6CP6#W(%NC;6(K#L>ELF('  "=;&45  "  '7X  "  (  3SVF4V'O12VD
MEF...D&BZV48+A&A?F9Y(!.A!V=6#M&BX6<*  ":WFGN  "  'H\  "  (
M3L>D"VBG1*.B66G>.:2@MFL!+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "
M 'W_  "  (  3DNB"V]Q1"N@:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&.
M #66 '4)  "  (    "  (  3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:
MUW><#MB;J7=> '&3VGI4  "  (    "  (  37.?$WU50W^=@WVB.*N;SWVP
M++>:-WV>'R:977V,#M&9Y7VU +"2"7[.  "  (    "  (  322> X190TJ<
M<X1Q.(&:MH0R+)F9"(/?'PJ8$H/D#JJ8=X-[ +60F8![  "  (    "  (
M3/&=*8N/0RB;E(N&.&29T(L(+(:8$(J.'Q.6\XJO#MF7'HA$ -V/9X"6  "
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M:H(';J)>\H'?7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L$>9H]X$[  "  (
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M6H?*9 ]D3(<T5:YF#8:&1CUGF(7K-7!HDX6"(J1GI(6*"LMNSX1#  "  (
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M0XRQ67AJEHO-2^1KL(K./2ALDXH&+-QLWXFZ&BMK]HG,!)EX.H,<  "  (
M<15F<96-981H&I2.6/=I<),B2V5J@Y&>/+UK6)" +(IKA9!?&=!JM(Z(!&QX
MAX+]  "  (  ;,6"V5)[88*"S57G54B"]%DL1\N#.5P].-:#H5\!)]F$>&$L
M$O2&NV&5  "#.F6N  "  'P#:Y9_A%I.8)!_P5TA5&: !U_01Q" 56)3.$.
MN620)W2!:V9$$M>"^V9?  "!"6IB  "  '\V:H1\4V(C7V]\RV1>4W9],F9\
M1BY]D&AN-XM]^&HG)NI^BFMG$I1_B6L_  "  &]Z  "  (  :6UY9FGX7DYZ
M!&NA4E%ZA6TM14MZ]VZ8-K][:&_.)DQ[VW"A$CE\CW!(  "  '3^  "  (
M:&-VU7'3751WD'+U45UX)7/U1%%XHG31-B-Y"W6-)<AY8'8#$?5Y^'6>  "
M 'GB  "  (  9W-TH'G%7'!U>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2
M$==WN7M@  "  'X)  "  (  9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU
M.8%C)/=U+X%D$:EUVH&)  "  (    "  (  9A)Q28F:6S1R38E53V)S 8B]
M0H)S=(@%-&=SNX>+)')SB8>;$4MT:H;!  "  (    "  (  99AP%I&&6KYQ
M*)#J3NMQX(_;0A-R2XZS- MR?HX")"]R(8XV$1%S/XKP  "  (    "  (
M8*:,;U&85@>+[53<2G>+J5?]/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "
M &EI  "  'YP7X^)4EC^52N)$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X
M":2*J&/]  "  &XI  "  (  7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&
M)&@I'6*&]6C]":.'46CK  "  '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-
M.V>#:FQZ+56#B6V<'..$)&X8"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!
M$G!Q1O2!''&%.HN!%7)O+,"!)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (
M6_1^QW;$48A_"G>%1CU_'W@<.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "
M (    "  (  6SQ\\'X]4-=]3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$
M"8U]TG\S  "  (    "  (  6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][
MMH3#&XU[6H4;"5)\7(/?  "  (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM
M.*=ZS8N2*R=Z=8M(&V)YV8LR"4Q[*H9)  "  (    "  (  5*66W% ]2HR5
M\5-5/XF53U9*,R:5 ECZ),^5=UL6$N^84ENH 8*4I5V-  "  &T4  "  (
M4YZ3_5<_2;R31%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "
M ''X  "  (  4LN1#%X_2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6.
M @:-RV=G  "  ';D  "  (  4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2-
M 6K0$DJ.DVJ= A^*\&RD  "  'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU
M,'2*CV^>(N.*BG ]$?Z+OF_F BV(>'):  "  '\&  "  (  4(*)JW. 1IF)
M9W1<.]*(_74-+^J(C'6/(FF(:'77$>*)'W6( D6&57A*  "  (    "  (
M3^*'XGJI1@R'N'LM.UB'5'MU+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "
M (    "  (  3V"&8X'$18B&4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('#
M F&#$8%U  "  (    "  (  3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#
M@X@:$>2#'8<D M>!M('L  "  (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V
M*%F@*%9.&<.A<U>_"*.C&UAE  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>
M[%=W,WB>&EG%)X^=KUN\&46>H5S8"*>?<UU9  ".W&1^  "  '51  "  (
M1IN=#5N=/32<+5VL,L*;;U^.)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "
M 'FI  "  (  1@>:/&(Z/(29;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?
M  ")WFY\  "  'V   "  (  1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N6
M3&Q+"'65#VRO  "'QG0O  "  (    "  (  1,65DV^^.TJ5"G"G,.246W%?
M)4R3OG'3%[B4 ''0")*2*7)D  "&$'EG  "  (    "  (  1#N3PG:<.L^3
M6G<Y,(*2KG>6)/B2 7>\%VB2'G>9"(*/TGB;  "$LGW*  "  (    "  (
M0\F207V0.FV1]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18    "
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M#)@6;59'BI7U7H9+DI/R3J!/"I)%/8)119$=*N%0K9$3$]]>:8U   "  (
MB!UA[$X,>L-D!U(=;+%F)E8779MH.5GL359J+EV1.Z1KVF#O)_)LF&.I#I-P
MZV1H  "  '&TAB=<^5<;>4A?BUIW:V-A_EVV7'MD46#33%EF<F/#.LQH*69U
M)T)HAVB4#D-N$6C_  "  '9HA&Y88F!&=[1;6V+?:BU>'&5C6UQ@HV?%2VEB
MZ&H#.@MDH6P-)KEDDFV9#A-KAVW%  "  'J+@KM4,&EI=A=7>6M":)5:=&T+
M6A1=,&ZZ2C]?H'!*.11A57&T)?E@R'*]#;AI>'+/  "  'XC@3)0:W*(=*I3
M]'.J9T%7*72Y6-1:#W6R25Q<GW:=.$Q>2W=Q)6==@W@)#7YI,7@Z  "  (
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M:7G'7+!;*WI.3Q%=EGJ\0%1?B7LB, =@6'N#'4]@B7N[!M9T<GSJ  "  (
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MXW[T4AM@'W\,139A\G\+-QMC*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "  (
M:"59 X; 741;NX:/47E>"X871*!?XX6)-HEA"(4I)K1@884F% 9E5(5$ 3!]
M_H#.  "  (  9YY7+8[&7,5: (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)
M$[!D.(GS 0]^-8"X  "  (  9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]
M3%K;(91^@%T-#,R H%UX  "  &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%
M0"IXI%W8,<AY@F!3(1QZ9V(1#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR
M[E\72^YT$F&0/R]U#V/7,/IUYF70((%V>&<>#'QY06<:  "  &]6  "  (
M8+!MU60R5AMO468T2K!PEV@=/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "
M '31  "  (  7X1J7&OH50-L!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&(
M"_YST'%N  "  'FR  "  (  7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L
M=':P'P-KVW;]"_1QF7<?  "  'W3  "  (  79ADDWMX4TMFE7OS2!MH,WPZ
M.])I7WQB+C-IZ'R+'GII'7RL"]=OPGT]  "  (    "  (  7.=B2H,R4J1D
M;8-!1WUF(8,'.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[  "  (    "  (
M7&)@;8KL4B9BJHJE1O]D;HGU.LQEE8DM+4MEV(C,':AE)HDJ"UEM/H:J  "
M (    "  (  6/.#7$Q@3JN#ED_=0X2$!%,^-PJ$FE9A*+R%@%D"%U:'B5I<
M!'&'U5NB  "  &DU  "  'X:5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!
ML5Y)%O&#,U]#!(V$"&!N  "  &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J
M-3Y]7V'7)U-^ F.1%FM^^V0O!(J MF56  "  ',D  "  (  52MWHF'U2S%X
MDF/]0%9Y567D-%AY]V>:)HAZ?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (
M5!IT.6E'2BEU4FK./U5V+VPV,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "
M 'QR  "  (  4R9Q+'"K24-R;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3
M!&)Y0W7?  "  (    "  (  4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%Q
MFWF?%*)R)GF !)!X2GMS  "  (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q
M,:AOB7^-)&5O4G^)%$)P.G^P!%QXHH G  "  (    "  (  425J/X;R1V]L
M 8;I/-QM089X,3EMSH7S)!%M9(7;%!!NI(6X!%%XM8+K  "  (    "  (
M3.^-H$K70V"-:DXV.-6-@U%I++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "
M &RM  "  (  2Y.)RU&40CB)YE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6
M  "&3F#?  "  '&.  "  (  2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'
MU&"$"^2(GF"_  "#5&6Z  "  ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K
M*@&#@62_'""$,66K"XB$MV7"  " JFK>  "  'KK  "  (  2)M^\68\/R=_
MCV?.-,)__FDW*1Z 3VI7&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "  (
M1[I[XFU,/DU\L&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "
M (    "  (  1OAY,71=/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L
M  "  'M'  "  (    "  (  1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IX
MA'O["FUZ;WRM  "  ']X  "  (    "  (  1=-TVX*\/(=V1(+@,F]W((*?
M)SIW.8)+&B1V<H);"LYXM8(&  "  (    "  (    "  (  0)F914BK-[*8
MK4OE+:.8E$[4(:J945$[$GF<,E)3 U*9OE1@  "$LE^*  "  ' -  "  (
M/S>5O$\$-E25CE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "
M '4!  "  (  /D&2%E5X-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN
M  "  &DC  "  'ET  "  (  /6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0
MUV$J JJ-!F,Z  "  &Y6  "  'U8  "  (  /)J+%&*:,W2+:60F*42+K65T
M'9F,(F9+#Z>-$&9G IF)Q6B'  "  '0$  "  (    "  (  .\N'\FE=,J:(
MAVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[  "  (    "  (
M.Q6%*7 I,?2%_G#O)_B&=W%Y'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "
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M?CQ\/7P^?#]]0']!@D*%0XE$C4621IA'FDB;29U*GTNC3*9-JDZO3[10NE'
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M&IV$F AI(YEFE(585I51D05( I$PC6LX6HSPB:\J#8ANA=2KGJGOJUZ;1*6
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M:K2(B$!3'ZU<AOI&,*7PA=<Y]YXLA,4NN98%@]TE&XV-@QJ)(\A"E%![@L&
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M@.<F>HHI@1"8(J^6BWN)R:KTB=M[+J9:B&)L6:''AQM=8IT_A@-.DIBAA0%
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MAKIGQK;2A71;*;!0A'1.K*FB@[1"A:*W@Q4W%IM]@HHLGI/P@B4CP(PS@=^
M^\)3CJ]T6[PJC*-GL+77BL];#*]6B2U.H*BFA[E"B:'-AF4W+YJDA1@LUI,P
M@^8D'(N8@M: W,&4E1]T2[M@DGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\B8,W
M2IGFAW4M!Y*,A7LD:(L6@ZJ O<#YFV)T0+JZF"-GJK13E05;$ZW.DA!.J:<K
MCS5"I*!:C&0W99E#B9<M,Y(!AMTDIXJLA%R G\!^H7)T.;HSG8QGK[/"F;M;
M'*TUE@Y.LZ:7DH%"LI_7COHW?)C*BWDM6)&0B XDVHI5A.^ A\ 9IU!T.+G
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MIV*<[8 $HO:)^7^7GG%VYW]7F?)CY7\ZE651+G\SD*T^MW]>BYTM$'^@A@G
M9(#&M2JNIH EL V<+7^+JJ&)-G\6I0EV,G[9GWAC1W[,F==0N'[2E  ^<'\"
MC<(L\']1AP2_[8!TOJ&N'G_5N)B;BG\QLAJ(B7ZOJU]UEGYOI*]BRGYIG?)0
M6WY]EOP^,GZ[CYTLUW\2A]6Y=Y"N<$:I$H[F<9*7^(U,<M"&'HO4=!%ST8II
M=6YA6HD'=O)/&8>E>)L] X90>H\KIH4'?/.X?H]$>96H+(V<>>J7!8P4>D.%
M-XJG>JYR]XE*>S9@E8?\>]U.;(:P?)H\B85U?8@K?H1#?K*W>HWY@LNG!(QC
M@C^5^XKA@;:$+(F%@4MR"X@[@/E?S8<$@+Y-S(70@(P\'82N@&HK6H.3@%2V
M:(S%C "EVXLYBIV4PXG(B3:#)HAPA^EQ&H<]AK9?!H8:A8]--(3_A&([NX/Y
M@RPK.H+Y@=>U3HO,E2:DUXI#DO:3NXC9D,&"$H>/CH]P+(9DC&A>/H5;BD],
MH(12B!T[88->A<@K(()S@S:T6HL-GDFCX(F)FTV2R(@@F#F!+8;;E1QO8(6V
MD@%=E(2MCN%,)(.WBZD[%8+9B#0K"8( A&VSDHIVIU6C&(CWHX>1_X>,GXR
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MKWK8I.ZF$GKDH7^4R7KRG<V"^WL;F?=Q 'MNEAU?!GOFDC%-97QXCAX\%7U
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M&F'WN>NQ]&1@M%*?&6:?KE>+V&CHJ"UXD6MKH@=E;6XIF]!2IW$5E5Q /W1
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MKX.(;E.6E8,2;^^'C(*O<71WQH)<<O9G?H(8=(A7#8'E=C1&ZH'!=_PW(X'
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M?(<F/H,'?=V6(HDC?AJ(^8@0?D=[)H<,?E]LV880?G%>$H4N?H]/2H1;?KA
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MD%MIT78-CI5=E';7C)A1+'?4BI9$WWD*B)0Y0'I<AI(N07OMA'PDDGVA@F2
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M=U0Q.HX2>/HJ&XK=>JTCNX?2?'8>E(4>?BQ91IM4=_112YCQ>+Y))98X>7Q
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M<?$FV7VB=RN3YF>C7FJ'8FG789!Z"&P)9*-L#FY,9[!=F7"Q:LE/"'-);@1
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M34UQ8XN0DU'Y9BB";59W:,-SEUL+:V)D7E_5;@Y5!F3J<-A&'6I$<\HWR'
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M>@@H>W=]?*:0=DUU=3>$'%(P=C]W,U;.=T-IP5M[>$-<"&!H>4U.$V6D>FQ
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M,8%L?ODQ)($/?S K5(#*?WPF*("6?]$AFH">@!L>!8#$@%0  /__  #__P
M__\  &UF=#$      P0A   !                     0
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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M<)1WSW27=<YWF'/->9IRS7N;<<Q]FW#+?YQORX"=;\N G6_+@)UORX"=;\N
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9D92>V9&4GMF1E)[9D92>V?^D."K_H$5
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MA*>2SX"FG-" HZ7/@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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M;W^LHG6*I)Q\DYR8@YJ5E(J@CY&2I8J.FZB&C:2K@XROK(&-O:R"C+^K@XK
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M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
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MEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J
MRYN*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;BH#+F_]_(@;_A3 /_Y4V
M%O^?.QW_I3TD_ZM!*O6P12_LM4PTX[I4.=BW64C+KV%8P:AH9K>A;W*OFW5\
MIY5\A*"1@XN:C8N1E(J3EH^'FYJ+A:6=B(2PGX:$OI^%A<F>A83)G86$RIR%
MA,N;A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;A83+F_^ (@;_AR\/_Y<U%O^@
M.AS_ISPB_JT_)_.S1"SINDLPX;]2-=.Z6$?'LU]7O*QF9;*E;7&IGW-[H9IZ
MA)J6@8N4DHB1CH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR B,N;
M@(C+FX"(RYN B,N;@(C+FX"(RYN B,N;@(C+F_^!(@;_B2X/_YDU%?^B.!O_
MJ3H@^[ ])/"X0BCFOTHJW<-/-,Z]5D;"MEY6M[!E9*VI:W"DI'%ZG)]X@Y2;
M?HJ.EX:0B)6.E8*2EIE^D*"<>H^KGGB/N)]WD,F>>8[*G7J,RYM[C,N;>XS+
MFWN,RYM[C,N;>XS+FWN,RYM[C,N;>XS+F_^!(@;_BRT._YLT%/^D-QG_K#@>
M^+0Z(>V]0"/DQDDCU\=,,\G!546]NEQ5LK1C8ZBN:6^?J6]YEJ5V@HZA?(F'
MG8./@9N+E'R8E)AWEYV;<Y:HG7&6M9YPEL:=<I3*G'22RYMUD<N:=9'+FG61
MRYIUD<N:=9'+FG61RYIUD<N:=9'+FO^"(@;_C2P-_YTT$_^F-!C_KS4;]+@W
M'.G#/AS@S44?T<M+,L3%5$.XOUM3K;EA8:*T:&V9KVYWD*MT@(BG>H>!I(&-
M>Z*)DG6@D99PGIN9;9VFFVJ=LYQIGL.<:YS+FVZ8S)IOE\R9;Y?,F6^7S)EO
ME\R9;Y?,F6^7S)EOE\R9;Y?,F?^#(0;_D"L-_Z S$?^I,A7]LS$7\+XT%^7+
M.Q7:U#\=R\]),+[)4D*RQ%E1I[]@7YRZ9FN2MFQUB;)R?H&O>(5ZK'^+=*J'
MD&^HCY-JIYF69Z:DF&2FL9ECI\&99*7-F&>@S9AHG\V7:)_-EVB?S9=HG\V7
M:)_-EVB?S9=HG\V7:)_-E_^$(0;_DRD+_Z(P#_^M+A+XN"P2Z\8O$.#5. O2
MVCT<Q=1(+KC/4$"LREA/H,5>797!9&B+O6IR@[IP>GNW=H%TM7V';K.%BVBR
MCH]DL9B28;"CE%ZPL)5=L;^57;'0E&"JT)1AJ-"48:C0E&&HT)1AJ-"48:C0
ME&&HT)1AJ-"48:C0E/^&(0;_ER@*_Z8L#?^Q* [RP"8,X] H!]3?,@O)WSX9
MO=M'++'63SVDT59,F<U<68[)8F6$QFAN>\1O=G3!=7QMP'R":+Z$AF.]C8E?
MO)>,6[RBCEF\KX]8O;Z.5[[4CEFVTX]:M-.06K33D%JTTY!:M-.06K33D%JT
MTY!:M-.06K33D/^((0;_G"<(_ZHG"ORX(0GIRAL%U=X@!,GE, ^^XST=M.%&
M+*C>3CJ<VE5(D=9;58;386!\T&=I=,YN<&W-=79GRWQ[8LN$?E[*C8):RI>$
M5\JCAE7*KX94R[Z&4\S5AE3$V8A5P=F)5<'9B57!V8E5P=F)5<'9B57!V8E5
MP=F)5<'9B?^-'07_HB4&_[ ?!?+"% /9VPX!R>8@![WH+Q2RYSHBI^5#,9OC
M2CZ0X5!*AM]75'S>7EUTW65D;-ML:F;;=&]AVGQS7-F$=EG9CGE5V9A[4]JC
M?%':L'U0V[Y]4-S3?%#4X'Y1T.!_4=#@?U'0X']1T.!_4=#@?U'0X']1T.!_
M4=#@?_^5&@/_J1\#^[H2 M3-"P#)Y@\"O.T@"[#M+AFE[#DGFNM"-8_J24&%
MZ5!+>^A74W+H75IJYV-@9.=J95_G<FE;YWIL5^>";E/GBW%0YY5R3NB?=$SH
MJG5+Z+5V2N?#=DKHW79+Y.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'5+Y.!U2^3@
M=?^=%@'_L1(!T\,) ,?1"@"[\A$$K_,A#Z/S+AV9\SDJCO-"-H3S2D%[\U))
M<O-74&GS7%9C\V-:7?-I7EGS<&%5\W=C4O-_9D_RAV=-\(]I2^^8:TKOH&Q)
M[JEM2.ZS;4?MP&Y&[<=N1NW';D;MQVY&[<=N1NW';D;MQVY&[<=N1NW';O^G
M#P#3N@< Q<<' +K6"0"M^A,&HOHB$I?Z+Q^-^SHK@_Q#-7K]3#YQ_5%%:/U6
M2V'^6T]<_F)35_YH5E3];UA1^W5:3OI\7$SY@UU*^(I?2/>18$?VF6%&]J!B
M1?6G8T3TL61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM61#]+5D0_2U9-:R! #$
MO@8 M\P& *S<"0&@_Q8(E?\E%(O_,A^"_SPI>?]%,F__2CEG_T\_7_]50UK_
M6T=5_V%*4O]G3$__;$Y-_W)/2_]X44G_?E)'_X131?^+5$/_D55"_IA60?V>
M5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6,:X! "VQ 0
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M7NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3,O^
M6CS_?&)%_W=J3O]Q=%7_;G];_6J)8/IFDF3X9)EH]F&@:_5?IVWS7JUO\ERS
M</);NG'Q6L-R\%G-<^Y9W7/H6N)TX5SE<]E>YG/07^=TT%_G=-!?YW307^=T
MT%_G=-!?YW307^=TT%_G=/]L(P3_:S$*_W,[%/]]0AW_@DHG_X11,O^#63O_
M@&!%_WMH3?]T<57_<'Q;_&R'8?EHD&;W99AI]6.?;/-AIF_R7ZQQ\5VS<O!<
MNW3O6\5U[UK0=>I:WW;B7.)VVU_E==%@YG;*8>5WRF'E=\IAY7?*8>5WRF'E
M=\IAY7?*8>5WRF'E=_]M(@3_;#$+_W8Z%/^ 01W_A4@G_XA/,?^'5SO_A%Y$
M_W]F3?]X;E7_<WE<_&Z$8OEJC6?V9Y9K]&2>;O)BI7'Q8*QS[UZT=>Y=O';N
M6\=W[5O6>.5<X'C<7^-XTF#D>,MAY'G$8^-ZQ&/C>L1CXWK$8^-ZQ&/C>L1C
MXWK$8^-ZQ&/C>O]N(@3_;3$+_W@X$_^#/QS_B4<F_XM.,/^+53G_B%Q#_X-C
M3/]]:U3_=G5<_'* 8OAMBF?U:91L\V:<</%CI'/O8:QU[E^T=^U=OGGL7,MZ
MZ%S<>MY?X7K28>-[RF+B?,1CXGV^9>%]O67A?;UEX7V]9>%]O67A?;UEX7V]
M9>%]O67A??]N(@3_;C +_WLW$_^&/AS_C$4E_X],+O^/4SC_C5I!_XAA2_^#
M:5/Z?'%;]W9\8O-QAVCP;9!M[6F9<>IFH77H8ZEXYF&R>N1@NWOB7\=\X%_:
M?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;L08
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M=%.UY'14L.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=?^#$@'_EA$
M_Z@1 -FX"@#.Q D Q](* +_9&0&TV"L'J=8Y%)_31"*4T$TOBLU4.X'*6T1X
MR&)-<<=I4VO%;UEEQ'9>8,-^8ES"AV98P9%H5<&<:U+!J&Q0P;=M3\+*;4_"
MY&Q/O>QN4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;_^)$ '_G0X VJ\(
M ,V[" #$QP< O-8+ +/?&@&JWRL'H-XY$I;=0QZ,VDLJ@MA3-7G56C]QTV%&
M:M)H3&71;U)@T'966]!^6E?/AUU3SY%?4,^<84[/J6-,S[AC2]#+8TS0Y6)*
MSO)E2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F2\CR9O^2#0#>I@0 SK0& ,*_
M!@"YS @ L-T, *?E'0.>Y2T+E.4Y%HKD0B"!XTHJ=^)0,V_A6#MIX%]!8^!F
M1E[?;DI:WW5.5M]]45+?AE-/WY!63=^;5TO@IUA)X+592.'&64CAWUE'W_!9
M1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;1MSU6^V<! #1K00 PK@% +?#!0"M
MT0@ I.T0 9OM( 62[2X.B>PZ&(#L0R%V[$HJ;NQ0,6;K5C=@ZUP\6^MD0%?K
M:T-3ZW)&4.MZ24WL@TM*[(Q-2.R63D7MH5!#[:Y10NZ\44'OS%)![^520.WQ
M44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @
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M3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0(
MN[," +"] P"ER04 F]8) )3H% &,Z24$A.@S"WOH/!1SZ$0;:^A+(F3G4BA>
MYUDM6>=@,E7G:#52YV\X3^=W.TSG@#U)YXD_1^B4043HGT)"Z:Q#0>FZ1$#J
MS41 ZN1$0.CU1$#G^$- Y_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$ L+@!
M *3$ @"9T 4 C^$* (GQ&@&!\2@%>/(R#'#R.Q-I\D,98O)*'USS4"-6\U<G
M4O->*T_S92U,]&PP2?1S,D;T>S1#](0V0?6.-S[UF3D]]J0Z._:P.SKWOSPY
M^,\\./?H/#CW[#PX]^P\./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\  )C*
M 0",V 0 A/H. 'S[&P)T^R8%;/PP"F7\.!!>_4 56/Y'&5/^31U/_U0@2_]:
M(DC_825%_V<F0O]M*$#_=2H]_WTK.O^&+3C_D2XV_YLO-/^F,#/_LC$R_[XR
M,?_0,C'_UC(Q_]8R,?_6,C'_UC(Q_]8R,?_6,K*O  "EN@  F,8  (O2  !_
MWP( >?\1 6__&0)G_R($8/\L!UK_- Q4_SP/3_]#$TK_215'_T\70_]5&4#_
M6QL^_V$<._]F'CG_;1\V_W0@-/]](3'_AB,O_Y$D+?^;)2S_I28K_Z\F*O^[
M)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0<
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M5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+
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M(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7&
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M5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];4*S
M6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#AD@$
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M*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y 1-2_04/5V$!$T^Q
M0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">
MPP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C31M<XU4@5^-=)%3C
M9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X-S_ERS<_Y>0W/^/S
M-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP  JK0  )Z^  "3R0(
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M2WTI_TB(+/]&DB[_19LP_T2B,O]#J3/_0K T_T*W-?]!OS;_0<DV_T#7-_]
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M6"Z(FU\U@IEF/'V6;4%XE'1&<Y)[2V^0@T]KCXQ29XZ6562-HEAAC*]97XS
M6E^,V5E?C.Y97XS[6&&*_5=AB?U788G]5V&)_5=AB?U788G]5_]O# #_?PD
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M24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0
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M(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP  ==4! &GA!@!D\Q$
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M4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H
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M2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@(
MLJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!J
MGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7
M_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@
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M-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R <
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M&P!6XR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>:
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M1'UFV41\9^]#?&?\07QH_T!\:/] ?&C_/WQH_S]\:/\_?&C_/_];# #_9PD
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M0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C ,
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M/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T
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M)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$
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M!R7PIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP
MA+@  '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q
M^#  +ODV 2OY/0$I^D0!)_I* B7[4@(C^UH"(/QC Q[\;@,<_7L#&_Z)!!G^
MF 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,
M &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R<
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M-)!6W32.5_ TC5?],XQ8_S.,6/\RC%C_,8Q8_S&,6/\QC%C_,?]1# #_6PD
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M.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P,
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M-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0  KHT  *2/  "=D1
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M%S>]M1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF
MGY\  ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'
MRCL!1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+
ML@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4
M (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$
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M A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0
M2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5
M_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_
MK@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P
M #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R,
M"_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0
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M'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH
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M*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60  XF   -5G  #,:@,
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M*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D>Q(
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M(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0
ML(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!FI24 8Z4Q 5^D.P-;
MI$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@AAI"GY,<0)^B'3Z?
MLAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9
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M""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP
M:[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ N
MT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3
MZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X
M %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#<
M'^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3
MY>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*
M   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U
M !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD
M"/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   Q
MV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^
M,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.
M  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0
M'.4  !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P
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M"<DQZ@K&,?<,PS'_#L$Q_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\
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M')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#95@4
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M(758_R%U6/\A=5C_(?]-  #E5P  TU\  ,AD  "_9P  MV@  +%G!P"I:!0
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M:0  O'(  +)X  "I?0  GW\  ))^  "*?P< A( 3 ("!(0![@2X!=X Y W*
M0@5N?TH(:WY1"VA]6 YD?%\18GMF%%]Z;1=<>74967A_'%=XBAY4=Y8A4G:D
M(E%VLR-0=L8D4';C(U!U]2-1=?\B473_(5%T_R%1=/\A473_(=AC  #%;0
MN'8  *Y]  "E@@  FH,  (V#  "$A , ?840 'F&'@!UARL!<8<V FV&/P1I
MA4<'981/"F*#5@U?@UP/7()C$EJ!:Q57@',85']]&E%_B!Q/?I0?37ZB($M]
ML2%*?<0B2GWA(4M\]"%+>_\@2WO_($M[_R!+>_\@2WO_(-!G  # <@  M'L
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M%3F8[Q8YE_P6.);_%SB5_Q<XE?\7.)7_%[MZ  "OA0  I(P  )B1  "-E0
M@9H  '6=  !HH   6Z0  %:E# !3IA< 4:<C $^G+P!,IS@!2J=! 4BG20)&
MIU $0Z=8!4&G7P8_IF@(/:9R"CJF?0LXIHH--J69#C2EJ0\SI;L/,Z74#S.D
M[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC   G9(  )*7  "&G   >:$
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M 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M  !HLP  7+D  %"]  !$P0
M.<0  ##(   HS $ (- & !G5"P 6UQ  %=@9 !79(@ 4V2L $]HT !/:/0 2
MVT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0 #>"X  S@T@ +W^T #-[W  S=
M^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0  +LT
M "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )ZCL
M!^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L[P
M[.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8  !O;
M   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X  /4W
M  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT   ^-
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M ?\.A '_#HL!_PZ2 ?\.F '_#IT!_PZC ?X.J '\#JX!^PZU /H.O@#X#LD
M]0[; /(.Z@#N#O4 [ [_ >L/_P'J#_\!ZA#_ >D0_P'I$/\!Z1#_ ?\B'P#_
M(AP _R$< /\?( #_'RD _QPT /\:0 #_%TP!_Q58 ?\48P'_$VX!_Q-W ?X3
M@ '\$X@!^A*. ?D2E0'X$IH!]A*@ ?42I@'T$JP!\Q*S ?$2O 'P$L<![1+8
M >D3Z 'F$_4!Y!3_ >(4_P+A%?\"X17_ N 5_P+@%?\"X!7_ O\E&P#_)A<
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M"K P_PNN,/\+KC#_"ZTP_PNM,/\+K3#_"_\S# #_-@8 _SP) /\^# #]/1
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M%85'_Q6%1_\5A4?_%?\_  #L2   W4\  ,]3  #&50  P%,# +M1# "S4AD
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M'%QBLAU;8L4=6V+A'5MB]!Q;8O\;7&+_&EQB_QI<8O\:7&+_&N!5  #+7P
MO6<  +)L  "I<   GV\  )1L  ",;0@ AFX3 ()O(0!];RT!>6\X G5N00-R
M;4D%;FQ0!VMK5PII:UX,9FIE#F1I;!%A:7037VA^%EUGB1A;9Y4:66:B&U=F
ML!Q69L,=5F;?'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_&MM9  #'8@  NFH
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M&49W[QA'=OP81W;_&$=U_Q='=?\71W7_%\EE  "Z;P  KG<  *1]  "8?P
MBW\  'Y_  !S@0  ;(,) &B$$P!EA2  8H8L %^&-@%<AC\"685& U>%3@54
MA54'4H1<"4^#8PM-@VL-2X)T#TB"?Q%&@8P31(&:%4* J19!@+H60(#2%D%_
M[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0  JGT  )^"  "2@P  A80
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M"BV;_PHMF_\*+9O_"J^   "CB0  EXX  (V3  !_E0  <I@  &:<  !;H
M3Z0  $6G   ^J0P /*H4 #JJ'P YJBD .*LR #>K.P UJT, -*Q+ #*L4P$Q
MK%P!+ZQF BVL<0(KK'\#*JR. RBLG@0GK+ $)JS%!":KY ,EJ?4$):C_!26G
M_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@  :Z(  %^F  !3J@  2*T
M #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ IMSH *+=# ">W3  FN%4
M)+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT_P(;
MM/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8  #6Y
M   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H %L55
M !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0P_\
M$,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!   C
MQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))  G3
M50 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8  =7V
M (Z=  " I   <ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9S@
M$M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A1P
MXE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G (.D
M  !UK   :+,  %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0  "]T
M  7A    Y    .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0  [T4
M /!3  #Q9   \78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M  !J
MM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8   #J
M    [@   .X   #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4  /U#
M  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_%2$
M_Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\ @P#_
M (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1 /(
MY #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T _Q4=
M /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_ X<
M_P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!XP#J
M >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8 /\5
M'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H, ]PJ*
M /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B"O
MWPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<&0#_
M&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"& .H0
MC #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X W@_, -H0X0#5$?  TA+[
M ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_(@\ _R$/ /\B% #_(AP
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M")PQ_PB<,?\(G#'_"/\P  #_-0  [S@  .(Z  #;.00 UC4) ,XT$P#&-B(
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M  #93   R%,  +U7  "T6   K%<  *52 0">4P\ F%0< )-4*0"/5#4 BU-
M 8A32 *%4E $@E%7!7]07@9]4&0(>T]K"7E/<@MW3GL-=4Z$#G--CA!Q39D1
M;TVE$VU-LQ1L3<44:T[A%&M.]!-K3O\2:T[_$FM._Q%K3O\1:T[_$>A&  #3
M4   Q%8  +E:  "P7   IEH  )]6  "85@T DE<9 (Y8)@")6#( AE@] 8)7
M10)_5DT#?%54!7E46P9W5&$(=5-H"7-3< MQ4G@-;U*!#VU2BQ!K49<2:5&C
M$V=1L11F4<,595+>%652\A1E4O\395+_$F52_Q)E4O\295+_$N1*  #/4P
MP%H  +5>  "L8   HEX  )I9  "26@L C5L6 (A<(P"$7"\ @%LZ 7U;0P)Y
M6DL#=EE2!'186 9Q6%\';U=F"6U7;0MK5G4-:59^#V=6B1%E59428U6A%&)5
MKQ5A5<$68%7;%F!6\15@5OX48%;_$V%6_Q)A5O\285;_$N!-  #+5@  O5T
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M%5%A[1528?L44F'_$U-A_Q)38?\24V'_$M%6  # 7P  LV8  *EK  "<:P
MD&H  (5G  !]:0  =VH- '-K%P!O:R0 ;&PO &EL. %F:T$"8VM) V%K4 1>
M:E<&7&I=!UII90E8:6T+56AV#5-H@0]19XT13V>:$DYGJ11-9[D43&?/%$QF
MZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P  L&H  *5O  "8;@  C&T
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M#CQX_PX]=_\./7?_#KQH  "O<@  I'D  )9Z  "(>@  ?'H  '!\  !C?P
M7((  %>$"P!3A10 488@ $^&*@!.AS0 3(<\ 4J'1 %(ATL"1H=3 D2&6@-"
MAF($0(9L!CZ%=@<[A8,(.861"CB$H LVA+$+-H3&"S:#Y LV@O8+-H'_##:
M_PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P  =X   &N"  !>AP  58H
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M J*&  "7C   BX\  'V1  !OE   8Y@  %>=  !-H0  0Z4  #BH   PJP
M**X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z !VQ0@ <L4P &[%6 !JQ80 9
MLF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L $Z_Y !.N_P$3KO\!$Z[_ 9J-
M  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0  (+@
M !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -OF4
M#+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4  "'
MF0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$  !'$
M 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD  ,MH
M  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\H0
M;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.   $
MT@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:  #=
M:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0  9+
M %:W  !)O   /,   "_$   DQP  &\L  !//   -T@  !]8   #;    W@
M -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L6@
M[6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D  $O
M   ]Q0  +\D  "3-   9T0  $=8   O;   #W@   .$   #E    Z    .D
M  #J    ZP8  .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@  _%L
M /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!( #_
M "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ", /L
MD@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L [0#W
M .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_ R4
M_P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0 CP#R
M )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U .,
M_@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R( _P@M
M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J )$
MZ "6 .< G #F *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -< _0#5
M O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH /\,
M- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT WP:2
M -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(#/\
MQPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1+@#S
M$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/ - -
ME0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8 P!'U +T2_P"\$O\ NQ+_
M +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_'1( ^!H; .X6)@#F%#,
MX!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5?0#&%80 Q!6* ,,5D0#!
M%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR ;$:_P&O&_\!KAO_ :X;
M_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH T!LX
M ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?> "Y'WX MQ^% +8?C "T'Y,
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M!?\M  #J-0  W#H  ,X]  #&/   P#<" +LS#0"S-!D KC8G *DW- "E-T
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M"G= L@IU0,,+=$#="W-!\0MR0?\*<D'_"G)!_PER0?\)<D'_">D\  #510
MQ4L  +I.  "P3@  ITL  *)&  ";1@X ED<: )%()P".2#, BD@] (='1@&$
M1TX!@D95 H!&7 -^16($?$5I!'I%< 5X1'@&=D2!"'1$BPER1)8*<$2B"V]$
MKPQN1, ,;479#6Q%[PQK1?T+:T;_"VM&_PIK1O\*:T;_"N5   #/20  P4\
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M#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*  ##4P  MED  *M<  ">6@
MDUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q '!7.@!M5T(!:E=) FA64 )F
M5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+652:#5A4IPY65;@/5E7,#U95
MZ0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@  LUP  *=>  ":70  CUP
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M#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF  "-9@  @F4  '9D  !N90
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M!K!L  "D=0  E'4  (9U  !Y=@  ;G<  &-Y  !7?0  3X$  $>$  !"A@P
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M !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/A@
M@H8  '2'  !GBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH"P :
MJ1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT  ZK
MA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C   >HT
M &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /M0H
M#;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W>P
MMXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<  &6<
M  !8H0  3*8  $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4  \$-
M  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P  Q8$
M ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI  !0
MK@  1+,  #>V   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'  #,
M#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,  -:'
M  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%N
M.+P  "N_   AP@  %\8  !#)   *S    M    #4    UP   -@   #:!0
MVPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW  #I
MC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP   +,0
M "#(   6S   #M    ?4    V0   -T   #A    XP   .0   #F    YP$
M .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y>@
M^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R /\
M/P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )( ]@"8
M /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H /\
MZ #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\ .P#_
M $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4 .P
MF@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\ W0#_
M -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_ $(
M^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .( E@#A
M )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_ ,T
M_P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P [P!)
M .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2 )@
MT "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "_P#
M O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-" -\#
M3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90 Q 6;
M ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T#/\
MM S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,1P#,
M#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8 +<.
MH "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\ IQ/_
M /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_%$L
MO!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7G "I
M%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_ ?\=
M  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4 L!Y/
M *T>5P"K'E\ J1]F *@?; "F'W, I1]Y *,?@ "B'X< H""/ )\@F "=(*(
MFR"L 9HAN0&8(<H!EB+D 90C]0&2(_\!D2/_ 9 C_P&0(_\!D"/_ ?\B  #K
M*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH L"4H *PF- "H)D  I2=) *(G
M4@"@)UH GB=A )PG9P";)VT F2=T )@G>P&6)X(!E2>+ 9,GE &1*)X!D"BI
M 8XHM0*-*<8"BRG? HDJ\@*'*O\"ABK_ H8J_P*&*O\"ABK_ O0H  #C,0
MT38  ,4X  "\-@  MC   +(K"0"K+!0 IBTB *(N+P">+CH FRY$ )@O30"6
M+U4 E"Y< )(N8@"0+FD!CRYO 8TN=@&,+GX!BBZ& H@NCP*'+IH"A2^E X,O
ML@."+\(#@3#: W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_ ^TO  #;-P  R3T
M +X^  "S/   K#@  *<S! "B,A$ G30= )DU*@"5-34 DC5  (\U20"--5
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M1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T @D W '] 0 !]0$@ >T!/ 7E
M5@%W/UT!=3]C G,_:@)Q/W(#<#]Z VX_A 1L/Y %:S^<!FD_J09H/[@'9T#,
M!V9 Z =F0/D&94#_!F5 _P9E0/\%94#_!=P^  #'1@  N4L  *Q,  "@2@
MET<  )%#  "+0P@ AD,2 ()$'@!^1"D >T4T 'E%/0!V144 =$1, 7)$4P%P
M1%D!;D1@ FQ#9P)K0V\#:4-W!&=#@05F0XT&9$.9!F)#IP=A1+8(8$3*"&!$
MY@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20  MDX  *=/  ";30  DDL
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M!U%/_P=13_\&44__!LE+  "Y4P  JU<  )Q6  "/50  A50  'Q0  !U40
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M!KE9  "K80  FF$  (MA  !_80  =&$  &EA  !?8@  660  %1F"0!19Q$
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M BUYD@(K>*,"*GBU BIXS (J=^H"*G;Y RIU_P,J=/\#*G3_ ZIJ  ":;0
MB6P  'QM  !P;0  9FX  %MQ  !0=0  2'@  $%[   Z?@4 -G\. #2 %@ S
M@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E  *X): "J"9  H@G  )H)_ 26"
MCP$D@J !(X*R 2*"R0$B@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0  @W$
M '9Q  !L<@  8'4  %9X  !,?   0X   #N#   SA@  +8D* "J*$0 IBQD
M)XLB ":+*@ EC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-B@ ;
MC9P &8VN !B,Q  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78  ')W
M  !E>0  6GP  %"   !&A   /(D  #2,   MD   )9," !^5#  =EA( ')8:
M !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0F)8
M$)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^  !?
M@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2 !"C
M&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX !*.A
M  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8C
M39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O$@ "
MKQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7  "O
MJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F   19T
M #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@  NA,
M +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^GP
MO;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L  #*O
M   HM   'K8  !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X  ,<2
M  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP  SZ8
M ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ   =
MO0  $\    W$   &QP   ,H   #.    T    -$   #2 @  TP@  -4,  #6
M$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@  .6I
M  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2R
M#,L   //    TP   -@   #<    WP   -\   #A    XP   .0#  #F"
MZ T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9  #X
MI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@ _P!4
M /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q )X
M\ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0 _P#D
M /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/ /H
M6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H Y0"@
M .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8 /\
MV #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$ 50#M
M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "< -4
MHP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\ R #_
M /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A %D
MW@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,< H #%
M *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_ /\.
M!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %, S@!;
M ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y *0
MMP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0  #_
M#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016 +X%
M70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$ JP>K
M *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\$@
M[!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.5P"P
M#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I )\0
MM0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P  X!\
M -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D%ED
MHA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9L@"1
M&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD  ,<J
M  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0 EQ];
M )4?80"4'V< DA]M )$?= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&(KT
MA2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ  "Q
M+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4 DR8_ )$F1P"/)D\ C296 (LG
M7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0& *),!?BB> 7TIJP%[*;D!>BG-
M 7@JZ %W*_D!=BO_ 78K_P%U*_\!=2K_ >4L  #0-   P3@  +,X  "H-0
MHC$  )TM  "9*@X E"L8 ) L) "-+3  BBTZ (<M0P"%+4H @RU1 ($N6 "
M+EX ?BYD 'TN:P![+G,!>2Y[ 7@NA0%V+H\!="^; 7,OJ )Q+[8"<##) F\P
MY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0  NSX  *P]  "A.@  FC<
M )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!],T8 >S-- 'DS5 !W,UH
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M UD__P-9/_\#63__ \P_  "\1@  JT@  )Q'  "11@  B$0  ()   !\/P
M=T , '- %0!O02  ;$$J &I!,P!H03L 9D)# &1"2@!C05  84%7 &!"7@%>
M0F4!74)N EM"> ):0H0#6$*0 U="G@160ZT$54._!%1#V@140_$$5$/^ U1#
M_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20  @T<  'U#  !V0P  <40*
M &U$$@!J11T 9T4G &1%, !B13@ 8$4_ %]%1P!=14T 6T54 %I&6P%91F,!
M5T9L 59&=@)41H$#4T:. U)'G 101ZL$4$>]!$]'U@5/1^\$3T?]!$]'_P-/
M1_\#4$?_ \1%  "U30  HTT  )5,  ")2P  ?TH  'A&  !Q1P  ;$<' &A(
M$ !D2!H 84DD %])+0!=234 6TD] %E)1 !724H 5DE1 %5*60%42F$!4DII
M 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+TP5*2^X$2TO]!$M*_P-+2O\#
M2TK_ \%(  "R4   H$\  )%/  "%3@  >TT  '-)  !L2@  9TL$ &),#@!?
M3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!3DYG 4Q.
M<@)+3GT"24Z+ TA.F01'3Z@$1D^Z!$9/T01&3^T$1D[\!$9._P-'3O\#1T[_
M [U,  "N4@  G%$  (U1  "!40  =U   &Y,  !G3@  8D\  %U0#0!:4!0
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M CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;_P,X6_\#.%K_ [)7  "@6@
MCUD  (%9  !U60  :UD  &!:  !66P  45T  $Q> @!(8 T 16 4 $1A'@!"
M8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4 .6-> #AC: $V8W0!-6.! 3-C
MD0(R8Z$",6.S C%CR (Q8N<",6'X C%A_P(R8/\",F#_ JY<  ";70  BET
M 'Q=  !P70  9ET  %Q>  !28   3&(  $5E  !!9@H /F<1 #QH&@ [:"(
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M !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C:@
M66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$(@ <
MA2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F !&%
MNP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<   4W,
M $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2D"(
M$9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0LP '
MC\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T  $.!
M   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H !YPB
M  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@  F[\
M )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,   R
MD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<  "H
M(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4  *C+
M  "GY   I^\  *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   JG@
M(:(  !FF   2J0  #:P   >O    L@   +,'  "S#   LQ   +05  "T&P
MM2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^  "W
MT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP  &:\
M !&S   +M@  !+D   "\    O@   +X   "_!@  P L  ,$/  #"$P  PQD
M ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*P0
MR=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P   J_
M   !P0   ,0   #(    R@   ,H   #,    S0,  ,X(  #0#0  T1   -,6
M  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@  X+X
M .## &:?  !9I@  3*T  #^T   RN   )+P  !B_   0PP  ",<   #*
MS0   -$   #5    V    -D   #;    W0   -\   #A!   XPH  .4.  #G
M$P  ZAP  .TG  #P-0  \48  /)8  #S:P  \X   /24  #THP  ]*X  /2R
M /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^ &,
M^P!K /D <@#W '@ ]0!^ /0 A #R (D \0". /  DP#N )D [0"? .P I@#J
M *X Z "X .8 Q0#E -L XP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_ /\
M$ #_  X _P - /\ $@#_ !L _P H /\ - #^ $$ ^P!, /< 5@#T %\ \0!F
M .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#> *H
MVP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\ #0#_
M  D _P * /\ #P#_ !8 ^P B /< +P#T #L \ !' .T 40#I %H Y0!B .(
M:0#@ &\ W@!U -P >@#: (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8 RP"O
M ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_  $
M_P & /\ # #Y !$ \0 = .L *0#G #8 XP!! -\ 2P#; %0 U0!< -( 8P#/
M &H S0!P ,L =0#) 'L R "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K +L
MM@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T /\ M #_ /\$  #_    _P
M /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#! &0
MOP!J +T < "\ '4 N@![ +D @0"W (< M0". +, E0"R )X L "G *X L@"L
M +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,  .@
M  #A  < U0 0 ,T &P#' "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\ L@!E
M +  :@"O '  K0!V *P ? "J (( J0") *< D0"E )H HP"D *$ K@"@ +L
MG@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/  #.
M"P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4( K09* *H&4@"H!UD I@=? *4'
M90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":"9< F JA )8*K "5"[H DPO,
M )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^%0
MN1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/8 "8
M$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++ (83
MY@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P  JQH
M *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )061P"2%DX D!95 (X76P",%V$
MBQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<X@!Z
M'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0  ORP  + J  "G)P  H",  )T?
M  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP @!]B
M '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4BI !T(K( <R/# '(CWP!P)/,
M;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(  *@P  ">+@  ERH  ),G  "0
M(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0 ?"9+ 'HF4@!X)E@ =R9> '4F
M90!T)VP <B=T '$G?0!O*(@ ;BB4 &PHH0!K*:\!:BG  6DJVP%G*O$!9RO_
M 68K_P%F*O\!9BK_ =0O  #"-@  KS8  *$U  "6-   D#   (HM  "'*@8
M@RD0 '\J&@!\*R4 >2LO '<L. !U+$  <RQ' '$L30!P+%0 ;BQ: &TL80!K
M+6@ :BUP &@M>@!G+H4 92Z1 60NG@%B+ZP!82^] 6$PU0%@,.\!7S#] 5\P
M_P%?,/\!7S#_ <TT  "\.P  J3H  )LZ  "0.   B34  (,R  !_, $ >R\.
M '<P%@!T,"$ <3$K &\Q- !M,3P :S%# &HQ2@!H,E  9S)7 &4R70!D,F4
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M < _  "N0P  G$,  (Y#  ""0@  >D   ',]  !M/   :#T% &0]#@!A/A<
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M 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)_P) 2/\"0$C_ ;9)  "B2@
MD4H  (-*  !W2@  ;DD  &5%  !>1P  64@  %5)" !12A  3TH8 $Q*(0!*
M2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#358 0DU? $%-: ! 370!/DV! 3U-
MD $\3: !.TZQ CI.Q@(Z3N0".TWV CM-_P$[3/\!/$S_ ;--  ">3   C4P
M '],  !T3   :DP  &!*  !92P  5$P  %!-!0!,3@X 24\5 $=/'@!%3R8
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M 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5  "/50  ?U4  ')5  !G5@
M7E8  %17  !,60  15L  #]=   Z7P0 -F - #1A$P R8AP ,6(C #!B*P O
M8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D )V1V "9DA@ E9)< )&2I "-D
MO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60  6EH
M %!<  !(7@  06   #IC   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G:BX
M)FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MKN@ :
M:]0 &VKN !QI_  <:/\ '&C_ )5<  "#7   =5P  &E=  !?70  5EX  $QA
M  !#9   /&<  #5J   O;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@ '70P
M !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1=,\
M$G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A  !;8@  460  $AG   ^
M:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ !)^
M,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8 "GWD
M  I\]  +>_T "WK_ (9E  !W90  :F4  &%F  !6:   3&L  $)O   Y<P
M,7<  "IZ   C?@  '($  !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)*P )
MB3, "(D]  :)2  %B50 !(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:  "&
M[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0<   1G0  #QX   S?0  *H$
M ".%   <B   %8P  !"/   ,D@8 !I,,  *3$0  E!8  )0=  "4)   E2P
M )4U  "50   E4P  )99  "6:0  E7H  )6.  "4H0  E+4  )/,  "2Y@
MDO(  )+W 'AP  !M<   8'(  %1U  !)>0  /WX  #6#   LB   (XT  !N1
M   4E   #Y<   J:   $G0,  )X)  "?#@  GQ(  * 7  "@'0  H24  *(M
M  "B-P  HT,  *-0  "C7P  HW$  *.$  "BF0  HJT  *'"  "AW   H>L
M *#R '-V  !F=P  67L  $V   !"A0  .(L  "Z0   DE0  &YH  !2>   .
MH0  ":0   *G    J@   *L$  "K"@  K T  *T1  "M%@  KAP  *\D  "P
M+0  L3D  +%&  "R50  LF8  +)Y  "RC@  L:,  +*W  "QR@  L>   +'I
M &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>   <HP  $Z<   VK   'K@
M +(   "U    MP   +@   "Y @  N0@  +H,  "[$   O!0  +T;  "_(P
MP2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3: &6)
M  !8C@  2Y4  #^;   SH@  **@  !VM   4L0  #;8   :Y    O    +\
M  ##    Q    ,4   #&    QP   ,D$  #*"0  RPT  ,T1  #/&   TB$
M -4M  #6/   V$T  -E?  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6  !1
MG   1*,  #BJ   LL0  (+<  !6[   -O@  !,(   #%    R0   ,T   #0
M    T@   -(   #5    U@   -D   #;    W@4  . *  #B#P  Y18  .@@
M  #L+0  [3X  .U1  #N90  [WH  .^/  #PGP  \*L  /"S /\ $ #_  X
M_P . /\ $@#_ !T _P I /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8 ;0#T
M '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S .,
MP #A -( X #J -\ ^0#= /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H _P )
M /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I &\
MYP!U .4 >@#C '\ X@"% .  B@#> )  W "6 -H G0#8 *4 U0"O -( N@#0
M ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P % /\
M# #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D %4 X != -T 9 #: &H V !P
M -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#! ,,
MOP#: +X [@"] /P O #_ +P _P"\ /\ O #_ /\   #_    _P   /D !P#Q
M !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J ,4
M< ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y )P MP"E +4 L "S +T L0#/
M *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\   #_    _0   .X  0#C  P
MV@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8 :@"T
M &\ LP!U +$ >@"P ($ K@"( *T CP"K )@ J0"A *< JP"E +@ HP#( *(
MX@"A /, H #^ *  _P"@ /\ H #_ /\   #V    Z@   .    #3  8 R0 /
M ,( & "] "0 N0 O +8 .@"T $, L0!, *X 4P"L %D J@!? *D 9 "G &H
MI@!O *0 =0"C 'L H0"" *  B@"> ), G "= )H IP"8 +0 E@## )4 W "4
M .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P  W T  ,L*  #"!0  O  * +8
M$0"Q !P K@ H *H ,P"G #T I !% *( 30"@ %, G@!9 )P 7P"; &0 F@!J
M )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(!NT
MB ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4  +P2  "S$   K@P  *L&#0"G
M Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE (T*
M:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\ ? _]
M 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<  "F&0  H14  )X0! "=#0\
MF X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/ (<050"%$%L A!%A ((19P"
M$6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;] '$6
M_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<(0  EAX  )(9  "1% L C104
M (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V&&D
M=!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>_P!G
M'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*   C24  (@B  "&'08 @QL0 '\<
M&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4 :R!M
M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?)/\
M7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H  ( H  !])   >B(- '8C%0!S
M(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I &$F
M<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\ 6"K_
M ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K*1L
M:2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL;P!8
M+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__ ,$V
M  "J-@  F38  (LV  "!-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@ 8BXA
M & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2,G<
M43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY  "F
M.0  E3D  (<Y  !\.0  =#<  &XT  !I,P  93(" &$R#0!>,A0 7#,> %HS
M)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4 2S>"
M $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B/
MD3P  (,\  !X/   <#H  &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W(P!2
M-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN  $4[
MC@!$/)X 0SRN 4(\P@%"/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@  C3X
M '\^  !U/@  ;#T  &8Z  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,.R@
M2SLO $D\-@!'/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _C0 _
M0)P /D"M 3U P $]0-T!/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$  'Q!
M  !Q00  :$   &$\  !;/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4 1D L
M $1 ,P!#0#H 0D%" $%!20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z1)L
M.42K 3E$O@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#  !N
M0P  94,  %U   !60   44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J #]%
M,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D -$BJ
M #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J1@
M844  %E$  !11   3$8  $A'  !$1PH 04@0 #])&  ]22  /$DG #I*+@ Y
M2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH "Y-
MNP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20  74@
M %5(  !,20  1TH  $)+   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S3S,
M,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U "M1A  J4I4 *5*F "E2N0 H
M4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@  >DL  &U+  !C3   6DP  %%,
M  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\ +%8W
M "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B5\\
M(E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X  &E.  !?3P  5D\  $U0  !%
M4@  /U,  #E6   S6   +UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS "1=
M.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P &UWI
M !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12  !;4@  4E,  $I4  !!5P
M.UD  #5;   N7@  *& # "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD-@ ;
M93X &F5' !EE40 895T %V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G !-C
M]P 48O\ %&+_ (E4  !X50  :U4  &!6  !75@  3U<  $99   ]7   -E\
M #!B   I9   (V<  !UJ!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3;3D
M$FY" !%N3  0;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -
M:_T #6K_ ()9  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II
M   D;   '6\  !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\
M  EW1P (=U( !W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8
M G3\ 'M=  !M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >
M=0  %WD  !)\   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""
M0   @DP  ()9  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y
M '1B  !H8@  7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@
M$8,   V&   (B00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0
MCD0  (Y1  ".8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH
M  !D9P  6&D  $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\
M  :2    E0   )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L
M )Q(  "<5P  G&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>
M;P  47(  $9W   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@
M    H@   *,!  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^
M  "L30  K%T  *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0
M2WX  #^$   TB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N
ML    +    "Q    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]
M00  O5(  +UD  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L
M #B2   LF0  (9\  !>D   0J0  ":X   "R    M@   +D   "]    OP
M +\   #     P0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0
MT44  -)7  #2:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B
M   EJ   &JX  !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T
M  #/    T    -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@
M .A*  #I70  ZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_
M !H _P F /\ ,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X
M>@#L '\ ZP"$ .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F
M -D ]P#8 /\ V #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4
M_@ A /H + #W #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#>
M 'H W0!_ -L A0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@
M\0#' /\ Q@#_ ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 <
M .P )P#I #( Y@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4
MR@!Z ,D ?P#' (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W
M /L M@#_ +8 _P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L
M(0#5 "T T0 W ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T
M +D >@"W (  M@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4
MIP#_ *< _P"G /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #"
M "8 OP Q +P .P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H
M= "I 'H IP"! *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#]
M )@ _P"8 /\ F #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "
ML  K *T -0"K #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@";
M '4 F@![ )@ @P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P
M_P", /\ C #_ /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D
M *  +@"> #< G !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\
MC0!V (L ?@"* (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_
M /\ ?P#_ .@-  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4
M)P"2 #$ D  Y (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R
M ( $>@!^!(0 ?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\
M<PK_ -T5  #$%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "(
M"2H A0HS (,+.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-
M=@!T#8  <@V, ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_
M - =  "Y'@  J!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0
M>Q M 'D0-@!W$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I
M$WT :!.) &83E@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B
M  "P(P  GR0  )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H
M &\7, !N%S@ ;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D
M7QJ% %T;D@!<&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I
M*   F2@  (LH  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=
M+ !E'3, 8QXZ &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&"
M %4AD !4(IX 4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+
MDRP  (8M  !\+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=
M(R\ 7",V %HC/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XG
MC0!-*)P 3"BL $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC
M ($P  !W+P  ;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L
M52@R %,H.0!2*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'
M+9H 1BVJ $4NO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS
M  !R,P  :S$  &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO
M $TM-@!,+3P 2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@
M03*H $ RNP _,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N
M-0  9C4  &$R  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q
M,@!&,3D 1#%  $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G
M #LVN0 Z-M$ .C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.
M8S<  %TV  !7,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P!
M-38 /S8] #XV1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8Z
MN  U.L\ -CKL #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH
M %DY  !3-@  3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0
M.CH[ #D[0@ X.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q
M/LT ,3[J #$^^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\
M  !..@  23L  $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X
M #0_0  S0$@ ,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL
M+$+I "Q"^0 M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)
M/@  1#\  $!    \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$
M/0 N144 +45. "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G
M "=&^  H1?\ *$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@
M/T0  #M%   W1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H
M2D( )TI+ "9+50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+
M]P B2O\ (DK_ )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@
M #=)   R2P  +DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\
M(5!( "!04@ ?45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;
M3_\ '$__ (I&  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.
M   N4   *%," "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$
M !E73@ 85UD %UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\
M%%7_ (1)  !T2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I
M5@  )%D  !Y;!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?
M2@ 17U4 $%]B  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_
M 'Y-  !N3@  8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70
M'U\  !EB 0 390D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *
M9U  "6==  =G;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1
M  !I4@  75(  %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<
M !-J   /;08 "W ,  AP_^+_XDE#0U]04D]&24Q%  0)$0 '<!8 !7 =  1P
M)  #<"P  G U  !P/P  <$H  '!7  !P90  <'8  '"*  !OG@  ;[(  &[(
M  !MY0  ;?(  &WY '!6  !C5@  658  %%7  !'6   /EL  #9?   N8@
M)F8  !]J   9;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y'P
M>B8  'HO  !Z.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"  !X
MWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;   ('
M !ET   3=P  #GL   E^   $@0(  (((  "##0  @Q   (04  "%&0  AB
M (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%TP
MA.H  (3T &5@  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L  !*
M   -@P  "(<   **    C0   (X$  "."0  CPT  ) 0  "1%   DAD  ),@
M  "4*0  E3,  )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R   D^(
M )/N &%E  !69@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-   &
MD0   )0   "8    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8  "C
M(   I2D  *8V  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$  *3D
M %ML  !/<   0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<    H
M *,   "F    J    *D   "J    K    *T$  "N"0  L T  +$1  "S%P
MM2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0 %1V
M  !(?   /((  #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@   +(
M  "V    N    +@   "Z    NP   +T   "^    P 4  ,$+  ##$   QA8
M ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#  !!
MB@  -9$  "F9   >H   $Z8   RL   #L0   +8   "Z    O@   ,(   #&
M    R    ,@   #*    RP   ,T   #.    T    -(!  #5"   V0X  -T5
M  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_  4
M_P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /  8P#N
M &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J -H
MM@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_    _P !
M /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#? &0
MW0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,< L #&
M +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P   /H
M!P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\ R0!E
M ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V +<
MM #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H  @#A
M  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !? +<
M9 "U &D M !N +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$ I #!
M *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+  @
MPP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *< 7@"F
M &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z )0
MSP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  ( LP ,
M *T $@"J !P IP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7 %T
ME@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8 QP"%
M .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ ' *
M#@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@ B0!=
M (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y -T
M> #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4 "@"1
M !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8 'P
M7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8 ;0+M
M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'!0P
MA $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%60!P
M!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL &(,
M^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8 ? H.
M '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G#5P
M90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1_0!9
M$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$) &\0
M$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@ 7!)?
M %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1%_\
M41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85#@!C
M%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA< %(9
M9 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\ 2AW_
M *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;&Q(
M61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?80!)
M'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_ *8G
M  "3*0  @RH  '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\ 4B$6
M % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#)&D
M0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J  ".
M*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43 $HF
M&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68 /"IR
M #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*+@
M>R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J%P!"
M*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP #8O
M?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0  =S(
M &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]+AP
M.RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S?0 P
M,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0  &@U
M  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD -C,@
M #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K-XL
M*CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W  !;
M-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@= "\X
M)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D )3R;
M "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8.@
M43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H](0 I
M/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9 !]!
MJP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/   33P
M $<\  ! /   .#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C0R4
M(D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&J0 8
M1KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\  $0_
M   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22( '$DI
M !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 22[P
M$4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"   Z
M0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E !10
M+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@ #%'1
M  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V2
M+TH  "E,   D3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8*  -
M6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*  57
MY@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2   04D  #I*   R30  *U
M "52   @50  &E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %8"L
M!& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>X@
M7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8  "!9
M   :7   %5\  !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28  &DN
M  !I.   :4,  &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW   9NX
M &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB   4
M90  $&@   QK   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H  !S
M,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L  '#T
M &%3  !64P  3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /;P
M"W(   9V    >0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  " *@
M@#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ %Q8
M  !46   25H  #]=   U80  +&4  "-J   ;;P  %',   YW   )>P   W\
M  ""    A    (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@  CRP
M (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=  !.
M7P  0V(  #AF   N;   )'$  !QW   4?   #H$   B%    B0   (T   "0
M    D@   ),   "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,  * N
M  "@/   H$P  *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !':
M/&T  #%S   G>0  '7\  !2%   -BP  !I    "4    F    )P   "?
MH0   *(   "D    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C  "R
M,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P  -7H
M "J!   ?B   %8X   Z5   &F@   )\   "D    J    *P   "O    L0
M +$   "S    M0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%)@
MQ3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD  "*0
M   7F   #Y\   >E    J@   *\   "S    MP   +P   "_    P0   ,(
M  #$    Q0   ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@  W2H
M -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\ # #_
M !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I .<
M;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,  SP#:
M ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[ !
M]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -, :0#1
M &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#- +P
MZ@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T Y  4
M -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_ &D
MO0!N +L <P"Z 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P X0"K
M /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1 ,<
M&0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &, K !H
M *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@"; .X
MF@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0 % "Q
M !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B )L
M9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8 BP#Y
M (H _P"* /\ BP#_ /    #;    QP   +H   "P    J  * *0 $ "@ !@
MG0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P 80"+
M &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R 'T
M_P!] /\ ?0#_ .    #&    M0   *H   "B    FP % )4 #0"2 !, D  <
M (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^ &(
M?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '  ^P!P
M /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6 ($
M'@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T <0!C
M &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E /\
M90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '< & !U
M "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!? &4
M9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX 6P;_
M +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L!!L
M:04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)8P!:
M"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_ *T5
M  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4 80P=
M %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2#FL
M4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49  "2
M'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8 %<1
M( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V< 2!1S
M $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",(
M?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6' !.
M%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP #\:
M?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P  >"0
M &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'&R
M11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?>P X
M((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<  &@H
M  !?*   6"<  %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P /R C
M #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R)8D
M,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J  !<
M*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20? #<D
M)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8< +"F8
M "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9+0
M42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H(P P
M*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7 "8N
MJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P  3B\
M $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K+2<
M*BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$RIP A
M,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$  $4Q
M  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0 )3,K
M "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;-KD
M&S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S   ]
M,P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H !\X
M,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[< %3O0
M !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z-@
M-#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^+0 9
M/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#. !$_
MZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0  ,3H
M "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 31#$
M$D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%Y0 -
M1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX  "A
M   C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT #4LV
M  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %2O
M!DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%   ?
M1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R  12
M.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X  %#W
M &A   !;00  4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;30
M%E   !%3   .500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9-@
M64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V &-$
M  !610  344  $5%   _10  -T<  "])   H3   (D\  !M2   650  $5@
M  U:   )70, !%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0  8CL
M &)'  !B50  8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(  !2
M20  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6    AC
M   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30  &U
M  !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.30
M2$P  #Y.   U40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N
M<    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY  !Z
M1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40  0E(
M #A5   O60  )EX  !YB   69P  $&L   MO   %<P   '<   !Z    ?
M 'X   !_ @  @ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*/@
MB4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H  #)?
M   H9   'VD  !9O   0=   "GD   )]    @0   (4   "(    B@   (P
M  "-    CP   ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-   FT0
M )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ   A
M<0  %W<  !!]   )@P   8@   ",    D0   )4   "8    F@   )L   "=
M    GP   *    "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D  *U+
M  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9?P
M$(8   F-    DP   )@   "=    H0   *4   "H    JP   *L   "N
MKP   +$   "S    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)   #"
M5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D   "I<
M  "=    HP   *@   "M    L@   +8   "Y    NP   +P   "^    P
M ,(   #$    Q@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #920
MVEX  -MU  #;C   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9 /X
M) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X W@!S
M -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#& /\
MQ0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X 'P#K
M "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M ,<
M<P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L M #_
M +0 _P"S /\ K@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2 "0
MSP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4 ;0"S
M ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_ *,
M_P"C /\ H@#_ /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\ N0 H
M +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A &P
MH !S )X >@"= (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ), _P"3
M /\ DP#_ /<   #D    T    ,$   "W  ( KP + *L $0"G !D I0 B *,
M*P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8 D !M
M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$ /\
MA #_ .4   #-    O    *\   "F    G@ ' )H #@"6 !0 E  = )( )0"1
M "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G (
M;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\ =0#_
M -    "[    JP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( "" "<
M@0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ', :0!Q
M '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_ ,
M  "L    G (  ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "( =  I
M ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E &P
M9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'  "@
M"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C &@
M*@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@ 6@!R
M %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6#@
MAQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X )0!=
M "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O $\$
M>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@  ?A0
M ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5!R<
M4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+>@!&
M#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@  &P9
M  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2( 3 TH
M $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^$(@
M/1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=  !>
M'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D $01
M*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84 -A66
M #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:(
M4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5)P [
M%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4 "X;
MI0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P  3R(
M $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U&BD
M-!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?I  H
M(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4  $<D
M  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8 +A\M
M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B)+4
M(B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G   _
M)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J "<C
M,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0 '2C*
M !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \*
M-R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H+@ A
M*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S) !@L
MYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P  -"H
M # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <+3,
M&RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,PY0 4
M,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T  "PM
M   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$ %C,Y
M !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0-/4
M$#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ   D
M,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV ! Y
M0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$ ##C\
M &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A-@
M'3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^/  +
M/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W &DS
M  !;-   4#4  $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P  &CP
M !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #14(
M D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V  !7
M-P  3#@  $,X   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(  !)$
M   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX  $Q)
M  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2.P
M2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+   +
M3@, !U (  )1#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%  !3
M4@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@  13X
M #X^   X/@  ,$   "E"   C1   '4<  !=*   230  #E    M3   &50(
M %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<30
M7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(  #Q"
M   T0P  +$8  "5)   >3   %T\  !)3   .5@  "ED   5;    7@   & $
M  !A"   8@P  &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@  9U4
M &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='   O
M2@  )DT  !]1   850  $ED   U<   (8    F,   !F    :    &H   !K
M!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X  '-?
M  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I4@
M(%8  !A;   27P  #60   =H    :P   &\   !R    =0   '8   !W
M>0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16  "#
M:@  @X$  (*9  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7   &6(
M !)G   ,;   !7$   !U    >0   'T   "!    @P   (4   "&    B
M (D   "+!   C0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "58
ME78  )20  "3IP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\   QU
M   $>P   (    "%    B0   (T   "1    DP   )0   "6    F    )H
M  "<    G@   * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@  J&T
M *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%
MBP   )$   "6    FP   )\   "B    I    *4   "G    J0   *L   "M
M    L    +(   "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$  +QZ
M  "[E   NJD  +JY #=J   K<   ('@  !:    -B   !8\   "6    G
M *(   "G    K    +    "S    M@   +<   "Y    NP   +T   "_
MP@   ,4   #(    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N  #4
MA@  U)L  -.K /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H ]@ T
M /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3 'D
MT "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T _P"W
M /\ L@#_ /\   #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N -\
M. #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ', O0!Z
M +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I /\
MI@#_ /\   #_    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4 ,@#
M #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S *D
M>P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\ F0#_
M /P   #N    W0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M #0
MJ0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )< = "5
M 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_ .T
M  #8    Q0   +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X EP U
M )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"% '8
MA "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D   #!
M    L0   *0   "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O (4
M-@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '  =0!Z
M ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O
MH    )0   ",    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '< , !U
M #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T &8
M@ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@    D0
M (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I #
M:  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H >@!9
M (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<  'H'
M  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L 70 P
M %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/ (0
M3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -  !H
M#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K %(
M,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (  10"0
M $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@$0
M6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"+ !)
M C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:. #P'
MGP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0  5!0
M % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!"2X
M0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-GP S
M#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@  $H6
M  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H .0TP
M #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L$;(
M*Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:  !"
M&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M #(1
M,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;  )17&
M "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^'
M.AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5,  J
M%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$ !\9
MX@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@  -QT
M #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D&C4
M(QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>X  :
M'?, &QW_ '<=  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R   # ?
M   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C( 'A\Z
M !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5(?(
M%B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB   I
M(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X !@D
M00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$ $B7]
M ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F)
M(B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I/@ 2
M*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[ &PD
M  !=)@  42@  $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*   'BD
M !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .+D8
M#2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G  !:
M*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT  !@N
M   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T( "3-.
M  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6+
M2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R   2
M- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*   Y
M5P  .64  #EW   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@  2"\
M #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /.0,
M##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _4P
M/V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(  #PR
M   U,@  ,#$  "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P, "$$(
M  1##   0PX  $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@  1ET
M $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU   S
M-   +C0  "@U   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&  !)
M"@  2@T  $L0  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@  $UI
M  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q-P
M*CD  "0[   >/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1"
M4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C  !6
M=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/   )C\
M !]"   910  $T@   Y+   +3P  !5$   !4    5P   %@!  !:!0  6P@
M %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A<
M8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\  #%    I0P  (48  !I*
M   33@  #E$   I5   $6    %L   !>    80   &,   !D 0  900  &<(
M  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:   ;7\
M &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4   .
M6   "%P   )@    9    &<   !K    ;0   &\   !P    <@   '0"  !U
M!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<  'R0
M  ![J   >L   'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '90
M &H   !N    <@   '8   !Y    ?    'X   !_    @0   (,   "%
MAP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&  ".
MGP  C;4  (S- #U.   R40  *%8  !Y<   58@  #F@   =N    =    'D
M  !^    @@   (8   ")    C    (X   "0    D@   )0   "6    F
M )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "CE
MH:L  *&_ #97   L7   (6(  !=I   /<   !W<   !^    A    (H   "/
M    E    )@   ";    G@   )\   "B    I    *8   "H    JP   *T
M  "P    LP0  +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP  MZ$
M +>S #!B   E:0  &G   !!X   )@    (@   "/    E@   )L   "A
MI@   *H   "N    L    +$   "T    M@   +@   "[    O0   ,    ##
M    QP   ,L#  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98  ,RI
M /\   #_    _P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I $
MY@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@ @@#&
M (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_ /\
M  #_    ^P   /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L S !"
M ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R (4
ML "0 *X G "L *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T   #V
M    ZP   -\   #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \ +,
M0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T G@"(
M )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F
MT0   ,(   "X    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\ / "=
M $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "! (H
MC0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+    N@
M *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+ #P
MB0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H A@!X
M )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@   )H
M  "2    B@   (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8 >@ [
M '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I (T
M: "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H   "!
M    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U &H
M.@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (< 6P"6
M %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S
M;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X -0!=
M #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1 $\
MH@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P  8@$
M %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2 #0
M40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4 G0!%
M +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D  %4'
M  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #  2  U
M $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \ *L
M/ #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,  !+
M"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q #X
M-@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@ ,P"\
M #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$#@
M0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#,@ V
M!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z "L'
MT@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@  /!
M #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O"C8
M+@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-T@ C
M#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,  #41
M   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0 * X[
M "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =$.X
M'1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5   N
M$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y "$1
M0@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X &!/Z
M ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J%@
M*!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5/P :
M%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z &P9
M  !=&P  41T  $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0  )!@
M "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5&D<
M%!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;  !:
M'0  3A\  $4?   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L  !T;
M 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4 $!]0
M  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7'P
M3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@   6
M( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-  LD
M60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0  22,
M $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3) ,
M$24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H50 %
M*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4  #TE
M   U)0  +R4  "HD   F)   (B,  !\C   ;)   &"4  !0F   1* , #RD(
M  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@  +F
M "YQ   MA   +9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG   S
M)P  +2<  "@F   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'  DP
M#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT  #-M
M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P*@
M*RD  "<H   C*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U"P "
M-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI   Y
M?0  .),  #BH   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+   *BL
M "4K   @+   &RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@  / T
M #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _>
M/X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X  "(O
M   =,   &#(  !,U   0-P  ##H   D\   %/@   $$$  !""   0PL  $0-
M  !&$   1Q0  $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P  1XH
M $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T   9
M-@  $SD  ! \   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+  !.
M#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0  $^=
M  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4/@
M$$$   Q$   '1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7"P
M60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7  !9
MKP  6,L  %?J #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P  "TH
M  5.    40   %0   !7    6@   %P   !=    7P   & $  !B!P  9 L
M &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !FJ
M9<(  &3C #T]   W/   +CT  "5    =1   %DD  !!-   *40  !%4   !:
M    70   &    !C    9@   &@   !J    :P   &T   !O @  <08  '0*
M  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP  =;<
M '32 #Q!   R0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G
M:P   &\   !R    =0   '<   !Y    >P   'T   !_    @@   (0#  "'
M"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T  (?%
M #9'   L2P  (D\  !E5   06P  "F$   %G    ;0   '(   !W    >P
M '\   "#    A@   (@   "*    C0   (\   "1    E    )<   ": 0
MG0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW #!0
M   E50  &UL  !)B   +:0   7    !W    ?0   (,   "(    C0   )$
M  "5    F    )H   "<    GP   *$   "C    I@   *D   "L    L
M +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;   >
M8@  %&D   QQ   ">0   ($   ")    CP   )8   ";    H    *0   "H
M    JP   *P   "O    L@   +0   "V    N0   +P   #     Q    ,@
M  #-!P  TA   -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_
M^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X 20#:
M $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2 +L
MG@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W    \@
M /    #G  , X0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_ $D
MO !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@ EP"E
M *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP   -,
M  #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $, J !(
M *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3 )X
MD0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@   "N
M    J  $ *4 # "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!" )(
M1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8 ?P"G
M 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9
MDP   (\ "0"-  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (  0 !_
M $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"? &X
ML@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K    FP   (\   "'    @
M 'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N #\
M;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\ J@!>
M ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@   '\   !W    <0   &T
M  !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D 8  ^
M %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2 +@
M40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$   !I    9    &    !>
M  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X %,
M/0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$ 1P#,
M $8 \ !' /\ 1P#_ )    !^    <    &8   !>    60   %8   !3  $
M4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@ . !'
M #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0## #T
MY@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0  20 $
M $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^ #H
M/0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0 W0 T
M /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4! #\!
M!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4 -  \
M #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L .X
M+ #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@) P W
M!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X "P
M0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@ )0#W
M '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P"P4
M, @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%/0 D
M!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S &T.
M  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@, *@T'
M "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >"T0
M'0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0  !:
M$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $ ",.
M"  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0 %PY0
M !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7%
M2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1!@ =
M$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A). !$2
M6@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@  21@
M #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9$@8
M%Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X65P -
M%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH  #T:
M   U&P  +QH  "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0 $Q8)
M !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )&F$
M!QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<   S
M'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'  X;
M#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX  A]N
M  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P'@
M*AX  "4=   A'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?"P *
M( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K   C
M?@  (Y,  "*G   BO   (=<  "'M %4=  !('P  /B   #4@   N(   *"
M ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &)0T
M!"40  (F%   )AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G>P
M)Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$  "(A
M   >(   &Q\  !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T  "L/
M   L$@  +!<  "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P  +(T
M "RD   KN@  *]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B   =
M(@  &2(  !4C   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .   R
M$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH  #*A
M   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;)0
M%B8  !(H   0*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X#@
M.A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>   X
MM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0  $RL
M ! N   -,   "3(   4U   !-P   #D"   [!0  / @  #X+   _#0  01
M $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _L@
M/L\  #[O #\L   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(   TU
M   (.   !#H    \    /P   $$   !# @  104  $8(  !("P  2@X  $P1
M  !-%@  31X  $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0  2,H
M $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]   "
M0    $,   !&    2    $H   !,    3@$  $\$  !1!P  4PL  %4.  !8
M$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(  %+F
M #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,0   !T0   !'    2@
M $T   !0    4P   %4   !7    60   %H   !< P  7@<  &$+  !D#@
M9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[< #4W
M   P-0  *#<  " Z   8/0  $4(   Q&   &2@   $\   !3    5@   %D
M  !<    7P   &$   !D    90   &<   !I    ; $  &X&  !Q"P  = \
M '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z   K
M.P  (C\  !I#   22   #$T   52    5P   %P   !@    9    &@   !K
M    ;@   '$   !S    =0   '<   !Z    ?    '\   ""!   A@H  (H/
M  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E1
M'$D  !-.   -5   !%H   !A    9@   &L   !O    =    'D   !]
M@    (,   "%    AP   (H   ",    CP   )(   "6    F0(  )X)  "B
M$   HAH  *$I  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@  %50
M  Y;   %8@   &D   !P    =P   'T   ""    A@   (L   "/    DP
M )4   "7    F@   )T   "@    HP   *8   "J    K@   +(   "W"@
MNQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(   =J
M    <P   'L   ""    B0   )    "5    F@   )\   "C    I@   *@
M  "K    K@   +    "S    M@   +H   "]    P@   ,<   #, 0  TPL
M -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$   #S
M  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/ ,X
M5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L L0#
M *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?
MV0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4 3@"S
M %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V )L
MU "9 /D E@#_ (T _P"( /\ A #_ .@   #?    V0   ,D   "_    N  $
M +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 "> $P
MG !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D Q0"(
M .X A@#_ '\ _P!Z /\ > #_ -D   #-    NP   *X   "E    GP   )P
M"0"9  \ F0 5 )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+
M (8 4 "% %4 @P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .
M=0#_ '( _P!N /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$
M  P @@ 1 (( %P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4
M20!S $\ <@!5 '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U
M &0 _P!A /\ 8 #_ +0   "@    D    (4   !]    =P   ',   !P  @
M;P . &\ $@!O !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C
M $@ 8@!. &$ 50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %<
M_P!6 /\ 5 #_ *$   ".    ?P   '4   !L    :    &0   !A  0 8  +
M %\ #P!? !, 7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $,
M50!) %, 4 !2 %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!*
M /\ 2@#_ )(   "     <@   &<   !?    6@   %<   !5  $ 4P ' %(
M# !2 !  4@ 4 %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!#
M $@ 2@!& %( 10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\
M0 #_ (4   !T    9P   %T   !5    3P   $P   !*    2  $ $< "@!'
M  T 1@ 1 $8 %0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T
M10 \ $X .P!7 #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_
M 'P   !K    7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L
M/0 . #P $0 \ !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S
M $D ,@!3 #$ 7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!
M  !D!0  5P<  $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  ,
M #0 #P T !( ,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4
M*@!/ "D 6@ H &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>
M"0  4@L  $@,  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P
M#0 L !  *P 3 "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+
M "( 5P A &0 ( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#
M30T  $,.   \#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E
M PX ) $0 "0!%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!
M5  : 6$ &@%P !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\
M $ 0   X$   ,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP
M'@8. !X%$0 <!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5
M!U\ % =N !,'@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1
M   U$0  +Q$  "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H-
M !@)$  7"1( %@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\
M#PQN  X,@  .#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R
M$P  +!,  "<2   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,
M#0 2#!  $@P4 !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M
M  H/?P )#Y, "0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%
M*10  "44   A$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .
M#@X #@\2  T0&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82
M?  %$I  !!*D  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8
M "(5   >%   &Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X
M"Q(1  H2%0 )$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@
M%8X  !6C   4MP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6
M   <%@  &14  !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80
M  86$P %%AD !!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P
M !BB   8MP  %\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;
M%P  &!8  !45 @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;
M$@ !&Q8  !L=   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@
M   <M@  &]   !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0
M%Q@  !07 P 2%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$
M(!0  "$:   A(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @
MM@  ']$  !_M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD!
M !,9 0 1&0$ #AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(
M "88   G'P  )R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM
M)-$  "/N $0=   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<
M   .'0  #1\   HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5
M   M'   +20  "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M
M "GO $ @   V(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -
M(@  "B0   8F   "*    "L"   M!   +P8  # )   R#   - X  #42   U
M&   -2   #4J   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O
M #PC   R)   *B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0
M!2L   $N    ,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%
M/AP  #XF   ^,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G
M   O)P  *"8  ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,
M   U    .    #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<
M $@A  !(+   1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L
M*@  )R@  "(G   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^
M    00   $,   !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<
M  !3)P  4S0  %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+
M)BL  !\L   8+@  $C(   TU   (.0   CT   !     0P   $8   !)
M3    $X   !1    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C
M'P  8BP  &$\  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C
M !HS   3-P  #CL   @_   !1    $@   !,    3P   %(   !5    6
M %L   !=    8    &(   !D    9@   &D   !M!0  < L  '00  !T&
M<R4  '(T  !R10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\
M   .00  !T<   !,    40   %4   !9    70   &$   !E    :    &L
M  !M    ;P   '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P
M (@K  "&/0  A%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (
M3@   %0   !:    8    &0   !I    ;@   '(   !V    >@   'T   "
M    @@   (4   "(    BP   (X   "2    E@   )L#  "@#   HA,  * A
M  "?,P  G4<  )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7
M &,   !J    <0   '8   ![    @    (8   "*    C@   )$   "3
ME@   )D   "<    H    *,   "G    JP   +    "V!   O T  +H7  "Y
M*   MSP  +12  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0
M  !\    @P   (D   "/    E    )H   "?    H@   *0   "G    J@
M *X   "Q    M    +@   "\    P0   ,<   #-    U 4  -@0  #5'@
MTS$  -!(  #-7P  RW8  ,B.                       ! P0%!@@)"@L-
M#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&
M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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M________________________________________________
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M^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
MLVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\
MNZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[
MQ+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6H
MB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN;9RPD;Y\X-.>C-$&#<R0V2R[LPJ\:X3[3 LV>]NZY[Q+6IB,NR
MIH?1KZ.'U:V@B-FKGHG<J9R*WJ>;C."EF8_CH9B0Y*&8D.2AF)#DH9B0Y*&8
MD.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0
MY*&8D.39RPD:Y,X-.>?.#F#:R@R2R[PNJ\6Y3;3 M&:]NJYZQ;6IA\NQIH?1
MKJ.'U:R@B-FJGHG<IYR*WJ6;B^"BFHWBGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>
MF8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9
MC^/8RPD:X<\,.>7/#F#9R@R1R[XLJ\6Y3+6^M&>]N:Y[Q;2JA\RPIH?1K:.'
MU:N@B-FHGHC;I9V)W:.<BM^?FHOAFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[B
MFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN+8
MRPD:W- +.>/0#6#8RPN1R[\KJ\2Z3+6]LV>^N*Y[Q;2IA\RPIH?1K*.'U:F@
MA]BFGXC;HYV(W:"<B=Z=FXK@F)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-
MX9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>'7S D:
MVM$+.-[1#%_6RPN1R\ IK,*Y3;:\LVB^MZY[QK.IA\ROIH?1JJ.&U:>AA]BD
MGX?:H9Z'W)Z=B-V:G(G>E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;
MC."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C.#6S D9V=$+
M.-K3#%_4S N1R< IK<"Y3K:ZLVF_M:Y\QK*IA\RMIH;1J:.&U*6AAM>BH(;9
MGY^&VIN>A]R7G8C=DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3
MG(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B][5S D9V-(+-]C3
M"U[2S N3Q[\KK;ZX4+>YLFJ_M*U\QK"IA\RKIH;0IZ2%U*.BA=:?H878G*"%
MV9B?AMJ4GH?<D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=
MD)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMW4S0D9UM(+-];4"U[0
MRPJ5Q+XMKKRX4;BWLFK LZU\QJZIA\RIIH;0I:2%TZ"CA-6=HH36F:&%V)6@
MA=F1GX?:CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)
MVXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=O3S0H8U=,+-M34"U_.RPF7
MP;XPK[JW4[BULFS L*U]QZRJALNGIX7/HJ6$T9ZDA-.:HX35EJ*$UI.AA=>/
MH(;8BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@
MB=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=G2S@H7T]0+-='3"F++S F9OKTS
ML;>W5;FRL6W!K:U]QJJJALNDJ(3.GZ>$T)NE@]*7I(/3DZ.$U)"CA=6,HH;6
MB:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)
MH8C7B:&(UXFAB->)H8C7B:&(UXFAB-?0SPH6T=0+-\[3"F7&R@N=N;PXLK2V
M6+JML6[!JJY]QJ>KA<FAJ83,G*B#SI>G@\^3IH/1D*6$THVEA=.*I(;3AZ.(
MU(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4
MAZ.(U(>CB-2'HXC4AZ.(U(>CB-3.T H5SM0*.LK3"FC R ^AM;L^M*VU6[NI
ML6_!IJ]]Q*.MA,>=JX/*F*J#RY.I@\V0J(3.C:>$SXJGA<^'IH?0A::(T86F
MB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(
MT86FB-&%IHC1A::(T86FB-',T D8RM0*/L73"FVXQ1:EKKE$M:>U7KNCLG#
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M@:6-TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]*
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MF;"$PI2OA,.0KX7$C:Z%Q8JNAL:(K8;&AZV'QH6MB,>#K8G'@:V+QX"LB\>
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MSM$*',;7"D&OZ@YAG>8<>)#:,HB+TDR4B<M?G(C&;J.(PWBHA<!\JX._?ZZ
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MSWVGFL__N0\'_[H7'/^Y(CG_M2U:[+,P>MW 'Y#)PR&HM;I(M*NU8KRFLG/
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M=5/HCG53Z(YU4^B.=5/HCG6\R04 J]L!")K_"Q:/_QDCA?\K+7[_.3=X_T9
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MH%-[X*!7C=2>7Y[*FVNLQ9MUM,.;?KC FX>\O9>*P+J1C,6WBI#*M(27S[*
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M+23_JS8[_[8O2//$*%'@UB96S.0B<;O:*(BJS$&;G\-7J9F\:;*6MW:YE+2
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M&4JB^25>ENTS;HSE07J%WD^#@=E>BG_5:H]ZTG"3=L]UEW/.>9EQS'V;;\N
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M."__LCHN_\ [+O_3.RW_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/"W_ZSRXL
MJ+P  )K)  ",V0  @?4# 'G_$ %N_Q8#9?\?!E[_)PM7_S /4?\W$TO_/A=&
M_T490?],&SW_4ATY_U@?-O]?(33_9B(Q_VXD+_]W)2W_@"8K_XPH*?^7*2C_
MHBHG_ZTK)O^Y+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4
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M)@3ML2D%XKHO!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB):
M=8"2BWMZCY: =(ZDA'&-MH5OCM&%<8O=@W.)WX%UA^!^=H7A?7>$XWMW@^1Z
M=X/D>G>#Y'IW@^1Z=X/D>G>#Y'K_;!0!_W,6 O^%$P'_E!8!_Z(> ?6M( +G
MN"$"W<,F M##- W$OD(>N;E-+ZZS5CZDKEY,FJEE5Y&E;6*)H75K@)U^<GF:
MB'EREY1^;9:B@FF5LX1GELV#:9/>@FR/WX!OC.%^<(KB?'*(XWIRA^1Y<H?D
M>7*'Y'ERA^1Y<H?D>7*'Y'G_;1,!_W83 ?^($@'_F!, _Z<9 >^S%@'BP!4
MU<H> <G',@R^PT <L[Y++*BZ5#R>M5Q)E+!C58JL:U^!J7)H>:5[;W*CA79K
MH)%[9I^??V*?L8%@G\J 8IS@?V67X7YHD^)\:I#C>VR-Y'EMC.5X;8SE>&V,
MY7AMC.5X;8SE>&V,Y7C_;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L S<X;
M <+,+PJWR3T9K,5)*:' 4CB7O%I&C;AA48.U:%MZLG!D<J]Y:VNL@W%DJX]V
M7ZF>>ENIKWQ9JLE\6J?B>UZ@XWMAF^-Z8Y?D>6:4Y7=FDN9W9I+F=V:2YG=F
MDN9W9I+F=V:2YG?_<!(!_X . ?^2#@#RHPL V;,) ,^^"0#+S D Q-,7 +K2
M+ >PSSL6I<Q&)IK(4#6/Q%A!A<%?37R^9U9SO&]>:[EW962X@FM>MHYP6;6=
M<U6UKG54MLAU4[/G=E>KYG9:I.9V7*#G=5^<YW1@FNAT8)KH=&":Z'1@FNAT
M8)KH=&":Z'3_<A(!_X8, /N8"0#9J08 SK4' ,;!!P# SPD NML3 +':*06G
MV#<2G-1$(9+133"'SE4\?<M=1W3)95!LQVU79<5V7E[$@6-9PXYH5,.=:U'#
MKFQ/Q,AM3L+M;5"XZV]3L.MP5:OJ<%BFZW!9H^MP6:/K<%FCZW!9H^MP6:/K
M<%FCZW#_=P\!_XT( -Z@ @#/K@4 Q+D% +O%!@"UTPH KN$6 :;A*0:=X#<1
MD]Y"'8G<3"E_VE0U===</VW59$AETVQ/7])V5%G2@5E4T8Y=4-&=8$W2L&)+
MT\EB2M+M8DO(\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O
M[VG_?PH [98  -*F 0#$L@, N;P# +#)!@"IV H H><9 IGG*@F0YS<4A^9"
M'WWE2BETY%$S:^-9.F3B84%>XFM'6.)U2U/A@$]/XHU32^*;54GCK%='Y,17
M1N/I5T;=]EE'T/=<2<CW7DK!]F!+O?9@2[WV8$N]]F!+O?9@2[WV8$N]]F#_
MB0  V9X  ,>L 0"YM@( KL$# *7.!@"<Y P E>\= XWO+ N%[SD5?.]!'G/O
M22=J[E O8NY7-5SN7SI6[F@_4NYQ0DWO?$9)[XE)1O"62T/PIDU \;E./_+;
M3S[P]TY"YOM/0]W[4434_%-%S_Q41<_\5$7/_%1%S_Q41<_\5$7/_%3AE0
MRZ8  +NP  "NNP$ HL@" )C5!0"0^ \!B?@@!(+X+@MY^3<3</D_&VCY1B)@
M^DTH6OI4+53Z7#%/^V4U2_MM.$?\=SM#_(,]/_V0/SS]GT$Z_J]#./_&1#?_
MZD4V_/U%._+_1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P
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M'AS_YA\;__ ?&__P'QO_\!\;__ ?&__P'QO_\!^DM0  E<(  (;/  !WW@
M:_0  &+_ P!9_PL!4?\1 4K_%P)$_Q\#/_\F!#K_+04V_S0&,O\Z!R[_0 @K
M_T8(*/],"27_4@DB_UD*(/]B"QW_:PP:_W8-%_^$#A7_D@\4_Z 0$_^M$1/_
MNA$3_\,2$__#$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T
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M74NY]U].L?9@4:KV8%.E]F!5H?9@5:'V8%6A]F!5H?9@5:'V8%6A]F#_=P@
MZXP  -.;  #&J ( N[$" +*[ @"JQP8 HM,* )W6&@&5UBP&C-0Z$8/21AUZ
MT$\G<LY8,6K-8#ADRV@_7LIR15C*?$E4R8A-3\F544S)I5-*R;E42<K<4T?(
M]U5(P/Q82KC[64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),
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M-#?L_S8YY?\X.>7_.#GE_S@YY?\X.>7_.#GE_SC(G@  MJD  *BR  ";O0
MC\@  (/4  !YZ < <_P2 6O]'0)D_2<$7OXQ"%C^.PU3_T,13?]+%4G_4QA%
M_UH:0?]C'3[_;!\[_W8A-_^"(S3_D"4R_Y\G,/^P*"[_R"DM_^HJ+/__*BS_
M_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$
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M"0W_TPD-_],)#?_3"0W_TPF1O   @<D  '+7  !DY   5.L  $O_  !$_P
M/?\$ #?_#  Q_Q !+/\6 2C_' $D_R("(/\G AS_+ (9_S$#%O\V Q/_/ ,1
M_T(##_])! W_400+_UH$"?]F! ;_<P4#_X$% O^0!0'_G 4!_ZL% ?^K!0'_
MJP4!_ZL% ?^K!0'_JP7_1"0"_S\N _\\-@3_0#@$_T$]!O]!10C_05$-_T!=
M$_\_:AC_/'<<_SJ$(/\WD2/_-ILE_S6D)_\TK"C_-+4J_S.^*_\RR"O_,M4L
M_S'E+?\Q\2W_,?LM_S#_+?\P_RW_,_\M_S;_+/XX_RWY.O\N]CO_+O8[_R[V
M._\N]CO_+O8[_R[_12,"_S\N _\^- /_0C8$_T0[!O]$0PC_14\-_T1;$_]!
M:!G_/W4=_SR"(?\ZCR3_.)HG_S>C*?\VK"K_-K0L_S6]+?\TR"[_--8N_S/F
M+_\S\B__,OPP_S+_,/\S_R__-O\O_SG_+_D[_S#T/?\Q\3W_,?$]_S'Q/?\Q
M\3W_,?$]_S'_1B,"_T M _]!,@/_1C,$_T@X!O](0 C_24P._TA8%/]%91K_
M0G(?_T!_(_\]C";_.Y@I_SJA*_\YJBW_.+,N_S>]+_\VQS#_-M4Q_S;F,O\U
M\3+_-?LR_S7_,O\V_S+_.O\Q^CW_,_,^_S3M0/\TZD'_-.I!_S3J0?\TZD'_
M-.I!_S3_1R("_T$L _]%+P/_23 $_TPU!O]-/0C_3D@._TU4%?]+81O_2&X@
M_T5[)?]"B"C_/Y0K_SZ>+O\]IR__/*\Q_SRX,O\[PS/_.L\T_SKA-?\Z[C7_
M.O@U_SK_-?\Z_S7[/O\U\D'_-^M"_SCE1/\XX47_..%%_SCA1?\XX47_..%%
M_SC_2"("_T,L _](+ /_3BT$_U$Q!?]3.0C_544._U-1%?]171S_3FHA_TMW
M)O](@RO_18\N_T29,/]"HC/_0:LT_T&T-O] O3?_/\DX_S_;./\_ZCG_/_4Y
M_S__.?M _SCQ0_\ZZ$7_/.%'_SS:2/\]U4G_/=5)_SW52?\]U4G_/=5)_SW_
M22$"_T0J _]-* /_4RD$_U<M!?]9-@C_7$(._UM.%?]861S_564B_U)R*/]/
M?BW_3(HP_TJ4,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^
M//%%_S[F2/] W$K_0=)+_T',3?]!R4W_0<E-_T')3?]!R4W_0<E-_T'_2B "
M_T@G O]1)0/_6"4#_UTJ!/]@,P?_8S\._V)*%?]@51S_7&$C_UEM*?]5>2[_
M4H0S_U"/-OU.F3G[3*([^DNJ/?A*M#_W2KY ]4G,0/%)X4'M2O!!ZDK\0N1*
M_T383/]%S$__1L90_T; 4?]&OE'_1KY1_T:^4?]&OE'_1KY1_T;_3" "_TPD
M O]5(0+_72$#_V,G!/]G,0;_:CP,_VI'%/]G4AO_8UPC_U]H*OM<=##W67\U
M]5:*.?)4E#SP4IT_[E&F0>Q0KT/J3[I$Z$['1.9/W47A3^Y%W4[[2-1/_TG(
M4?]*P%/_2KI4_TJV5?]*M%;_2K16_TJT5O]*M%;_2K16_TK_31\"_U A O]:
M'@+_8AX"_VDE _]M+07_<3D+_W%$$O]O3AK[:U@B]69C*?%C;S#M8'HVZ5R%
M.^9:CS_D6)A"X5:B1-]5JT;<4[9(VE+#2M92V$K14^Q+S%/Z3<54_TZ\5O]/
MM5?_3[!8_TZL6?]-JEK_3:I:_TVJ6O]-JEK_3:I:_TW_3AX"_U,> O]>&P+_
M9QL"_VXB _]S*@3_=S4)_WA $/EW2ACR<U0@[&]>*.=K:C#B9W4VWF. /-E?
MBD'479-&T5N=2<Y9IDS+6+!.R%>\4,96S5'#5^91OE?W4KA8_U.P6O]3JUS_
M4J==_U*C7?]1HEW_4*)=_U"B7?]0HEW_4*)=_U#_3QX"_U<; O]B%P'_;!D"
M_W0@ O]Y)P/_?C('^8 \#?%_1A7J>U =Y'=;)MUS9B[5;7 WT&EZ/LMEA$3'
M8HY)Q&"73<!>H%"]7:I3NUNV5;A;Q5:U6]]6LESS5ZQ=_5>F7OU6H6#^59Y@
M_U2<8?]3FF'_4YIA_U.:8?]3FF'_4YIA_U/_4!T"_UH9 ?]E%0'_<!<!_W@=
M ?]_) +]A"X%\X8X"NJ&0A'CA$L9VW]7(]%Y8B_+=&PXQ6]V0,!L?T:\:(A+
MN&:14+5CFU.Q8:56KF"P6:M?OUJI7]1;IF#O6Z)A^EJ=8_M9F63\6)9D_5>5
M9?Y5E&7^591E_E649?Y5E&7^591E_E7_4!T"_UT7 ?]I$@'_=!4!_WT: ?^$
M(0'WB2H#[8TT!^2-/0W<BT@6T854(\E_7B[">F@XO'5Q0+=Q>D>R;H1-KFN-
M4JIHEE:G9J!9HV6K7*!DN5Z>9,U>FV3J7IAF^%V49_E<DFC[6I!H_%F.:/U7
MCFC]5HYH_5:.:/U6CFC]5HYH_5;_4AP!_U\4 ?]L$0'_>!,!_X$7 ?^('0'R
MCR4"YY,O!-Z5. G3D$45RHM1(L*%6RZ[@&4XM'MN0:]W=TBJ='].I7"(4Z%N
MDE>=:YQ;F6JG7I9IM6"4:,AADFGF8(]J]U^-:_A=BVOY7(EL^UJ(;/Q8B&O\
M6(AK_%B(:_Q8B&O\6(AK_%C_5!H!_V(3 ?]O$ '_>Q( _X44 /J-&0#MDQ\!
MXIDH MB9,PC,E4(4Q)!.(;R+62VTA6(WKH%K0*A\<TBB>7Q.G7:%5)ESCEB5
M<9A<D6^D8(UNL6*+;<-CB6[B8H=O]F&&;_=?A6_Y781O^EN#;_M9@V_\6(-O
M_%B#;_Q8@V_\6(-O_%C_5A@!_V01 ?]R#@#_?A  _X@1 /61% #HF!D W9X@
M =&>,0?'FD 3OI5,(+:05BRNBV WIX9H0*&"<$B<?GE.EGN"5))XBUF-=I5=
MB72@885SKF."<K]D@'/>9(!T]6)_=/9@?W/X7GYS^5Q^<OI:?G+[67YR^UE^
M<OM9?G+[67YR^UG_6!<!_V<0 ?]U#@#_@0X _XP. /&5$ #CG1$ UJ,; ,NA
M+P;"GCX2N9E*'K"45"NID%TVHHMF/YN';D>5A'9.D(!_5(M^B%F&>Y)=@7F>
M87UXJV1Z>+QE>7C997AY]&)Y>/9@>7?X7GEV^5QY=?I:>77[6GEU^UIY=?M:
M>77[6GEU^UK_6A4!_VD. /]X# #_A P [Y + -V:"@#9H@L T*88 ,:E+ 6]
MHCP0M)Y(':N94BFCE5LTG)%C/I6-:T:/B7--B89\4X2$A5A_@9!=>G^;879^
MJ&1S?;EE<7[397%^\F-R??9@<WOW7G1Z^5QT>?I;=7G[6G5Y^UIU>?M:=7G[
M6G5Y^UK_71,!_VP- /]["P#VB D W),& -6="0#1I0H RJH5 ,&I*@2WICH/
MKJ)&&Z:>4"B>FEDSEI9A/(^3:42)CW%,@XUY4GV*@U=XB(U<<X:98&^$IF-L
MA+=D:H3/9&J$\&)L@O9@;8#W7F]_^5QO??I;<'S[6G!\^UIP?/M:<'S[6G!\
M^UK_7Q$!_V\* /]^" #CC , UI<% ,^@!P#*J @ Q*X3 +NM)P.RJS<-J:=$
M&:"D3B:8H%<QD9Q?.HJ99T.#EF]*?9-W4'>1@%9RCXI:;8V67FB+HV%EB[1C
M8XO,8V.+[F%EB?=?9X;X7FF$^5QJ@OI::X'[6FN!^UIK@?M::X'[6FN!^UK_
M8A  _W(' /B" P#;CP( SYH% ,FC!@##K 8 O;(0 +6R) *LL#4+HZU"%YNJ
M3".2IE4NBJ-=.(.@94!]G6Q'=IMT37"9?5-KEHA89I647&*4H5]?D[)@79/)
M8%V3[5]>D/A>88SY7&.*^EMDA_M:98;[666&^UEEAOM998;[666&^UG_9@T
M_W<# ..'  #3DP$ RIX$ ,*G! "[KP0 M;8- *ZW(0*EMC()G;,_%92P2B",
MK5,KA*I;-'VH8SQVI6I#<*-R2FJA>T]EH(948)Z16%N=GUM8G;!=5IW'75:=
MZUQ7FOI;6I7Z6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP
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M2D>S_TM)K?],2JO_3$JK_TQ*J_],2JO_3$JK_TSI?P  T9   ,*>  "UIP
MJJ\  *"X  "6P0( C,L' (35#0" U1X!>=4N!7+4/ QLTT<49=)0&U_162%:
MT6(G5=!K+%'0=3!-SX$T2<^.-T;/G3E$T*X[0M#&.T/0ZCI S?T^/LO_0$##
M_T)!O?]#0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0
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M'2KW_QTJ]_\=*O?_'2KW_QVSHP  I*L  )>V  ")P0  >\L  &_6  !CWP
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M5FYZYE5N>OQ3;WG_47!W_T]Q=O]-<77_3'%U_TQQ=?],<77_3'%U_TS_6PX
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M35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:   Y7D  -&'  #%D@
MNYP  +&B  "IJ0  H;$" )NS%0"5LR@"CK(V"8:P0A)_KDP;>*Q4(W*J7"IL
MJ&0Q9Z=L-F*E=3M=I'] 6:.*0U6BET=1H:=)3Z&Z2DZBV4E.H/5)3I__25"9
M_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-  "^F   LZ
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M-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP  FJ\  (ZW  "#OP
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M"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X   0^4  #[[ 0 Z_PP
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M1W]FX4=_9_A%?FC_0WYH_T%]9_\_?&?_/GQG_SU\9_\]?&?_/7QG_SW_4@X
M_UT# /UI  #A<@  UGH" ,Y_!0#*@P@ Q882 +R')@&UAC8&KH-##Z> 3ABA
M?%@@FWE@)Y9W:2V2=' SCG)Y-XIP@3R&;HL_@VV50W]LH45\:ZY'>FN_2'AK
MW4AX;/9&>&S_1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_5 P _U\
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M1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0 ]VD  -UV  #-@
MPX@  +N.  "TDP$ K9<) *>8&@"@F"P#F98Z"I*411*,DD\:AH]7(H"-7RA[
MBV<N=HEO,W*'=SAMA8$\:82+0&:"ET-B@:5&8(&V1UZ!S4=>@>]&7X'_1&!_
M_T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y  #(A   OHP
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M.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP  K)H  **?  "9I0
MCJL  (6P"P"!L1L ?+$K G>P. =QKT,-:ZY-%&:M51EAK%T>7:ME(UFJ;B=5
MJ7<K4:B"+TVGCS)*IYXU2*>O-D>GQC9&INDV1:3^-T6C_S=&H/\W2)S_-TF:
M_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X  )ND  "0JP  A;$
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M(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP  9L8  %O, @!0T@<
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M Q?_G@,5_[,$%/_3!!3^] 03_/\#$_K_ Q/Y_P,3^?\#$_G_ Q/Y_P.=I0
MCZX  ("X  !RP@  9,L  %;3  !)V@  /M\  #3D   N]   *_\* "C_$  E
M_Q< (O\? !__)@ <_RT &?\T !?_/  4_T0!$O]. 1#_60$._V<!#/]W 0O_
MB@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?__P*1K0  @K@
M '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$ !S_#  9_Q$
M%O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0  /]B 0#_<P$
M_X<! /^= 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$  &7,
M  !6V   1]\  #GE   MZ@  (^X  !S]   8_P  %?\  !'_!  /_PL #?\.
M  G_$0 &_Q4  _\:  #_(   _R8  /\N  #_-P  _T$  /]-  #_7   _VT
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MXCJV%N [PA;?.](6VCOH%]0Z]AK0.O\<S3K_'LLZ_Q[*.O\?Q#O_'\ \_Q[
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M,Y94X3235?8SDE7_,I%6_S&/5O\PC5;_+HQ7_RV,5_\MC%?_+8Q7_RW_20X
M_U$% /]: 0#N8@  WV<# -AJ!@#5:PH S6T5 ,5N*0&^;3D$MVM'"[%H4A&L
M9EP8J&1E':1B;2*A8'4FGEY^*9M=ABV87(\OE5J9,I-9I#206; VCEG -HQ9
MVS>*6?,VB5K_-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP _U0
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M.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400 _UP  .)G  #2<
MQW8  ,!Z  "Z?0( M'\, *V!'0"G@2X"H'\\")I]1P^5>E$6D'A:'(MV8B&'
M=&DF@W)Q*W]Q>B]\;X,R>&Z--75MF#AR;*4[<&NT/&YKR3QM:^D[;6S^.6UL
M_S=N;/\U;FO_-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\  -YJ  #-<P  PWH
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M-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@  MH8  *Z+  "EC@
MFY$  )63$0"0E"(!BY,Q X62/0E_D4@/>H]1%G6-61MQC& @;(IH)6B)<"ED
MAWDM88:#,5V%CS1:A)PV5X.L.%6#OSE5@^$X58+Y-U:"_S56@?\T6'__,UE]
M_S)9??\R67W_,EE]_S+O8   VVX  ,=Z  "[@P  LHL  *B0  "?DP  E)8
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M*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP  ?J@  '"N  !JL X
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M#C'(M0\PR-,/,,;T$"[$_Q,MPO\5+,'_%BO _Q<KP/\7*\#_%RO _Q>XC0
MJI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*R ( 0,T' #K2#@ Y
MTAL .-,H #?3-0 VU$  --5+ 3/550$QUF "+]9L RW7>@0KV(L%*MB=!2C9
ML08GVLT&)]?O!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@  H)T
M )2D  "&K   >;0  &R[  !@P@  5,8  $C+   ^T   -=4$ "W="@ LX1,
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M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@R
M4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_$0 )
M_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5  #_
MK   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2TP  0]L
M #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&  #_"@  _PX
M /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4  /]Z  #_D0
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M&K-!YAJO0?<<K4'_':M!_QVI0?\<J4'_'*9!_QNE0?\;I4'_&Z5!_QO_/1
M_T() /](!0#_30@ _U + /E1#P#K4!4 X4\@ -A0,0#/4$$"R4].!<1.6@G
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M*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\  .=8  #98
MS60  ,9F 0#!9@0 NV8. +1I( "N:3$"J&@_!:-F2@J?950/FF-=%)=A91B3
M8&T<D%YU'XY=?2*+7(8EB%N0*(5:FBJ#6:8L@%FT+7]9QRY]6>8M?%KZ+'M:
M_RI[6_\H>UO_)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(  .-<  #28P  QV@
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M*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@  NW,  +-W  "K>0
MI'@# )UZ% "8>R4!DWLT XYZ0 >)>$H-A'93$H!U6Q=\<V(;>')J'W5Q<B)R
M;WLF;VZ%*6QMD"QI;)PN9FRJ,&1LO#%C;-DP8VST+V-L_RUD;/\K9&O_*65J
M_RAE:O\H96K_*&5J_RC]4P  XU\  ,YI  #!<0  MW<  *][  "G?0  GGT
M )A^$0"3@"( CH Q HE_/@:$?4@,?WQ1$7MZ619W>6 :<W=H'F]V<"%L=7@E
M:72"*&9SCBMC<IHN8'&H+UYQNC!=<=0P77'R+EYQ_RQ></\K7W#_*6!O_RA@
M;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N   "B@@  F($  )&#
M#P"-A1\ B(4N H.$.P5^@T4*>H%.#W6 5A1Q?UX8;GUF'&I\;2!G>W8C8WJ
M)V!YBRI=>)@L6G>F+EAWN"]7=]$O5W?Q+EAV_RQ8=O\J677_*5IT_RA:=/\G
M6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@  D8<  (J)# "&
MBAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA@G0A78%])%J
MB2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z_R=4>O\G5'K_
M)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T  (./" !^D!<
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M'T":L" _FL@@/YGK'S^8_R ^EO\A/I7_(3^4_R$_E/\A/Y3_(3^4_R'-<
MO'T  +"(  "DCP  F90  (Z8  "#G0  =Z   &FD  !@IP@ 7:@4 %NI) !9
MJ3$!5JD\ E.I1010J$X&3:A7"4JH7PQ'IV@.1*=S$4&F?Q0^IHT6/*:=%SJF
MKQ@YIL<8.:7J&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?_QS$>   M84
M *F/  "=E0  DIH  (:?  !ZHP  ;J@  &*L  !5L   4+(. $ZR&P!-LR@
M2[,U $FS/P%&LTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.-;*:#S.SK1 R
ML\40,K+I$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX  *&5
M  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X /KXK
M #R^-@ [OT$ .;]+ 3>_5 (UP%\",\!J!#' =P4OP(8&+<"7!RO J@@JP<((
M*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC   I90  )F:  "-
MH0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  NRA$ +<H= "S+
M*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/I0(@T+T"(,_D
M A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H  )"A  ""J
M=*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H &]H0 !O;&@ :
MVR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3XK$ $N// !+@
M]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0  :+@
M %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J%  1ZQT
M$.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3QY  "
M\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(  $W(
M  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4 !_L<
M  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0  _.L
M /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1   R
MUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2  #_
M%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(  /_G
M  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8  #'=   EX@
M&N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4  /\*  #_#@
M_Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C   _Z0  /^Y  #_
MU   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+. '_ T0!_P!1
M ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H /\ KP#_ +8
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M M@DZ@/2)/D%SR7_!LTE_P?+)?\(RB7_",HD_PC*)/\(RB3_",HD_PC_+A0
M_S$0 /\R#0#_- X _S44 /\U' #_,R< ^C$T /,O00#N+4X!Z2Q: >4L90+B
M+' "WRMY MTK@@/:*XL#V"N2!-4KF@33*Z($T2NJ!<\KLP7-*[\&S"S/!L@M
MYP?$+?<)P2W_"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$ _S4,
M /\V!P#_.@L _SP0 /\[%0#X.1\ [S<K .<V.0#A-4< W#54 =4U8 +1-6H#
MSC1S!,PT? 7*-(4&R#2-!\8SE C$,YP)PC.E"<$SK@J_,[D+O3/("[LTX0NW
M-/,-M#3_#[$T_P^P-/\0KS3_$*XT_P^N-/\/KC3_#ZXT_P__-0X _S@' /\\
M @#_0 8 _T$+ /I!#P#M/Q8 XSPB -H],0#2/D$ S#Y/ L@^6@/$/60%P3UN
M![\\=@B\/'X*NCN'"[@[CPRW.Y<-M3J?#K,ZJ0^Q.K00KSK"$:XZV1&J.^\2
MISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H _SP  /]!  #U
M10  YD8" .%%!P#C0@T U4,9 ,Q%+ #&1SP!P4=) KQ&502Y15\&M41H";-#
M<0NP0WD-KD*!#ZQ"B1"J09$2J$&:$Z= I!2E0*\5HT"\%J% T!:>0>H7G$'\
M%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8 _S\  /E&  #E2P
MW$X  ---! #12@D RDH4 ,)-)P"\3C<!MTY% K)-4 6O3%H(JTMC"JA*; VF
M270/I$E\$:%(A!.?1XP5G4>5%YM&GQB91JH9ET:X&I9&RAN31N8;D4?Y&X]'
M_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+  #=40  T50
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M'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@  OV(  +=D  "Q8P
MJV$( *1C%P"?9"@ FF4W I9D0P618TT(CF%5#(I@71"'7V43A%YL%H%==!E^
M7'T<?%N&'GE:D2!W6ITB=%FJ)')9NB5Q6=(E<%KP(V]:_R)O6O\@<%K_'G!:
M_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8  +-H  "L:   I68%
M )]G% "::24 E6DT I!H0 2,9TH(B&93#(1E6Q"!9&(3?F-J%GMB<AEX87H<
M=F"$'G-?CB%P7IHC;EZH)6Q=N"5J7LXF:5[N)&E>_R)J7O\@:E[_'VI>_QYJ
M7O\=:E[_'6I>_QWY2@  XU4  ,]?  #!90  MVH  *]L  "G;   GVH! )EK
M$0"4;2( D&XQ 8MM/02';$<'@VM0"W]J6 ]\:& 3>&=G%G9G;QES9G@<<&6!
M'FUDC"%J8Y@C:&*F)69BMB9D8LPF9&+L)61B_R-D8O\A96+_'V5B_QYE8O\=
M96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<   F6X  )-P$ "/
M<A\ BG(N 89R.P."<44'?7!."WIN5@YV;5X2<VQE%7!K;1AM:G4;:FE_'F=I
MBB%E:)8C8F>D)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F_QY@9O\>8&;_
M'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==   E',  (UT#0")=AP
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M(4]YKB).><,B37CE(DUW^R%.=_\?3G;_'D]U_QU/=?\=3W7_'4]U_QW?7
MR&@  +ER  "N>@  I8   )J"  ".@@  @(,  'F% @!TAA$ <8@@ &Z(+@%J
MB#D"9X=#!6.'3 A@AE,+785;#EJ$8Q%7A&L45(-U%U&"@!I.@8T<2X&;'DF!
MK!](@,$@1X#C'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\_QS680  PFX
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M#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P  KX,  *.+  "8D0
MC94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#JA\ 0:LK $"K-P _
MK$$ /:Q* 3NL4P(YK%P#-ZQG!#6L<P4RK($&,*R1!RZLHP@MK+@)+*S9""RJ
M]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1  "1E@  A9P
M 'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A #*V+  QMS<
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M  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0  %>Z  !)OP
M/<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$ !=\:  3@)  "
MX2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR   Y_   .C_  #H
M_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \QP  ,,L
M "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1  #J&   ZR$
M .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M   /?S  #W_P
M]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0  (]8  !G<
M   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V#P  ]A0  /@=
M  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_[0  __D
M /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0  %N(   [F   (
MZ@   .T   #P    ^    /\   #_    _P   /\   #_!@  _PP  /\0  #_
M&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP  _]4  /_5
M  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_ &D
M_P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\ P #_
M ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0 _P!P
M /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^ ,@
M_0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D _P#_
M&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K /\
M=@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0 ]0#2
M /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_'AT
M_QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&<0#_
M!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<  [07. .L%
MY #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_(1@ _R$3
M /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.:P#V#G4
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M!+@E_P6V)?\%M27_!K4E_P:U)?\%M27_!;4E_P7_+ T _RT% /\N 0#_,04
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M$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X  ,!-  "[2@(
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M%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>$ "08!\
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M&UQBK!Q:8K\<66+?'%EB]QI:8O\96F'_%UMA_Q9;8?\56V'_%5MA_Q7G30
MSUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_;14 ?&XE 'AN,@%U
M;CT"<6Y&!&YM3P=K;%8):&Q>#&5K90]C:FT18&EV%%UI@19;:(T86&>;&E9G
MJAM59[T<5&?<'%1G]AI49O\856;_%U5E_Q969?\55F7_%59E_Q7B40  RET
M +MF  "O;   IG$  )EP  ".;P  @VX  'UP!0!X<A( =7,A ')S+P%O<SH"
M;'-$!&ER3 9F<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55;HL74VV9&5%MJ!I/
M;;L;3FW9&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50  Q6$  +=J
M  "L<0  HG4  )1T  ")=   ?',  '9U  !Q=Q  ;W@= &QY*P!I>3<!9GE
M V-Y205@>%$'77=8"5MW8 Q8=F@.575Q$5)U?!-0=(@63727%TMSIAA)<[D9
M2'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@  P&8  +-O  "H
M=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B@#(!7X ] ER
M1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[I!9$>[<60WO2
M%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL  *YT  "D?
MEWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX 6(<X 56'0@)3
MATH#4(=2!4Z&6@=+AF()285L"T:%=PU#A(,/0822$3^$HA(]A+43/(3/$SR"
M\!(\@?\2/8#_$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$  *I[  "?@@  DH(
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M!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP  ?I4  '"8  !CFP
M5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P GKRT )K W "6P00 D
ML$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQYP$;K_X"&JW_ AJL
M_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB  !;I0  3ZD
M $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4O4
M$[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z_P$0
MNO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0  #JV
M   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC( !LL^
M  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !RO\
M <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_   C
MPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@  V"<  -DQ  #;
M/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P  W_\  -__
M  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')   8S0
M$-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I+P
MZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\  /#_  #P
M_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75   .V@  !]X
M  #B    Y@   .D   #J    [    .X%  #O#   \1   /,7  #U(   ^"L
M /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U  #_]0!T
MK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #Y@   .D   #L
M    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_$@  _QL  /\H
M  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_#R0
M_PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_
M (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3 /\
MYP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$ _Q >
M /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\
M_P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D X@#X
M /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,: /\0
M&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _@"#
M /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\ W #N .P
M[0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3$P#_
M#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^ /(
MA0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B .D X0#W
M -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_$@X
M_Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"@ #F
M X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N< T CX ,X*
M_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_&0L _Q@1
M /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L->P#9#8,
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M!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\  -DK! #6(@H
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M"GA!_PKV-@  YD   -%(  ##30  N4X  +%-  "I20  I$4& )]&$P":2",
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M$FA0JQ-F4+P395#8$V10\Q)D4/\09%#_#V10_PYE3_\-94__#&5/_PSL00
MU$P  ,-4  "V60  K%P  *!:  "75P  D50  (M5# "&5QD @U@G (!9- !]
M63\!>EE( W=84 1T6%@&<E=?!V]79@EM5FX+:U9W#6A5@0]F58T19%2:$F)4
MJ1-@5+H47U33%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3_PWG1   SU
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M$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH  +1C  "I:0
MFV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0 9&P] 6)L1@)?
M:TX$76M6!5IJ70=8:F4)5FEN"U-I> U1:(0/3FB2$$QGH1)+9[(226?)$DEG
MZQ))9O\02F;_#TIE_PY+9?\-2V3_#4MD_PW15   OEX  +%G  "F;0  EVP
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M"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD  'MY  !P>@
M9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X 08E' 4")3P$^
MB%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <PA?L(,(/_"#""
M_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_  !J@   7H,
M %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)  #:220 TDU(
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M 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*   #ZD   TIP
M*JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38 #+9!  NV3@ *
MMEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (L_\ ";+_  FR
M_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P   JLP  (;4
M !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##0@  PU
M ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##_P"3
ME   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L   !##
M   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1-0  TT,  -12
M  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6_P"*FP
M>Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP  #<L   ;.
MT@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,  .="  #H
M5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP  ;JL
M %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@   #=    X0
M .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y00
M^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !QK   8;4  %*]
M  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H    [    .\
M  #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_+P  _T$
M /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<> /\ '0#_
M "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"' /\
MC@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /  _@#]
M /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_ !H
M_P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\ B0#_
M )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y /,
M_P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0 _P 9
M /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W (L
M]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U .8 _P#G
M /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5 /\
M( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8 Z@",
M .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P -< _@#5 /\
MU #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#&@#_
M "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (  W "' -H
MC@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#% /\ Q '_
M ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\!Q\
M\0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$B0#(
M!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_ +0-
M_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8 XPDB
M -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\#XT
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M HXG_P+_)@  \BD  .,Q  #2-   R#0  , P  "[*0( N",. +$F' "L*"L
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M!WD[K =W.[P(=CS5"'0\\0AS//\'<CS_!G(\_P5R//\%<CO_!7([_P7Q,@
MWCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT C4$K (I". "'
M0T( A$-+ 8)#4P& 0UL"?D)B WQ":01Z0G$%>$)Z!G9!A =T08\(<D&;"'!!
MJ0EO0;D*;4'0"FQ![@EK0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P  UD(
M ,1)  "W30  JTT  *!*  "81P  DT(  (Y##0")11H AD8H (-'- " 2#\
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M#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT  +A4  "L60
MG5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8 ;%9  6I62 %H
M5E "9E97 V167@1B568%8%5O!UU5> A;5(0*6521"U=4H Q54[ -5%/%#5-3
MY@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H6P  F5H
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M"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9   C&,  (!C  !V8P
M:F(  &-D  !?9@8 6V<1 %EH'0!7:2D 5FHS %1J/ !2:D4!4&I, 4YJ5 ),
M:EP#2FIE!$AI;P5&:7H'1&F("$)HF E :*D*/VB]"CYHW@D^9_<)/F;_"#]E
M_P<_9?\'/V3_!S]D_P?#5P  LV$  *=I  "6:   AV<  'MG  !Q9P  96@
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M RE[_P.Q:@  I70  )5V  "%=0  >'4  &UU  !A=P  5WH  $Q^  !#@0
M.X4  #6("0 RB1$ ,8D; #"))0 OBB\ +HHX "V+00 LBTH *HM4 "F+7P H
MBVL )HMZ 22+BP$CBYX!(HNS 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%
M_P*K<@  H7P  (][  " >@  <WH  &9\  !;?P  4((  $:&   \B@  -(T
M "R1   FDPP ))03 ".4'  BE28 (94O ""5.  ?ED( 'I9, !V66  <EF0
M&I=T !F7A@ 8EYD %Y>N !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E
M>P  F8,  (F!  ![@   ;((  %^$  !4B   28L  #^0   UE   +9<  "6:
M   =G@$ %J , !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K
M  VC?0 -HY( #*.G  JBP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">A
MDHD  (.(  !SB   98L  %B.  !,D@  09<  #>;   NG@  )*(  !RE   5
MJ   #ZL$  JN#  'K1( !JT;  6M)  $KBX  JXY  &N10  KE(  *YA  "N
M<P  KH<  *Z=  "NM   KM4  *WT  "M_P  K/\  *O_  "K_P"6BP  C)
M 'N0  !KD@  798  %":  !$GP  .:,  "^G   EJP  '*X  !2Q   .M
M";<   &X"0  N X  +D4  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\9P
MO'L  +R1  "\J0  O,0  +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;
M  !CGP  5:,  $>H   [K0  ,+$  "6T   ;MP  $KH   R]   %OP   ,,
M  #$ @  Q0H  ,4.  #&%   QQL  ,@D  #*+@  S#H  ,U)  #-60  S6P
M ,Z#  #.FP  S;4  ,[:  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:
MK   3+(  #ZV   PN0  )+P  !F_   1P@  "L4   +)    S    -    #1
M    T@$  -,(  #5#0  UQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R
M  #DBP  Y:4  .7   #EY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@
M/[P  #"_   CPP  %\<   _*   'S@   -$   #6    W    -\   #@
MX@   .0   #F P  Z D  .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W
M>0  ^),  /BM  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4
M "+)   6S@  #=(   38    W0   .$   #D    Z    .L   #M    [P
M /$   #S    ]@   /@#  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_9@
M_W\  /^9  #_KP  _\,  /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\
M*P#_ #@ _P!& /\ 4P#_ %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5
M /\ FP#_ *$ _P"H /\ KP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\
M^P#_ /H _P#T /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_
M #0 _P!" /\ 3@#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P
ME@#Z )T ^0"C /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_
M .X _P#N /\ Z@#_ .H _P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X
M_P \ /\ 20#_ %0 _@!? /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O
M )@ [0"? .P I@#J *X Z "Y .< QP#E -X XP#P .( _@#@ /\ X #_ .$
M_P#A /\ X0#_ .$ _P#_#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V
M /D 0P#V $X \@!9 .\ 8@#L &L Z@!R .@ >0#F (  Y "& .( C #A ),
MWP": -T H0#; *H V "T -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#,
M /\ S #_ ,P _P#_$ P _PP' /\# @#_  @ _P . /\ %@#V "( \  O .P
M/ #I $@ Y0!3 .$ 7 #> &4 VP!L -< <P#4 'H T@"  -  AP#. (X S "5
M ,H G0#( *4 Q@"O ,0 NP#" ,L P #E +X ]0"] /\ O #_ +P _P"\ /\
MO #_ +P _P#_$04 _PX  /\*  #_" $ _P0* /@ $ #I !H XP H -X -0#9
M $$ TP!, ,\ 5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P
MF "Z *$ N "K +8 MP"T ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_
M *T$_P#_%   _Q   /\/  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH
MQ -% , #4 "]!%D NP5A +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M
M"9X JPFH *H*M0"H"L4 I@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\.
M_P#_%P  _Q,  .\8  #D&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^
M +0.20"Q#E, KQ!; *T08P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL
MH!.F )X3LP"<$\, FQ3> )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_
M&@  ]!T  .4C  #5)0  RB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<8
M0P"E&4T HAE6 * :70">&V4 G1ML )L<<P":''L F!R# )<=C0"5'9< DQZB
M )(>KP"0'K\ CQ_8 (P@\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z'@
MZR8  -HM  #*,   OBX  +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB/@"9
M(T@ ER11 )4D60"3)6  DB5G ) F;@".)G8 C29_ (LFB &*)Y,!B">> 88G
MJP&$)[L!@RC1 8 H[@%^*?\!?2G_ 7PH_P%\*/\!?"C_ 7PH_P'U)   XRX
M ,\U  #!.   M#8  *LQ  "E+   HB8& )XF$P"9*"$ E2HN )(K.0"/+$0
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M!64\Y05D//H$9#S_ V,[_P-C._\#8SO_ F,[_P+E-0  S3\  +U&  "N1P
MGT4  )5#  ".0   B3P  (0\"@" /10 ?3XB 'H_+@!X0#@ =4%" '-!2@!R
M05$!<$%9 6Y!8 )L06<":D%P VA!>0-G080$94&1!6-!GP5A0:X&8$'"!EY!
MX@9>0?D%74'_!%U _P-=0/\#74#_ UU _P/?.0  R$,  +E*  "I2P  FTD
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M!4U-_P1-3?\$3DS_ TY,_P/.1   O$X  *Y4  "<4P  CE(  (-1  !Z4
M<DT  &Q/  !H4 L 95$5 &-2(0!A4RP 7U,V %U4/P!;5$< 6E1. 5A45@%6
M5%T"5%1F U)3;P-04WL$3E.(!4Q3EP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1
M_P1)4?\$25#_ TE0_P/*2   N5(  *I7  "85@  BE4  ']4  !V4P  ;%$
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M SE>_P.\50  K5\  )Q@  "+7P  ?5\  ')?  !H7P  76   %5B  !/9
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M "9ZAP$E>ID!(WJL 2)ZQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:
MG6X  (IM  ![;   ;VP  &5L  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I
M@0T )X(4 ":"'@ E@B< )((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$
M@@ ;A)4 &H2I !B$P0 8@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,
M (1R  !V<0  :W$  %YS  !4=@  27D  #]]   W@0  +X0  ">(   @BP4
M&XT. !J-%0 9C1X &(XG !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0
MCX\ #X^D  Z/NP -C^  #HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW
M  !R=P  9'@  %A[  !-?@  0H(  #F&   OB@  )XX  ""1   8E0  $I@%
M  Z:#@ -FA0 #)H=  N:)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8
M IJ;  ":L0 !F<\  IGP  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K
M?@  78$  %"%  !%B0  .XT  #&2   HE@  'YD  !B=   1H   #*,"  :E
M"@ !I1   *46  "F'P  IB@  *8R  "G/0  ITH  *=8  "G:   IWP  *>1
M  "FJ   IL,  *7I  "E_   I?\  *3_  "D_P"1AP  @H8  '*&  !CB
M58P  $F1   ]E@  ,IH  "B>   ?H@  %Z8  !"I   +K   !*\   "Q!@
ML0P  +(1  "R%P  LQ\  +,H  "T,@  M3\  +5-  "U70  M7   +6&  "U
MG0  M;8  +7<  "T]P  M/\  +3_  "T_P"+CP  >HX  &J1  !;E0  39H
M $"?   UI   *J@  ""L   6L   #[0   FW   !N0   +T   "^    O@8
M +\,  # $   P18  ,(=  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'D0
MQZD  ,?'  #'[   Q_X  ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN
M   LLP  (+<  !:Z   .O0  !L    ##    QP   ,D   #*    S    ,T#
M  #."0  T X  -(3  #4&P  V"4  -LR  #=0@  W50  -YI  #>@0  WIP
M -^U  #?V0  W_,  -__  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?
MOP  %,(   S&   #R0   ,P   #0    U0   -D   #:    W    -X   #@
M    X@4  .0+  #G$   ZA@  .TD  #P,@  \40  /)8  #S;P  ](H  /2D
M  #TOP  ]-\  /3S  #T] !JJ   6Z\  $RW   ]O0  +<$  !_&   3R@
M"\X   #2    UP   -P   #@    Y0   .<   #I    ZP   .T   #O
M\0   /,   #V!P  ^0X  /P6  #_(@  _S,  /]'  #_70  _W8  /^1  #_
MJ0  _[X  /_8  #_VP#_ !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!#
M /\ 3P#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P
M_P"C /\ JP#_ +0 _@"_ /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N
M /\ Z0#_ .< _P#_ !0 _P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\
M2@#_ %8 _P!@ /\ : #_ '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P">
M /4 I@#T *X \@"Y /$ QP#O .  [@#R .P _P#L /\ [ #_ .L _P#E /\
MX #_ -X _P#_ Q  _P . /\ #0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^
M %  ^P!: /@ 8P#U &L \P!R /$ >0#O '\ [@"& .P C #J )( Z0"9 .<
MH #F *D Y "S .$ P #@ -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_
M -( _P#_!PT _P ) /\ !@#_  D _P / /\ & #[ "4 ^  R /4 /P#R $H
M[0!4 .H 70#G &4 Y !L .( <P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2
M *0 SP"M ,T N0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,<
M_P#_"@8 _P$  /\   #_  0 _P + /0 $@#O !\ Z@ L .4 . #B $, W0!.
M -D 5P#4 %\ T0!G ,X ;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X
MOP"H +T LP"Z ,( N0#; +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_
M#   _P0  /\   #^    ]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8
M40## %D P !@ +X 9P"\ &X N@!T +D >P"W (( M0") +, D0"R )H L "D
M *X KP"L +T J@#0 *@ ZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0
M_P<  /0)  #J"0  X@0  -H !P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T
M %, L@!; +  8@"N &@ K !O *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$
MJP"? ;D G0/, )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q
M .@4  #<%0  SA$  ,8-  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T
MI@A5 *0)7 "B"F, H IJ )\+<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4
M#;@ D@W, ) .Z@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@
M  #,(0  OQT  +<7  "S$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0
M )@25P"6$EX E1-E ),3; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4
MAA;) (07YP""&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  #
M*@  LR8  *HB  "E'   I!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<
M4@"+'%D B1U@ (@=9P"&'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+( >R#%
M 'DAY !W(OD =B+_ '4B_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V,0
MJ2X  * J  ";)@  F"$! )4>$ "0(!L C2$H (DC,P"')#T A21& (,E3@"!
M)E4 ?R9< 'XF8P!\)VL >R=S 'DG? !X*(< =BB3 '0HH %R**\!<2G! 6\I
MX %M*?<!;"G_ 6LI_P%K*?\!:RC_ 6LH_P'H*   T#(  , X  "N-P  H34
M )@R  "2+0  CBD  (LG# "'*!< @RHC ( K+P!^+#D ?"Q" 'HM2@!X+E$
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M TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P  N4@  *9*  "520
MAT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=1R@ 7$@R %I(.P!9
M24, 5TE* %9)4@!425D!4TEA 5%):P%/278"34F" DM)D0-*2:$#2$FS T=)
MR@-&2>P#1DC_ D9(_P)'1_\"1T;_ D=&_P+&0P  MDP  *),  "13   A$L
M 'E*  !P20  :48  &1'  !?208 7$H0 %I+&P!83"4 5DPO %5-. !334
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M C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5   >%0  &U4  !D5
M6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"7#8 05P^ #]<1@ ^
M74\ /5U7 #M=80 Z76P!.%UY 39=B $T79D",UVK C%=P@(Q7.4",5O\ C%:
M_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6   <U<  &E7  !@6   5%D
M $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W8TL
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M 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W;P
M,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\3@ 6
M?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_ !)W
M_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>   *7L
M ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,AU,
M"X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"_P"5
M<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4  !N)
M   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL  )-9
M  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-=P
M?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4   .
MEP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0  "@
M7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0  >'P
M &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &I
M *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O5
MKV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80  &&'
M  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O    L@   +8
M  "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2   P%H
M ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4  !+
MF@  /:   #&E   EJP  &J\  !&S   +N    KL   "^    P0   ,0   #%
M    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P  -9@
M  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#J@
M-;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP   -(   #3
MU@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1  #N
M9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@  *KX
M !S"   0Q@  !\H   #.    T@   -8   #<    X    .,   #D    Y@
M .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_50
M_VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9 /\
M)0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4 _P"+
M /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V /\
M]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\ ( #_
M "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"& /8
MC #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\ YP#_
M .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_ "@
M_P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .< A@#F
M (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_ -(
M_P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "( \P N
M .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1 (<
MSP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X _P"^
M /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G -T
M,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (  O0"(
M +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N /\
MK@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4 S  A ,@ + #$
M #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0"" *P
MB@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\ G@#_
M )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T #$
ML0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X A0"<
M (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_ (\
M_P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D I0 T
M *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0!(H
MC@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+_P#V
M$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN )8*
M. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H< @PZ3
M ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O%P
MVR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2,@")
M$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/ '88
MG !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(   T"D
M +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^'#<
M?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PAF !K
M(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\  +0Q
M  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#, <R4\
M '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B( &0IE0!B*:0
M8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+   PS4  *TU  "=
M-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M*R\ :RPX &HL
M0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$ %POD@!:+Z$!62^R
M 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0  O3H  *@Y  "7.
MBC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F,2L 9#(T &,R/0!A
M,T0 8#-+ %\T4@!=-%H 7#1B %HT:P!9-74 5S6" %4UD %4-9\!4C6P 5$U
MQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\  "2/   A3L
M 'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q %TX.@!;.$$
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M 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10  >40  &]$  !G0@
M8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+1CD 2D=! $E'2 !(
M1U  1D=8 $5'80!#2&P 0DAX 4!(AP$^2)<!/$BI 3M(O@$Z2-\!.D?X 3I&
M_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'  !C1@  6T,
M %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"3$T
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M 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(  $=3  !!50
M.U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$, +5Q, "Q<5@ K
M76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C6O\ (UG_ "18
M_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P  -ET
M #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B9%P
M(61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?_P"A
M60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,  "IF
M   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@ %VQE
M !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"970
MA5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M   >
M< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?  UU
M;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@  ?V$
M '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7>0
M$7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_9P
M?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<  &MF
M  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P  #(8"
M  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P  BW$
M (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL  !:
M;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +CP  !)(   "4
M!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@  )E]
M  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3=@
M1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G    *    "A
MH@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER  "H
MB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@  /H<
M #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X   "O    L
M +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[?0
MNI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<  "J=
M   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_    P    ,$
M  ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@  T8@
M -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M   6
MLP  #K@   :\    P    ,,   #&    RP   ,T   #.    T    -$   #4
M    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@  .N4
M  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .P@
M!,4   #*    S0   -$   #8    VP   -\   #@    X@   .0   #F
MZ0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"  #_
MG0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\ _P [
M /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^ ),
M_0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D _P#@
M /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V /\
M00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T [P"4
M .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1 /\
MS #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L .P#W
M $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@". -P
ME0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\ OP#_
M +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G $
MX@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8 CP#$
M )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_ +
M_P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D RP!#
M ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R )(
ML "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0 _P#_
M    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ] +4
M1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P H "6
M )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_
M]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8 /P"C
M $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1 )
MG ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@  Z0P
M -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6 $$
ME !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0 F ""
M *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4  ,45
M  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP B 1#
M (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W"J,
M=0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=  "I
M'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^ 'P.
M1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:( :Q*R
M &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@(P
ME"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(600!Q
M%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO & :
MQ !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0  C"@
M (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H'D0
M9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<BP !6
M(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T  'PK
M  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$ 7R9(
M %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/*=X
M3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P  !P
M+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$ %<M
M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L 2"_V
M $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K,@
M9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R20!0
M,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T $(T
M_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@  83,
M %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*-TX
M23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX_P ]
M-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<  %@V
M  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L 1#Q3
M $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X._\
M.#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z  !/
M.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1 #U!
M6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\ ,S__
M #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*0
M1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&6  V
M1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_ "Y#
M_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10  048!
M #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P2U\
M+TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'_P"G
M1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL  #=,
M"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P *%!H
M "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A20
MC$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2!  M
M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E !]6
M=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30  ADT
M '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F6@D
M(UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==<  5
M78$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$  '!1
M  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80, &F,,
M !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .97T
M#661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5  !?
M50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL% !!M
M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8  FZ*
M  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<60
M4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW"@ %
M=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$  !X
MF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@  35\
M $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "   @0T
M ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$DP
M@ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<  #QK
M   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ", P  C D  (T.
M  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP  D:(
M )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V   J
M>P  ((   !>%   0B0  "XT   21    E0   )@   "9    F@,  )L(  "<
M#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH  *&S
M  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   AB@
M%X\  !"4   *F0   9T   "@    I    *<   "H    J0   *H   "L!@
MK0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H  "T
MQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@  $)\
M  FD    J0   *T   "P    M    +<   "X    N0   +L   "\    O@(
M , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*N
MRMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";    "U
M    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.    T    -(
M  #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ   Y<4
M .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%
MR0   ,T   #2    U@   -H   #;    W@   .    #B    Y    .<   #I
M    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\  /W'
M  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_ $T
M_P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D G #W
M *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_ ,H
M_P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $< _@!1
M /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H )\
MY@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X _P#_
M  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+ .P
M5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@ SP"B
M ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_
M_P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4 30#1
M %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"< +D
MIP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_    _P
M /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\ $X
MN@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *< H "E
M *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _    .X
M  #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@ J !/
M *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5 *<
MDP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L   #)
M    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !) )8
M3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *( A0"Q
M (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W!P
MK ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D 20"'
M %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L '8
MO@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$   G@X
M )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\ $L
M>@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#NP!I
M!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4  (L2
M  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48 < I,
M &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@#=@
M7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:  ![
M%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%) &81
M3P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4 517S
M %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S'@
M;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T82P!<
M&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ $P<
M_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)   :"$
M &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4($\
M4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C_P!%
M(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8  %\D
M  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP 3"94
M $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _*/\
M0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH  !7
M)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1 $4L
M6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\ .BS_
M #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1+
M3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q5P ^
M,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_ #4P
M_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0  23$&
M $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y-E\
M-S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T_P"I
M-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8# $$W
M#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT ,CMH
M # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D.
MCCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\"P Z
M/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F "M
M=  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P  BCP
M '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T00\
M,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%<0 C
M18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\  '1
M  !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT *T@2
M "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =2G\
M&TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#  !C
M0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0 ").
M%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P %%"/
M !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?1P
M54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6$0 9
M5A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,  U7
MH  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@  44H
M $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 07A,
M$%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->FP "
M7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX  $=.
M   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q  !F<5
M  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0  9JP
M &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3   Y
M50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2  !O
M&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<  &_!
M  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R70
M*F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z$P
M>QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ  ![
MX@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P  (VL
M !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P  B!,
M (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")V
MB/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@  !-]
M   -@0  !H4   ")    C0   )    "2    D@   )0%  "5"@  EPX  )@2
M  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0  FO
M )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,   $
MD0   )4   "9    G0   *    "A    H@   *0   "E 0  IP<  *D,  "J
M$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8  *S\
M  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=    H@
M *8   "J    K@   +    "Q    LP   +0   "V    N    +H$  "\"@
MOA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R  ##
M_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N    L@   +<
M  "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T   #/    T@@
M -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@] !.
MBP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_    Q    ,@   #.
M    T0   -0   #5    V    -H   #=    WP   .(   #D    YP   .L%
M  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_  L
M_P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\ 6@#_
M &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J /(
MMP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0 _P
M /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W %P
M] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .  L #=
M ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P   /\
M  #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8 X0!<
M -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$ +<
MP0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\   #Z
M    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6 ,0
M7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\ K@#!
M *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H
MW    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +  50"N
M %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X )H
MT "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2    Q0
M +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"< %4
MF@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H Q0"(
M .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP   *H
M  "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\ B@!4
M (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z -L
M> #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L   "6
M  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/ 'P
M50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X ; #N
M &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "( @
MA0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '  4 !N
M %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I &
M_ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0  >0D!
M '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E!%(
M8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*^P!5
M"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A   &T-
M!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\ 6PU6
M %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-$/\
M31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04  !D
M$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3 %$3
M6P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\ 117_
M $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;%P(
M6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:6 !(
M&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_ #X;
M_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0  4QP+
M %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"(%\
M0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A_P"J
M)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"(' $HB
M$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP .B9G
M #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E*0
MCRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G#0!"
M*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME #,K
M<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+   BRT
M 'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]+!$
M.RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP<  L
M,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS   '8Q
M  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1  -C(6
M #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G-7X
M)360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T  !E
M-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3 "\W
M&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP (#J.
M !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A-P
M5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\&  H
M/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^, !@_
MH  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@  4SH
M $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A0AL
M($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$G@ 1
M1+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T  $@]
M  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921< &$D>
M !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,2K
M"DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5    _
M0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9 !!0
M(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L  E#%
M  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \1
M-44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8'  '
M6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?   !6
MY0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2   ,$H
M "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&   8!\
M & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?X@
M7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$  "-4
M   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D  &HA
M  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0  :/<
M &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=   6
M8   $&0   QG   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;  !V
M(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4  '/_
M  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0;
M"G    1S    =@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$&P
MA20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_  "
M_P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0   7X
M  "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/  "3%   E1L
M )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2_P!=
M80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$    B0   (X   "2
M    E@   )@   ":    FP   )T   "?    H0,  *,(  "E#0  IQ,  *D<
M  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6:
M2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C
MIP   *H   "K    K0   *\   "Q    LP   +4   "X!0  N@P  +T2  #
M'   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=   0'D
M #)_   EAP  &8X  !"5   'G    *(   "G    K    +    "U    N0
M +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(  - +  #5$@
MUB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D  "N0
M   =F   $J    JG    K@   +0   "Y    O@   ,(   #(    RP   ,X
M  #/    T@   -0   #6    V@   -T   #?    X@   .8   #J"@  [Q,
M / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\ !0#_
M  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D /\
M:@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0 Z0#D
M .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_  (
M_P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X 8P#L
M &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4 ,\
M\@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_    _P &
M /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4 &,
MT0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D Z "X
M /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP ! .0
M# #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P N0!A
M +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C /4
MHP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?    T    ,< !P#!
M  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !: *,
M8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L D0#_
M )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@   +$  @"K  P
MIP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )  6@"/
M %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y '\
M_P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *    "9  < E0 .
M )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_ %D
M?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '  _P!P
M /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+  ( A@ + (,
M$0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0 < !:
M &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C /\
M8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '< #@!U
M !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6 &,
M70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\ 6 #_
M %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K !
M:0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H 60!8
M &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_ $X#
M_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P 8001
M %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0"5\
M3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,_P"P
M%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P- %<,
M% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX 1P]H
M $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I&0
MDAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0$ !.
M$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E #X5
M<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'   C1X
M 'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'%Q4
M11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;;P U
M&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(  '<C
M  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!( /QT9
M #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O('P
M+2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F  !E
M)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6 #@B
M'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H *"6,
M "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B*@
M5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G&P Q
M*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ* "$J
MG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+   5"P
M $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L+!\
M*BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !POFP :
M+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\  $DO
M  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P )3(C
M "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4,ZX
M$S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R  !
M,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@ !XW
M)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T #CC'
M  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]-
M.#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<](P 6
M/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!  H]
MY  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P  -3<
M # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 01"<
M#T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#X  #
M0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH  "T[
M   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B, "$HK
M  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0  2?4
M $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E    C
M0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F  !1
M+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4  $__
M  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,  "1&   >2
M%TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:*0
M6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_  !7
M_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84   $E,
M  Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P  9"T
M &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@_P!?
M2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   260  #5T   A@
M   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28  '$Q
M  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:3P
M4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K
M;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H  "
M-0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65   3E,
M $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8   !Z    ?0
M (    "#    A    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2+
MDCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H  #M=
M   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+    C@   )$
M  "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06  "F(0  IC$
M *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I   G
M;@  &W4  !%\   +@P   (D   ".    DP   )@   "=    H0   *0   "E
M    IP   *D   "K    K0   +    "R    M0@  +@.  "\%@  O"4  +PW
M  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ??P
M$X8   N.   !E0   )L   "A    I@   *L   "P    LP   +<   "W
MN@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K  #4
M0   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0  #9D
M  .@    IP   *X   "S    N    +T   #"    Q@   ,H   #*    S0
M ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M,P
M[DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P . /\
M%0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L ^P!Q
M /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B /\
MVP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\ $ #_
M !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J .0
M< #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\ Q0#_
M +L _P"T /\ K0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q !,
M[0 > .P * #I #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D : #&
M &\ Q !V ,( ?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_ *P
M_P"E /\ H #_ )P _P#_    _P   /L   #N    Y    -P " #3 !  SP 8
M ,L (@#) "L Q@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N &<
MK !N *H =@"H '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P _P"6
M /\ DP#_ )  _P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3 +$
M' "O "4 K@ N *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F
M )8 ;@"4 '< D@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"' /\
MA0#_ (( _P#S    XP   ,P   "\    L    *<   "A  @ G@ / )L %@"9
M !\ F  G )8 +P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@ (0
M9P"" &\ @ !Z 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_
M '4 _P#F    RP   +<   "H    G@   )8   "/  0 BP , (@ $@"' !D
MA0 A (0 *0"" #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R
M &D <0!S &\ ?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_ &D
M_P#2    N    *4   "7    C0   (8   "!    ?  ( 'D #@!W !0 =@ <
M '0 (P!S "L <0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E &,
M8P!M &( > !@ (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"
M    J@$  )@#  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7 &@
M'@!F "4 90 L &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H
M %< <P!5 ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P
MGPD  (T+  !^#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T &@!<
M "$ 6P G %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T
M;P!, 'T 2@"- $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X
M (,0  !U$   :Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3 !P
M4@ C %$ *0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!#
M WH 0@.+ $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3
M  !N%   9!0  %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@?
M $D()0!("2L 1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD
M.@R* #@,G  W#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I
M&   7A@  %88  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.
M(0!"#B@ 0 XN #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D ,A"*
M #$0G  O$+  +1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'
M61P  %$<  !,&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [
M$R4 .A,K #@3,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6( "H5
MF@ H%:X )Q7' "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\
M $X?  !('@  0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U&"(
M,Q@H #(8+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B
M&JT (1K% " :Z  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB
M  !$(0  /R$  #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE
M "T>+  K'C, *AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL
M&Q_# !L?YP ;'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E  !!
M)   /",  #@C   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B
M*0 F(S  )2,X ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H %B3!
M !4DY0 6)/P %R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^)P
M.28  #4F   Q)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G)P A
M*"X ("@V !XH/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$H
MY  1*/L $RC_ !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0  -BD
M #(H   N*   *B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L
M&BTS !@M/  7+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -
M+?D #BS_ ! L_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L  "\K
M   K*P  )BP  "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P
M !,R.0 2,T, $3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0
M"C'_  LQ_P!W*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN   I
M+@  (S   !\R   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX
M-0 -.#\ ##A*  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_
M  4V_P!S+@  8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E,@
M(#,  !LV   7.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &
M/CL !3Y&  ,^4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_   \
M_P!M,@  73,  % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@  '3@
M !@Z   4/0  $#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0  1#8
M $1!  !$3@  1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"_P!H
M-@  6#<  $PX  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T  !-
M   00@  #44!  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(  $L]
M  !,20  3%<  $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@
M5#L  $D[  ! .P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'   ,
M20  "$P   )/!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W  !4
M1   5%(  %1C  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P  3S\
M $4_   ^/@  -ST  "\^   G0   ($,  !E&   320  #TP   M/   &4@
M %0   !7 @  6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0
M7DP  %Y=  !><0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,  $-"
M   \00  ,D(  "E%   A2   &DL  !-.   .4@  "E4   -9    6P   %X
M  !@    8@(  &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4
M &M6  !J:@  :H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&   W
M1P  +$H  "--   ;40  $U4   Y9   (70   6$   !D    9P   &H   !L
M    ;@   '    !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT  'I.
M  !Y8@  >7D  'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P3P
M)E,  !Q8   37   #6$   9F    :@   &\   !R    =@   'D   !\
M?0   '\   "!    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$  ",
M6   BV\  (J,  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@  'E\
M !1E   -:@  !7    !V    >P   '\   "#    AP   (H   "-    C@
M )$   "3    E0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A3@
MH&4  *"!  ">H   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX   YU
M   %>P   ($   "'    C0   )(   "6    F@   )T   "?    H0   *0
M  "F    J    *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P  MUH
M +5V  "TEP  M+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'
MC@   )0   ":    H    *4   "J    K@   +$   "R    M0   +<   "Z
M    O    +\   ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ
M  #-B@  RJL  ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":    H0
M *<   "M    LP   +D   "^    P@   ,4   #&    R0   ,P   #.
MT@   -4   #:    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>  #J
M>@  ZYD  .NU  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L _P E
M /\ +P#_ #H _P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@
M] "  /$ B0#O )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U
M /\ L #_ *T _P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ? /\
M*0#[ #, ]P ] /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X
M -8 @ #2 (H SP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\
MI #_ *$ _P#_    _P   /T   #Z    ^    /  "0#L !$ Z  9 .< (P#E
M "T W@ V -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P
M> "Y ($ MP"- +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_
M )0 _P#_    ^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#" "8
MOP O +L -P"W #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A
M 'D GP"$ )T D0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8
M_P#W    [    -X   #)    O    +0   "O  H JP 0 *D %P"H "  IP H
M *( , "? #@ G  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "- '$
MBP![ (D B "' )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I
M    UP   ,$   "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B (X
M*@"+ #$ B0 X (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S
M '8 ?P!U (X <P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:
MOP   *P   ">    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z
M "L =P Q '4 -P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &<
M> !F (8 9 "7 &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%    K0
M )L   "-    @P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K "4
M:0 L &< ,0!F #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9
M (  5P"0 %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T
M  !_    =0   &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F
M %L + !: #( 6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H
M3 "* $L G !* +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('  !T
M"   :@@  &,&  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$
M* !0 "T 3@ S $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"%
M $$ F !  *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L#0
M80T  %H-  !5"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!'
M "D 1@ O $4 - !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@"" #D
ME  X *< -P"^ #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$
M %,0  !.$   2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4
M/@,K #T$,0 \!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P
M!J4 +P6[ "X%W0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510  $X4
M  !($P  1!(  $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH
M #<++@ V"S4 -0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4
M)PR[ "4,W0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#
M%P  /Q4  #P4   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/
M+  P#S( +Q Z "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"]
M !X0X  >$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  ! &@
M.QD  #@8   U%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J
M$S  *!,W "<4/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5
MW@ 8%?@ &13_ !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0  -QP
M #0;   Q&@  +QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T
M(Q@T "(9/0 @&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3
M&?8 %!G_ !48_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\  #$>
M   M'0  *QP  "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR
M !P>.@ ;'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4
M$!W_ !$=_P!Z'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA   J
M(   )R   "0?   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B
M.  5(T$ %"-, !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_
M  TA_P!V'P  9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H(P
M)",  " C   =)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1
M*#\ $"A*  XH5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F
M_P!Q(@  8"0  %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0  (B4
M !TG   9*   %BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L
M"RU&  HM4@ (+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M
M)0  72<  $\H  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@  !LJ
M   7+   $RX" ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"
M  ,R3@ !,EP  #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H*0
M6"H  $PK  !!+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N   3
M,   $#("  XT!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^   X
M2@  .%@  #AH   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+   5"X
M $@O   ^+P  -BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0-0
M#C<!  HZ!P &.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^1@
M/E0  #YD   ^=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$  $0R
M   [,@  -#$  "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P  "CT
M  5 !0  00H  $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00  1D\
M $9?  !&<P  18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U   Y
M-0  ,C0  "TS   F-   (#4  !HX   4.@  $#T   U    )0@  !$4   !'
M P  2 <  $H+  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH  $]:
M  !.;0  3H4  $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W.
M,3<  "DW   A.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/
M400  %('  !4"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4  !8
M9P  6'\  %>:  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P  +#P
M "0^   <00  %40  !!(   +2P  !4X   !1    5    %<   !9    6P
M %T"  !>!@  8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E8
M97<  &23  !CL0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,  !Y&
M   52@  $$X   I2   #5@   %H   !=    8    &,   !E    9P   &D
M  !K 0  ;04  &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60  =&\
M '.+  !RJ0  <,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1   0
M5@  "5H   %?    8P   &@   !K    ;P   '(   !U    =P   'D   ![
M    ?0   ( #  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8  (6!
M  "$H   @L(  ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )9
M &D   !O    =    '@   !\    @0   (0   "'    B    (L   ".
MD    ),   "6    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV  "9
ME@  F;4  );E  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =    'L
M  "!    A@   (L   "0    E    )<   "9    G    )\   "A    I
M *<   "J    K0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "RB0
ML*H  *[/  "M]0 W7   *V$  !YH   3<   "W@   "     AP   (X   "5
M    F@   )\   "D    J    *P   "M    L    +,   "U    N    +L
M  "_    PP   ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@  R9X
M ,B^  #%Z0 O:0  (W   !9Y   -@0   8L   "3    FP   *(   "H
MK@   +0   "X    O0   ,    #"    Q0   ,@   #+    S@   -$   #6
M    VP   -\   #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S
M  #CU #_    _P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_ #4
M_P ^ /\ 1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M
M (X Z@"9 .8 IP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *(
M_P#_    _P   /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X ]  X
M /  0 #L $@ Z0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#- (4
MR@"1 ,< G@## *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_
M    ^@   /0   #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q -
M.0#+ $  R !' ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"(
M *X E0"K *0 J "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y
M[P   .<   #?    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q
M #H K@!  *L 1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^ )8
MC "4 )L D@"M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M    X
M -$   "_    LP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8 #(
ME0 Y ), /P"1 $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V (( @@"
M )( ?@"C 'P N@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP   +8
M  "G    G0   )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P @@ R
M '\ . !] #T >P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M (D
M; ": &H K@!I ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$   "3
M    B0   ((   ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L &X
M,@!L #< :@ \ &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (  70"2
M %L I0!: +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#
M>0   '$   !M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &  + !>
M #$ 7  W %L / !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\
MG@!. +0 30#: $T ^P!- /\ 30#_ $T _P"J    E    ((   !U    :P
M &0   !@    70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P
M40 Q $\ -P!. #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!#
M *P 0@#) $( \0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800  %H#
M  !5 0  4@   %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "< 1P M
M $4 ,@!$ #@ 0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8
M. "_ #@ Z  X /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*  !,
M"   208  $<#  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I #T
M+@ [ #0 .@ Z #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X
M "\ W@ O /D +P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%#0
M00P  #\*   ^" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T
M #  ,P W #( /@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S "<
MT0 G /( )P#_ "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $   / \
M #D.   W#0  -@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N!BX
M+08T "L&/  J!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?
M!>T 'P;^ !\'_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(  #01
M   R$   , \! # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR
M "8,.@ D#$, (PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L
M%PW\ !@,_P![$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4   M
M$P  *Q(  "H0 P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0
M.0 >$$( '1!, !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^
M !(0_P!W$P  914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I%@
M)Q4  "84 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9
M%$  %Q1* !845@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3
M_P!S%0  81@  %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&   )!@
M "(7   @%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T
M$AE( !$95  0&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O
M&   7AH  % <  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H  !X:
M   <&@  &AL% !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%
M  T>40 ,'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@
M6QT  $T>  !"'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=   8
M'@  %1\" !,@"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB
M30 '(EH !2)I  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0  5Q\
M $HA  ! (0  -R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6(0
M$B," ! D!P .)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !
M)U8  "=F   G>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(  $<C
M   ])   -"0  "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)   $"8"
M  XH!P +*@L ""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10  +%,
M "QC   L=@  +(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z
M)@  ,B8  "LF   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"  LM
M!@ '+PL !# .   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?
M   R<@  ,8D  #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W*0
M+RD  "DH   E)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R!0 #
M- D  #4,   V#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;   X
M;@  .(4  #>?   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+   +2L
M "@J   D*0  'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!   .@<
M #L*   ]#0  /A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  ! :0
M0(   #^;   ^MP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T  "<L
M   @+0  &B\  !4Q   1,P  #38   DX   %.P   #T   !  0  000  $,'
M  !%"P  1@X  $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9   2'L
M $B7  !'M   1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q   <
M,P  %C4  !$X   -.P  "#X   -!    0P   $8   !(    2@   $P$  !.
M!P  3PL  %$.  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0  %*0
M  !1K@  4-<  $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7.@
M$3T   Q!   '1    $@   !*    30   %    !3    50   %<   !8 @
M6P8  %T+  !?#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)  !=
MIP  7,P  %KX  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P  #$<
M  9+    3P   %,   !6    60   %P   !?    80   &,   !E    9P$
M &H%  !M"@  < X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !MGP
M:\$  &GQ  !H_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0   !8
M    70   &$   !E    :    &L   !N    <0   ',   !U    >    'L
M  !^ P  @0H  (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@  ?K8
M 'SG  !Z_P _1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H
M;0   '$   !V    >@   'X   "!    @P   (8   ")    BP   (X   "2
M    E0$  )D)  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H  )+4
M  "0^@ X2P  +$X  "!3   560  #6    -G    ;@   '0   !Z    @
M (0   "*    C@   )(   "5    EP   )H   "=    H    *,   "G
MJP   *\   "T"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!  "I
M[@ Q50  )%L  !AA   .:0  !7$   !Y    @0   (@   "/    E    )H
M  "?    I    *@   "I    K    *\   "S    M0   +D   "]    P0
M ,8   #+    T0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I
M8@  '&D  !%Q   '>P   (0   "-    E0   )T   "C    J0   *\   "T
M    N0   +P   "^    P@   ,4   #(    S    -    #4    V@   -\
M  #D    Z@   .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_
M_P   /\   #\  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_
M $D _@!0 /L 5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5 .0
MHP#@ +4 VP#0 -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P
M /8   #S    \P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I $,
MY@!) .( 3P#> %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_
M *H NP#! +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0   .H
M  #G    YP   .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L P@!"
M +\ 2 "\ $X N@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F *$
MHP"U *  V "> /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H   #3
M    Q@   +\   "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [ *0
M00"A $8 GP!, )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )< C "I
M (D Q "( .\ A0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V
MJ0   *$   "=  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P .@"*
M #\ B !% (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4
MM@!S -\ <@#_ &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=    DP
M (H   "%    @@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@
M=  ^ '( 0P!P $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B
M ,D 80#V &  _P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@   '@
M  !S    ;P ! &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #( 8P W
M &( / !@ $( 7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L
M4@#I %( _P!0 /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<   !C
M    8    %T !0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q %,
M-@!2 #P 40!" $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8
M $8 _ !% /\ 10#_ $4 _P"?    B0   '@   !L    8@   %L   !6
M4P   %$  @!/  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@ ,0!'
M #< 10 ] $0 1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#' #L
M\P [ /\ .P#_ #P _P"3    ?@   &X   !A    6    %$   !,    20
M $<   !%  4 1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ] #(
M.P X #H /P Y $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$ YP Q
M /\ ,@#_ #, _P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!
M   \  , .P ( #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X ,P T
M #( .P P $, +P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I /L
M*0#_ "H _P"!!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(   U
M!0  - (& #, "@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P "H
M-P I #\ * !) "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /, (0#_
M "( _P!["0  : P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N"P
M+0D# "T&"  L! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0 -  C
M 3T (@%& "$!40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H
M_P!U#   9 X  %4/  !*$   0!   #D0   S$   +P\  "P.   I#@  )PT!
M "<,!0 G"@H )@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH
M' A$ !H(3P 9"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q
M#@  7Q   %$1  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q   "(.
M!  A#0< (0P+ " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U#
M !4-3P 3#5P $@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M$
M7!$  $X3  !#%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1 P <
M$ 4 ' \( !L/#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 0
M4  .$%T #1!K  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0
M $L5  ! %@  -Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0
M%Q(& !82"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P42P +
M%%@ "11G  <4>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518  $@7
M   ]&   -!@  "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4%
M !(6"  1%@T $!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %&%0
M!!AC  (8=0 !&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:   [
M&@  ,AH  "L:   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9
M!P .&PL #!L/  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@
M   =<@  '(@  !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X'
M+QT  "D<   C'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,
M'@L "1\.  8@$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=   A
M;P  (88  "">   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P  +1\
M "<>   B'0  'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )(@H
M!2,-  (D$   )1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F;
M)H,  "6<   EMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$  "4@
M   @'P  '1X  !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD  "@+
M   J#@  *Q$  "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0  +(
M "N:   JM0  *=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B   ?
M(0  '"   !<@   3(0  $",   XD   +)@  ""@   0J!   + <  "X)   P
M#   ,0\  #,3   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL  #*7
M   QLP  ,-X  "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >(P
M&2,  !0D   1)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W"@
M.0T  #H0   [%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2   X
ML   -]L  #;\   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P  %2@
M !$J   .+   "B\   8Q   !-    #8    X    .P$  #T$   _!P  00H
M $,.  !%$0  11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!JP
M0-(  #_Z   ^_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X   TQ
M   )-   !#<    Z    /    #\   !!    1    $8   !( P  2@<  $P+
M  !.#@  4!,  % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I   2LH
M $GX  !(_P ^,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ   "
M/0   $    !$    1P   $D   !,    3P   %$   !3    50$  %@&  !:
M"P  70X  %\5  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\   %7R
M  !4_P Z-@  ,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%    20
M $P   !0    4P   %8   !9    6P   %T   !@    8@   &4   !H!0
M:PL  &\0  !O&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I  !B
M_P X.0  ,C<  "@Y   >.P  %3\   Y$   '20   $T   !2    5@   %H
M  !>    8@   &4   !H    :P   &T   !P    <P   '8   !Y    ?00
M ($+  "%$0  A!T  ((L  " /@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X
M/0  +#X  ")!   71@  #TL   =1    5P   %P   !B    9@   &L   !O
M    =    '@   ![    ?@   (    "#    A@   (H   "-    D0   )8#
M  ";#   G1,  )LA  ":,P  ETD  )1B  "3?P  D*   ([%  ",\P Q1
M)4@  !I-   04P  "%H   !A    :    &X   !T    >0   '\   "$
MB0   (T   "1    DP   )8   "9    G0   *    "D    J    *P   "R
M P  MPT  +<7  "U*   LCX  +!6  "L<P  JI0  *FT  "EY0 J3P  'E0
M !);   *8@   &H   !S    >P   ((   ")    C@   )0   ":    GP
M *0   "F    J0   *T   "P    LP   +<   "[    P    ,4   #+
MT00  -4.  #3'0  T#(  ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(   QK
M   !=    'T   "'    D    )<   ">    I    *L   "Q    M@   +H
M  "\    P    ,0   #(    RP   ,\   #4    V@   .    #F    ZP
M /$&  #P$P  [B<  .P_  #J6P  YWH  .2;  #@NP#_    ^P   /8   #S
M    ]  % /8 # #Z !$ _P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H
M4@#W %@ ]0!> /, 9 #Q &H [@!R .P >@#I (4 Y0"1 .$ H #= +( V #.
M -( ]@#! /\ K0#_ )X _P"6 /\ D #_ (P _P#Z    \@   .P   #I
MZ0   .P !0#R  P ^  2 /< &P#U "4 \  N .L -P#F #X X@!% -T 2P#8
M %  TP!6 -  7 #- &( R@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0
MZ "N /\ G0#_ )  _P"( /\ @P#_ (  _P#P    Y0   -X   #:    VP
M -P   #8  < T0 . -$ %0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W $D
MM0!/ +( 50"P %L K@!A *P :0"I ', IP!_ *0 C0"A )X G@"R )L U0"9
M /P C #_ (( _P![ /\ =@#_ '0 _P#B    TP   ,H   #'    O    +8
M  "P  $ KP + *P $0"M !@ K0 @ *@ * "D "\ H  V )T / "; $( F0!'
M )< 30"5 %, DP!9 )$ 80"/ &H C !U (H @P"( )0 A@"G (, P@"" /
M? #_ ', _P!M /\ :@#_ &@ _P#/    P0   +D   "M    H    )@   "4
M    D0 & )  #0"0 !( CP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!  (
M10!^ $L ? !2 'H 60!X &( =@!L '0 >0!R (D <0"= &\ M !M -\ ; #_
M &4 _P!@ /\ 7@#_ %P _P"^    L0   *    "2    B0   ((   !\
M>@ ! '@ "0!W  X >  4 '< &@!T "$ <@ G '  +0!N #, ;  X &L /@!I
M $0 : !* &8 40!D %H 8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %<
M_P!4 /\ 4@#_ %$ _P"P    GP   (T   !_    =    &X   !J    9@
M &4 ! !C  L 8P 0 &, %0!C !L 80 A %\ )P!= "P 7  R %H -P!9 #T
M5P!# %8 2P!5 %, 4P!< %( : !0 '< 3P") $X GP!- +H 3 #I $L _P!)
M /\ 1P#_ $< _P"B    C0   'P   !N    90   %X   !9    5P   %4
M 0!4  < 4P - %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ]
M $D 1 !' $P 1@!6 $0 80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\
M/0#_ #X _P"4    ?P   &\   !C    60   %$   !-    2@   $@   !'
M  0 1P * $8 #@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T
M/@ \ $< .@!0 #D 6P X &D -P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_
M #4 _P"(    =    &4   !8    3P   $@   !#    /P   #T    \  (
M/  ' #L #  [  \ .P 2 #H %P Y !P -P A #8 )@ U "P -  R #, .0 Q
M $$ , !+ "\ 5@ N &, +0!S "P B  L *  *P"[ "L Z@ K /\ *P#_ "P
M_P!_    ;    %T!  !1 @  2 ,  $ #   [ @  -P   #0    S    ,@ %
M #( "0 R  T ,0 0 #$ $P P !@ +P = "T (@ L "@ *P N "H -0 I #T
M* !& "< 40 F %X )0!N "0 @@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W
M    900  %8&  !+!P  0@@  #H(   U!P  , 8  "T%   L P  *P # "H
M!P I  L *0 . "D $0 H !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D (0!#
M "  3@ ? %H '@!I !T ?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P!0
M7P@  %$*  !&"P  /0L  #4+   P"P  *PH  "@)   E"   ) <" ",$!@ C
M @D (@$, "( #P A !( (  6 !\ &P > "  '0 F !P +@ ; #8 &@ _ !D
M2@ 8 %< %P!F !8 >  5 (\ %0"F !0 PP 4 .X % #_ !4 _P!K"   6PL
M $T,  !"#0  .0T  #$-   L#0  )PT  ",,   A#   'PL! !X*!0 =" @
M'08+ !P%#0 <!!  &P04 !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3
M U0 $@-C !$#=0 0 HH $ &B  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.
M   ^#P  -0\  "X/   H#P  ) X  " .   =#@  &PT! !D-!  8# < & L)
M !<)#  7"0X %@D2 !4)%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /"5(
M#@EA  T)<P ,"(@ "PB?  H'MP *!ML "@7V  H$_P!C#0  4PX  $80   [
M$0  ,A$  "L1   E$   (1   !T0   :#P  & \! !8.!  5#@< % T) !,-
M"P 3# T $@P0 !$,%  0#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@
M  @-<0 &#88 !0V=  0,M  ##-(  @SQ  (+_P!?#@  4!   $,1   X$@
M+Q(  "@2   C$@  'A$  !L1   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0
M#@P #@X.  X/$@ -#Q< #! =  P0)  *$"P "1 V  @000 &$$X !1!=  ,0
M;P !$(0  !"<   /M   #M0   [S   ._P!<$   31(  $ 3   V%   +10
M "84   A$P  '!,  !D2   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L
M#!$-  L2$0 *$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3;
M$X(  !*;   2M   $=<  !'U   1_P!8$@  210  #T5   S%@  *Q8  "05
M   ?%0  &A0  !<4   4$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-
M  <5#P &%A, !!88  ,6'P "%B<  !<P   7.P  %T@  !=8   7:@  %H
M !:9   5M   %=D  !3W   3_P!5%   1A8  #H7   P&   *!@  "(7   =
M%@  &18  !85   3% , $A,& ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:
M#@ !&A$  !H6   ;'   &R0  !LM   ;.   &T8  !Q5   ;9P  &WT  !N7
M   :LP  &=L  !CY   7_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;&
M&!<  !46 0 3%04 $14$  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0
M(!   " 3   @&0  ("$  "$J   A-0  (4(  "%2   @9   ('H  !^5   ?
ML0  'ML  !WZ   <_P!-&0  /QL  #0<   K'   )!P  !X;   :&@  %Q@
M !07 @ 2%P( $!@!  T9 0 +&@( "!P#  4=!  "'P8  "$(   C"P  )0X
M "81   F%@  )AX  "<G   G,@  )S\  "9.   F8   )G<  "62   DKP
M(]H  "+[   A_P!('0  /!X  #$?   H'@  (AX  !T<   9&P  %AH  !(:
M   0&P  #1P   L=   ('P  !"$   $C @  )00  "<&   I"0  + P  "X/
M   N$P  +AH  "XC   N+@  +CL  "Y*   M7   +7(  "R.   KK   *M0
M "G[   H_P!$(   ."$  "XA   F(0  ("   !P>   8'0  %!T  ! >   .
M'P  "R$   <C   #)0   "<    I    + $  "X#   P!@  ,PH  #4-   V
M$0  -A<  #8?   V*0  -C8  #9%   U5P  -6T  #2)   RJ   ,<\  ##Z
M   O_P _)   -"0  "LD   D(P  'R$  !L@   6(   $2$   XC   *)0
M!B@   (J    +0   "\    R    -    #<    Y P  .P8  #X*  ! #@
M01(  $$:  ! )0  0#$  $!    _4@  /F<  #V"   \H@  .L<  #GX   X
M_P Z*   ,"@  "DG   C)0  'R,  !@D   2)0  #B@   HJ   %+0   #
M   S    -@   #@    [    /@   $    !"    10(  $<&  !*"@  30X
M $T5  !,'P  3"L  $LZ  !*3   26$  $A\  !'FP  1;\  $/S  !"_P V
M+   +2L  "<I   C)P  &R@  !0J   .+0  "C    0S    -P   #H    ]
M    0    $,   !&    2    $L   !-    4    %,!  !6!@  60L  %L0
M  !;&0  6B4  %DT  !81@  5UH  %5T  !4DP  4K4  %#J  !/_P S,
M+"X  "<L   >+0  %B\  ! R   *-@   SH    _    0@   $8   !)
M3    $\   !2    50   %@   !:    70   &    !C    9P8  &L,  !L
M$@  :QX  &LL  !I/0  9U(  &9J  !DB0  8:L  %_<  !=_P Q,P  +#$
M "(R   9-0  $3D   H]   "0@   $<   !,    4    %0   !8    6P
M %\   !B    90   &@   !K    ;@   '$   !U    >0   'T&  ""#0
M@A8  ( D  !^-0  ?$D  'MA  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[
M   20   "T4   )+    40   %8   !;    8    &4   !I    ;@   '(
M  !V    >0   'P   !^    @@   (4   ")    C@   ),   "8!@  G X
M )L:  "8*P  ED   ))9  "1<P  C94  (NU  "(Z  K/@  ($$  !5'   -
M30   E0   !;    80   &@   !N    <P   'D   !^    @P   (@   ",
M    CP   )(   "5    F0   )T   "A    I0   *H   "P    MP<  +@1
M  "U(0  LC4  *]-  "J:0  J(@  *:H  "BT0 C2   &$X   Y4   $7
M &0   !M    =0   'P   "#    B0   (\   "5    FP   *    "C
MI@   *D   "M    L0   +4   "Y    O@   ,0   #*    T@   -H*  #6
M%@  TBD  ,Y!  #*7   Q7P  ,*=  #!O0 <50  $5P   =E    ;@   '<
M  !_    B    )    "8    GP   *4   "M    LP   +@   "Z    O@
M ,(   #&    R@   ,X   #3    V@   .    #G    [0   /,   #T#@
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M_____________________________________________________P
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M]/7V]_CY^OO\_?[_;69T,0     #!"$   $                    !
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M ,;4"0"X]Q0$J_\I#I[_-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V]
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
ME9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340
M_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8
M?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[
M%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9
MU'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@
M1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@
MGM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_
MIDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%U
MI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM
M_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/
M<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9
M//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFE
MS7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E
M9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&N
MJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VN_Y,=!/^0*0G_CS00_YH[%_^B1"#_J4TM_ZI8//^H8DS_
MI&Q<]9]V;.R9?WKDD8>&WHF-D-B#DYC3?IF?T'J=I,UVHJG+=*>LR7&MK\=O
MM++!;+FTO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[
ML;QLN[&\;+NQ_Y0=!/^1* G_D3,0_YPZ%O^D0R#_K$PM_ZU6/?^M8$W^J6I>
M]*5T;NJ??7WAEH.+V8Z*EM.'D*#.@96GRGR:K<=XG[+$=:6VPG*KN<!PM+NW
M;K6YLV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM;-O
MN+6S;[BU_Y0=!/^2* G_DS(/_YXZ%O^G0R#_KDLM_[%5/?^P7T[]KFA?\JIR
M<.>D>H'>FH"/U9*'G,Z+C*;)A)&OQ'Z7M<%YG+N^=J._O'2KPK1OKL.N<K.\
MJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK
M<[:X_Y4<!/^2* G_E3(/_Z Z%O^I0A__L$HM_[14/?^T7D[]LV=@\:]P<N:I
M>(/;GWZ3TI>#H<N.B:S$AHZUP("4O;Q[FL.Z>J/%MWFKQZQSK,:G=;&_I7>U
MNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6Z
M_Y4<!/^3* G_EC$/_Z$Y%?^J0A__LDHL_[93//^W74[[MF5A\+1N=.2M=8;9
MI'N6SYN I<>2A;'!BHN[O8>4P+N%G<2V@J3'L'ZJR*5WJLBA>;#!GWJSO)]Z
ML[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\_Y4<
M!/^3* G_ES$/_Z,Y%?^L0A__M$HL_[E3//^Z7$[XNF1B[[AL=>.R<XC8J7F9
MS9]^J<68A+2_DXR\N(V3P;.)F<6NAJ'(JH2IR9]\J<J;?:["F7ZRO9E^LKV9
M?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]_Y8<!/^3
M* G_F# ._Z0Y%?^M01[_M4DL_[M2//V]6T[VO6-B[KUK=N*V<8G5KG>;RZ5\
MJL*=@[2YEHF\LI&0P:R,EL:GB9W(HX>FRIF J,N6@:[$E8&QOI6!L;Z5@;&^
ME8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^_Y8<!/^4)PG_
MF3 ._Z4Y%/^N01[_MTDK_[U1//R_6D[TP6)B[,%I=^&[<(O2L72=QZA[JKR@
M@;2TFH>\K)2-PJ:0E,:@C9O)G(NDRY6&J,N1A:W%D(6QOY"%L;^0A;&_D(6Q
MOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&__Y8<!/^4)PC_FC .
M_Z8X%/^P01W_N$DK_[]1//K"64[RQ&%CZ<5H=]V^;8S-M'.=PJMYJK>D?K2N
MG82\IIB*P:"4D<::D9C)EH^ARY"+J,R,B:S%C(FPP(R)L,",B;# C(FPP(R)
ML,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# _Y<<!/^5)PC_FS ._Z<X
M%/^Q01W_NDDK_\)0._C&6$[PR%]CYLAF>-C!:XW)MW&=O:]WJ;*G?+.IH8*[
MH9R(P9J8C\:4EI;)D)2?RXN1J,R'CJS&AXVPP8>-L,&'C;#!AXVPP8>-L,&'
MC;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!_Y<; _^5)PC_G2\-_ZDX$_^S
M0!W_O$@J_,5/._;)5T[MS5YCXLMD>-+$:HS$NV^<N+)UJ:VK>[.CIH"[FZ&&
MP92=C<6.FY3(BIF=RH:9J,N"DZS&@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!
M@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!_Y<; _^5)PC_GB\-_ZHX$_^U0!S_
MOD@I^<A..O/-5DWJTUQBWL]B>,W':(N_OFZ;LK=SJ*>P>;*>JWZZE:>$P(ZC
MB\2(H9+'@Y^:R8"@I\I]FJS&?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BO
MP7V8K\%]F*_!?9BOP7V8K\%]F*_!_Y@; _^6)PC_H"\-_ZPW$O^W0!O]P4@H
M]LM..>_35$SFV5IBV-1A=\?+9XJYPVR:K;QRIZ&V=[&8L7VXCZV"OHBJB<."
MJ)#&?:>9R'JGI<EWHJS%>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?
ML,%XG[#!>)^PP7B?L,%XG[#!_Y@; _^7)@C_HB\,_ZXW$O^Y/QKYQ$<G\<Y-
M..K;4TO@WUE@T-I?=L'098FSR6N9IL)PI9N]=:^1N'NVB+6 O(&RAL![L(W#
M=JZ6Q7.NH<9RK:W$<JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!R
MJ;# <JFPP'*IL,!RJ;# _YD; _^8)@C_I"X+_[$V$?Z]/QGTR$<EZ]1--N7C
M4$G9XU=?R=]>=+K79(:LSVF6G<=MHY' <:R&NW6S?K=ZN7>T?[URLH6_;;&-
MP6JPE\)IL:7!;+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO6RTLKULM+*]
M;+2RO6RTLKULM+*]_YH; _^9)@C_IRT*_[4V#_G!/Q?NSD8CY-Q,,MWG3TG/
MZ%9>P.1=<K+>9(*CU&F1E<MMG(G%<*5_P'.L=[QWL7"Y?+5KMX&X9[:'NF.U
MD+MAM9N\8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>F
MN6.WIKECMZ:Y_YL; _^;)0?_JRT)_[DU#?+'/A7EU48?VN-),\_K3DG&[51=
MM^I<;JCB8WV:V6F*CM)ME(3,<9M[R'6A<\1XIF["?*EIP(&L9;Z'KF*]CK!?
MO9>Q7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\
MGK%>O)ZQ_YP: _^@) ;_L"P(^< T"^G//1#:WT(=SNE),\3Q3DB[\E):K?!;
M:9[G8W:2X&F!A]IOB7[4<Y!WT7>5<<Y[F6S,?YQHRH.>9,F(H&''CJ)>QI6D
M7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<
MQIND_YX: _^E(P7_MRH%\,@R!]S;-0S.YT(?PO%(-+CY3$:O]U%5HO5;8I7M
M9&V*YVMV@.)P?7G>=8)SVWJ';ME^BFO7@HQGU8:.9-2+D&'3D))>T9:47-&;
ME5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N5
M_Z$9 O^M(0/XOR8#XM0E \[E,P_"\$(AMOI',ZO^2T*B_E!/E_M;6HOU96."
M\&QJ>NQR<'3I>'1OYWQW;.6!>FCCA'QFXHA]8^&,?V#@D8%>WY:"7-Z:@US>
MFH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#_Z,9
M O^V'0'IS!<!S^,> \+P,Q*U^D BJ?]$,)W_23V5_U!(B_];4(+]95=Z^6U=
M=/9S86_T>61K\GYG:/&":6;PAFID[XIL8NZ.;6#MDFY=[)=P7.N;<5SKFW%<
MZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ_ZP5 ?/#
M$ #1V@L P>\?!K3[,Q.H_SP@F_]"+)#_2#:'_T\_?_]:1GC_94MQ_VU/;/]S
M4FG_>55F_GY79/V"6&+\AEEA^XI:7_J.6U[ZDEQ<^9==6_B;7EOXFUY;^)M>
M6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+"0#
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M7C'_B6L\_X5W1O^!@T[_?8]6_WF87/QUH&'Y<J9E]V^M:?5LLVSS:KEO\FC
M<?!FR'/L9,UUZ&'4=N-?WG?;7>-YU5WE=M5=Y7;57>5VU5WE=M5=Y7;57>5V
MU5WE=M5=Y7;57>5V_WL< _]W)P;_=S *_X(U#O^*/!7_CT8=_Y)/)_^17#+_
MCF@]_XIT2/^&@%+_@8M:_'V58?AXG6?U=*1M\G&J<?!NL'3N:[9W[&F^>NIG
MQWWG9<Y_XF+6@-E?W8'07^!^S&#C>\Q@XWO,8.-[S&#C>\Q@XWO,8.-[S&#C
M>\Q@XWO,8.-[_WP< _]X)@;_>B\*_X4S#O^-.Q3_DD0<_Y9.)_^56C+_DF4^
M_XYQ2O^*?57^A8A>^8"29_1[FF[P=J%S[7*G>.IOKGWH;+2 YFF\@^1GQH;A
M9<^(V6+7BL]AV8C(8MV"Q&/@?\1CX'_$8^!_Q&/@?\1CX'_$8^!_Q&/@?\1C
MX'_$8^!__WT; _]Y)@;_?"X*_X@R#O^0.A3_E4,<_YI,)_^96#/_EF,__Y)N
M3/^.>E?\B85B]82/:_!^EW/L>9YZZ'2E@.5PJX7B;+.)X&J[C-YHQH_:9M&2
MSF+1DL=DU8S!9=N&O6;=@KUFW8*]9MV"O6;=@KUFW8*]9MV"O6;=@KUFW8*]
M9MV"_WT; _]Z)@;_?RP*_XLQ#?^3.A/_F$(<_YU+)O^=5C/_FV% _Y=L3?N2
M=EKWC8%F\HB,<.R"E'GG>YN!XW6BB-]QJ8[<;;&2V6N[EM=IR)G,9,N;Q67.
ME\!GTI&Z:-B*MFG;AK9IVX:V:=N&MFG;AK9IVX:V:=N&MFG;AK9IVX:V:=N&
M_WX; _][)@;_@2L)_XTQ#?^5.1/_FT(;_Z!*)O^A5#/_GU]!^YQI3_:7<UWQ
MDGYJ[(R(=>>%D8#B?IB)W7B@D=ARIY?2;:^=SVRYG\QKQ:##9\>@O&C+F[=J
MT)2R;-6-KVS9B:]LV8FO;-F)KVS9B:]LV8FO;-F)KVS9B:]LV8FO;-F)_WX:
M _][)0;_@RH)_X\P#/^8.!+_GD$;_Z-))O^F4C/]I%U!]Z%G4/&<<5_KEWMM
MY8^#>MZ'BX;5?I*1SWB9E\ITH9S'<:J?PV^SH<%NOZ.Z:\6CLVO(GZ]MS9BK
M;]*1J7#6C*EPUHRI<-:,J7#6C*EPUHRI<-:,J7#6C*EPUHRI<-:,_W\: _]\
M)0;_ABD(_Y(O#/^;.!+_H4 :_Z=()?^J43+YJ5M!\Z9D4>RB;F'EFG9PW)%^
M?]*)AHO+@HV3Q7V5F<!XG9Z\=:6AN7.NI+9RN:6R<,.FJV_&HJAQRYND<]"3
MHG34CJ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CJ)TU(ZB=-2._X : _]\)0;_
MB"@(_Y0O"_^=-Q'_I#\9_ZI')/VN3S+VK5E![ZMB4N>F:V+>GG)STI5Z@<J-
M@HO#AXJ3O8&1FK=]F9^S>:&CKW>JIJQVM*>J=L&HHW/#I:!UR9Z>=\^6G'?2
MD9QWTI&<=]*1G'?2D9QWTI&<=]*1G'?2D9QWTI&<=]*1_X : _]])0;_BB<(
M_Y8N"_^?-A#_IS\8_ZU'(_NR3C'SLE=!Z[%@4N*J:&36HG!TS)EW@<.2?XN\
MBX:4M8:.FJ^!E:"J?IVDIGNFIZ-ZL*FA>;RIFW?!J)EYQZ"8>LV8EWO1DY=[
MT9.7>]&3EWO1DY=[T9.7>]&3EWO1DY=[T9.7>]&3_X$: _]^) ;_C"8'_Y@N
M"O^B-A#_J3X8_Z]&(_BU33#PMU9 Y[5>4MVN9F30I6YSQIUU@+V6?(NUD(.4
MKHJ+FZB&DJ"C@IJEGW^CJ)M^K:J8?;FKE'O JI-]QJ*2?LR9D7_0E)%_T)21
M?]"4D7_0E)%_T)21?]"4D7_0E)%_T)21?]"4_X$9 _]^) ;_C28'_YHM"O^D
M-0__K#T7_K)%(O:X3##MO%1 Y+A=4=>R9&/+J6QSP*%S@+>:>HNOE("3J(^(
MFZ**CZ"<AY>EEX2@J)2"J:J1@K6KC8&_JXV!Q:2,@LN;C(+/E8R"SY6,@L^5
MC(+/E8R"SY6,@L^5C(+/E8R"SY6,@L^5_X(9 _]_) ;_CR4'_YPM"?^F-0[_
MKCT6_+5%(?.\2R[JP5(_X+Q;4=&U8V/&K6IRNZ5Q?[*>=XJIF'Z3HI.%FIN/
MC:"6C)6ED8F=J(V'IZN*A[*LAX>_K(:&Q*6'ALJ<AX;.EX>&SI>'ALZ7AX;.
MEX>&SI>'ALZ7AX;.EX>&SI>'ALZ7_X(9 _^ (P7_D24&_YXL"?^H- W_L3P5
M^KA$'_"_2RWGQ5$]W,!:4,VX86+!L&AQMJEO?JRB=8FDG7R2G)B"FI64BJ"/
MD9*EBHZ;J(:-I:N#C+"L@8V^K("+PZ:!B\F=@8O-F(&+S9B!B\V8@8O-F(&+
MS9B!B\V8@8O-F(&+S9B!B\V8_X,9 _^"(@7_DR0&_Z L"/^K,PW_M#P4][Q#
M'N[$2BODR5$[U<183\B\8&&\M&=PL:UM?:>G<XF>HGF2EIV F8^:B)^)EY"D
M@Y28J'^3HJI\DJVK>I*[K'J1PZ9[D,F>?(_-F'R/S9A\C\V8?(_-F'R/S9A\
MC\V8?(_-F'R/S9A\C\V8_X,8 O^$(07_E20&_Z(K"/^M,PO^MSL2],!"'.K)
M22C@S4\YT,=73L/ 7F"WN&5OJ[)K?*&L<8>8IWB0D*-^F(F@A9Z"G8VC?9N6
MIWB9H*EUF:NJ<YFXJW.8PZ9UELF>=I7-F7:5S9EVE<V9=I7-F7:5S9EVE<V9
M=I7-F7:5S9EVE<V9_X08 O^'( 7_ER,%_Z4J!_^Q,@K[NSH0\<5!&>?/2"7;
MTDTXR\M53+W$75ZQOF-NI;AJ>YNR;X:2KG:/B:I\EH*G@YQ[I(NA=J*4I7&A
MG:=NH*FI;*&VJ6VAPZ9OG<F><)S-F'"<S9APG,V8<)S-F'"<S9APG,V8<)S-
MF'"<S9APG,V8_X48 O^*'@3_FB($_Z@I!O^U, CVP#@.Z\M %>'81B#3V$LV
MQ=!42[?)6URKPV)LG[YH>)2Y;H.+M7.,@[)ZDWNO@9EUK8F>;ZN2HFNJG*1H
MJJ>E9JJTIF:KQ:1HILJ<::3-EVFDS9=II,V7::3-EVFDS9=II,V7::3-EVFD
MS9=II,V7_X87 O^-' 3_GB$$_ZPG!?VZ+P;OQS8*X]0^$-C?0Q_+WDHTOM92
M2+#06EJDRF!IF,9F=HW!;("$OG*)>[MXD'2Y?Y5NMX>::;:0G66UFZ!BM*:A
M8+6SH5^VQ:!AL<R:8J[/E6*NSY5BKL^58J[/E6*NSY5BKL^58J[/E6*NSY5B
MKL^5_X<7 O^1&@/_HB #_[(E _7 *P3FSS$&V-XX#\SE0R##XDDSMMY11JG8
M6%><TEYED,YD<H;+:GQ\R'"$=,9WBF[$?H]HPX>48\*0EU_!FYE<P:::6\*S
MFUK#Q9I;OL^57+K2D5RZTI%<NM*17+K2D5RZTI%<NM*17+K2D5RZTI%<NM*1
M_XD6 O^6&0+_J!T"_K@A NS)(@+9W24$S.4W$<+J0R*WYT@SK.1/1*#@5E.4
MW5U@B-IC:W[6:G5UU'!];M)W@V?1?XABT(>+7M"1CEK0G)!8T*>15M"UDE72
MQY%6S=2.5LC6BU;(UHM6R-:+5LC6BU;(UHM6R-:+5LC6BU;(UHM6R-:+_XL5
M O^=%P'_KQD!],$8 =W8$0#,Y28%P>XW$[;O0B.K[4<RH>M,0);I54V+YUU8
M@N9E87GD;&ERY'1O;.-\=&?BA'ABXHU[7N*5?EO@GH!8WZ>"5=ZQ@U/>OH-2
MWM*#4=G<@E'9W()1V=R"4=G<@E'9W()1V=R"4=G<@E'9W()1V=R"_X\3 O^D
M$P'^N!( ULP+ ,SD$0' [R8'M?4X%:KT0"*?\T8PE?)+/(SQ5$:"\%U/>O!F
M5G3P;EQN[W9A:>]^9&7OAFAA[XYJ7NZ6;5OMGF]8ZZ5P5NNN<53JN')2ZL=S
M4>G5<U'IU7-1Z=5S4>G5<U'IU7-1Z=5S4>G5<U'IU7-1Z=5S_Y@0 ?^N#@#4
MP0D R<\) +[P$@*S^2<*J?LX%9[[/B&3^T0LB?I*-8'Z4SYY^EU%<OIF2FWZ
M;TYH^G929/I^56'ZAE=?^XY:7/J66UKYG5U7^*5>5?>L8%/WM6%2]L%A4/;*
M8E#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8E#VRF)0]LIB_Z,+ -:X!@#&Q <
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MD]B)_WP8 O^$' /_E1\#_Z,E!/^O+ ;WNC,)[,0[#^+.0AC3SD@LQL=20+G
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M?E3#X7U4P^%]5,/A?53#X7U4P^%]5,/A?53#X7U4P^%]_X<3 ?^<$@'_KA$
MVL(* -#2"@#'Z!@!O.PL"K+K/!>HZD,EG>A(,Y+F4$"(Y%E+?N)@5';A:%QO
MX&]B:-]W:&/>?VQ>WHAP6MZ1<U?>FW54WJ=W4M^T>%#?Q'A/X-YX3];E=4_3
MYW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T_X\/ ?^D#@#;N @ S<4)
M ,75"@"Z\1H#L/(M#*;Q.QB;\$$DD>]'+X?N3CI^[EA#=^UA2G#M:5!J['%5
M9>QY66'L@5Q=[(I?6NR385?MG6-5[:=E4NVS9E'NP&=/[]1H3NOF:$WHZ&A-
MZ.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&A-Z.AH_YD+ -VN! #,O 8 P<D' +C;
M"@"M^!P$I/@O#9GX.1>/^#\AA?A&*GSX33)U]U<Y;O=@/VGW:4-D^'%'8?AY
M2EWX@4Q:^(E/6/B245;YFU)3^:544?JO55#ZNU9.^LI73?OC5TS[Z5=,^^E7
M3/OI5TS[Z5=,^^E73/OI5TS[Z5=,^^E7Y:4  ,ZT! "_OP4 M,X& *KK#0&@
M_Q\&E_\O#8S_-A6"_ST=>/]$)'#_3"IJ_U0O9?]>,V'_9S==_V\Y6O]V/%C_
M?CY6_X8_4_^.05'_ET)0_Z!#3O^I14W_LT5+_[Y&2O_01TG_W$=)_]Q'2?_<
M1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'T:X  +^Y P"RQ0, I]4% )S]#P*4_R(&
MB?\K#'[_,A)U_SH8;/]"'67_22)?_U$E6O]:*%?_8RM4_VLM4O]R+U#_>3!/
M_X Q3?^(,DO_D#1*_Y@U2/^A-4?_JC9&_[,W1/^_.$3_Q3A$_\4X1/_%.$3_
MQ3A$_\4X1/_%.$3_Q3A$_\4XP;,  +*^ @"ES $ F=T# )#_$@*&_Q\%>_\G
M"G'_+@YH_S838?\^%UK_1AI5_TT=4?]5'T[_72!+_V0B2?]K(T?_<21&_W@E
M1/]_)D/_AB=!_XXH0/^6*#__GBD]_Z<I//^P*CS_M"H\_[0J//^T*CS_M"H\
M_[0J//^T*CS_M"H\_[0JL[@! *7&  "7U0  B^\$ 83_$P)W_QH$;?\B!V3_
M*@M<_S(.5?\Y$5#_01-+_T@52/]/%T7_5AA"_UP90/]A&C[_9QH\_VT;._]S
M'#G_>1PX_X =-O^('37_CQXT_Y<>,O^@'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?
M,O^D'S+_I!\R_Z0?IL   )?.  ")W@  ?_\' 73_$ )I_Q4#7_\<!5?_) A0
M_RP*2O\S#$7_.PY!_T$//?]'$#K_31$X_U(1-O]7$C3_7!,R_V$3,?]F%"__
M:Q0N_W$5+?]W%2S_?14J_X,6*?^+%BG_CA8I_XX6*?^.%BG_CA8I_XX6*?^.
M%BG_CA8I_XX6_V8@ _]A*@7_83,(_VDV"_]N/0__<485_W-1'/]S7B/_<&TI
M_VY\,/]KB37_:98Y_V>A/?]FJD#_9+)"_V.Y1/]APD;_8,A'_U[-2/]<U$K_
M6]Y+^UGD3/=8ZDST5^]-\%;S3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X3>Q5
M^$WL5?A-_V8@ _]A*@7_83,(_VDV"_]N/0__<485_W-1'/]S7B/_<&TI_VY\
M,/]KB37_:98Y_V>A/?]FJD#_9+)"_V.Y1/]APD;_8,A'_U[-2/]<U$K_6]Y+
M^UGD3/=8ZDST5^]-\%;S3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL
M5?A-_V8@ _]B*@7_8S$(_VLU"_]P/ __<T45_W5/'/]V72/_<VPJ_W!Z,?]M
MAS;_:Y0[_VF?/_]HJ$+_9K!%_V2X1_]CP$G_8<=*_U_,3/]=TTW\7-Y.^5KD
M3_59ZE#Q6.]1[5?T4>E7^5#I5_E0Z5?Y4.E7^5#I5_E0Z5?Y4.E7^5#I5_E0
M_V<? _]C*@7_93 (_VXS"_]T.@__=T,5_WE.'/]Z6B3_=V@K_W1V,_]QA#G_
M;I __VR;0_]JI4?_:*U*_V>V3/]EOD[_8\50_V'+4OU?TE3Y7=U5]%OD5O!:
MZE?K6/!8YUCU5^-9^E3C6?I4XUGZ5.-9^E3C6?I4XUGZ5.-9^E3C6?I4_V@?
M _]C*07_:"X'_W$R"O]W. __>T(5_WU,'/]^6"3_>V8M_W=S-?]T@#S_<8Q"
M_V^71_]LH4O_:JI/_VBR4O]GNU3_9<16_F+*6/E@T5KU7MQ<\%SD7>I:ZU[F
M6?%?XEKU6]Q;^5?<6_E7W%OY5]Q;^5?<6_E7W%OY5]Q;^5?<6_E7_VD> _]D
M*07_:RT'_W0P"O][-P[_?T$5_X%*'/^"527_?V,N_WMP-O]X?#[_=8E%_W&4
M2_]OGE#_;*94_VJN6/UHMUO\9L!=^F3)8/5AT&+P7MQCZESE9>5;[&;>6O!C
MV%OT8-%=^%O17?A;T5WX6]%=^%O17?A;T5WX6]%=^%O17?A;_VD> _]E* 7_
M;BL'_W@N"O]_-@[_@S\4_X5('/^'4R7_A& O_X!L./]\>4'_>(5)_G204/MQ
MF5;Y;J):^&NJ7_9HLF+T9KME\V3%:/!BT&OJ7]UMXUWG;MM;ZFW37.]HS5[S
M9,A?]U_(7_=?R%_W7\A?]U_(7_=?R%_W7\A?]U_(7_=?_VH> _]F* 7_<2D'
M_WLL"?^#-0W_ASX4_XI'&_^,4"7_B5TO_X5I.OV!=43Z?(!-]WB+5?1SE5SQ
M;YUB[VRE9^UIK6OK9K9OZ&/ <N9AS'7C8-]WUESD>,Y>Z7+)7^UMQ&#P:+]B
M]&._8O1COV+T8[]B]&._8O1COV+T8[]B]&._8O1C_VL= _]G)P7_="<&_W\K
M"/^',PW_C#P3_X]%&_^13B7_CUHP_(MF._B&<4;S@7Q1[WR'6NQVD&+H<9AI
MY6R@<.%HJ'7>9+!ZVV*Z?MAAQW_48=I_RU_A?L1AY7>_8NERNV/M;;9D\6>V
M9/%GMF3Q9[9D\6>V9/%GMF3Q9[9D\6>V9/%G_VP= _]J)@7_=R8&_X(J"/^*
M,@S_D#L2_Y-#&O^63"3]E5<P]Y%B//*,;4GLAGA4YW^!7^)XBFG<<I)RUFV:
M>-)JHGS.9ZM_RV:T@<EEOX/'9,Z$P6/=@[IDXGRV9N9VLF?J<:YH[VJN:.]J
MKFCO:JYH[VJN:.]JKFCO:JYH[VJN:.]J_VT< _]L) 7_>B0%_X4I!_^.,0O_
ME#D1_YA"&?^;2B3XFU0P\I=?/>N2:DOEBG-8WH)\9-5\A6[/=HUURG*5>L9N
MG7[#;*6"OVJOA+UIN8:Z:,>'MVC:A[%HWH&M:>-ZJ6OH=*9K[&VF;.UMIFSM
M;:9L[6VF;.UMIFSM;:9L[6VF;.UM_VT< _]N(P3_?2(%_X@H!_^1, K_F#@0
M_YQ &/N?22/TH5(O[9U</>669DS=CF]:TX=X9<R!@6[&>XEVP7>1>[QSF8"X
M<*&$M6ZJA[)MM(FO;,&*K6S2BJALW(6E;>%^HF[E=Y]OZW"?;^MPGV_K<)]O
MZW"?;^MPGV_K<)]OZW"?;^MP_VX< _]Q(@3_?R$%_XLG!O^4+PG_FS</_Z _
M%_BD1R'PIT\NZ*):/=^;8TW4E&Q:RXQU9<2&?6^^@(5VN'R-?+-XE8&O=9V%
MJW*EB:AQKXNE<+N,HW#+C:!QV8B=<=^!FW+D>IESZ7*9<^ERF7/I<IESZ7*9
M<^ERF7/I<IESZ7*9<^ER_V\; _]S( 3_@B $_XXF!O^7+@C_GS8._:0^%?2H
M1B#LK$TMXZ=8/-F@84S-F&I9Q9%R9;V+>FZVA8)VL(")?:M]D8*G>9F&HW>B
MBI]UJXV<=+>.FG3&CYAUUHN6=MV#E';B?)-VYW22=NATDG;H=))VZ'22=NAT
MDG;H=))VZ'22=NAT_V\; O]U'P3_A!\$_Y E!?^:+0C_HC4,^J@]%/&L11[H
ML$PKWZM7.]*D7TO(G&A9OY5O9+>/=VZPBG]VJH6&?:2!CH*??I:'FWN>BY=Y
MJ(Z4>+./DGC"D)%ZU8V/>MN%CGKA?HUZYG:->N9VC7KF=HUZYG:->N9VC7KF
M=HUZYG:->N9V_W ; O]V'@/_AAX$_Y,E!?^=+ ?_I30+]ZL\$NZQ0QSEM$LI
MVJ]5.LVH7DK"H&98N9IM9+&3=6ZJCGQVHXJ#?9Z&BX*9@I.'E(";BY!^I8Z-
M?;"0BGV^D8I_TX^)?MJ'B'[??X=^Y7>'?N5WAW[E=X=^Y7>'?N5WAW[E=X=^
MY7>'?N5W_W ; O]X'0/_B!X#_Y4D!/^@*P;_J#(*]*\Z$>NU0AKAN$HGU+-3
M.<BK7$F^I&17M)YK8ZR8<FVDDWEUGHZ!?)B+B(*2AY"'C869BXF#HHZ&@JZ1
M@X*\D8*#SI&#@]F(@H+?@8*"Y'F"@N1X@H+D>(*"Y'B"@N1X@H+D>(*"Y'B"
M@N1X_W$: O]Z' /_BAT#_Y<C!/^B*07\K#$)\;,Y#^BZ0!?=O$@ES[92.,.O
M6TBYJ&)6KZ)J8J><<&R?EW=UF)-^?)*0AH*,C8Z'AXJ7BX.(H(Y_AZN1?(>Y
MD7N'RY%\B-B)?8?>@GV&Y'I]AN1Y?8;D>7V&Y'E]AN1Y?8;D>7V&Y'E]AN1Y
M_W$: O]\&@/_C1P#_YHB _^E* 3YKR\'[K@W#.2_/Q38P$8DRKI0-[^S64>T
MK&%5JJ9H8:&A;FN9G'5TDIA\>XR5@X&&DHN&@9"4BWR.GHYXC:F0=HRVD72-
MR)%VCMB*=XS=@G>*XWIWBN-Z=XKC>G>*XWIWBN-Z=XKC>G>*XWIWBN-Z_W(:
M O]_&0+_CQL"_YT@ _^I)@/VLRT%ZKTU">#&/!#2Q$0CQ;U/-;JW6$:OL5]4
MI:MF8)RF;6J4HG-SC)YZ>H:;@8" F(F%>I:2B764FXURDZ:/;Y.TD&V4Q9!P
ME=B*<)+=@W&0XWMQD.-[<9#C>W&0XWMQD.-[<9#C>W&0XWMQD.-[_W,9 O^"
M%P+_DAH"_Z ? O^M) +RN"H$YL,Q!MO,-0_,R$(AP,)--+2\5D2IMEY2G[%D
M7I:L:VB.J7%QAJ5X>'^B?WYYH(>#=)V/B&^<F8MKFZ2-:)NRCF>;PHYIG=B*
M:IG=@FN6XWMKEN-[:Y;C>VN6XWMKEN-[:Y;C>VN6XWMKEN-[_W09 O^%%0+_
MEA@!_Z0< ?NR( 'MOR4"X<PJ ]31,@W'S$$?NL=,,:[!5$*CO%Q0F;=B7)"S
M:6:'L&]N@*UV=7FJ?7MSJ(2 ;::-A6BEEXAEI*.*8J2PBV"DP8MBIMF(8Z+>
M@66>XWIEGN-Z99[C>F6>XWIEGN-Z99[C>F6>XWIEGN-Z_W88 O^)$P'_FA8!
M_ZD8 ?:X&P'GQQH!V]D< <W6, O TC\=M,U*+ZC(4C^=PUI-DK]A6(F[9V*
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M_%BW8_Q8MV/\6+=C_%BW8_Q8_V,? _]F(P3_<B($_WTG!O^%+@G_BC<._XU
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M,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2
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M:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D
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MEQLP_Z$;+_^J'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4
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M7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1  _YL0 /2H#P#EM0T
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MLSA"\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ
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M%BC_LQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S
M>MH  &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S
M_T4(,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_
MH0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,
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M5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/]
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M47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1,
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MH?]0_W<' /")  #6F   RZ0# ,&M! "YM@, LL $ *O%% "CQ2@$F\(W#I'
M0QF)O4PD@+I5+GFX7#9RMF,];;1J0V>S<4ABL7E,7K"!4%JOBU16KY=64ZZC
M6%"NLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-
M_WT  -^/  #.G0  PZ@" +FP @"PN@( J,0% *',#P";S","DLHS"HG(/Q6!
MQDD?><12*'+"6C!KP6$W9K]H/&&^<$%<O7A%6+R!252\BTQ1NY9/3KNC44R[
MLU)*N\922KOD44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4
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M+CWJ[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0
MG+P  )#'  "$T@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),
M]5442?9=%T;V91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;Y
MXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P
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M_W(9 ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O
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M&0'[AR ![XPG N2., 7:C3T,SX=*&,>"52._?5\MN7AH-;-T<#RO<7A"JVZ
M1J=LB$JD:9!.H&B849UFH5.;9:M5F&2X5Y9DR%B49.%8E6CT4)9K_TJ7;/]%
MEFW_099M_T"6;?] EFW_0)9M_T"6;?] _UD5 ?]F$ '_<A  _WT2 /^%%@#V
MC!L!ZI$B =^4*P/3D3H+R8Q'%\"'4R*Y@EPLLGUE-:UY;3RH=75"HW-]1Z!P
MA$N<;HQ.F6R54I5KGE22::A7D&FT68YHPUF,:-Q:C6SR4X]N_TR0</]'CW'_
M0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\ _X 1 /^)$P#RD!<
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M14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP
MM*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUA
MR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$
M\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP
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M&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0
M9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV
M_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_
M]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<
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M2U>2[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP
MQ)4  +J=  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-R
MI%TJ;:)D+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;
M[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH
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M+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N
MA;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5SU,04<];%$[/8QA+
MSFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-[R4[S/LE.\O_)3O*
M_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<
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M"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0  4M\  $CH  !#_P@
M/_\0 #O_&0 W_R$ -/\I 3#_, $M_S<"*O\^ B?_1 (E_TL#(O]3 R#_7 ,=
M_V8$&_]R!!G_@ 47_X\%%O^?!A7_KP84_\ &%/_6!A/_Z083_^D&$__I!A/_
MZ083_^D&EZ\  (BZ  !ZQ0  ;,\  %[:  !0X   1.8  #SU   W_P0 ,_\-
M "__$P K_QH */\A "7_)P$A_RT!'O\R 1O_. $9_S\!%O]& A3_30(1_U8"
M$/]@ @[_; (,_WL#"_^+ PK_F@,*_Z@#"?^U PC_P@,(_\(#"/_" PC_P@,(
M_\(#BK@  'O#  !LS@  7ML  $_B  !"YP  -NP  #'_   L_P  )_\' "/_
M#@ @_Q( '/\8 !C_'0 5_R$ $O\F !#_+ $._S$!#?\W 0K_/@$(_T8!!?]/
M 0'_60$ _V8! /]T 0#_@@( _Y " /^< @#_I@( _Z8" /^F @#_I@( _Z8"
M_RXO O\S+ +_-RT"_S@P O\W-@/_-#\$_S%+!O\O6 ?_+&8(_RIT"?\I@0K_
M*(T+_RB7"_\HGPO_**8,_R>M#/\GM S_)[L,_R?$#/\GS@S_*-X+_RCI"_\H
M\PO_*/L+_RC_"O\I_PK_*?\*_RG_"O\H_PK_*/\*_RC_"O\H_PK_*/\*_S M
M O\V*@+_.2H"_SLN O\Z- /_.#P$_S9)!O\S5@?_,6,)_R]Q"O\M?@O_+8H,
M_RR4#/\LG W_+*0-_RRK#?\LL0W_++D-_RO!#?\LRPW_+-H-_RSG#?\L\0W_
M+/H-_RS_#/XM_PS]+?\,_2W_#/TL_PO]+/\+_2S_"_TL_PO]+/\+_S(K ?\Y
M* +_/2@"_S\J O\^, /_/3H$_SQ&!O\Y4PC_-V )_S5M"_\S>@S_,H8-_S&0
M#O\QF0[_,:$/_S&H#_\PK@__,+4/_S"]$/\PQQ#_,-00_S#D$/\Q[Q#^,?D/
M^S'_#_DQ_P_X,?\.]S'_#O<Q_P[V,?\.]C'_#O8Q_P[V,?\._S4H ?\\)0'_
M0"0"_T,G O]#+ /_1#<$_T)#!O] 3PC_/5P*_SMI#/\Y=@W_.((/_S>,$/\W
ME1'_-IT1_S:D$O\VJQ+_-K(3_S6Z$_\UPQ/_-<\3_#7A$_DV[1/V-O<3\S;_
M$_$V_Q+P-O\2\#?_$>\W_Q'O-_\0[S?_$.\W_Q#O-_\0_SDE ?] (0'_12 !
M_T<B O])*0+_2C0$_TD_!?]&2PC_1%@*_T)E#?] <0__/GT1_SV'$O\]D13^
M/)D5_3R@%?P[IQ;Z.ZX7^3NV%_@[OQ?V.\H8]#O<&/ [ZACM._88ZCO_%^@\
M_Q?G//\6YCW_%>4]_Q3E/?\4Y3W_%.4]_Q3E/?\4_STB ?]$'@'_21P!_TT>
M ?]0)@+_43 #_U [!?].1@C_2U,+_TA@#O]&;!'[17@3^$2"%?9#C!?T0I08
M\T&<&?%!HQOO0*H;[D"R'.T_NQWK/\8>Z3_5'N4_Z!_B0/0>WT#^'=U!_QO;
M0O\:V4+_&-A"_Q?80O\7V$+_%]A"_Q?80O\7_T ? ?](&@'_3A@!_U(; ?]6
M(P+_6"P#_U<W!/]50@?_4DT+^5!:#O5-9Q+Q3'(6[DI]&.M(AAOI1X\=YT:7
M'^5%GB#C1*8BX42N(^!#MR3>0\(EW$/0)M=#Y2;31/,DT$7^(LU&_R#,1_\>
MRD?_',E(_QO)2/\;R4C_&\E(_QO)2/\;_T0; ?],%@'_4A0!_U@8 ?]='P'_
M7R@"_UXR _U=/0;V6DD*\%=5#^I58A/F4FT8XE!W'-].@1_<3(HBV4N2)-5*
MFB;32:$HT4FI*<](LBK-2+PKRTC)+,A(WRS%2.\KPDK\*,!+_R6_3/\BODW_
M(+U-_Q^]3?\>O4W_'KU-_QZ]3?\>_T<8 ?]/$P'_5A$ _UX5 /]B' '_920!
M_F4M O1D. 7M84,)YE]1#N!<713:6&@:U%9R'M!4>R+,4H0FRE",*,=/E"K%
M3ILLPTZC+L%-K"^_3+8PO4S",;M,TS*X3.DQMD[X+;10_RJS4?\GLU+_)+)2
M_R*R4O\BLE+_(K)2_R*R4O\B_TH5 ?]3$0#_6P\ _V(2 /]H%P#_:A\!]FLH
M >QK,@/D:3X'W&9,#=-B6!3-7V,;R%QM(,1:=B3!6'XHOE:&*[M5CBZY4Y8P
MME*>,K12IC.R4; UL%&\-JY0RS>L4.,WJE+T,ZE4_RZH5O\KJ%?_**A7_R6H
M5_\EJ%?_):A7_R6H5_\E_TT3 /]6#@#_7PT _V<0 /]L$P#[<!D [W$B >1Q
M+ +;<#H%T6Q(#,EH5!3#95\;OF)H(;I?<2:V77DJLUN!+;!:B3"N6)$SJU>9
M-:E6H3>G5JLXI56V.J-5Q3NA5=T[GU;P-Y]8_C*?6O\NGEO_*YY<_RB>7/\H
MGES_*)Y<_RB>7/\H_U 1 /]9# #_8PP _VL- /]P$ #U=!, Z'8: -UW)0'1
M=C8$R')$#,%N4!2[:UL;MF=D(;%E;2>M8G4KJF!\+Z=?A#*D78PTHER4-Y];
MG3F=6J8[FEFQ/9A9OSZ76=,^E5KL.Y5=^S667O\QEE__+99@_RJ68/\JEF#_
M*I9@_RJ68/\J_U(/ /]<"@#_9@D _VX* /9T# #O> X X7L2 -1\( #*>S,$
MP7=!"[IT31.T<%@;KFQA(:EJ:2>F9W$KHF5X+Y]D@#.<8H@VF6&0.)9?F3N4
M7J(]D5ZM/X]=NT"-7<U!C%[H/XUA^3B-8O\SCF3_,(YD_RR.9?\LCF7_+(YE
M_RR.9?\L_U4. /]?!@#_:08 ]'(& .)X!@#;? D V7\, ,V!'0#$?S #NWP_
M"K1X2Q*M=54:J'%>(:-N9B:?;&XKFVIU+YAH?3.59X0VDF6,.8]DE3R,8Y\^
MB6*J0(=AMT*%8<E"A&+D085D]SN&9O\UAV?_,8=H_RZ':?\MAVG_+8=I_RV'
M:?\M_U<, /]A! #^; , Y'4! -M[!0#3@ @ T(,* ,>%&@"^A"T#MH$\":]]
M2!*H>5(9HG9;()US8R:9<&LKE6YR+Y%M>3..:X$VBVF).HAHDCR%9YP_@F:G
M08!FM$-^9L5$?&;A0WYH]3Q_:O\W@&O_,X%L_R^!;/\O@6S_+X%L_R^!;/\O
M_UD+ /]C 0#T;P  WW@  -1_! #.@P8 RH<( ,*(& "YARL"L84Z"*J!1A&C
M?E 8G7I9'YAW8263=6@JCW-O+XMQ=S.(;WXVA6Z&.H)LCSU_:YE ?&JE0GEJ
ML41W:L)$=FK=1'AL\SYY;O\X>F__-'MP_S!\</\P?'#_,'QP_S!\</\P_UL(
M /]F  #G<@  VGL  ,^" P#)AP4 Q(H& +R,%0"TBR@"K(DX!Z6%1!">@DX8
MF']7'I-\7R2.>68JBG=M+H9U=#*"='PV?W*$.7QQC3UY<)= =F^B0G-NKT1Q
M;L!%<&[917)P\3]S<O\Y=7/_-79T_S%V=/\Q=G3_,79T_S%V=/\Q_UT& /]I
M  #B=   U'T  ,N% @#$B@0 OXT% +>/$P"PCR8!J(TU!Z"*0@Z:ADP6DX-5
M'8Z!722)?F0IA7QK+8%Z<C)]>'DU>G>".79VBSQS=95 <'2@0FUSK41K<[U%
M:G/516QT[T!N=OXZ;W?_-G%X_S)Q>/\Q<7C_,7%X_S%Q>/\Q_U\" /=L  #>
M=P  T($  ,>( 0# C0, N9$# +*3$0"KDR,!HY$S!IR.0 V5BTH5CXA3'(F&
M6R*$@V(H@(%I+7Q_<#%X?G<U='R .'%[B3QN>I,_:WF>0FAXJT1F>+M%9'C1
M169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@
MS(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+62%_
MB6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/1&!_
M[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<
M +Z/  "VE0  KID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]ZCUXE
M=8YE*G&,;"YMBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%ZC]<
MAOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP  +F3
M  "PF0  J)T  )^@"0"9H1H DZ K XR?. B%G4,0?YI,%WF85!UTEUPB<)5C
M)VN3:BQGDG$P9)%Y,V"/@C=<CHTZ68V9/5>-IC]4C;9 4XW+0%2-Z3U6C?HY
M5XW_-5F._S)9CO\Q68[_,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28  "J
MG0  H:$  )>F! "1IQ4 C*<G H6F-09_I$ ->:)*%'.@4AINGUD?:9U@)&6<
M9RAAFV\L7IIW,%J8@#-6EXLV4Y>7.5&6I3M/EK0\3I;)/$Z6Z#I/EODV49;_
M,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0
MF:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F921;
MI&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__,$N?
M_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P
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M'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0  =,   &C'  !=S04
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M> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX
M (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$
M(/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%
M_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!
M  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0
M !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX
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M.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0
MT74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8>TH0DGE3%HUV6QN)
M=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!JJCEN:KDZ;6K..FUK
MZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@
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MB@  K(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7.
M:B5O?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_
M+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@
MII$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-J
MAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"
M_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4
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M)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4
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MF DMTZD)+-.^"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@
M **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ
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M 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP
M8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1
M_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_
MD   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,
M $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q
M!/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>
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M+(-7[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P
MV&8  ,YJ  #'; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A64
M8F48D6!L&XY?=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;
M["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH
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M)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P
MK7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU
M;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M
M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8
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M(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&D X
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MEQH]HZ<;/*.Y'#NCTAL[HN\;.Z#^&CN?_QD\G_\8/)__&#R?_Q@\G_\8Q'P
M +:)  "JD@  GY<  )6<  ")H0  ?:8  '&J  !DK@  6K$( %>Q% !5LB,
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M!"7-S@0ER^X$),G\!B/(_P<CQ_\'(\?_!R/'_P<CQ_\'J98  )Z=  "2HP
MA:L  'BR  !KN   7[X  %+"  !'Q@  /<H  #3/!  KU D )MD/ "79&0 E
MVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @W6@ 'MYV !W>AP$<WYD!&M^L 1G?
MQ $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP  >;,
M &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;Z1X
M&>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [PLP -
M\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P  %_$
M  !2R@  1<X  #G3   OV   )=T  !WA   8[ ( %O<+ !3W$0 1^!< $/@>
M  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP  _+4
M /S1  #\[0  _/P  /S]  #\_0  _/T BZL  'VT  !NO0  8,8  %+-  !$
MT@  -]@  "S=   BX0  &>4  !/J   0^@  #O\&  W_#  *_Q  !_\4  3_
M&@ !_R   /\G  #_,   _SH  /]%  #_4P  _V(  /]U  #_B@  _Y\  /^S
M  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]  !AQP  4]   $/6   VW0
M*N(  !_F   6Z@  $.T   SZ   )_P  !O\   +_!   _PD  /\-  #_$
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M.-<0M3CL$+(Y^P^P.O\.KSK_#:XZ_PRM.O\+K3K_"ZTZ_PNM.O\+_SP- /]
M!@#_100 _TD) /]+#0#Y2A$ [4D: .-&)@#:1C8 T49% <M%40/&1%P%PD)F
M"+]";PJ\07<+ND!_#;@_A@ZV/XX0M#Z5$;(^G1*P/J83KSZP%*T^O12K/LT5
MJ3[F%:8_]Q.D0/\2HT#_$*) _P^B0/\.HD'_#J)!_PZB0?\._S\) /]$  #_
M2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33  QDT_ <!,3 2[2U<&MTEA";1(
M:0RQ1W$.KD9Y$*Q&@!&J18@3J$20%*9$F!:D0Z$7HD.K&*!#MQF?0\<9G4/@
M&IM$\Q>91?\5F$;_$YA&_Q&81O\0ET;_$)=&_Q"71O\0_T(% /]'  #W3P
MY5,  -U5 0#7508 U5(+ ,M3&0##5"L O%0[ ;922 2Q45('K5!<"JE.9 VF
M36P/I$QT$:%+>Q.?2H(5G4J*%YM)DQB929P:ETBF&Y5(LAR42,$=DDC8'9!)
M[QN/2OX8CTO_%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2_T4  /]+  #I4P  WE@
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M&W=9_QEW6?\7=UG_%G=9_Q9W6?\6_TP  .E6  #97P  RV4  ,%H  "Z:0
MM&@  *UG#0"F:!P H&@M 9IG.@.5944&D&-."HQB5PV)85X0AE]E$X->;!:
M77,8?EQ[&GM<@QUY6XT?=EJ8(71:I"-R6K(D<5K$)6]:X25P6_8@<5S_''%=
M_QIQ7?\8<5W_%W%=_Q=Q7?\7_4\  .59  #38@  QV@  +UL  "V;0  KVP
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M&6)H_QEB:/\9[%<  -EB  #':P  O'(  +-W  "J>0  H7D  )=W 0"0>!$
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MEAY,?Z4@2G^V(4E_S"%)?NL?2G[\'$M^_QI+?O\93'[_&$Q^_QA,?O\8U6<
M ,-S  "V?   K(0  **)  "8BP  C8T  'R-  !UC@0 ;X\2 &V0(0!ID"X!
M98\Y F*.0@1>CDL'6XU2"EB,60Q6BV$/4XMH$E"*<11-B7L72HF'&4B(E1M&
MB*,=1(BT'4.(RAU#A^H<1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T  +UX
M  "Q@@  IXH  )R.  "2D   AI,  'F5  !LEP  9I<. &.8&P!AF"D 7I@U
M 5J7/@-7ET<%599/!U*65@E/E5X,3)1F#DJ4;Q!'DWD31).%%4*2DQ= DJ(8
M/I*S&3V2R1D]D>D8/9#Z%SZ/_Q8^C_\5/H__%3Z/_Q4^C_\5Q7,  +=_  "L
MB0  H8\  ):3  "+E@  ?YD  '.<  !DGP  7* ) %F@% !7H2( 5:$O %*A
M.0%0H4,"3:!+!$J@4P5(H%H'19]C"4.?; M GG8./IZ#$#N>D1$YG: 2.)VR
M$S>>R!,WG>@2-IOZ$C::_Q(VF?\1-YG_$3>9_Q$WF?\1OGL  +&'  "ECP
MFY0  )"8  "$G   =Z   &ND  !?IP  4JH  $VK#@!+JQH 2JLG $BK,P!&
MJST!1*M& 4*K3@) JU8#/JM?!3NK: 8YJG,(-ZJ "32JCPLRJI\,,:JP##"J
MQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E_PTOI?\-MH0  *J.  ">E   E)D
M (>>  ![HP  ;Z@  &.L  !7KP  2[(  $&U!@ ^MA$ /;8> #NV*0 ZMS0
M.;<^ #>W1P VMU !-+=: 3*W9 (PMV\#+K=\!"RWBP4JMYP%*;>N!BBXQ04H
MM^8%)[7Y!R:S_P<FLO\()K+_"":R_P@FLO\(KXT  **4  "7F@  BZ   'ZF
M  !QJP  9;   %FT  !-MP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD *L0S
M "G$/0 HQ4< )\51 ";%7  EQF@ (\9V 2+&A@$@QI@!'\:K 1['P0$>QN0!
M'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90  )J:  ".H0  @:<  '.N  !G
MM   6KD  $Z]  !"P   .,,  "_'   FRP0 'M * !O1$0 :TAH &=(E !C3
M+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2UX\ $=BD !#9NP 0V=X $-7S
M !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#J   =;   &BW  !;O0
M3L$  $+%   WR   +<P  "30   <U0  %=H% !#B"P 0XQ$ #N0:  [D(P -
MY2T #.4W  OF0@ *YD\ ">==  CG;0 &YH  !>:5  3FJP "YL0  >;F  #G
M^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !WL0  :;D  %O   !.Q@  0<H
M #7.   JT@  (=8  !G;   2WP  #>,   OQ"  )\PX !_,3  3R&@ "\B(
M /(J  #R-   \C\  /),  #R7   \FT  /*"  #RF   \ZT  //&  #TY0
M]/8  /3[  #T^P  ]/L AZD  'FR  !JN@  7,(  $[)  ! S@  ,],  "C8
M   >W0  %>$   _D   *Z   !?,   /] 0  _ @  /L-  #[$0  ^Q8  /P>
M  #\)@  _#   /T\  #^20  _EH  /YM  #_@@  _Y@  /^L  #_P   _]@
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M ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\ _0#_ /T _P#] /\ _0#_ /T
M_P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_#C( _PQ  /\)30'_!UH!_P1G
M ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"H@#_ J@ _P*O /\!M@#_ ;X
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M!;HK^0:X+/\&MBS_!;4L_P6T+/\%M"S_!;0L_P6T+/\%_S0, /\V!0#_.0,
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M$(E&_PZ(1O\-B$;_#8A&_PV(1O\-_T   /)'  #C3P  U%,  ,M5  #$5
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M$6Q8_Q%L6/\1\4L  -]6  #,7@  P&0  +=G  "N:   IV8  )]B!@"88Q0
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MEAI89Z0<5F>T'55GRAU59^@;5F?[&%=G_Q97:/\46&?_$UAG_Q-89_\3X5@
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M=   JWL  *)_  "7@0  C($  'I^  !S?P( ;G\1 &N '@!H@"P 98 W 6*
M0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/>W@13'N#%$IZD19(>I\71GJO
M&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X_Q%'>/\1S64  +UP  "Q>0
MIX   )R$  "2A@  AH8  '>&  !KA@  9H<- &.'&0!@B"< 7H@S 5N(/ )8
MAT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/1H.!$42#CQ-"@YT40(*N%3^#
MPA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q! @/\0QFL  +=V  "L?P  HH4
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M!RFA_P<IH/\(*9__""F?_P@IG_\(L8(  *6+  ":D0  D)8  (.:  !VGP
M:J(  %ZF  !2J0  1JL  #RM   UKPP ,[ 5 #*P(0 QL"L +[ U "ZQ/@ M
ML4@ ++%1 "NQ6P IL6<!)[%T 2:Q@P$DL90"([&F B*RNP(ALML"(:_S R"N
M_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1  "3EP  AYP  'JB  !MIP  8*L
M %6O  !)L0  /K0  #.W   JN@, )+P- "*]%0 AO2  (;TJ ""],P ?OCT
M'KY' !V^4@ <OUX &K]L !F_?  8OXX %\"A !; M@ 4P-, %;[Q !6\_P$5
MN_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@  ?:0  &^J  !BKP  5K0  $JW
M   ^N@  ,[T  "K    AQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\ #LTZ
M  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )R_\
M"<O_  G+_P )R_\ F)@  (V>  !_I0  <:P  &2S  !7N0  2KT  #[    R
MPP  *,8  !_*   7S0  $=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN  ';
M.0  W$4  -U2  #>8@  WG,  -Z(  #?G0  W[,  -_.  #@[@  W_H  -__
M  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]  !*P@  /<4  #')   FS
M'=   !34   .V0  "=T   /A    XP<  .,-  #D$@  Y1D  .8B  #G*P
MZ38  .M#  #L4@  [&(  .UV  #NC   [J$  .^W  #OT0  [^L  /#V  #P
M]@  \/8 A*<  '6O  !GMP  6;\  $O&   \R@  +\X  "32   :V   $MP
M  S@   %XP   .<   #K    ZP   .T%  #N"P  \!   /$5  #S'@  ]"<
M /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC  #^M@  _LD  /_?  #_WP
M_]\ =[   &BY  !:P0  3,H  #S/   NU   (MH  !?>   0X@  ">8   #I
M    [    /    #V    ]@   /<   #X    ^@<  /L-  #]$0  _QD  /\C
M  #_+P  _SX  /]/  #_8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@  _[H
M_Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\ = #_
M 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#' /\
MU@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\ _QH@
M /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H
M_P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H T #X
M ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT< /\<
M&0#_&1D _Q0; /\._^+_XDE#0U]04D]&24Q%  @)(0#_#"P _PDY /\%1@#_
M E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@
MK@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_
M .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X
M_PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M
M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,
M_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5
M /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\
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M /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED
MPRIB < J:P&]*G,!NRIZ KDJ@@*X*HD"MBJ0 K0JF .S*J$#L2JJ Z\KM02N
M*\0$K"O;!*@L[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(  /\S
M  #Y.   Z3D  .(Y  #>-0< WBX- -$O&P#),2P PS,[ +TS2 "Y-%,!MC-<
M ;,S90*P,VT"KC-T ZPR>P.K,H,$J3**!*<RDP6E,IL&I#*E!J(RL >@,KX'
MGS+1!YPSZ@>:,_L'F#3_!Y<T_P:6-/\&EC3_!98T_P66-/\%_S4  /\X  #J
M/@  WT(  -5"  #//P, S3@( ,4X%0"].B8 MSLV +(\0P"N/$X!JCM7 J<[
M8 .E.F<#HSIO!*$Z=@6?.7T&G3F%!YLYC0>9.)8(F#B@"98XJPJ4.+@*DSG*
M"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10
MU$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;
M06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_
MX Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\
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M$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@
MI%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU
M4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693
M_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\
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M#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@  DVT  (5G  !^9PD
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M' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z
M#DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-
MS%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?
M>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5U
MB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0
M +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"
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M!BV2MP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B
MD8P  (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ T
MGBP ,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>
MM0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(
M '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB(
M)JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9
MJ\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>
M  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A
M !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0
M#;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>
MJP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%
M'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2
M  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M
M1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@
MT1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6
MX   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$
M "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0
M .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0
MZ>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.
M   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1
M  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(
M /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -
MWP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z
M#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y
M  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D
M_P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_
M +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H
M_P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A
M /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0
M^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P
M /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\
M9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X
M .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\
M_QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z
M &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .(
MOP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0
M /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8
MZ@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0
M!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@
M!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI
M -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@
MPA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_
M(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6
M:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6
M + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@
M[RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W
M(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,D
MZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0
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M!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20
MKT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%
M/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1
M_P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH
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M"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70  F%H  (U3  "&4@P
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M'P!N7"L :UPV &A;/P%E6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF
M"E59C M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(
MU%$  ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H
M8"@ 9F S &-@/ %A8$0!7U], EQ?4P-;7UH$65]A!5=>:0957G,(4UY^"5%=
MB@M/79D,35VH#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0
M +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4
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M"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P
MG7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)
M>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5X
MLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X
M (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C(
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M 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0
M89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;
MI#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B
M^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$
M $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L
M#;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %
MK_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M
M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK
M  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8
M +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   J
MN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+
M*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X
M  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@
M%<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P
MWB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E
M\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$
M  35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H
M .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP
M]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
M    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6
M  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\
M_PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_
M '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\
MR0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9
M /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '(
M_P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T
M -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/
M$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V
M /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L
MYP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_
M#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T
M> #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9
M -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4
M_PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#>
M 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4
MZ ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,%
M /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7,
MR@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U
M"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46
M!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT
M +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/<
MI17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<
M&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9
M=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_
M 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P
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M VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!
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M(@!V2"X <T@X '%(00!N2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84>
M!6!'C09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$
MVT0  ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P
M3"L ;4PU &M,/@!H3$8 9DQ- 61,4P%B3%H"84QB E],:@->3',$7$M^!5I+
MB@982Y@'5TRG"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@
M ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@
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M!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80
MH68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!4
M7CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>
ML0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH
M )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@
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M RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0
M<GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T
M>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z
M]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0
M %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X
M*85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>
M@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,
M  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%
M !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\
M%(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%
MEP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>
M00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_
M  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H
M,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "
MJD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G
M_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL
M !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D
M +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P
MMO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X
M   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z
M  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T
MA9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #
MQP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=
M.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$
M &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP
M -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P
M\#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ
M  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8
M  #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD
M /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_
M !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\
M@P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J
M /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !,
M_P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_
M (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\
M\P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0
M /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\
M\P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#?
M /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\
M$@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"
M ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8
MR@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_
M !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -
M@ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^
M +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1
MZ  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_
M ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%
M_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2
M -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L
MKPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<
M#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+
M%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%]
M *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\
MCA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R
M%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;
M?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_
M 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@
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MC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L
M ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L
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M!%!'L01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5
MI%<  )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;
M23P 64E# %=)2@!625( 54I9 51*80%22FH!44IU D]*@0-.2H\#3$N?!$M+
ML 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L
M )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H
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M SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0
M>6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"
M74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>J0,U7KT#-%_= S1>
M]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP
M &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4
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M 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@
M0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >
M?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[
M_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@
M #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP
M$HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .
MAO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2
M   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0
M  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\
MF((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9
MG@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D
M5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H
M (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@
M#*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3
MLEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5
M  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@
M  "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\
M ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !E
MHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
M    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3
M  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K
M2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
MU@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N
M5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP
M "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@
M .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@
M_UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\
M'0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+
M /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\
M]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_
M "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H
MC #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_
M .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\
M_P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L
M (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -<
M_P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F
M /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (<
MV@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P##
M /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H
M+0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"'
M ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\
ML@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3
M #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0
MB "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_
M *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H
MOP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D
M (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)
M_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N
M *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8
ME@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'
M$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0
M,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+
M (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\
M[R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1
M&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>
MD0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@
M -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C(
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M 5PSL0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10
MJ$@  )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E
M-C\ 8S9& &(V30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54X
MKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P
M )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP
M73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K ).
M/L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1
M  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY
M %4_1@!4/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"
M2$+> DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+
M4P  @%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"
M0P!/0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;<
M D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6
M?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*
M1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*IP(_2KL"/DO8 CY*
M\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD
M &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8
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M 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@
M35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P
M7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=
M_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<
M #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950
M)V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A
M8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN
M   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY;
M !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\
MI&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K
M=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X
M8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$
M )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@
M'((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )
M@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^
M  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X
M  ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4
M (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""
MB0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;
M   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN
M  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD
M:I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
MJ00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L
M=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP
M %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0
M +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P
MO8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J
M   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,
M  #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,
M -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   J
MM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
M    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\
M  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P
M$<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
MYP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_
M@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T
M /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ),
M_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4 _P#Q
M /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N /\
M/ #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X ]@"4
M /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F /\
MX #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\ -@#_
M $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP". .4
ME0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\ SP#_
M ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P #P
M[0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -  CP#-
M )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_ +P
M_P"\ /\ _P(  /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4 VP!!
M -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\ )
MN@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P _P"K
M /\ _P0  /\   #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z ,,
M1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H J0"2
M *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P"; /\
M_P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +, /0"P
M $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"- )D
MEP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\ ^0X
M .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B #\
MH !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%D@"*
M!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14  . =
M  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@ DPQ!
M ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^#YL
M? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F  ##
M*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[ (03
M0P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8 <1>D
M &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\,0
ML#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;/@!W
M'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@ &4@
ML !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.   JCD
M *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M(T$
M:R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TGK0!;
M*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\  )P_
M  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P 8RE#
M &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4+KT
M4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$  "/
M00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]  %HO
M1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L 3338
M $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+1P
M@4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T0P!2
M-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3 48X
M\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@  G$T  ))-  "(2P  ?D<
M '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,.$<
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M 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9  " 6   =E8  &A0  !=3
M4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q #Y%.  ]13\ /$9' #M&3P Z
M1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$ ,DG) #%)ZP R2?X ,DC_ #)(
M_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@  4$X
M $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T3%8
M,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,_P M
M3/\ L%   *18  "970  CV$  (9B  ![80  <%\  &);  !86   3E4  $-1
M 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45, +5)=
M "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G4?\
MK%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8   U
M5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA: "58
M9P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\ J%H
M )UB  "39P  BFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q7@,
M*ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?8P <
M8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&   )EH
M  "0;@  AG   'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P  (V8(
M !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3:&X
M$FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O  ",
M<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$  !9P
M"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D "W%Z
M  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'>0
M?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\!  ,
M? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT  !\
MAP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@   >8,
M &R$  !>A0  488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &B0H
M 8D/  ")%   B!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(@0
MAY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D  &.+
M  !6C0  28\  #R1   PD0  ))$  !J2   2DP  #90   :5    E@8  )8,
M  "5$   EA4  )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>   E8X
M )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4  !,
MEP  /YD  #*:   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'  "C
M#   HQ   *05  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80  *6;
M  "DLP  H]   */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!H
M,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O    L    +    "P!0
ML0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0  "V
MJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0  )JL
M !JM   0KP  ";(   "T    MP   +H   "\    O0   +X   "^    P (
M ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,G
MR[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4  !"X
M   'NP   +X   #!    Q    ,@   #+    RP   ,T   #.    T    -(
M  #5 P  V H  -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0  YJ4
M .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$
MQP   ,L   #/    U    -@   #<    W0   -\   #A    XP   .4   #H
M    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4  /RJ
M  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_ $D
M_P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X FP#]
M *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_ -P
M_P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0 _P!/
M /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O )T
M[0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X _P#+
M /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!) /,
M4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )< W "?
M -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^ /\
M_P   /\   #_    _P   /L "P#V !, \0 @ .T + #J #@ YP!# ., 30#@
M %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9 ,0
MHP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\ _P
M /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#* $\
MQP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$ G "O
M *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P   /P
M  #Q    Z    .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@ M0!0
M +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"? *$
MG0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %  #C
M!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!* *,
M40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L C@"G
M (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1$@
MQ1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4 2@"3
M %$ D0!7 (\ 70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C 'X
ML0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0  NAP
M +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&!DL
MA 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*KP!Q
M"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28  *@D
M  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4 > Y+
M '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F$L
M91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M  "8
M*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15& &P5
M3 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P 7!K8
M %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2,0
MB2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=2 !@
M'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2 %(B
M\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.   @S(
M 'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8(TH
M5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH[@!+
M*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD  '4S
M  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8 4"E-
M $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$+O\
M1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y  !G
M-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U* $@N
M4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X /S+_
M #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C.0
M6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R3P!!
M,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_ #HV
M_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@  5CD
M $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \-U4
M.SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z_P U
M.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\  $@Z
M!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%, -CQ=
M #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P/O\
ML4<  *1-  "94@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5  P _
M/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%; #!!
M9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\ KDH
M *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z0PH
M-D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&9  I
M1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\  )]5
M  "46@  BUX  (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@< ,$D.
M "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C3'
M(4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:  "2
M7P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E , "=/
M$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT &E-]
M !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/90
MA6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7#@ >
M5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ !):
MC0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P  @FT
M 'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 58!
M%& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MBB0 *
M89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,  '5U
M  !J=   7',  $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P #6H2
M  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA   :I@
M &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![  !C
M>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/  !V
M%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),  '2H
M  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;@@
M3H(  $&"   U@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""$0
M@A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B  !_
MN@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@  18L
M #F,   LC   (8P  !>,   0C0  "8X   */    D ,  (\)  "/#@  CQ(
M ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".LP
MC=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4  "Z6
M   BE@  %Y<   ^8   (F0   )L   "=    G0   )T#  "="0  G0T  )X1
M  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP  G<8
M )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?   7
MH   #J(   >D    I@   *@   "J    J@   *H   "K 0  JP<  *P,  "M
M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H  *_=
M  "O\@  K_T >)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .JP
M!:X   "P    L@   +4   "W    MP   +@   "Y    N@   +P#  "]"0
MO@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(  #%
MY0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP   +H
M  "]    P    ,0   #&    Q@   ,@   #)    RP   ,P   #.    T 8
M -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #ASP
MX>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<   #*
M    SP   -,   #6    UP   -H   #<    WP   .$   #C    Y@   .D!
M  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN   ^,D
M_P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\ 60#_
M &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G /<
ML0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\ _P '
M /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[ %T
M^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@ JP#F
M +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P   /\
M  #_    _P ! /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %< Z0!>
M .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/ *\
MS0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\   #_
M    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8 -
M7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@ N0"V
M +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z
M\0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T 60"Z
M %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N *4
MO@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K    X0
M -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I %@
MIP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0 M@"2
M ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $  ,0
M  "]  ( M@ - +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %( F !8
M )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"# ,$
M@0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+  "O
M P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1 (@
M5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L = #4
M '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C$
MG0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L 40!Y
M %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7. &<'
M[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P  DA0
M (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M"E(
M; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.[0!<
M#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\  ((8
M  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T 81!3
M %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2%?\
M4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA  !R
M&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/ %87
M5@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T 2AS_
M $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L(P
M9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=4@!-
M'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_ $,B
M_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@  7B0"
M %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&(U<
M1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG_P ]
M)_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H  %$E
M"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0 /BA=
M #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X+/\
MM3H  *=   "<1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK!P!'
M*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U; #@N
M9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\ L3X
M *1$  "92   CTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"+@T
M/RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R9  Q
M,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$  *)(
M  "73   C4X  (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL .3,1
M #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L-V\
M*S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+  "4
M3P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/ #(X
M%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T )3Q]
M "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "24P
MB58  ']7  !U5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]$P K
M/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z !Y!
MC0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06   AEL
M 'U<  !R6P  9U@  %M4  !14@  2$X  #U*   S1P  *D,+ "9#$  E0Q8
M)$,> "-$)0 B1"P (40T "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'B@ 7
M1YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\ HE(  )=8  "-70  A&   'IA
M  !P8   95X  %E:  !/6   1%0  #E1   O3@  )DL& "!*#@ >2A, '4H:
M !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,5P 43&4 $TUU !)-B  139P
M$$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<  )1=  "+8@  @64  '=F  !M
M9@  8V0  %9A  !*7@  /UL  #58   K5@  (E0! !I2"@ 64A  %5(6 !12
M'0 34B0 $E(L !%2-  14CX $%-(  ]35  .4V( #51R  Q4A  +5)@ "52M
M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K;
M7VH  %)G  !%9   .F(  #!@   F7@  '5T  !5;!0 06@P #EH1  Y:&  -
M6R  #%LG  M;,  *6SH "5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH  !;
MP   6N(  %KV  %:_P "6?\ EV0  (YK  "$;@  >W   ')R  !G<0  67
M $QN  ! ;   -6L  "II   A9P  &&8  !%F 0 ,90H !V4/  1E%  #9!L
M F0C  !D+   9#4  &1   !D3   9%H  &1I  !D>P  9(\  &.D  !CNP
M8MT  &+T  !B_P  8?\ DVP  (EQ  " =0  >'<  &UX  !@=P  4G8  $9U
M   Y=   +G0  "-R   :<0  $G$   UQ   &<0@  ' -  !P$@  <!<  &\?
M  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@  ;-8
M &OR  !K_P  :_\ CG,  (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^   R
M?@  )GT  !Q\   3?   #7P   9]    ?04  'P+  !\#P  ?!,  'P9  !\
M(0  ?"D  'PT  ![0   >TX  'M>  ![;P  >H0  'J:  !YL0  >,X  '?O
M  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%  !/A@  0H<  #6(   IAP
M'8<  !2'   -B   !HD   "*    B@   (D&  ")#   B0\  (D3  ")&@
MBB(  (HL  "*.   BD8  (E6  "):   B7P  (B4  "'JP  AL8  (7J  "%
M^P  A/\ A8(  'V&  !OB   88L  %.-  !%CP  .)$  "N1   ?D@  %)(
M  V3   $E    )8   "7    F    )<   "7!0  EPL  )@.  "8$P  F1H
M )DB  ":+@  FCT  )E-  "97@  F7,  )B+  "8HP  E[P  );B  "6]P
ME?\ @(D  '*,  !DCP  5I,  $B6   ZF0  +)H  !^;   4G   #)X   .?
M    H0   *,   "E    I0   *4   "E    I@(  *<(  "G#0  J!$  *D9
M  "K(P  JS$  *M!  "L4P  K&<  *N   "JF@  JK,  *K0  "I[P  J?L
M=8\  &>4  !9F   2IP  #R?   MH@  (*,  !.E   +IP   :D   "K
MK@   +$   "R    L@   +,   "T    M0   +8   "X!   N0L  +L0  "]
M&   OR0  +\U  # 1P  P%L  ,!R  # C0  P:8  ,#!  "_XP  OO, :I<
M %N<  !-H0  /J4  "^I   AJP  $ZT   NP    LP   +4   "X    O
M +\   #!    P0   ,,   #$    Q@   ,<   #)    RP   ,X(  #1#P
MU1@  -@G  #9.0  VDT  -MD  #;?@  W)D  -RP  #<R0  W., 79\  $^E
M  ! J@  ,J\  "*R   4M0  "K@   "[    OP   ,,   #&    RP   ,X
M  #1    T0   -0   #6    V0   -L   #>    X    .0   #G!@  ZPX
M .\9  #P*@  \C\  /-5  #T;0  ](@  /2A  #TM@  ],< _P ) /\ !@#_
M  < _P , /\ $0#_ !P _P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E /\
M; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D \0#+
M /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_
M_P $ /\ #@#_ !< _P C /\ +P#_ #L _0!& /H 4 #W %@ ] !? /( 9@#P
M &P [P!R .T > #L 'X Z@"% .D C #G ), Y0"< ., I@#A +$ WP#! -T
MW0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y /\ _P   /\   #_    _P
M /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D 2@#F %( XP!9 .  8 #> &8
MW !L -H <@#7 '@ U !^ -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4 S0##
M .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\ _P   /\   #_    ^0   /(
M!@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &  Q0!F
M ,, :P#! '$ OP!W +T ?@"[ (8 N0". +< F "U *, LP"P +$ P@"N .
MK #W *L _P"J /\ J #_ *, _P"@ /\ _P   /\   #U    ZP   .$   #6
M  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4 N !- +8 5 "S %H L0!? +
M90"N &H K !P *L =P"I '\ IP"' *4 D0"C )P H "I )X N "< ,X F@#N
M )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$   #E    V0   ,T   #$  8
MO0 / +< & "S "( L  L *T -@"I #X IP!& *0 30"B %, H !9 )\ 7@"=
M &0 FP!J )H < "8 '< E@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C (@
M^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1    Q0   +T   "V    K@ +
M *@ $@"D !P H  F )P +P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "- %T
MBP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@ \@!X
M /\ =P#_ '< _P!W /\ YP<  -$,  ###0  N P  *X(  "H    H@ % )L
M#@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %< ?0!=
M 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J /P
M:@#_ &H _P!J /\ VA   ,84  "X%@  K14  *02  "<#@  E@<  )  "0"*
M !  A0 8 ($ (0!^ "H >P R 'D .0!W $  =0!& ', 3 !R %$ < !7 &X
M7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@ 7@+_
M %X"_P!> O\ SA@  +T=  "P(   I1\  )L<  "3%P  BQ$  (0,  !^! L
M>0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$60!A
M!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_ %0+
M_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+(0  @QL  'L4  !T#@, ;@D-
M &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7#5P
M50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1_P!+
M$/\ OR8  + K  "D+P  F2\  (\M  "&*0  ?20  '0>  !L%P  91$' %\.
M$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5< 3!)@
M $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#%O\
MNBL  *LQ  "@-   E34  (LT  "!,0  >"L  &\F  !F(   7AD! %<4#0!4
M%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!== $,8
M9P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\ M3
M *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM  !A)P  62$  %$;"0!,&1
M2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>9  [
M'G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0  *0Z
M  "9/@  CS\  (4_  ![/   <#@  &<R  !=+0  5"@  $PB!0!&'PX 0Q\4
M $$?&P _'R( /B I #T@,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T(VX
M,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^  "6
M0@  C$,  ()#  !X00  ;CT  &,X  !:,P  42X  $@H 0! ) P /2,1 #LD
M&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P +BA[
M "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "41@
MBD<  (!'  !V10  ;$(  &$]  !7.   3C,  $0N   \*0D -R@0 #4H%0 S
M*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY "<M
MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F+O\ J3\  )U%  "220  B$L
M 'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T   X+P8 ,BT- # M$P N+1D
M+2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(RB0 A
M,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\ ID,  )I)  "030  AD\  'Q0
M  !S3P  :$P  %Q&  !20P  23\  #\[   V-@( +C(, "LR$0 I,A< *#(>
M "8R)  E,RL )#,R ",T.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;-YL
M&C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4  !Q
M4P  9E   %I,  !020  1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@; "$X
M(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D %#RM
M !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51  "+50  @E@  'E9  !N6
M9%8  %A1  !.3P  14L  #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^'@ :
M/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&  $D%P !%!@@ 009< #T&L  Y"
MQ  .0N< #T'\ !!!_P 00/\ G5   )-6  ")6@  @%T  '9>  !L70  8EL
M %97  !,50  05$  #9.   L2P  (T@  !M%"0 71 \ %404 !1%&P 312(
M$D4I !%%,0 113L $$9%  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'O@ (
M1^  "4?V  I&_P +1O\ FE4  )!;  "'8   ?6(  '-C  !J8@  8&$  %->
M  !'6@  /%<  #)5   H4@  'U   !=.!  13 P #TP1  Y,%P .3!X #4TE
M  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.>P "3H\  4ZD  !-N@  3=L
M 4WR  %-_P "3/\ EEL  (UB  "$9@  >F@  '%I  !H:0  7&<  $]D  !"
M80  -U\  "U<   C6@  &E@  !)7 0 -5@D "54.  =5$P &51H !%4B  -5
M*@ "530  %4^  !52@  5E<  %9E  !5=P  58L  %6@  !5M@  5-0  %3Q
M  !3_0  4_\ DV(  (IH  " ;   =VX  &]O  !C;@  5FP  $EJ   ]:
M,F8  "=E   =8P  %6(   YA   )8 @  V -  !?$0  7Q<  %\>  !?)@
M7R\  %\Z  !?10  7U,  %]A  !><@  7H<  %V<  !=L@  7,\  %SO  !;
M_0  6_\ D&H  (9O  !]<@  =70  &IU  !==   3W,  $)R   V<   *V\
M "!N   7;0  $&P   IL   ":P8  &L+  !J#P  :A0  &H:  !J(0  :2H
M &DT  !I0   :4X  &E<  !I;0  :((  &B8  !GK@  9LH  &7M  !E_
M9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P  2'H  #MZ   O>@  (WD  !EX
M   1=P  "G<   -W    =P(  '<(  !V#0  =A   '85  !V&P  =B,  '8N
M  !U.@  =4<  '56  !U:   ='P  '22  !SJ@  <L0  ''I  !P^P  </\
MAGD  ']]  !V?P  :($  %J"  !,@@  /X,  #*$   E@P  &H,  !&#   *
M@P   H,   "$    A0   (0#  "#"   @PT  (,0  "#%0  A!P  (0F  "$
M,@  A#\  (-/  "#8   @G4  (*,  "!I   @+T  '_C  !^^0  ?O\ @H
M 'J$  !LA@  7H@  %"*  !"BP  -8T  ">-   ;C0  $8X   J.    CP
M )$   "2    D@   )(   "2 0  D@<  )(,  "2$   DQ4  ),=  "4*
ME#8  )1%  "35P  DVL  )."  "2G   D;8  )#8  "/\P  C_\ ?H<  '"*
M  !AC0  4Y   $63   WE0  *98  !R7   1F   "9D   ";    G    )X
M  "@    H    *    "@    H0   *$$  "B"0  HPX  *04  "E'0  IBH
M *8Z  "F3   I6   *5X  "ED@  I*P  *3)  "CZP  HOH <XX  &21  !6
ME0  1YD  #F<   JG@  ':   !&A   (HP   *4   "G    J0   *P   "N
M    K@   *X   "O    L    +$   "R    LP8  +4-  "W$P  N1X  +DN
M  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*G@
M.Z(  "RF   =J   $:H   >L    KP   +$   "T    N    +L   "\
MO    +X   "_    P    ,(   #$    Q@   ,@#  #+"P  SQ(  -$@  #1
M,@  TD8  --=  #4=@  U)(  -6K  #5Q   U.( 6YT  $RB   ]IP  +ZP
M !^O   1L0  ![4   "X    NP   +X   #"    QP   ,H   #,    S
M ,X   #0    T@   -4   #8    VP   -\   #B    Y@L  .L3  #L)
M[3@  .Y.  #O9P  \((  /"<  #PL@  \<4 _P # /\  0#_  0 _P ) /\
M#P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T ^@!S
M /D >0#X '\ ]@"% /4 C #S )0 \@"= /  IP#N +, [ #$ .L X0#J /@
MZ0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P   /\   #_    _P   /\ # #_
M !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M .@
M<P#G 'D Y0!_ ., A@#A (X WP"6 -T H #; *P V "[ -0 T0#3 /  T #_
M ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\   #_    _P   /T " #W !
M\P : .\ )@#M #$ Z  [ ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$ ; #/
M '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[ +@
M_P"W /\ L #_ *D _P"E /\ _P   /\   #^    ]0   .P  P#E  T WP 5
M -H ( #4 "H T  U ,L /@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z &P
MN !R +8 > "U (  LP"( +$ D@"N )X K "J *D NP"H -4 I@#S *0 _P"C
M /\ H0#_ )L _P"8 /\ _P   /L   #P    Y0   -@   #.  D QP 1 ,(
M&@"^ "0 NP N +< . "T $  L0!( *X 3@"L %0 J@!: *D 7P"G &4 I0!K
M *0 <0"B '@ H "! )X BP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1 /\
MD #_ (T _P"+ /\ ^0   .L   #=    SP   ,8   "\  0 M0 - +  %0"L
M !X J  H *4 ,0"B #D GP!! )T 2 "; $X F0!3 )< 60"6 %X E !D )(
M:@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\ ?P#_
M '\ _P!^ /\ [    -H   #)    O@   +8   "N    IP ) *$ $ "< !@
MF  B )4 *@"2 #( D  Z (T 00"+ $< B0!- (< 4@"& %@ A != (( 9 "!
M &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_ '
M_P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A    FP # )0 # "/ !, B@ ;
M (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R &0
M< !M &\ =@!L (( :@"/ &D G0!G *X 90## &0 Y !C /H 8P#_ &( _P!C
M /\ T X  +\2  "R$P  IQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5 'H
M'@!V "4 =  M '$ - !O #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\ 9 !G
M &( <0!@ 'P 7@") %P F !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7 /\
MQA8  +8:  "J'0  GQP  )49  "-%   A0\  'X)  !W 0H <@ 0 &X %P!J
M !\ :  G &4 +@!D #0 8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B %<
M; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\ OQT
M + B  "C)0  F24  (\B  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!? AD
M70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(9P!+
M"', 20F! $@)D@!'"J, 10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20  *HI
M  ">+   E"P  (HJ  " )@  =R$  &X;  !F%   7P\% %D+#0!5"A, 4PL;
M %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"#G
M0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O  ":
M,@  D#(  (8Q  !\+0  <B@  &DC  !A'0  618  %$1" !,#Q  2A 6 $@0
M'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT .1-\
M #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7-P
MC#@  ((V  !X-   ;BX  &4J  !<)   5!X  $P8! !&% T 0A02 $ 4&0 _
M%"  /14G #P5+0 [%30 .18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY # 9
MB@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P  BCP
M ( \  !V.0  :S0  &(O  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X&1T
M-AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>B  I
M'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\ J38  )T\  "2/P  AT$  'U
M  !T/@  :3H  %\U  !6,   32L  $0E   [( < -AX. #,>$P R'AD ,!X@
M "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C(YD
M(B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_  "/0P  A44  'M$  !R
M0P  9S\  %TZ  !3-@  2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(= "DB
M(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)< '2BK
M !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P1P
M9D0  %H_  !1.P  1S<  #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G(0 C
M*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI !8M
MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+2P  @DT  'A-  !N3   9$D
M %A$  !/0   1CT  #TX   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >+24
M'2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$ROP 1
M,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P  @%$  '92  !M4   8DX  %9)
M  !-1@  1$,  #L_   Q.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B( %S,I
M !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  --]T
M#3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8  '56  !J50  8%,  %5/  !,
M3   0DD  #A%   N00  )#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF !$Y
M+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4 "#SP
M  D[_P *._\ F$X  (Y4  "%6   ?%L  ');  !H6@  7E@  %-5  !)4@
M/DX  #1+   J1P  (40  !A" P 20 L $#\0  X_%0 ./QP #4 C  Q *P +
M0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H  4&?  !!M   0=   4'N  %!
M_  "0/\ E50  (Q9  "#7@  >6   '!@  !F8   75X  %%;  !%5P  .E0
M "]1   E3P  '$P  !1*   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #2#$
M D@[  !(1P  2%,  $AB  !(<P  2(8  $B;  !(L0  1\P  $?M  !'^P
M1_\ DEH  (E@  " 8P  =V4  &YF  !E9@  660  $Q@  ! 70  -5L  "I9
M   @5P  %U4  !!3   +4@< !5$-  %0$0  4!8  % =  !0)0  4"X  % X
M  !00P  4%   %!>  !0;P  4(,  $^8  !/K@  3LD  $[K  !-^P  3?\
MCV$  (9F  !]:0  =&P  &QM  !A:P  4VD  $9G   Z9   +V,  "1A   :
M7P  $EX   Q<   &7 8  %L+  !:#P  6A,  %H9  !9(0  62D  %DS  !9
M/P  64P  %E:  !9:P  6'X  %B4  !7JP  5\4  %;I  !5^P  5?\ C&@
M ()M  !Z<   <G(  &=R  !:<0  3'   #]N   S;0  *&L  !UJ   4:
M#6<   =G    9@,  &8)  !E#0  91$  &05  !D'   9"0  &0N  !D.@
M8T<  &-5  !C9@  8WH  &*0  !AIP  8,$  %_F  !?^@  7O\ AV\  ']T
M  !X=P  ;G@  &!X  !2=P  17<  #AV   K=@  ('0  !9S   .<P  !W(
M  !R    <@   '$%  !Q"@  <0X  ' 1  !P%P  <!X  ' G  !P,P  ;T
M &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[  !S
M?0  97X  %=_  !)?P  /'\  "^    B?P  %WX   ]^   '?@   '\   !_
M    ?P   'X   !^!0  ?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D  'U(
M  !]60  ?&T  'R$  ![G   >K8  'G:  !X]0  =_\ @'\  '>"  !I@P
M6X4  $V&   _B   ,HD  "2)   8B0  #XD   >*    BP   (P   "-
MC0   (P   ",    C ,  (P(  "-#0  C1$  (T7  ".(@  CB\  (X_  "-
M4   C60  (Q[  ",E0  BZX  (K-  ")[P  B?\ >X4  &V(  !>B@  4(T
M $*/   TD0  )I(  !F3   .E   !I4   "6    F    )H   ";    FP
M )L   ";    FP   )P   "=!0  G0L  )X0  "?%P  H"0  * T  "@1@
MH%D  )]P  "?B@  GJ4  )["  "=Z   G/D <(P  &&/  !3D@  1)8  #:9
M   GFP  &9P   ^=   %GP   *$   "C    I0   *@   "I    J0   *D
M  "J    JP   *P   "M    K@$  + )  "R#P  LQ@  +0G  "T.0  M4T
M +1D  "T?@  LYH  +.T  "SU0  L_  9),  %67  !'FP  .)\  "FB   :
MI   #J8   2H    JP   *T   "P    M    +8   "X    N    +D   "Z
M    O    +T   "_    P    ,,   #%!P  R0\  ,H:  #++   S$   ,U6
M  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@   ZI0  +*D  !RK   /K@
M!+$   "T    MP   +H   "^    PP   ,8   #(    R    ,H   #+
MS0   ,\   #2    U0   -D   #=    X04  .8/  #G'@  Z#(  .E(  #J
M8   ZWL  .N7  #LK@  [,( _P   /\   #_    _P & /\ #0#_ !4 _P A
M /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T 'H
M\@"  /$ AP#O (\ [0"7 .L H0#I *T YP"] .4 V #D /, X@#_ .  _P#0
M /\ Q #_ +P _P"V /\ _P   /\   #_    _P   /\ "0#_ !$ _P < /T
M)P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ', WP!Y
M -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#! /\
MMP#_ *\ _P"K /\ _P   /\   #_    _P   /@ !0#R  X [@ 7 .H (@#F
M "P X0 W -T 0 #8 $D TP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S ,0
M>0#" ($ P "* +X E "\ )\ N0"L +8 O@"T -T LP#W +$ _P"P /\ J #_
M *( _P"> /\ _P   /\   #Y    [P   .8   #?  L U@ 2 -  ' #, "8
MR  P ,0 .@#  $( O0!* +L 4 "X %8 M@!; +4 80"S &8 L0!L +  <@"N
M 'H K "" *D C "G )@ I0"E *, M "@ ,L GP#N )T _P"< /\ F0#_ )0
M_P"1 /\ _P   /8   #J    W0   ,\   #'  8 P  / +L %P"W "  LP J
M +  ,P"M #L J@!# *< 20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P"; '(
MF0![ )< A0"4 )  D@"= )  K ". +\ C #B (L ^@") /\ B0#_ (8 _P"#
M /\ ]    .0   #4    R    +\   "U  $ K@ + *D $@"E !L H0 C )X
M+ "; #0 F  \ )8 0P"4 $D D@!. )  4P". %D C0!> (L 9 ") &L AP!S
M (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U /\
MY0   -$   ##    N    *\   "H    H  & )H #@"5 !4 D0 > (X )@"+
M "T B  U (8 / "$ $( @@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M '8
M=@!S ($ <0". &\ G0!M *X ; #$ &H YP!I /T : #_ &@ _P!I /\ U0,
M ,,'  "V"   JP8  *(   ";    E    (T "@"( !  @P 8 '\ ( !\ "<
M>@ N '< -0!U #L = !! '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &< < !E
M 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T  +D0
M  "L$0  H1   )<-  "/"   B    (( !0![  T =P 2 ', &@!O "$ ;  H
M &H +P!H #4 9P [ &4 00!C $8 8@!, &  4@!? %D 70!A %L :@!9 '4
M5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8  "D
M&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @ :P . &< % !D !L 80 B %X
M*0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3 %0 4@!< %  90!. '  3 !]
M $L C0!) )X 2 "P $< QP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">(@
MDR(  (D?  " &@  =Q4  &\0  !H"P  800* %T $ !9 !8 5@ = %0 (P!2
M "H 4  P $\ -0!. #L 3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y $$#
MB0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0  CBD
M (0G  ![(P  <1X  &D8  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(!B0
M1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+AP W
M"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\ K2<  * L  "5+P  BR\  ( N
M  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\ /@PE
M #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N$)@
M+1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT  !T
M,0  :BL  & G  !8(0  3QL  $<6  ! $0D .Q / #D0%  W$!L -A A #00
M)P S$2T ,A$T #$1.P P$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4 )A2I
M "45P  D%>, )1;Z "86_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q-@
M9S$  %TM  !4*   3"(  $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4)  L
M%"H *Q4Q "H5.  I%D  *!9* "<75  F%V  )!AO ",8@  A&9, (!FG !\9
MO@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P  93<
M %LR  !2+0  22@  $ C   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F&2<
M)1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>O  8
M']T &1_V !H?_P ;'O\ H3@  )4]  "+00  @4(  '="  !M0   8SP  %DW
M  !/,P  1BX  #TI   U)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20 (!XK
M !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3(]H
M%"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8  '5&  !L1   8D$  %<\  !-
M.   1#0  #PP   S*P  *B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H !HC
M,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8 $"CT
M !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*  !J20  8$8  %5!  !,/@
M0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H+0 3
M*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO  TL
M_P -*_\ F40  (])  "%3   ?$X  '-/  !I3@  7DL  %-'  !*1   0D
M #D]   O.   )30  !TP!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /+C,
M#BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P_  (
M,/\ ET@  (U-  "#40  >E,  '%4  !G4@  75   %),  !)2@  0$8  #5"
M   K/@  (CH  !HW 0 2- D #S,.  XS$P -,QD #3,@  PT*  +-#$ "C4[
M  @U1@ '-5( !39@  0V<0 "-H0  #:9   VKP  -L@  #;H   V^0 !-?\
ME$T  (I2  "!5@  >%@  &]9  !E6   6U4  %%2  !'3P  /$P  #%(   G
M1   'D$  !8_   0/ < "SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX  $\
M0P  /$\  #Q>   \;@  /($  #R7   \K   .\4  #OG   [^   ._\ D5(
M (A8  !_7   =ET  &U>  !C70  6EP  $Y8  !"5   -U$  "U.   C2P
M&DD  !)&   -1 8 !T,,  -#$   0Q4  $,;  !#(P  0RL  $,U  !#0
M0TT  $-;  !#:P  0WX  $.4  !"J@  0L,  $'F  !!^0  0?\ CE@  (9>
M  !]80  <V,  &MD  !B8P  5V$  $E=   ]6@  ,E@  "=5   >4P  %5$
M  Y/   )304  DT+  !,#@  3!,  $L8  !+'P  2R@  $LR  !+/0  2TD
M $M7  !+9P  2GL  $J0  !)IP  2<   $CD  !(^   1_\ BU\  (-D  !Z
M9P  <6D  &EJ  !>:0  4&8  $-D   W80  +%\  "%=   86P  $%D   I8
M   #5P,  %<)  !6#0  51   %45  !4&P  5",  %0M  !4.0  5$4  %13
M  !49   4W<  %.-  !2I   4;T  %#B  !0^   3_\ B&<  ']K  !W;@
M;W   &5P  !7;@  2FP  #UK   P:0  )6@  !IF   19   "V,   1B
M8@$  &$&  !@"P  8 X  %\2  !?%P  7QX  %XH  !>,P  7D   %Y/  !>
M7P  77(  %V(  !<H   6[D  %K?  !9]P  6/\ A&X  'QR  !U=0  :W8
M %UU  !/=   0G,  #5S   H<@  '7   !-O   ,;@  !&X   !N    ;@
M &P"  !L!P  :PL  &L.  !K$@  :AD  &HB  !J+0  :CH  &E)  !I6@
M:6P  &B#  !GFP  9K4  &78  !D]0  9/\ @'4  'IY  !P>P  8GL  %1\
M  !&?   .7P  "Q\   ?>P  %'H   UZ   $>@   'H   !Z    >@   'D
M  !Y 0  > 8  '@+  !X#@  >!,  '@:  !X)0  >#(  '=!  !W4@  =V4
M '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT  '6   !G@0  6((  $J#   \
MA   +H4  "&%   5A0  #84   .%    A@   (<   "(    B    (<   "'
M    AP   (<$  "'"0  APX  (@3  "('   B"D  (@X  "'2@  AUT  (9S
M  "&C0  A:<  (3%  "#[   @OX >(0  &J&  !<B   38H  #^,   QC@
M(X\  !:/   -D    I$   "2    DP   )4   "6    E@   )8   "6
ME@   )<   "7    EP<  )@-  "9$P  FA\  )HM  ":/P  FE(  )IH  "9
M@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0D   09,  #.6   DEP  %I@
M  V9   !FP   )T   "?    H0   *0   "E    I    *4   "E    I@
M *<   "H    J0   *H$  "L#   KA,  *XA  "N,P  KD<  *Y=  "N=@
MKI,  *ZN  "MS0  K.\ 89$  %.5  !$F   -9P  ":?   7H0  #:,   "E
M    IP   *H   "L    L    +(   "T    LP   +0   "U    MP   +@
M  "Y    NP   +T   "_ 0  PPL  ,45  #%)0  QCD  ,=/  #':   QH4
M ,:B  #&O   QMX 59D  $>=   XH@  *:8  !FH   -JP   *T   "Q
MM    +<   "Z    OP   ,$   #$    PP   ,4   #&    R    ,H   #-
M    SP   -(   #6    VP   . ,  #A&   XRL  .1!  #E6@  YG0  .:1
M  #EK   Y<0 _P   /\   #_    _P ! /\ "@#_ !( _P = /\ * #_ #0
M_P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I /  ;P#O '0 [0![ .L @0#I
M (D Z "2 .8 G #D *@ X@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_ +4
M_P"P /\ _P   /\   #_    _P   /\ !@#_  \ _  8 /@ (P#T "X \  X
M .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1 ((
MSP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@ _P"D
M /\ _P   /\   #_    ^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R -,
M/ #/ $0 S !+ ,D 40#& %< Q != ,( 8@#! &< OP!M +T = "[ 'L N0"$
M +< C@"T )D L@"G *\ MP"M -  JP#R *H _P"I /\ H0#_ )L _P"7 /\
M_P   /\   #T    Z0   .    #5  @ S@ 0 ,D & #% "( P0 K +P -0"Y
M #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\ *(
MA@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\ _
M /    #C    U    ,@   "_  , N0 - +, $P"O !P K  E *D +@"E #8
MHP ^ *  1 "> $H G0!0 )L 50"9 %H EP!? )8 9@"4 &P D@!U )  ?@".
M (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0   -T
M  #,    P0   +@   "N    IP ) *( $ "> !< F@ ? )< )P"4 "\ D0 W
M (\ /0"- $, BP!) (D 3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\ ((
M>@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_ '  _P!N /\ W0   ,D   "\
M    L0   *D   "A    F0 # ), # ". !( B@ 9 (< (0"$ "D @0 P '\
M-P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L :@"(
M &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O!0
MI0(  )P   "4    C0   (8 " "!  X ?  4 '@ &P!U ", <@ I '  , !N
M #8 ;0 \ &L 00!I $< : !, &8 4@!D %D 8P!@ &$ :0!? '0 70"! %L
MD !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P  FPX
M )(+  ")!0  @@   'L  @!U  L <  0 &P %@!H !T 9@ C &, *@!A #
M8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\ B@!-
M )L 3 "N $L Q@!* .H 20#^ $D _P!) /\ N1(  *H6  ">%P  E!8  (H3
M  "!$   >0L  '$#  !K  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H 5  P
M %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!# )<
M00"I $  OP _ .( /P#X #X _P _ /\ LAD  *0>  "8'P  CA\  (0<  !Z
M&   <A(  &H.  !B"   7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K $@
M, !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ), . "E
M #8 N@ V -L -0#T #4 _P U /\ K"   )\D  "4)@  B28  '\D  !U(
M;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\ *P ^
M 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C "T&
MN  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0+   ABT  'LK  !R)P  :"(
M %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U""P
M,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML "D+?  H#(\ )@RB "4,MP D
M#-, (PWP "0-_P E#?\ I"H  )@O  "-,@  @S(  'DQ  !O+@  92D  %PD
M  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@ *PTN
M "H--0 I#3T )PY& "8.4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <$-0
M'1'R !T1_P >$?\ H2\  )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ  !0
M)0  2"   #\:   X%0  ,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J ",1
M,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$ %A7Q
M !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[  !K.   830  %<O  !.*P
M128  #TA   T'   +1<% "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+P <
M%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO !(9
M_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I/0  7SD  %4U  !,,   0RP
M #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30
M%AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=_P /
M'?\ F3H  (\_  "$0@  >T0  '%#  !H0@  7CX  %,Z  !*-@  03(  #DM
M   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C( $1\\
M ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +(?\
MESX  (Q#  "#1@  >4@  '!(  !G1@  7$0  %(_  !).P  0#@  #@T   O
M,   )RP  !XG P 6(PH $B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y  PD
M1  +)5  "B5>  DF;P ')H( !B:6  0FK  #)L0 !";E  0F]P &)O\ E4(
M (I'  "!2@  >$P  &],  !E2P  6T@  %!$  !'00  /SX  #<[   M-@
M)#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J0@ &
M*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$  "OC   K]@  *O\ DD8  (A+
M  !_3P  =E$  &U1  !C4   6DT  $]*  !'1P  /D0  #-    I/   (#@
M !<T   1,04 #"\,  DN$  '+A4 !B\;  4O(P #+RL  C U   P/P  ,$P
M #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A   P]0  +_\ D$L  (90  !]
M5   =58  &M6  !B50  6%,  $Y0  !%30  .DD  "]%   E0@  '#X  !0[
M   ..04 "3<+  0V#P !-A,  #89   V(   -BD  #8R   W/0  -TD  #=7
M   W9P  -WD  #>/   VI0  -KT  #;@   U]0  -?\ C5   (16  !\6@
M<EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X  "I+   @2   %T8  !!#   +
M000 !$ *   _#@  /A$  #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4   ^
M9   /G8  #V,   ]HP  /+L  #S>   []0  ._\ BE<  ()<  !Y7P  <&$
M &AA  !?80  5%X  $=;   Z5P  +U4  "52   ;4   $DT   Q+   &2@,
M $D)  !(#0  1Q   $<4  !&&@  1B(  $8L  !&-P  1D,  $91  !&8
M17,  $6)  !$H   1+@  $/<  !"]0  0O\ B%T  ']B  !W90  ;F<  &=H
M  !;9@  3F,  $%A   T7@  *5P  !]:   55P  #E8   =4    4P$  %(&
M  !1"P  40X  % 1  !/%@  3QX  $\G  !/,@  3S\  $]-  !.70  3F\
M $Z%  !-G0  3+4  $O8  !*]0  2O\ A64  'QI  !T;   ;6X  &)M  !4
M:P  1VD  #IG   M90  (F0  !AB   08   "5\   !>    7@   %T#  !<
M"   6PP  %H/  !:$P  61D  %DB  !9+0  63H  %E(  !86   6&L  %>!
M  !7F0  5K(  %72  !4]   4_\ @6P  'EP  !S<P  :',  %IR  !,<0
M/W   #)O   E;@  &FP  !%K   ):@   &H   !I    :0   &@   !G P
M9@@  &8,  !F#P  910  &4<  !E)P  9#0  &1#  !D4P  9&4  &-[  !B
ME   8:T  &#-  !?\0  7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0  -G@
M "EX   <=P  $78   IU    =0   '4   !V    =0   '0   !T    <P(
M ','  !S#   <A   '(5  !R(   <BP  '([  !Q3   <5\  '%T  !PC@
M;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@  57\  $>    Y@0  *X(  !Z!
M   2@0  "H$   "!    @@   (,   "#    @P   ((   ""    @@   ((
M  ""!0  @@H  ((/  ""%P  @B,  ((R  ""0P  @58  (%L  " A@  ?Z$
M 'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<  #R)   NB@  ((L  !.+   *
MBP   (P   "-    CP   )$   "2    D0   )$   "1    D0   )$   "2
M    D@(  ),)  "4#P  E!D  )0G  "4.   E$P  )-B  "3?   DY@  )*S
M  "1V   D/8 :H@  %R*  !-C0  /Y   #"2   AE   %)4   J6    EP
M )D   ";    G0   )\   "@    H    *    "@    H0   *(   "C
MI    *4   "F!P  J!   *@<  "H+0  J4   *E6  "I;P  J8L  *BH  "G
MQP  INP 7X\  %"2  !!E@  ,YD  ".<   4G0  "I\   "A    HP   *8
M  "H    K    *X   "O    KP   +    "P    L@   +,   "T    M@
M +<   "Z    O0<  +\0  "_'P  P#,  ,!)  # 8@  P'X  ,";  # MP
MO]@ 4Y<  $2;   UGP  )J,  !:E   +IP   *H   "M    L    +,   "V
M    NP   +T   #     OP   ,$   #"    Q    ,8   #(    R@   ,P
M  #/    TP   -H'  #;$P  W24  -X[  #?4P  X&X  -^,  #=J0  W<(
M_P   /\   #_    _P   /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D 0P#U
M $L \P!2 /$ 60#O %X [0!D .L :0#I &\ YP!U .8 ? #D (0 X@"- .
MEP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\ _P
M /\   #_    _P   /\  @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B $4
MW@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8 D #"
M )L P "I +X N@"[ -D N0#W +@ _P"T /\ J0#_ *( _P"= /\ _P   /\
M  #_    ]@   .X   #G  H X0 1 -P &@#7 ", T  N ,L -P#' #\ Q !&
M ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M ),
MJ@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P   #N
M    XP   -@   #-  4 Q@ . ,$ %0"] !X N0 G +4 , "R #@ KP!  *P
M1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"? &X G@!V )L @ "9 (P EP"9
M )0 J "2 +P D #? (X ^P". /\ BP#_ (8 _P"# /\ ^    .D   #<
MS    ,$   "X    L@ * *P $0"H !@ I0 A *( *0"> #( G  Y )D /P"7
M $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &< BP!O (D > "& (0 A "1 ((
MH "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U /\ Y@   -,   #&    NP
M +$   "G    H0 % )L #0"7 !, DP ; )  (P", "L B@ R (@ . "& #X
MA !$ (( 20"! $X ?P!3 'T 60![ &  >0!H '< <0!U 'P <P") '  F !O
M *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\ TP   ,,   "U    JP   *,
M  ";    D@   (P "@"' !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@ =  ]
M '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!? *(
M7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0   +8"  "I @  GP   )8   ".
M    AP   (  !0!Z  P =0 1 '$ & !N !X :P E &D *P!G #$ 9@ W &0
M/ !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L 40"N
M %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-  "@#0  E0P  (P(  "# @
M?    '4   !N  @ :0 . &4 $P!B !D 7P ? %T )0!; "L 60 Q %@ -@!6
M #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H $0
MOP!# .0 0@#\ $( _P!" /\ LA$  *44  "9%0  CA,  (01  ![#0  <P@
M &P   !E  , 7P + %L #P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+ #8
M20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O #X ?@ \ )  .P"C #H N  Y
M -D . #U #@ _P X /\ K!<  )\;  "3'0  B1P  '\9  !U%0  ;!   &0,
M  !=!@  5@ & %$ # !- !  2@ 5 $< &@!% "  1  F $( *P!! #$ /P V
M #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0 >@ R (P ,0"> #  LP O ,X
M+P#O "X _P N /\ IQX  )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3  !7
M#@  4 H  $D#" !%  T 00 1 #X %@ \ !L .@ A #D )@ W "P -@ R #0
M.  S #\ ,0!' #  4  N %L +0!G "L =@ J (@ * "< "< L  F ,D )0#J
M "4!^P E ?\ HB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0
M2Q   $,, @ ]!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J
M SL *01# "@$30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(
M^  ="?\ GR@  ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<
M #\2   X#@0 ,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3<
M(0I  " *2@ ?"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6
M#?\ G"T  ) Q  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8
M   T$P  +1 & "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X]
M !D.1P 7#E, %@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\
MF3$  (XU  "$.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q
M&@  *A4! ",1!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,1
M10 2$E$ $1)? ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4
M (PY  ""/   >#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0
M*!P  " 8 P 9% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .
M%D\ #19<  P7;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]
M  " 0   =T$  &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,
M !\?   7&@@ $A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP
M"1M:  <<:0 %''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_
M1   =44  &Q%  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE
M   4(00 #QT+  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7
M  $A9P  (7D  "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2
M=$H  &M*  !B20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2
M* 0 #20*  DC#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F
M90  )G<  ":,   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\
M &I/  !@3@  5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@,
M"BP*  4K#@ !*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@
M+'4  "R*   KH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4
M  !?4P  5E$  $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)
M   R#0  ,A   #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(
M #*'   QG@  ,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>
M60  55<  $E3   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [
M#   .@\  #D2   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%
M   XG   -[,  #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P
M4EP  $18   X50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@
M0PT  $(0  !!%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _
MF0  /[$  #[0   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$
M #Y>   R6P  )ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P
M $L.  !+$@  2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@
M1Z\  $;-  !%\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D
M   J8@  'V   !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,
M  !5$   5!0  %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L
M %#*  !/[P  3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B
M:@  %VD   YG   &9@   &4   !E    90   &,   !B    8@0  &$(  !A
M#0  8!   & 7  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%
M  !:[0  6?\ >W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P
M$'(   =Q    <0   '$   !Q    <0   &\   !O    ;@   &X"  !N"
M;0P  &T1  !M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !G
MZ   9OX >7H  '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT
M  !]    ?0   'X   !_    ?@   'T   !]    ?    'P   !\    ? 8
M 'P,  !\$@  ?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP
M=_H <X   &6!  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")
M    B@   (P   "-    C0   (P   ",    C    (P   ",    C0   (T$
M  ".#   CA,  (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO,
M:(8  %J(  !+BP  /(T  "V/   >D   $9$   >2    DP   )4   "7
MF0   )L   "<    FP   )L   "<    G    )T   ">    G@   )\   "A
M P  H@P  *(6  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T
M $V0   _DP  ,)8  "&9   2F@  !YL   "=    H    *(   "D    J
M *H   "K    J@   *L   "L    K0   *X   "O    L0   +(   "T
MMP$  +D-  "Y&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8
M   RG   (Z   !.B   (I    *<   "J    K    *\   "R    MP   +D
M  "[    N@   +P   "]    OP   ,    #"    Q    ,8   #)    S0
M -(!  #4#P  U1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_
M    _P   /\  P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L
M5 #I %H YP!? .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K
M ,T O0#+ .  R0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_
M_P   /P   #V  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/
M %0 S0!9 ,L 7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8
MM "T ,T L@#R +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0
M .@   #@  8 V0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T
MM@!3 +0 6 "R %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"?
M ,  G0#F )L _P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X
M  #&  $ OP + +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!,
M )\ 40"> %8 G !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4
MB0#3 (< ]P"& /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q
M    JP ' *4 #@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T
M2@"+ %  B0!5 (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$
M '0 ZP!S /\ <P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A
MF@ " )0 "P"0 !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y
M $D > !. '8 5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0
MW@!C /L 8@#_ &( _P!@ /\ S    +P   "O    I0   )T   "4    C
M (8 !P"!  T ?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $(
M: !( &< 3@!E %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5
M /( 5 #_ %0 _P!4 /\ O@   +    "D    F0   )    "(    @0   'D
M @!S  H ;P / &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!"
M %D 1P!7 $X 5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@
M1P#_ $< _P!' /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H
M  4 8P , %\ $ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T
M0@!+ $@ 20!0 $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X
M #P _P \ /\ K!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $
M60 ( %4 #0!1 !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !
M $, /@!+ #T 4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$
M_P Q /\ IA8  )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $
M $P "@!(  X 1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X
M- !& #, 3P Q %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H
M /\ H1P  )4@  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0
M!@!   L /  / #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!"
M "H 2P H %4 )@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\
MG2(  )$F  "&*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X
M!0< -  , #$ $  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "(
M1P @ %( 'P!> !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<
M (XK  "$+0  >2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0(
M+0D) "D%#0 F Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9
M!4\ %P9< !8&:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO
M  "!,0  =S(  &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$
M ",,"0 ?"0T '0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT
M$0M: ! +:0 .#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_
M-@  =C8  &PU  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0
M!0 9#@H %0P. !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8
M  L/9P *$'D "!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@
M=#L  &LZ  !A.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7
M$P8 $1 +  X.#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  83
M90 $$W8  Q.+  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\
M &H_  !@/0  5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@(
M$!4)  P3#@ *$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@
M&'0  !B)   8GP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#
M  !?0@  5C\  $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)
M  D9#0 &&1$ !!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(
M !V'   <G0  '+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>
M1@  540  $M   !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@
M#0 !'Q   !\4   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%
M   AFP  (;(  "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P
M5$D  $I&  !"0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#
M)@X  "42   F&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   G
MF0  )K   "7,   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\
M $I,  !!20  -40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X
M "T1   M%@  +1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP
M+*\  "O+   J[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1
M   [30  ,$D  "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/
M   T%   -!L  #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT
M #'*   Q[@  ,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V
M4@  *D\  "!,   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]
M$0  /!@  #PA   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(
M   X[0  -_\ @5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6
M)%4  !E3   040  "D\   %-    3    $H   !)!   2 @  $<,  !&#P
M1A0  $4<  !%)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  !
M[   /_\ ?F$  '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T
M !);   +60   E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!
M $\8  !/(@  3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@
M2/\ >VD  '1L  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD
M   #8@   &(   !A    8    %\   !>    70   %P$  !<"0  6PT  %L2
M  !;'   6B@  %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X
M>7   '-T  !I=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M
M;0   &T   !M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H
M%0  9R$  &<O  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@
M &UZ  !?>@  4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0
M 'H   !Z    >@   '@   !X    =P   '<   !W    =P$  '<(  !W#@
M=Q@  '<F  !V-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_
M  !4@   18(  #:#   HA   &H0   Z#   $A    (0   "%    A@   (@
M  ")    B    (<   "'    AP   (<   "'    B    (@   "(!P  B1
M (D<  ")+   B#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(
MB   .8H  "J,   ;C0  #XT   2.    D    )$   "3    E0   )<   "8
M    E@   )<   "7    EP   )@   "8    F0   )H   ";    G0<  )T1
M  "=(0  G3,  )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0
M+9,  !Z5   0E@  !)@   ":    G    )X   "A    I    *8   "G
MI@   *<   "G    J    *D   "J    K    *T   "O    L0   +,)  "S
M%0  M"<  +0]  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T
M !&?   %H0   *,   "F    J0   *P   "O    LP   +4   "W    M@
M +<   "X    N@   +L   "]    OP   ,$   #$    QP   ,L   #-#
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M^_S^______________________________________________________\
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M\/'R\_3U]O?X^?K[_/W^_VUF=#$      P$A   !
M 0                    $    ! @,$!08'" @)"@L,#0X/$!$2$Q05%A<8
M&1H:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C] 04)#
M1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P
M<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=
MGI^@H:*CI*6FIZBIJJNLK:ZPL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+
MS,W.S]#1T]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ
M^_S]_O\  0$" @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186
M%Q<8&1D:&AL<'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W
M.#DZ.SP]/C] 0D-$149(24I,34]04E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#
MAHF+CI"2E9>9FYV?H:.EIZBJK*VOL+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+
MS,W-SL_0T=+2T]35UM;7V-G9VMO;W-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KK
MZ^SL[>[N[^_P\/'R\O/S]/3U]O;W]_CX^?GZ^_O\_/W]_O[_  $! @(# P0$
M!08&!P<(" D)"@L+# P-#0X/#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?
M(" A(B(C)"0E)B8G*"DI*BLL+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&
M2$E*3$U/4%)355=86EQ>8&)D9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&C
MI:>HJJRMK["RL[6VM[FZN[R]O\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6
MU]C9V=K;V]S=W=[?W^#AX>+CX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S
M\_3T]?;V]_?X^/GY^OO[_/S]_?[^________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^*!\$E#0U]04D]&24Q%  D)____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________T________
M_________________________________^O1________________________
M__________________?I_O______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^'-U_______________________________________
MW:^6M_3_____________________________________Q8QHI^?_________
M____________________________S)R)I.?_________________________
M____________^LZ[QO7_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________]S%O?7_________
M____________________________OY-ZA<7_________________________
M___________;D%L]9:CV__________________________________Z\=30
M5)OK_________________________________].4?DDL3IKL____________
M____________________V-3*LWYE;:7Y____________________________
M________],6NK\G_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________#6QNS____________________________________FNY%T
M8ZOW________________________________]L2:<T4F-'W,____________
M____________________M8!5, H &6"R____________________________
M___/=#4+    "E*G______________________________^6-        $^G
M______________________________9I'0  "0P&"5*Q________________
M_____________\L[#A,U3%M-3%[#_____________________________ZE@
M-F"&G[:LJ;C9_____________________________^"7C;[E____________
M___________________________M^?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________Z]G*O,?_____________
M_____________________\^:@6U:1HCJ____________________________
M____Q'P^)A   %2P_______________________________@@SP      "Z'
M[?____________________________^L4Q       !=MUO______________
M______________N ,0        EAS/___________________________]):
M @        !=S/___________________________Z@U          !<T___
M_________________________WT-          !4UO__________________
M________[GU%          !$U/___________________________*ID+P(
M  0B-TE8SO___________________________^FD:T$H/V-_E:>ZVO______
M________________________U;*LLLSD^O__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________Y;N7=V+(_________________________________]N>9S8*  *,
M________________________________R'\_!0    !>S_______________
M_______________9@3D        \JO____________________________^>
M3          CD/___________________________]QO&@         0??G_
M_________________________Z](            ;^[_________________
M_________X03            9.;_________________________[%$
M        5][_________________________N!4             2-;_____
M____________________=!0             .,______________________
M___YHEH3            (\7_________________________WYM<+
M    #;K__________________________^^Q?54Y(A$' 0(1(K+_________
M_____________________]^_I9F8FJ"LO=K_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^.^G8!\^_______________
M__________________*WA%<P#@ =K/______________________________
MTHI,%0      <O/____________________________6?S8         2\G_
M__________________________J1/@          +ZO_________________
M_________\!:            &I7__________________________XTD
M        "(3_________________________YUX              '?_____
M____________________M"4              &K_____________________
M____?0               %OT_______________________]*P
M     $SK______________________^E                 #SA________
M______________\P#                "W9_____________________YF*
M82<              "?7_______________________MOHE5)P
M "7<__________________________[*G79=2CPR+2PP.4?>____________
M___________________]YMW6TM#3V>3_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________[]2[UO_________________________________GN(]J2R\5;___
M____________________________Y*%G- <     /,G_________________
M___________6@CL         $I?__________________________^V%,0
M         &___________________________Z9"             %#A____
M____________________[&D              #?)____________________
M____LR\              "*V________________________>0
M     !"G_______________________R-                 "9________
M______________^I                  ",______________________]&
M                  !______________________]\
M  !T_____________________Y<                   !J____________
M_________\X                   !C______________________\I(@$
M              !A______________________^YHX!7-Q<           !H
M___________________________ZTZZ4AGQU<7!R=X&4________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________]NZG8)I:=/______________________________\B3
M93T9    '9[____________________________;CDP3         &[_____
M_____________________]M\+            $77____________________
M_____XLJ             "*T________________________PD0
M      .7________________________?0$               !_________
M_______________G-@                !J______________________^=
M                  !8______________________]&
M  !'^/___________________^D                    UZ?__________
M_________Y8                    EV____________________[P
M               8SO___________________^L                    /
MPO____________________\                    *N?______________
M______\G                   *M?____________________]P
M           -N?_____________________@G(QP54(S)AL4#PT.$AHFO___
M__________________________GDV-+.S,O,S];@_/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^O3O./_____
M___________________________2J85E2"P2 87_____________________
M_______QJW$\#P       $_@_________________________]5_-0
M     !^R________________________XW4=              ")________
M________________D",               !G_______________________5
M0P                !(]O____________________^*
M   NW?____________________\X                   7R/__________
M_________[X                    $MO___________________YP
M                I?___________________[H
MD____________________]P                     @O______________
M______\                     =/____________________\3
M            :/____________________]"                    8/__
M__________________]Z                    7?__________________
M___1                    8?______________________)
M        9O______________________R:R9B7UV<6QI9V9G:W!ZC/______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^+%
MJI%Y87?_____________________________W:9W4"P,     #'$________
M_________________^"23A,           "/________________________
MTG =              !@_______________________N;P\
M   WXO____________________^6'                  4P/__________
M__________]                     H____________________ZX
M                B?___________________YX
M<O___________________[P                     7_______________
M_____]H                     3?____________________H
M            ._____________________\.                    *OG_
M__________________\S                    &^G_________________
M__]>                    #]O___________________^/
M        !M#____________________0                     ,K_____
M________________*P                   ,C_____________________
M@                    ,O_____________________]Q8!!04# 0
M 08-&,O_______________________SKX=C/S,W/T-+4U]SBZO__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________QVL;_________________________
M______'&HX1H33(8 !6K__________________________^Y?$88
M  !Q________________________UWPO               [X___________
M___________?9 D                ,M?____________________]T P
M                C?___________________\45
M:O___________________YD                     2_______________
M_____[8                     ,/W__________________]<
M            &>?___________________8                     !=/_
M__________________\.                     ,'_________________
M__\O                     *____________________]2
M         )[___________________]Y                     ([_____
M______________^E                     (#____________________8
M                     '3_____________________-@
M     &W_____________________?                    &G_________
M____________UPT                  &C______________________W
M                 &'_______________________]0/$9.5%E=861H;'!V
M?HG_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^_5NZ.+<UJ5____________
M_______________XOXYD02$%      !2_/______________________]YU6
M&              7P?_____________________E;!8
MC?____________________]C                    7O______________
M_____YT                     -?S__________________Z$
M            $=G__________________\H                      +O_
M_________________^X                      *'_________________
M__\,                     (K___________________\M
M         ';___________________]-                     &3_____
M______________]O                     %+___________________^4
M                     $#___________________^\
M     ##____________________J#@                   "+_________
M____________1                    !7_____________________@0
M                  OU____________________R L
M  +L_____________________UX                   #E____________
M_________\D<                  #:______________________^= 0
M           '#A?%________________________U;F\P<?.U=OAYNWT^___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________^-_/_____________________________^S&I8AM5#LA!P R
MWO_______________________]>262D             H/______________
M________B38                 9_____________________]F
M            ,O;__________________Y4                      \C_
M_________________Z<                      *#_________________
M_]<                      'S___________________\
M         %[___________________\E                     $/_____
M______________](                     "S___________________]J
M                     !C___________________^+
M      7S__________________^O                      #A________
M___________5                      #/____________________)
M                  "^____________________5
M  "N____________________BP                    "?____________
M________RPX                   "2_____________________U<
M              "&_____________________ZH*                  !Y
M______________________]M                  !F________________
M_______W50                !%_________________________VHC*S4_
M2E5@:G5^AY&<________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________HS[:=@VE.N?_________________________LLH-<
M.AT"        >_______________________Q6TI                0/__
M__________________^#&P                  !\O_________________
M_Y(                      )C__________________Z0
M         &K__________________]T                      $'_____
M______________\.                     !W___________________\Y
M                      #H__________________]@
M      #.__________________^%                      "W________
M__________^H                      "C___________________+
M                  "0___________________O%@
M  !]____________________/@                    !L____________
M________:0                    !:____________________F0
M              !)____________________TA8                    Y
M_____________________U@                    I________________
M_____Z(                    9______________________56
M           $______________________^[+P                  ^/__
M____________________JRD                 S___________________
M_____\E'      <3("X^4FB$[?__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________35R?__
M__________________________K2L))W74(H#   2O__________________
M_____\5]11<             $=C____________________$4
M         )___________________Z(,                     &C_____
M_____________Y0                      #;__________________]H
M                      ?L__________________\5
M      #$__________________](                      "B________
M__________]U                      "#__________________^=
M                  !I___________________#
M  !2___________________G#P                     ^____________
M________,P                     K____________________6
M               8____________________@0                     %
M____________________K                       ________________
M____WB(                     \O___________________UP
M            W____________________Y\                     S/__
M_________________^A*                    M___________________
M__^@%@                  G/______________________>@(
M        =________________________WH+               %3/______
M__________________^B5VAT@(V<J[S0Y___________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______MX___________________________TJ-Z6#HI(QP6#@8  )______
M________________K%(.                 &G__________________^1#
M                     #3__________________WD
M      #C_________________\T                       "R________
M__________\3                      "%__________________]/
M                  !=__________________^#
M   Z__________________^R                       <____________
M_______; P                     "____________________*@
M                ^___________________3P
MY___________________=                       U/______________
M____FP                      P/__________________Q <
M            K?__________________\#,                     FO__
M_________________V<                     AO__________________
M_Z,                     <O___________________^-$
M        7/____________________^1!@                  0?______
M_______________K7P                  '?______________________
MRDL                  /_______________________\M7   ,&"0Q/TY@
M=(NGQ___________________________U^?R________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z]3-Q\*^NK>S
ML*VIJ*7____________________=?E,_,",9$0D"          #;________
M_________W8                       "G_________________[H
M                  !U__________________\'
M  !&__________________].                       :____________
M______^,                        _?_________________!
M                V__________________Q&0
MOO__________________1                       I/______________
M____:P                      C?__________________D0
M            >?__________________MP                      9O__
M________________WB$                     4___________________
M_TH                     /____________________W<
M        *____________________ZP*                    %O______
M_____________^=%                     /____________________^*
M                     /_____________________630
M     /W_____________________IRX                  -7_________
M_____________Y@J           &&"U%8.#_______________________^H
M8W2!CYRKN\WB^O______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________Y\NWJ9V5CHF$@'QX='!L
M:&60_________________[QJ2"T9"@                 Q____________
M______\                        #__________________]"
M                W/________________^.
MLO_________________.                        C?______________
M____*0                      :___________________6@
M            3O__________________A@                      -/__
M________________K@                      'O__________________
MU!<                     "O__________________^CT
M         /___________________V4                      /______
M_____________XX                      /___________________[P9
M                     .____________________%.
M     -C___________________^+                     +__________
M___________,0P                   *'_____________________D1D
M                 'K_____________________\G0*
M$5_______________________^AT$Q\L.$538G*%F[32]?______________
M____________U^CT____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___[]_/Q[NSKZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@C
MQ/________________]+)0L                     DO______________
M__^(                        9O_________________7
M            /?__________________,P                      &/__
M________________;                        /__________________
MG0                       /__________________R0P
M         /;_________________\34                      -______
M_____________UL                      ,O__________________X(
M                     +?__________________ZD&
M     */__________________],O                     (W_________
M__________]>                     '?___________________^3!P
M                 %[____________________-0P
M $#_____________________AQ                   !S_____________
M________V%X                   #______________________[].
M   .'"P^4FJ&I<C________________________"?(R:I[;%UNC]________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________NX=?/R<.^
MNK:QK:FGIJ:GKO________________^^AFU;3$ W+R@B'!80"P0     %/__
M_______________7!0                       /__________________
M-                        /;_________________=@
M         -+_________________L                        ++_____
M____________X20                      );__________________U$
M                     'S__________________WD
M     &;__________________Z                       %'_________
M_________\<C                     #S__________________^Y+
M                 "?___________________]T
M !#___________________^C%@                    #_____________
M_______83                     #_____________________B \
M              #_____________________RU,                   #_
M_____________________Z4X           )'31.:XS_________________
M______^9.4-17VY]CJ"UR^7_____________________________Z_G_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Z\RYK*&9D8N&@7QX
M='!K:&9F:/'_________________844R(Q@.!@               )[_____
M____________?@                       '7_________________PP
M                     %+_________________^S<
M     #+__________________VH                      !;_________
M_________Y8                       #__________________[\;
M                  #__________________^9"
M  #___________________]I                      #_____________
M______^0 @                    #___________________^Y+
M              #T___________________H7                     #9
M____________________D1@                   "\________________
M____RE,                   "=_____________________Y@N
M     ! I1F;$_____________________^Y_'0P:*#=&5VE^E:_,[O______
M___________________GH*JYR-CI_/______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__WU\.OFXM_;V-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ
M-C(O+C'_________________TB41 P                    #_________
M_________T(                       #__________________WT
M                  #__________________[ +
M  #V_________________]TY                      #<____________
M______]B                      #%__________________^)
M              "O__________________^O(@                    "9
M___________________62                     ""________________
M____<@                    !I____________________H2@
M          !.____________________TUP                    S____
M_________________Y8N               5,E)W____________________
M_^!R$P   0\?+T)8<(NHR.S________________________*;VY^CIZPP]CO
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________G@TLC
MNK6PK*BEHI^=FYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$
M  #4_________________Y(                       "M____________
M_____\P>                      "+__________________M2
M              !M__________________^                       !1
M__________________^I&P                     Z________________
M___00@                     C___________________U:
M           ,____________________CQ0                     ____
M________________N#X                     ____________________
MY6T#                    _____________________Y\W
M   0+U!T_____________________]UR%      &%RI!6G64MMK_________
M______________^\6$149'6&FJ_(X_______________________________
MTLWA\?______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________/OZ^_W______________________^ZYJ)V6CXJ&
M@G][>'9T<G-U>'^0_________________^M/.C H(1L5$ L' @         C
M__________________]I                        ________________
M__^;"@                      ___________________(.0
M            ___________________P8P                      ____
M________________B@X                     ____________________
ML#0                     ____________________U5L
M        _____________________X4:                   #[/______
M_____________[%)               8.5V!_____________________^5[
M'@      #"$X4F^/L]G_______________________^[6"DY25IL@)>PS>W_
M____________________________LYZTQ=?K________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____^N_GX=S9UM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>
M6UE85U=97F5Q__________________^_,1\6$ H%                ____
M_______________M5@                      Z/__________________
M@@0                     S/__________________JR\
M        L___________________TE<                     F_______
M____________]WP0                    A?___________________Z(W
M                  4KE/___________________\MA @            PL
M4':>T?____________________6-,       #2,[5W:9ON7_____________
M___________#8Q@J.TQ?=(VGQN?_____________________________J'^6
MJ+O0Y_____________________________________W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MW<[%O[RYMK2SL;*RM;G R=7C____________________EVQD7EE544],2DA'
M1DA+4%EFH?__________________IR8.!P(                 5O______
M____________SE                      .O__________________]'D+
M                    (?___________________Y\R
M    #O___________________\18                "#%:A/__________
M_________^E_'P          !B=+<9K"Z?____________________^G20
M   "%R]*:(JNU?S________________________3=1XF.$I>=8^KR^______
M________________________KG*%F*S"V_;_________________________
M_________]_O________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________[^R
MJJ:CH:"?GZ&CIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'
M3EEI??___________________YXN!@                   /__________
M_________\-6                   50?___________________^=[&@
M           )-&"+M/____________________^?/P         $)4IQF<+K
M_______________________&9@\    3*D1B@Z?-]?__________________
M_______KCC4K/E%H@9V\WO______________________________OG9_E*G!
MW/G__________________________________]+8\___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________]O+P[^_O\?/X_?____________________________BPGYJ7
MEI:6F)N?I*RVPM'A[O____________________Z.4$I'141$1$5&1TM16FB#
MJ?____________________^F00$           <V8X^ZX?______________
M_______&90H       0G3'.<Q.S________________________EB"\  !,J
M1&*"ILST____________________________JU V2F%[EK36^O__________
M____________________TH=\F+'+Z?______________________________
M_____]3.[?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________[>7CX^3FZ.WQ^?_____________________________]L922DI69
MG:.ILKS0[?__________________________G5-'24U15F!SBJ_6_/______
M____________________LE8 &C50;8NNTO?_________________________
M____S6\^7WN9M]?Y________________________________[I^#IL+A____
M_________________________________^/.Z_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________P
M
M
M                    ________________________________________
M____________________________________________________________
M____________________________________________________________
M__________\   #_[@ A061O8F4 9$     " P 0 P($"
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M-R];E_@
M
M                               "[77[W6VJT&;T]L8H\M\3)KHUCH57
M\<_& !2/)P<N-/=H_>PXJ,?]/ 6K1?V<$*K&?7\?ZX_T
M
M
M !S?'TSHQ\N\SKQZN\\GN]9JPR\QY6+N%$ !=#@[O7S7IDB\O8S1Y;X>R2BR
M_P .J/CFXP  "@^7J\VK:NPNH-.TB@%36![=+[@
M
M                                                     !6="JC?
M/KLS$;[]=&8[)6U<\ %*5BG(DNYS6RTS9SXM@  KKB[/#M[CT]IO=!&[A4O6
M_%V>$   Z?[\_P!U85V%5#HHE-LZMM+V.CV0
M
M                                                #<A@[E"E*ZBM
MA*_-NYB   *=J?10%?1MIM8VW2@@   N;P=S@D 1.Z5&[/Z',_     HSDZ_
M+H0E=L*PU+2""U'_
M
M                            !7% JR6/IMV/-S^"N4X     BQ[>=>:/
M[LBPP    !M)H4TI^1!$+L474?QR\8   &M2M0_W8Y,QM+6]*<G!R
M
M
M  &0-MIHFCZ)=J+-:P]U@     $8C;)@$CL;-\(0    !EW3Z]YLH.#7GH&Y
MW#W.N   !BAWZ'Z,7*<V7K^U_/TNP
M
M                                    !DI:R=INV@O;*R4M7.P
M'6Y>-!"]#FG]A/?JU      #(_IU?HRIH'>RWUU^#O=8   #&CNT?OQ3YY9&
MX5NN;J<X
M
M              7C@\H3E?/UMP936AN&      ZO-QHNVV[7TCZ;)\+0
M  !E!T:UT)6<#O=;RN>+L\(   &$E3CGJQ7YW92X/G?OQ^@
M
M                                                   #U>GV4V_0
M?MA;&L8+X@    "W,HH;4)FKC.T'[&,-V"60UH         9XTJ3>1*-@UZ;
M?][\^OX   !H]D]MZLT:RBVU6
M
M                              $FC5'GPD;:P,XP   'Y_36YE)8EHBV
M&X@-1>:>-*EZM3P          ;H(W<*E]]D4N?1X   'C?7'^X>UQ+!W+LKV
M:=V@
M
M       ,Y<?KN)U/GNV\O0ZW,  #@Y/EI^S9QD1R]G^#C!V_]I
M   <C]2C(->B@,_*3*/&    T<R>V]6:.91;:K
M
M                                         #^_A. T#;:6QW%Z^0
M-=>3=D$6';WKR8)Y"V@              !>'K=_K2\[?7YMM7'%V>$   U>U
MR&>_&UF=H:Y
M
M              -GN)F0";#H7VM@ *+KM*1>=MNOQHAV'8?.'[^0
M       &V:@3FG)$T/NQ10  !HZD]MZLT<2BVU6
M
M                                          $T+11M/;7,.\C !B1>
M>VJ&MO)U=,0;UVS                 '*_4H&#WFH#8-2)5XP %N^;J<\1"
MX-A[D6F['1[(          !=>'2-E?9RXRZ$2D#GX_M1];IBPMQ8<Q=NY;YY
MW9X
M                                                 %ZX%*WT)/-5
MNJ=_K<P-=63ED$,/>GJR6REE                   !4'QR_C?1%;G4AM=H
M$XIVHOCE_&%=3COJ1[)=:NM,7^]1>^         !W.#E;Q]?V6[?;KIS&9M6
M$NPY/G]  !HRV"8C(EVY?6Z
M
M         WD:_<N$M;3-LC!KQR9LDA1[Y=4RBZ[2@
M =O\^OYZ/Y]?GP_KC_8          5)2^\F6Z--H[:;B'D,    "/YLCPP19
M-O&O,                  %:\78XLTJ;(O+R>Z-9\^[?7[_ %O<^>7\^)]<
M7ZM=S]+L8Z=VD][#2HQ[T[2]CH]D
M                                                )=FEG9:W98%9
M7,8[L0!!5]".H9:>91P         !N(PBR>2>=3.?P  */K=,0+O11IV
M              !*2U&;"4@S6OFD     (W>TC!9&EVIX&@
M   #.&ER3R=RT<N#3&P*D2GQO3_/O\@   ?D8@5&@>GJ0D$%J/5K7(54'F_7
MQ^@
M                     GD^=S<,S"LE<Y!L] FH]@/D99L          &\3
M #+9+:TQ[)0  417Z2^<QZ?-'0                 "Z\.D;Z$OFHW5JBIG
M=     $7K;9K\1YME^$X               "X'#VN&1#$+KT5LKHLP\(
M   #'/N4GO1SIC:6ML,*E'O4
M                                          ^C#YAMX;1?L&Q$1;MN
M>O<           ;Q, ,MDMK3'LE  !1%?I+YS'I\T=
M-S.#&4B8+I+V;@  #^#':YT(6_DE%9(6NG2+EMPU\-%&PK$(
M   7?Z_?ZTJ:"7MM[D/TZKT@        "C.3K\L.FXM@;FV\YNIS
M
M        !ZW3[+Z)/F3W<OGY^DG2^M9+XZ           -XF &6R6UICV2@
M HBOTE\YCT^:.@                 $F?5)GND;ZO\ .0  %)5FFH5&^/5.
MURY/V.!ZO3[*LZ%5%MY30@              >Q\\GYEB0&^-NLL.A7/.
M     //_ 'Y_48^;V;KS7G5XI[0                           &UV@SB
MG=D5%EWA@ !KCK,2]S4Y7X-40
M        %44BH)/>IG/]%<V^Z\            &\3 #+9+:TQ[)0  417Z2^
M<QZ?-'0                 "6GIGV1MY>OS+@  &D;/G$Y$:W1:U0
M           &ZJ-7$I;?%%;FT@         <;\1Q9E:6N-6-=A-0
M                    !OQBESZ/W-QNX5+@ !IKD=OJGT#RRU]8@
M                                    <OQ],X+ W:8-9 VC
M    ;Q, ,MDMK3'LE  !1%?I+YS'I\T=                  )?.E'9DW2X
M)94@  C';8,!$=+9W@^                 ._\ GU_)E=N,@K872X.[UP
M"U_/TNQJKKL)J'#FI1_TZ,Y.ORW<Z_?ZV<5,DGD[,J),?!JWCY^,-!<KM?6.
MF>26^J<                             WXQ2Y]'[FXW<*EP  TUR.WU3
MZ!Y9:^L0                                       ,HNC6O/NKU^[P
M=3]_'9?O\P/JL9]CB?@ #*3HUKS\A>G5>ECYW*7W<6>]1/0         -XF
M&6R6UICV2@  HBOTE\YCT^:.@                 $O[2?LT;H,%,IP  1<
M-N6O='PV4X6                 #-.FR+RI7,"O?;P   PKJ4=]6+].+,U]
M1'+UN4  +E\'<X)',.NW1&,'>HW?T-2JV-7@
M     ;\8I<^C]S<;N%2X  ::Y';ZI] \LM?6(
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MCX;*<+                 !N[C%QZ4WHQ>Y5)   $-VXV/]SK*]FG=H
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MU@YQ   U-9E8X(MFW37L#='&KATOOIBMSJ/   -"LKMC6&EV26\J@
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M_K\J\6]FMN+L\4U:VN1%K    (3MR\=;J4KR<'(       ;Q, ,MDMK3'LE
M !1%?I+YS'I\T= "X,:K3Z+OF)W@@  P/R(L^B:[D];Z:WH:VM+OPF3
MQ&O1;5!_W]:EUFIS%@3$=(FSMN-P?R@        417Z2^<QZ?-'3=!@IE.E_
M:3]F@  -9V5EA4)+??J>   $@_6MFFE'ZC=A   -+^=>+"(#NPUE@V04:7>'
M)LA-XZ#   .G^_/]TC2:W-5Z8Y);VJ*4Y.#D      V:T28^#)7A=X*%   (
MC=P+$W(Q7[]$]    #8W1I;XDG&$WDH(  +#]JF=R'A<6P5S.)^,TJ;(?+DN
M0J\-"7>Z_?ZP     %)\G!R1]);:NL]55>A-0[CHY<"F-_T3NC1P
M6JY^EV(9%R,>[H  !GQ291X\B"(76HJ^G5J?4      L-VJ9W(R\VLY7F*G?
MHGH  !*&@UYZ V#4F5>,  $1&X-A[D[^HG=&CL]*5)_'    #&_N4CO14YY9
M*X5NN;J<\E2%W?H79;19AX0    >5]?'ZC/36SM=ZZ:Q$_;#)[HUGH78Z_>Z
MW6_?S^\C]8)56,^OQOQZ/S]_F;I;+(VU7._?X   1![A6&N5C7W:/W@
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MB-4*%Z6\:,7(I,     "C>3K\L/^X=A+E6E['1[(    3%;=7^MG??JU/I@
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MDMY5       !O$P RV2VM,>R4  %$5^DOG,>GS1T +@QJM/HN^8G>"
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M8.]1N^$H:#7GH#8-295XP  >#]<7[B W#L+<JQ_:IO;  DG0N[U#;/J),_
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M,-NY0X  ?P0T+CX^W/M'V.AV0  F(6[O[;._G4JG3  "+M.++U_K\J\6]D
M  +^=2J=.7_;R_5M?1_/O\@ !'JEUJJTU$2&!U(      &\3 #+9+:TQ[)0
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M55HCE5LZN"4-!KST!L&I,J\8  -$<IMG5VD^36ZJH  ,\:5)O(E-P6]=O@
MM1S]'L0RKD8^70   ):$ OG;K+RGU[S   C#S>S5>ZZZQ$_;     )!<1NI1
MFX&/3VF@  P:JD:]:*Q.[)W"      #>)@!ELEM:8]DH  *(K])?.8]/FCH
M7!C5:?1=\Q.\$   ?.>]/&CU04CHP  ,O;*7,3X?.?N/  !;^245\Z'T[Z/@
M  2_M)^S1N@P4RG  !%PVY:]T?#93A8  #=!@IE.E_:3]F@  -9V5EA4)+??
MJ>   $@_6MFFE'ZC=A   -+^=>+"(#NPUE@       .1^MI-"FE/R&8A=:BZ
MF^.;C   (B=P;#W)Q?[U&[X<_P"?O\F!6\OW;7(/J57I  !&#F]F:^UWUB*>
MU[OQR?B9_;?(6U]8<?8X@ ,(ZG'/5BGSRR-PP -W,9N-2F].+7+I(
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M<T\  "B>3K\L,RY&/=T*<^^+]@  &1/3JW2V[1Z>4WL=H\M\.^'5J74
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M0  :7\Z\6$0'=AK+  !M&H<TI^_'4J?4T@R>W%5@   !DMTJQT)>UO;\VV
M (H$]L?<3#*I1[U  -_D3NC1VY".7 I@  -'$GMM5FY>.7!IBL./L<0 &HJ0
M02I(]$OM36@     %\.K4NIF33I!YF:%-D/E[#*/*_%OOU:GTP  #%_O4;T(
MB=P;#W(  WXQ2Y]'[FXW<*EP  U"2&!U+'NEUJJS   -F5$F/@R6H7>"A0
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M2GQI/$(O+07I?GW^=3=?@U1Z$)7;"L*&Y>MR@ !7'%V>*3O"+RT#F[3)'Y0
M =;]_/["RN3CQ=*B>7K<H %^NI4^G,)MW?VVG9?O\  \O]^/UZGY]_D  (E,
M_L7<;$FH4+T@   ,A.G5>E8WM4WM^;]?'Z  YOS]_F\J+W)I/=Y&;CTH  %&
M\G7Y84MR\=KI@ ;\8I<^C]S<;N%2X  8'U6,^O%CG5E+@@  %P^'M\,S>V^0
M=K_2_/O\@ >']<?[B!W#L)<JQ?:IO;   .Y^?7\W"QV?4SJ1D$$J2G/OB_8
M !*&@UYZ V#4F5>,  $=:86GK;4Y7X-40  9QTN2>3*I@E[;>@ !CEW*3WH@
M%P["7*   )9L OG;K+^GU[S   C$3>S5>ZZJQ$_;       .[^?7\D:PZ[5$
M;2J%-:? .,19IU92X."%5C/K@   !O$P RV2VM,>R4  %$5^DOG,>GS1T +@
MQJM/HN^8G>"   /G'^H'1LI&M4T  &7-E[E)\OG,W(@  M_)**^=#Z=]'P
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M7MMZ  &.7<I/>B 7#L)<H   EFP"^=NLOZ?7O,  ",1-[-5[KJK$3]L
M  #E?K>5%[DTENXC%QJ5Y7[_  +2=CH]F)//[%7&M-V.CV0   -XF &6R6UI
MCV2@  HBOTE\YCT^:.@!<&-5I]%WS$[P0  !\X_U Z-E(UJF@  RYLO<I/E\
MYFY$  %OY)17SH?3OH^  !+^TG[-&Z#!3*<  $7#;EKW1\-E.%@  /[^'T)O
M-1NL7WMY+P          :7\Z\6$0'=AK+!DCTJOT96\#O?;RXG#V^
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MV^4O1K7G@   >!]<7[AG7(Q]N?0?+U>8  *IX^;CE202]MO<OZ?7O-
M  ".O,+3UMJ;K\&J( #-.FR+RY7,"O?;L     "U7/TNQ#(N1CW=  VT4"<T
MY(DA]V**          CQR^U-:ZCY!!*C )0T&O/0&P:DRKQ@  CK3"T];:G*
M_!JB  #..ER3R95,$O;;T  ,<NY2>]$ N'82Y0  !+-@%\[=9?T^O>8  $8B
M;V:KW756(G[8         %5\?/Q[HXW<.EMQL<G],UCQ]CBQ(J%"]*+[.+,5
M]:SGZ78  #>)@!ELEM:8]DH  *(K])?.8]/FCH 7!C5:?1=\Q.\$   ?./\
M4#HV4C6J:  #+FR]RD^7SF;D0  6_DE%?.A].^CX  $O[2?LT;H,%,IP  1<
M-N6O='PV4X6   #)^TMP$]?SJ;BU44FH      -9.5]@FS;%"_H  -+^=>+"
M(#NPUEKC</;X),\)O%0F;],DGD@         8CU"A>E%CG5E+@4/R];F
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M(J&/G+;65G2O)P<@    ![WQR_B9);G("V-RN'N<   !%8G=D[A8-52->L
M 7RZM2ZDD:&7=H?-2FR+R@      #6G6H?[L<V8VEK>D>3@Y   "_/4J?3E3
MP2]MOKV=:H]0    +5<_2[$,BY&/=T   S_I,I\:0]#[K47>_K5+J      4
MW]\/)HWE%MJLTRR.WU3\/[^?T "4-!KST!L&I,J\8  (ZTPM/6VIROP:H@
MSCI<D\F53!+VV]  #'+N4GO1 +AV$N4   2S8!?.W67]/KWF  !&(F]FJ]UU
M5B)^V             7 X>UPY?T^O^;BUWJ)Z%I>QT>P ;B,(LGDGG4SG\
M"CZW3$"[T4:=@!7$?JR>3YW-PP   @3>BS3FI>KT\  &4%I+@)L.A?:X  "A
MY!2$#;T1Z>@  2F=1&PMMHPSR1  !''V@X--&VP+$@    &Q3&.]Z39JASY;
M&<8;XN7X^@ %@;CPU'9V;X0M"&Q?#AF-8^Z"9AHRVD   U+YF8W(LVW?7H
MNOU^]U]PD>GU,[3*%-:?O+UJAU0    \+ZX_WKLK$3]O3/)+>U/AW4:!Z8
M    !O5BURZ2W;QFXU*  !C_ -NE]V'O<2P=R^-^    .0;$J/+/$VR4"<T[
MG=2I-Y%2?'-Q@  %$\O7Y=?]6BWLZBY! ZDP=JD;]8     N!P]KAW<QFX]*
M;4*%-:?N'P]O@   ,3^_0_1B1W L5<<   ]OYY/QM-H,VI_:G0IM3V8].K_F
M=K\^OX  %E.S3NWJ_KD,][3U(H#4UH^QT.R   2,8==JB<XZ7)/)  #0_*K9
M5?K+K<.]T  ,Q:=7_,DGPN[]#  !83MTSN19IU92X   !)NA%XZ#RFZ-;\\
M ([<PM/6N!]5C/K@
M       7G@LJ9IV(NHN["I*\[M<+%V[=OF$U^[3NIS<8         _8R;Z-9
MZ&7-/KWFWZZE3Z=?\7;X>[^?O\I7[X>2SG9I_9Q?[U%]##6I1_TZ9^^'D
M     #=;&KBTMO?BMS*0  #1#*;9U=I1DUNJJ      #TOG[_.1O3JW2O;UJ
MEU*QXN?BZ_[^?VA.7K<UC>U3>W8#MTKN=;]_/Z       !V_SZ_F2G2J_1OK
MU:GTZJX^?CZ?[\_VWW-U.?'ON4KN62[-.[8     %8<?8XLG.C6>A=SK][K>
MK\\GYH?EZW-CIW*1W;#=NF=S^
M
M             #F_/U,(MY?RV=_NI5.F !T?WY_L-RXV/USK2=CH]D
M
M
M                   V)4>6>+)ZA%Y:!  #756(G[<8B;V:KT
M
M
M               NUU^]UI6T#O?;R_G4JG3  ",--[-5[KLK$3]L
M
M
M              -[\5N92/;_ #Z_GJ?/W^;K<'>Z^P*D2GQ:VX^SQ  !9OLT
M_M0X[BV N;T_WY_H
M
M                                      3=[8Y'6I]7\^_R     :&)
M5;&K]+4EMY5(
M
M                                  !-WMCD=:GU?S[_ "    %GNQT.
MU#]N'82Y5+<G!R
M
M                                     $W>V.1UJ?5_/O\ (   'C?7
M'^HN4YLO<#!FJ1KU@
M
M                                        )N]L<CK4^K^??Y   ,8N
M]1N_'AE]J:UPNJ4=]0
M
M                                          )"T0NK1?=_/K^!^!2O
M)P<MD>U3NUAI48]ZF(M1H/I?@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  '+\?3*RSUQ57T6IL8;LP!;V2T0   !^OS]71B,@4E6J:IFJ]    >]3NXK
M6@U4  %LY707!R?  K"B5-4=+[P #B^_E;&64          <OQ],K+/7%5?1
M:FQANS %O9+1   >GU.PN!&ZRH:04AXO?ZH "XL8K;K<OPH.14<   !<B+5U
MY7<ZRC*[2P  !Z/5YUPHU6@!U^7X6XE%#<?U\@  NG$)"   */K=,4Y5.B
M    #T.MS+AQFM@  "WTEHKS>UP "O8Y6'K=/L@"CJY3%.U/H@  "Y\2K[H]
MCB6^DM%!R_'TN=$Z^\.H=11%?I(  *DI?>9:69N2\KN==BI>"W3Q^]U0 %84
M2IJCI?>  !T>QQ+=2>A@#M</(N3%JZ  "C:[2U/5+I #F^/I<V)U\'Y_?Q0<
MBI#RNYU@  !=N&21<Z)R!:>8QQ;^245=&(R%9V<1<
M   &3=J)\F<Z+=IC,JQMT0>?V>%JGS"QT0[=W>L13=5Z   -FF*-_$VK0EM?
M:D\S<;4,W>=JV   &ZG _*M+UTJ;,   ?/'],6DU9F<Q8 2K-/NQ-ORUS9D
M +:RJA/G5^G'2"        #)NT\^3.=%VTQF58VZ(//[/"U39A8Z(=V[S6&I
MNJ=$ ;,L4K]IMFA'; TSYS8MH?.[760 ,UK#763LO/3M\:[\FK)(0^_74T
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M*]&NT9@!DA9EU^7C4]4^DWKZ],O4"CT5Z='X^OP
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M7J4                      F/Z/-H+;WA3DRBE[A]=#3MF[C"M%-8T
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MQV[UIRS@Q?0[MW>L0 !(.UK9J)0FI38$[G!RJ.KE+:5<\,547C;;KZ4'(J.
M #8MC%>].(T [;$9[:Q@4CA;0\&0  9*6LG;Z!7FWW0   ^=IZ;-(JUDOCP
MNG$)"^B7YD]W32_G7BPB [L-98 ^B/YE=W#&ZZ4%02?0QJ!
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MZ4=F;='@EE0^?SZ1=,+&>ZT" $B_6'G"DWZH,^@  8\W,A+Y_GI#TQ/*[G7
M&ZG _*M+UTJ;,$1/=-K3:3<]<4    $JS3[L3;\M<V9" AZ.--3%"\=N0  !
M5E&J2HJ9W5L990     !5]$J;8MC'?!J\RVQ]?G]_$OS2ALS;HL$\J'S]_2-
MI@8TW5@8 E4Z?MB3?KKES)0+O1/IV4O5Z>GG>=G<0TEY[8H(H&XW7(F2Z.-H
MC;SA7DN^=EZ;=(BUTNCX V[X5Y+ID^CC:(  "G*IT7S[O27I=65GD4 &>&.]
MX4Z[SV;>D<O9]@ZC*[7<!DP[2-LZ;C<'LH$(;?MJ9:W<I+%@  "7]I/V:-T&
M"F4[YWWIGTDK132- "N(_5G9XN1;Z2T4      $^_P X^Y5[=/[;Y^OI(TO@
M  ";+H5VNMF&*=^GS:O4MHH9TX^7>3K_ #U;>VK'+W'E"UWMZK   3Y/.;N0
M7RM_+D!ST8Z;UC+@Q%MUPMR63*=&VT5']V188HL>WG7D  S(L==!XO?ZK%&\
M5N7I=7G?0N\T>Z]9V;Q= A]%^G$  &Q;&*]Z<1H!VV(SVUC I'"VAX,@  R4
MM9.WT"O-ON@:*-A6(2)QN1UP@   +IQ"0OHE^9/=TTOYUXL(@.[#66O)!Y0D
MQ:IL]F]C7KEZB^;:]?J/)LPPF!>&$2=;:4T)X_>ZH
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MP\LK -".Q?#EY/<ZP  ,J;/W$2*-9&;S49FEC2U0YBXY@  NU#)(D[ZF\_@
M :D<S\;&IS,C'  5G0JHE/:A=AP/Q]?*U4PCK6;E981J\RWQ^<?U\@KF/U=+
MFTN;*FJ',;')H^S]Q+
M
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M?(K!3Y:3(L$'!4C9#:$*EAJNP$==@(Z[ 1UN#A! WSAVWRY<9H=@(Z[ 1UV
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M*F4G 'VH,2@6B)<[QA;W[2%9[MA3OWT2KWA"A=W\R<I5254FHM/C_K22?D=
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M4L2+0/6BH-Y8BUTT9&\'Y530QM;?=,YWZAN38.TUV9/+;?11]72Q7O-:4OK
MB[J@U[CPYE>FK6VI^RAOIT2UC_8I0OZZ/XV73K^-ETZ_C9=.FVE5H3=XW!\
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M45WR>=+YN7['AOU)A7^XO;,/Z?RVMAS3,55*/M=%%0E:<2H3R,1U1))P1U_
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M&_4F%?[BXMOQ%'>+)='8)ERWKNBZQ15-2&K0KCOUM"V=RG^-GHLJTB2E:#5
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M->*2>U35373RUE(+K),T6&)F." HS2U24Y3E!.4IR62$TQ3X@A5CC%"]!0K
MI':$\@()6*)IA3E\5A6$ZE53CI$TGC\VW_[:&X'[6(B5J.G PZ @X'$HS3$G
M_<;./5'$:%PE.Q+7!F=PPCC!EP592&5CT#)4JCB;$]EJL&F!$4:TM2E.4Y0N
MD/W:_P AC*7OR42N4["I\O#?J3"O]Q<6WXBBRO<PBU=*'$1>K3;F0O\  [2P
MX<0>E<.:'B*'$'JI#DWT3BPO\10Y?=*^025%!.J(OTS1HDZ44]J4Y52Y+Z2I
M5!\6DI?$$B%^I_XT<681[6L0OQ0_(#P98\@5V(T3*G0SC%3!IF6(JA:,H*P4
MU.4Y3Y-O_P!M#<#]K$R"LAUF%XIRDI@_*;@U\IN#7RFX-?*;@U\IN#7RFX-?
M*;@TS4M13*(7X!^13X,SN&%[')ET>%BCS#5X?]:5#DSZA"B#3,)$+SE^"_R$
M91K2E$,2@4.%^$O='N7AOU)A7^XN+;\11734:E6Y,./QRHC>.%U4_G;$.(/2
MN'-#Q%#B#U4AR;Z)Q87^(H<ONE?+)J:@GS(/PT'I-7TM4Y!\I0>)5TU45<&>
MI=A5H50C2HI]=%0=?!CD>SI4$YRE)<4)J:IP)F:R9LN.&9 Y)E/(G9'6.E&-
M*315T^7^H[?_ +:&X'[6*WX/_A['<$/\0N#,[AAN +.8L+/J_!P0J8LP4V)L
M3_%!A>O?O)9"Q[\O"["';D;EX;]285_N+BV_$43B%F,X(;,U3HNO"Y/#L.(/
M2N'-#Q%#B#U4AR;Z)Q87^(H<ONE?-E.<IHCR-DJBY@$V#$X@)%EOA*<Z9HBC
M)43(7BG]B5] A5CC%"]!0K ZE#X>CP,M>IHES%ELIZO2II9M),PV_P#VT-P/
MVL3!I_!,]C?TO_\ .X,SN&%_3_\ ].%H>(H5[N6)K]PPO7OWDDS8Q$TFJ "F
M3@G*54EDA-,4N5AOU)A7^XN+;\11+7?$-F^JT+D\.PX@]*X<T/$4.(/52')>
MF=5DHL+0YS6H<ONE?/9BQ64/1/.B5*_Q8JE[HU"\T_MB1IF$>UK$+X4.TJ4$
MISE-OO*F=-%= E/+5DHLKDSA08B:@M_^VAN!^UB8-7XIGL;^[LX,SN&%^]ZP
MM#Q%"O=RQ-?N&%Z]^\IK+LTDW*<JI0/I,]Z7Y6&_4F%?[BXMOQ%$M=\0V;ZK
M0N3P[#B#TKAS0\10XAU?ENK#?TG4>L]%A:GU!I4.7W2OGE!*@C43UG^*[Q*F
M1"9DH:#.E8!**!:%(E6G'V.1[.E0'#(9(J8'$,CQ)JVI)4R#\*B2*+"6>Y;\
M3I3H@M_^VAN!^UBM^+_X0C&2Y?7Q%/U\13]?$4_7Q%/U\13]?$4_7Q%/U\13
M]?$4_7Q%/U\13]?$4_7Q%/T^314=.X,SN&%^]ZPM#Q%"O=RQ-?N&%Z]^\MG.
M+\90&  C0"D1%33W)PWZDPK_ '%Q;?B*):[XALWU6A<GAV'$'I7#FAXBAQ/'
M]U=Z%U(\G"V!0A !8<9&R(W+20Y?=*X6JVYJ0CK;$_QY" 1K4%:)U"^^7X&(
MI>\+PO9)K%-E"]!0K ^U#W)+E%EA4)Z+/A8!T5?Q*O1%93%*-Q%Y&D2"W_[:
M%_43FGQ,@U(!9A?!&9E*]@9G<,+][UA:'B*%>[EB:_<,+U[]Y<ISE-K.62C1
M ]$;MA3DX;]285_N+BV_$42UWQ#9OJM"Y/#L.(/2N'-#Q%#C>=[#>>+)6WAA
MEW"@M-;E0N:\2I4N1*PY?=*X&TW1%@<,,,(/2\S@3LS9,T1%A*$S)X=N( :(
M7AJJIHI.&)FC<",H5):E35373!6&&)$Y%#XDKQI2,>6*Q ZPJX)3G3-IN8P.
M/";IE64@M_\ MH7>4J-H<1 U41.AB4"AP# AF 5=,&23T5%%0E4V*/-,' &+
M"Q,SN&%^]ZPM#Q%"O=RQ-?N&%Z]^\RBNL.MM.FA1IXSE*<G.B32#O(PWZDPK
M_<7%M^(HEKOB&S?5:%R>'8<0>E<.:'B*&W"M)"?\3X8[?N$WW]C'<9HF3J,L
M)HB>W7 K",;%VY#I'M[;ILVT0XLONE?%OH0RT9+EP2@'$T3*G0CK#("S'8RP
M'.;/<,I@LA<$F28(%$R2>23@HG6?D118F:I=N2N2XE#X:D1I*495S:<G%DLH
MXFP$KTFBADD- VBPIE;A4!)!$(+?S_\ GAJIIKI<#8-)8W$JG'3LN#+4Y'$V
M%=0P%LJ?3C:88@ +C&A6VUJ$O@KH9%9"5T,\C"PLSN&%^]ZPM#Q%"O=RQ-?N
M&%Z]^\V4YRFWGC*<I3E5+@I)Y=4)J2>82S<>&_4F%?[BXMOQ%$M=\0V;ZK0N
M3P[#B#TKAS0\10RG.4[?N*EVLCV'+[I7P1D<PLFR)(LG%O87BJR/J4344OAR
MOR7VH>].1$")E2-(Z061BG \FDE((ZP0ZIB,E<HG2RUZJ95@FZII:,11PH78
M;D40X+?C2D/&81$@U/Y4;_X@H"*!-1IIH3.",IB)"@",$8!A.$2B@">8(-4Q
M&2N43H92[7,FP*OQ3TE/2P^(X )D)>9PQ2%F=PPOWO6%H>(H5[N6)K]PPO7O
MWGH;H.)$TY5(JH/!>0P%HJ;*&")B+#?J3"O]Q<6WXBB6N^(;-]5H7)X=AQ!Z
M5PYH>(HL/GI0HM;V'+[I7I,33*J;2TPLDE/874NR2BG^^0WE+XHE1CC!EP3I
MH0Z;A+EQC8Z A HI7G/A4D9.P-8[(BM\I3[MXM%Q2(U^P/<))",\69W#"_>]
M86AXBA7NY8FOW#"]>_?8"YDP4&27U*>BQLL<"TN()5: 4$\VF&(<-^I,*_W%
MQ;?B*):[XALWU6A<GAV'$'I7#FAXBBM>^S=N'JE*B>N)G*>5V RMUH<ONE>B
M1XTG&$)R%%FCV!=7BR*7.&S!XQR&.I=G/QO=0[,F1,Q-(@D><Y%X-&*UUU"5
M02G.4VXKTJZ=R5/NV!LNR0$I3E5+FN-T I= @@@PG%F=PPOWO6%H>(H5[N6)
MK]PPO7OWV(J<-$A$]]FPM$G0B'M*":15RRVV3R1.##?J3"O]Q<6WXBB6N^(;
M-]5H7)X=AQ!Z5PYH>(H\>+\280Y8R7.%^1?._J7;DG8XZ<4KW0Y?=*^%%=8=
M2*]ZJ) & #07,G.4I+CR*DI&3(YL;D@C"%QD\X&H$HG6H=O68DM6.)!A&<J>
MKT\Q==I1.D9-#G!XDE5,HYM,5":L6Y"GW;"ANDXD:3E8@JA<H<P 5"7'K6+*
M<YU3@9G<,+][UA:'B*%>[EB:_<,+U[]]E+'CI.8#Q7 I'C8!ROCBDX4%MO\
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MIGR1E-/<<*B_X%]9"CS%O/CU=2FY#-T((&$'?JZ%=S'KB\+[RRXE%(M X50
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MB[%#CCFA]8B86OS*1=LS8FU]@FKRGNQ&=<EMYF[<*[9POK9SZE<Z^W1"'$_
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MO)OMT0@P.W$J&F7+F #8'-S<S[;E@D]<7%ARK''; ]($.\!Z@H=MSUI0Y?\
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M+\S?1]%L[?\ 'Q712)1_#?M^ZELX;?DIV(PSQBQH,ZWULHT5ZO."TW2O=/\
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M9_?@R29X5B]ZK$*ZQE*54M<3<G\>F=E%9)RMY6:+CX_U[DKW:7K=,4:CF?\
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MPU555U<MM&IRKY#B ]V>B; GXA?XD)10+0J)8A 3F &!RU9%Q2GJ@2@6CB9
MI,@"AU@B0MXU[XG"OF/<D(4$KV@]I2'F7(Q$$ <U30WDZF5;>3JI&6T+3(4$
M4"O1 @,?&*E02@/!S?H<XI^ZX'S=)$J()6*)!*7XZ(MX<>0*.G 2D7 ID*0)
M#2.MRB<A0A :X6X<_.'Q7^\_;2 _9SG(<1?WI.)N"_D/?XF(&&-0HH(H$^:0
M4C!"LF<!.@\7$4]T8A1#79C\+B,>].PH!7W!'3CKG20A1R]!E0@.$2YX*A"-
MS.%BP)0+C^$IZ_"6OPEK\):<TI2%A;,I3'_"6OPEK\):_"6OPEQ<!R8YN%#2
MJ0Z(59-H/ SE.4X"!F90WQ7^\XB) <^(50B)>5  (<A"X LE%OAU43E.4XI2
M_'2>WIUT@IY("7NZ/P,I1$U2HIHJ>+$4$]\5C&"I'!%#J!%A3QO<'?\ %3J2
M4.Z-H)TOJ<ITSY9 \*0'!%#'"X*13MA.&4_PTGF9&RG$2ND(,86H<: H!4:,
MTTTT4Z<LO_CA(FIDC1<P":#YKG_5A;/Z\1D:1<"NJJNJ!**2.'8UXM(N?A2Q
M^T$."_WG"&'4*(2*!DB\#A*2 -Q-Y/IKG H%9'"D2-5^=,Y#C*>[,1$1^TD_
M\6,$RIN1AM!5:,(R@7U.4Y3Y+<.SE7Q6RG93T+:-?A5Q7S'N2$+:*_FKX+X<
MQ$Z($<8O6 XS@<@7(3KT"I$!^6Y_U86S^O$X1O=D(4$T4*5_&TO7QM+U\;2]
M?&TO7QM+U\;2]?&TO2\<*'*H6T)^8GP7^\X6\!(4_"XP_P Q&(F!(L5A4 Y!
M'H4"?XIG(/E*3I6JFJBJ%MF/SEO\9')E3,C+;!KT;3#A/D%AJBQBF<JI<%TI
MVDE"3,3*FJ:I54\'$8]Z=A3BW9"? <&D<$4.L$3D@FC)?1=Q'0M%%PB9Y#G_
M %86S^O$YZ__ "]C;%?_ )\%_O.%L4?^$*[+\4N$G1(0W$L=Y0M_NWDN$C[L
M6%%,]F/_ .-SE^.E!! ,2%"$!$B2Q)BI_"<I3DH%9DS<*"9[01T)72$&,+4.
M- C%>U'X' FSJYI!7-$9E#@!T*%S_JPMG]>)RS_^OV-LS_\ JX+_ 'G"VI?_
M !PKG=<*;WA$L]YPM_NWDC@!F03940F8@E.<ID#,C93_ !Q?(TCEHD"?XIO%
MQE/S@PH!KW![2^8]R0A;I7W)2"<OQTIH,_QJIJIGRR)T4B. .&9!@<_ZL+9_
M7B<LO_L]C;7[S@O]YPMK]E"N=UPIG>$2SWG"W^[>4LIO;@)RG*<#<.?D%_QP
M>F58,3?E^";Q&"H'"'!K+C04U545%#$C19Q&/>G8  :C P0=((<1M/*'9&6T
M-3H<B<+<MMFI_F@<_P"K"V?UXG/1_P"4(8(HNNR&M=D-:[(:UV0UKLAK79#6
MNR&M=D-:[(:UV0UKLAK79#6NR&M-T 8(WP7^\X6U^RA7.ZX4SO")9[SA;_=O
M+74O\(0A*P1"AF@V7_Q%95I%*458ER5,Q25(Q(M'Y$R!R%/R"PMX[30 ,+4.
M- W"OO#'*&($S&A6Z0KT,VC%.C) X4C2A?<J$#G_ %86S.7:8G$#[PA"W3$@
MCGL"_P!YPMK]E"N=UPIG>$2SWG"W^[>7.7XZ64B96J! /^X&_P 05E2D@'55
M575I-7JR\@1P3%$(XX)8-54ZE 6&4IU3 "D"! ?*R.%)RG3."FNJB))+=E(Q
MG#Y<C335373!.4IR6T@(,.$"?Y1H'/\ JPH8T@5&(R#(P!73515 &)6$(1-T
M'2T554J92<84C88H8U$2_P!YPMK]E"N=UPIG>$2SWG"W^[>953372KHU16?&
M4_PTCJ,CQ?\ PY34@T\$44083B".,7K+N0S1H-QD*]?'4O5;A3J=&'*)5(P:
M,&JXD4MVD_$O%.SG>2E%>UGHSIP$B :-"G!DI8K(S!&",!P*PM 2?"6I_.9@
M<\O_ .R&4YTS2U<$X'Q'-%R\^#@)^X-PIJB*GC%C0!L* 04,&A66:CG BHF"
M%9%1+GZ(5_O.%M?LH5SNN%,[PB6>\X6_W;S9RE.2H@S_ !G*<I\"AH4F.4-!
M' /\,/GPB !@P*:&]A024RQ2):*=J(\EME?R 1&3(10$^>%/C\"QLP4K+N:J
M4J'"G52FX$V4AG,!*1P^9/5PH@,QE&!ST?B%&$HG@9?&E/\  134!-%9SJ-\
M% G2>*B!UA"0@&!RU9=RUTRH<*=5*IP)M,AW-+\#1TR<JXAB"!5IJ\&/"O\
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M'<-Q+#PU/A.;@N(UWRW-S"6@]K$YX,C?] \7M\15 "Z(Q6>('5SMO($GBJ=
M,D:@G57,^%16XP*]G*L=4/ :CL&O:IE6$B0=@]@Z.WEL2J5.\13/VH6*G@/=
MW\MFZ7;&^-![&H]K*L+5.\=!')^ _K-EQ[I3>PX?9P^KFGD6-!O"K$59J45%
MJS'0H)T92X3_ "@P_P"7RBJB^O \=OXT-L"D\HWFF:WH1IC=<FDZ;XU<7<1-
M1;AN:M5TZ-FVB"0@C0-HH7-!M,3IS(<>Z-W<MC>V[;4<T+M'(AX&4@T(T,IJ
MK*2K @D9+T%Z=F.WZ1Q(3%(H"18@B"K,B"@2Y107EB6B.H:6(*JO''F[$RAA
MPCN;W)D7LVI[5O2/?[.7-S*5/#^&GDS]I30C()=?"+O^N'?Y=/#EMP,&&[OC
MC&L?UE3]&N@PCQW&TJK%6K8VKC01-*AK-(I]5# =!#+)-$XV2<:Z=XC)>R G
MFXR=F" 'UL$"TCB%* E5VWH#(SMIS[;'L$F:VO+.5)H94-&CDC8,C#B(&@U!
MU$$&F6$]/+<!)+R*D\:ZHKJ(F*XC -2%$J,8ZZ3&4;UV?S<ZAAW.(ZQD9+>K
MI_>''OCA'8ZP)(6*L-T?AVLA%=T1M_UI[Q[7%J_K'N.DO2J\CL;&U7:DFE;9
M51N :RSL:*D:!G=B%168@&?HE_+PRX1@)JCR [%Y>KJ/.,IK! P_R(SM.M>>
M=E8Q+UGI'T6D8E+&\M[A ?6_+(7C8#@K9UIJJ2=9/63-;463>W&[QX>SOY&.
M0%6&L'K BF\*/MKQ<'!V,A+$=I3J(_K$EZ6=,KCFHEJL42T,]S+2JPP(2-MV
MW22$C6KR,J L/EV.O\FPV!C\DL(V)A@4Z [G1SUPR^KF8 Z2L:QQT0=:Z68Z
MP/-7,]A IW"UM'=2..,"Z2O&.M>%X+C4WI'?'X#(PS"A'8(WQOCK%4TH=:[A
MX1O'A[.0FA-0>R#O'A_#5_6%+TMZ5R5UI;VZ$<]=3TJL,0/9DD/@Q)5FW 9.
ME72V:M*K;VZ$\Q:PUJ(H5/(9)#X<K>$YU =:2VMD:221@J(H+,S,:*JJ*DLQ
M(  %230989T5O5"W\H:[O:4_:KBC.A(J"8(Q';[0T-S.T-?6^;DT$:CN@][?
M&[QZ<C#,*$=@C?'!^&OK'.)I4^J&^._O'TLA-":J?PH>$?U@7?33I;/S-I:K
MJ%#)-(:\W!"I(VY93H5:@#2[E45F67I5TC?8B7:2TM58F*T@K58TU;3MH::4
M@-*^FBH$1.M):VJ-++(P5$0%F9F-%55 )9F)   ))-!E;_S3_FI;A,12CV%@
MX!-J3JN;D:1\I TPPZ?DY\-_APJP]<V&T,/4G>/>.Z/3R,,HHP_#L=8\+3&W
MJAO<(X1VQR9!E-0=(/!_5]/BN)RK!;6T;RRRN0J1QQJ6=W8Z JJ"23H &1&'
ML\6 8<S)8P&J\YN-=S+_ *LP'@J?S,6S&/",K/UD85T.PRYQ.XT52WA>4J#Z
MYRH*QKONY51K)&4=WTZO;; ;=J%HP?EEV!KIS<3+;BHT5^4DJ=:&E"M]T?LS
M=XF!0W]V5EN!44/-458[<&I'P*(Y4[,COU_:31(NH[_ ?2WCRY%6%"-!'6/D
M4IX4]-?3'+P?U?-_)#HC/\%$5?%I4/JY!1XK(,/6QZ);@"M9.;B)!CE0Y^RN
MDG*.^6P_V?#WH?E.(;4&TITUB@V6N)*C2C<TL3:/A0#7*.]Z9R3=([Q:$B4F
MWM P]C;Q.7;3K$T\J,*5C&D9)A'1VS@L+6/U,-O$D,2\21JJCA--/H(WL(TC
MU0WQ[+C&[P:=SK D0T*FH/",DG&Z-/ =T=G^KRYZ01,K8I=UML/B-#M7+J?A
M67=BMUK*]?!8A(B095REQ"_D::>=VDDD<EG>1V+.[L:EF9B68G2223G+! I=
MW(554$LS$T  &DDG0 -).@918MTR_P#^;PUZ-\.A:]D77X%I53%756Y>)ET,
M(I!E'<='<,6YQ!*?\]>;-Q=;0]=&S*(X#\WCBJ/5;6OT+0Y;<8^#?5P'='>X
M.(]8DMCP,.X?2_J[J<KB7#9=O!\(V[2Q -4=5;X>Z&X3<R+M*V@F!( 153G1
MXE:Q?[5@I/A7]RC!'%=/R6+P7N6UZ5*0@@JTRMH*7.!6?RS% */B%T%DN*D>
M%S.C8MD.D;,*JQ6@D>0BOHAH)-W4=X[A_#BR:&04930_APYYI[ ]U?ZN[FTP
MV7F\3QTM8VU#1TC=3\JG&HCFX245@:I+-$VYFP='.BUG+?7URVS'#"I9V.Z=
MY54>$[L0B*"SLJ@D0=*?YOB/%<3%'2Q'AV5N=8$W_P"+E7=!_P"6!J-B8!9,
MEAA4(B *JJ  H H  -  &@ : /17RJ,>$FOA7^SN5SY+@\"CNGTOZN[G!;.3
M;L>CJFQB /@F<':O'IN-SWP#;ZVZ',_V?HK#S=K"5-U>R@BWMD/LB/5RL*\W
M GAN=)V(P\B?[=T6@YV\E4"ZOI0#<W+#206_RX0=*01T1: MMR;4C>BZ'+G(
MQ\&VK@.\?2X,T0Q"I/:X3P#)8$U+VSNGE/H,CI7C=CAI'K;F[@A;D61U8D[@
M ).YD4N>D\,A'^A!>7 /$T%O(O+M4X<ME,3N9!OK8W0']^-#VLO"Q&Z7CL;C
M_"IR"GI"86.Y)8X@O]X6K*.5AD$PSI7AA9M2RW4=NY)W EP8F)X ">#);NPF
M2>)_4O&RNAXF4D'D/]4.,]-[BA_VVUEF13J>8+LP1_\ $F:./\;*6_O7,LT[
MM)([&K.[L69F.Z68DD[YZORF3;L< M' NKRFEB*$V]J&%'G92-IB#' I#R5)
MCCEM^B?0ZS2RL;845$&EF--J21S5I)7(J\CDLQUG0*>C3'(*J=8.1DL_"7V)
MUCB.[W>/+9E4J>$$=W*@R'@["[[:.P-9[G#ELQZ6.MCK/>'!W?0,EY>2+%%$
MI=W=@J(JBK,S,0%50"220 !4G*7!/Y7VPQZ\2JFZ=FCP]&'L"M);JAT'F^9B
M84:.=QDZXWCT]O;/4?)K-C9P!3ZQE@*O*OZ=Y3PZ!D7<EF8U))J23K).Z3G8
MN0[<RF$3$I4[)=KRQ"L5K0L%#@$BH!-/ZH<.Z&0/LR8W>!G%?56]DHE<4^<2
M6K;W@[^KJ?#[=K@-BRF]N@*$^N%K;D@JUQ(-9H5@0\ZX),<<MKT8Z,VR6=C9
M((X8HQ154;I)J69B2SNQ+NY9W9F8D_T!1A7+P0!Q#T%<X_CMPEK9V<;2S2R&
MB1QH*LQ/ !H J2:  D@92]'\!>2PZ,PO2.W!V9+O9/@SW9&NI :.WJ8XO!)V
MY!M]9Z27U/S=C GZRXVO_:[7H[:E8*.$@94#%_%'?H,O@XB>,@=P'+P8U'*3
MWLO4)V^_EX4:GE([^7AQ$<35](9>$63C'>KE\"ZMP Z>QK_\=V?1N-JQX1A\
M09=Z>Y=YW/!6'Y-V*[W4MNAN #81OA+JX*DI:VRD"29]53I"1)4<Y*R)502R
MV?0SHG (+.S39&HO(YTO-*U!MRRM5W:@J30!5"J/0&&8GT0Q*ZPNYDQ>&)I;
M2>6WD:,V=\YC9XF1BA9$8J30LJFE0,OOAC7\4O?CLOOAC7\4O?CLOOAC7\4O
M?CLOOAC7\4O?CLOOAC7\4O?CLL/@GZ78RZ/<P*RMB=X593*H*D&:A!!H0=!'
MHY?Y+='9J6=@4EQ)D.B:Z(#Q6Y(UI;J5D=:D&=P& >W'6NF-Z1ZE<+0'QC?L
MWO5[/HPK7;?>7TSJ'=X,J1GFUX-?9U]BF6TY).^=/6:*^T-YM([XY",@MP.;
M._K7OCN<.09#4'=&D?\ CCI7B);:V+^2V!X+(+9BG!2 4RAPW#HFGN+ATBBC
M0%GDDD8*B(HTLS,0J@:22!E%ADZJ^,WX2;$9A0UEIX-NC;L-L&*)IH[F26@Y
MS9'H'"?/4'U'$,[#?G5OY9/1N+=-;^ACPRUFN-DFFVR(3'$#ORR;,:^V897>
M/8O(9KJ]FDGF<ZWEE<R2,?&9B>M=*;VGYRZLT_5PS-_[O;]%&68[*C\*#?.1
MC@\!.V>,[G$.4GKU86T;JG4>3TQIRV1X+[JGTM\=O@_\;XIC+':-W=W,Q._S
MLSO7EVLIOYS=(8=JVPYF@PY6&A[K9^&N #K%NC".,T(YZ1F!#P#T'A/GJ#ZC
MB&=AOSJW\LGHV/H_ U'QJ^@A8:JPP![ISQ"6* $>VZPMS@71C%+F)M(D2RN.
M:/%*8Q&>1LC*_1+$B![&W9S[E-ICR#(6W2G#+O#9#J2ZMYK=CQ+*B$]C+&[V
MGYS%W3]79VC?^[V_1)FF.@:AND[PRYR4Z!J&X!W]\[OH!5@KMUT4UUR5;@AG
M TD;_P"'9WA_XUGNEUQQNP_%4GTLL/Z(X&G.7>)3QP1#30-(P7:8[B("7=M2
MHK,= RPWH1@*[-KAL"0J: %V&F25Z:-N:0O+(1H+NQ]!X3YZ@^HXAG8;\ZM_
M+)Z-Z)X K:(XKZX8;YD:VC0GBYJ0#C.=9]&L!A-Q>W\T<$,8UM)(P5174!4U
M9C154%F( )RM[N:VBQ/']D--?S('*24TK9JX(MXU-55E FD&F1R"$7J/88I!
M'<P2"CQRHLD;#>9'!5AP$'*?#>AN'P89;7$S7$D5N@CB,SI'&SB-:(E4B1=E
M J^"*"M:^AR[F@ J3P9;>I!H4<&_QG=[&YZ "J*DZ ,N<DTR-K]J-X>F?Z,1
M8"!M UJ*Y>J'N1EZH>Y&7JA[D9>J'N1EZH>Y&3K.00H!% !N_P#@2]B76UO,
M.S&PRQ+^:.(1UBPB/Y+:DC1\JN5//.I]E#;> 1O70.YH]!X3YZ@^HXAG8;\Z
MM_+)Z-PBRW(L'B?EDO;T'M1C.O>EEV@=<#LF,51ZFYNVYE&_4"Y&_4@C5Z-%
MFAUZ6XMP>GV/0%!D+B<?"'4/8COG=WM6_P#T;%Q'NC.E\4=W_P "-$^D,"#Q
M$4.6$='[I-B\G5KRZT4;GKD\X PW&BAYJ$_HO0F$^>H/J.(9V&_.K?RR>C;0
M>QP>U'_]5>GT\[I;?CU4DV'Q\D:7;#MRGT86;0!I.3SMZXUY-P<@T9^Q I8]
MH<9U#ERK<2 <"BO;-.X<O"#-QGO4R_-_WF[^7@%EY01VQZ>58&#C>]2>WH[>
M6Q*I4[Q%.J+NY'A>M4[G">'>WM>O5_1L7$>Z,Z7Q1W?Z>$* R2G4BZ^7>&6T
MSI"-X#:/*3HKQ952Y#<#( .R-.0CQ%-BN@.NE#Q[J\O<RJ,W9DD%=X:3VJTY
M<J>%V/[<MF.05WCH/;I7D] 83YZ@^HXAG8;\ZM_+)Z-M?-%K]8O,[I/\\MO(
M/Z,D(UMX/9T'M5S].A%]4?2'">UV,A%"H51O?AI/#G<W.H8=SB.L9<['X49W
M=T<![_<R%W<C1K4'=]L>#>&[KU:_Z.BXCW1G2^*.[_3I=15V(51OL=7?REE)
MK,49F?=K0G0=X'5V<A'%([,=0&O(/*74;[#1VQ3)[>Z4%@-.\PWZ;A&[R$9'
M#W-4(VHR=[=7DW.#DZIED-%723D8XB4CWMT\9]+5QY@BG):/LE>+@X.QD'0U
M!T@]>PGSU!]1Q#.PWYU;^63T;:^:+7ZQ>9W2?YY;>0?T9&F^U>P#W\^-1K8;
M1XVT]R@Y.L%7%0=8.K^D(N(]T9TOBCN_T[!$=2*S\NH=C7E-XC^].2W#"H6N
M@<((]/(V\:$;5*DG>-='8R:ZE&R&% #K.D$FG(*;^4-P-:2+V&T$<NCJ_)$/
M@IKX6_L';KG&S<ZM*^F/3[/7L)\]0?4<0SL-^=6_EDZ\+WI=BEIAD1K1KJXB
M@#4W%YQEVCP+4DZ *Y&%<<:\==8MK2ZD')(84B-?:R'ARV5CQ1QOBTBI_>N5
M/:R"SW%]; [LEDY X?@6E/8!R6/#NE-I$S:*77.V6G>K>1P+RUIO');_  BX
MBNH']3)#(DL;>*Z%E/(>M6OFBU^L7F=TG^>6WD']&0CQO\.?$PW57N#^B:2R
M*#O5%>QKRT/7B4]X9>N[ [^7KAR?VY?G*<8;O94CD4G>J*]C7UJ+B/=&=+XH
M[O7ZRL%XR!W<M,H/$">X#EH+'\7OTRU-V!W\M+D<:GT@<J1R*3O5H>P=/H.K
M&@RHTH/%5NY7+1M'D[Y&6G:')WB<J"4#CJ.Z ,MI""-\&N?4Z!E1Y1R>%W*Y
M:"QXE[],M3=@=_+2Y7C4^D#E\"ZMP BO8UYL$IU.&3EUCLG*;Q']Z<DAF%5-
M:C2-2D[G",D, HK@Z*UTBF_QC(HYJ4-!Q4J/3R@MQK>1>PND]C1U"3N9-*VM
MB3V37.CEWF%>(Z#VJ]>PGSU!]1Q#.PWYU;^63,Q*YMG,<D=K<,K*2&5EA<JR
MD:000""-(.G+[X8Q_$;OXW+[X8Q_$;OXW+[X8Q_$;OXW+[X8Q_$;OXW+[X8Q
M_$;OXW+HW@N/=)L3O;.XN666":^N98I%YB4T>-Y"K"H!H0=(!ZAZ0=.KY;6-
MJB*(>'<7#@5YN"$':D;2*MHC2H,KHOA92X9_+M?_ ([AQ) D79DOY%U5>8@I
M!700MNHD0Z/E#C)\3QJYEO+F4U>6>1Y97.^TDA9F/"2<T8GT/Q.YPR<4J]M-
M)%M4W'", Z[ZN&4C001E%@_\X;48E:FBF^MD2*ZC&K:E@79@G W>;$#@5-)6
MHIAZ3]#KZ*_L9QX,L1K0BE4=31XY%J \<BK(AT,H.8N#]$^D&(8;:?[?:R<S
M;7<\$6VSSAGV(W5=I@H!-*F@KJR^^&,?Q&[^-R^^&,?Q&[^-R^^&,?Q&[^-R
M&+=+L1N<3NE01B:ZFDGD$:EF5 \C,VR"S$+6@+$@:3G2VW0W&K["HYV#2+:7
M4UNLC***SB)U#$ D FI T9??#&/XC=_&Y??#&/XC=_&Y??#&/XC=_&Y8?;S]
M+<7='N8%96Q"Z(96E4$$&6A!!H0=!'4M\6Z(XC<X9=-B=M&9K6:2"0QM!=LR
M%XV5MDE5)6M"5!(T#+[X8Q_$;OXW+[X8Q_$;OXW+[X8Q_$;OXW+[X8Q_$;OX
MW+[X8Q_$;OXW+ L"Z2](\2Q"RG%]SD%Q>W$T+[&'W4B;4<DC*VRZJZU&AE!&
MD#/Z/7/0W%;O"I)[JX61K2XEMVD584*JYB92P!)(!J =.7WPQC^(W?QN7WPQ
MC^(W?QN7WPQC^(W?QN7WPQC^(W?QN7WPQC^(W?QN5QA/2['\0Q.U7#+F00W5
MW//&)%GM%5PDCLNT S -2H#$ Z3U8FWBP[('>S_D4ATBI7A&LCC&OBXNNLJR
MN%;PE\(ZCN:]PU'%3+\\_NCW\OSS^Z/?R_//[H]_+\\_NCW\OSS^Z/?R3GY&
M9":$$DC3HKIWM?63(VI02>(9%Q*PJ2:!C0< R_//[H]_+\\_NCW\OSS^Z/?R
M_//[H]_+\\_NCW\E:=BS/X6DDT!U#3P4Y>KSDS!5&Z<BMHM?;-Z0[Y'%E\+(
M2-X:!V!09_P,A WJU'8-1ELW:5&^NOL'7R$<66W P8=L<8UCJQF%BI).HD;G
M!E^>?W1[^7YY_='OY?GG]T>_D#,Y:FJI)[N<3"Y6NNA([F7YY_='OY?GG]T>
M_E^>?W1[^7YY_='OY1JTKD%E]<=\<.>7D(4#=.@9;-N.<._J7OGL#CR]7L#>
M71V]?;RVF-3G? N0-[6.P=&02\6GMEU<HU]BO%D)(B&4[HSV2*1E%!H!(&K+
M\\_NCW\OSS^Z/?R_//[H]_+\\_NCW\OSS^Z/?RB=S4E%))W= R+,: :R<C'9
MC:/LCJY!N\9[!RVIW+=SD&H<F;MQ,5/ :9!+P;0]D-!Y1J/)3ER$L+!E.Z/P
M[75J= &1CLQM'V1U<@W>/5QY5G<MW.0:AFU&0&UMKO-I[!UCN<&5$\%]U3KY
M-\?@0.J44T<$,IWF&KO92P4I,%9674=JA&BNX3N[F233)116IJIUJ1N$G7DH
M@%64ZJ@:"-.N@WLI&O%V(R 2=I30C5J).FIY:9'$9!10-F,'>W6Y>YP4ZC^*
M>YUA7WP#V1UW"?/4'U'$,[#?G5OY9,S%OF=UY!\[HK\Z;ZO-E_N=\!=8K=AE
ML;,-0RN!IDD(TI;Q$@R/K8E8T\)JB?I9TTO&N[N8Z*Z(XDJ2L,$?J8HDKX*+
MNDLQ9V9CUA<<Z.2&6TE*B[LG8B"ZC&XPT[$J DPSJ"T;:"'C9XWL^FO1.;G;
M2[7U)H)(9%T203*"=B6)O!85(.AT+(RL>HOFRT\I<=>PWYU;^63J6OG>U^KW
MF=T=\7$/^F7F?T8^>7/D$SKKS1=?6+/JEAZQ@?2]//#*:$9"*]]T/3'ICL9;
M<3!AO@UZWSR^JCT\AU^D>0YZ2'U0%#QC1V]?+U@QC7(:<FL][ESDAW"=/$-)
M[65!U*>JD.I?3.\.[N;XYR=JG<&X.(;G6Q)$Q5ANC(07-%?<.XW>/:.YO=2/
MQCW.OQ^,O=&=S:^')O;W&?2U\6O+:G:N\-P<0_ ];VX3QC</&/3UY530PUKN
MCOCA[.<W$O<&=%)(:*$4D\@RV$\&,:AO\)[VYV^L[<>D'6NX1W]X_P#TR$T1
MJ#V0=X\(R+-H R,,)I$/[W">#>'*>#K =#0C2",N:ET2+_>&^.'?'+Q=02J3
M'(-3KKY=\9;+(DXWP=@\M='8RHEN$X6<$=@:<A)B+\Y32$&A!Z;<O+7*@ZA7
M?&5#GQ-[4#L:/2Z[A/GJ#ZCB&=AOSJW\LF9BWS.Z\@^=@?2[I%+S-EA\LLTK
M4J=E;>;0JC2SL2$1?7,P&[E>]-^D#$-.VS!#4E+:V4GF;>/4*(IJS #G)6>4
MC:<];CZ)8S-3!.D#I!(&/@079\"VN!70H9B()CH!C=9')YA1U5\V6GE+CKV&
M_.K?RR=2U\[VOU>\SNCOBXA_TR\S^C'SRY\@F==>:+KZQ9]5H6U,".SD8WT%
M20>,=8VX6*G@-,J3J)!OZCVM':RHY,9X1H[(KVZ9;43!AO@@]SK!5A4'0>+)
MX#ZTZ.$;A[&<ULVIQ4<8U]D=SK A&J,4Y3I/:IG/=-N^".Z?2[?4,ATL="C?
M/>&[V-W(RRFK'6>N\W'H UMN =_>&2I4F@ J=9X3PY1^,>YU^/QE[HS3;6A\
M+4S;W .'?.YQZJG7UT2Q&C#\.QESBZ&&AAO'O'<S6XE[@SH;2(^"BKM<+4&C
MD[O%UL1N? DT'@.X?2/!Q9?(HCXY[B^F>0;_ %M9HS1E-1^'=R6=-3#L'='(
M>LRQ[S'L$U':SU7V)8=NOI]=PGSU!]1Q#.PWYU;^63,Q;YG=>0?T$&4T(RP;
MI5=/SEX(ODUV3ZHW5L>:D=MXS!5GIN+*.+J+YLM/*7'7L-^=6_EDZEKYWM?J
M]YG='?%Q#_IEYG]&/GESY!,ZZ\T77UBSS/EL8T'0W =P\NKCIO\ 6]J-BIWP
M:'M94<B0>V&GLBA[-<J3 QGLCLC3VLMN-@P.Z#49RW:C5X+<6X>S4<HSEF36
MI!_LY=60D32& (XCG&1M2@D\0R:5M;$GLYH5=).20#UHT\>L]OJ,0?!70O)K
M/*>U3KO-QZ /5-N =_>'I:<A#"* =DG?/#U(_&/<Z_'XR]T9GR6 ^&PTGV([
MY[0T[H] "9=(U,-\?AI'#D)$-0PJ#P',;B7N#T$68U)UGKCVK:CX0XQK[([G
M61*-3J#RC1W*9\L6\0>R*>EUW"?/4'U'$,[#?G5OY9,S%OF=UY!_0?23H!.^
MA&@Q"%?&!M[DT_$M!RZ=SJ+YLM/*7'7L-^=6_EDZEKYWM?J]YG='?%Q#_IEY
MG]&/GESY!,ZZ\T77UBSS#'(*@BA&51IC.H^D>'N]FG7-N%BIX/3&H\N0CO!3
MVPU<H[W8R#QD$'41I&8T#ZF%/[>0Z<FC?05)!XQG&%M<9IR'2/3'8SC&-<AI
MR:SWN7.#GU,?A<NYV]/)U))1K H.,Z!VSGB68\VIU:*L>3<Y>QE1MIN,]ZF7
M@[2\1[X.6U;/M<!T'LZNS3(QRJ58;AZFPFA1K;<']N\/2R$,(H!V2=\\/5C\
M8]SK\?C+W1U6F;7J WR=7?/!D9)#4L:DYM!D)+D\VN]ZX][EJ>#+1&&.^WA=
MW1V!E0(HY!E22-3R 'LC3D7LS0^Q.KD.L<M>,9&.4%6&L'.:T<Z5TKQ'6.0]
MW,;B7N#T='+O,*\1T'M'K(F&N,]HZ#VZ9YC/KU(Y10]P'KN$^>H/J.(9V&_.
MK?RR9F+?,[KR#]8@Z9=.9I,'P*6C0JJCY9>)N/$'!2"%M:32*YD%#'$R,),D
MCP3HY9R2H!\/=QB\G)W6YRYYTH3NB+84:@H&C+F;>S@C3V*Q1J.P% R:WZ3]
M'K"[VQ3;:VB685]A.BK,AX4D4\.5QTU_DT9;FV@5I)\,D)EFCC459[.3U<RH
M-)@DVIJ E))6(CS[*PVJ+BMI>VIWCLQ?+ #QM:+3AIU-N6-6.^5!/9(R_,Q^
MX7O9?F8_<+WLOS,?N%[V5LD*A1_M-J:  #]HO-[.Z3&9%>EY;4VE!_R7WQE^
M9C]PO>R_,Q^X7O9?F8_<+WLJB%/<+WNI:^=[7ZO>9W1WQ<0_Z9>9_1CYY<^0
M3.NO-%U]8L\TQR#:4ZP<C+:U=-[UP[X[?=Z]6,U4ZU.H]X\/9KD)83QC=!WC
MF"Y74^@^,.^.X<Y0?4OX)Y=7;IG"$:HQ3E.D]JF=SC>JDT\FYW^7J!?9,!VB
M?2SD1](%2>05[M,WFYAQ'='%WM1R-NVA1IV]RG!P\'I:<A#"* =DG?/#F:<M
M66K+5E%3>/=&=)7>'=RU9:LM66K+5U>84^#'H_&.OL:NSG"[G%6.E1O#?XSN
M;PX<[:4?"*-!W_:GCW-X\N5#FI-N Z>(Z#VLQN)>X,_8B&@:R=0_#<&0+CG&
MWVU=C5V:\>5$0 <  RI(BL.$ Y&6R%&'K=P\6\>UQ94.?09"6\)%?6C7RG<X
MAIX1E2.-1PTJ>R:G*E!V,J.@!WUT'M:^6N6RVE3J;?X#O'/CD]DJGLCK#0OJ
M8$=G)HGUJ2#R9T<IU!A7B.@]H]=PGSU!]1Q#.PWYU;^63,Q;YG=>0?/#X[%S
MF"X*J7-XI'@S,6(M[5N"9U9I!ZZ&&500S*<EBB4*J@      4  &@ #0 - &
M;_O.!Q"'#.D*/=1(HHD5RK 7<2 : NT\<Z@4"B?84!4&=T2NJTV\2MX?I#?)
MZ<O.TY<ZU\T6OUB\SND_SRV\@^=:^=[7ZO>9W1WQ<0_Z9>9_1CYY<^03.NO-
M%U]8L\_:8;+^R&@\NX>73PY%HQSB\&OW.OL5RHPH1UP2II'KAOCO[QR66,U5
MA4=5XAZK6O&-79U<N=49)-ND:>,:#V\PR-J4$GB&32MK8D]G-2!?7&G)NGD&
MG(*N@#0.HA]N/>MG+.!4#6-\'0?[.'(2PMM ]K@.\>O1<1[HSI?%'=SWF;UH
M)R+MI)-3QG-6-O4C2>(=\T'+U@LNJ0;7+J/;%>7.CD.NE#QC1Z5>JW$O<&<(
MT%2Q '&<A"FYK.^=T_AN9HF0:)-/XPU]G0>.N>;R45 -%X]T\FH<-=[-:$ZZ
M5' 1J[W$<J'.B/ 1V"1UD72C0^@^,.^.X<^.;=8"O'J/;KUS"?/4'U'$,[#?
MG5OY9,S%OF=UY!\^/I"Z 7&/7,]RS>NYF%S:PH?:CF9)5_3$[N=!TC5?A<'O
MX7VJ:1#<AK>1:[@:5[<GA0#.Z,WNKF<5PY_<7D+>EG6OFBU^L7F=TG^>6WD'
MSK7SO:_5[S.Z.^+B'_3+S/Z,?/+GR"9UUYHNOK%GUFDZ!N'=[(T]O*MLY7@;
M2.SH([>52FT-]=/:U]D94/6C9N=!TKQ[H[&GD.82H\%_"'+K'9[1&<]JV[X0
M[A]+L',,8UR&G)K/>Y<Y[IMSP1QG2>U3L]5B/6D'TO3S]N%BIX#^%<J3*''8
M/:T=K*DJLG;':T]K+X.5>4T/8-#E4=:BXCW1G2^*.[G[ ]>P'(-/I#.DDN&V
M20 -!.^3J!X,OSO:;O9?G>TW>R_.]IN]E^=[3=[+\[VF[V7YWM-WLOSO:;O9
M1M;MM4VJZ"-ZFL#ASFC/K6[1 ].O5;B7N#.VSJ0$\NH=TGDS@^ZK#L$$=[/2
M$>M KQ[O;KG2H-QCVS7.3@+=T]9: ZSJX"-7X;V11A0C0>/.>W.M#4<1_M![
M/7,)\]0?4<0SL-^=6_EDS,6^9W7D'S^BN%J*&/"K$M^D>VCDD/+(S'ESNE-L
MPKLVT<O+!<P3@\ACKG8-)JV;ZT/8N(SG6OFBU^L7F=TG^>6WD'SK7SO:_5[S
M.Z.^+B'_ $R\S^C'SRY\@F==>:+KZQ9]<I.@;AII[.OMY5MG*G>.D=G6.WE6
M5/!WQI'9W.6G6$F7UI![XY1HR##4>J77U4?A#B]<.QIY,Y)QZTZ>+41V,@RZ
M0>J(1JC%.4Z3VJ9R0[H%3QG2>]U6A;4P([.31N*%20>,=:^!=EXB:=C5E28"
M0=@]D:.UD%)YMMYM7(=79IQ=8BXCW1G2^*.[GQ1^,>X!Z?H25-\*>Q7O]5N)
M>X,Z63?*CL5[^=(=[9]\,Z-#NLH[8SY>/TAG#C;N]:%W&-#Z&X&W^4=L<.<M
M=3^">75VZ=<PGSU!]1Q#.PWYU;^63,Q;YG=>0?/PNW H([2V7W,*#TL[I<K?
M_P"+NSRB)B.V,["OGEMY=,ZU\T6OUB\SND_SRV\@^=:^=[7ZO>9W1WQ<0_Z9
M>9_1CYY<^03.NO-%U]8L^O4.1DMJ(^]ZT\FYR:.#(Q2C98:QGQ-[6G8T>EU:
M')X=P&HXCI'>X\X(?51^#R;G:T<G4,C:E!)XADTK:V)/9S5!]2GA'DU=NF;\
MMA'CCN-Z1Y#O]="UVT]B?2.YW.#+G837?&Z#O'\.+.BXCW1G2^*.[GH/:>F?
M0D@]KZ8ZK<2]P9SGV_I#.D_%]^N=#XZ]W/EX_2&</&;N]::&055A3^WC&L9-
M!)K';&X>7-J,DFW2-/&-![?6\)\]0?4<0SL-^=6_EDS,6^9W7D'S[#YM!Y)<
M[I=YJO/(MG85\\MO+IG6OFBU^L7F=TG^>6WD'SK7SO:_5[S.Z,EM_$!V<+O@
M.WG]%;>NEKF];W,4 _QC.NO-%U]8L_0'RI!X<>OA7=[&OLYZC>+=VOIYBW2Z
MTT'B.KL'NYPC;U,FCEW.]R]0QC7(:<FL][ESC.VN0]H:!VZ]K-H<C/9#1NI^
M3WNQO9%6%"-P]<$L?*-PC>[V]DLT9JK"OX<(U'-BXCW1G2^*.[GH?:>F?0C^
M)Z8ZK<2]P9S^.?>KG2?B^_7.A\=>[GR\?I#.'C-W>M[<8^$35PC='>X>,Y4.
M:UHYT-I7C&OLCN=;PGSU!]1Q#.PWYU;^63,Q;YG=>0?/L/FT'DESNEWFJ\\B
MV=A7SRV\NF=:^:+7ZQ>9W2?YY;>0?.A;V.*VA_\ 1NQZ>=T5N6- UVT7+/!-
M !RF0#ES^BF J?"MX+ZX8<%Q);1J2..V>G+G77FBZ^L6?H!D;401V1GKPEN[
MF-$^I@0>7)H7UJ2,T,N@C2,DG7UP[>Z.0U&0A&J,4Y3I/:IFK"FMB!V<EB34
MH '$,_X9=.^-![/?J,JVSAAO'0>SJ/:R^&C8#?I4=D5';ZV]HVKU2]PCN'LY
ML7$>Z,Z7Q1W<^*3QAW#W\[X-2U-X$]S+\VWN3WLOS;>Y/>R_-M[D][+\VWN3
MWLOS;>Y/>R_-M[D][+\VWN3WLOS;>Y/>R_-M[D][+\VWN3WLOS;>Y/>R_-M[
MD][+\VWN3WLG,BE1L;H(W1O]5N)>X,Y_'/O5SI/Q??KG0^.O=SY>/TAG#QF[
MO7#>P#QQ_B[_ &=_-65#0J01R9+.FIAV#NCD/6L)\]0?4<0SL-^=6_EDS,6^
M9W7D'S[#YM!Y)<[I=YJO/(MG85\\MO+IG6OFBU^L7F=TG^>6WD'SKB6GYB^L
MGXJNT?\ [E,[!^E:U_\ VR]M;J@UD6\Z2D<H6E-VM,DN;=@\<BAE8&H96%58
M'=!!!!W1G8E#:N'@P:*'#D(U;4 :2X'&EU-/&>%,ZZ\T77UBSSC;P'X0ZS[$
M=_>WM>]D+2Z/BL>X?2/)O=9DD.NE!QG0._GQ [H)[))S5NUU-H/&-79'<SI(
M9#H0%QQ>N[&CLY-*VMB3V<UKEAH04'&>\.[UOX6-3PTH>R-.7P>TG$:CMU/;
MRK#(&XP5/ICN9?#H0-_6.R-&?$V^P'NM'IYL7$>Z,Z1=]>X1W\_G!ZQ@>0Z/
M3&<8CJD%.4:1VJ^@6XE[@SG\<^]7.D_%]^N=#XZ]W/EX_2&</&;N]<H<C<0#
MX,ZQ[$][>WM6]F_)9#X+ZN!O[=7'3K6$^>H/J.(9V&_.K?RR9F+?,[KR#Y]A
M\V@\DN=TN\U7GD6SL*^>6WETSK7S1:_6+S.Z3_/+;R#YW22-15H4M)AP<U?6
MSL?<!QQ'/M<!NY0<5Z/)'9W"$^$T" K9S@:RKPJ(F8U)EAD)H&6N9=]*[QE:
M]=6AL("=,]VRGFQLZS'%^=F;12-2 =MD5IL2Q"1IKBXD>661C5GDD8N[L=UF
M8DD[YSKKS1=?6+/-YN/3*VH;PWSZ0W>+(NYJ3I)Z@ANJLFX=T=\=OCU9<Y"P
M8<'X:.7.,DS!5&_^&DY471&NH>F>'N=G.H-9R2(>M '8%,UX-TC1QC2.WVLJ
M'01FG9-*BAXCN9R(11CX1XSWA0<G6 TQ]4: #7PGB&[D'0U!T@C-H=.1N[8;
M-/5*-5-\;W"-6[HSD(W".[FQ<1[HSEKH#U7LZNV!GO"?7 C\.+(HV@@T/)FB
M1#0J01QC)9DW=8WCNCO<&>68T R*,OP6H-N\=-X[VNG8R$D9#*=1&>W$O<&<
M_CGWJYTGXOOUSH?'7NY\O'Z0SAXS=WKI5A4'(SVXK'NC=7^SAW-W?S*C*CGX
M1-!X=X\N[P\G6<)\]0?4<0SL-^=6_EDS,6^9W7D'S[#YM!Y)<[I=YJO/(MG8
M5\\MO+IG6OFBU^L7F=TG^>6WD'SNDG1Z-=J2[PV]2,:_A3;R&+1P2!3GP=,N
MAT_-7,55=&!:&XA8@O!.@(VXGH"14,K!9(V61%816_22[7HYB9 $D-XVS;%M
MTQ7A A*5U<^8)-?@$#:(N,'O[>[C;4T,\4JGB*,P/9R,^.XI:62+K:>YAA4<
M9D=0,I+?HS<'I'B !"16E1;!MPRWC+S6QPVXN&WU -<FZ3],IPQ4%+>WCJMO
M:Q$UYN%"214T+NQ:20@%V-% SKKS1=?6+/,KK=O4CTSP#MZN(RRFK-K.9MPL
M5/ ?PKE2=0_"/!/ICM#+PPR\E>X3W,OSG]UN]EX)9N(=^F5+>,+PL:]H4[IR
MVYV+'M#B&H<F>M=2>$>35VZ9YD4>#)IY=WO\O6DC(\$:3Q#OZ!R]8,TO(-TG
M>_#5D9I3I/8 WAP9<U+X49[*\(X-\=CA$D+!E.Z/P[6;(7]<"HXSH'?Y,Z-!
MNLH[8S8CP-W1G5&@C(1RD+*-P^NX1WO2S LK %B !NFNC5K]+J\^H\&33^-N
M]G7V<[:72I]4-_AXQD)8&J.V. C<.:9)"%4:R<N8@T1[N^W>'!V=X95B-5.M
M3J/>/",JQFC#6IUCOCASFXE[@SG\<^]7.D_%]^N=#XZ]W/EX_2&</&;N]>H<
MC/9#C3\GO=C>RH>J)XM8W-\;H/'_ &Y":(Z#V0=T'AZQA/GJ#ZCB&=AOSJW\
MLF9BWS.Z\@^?8?-H/)+G=+O-5YY%L["OGEMY=,ZU\T6OUB\SND_SRV\@^=0Z
M0<L=Z',NPMA>SQQC?@VRUNW$\#1N. ^@KKS1=?6+/J\X^DGU(W2>]OG(S3&I
M/X4' /07.N/"DT\0W!Z?+P9[;/JD\(<FL<H[=.M-<L-+F@XAWSW,\S3&@';X
M!PG(RR: -0WAW]\]7;@8J>T>,:CE2YCKPJ:=H]_+267C'>KEH8G\4^GE2",D
M^VH!VJ^EEM3'0-0&H<7?.G.3>6K'DU=NF;%)O$CL@'TNL4CE8#>K4=@UR_.G
ML+WLJ-*W(:=RF49.D[:]T=5H6UZP=XC5WCP9&-Q0J:$9W.0,5/!Z>X>7*ERE
M>%=':/?&5267C'>KEH)/$I].F5+:/E;O#OY;4[$[PW!Q#\#F"2,E6&HC(0W=
M%?<;</'O'M<6K-;B7N#.?QS[U<Z3\7WZYT/CKW<^7C](9P\9N[Z ,B^!)O[A
MXQZ>OCU9;$ZTWCN'B/X'?ZNT-*'U0W^$<(_LR$L1JI_#LY^$^>H/J.(9V&_.
MK?RR9F+?,[KR#Y]A\V@\DN=TN\U7GD6SL*^>6WETSK7S1:_6+S.Z3_/+;R#Y
M^'?S.LH_^7QB$6UPP&@7=JM(RQWY;785!_\ EG/H*Z\T77UBSZAFE.@:AND[
MPR,TIXAN ;P]!<Y(/@TU\)WN_P ''UEHAZDZ5XCWM7)U@1II+$ <9R6%-2@#
M^WESC+*:*NDG*NI%]2/3/">UJZ^;EQIDU>*.^>T!FN!K7PAR:^U7K<?C+W1F
M?*H!X8UCV0[X[8XAZ!/.FL0T+777@.\.[H&[F-Q+W!G/XY]ZN=)^+[]<Z'QU
M[N?+Q^D,X>,W=] F.50RG<.1>R/XI](]_LY;$RE3O'J572AUKZ8WC^!R$L)J
M#V1P$;ASL)\]0?4<0SL-^=6_EDS,6^9W7D'S[#YM!Y)<[I=YJO/(MG85\\MO
M+IG6OFBU^L7F=TG^>6WD'S\1Z#7A5)9EYRUE85YB[BJT$FHD+M5CEII,,DBC
M2V5UT=QV!K:\LI7AFB?U221L593N'2-!!*L*,I((/6^E?\[.E$!6WM[7FL+5
MJCG)OE$2378U52(;4$6M7D:4T!B4G-NO-%U]8L^H8IA4'M<(WCEM#PHSJ;>X
M#O'M'M>@:#0@UMZ0WS^!R$,0HJ_AV>LBX4:8]?BGO&G;ZP9FU1CMG0.U4]C/
M^3N"J+J'LO;=[>X^OU;1&OJCO\ X3N[PY,@JB@&<5 \!M*\6]R:NP=WK4?C+
MW1FFYM!X6MEW^$<.^-W<TZZ'KPFF&S&.RW%P;YY!P!$% -  S&XE[@SG\<^]
M7.D_%]^N=#XZ]W/EX_2&</&;N^@]B90PX1EM6S%#O'2.SK';RJ4VAOKI_M[6
M6W$:'=!U'@(R"'P)/8G=XCN]WNYN$^>H/J.(9V&_.K?RR9F+?,[KR#Y]A\V@
M\DN=TN\U7GD6SL*^>6WETSK7S1:_6+S.Z3_/+;R#]8;^870*)5Z16L8$T(HH
MQ"%!X*UT 74:C9B9B!(@$+GP8BLMA?Q/!/"S))'(I1T=259'1@&5E((92 00
M017K,/2OI;')9=&(7J7-4EORITPVVHB*HV9KD:!ICB)EVC%TCPC"84MK6VL8
MHHHHU"I'&DT"HB*-"JJ@  :@,ZZ\T77UBSZI5A4'<R,MEH/L3JY#N<1[(R,<
MH*L-P]>$EU5$WO7'O#CT\&[D(X@%4:@.M&-](8$'B.30/K4T[QY1ISUKZI_"
M/+J[5.6N?S<PXCNCB_"F6T1M)[(>F-SN</71)/5(^V>(;@X3R5R$40V5&H9Y
MBDY#N@[_ 'QNY<U,.([A&^/PT=9C\9>Z,XR)X$F_N'C'IZ^/5ELSK3>.X>(_
M@>#K8CB!8G<&G(2WND[B[G*=WBU<>5!FMQ+W!G/XY]ZN=)^+[]<Z'QU[N?+Q
M^D,X>,W=]#4F0-Q@'*JJ4/M2?3KEL-(7 U;5*]D4KRBO#F89AG1##;K%+F/%
MX96BM();B18Q9WR&1DB5V"!G12Q% S**U(R^Y^-?PN]^)R^Y^-?PN]^)R^Y^
M-?PN]^)R^Y^-?PN]^)R^Y^-?PN]^)RP^>?HCC*(ES S,V&7@55$JDL28:  "
MI)T 9F)VULADDDM+A5502S,T+A54#2220 !I)T#+[GXU_"[WXG+[GXU_"[WX
MG+[GXU_"[WXG+[GXU_"[WXG+[GXU_"[WXG+[GXU_"[WXG*RAF4HZ6\*LI%""
M(U!!!T@@Z"#J.=THPG![>2ZNKC#;N.*&)&DED=HF"I'&@+.S'0%4$DZ ,ON?
MC7\+O?B<ON?C7\+O?B<ON?C7\+O?B<ON?C7\+O?B<ON?C7\+O?B<L,N;CHCC
M,<<=U;LS-AMX%55F0LS$PT  !))T :3G6^*]$L Q'$[5<+MHS-:V5Q<1"19[
MMF0O%&ZAU#*2M:@,"1I&7W/QK^%WOQ.7W/QK^%WOQ.7W/QK^%WOQ.7W/QK^%
MWOQ.7W/QK^%WOQ.72*VZ8X3>85)/=6[1K=VTULTBK"X9D$R(6 ) )%0#H/66
MQ.Z4X7C86B7]NBEGH**MU%55N4   )9)E "I,J J9+@X:V,6"5(NL/#7 V1N
MR0!?E$5!I<M$8ETTE8"N1BE4JRD@@BA!&@@@Z00=8.:+3H+@]Q?BM&E5-BWC
M/_F7,FQ!'Q-(":&@.4/2+^<$\>+72$,MA#M?(D.L<^[!9+H@TK&%CAJ"KB=#
MDEI:1K%%$H1$10J(JBBJJJ %50     !0"F723!L!M9;V[N+95B@@C>661N?
MB.RD:!G8T!-%!- 3N9?<_&OX7>_$Y?<_&OX7>_$Y?<_&OX7>_$Y?<_&OX7>_
M$Y?<_&OX7>_$Y7&*]+< Q'#+5L+N8Q-=65Q;Q&1I[1E0/+&BEV"L0M:D*2!H
M.;L3J&[HXCK&1:T>O VOD(],#CRI,A7AIH[(T=OK.S&"QW@*G*LU(UX=)[ ]
M,C+:0;3>R.D\FX.33P]=6[7=\%O2/='8SDAW"=/$-)[65!UBAR+1_!MP:NQW
MJ950"0>UU]@Z>Q7+9D4J>$$=W/I$A;B!.59:1CATGL#TR,@P&VPW6T]@:AW>
M'K1CF4,#O^EO'BR+VC;0]B=!Y#J/+3+9F0KQCT]W/C>-"5# DTT4!&Z=&>4D
M 8'<.D9%K9N;.]K7OCM\652FT-]=/:U]K*C"ASO@4+<--'9.CMY;5V]!O+K[
M)T=@'CRV8%"]T\9UG/9XHV84&D*2-6^!E^9?W+=[+\R_N6[V7YE_<MWLOS+^
MY;O9?F7]RW>R=9E*DN30@C<&_G2)&"S'9T 5/JAN#+\R_N6[V7YE_<MWLOS+
M^Y;O9?F7]RW>R_,O[EN]E$SQ. &%25( T\6?(\<3L"=!"DC4-VF7YE_<MWLO
MS+^Y;O9?F7]RW>R_,O[EN]E^9?W+=[()*I4U.@BAU[Q_\($],,#L<1<BG.3V
MT4DH'M92O.KQJX.1DCP22S=M9M[R[4<B/-)&O$J <&1,<V*Q<"W<) ]W:N>R
M<@\XQ*Y'L9+Q0#^I@B/8.2S87T8M)9%U/=\Y>FOL@+QYU4UT@JJT/J:9):VD
M:Q11@*J(H55 U!54  #< %/0-7C%=\:#VJ951F7E!'<KV\O F[*_VY:)%[?>
MRTNG;[V7A2@<0)],9?"2,>( =VN5=C:/MB3VM [66S$H4;P '<Z^EJN[X1XM
M0[=>P,Y[IMWP1Q:SVZ=@]<V7 (X=.7A1+R"G<IEH4CB8^G7+6_9'>RUL>4=[
M+2A/&Q](C*J1+V*]VN5!H'7J,*C+PXEY-'<IEH!'$Q].N6M^R.]EIVCR_P!F
M6E*\;-W\O@XU'#05[.OK=)5#<8![N53&!Q$CN&F6C:'$>^#EK?LCO9:5+<;'
MTJ9?!Q*#OTJ>R=/]4M3D\VX3HXAH':S0JZ2= R2 >M';W3RG^MPQJ?"DT#BW
M3V-'+G"0^IC\+EW.WIY/ZW#+,:#MG@ W<C,^C< WAO=_ASA(WJI/"Y-SM:>7
M^M@CFAV3WLOS0[)[V6B->R?[,J*%7B&GMDCM9;<S%CPYR0#UQT\6LGL9!5T
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MW,/^F6WQF7VYA_TRV^,R^W,/^F6WQF7VYA_TRV^,R6*+&K!G8@*HO+<DDF@
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M(VMY(J[12"XBE8*"!M%8W8A:D"I%*D#61GO>XA,D$,8J\DCJB**TJSL0JBI
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MQQ>RFFD(5$CNH'=F.H*JR%F)W  3F/=W;K%%$K.[NP5$102S,Q("JH!+,2
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M%N(-H<[;RC4T<J@J0?4MLNI5U5@"-WK?2_SO?_6),NAWGS"?K]OGX_XF'_\
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M"S.5BB<J=#"-Y%<J=!"D'0<IL6Q>=[FZN7:2665B\DCL:L[NQ)9B=)).4/\
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MISE)_,+^84D38NT30VUM"W.):I)02R22@!7G=1S:K'M1I&S^'(T@$?\ 7?\
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M-=T LX!"'*.SM$6.*)51$4 *J* JJH&@*H   T "F<TLK!54$DDT  TDDG0
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M!1550%50%4!0!_0.TA(.^-&5)'+<9)[OH*'"<*B:>YN'6..-!5G=C0 <NZ:
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M%&HU*D:A$4<2@#K6!6OL(+AO=R1C_!Z*%M:(7<[@W!ODZ@!OG(3WE)IM>D>
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M\FWHW'\68:7>UA4[VPL[L.7;2O$,ZXQO%9!%;6L;2R.?6H@+$TUDT% !I8T
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M5W,H(\*D,MPK$! C@E6&G2R@:"H.DZ!4Y+@%NP:0G;N&&K:W(P=T+N\(&HU
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M@'6^:NTJ1ZEAH9>(^D:@[HRV9?"C;U+C4> [S;X[!(SH_&?WQSKB"!2SO,X
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MGP3R,:?C<'6\0\V2_6K3.O?T$WDVS+#YS!Y5<^[_ $TOOVSNCWS^V\HN=?\
MS:?R39T_G"?R-MG8)\VG\JN=*-^PN!_ZMN?2SL>A45V;<2<D4L<I/($KGX_B
MI&B66UB!X8DF=A_ZRUY,Z#SA!Y&Y] 12IK5U(XP0<]QO(G<KZ>8EU":-&P8<
MAKV#J/!E'=P^ID4,.7<XQJ/#FF.055@01O@Z",I;)_\ +8@<(UJ>52#RY&[8
M>%.U?Q5\$=O:/$<V2[E]3&I8\@U<9U#AR>XE-6=BQXR:G/\ ^4D(7=0Z4/(=
M7&*'AR"8C$8S[)/"7L'PAR;60^2SHQ.Y6C>Y-&[76XL4C&D'8?BTE3R:17A
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MZU<?HY/>G-7#L4;P-22'UN\K>UWFW-1T:0&4U!Z\;2S(>X/*(^%M]MY>5M%
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M-1^'!N==J<FM\-I-+JVM:+R^N/ -&^=S)KBY8N[:23^&K> T#4.M+/$:,A#
M[Q!J,HKR+5(H/$=T<AJ.3/DV35(?@U_%]4>5JZ=ZF?S]HU*^J4^I8;Q'<.L;
MAR$8/-S;J,=?BG4P[>^.NFWLB)I]6C2BGVQ&L^U'*1DUS<L7=C4D_AH W -
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MX-P<)/\ 6TO$.YGGY3("^XBZ7/)N<;$#+8;X.$'0@/;8^N/:&X-W^ML*89=
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MXMA#K3;=F*T+*A)4 W]AA\\>Z%CN(VY&^4.!RH<DL>DL;X+</0!I&$ML2?\
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MQ)5*O);K)SQ4BA"R22.$J-&TBJXUJX.5YA_1V&UD6^96D:>.5V!164;!CFB
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M9D]39RR*G*!><Q*4=4P&V&_DMF5%>=C28SK;\>0PXME]A]E8<:>9=;(4E:5
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M;],8&#,"BT* W3*9#;[S;+2$X\^&)[5YMU'S8^0V3?U2R8^E]EJ[3XN;#O\
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M"3UJ2E;55MVX*;+H]=H=0ETJKTJ>RN/-I]1@OJC2X<IE?%*VUI*5#O=NU/\
M[NES?I+M3>U!]I%U_B&1\FW%[_%\>Y.WM[S=?>_O+W1QODS5*YU(S*HFFT>B
MMDIQ#:[CN:++*DD\BLM-4D'EP*AR$[^JM1DR7':=:=PS-/+>CE94Q#I-E27*
M,XF+CR(D3$2YI[JWU$<" -^GUV@52H42M4F4S.I=6I,R13ZE3IL=>=B7"FQ5
M(<:<01BE:% CF.RW75K===6IQQQQ2EN..+5F6M:U8DDDDDDXD_J?K?[:[0_%
M$O>T6]N5S?B1G]7?.AO: 2U6=0KVTXT>:G(X/1**UGN6X(K2^9$V,ZJ.^G$Y
MDY>&(!V\WGW\M)O=[3]KUTFHE8I] J=T.6RN-5:JS)?@Q10KM@W$\'VH@+AS
MMQ%-IRC@I0)X8[4/5N[-3:57G;8A5QJDT*W*34(K4N97:-(H#KM3GSW$GJ6F
M)+JTLH9)4YD)6D((7:&B%BUNGW5.MJ['+NO&K4B0U-I5(J4&DRJ'3* S46"I
MI^1EFRG)B6E$,E#:%'K"M#?G)Z13/5:-J1YN=]RDQE<6D779*$5JTZJI!Q!5
M%4N2I'#'%0P([+^OUR4]"[MU"3+I]H*DM8NT2QX<HQGI4=*P"AVJ26EK4O#C
M&:8*%!+S@5NT#SCK8@)9<G2HEH:DHC- )?DE@IM6YI 3R**&E4Z0X>7"(D#'
M,3VW4_\ NZ7-^DNU-[4'VD77^(9';E4C2[3>^=1*DVI"'XEEVK6[E=B]9Z5<
MWV(8=#",.)<=*4@8DD $[-2EZ-1[3AO92A^\KXLFD/8*XDNTIF>_.;PYPY%2
M>YCQP"W)VBL57#U)^_*RIP<.<QJ.XG_*V4N'0]-+@4E)4&J1J)!9<6</2)->
M8A)Q^R4!W]GGZ[YMM^5!AA*G%.64:'J,5-IXE:&+ F5)WDXX%O,.<#:11+HH
M59MNM1"!+I%?IDVCU2*3R"1 J*&W4'A],@=JN+W^+X]R=O;WFZ^]_>7NCC?)
MGG$/G#.W$TK93P&.1]ZXEKP/A;3COZW46<A:)$+5:_<"L$%Z-(N:3*A2ACQR
MO,K;=2><*!_4EE^R=(=0[AAOA):JD*U*P*,H+XH)K4AI$1./*,SPQ''DV0Z]
MIM H#+@!0NNWK9S*\#SKBP)LE]'@6T#WM@IR1I?%4?\ -OW=45+'A,:FN)]!
M6V9DZ:SC@3DBWA*0K'ZG&= 93CX\._LMU.EC-:8;!*G:'>5DS%</J(;U0:D*
MQY@ED[.O7GI#J-;T1D*+E2J%HUM-) 1Z<IK#;*HJL.4Y7C@./:M;_;7:'XHE
M[VBWMRN;\2,]O,*RK-NJ\)B5)0J+:]O5>OR4K5Z5*F*4RZH$\P(V0[ T4N"
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M8T2&P[)E2'5>E:8CLA2UJ/,E()V9?H&B%Z-1WTA;,FY8T*RF'&CQ#K;MY/0
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M$;^NU/U9TTL74J#1;(M291X=\VM1KHC4N7*KS[$F3 8K++R6G'$)2E:T $@
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MQ)4_%3&EH;3@$B-(6>*CO7MIO70GV,O.VZI07GB@.*A/38RD0JFR@\.MBO\
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M_5JG_P ?*_=[?]6J?_'ROW>Q2JJU(@@@@SI1!!X$$%78N+WA[X]UEO;VO/\
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M:0IJFT:FM+4J%1*'!*E)CQ(X40VV"225..*6ZMQQ7948[[S!4 %%EU;14!Q
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M"90:$"HXGJK>M\Q8*.X,L<<.&WE0K]:$H',)(JDX/A6..;KNLS8X\<<=HK]
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M=:Q)03OPJ52X4JHU.I2XT"G4^"P[*FSITQX1XD.'%8"EN.NN*2AMM"2I2B
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M?HHKN]K][U5Y?B9W?T/]K=2]U$_>N'VFV3^*?D-JY-.[ON"S:VWE29] J4F
MN0TE6;R:<TTKJY#)/IF'T+;5],D[1:7K59=+O^"@(:=N>V%,VO= 2/3R9E,R
MJILM?<;81"3W5=V,Q3]2H%H5F0$ T'45 LZ:VXOTC J,]1ICSA/1"(T]TD\
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M6GUD3 XRY:5C*DTY,Z(OH]37:\M:ITP*3T76@ZW'7SQQVJ'>>FUTU.U+AA]
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M%29<8I(Z3*@<-A7-4KVK%T/M..+@4]]U$6A4<.<%-T:@00W#C C!*E-,A:\
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M;)3,NZUJ^4C KJUC6ZRI??4*$U"'[4#8)72=)9!&.*WK3KR5*X8<0Q6$#O\
M ;*2U#TMAE7(N-:-44I'##HB74W1W^(.RFXVH=(H25XA7L-8UG9\I^E2[584
MI:?"E0/?V<:K^N6I+T=X%+T.FW-/M^ ^E7*AZ!;ZHK*T_6J;([VSTR?*DS9D
MA9<D2I;[LF2^X>5;S[Q4I1[ZB3VYB?39LNG3HRPY&FP9#T27'< P#C$F.4K0
MKOI(.S35!UROMQED ,L7%4&;SCM(3P2VVQ>+4] 0.0("<H' #9(F7%9U>*0
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M1CB.(X;T6C6_2:G7:Q.4XB%2J/ E5.I3%M-*?=3%@PD+=<*6T*6H(0<$@D\
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M\W>_#</'V"" 00001B"#P((.SMW672O)=%M8I51N"T41&<L"T[D#@D7/8IR
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M+>>9+IU(AJ1>U"9*05J$FE]=(;80"79,:,D#'>\VOV[S/<M4.QYK/_?-7?\
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MWLMM8Q0M*D*&)&*5#*H8CO;?F@KGPHZF_P!+; G1^MJ ()2=4=3L% 'D.6K
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M@5JB5)" \PYE#K$B.^R5-2([[:D/1I3"UM/-*2XTM2%!1W?-U_[EJ!^B6O\
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MHQYQ]XTJXHU]VW/.G4Z/:]L6PN!>-OH55WJ2XNWHL1+J)]/1+*2^5D/,,MM
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M.L1^SA\MSRQI/JK"?5 .5;/+CX4\O@Q[@WY,DCA@EA![O'.Y_P"GY;A!&(/
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M$E3GI >XGEV_"A]R?_<[?A0^Y/\ [G;\*'W)_P#<[?A0^Y/_ +G;\*'W)_\
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MIWD?PKOVW;,#Q!X$'GV,F.G&,H]- _S"B>3[$\W<Y.YNF(ZK!J0H=63R(?Y
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M>#BGQ=H0T@8K<6E"1W5*.4#9IA'I6FTH'?P'%1[Y/$[RW75!#:!F4H\@'^'
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M(/U?3<P[S:3\\C8*0CK'1QZYW!2@?K!R)\7'O]M9F)'IO47<!SC%3:CXL0?
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>2\O[!*&_MLVP*8Z%J'TSN+IQ[N"\0/$/_P"M.__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>infu-20251231_g2.jpg
<TEXT>
begin 644 infu-20251231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBO!?B]_P4]_8,^!?BB?P7\2?VC](M]4M)3%=V>F6
MEUJ+6\@X*2?8XI1&P/!5B"#P10![U17GWP&_:K_9U_:>TR?5?@-\7='\2+:@
M&[M[.8K<6X/0R02!98P>Q90#@XZ5VVKZ]H?A^&&XU[6;2RCN+N*UMWN[A8Q+
M/*X2*)2Q&YW<A54<L2  2: +=%%% !1110 45A?$OXE^!?@[X&U'XE_$SQ)!
MI&A:3$LFHZE<JQ2!2ZH"0H)^\RC@=ZM^#/&'AKXA>$=,\>>#-7CU#2-9L(;W
M2[Z$$)<6\J!XY!D X92#R >: -*BBJ^KZMIV@Z3=:YJ]TL%I96[SW4[YQ'&B
MEF8X[  F@"Q17SQ_P]A_X)W?]'3Z!_WXN?\ XU77?"/]NS]CWX[>(8_"7PH_
M:(\,:OJT^1;Z6E^(KF<CJ(XI0K2' SA0>.: /6:*** "BBB@ HKQK]H+_@H-
M^QS^RSXJA\#_ !U^.%CHNL30K,-,BL+J\FC1ONM(EK%(8@1R-^W(Y'%>L^'=
M?TCQ9X?L?%.@7?VBPU*SBNK*?RV3S(9$#HVU@&&5(." 1GD4 7**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HKAOCA^TS\ ?V;-'BUSXZ?%G1?#
M4-QG[+'J-V!-<8Z^5"N9)<=]BG&:\N\"_P#!6C_@G;\1O$$7ACPW^T_I$=W-
M($C.KZ?>Z=$S$X \V[@CC_\ 'J /HJBFPS0W$*7%O*LD<BAD=&R&!Y!!'44Z
M@ HHHH **** "BL'XG_$_P  _!CP)J'Q-^*'B:#1]!TI$?4-2N58I K.L:DA
M03RSJ.!WJ[X0\6>'?'WA/2_'7@_58[_2=:TZ"_TN^B!"7%O-&LD<BY .&1E(
MR >: -&BBB@ HKD_C)\<?A;^S_X2C\<?%OQ4NE:=/J,%A:LMI-<RW-U,^R*"
M*&!'EED8]%12< D\ D5OCM^T7\%/V9O Y^(WQT^(5EX=TCS1%%/=AVDGD()$
M<42*TDKX!.U%)P"<8!H [6BODW]G;_@LO^QC\?\ Q[>_#F3QJ/#>H2:\]CX9
M.M1RQQ:S!M3RIQ(T:I SNS((9&#948)+ 5]$?&7XV?#']GWP2_Q(^+_B4Z/H
M45Y!;7&IM8SS10/-((XS*84?RD+LJF1\(I8989% '544V&:&XA2XMY5DCD4,
MCHV0P/(((ZBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y9^W!J/Q)TC]D#XDZG\
M(?M(\1P>#KYM,:RSYZ-Y3;FBQSY@3<5QSN QSBODO_@C_P"'_P#@FWXG_9F\
M/:/#I/@#5/B+<12?\)7;>*;:UFU9[HR,"$6X!<P[=H7RODQC/SEJ^T_C_P#M
M ?"[]F+X87OQA^,>MS:=H&GRQ1W5W!82W+(TKB-!LB5FY9@,XP,C)%?/OQ3_
M ."3O_!/;]L+2;;XP:1X$GT*7Q/8Q:E;Z[X-O39?:8YT$J2F!E>#+!@Q/E D
MGDF@"K\2/^"9UUX1_;0^'?[5W[&$?ACP+%IEZT?Q%T6,RVEOJEBSQAU@@@B:
M/S'B,P8'8NY87^\"U>(?\%=/VA?%FD_MN? GPY;_  (\:7-OX#^(%OJ-A<6]
MB3!XLE=M.F\C3^TTT9S"1V>3'>L_XF>"/VEO^"+OQ!\#^._!G[1^L^._A)XC
M\2Q:-JWA/Q&S-):!P6Q$I9E5_+21EEB$?S1A71E.#ZO_ ,%7_P#D\;]CW_LJ
MY_\ 2S2J /?/&G[=7PO^#G[+UA^T]^T-X;UWP+!?AHXO"FM6.-6-SOD5+98,
MC,C+&7&2%"G<Q4 FO&+C_@L/>>$]+M?B)\7/V$?BYX5\!7DB"/QC>Z2'CBCD
M($<LL>%V(V00=YSGY=V0#S?_  4CLK/QU_P4R_9=^&?CB)9O#7]I7-\+.X&8
M9[L2HP5U/#_-#"N#GAR/XCG[A\>>%?"_CGP1J_@SQO90W.CZKID]IJD%P!L>
MWDC*R!L\8VDT 9EA\;?A/J?P@7X^6/CW3G\&MHYU7_A(?.Q;BT"%VE)/(P <
MJ1N!!!&1BOE:/_@L0WC"PO\ QY\$/V'OBOXS\":;)(MQXRL=*$<,J1DB22)"
M&WJH!)RRD#[P3G'Q=X/\?>.8O^" GBS0XK^X:QB^+2Z3 V2 NGLUI=%1Z*;A
MFR/5B.YK]<?V=?"_AGP5\ O!7A3P;:PPZ78>%;"*Q2!0%,8MTPW'4G[Q/<DD
M]: /F/\ ;7_::^$O[6__  2,^(GQF^#6M276E7>EPPS0W,7EW%E<)>6V^WF3
M)V2+N4X!((964E6!/9?"']IKX3?LE?\ !,/X7_&+XPZ\+33[/X9Z(EK:Q8:X
MU"X-A$4MX$)&^1L'T  +,0JDCA?VZ?A+^S+\'_\ @G)\=]"_9NTW1+(74R7/
MBBST;5C<^5J!OH5<2(9'\AP59=@"@;-N!MP/CKX5:A\5/AWX[_9M_:*_X*&^
M"K34?@]+H-KHO@.W-P7L] $=O$MK?W,(RA>0(MP=Y8L@9L#R5C4 _5_]F[XR
M:_\ 'WX4V'Q5UOX2ZSX,CU5?-T[2?$$D?VM[<@%)G1"?+#9R%8[L8) R*U/C
MA_R17QA_V*VH?^DTE=-%+%<1+/!*KHZAD=&R&!Z$'N*YGXX?\D5\8?\ 8K:A
M_P"DTE 'PK_P15_91_9C^+_[$-IXR^*O[/W@WQ'JS^)M0A;4M;\.6US.8U9-
MJ;Y$+8&3@9XJ+_@LS^QK^RG\&?V41\=_A)\.=#\!^+_#_B&P&@WOA>V33WNG
M>8!HBL6T,RJ&F5L;U,'! W ^4?\ !+K]B/\ :D^/'[*MMX_^$W_!0[Q5\-=(
M?7;R!?#.D:/+-"DB%=TNY;V$9;(R-G;J:^D/#?\ P1D7QAX[TGQK^V5^V)XX
M^,,.B7 GL=#UD/;V18$':Z23SG8<#<J%-W0DC((![?=?MA>!_@/^Q7X0_:6_
M:>UXZ9)J'A'2KC4((X-UQ=:C<6:2M;PQ#&Z0MO\ EX "L6*JI(\>D_X+!W?A
MK2K7XC_%7]A/XN>&/A_=R)L\9WFD!XX8G($<TL6!L1L@@ASG(V[R0#YG_P %
MFKKXAZG^UO\ LW_#_P "^#M.UXIJUQ>Z/X;U>X$%CJ5^D]L$AF)*KMPBK@GI
M(1_$<^B>-?B)_P %AOB#X.U7P)XH_84^&=SINM:=-8W]O)XSC*R0RH4=2#<8
MY5C0!]#?&C]K7X:?";]E>_\ VNM*9_$_A>TTJWU"U;1I5W7L$TL<:%"Y ',@
M)#8(P00",5\]6?\ P6F\&^+O%5GI'P?_ &4?B5XUTNY@BB?6_#VG+)"-0> 2
MFS0_=D9&/ELVX$LK%5<;2WENL? ;X^?LT?\ !"KXD?!O]H;28K'5-+O&;2[6
M'48KI4LI=0LY5P\3,H_>O.=N<C\:^P?^"<_A?1O"'["'PDTO0[-((9_ .FWL
MB1J &FN8%N)6/NTDKL3ZF@#\\_V=OCM:^+_^"DGQ>^*?Q!_8(\;>,[_79;&U
M7P_>>%DO+OPNA\N,O=1R*PA!2- &QG:I'0FON7]IW_@HW\)OV9_B%8?L\>!_
MAQXB^(/Q N+5'M_!'@C3Q+):0[-R&8CB(%/F"JK,%PQ55*D^3?L'_P#*6#]J
M7_?TW^54/^"2EG:>+/VQ/VJOBAXIB6;Q/%\1&TWS9AF6TLQ=WN(5)Y5#Y,:X
M_P"G=/[M 'JGP1_X*C>!O'/QFLOV=_CS\$_&'PD\9:OC^P;#QE:!;?4R20J0
MS@#+L00N5"LWRJQ8A3T'[7/_  4;^#?[%_Q.\-_#SXMZ)JAA\1:+?ZC'JMD(
MVCA%M&["'86#-)*RK&@'!:1<D#)KQ;_@X"TG1K3]D?PW\28F6U\0^'OB!9-X
M?U*,[9X7>&<NB-U /E(Y [PJ>U8W[=F@V?C_ /X*@?LI6/C#3(Y!-!+>7-K*
MF5$T3B=00>PD0<'TH ]*\$_\%9=+U_X)?$3XV^,_V5O'_A>S^'MG8W<]KK-O
M'$VH0W<_DQ>29-GS<%B,%0!][) .3K__  62T&_T&3QM\#OV1OB5X^\-:;81
MS^(_%&C:65L-/D\M9)H1-M82M""0[?*H*D@E?FKOO^"OW_*.#XH?]@RS_P#3
MA;5UG_!/CPKH.@?L&_"71-,TR&.UN?AWI=S/ (QMDDN;5)YF([[I)78^I8T
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MW#=@9:N1\3^&]'U__@X#T*ZU:QCG;2_A4;RS\Q01',$GC#C/<"1L'L>:T_\
M@X)L+.Y_83M+R>W1I;7QYI[V\A7F-C#<J2#VR&(H ^H?VG?VHO@]^R'\*[GX
MO?&K7WL],AF6"UM[:+S+F^N&!*P0QY&]R%8\D* I9B "1\X3?\%B9/".GV/Q
M ^,_[#GQ7\'^ M1N(XX?&>HZ4'BB20@1RRQX4HK9!&&8D?<#G /*?\%(DB\=
M?MZ_LF?#CQL@G\/7&MRWTUK/S%=70DM2%<'A^41<'M(P_B-?;GQ9\%_#CXB?
M#/7?!/Q>TZSNO"^HZ9+%KT.H3F*'[-M)=FD#*8PH&[>&4KMW @C- ')?&_\
M;"_9_P#V?_@/#^T?X^\=0GPO?6T,NC7.GCSI-5,R>9"EL@(\QG3YAR %!9BJ
M@D?/LG_!8*Z\,:9:_$3XM_L*_%OPKX O)$">,[W2 \<,;D".:6( ;$;(P0S9
MR-N\D ^&?\%+](M=%^/7[+7P;_9:\'Z!XA\,Z9<7-SX,\-S:SOTK4+I+J';"
M\[2$.H,87ES]]E_B(KVGQW\0/^"PWQ&\$ZO\/_%/["OPSN=-UO3)[&_@D\9Q
ML'AEC*.,&XQT8T ?8W@KQIX4^(WA'3?'G@;7K?5-'U>SCN]-U"T?='<0NH97
M4^X/0\CH<&JWQ1^(&B_";X:>(?BEXDW?V?X;T.[U2^"'YC%;PM*X'N0A ]Z\
M(_X)0_ GX]_LU_LB6?P:_:%TJ*RU72==O3IMM#J,5TJ64K+*N'C9E'[UYOES
MD?C7HO[:W@;7/B7^R%\3? ?AF!YM2U3P-J<%A!&,M-,;9RD8]V8!?^!4 ?&W
M_!,O]E'0?VX'UC_@HQ^VEHEOXRUCQ5K=Q%X2T35T\_3M/LX)&CRL#Y1U619(
MD1@541%L%G)'UM\9OV _V0?CGX&N_ OB_P" 7A>WCN+=H[;4M(T2"TO+)B,"
M2&:) R$'!QDJ<88,.*\H_P""'WQ%\.^-_P#@GCX4\/Z1>1M>^%[[4=-U>W5A
MF&4WDMPF1_M13QMGN2?2MK]I/]E+]N_XH?&#4O&GP0_;[G\"^&[J*W6R\,IX
M82Y%JR0HDC>87!.]U9^G&[% &U_P3;^ W[1?[+O[/$OP8_:&\6:9K2Z)K%PO
MA*ZL+R2:2/2N/+BEWH-I#!V50SA4=5R H%>*V_\ P7A^$GB7PEIVM_#']G#Q
MYXHU&59I];T;2+=)7T:T20H)IWCWJ"Y#%5X^499ERN;W_!)+XS_M%_$'Q]\?
M?A=^T'\9;WQI/\/?%%OH^GW]W;1Q#,<NH0RR*J ;0Y@1L$G& ,UE?\&\/A?1
MM+_8QU_Q1;6<8OM5\?727=SM&]XXK6U$:$]U4M(0.QD;UH ]L_:(_P""D7PQ
M^ -UX5\#Q?#/QAXH^('C+28M0TCX=>'M,6;4X8I$+?Z0%8K%@JZG:7.8W(!4
M%JX32_\ @KOIO@_XCZ)X _:J_9,^(/PH@\1W2VNDZ]X@MEDLFE8@8=PJ;5&X
M;BN_;D%@!DBC^T;^U%\*/A7^W)<>&OV9OV.[SXJ?'H^'5AUV]T_4/LD>F6#+
M$RI-,X=%.WR23L4 2*OF N5KYK_X*]>._P#@H+X__98T[5/VGO@-X%\!^%8O
M&5H;*RLM>.H:LUZ;>YV8DB=H1&(_-W=&SMQQF@#[[_;&_;G^&'[$\_@J;XJZ
M3?/I_C#7O[-;4[4KY>F(-A>XF!^9D57W$("V%. 3BO'=5_X+"1>'-&@^+'BC
M]B7XKZ?\,+J=!;^/I]+01F!R!'<M 2-L39!5B_S C;DD+7.?\%D?#/AWQWX\
M_9C\&^,XHY=)UGXM6MGJL<WW7MY9;5)0WL59@?K7VE\3?"WA7Q5\+]?\&^+;
M*!]%O]"N;348)4'E_9GA97!'0#:3]* /G'_@J+X]\'_%'_@E3X[^(OP_U^#5
M-%UK0=.N],U"V)*3PO?VI5AG!![$$ @@@@$$5Y5^SQ_P5'_X1#]E[P!X0^"/
M[(OQ+^)EKX.^'NC6'BGQ#X=T9UL+2[@T^!9X$DV,97C8,&X &,@D<UXQ\$==
M\0:Q_P &[WQ%LM:ED:WTS79;72MY.!;G4K&4A?;S99OQS7Z$?\$]_#FC>%OV
M%_A%INA6$=M#+\.M(O)(XE #37%I'/,YQW:21V)[EC0!=_8__;!^$?[:_P )
ME^+/PCGO(X(KQK/5-+U.)8[JPN556,<@5F4Y5E8,I((;U! ]4KX2_P"".-M!
MIGQL_:ET+3XEAL[/XOSI;6\8PD2BYOE  [#"J/P%?=M 'Q8-;/[8W_!6R7PG
M=M]H\%_L[:*MVEM]Z*X\1W04+*P[F)2P7/*O:L1]XUQ'_!1[4O >B?\ !4_X
M ZO^U$L ^%4.AW?D2ZPH.G1ZMNN/FFW?+M#_ -G%BWR@!2WR@UM_\$<R^I?'
MG]J?Q-JASJ=Y\69$O"WW@JW-^5'T!=P![5],_&^W_9#^/_B1?V1_CD?#/B+6
M;VS.H0^$=0D#7<<2J?\ 2(]I$D+!=V)%96QG!ZT ?,/P]_8]^#7[>?PM^/WP
M^U^^MH8F_:,U&[\/>*=*@BGEL0MGI;%K=_NE)(PR$ [2'!Y*BOL#5?@AX=\6
M_L_/^SS\1=1NO$.FW7A9=$U6_P!1VFXOD$ A:X<@8$I(\S< ,/R,8%?F O[%
MGB7X$>!/CO\ M/\ ['?QR\2^!M3^#_Q1U2RM- AU!I;&^TJTMK.?RY ^3)(!
M/+_K?,5PBJ5!):OTI_8\^.-]^TG^S!X(^..JZ;':7OB+0HKB_MX01&ER,QR[
M >0AD1BH))VD<F@#Q/\ X)#_ !D\5^(?@YXF_9@^)^I-=>*_@GXGG\,7L[DE
MI[*-Y$M9#GL!%+$/]F!3DDFOK:OA#]B#=H__  6"_:;T'23BPN;*QN[E4^Z;
M@B%LGWS--^9K[OH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI-JNB:YX;,DFGVEQ]H+)%DEG",D5LQ8;BDD>1N&5;D_&_A7_ (+8?'+P#<_
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M> ].TJYOK$^:++4+:VC1+F!F"D[)4R.!N7*GAB*]]HH \'_X)W_##]J3X'?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.!DDY9F9O4Z "BBB@"*\M8[ZU>TF9@LBX8HV#^!K,_X0?2/^?F]_\"VK8HH
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK
M8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV
M** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK
M8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV
M** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VJUI6@66CR/):RSL77!\V8L/UJ]10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME*+#*I9<_>#9(D4G[=H **** "BHKRUCOK5[29F"R+ABC8/X&LS_ (0?2/\
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%8WCWX@>#OAAX6NO&GCS7X--TVT7,US.3U[*H&2['H% ))Z"OE[Q5_P
M5M\#:?JKVW@[X1:EJ=HKX%U?:FEHSC/4($DX],D'U KWLGX8S[/U*6 H.:6[
MT2OVO)I7\KW/ SGBG(.'W&.88A0;V6K=N_+%-V\[6/KJBO$OV>?V\/@W\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBO._B5^UC^SU\)O,A\8_%'35NH\AK"QD-U< ^ACB#%3_ +V![UU83!8S'U?9
M8:G*<NT4V_N1RXO'8++Z7M<55C3CWDU%?>['HE%?('C?_@JG#J=]_P (_P#
MGX/WVJW<K;;:?5B07;_9MX-S./\ @:GVK"_X1C_@II^TMSK>K3>#=(G_ .6<
MDO\ 9BJIZJ4C!N6&.SY%?84N <UI4U5S.K3PL'_S\DN9^D5=M^3LSXRKX@Y3
M6J.EE=*IBYK_ )]P?*O63LDO-71]8_$3XY?"#X30M)\1/B+I6E.%W"VGN@9V
M'JL2Y=OP4U^1^L:A<:MJ]UJEW<&66YN7EEE.<NS,26YYY)S7W5\._P#@E-X
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M%>3Y^W3HR<:L?BIS7+4B^MXO>W=71T5%%%?.'T@4444 %%%% !1110 4444
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MGYIK1KT9]AD^>Y3GV&]O@:JG'K;=>4D]4_5#J***\H]8**** "BBB@ HHHH
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M6EG;I%%&H6.*) JJ!V ' %/HHKY9MMW9]6DDK(****0PHHHH **** "BBB@
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MJ*<'LXM-?@%%%%<QTA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD_M??&?]KN3XJ:W\8O#?]@MX?\;#3])\-26@CFTB 19-O,Q4,\H8?,6 .[(
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M7:;,^^S./:OL>@ HHHH **BO)Y+:U>>&V:9E7*Q)U;V%9G_"2ZO_ -"A>_\
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MR/YE\6N(<RK<03RQ3<:--1]U.RDY14FWWWLKZ*VF[.U^$W[0WQ@^">LPZMX
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M.""=A1_TMMK:"SMH[.UB6.*) D:*.%4#  _"ECBBBW>5&J[FW-M&,GU/O3J
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M+L_1+J?6%%?%?P__ &\/CA^SWXAC^&/[7O@*_G6/Y8]62%4NP@XW\?N[I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$VF#2:/F+XL_\$N/@_XXUF;7? 'B6\\*O<.7ELH;9;FU4GD[(RRL@SV#[1T
M H^$W_!+CX/^"-9AUWQ_XFO/%3V[AXK*6V6VM6(Y&^,,S.,]B^T]""*^G:*^
ML_UZXM^I_5?K<N2UNG-;_';G_P#)CY'_ %"X/^N_6OJ<.>]^O+?_  7Y/_)1
MEO;P6D"6MK D442!(XXU"JB@8  '  ':GT45\FVVSZY))604444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!,?BSQ3)>-XDN_*:&XO77:B?9U$A,8V9+%26#1LM97Q M_@Q^T=^W%\<-?\
MVD_VR_$7PU\)>#M4TG0/"UMI7Q!CT=+J[2U(O %E#"0K(F3M7(\SD\4 ?I11
M7AO[$O[-WP>^"/A_5?&7P6_:$\6?$/2?%26Q34_$/C*/6;=! 9@#;21HJKN,
MK!\$YV+TVU[E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNFM4TSUH3A4@I1=TPHHHK<H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44
M 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVX/EVT>>78_R'4GBOO\ K-\.^#_"WA'[5_PC.@VUC]NN6N+O[/&%\V0]6/\
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M5X-->04445U%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 RYN8+.!KJZE"1H,N[= *H?\)CX8_Z#4'_?5:+HDBE)$#*>H89!J+^SM/\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *VL:/I?B#2Y]$UNPBNK2ZB,=Q;S+E74]017R!\=OV6/%
M/P^\4P_\(3IMSJ>DZG<B*P\I"\D$C'B%_P"C="!S@BOLBBOD>+>#<KXOPL:>
M(]V<?AFOB2ZKS3[/9ZHX<;@*..@E+1K9GEO[./[..E?!W2AK>MI%=>(;J+%Q
M<#E;53UBC/\ -N_TKU*BBO<RC*,!D> A@\'#EA'[V^K;ZM]6=-"A2P])4Z:L
MD%%%%>D:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\J?M9_'#]HOQK^UYX4_81_9G^(%EX'O-3\)R^
M)_%7C:YTF.^GMK%9G@2&VAE^0R,\9R3R ZD%=IS]5UX!^UU^Q+!^T)X_\.?&
MKX6_&C4?AS\4?"EG+#H?BC3(([D2VC,2T%Q;N0)HMSMQD >:V0P.* /!O^">
M7BO]O7P$/A2/%GB.]^)_PN^(&C7;7E_-I:+>^#[F*1@IEN <SQ2-MP7)."^
MOE_/Z1\3?V@OVM?CY^UGXH_91_9!UKP]X/T[X?Z;9S^-/'?B'2&OY#=72;X;
M:U@)",-H;+/U,;\KM ?Q/]@O]K/]I?\ 9F\+?!7X6?M#^%/#NI_#3XE3G2/
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M/!!(-?('[3NDZ7H7_!5/]E/1=#TVWL[.UTKQ3%:VEI"L<4*+IK!455 "J!P
M!@4 >H_MY_M3>/\ ]G3PMX5\)?!3P?9ZWX^^(GB>'0?"=OJI<65M*Y&^YN"A
M!,:;D& 1RX.<*0?'?CA\7_\ @HW^P5X1M/VBOCG\4?!?Q-\#VVIVMOXST72_
M#/\ 9EWID,\JQ"6TE5L2XD95_>#)W+\N"63[4U/4]-T33;C6=9U""TL[2!YK
MJ[NI1''#&H+,[LQ 50 22> !7PM\4O%7B3_@K]\0;?X'?!^UNK+X >&==BN/
M'7CJ5&B_X2BX@;<MA8@@%HPV"TG8[7XVQB4 ^D/VV/V@[OX#_L>^+OC=X(O
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M;Q[X,\(?9-<^('_"+:=_;S>&9K ZS]C3[5]E599%@\W&_P L.[MLSC+$XR:
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M2$;:#M8BY_P39^./Q#_:2_8J\%?&OXKZE#>:_KBZ@U_<6]JD"-Y6HW,* (@
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M*A.\:C"_,7^NJ* ,GQ_HM[XD\":UX>TW9]HO](N;:#S&PN]XF5<GL,D5X?\
ML7_ [XV_LJ?\$\])^#%WI6GWOCSP[H>L&QLK.^5K>>\ENKNXMD$KA5 )EB!+
M8 R<]*^AJ* /%/V4_@?X^_9C_8>T'X3Z%86=SXUTKPK/<2P7EUF"?7)Q)<2+
M)*N=R?:92I<9^49%?)_[,O[,'_!67]F37_$OC[2?A=\&?$WC#Q?J+W7B#QGX
MIUJ\GU&X#$$0!XV18X01D(J@=,Y"J%_1NB@#RK]EO6?VR-8TG5W_ &PO"'@;
M2+U+B(:(G@BZN)8Y(MK>89?.=B&#;<8QQFN1_;D_9J^)/[0/C;X)Z_\ #];
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M)]5HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<"5# 'V;7,>.OC/\+_AIXG\-^#?'7C&VTW5/%]^UEX;LYU<M?W"A2T:;00"
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MA\$6LUTTEY>Z:&(2[G4J%C\SC:JYR 6!*LI(![+1110 4444 %%%% !1110
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MM5;XT_L_?!7]HKPPG@[XW_#32?$NG13>;;P:G;!C!)C&^-QAXVQP2I!(XZ4
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M]G?P]I>KPMNMM3>%[F>W;^]$\[.8CVRF#@D=ZPOV[?V@/C!\+/"'_"MO@O\
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M:7J,/F0S^7(LJ;E[X=$8>ZB@#XN_;@C27PY^Q;'(@96^+GA,%2.#^[AKK/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 25, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INFUSYSTEM HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3341405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3851 West Hamlin Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rochester Hills<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">291-1210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INFU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,267,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,215,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for its 2026 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001337013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Detroit, Michigan<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">22,901<span></span>
</td>
<td class="nump">21,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">5,391<span></span>
</td>
<td class="nump">6,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,858<span></span>
</td>
<td class="nump">3,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,336<span></span>
</td>
<td class="nump">32,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentHeldForSaleOrRental', window );">Medical equipment for sale or rental</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="nump">3,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation', window );">Medical equipment in rental service, net of accumulated depreciation</a></td>
<td class="nump">34,456<span></span>
</td>
<td class="nump">39,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property &amp; equipment, net of accumulated depreciation</a></td>
<td class="nump">3,359<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,710<span></span>
</td>
<td class="nump">3,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">6,866<span></span>
</td>
<td class="nump">6,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">4,178<span></span>
</td>
<td class="nump">5,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">7,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">100,560<span></span>
</td>
<td class="nump">103,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,821<span></span>
</td>
<td class="nump">9,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">9,361<span></span>
</td>
<td class="nump">7,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,182<span></span>
</td>
<td class="nump">17,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">19,625<span></span>
</td>
<td class="nump">23,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">3,427<span></span>
</td>
<td class="nump">4,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,234<span></span>
</td>
<td class="nump">46,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: authorized 200,000,000 shares; 20,209,636 shares issued and outstanding as of December&#160;31, 2025 and 21,272,351 shares issued and outstanding as of December&#160;31, 2024</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">117,461<span></span>
</td>
<td class="nump">113,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(60,702)<span></span>
</td>
<td class="num">(57,460)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">57,326<span></span>
</td>
<td class="nump">57,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 100,560<span></span>
</td>
<td class="nump">$ 103,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentHeldForSaleOrRental">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents medical equipment held for sale or rental as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentHeldForSaleOrRental</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents medical equipment in rental service, net of accumulated depreciation, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock,, authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">20,209,636<span></span>
</td>
<td class="nump">21,272,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">20,209,636<span></span>
</td>
<td class="nump">21,272,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues</a></td>
<td class="nump">$ 143,436<span></span>
</td>
<td class="nump">$ 134,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">63,140<span></span>
</td>
<td class="nump">64,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">80,296<span></span>
</td>
<td class="nump">70,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">10,487<span></span>
</td>
<td class="nump">11,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">56,969<span></span>
</td>
<td class="nump">51,209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total selling, general and administrative</a></td>
<td class="nump">68,376<span></span>
</td>
<td class="nump">63,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">11,920<span></span>
</td>
<td class="nump">6,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,299)<span></span>
</td>
<td class="num">(1,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) before income taxes</a></td>
<td class="nump">10,623<span></span>
</td>
<td class="nump">5,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(3,996)<span></span>
</td>
<td class="num">(2,714)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,627<span></span>
</td>
<td class="nump">$ 2,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">20,657,877<span></span>
</td>
<td class="nump">21,271,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">21,097,323<span></span>
</td>
<td class="nump">21,707,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,627<span></span>
</td>
<td class="nump">$ 2,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent', window );">Unrealized gain (loss) on hedges</a></td>
<td class="num">(733)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent', window );">(Provision for) benefit from income tax on unrealized hedge gain (loss)</a></td>
<td class="nump">179<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(554)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive income</a></td>
<td class="nump">$ 6,073<span></span>
</td>
<td class="nump">$ 2,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Retained Deficit</div></th>
<th class="th"><div>Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 52,302<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 109,837<span></span>
</td>
<td class="num">$ (58,625)<span></span>
</td>
<td class="nump">$ 1,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Shares issued upon restricted stock vesting and option exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Shares issued upon restricted stock vesting and option exercise</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="nump">52,965<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Employee stock purchase plan</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock repurchased as part of share repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock repurchased as part of share repurchase program</a></td>
<td class="num">$ (1,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)</a></td>
<td class="num">(108,607)<span></span>
</td>
<td class="num">(109,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation</a></td>
<td class="num">$ (816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">21,272,351<span></span>
</td>
<td class="nump">21,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 57,529<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">113,868<span></span>
</td>
<td class="num">(57,460)<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Shares issued upon restricted stock vesting and option exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Shares issued upon restricted stock vesting and option exercise</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="nump">61,470<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Employee stock purchase plan</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock repurchased as part of share repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,327,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock repurchased as part of share repurchase program</a></td>
<td class="num">$ (9,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)</a></td>
<td class="num">(132,909)<span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation</a></td>
<td class="num">$ (1,105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 6,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">20,209,636<span></span>
</td>
<td class="nump">20,210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 57,326<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 117,461<span></span>
</td>
<td class="num">$ (60,702)<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481117/718-50-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,627<span></span>
</td>
<td class="nump">$ 2,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,374<span></span>
</td>
<td class="nump">11,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on disposal of and reserve adjustments for medical equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">519<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of medical equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,308)<span></span>
</td>
<td class="num">(2,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">920<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,363<span></span>
</td>
<td class="nump">4,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,726<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets - (increase)/decrease:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263<span></span>
</td>
<td class="num">(701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,140<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(903)<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in liabilities - (decrease)/increase:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(676)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,408<span></span>
</td>
<td class="nump">20,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates', window );">Acquisition of business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,412)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_PaymentsToAcquireMedicalEquipment', window );">Purchase of medical equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,126)<span></span>
</td>
<td class="num">(16,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(1,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of medical equipment, property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,308<span></span>
</td>
<td class="nump">4,594<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,790)<span></span>
</td>
<td class="num">(13,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Principal payments on long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52,349)<span></span>
</td>
<td class="num">(56,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Cash proceeds from long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,226<span></span>
</td>
<td class="nump">50,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(197)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock repurchased as part of share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,869)<span></span>
</td>
<td class="num">(1,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,105)<span></span>
</td>
<td class="num">(816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Cash proceeds from exercise of options and ESPP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">335<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,959)<span></span>
</td>
<td class="num">(6,924)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">527<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,186<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">543<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH TRANSACTIONS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions to medical equipment and property</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,094<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts consist of current liabilities for medical equipment and property that have not been included in investing activities. These amounts have not been paid for as of December 31, 2025 and 2024, respectively, but will be included as a cash outflow from investing activities for purchases of medical equipment and property when paid.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_PaymentsToAcquireMedicalEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of cash paid during the period to acquire medical equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_PaymentsToAcquireMedicalEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation and Nature of Operations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt">Basis of Presentation and Nature of Operations</span><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem Holdings, Inc. and its consolidated subsidiaries (collectively, the &#8220;Company&#8221;) are a leading national provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from seven locations in the United States ("U.S.") and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site healthcare providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem, Inc. is the operating subsidiary of the Company. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s core service is supplying electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company&#8217;s pumps are electronic infusion pumps. ICU Medical, Inc. supplied approximately 60% of the ambulatory pumps purchased by the Company in 2025. The Company has a supply agreement in place with this supplier. Certain &#8220;spot&#8221; purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (&#8220;NPWT&#8221;) medical equipment, as well as related disposables and ancillary supplies.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company&#8217;s ambulatory infusion pump management service.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt">Summary of Significant Accounting Policies</span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in two reportable segments, Patient Services and Device Solutions based on management's view of its business for purpose of evaluating performance and making operating decisions. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company&#8217;s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker ("CODM"), reviews segment financial information. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i13594bbbfc1e4b049c5f01f53e10e953_142" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 14</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for segment disclosures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions.  For intangible assets, the Company typically uses the income approach to determine their estimated fair values. Key estimates and assumptions in that approach include the amount and timing of projected future cash flow, the discount rate selected to measure the risks inherent in those cash flows and the assessment of the asset's useful life. Initial purchase price allocations are subject to revision within the measurement period, not to exceed one year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains substantially all of its cash and cash equivalents primarily with two financial institutions that are insured with the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits. Accounts at banks with an aggregate excess of the amount of outstanding checks over the cash balances are included in accounts payable in current liabilities in the consolidated balance sheet. At December&#160;31, 2025, and 2024, the Company did not have any cash equivalents.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from multiple sources including from the sale and rental of our products as well as service contracts. Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") stipulates revenue recognition at the time and in an amount that reflects the consideration expected to be entitled for the performance obligations that have been provided. ASC 606 defines contracts as creating enforceable rights and may be established through written contracts, oral agreements and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three separate and distinct performance obligations offered to its customers: a rental service performance obligation, a product sale performance obligation and a service performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial payers, government insurance payers, medical facilities and patients.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates a significant amount of its revenues that are accounted for under ASC 606 from the rental service of infusion pumps to its customers and the remainder of its revenue from product sales and services. For the rental service performance obligation revenue is based on its standalone price, determined using reimbursement rates established by third-party payer or other contracts. Revenue is recognized over the contract term in the period in which the related performance obligation is satisfied. The Company&#8217;s revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms, or when the customer uses the products in the case of when our products are stored at a customer's location. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products. The Company's revenues related to services are recognized as the service work is completed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and product performance obligations. These judgments include, among others, the estimation of variable consideration. The Company allocates variable consideration using standalone selling price when appropriate and available. When an appropriate standalone selling price is not available, the Company allocates based on a best estimate approach using the relative fair market value. Variable factors include differences in transaction price and changes in the expected total volume of services during the contract period.  In calculating the variable amount of revenue for these performance obligations, variable consideration is estimated as price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other customer concessions. The contract period starts at contract inception and typically extends 30 days past the end of each reporting period representing the non-cancelable period of each agreement.  These estimates for variable consideration are based on historical service volumes with our customers and prices with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn&#8217;t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that is expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the components of variable consideration.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as changes in volume and actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer&#8217;s ability to pay are recorded as an adjustment to the allowance for credit losses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Arrangements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generates its revenues from the rental of infusion pumps to its customers as leases. Under Accounting Standards Codification Topic 842, "Leases" ("ASC 842"), leases may be classified as either financing, sales-type, or operating, and the Company is required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition and classification within the statement of operations. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient for all qualifying non-lease components. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial insurance payers, government insurance payers, medical facilities and patients.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily participates in operating leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. The Company&#8217;s operating leases are primarily for medical equipment under operating lease arrangements that expire at various dates over the next twelve months. The Company&#8217;s leases do not contain any restrictive covenants. Most of the Company&#8217;s equipment leases do not contain any material residual value guarantees. For the agreements that have guarantees, the residual value reflects management's best estimate of the expected sales price for the equipment at lease termination based on sales history adjusted for recent trends in the expected exit markets. The Company&#8217;s equipment leases may contain renewal options which range from one week to one year. Lease payments receivable reflect contractual lease payments adjusted for renewal or termination options that the Company believe the customer is reasonably certain to exercise. As of December&#160;31, 2025, the Company did not have any operating leases that contained renewal options with increasing rental amounts. Many of the Company's leases allow the customer to extend the lease at prevailing market terms. The Company's operating leased assets are not protected against casualty loss through third-party insurance.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates, including management's assessment of probability of collection, are required to record revenue and accounts receivable at their net realizable values, otherwise, if probability of collection is not met, the Company records revenue for such leases on a cash basis. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in variable lease payments that require adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. The Company adjusts revenue for historical trends on revenue adjustments due to timely filings, deaths, and other types of analyzable adjustments on a monthly basis to record rental revenue at the expected collectible amounts. Consistent with Accounting Standards Codification Topic 450, "Contingencies", for contracts where collection is considered probable, accounts receivable is reduced by an allowance for credit losses which provides for those accounts from which payment is not expected to be received although product was delivered and revenue was earned. The Company records an allowance for credit losses based upon an analysis of historical collections. The Company has elected to record the adjustments to accounts receivables in net revenues on the <span style="-sec-ix-hidden:f-302"><span style="-sec-ix-hidden:f-303">Consolidated Statements of Operations and Comprehensive Income</span></span>. The determination that an account is uncollectible, and the ultimate write-off of that account occurs once collection is considered to be highly unlikely, and it is written-off and charged to the allowance at that time.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also participates in sales-type leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. In a sales-type lease, lessors are required to recognize a lease receivable, selling profit, initial indirect costs, and residual asset values for all of these types of leases, and to disclose key information about leasing arrangements. The Company&#8217;s sales-type leases are primarily for medical equipment under sales-type lease arrangements that expire at various dates over the next three years. The Company&#8217;s leases do not contain any restrictive covenants. The Company&#8217;s equipment leases do not contain any material residual value guarantees or renewal options.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease revenue for leased assets is recognized in net revenue. The Company further recognizes any variable lease payments that are not included in the net investment in the lease as income in profit or loss in the period when the changes in facts and circumstances on which the variable lease payments are based occur.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowance for Credit Losses, and Contingencies</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts billed that have not yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at net </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">realizable value, inclusive of adjustments for variable consideration. These adjustments reflect the amounts expected to be collected from payers based on an analysis of historical collections. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for credit losses, and contingencies, is established as a result of an adverse change in the Company&#8217;s payers&#8217; ability to pay outstanding billings. The allowance for credit losses was $0.3 million and $0.2 million as of December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (first-in, first-out basis) or net realizable value. Cost primarily represents the purchase price paid for the items on hand. The Company periodically performs an analysis of slow-moving inventory and records an adjustment to reflect the recoverable amount.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment (&#8220;Equipment&#8221;) consists of equipment that the Company purchases from third-parties and is (1) held for sale or rent, and (2) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically seven years. The Company does not depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a gain or loss is recorded in the current period. The Company periodically performs an analysis to identify potentially missing Equipment and records a reserve equal to the underlying net book value, which was $2.7 million and $2.5 million as of December&#160;31, 2025 and 2024, respectively. This amount approximates the accelerated depreciation the Company would recognize over the remaining useful lives of the assets determined to be missing. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than $0.1 million as of both December&#160;31, 2025 and 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Medical Equipment in the Consolidated Statements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (&#8220;Unallocated Assets&#8221;). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its two primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from <span style="-sec-ix-hidden:f-316">three</span> to seven years. Externally purchased information technology software and hardware are depreciated over <span style="-sec-ix-hidden:f-318">three</span> and five years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are expensed to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually or more frequently when certain events or circumstances trigger a review. Management has the option to first assess qualitative factors such as current performance and overall economic conditions to determine whether or not it is necessary to perform a quantitative goodwill impairment test. If the Company chooses that option, then the Company would not be required to perform a quantitative goodwill impairment test unless the Company determines that, based on a qualitative assessment, it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines that an impairment is more likely than not, or if the Company chooses not to perform a qualitative assessment, the Company will then proceed with the quantitative assessment. Under the quantitative test, if the fair value of a reporting unit exceeds its carrying amount, then goodwill of the reporting unit is considered to not be impaired. If the carrying amount of the reporting unit exceeds its fair value, then an impairment loss is recognized in an amount equal to the excess, up to the value of the goodwill. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that there was no impairment. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of trade names, physician and customer relationships, unpatented technology, non-competition agreements and software. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from <span style="-sec-ix-hidden:f-322">fifteen</span> to twenty years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others. The useful lives of these relationships are based on the expected attrition rates. Acquired software is amortized on a straight-line basis over the period of expected benefit, which ranges from <span style="-sec-ix-hidden:f-324">three</span> to five years. Acquired unpatented technology arose from recent acquisitions and is amortized on a straight-line basis over the period of expected benefit, which is seven years. This asset represents acquired knowledge of repair solutions that will be leveraged into opportunities into the acute care market. The non-competition agreements arose from recent acquisitions and are amortized on a straight-line basis over the terms of the agreements, which is five years. Trade names associated with the original acquisition of InfuSystem are not amortized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. Management has the option of first performing the impairment test for intangible assets with indefinite lives on a qualitative basis, by evaluating factors to determine whether it is more likely than not that an impairment exists. If it is more likely than not that an impairment exists, or if the Company chooses not to perform a qualitative assessment, then a quantitative impairment test is performed. Impairment exists when the carrying amount of the intangible asset exceeds its fair value. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in no impairment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization and Depreciation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of <span style="-sec-ix-hidden:f-330">three</span> to five years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The Company did not capitalize any internal-use software for the year ended December&#160;31, 2025, and 2024. Amortization expense for capitalized software was $0.1 million as of both December&#160;31, 2025 and 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. For the year ended December&#160;31, 2025, the Company assessed the impairment indicators and found none to be present.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value may not be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management&#8217;s best estimates, appropriate assumptions and projections at the time. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group. For the years ended December&#160;31, 2025 and 2024, respectively, the Company assessed the impairment indicators and found none to be present.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For policies related to the Company acting as a lessor, refer to the "Lease Arrangements" policy section above.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the policies related to the Company as lessee, under ASC 842, lessees are required to recognize a lease liability and right-of-use asset (&#8220;ROU asset&#8221;) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than twelve months.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient. The company also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did not recognize ROU assets and lease liabilities for these leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In adopting ASC 842, the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company&#8217;s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next seven years. The Company&#8217;s leases do not contain any restrictive covenants. The Company&#8217;s office leases generally contain renewal options for periods ranging from <span style="-sec-ix-hidden:f-342">one</span> to five years. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company&#8217;s office leases do not contain any material residual value guarantees. The Company&#8217;s equipment leases generally do not contain renewal options. The Company is not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company&#8217;s office leases, the implicit rate is typically not available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments due under the Company&#8217;s operating leases include fixed payments as well as variable payments. For the Company&#8217;s office leases, variable payments include amounts for the Company&#8217;s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company&#8217;s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues include the costs of servicing and maintaining pumps, products and services sold, shipping, depreciation of medical equipment, and other direct and indirect costs related to net revenues, and these expenses are expensed as incurred. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and 2024, the Company had contracts with nearly 840 and 835 third-party payer networks, respectively. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless the Company or the contracted payer elect not to renew. The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of its Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of the Company's net revenue in 2025 or 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred&#160;income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all of any deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities.&#160;Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a two-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-not that the position will be </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sustained upon examination. Second, for positions that are determined are more-likely-than-not to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than 50% likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which may include open market transactions or privately negotiated transactions and may be made under a Rule 10b5-1 plan, or in targeted stock purchase agreements approved by the Board. Treasury stock is accounted for using the par value method. As of December&#160;31, 2025 and 2024, respectively, the Company did not have any shares being held in treasury.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, &#8220;Share-Based Awards&#8221;) on the date of grant using either the grant date price of the Company's common stock or option-pricing models which are affected by the Company&#8217;s stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company&#8217;s expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company&#8217;s stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. Forfeitures are recognized as they occur. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company also determines the fair value of performance-based restricted stock units (&#8220;PSUs&#8221;) based upon the type of performance measure. These awards typically vest after the Company&#8217;s achievement of either a specific Company performance metric or when the market value of the Company&#8217;s stock meets a specific metric such as when the closing price of the Company's stock reaches a target value for a minimum number of consecutive trading days. Under FASB Accounting Standards Codification Topic 718, "Compensation: Stock Compensation", the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A third-party valuation expert was engaged to prepare a &#8220;Monte Carlo simulation&#8221; to account for the market condition to assist management in its conclusion of fair value. That simulation takes into account the beginning stock price of the Company&#8217;s common stock, the expected volatilities for the Company&#8217;s stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. Compensation costs are accelerated if the market condition is satisfied prior to the end of the service period derived under the Monte Carlo simulation. The grant date fair value of the other PSUs is calculated as the closing price of the Company&#8217;s common stock on the grant date multiplied by the number of shares estimated to be delivered subject to the award terms. Company performance measure goals are considered a performance condition and the timing and amount of compensation cost for those PSUs corresponds with management&#8217;s expectation of the probable outcome of the performance conditions as of the grant date and during the vesting period.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Debt Issuance Costs</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized debt issuance costs as of December&#160;31, 2025 and 2024 relate to the Company&#8217;s credit facility. The costs related to the agreement are netted against current and non-current debt and is recognized in Interest expense. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its earnings per share which includes the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the 2014 and 2021 stock incentive plans. Anti-dilutive stock awards are comprised of stock options and unvested </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method. In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Numerator (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,657,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,271,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">439,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">435,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,097,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,707,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options of 2,072,460 and 1,950,403 shares were not included in the calculation for the years ended December&#160;31, 2025 and 2024, respectively, because they would have an anti-dilutive effect.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company&#8217;s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (&#8220;AOCI&#8221;) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s derivative financial instruments are categorized as Level II of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets as of December&#160;31, 2025 and 2024 for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company&#8217;s long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted Accounting Standards Codification Topic 820, "Fair Value Measurement", which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;quoted prices in active markets for identical instruments;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level II</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level III</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements and Developments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#8221; (&#8220;ASU 2023-09&#8221;). ASU 2023-09 enhances existing income tax disclosures primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments in this ASU require public entities to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. Public entities are also required to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes and also disaggregated by individual jurisdictions. The Company adopted the standard on January 1, 2025.  Because the ASU affects disclosure requirements only, adoption did not impact the Company's consolidated financial position, results of operations, or cash flows.  See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which reflects the expanded disclosures required under the amended guidance.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued Accounting Standards Update 2024-03, &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221; (&#8220;ASU 2024-03&#8221;), which requires disclosures, in the notes to the financial statements, about the types of expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In July 2025, the FASB issued Accounting Standards Update 2025-05, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&#8221; (&#8220;ASU 2025-05&#8221;), which provides a practical expedient election that assumes current conditions as of the balance sheet date remain unchanged when developing forecasts for estimating expected credit losses. ASU 2025-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2025, with early adoption permitted.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently evaluating the impact of ASU 2025-05 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">n September 2025, the FASB issued Accounting Standards Update 2025-06, &#8220;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), Targeted improvements to the Accounting for Internal-Use Software&#8221; (&#8220;ASU 2025-06&#8221;), to update accounting for software costs that are accounted for under Subtopic 350-40. The ASU 2025-06 removes all references to prescriptive and sequential software development stages throughout Subtopic 350-40. The amendments in ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company&#8217;s project to replace its enterprise resource planning application is expected to be completed prior to the required adoption period. The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">n December 2025, the FASB issued Accounting Standards Update 2025-09, "Derivatives and Hedging (Topic 815): Hedge Accounting Improvements" ("ASU 2025-09"), which provides clarifications to certain hedge accounting requirements.  The amendments are intended to improve consistency in the application of hedge effectiveness and related disclosures.  The standard is effective for fiscal years beginning after December 15, 2026.  The Company is currently evaluating the impact of ASU 2025-09 on its consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions Accounted for Using the Purchase Method</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company acquired certain assets of Apollo Medical Supply (&#8220;Apollo&#8221;), a privately-held wound care service company based in Florida. As part of the Company&#8217;s Patient Services segment, this acquisition supplements the Company&#8217;s existing wound care business by providing access to an advanced patient service fulfillment know-how and software platform that the Company plans to integrate into its existing operations. Apollo&#8217;s results of operation are included in the Company&#8217;s consolidated statements of operations and comprehensive income since the Closing Date.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, &#8220;Business Combinations,&#8221; the purchase price for the acquisition was allocated to the assets acquired and liabilities assumed based upon their estimated fair values as of the respective acquisition date. The preliminary purchase price allocation was primarily based upon a valuation using </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s estimates and assumptions. Upon completion of the final purchase price allocation, the Company expects to specifically identify intangible assets and allocate the excess of the purchase price over the net assets to goodwill, if any. The preliminary allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Apollo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">140&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company updated the valuation of Apollo with immaterial changes in accounts receivable, intangible assets and other liabilities. As the amounts are immaterial, the unaudited pro forma financial information has not been presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 46<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-46<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 45<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-45<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479326/805-40-45-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-30/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-20/tableOfContent<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s disaggregated revenue by offering type (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services revenue recognized at a point in time:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third-Party Payer products</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services revenue recognized over time:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct rental services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third-Party Payer rental services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Patient Services accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions revenue recognized at a point in time:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions revenue recognized over time:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Device Solutions accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue Accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">106,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services Lease Revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions Lease Revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue accounted for under ASC 842</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Revenue</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,436&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Change in 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The change in contract assets during the fiscal year ended December&#160;31, 2025 was mainly due to $8.7 million of contract assets reclassified to accounts receivable as our right to consideration for these contract assets became unconditional, partially offset by $9.4 million of revenue recognized for which the payment is subject to conditions other than the passage of time. Contract assets are included in other current assets on the Company's consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentAbstract', window );"><strong>Medical Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentAndPropertyDisclosureTextBlock', window );">Medical Equipment</a></td>
<td class="text">Medical Equipment<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental - pump reserve</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental - net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service - pump reserve</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,530)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(71,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(65,323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service - net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34,456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for medical equipment for the years ended December&#160;31, 2025 and 2024 was $11.1 million and $10.2 million, respectively, which were recorded in &#8220;cost of revenues&#8221; for each period. The pump reserve for medical equipment in rental service represents an estimate for medical equipment that is considered to be missing. The reserve calculated is equal to the net book value of assets that have not returned from the field within a certain timeframe. Sales of the Company's medical equipment are included in net revenue.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentAndPropertyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for medical equipment and property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentAndPropertyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Automobiles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,164)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,148)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property and equipment for each of the years ended December&#160;31, 2025 and 2024 was $1.2 million and $1.3 million, respectively. This expense was recorded in &#8220;general and administrative expenses&#8221; for each period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying value of goodwill by segment are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Device Solutions (a)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,710</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of December 31, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,710</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(a) The Patient Services segment has no recorded goodwill. </span></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nonamortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade names</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade names</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Physician and customer relationships</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(35,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(34,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unpatented technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-competition agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total nonamortizable and amortizable intangible assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47,036)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(46,116)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,456&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets for the years ended December&#160;31, 2025 and 2024 was $0.9&#160;million and $1.0 million, respectively, which was recorded in "amortization of intangibles expenses" for each period. Expected remaining annual amortization expense for the next five years for intangible assets recorded as of December&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2031 and <br/>thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;5, 2021</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the Company entered into a Credit Agreement (the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2021 Credit Agreement&#8221;) with JPMorgan Chase Bank, N.A., as administrative agent (the &#8220;Agent&#8221;), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the 2021 Credit Agreement are InfuSystem Holdings, Inc. and its subsidiaries (collectively, the &#8220;Borrowers&#8221;).</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement provides for a revolving credit facility (the &#8220;Revolving Facility&#8221;) of $75.0 million. The Revolving Facility may be increased by $25.0 million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7.0 million in letters of credit subject to the satisfaction of certain conditions. The 2021 Credit Agreement has customary representations and warranties. The ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement includes customary events of default. The occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder. Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company entered into a First Amendment to the 2021 Credit Agreement (the &#8220;First Amendment&#8221;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things: (i) an extension of the maturity date for the 2021 Credit Agreement to April 26, 2028, (ii) the replacement of London Interbank Offered Rate with Adjusted Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as a benchmark interest rate, and (iii) an increase of the maximum dollar amount of incremental revolving loans from $25&#160;million to $35&#160;million. Incremental revolving loans continue to be subject to certain conditions, including the consent of the Agent and obtaining necessary commitments.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2025, the Company entered into a Second Amendment to the 2021 Credit Agreement (the &#8220;Second Amendment&#8221;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things, an extension of the maturity date for the 2021 Credit Agreement to July 15, 2030.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The First Amendment and Second Amendment were accounted for as debt modifications. As of December&#160;31, 2025, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement, as amended</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands):</span></div><div style="margin-top:10pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross availability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding draws</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(24,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Availability on Revolving Facility</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had future maturities of its long-term debt as of December&#160;31, 2025 as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2031 and <br/>thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a breakdown of the Company&#8217;s current and long-term debt (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Current<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Current<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized value of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement, as amended, bear interest at a variable rate equal to, at the Company&#8217;s election, Adjusted Term SOFR for Term Benchmark loans or an Alternative Base Rate for ABR loans, as defined by the Second Amendment, plus a spread that will vary depending </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">upon the Company&#8217;s leverage ratio. The spread ranges from 2.05% to 3.05% for Term Benchmark Loans and 1.05% to 2.05% for base rate loans. The weighted-average Term Benchmark loan rate at December&#160;31, 2025 was 5.83% (Adjusted Term SOFR of 3.78% plus 2.05%). The actual ABR loan rate at December&#160;31, 2025 was 7.80% (lender&#8217;s prime rate of 6.75% plus 1.05%).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments and Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments and Hedging Activities</a></td>
<td class="text">Derivative Financial Instruments and Hedging Activities<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a derivative investment policy which provides guidelines and objectives related to managing financial and operational exposures arising from market changes in short term interest rates. In accordance with this policy, the Company can enter into interest rate swaps or similar instruments, will endeavor to evaluate all the risks inherent in a transaction before entering into a derivative financial instrument and will not enter into derivative financial instruments for speculative or trading purposes. Hedging relationships are formally documented at the inception of the hedge and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 Credit Agreement. The Company uses an interest rate swap agreement to manage exposure arising from this risk.  The swap has a constant notional amount over a five-year term that ends on April 26, 2028. The agreement pays the Company 30-day SOFR on the notional amount and the Company pays a fixed rate of interest equal to 1.74%. The Company does not have any other derivative financial instruments.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Notional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Fair Value Derivative Assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">748</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="21" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:40.57pt"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Notional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Fair Value Derivative Assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,481</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="21" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:40.57pt"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.102%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Gain on cash flow hedges - interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,119</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,088</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(227)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">734</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amounts reclassified to interest expense (a)(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(506)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(694)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">179</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">565</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,119</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(a) Negative amounts represent interest income and positive amounts represent interest expense. Interest expense as presented in the consolidated statement of operations for the years ended December&#160;31, 2025 and 2024 was $1.3 million and $1.8 million, respectively.</span></div></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(b) As of December&#160;31, 2025, $0.3 million of income is expected to be reclassified into earnings within the next 12 months.</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not incur any hedge ineffectiveness during the years ended December&#160;31, 2025 and 2024, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 185<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-185<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 184<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-184<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 183<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-183<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, U.S. Congress enacted the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;), which included significant provisions modifying the U.S. tax framework. While the Company continues to evaluate the impact of OBBBA, these legislative changes did not and are not expected to have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s income before income taxes (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s components of the consolidated provision for income taxes (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S Federal income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. Federal income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,501)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total state and local income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,996)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,714)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a reconciliation of the Company&#8217;s income tax (expense) benefit from the effective income tax rate to the U.S. federal statutory rate (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">% of Pretax Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">% of Pretax Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at the statutory rate</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,231)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,062)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax expense, net of federal income tax effect</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.4</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Meals and Entertainment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-deductible Officer's Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Income for Canada Disregarded Entity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Tax Effects</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciling Adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit at effective income tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,996)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37.6</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,714)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53.6</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:14pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> During 2025, state and local taxes in California, Kansas, Michigan, and Texas comprised the majority of the state and local income taxes, net of federal effect category.  During 2024, state and local taxes in Texas, Michigan, Kansas, Illinois, and New York comprised the majority of the state and local income taxes, net of federal effect category</span></div><div style="margin-top:14pt;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">The following table illustrates incomes taxes paid by jurisdiction (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S State and local</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Florida</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Georgia</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Illinois</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michigan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;New York</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pennsylvania</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Texas</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Canada</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a) The amount of income taxes paid during the year does not meet the 5% disaggregation threshold and is included in other.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Federal, state and local tax assets &#8211;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss (a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred Federal, state and local tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Federal, state and local tax liabilities &#8211;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and asset basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred Federal, state and local tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) At December&#160;31, 2025 and 2024, this includes state and local net operating losses of $0.2 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. federal net operating loss carryforward for tax purposes was $5.8 million at December&#160;31, 2025, resulting in a federal deferred tax asset of $1.2 million; such net operating loss carryforwards have an indefinite life. The Company&#8217;s state net operating loss carryforward of approximately $0.2 million is comprised of various jurisdictions. These state net operating losses can be used for a period of 5 to 20 years and vary by state, and if unused, begin to expire in 2026, though a substantial portion expires beyond 2026. Approximately less than $0.1 million of the state net operating loss carryforwards have an indefinite life. Tax benefits of operating loss and tax credit carryforwards are evaluated on an ongoing basis, including a review of historical and projected future operating results, the eligible carryforward period, and other circumstances.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor shifts in past ownership (as defined under Section 382 of the Code).  The Company had no uncertain tax positions for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation for Federal and various state jurisdictions in the U.S. and Canada. The Federal income tax returns of the Company for the years 2022 through 2025 are open to examination by the Internal Revenue Service. The state income tax returns and other state tax filings of the Company are subject to examination by the state taxing authorities, for various periods generally up to four years after they are filed. Canadian income tax returns of the Company for the years 2020 through 2025 are subject to examination by the Canada Revenue Agency.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time in the ordinary course of its business, the Company may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not at this time involved in any proceedings that the Company currently believes could have a material effect on the Company&#8217;s financial condition, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As Lessee:</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s operating lease costs consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs for the years ended December&#160;31, 2025 and 2024 of approximately $2.4 million and $2.3 million, respectively, were recorded to G&amp;A expenses. Expense related to short-term leases, which are not recorded on the Company's consolidated balance sheets, was $0.8 million and nil for the fiscal years ended December&#160;31, 2025, and 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to the Company&#8217;s leases are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities and right of use assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increases to right of use assets resulting from lease modifications:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for the Company&#8217;s operating leases are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.9%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of December&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The long-term portion of the lease liabilities included in the amounts above is $3.4 million with the remainder included in other current liabilities in the Consolidated Balance Sheets. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As Lessor</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient for all qualifying non-lease components.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s lease revenues consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of our net investment in sales-type leases as of December&#160;31, 2025 and 2024 were (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December&#160;31, 2025 and 2024 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of sales-type leases as of December&#160;31, 2025 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sales-Type Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(530)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As Lessee:</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s operating lease costs consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs for the years ended December&#160;31, 2025 and 2024 of approximately $2.4 million and $2.3 million, respectively, were recorded to G&amp;A expenses. Expense related to short-term leases, which are not recorded on the Company's consolidated balance sheets, was $0.8 million and nil for the fiscal years ended December&#160;31, 2025, and 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to the Company&#8217;s leases are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities and right of use assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increases to right of use assets resulting from lease modifications:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for the Company&#8217;s operating leases are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.9%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of December&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The long-term portion of the lease liabilities included in the amounts above is $3.4 million with the remainder included in other current liabilities in the Consolidated Balance Sheets. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As Lessor</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient for all qualifying non-lease components.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s lease revenues consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of our net investment in sales-type leases as of December&#160;31, 2025 and 2024 were (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December&#160;31, 2025 and 2024 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of sales-type leases as of December&#160;31, 2025 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sales-Type Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(530)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various stock option and stock-based incentive plans and agreements whereby equity based awards are granted to certain employees, directors and others approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or Compensation Committee. Grants may be made in the form of stock options, restricted stock awards ("RSUs" or "RSAs"), performance-based restricted stock units ("PSU's), unrestricted common stock in addition to other award types. Stock options are granted with an exercise price at, or above, fair market value on the date of grant, generally expire in 5 to 10 years from the grant date and generally become exercisable over a period of up to 3 years. RSUs generally become vested over a period of up to three years. PSUs generally become vested over a period of up to three years based on the performance of a specific achievement. Awards typically vest and are issued only if the participants remain employed by the Company through the vesting date. Common stock issued under these awards is issued from shares reserved under the Company&#8217;s plan described below. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2021, the Company&#8217;s Board adopted the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan was approved by the Company&#8217;s shareholders at the 2021 Annual Meeting on May 18, 2021 and became effective at that time. The 2021 plan supersedes the 2014 Amended and Restated Stock Incentive Plan (the "2014 Plan"). The 2021 Plan provided for the issuance of a maximum of 2,500,000 shares of common stock in connection with the grant of stock-based or stock-denominated awards, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan, which as of December 31, 2025 totaled 428,067. On May 16, 2023 at the 2023 Annual Meeting, the Company's shareholders approved the First Amendment (the "First Amendment") to the 2021 Plan. The First Amendment increased the maximum number of shares of the Company's common stock reserved for issuance under the 2021 Plan by 2,500,000 shares to 5,000,000 shares, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan. On May 15, 2025 at the 2025 Annual Meeting, the Company's shareholders approved the Second Amendment (the "Second Amendment") to the 2021 Plan. The Second Amendment increased the maximum number of shares of the Company's common stock reserved for issuance under the 2021 Plan by 1,000,000 shares to 6,000,000 shares, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reductions in the available share limit associated with these grants are based on a fungible ratio of 1:1 for stock options and stock appreciation rights and 2:1 for all other types of awards. Any shares subject to an award that expires or is cancelled, forfeited, or terminated without issuance of the full number of shares of stock to which the award related again become available for issuance under the limit. As of December&#160;31, 2025, a total of 639,308 common shares remained available for future grant under the 2021 Plan. This amount reflects reductions from the original limit for grants reflective of the respective fungible ratios. The available amount also reflects the maximum potential share issuance potential in the case of performance grants that provide for variable share payouts.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On April 23, 2014, the Company&#8217;s Board adopted the 2014 Plan. The 2014 Plan was approved by the Company&#8217;s shareholders at the 2014 Annual Meeting and became effective as of the date it was adopted by the Board of Directors. The 2014 Plan provided for the issuance of a maximum of 2,000,000 shares of common stock in connection with the grant of stock-based or stock-denominated awards. On July 19, 2018, the Company&#8217;s stockholders approved the reservation of an additional 1,000,000 shares to be issued under the 2014 Plan. On May 15, 2019, the Company&#8217;s stockholders approved the reservation of an additional 1,000,000 shares to be issued under the 2014 Plan. The 2021 Plan replaced and superseded the 2014 Plan, so as of the adoption date of the 2021 Plan, no common shares remained available for future grant under the 2014 Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All stock option awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock option expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shares Forgone to Satisfy Minimum Statutory Withholdings</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025 and 2024, shares of common stock were issued to employees and directors as their restricted stock awards vested or stock options were exercised. Under the terms of the Company&#8217;s stock plans, at the election of each employee, the Company can authorize a net settlement of distributable shares to employees in order to satisfy an individual employees' tax withholding obligations. For the years ended December&#160;31, 2025 and 2024 the Company received 132,909 shares and 108,607 shares, respectively, from employees for tax withholding obligations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards entitle the holder to receive, upon meeting certain time-based vesting criteria, a specified number of shares of the Company&#8217;s common stock. Stock-based compensation cost of restricted stock awards is measured by the market value of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted share activity, excluding the Company&#8217;s employee stock purchase plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant<br/>date fair<br/>value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">503,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">228,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(110,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested shares forgone to satisfy minimum statutory withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(65,989)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(75,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">480,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of awards granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">824,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,122,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares forgone to satisfy minimum statutory withholding</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">493,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">651,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $1.3 million of pre-tax total unrecognized compensation cost related to non-vested restricted stock awards, which will be adjusted for future forfeitures, if any. The Company expects to recognize such cost over a weighted average period of one year.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company granted approximately 364,905 PSUs and during the year ended December&#160;31, 2024, the Company granted approximately 117,582 PSUs. PSUs entitle the holder to receive, upon meeting certain performance-based vesting criteria, a specified number of shares of the Company&#8217;s common stock. These market-based awards vest after the Company&#8217;s achievement of either a specified trading price metric of the Company&#8217;s stock, such as when the trading price reaches a target value for a minimum number of consecutive trading days, or after an attainment of total shareholder return ("TSR") metric relative to a TSR for a benchmark group of other companies. In the case of the awards having a trading price metric, awards are paid in stock either immediately upon achievement of the performance condition or expire without any payment after the third anniversary of the grant date. In the case of the awards having a TSR metric, awards can be earned at an amount of 50% of the target number of shares for achieving a minimum threshold below the target or up to 200% of the target number of shares for exceeding the target, with a linear adjustment between the threshold and target or between target and maximum performance achievement. The TSR awards also have a time-based vesting criteria. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s PSU activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>grant <br/>date fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">189,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">364,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(30,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested shares forgone to satisfy minimum statutory withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(121,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">382,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of awards granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">309,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares forgone to satisfy minimum statutory withholding</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $1.5 million of pre-tax total unrecognized compensation cost related to non-vested PSUs, which will be adjusted for changes to management&#8217;s expectations of the probable outcomes of the performance conditions, if any. The Company expects to recognize such cost over a weighted average period of one year.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">At the 2023 Annual Meeting of Stockholders held on May 16, 2023, the Company's stockholders approved the InfuSystem Holdings, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP"), which was previously approved by the Company's Board.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the adoption of the 2023 ESPP, the Company's Board terminated the InfuSystem Holdings, Inc. Employee Stock Purchase Plan (the "Original ESPP").</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Following termination of the Original ESPP, all rights the Company intends to grant under an "employee stock purchase plan" as such term is defined in section 423 of the Internal Revenue Code of 1986, as amended, will be granted under the 2023 ESPP.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The 2023 ESPP provides that a maximum of 300,000 shares of Common Stock, plus any shares remaining under the Original ESPP after the close of its final offering period, are available for sale under the 2023 ESPP.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The terms of the 2023 ESPP provides eligible participants electing to participate in the plan with an option to acquire shares of Common Stock during specified offering periods.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The per share option exercise price at which shares of Common Stock will be sold under the 2023 ESPP will be equal to the lesser of (i) 85% of the closing price of a share of Common Stock on the NYSE American (or such other exchange on which the shares of Common Stock are traded) on the first day of an offering period or (ii) 85% of the closing price of a share of Common Stock on the purchase date.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">No employee may purchase more than $25,000 worth of fair market value shares in any calendar year. As allowed under the 2023 ESPP, a participant may elect to withdraw from the plan, effective for the purchase period in progress at the time of the election with all accumulated payroll deductions returned to the participant at the time of withdrawal. The 2023 ESPP is administered by the Board's Compensation Committee.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Eligible participants under the plan include all full-time employees and certain part-time employees of the Company who meet certain eligibility requirements set forth in the 2023 ESPP.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Participation in the 2023 ESPP for any eligible employee is voluntary.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2025, there were 209,321 shares remaining available for future issuance. The following table summarizes the activity relating to the Company&#8217;s ESPP program:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">139,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">93,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares of stock sold to employees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per ESPP award</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value of stock option awards using the Black-Scholes option pricing model, which incorporates various assumptions including volatility, expected term, risk-free interest rates and dividend yields. The expected volatility assumption is based on historical volatility of the Company&#8217;s common stock over the most recent period commensurate with the expected life of the stock option granted. The Company uses historical volatility because management believes such volatility is representative of prospective trends. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the stock option awarded. The Company uses historical exercise data to determine the expected lives. Dividend yields have not been a factor in determining fair value of stock options granted as the Company has never issued cash dividends and does not anticipate issuing cash dividends in the future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables detail the various stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2014 Plan (Options)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number<br/>of Authorized<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">535,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,588,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(49,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised shares forgone to satisfy minimum statutory withholding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(32,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares tendered for cashless exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(27,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and expirations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(75,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2021 Plan (Options)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number<br/>of Authorized<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,840,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,504,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">889,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised shares forgone to satisfy minimum statutory withholding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cashless exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(177,214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and expirations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(236,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,289,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,888,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">911,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">729,868&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46% to 57%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46% to 51%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.56% to 4.01%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.22% to 4.60%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected lives at date of grant (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.08</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$2.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$2.97</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">926,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">322,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2024, our Board of Directors approved a stock repurchase program (the "Share Repurchase Program") that authorizes the Company to repurchase up to $20.0 million of the Company's outstanding common stock through June 30, 2026. The Share Repurchase Program supersedes the previous authorization, which was set to expire on June 30, 2024. Repurchases under the Share Repurchase Program are subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's existing credit agreement. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had repurchased and retired approximately $11.0 million, or 1,498,376 shares, of the Company's outstanding common stock under the Share Repurchase Program. The Company had repurchased and retired approximately $6.2 million, or 553,149 shares under the previous authorization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Business Segment Information</a></td>
<td class="text">Business Segment Information<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s reportable segments are organized based on service platforms, with the Patient Services segment reflecting higher margin rental revenues that generally include payments made by third-party and direct payers and the Device Solutions segment reflecting lower margin product sales, direct payer rental and services revenues. Resources are allocated and performance is assessed for these segments by the Company&#8217;s Chief Executive Officer, whom the Company has determined to be its CODM. The CODM uses gross profit for each segment predominantly in the annual budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making operating and capital resource allocation decisions among each segment.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial information summarized below is presented by reportable segment:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Patient Services</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Device Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - external</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - internal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,192)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant Segment Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and material costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,623&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Patient Services</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Device Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - external</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - internal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,254)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant Segment Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and material costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,842&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Other<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans and Other</a></td>
<td class="text">Employee Benefit Plans and Other<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution plan in which the Company makes discretionary matching contributions for a certain percentage of employee contributions.  For the years ended December&#160;31, 2025 and 2024, the Company&#8217;s matching contributions was $1.4 million and $1.3 million, respectively.   The Company does not provide other post-retirement or post-employment benefits to its employees. As of December&#160;31, 2025 and 2024, accrued payroll liabilities included in Other current liabilities were $5.5 million and $4.8 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risk Assessment</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We conduct regular risk assessments and penetration tests, leveraging AI-driven threat detection and continuous monitoring tools to identify vulnerabilities impacting confidentiality, integrity, and availability of systems and data. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Policies and Procedures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: InfuSystem has established and maintains cybersecurity policies and procedures that align with industry best practices and regulatory requirements. These policies address areas such as data protection, access control, incident response, and vulnerability management.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Training and Awareness</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We provide ongoing cybersecurity training and awareness programs to our employees and contractors, emphasizing the importance of their role in safeguarding sensitive information and reporting security incidents.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Use of Third-Parties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: InfuSystem works with a third-party Cybersecurity risk partner whose systems ingest information regarding the current state of the Company&#8217;s information and technology environment and using specialized algorithms provide assessments of the company&#8217;s Cybersecurity risk exposure as well as providing targeted advice to mitigate any risks identified.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Third-Party Risk Management</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: InfuSystem evaluates the cybersecurity practices of third-party vendors and suppliers, ensuring that they meet our cybersecurity standards and pose no undue risk to our medical devices and data.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Incident Response Plan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We maintain a robust incident response plan that outlines the steps to be taken in the event of a cybersecurity incident. This plan includes procedures for reporting incidents, containing threats, and notifying affected parties as required by law.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the critical importance of cybersecurity in safeguarding sensitive information, maintaining operational integrity, and ensuring the safety and efficacy of our medical devices. Our cybersecurity risk management program, which is based on recognized cybersecurity frameworks established by the National Institute of Standards and Technology ("NIST")</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">and led by our Chief Information Officer (CIO), is fully integrated into our overall enterprise risk management program, and shares common reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, operational and financial risk areas. We are dedicated to maintaining the highest standards of cybersecurity to protect our customers and stakeholders. We will continue to adapt to evolving threats and regulations to ensure the safety and security of our products and information.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Please see the Item 1A. Risk Factor above entitled "</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">" for more information regarding cybersecurity incident risks associated with InfuSystem.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem maintains a dedicated cybersecurity governance framework. While senior management is primarily responsible for assessing and managing our exposure to risk, our Board of Directors oversees our ERM, including cybersecurity risk management, and ultimately approves ERM policies and procedures. Our Board conducts much of its risk oversight activities, including cybersecurity risk oversight, through our Audit Committee. Given the ever-increasing volume of cyber </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">threats and the magnitude of a potential breach, cybersecurity is a standing topic for the Board of Directors and Audit Committee.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board conducts much of its risk oversight activities, including cybersecurity risk oversight, through our Audit Committee.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">CIO has over a decade of executive-level experience managing information systems and cybersecurity programs in the healthcare industry. The CIO serves as an Executive Officer who reports directly to senior management and, at least quarterly, makes reports to the Audit Committee. Senior management reports to the full Board of Directors with respect to cybersecurity matters on at least a quarterly basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem is committed to continuous improvement in our cybersecurity risk management practices. In the coming fiscal year, we will focus on:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Enhancing our threat detection and monitoring capabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Conducting regular tabletop exercises to improve incident response readiness.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Staying abreast of emerging threats and adjusting our cybersecurity posture accordingly.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Collaborating with industry partners and regulatory authorities to enhance overall cybersecurity resilience in the medical device industry.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">As noted above, our CIO leads our cybersecurity risk management program.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our CIO has over a decade of executive-level experience managing information systems and cybersecurity programs in the healthcare industry. The CIO serves as an Executive Officer who reports directly to senior management and, at least quarterly, makes reports to the Audit Committee.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The CIO serves as an Executive Officer who reports directly to senior management and, at least quarterly, makes reports to the Audit Committee. Senior management reports to the full Board of Directors with respect to cybersecurity matters on at least a quarterly basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in two reportable segments, Patient Services and Device Solutions based on management's view of its business for purpose of evaluating performance and making operating decisions. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company&#8217;s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker ("CODM"), reviews segment financial information. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i13594bbbfc1e4b049c5f01f53e10e953_142" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 14</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for segment disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions.  For intangible assets, the Company typically uses the income approach to determine their estimated fair values. Key estimates and assumptions in that approach include the amount and timing of projected future cash flow, the discount rate selected to measure the risks inherent in those cash flows and the assessment of the asset's useful life. Initial purchase price allocations are subject to revision within the measurement period, not to exceed one year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains substantially all of its cash and cash equivalents primarily with two financial institutions that are insured with the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits. Accounts at banks with an aggregate excess of the amount of outstanding checks over the cash balances are included in accounts payable in current liabilities in the consolidated balance sheet. At December&#160;31, 2025, and 2024, the Company did not have any cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from multiple sources including from the sale and rental of our products as well as service contracts. Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") stipulates revenue recognition at the time and in an amount that reflects the consideration expected to be entitled for the performance obligations that have been provided. ASC 606 defines contracts as creating enforceable rights and may be established through written contracts, oral agreements and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three separate and distinct performance obligations offered to its customers: a rental service performance obligation, a product sale performance obligation and a service performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial payers, government insurance payers, medical facilities and patients.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates a significant amount of its revenues that are accounted for under ASC 606 from the rental service of infusion pumps to its customers and the remainder of its revenue from product sales and services. For the rental service performance obligation revenue is based on its standalone price, determined using reimbursement rates established by third-party payer or other contracts. Revenue is recognized over the contract term in the period in which the related performance obligation is satisfied. The Company&#8217;s revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms, or when the customer uses the products in the case of when our products are stored at a customer's location. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products. The Company's revenues related to services are recognized as the service work is completed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and product performance obligations. These judgments include, among others, the estimation of variable consideration. The Company allocates variable consideration using standalone selling price when appropriate and available. When an appropriate standalone selling price is not available, the Company allocates based on a best estimate approach using the relative fair market value. Variable factors include differences in transaction price and changes in the expected total volume of services during the contract period.  In calculating the variable amount of revenue for these performance obligations, variable consideration is estimated as price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other customer concessions. The contract period starts at contract inception and typically extends 30 days past the end of each reporting period representing the non-cancelable period of each agreement.  These estimates for variable consideration are based on historical service volumes with our customers and prices with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn&#8217;t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that is expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the components of variable consideration.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as changes in volume and actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer&#8217;s ability to pay are recorded as an adjustment to the allowance for credit losses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Lease Arrangements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Arrangements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generates its revenues from the rental of infusion pumps to its customers as leases. Under Accounting Standards Codification Topic 842, "Leases" ("ASC 842"), leases may be classified as either financing, sales-type, or operating, and the Company is required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition and classification within the statement of operations. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient for all qualifying non-lease components. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial insurance payers, government insurance payers, medical facilities and patients.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily participates in operating leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. The Company&#8217;s operating leases are primarily for medical equipment under operating lease arrangements that expire at various dates over the next twelve months. The Company&#8217;s leases do not contain any restrictive covenants. Most of the Company&#8217;s equipment leases do not contain any material residual value guarantees. For the agreements that have guarantees, the residual value reflects management's best estimate of the expected sales price for the equipment at lease termination based on sales history adjusted for recent trends in the expected exit markets. The Company&#8217;s equipment leases may contain renewal options which range from one week to one year. Lease payments receivable reflect contractual lease payments adjusted for renewal or termination options that the Company believe the customer is reasonably certain to exercise. As of December&#160;31, 2025, the Company did not have any operating leases that contained renewal options with increasing rental amounts. Many of the Company's leases allow the customer to extend the lease at prevailing market terms. The Company's operating leased assets are not protected against casualty loss through third-party insurance.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates, including management's assessment of probability of collection, are required to record revenue and accounts receivable at their net realizable values, otherwise, if probability of collection is not met, the Company records revenue for such leases on a cash basis. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in variable lease payments that require adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. The Company adjusts revenue for historical trends on revenue adjustments due to timely filings, deaths, and other types of analyzable adjustments on a monthly basis to record rental revenue at the expected collectible amounts. Consistent with Accounting Standards Codification Topic 450, "Contingencies", for contracts where collection is considered probable, accounts receivable is reduced by an allowance for credit losses which provides for those accounts from which payment is not expected to be received although product was delivered and revenue was earned. The Company records an allowance for credit losses based upon an analysis of historical collections. The Company has elected to record the adjustments to accounts receivables in net revenues on the <span style="-sec-ix-hidden:f-302"><span style="-sec-ix-hidden:f-303">Consolidated Statements of Operations and Comprehensive Income</span></span>. The determination that an account is uncollectible, and the ultimate write-off of that account occurs once collection is considered to be highly unlikely, and it is written-off and charged to the allowance at that time.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also participates in sales-type leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. In a sales-type lease, lessors are required to recognize a lease receivable, selling profit, initial indirect costs, and residual asset values for all of these types of leases, and to disclose key information about leasing arrangements. The Company&#8217;s sales-type leases are primarily for medical equipment under sales-type lease arrangements that expire at various dates over the next three years. The Company&#8217;s leases do not contain any restrictive covenants. The Company&#8217;s equipment leases do not contain any material residual value guarantees or renewal options.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease revenue for leased assets is recognized in net revenue. The Company further recognizes any variable lease payments that are not included in the net investment in the lease as income in profit or loss in the period when the changes in facts and circumstances on which the variable lease payments are based occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Credit Losses, and Contingencies</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowance for Credit Losses, and Contingencies</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts billed that have not yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at net </span></div>realizable value, inclusive of adjustments for variable consideration. These adjustments reflect the amounts expected to be collected from payers based on an analysis of historical collections. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for credit losses, and contingencies, is established as a result of an adverse change in the Company&#8217;s payers&#8217; ability to pay outstanding billings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (first-in, first-out basis) or net realizable value. Cost primarily represents the purchase price paid for the items on hand. The Company periodically performs an analysis of slow-moving inventory and records an adjustment to reflect the recoverable amount.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentPolicyTextBlock', window );">Medical Equipment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment (&#8220;Equipment&#8221;) consists of equipment that the Company purchases from third-parties and is (1) held for sale or rent, and (2) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically seven years. The Company does not depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a gain or loss is recorded in the current period. The Company periodically performs an analysis to identify potentially missing Equipment and records a reserve equal to the underlying net book value, which was $2.7 million and $2.5 million as of December&#160;31, 2025 and 2024, respectively. This amount approximates the accelerated depreciation the Company would recognize over the remaining useful lives of the assets determined to be missing. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than $0.1 million as of both December&#160;31, 2025 and 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Medical Equipment in the Consolidated Statements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (&#8220;Unallocated Assets&#8221;). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its two primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from <span style="-sec-ix-hidden:f-316">three</span> to seven years. Externally purchased information technology software and hardware are depreciated over <span style="-sec-ix-hidden:f-318">three</span> and five years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are expensed to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div>Goodwill is tested for impairment annually or more frequently when certain events or circumstances trigger a review. Management has the option to first assess qualitative factors such as current performance and overall economic conditions to determine whether or not it is necessary to perform a quantitative goodwill impairment test. If the Company chooses that option, then the Company would not be required to perform a quantitative goodwill impairment test unless the Company determines that, based on a qualitative assessment, it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines that an impairment is more likely than not, or if the Company chooses not to perform a qualitative assessment, the Company will then proceed with the quantitative assessment. Under the quantitative test, if the fair value of a reporting unit exceeds its carrying amount, then goodwill of the reporting unit is considered to not be impaired. If the carrying amount of the reporting unit exceeds its fair value, then an impairment loss is recognized in an amount equal to the excess, up to the value of the goodwill. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that there was no impairment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of trade names, physician and customer relationships, unpatented technology, non-competition agreements and software. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from <span style="-sec-ix-hidden:f-322">fifteen</span> to twenty years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others. The useful lives of these relationships are based on the expected attrition rates. Acquired software is amortized on a straight-line basis over the period of expected benefit, which ranges from <span style="-sec-ix-hidden:f-324">three</span> to five years. Acquired unpatented technology arose from recent acquisitions and is amortized on a straight-line basis over the period of expected benefit, which is seven years. This asset represents acquired knowledge of repair solutions that will be leveraged into opportunities into the acute care market. The non-competition agreements arose from recent acquisitions and are amortized on a straight-line basis over the terms of the agreements, which is five years. Trade names associated with the original acquisition of InfuSystem are not amortized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. Management has the option of first performing the impairment test for intangible assets with indefinite lives on a qualitative basis, by evaluating factors to determine whether it is more likely than not that an impairment exists. If it is more likely than not that an impairment exists, or if the Company chooses not to perform a qualitative assessment, then a quantitative impairment test is performed. Impairment exists when the carrying amount of the intangible asset exceeds its fair value. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in no impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationOfInternalCostsPolicy', window );">Software Capitalization and Depreciation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization and Depreciation</span></div>The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of <span style="-sec-ix-hidden:f-330">three</span> to five years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets</span></div>Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value may not be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management&#8217;s best estimates, appropriate assumptions and projections at the time. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For policies related to the Company acting as a lessor, refer to the "Lease Arrangements" policy section above.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the policies related to the Company as lessee, under ASC 842, lessees are required to recognize a lease liability and right-of-use asset (&#8220;ROU asset&#8221;) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than twelve months.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the &#8220;combining lease and non-lease components&#8221; practical expedient. The company also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did not recognize ROU assets and lease liabilities for these leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In adopting ASC 842, the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company&#8217;s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next seven years. The Company&#8217;s leases do not contain any restrictive covenants. The Company&#8217;s office leases generally contain renewal options for periods ranging from <span style="-sec-ix-hidden:f-342">one</span> to five years. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company&#8217;s office leases do not contain any material residual value guarantees. The Company&#8217;s equipment leases generally do not contain renewal options. The Company is not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company&#8217;s office leases, the implicit rate is typically not available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments due under the Company&#8217;s operating leases include fixed payments as well as variable payments. For the Company&#8217;s office leases, variable payments include amounts for the Company&#8217;s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company&#8217;s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues include the costs of servicing and maintaining pumps, products and services sold, shipping, depreciation of medical equipment, and other direct and indirect costs related to net revenues, and these expenses are expensed as incurred. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Customer Concentration</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and 2024, the Company had contracts with nearly 840 and 835 third-party payer networks, respectively. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless the Company or the contracted payer elect not to renew. The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of its Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of the Company's net revenue in 2025 or 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred&#160;income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all of any deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities.&#160;Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a two-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-not that the position will be </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sustained upon examination. Second, for positions that are determined are more-likely-than-not to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than 50% likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_TreasuryStockPolicyPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock</span></div>The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which may include open market transactions or privately negotiated transactions and may be made under a Rule 10b5-1 plan, or in targeted stock purchase agreements approved by the Board. Treasury stock is accounted for using the par value method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, &#8220;Share-Based Awards&#8221;) on the date of grant using either the grant date price of the Company's common stock or option-pricing models which are affected by the Company&#8217;s stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company&#8217;s expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company&#8217;s stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. Forfeitures are recognized as they occur. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company also determines the fair value of performance-based restricted stock units (&#8220;PSUs&#8221;) based upon the type of performance measure. These awards typically vest after the Company&#8217;s achievement of either a specific Company performance metric or when the market value of the Company&#8217;s stock meets a specific metric such as when the closing price of the Company's stock reaches a target value for a minimum number of consecutive trading days. Under FASB Accounting Standards Codification Topic 718, "Compensation: Stock Compensation", the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A third-party valuation expert was engaged to prepare a &#8220;Monte Carlo simulation&#8221; to account for the market condition to assist management in its conclusion of fair value. That simulation takes into account the beginning stock price of the Company&#8217;s common stock, the expected volatilities for the Company&#8217;s stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. Compensation costs are accelerated if the market condition is satisfied prior to the end of the service period derived under the Monte Carlo simulation. The grant date fair value of the other PSUs is calculated as the closing price of the Company&#8217;s common stock on the grant date multiplied by the number of shares estimated to be delivered subject to the award terms. Company performance measure goals are considered a performance condition and the timing and amount of compensation cost for those PSUs corresponds with management&#8217;s expectation of the probable outcome of the performance conditions as of the grant date and during the vesting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Debt Issuance Costs</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Debt Issuance Costs</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized debt issuance costs as of December&#160;31, 2025 and 2024 relate to the Company&#8217;s credit facility. The costs related to the agreement are netted against current and non-current debt and is recognized in Interest expense. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its earnings per share which includes the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the 2014 and 2021 stock incentive plans. Anti-dilutive stock awards are comprised of stock options and unvested </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method. In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company&#8217;s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (&#8220;AOCI&#8221;) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s derivative financial instruments are categorized as Level II of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets as of December&#160;31, 2025 and 2024 for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company&#8217;s long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted Accounting Standards Codification Topic 820, "Fair Value Measurement", which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;quoted prices in active markets for identical instruments;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level II</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level III</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;significant inputs to the valuation model are unobservable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Developments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements and Developments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#8221; (&#8220;ASU 2023-09&#8221;). ASU 2023-09 enhances existing income tax disclosures primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments in this ASU require public entities to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. Public entities are also required to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes and also disaggregated by individual jurisdictions. The Company adopted the standard on January 1, 2025.  Because the ASU affects disclosure requirements only, adoption did not impact the Company's consolidated financial position, results of operations, or cash flows.  See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which reflects the expanded disclosures required under the amended guidance.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued Accounting Standards Update 2024-03, &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221; (&#8220;ASU 2024-03&#8221;), which requires disclosures, in the notes to the financial statements, about the types of expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In July 2025, the FASB issued Accounting Standards Update 2025-05, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&#8221; (&#8220;ASU 2025-05&#8221;), which provides a practical expedient election that assumes current conditions as of the balance sheet date remain unchanged when developing forecasts for estimating expected credit losses. ASU 2025-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2025, with early adoption permitted.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently evaluating the impact of ASU 2025-05 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">n September 2025, the FASB issued Accounting Standards Update 2025-06, &#8220;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), Targeted improvements to the Accounting for Internal-Use Software&#8221; (&#8220;ASU 2025-06&#8221;), to update accounting for software costs that are accounted for under Subtopic 350-40. The ASU 2025-06 removes all references to prescriptive and sequential software development stages throughout Subtopic 350-40. The amendments in ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company&#8217;s project to replace its enterprise resource planning application is expected to be completed prior to the required adoption period. The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">n December 2025, the FASB issued Accounting Standards Update 2025-09, "Derivatives and Hedging (Topic 815): Hedge Accounting Improvements" ("ASU 2025-09"), which provides clarifications to certain hedge accounting requirements.  The amendments are intended to improve consistency in the application of hedge effectiveness and related disclosures.  The standard is effective for fiscal years beginning after December 15, 2026.  The Company is currently evaluating the impact of ASU 2025-09 on its consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for medical equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_RevenueRecognitionCostOfRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the cost of revenue for servicing and maintaining products sold including shipping and handling costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_RevenueRecognitionCostOfRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_TreasuryStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for policy of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_TreasuryStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfInternalCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for capitalization of internal cost for acquisition, exploration, and production in oil- and gas-producing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfInternalCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Numerator (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,657,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,271,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">439,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">435,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,097,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,707,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The preliminary allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Apollo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">140&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s disaggregated revenue by offering type (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Total Net</span></div><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services revenue recognized at a point in time:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third-Party Payer products</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services revenue recognized over time:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct rental services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third-Party Payer rental services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Patient Services accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions revenue recognized at a point in time:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions revenue recognized over time:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Device Solutions accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue Accounted for under ASC 606</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">106,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient Services Lease Revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Device Solutions Lease Revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue accounted for under ASC 842</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Revenue</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,436&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable</a></td>
<td class="text"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Change in 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentAbstract', window );"><strong>Medical Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ScheduleOfMedicalEquipmentTableTextBlock', window );">Schedule of Medical Equipment</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental - pump reserve</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment for sale or rental - net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service - pump reserve</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,530)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(71,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(65,323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical Equipment in rental service - net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34,456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ScheduleOfMedicalEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of medical equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ScheduleOfMedicalEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Automobiles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,164)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,148)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying value of goodwill by segment are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Device Solutions (a)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,710</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of December 31, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,710</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(a) The Patient Services segment has no recorded goodwill. </span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock', window );">Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nonamortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade names</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade names</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Physician and customer relationships</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(35,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(34,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unpatented technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-competition agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total nonamortizable and amortizable intangible assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47,036)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(46,116)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,456&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text">Expected remaining annual amortization expense for the next five years for intangible assets recorded as of December&#160;31, 2025 is as follows (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2031 and <br/>thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount and accumulated amortization of identifiable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Line of Credit Facilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands):</span></div><div style="margin-top:10pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross availability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding draws</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(24,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Availability on Revolving Facility</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had future maturities of its long-term debt as of December&#160;31, 2025 as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2031 and <br/>thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a breakdown of the Company&#8217;s current and long-term debt (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Current<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Current<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term<br/>Portion</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized value of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Notional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Fair Value Derivative Assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">748</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="21" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:40.57pt"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Notional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Fair Value Derivative Assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,481</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="21" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:40.57pt"><span><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Designated as Hedging Instruments in AOCI</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.102%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Gain on cash flow hedges - interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,119</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,088</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(227)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">734</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amounts reclassified to interest expense (a)(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(506)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(694)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">179</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">565</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,119</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(a) Negative amounts represent interest income and positive amounts represent interest expense. Interest expense as presented in the consolidated statement of operations for the years ended December&#160;31, 2025 and 2024 was $1.3 million and $1.8 million, respectively.</span></div></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(b) As of December&#160;31, 2025, $0.3 million of income is expected to be reclassified into earnings within the next 12 months.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s income before income taxes (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s components of the consolidated provision for income taxes (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S Federal income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. Federal income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,501)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total state and local income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,996)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,714)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a reconciliation of the Company&#8217;s income tax (expense) benefit from the effective income tax rate to the U.S. federal statutory rate (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">% of Pretax Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">% of Pretax Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at the statutory rate</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,231)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,062)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax expense, net of federal income tax effect</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.4</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Meals and Entertainment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-deductible Officer's Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Income for Canada Disregarded Entity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Tax Effects</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciling Adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit at effective income tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,996)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37.6</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,714)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53.6</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">The following table illustrates incomes taxes paid by jurisdiction (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S State and local</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Florida</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Georgia</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Illinois</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michigan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;New York</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pennsylvania</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Texas</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Canada</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a) The amount of income taxes paid during the year does not meet the 5% disaggregation threshold and is included in other.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Federal, state and local tax assets &#8211;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss (a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred Federal, state and local tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Federal, state and local tax liabilities &#8211;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and asset basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred Federal, state and local tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) At December&#160;31, 2025 and 2024, this includes state and local net operating losses of $0.2 million and $0.4 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of the Components of Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s operating lease costs consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to the Company&#8217;s leases are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities and right of use assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increases to right of use assets resulting from lease modifications:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for the Company&#8217;s operating leases are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.9%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of December&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of Leases Revenues</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s lease revenues consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetInvestmentInSalesTypeLeasesTableTextBlock', window );">Schedule of Net Investment in Sales-type Leases</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of our net investment in sales-type leases as of December&#160;31, 2025 and 2024 were (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December&#160;31, 2025 and 2024 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Future Maturities of Sales-type Leases</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of sales-type leases as of December&#160;31, 2025 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sales-Type Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(530)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_NetInvestmentInSalesTypeLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Investment In Sales-Type Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_NetInvestmentInSalesTypeLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock option expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted share activity, excluding the Company&#8217;s employee stock purchase plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant<br/>date fair<br/>value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">503,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">228,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(110,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested shares forgone to satisfy minimum statutory withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(65,989)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(75,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">480,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of awards granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">824,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,122,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares forgone to satisfy minimum statutory withholding</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">493,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">651,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of PSU Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s PSU activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>grant <br/>date fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">189,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">364,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(30,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested shares forgone to satisfy minimum statutory withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(121,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">382,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of awards granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">309,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares forgone to satisfy minimum statutory withholding</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity</a></td>
<td class="text">The following table summarizes the activity relating to the Company&#8217;s ESPP program:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">139,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">93,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares of stock sold to employees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per ESPP award</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables detail the various stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2014 Plan (Options)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number<br/>of Authorized<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">535,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,588,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(49,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised shares forgone to satisfy minimum statutory withholding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(32,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares tendered for cashless exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(27,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and expirations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(75,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2021 Plan (Options)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number<br/>of Authorized<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,840,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,504,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">889,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised shares forgone to satisfy minimum statutory withholding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cashless exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(177,214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and expirations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(236,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,289,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,888,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">911,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">729,868&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46% to 57%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46% to 51%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.56% to 4.01%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.22% to 4.60%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected lives at date of grant (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.08</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$2.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$2.97</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">926,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">322,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718-50/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial information summarized below is presented by reportable segment:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Patient Services</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Device Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - external</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - internal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,192)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant Segment Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and material costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,623&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Patient Services</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Device Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - external</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues - internal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,254)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant Segment Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and material costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,842&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>location</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NumberOfLocations', window );">Number of locations</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=infu_AmbulatoryPumpsMember', window );">Ambulatory Pumps | Minimum | Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk | Smiths Medical, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage (as a percent)</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_NumberOfLocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Locations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_NumberOfLocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=infu_AmbulatoryPumpsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=infu_AmbulatoryPumpsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=infu_SmithsMedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=infu_SmithsMedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>network </div>
<div>segment </div>
<div>financial_institution </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>network </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NumberOfFinancialInstitutions', window );">Number of financial institutions | financial_institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList', window );">Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Revenues<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList', window );">Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Revenues<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorSalesTypeLeaseTermOfContract1', window );">Sales-type lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentInRentalServicesUsefulLife', window );">Medical equipment in rental services, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentInRentalServicesReserve', window );">Medical equipment in rental services reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,727,000<span></span>
</td>
<td class="nump">2,530,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentHeldForSaleOrRentalReserve', window );">Medical equipment for sale or rental, reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NumberOfContractsWithThirdParties', window );">Number of contracts with third parties | network</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_TermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_TermOfRenewal', window );">Term of renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Treasury stock, shares, retired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072,460<span></span>
</td>
<td class="nump">1,950,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets held-for-use</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnpatentedTechnologyMember', window );">Unpatented Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-competition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=infu_InformationTechnologySoftwareMember', window );">Information Technology Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Physician and customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentHeldForSaleOrRentalReserve', window );">Medical equipment for sale or rental, reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Physician and customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentHeldForSaleOrRentalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reserve associated with medical equipment for sale or rental, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentHeldForSaleOrRentalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentInRentalServicesReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of medical equipment in rental services reserve, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentInRentalServicesReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentInRentalServicesUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the useful life of medical equipment in rental services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentInRentalServicesUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_NumberOfContractsWithThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contracts With Third Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_NumberOfContractsWithThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_NumberOfFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of financial institutions where the entity maintains its cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_NumberOfFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_TermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Of Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_TermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_TermOfRenewal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Of Renewal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_TermOfRenewal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorSalesTypeLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's sales-type lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorSalesTypeLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes operating lease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479016/842-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes sales-type lease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479016/842-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnpatentedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnpatentedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=infu_InformationTechnologySoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=infu_InformationTechnologySoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=infu_PhysicianAndCustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=infu_PhysicianAndCustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 6,627<span></span>
</td>
<td class="nump">$ 2,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">20,657,877<span></span>
</td>
<td class="nump">21,271,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of common stock equivalents (in shares)</a></td>
<td class="nump">439,446<span></span>
</td>
<td class="nump">435,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">21,097,323<span></span>
</td>
<td class="nump">21,707,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed (Details) - Apollo<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Other assets</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable acquired in business combination and recognized at acquisition date, classified as current. Includes, but is not limited to, receivable from customer for product and service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of identifiable intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 45<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-45<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory acquired in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=infu_ApolloMedicalSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=infu_ApolloMedicalSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Lease revenue</a></td>
<td class="nump">$ 30,356<span></span>
</td>
<td class="nump">$ 28,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total net revenues</a></td>
<td class="nump">143,436<span></span>
</td>
<td class="nump">134,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesAndDeviceSolutionsMember', window );">Patient Services and Device Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">113,080<span></span>
</td>
<td class="nump">106,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Lease revenue</a></td>
<td class="nump">30,356<span></span>
</td>
<td class="nump">28,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember', window );">Patient Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">78,187<span></span>
</td>
<td class="nump">72,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Lease revenue</a></td>
<td class="nump">8,345<span></span>
</td>
<td class="nump">7,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember', window );">Device Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Lease revenue</a></td>
<td class="nump">22,011<span></span>
</td>
<td class="nump">20,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember', window );">Device Solutions | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">34,893<span></span>
</td>
<td class="nump">33,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=infu_ThirdPartyPayerRentalsMember', window );">Third-Party Payer Rentals | Patient Services | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17,750<span></span>
</td>
<td class="nump">15,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=infu_ThirdPartyPayerRentalsMember', window );">Third-Party Payer Rentals | Patient Services | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">50,091<span></span>
</td>
<td class="nump">47,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=infu_DirectPayerRentalsMember', window );">Direct Payer Rentals | Patient Services | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,755<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Patient Services | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,591<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Device Solutions | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17,274<span></span>
</td>
<td class="nump">16,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Device Solutions | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">11,829<span></span>
</td>
<td class="nump">8,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Device Solutions | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 5,790<span></span>
</td>
<td class="nump">$ 8,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Patient Services and Device Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">78.80%<span></span>
</td>
<td class="nump">78.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Patient Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">54.50%<span></span>
</td>
<td class="nump">53.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Device Solutions | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Third-Party Payer Rentals | Patient Services | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="nump">11.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Third-Party Payer Rentals | Patient Services | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">34.90%<span></span>
</td>
<td class="nump">35.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Direct Payer Rentals | Patient Services | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Products | Patient Services | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Products | Device Solutions | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Services | Device Solutions | Transferred at Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Services | Device Solutions | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk | Patient Services and Device Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">21.20%<span></span>
</td>
<td class="nump">21.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk | Patient Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk | Device Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Total Net Revenues</a></td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesAndDeviceSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesAndDeviceSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=infu_ThirdPartyPayerRentalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=infu_ThirdPartyPayerRentalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=infu_DirectPayerRentalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=infu_DirectPayerRentalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 22,901<span></span>
</td>
<td class="nump">$ 21,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ContractAssets', window );">Contract assets</a></td>
<td class="nump">1,244<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ContractAssets', window );">Contract assets</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ContractAssetsRevenuePartiallyOffsetAmount', window );">Contract assets partially offset amount</a></td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ContractAssetsRevenueRecognized', window );">Contract assets, revenue recognized</a></td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ContractAssetsRevenuePartiallyOffsetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Assets, Revenue, Partially Offset Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ContractAssetsRevenuePartiallyOffsetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ContractAssetsRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Assets, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ContractAssetsRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Equipment - Schedule of Medical Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentAbstract', window );"><strong>Medical Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentHeldForSaleOrRentalGross', window );">Medical Equipment for sale or rental</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 3,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentHeldForSaleOrRentalReserve', window );">Medical Equipment for sale or rental - pump reserve</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentHeldForSaleOrRental', window );">Medical Equipment for sale or rental - net</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="nump">3,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentInRentalServicesGross', window );">Medical Equipment in rental service</a></td>
<td class="nump">109,060<span></span>
</td>
<td class="nump">107,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentInRentalServicesReserve', window );">Medical Equipment in rental service - pump reserve</a></td>
<td class="num">(2,727)<span></span>
</td>
<td class="num">(2,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="num">(71,877)<span></span>
</td>
<td class="num">(65,323)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation', window );">Medical Equipment in rental service - net</a></td>
<td class="nump">34,456<span></span>
</td>
<td class="nump">39,175<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentNet', window );">Total</a></td>
<td class="nump">$ 39,045<span></span>
</td>
<td class="nump">$ 42,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentHeldForSaleOrRental">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents medical equipment held for sale or rental as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentHeldForSaleOrRental</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentHeldForSaleOrRentalGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents medical equipment held for sale or rental as of the balance sheet date, before reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentHeldForSaleOrRentalGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentHeldForSaleOrRentalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reserve associated with medical equipment for sale or rental, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentHeldForSaleOrRentalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents medical equipment in rental service, net of accumulated depreciation, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accumulated depreciation related to medical equipment in rental services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentInRentalServicesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the gross amount of medical equipment in rental services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentInRentalServicesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentInRentalServicesReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of medical equipment in rental services reserve, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentInRentalServicesReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the net amount of medical equipment, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_MedicalEquipmentAbstract', window );"><strong>Medical Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_DepreciationExpenseRelatedToMedicalEquipment', window );">Depreciation expense related to medical equipment</a></td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_DepreciationExpenseRelatedToMedicalEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of depreciation expense related to medical equipment recorded during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_DepreciationExpenseRelatedToMedicalEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_MedicalEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_MedicalEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross Assets</a></td>
<td class="nump">$ 11,523<span></span>
</td>
<td class="nump">$ 11,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(8,164)<span></span>
</td>
<td class="num">(7,148)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">3,359<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross Assets</a></td>
<td class="nump">6,358<span></span>
</td>
<td class="nump">6,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(5,032)<span></span>
</td>
<td class="num">(4,588)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross Assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross Assets</a></td>
<td class="nump">5,099<span></span>
</td>
<td class="nump">4,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(3,066)<span></span>
</td>
<td class="num">(2,473)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">$ 2,033<span></span>
</td>
<td class="nump">$ 2,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation, nonproduction</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 3,710,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">3,710,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember', window );">Device Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">3,710,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">3,710,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember', window );">Patient Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Trade names</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(47,036)<span></span>
</td>
<td class="num">(46,116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total nonamortizable and amortizable intangible assets, gross</a></td>
<td class="nump">53,902<span></span>
</td>
<td class="nump">52,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total nonamortizable and amortizable intangible assets, net</a></td>
<td class="nump">6,866<span></span>
</td>
<td class="nump">6,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=infu_PhysicianAndCustomerRelationshipsMember', window );">Physician and customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">40,164<span></span>
</td>
<td class="nump">38,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(35,627)<span></span>
</td>
<td class="num">(34,996)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">4,537<span></span>
</td>
<td class="nump">3,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Unpatented technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(662)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-competition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Assets</a></td>
<td class="nump">10,300<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,280)<span></span>
</td>
<td class="num">(10,220)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=infu_PhysicianAndCustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=infu_PhysicianAndCustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">$ 920<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2031 and thereafter</a></td>
<td class="nump">$ 1,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - The 2021 Credit Agreement<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th">
<div>Apr. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 25, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_PercentageOfTotalDepreciationExpense', window );">Percentage of total depreciation expense (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio', window );">Debt instrument, covenant, minimum fixed coverage ratio</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_DebtInstrumentCovenantMaximumLeverageRatio', window );">Debt instrument, covenant, maximum leverage ratio</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Term Benchmark Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">ABR Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Secured Overnight Financing Rate (SOFR) | Term Benchmark Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Prime Rate | ABR Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Minimum | Term Benchmark Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Minimum | Secured Overnight Financing Rate (SOFR) | Term Benchmark Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Minimum | Base Rate | ABR Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Minimum | Prime Rate | ABR Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Maximum | Term Benchmark Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Maximum | Base Rate | ABR Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Revolving Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions', window );">Revolving credit facility</a></td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_DebtInstrumentCovenantMaximumLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum leverage ratio required by the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_DebtInstrumentCovenantMaximumLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_DebtInstrumentCovenantMinimumFixedCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum fixed coverage ratio required by the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_DebtInstrumentCovenantMinimumFixedCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional borrowing capacity under the credit facility subject to certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_PercentageOfTotalDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of total depreciation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_PercentageOfTotalDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=infu_The2021CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=infu_TermBenchmarkLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=infu_TermBenchmarkLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=infu_ABRLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=infu_ABRLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Line of Credit Facilities (Details) - Revolving Facility - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Gross availability</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding draws</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(24,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Availability on Revolving Facility</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 50,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Maturities of Long-term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2030</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2031 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2030</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2031 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 24,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_UnamortizedDebtIssuanceExpenseCurrent', window );">Unamortized value of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_UnamortizedDebtIssuanceExpenseNoncurrent', window );">Unamortized value of the debt issuance costs, long-term debt</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized value of the debt issuance costs, total</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">19,625<span></span>
</td>
<td class="nump">23,864<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">19,625<span></span>
</td>
<td class="nump">23,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_LongTermDebtGrossCurrent', window );">Current Portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_LongTermDebtGrossNoncurrent', window );">Long-Term Portion</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">24,124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 24,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_LongTermDebtGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of the current portion of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_LongTermDebtGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_LongTermDebtGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, excluding the current portion. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_LongTermDebtGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_UnamortizedDebtIssuanceExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of unamortized debt issuance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_UnamortizedDebtIssuanceExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_UnamortizedDebtIssuanceExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of unamortized debt issuance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_UnamortizedDebtIssuanceExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments and Hedging Activities - Narrative (Details) - Interest Rate Swap - Designated as Hedging Instrument - Cash Flow Hedging - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Term of contract (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Fixed interest rate (as a percent)</a></td>
<td class="nump">1.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss', window );">Net hedge effectiveness</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on derivative instrument designated and qualifying as fair value hedge included in assessment of hedge effectiveness, recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480682/815-20-25-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Fair value derivative assets</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Interest Rate Swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Fair value derivative assets</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480682/815-20-25-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments and Hedging Activities - Schedule of Designated as Hedging Instruments in AOCI (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 57,529<span></span>
</td>
<td class="nump">$ 52,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">57,326<span></span>
</td>
<td class="nump">57,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">1,299<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Cash Flow Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Cash flow hedge gain (loss) to be reclassified within 12 months</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gain/(Loss) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gain recognized in AOCI</a></td>
<td class="num">(227)<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to interest expense</a></td>
<td class="num">(506)<span></span>
</td>
<td class="num">(694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax benefit (provision)</a></td>
<td class="nump">179<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 565<span></span>
</td>
<td class="nump">$ 1,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Before Income Tax, Domestic and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S income</a></td>
<td class="nump">$ 9,322<span></span>
</td>
<td class="nump">$ 3,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S. income</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) before income taxes</a></td>
<td class="nump">$ 10,623<span></span>
</td>
<td class="nump">$ 5,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>U.S Federal income tax expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(2,496)<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Total U.S. Federal income tax expense</a></td>
<td class="num">(2,501)<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State and local income tax expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="num">(750)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total state and local income tax expense</a></td>
<td class="num">(982)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign income tax expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="num">(513)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit at effective income tax rate</a></td>
<td class="num">$ (3,996)<span></span>
</td>
<td class="num">$ (2,714)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at the statutory rate</a></td>
<td class="num">$ (2,231)<span></span>
</td>
<td class="num">$ (1,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax expense, net of federal income tax effect</a></td>
<td class="num">(776)<span></span>
</td>
<td class="num">(579)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and Entertainment</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock Options</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount', window );">Non-deductible Officer's Compensation</a></td>
<td class="num">(491)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount', window );">Income for Canada Disregarded Entity</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount', window );">Tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax (Canada)</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Reconciling Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit at effective income tax rate</a></td>
<td class="num">$ (3,996)<span></span>
</td>
<td class="num">$ (2,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>% of Pretax Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at the statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax expense, net of federal income tax effect</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and Entertainment</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock Options</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent', window );">Non-deductible Officer's Compensation</a></td>
<td class="nump">0.046<span></span>
</td>
<td class="nump">0.030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent', window );">Income for Canada Disregarded Entity</a></td>
<td class="nump">0.016<span></span>
</td>
<td class="nump">0.034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent', window );">Tax credits</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax (Canada)</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Reconciling Adjustment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax (expense) benefit at effective income tax rate</a></td>
<td class="nump">37.60%<span></span>
</td>
<td class="nump">53.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Taxes Paid Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived', window );">U.S. Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived', window );">Foreign</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Total</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_FL', window );">Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_GA', window );">Georgia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_IL', window );">Illinois</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_MI', window );">Michigan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_TX', window );">Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">U.S State and local</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidFederalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidForeignAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_MI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_MI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 1,385<span></span>
</td>
<td class="nump">$ 3,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards, total</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards, total</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_OperatingLossCarryforwardsWithADefiniteLife', window );">Operating loss carryforwards with a definite life</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_OperatingLossCarryforwardsExpirationPeriods', window );">Operating loss carryforwards expiration periods</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_OperatingLossCarryforwardsExpirationPeriods', window );">Operating loss carryforwards expiration periods</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_OperatingLossCarryforwardsExpirationPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of operating loss carryforwards before expiration begins.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_OperatingLossCarryforwardsExpirationPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_OperatingLossCarryforwardsWithADefiniteLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of operating loss carryforwards that have an indefinite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_OperatingLossCarryforwardsWithADefiniteLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Carry Forwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Bad debt reserves</a></td>
<td class="nump">$ 5,673<span></span>
</td>
<td class="nump">$ 4,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,343<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">3,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventories</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research &amp; development credits</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Other credits</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred Federal, state and local tax assets</a></td>
<td class="nump">13,139<span></span>
</td>
<td class="nump">14,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and asset basis differences</a></td>
<td class="num">(6,502)<span></span>
</td>
<td class="num">(4,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Goodwill and intangible assets</a></td>
<td class="num">(731)<span></span>
</td>
<td class="num">(737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="num">(1,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Derivative financial instruments</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred Federal, state and local tax liabilities</a></td>
<td class="num">(8,499)<span></span>
</td>
<td class="num">(7,268)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">7,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards, total</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,989<span></span>
</td>
<td class="nump">$ 1,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 2,449<span></span>
</td>
<td class="nump">$ 2,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost, total</a></td>
<td class="nump">$ 2,449,000<span></span>
</td>
<td class="nump">$ 2,269,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Short-Term Lease Payments</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">3,427,000<span></span>
</td>
<td class="nump">4,560,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost, total</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow from operating leases</a></td>
<td class="nump">$ 2,025<span></span>
</td>
<td class="nump">$ 1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications', window );">Operating leases</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increases to Right of Use Assets Resulting From Lease Modifications</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted Average Table (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term:</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate:</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 1,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">7,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(2,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 4,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Net operating lease revenue</a></td>
<td class="nump">$ 30,006<span></span>
</td>
<td class="nump">$ 27,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncome', window );">Sales-type lease revenue</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Total lease revenue</a></td>
<td class="nump">$ 30,356<span></span>
</td>
<td class="nump">$ 28,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479016/842-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from variable lease payments, interest income from net investment on sales-type lease, and profit (loss) recognized at commencement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479016/842-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Net Investment in Sales-Type Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Lease receivable</a></td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="nump">$ 1,934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLease', window );">Net investment in leases</a></td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="nump">$ 1,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of net investment in sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Net Investment in Sales-Type Leases in Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems', window );"><strong>Sales-Type Lease, Net Investment In Lease [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 100,560<span></span>
</td>
<td class="nump">$ 103,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_LeaseClassificationAxis=infu_SalesTypeLeaseNetInvestmentMember', window );">Sales-Type Lease, Net Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems', window );"><strong>Sales-Type Lease, Net Investment In Lease [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="nump">$ 1,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_SalesTypeLeaseNetInvestmentInLeaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-Type Lease, Net Investment In Lease [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_SalesTypeLeaseNetInvestmentInLeaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_LeaseClassificationAxis=infu_SalesTypeLeaseNetInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_LeaseClassificationAxis=infu_SalesTypeLeaseNetInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Sale-Type Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears', window );">2027</a></td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears', window );">2028</a></td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears', window );">2029</a></td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived', window );">Total undiscounted lease payments</a></td>
<td class="nump">2,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable', window );">Total lease receivables</a></td>
<td class="nump">$ 1,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 16, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 19, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 18, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 23, 2014 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio', window );">Options, reduction ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio', window );">Other types of awards, reduction ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for tax withholding obligation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,909<span></span>
</td>
<td class="nump">108,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP', window );">Employee stock ownership plan (ESOP) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum', window );">ESOP purchase per employee maximum | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance', window );">Stock issued during period shares employee stock ownership plan number of remaining shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,869,000<span></span>
</td>
<td class="nump">$ 1,180,000<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,376<span></span>
</td>
<td class="nump">553,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share-based payment award, shares allowed for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember', window );">2021 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Share-based payment award, increase in shares allowed for issuance (in shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember', window );">2021 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share-based payment award, shares allowed for issuance (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=infu_A2014EquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod', window );">Exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Nonvested award, excluding option, cost not yet recognized, amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based compensation arrangement, equity instruments other than options, grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Nonvested award, excluding option, cost not yet recognized, amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based compensation arrangement, equity instruments other than options, grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,905<span></span>
</td>
<td class="nump">117,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Share-based Payment Arrangement, Exceeding Minimum Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned', window );">Share-based compensation arrangement by share-based payment award percentage of target number of shares to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Share-based Payment Arrangement, Achieving Minimum Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned', window );">Share-based compensation arrangement by share-based payment award percentage of target number of shares to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum threshold, per employee, of purchases made in the employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Award Exercisable Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Reduction Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Reduction Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of target number of shares to be earned under share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares employee stock ownership plan number of remaining shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the number of shares provided to the Employee Stock Ownership Plan (ESOP) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=infu_A2014EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=infu_A2014EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted share expense</a></td>
<td class="nump">$ 2,384<span></span>
</td>
<td class="nump">$ 2,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,363<span></span>
</td>
<td class="nump">4,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to stock-based compensation</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details) - Restricted Stock - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">503,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based compensation arrangement, equity instruments other than options, grants in period (in shares)</a></td>
<td class="nump">228,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, number of shares (in shares)</a></td>
<td class="num">(110,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod', window );">Vested shares forgone to satisfy minimum statutory withholding, number of shares (in shares)</a></td>
<td class="num">(65,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeitures, number of shares (in shares)</a></td>
<td class="num">(75,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">480,879<span></span>
</td>
<td class="nump">503,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 8.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">6.12<span></span>
</td>
<td class="nump">$ 7.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">9.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue', window );">Vested shares forgone to satisfy minimum statutory withholding, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">9.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 7.31<span></span>
</td>
<td class="nump">$ 8.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 824,800<span></span>
</td>
<td class="nump">$ 1,122,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue', window );">Total fair value of shares forgone to satisfy minimum statutory withholding</a></td>
<td class="nump">$ 493,515<span></span>
</td>
<td class="nump">$ 651,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards expired during the period, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards expired during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - PSU Activity (Details) - Performance Shares - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">189,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">364,905<span></span>
</td>
<td class="nump">117,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(30,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone', window );">Vested shares forgone to satisfy minimum statutory withholding (in shares)</a></td>
<td class="num">(19,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeitures, number of shares (in shares)</a></td>
<td class="num">(121,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">382,802<span></span>
</td>
<td class="nump">189,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 7.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">5.70<span></span>
</td>
<td class="nump">$ 5.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue', window );">Vested shares forgone to satisfy minimum statutory withholding (usd per share)</a></td>
<td class="nump">3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">9.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="nump">$ 7.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 309,921<span></span>
</td>
<td class="nump">$ 83,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue', window );">Total fair value of shares forgone to satisfy minimum statutory withholding</a></td>
<td class="nump">201,079<span></span>
</td>
<td class="nump">67,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Shares Forgone, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Activity Relating to Company's ESPP Program (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 139,140<span></span>
</td>
<td class="nump">$ 93,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares of stock sold to employees (in shares)</a></td>
<td class="nump">61,470<span></span>
</td>
<td class="nump">52,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased', window );">Weighted average fair value per ESPP award (usd per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average purchase price of shares purchased under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2014 and 2021 Plan Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=infu_A2014EquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Authorized Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of authorized shares (in shares)</a></td>
<td class="nump">535,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, number of authorized shares (in shares)</a></td>
<td class="num">(49,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Exercised shares forgone to satisfy minimum statutory withholding, number of authorized shares (in shares)</a></td>
<td class="num">(32,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod', window );">Cashless exercise, number of authorized shares (in shares)</a></td>
<td class="num">(27,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expirations, number of authorized shares (in shares)</a></td>
<td class="num">(75,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of authorized shares (in shares)</a></td>
<td class="nump">349,917<span></span>
</td>
<td class="nump">535,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, number (in shares)</a></td>
<td class="nump">349,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (usd per share)</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (usd per share)</a></td>
<td class="nump">2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised shares forgone to satisfy minimum statutory withholding, weighted average exercise price (usd per share)</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice', window );">Cashless exercise, weighted average exercise price (usd per share)</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeitures and expirations (usd per share)</a></td>
<td class="nump">8.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (usd per share)</a></td>
<td class="nump">8.09<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (usd per share)</a></td>
<td class="nump">$ 8.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted average remaining contractual term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted average remaining contractual term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 960,120<span></span>
</td>
<td class="nump">$ 1,588,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 960,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Authorized Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of authorized shares (in shares)</a></td>
<td class="nump">1,840,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">889,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, number of authorized shares (in shares)</a></td>
<td class="num">(12,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Exercised shares forgone to satisfy minimum statutory withholding, number of authorized shares (in shares)</a></td>
<td class="num">(14,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod', window );">Cashless exercise, number of authorized shares (in shares)</a></td>
<td class="num">(177,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expirations, number of authorized shares (in shares)</a></td>
<td class="num">(236,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of authorized shares (in shares)</a></td>
<td class="nump">2,289,333<span></span>
</td>
<td class="nump">1,840,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, number (in shares)</a></td>
<td class="nump">911,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (usd per share)</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (usd per share)</a></td>
<td class="nump">6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (usd per share)</a></td>
<td class="nump">8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised shares forgone to satisfy minimum statutory withholding, weighted average exercise price (usd per share)</a></td>
<td class="nump">7.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice', window );">Cashless exercise, weighted average exercise price (usd per share)</a></td>
<td class="nump">8.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeitures and expirations (usd per share)</a></td>
<td class="nump">8.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (usd per share)</a></td>
<td class="nump">8.00<span></span>
</td>
<td class="nump">$ 8.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (usd per share)</a></td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted average remaining contractual term</a></td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">8 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted average remaining contractual term</a></td>
<td class="text">7 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 3,888,088<span></span>
</td>
<td class="nump">$ 1,504,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 729,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares exercised in a cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of awarded shares exercised in the period in a cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=infu_A2014EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=infu_A2014EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=infu_A2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">3.56%<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives at date of grant (in years)</a></td>
<td class="text">4 years 2 months 26 days<span></span>
</td>
<td class="text">4 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average fair value of options granted (usd per share)</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 926,116<span></span>
</td>
<td class="nump">$ 322,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesExternal', window );">Net revenues - external</a></td>
<td class="nump">$ 143,436<span></span>
</td>
<td class="nump">$ 134,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesInternal', window );">Net revenues - internal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total net revenues</a></td>
<td class="nump">143,436<span></span>
</td>
<td class="nump">134,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Significant Segment Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies and material costs</a></td>
<td class="nump">35,218<span></span>
</td>
<td class="nump">34,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee-related expenses</a></td>
<td class="nump">16,328<span></span>
</td>
<td class="nump">18,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation', window );">Depreciation</a></td>
<td class="nump">11,144<span></span>
</td>
<td class="nump">10,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">80,296<span></span>
</td>
<td class="nump">70,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Selling, general and administrative expenses</a></td>
<td class="nump">68,376<span></span>
</td>
<td class="nump">63,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,299)<span></span>
</td>
<td class="num">(1,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) before income taxes</a></td>
<td class="nump">10,623<span></span>
</td>
<td class="nump">5,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">100,560<span></span>
</td>
<td class="nump">103,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_PaymentsToAcquireMedicalEquipment', window );">Purchases of medical equipment</a></td>
<td class="nump">8,126<span></span>
</td>
<td class="nump">16,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">13,294<span></span>
</td>
<td class="nump">12,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=infu_CorporateAndEliminationsMember', window );">Corporate/Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesExternal', window );">Net revenues - external</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesInternal', window );">Net revenues - internal</a></td>
<td class="num">(7,192)<span></span>
</td>
<td class="num">(7,254)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total net revenues</a></td>
<td class="num">(7,192)<span></span>
</td>
<td class="num">(7,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Significant Segment Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies and material costs</a></td>
<td class="num">(7,192)<span></span>
</td>
<td class="num">(7,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_PaymentsToAcquireMedicalEquipment', window );">Purchases of medical equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember', window );">Patient Services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesExternal', window );">Net revenues - external</a></td>
<td class="nump">86,532<span></span>
</td>
<td class="nump">80,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesInternal', window );">Net revenues - internal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total net revenues</a></td>
<td class="nump">86,532<span></span>
</td>
<td class="nump">80,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Significant Segment Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies and material costs</a></td>
<td class="nump">23,478<span></span>
</td>
<td class="nump">20,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation', window );">Depreciation</a></td>
<td class="nump">7,357<span></span>
</td>
<td class="nump">6,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">55,373<span></span>
</td>
<td class="nump">52,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">53,518<span></span>
</td>
<td class="nump">54,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_PaymentsToAcquireMedicalEquipment', window );">Purchases of medical equipment</a></td>
<td class="nump">4,560<span></span>
</td>
<td class="nump">6,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">8,492<span></span>
</td>
<td class="nump">7,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember', window );">Device Solutions | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesExternal', window );">Net revenues - external</a></td>
<td class="nump">56,904<span></span>
</td>
<td class="nump">54,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_NetRevenuesInternal', window );">Net revenues - internal</a></td>
<td class="nump">7,192<span></span>
</td>
<td class="nump">7,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total net revenues</a></td>
<td class="nump">64,096<span></span>
</td>
<td class="nump">61,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Significant Segment Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies and material costs</a></td>
<td class="nump">18,932<span></span>
</td>
<td class="nump">21,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee-related expenses</a></td>
<td class="nump">16,328<span></span>
</td>
<td class="nump">18,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation', window );">Depreciation</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="nump">3,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">24,923<span></span>
</td>
<td class="nump">17,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">45,042<span></span>
</td>
<td class="nump">47,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infu_PaymentsToAcquireMedicalEquipment', window );">Purchases of medical equipment</a></td>
<td class="nump">3,566<span></span>
</td>
<td class="nump">10,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">$ 4,802<span></span>
</td>
<td class="nump">$ 4,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_NetRevenuesExternal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of external net revenues recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_NetRevenuesExternal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_NetRevenuesInternal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of internal net revenues recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_NetRevenuesInternal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infu_PaymentsToAcquireMedicalEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of cash paid during the period to acquire medical equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infu_PaymentsToAcquireMedicalEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=infu_CorporateAndEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=infu_CorporateAndEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=infu_PatientServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=infu_DeviceSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Other (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related liabilities, current</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>472</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Basis of Presentation and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BasisofPresentationandNatureofOperations</Role>
      <ShortName>Basis of Presentation and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Medical Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/MedicalEquipment</Role>
      <ShortName>Medical Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Derivative Financial Instruments and Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivities</Role>
      <ShortName>Derivative Financial Instruments and Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Business Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BusinessSegmentInformation</Role>
      <ShortName>Business Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Employee Benefit Plans and Other</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/EmployeeBenefitPlansandOther</Role>
      <ShortName>Employee Benefit Plans and Other</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://infusystem.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/SummaryofSignificantAccountingPoliciesEarningsPerShareTables</Role>
      <ShortName>Summary of Significant Accounting Policies - Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/BusinessCombinations</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/Revenue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Medical Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/MedicalEquipmentTables</Role>
      <ShortName>Medical Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/MedicalEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/PropertyandEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/Debt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Derivative Financial Instruments and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables</Role>
      <ShortName>Derivative Financial Instruments and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/ShareBasedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Business Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BusinessSegmentInformationTables</Role>
      <ShortName>Business Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://infusystem.com/role/BusinessSegmentInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Basis of Presentation and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails</Role>
      <ShortName>Basis of Presentation and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://infusystem.com/role/BasisofPresentationandNatureofOperations</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://infusystem.com/role/SummaryofSignificantAccountingPoliciesEarningsPerShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Business Combinations - Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Revenue - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Revenue - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/RevenueContractBalancesDetails</Role>
      <ShortName>Revenue - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Medical Equipment - Schedule of Medical Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails</Role>
      <ShortName>Medical Equipment - Schedule of Medical Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Medical Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/MedicalEquipmentNarrativeDetails</Role>
      <ShortName>Medical Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Debt - Schedule of Line of Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails</Role>
      <ShortName>Debt - Schedule of Line of Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Debt - Schedule of Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DebtScheduleofDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Derivative Financial Instruments and Hedging Activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails</Role>
      <ShortName>Derivative Financial Instruments and Hedging Activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Derivative Financial Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails</Role>
      <ShortName>Derivative Financial Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Derivative Financial Instruments and Hedging Activities - Schedule of Designated as Hedging Instruments in AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails</Role>
      <ShortName>Derivative Financial Instruments and Hedging Activities - Schedule of Designated as Hedging Instruments in AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Income Taxes - Schedule of Income Before Income Tax, Domestic and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Before Income Tax, Domestic and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Income Taxes - Schedule of Income Taxes Paid Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Taxes Paid Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Income Taxes - Carry Forwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/IncomeTaxesCarryForwardsDetails</Role>
      <ShortName>Income Taxes - Carry Forwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Leases - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>Leases - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Leases - Supplemental Cash Flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesSupplementalCashFlowDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Leases - Weighted Average Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesWeightedAverageTableDetails</Role>
      <ShortName>Leases - Weighted Average Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Leases - Lease Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesLeaseRevenueDetails</Role>
      <ShortName>Leases - Lease Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Leases - Net Investment in Sales-Type Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails</Role>
      <ShortName>Leases - Net Investment in Sales-Type Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Leases - Net Investment in Sales-Type Leases in Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails</Role>
      <ShortName>Leases - Net Investment in Sales-Type Leases in Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Leases - Maturities of Sale-Type Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails</Role>
      <ShortName>Leases - Maturities of Sale-Type Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Share-Based Compensation - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Share-Based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Share-Based Compensation - PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails</Role>
      <ShortName>Share-Based Compensation - PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Share-Based Compensation - Summary of Activity Relating to Company's ESPP Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Activity Relating to Company's ESPP Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Share-Based Compensation - 2014 and 2021 Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails</Role>
      <ShortName>Share-Based Compensation - 2014 and 2021 Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Business Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/BusinessSegmentInformationDetails</Role>
      <ShortName>Business Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://infusystem.com/role/BusinessSegmentInformationTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="infu-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Employee Benefit Plans and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://infusystem.com/role/EmployeeBenefitPlansandOtherDetails</Role>
      <ShortName>Employee Benefit Plans and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://infusystem.com/role/EmployeeBenefitPlansandOther</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="infu-20251231.htm">infu-20251231.htm</File>
    <File>infu-20251231.xsd</File>
    <File>infu-20251231_cal.xml</File>
    <File>infu-20251231_def.xml</File>
    <File>infu-20251231_lab.xml</File>
    <File>infu-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>infu-20251231_g1.jpg</File>
    <File>infu-20251231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="899">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>108
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "infu-20251231.htm": {
   "nsprefix": "infu",
   "nsuri": "http://infusystem.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "infu-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "infu-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "infu-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "infu-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "infu-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "infu-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 409,
   "keyCustom": 63,
   "axisStandard": 26,
   "axisCustom": 1,
   "memberStandard": 50,
   "memberCustom": 19,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 9
   },
   "contextCount": 212,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 784,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 899,
    "http://xbrl.sec.gov/dei/2025": 38,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://infusystem.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://infusystem.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://infusystem.com/role/BasisofPresentationandNatureofOperations",
     "longName": "9952156 - Disclosure - Basis of Presentation and Nature of Operations",
     "shortName": "Basis of Presentation and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://infusystem.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://infusystem.com/role/BusinessCombinations",
     "longName": "9952158 - Disclosure - Business Combinations",
     "shortName": "Business Combinations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://infusystem.com/role/Revenue",
     "longName": "9952159 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://infusystem.com/role/MedicalEquipment",
     "longName": "9952160 - Disclosure - Medical Equipment",
     "shortName": "Medical Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "infu:MedicalEquipmentAndPropertyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "infu:MedicalEquipmentAndPropertyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://infusystem.com/role/PropertyandEquipment",
     "longName": "9952161 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://infusystem.com/role/GoodwillandIntangibleAssets",
     "longName": "9952162 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://infusystem.com/role/Debt",
     "longName": "9952163 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivities",
     "longName": "9952164 - Disclosure - Derivative Financial Instruments and Hedging Activities",
     "shortName": "Derivative Financial Instruments and Hedging Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://infusystem.com/role/IncomeTaxes",
     "longName": "9952165 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://infusystem.com/role/CommitmentsandContingencies",
     "longName": "9952166 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://infusystem.com/role/Leases",
     "longName": "9952167 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://infusystem.com/role/ShareBasedCompensation",
     "longName": "9952168 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://infusystem.com/role/BusinessSegmentInformation",
     "longName": "9952169 - Disclosure - Business Segment Information",
     "shortName": "Business Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://infusystem.com/role/EmployeeBenefitPlansandOther",
     "longName": "9952170 - Disclosure - Employee Benefit Plans and Other",
     "shortName": "Employee Benefit Plans and Other",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-212",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesEarningsPerShareTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Tables)",
     "shortName": "Summary of Significant Accounting Policies - Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://infusystem.com/role/BusinessCombinationsTables",
     "longName": "9955513 - Disclosure - Business Combinations (Tables)",
     "shortName": "Business Combinations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://infusystem.com/role/RevenueTables",
     "longName": "9955514 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://infusystem.com/role/MedicalEquipmentTables",
     "longName": "9955515 - Disclosure - Medical Equipment (Tables)",
     "shortName": "Medical Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "infu:ScheduleOfMedicalEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "infu:ScheduleOfMedicalEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://infusystem.com/role/PropertyandEquipmentTables",
     "longName": "9955516 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://infusystem.com/role/GoodwillandIntangibleAssetsTables",
     "longName": "9955517 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://infusystem.com/role/DebtTables",
     "longName": "9955518 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables",
     "longName": "9955519 - Disclosure - Derivative Financial Instruments and Hedging Activities (Tables)",
     "shortName": "Derivative Financial Instruments and Hedging Activities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://infusystem.com/role/IncomeTaxesTables",
     "longName": "9955520 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://infusystem.com/role/LeasesTables",
     "longName": "9955521 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://infusystem.com/role/ShareBasedCompensationTables",
     "longName": "9955522 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://infusystem.com/role/BusinessSegmentInformationTables",
     "longName": "9955523 - Disclosure - Business Segment Information (Tables)",
     "shortName": "Business Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
     "longName": "9955524 - Disclosure - Basis of Presentation and Nature of Operations (Details)",
     "shortName": "Basis of Presentation and Nature of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "infu:NumberOfLocations",
      "unitRef": "location",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "infu:NumberOfLocations",
      "unitRef": "location",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails",
     "longName": "9955526 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
     "longName": "9955527 - Disclosure - Business Combinations - Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Business Combinations - Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-45",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-45",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails",
     "longName": "9955528 - Disclosure - Revenue - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "Revenue - Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://infusystem.com/role/RevenueContractBalancesDetails",
     "longName": "9955529 - Disclosure - Revenue - Contract Balances (Details)",
     "shortName": "Revenue - Contract Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "infu:ContractAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://infusystem.com/role/RevenueNarrativeDetails",
     "longName": "9955530 - Disclosure - Revenue - Narrative (Details)",
     "shortName": "Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "infu:ContractAssetsRevenuePartiallyOffsetAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "infu:ContractAssetsRevenuePartiallyOffsetAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails",
     "longName": "9955531 - Disclosure - Medical Equipment - Schedule of Medical Equipment (Details)",
     "shortName": "Medical Equipment - Schedule of Medical Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "infu:MedicalEquipmentHeldForSaleOrRentalGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "infu:ScheduleOfMedicalEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "infu:MedicalEquipmentHeldForSaleOrRentalGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "infu:ScheduleOfMedicalEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://infusystem.com/role/MedicalEquipmentNarrativeDetails",
     "longName": "9955532 - Disclosure - Medical Equipment - Narrative (Details)",
     "shortName": "Medical Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "infu:DepreciationExpenseRelatedToMedicalEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "infu:DepreciationExpenseRelatedToMedicalEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "longName": "9955533 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://infusystem.com/role/PropertyandEquipmentNarrativeDetails",
     "longName": "9955534 - Disclosure - Property and Equipment - Narrative (Details)",
     "shortName": "Property and Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationNonproduction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationNonproduction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
     "longName": "9955535 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails",
     "longName": "9955536 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "infu:CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "infu:CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://infusystem.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "longName": "9955537 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails",
     "longName": "9955538 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://infusystem.com/role/DebtNarrativeDetails",
     "longName": "9955539 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-117",
      "name": "infu:PercentageOfTotalDepreciationExpense",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "infu:PercentageOfTotalDepreciationExpense",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails",
     "longName": "9955540 - Disclosure - Debt - Schedule of Line of Credit Facilities (Details)",
     "shortName": "Debt - Schedule of Line of Credit Facilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails",
     "longName": "9955541 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details)",
     "shortName": "Debt - Schedule of Maturities of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://infusystem.com/role/DebtScheduleofDebtDetails",
     "longName": "9955542 - Disclosure - Debt - Schedule of Debt (Details)",
     "shortName": "Debt - Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "infu:UnamortizedDebtIssuanceExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
     "longName": "9955543 - Disclosure - Derivative Financial Instruments and Hedging Activities - Narrative (Details)",
     "shortName": "Derivative Financial Instruments and Hedging Activities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:DerivativeTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:DerivativeTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
     "longName": "9955544 - Disclosure - Derivative Financial Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)",
     "shortName": "Derivative Financial Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DerivativeAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails",
     "longName": "9955545 - Disclosure - Derivative Financial Instruments and Hedging Activities - Schedule of Designated as Hedging Instruments in AOCI (Details)",
     "shortName": "Derivative Financial Instruments and Hedging Activities - Schedule of Designated as Hedging Instruments in AOCI (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails",
     "longName": "9955546 - Disclosure - Income Taxes - Schedule of Income Before Income Tax, Domestic and Foreign (Details)",
     "shortName": "Income Taxes - Schedule of Income Before Income Tax, Domestic and Foreign (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9955547 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955548 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails",
     "longName": "9955549 - Disclosure - Income Taxes - Schedule of Income Taxes Paid Jurisdiction (Details)",
     "shortName": "Income Taxes - Schedule of Income Taxes Paid Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955550 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails",
     "longName": "9955551 - Disclosure - Income Taxes - Carry Forwards (Details)",
     "shortName": "Income Taxes - Carry Forwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://infusystem.com/role/LeasesLeaseCostDetails",
     "longName": "9955552 - Disclosure - Leases - Lease Cost (Details)",
     "shortName": "Leases - Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://infusystem.com/role/LeasesNarrativeDetails",
     "longName": "9955553 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShortTermLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://infusystem.com/role/LeasesSupplementalCashFlowDetails",
     "longName": "9955554 - Disclosure - Leases - Supplemental Cash Flow (Details)",
     "shortName": "Leases - Supplemental Cash Flow (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://infusystem.com/role/LeasesWeightedAverageTableDetails",
     "longName": "9955555 - Disclosure - Leases - Weighted Average Table (Details)",
     "shortName": "Leases - Weighted Average Table (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9955556 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://infusystem.com/role/LeasesLeaseRevenueDetails",
     "longName": "9955557 - Disclosure - Leases - Lease Revenue (Details)",
     "shortName": "Leases - Lease Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseLeaseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseLeaseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails",
     "longName": "9955558 - Disclosure - Leases - Net Investment in Sales-Type Leases (Details)",
     "shortName": "Leases - Net Investment in Sales-Type Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:SalesTypeLeaseLeaseReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "infu:NetInvestmentInSalesTypeLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:SalesTypeLeaseLeaseReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "infu:NetInvestmentInSalesTypeLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails",
     "longName": "9955559 - Disclosure - Leases - Net Investment in Sales-Type Leases in Balance Sheet (Details)",
     "shortName": "Leases - Net Investment in Sales-Type Leases in Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-160",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "infu:NetInvestmentInSalesTypeLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails",
     "longName": "9955560 - Disclosure - Leases - Maturities of Sale-Type Leases (Details)",
     "shortName": "Leases - Maturities of Sale-Type Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
     "longName": "9955561 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails",
     "longName": "9955562 - Disclosure - Share-Based Compensation - Stock-based Compensation (Details)",
     "shortName": "Share-Based Compensation - Stock-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestrictedStockExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestrictedStockExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails",
     "longName": "9955563 - Disclosure - Share-Based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details)",
     "shortName": "Share-Based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-176",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-177",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
     "longName": "9955564 - Disclosure - Share-Based Compensation - PSU Activity (Details)",
     "shortName": "Share-Based Compensation - PSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-184",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-180",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails",
     "longName": "9955565 - Disclosure - Share-Based Compensation - Summary of Activity Relating to Company's ESPP Program (Details)",
     "shortName": "Share-Based Compensation - Summary of Activity Relating to Company's ESPP Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails",
     "longName": "9955566 - Disclosure - Share-Based Compensation - 2014 and 2021 Plan Activity (Details)",
     "shortName": "Share-Based Compensation - 2014 and 2021 Plan Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails",
     "longName": "9955567 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-164",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://infusystem.com/role/BusinessSegmentInformationDetails",
     "longName": "9955568 - Disclosure - Business Segment Information (Details)",
     "shortName": "Business Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "infu:NetRevenuesExternal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "infu:NetRevenuesExternal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://infusystem.com/role/EmployeeBenefitPlansandOtherDetails",
     "longName": "9955569 - Disclosure - Employee Benefit Plans and Other (Details)",
     "shortName": "Employee Benefit Plans and Other (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "infu-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "infu_A2014EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "A2014EquityIncentivePlanMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Equity Incentive Plan",
        "label": "2014 Equity Incentive Plan [Member]",
        "documentation": "2014 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "infu_A2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "A2021EquityIncentivePlanMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Equity Incentive Plan",
        "label": "2021 Equity Incentive Plan [Member]",
        "documentation": "2021 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ABRLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ABRLoansMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABR Loans",
        "label": "ABR Loans [Member]",
        "documentation": "Information related to the ABR loans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r1027"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/RevenueContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r163",
      "r776"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/(Loss) on Cash Flow Hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r187",
      "r188",
      "r624",
      "r696",
      "r697",
      "r698",
      "r699",
      "r911",
      "r1183"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r63",
      "r170",
      "r772",
      "r812",
      "r816",
      "r1380"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r16",
      "r690",
      "r693",
      "r750",
      "r807",
      "r808",
      "r1183",
      "r1184",
      "r1185",
      "r1244",
      "r1245",
      "r1246",
      "r1248"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r1027",
      "r1443"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r1244",
      "r1245",
      "r1246",
      "r1248",
      "r1381",
      "r1445"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r511"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1080",
      "r1090",
      "r1123"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1083",
      "r1093",
      "r1126"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1118",
      "r1127",
      "r1131",
      "r1139"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r500",
      "r509"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowance for credit loss, current",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r301",
      "r307"
     ]
    },
    "infu_AmbulatoryPumpsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "AmbulatoryPumpsMember",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ambulatory Pumps",
        "label": "Ambulatory Pumps [Member]",
        "documentation": "Information related to the ambulatory pumps."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r398",
      "r1233",
      "r1394"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangibles",
        "verboseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r198",
      "r330",
      "r337",
      "r905",
      "r912",
      "r913",
      "r915",
      "r917"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "infu_ApolloMedicalSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ApolloMedicalSupplyMember",
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apollo",
        "label": "Apollo Medical Supply [Member]",
        "documentation": "Apollo Medical Supply"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r108",
      "r167",
      "r208",
      "r211",
      "r212",
      "r251",
      "r263",
      "r288",
      "r292",
      "r302",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r622",
      "r625",
      "r711",
      "r762",
      "r763",
      "r769",
      "r852",
      "r930",
      "r931",
      "r943",
      "r1027",
      "r1033",
      "r1034",
      "r1047",
      "r1306",
      "r1307",
      "r1401"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r175",
      "r208",
      "r211",
      "r212",
      "r302",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r622",
      "r625",
      "r711",
      "r1027",
      "r1306",
      "r1307",
      "r1401"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "infu_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://infusystem.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://infusystem.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://infusystem.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "us-gaap_AutomobilesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AutomobilesMember",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Automobiles",
        "label": "Automobiles [Member]",
        "documentation": "Vehicles that are used primarily for transporting people."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BaseRateMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": [
      "r1173",
      "r1305"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Nature of Operations",
        "label": "Basis of Accounting [Text Block]",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1235"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Domain]",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r617",
      "r618",
      "r819",
      "r960",
      "r961",
      "r1360",
      "r1362",
      "r1364"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Axis]",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r617",
      "r618",
      "r819",
      "r960",
      "r961",
      "r1360",
      "r1362",
      "r1364"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Line Items]",
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r558",
      "r559",
      "r560",
      "r561",
      "r567",
      "r568",
      "r569",
      "r570",
      "r576",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r612",
      "r613",
      "r614",
      "r618",
      "r969",
      "r979",
      "r1360",
      "r1362",
      "r1364"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/BusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combination [Text Block]",
        "documentation": "The entire disclosure for business combination."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r558",
      "r562",
      "r571",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r583",
      "r589",
      "r592",
      "r593",
      "r599",
      "r600",
      "r601",
      "r609",
      "r613",
      "r614",
      "r615",
      "r617",
      "r619",
      "r969",
      "r970",
      "r971",
      "r972",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable",
        "label": "Business Combination, Recognized Asset Acquired, Receivable, Current",
        "documentation": "Amount of receivable acquired in business combination and recognized at acquisition date, classified as current. Includes, but is not limited to, receivable from customer for product and service."
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts payable and other current liabilities",
        "label": "Business Combination, Recognized Liability Assumed, Accounts Payable, Current",
        "documentation": "Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill",
        "documentation": "Amount of identifiable intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r974",
      "r977",
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Business Combination, Recognized Asset Acquired, Inventory, Current",
        "documentation": "Amount of inventory acquired in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r974",
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total purchase price",
        "label": "Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_BusinessCombinationSegmentAllocationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationSegmentAllocationTable",
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsScheduleofPurchasePricetoFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Goodwill, Reportable Segment Assignment [Table]",
        "label": "Business Combination, Goodwill, Reportable Segment Assignment [Table]",
        "documentation": "Disclosure of information about goodwill acquired in business combination by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r614"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combination [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for business combination."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r563",
      "r565",
      "r576",
      "r588",
      "r592",
      "r969",
      "r975",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to medical equipment and property",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_CapitalizationOfInternalCostsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizationOfInternalCostsPolicy",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software Capitalization and Depreciation",
        "label": "Oil and Gas, Internal Cost Capitalization [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for capitalization of internal cost for acquisition, exploration, and production in oil- and gas-producing activities."
       }
      }
     },
     "auth_ref": [
      "r1409"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized computer software, amortization",
        "label": "Capitalized Computer Software, Amortization",
        "documentation": "Amount of expense for amortization of capitalized computer software costs."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized computer software",
        "label": "Capitalized Computer Software, Gross",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r901"
     ]
    },
    "infu_CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets",
        "label": "Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount and accumulated amortization of identifiable intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r161",
      "r906"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r77",
      "r205"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r77"
     ]
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedge gain (loss) to be reclassified within 12 months",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH TRANSACTIONS",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r357",
      "r358",
      "r897",
      "r1296",
      "r1301"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, shares allowed for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1037",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1045",
      "r1244",
      "r1245",
      "r1248",
      "r1381",
      "r1442",
      "r1445"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock,, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r840"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r840",
      "r858",
      "r1445",
      "r1446"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value: authorized 200,000,000 shares; 20,209,636 shares issued and outstanding as of December\u00a031, 2025 and 21,272,351 shares issued and outstanding as of December\u00a031, 2024",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r409",
      "r415",
      "r771",
      "r1027"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r182",
      "r184",
      "r190",
      "r760",
      "r781",
      "r782"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r1003",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288",
      "r1291",
      "r1292"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r299",
      "r820",
      "r821",
      "r896",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r299",
      "r820",
      "r821",
      "r896",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r299",
      "r820",
      "r821",
      "r896",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r710"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage (as a percent)",
        "verboseLabel": "% of Total Net Revenues",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r299",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r299",
      "r820",
      "r821",
      "r896",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r123",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r208",
      "r209",
      "r216",
      "r218",
      "r251",
      "r265",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r765",
      "r930",
      "r931",
      "r1170",
      "r1171",
      "r1306",
      "r1307"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r123",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r208",
      "r209",
      "r216",
      "r218",
      "r251",
      "r265",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r765",
      "r930",
      "r931",
      "r1170",
      "r1171",
      "r1306",
      "r1307"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r919"
     ]
    },
    "infu_ContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ContractAssets",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/RevenueContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract Assets",
        "documentation": "Contract Assets"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ContractAssetsRevenuePartiallyOffsetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ContractAssetsRevenuePartiallyOffsetAmount",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets partially offset amount",
        "label": "Contract Assets, Revenue, Partially Offset Amount",
        "documentation": "Contract Assets, Revenue, Partially Offset Amount"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ContractAssetsRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ContractAssetsRevenueRecognized",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets, revenue recognized",
        "label": "Contract Assets, Revenue Recognized",
        "documentation": "Contract Assets, Revenue Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/RevenueContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract Liabilities",
        "documentation": "Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "infu_CorporateAndEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "CorporateAndEliminationsMember",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate/Eliminations",
        "label": "Corporate and Eliminations [Member]",
        "documentation": "Represents information regarding corporate and eliminations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r755",
      "r913",
      "r918",
      "r1010",
      "r1226"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSoldDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Cost, Depreciation",
        "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1186",
      "r1294"
     ]
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsProductLineMember",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service, Product and Service Benchmark",
        "label": "Cost of Goods and Service, Product and Service Benchmark [Member]",
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1255"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/DebtScheduleofDebtDetails",
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails",
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r1304"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/DebtScheduleofDebtDetails",
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails",
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r1304"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1236",
      "r1241",
      "r1358"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1236",
      "r1241"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1236",
      "r1241",
      "r1358"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1253"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1150"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1150"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1154"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1145"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1146"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1146"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1147"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1150"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1153"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1151"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1148"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r208",
      "r210",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r363",
      "r364",
      "r376",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r392",
      "r399",
      "r400",
      "r402",
      "r684",
      "r721"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r43",
      "r44",
      "r98",
      "r100",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r1025",
      "r1236",
      "r1237",
      "r1238",
      "r1243",
      "r1297",
      "r1298",
      "r1299",
      "r1393",
      "r1395",
      "r1410"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate (as a percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails",
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r100",
      "r403"
     ]
    },
    "infu_DebtInstrumentCovenantMaximumLeverageRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "DebtInstrumentCovenantMaximumLeverageRatio",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, maximum leverage ratio",
        "label": "Debt Instrument Covenant Maximum Leverage Ratio",
        "documentation": "The maximum leverage ratio required by the debt agreement."
       }
      }
     },
     "auth_ref": []
    },
    "infu_DebtInstrumentCovenantMinimumFixedCoverageRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "DebtInstrumentCovenantMinimumFixedCoverageRatio",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, minimum fixed coverage ratio",
        "label": "Debt Instrument Covenant Minimum Fixed Coverage Ratio",
        "documentation": "The minimum fixed coverage ratio required by the debt agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage (as a percent)",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r405",
      "r721",
      "r722",
      "r1025"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/DebtScheduleofDebtDetails",
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails",
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r684",
      "r765",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r1025",
      "r1236",
      "r1237",
      "r1238",
      "r1243",
      "r1393",
      "r1395"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r1025",
      "r1236",
      "r1237",
      "r1238",
      "r1243",
      "r1297",
      "r1298",
      "r1299",
      "r1393",
      "r1395",
      "r1410"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/DebtScheduleofDebtDetails",
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails",
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r36",
      "r40",
      "r89",
      "r90",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r684",
      "r765",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r1025",
      "r1236",
      "r1237",
      "r1238",
      "r1243",
      "r1393",
      "r1395"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Debt Issuance Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1241",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r518"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r120",
      "r1236",
      "r1241"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred Federal, state and local tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r99",
      "r534"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1241",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred Federal, state and local tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "infu_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research &amp; development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt reserves",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Derivative financial instruments",
        "label": "Deferred Tax Liabilities, Derivatives",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Goodwill and intangible assets",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation and asset basis differences",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "infu_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "documentation": "Amount of deferred tax liability attributable to right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/EmployeeBenefitPlansandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions by employer",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r444",
      "r452",
      "r453",
      "r454",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32",
      "r197",
      "r912",
      "r913",
      "r915",
      "r917"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization of intangible assets",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32"
     ]
    },
    "infu_DepreciationExpenseRelatedToMedicalEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "DepreciationExpenseRelatedToMedicalEquipment",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense related to medical equipment",
        "label": "Depreciation Expense Related To Medical Equipment",
        "documentation": "Represents the amount of depreciation expense related to medical equipment recorded during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, nonproduction",
        "label": "Depreciation, Nonproduction",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32"
     ]
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAssetNotionalAmount",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional",
        "label": "Derivative Asset, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r886",
      "r887",
      "r889",
      "r1367",
      "r1368"
     ]
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative financial instruments",
        "terseLabel": "Fair value derivative assets",
        "label": "Derivative Asset, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r638",
      "r639",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r830",
      "r832",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r865",
      "r866",
      "r867",
      "r868",
      "r871",
      "r872",
      "r873",
      "r874",
      "r884",
      "r885",
      "r888",
      "r890",
      "r908",
      "r909",
      "r910",
      "r1011",
      "r1012",
      "r1036",
      "r1038",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390"
     ]
    },
    "us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFairValueHedgeIncludedInEffectivenessGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net hedge effectiveness",
        "label": "Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)",
        "documentation": "Amount of gain (loss) on derivative instrument designated and qualifying as fair value hedge included in assessment of hedge effectiveness, recognized in earnings."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r646",
      "r688"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate (as a percent)",
        "label": "Derivative, Fixed Interest Rate",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r638",
      "r639",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r830",
      "r832",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r865",
      "r866",
      "r867",
      "r868",
      "r871",
      "r872",
      "r873",
      "r874",
      "r884",
      "r885",
      "r888",
      "r890",
      "r908",
      "r909",
      "r910",
      "r1011",
      "r1012",
      "r1036",
      "r1038",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments and Hedging Activities",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r687",
      "r700",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r1379"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeTable",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r1379"
     ]
    },
    "us-gaap_DerivativeTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeTermOfContract",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract (in years)",
        "label": "Derivative, Term of Contract",
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r217",
      "r236",
      "r627",
      "r665",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": []
    },
    "infu_DeviceSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "DeviceSolutionsMember",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Device Solutions",
        "label": "Device Solutions [Member]",
        "documentation": "Device Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "infu_DirectPayerRentalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "DirectPayerRentalsMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct Payer Rentals",
        "label": "Direct Payer Rentals [Member]",
        "documentation": "Direct Payer Rentals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://infusystem.com/role/RevenueContractBalancesDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://infusystem.com/role/RevenueContractBalancesDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r464",
      "r495",
      "r496",
      "r498",
      "r963"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076",
      "r1119"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Jurisdiction",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r191",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r233",
      "r238",
      "r240",
      "r245",
      "r246",
      "r247",
      "r250",
      "r407",
      "r499",
      "r553",
      "r621",
      "r703",
      "r704",
      "r761",
      "r783",
      "r921"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r191",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r233",
      "r240",
      "r245",
      "r246",
      "r247",
      "r250",
      "r407",
      "r499",
      "r553",
      "r621",
      "r703",
      "r704",
      "r761",
      "r783",
      "r921"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r249"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per share",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax (expense) benefit at effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r968"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "% of Pretax Income",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense at the statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r215",
      "r522",
      "r544",
      "r968"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign income tax (Canada)",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r526",
      "r968",
      "r1236",
      "r1242",
      "r1347"
     ]
    },
    "infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income for Canada Disregarded Entity",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income for Canada Disregarded Entity",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Income for Disregarded Entity, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Meals and Entertainment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1242",
      "r1347",
      "r1349"
     ]
    },
    "infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-deductible Officer's Compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "infu_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible Officer's Compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer's Compensation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1236",
      "r1242",
      "r1347",
      "r1349"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1236",
      "r1242",
      "r1347",
      "r1349"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciling Adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1236",
      "r1242",
      "r1347",
      "r1348"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax expense, net of federal income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r968",
      "r1236",
      "r1242",
      "r1347"
     ]
    },
    "infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "infu_EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit Including Netting, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/EmployeeBenefitPlansandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related liabilities, current",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost not yet recognized, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested award, excluding option, cost not yet recognized, amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1342"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit related to stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r965",
      "r966"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOwnershipPlanESOPSharesContributedToESOP",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock ownership plan (ESOP) (in shares)",
        "label": "Employee Stock Ownership Plan (ESOP), Shares Contributed to ESOP",
        "documentation": "This item represents the number of shares provided to the Employee Stock Ownership Plan (ESOP) during the period."
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "infu_EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESOP purchase per employee maximum",
        "label": "Employee Stock Ownership Plan ESPP Purchase Per Employee Maximum",
        "documentation": "The maximum threshold, per employee, of purchases made in the employee stock ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "infu_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value per ESPP award (usd per share)",
        "label": "Weighted average fair value per ESPP award (in dollars per share)",
        "documentation": "The weighted average purchase price of shares purchased under the employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r151",
      "r153",
      "r154",
      "r186",
      "r187",
      "r188",
      "r219",
      "r220",
      "r221",
      "r223",
      "r231",
      "r234",
      "r236",
      "r253",
      "r303",
      "r306",
      "r345",
      "r406",
      "r419",
      "r499",
      "r542",
      "r543",
      "r550",
      "r551",
      "r552",
      "r554",
      "r620",
      "r621",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r723",
      "r726",
      "r750",
      "r780",
      "r807",
      "r808",
      "r809",
      "r827",
      "r877"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1080",
      "r1090",
      "r1123"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1077",
      "r1087",
      "r1120"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "stpr_FL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "FL",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Florida",
        "label": "FLORIDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1391"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total U.S. Federal income tax expense",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r213",
      "r519",
      "r521"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S Federal income tax expense",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible asset, useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r313",
      "r336",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2031 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1289",
      "r1447"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r901",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r901",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r901",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r901",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r901",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r340",
      "r341",
      "r756",
      "r757",
      "r819",
      "r901",
      "r905",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross Assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r336",
      "r757",
      "r905"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r336",
      "r340",
      "r341",
      "r343",
      "r756",
      "r901",
      "r905",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r340",
      "r341",
      "r819",
      "r901",
      "r905",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r1288"
     ]
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign income tax expense",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixtures, and equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_GA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "GA",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Georgia",
        "label": "GEORGIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of medical equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r1233",
      "r1293",
      "r1295"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r861"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning balance",
        "periodEndLabel": "Goodwill, ending balance",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r315",
      "r758",
      "r931",
      "r937",
      "r969",
      "r973",
      "r974",
      "r1009",
      "r1017",
      "r1027",
      "r1271",
      "r1278",
      "r1366"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill acquired",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r611",
      "r614",
      "r618",
      "r937"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1269",
      "r1281"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r326",
      "r937"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r342",
      "r344"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r937"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r68",
      "r107",
      "r208",
      "r211",
      "r212",
      "r302",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r711",
      "r924",
      "r930",
      "r1251",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1306"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r1370",
      "r1372"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r1370",
      "r1372"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "IL",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Illinois",
        "label": "ILLINOIS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets held-for-use",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31",
      "r85",
      "r193",
      "r913",
      "r1016"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of and reserve adjustments for medical equipment",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r83",
      "r1018"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r86"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r214",
      "r520"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (Loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r103",
      "r107",
      "r762",
      "r764",
      "r778",
      "r914",
      "r916",
      "r918",
      "r924",
      "r930",
      "r1251",
      "r1258",
      "r1259",
      "r1260",
      "r1261"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxDomesticandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r214",
      "r520"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r353",
      "r354",
      "r639",
      "r646",
      "r663",
      "r666",
      "r706",
      "r707",
      "r708",
      "r712",
      "r713",
      "r714",
      "r804",
      "r806",
      "r862",
      "r901",
      "r903",
      "r969",
      "r974",
      "r1012",
      "r1014",
      "r1019",
      "r1024",
      "r1359",
      "r1361",
      "r1413"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r639",
      "r646",
      "r663",
      "r666",
      "r706",
      "r707",
      "r708",
      "r712",
      "r713",
      "r714",
      "r804",
      "r806",
      "r862",
      "r901",
      "r903",
      "r969",
      "r974",
      "r1012",
      "r1014",
      "r1019",
      "r1024",
      "r1359",
      "r1361",
      "r1413"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r522",
      "r523",
      "r530",
      "r539",
      "r968",
      "r1354"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r522",
      "r523",
      "r530",
      "r539",
      "r968",
      "r1354"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1350"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r215",
      "r513",
      "r522",
      "r527",
      "r528",
      "r529",
      "r532",
      "r537",
      "r545",
      "r547",
      "r548",
      "r549",
      "r767",
      "r818",
      "r826",
      "r968"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for income taxes",
        "negatedTotalLabel": "Income tax (expense) benefit at effective income tax rate",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r121",
      "r208",
      "r235",
      "r236",
      "r251",
      "r271",
      "r292",
      "r519",
      "r522",
      "r546",
      "r784",
      "r914",
      "r916",
      "r918",
      "r968"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidFederalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal",
        "label": "Income Tax Paid, Federal, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r538"
     ]
    },
    "us-gaap_IncomeTaxPaidForeignAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidForeignAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income Tax Paid, Foreign, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r538"
     ]
    },
    "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S State and local",
        "label": "Income Tax Paid, State and Local, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r538"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r515",
      "r516",
      "r532",
      "r533",
      "r536",
      "r541",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign income tax (Canada)",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r526",
      "r968",
      "r1347"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense at the statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r968"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Meals and Entertainment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r1347",
      "r1349"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1347",
      "r1349"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Stock Options",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1347",
      "r1349"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reconciling Adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1347",
      "r1348"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State and local income tax expense, net of federal income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r968",
      "r1347"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r79",
      "r1234",
      "r1352",
      "r1353"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r204",
      "r538",
      "r539"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets - (increase)/decrease:",
        "label": "Increase (Decrease) in Operating Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in liabilities - (decrease)/increase:",
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "infu_IncreasesToRightOfUseAssetsResultingFromLeaseModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "IncreasesToRightOfUseAssetsResultingFromLeaseModifications",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Increases to Right of Use Assets Resulting From Lease Modifications",
        "documentation": "Increases to Right of Use Assets Resulting From Lease Modifications"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of common stock equivalents (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r247",
      "r463"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade names",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r339",
      "r905"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1118",
      "r1127",
      "r1131",
      "r1139"
     ]
    },
    "infu_InformationTechnologySoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "InformationTechnologySoftwareMember",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Information Technology Software",
        "label": "Information Technology Software [Member]",
        "documentation": "Represents the external information technology software used."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total nonamortizable and amortizable intangible assets, gross",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total nonamortizable and amortizable intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r1288",
      "r1290"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r914",
      "r918",
      "r1188"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r202",
      "r203"
     ]
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1043",
      "r1044",
      "r1373"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r907",
      "r1027"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r160",
      "r172",
      "r310",
      "r311",
      "r312",
      "r754",
      "r920"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related expenses",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r916",
      "r1187"
     ]
    },
    "infu_LeaseClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "LeaseClassificationAxis",
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Classification [Axis]",
        "label": "Lease Classification [Axis]",
        "documentation": "Lease Classification"
       }
      }
     },
     "auth_ref": []
    },
    "infu_LeaseClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "LeaseClassificationDomain",
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Classification [Domain]",
        "label": "Lease Classification [Domain]",
        "documentation": "Lease Classification [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesLeaseCostDetails",
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "terseLabel": "Lease, cost, total",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r1026"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Components of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1397"
     ]
    },
    "us-gaap_LeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/LeasesLeaseRevenueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesLeaseRevenueDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease revenue",
        "totalLabel": "Total lease revenue",
        "label": "Lease Income",
        "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r741"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r742"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r742"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1398"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r1237",
      "r1243",
      "r1410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r1237",
      "r1243",
      "r1410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r1237",
      "r1243",
      "r1410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r1237",
      "r1243",
      "r1410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r1237",
      "r1243",
      "r1410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r1237",
      "r1243",
      "r1410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r1237",
      "r1243",
      "r1410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, expiration",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://infusystem.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorLeasesPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangements",
        "label": "Lessor, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r745"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Maturities of Sales-type Leases",
        "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1399"
     ]
    },
    "us-gaap_LessorOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorOperatingLeaseRenewalTerm",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessor, Operating Lease, Renewal Term",
        "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "us-gaap_LessorSalesTypeLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorSalesTypeLeaseTermOfContract1",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-type lease, term of contract",
        "label": "Lessor, Sales-type Lease, Term of Contract",
        "documentation": "Term of lessor's sales-type lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r43",
      "r44",
      "r45",
      "r48",
      "r49",
      "r50",
      "r53",
      "r208",
      "r211",
      "r212",
      "r302",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r623",
      "r625",
      "r626",
      "r711",
      "r839",
      "r923",
      "r943",
      "r1047",
      "r1306",
      "r1401",
      "r1402"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r101",
      "r774",
      "r1027",
      "r1033",
      "r1034",
      "r1236",
      "r1240",
      "r1267",
      "r1392"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r159",
      "r208",
      "r211",
      "r212",
      "r302",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r623",
      "r625",
      "r626",
      "r711",
      "r1027",
      "r1306",
      "r1401",
      "r1402"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails": {
       "parentTag": "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Outstanding draws",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r100",
      "r1411"
     ]
    },
    "infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving credit facility",
        "label": "Line Of Credit Facility, Additional Borrowing Capacity Subject To Certain Conditions",
        "documentation": "Additional borrowing capacity under the credit facility subject to certain conditions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross availability",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r47"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r47"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails": {
       "parentTag": "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Availability on Revolving Facility",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r47",
      "r364"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://infusystem.com/role/DebtScheduleofDebtDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r100",
      "r209",
      "r218",
      "r389",
      "r404",
      "r765",
      "r939",
      "r940",
      "r1025",
      "r1411"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current portion of long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "infu_LongTermDebtGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "LongTermDebtGrossCurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Portion",
        "label": "Long-Term Debt, Gross, Current",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of the current portion of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": []
    },
    "infu_LongTermDebtGrossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "LongTermDebtGrossNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-Term Portion",
        "label": "Long-Term Debt, Gross, Noncurrent",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, excluding the current portion. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2031 and thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r1237",
      "r1243",
      "r1309",
      "r1410"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r209",
      "r218",
      "r394",
      "r765"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r209",
      "r218",
      "r394",
      "r765"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r209",
      "r218",
      "r394",
      "r765"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r209",
      "r218",
      "r394",
      "r765"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r209",
      "r218",
      "r394",
      "r765"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/DebtScheduleofDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net of current portion",
        "totalLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1297",
      "r1298",
      "r1299"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r34",
      "r1297",
      "r1298",
      "r1299"
     ]
    },
    "stpr_MI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "MI",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Michigan",
        "label": "MICHIGAN"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r135",
      "r136",
      "r137",
      "r149",
      "r150",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r458",
      "r490",
      "r491",
      "r492",
      "r512",
      "r705",
      "r753",
      "r803",
      "r805",
      "r817",
      "r831",
      "r832",
      "r880",
      "r881",
      "r882",
      "r883",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r898",
      "r899",
      "r936",
      "r944",
      "r962",
      "r969",
      "r976",
      "r979",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1029",
      "r1308",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "infu_MedicalEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical Equipment [Abstract]",
        "documentation": "Medical Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentAndPropertyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentAndPropertyDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/MedicalEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Equipment",
        "label": "Medical Equipment and Property Disclosure [Text Block]",
        "documentation": "The entire disclosure for medical equipment and property."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentHeldForSaleOrRental": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentHeldForSaleOrRental",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": "infu_MedicalEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical equipment for sale or rental",
        "totalLabel": "Medical Equipment for sale or rental - net",
        "label": "Medical Equipment Held For Sale Or Rental",
        "documentation": "Represents medical equipment held for sale or rental as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentHeldForSaleOrRentalGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentHeldForSaleOrRentalGross",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": "infu_MedicalEquipmentHeldForSaleOrRental",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Equipment for sale or rental",
        "label": "Medical Equipment Held For Sale Or Rental, Gross",
        "documentation": "Represents medical equipment held for sale or rental as of the balance sheet date, before reserves."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentHeldForSaleOrRentalReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentHeldForSaleOrRentalReserve",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": "infu_MedicalEquipmentHeldForSaleOrRental",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical equipment for sale or rental, reserve",
        "negatedTerseLabel": "Medical Equipment for sale or rental - pump reserve",
        "label": "Medical Equipment Held For Sale Or Rental, Reserve",
        "documentation": "Represents the amount of reserve associated with medical equipment for sale or rental, as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": "infu_MedicalEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical equipment in rental service, net of accumulated depreciation",
        "totalLabel": "Medical Equipment in rental service - net",
        "label": "Medical Equipment In Rental Service, Net Of Accumulated Depreciation",
        "documentation": "Represents medical equipment in rental service, net of accumulated depreciation, as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentInRentalServicesAccumulatedDepreciation",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": "infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Medical Equipment In Rental Services, Accumulated Depreciation",
        "documentation": "Represents the amount of accumulated depreciation related to medical equipment in rental services."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentInRentalServicesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentInRentalServicesGross",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": "infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Medical Equipment in rental service",
        "label": "Medical Equipment In Rental Services, Gross",
        "documentation": "Represents the gross amount of medical equipment in rental services."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentInRentalServicesReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentInRentalServicesReserve",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": "infu_MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical equipment in rental services reserve",
        "negatedTerseLabel": "Medical Equipment in rental service - pump reserve",
        "label": "Medical Equipment In Rental Services, Reserve",
        "documentation": "Represents the amount of medical equipment in rental services reserve, as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentInRentalServicesUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentInRentalServicesUsefulLife",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical equipment in rental services, useful life",
        "label": "Medical Equipment In Rental Services Useful Life",
        "documentation": "Represents the useful life of medical equipment in rental services."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentScheduleofMedicalEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Medical Equipment, Net",
        "documentation": "Represents the net amount of medical equipment, as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "infu_MedicalEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "MedicalEquipmentPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Equipment",
        "label": "Medical Equipment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for medical equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r135",
      "r136",
      "r137",
      "r149",
      "r150",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r458",
      "r490",
      "r491",
      "r492",
      "r512",
      "r705",
      "r753",
      "r803",
      "r805",
      "r817",
      "r831",
      "r832",
      "r880",
      "r881",
      "r882",
      "r883",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r898",
      "r899",
      "r936",
      "r944",
      "r962",
      "r969",
      "r976",
      "r979",
      "r1020",
      "r1021",
      "r1022",
      "r1029",
      "r1308",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "stpr_NY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NY",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York",
        "label": "NEW YORK"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r80",
      "r104",
      "r154",
      "r157",
      "r180",
      "r183",
      "r188",
      "r208",
      "r211",
      "r212",
      "r216",
      "r222",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r235",
      "r236",
      "r244",
      "r302",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r407",
      "r410",
      "r412",
      "r416",
      "r499",
      "r553",
      "r621",
      "r704",
      "r711",
      "r779",
      "r859",
      "r875",
      "r876",
      "r914",
      "r916",
      "r918",
      "r1046",
      "r1306"
     ]
    },
    "infu_NetInvestmentInSalesTypeLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "NetInvestmentInSalesTypeLeasesTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Investment in Sales-type Leases",
        "label": "Net Investment In Sales-Type Leases [Table Text Block]",
        "documentation": "Net Investment In Sales-Type Leases"
       }
      }
     },
     "auth_ref": []
    },
    "infu_NetRevenuesExternal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "NetRevenuesExternal",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenues - external",
        "label": "Net Revenues, External",
        "documentation": "Represents the amount of external net revenues recognized during the period."
       }
      }
     },
     "auth_ref": []
    },
    "infu_NetRevenuesInternal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "NetRevenuesInternal",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenues - internal",
        "label": "Net Revenues, Internal",
        "documentation": "Represents the amount of internal net revenues recognized during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements and Developments",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1118",
      "r1127"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-competition agreements",
        "label": "Noncompete Agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288",
      "r1291",
      "r1292"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "infu_NumberOfContractsWithThirdParties": {
     "xbrltype": "integerItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "NumberOfContractsWithThirdParties",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of contracts with third parties",
        "label": "Number of Contracts With Third Parties",
        "documentation": "Number of Contracts With Third Parties"
       }
      }
     },
     "auth_ref": []
    },
    "infu_NumberOfFinancialInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "NumberOfFinancialInstitutions",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financial institutions",
        "label": "Number Of Financial Institutions",
        "documentation": "Represents the number of financial institutions where the entity maintains its cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "infu_NumberOfLocations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "NumberOfLocations",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of locations",
        "label": "Number Of Locations",
        "documentation": "Number Of Locations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r935",
      "r1257"
     ]
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain recognized in AOCI",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total selling, general and administrative",
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r914",
      "r918",
      "r924",
      "r1251",
      "r1258",
      "r1259",
      "r1260",
      "r1261"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r1026"
     ]
    },
    "us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseIncomeComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes operating lease income."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLeaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesLeaseRevenueDetails": {
       "parentTag": "us-gaap_LeaseIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesLeaseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating lease revenue",
        "label": "Operating Lease, Lease Income",
        "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r744",
      "r747"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Leases Revenues",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r747"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r736"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://infusystem.com/role/LeasesWeightedAverageTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate:",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r1026"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://infusystem.com/role/LeasesWeightedAverageTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term:",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r1026"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessor, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, total",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "infu_OperatingLossCarryforwardsExpirationPeriods": {
     "xbrltype": "durationItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "OperatingLossCarryforwardsExpirationPeriods",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration periods",
        "label": "Operating Loss Carryforwards Expiration Periods",
        "documentation": "The duration of operating loss carryforwards before expiration begins."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "infu_OperatingLossCarryforwardsWithADefiniteLife": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "OperatingLossCarryforwardsWithADefiniteLife",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards with a definite life",
        "label": "Operating Loss Carryforwards With A Definite Life",
        "documentation": "Represents the amount of operating loss carryforwards that have an indefinite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r930",
      "r931"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r166",
      "r768",
      "r931",
      "r1033",
      "r1034",
      "r1047"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r1027"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent",
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Provision for) benefit from income tax on unrealized hedge gain (loss)",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent",
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r95",
      "r181",
      "r184",
      "r231"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit (provision)",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r95"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r1027"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "verboseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1010"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1082",
      "r1092",
      "r1125"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "stpr_PA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "PA",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pennsylvania",
        "label": "PENNSYLVANIA"
       }
      }
     },
     "auth_ref": []
    },
    "infu_PatientServicesAndDeviceSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "PatientServicesAndDeviceSolutionsMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patient Services and Device Solutions",
        "label": "Patient Services And Device Solutions [Member]",
        "documentation": "Patient Services And Device Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "infu_PatientServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "PatientServicesMember",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patient Services",
        "label": "Patient Services [Member]",
        "documentation": "Patient Services"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock repurchased as part of share repurchase program",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesAndInterestInAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of business",
        "label": "Payments to Acquire Businesses and Interest in Affiliates",
        "documentation": "The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "infu_PaymentsToAcquireMedicalEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "PaymentsToAcquireMedicalEquipment",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of medical equipment",
        "terseLabel": "Purchases of medical equipment",
        "label": "Payments To Acquire Medical Equipment",
        "documentation": "Represents the amount of cash paid during the period to acquire medical equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/EmployeeBenefitPlansandOther"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans and Other",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r455",
      "r456",
      "r457",
      "r958"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "infu_PercentageOfTotalDepreciationExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "PercentageOfTotalDepreciationExpense",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of total depreciation expense (as a percent)",
        "label": "Percentage Of Total Depreciation Expense",
        "documentation": "The percentage of total depreciation expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "infu_PhysicianAndCustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "PhysicianAndCustomerRelationshipsMember",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Physician and customer relationships",
        "label": "Physician and Customer Relationships [Member]",
        "documentation": "Represents information pertaining to physician and customer relationships."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r417"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r840"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r417"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r409",
      "r414",
      "r770",
      "r1027"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate",
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": [
      "r1173",
      "r1305"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from long-term debt",
        "label": "Proceeds from (Payment for) Other Financing Activity",
        "documentation": "Amount of cash inflow (outflow) from financing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1161",
      "r1231"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of medical equipment, property and equipment",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from exercise of options and ESPP",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Information [Line Items]",
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r918",
      "r945",
      "r947"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r147",
      "r296",
      "r755",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r904",
      "r913",
      "r916",
      "r918",
      "r945",
      "r947",
      "r1028",
      "r1029",
      "r1030",
      "r1032",
      "r1035",
      "r1166",
      "r1172",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1302",
      "r1303",
      "r1412",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1440",
      "r1441"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r147",
      "r296",
      "r755",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r904",
      "r913",
      "r916",
      "r918",
      "r945",
      "r947",
      "r1028",
      "r1029",
      "r1030",
      "r1032",
      "r1035",
      "r1166",
      "r1172",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1302",
      "r1303",
      "r1412",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1440",
      "r1441"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r741"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r114",
      "r118",
      "r119"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Assets",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r162",
      "r777"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property &amp; equipment, net of accumulated depreciation",
        "totalLabel": "Total",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r741",
      "r766",
      "r777",
      "r1027"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r114",
      "r118",
      "r775"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r741"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for doubtful accounts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r195",
      "r308"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r135",
      "r136",
      "r137",
      "r149",
      "r150",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r442",
      "r458",
      "r490",
      "r491",
      "r492",
      "r498",
      "r512",
      "r705",
      "r751",
      "r752",
      "r753",
      "r803",
      "r805",
      "r817",
      "r831",
      "r832",
      "r880",
      "r881",
      "r882",
      "r883",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r898",
      "r899",
      "r936",
      "r944",
      "r962",
      "r969",
      "r976",
      "r979",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1029",
      "r1038",
      "r1300",
      "r1308",
      "r1382",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails",
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r135",
      "r136",
      "r137",
      "r149",
      "r150",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r442",
      "r458",
      "r490",
      "r491",
      "r492",
      "r498",
      "r512",
      "r705",
      "r751",
      "r752",
      "r753",
      "r803",
      "r805",
      "r817",
      "r831",
      "r832",
      "r880",
      "r881",
      "r882",
      "r883",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r898",
      "r899",
      "r936",
      "r944",
      "r962",
      "r969",
      "r976",
      "r979",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1029",
      "r1038",
      "r1300",
      "r1308",
      "r1382",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts reclassified to interest expense",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Segment Expenses:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1077",
      "r1087",
      "r1120"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on long-term debt",
        "label": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security",
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://infusystem.com/role/RevenueContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period, Adjustment",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r233",
      "r234",
      "r250",
      "r702",
      "r703",
      "r724",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1167",
      "r1168",
      "r1247",
      "r1262"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAxis",
     "presentation": [
      "http://infusystem.com/role/RevenueContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r196",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r250",
      "r304",
      "r305",
      "r406",
      "r407",
      "r499",
      "r551",
      "r552",
      "r553",
      "r554",
      "r620",
      "r621",
      "r701",
      "r702",
      "r703",
      "r704",
      "r724",
      "r749",
      "r750",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r822",
      "r1262"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1078",
      "r1088",
      "r1121"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1122"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1086",
      "r1096",
      "r1129"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementDomain",
     "presentation": [
      "http://infusystem.com/role/RevenueContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r196",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r250",
      "r304",
      "r305",
      "r406",
      "r407",
      "r499",
      "r551",
      "r552",
      "r553",
      "r554",
      "r620",
      "r621",
      "r701",
      "r702",
      "r703",
      "r704",
      "r724",
      "r749",
      "r750",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r822",
      "r1262"
     ]
    },
    "us-gaap_RestrictedStockExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share expense",
        "label": "Restricted Stock or Unit Expense",
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1250",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r91",
      "r773",
      "r811",
      "r816",
      "r825",
      "r841",
      "r1027"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r219",
      "r220",
      "r221",
      "r223",
      "r231",
      "r234",
      "r236",
      "r303",
      "r306",
      "r345",
      "r406",
      "r499",
      "r542",
      "r543",
      "r550",
      "r551",
      "r552",
      "r554",
      "r620",
      "r621",
      "r689",
      "r691",
      "r692",
      "r694",
      "r702",
      "r723",
      "r726",
      "r807",
      "r809",
      "r827",
      "r1445"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r251",
      "r264",
      "r265",
      "r286",
      "r292",
      "r296",
      "r298",
      "r299",
      "r436",
      "r437",
      "r438",
      "r755",
      "r914",
      "r918"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1253",
      "r1254"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r902"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://infusystem.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r438",
      "r439"
     ]
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "infu_RevenueRecognitionCostOfRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "RevenueRecognitionCostOfRevenuePolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenues",
        "label": "Revenue Recognition, Cost of Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the cost of revenue for servicing and maintaining products sold including shipping and handling costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net revenues",
        "totalLabel": "Total net revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r189",
      "r208",
      "r211",
      "r212",
      "r251",
      "r264",
      "r265",
      "r286",
      "r292",
      "r296",
      "r298",
      "r299",
      "r302",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r711",
      "r762",
      "r764",
      "r930",
      "r1010",
      "r1033",
      "r1034",
      "r1306"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails",
      "http://infusystem.com/role/DebtScheduleofDebtDetails",
      "http://infusystem.com/role/DebtScheduleofLineofCreditFacilitiesDetails",
      "http://infusystem.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r1026"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1253",
      "r1254"
     ]
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails_1": {
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease receivables",
        "label": "Sales-type and Direct Financing Leases, Lease Receivable",
        "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r748"
     ]
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Sales-Type and Direct Financing Leases, Payment to be Received",
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r592",
      "r746"
     ]
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails": {
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Four",
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails": {
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year One",
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails": {
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Three",
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails": {
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Two",
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails_1": {
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesMaturitiesofSaleTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Imputed interest",
        "label": "Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount",
        "documentation": "Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes sales-type lease income."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_SalesTypeLeaseLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeLeaseLeaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/LeasesLeaseRevenueDetails": {
       "parentTag": "us-gaap_LeaseIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesLeaseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-type lease revenue",
        "label": "Sales-type Lease, Lease Income",
        "documentation": "Amount of lease income from variable lease payments, interest income from net investment on sales-type lease, and profit (loss) recognized at commencement."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r744",
      "r747"
     ]
    },
    "us-gaap_SalesTypeLeaseLeaseReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeLeaseLeaseReceivable",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails": {
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease receivable",
        "label": "Sales-type Lease, Lease Receivable",
        "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesTypeLeaseNetInvestmentInLease",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net investment in leases",
        "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r309",
      "r748",
      "r1268"
     ]
    },
    "infu_SalesTypeLeaseNetInvestmentInLeaseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "SalesTypeLeaseNetInvestmentInLeaseLineItems",
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Type Lease, Net Investment In Lease [Line Items]",
        "label": "Sales-Type Lease, Net Investment In Lease [Line Items]",
        "documentation": "Sales-Type Lease, Net Investment In Lease [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "infu_SalesTypeLeaseNetInvestmentInLeaseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "SalesTypeLeaseNetInvestmentInLeaseTable",
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Type Lease, Net Investment In Lease [Table]",
        "label": "Sales-Type Lease, Net Investment In Lease [Table]",
        "documentation": "Sales-Type Lease, Net Investment In Lease [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "infu_SalesTypeLeaseNetInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "SalesTypeLeaseNetInvestmentMember",
     "presentation": [
      "http://infusystem.com/role/LeasesNetInvestmentinSalesTypeLeasesinBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Type Lease, Net Investment",
        "label": "Sales-Type Lease, Net Investment [Member]",
        "documentation": "Sales-Type Lease, Net Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://infusystem.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Designated as Hedging Instruments in AOCI",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings."
       }
      }
     },
     "auth_ref": [
      "r1369",
      "r1371",
      "r1374"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r641",
      "r664",
      "r1012"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesEarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1249"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r968",
      "r1347"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r336",
      "r340",
      "r341",
      "r343",
      "r756",
      "r901",
      "r905",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r937"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Before Income Tax, Domestic and Foreign",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1241"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://infusystem.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Line of Credit Facilities",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r47"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "infu_ScheduleOfMedicalEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ScheduleOfMedicalEquipmentTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/MedicalEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Medical Equipment",
        "label": "Schedule of Medical Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of medical equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://infusystem.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r741"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/BusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Purchase Price to Fair Values of Assets Acquired and Liabilities Assumed",
        "label": "Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r498"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of employee stock purchase plan activity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r1345"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Arrangement, Option, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r1289"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1379"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r251",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r299",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r343",
      "r355",
      "r356",
      "r611",
      "r614",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r927",
      "r930",
      "r931",
      "r937",
      "r1031",
      "r1412",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1440",
      "r1441"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r251",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r275",
      "r277",
      "r278",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r925",
      "r928",
      "r929",
      "r930",
      "r932",
      "r934",
      "r935"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r277",
      "r278",
      "r292",
      "r930"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r295",
      "r298",
      "r926",
      "r927",
      "r933"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses:",
        "label": "Selling, General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r918",
      "r945",
      "r947"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Exercisable Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Exercisable Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares forgone to satisfy minimum statutory withholding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options, Expiration In Period Fair Value",
        "documentation": "Fair value of share-based awards expired during the period, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested shares forgone to satisfy minimum statutory withholding, number of shares (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expirations In Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested shares forgone to satisfy minimum statutory withholding, weighted average grant date fair value (usd per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Expirations, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards expired during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeitures, number of shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures, weighted average grant date fair value (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement, equity instruments other than options, grants in period (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, weighted average grant date fair value (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested, number of shares (in shares)",
        "periodEndLabel": "Unvested, number of shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested, weighted average grant date fair value (usd per share)",
        "periodEndLabel": "Unvested, weighted average grant date fair value (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other types of awards, reduction ratio",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Reduction Ratio",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Reduction Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested, number of shares (in shares)",
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, weighted average grant date fair value (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested shares forgone to satisfy minimum statutory withholding (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested shares forgone to satisfy minimum statutory withholding (usd per share)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone, Weighted Average Grant Date Fair Value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested Shares Forgone, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options granted (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cashless exercise, number of authorized shares (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cashless Exercises In Period",
        "documentation": "The number of shares exercised in a cashless transaction."
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cashless exercise, weighted average exercise price (usd per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cashless Exercises In Period, Weighted Average Exercise Price",
        "documentation": "The weighted average exercise price of awarded shares exercised in the period in a cashless transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, number (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted average exercise price (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised shares forgone to satisfy minimum statutory withholding, number of authorized shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares forgone to satisfy minimum statutory withholding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Shares Forgone, Fair Value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Shares Forgone, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited and expirations, number of authorized shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures and expirations (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, number of authorized shares (in shares)",
        "periodEndLabel": "Outstanding, number of authorized shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Authorized Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, weighted average exercise price (usd per share)",
        "periodEndLabel": "Outstanding, weighted average exercise price (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, reduction ratio",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Reduction Ratio",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Reduction Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, increase in shares allowed for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned": {
     "xbrltype": "percentItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award percentage of target number of shares to be earned",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Target Number Of Shares To Be Earned",
        "documentation": "The percentage of target number of shares to be earned under share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails",
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails",
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofRestrictedShareActivityExcludingCompanysEmployeeStockPurchasePlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, weighted average exercise price (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised shares forgone to satisfy minimum statutory withholding, weighted average exercise price (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, weighted average exercise price (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r468",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of PSU Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Axis]",
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Domain]",
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedPaymentArrangementAchievingMinimumThresholdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedPaymentArrangementAchievingMinimumThresholdMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Achieving Minimum Threshold",
        "label": "Share-Based Payment Arrangement, Achieving Minimum Threshold [Member]",
        "documentation": "Represents information related to the achievement of minimum threshold under the share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "infu_ShareBasedPaymentArrangementExceedingMinimumThresholdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ShareBasedPaymentArrangementExceedingMinimumThresholdMember",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Exceeding Minimum Threshold",
        "label": "Share-Based Payment Arrangement, Exceeding Minimum Threshold [Member]",
        "documentation": "Represents information related to exceeding the minimum threshold under the share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseBasedonFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected lives at date of grant (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock, percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)",
        "terseLabel": "Shares withheld for tax withholding obligation (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_ShortTermLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Lease Payments",
        "label": "Short-Term Lease Payments",
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207"
     ]
    },
    "infu_SmithsMedicalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "SmithsMedicalIncMember",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Smiths Medical, Inc.",
        "label": "Smiths Medical, Inc. [Member]",
        "documentation": "Information related to Smiths Medical, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total state and local income tax expense",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r1236",
      "r1241",
      "r1346",
      "r1358"
     ]
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax expense",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesCarryForwardsDetails",
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_StateAndLocalTaxJurisdictionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalTaxJurisdictionOtherMember",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "State and Local Tax Jurisdiction, Other [Member]",
        "documentation": "Designated state and local jurisdiction entitled to levy and collect income tax in country of domicile, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1234",
      "r1353"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails",
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r156",
      "r251",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r299",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r343",
      "r347",
      "r355",
      "r356",
      "r611",
      "r614",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r927",
      "r930",
      "r931",
      "r937",
      "r1031",
      "r1412",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1440",
      "r1441"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r59",
      "r60",
      "r151",
      "r153",
      "r154",
      "r186",
      "r187",
      "r188",
      "r219",
      "r220",
      "r221",
      "r223",
      "r231",
      "r234",
      "r236",
      "r253",
      "r303",
      "r306",
      "r345",
      "r406",
      "r419",
      "r499",
      "r542",
      "r543",
      "r550",
      "r551",
      "r552",
      "r554",
      "r620",
      "r621",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r723",
      "r726",
      "r750",
      "r780",
      "r807",
      "r808",
      "r809",
      "r827",
      "r877"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r253",
      "r408",
      "r409",
      "r411",
      "r413",
      "r726",
      "r755",
      "r823",
      "r828",
      "r829",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r840",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r860",
      "r861",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r877",
      "r916",
      "r918",
      "r1039",
      "r1444"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r253",
      "r300",
      "r408",
      "r409",
      "r411",
      "r413",
      "r726",
      "r755",
      "r823",
      "r828",
      "r829",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r840",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r860",
      "r861",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r877",
      "r916",
      "r918",
      "r1039",
      "r1444"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1081",
      "r1091",
      "r1124"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period shares employee stock ownership plan number of remaining shares available for future issuance (in shares)",
        "label": "Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance",
        "documentation": "Stock issued during period shares employee stock ownership plan number of remaining shares available for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/ShareBasedCompensationSummaryofActivityRelatingtoCompanysESPPProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee stock purchase plan (in shares)",
        "terseLabel": "Shares of stock sold to employees (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54",
      "r55",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon restricted stock vesting and option exercise (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensation2014and2021PlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised, number of authorized shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54",
      "r55",
      "r91",
      "r474"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon restricted stock vesting and option exercise",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option expense",
        "label": "Stock or Unit Option Plan Expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock repurchased as part of share repurchase program (in shares)",
        "terseLabel": "Stock repurchased and retired during period (in shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54",
      "r55",
      "r91"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock repurchased as part of share repurchase program",
        "terseLabel": "Stock repurchased and retired during period",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54",
      "r55",
      "r91"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://infusystem.com/role/DerivativeFinancialInstrumentsandHedgingActivitiesScheduleofDesignatedasHedgingInstrumentsinAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r59",
      "r60",
      "r81",
      "r842",
      "r858",
      "r878",
      "r879",
      "r1027",
      "r1047",
      "r1236",
      "r1239",
      "r1240",
      "r1267",
      "r1392",
      "r1445"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURES",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://infusystem.com/role/BasisofPresentationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "us-gaap_SuppliesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SuppliesExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/BusinessSegmentInformationDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/BusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplies and material costs",
        "label": "Supplies Expense",
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "TX",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesScheduleofIncomeTaxesPaidJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Texas",
        "label": "TEXAS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpatented technology",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288",
      "r1291",
      "r1292"
     ]
    },
    "infu_TermBenchmarkLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "TermBenchmarkLoansMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Benchmark Loans",
        "label": "Term Benchmark Loans [Member]",
        "documentation": "Term Benchmark Loans"
       }
      }
     },
     "auth_ref": []
    },
    "infu_TermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "TermOfContract",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract",
        "label": "Term Of Contract",
        "documentation": "Term Of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "infu_TermOfRenewal": {
     "xbrltype": "durationItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "TermOfRenewal",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of renewal",
        "label": "Term Of Renewal",
        "documentation": "Term Of Renewal"
       }
      }
     },
     "auth_ref": []
    },
    "infu_The2021CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "The2021CreditAgreementMember",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The 2021 Credit Agreement",
        "label": "The 2021 Credit Agreement [Member]",
        "documentation": "Information related to the \"2021 Credit Agreement\"."
       }
      }
     },
     "auth_ref": []
    },
    "infu_ThirdPartyPayerRentalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "ThirdPartyPayerRentalsMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third-Party Payer Rentals",
        "label": "Third-Party Payer Rentals [Member]",
        "documentation": "Represents third-party payor rental."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r945",
      "r952"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r945",
      "r952"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses, and Contingencies",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://infusystem.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountandAccumulatedAmortizationofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade names",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://infusystem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred at Point in Time",
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r952"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://infusystem.com/role/RevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred over Time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r952"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "infu_TreasuryStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "TreasuryStockPolicyPolicyTextBlock",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for policy of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesRetired",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares, retired (in shares)",
        "label": "Treasury Stock, Shares, Retired",
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r91"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Unamortized value of the debt issuance costs, total",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "infu_UnamortizedDebtIssuanceExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "UnamortizedDebtIssuanceExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized value of debt issuance costs",
        "label": "Unamortized Debt Issuance Expense Current",
        "documentation": "The current portion of unamortized debt issuance expense."
       }
      }
     },
     "auth_ref": []
    },
    "infu_UnamortizedDebtIssuanceExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://infusystem.com/20251231",
     "localname": "UnamortizedDebtIssuanceExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized value of the debt issuance costs, long-term debt",
        "label": "Unamortized Debt Issuance Expense Noncurrent",
        "documentation": "The noncurrent portion of unamortized debt issuance expense."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_UnpatentedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnpatentedTechnologyMember",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpatented Technology",
        "label": "Unpatented Technology [Member]",
        "documentation": "Technology-based innovations or scientific advances that have not been patented."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r1004",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288",
      "r1291",
      "r1292"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://infusystem.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r531",
      "r967"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r254",
      "r256",
      "r257",
      "r258",
      "r762",
      "r764",
      "r922"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://infusystem.com/role/LeasesLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/LeasesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r1026"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": [
      "r1173",
      "r1305",
      "r1379"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://infusystem.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": [
      "r1173",
      "r1305",
      "r1379"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://infusystem.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r247"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://infusystem.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r247"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://infusystem.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-14"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481117/718-50-35-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-10/tableOfContent"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-20/tableOfContent"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-30/tableOfContent"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479326/805-40-45-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4I"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-1A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-30/tableOfContent"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-10"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-20"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-9"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-45"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "46",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "183",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-183"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "185",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-185"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718-50/tableOfContent"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0001628280-26-012804-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-012804-xbrl.zip
M4$L#!!0    ( /& 6URG_E-U*%8" *&/&@ 1    :6YF=2TR,#(U,3(S,2YH
M=&WLO6ESVTB6-OI]?@6NNGO*CB!IDMHLN<IOR+)<I6E;TDCRU-2]<:,C"21)
ME$& A00DL7_]>Y;,1(*+%HL201D3$]46"2*WDV<_S_GY_]R,(N]*IBI,XE]^
MZK3:/WDR]I,@C >__'1P<7A\_-/_>?\?/_\_S>;_?CC_['U,_'PDX\P[3*7(
M9.!=A]G0RX;2^SU)OX57PCN+1-9/TE&SR3\[3,:3-!P,,Z_;[NZ8Q\RWZ?[N
MV\Y6K[/9;NY)\;:YM;6WV^P%6WYS=[O3[LDMN=L-MAN#_;;<]H/MO6Y3[.RV
MFUN[F_"8#&1S3\C^UJY\ZV_UVHU@O[.YO;?5Z_7Z?D?")UM[_G:_W>EO;\I.
M6^YM;]*XPPS6#.N.U2\;PRP;[[]Y<WU]W;K>;"7IX$UG;V_OS0T^L\$/[8<W
M6>G!FUX:T:-A'(6QQ(UYDZ4B5KAND<%.OH&UMIOM;K/3=5[25-(OO0C^;@V2
MJUO?T]ENMM\V-SO%>^;/!9[<=%YD'K]1X;Q%=MOMSIO__?+YPA_*D6B&L<I$
M[$OSJT 6OZ(1S$SA"US;MGDP5\V!$&/[<%^H'@V@OR@]K-)L]D'XL/Q0-D[G
MCXW?E![%;\-%N]'&W2BO*E3)5K>S>]LO^ GS W\2S)\*?#$SDV!JR_1+=][P
ME^91Z2]X)WQ1>F<8]W/[)/ZA)BJ3HY:?C.BY3K<@"CCU;[<L"[_N"64WXF;F
M^1+MX[?TZ'XD@ ULR+CY]6+C_<]#*8+W/X]D)CS\:5/^E8=7OVP<)G$&+*%Y
M.1G#"#[_]<M&)F^R-W2-WKS_C__XCY^S,(OD>UQ(TTS_YS?\X<]O^-6]))B\
M_SD(KSR532+YRT80JG$D)OMQ$DN80'BSCP_*E/\9!H&,Z9_P_0GPI33T>?R;
M[%SV?]GPF[!#L1CAFV2X?Q3#<)-#F%TJHN,XD#?_E),-+X0#Z3<WNQOOVW K
M-C=WX3\_ORF]]0&#& [Y*52^B/Z0(OT$GR@[S.;&>US^L@8X@\>3H#S$UL;[
M3W]\_P '\/: 1HC$8,-C9O3+!C"P_7YX(X-F7T1(2WJT[8WW],'W#:CYQ/Z%
MB*1""OHL@5"/002-Y&$R&J=R*&,57NF/CFXR_+,7R<^ARNP<VG!XMW&@OYW+
M*QGG4CUNDJ=CF0)?C@??-\G-IYCDYLPLS]($YIE-0!+'V4$<',$U'>-Y?E6R
MGT>?PWYQ>)V=C?=GFP\C%K@ICQGQ[7>,N#4]XJ<P#C/8WBL9',? Y >XVP=*
MR7E#=H$ZSCK;#QQSYW%C;GW',A\WY&;[.X:<H9[/$EXORY1^+F-Y+:)+F8X*
M)D.;NHS1DO26T1SN@^K3?I"G@2B8]FYGX_WNS!S>E*5#*OLR!:U6JCE"#87=
MOB(U"&;ID?#;SX 1_;*APM$X0J%)GPU37$1)?K5N5 #2C<8K!M%CJB1/Z2]2
M4_9S.$F:=0Z_,1^.8+UY"E*1]8[]KQ<??WY3_LK\C;^?>9<:"AAHYG7\%W_Y
MH/?!W$"@7. /[4M!'(>!=!^E?199DG[G,F9^CQ]^E'$R"N-YK[WO<DJO>%.>
M_6VKCA*?M.W98X'#WC??/F@CXWS4D^F"@QG#/Q]VS'* W'3^_/27#WIA'W8I
M]D,1_0MUY##+%R]_[J,/VPN978/5-__U^LO[O%#S$GHG"F?SN22USOP%IPU_
M]T.9>G2KY5R+Z_#XGV5U;_K'=@;EMX])W3)_@7F19A_!#B:5KMGNP/^;WQ7?
MV6D&Q:.=;G.S4PS!WYB_S2!O2NN>OPW="FP#VUF9WH0=T'3LB_0WW[.RS6JM
M; ?->=3;'[^RK6JM;(H:'[.R[6JM;&MY*]NIP,I*[&;K_NQF:WGL9O>IMT&O
MAF4:_QG 8#?C*/3#[(M$L>H%X0@-K"1V[,<,EH2_0=L#C'RPRI(8_E0'-R$H
M2.8Q^'R4Q!=9XG_C=_W\9NX0=C?L3!Y&>9O+H[RW:[[E!T$0HLX@HC,1@AES
M*,9A)J)UV?Z]-=_^<YF),);!D4ACL+#4NNQ[I[WF&W_@^_DHCS!*<IH-93K'
M4;0V9U$%9?N)EO;D"O0Z2[0*:!R=)[<#7HK\J\)A/;EIL_;2L@JG].1FVDL4
MK54XN">W0M=96#V-X=]9=Y-W%?;7,O=_W>W?9S7 EKGQZV[YKMH 6^)9=-?=
M&'X^*V5%89@GMY!?BI2HPF&MN\W_S%;*BDYI[0W_E5LI*SJX=7<"/)>5LL3
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M\*B%QP]H>50NG%[S](JJ&94+<%>+U?X +*Z^0(^Y0&\K%W*N*:6:0OEMY8+
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MKF6[>[$\#$CMONMNM5N=]L=F!Z[7*HB4SN#%"&"*3ZFAC")KI+R:D\E8"L0
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M#)61(I<KDX\;P_$J)5*X1,#NX7Q@_0J%<?D-:$DG)"5 [HY!?U XD/1BPB7
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M>E$_E5(M2YW-\_@3B(J"/-"6N)HT G%"2I?CE:>XDR3L A3ZG#Y9W+XP!J7
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MB1H/"OVH,!*WD213(<3\@P,C%(MDS-AT9?609K T$N-,.D"+SBW.["))@.6
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M<WA@T?X=D-V%TUT]LSNUF+T2T4UZI'*87G*@X*_&97>++7M]?=TBCQ!!3+:
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MZ[L0&A[!GPRX3]BWV"S)M6T+T)N4*_6* RR6@@NF/#D\=3HGS%[1:8BJH:O
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MS,X9U3J,K3/( 4AB1U'.F:34NTDCS1==5<O)[=PA"ET^UM6GK$0.46BB+D$
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M(6V_&\;6NV0M#RXF<>XIO_RU(&U(IS6Y>E4?R[7S0J89K?4VIEATPF$>#&>
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M84D("#\1N6L;;8?9[JPO]U@1Y;0GKIA;V:&"YD(2WXW0W5<&1U>?S3"2=.H
MBF1MU%(T,<#286ODVT6VU=S6F$:!%79\>[,CO&],(0,.E>1(&XH_#OAB'[([
MCG0"WD[* M(U[V_=_+UJC4KX#$&.WJ&CS;;1#B?*J(T1NC2W/ SM-X?)UE)"
MM#"<V^8?7 $[E:GC7/LPA0GC)/1"4,"G!2K*)H$D$\L-;*1N4KB&(41&Y]V:
MLZQ:(/FAJ#+06$6'4K(W8!NY,'];#G2F3AZ"FI(^#!2K%FK'!^9.FR:W&8#J
M4#96,,*N[NPS=6[:G3,C@60S"=7A\_2%#Y\A(ERTA.8]?\QJ(F6\E$9NO*FW
MV]O 3.=?_]8@)Y;:%$9S<\4$1T$E/,6#</E0GPD'6<*BAX@12G?3!"4>Q;\K
MM<$#AAN9!ZX',B._M%N(G7&\LSPGH?? =I2J.[K5DB&HA;144 )J=50VE!!!
M<\/KB^2@Q;'@BOD@6<"MJZ5S2&B2 ,3X9H('(!!N^F_X6RRF!H?J/,R^*M N
MR*WPM-(Y=JH'S^U$;^)"8>L!:->KZ?%!_F/DX$8P,Z9,K+4N*27S!:Z'HI^H
MP;@0T2O\K[JZ6QB"P!!Z6QC"CP=#>'#%UJ''&-I**LFUG)>C W-D]8/ 0 *0
MHA$51]1_@#)P289W&C[*V?WA;>KI )-1A<)B4H!-M/AQ:7]WI3]2H-.1BG<:
MGPHZ*/_F>,(3#G8YTR&\6L4B&X1D3UK*37%@='8-%S1V4_V(7L?2]YA+225?
M*)A.NNVT%DV+9K3SK*U2LO0:288.19^X>K!@2VT.N9LJN?OPHN!X7#8GD Q;
M5X-8LCWWXP:7L3@FHFZ&+I#F.JN@2R-VJS251F"#7.-$R"5U<BH;TDO!,7"1
M'Z'T7!.N67,?6I!EY^*X[FIKKU!F@\+=3.#=ZDJI) ,(A:VGJ.BEY+HOE)Y!
MG]=KV*-<?+B@BH&QQS=>OM5;W/"U<8"UEE8;E@ /0<;L[JL<\*YSW#38=!N/
M=5Y/J2Y ,-RFY>F)"0\(983+%.5/A1D01VK!Z21X#+:,FZ0C/-)9CH$<+DW%
MTHQ&\DI7U*\5<:OK-23BD+?"S6OI*6SY5[S:.XZBB&[484?ST@L#T"S@_>(V
MO:(8 +:W1,^)N!>X&,0>A%3;RIDOF/VF\EU9!-!Z\.ZA5XV:(_*[C^^5!)ZM
MUPO:LOC%F\UW:9I0[HS=Z-*+M,^;L9UH,/DE%UK6V37A@]N^)$:6T$$8<0C$
M^0\:JO?6DP^1E_&Q;3 T54K]3NS(M3YH;J%]Y^50F%E=);YBT^LB )K]N-?&
M".-S7!<&ZH4+?WE.6A%"_.F=E>/D*7)ENS),\'YC0(N_Y>^5;)"NHB7O^5HB
MCO6[&!JP2KIP7?3'R:!-E(FC;<-*W*BMZ/@P%T'@AV--#'8T@@OVQ]],V0[\
M*$[M5H :K6Y6I0F=?RG<QB,^26[TGO.ZS6F%6V- \CX.:;5'YUYBR6[\9.(H
MQ;)$DXV3L6L=ITVZ*-Q%6%R=("H6+D@:)E7"9J-$JUP<4EOH8%B66]7<>JQO
M%!R<N>AYZ:*SK0W8C=X[J8^TB)I6 :,>A22SJ:>.WUV,UX2R27JV3%%H<V;M
MG^-P%66"<2*^!W&B:%K0-#G]&3Q#:^AA<8IDEENV([QZ96VX2X1?!>7T>&([
MNL(.:=21ROC +(%#%G3X66*$K-ZYC2NW@-;>8<SY,#(D1RWYE+"0GS+F*/##
M5DU[?9 \MT-8$7)I*=%<Q)=?UR_Z\&BV[1?=T2_ZV=\LO *Y]B5VB>>X0O@U
MHW2'?]6EQ5\K#;2F=/L8="9R9] @@69$8S2XN&#R9X>_;#?P?C>0 P"PV*\T
M*J!!YI3B1+"A(SRKX#484#&V&XQT;8?#*[8RIEZV6_0]MD@-<S(^],)R-HN9
M;X3PYKJ,'WHG'C56<+YL#HHW$3ZTW<?[W<=A,B4V]3RL3&!SS7>!U!83OI.-
MLJXS6SC-EJK>Y5M2E<4X[U&23C#VZF,-)6A@\WT8249N"&0-L9X?F5Y,$6DK
MVV29.SI <)\L+0.'>_N57>%+VZQLDP2.*]R5(I.Q2RUV3T3/)R&!Q!68RX;8
M#EQ+5NXH381-7)G(72FH]1#36-UZE7(2R^;XNLFN$ALE(U2)ZQ<DH?G8[AEG
M(55XE=!A2%SXLM4S;LH\&CFJK&Z\J>4ZL@0+LAJ*@FLSG>(?W,$*#^ARU2Q<
M#>\MA32NE( !1<!D\/$\*29G%"EKF3GL5@L9Y_+.=NVKS%4C5 2^8/@99CPT
M"RWKMTDJX9+S,BF("E+$L&./"8(%4 \;W^RD]5#Q0473!"IS<SMI <X 95K*
M %XLC4JY6_W=PZ ./$B%P _6Z(F]]GQ(I;QKLTOSSI=<%W?L44IAYD=[O$9E
M5]2((!GT9PDEETVIT% //' )X=B-[E^T%*3+W.'\5#JR,AT!IG. HKM!.PV"
MT)+>>EBB36J>9A^I$KP%EPBX9'\++OGQP"5KTZJC\R)QR@H/-@=V-!_)JD=@
M;DLHG>]R'PDU/#HHXR102I:_FJ+%_5#?"2B/0B):=MP(C,RYY%:PKS;)4*$8
MLF0,6YW8!#V2#+&,NY(BI6OF',;Z HQLF(UR-W"Z;3) !ZL4#/ZX1E[@RE#^
MO"9P_(C3,<PH*X18L1(T:OGN@CJ>X$7L<ERG19YQTXR+W!+B=37-((0"<VIY
MTNR(N0@NJC^ ?&,N1_->_(2\X+)UZFX\-%\X=>%EBSS0T:C(_XU0;#IBW!2[
MN4Y<0 +'@\IYR 5SW)0^W1:3MC0FQ09]D":RS"K*!]A>!+(?R#4V13YLOU<Z
MA5A+S)=@T3FN#+"P)0O*"] U1'%JL.%;CA^?,HD+U5'2H1C8RFT'L>HZ3IMT
M1GSU2:EK13<W^LAI+X]KIH%H<OPW>)IS3]'8))2[#8B737I#VOP@P6RP"276
M4(ZO>%-E![G/)N$WB,)&6L8,12F)7TSQ;ZTL<5 (B<:Z\>@(;#Y$Q\#5G@RD
M<UI!35DI7Y&Z32)BL+ 42=X),,,38<V=>*7=ZMSUS1A_&SS'IYV5 E;OB<@V
M_84@BLIG9-=E&=JZ#C# CQ2UDVZ5S#DROM6:GA+7/\FD^V' 033B//" FE@(
MUT>2=?$_?5P<#EF";D.H3TMM8JWO%5N*RJ9L63*S44D=-S-=<=4#_<4R(= C
M/>$E^X@PKJ-Z0G C4*B5.+C\\F$*A@T%8C8RH T+3RT:Y'RTMKR4\\;!0BG9
M"4BG@M6/^9JA0ALZEE4ZB!%+/,3RK<%G1E7#F2[@,I/OH## >V;YK';P+;LE
MM \R@#S#0SEJ,.[8PX=[B[A%)IE@UK,;O)OZMD4*,G+27WTV'<L5D]<5BHUV
MM/&;A6H]VZ*>J.J!,^S!(J&9L-@*N.TV@-506:1=ITK3&#O^*QR\C21I/7->
M\._XJO8I;YK,/XY[QVY=.,+@-LKN&*YW/&RD5@Z&?V F7$^#TU)R>PNYDCI2
MVT&$L=F8NZ.X*_W2=<OU2C)=TP >BNL2PG?31FG9CQX<T &1$-4I[A]U&4&T
MD9FPE:7]95%"D"QNAX)4H(ZZ ^C!9O#WC:NLTP<2K':>:X>[5=:HY#9)L^'*
MT@FRI]2M,U?VA0NZ&UWBA:&FCUN8J-&<TU\RAT0NY<MLZVH)B1X6 ;S&;-F$
MK2B4^BN0ZPR_!=X6ZB$_V6);&]_&<J0T2U8F$SS&'OZ/K'/;J+EO*GR+3^1A
MA.5>J+/**RKA( 9I/')H4SF9# HJ%20E"D<*F+WU#?II:3?F@=?;E/GT&PVS
M9W4EAJ?4=4\,-Y(39'<YQ>)- G';*$LL%1A=:Q11=--RC]7M!M$P)#$KW$>I
MHM,_:L.T!),0=BO!/$- [E*%_:D=LA=+&YG[/\;UL 8K;I>L=\!7+9UBU'UR
M%9D-_NCN4VY9 [U#+L8POVQ)>HB[;5C=^J<7YO'%-Z!(\MKM>!3SG+3S*%TL
M>[T<?MJIIBZ1 $J#1H> !!TO>9HDC^?C,?9&QY/E+XW&(]Q5I2M4$.8>(YD%
MZ5JMS.?#;.%S5(G@ P>&^: FN)UP'Y)]P!  I'.Q;T9*=MD8 OQ;US3T'EQ>
M1]4Z?*G9YDS?[R&48ZO;:E$N[=NDK6:$X"EI%._;FOJ0YHG.X%V]76Z,I7P(
MJ0ZZ4$3810OL+_CXCLC$B/[OEP>0$.DX\RC@IF=_N[/1S63BJLCI0N?JD HY
M2%%GN -\+SK \FEAI2)(T9(BU K7?XO6;X7WGX+6]P-G>OZ3K$;$!N=XC6LS
M=T.+"UO<K[%Q=#KR<&#N4^XCA/BMN92+*6.H_YJ2^Z)9!RHO+:GPE8BJ6C7(
MN!'4BD=]81NV#;,VH)2TA(DC)]1;IHMVK&/_YU-!;=25LL1.<DV7:FYO+Q/9
M%U>IA@:ZN*+V&4090J:GO\FNF$TV/.8^4XIWLQ5N;<D@GYD8:8*FZ!+II[9U
M*_)9SJ\T$W/;KTV4D@P8H),?]C;^JHL !GV3EG ?O2%9M1(_9U)];L75*;Z\
M^"IK:<:OTF9(90HB06H_'*<='5>.^B656X2$("0.M@B)+4+BT1 2M!#:ZXUR
M+X]!Q-L@7<TX>9,6-DH=*LC5=:M'G0B7.AG\'">6T.7*U:+K8 )]:B?;8L$%
M^V%9"D$RKWQ=E+6-S.8SI%-%6DSF&V,::4D>(!'#A#TFV-F_<G@(UO!7%@CL
M?6X OIDT18\]?J8A%EY7$L=0..Y_HA=%UB\*AX+SFAG39'"%F%VA)YM)6U^O
M(0#G*>8.$*]Q;U2;9 WYQ.H<R: ")EH)VU[",H EU@QTK=3,%S.H?5J&H)PC
MS!%1R_!WKIM<ZZ^20Q+)"45&+9\1'U[.\Y1=+UY%N)I[1Y:#B/)7?+_)>M?H
M_>= &G5*%)#DLF>4#'/H"Z8L9.FDEJ=$*(TR" /*2NW G&!W;FJ@()U_8^T%
M+*H1 _T?KVR61;NSMZ?5F%5K4B(9%*K$ <<=4PNR!XY*DFI_?8GPU+(8B/2J
MPDAWCHR$A*DBTPP<HHH1#$IZ[=<N\$%G=>R.><#9QFK!T9EH7-=O>NS"I.@-
M=*9#P@F%<[#CUWDV4#-@1U&S"IIKIK5JGH;A5^"B$X<Q^04II[XJA%)0;^J"
M2Y/U44EF5=6="?(DNPW6VLJJ-/'K2%]KMK!O8OMO+B>(\4H;L?1NU/W5G?(B
M%>,UXO*WMO ;JY-3+&Q_K+:(=B(,N&Y>[NN<Q !G%%M2M(GYXD%[O!7QX'I(
ME4N=5"4EQ<VV+#>)NX*YN-Y3%)*T]?2_GY+P+J&F[M1;B(T.Q9P%L0KFX++%
M.!VU1_C@1.%1?6K5E;"YHD8<0Q0<]UAPM;@L'IPQ<D.Y68Q=H]C+&#D3D$,^
M9,A(7JR11;>!.S*Q$">"U%654SRNGAS.($5W+<TF3YK!7 2'A(7*;PU"!HMD
M8I@YAC4)+,%,F-L0*R#ACN!)3J+A_7S%@0%D0.US>;3?6)M 'AC<TB449D^8
M0<T,Q=@D3M4-4<[6F?8J>UT%V&([9R4TQN=1=9CB ?R<-RU3EA,Q$1+,43\\
MA U)-R.'^MJ=[_NOWVG$VUH:EF1,>I1H&:E4*MMR4BX6LYV$F*R)#ZQ4XCE7
MB8(OBDYSY\-"TPD@(%)CTR/V1O6NSL:3 [EW_!P*H!WZA7V.45F<!NW_7O-N
M98A_]J@LA/^-;AK6 0Y<@)"M1$),WHVVXSC-2J'HFF(+AW];I! >DFQ,'%!P
M?E<!8*W##?:IPW=Q*$Z%EF/J@=-*+7JT(&Z<CQA1FZQ0$+@&1^03\3-_#LN#
MJ7W(@HE+U@W1J+9O4<"\XW0@/,YV;*:/@/^!7CXY(=+Z@;D++0&16TCR)N&'
MDD*2-D@<T.#[K&7*;N;=:!:ORS>QO? 4UD;'17J4^5^76R9RR:26M6/72W-(
MWCK%S>M6D =\9X'UA\@L;YASKC77V(Q/-^M\=BJL+F@5VM;9*+G.$?"_H>FA
M!06ECI*J2>JBC3E(H^;81_*1LIBJ\;_?ZU=<SB C;DTC0M#[0?WYY49Q,_K7
ME<YZ(AB)"ZW$:I'9.G7/L:^P50V+G.Y]%U]:2)])Q2O\+NU96R0UUXXD_5H.
MNV)Q];E$TR+5,-Y9:%!_<)R"QF [$<S_M )LMQQ6]\S+0N$U$:/05J#ZIW,X
M=CO_2 >?$?!!U=.4%&6C'#YTE?93VNMICMZ*8/KA+8C'PPX!I.MBH2T0CX91
M*GPM3.M,3FTLYCS'16"?Y*>8J[6PBL9VE"@,F(2%=#,D["8\?%@CG Y="?P5
M>'X!F6C!'2 X/5D,L&4SCX:80*4@,P&-G?MY6WZ>3%>;72C&;:AXF?D+6%K
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M\D[6Q(R3B4WW<.5-%V[+9:;")%0 OFCB?@(B=()TV8)'\$,D;-6D7/.B3.T
M6K=MRL8T";9Z0MSW:G*[44'K5XYH%>90J:AAQIFX))&MATDU*XN\=M'7"7:Z
M*J9MR%<KSK]1NL[KA^LO"O@C0TP\#0I3^;3?< 9'[(XPM9'>0#$3:C'-'_<1
MS8(/DS"-\?80Y@(IL[9IV)A;VDQPN55?@9W+-5Y&OG%S!8?"-07W\CD*H?+>
MH7@D'VXQ*YA1<)B6F$23.H159VNC GPE2FMD+R>)SM_P5A-B_$IX#SAXQ$\
MY\QIG^#=<E/465)75WD!.SG\QK$VR73PP[PV7B\RU'#P%F+HZM[^14L16X:U
M05(&95F$+RM+5'CDN7B/E4BY5:GT?=ELK$%$]<)B **^P^V.N+]>E8Z3,*%A
M$8$<"Z)FA,QLI2WSJ&YQ $=5E6CG4+*@35@HN\B8@1>0W0O:=Z9HBCS5(I!$
M"BYH^M%_EYPRWHRB60'WGWY^OVNLMIW6,K>H7_]F=98Z9ANENR] -#/2#()0
MTCIXFKN#L Y-O_)U %DDZ=)-BQZ_VR0V?2*+Q[2,4+)N*%'/%@4<:<(K<6-&
MM'NXK-ZA/\,O]_.BH*BNML_!%^SO[?>B"TJ31>>Z;@A:CLY!2TVB_6.JDCV@
M0VVD0SGAH)+H55K P3V';PRY)0U'N#H?Z0A?S\>Z;V0OHP(JN/?T+7.F5;GM
MG(>/ENZE\P?Z/S5(?>_(J^9MC//2H.GX/0>J&.TE!GQIS"-4[X)LK1P%>/!A
M+!\%Z.T?/OO;6XSMD^^_B:,_W=B11\]_ RW[PH^Z/+"25,,*S LN(&:H-^/I
M;]GM\3H=.!?2"_%3JM11)_DFC:-3F'N.J3^AG'9&_-[Y,>;#1V/'ZA3OHJ)(
M  =F?>@UWD5]F /=W&BTR3-BHE/E&U%K1]U%Y\&:[*M"_D)T;-)AFE Y*^JQ
M=A)PBS:XYY0"=\SCAFY>84NK]C=1<G5BUJ 6"B1'0S.B1K7]V_ER.3_QN-VD
MI3:)>/E,S+&<F"I+IH8;YE+HE!C_$.^(1N<D1;+;&7E!]FAI""$6R"T'QKA$
M<KL]W[@]5+^CH6Z_7*I1PK5=Z(<Z!VXSW$VU7?UO%7-3C W5,938@B@&30.R
M/:0=\4P;3A1C]Q_NX1V&*X6,APP"TD3;;;D/[8.J'C9&PRBX[ERWP]YFYL4Y
M+3ETXSO;C?CFYJ,"8\0H245<9%0?4.6#ST'F)!-<_V*,S';5EVMC: :31)EH
M/YOYF%46=XR*9T,']E,7Q7&D<^4O9<W(@.I/-+3[G ONQY)8M&0[+PC?E4=E
MODE9%DY-.(\-';EY#INRVX:9OD:CP#9!FGMXJWMTYA(0X$(D^&MT.6Q7AP&Q
MDR#2-TFO';F2>X*R^/,EI&Q(M28&5F,+N6.JWY;PM?X\2F'C;;.$JTMQX274
MC[\2I$6&5>H3FA@G!3V_.V"])'._53MD2WP[2P4U+DO&4SH@QB>/00[Q%H+4
MIBP(!['%<>>SH]6/F'^HRU*;?".=+"<3E@Y"$&+11B*\MC9VT460B#!W"=;$
MCKY>:'EP<;432GJA:TZ^Q$BO\AM#R>T[V@-V,&[+AGBXC"(M/Y?XS7Q G49X
MH,UT@9_SWZC\R.^PP/DT'41U)EM:W=H,6)HK@*  4<QG.>;0!HP0M-6F<[CQ
MZKNR)0S<PT[?Z>AVGJ[M@F&M5=H%RW'&D[R/N15:2LSV>]S$1/Q285HWNB;H
MB$T*2B5RHWZH&U4_1)Q.6EX%NI01/'00DFM0\;(A,185,I\N-X1%!\RE>;$Z
MP_^ 40%@CH&8NU_=8B@)D[-7>5$Q<L>U_B&G39H3:?,;)/]F4Y;UI#01HK)0
M)UA)'ZPN]THK1%[#E<83)&$_X%PS]7[GT=-:X0'5+N3OT&A[P\68%_ETFE;8
M-N4Y64-[O[QZ]^:"_MG[Y06%?X>L S0!XWH98508>UGH"/#.I5)S)@DM0?,2
M0^Y V$6XL@8'2%^ 6[$2Y&Q:M;NUH$.%^(_N ++4C4ZDPP 'FT$>N @6S]_@
ME@O'.3]-&'0.^"K939,\UY\+$GI)MM/;2[K(^-$T =6) 6$SB#"R3:# $/#"
M;ZK$9>HJ$&$5H;2XX*8(-%^ORA<&]$>7W) E,9NHLE4SPFL=55(:4U!+WL$*
M;B3A0X@%M""5MJ9+XY'9P8K+GAA]QP)BA!\-[7RT13O_N&CG)W1K_]TW9IP>
MT KI4&'AS0G:L2J5UD]).VRS=*QF*SGKQCU6V"!0T(7RLBCXBQZC%T]@/&#_
M'E _YE^UD79:%K7KF0MJFLI7_0O;4C;RW?BQ0'+=9$C60R7&'-HGF&O(2_;>
MP-(FWQINBG0TTC82KGI<*7ZH*14"BNBR(%@O@Q@6L",[1_05D<TD2-5PQ]BX
M*LJ-)W<8=;@.#?((*Z6"OT#3'*\/M10HEG,!UOPPP0+"+^F 4YH78%$EL;8?
ML@2-:F>@L\B^AFZ6\V;EHD5F(?!9B%+<&^*?NY>[5 <;<AD1$88T<Y-^?;!J
M1JP[XL60U0QM!8YPC(A-(OQ$W^B.Q9$P_7%+-?++P7.)'9F97.NZ@Y[+W6 )
M71G9M/9'G(F-03KGF]U<0;5(;'6!0T1IGED\*2)7B4.$X)I@F8=VN9Y\YTT9
M7V03UUB&"$\\E43&$(56BE@Y[FQ$V,$6R0_%D\6OMGR&S('$6.N8?QBFV(SE
MFB5+?J-,4@Y^F'JL7[#\PC:-L'(A'A&J118VHN%#H*BJQ(9?0+YWAVN(J6C1
MHP3X)\AA&9YG\&<(U.H8EVPA)GW6-MT-:56]-H;^5C>6FB1CF@R*W%>\P[3I
MCL$"3[#(!3UB7:U47: 462BE'MYU[PO[J*G65])SBC:[8,Z_ZD0KD!'F*U$P
M*4$0.JO$;UCFZ@XH-K<Z+_#\@%A'_&RC0AD7CHJN2KY(?WABJ)M,C-Y@!(N%
MOSJVM25NKT5AQ&]9M?6(,$LOF"%29H)TDLM%MYG4><1>4=<DY_ /-8*$=127
MCW1-1A;#Y%9 HH6Y3F%X_5OAC,*-N<:DI WE3<PX+2=J0N4#+8P0G,IKML(F
MT0<&0427'HL3?H &^1&5"%+>_X;4>Y7T-O9,%A$%:ZQXO;'DTJ^*/&$"7RER
MX=#Q L&@?-%5/B%@)X6TN;D,._?N2D9YN08; 3L;XD# ?,?>!&Q]6>60#ZGL
M1RJ[<D=;A5^AWH*B<C \BIT$2C0CV-NG"*<6-GBB2=7L/HC=-3?IY@FW@&C*
MV,\L\2D]F%@[.'CC8<QP__%"8'%89.D0FZYMMVQGW[)GZ*XE)E^EX*VY;%^^
M0*PBB59F.(.G\;&;N78.?H,ZN%$$FHORY.T=)NJ?&1$F(H$+;("UDTDV]9[[
M@,$)^M<Y[_?^WOZ^"INEXFR0O8@08I^,WG]@-]VTI.7T;5W.2?;K6ZP#!_F*
M+KW6;L'C),+1*:F.G)KDCPR0+F5&VR_=U7RR5E5IT?FDS(G.F%#3AQK,M^<0
MV:I_3<?1KR8!,P.I<7_%W<5%>8X?>O;NUU]_/7_V BR:TFVX+)/VP(71@#+#
MBQ$4H\E*]79T3>"630O;LJGTG:&/,+V+6KRL_\G[);ZZ$4V%CT@YQ@[= 5XA
MQD=?'XDC,L7+'C;06\2AM/HFY+P,RAN+^R"U5<ZXFR_<$26JS5N3H+>%.&_-
MC42:%G$%.27WV26"4K=YPM1-ALZ=3SOQVJ$'K:*ODTFMW,Q.0^%/M#NQEC1Z
MBEGUY3"5JAQ4$U+4:SG@D>VB88'HX[_&ZM@D)E+I*>85W29@.59DXI+ <3T6
M,[,3P"!ELA'ZWTXZLD#%[Y)D^T]A$O^2LD\-2<P]QFK:$"2SY;/=#CS#Z)1X
M5PMUA;81ZXRQ:XQWGR$_#N;KM9FO-4-EMJE7#QA>/*YPS61>T_#@ .Y&?ZR8
MLTLP(@^/Y-(\NFPHZ3EG?+'#,W.]YMR)=-O32TCS1MG*J.Y0&=BRM@R;@MJ"
M5.XXDA3%+=@K-]2MCXO+R>[C)B!HQXV\YE!=N>I.0\%UO,?2=73-_VT4B(9-
MV J_A.W.<<VT.S/L8EKP#9%LFA6.*7C?Y+YKVMSC 4]073"%$-ZJ/QWMGD93
M))?"^[R:FX!G\96[*;'O'!(]' 7>OC#P#S?AI][NOCX4FUAS4PJ^MVFQ#2,(
MF'$_J#=O/]#G!2>MTM[/-F:"F"@$Q^"[Y@TL19?\-02/JDWM'\$TJ"D'=4=7
M %4Y]@6<\1,9EJ>0'@G?UD=CWS9+$:ED"X*NC (9@1Z;OW6AEOCP^O(?T:OS
MBX_O/EQ&'W[_Y_G'UV__'GU\%[W[\T-T\>[-FW=OH\N/[R[^L6FJ3SA[07<,
M_/;4TUS-;C3_,-DLB=Q2[S]J+<'='22N:.*@;V!^0T%RE$_X $*?-9 L27?B
M $'-NTGZ::4ULS/V3<^^Q3]@WSOO4=*TA7DC) [F,:=Y?,G2\Z2A DII 'X%
M/C-82 -",-,PW ;IW2]3P(&V33$?LN%3<?"$)<^,&SJ:(%-)@X@%C7&,VG(1
MN%26=;.Z8Z27^L^BE=7HY0*+,9E0K:W3>*&GAVI*K!-_E,ZIKY;8JVV)UCTC
M7#'L@7G$J;*]A1W:P17,KQ741RD=F\#""*5&C,NJ1JIA=!UXN[=X[V_<%P\R
MXNB3YJ_JCX;G.-[B.7Y</,=6A2Q7T.:EE02:7!!HNW 4FU-%_Y7<N"*]1C]!
M>30YMNHW-8#O9YC1W^KW>[UW7?V]?\?ZK*C;!;]?0X=0DH-:<_YV_3L[0E)Q
M(EFT?G,]Q^GM]6S<[M,WEUPYE"U3JU5^25307(=9K+9+?@]-(1PZ7_(JXHEI
M>9#OA&T7_!L7')0\Q^!)HKV@@4!C"#[DJ:OM@G^K\I?<"?7[Q-8DR'?GS"._
MD8="%L5JHN!VKFC7R>UV*[[5L67L;T?VM-R6+-^'U8]T^!FG<;W@9)(ED]M2
M4 8*EQ =[W9@TT*[7>>ZD<_!' R70CJ.:ML@3VJL/L#?HU<<MI1:*P518>VH
M1"TM:GZUD.5&I5<_V:SH+'$5[9:=5BAF92$<8$=*BMT"K#;S-9"F/PGZ%\"X
MYI)%=A9:N[627'N08J!$#'>QI58J=IE=NW!\"M=++'R08(9S[$-DF-6:<M42
MA>>\]?Q<AU"M.\@5 P2H63DS>]]TB\!&B?$'1[S TTXH1QO[Z8R=/@&_B^9'
MZRRM'&&=^8*]1;@1+?\]]S#X0T,5-$[DO:1+6(/!('94&7EK4P2/N4G'A3//
MU-LLR.9D-<&Y<+&N$FDMW5IAW@Q;X?KA\D_5NB]6V"']^GOOZPQ&\_A1=+/P
MD#K^%-5/6O]P9X80+A"\0ZFU02 5WE=:+\5Z?@':CJ2[HG<ART%TZ5G[3,:#
MZ,AM>U:.X7F#HF $9O();&"_+AK"HX+9C2Z3">]%$A1(=>W6/(TSJ_MP]G2I
MP+CP)M=U)/A*,%C?364=_A)W.94>M0;#=)I*MDAP=EJ:%N *6>F5R<3NGI25
MN/5N4F4PG#:81(?8>'N"VV<W=LX)9K@%T[O8 \_KEQ:1YF+85LDJBL7>@"6&
M=.Z;=/@7LV1T';G]^/C@+-X_VO,$+=A\0C5[.Q!SS3H/ R]-B5VW#]Y/I[M[
M^[BD_.C8@7QZ\?YQ+]X[..*GRU?IRESZX6>[A][#&\SRJ+CP4X>G>_'IR9G,
M34"V'<\?%Z@BB<9LA )N<6P_G>P>]/PY-)=#C 8LU"S+FJ9 AQY%&!D!I?F(
MPBD)%J!JTVJ1]S+<@]/]^!36[.N'>[R[=_ UPYT:P]UR%/;9TO4Z&3#4"<"X
M45;'IZY.-F3V">8"EN!.6""I05F??IU.\*S3YPAPHA@+F*E5'1+)V"0-PMVT
MO8JWCOG$D4DI/G:=)H1H_2L/0NV,NL0!"!@62WRUL"1IM)%V"E=:]#1>9JML
M]%KF*PR+ /G-'I.P^Z[?A,KV@; 7.YO[:8L[J18;Y"Y1V*0-_13B]4&Q8W,'
MT _I2,/X6!9J5^ZYQ^[+55>7S.J$VDE#T!?YT+Q83,I$"[D* )6M($1V?TFG
M#,,.T*=7"7IHQ(8UPD))W,B161IJJ<4%\\4ZK/JD1B)2WY6P\[6T_'2@5-<8
MDOGWW]_^_N'\GY$/S5P!!+ (A?$@&KYWA):/ ];?F.2SM"JW394*85U  NN(
M6LNX,&=A""!.3.TAV9Q])'9#=73M\MQ.*G>F@7-]N) HC\Z=,94 _?5M8:F*
M(QS<*/72N>Y8&(VG%$'1V,(K+YKUQO:O@KY<?I.D,H_.-A=VI%R'G93@0:!!
M,P/-DNJA)"QE]T;:SJE9)J%*&D0Z[=Y9JT6XUS3F@YCL FM3R ?.O4)W,)I2
MP5]>)D4_@879>?=E8FY=31\8>@+YGM.W7?67;=[C%8VYWC^R8)8C8F"&U(K%
M8QVY>U4W2>3>- 7.V"-YW\O" 6:F").>5*[6F"Y.C2?U3<<G-/Z'?59>@QQ%
M9^>[%-GN]7[1"/?W2U#,U:#=RWKA+]A[NV"/DD"1] VL$@8D+*$:$TXN+N?[
MT?"6)UN\Y8^+MWQ VW&^=T'U^1Y%ZKA.,#YAQ #WRD-;IH+QKM6D\&*D5G,R
MJ4K[:VMBJKER\P@&K&T FVG)L-1S!5)A-)PL-V\\O[$.,<5R'#HD"(O5Q AR
M ? <>,* V2Q J O-%':M-%DXOK6F(119->Z^:^M]\?-_U<.Q4!38/J5(DUXE
MKM>@LFC+%B1^,1,WT\A]AE%OMX*/SDL22!IA-;,F8*);A[C5N>LFB%Q 9IH.
MXLC,4OH7MVRL2*UK/ATY4ZGQ*1F*R!$"ER9Q5/HM@GT6(P]-@\(RYI-*6(2
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M$@8*)VR(^9:%,\094>N:+E7->7*9XETSE0<B9M=KC:W0(3^.S.-RL7)BEJW
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MU9F:PEJ4>^N\CM!=B:[K"?*32&?S4+[[3#Y>LO\-FV]7_0JV@RM'42-S;C3
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M&K\*E:4"E+ADL98(<N?)EM"3:BM+A$?5ZK9V0H@9U/@B"TO,_O!QJ4?2 '=
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M>OWVU9^[$8.R7IE^48.'(^"<HSC:W]L_)DS653+D\ITO6LRSO[_/KQ3"7GP
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M?D)1\-[A4;S?6_4.OO>%6E-?>>$$Y\_NJ=[\][DJ:WLBSG8/][_#<5AR73;
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M=@.)(^X=2K65.7;]P/4)%M%;*ZZ'I 962%G97#&/:_(_NZ3 6[_PHZW5? 2
M]9)'K@]'+B, 3N^8 D^'<WM-2(>((9&;XUH41F'+RE\</<>%>$;8GNB#^[,
M=YZ]T%XNMKFR+!HUNG"?KV?XBY_V]W;W(ICOQ)7/>JN<UY4E60^T@\;4_J?.
MC&:N$"E/=;\WQ$>L2*V<Y[[/'SJD=N;1O.%C@3X6W@ZEX1]HH>L4&ZGII!)N
M;NY>5!J24O-EEJ(6RH(AP=O<.TH/_3_W_50DW ]JHZ=<(.%83/DXS@C?B32S
MR2Q%+%MFS+#L6$,N \8>)%YK#.6]MV3/HFV2@18R4]\=$(8LP;:Y;NCNR>9+
MRJ=C4!@D9+;'=N593Y-;ZJ>(ZL9U]8&19SI[T SPVUF17G/Y0V;&>95280S6
M"I4\[E+ZK&!_>_B?H9&7)]&'&BZ/WE[_:*='.NT.,1CFIF0B4=8E9H$DBT;T
MWES6Y8R ^[!35'>.XXQQ#E/8,>P&C&7H]"0XX\HX.DQ+6$BOCIQ/J%:'=-<
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M/*,(5]5.02UH_=G#SI$_<SE%TX.J;PP<V1LPE# ?KNGU?_[S(GHN@'C\@^#
M&9SY=_ %AK=@#OV:YA:C@0-_G0U@5"P1AYY$G&-($V.D3E[!-<38:S8N==-N
MZ&\Z1U1-3C+@J6C(<W]*B^.!C2LT&>M]>^&2<CK6_DAA;^^[;%+X11.((?;,
M+@JDN-1]H;E33(0A5FM&>^H_'><FXV!$H7AWMOSIQM@0?</*U;(.F?)_VG Y
MKQ)V*1LP5'$7 1(HX3:ERRO_/C,UHFD&U-A$PMW1;R(4SY^]O_CMZP[B5JE_
M-Z5^[N$Z'DVMW_@.GZ:A6\@>@J!@:0'W]HDI_G!7W0$5"X&SGT^,]I1-*!*:
M.)Q9*0K=+PZH2\*5"2*-7$W*:&JI@R#UD@%\'MZQ".)CL3V4$7/M>=O 4!X6
MK(9+,)OLK_R6 @LVKSS#-M[&1^0TUHI;JVO^=M%,&3S'MQ)7>E$3;KH[4P;^
MU!7<;?\VWI_EH++RY5;+J@9XASC$FY2EX3+6\QGZ!5;=7Z)^NK4:G_^J.C^F
ME*-T_04YF0Q]C6F1@]*?ECUFV-17(*4I5@J<E[S!85MD&]B:Y\'$[++Y:TIJ
M5&K2NAYENR%[X[/X]?ZM9Q*SD) (9YQQP^O)1FED3J-Z,DHG$U+&%K!&EWT^
MJFY$!U<2#Y#8DO;IY3;S%#"HS+C@T /^6'GCS)>H)M[JTV]VR"C:)TAJV+TW
M7AT!EH-71=JGHM7H' R*C)V>QU.]GS!6FW]FF ?5(E&:IJ#2Z8[2B&LLS 'E
MB#>V,S(]@\\W9P(#0A5RQ!@ LE3T%')8U;.CN<@!WC:I;7MP7\NS"AE<@>_(
M>HBK0<#K+ 2C29#RP,A8I)@1(5Q&! J(DHI^B2;2T-\O">3R^][FUQ3T1>6W
M'S;E]H#VJ,R<0,31Y6LI2J)9?/3,V9BMX&?!)YZ!.J15OP3WN$A0@^)WV/2%
MS])OG[W@A)OW(@M"R3,-2Q&L%?;,6I,5+E#%Y4:<.4BIJ$;@\!);BSF2KWD"
M+$)0\S06\U:#FBZ"S5@?+A\(8M"M<6J<WZL/0O.0[J,TR_)K]NWLH,L:D>"E
MK(=+5ZA.[3#K)Q)*12R2K=3!C%]>CSEN3F!7E":4!KB+##;,JRC5X]P+V9<!
M]4TG1((1J"5(C/D"_D_9$IA$>V+S)EY@[N0-K.P5W*U8BX0[3NAT-B4H,(*9
M(!^QBTB?=)RQ/4P)$S9$8-U=DO(=!D'>U ."5Q#DCF*J$V= 1_R9J?L,B3JX
MJ)-D.DU<K-309^ @8$X#]).KZYCBR.%#X$M$%*@EUTYRL@XL":_:WB[?ZW9Y
MW5FP((D#U::/:<:S@8J^HI^*PW\G5$J#EB2,_;.Y)2'O+L!HS,>>^M__W_<?
M?K^\C$E=_%J3>8K_O,BS#'S@F,NOV-_\H^['T:\8$:00Z6])>=7/DV((GSDY
MY,S\1]#R1#[P.KO*,?'@XJB@7#^^?@.:=0N&$C#4\18,M05#K4^NB@T)M.$\
M%,VR)2AI1DU[,TQ/5@S]9)PMFN/D:_N:"^9JM"0':PIA2VA]4<Z'##1:6&"+
MFLL&>*=@-K+9X/QI2A(G3+DB=3SDS_DT)^P[IUP?\-I^X0V9#H0)M482%5N4
M&+4>8$18/%N,'I0$^YW<JAU!J9HQ&"EC7 &L8R(F%RF"@$EQ503]L:Z4DP57
M+R-<#<)6Q/XSS,HTD<RJ/B2.AKR(20CV@+49<'B02G^R$EP)BG?8]LSSDN6P
MR&Z(4ACKGK5)E7M\3T67J/LIC[^9E7NM:716[MD*>(Q2<,TZV;I:W(O& /L-
M9B>_07-WED_,SA0Q4E*!.K=BRG,XYQ;N22TVO=/:JCN:%\%S74_)%9$Z5JJ8
M5@2.5WR'L7/B:> 2W)B #Z ?+-I*RER##&='K72K:L=W;A$UAN023"%AE0!7
M&K-W0^PG>5 M[0*>Y6<^REE=D&-&JS< "T- &$S$DG*=<AI6)=-HA$1%2\V_
M:7.$K03C!H912R7HG0$[IPF553GW29JM?S*RCACC'=5%'YQIWZT,RB']_;!@
M*4TFP/IBY3>B8C]J>3SI%T+O)]=).B&!<87EG%-#P>1Z<EMM)!?+O)GZ*6S9
M?29^">*T2/LW.7^#)?BM.*<W*2L^MFL]?/E_DJQ.BMN 9*!'>$L7JI38Z]Q8
MY;>*<J<8S:?#N4\I7DIL.Q;\W:]>1.4KEOT</C_A1>^=RJ*/N Y(R]@L=QK\
MCQ_,L.L_3TFB!\T>(!?<=Y;&2SG[=&$TVAY6)V(=M^%R7%E'^VO)E?4/XY59
MO3%5D0[*#;LL/1TQS3/A=/$)[BQK)=6!8K&0_<T4S"$;7R4'050H%P(60I&#
M:@I[.E'R%SU<3NI*_9'6P-I$!5?R?<84[E^UTB.0UD2C*BENNT&M5'653JET
MS.+]0/JZ!JGH@,!TTRIW[3^U \8JEJGFG$]CH 'GGD0]N<09[ZW_&RQDS,C8
M):1Q)9#.6 #9_4K)>)Q%[70_LT,)B$(,<!XZ71IS9D4)?#R$DJOV4),PJ_Y?
M3+]2$G,GG'*W\Z#9I$*-HZ(6LHZ @RP.%C\.MC,97&F.U'L=K:1]WS9BH1&+
MD_L@&3\ZW9*,_ZAACD<@$'=ID#_RR9 M)TKV=))"6VL7"\<CDR$&IYN**M!4
MRWS#,O1S9;#5!*2MT<]/9J5YJ?_X!5%0D^3V99K1I.A+O\ARBOI ^6_TFR Y
MX#_+T3@[VST].L#3(9T#Y<5R<'9AD7YN_W[_=/?D^+3S3WN[O<[?W^.CYO_^
MX/3H7@;5Z^T>'YS<TZ".#O:?]J .%[_\CKZ4VCEE#_NFR'.^T\?.6A_KZ++#
MU^?#-Z1I*2BZM/XW,E1$OP=Z(P*5T>Q/<X\KUKE?Q\LLW0,W*)H;_NM>RN>4
M5LWK$GW&&%/(!ANP7JE?C'P(_-,PJ9(7][?"2[=\75\QQ"MMB06Y>Z8_Q%(=
MWO_I7/MIOY:TQ,]D]SW_36IRPV.T<HMB:9J\/CIG8?>PMYZ__7*9XW+7?.\Z
M+=_K^W./X2I'>3NX.P?WQ%MVSVM2U$P5?]51:2S%RANVX/NK+/^V4^,C-0(^
MCL&'>;1FGEL1^P%$;"\^.#G=BM@Z[,43%;'CN'?T2 WO[W#S-]T6GV=[-!/#
MW\U,WU]M*3M/X'K)ZF&\=[9J>^1NH?ENZO#'W)A>?')PLMV8M=N8_?C@Z.QQ
M]F5E[;[@5G%PCLU1\^W__M.4R#2(;0LS6WZ#^*MBIT5'_GRI\._7^:2+I'Q9
MRVRMI/SY2=P[VV\MV 98R$]Z3_:/#K=[LDY[<OQ(T8KO9>C[ #\L)%R7=?Y(
MK2S6R<Y?*BB\&4)\=!R?[:WJL:ZZ#!M@B#ZE+3V,#T\/MEOZA+9T/S[<[ZWA
MCOZ@^2[_OW0[K5O":Q6CZPD=D][A07QXL&I(:]5UV !#^BGMZ<%A?'J\JO+;
M[NDZ[^EI?'1RM(8[^L13*'\O<FH,CO4]FXQF>G+?OR<SBN3]A MEUE0$-Q5!
M]'2C6$='\<')JM[B-KSX !NS'Y\>;BX@ZNENS'Y\=/"5]NB#^]L+LH^;>5$\
M6!AXF_QNBOUA?+;_E6'%#8L<;M;&]$[BHY4=Y.W&?/^-.8D/5LX1?D^XR%=Z
M%+VSS;LFMA':]3P2IWOQ_LJ8PVTP;YVW]&0O/MS[2@=RNZ5KN:5G\>G9.N[H
M$X_/7AIJSQMKCR)I+.FZT5\;R]/TF'[/$RK87.O!;</"Y],<QO=O']Z;9.,4
M:48WV:#;L-M@?V\;A5R_73E[I!CD=E<6XK1[#P[2W@:%Q7 2*DXD=(>?MI'A
M!PM @@=XNJU76\.-Z<4'O4>*0&XW9M$U<;I_M/P]L88QX<V\)_X^UZ_>>A,/
M67!RO&H1[=9T?8"-Z<7[>]N-6<.-B4^.'\D#OZ> *[UW_V@C[XQ6)I%:X#QZ
MF/;'JG\Z/HT/3KZ2JF0M<DS;+6UMZ4%\]+6^R79+UW)+L5!G'4N)GWB5XCO;
MQ"7-L.7T)OLR3^@T]'KQ5V=.UD+!;;>TS>YW^K59E^V.KN6.'L5[^U_I\Z[7
ME;592)=WU/M/G*1MHN;!PLZ]>/_LY,$#S]L]6;PGIP<KL*UM]^0!;H6#5:O3
MURM%LZYJ_S7Y)U'?C')N4(X_5<F7S49S/2%SJ+<7'Z]<X[6U<-=Y2\'"79FS
M=KNCZ[VC1RN'V1[-9WDZZ/SWV%B=6JQCT]!OOKQ^2,/J^4%\=G:\-7;7:D_V
MXY/>"M3"VSUY&$?]].&=PB?N?F [O_5,D7Q?ZV6=]F#EOC_+3WUM3_,Q.%6K
MPJ,WQ 3?"NY3%MS]^.!P'7D:MX*[%=P[D"A@/JVAX#[QM)XSL%SS];7-[JU6
MKGT NSW,Z_[$K&,Q^>:/[CZ+4PX/UAII_&M2IH--\T">]I6W&;?:WNZV0?)Z
M[,23%;#>YI(*; 5L$P1LY38V]R1@]TF2L.;VQ6_II*[,<-T,[V^.T*_3&B]_
M/KMFM\;G<V5FZ_5)!VT%;!,$;&4+8RM@6P%;R<)8M>9FO3ITKZN\?*(?S#!*
M8$#)V'!TKXSRNBJK)*,IK%M0XX?^_@]D\7Y]1&U;1O(U:<&]^/CH)#X]V7)^
MK>'F].+]DUY\O'>ZW9RUVYSGQ[V#^.1@!8[(]4)V;<)E\"WACX>XRY\</Q%H
MG+VSD_C@:PM'UB!V_*0WYV3O).X=;6Y@_^ENSO/CO;/X=/_TL2B#]3TZ*-#J
MS^9MV9(Z\0?^6.<=NW_8^L*JCOXPO;X_R3Q;3C"3%]'KK#+%3FG&4VS,6IAK
MD]7P;'#ZJ0!F,#%)E@KI<F%F20KB)-U;$?T#GYF:891G$?P/3BLR_ZK3&3YL
MUXH[38V$GA;OYRKI3XS^'OZC,YXFQ3C-&)2U1T)Z_R>5'O8RK6#U!XN7:'_O
M/WCSAF:0%]2<X"6<45/@IQ@%]4&6*YSI_!GQ\U)X2%:]W#_Y3E-<,"$>MMUE
MW.'JRD2W)BDB \,:1K^9@9GV3<'WR$$OCO;W]H^B&P,"\5,/C,+#" 8T@<6(
M0280!U:8I#38MN&GT]UC]T=X]/'NX7_$<$BF,Q"G853E\(2#P]TS_=#2[S_<
MC3Y>&?<R^,>DQD]?P<Q,$67-2<&INJ(G-SL.DQPWNTM&(O[E[K(;^?BB^>QO
M<YLIK[\0MG;%VT"6I./=(RLENNW#Z*?CW?U PDYV3T#"AG6!*FHY24[*0"+Q
M2[,BA6?A5U'.TM()VDV"G=136$&8?Y1459'V:U)?^%W4]"A H/4J^'Q%*O0:
MI I+!I%$$D?UDS^5?#0J8:KP]BI-)O#(_FWTT][N@?W )(>39I=B5.33J$PF
MIMRI;F<FFN"@2ERAM^\_?8QF]716RM&8SHK\&J8DK^^;S(Q2#.2^RW!#Q[?V
MH?C* W=2<1F/=O?^@T[&)[1"H@O4_N''PV7O'9["PN_"Z4JSZ$V2)6/C7Q\1
M:$S9L<;\1"WLPW>]5P7'UY[M45J4552!R/$2X+3?7_P&I[4RTRDN+2U/ E^_
MB<IZ-INDM'034M7E53J;?YQ%&@_WV<>=Y25MY$O^]K7YY28=5E=R3?I?Y.OZ
MY9[[2M(O48_,_XIG  P,WK8/?][V3QMWL???J\)9+F.STX>-^[R3C&"<+Y/)
M37);HM'C:Q-0)8WE:\Y\[OQ&H^\QOT6W]'\EZS",Z*HPH_]^]O^DO8.CL\-^
MOS\:],QA?^_P;' TVNN-C@Y,;\^<'1W\GY-G?_M(Z@6$_0)>B+?2?_V<_*TE
MR;S&?_NO?O'SW[HV=[WOKKG]G=?_[FH9#\V[Z^C8LW"\NVO?-YU #1Z2=21W
MU^I74],&*F!)X"+2D;C[I[>[UWCO&;Q7OM6RVEG7QM'-53JX\H;/BORH<?L>
MN"?UTUP?9AT$&<R\IYV$X_J/F.X@>=XP+4''TEFPSV4E?^=S]_V[;1_NMI;Y
MV%PMO.>G<)EU7/)XNPSJ$K2^*4J\\N$ULFDXVA*>:FBK2CCY\(M_U7"YP_A!
M%-AR?=.]Q-ZHA[1?.O'J"N2Y+FL:'HVR7]]B_A5G9[ZD)9& RI_<R&!2.(I!
M7>"?1&1^G;\I3H#@!LVSG<+@5TEB]CSK(!G^!:^@82=EF0_2!(V*FQ3LZP2E
M<^"M:S(N#(LNC#2))G!VC1VA[!6N=#(I\\B,1F9 +-IHL-O1)1-XUA"M%=2>
MN*5U!>.KHE&-]E*:7>?P.?@UK5S.DY87]U-N$%1613VHZL+L1K3QA<&]39DZ
MU1,!G? "T:7QROYXYIY86;0,.;'<N8WHLO'8K!L:?C9=#'#4LZI(!I4\I2YX
MP<#FZ1J//C^.HK__'OUADDEU-0!-P6>&GR\?5C]=!MG>MO#-B8P+#D!6CY+_
MR]ZW/Z>-9 O_*RIV]FY2A0GB33+75<1V9GPWL?T99Z?FIRT!C=$&)%8/.YZ_
M_COG=+?4 O$0#R-PW[H[2="KN\_[30?GX7Y1H[0'\ (X9G9&BMAPS!@^!K_Z
M[C!X1NTMG [@Y7#4ES$K \K$942 &-#^4O>56$MB:[@S-!\='T@'$'#\0J_%
M*WZ I\L_U@"2A37"1T)$# DXL7ODR,V2F> T]5(=U5TG1/ (ODIX"<0.:_(M
M[\7H Q4^(F%;N+3QV!A93XPLW@GN 79L#*TG$/7()D#[QBT@PPF1$T]=#X\;
M2!"QCAN=?<L?P?FYS[[@&;@5(H2?4R $?#6NG".!Q[<3<!%";Y6]YB.E=F=R
MK[*6W#-V_MWUY"T2\ RN*4ACJ5XH."EDN73<W&MA"S? (YIG<*K6!*R. )%"
MH ?*VS$+XH>/R 6P3._]S7-]W[CS7# "CTBYXLN>TK(S>*=B9:>E&M.*\M6.
M=3)AP99,T#?(@ORE68Y5LRS.A%FW%,D*ST8J!IX?S*@<"2L7413N$2+_4=TV
M,2) :C06,0,+D%55,=_]S]]:E4KY$W^&@Y!^,C^]+QF_*;\J^P=N#FHI&/D#
ME4?/Z)OU"ACFZOYCY1/78[N#.9=?M=0"Y>HS>MO<J#^Y]*9Q,D5=*M9GU0-)
M['J)'LQ/.KDU/&HN]"26S/F4I$\;CQIO%V<M[[\4PGC."WA$'."TG( )?$"(
M_5*OJS93 G=!R()^ <]S13SIB*[,&"HU0-/B"MLJ\J$)3Q:H.GTN%R01)0V]
M>27/$ABI4J8T46*/&+&<&>J"ATU8(BZL48OL%?E,3"L"^>/%65)/@5]A\:@R
MP,9_<M4$3V9^11$/*B[15-&S*"VP<:QZT+)")U9\$B_&#RN&%/G2TBE?GJ)R
MRS.Y TGMBWRIL1GJIQXNV09@2@&[L*9(,C@Y&E:*1D4O!"T++Y$YQ77T.8R3
MZ^C#*A[AP'"+=ZE;5TQ--)K@R<#V&&=S@'$#:P*L>L ]LB)6ABJN"$=,;-]'
M:-#EXIQ[M#(K?(@++D97P8V/BE&=DL=GH> BIE6IJ;K&4C[5G'4)F>2; 2;D
MI7.H1%PB(EMAGY(EC#UW$2WAE<BR%AOVL[:[8N<O->,1N=$8IK=Q=4B^DGD>
MAHQ=SV/<=$G7)01'M =DU\,! ;FGNR^2QKL:_<G"K/E[%D!1T2=JJ,TDI4SL
MLS#-4N/O"1?-&I&C- @M/O=99U:2U:&(  4NY9PX2.#'N?.W9U<I=R2-Y<0G
M(F@!.#B'X5^M_WT6$FU0GI-;G?6:1?$H^ /6RN'4=_U ,$2TQN!H@!DJSKO8
M/2!DF?UD!R^TO5CDI(JYA!X])^?\$+9L^;-./W+?R<A2B"M8E+N09]:ZS KL
M3%S P+_H=]SD->S?>;3Q&#L^B/YCXL*S>['CO5BTERS9#,BGRXJ;7O%-QFH7
M<NCRC.NH^7<CUN!6VH>2[GWLE3._8/A,?R09)+P'OPA_M<E/$6]V; ^!AWU6
M'9Z2_!/W^?T1D/68(_: #8%6 P9//Q%CG/UXY$FV"/_33ZJ8_(+0AE ?XUXK
M+B94194[Y-"Z92^N<TPZRC)"4D?/?Y.CYXVKV?&/^:<B=2.3:"-2R\V>$)0(
M"<W13BN^-F_0KUC*<C>(KRC1\$:,1"4^T2K52%;J# "1 =#6&0 Z V"?O'8Y
M^@EGJ1W3;<*+D8AV<)TL8-;$F!#K\9&U^"-[&)D)J/S!^? [(RTPBMFAVY^[
M"X GD/$-;P:8",=KI)SV75'E"N\:VC_I%U)14<*GY!:N9%H8K *Q&J\-&)CO
M.@X;X[\M]# 4E37QY2@!NB'N(\K>HJM3Z\5SQ^,SZ2L!F3Z!ET0?+QJ!9STQ
M/I^8N$L 6GKD^>2>#_A>'U9N.<P-_?E0TG$+Y]^4 <V=Y(#F=P<*6@D?_?Z^
MOKO#^Q]K,OW4.>0YF<=P3N^/4=L3P-U<OZLWU>2A6?=5757P,*AFEBI14*UN
M*MZ:#(G><VN.G4@^$WZ)B-&2@T&FY\*2K'X? [S$%I.SVH%-CFQO<(8^F1=D
MJI2R%#/S**0L,Q.*L<M+_%0TG-"C_%N$H34<%BDY2#HDX@=E'@97]E)E0)+1
M^PJK7L#OT=O(2&@ IQLR?,>8/49_AY7V?YSQI!C4@^'H"(71O^*'GH4)!XO$
M 7VA!*Q3IK=@H@4Y$WFT'(%'.*%D#$49(7#B7@@_^0Q%*7Y&&HF((4KN680#
M%ZBF.R__H*82CRX"X.+J5O6U^6$/FTT(WQF(? 2K-Z"WDVQ'/8)-IF/W)798
MDMN&JQABW4K0+W+84:08EQ9M(,(SF3V0</0/A*,S=IM:_)OD J6\ T]H*<)Z
M-WJNY9$I/[#1#^=ZOAKGL&#_(E0*;^O(E7-%(%Z5\IGDF8E/6N$ (^2V-TFF
M3R6#+K;'TV?XBV3L@E]0'++\93QM1::;P%%418Z,O!)'V94@^ZQK4#*((BE.
M_$A\B4J^8!M*XE]TSH KK3AO;ZCX!2,(*9NS'3P(?H@!ZX\<GN-.C@<9^;$P
M6[#/L\&-</KH68,(S!1D1EY 7 .IZS^8A$.^SQ[05>0[%5E](VL\C%/Z8E)1
M[-4>*),<@\9 "V,EDSUF !PE%@?'DD%&_@)5L^V_],=,>1_N]U&H/]&^HR7%
M *LJ-0CXS"]JQH,:F2/G4H1L/0L=2;U 1K,XM<.W5'^95%;GG,T4GK-BKY$@
M2\7!GL+M5YG]*C.*[?]JN]1,.@"J+?262YZC+"J*3I+UH:9ZG*$U<$8WR9>G
M9_-%]H,*K#%+M25.1,?FHWS%9$?$H"/4ABXSE E1IB%@ ?I9R7O*,)MQ1K8I
M92TQ0:A9TL(()>DS]XZLB4:J[:QFI2;<KTJ?)A!$GN<^4P*B<!O#JTSC G8$
MY!J)'LH#LB;\\^_(;XS!& 9K?X_QRR=W_$2I!/ [;KS/GX_33F6KJ&B'9&F?
M".(GYL%]^"QX':FX@AH>$L/A9C>[ .W3W#:KG\HML2@Z"N958U/X 1>K"X;I
M$0755.-B-E >YX?# X12E'#6Q# LA:]!4X(+\J5QN8.BK96,#-NH;;J-BJK/
MK+>->FWY)NIQV(DK6"FOB>I<I4TTL.$F3TTQ^E[JEM!4"4)00U_X8T+^R<@4
M7 1=;>SVA0,%\P?L1T=LCQQ0#!0M!W5(\0$'%<T>"YX9BX4['M>C P@V$ MS
M?QC3T)NZ*$2!0?A@:.#2H]]BY49]K>(+$_J$HCEB>!:,-]6^D=^'+=@3-*3@
MI\1U*F+G/C&XE_5#.D3A5\273N+R16)I^!JA,V(&@W1,"MN9N]JD]C9A:G;4
M/#7;@_\MK/;X-IJ%P_ILFZD<X*L-QSV0 ?@+D6%USWPP#S)D&KXN>T_?RNT3
MVD?L^4!>KH]'I"3] 8S%=LC41C,P,E5E$0/' L)YP(T0>T.224[E#=P4"20+
MFGE8T4=X!0PO:Q!A:*E6Q+;\K6-\83VP-X!UU8E%F[P !!<B2!HM>7@+>@P
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M&1D@5ELJ#+HX\&/DCK%)ITBPX/P=2V^#ES4%P9'RH]JQ:M>X\F,6!#4M"$Z
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M]^@6VYJUY>2T,@;&TW9W$@Q[?0=?5M:,[7VJQ4HU+[U9-/)KY-_81YD5^>N
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M&C :,!HPN0-,)G=F?;D52R+_0I7XUR3PO[J^?\."VR&8M'>NA]_I!(%G]\+
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MK8V=T/,2X-'HH^E: T:']T\;83*Y5UY)#E3*Y1S)@5,)].N!FSGDO#DLXM"
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M3N=Y[<58Z<6PG;X]M<980<-G/H((&[O.XUG O D-)-"NBD.XJN^9A @?W_<
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MOI$XDJJ5F>G9,&XJ^3SLS>D8W!Z@E6F028,N1H4YZ>K9/O\-G(W@>WD?Z8\
M=:7N@"1&^L>XB[?E64#Y65^GRX+W/-@^:5U+W1@%"]%KP?"V%>X8/6S#5<6P
M,J:H\IG$YH)XN<^"?T;+3@ME$@^G"0P*DTA&C1B>?]-.4?FMLN!2:V;1&HV:
ML K"84%?EIL.EN=AE9VHK,;R3>M9<*A'*V$V)@9( O+0/B5?A33GP5?Y<G#4
M8#$DB^$I5*9[CP:/(RK3I6TE_YBR6+X"OMJJLDBH"ZU(6"0T#.U TY/*.!:D
M( 1ZY.)#91GCE63K69S!P@I,AIZ*[%<+5\"?K;-6-('?HIA-RKLS.$@^UM:J
M,O!U9 I;2PP@4&RBJ6?5><3?8_;#9.WY/ #!SU#7+]0787NS*Y \P3.G(Z1O
M7ENN&07?PS4(9B+1KHQOQ=+P?FE$\W@'_L2IFN]8]/!E"@L?_N7/;5F['"\S
M4+<LGX0J)7K4'M/7F-!4M%9WJ5(&XLLHATF;2Y$DA*LN>MX:S.95]Y&'1G29
MO[!7*Z[V4C^BWJ-$@6A.D2])D2FB).29CI=T/\>7B(A%%=M3=IYT9BR>#Z:O
M1 U!#& %KL>/R5+/^INO&@BCKOG,Q2IY-R#)9),$!_J[OZ)KC]@*V%FA\XR:
MAX:QTH?U@_&?-3KVO%!>+B@NCM,N6Y7!Q._9C]@@X&O_Q.O RK\EL$4\GE49
MX<=@_>ZS-D].$X!:VMI505E.,3@*SM,DI#C*9J23=HH=6%0)CEEID?%35!^3
M3J(5@8@XPRB1X"WANH0FPY9;%^F9&D6XL2G6*[+\V#9!!G'$0H]W/\F<9/JG
MA=#3Y")2H:BY1YJ@[@>,3,//TM!2W1 BH&]%/Y+Y,)LS@OIZU((.EZI$M@5L
M[X>Q_#!$'B9G93Z01]Q%BQ@%WEO&_\@M@W('E@TM%&E$3$7X0HL#BY UQFRH
M]%^)!,WQP2M^=)?K!Y(1BKMF:T^N2@EW+M!;AO$)S&YK.:6N _$A=2,)DI/>
ME)_I3S6S[M/VM2R$Y8O]:%0K:BB4]ZN?Q80%3TP(2:[YX!"\>V$-J(V*-8G<
M3.1P(MJ3I]@3%IG6H:DDL;9 3L"Q$T2B\G@$3/T%;I.ME+T=9FQ %H$N\(UN
MVYA9SQB_\KGN$1/O&5*0)XN'Y0O@%QS&0%X/=A]1CREO_!$?D]]7;B3<+>?@
M,,.#N\ZX'I3 BKS!GP2R)/-32@Q.5C)*O/9B-A3=IOBK;X,$M3QER5IX3RIH
MQU4EK6 BK93ITO*E>4L_NQY"/KDHMZ=,8RH\FKF[M%W%<;+&099.HL-D^:[#
M7T! $+AK*:#B%$YGS:66I;-;4E4ZPFQ!]*JE#>P =AL2-;QX0H_BIFI$IB/7
M>#Z/VD@.(N0J=SI=>RDU0A,VM4#W&Z_LUZ%_[+B1A^JU2=9$QG5#5HW<J["@
MD?FB\1&![Z#79TC(!T4 O##_E<T78RR1XPS>($SR98UEH>B- &W+2]>B)$M*
MU462EW!O,P;6 O4@1Y0<ZG80S*(Y($.#U&4;.Y=M].NRC;IL0Q5HI)5M]#:4
M;8S+CV[SA06A3T$1@AFB-F+^#$T_S4@*]5^F9.$"N67<IGTK5.#P780S]$G+
MH+&"3\1&8ZU4'8PA%,Y8!^*O41_[^EJ$=<;;E:AR5(24N%Y<!>@/PJG:"."
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M/Y,GQQ7C2;$Q0^VL0IR96+M"YE&_48-?!)<2F84\E*A'"*<9B8I%F267-5M
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M^BG\$**1P]XJ-9U\'ZZ8_LQW)%#(T!@(3R(\ ?@P+YA0I38.G\9NRZF1!+X
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M!!$(/N(+2%"OT&T@X"OQ$5&K1K8Z@GAP-##,@7NHT:,#OT$CD,U/,Y^C(.Q
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MQ3CU-G K:.JH:/KAAEU(37$0=-?2[\"P!X<!%JY0="Z5I0%A$1RLK<=+^-P
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MZ++E<*\@(>Z>K!7O4-,DHG$CYDXB6?YN^8C,<A/V^M)T*\08]?ET/^P:H)$
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ML=549AOGC9>"4$II#=9$FE\ GC\Q;YKH#K='I0CSU *P6 %8;%[>[* [7 O
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M[1?5XU**NJ,:<.CE\5G^(MIMC)91/P7_7C+\!_#>S8,+^_Z3?I_)E[E9$@?
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MA6\S_^O\L^O<8Z41UI-FS$$8C'=-X99C?L@/+9&^L&;&G.8^R,(%;"_%<J;
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MC,WAX&;&Y)F6<,= 7LR,&]P$W])JN48$3W_E,6L&GX&U/MG+)>[E&;Z]8OP
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M*_+^?1O.FV(/BG":W&='86P]PD?@RPS;V4C9P!_P);"#G[C8!:-)'+!JRPC
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M^V]!J3K<AB_[\R.LR)H91T[[=LJ&\C0052[!'RD9/3BSWY&(<KEDAAM* [
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M'826,;5L*[#V=BN3<[N5Q<M/]UP;-*+U7EY;,S]<PD+A(3[%L8 L5ZYG>&M
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M$LMH*!2W_X?ZESYL.4@%11*W4K N +I4#F31#/#F A4]='OK#LOL]"9 I18
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M^,V=3\S[6>B]N/!,XB2'.![T)JB=8C/?70)L5=-6  '=KF.2.PI3(=/&]4\
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M*40:$%U3_@U$2@L#,'/X';(=!^M'C4DF(9[!>$*S:/,.=P?[8RZ@2'=JML
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MVP\]*! R^&TNR"RTR9=YOAZ2+C]%V##T]_UPR3[[CH?['5[PUH8+-\@*+R*
MPBMX5>"%I'?HY/=M[H*H\!V.=.[:MON"\6#+IV=L1'U(YX;E1>>_@N.GQAOL
M+@!"!>DG !K@U3-$)$" )ZS^IWF$]!D;4 DA%J4!T<?(P"XEL_LBC;*U*_3)
M!G;:'S"66J91]DCJZ_KAIL;%/]>4_)><TFE9:N*B9/G8HW*TGOB$@=!)\:L*
MMI(NV 0V]S*]5;UB*>W3)KG"!V _LRUO6)DVL<WW_=&M4FXN1.S\OH!V7=3,
M.J7'7K.PH*CK\^A.;P)415H#GX5'U=*/F2JRH_Y(:RZE?OBY(B9J%\^N#3J7
M;07KLU7F7:O;=4K1R>#ZY2&^UVIT(D_YKN&HGL?S]Q&T36J%I+3L&!O^F2##
M-] V_V!=#!);\4[>Z-]R;Z)F4\-_P28(+=RH\7/O1I7>1,O.9_QEQ\[B)-,$
MDM&OCTD'2$:MCV0:L-$#)*,!R62[&Q8GF0L)]@,Y*LV6W=\L_X<P]P@1+*1+
MX@>"AZ,HSA58/V-N0KOYS;;D4L]*AGCH'^',/T5'?HS;8#97/Z?'3 TB^@H;
M/<!M1L!6^X,J_(93Q1FE<+.H8HS(DM,IK@8IW"RJT'&CPVQB?..D\($6"LV6
MPHD%;5O/6-@?['CH<3[6NNA\K+-GK3;(Z7.0R^P)*PWSJ>N4P.DA';=@.L%H
M0-G(V6=-W.!!Z\TZ:(DJ%^,3#IH;,8?1($[NR8N" @_="6$VU+9I%F7]UVEM
M*;1+^A(.)Q6.Y-Y$!K3-J"W\_,]W_L,&G3\61O?UK+^U.0RWM?KJ=S<P,'4H
MSD3*L%IRKE[]96#9H:3'O-UU)*=1/6M)8Z:['T7=:M6-([4WT>6A*$EUC11M
M0-,_3E@=(RR]A82E]2:*+(NC'*G=),*JH!YL9QAG3$'X'X_1<ECRZI;[-D(%
M56:JP<KU+;SFWB,83'LFFT3(7[;]OE$:Y6!SBS'U73L,]M_2 %<QIHYON1=3
M/Q=)&?<*S+V[J4>,'W?&'-9Y;]@OQMI'>*=S4RWG;@=\NSO?N[_Y_!S[8S@(
MI."RSGKW@+O$PZM@.483EB$L/.0D?[,D1=/5Z70Z-R6B3@>J;FKS@337%"(-
MB*XI_QZ!0DAS?4$!Q'H:;#W_CU^-2295>'\>>)(-GL;^B"V,%>EN># I^RS(
M21]V;P%3L\PBZ8HTT_H;686>N0">*7SUW"?/6!;)EVY(8OD71_C#6 O2D!97
MJZ+@AI[PU@6>CR?[WO*(&;B>+QBKE><^H[LE*ACP-KM>L5T+KS"AO+</*+W7
M0K P L$(@X7KP1)9$CM*(L-98_PD]<APA1\<-$BSPF^TISK9]P(VPVJSJ&A-
M#_%:9@]+D"2!E BHX49 #3&CL)\-A0AP$C:N"@"5VLG??8#AIG>;Z2Z7KA,!
M+5B P'I:"/\W=(B@#"C,AWT!L_OW@4WPPQ7Q0!Y'\%IYY-ER0S^!(R4;47A9
M6.9">#%\P2<! H]V"2:8_9]^F]I/O<,7*.G3Y^Y]/W[LA]._ !'PL5&Y"<!^
M1N6*+[)E47T _;'&"NE'< B9^3F@@0MAQ=C4#J#X#(\@\(2X&B'B!#@;AT["
MB8X]*ELQ 0$='%V86O;FR>2GY=,'FQZ!I0G&DT>H4E-ZQTL@B,#X 9NR#1.3
M)***&N+$NW<]_'3E6<]&0.PU;/;)#2Q:;1& ,N6S=;-NS?BT*8%?,Q*]W!"^
MA< YI<%4NY/P)<X>%(@):^;"PAT7WCL%\8Q1HOV4$PT52KW9#WU8^HS,X*2(
M!V(1URGB'I9P8G,+B1H+0N!)P%3P;UHN8OD R""%WY0K]%O$VQXH_L4I\TR9
MC+M(B%L@7!BS% QG%'JX>0__1L[WD];2P$F79$E;Q7MW6NYDO<V!SQZ<V3?V
MVO2@O4BOSG(FG 0D'>!,])!+][T^4G!8:,F/T;-+V@)C'#>MZF-1&67-[ BU
MQ1+\]CBQ,\H[.Q[H9\4#'4>R9I,2JJ&!?C4T& ]Z$TU31"EG'&3,WS8GFR\0
M<PH9LT86ON^XJBOA%/3#_$Y&VXR9G7?H$Z$,;XL#WIV;!>:70DAJG_&][,^2
M=9CD"64IG+CKH91]#^+!=OW0RRFN'$N]C21_"*+/[C(EEV]#'Q;L^T+T<.&3
MPQ %#FAOQ'3W&,H5GN:8&M'2<A8LY]C'UQ)HDAQ5@4:LZK__-I:ET1L?V16<
M""N[9&#TJ<KF>D^&@YJM0 /;J ?"6Y^Q"A@TC@ !#:P4QPI2*OH*(,$C>&37
M^/'#X/ES&U0_9*T+6 H0'4-\^,)!/0^HCP#8?*;</Q$']#L;&*3EF'8(*L^*
MN9%\I@!-0<E86-[L;F5XP9KRUQFU,? ZXOF))OB>T*4^HLN"JE(YZ['=E\UR
M@#G/0GB.#\P$-I9^:KQ4?+8?[R]>-VJ'/A@]^!G"#1;OFE23P\M!6Z4HZ: >
MZ&.U+.!K5"4+R_130*=;RY[/NX5%YL*'G\0,T6$C?)G/X?T>*NSN<D<)\8'C
M,A4-%4D7E3<+GOSNR_L_(CD%?V&9+L:U72 <V/0<5%U<#3% _8^!!#QQYJ*F
MYP3T*%BIKP.(;PO3</9$6 $PW$=,@VG-\"A:48Z? RWXU@R/@UT,3.Z.]<L0
MG@W/0FCXB%"&\)\0SI%X\!+ ,@#0RX(JR3_PB2E5'Y\9V05>!.T8T$B(* I\
MIC"#['[:VDN_GN+Q'?:5XC1OU]&7.8Q,SN$+<I:1-5L-IK7CB NF10-XR<[!
M,EC"<AF3($!-B.* .CYZ_V:(T%GF<K_CDRWOTLS4C.]CUQ7ON377J<Y=I]QU
MNN%0.7Q+[AW2@?)XG72G[.5NUVCXH.O]L::4[?>@:OV!7*XAPJ'6"D?[(11N
MK:",^*):O"CU\,O;UI*A4M^!.GIS=/NRUJ##WB!8/H*\HN:%&_J@Y1>J52@)
MP K%3[FZ^*74M'QH[=K9A<MIJD.M64TZ=@W\BR!.LT#PSO56J$B27ZF*]\&V
M:'#F1J%!<XG*]#2Z;&>#"YMSGTFP<:W=";!(XCD[\+E !F!A4#8Y/5 ^*3VP
M^-:;F#MXN/(V)T8E#P9;,:JD,2\=O WH^"W"Q@\1*A:+ZB@;9QJ8DN.A" IX
M37E^I3LJ-2R[EM/6[="6=&;:4GL3;2CJ Y73%J>M&Z,MN0IMS:V?9';WO\1S
M\\A*ZTUH($]^P^F*T]5-T=6Y)=80DU,4457JJJ<Z*VEU=^96GK5)VX*=:FW6
M-&JK-9.TSF=I?7+*2ZQ1;1*KIA&,'&TN;43DHTT!ECSN34:BI%>VSSGFG!]S
M7E74D7U8//Q5.P[I^W H$QGBZ-,2QE.)[1R45OJ@:=*JIG8>3=7S6 \/)Z7M
MG:WEV"&2J<68;"T][=7_XK35F*+*,E]=NC$/.T>VT[7&RL@F]R9#51SHK;#?
M.;(U1-&LC'9*=063(UR3$:X&U;0RDJEM=$[N%#Y(48+V=9H=\OL[<G_'+:)'
M>+DUAX70G$Q6/8=-?AV?%!I =_9^S/S^AMQ?:VOE1A($+>YZ#%<KVTHZB 3P
M% -;K_C!:;Z"6W.OE6[:=]0=$)](Q)9**S-:;R*#+C.J:RPW=\PV!G..Z+]5
M,0=C]&-1K^Y/XIAS?LPYDZ%>%8=&/"#4!NRIT>JNBC'CWD311%EJBKRJM<5[
M<Q6_#\N5[:X)N:,-$L@,&PA2,^B:(:+N$M%1M>]W8^IZM*T6/8Y<:CH<7=7K
MSEYMF5.TR\ASA <709ZCK!C6-0 -<"@J<F5>S#&H:1BT)VV^+O8#2Y(X_^DH
M]ER(^\@-XS[==P%&I?DK#TXEZL/(?7Y74/[>N7[P9?Z;Z\Y\H*.X6<2C:\_2
MAU.>HFCT7-$JC]K@)GG3$.H(2SX70JE@K(NC,4>HSB'4$?WP%(0ZHB_65VW)
ML:E9V'0EYH3Q"TF4U,I5\=R36&JF3(!MHN->Q%9 EK[PRCC?&/.;-L6.AX]W
M6A_3T_D$A\)&WN02S@AGLM752X);[8U!E6.1FQ-0!4=VR!V:B<E1I9#Z=Q15
M2NA]/$[1532JG]](@]Y$U;(CCUKM$&RJ(O=;:LA$W8[ 8_?LS9CO:IN9<OMN
M(GNHOQ*2(N!7BG^EK3])PBE2HC)2:K+^BIW,E?P,G)PX.1W5[RN1D]R;R*JH
MRYR<.#G="#D=L8'VDM-A>T=2ZO9S<U*Z/F9Q4CK=#JPDE]3>9#P0Y>I]",Y.
M3'OJ=-52=;I-+8_C]W>B/+&I[/61V/#ADQA/&*7EB<9L:3F6'WATH%^UA/4B
M,5Q^_W7O[U(,O6X9^B6>MAI7KY>7I%IO,LP?O=[J<'E361IMF$?\(.9;O-M
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MS5[#60II;)NY@#>.&Z#(>@;9$XF9%?"JNPVS$MSH(X8@]*-IQ,!05.&O&'<
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M(2Q$V8K&KN/;+/V#CUIJ?!?&[Q''3SG%\<N43=\:1BE]+Z;MT*V%CA1N43S
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MCD_IY+RG=#-'.'PG_+S/=^-'=X/Q>!1<7ER\OKY6X!4KS][+1</O#4"/"R[
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M(&Z'Z+5M5Y9 KZ-!+Y%7<+KH57N#5FK>FX4]+#^B*TOZ$ZZ%F=X=A&T[\$1
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MJ8AI]A&L-]B4> ]U 2!7K#4L^0KUG!>(&&G7=:,YMQUZ[!JFZ#_)C/#68Z%
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M&DLQD R+COQ46YIOEMV,9E )YU:B;S3Y;7=/.V3L L=D<XK@)*MM:D5-WF"
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M>X 8@BO>1.JWLKLOJ1Q-%XYD5%%GI^MMT_6Z"1XANGKQA#",E(#WF&(_IG]
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M:0BC8E@,*5'05;>15 X(WF<%ABF>G>&NY-:FJ\?A=#_"O#>T,RJ,2LJ^;B:
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M[IB5X#A+45G!O.'[RO#LX4/R/YO*\*#9VW&;8?-Y_5&W?/_VI_\'4$L#!!0
M   ( /& 6UP<<U3?D6D  /+@!  5    :6YF=2TR,#(U,3(S,5]D968N>&UL
M[+U9=QM)DB[X?G]%3MW7L4K?ESK=?0^ES*S6C%+22*I>GGA\%=$) FH 5*;Z
MUX\Y"(@+ #("< ^04/:I5E(DA?C</@MW,W-;_NG__'$Y_N%+FLU'T\D__X7^
ME?SEAS0)TSB:?/KGO_SCXR]@_O)__N5__:]_^K\ _N/%^]<__#0-5Y=ILOCA
MY2RY18H__#Y:7/RPN$@__/MT]MOHB_OAW=@M\G1V"? ORW_V<OKYZVSTZ6+Q
M R-,K7]M_=/9W[2APE-.P"9G0 BKP4<10$M*?!))LRC_[T]_(TF&*"T#IS0!
MH3G^6HH)K$M9Z&2"\&3YH>/1Y+>_E3^\FZ<?<'F3^?*O__R7B\7B\]]^_/'W
MWW__ZQ]^-O[K=/;I1T8(_W']VW]9_?H?&[__.U_^-K76_KC\Z;=?G8^V_2)^
M+/WQ/WY]_2%<I$L'H\E\X2;AY@'X^+CX]@]OHY$_7O\0?W4^^MM\^>]?3X-;
M+ EZ= D_[/R-\C=8_QJ4;P%EP.E?_YC'O_S+__KAAVO)N5F83<?I?<H_K+[\
MQ_M7FTA'D\6/<73YX^IW?G3C,2)>?L+BZ^?TSW^9CRX_C]/Z>Q>SE'>B7R^Y
M@)(%SO\NG_;CP9@N$,@L7/D$^-TT*2I>$>.V3S\<\[?/@IBRNQHO*B+>_.RJ
M>*>7;E13P!L?70'M\H/@,EWZ-*L)]<[GWL*Y!GD?X6B2K^9?YXMT^=<PO?QQ
M">[EVS<?WKY^]=/9QY]_^O 1__SUYS<?/[S]Y</'MR__WW]]^_JGG]]_^/G_
M^\>KC__Y./+R^0B/2<JNW_#_W>/3;^%'11E-1F7O>8U_73VBH&VRDO3'(DUB
MNMZ.UA#&TW#GE\9E,YQ^8V_L?!HOOWM^-8=/SGT^_[# DZD<4H@YO<(OY^<Y
M1*,3<> #RR""8'C(: 5>"IF\\,$FO\G]?*U+V<W]DOW5(WXLHOTQC1?S]7>6
MPEX*>C>*:\%66-='Y\?I/!(2E-)X(B;G0!C*P1C"P(KD>!04CT[::DU+!'?7
M<Z,J9[/URE;O7:_C(\^FEU7Y7$RKB?&:*03]EQ^FLYAF:#'ACY:;P=_">#I/
M\9__LIA=I9MO3B<+U.J?Q\L'XKN:/I4OJFG"S_]]-5I\?3F]_#R=X%_G9W^,
M4#@YY"Q)QB5XM*BXBBB73(%$)@*)E <C6BG&-D 5]>2!(_T!O=F#Z%TZ<[#
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M,*TC(=9X<$[94IU:,ON9 9<XUS(90D*#<<./P3HAG6E%QI:8WL%Q_=VY*K=
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MME*X])>R]/1Z]"5M+./F!$\E)81J 3EF?",XPS?"RC(8ML1)\$?H0M7.U.F
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M BP3&:@TA&;E5+Y_(7_BL:M>O#X>N^HCWZ'"%ETP?8^QJUY<=8E?["/HH91
M>,>S<ZCBV7O<#[,'JZ-&90]!4FV84;5O-)YR[*HZ]WWD.WCL"KU?1Z5G0&-F
M("@IXYFB AZ5C]*RF'SM&KWG$+OJQ5FOV%4?@;>(/J"!_7%E8-\8WN_39_=U
M.73R;7XW&TW"Z+,;OYJ\0<OCX^]I_"7]BF;(!;X;P7F:\+60B:%L>)!@DK;@
M->?&!<8)J>ZN'@+XZ7BOAQB=PW%V;(7[S^1F'W^?GHM@O/><@[*EQY"-):45
MI:6H);@]XX]%I]8^K?1LA?,[5*]]&&I4@]@/,ZI).K>1\\PI Z.I!<&DQ,TW
M<[!$V9A#IJQZO_O]D'ZOFM6;I49%[KU0_S*]PG,]T]);/D+VCH((JC350N<1
M_Y\8B4:CKM[>9B^@WZEF]>:HP33 _J!'7]*Y,2%9ETOVO@EH,"H)/@8%RB%Y
M(1,:JK?-V0OH]ZI8?3EJD%G? _197J39-]PZN<0"TZ %04GEQ,&$:"&39(-E
MB=:?$K8OUN].O?9GJGDF_DLWFWU%!_?L<GHU69Q+EJ34.@%WI26LX12,<@PB
MNAXR2N5Y;CM)[RZ>T]"4:A(?/JV^ZF5DPXO'8UTR.F-EU#FA,A#TR 4:N4Y1
M"MZ$$&,F7-"VUW"O6UXRBJ"=X))#5,Z \#* M5Q#IL1F[F.L/S[]"5XR]N&X
MRR5C'ZD^X4M&;ZS/7$>PTJ(%GGP9F!$I:$8M[F=)$UO;2WK:EXR]>'W\DK&/
M?(>Z7^J"Z7N\9.S%59>+IGT$/=A<JD2#$T:!B3:7Z=L>+",6I"*>24^UN]];
MZ!F1W_^2L3KW?>0[^"5CXEFGF"6P7!HO)2O!V!P@.DZMHL[)ZB;!<[AD[,59
MKTO&/@*OWF/HEHO[]]ET/E\E8I]S+5127* AY"*:1,2!X<0O;]<YI4YIV6W6
MZ*XG/!W';Q_KKY[PFC/Z9CH)*UQ*&$H"R\!2F8!&1 !?&DPGU#&?4M8J=&O:
M\<!#3I'7/4788.M^,-"@LU%)<@,^>05E0"Y8;05$FD,DD2<6VN;#/M703CW_
M[@")U^[A](^)NYS.%J/_27&)<3Z_<I.05NVEUEM1E%DHE5!+D\;#Q>O2/4)I
MD,GXX%T4UJA.KWRGQSUORAN)M7:7IH<1WMJK1":!>%RTC*YT#C$<+*HE2&MH
M\CG';!^-[_5ZXLG3OZ=P&]PB/8SSG)@@ BL3IY3GY8[+@T>;%;(* 4T1JY2M
MW=_Y843/6S4:2+U1X_>UW;+>J$SBFA-J4#G+92=+Z,!0CO9HD$RC_A(>6EY(
MG\2Y4$N^.R]WZE!^>W-R45*S;  F2AHAU7A0E4(\HZ,V!'W66#M1>#N2TR-^
M3REO<J]K<G_.T!H1H3B:RK*2"(]ZF(D&%951U!G-4LLDS-/CN9=$-]DU#:YM
M9Z,OKK1L6PV,*DDMZ_7/W23^:XJ?BFM2VKHM,Q7>H+.R_ <'W>\>_-0*%\%U
M5U[MQG@-ZT;[1+0RTXA^@77H%RB!%D 4&CCUC!LN3?;U&XYMP#@\RK#^R.M[
M+^FXIK+$/DFY]XHR@A5< &.X <J0M+L?-ZJXJH%OB _C=#-ZL+\DG\K-\,T:
M;MZZ]Z/Y;\N[$1F--RJ@_>-L.0.)!^-3:1Z4HPW4\<S:J<8FGN/=%A_ \TZ=
M.5#>3>*/:VPO4=EF+MP>V=$%6Z.[XX=P'><.N1Z+.]6C$@5#JXD3G!LK&+!8
MANA$*1&C-:"REM9[3URN/8)N>/5XY);Y.-K11_(-M.)V_^$/O[O/ZS&)K(RX
MH!*\*/WGK&;@E>80@DT*E^NBK=V'<SN28S@QM=B:5A=U@_+"E9W^4YJ//DV6
MPS"6^LYCXHI%!ESF,O^$>T#/.@%AA B93&"R=C_&[4A.P7JH(.,&95J;J%9*
MW@57(YMA%Z;CV LU>'M4%0X0>H/S8">^Q"AQT:&+I52I*0RX367+03.;19(N
MR^IM&(=5AD>L@R%UH8^LFUB*UX!2/)NO,-Y81.L1?H%X(<H4E(!>N,@9#\+,
M+$3J<9\D/N*Y5=U@?!36\-9"'0XW#,:Z!#0P&[89R_._X\)?3^?S%U]7J-^G
M\5(F\XO1YVLSF@>7A&.0N,X@T(0&KPV^/='Y@*:U;5&YL0_24S [!N"H09'O
M%EAK1[H#L+9VR2:HIQ/(J,WL]L.J$BWM+)<M $F,AK/@(5%>BHM% B>M!2J<
MXIDS)>^/VGQN^K)'9.-HZM*'C1;%%6Y^\<MX^OL*X.HT-9I[QH(L:V,@.&ZS
MQGMTPITC5EGM.:D^?F ;D*,9,(<2=;_$XF I-[59RH7RV[R.[YSG,F9>* =*
ME8YE$9?K2M_]Q((S1.OD4_TDW>U8CAGOJGZ]MK^4F[*_G/!Y.QIWKIC4V;L(
MA)3F -+ARCW3$&@H:6.$)EE_\MU..*>D X?)NNDUR"]N-/LW-[Y*99/"DS&,
MKV+!^FT,WR3-OYV2Y]E+DXBSP(4HXB <'.$</,\^&>VU5+63]O:$>E+JTXRC
M8=K.]TV2N=U;88O--II\6. [5+Z>YF^?^6XZ7P+])JQ!<XOJ0CY"8E)#F3?,
M:J+<$QYX@NAE*8!UN637"6".!Y$U22[5;@0P0%83=US[H- RL)Z6P1$6#*,1
MM'5<2!-\8+7M\">4U=2'T\>RFOI(\BEG-77P4T5@*!M"@ <;2[O# (9'"DJJ
MD#EGVK+:_OWS#BKVTHTZ0<4^' T:'.H"[,^@8BUF.T>)]J%E4+VQ,B $KH J
M7CH$> %6EO9R*1,19#",U\Z0.8F@8AMUZ</&8$%%&:1-7"HP4DL0@4IT1Y;)
M0MQDZXSDLG;7CB<?5.Q%5*>@8A\I#W01^BUK,'"24HH9$BFMX\OT9AM91H<4
MO6,A\8>R_BWYT\_$KFU_["7O!AE5#Z8.=L'V9R9V;Q;[Y-KN0\'0F=C9AIQ(
MXB!,&9VH<^E88Q4HP6F4,6L6V\49GT,F=C/MZ"/YX3*QI8V:&RU 6A] N)S
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MG#BN+8T)3"A3DKD6X!)?CN8E-B7\CZE]?AX ][0U<2@>&T2&MM@(R= DL]5
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M>F6CTCIAX,E1:5UL,9914[OH=!Z5UFE46B>8'&+FU$ML/!;\IL*R09LAVJ!
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M6>L41MRR;\/;AE5T\LVNCZ$2U[1D%KOU=3N-3P*%Q(C6X3W-M:[:<M@)M-W
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MH*=! (Z )9A3 S2!_8 DF-(%TX: ,9@V!C]-0(HQ6*(!YBU!3Z4+YM5Y'!@
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M"U*\WOY:GV2DE:#RH*HE8 B(/-@GB(*$(@(. ;LHHZ0@K6AM T<H?:=/7_M
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MU,C$75CC>3RE,>>F9WB"3<@BS[[8H^Z=>(O(ZN.^^)8P7=5*@F$P<]5NPH7
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MVX'<6[,QT-+Y>?D9_["3#D4TYA9]Y=PBO\TJ0.8I1LBVD;0#C,<+.],%&#-
M+G^02_Q<;Z0^.?2,15BI<W#9ZQ#,2:'"ZJ PO=Z<-O:6W0T9P2S[;7=2X>PU
MBP12'_K=!KG \6(UG3-(L"+OJRZ-4W#6+=L;C;9L*9P3*:Z7E[,E_/3NL/3K
M847;ZE/"P\XLVIGRV(^+4!'DLCG;FA%*^EB](^6Z\XK2K$2Z95(!*KY;CY$=
M$C=[-R%=.39G6T7R@VBG17HILYBS0*Y5(->6LX<+ADG-58DY(:B14I&,*Y8!
M^8]3V_7<LN>DK-Z-2CN3-+FM.-DHQF<1,EF#N08 F)-D(/!VW>O*2Z2\*HF2
M&-1 24R!A"4]_W#.J)YGEG/VL=WD--'TX6UWDR[&)"PJ2*I@'@"Y^LF =\EU
MCOL@]LYE<W>J35XCRMW";'%MFSM!L[@RQ+T3.KM4T..(Z$B1FT?>[/ZB#L_]
M ,#X ')9M7#(3MB82T22K8US@S\QU_1:31M10_-T!8:X7:ZCN)EH(#I2,$'D
M"-H6])%Z ,!O!<AU\)H/_3P6=1%/4[-1K_?Q'C6-.E/CO4%3M?P0-5ZNMBB(
MZK5!*#^,^E[P6?XVZ@3()05R:5[%LU9@+9N0 :ML1,^Y,&U-7:MC_%9K;BK;
MQC@@5UIHXSNQ03Q/F_%DSO'<&)H)R+4?Y%)JC@SWP1ZYX!XZVV;=6>>@UZ:G
MJB+8VIH;2I>S-LDU%I@$=F\XFBO*\IS3G+./E@!R'0&YUEVY';\!:W ^)6:U
MS;:ZP$BV*;4R/SQ*4[%$*NR0W./\XV$'-P3GK S=.U<N>PWM&<AE1P:H$U?$
M4UNP!QM?)2G9*-0V<W:9)E8\CQW7/%;L%%,)79 7'9.[X6JV3'C7W* L$?IF
MD L+<MV]')V;AMW?:)SI:G.P=EL:GVE]A4IRH*9W47U2(E0E]WW"<[&Y690(
M@;D]F?IT2Y"+#'+57EY2>AZ[O^%\09^-=4U(SEO3M^7)63::]46;,[JAOKFF
M*3)BB,RN"#4AK8P".K=?OF3@+<U3T\.O\YUGK$=J_;CGB,>-+ +^"&YMD#.^
M >?G5DW8Y;GBV BAP3-+M8WHCC^V9@7I!F'AZV,>;.]7'<JXV=3><Z=Q9*I
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MSW6=)*DD!U_81&SG]!7($-FQ#E%>1/NH310I(BQ<^)0RD1AB=W@Y,9D]"-U
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M-JY.[WZ*+LPR#=U T^(N]YU%#VUVZ7J-6>@;WR[#D)SEK3Q,Q\S%;<<P+@"
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M)$>F'>$Y<*/&ZP#=TBNF,VB,),PXN210I-6_39LD^*(]%?F"K]0L6B_EB=1
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MGL6BK\4WQ0#H-@3'(&>Z%8'NNIJ^EM!J4TP_3\@:KP-$TU)H0OPOFCVM%GB
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M_K8%VZ&;"PHKK-&4@R5I,U0G(:>B0Y0QT'^"?!6SX5/=4^0,^(GYMHI;<#8
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M,O/^4,FM[9. [=$A;;Z@E4'[6\D0H\>-EB\5[K,/M.ZJ>#ZAL?4T+-?,3)^
M'1W/'1RCQK=$P2*B%,UD^,W 3TT[D<4>L4TIJ,K9*4VOT-83)$V9Z-_G@O8V
M2?#'6_M#)2$:MV*>1MYJM,-Y!8(;2O&Q"U?4GR?8.'QKR"1D3&#63R&L,3-3
M'V;X_VV-Q$/UM>3=D>GU-I2!@(=U0"ID86;M;NH%AZUU9M2S$TPF+]KO'48U
ME8O^#Q59NY_5%G&FMHP='B SK68WN(^8S-D['3"F^>SF";*J\YS?"E2Q7GC\
M;RKAF"E.6!U!K/DD?!405),C''$_4*T17G>(KZ8+CT[(-[P1<7Z?DDG_&S]&
M26JL%(<C%E:?5GSP?UL=I-C@WEP%4" =TJO&*=03E'J O-3,3$;]+]7QK>!2
MUJ6JHR43\ITD5F6NQ;GD<I!/&1S4!YT#SDO? ]L$LP^E(N!(Z7P(O ']P9PO
ME.#GM)W+5I9.,,[(]P.218JB]>#=I D ^XIWY>3R!*1UVC!D//K3$@FT"=?I
MM H:1&"95PH1Y#,MU]-6PI;I([/V(K8)7N>UH5T)NJ(X+!_H4KH"OSO5 -01
MGX:TE+\G7W>:#$JGNINW"#,8]YN>)D41$#I\V@;B%WY0UD6R!N^<MXTZ"7"]
MJ)BF3!&59M/?!!\%*)DA\\1EUUG6YOW"4&YEHTU<*(NC.9%LPU[*W9W.97_$
M[LJNX@R57LTOYX*3VXHPO*G!#L4HWH9Y-J47^(O-UPG=A9IZ=/2@1*3&QU^4
M$#BM*962<LR!C)N2C)+7.8<ERY(^Y]^6) 35%'1)2AV'2[PD*\RW"V=('M79
M1#3HJ*KTV"E:#7M=DK5F &.>IE5?+(G,JE7/3"K/7:7B!_GE+5$M<$07'5>9
MS/<+)T@#3!^76M?%*)'1>TTLUI?X5]4'T:24IJHEQ=LR=A@N)][,OJC?''@@
M9[;>T3&P<$WE"?.C@A_2$%-PZ)3VC8K=D>]:Q[.H<?%-*K15\L2&C&)">DP=
M/+$O"V!Z$*C- IMRYWXN.%/UQOR4X*-T::V\;'?6/\H$4$6^"PL(^5$<CA+"
M=&7^15+$%]"WA&BT0T65?PXF%K%NUA"6B1J-[!'/UW"+FDN:Y9=*=Y3]9/H"
M-X/3D6*PH8)5V%,1B.#$2^ X=+K?-@0(NV56-@J*N_XO15M;U9+[L")-9E%(
MA%^A-Y=L0^4B+,K.8-84%(/Z<._BX)"WQ*F^YZ#MI.LSU\'O_E%2;)CA>&8M
M[H4D)9=.&*!^+#0G%<,VEN23W^5[E0&HG%A<^1K:$]_I(!O&[)E+*[8RZ*/[
M-DL_+W4U0R4ZE'F#R:>8<E>QX!700A]V5%Y(23EG4DP=8 ?GH@\5L)W+GW$)
M\H0[>BZ+WNO6):6*'(6*M*VB+#(OZZ"(!D7EL43ZW.S"/:+!91]*G$07O3\6
M[Q5/G*$&(\1C71):33Q0W2$0I5BK)Y$:,Q)51$A'SGSEJ9RZ?)$R85EIX47%
M'>_6PDS%P1E%H.6*L:RTICOF3?4O_OK$XU6KB/?3 HSI$/,L#_W[',O<^LJS
MT2?R;^J^>/OFI^@.SU@,>J$=R\.J?RVS;YG/GY=@US2+6)RBJ_\(5F68:M]E
M=^78F)*B97E)-4Z+[^6NJID^_0X8:X@=>RVGBI?9=KP#B/'Y3H1U*(]B!U K
M)ASP,JL8YP>JB>S%7X>^]GQ':((/3JZEO$!@1L_9C2K/\B\ECMQ42&49&P^O
M^ G:7,Y'Y$$O9 )0-/B!B),8+Q33,QZCQM1-3B#98T9CRRR,@E0*@R:S-P*!
ML#LX7_ \)!Q8#NU!'\K PI[B+"-L$=V$21[;$"9B\^3I>#5Q].YT7J5L1V$
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M[=B8A0!+U5Y0(G"'JBJ/"[95.21V01XHM:':B@E*+X^-T JEQPQK9*$RT3Q
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M<P,_4ANX>/=N:BNW<\9RF@=78E7-2>?3_Z;R^@F>8D;*:^))\=;H4M)G\;K
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M\Y13E3]5K]0W-,>U6W7]E?5ZN8%JA%9E5T?7^)@<:VUJO]8]J[_6<*QQ>]-
M<VV+I)785M:>VA':N;!K1K=5]\?ECWNN]A[OV]6_;J!_1>M@S9!Z6+R2O8J\
M&KT&NK9L7>'ZG V9&],V)6].VI*X-6E;\O;4'>D[LW?E[R[9 ]H+WX?;3SO
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M4]I2&]/JTJLSC)F56;IL;8XF5Y.GS=<4: HU19IB;8FNM!)@**L"UI37@AK
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ME?E*N,24&_)4%*T=> _G?CYC?N,J]\'AV -?N>]V/1S^S(O8]++.@K=UM;O
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M6]*HOI;&B:3HC@[9,*FS2<_808ZSBDH74F8;*K8NH/RG&A>>3/TN=G1?2_=
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M9FD/5.TUK%8[5T\6;%8<KTFB7I*QL-;25Y*-^)F9]T1C",TQB_@#I"(_';>
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MW:?,Y'UQKA ]1[FK]W/D,/FFK?I=A=.Q!FQ2Y9$>9UP])MVX O^R^@7:1_3
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M\JC@)AV/_(:E5B\L\6=-E]=E:(!&R:I-F4"J /*K OPX5D<;X $3F^V@@F9
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M&!$W"=QD_P W>2+)OFJ$.THDRA^/\@4YR1*V!\]I(P(_1E]Z_X+:$-!^"*2
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MT UDEFE'G8'TQC#7'%?NK:DS$+<[*]=H\I.#I?L5Z9$:$5:2[-_(7R[8XL9
M;W&BUIR#;7 -;7_GJY+0ZKC6:V53"OF-A\J?9]+JP,I["9M,XS _P]QU\=@8
MGT;E3OR(TSE)! E>F<Z?2A72*CK'8HS5=BW7JXV%Q0W&FH.9^=9PW)2$]<:]
M>%:8JW8RT<YGK\*%],IYBG@YY<W*<[S1].4TN_818AOF1+.6-+YPN2V#1,M<
M9/Y)7I,PQD GOP^;I;Y->>YS0/XW]9MSL&@1W6>5+W<A@T\]UU;-@#&Y34F,
MA(*F^H4,IXQ#IB,,E_@]^C1&RH87JF,,N<\^V33&$^<BH1<S=968D\B\1,6T
MIB$QF%&-03"O(+IN(O1/QK;: <@^GJ*+!34;#BC/@\M]!J6.K#9G5+"+%;/J
M%FH#/E 7MC $$ZIZ&PIY^W?^MKIP"S+F&:]S)L4':JO8>S=8%.\1ND^O)!>.
M=*[C#T S5R]"Y['^I5QHOB9359%M>R6'=QZS4$0'TV\;EPO:X\=I]O+J-D"*
M2([59U#<QK8Y[^,OA1M6;V9;P(,44_,6S=NJ.)N[BK=3;GXNOY/>;.!(I\9=
MT:P1A6](EP_S:3Y-8CO. >=K/ -[_&H2.PRJIN":OIG65B74GS3X[Q2;RS7'
MTT7Z]\KY<8?5H!3<L%6^7#3*IU?4Q),ZO^!M0!U7ZY!/\*AJUIZZXMM%K?WC
M2F791[L\RRL23[7\J<1$7K"58*R!TTPL[!2/]]H,O,&^3O:"1%E^2%!#1:LC
M=C^NNE;4VC<+<R+[<N>8ZO\2'S>W8#='_E<_$?<H,+C6CM#FZ:.90-(Z3)9V
M4(ZL2.>GTZ=5.PQ:"=@BH.<4X63V4'L7,3[Q3-,6TNS(5]9>\N3 S8:[%$_/
MG:I+5(+#=HF2]GS%-5X^HZ+ZKX&-M/-%\=U5-&LVN2V;IDVL:QQ+.QQYR8*C
M+P_<HN^AZST1Y3##W:%!;&0\7AG)E3 ;,7?[YT!SBM9VA8.8[*16=];]1)SM
M%FM7Y$%S"FM!8**N 7CN6:<X!AQV>"0Z @RNK./<!88PN_M<N,E%LSNW<'RS
MPUM\T)F).^L?()\BNTQY\+O -.T@/-YSO_P5Y.0X7S01S%WYCK.)U8A1]Y+%
M>453.OC"$]DAS46"28G9]3-X89'-M6J.(#!+\Y7]PO.&W -)<XP2ED*75GF@
MY\ J#*/GDW)]T;3V=_*5V>%-PY(#B9EUVT61D2;C"_[MP%1-#A?Q?"HSHQL=
MRP3/D%FK"M!2:"ZFHD>ENU$TO[U&$YR=T.2B]$S,L1Z7_HRL,Z:(;@?FJ2_P
M+WN^D]ESGCC2!3![_BHAN@32G[-4+"CZOO=YY>N2X*9^3'M9M>)E36Z% >C'
MS:HZ5[X5?[-F?L8*X@B.&;&4?(]H[W&2EDD).;._M*_ZZ%!I^<&:QXUYE>VX
M"?+]&#[>@UE?4TG859:/VT7L38\A,,BS-N)(YREZCWPJB99_ZEMQ(XVQNZ_T
M$HUE>U[^F":4Y58^I0TP,)CWM ^E.=CY]+"M.'PV715^C7B3_L/C+TH;H_QD
M8-$U=-K UY+%[,GU_F41R#S)JXIBV(?N6&6 ""6;JU^"(VDV7 8X-CR2\(<5
M[#Y(_@)L/=Y8F"BE]E?O:A#SK0,E3X2U8EKY,OY>ZJ?**N[SXGC,(XY#ZD,L
MGIT2=I"P <YRKR%G@(N/;2]8HK_:YU5$UXZUT(N/J1:)$LIFR-TI#RIPDOA=
M!56_A:6IZVIZ>*2P.+P!C7'W(YV'^HYF[US;,*O7IU!LS3;3=]VNK1$FE;KI
M2.1?Y385N\A6%2'CI)AJIHH*-KS$S^+^=I](RD&6'M'F8[I6]! *;K>R3#V[
M[!H4 J"$:(')Z\J^&LB%7RO;U/DIRZNYLMD;U#BSH,KM/O$7.^W(HAU?]KSJ
M_EB0UY=L6EADZDCG7R]^WN1*DI:56?\JK*ATU%](;JR>J\S9$(K;(!*X'2!V
MH5D'0-R?(N].,?[W_X?W">%/Z2<^B32ZPH/$(T^OPA:64=RJ+R33J"6XQ- C
MM*O$.:[_,"24N!'[FA,8:@<+^Z?ZLN$1?C5V&0\F1/T_VSHB#K^OP$C:3W1*
M.D^Q(W6$1E*/4/)=1?1.6L:^3LQ%BJGM98T]Y;T>BRVE;N ZX#JI6@*),)XV
M=F<=D4QC)OU%GDP?%S)$^8=N<$VF/69L&G:HF@]K6S,Q(/1;^Z+Z#I2+WL(&
M@P?QB;@A,#"_BY#"&DY,)$UA!86$D7\  ZY+:1[ @J&]%281M?EKU6+A.(T0
MP^=3V,*:4=SGN%"LG).[XPP^B?UP2P/1&4D-ODP.@9I<WE+EK$-[9.5X34K3
MY8J?JE'JJBJ\G(U0,=\EW[#1-691^8[1N&K^G2TS"&7<T& <R<@N=3E)G09M
MV-U0QK%.:7Q>,:_VM@JLE.G_1]$YMM>9<&VXFMIV;*<QVB2-;3L[R;:];V-;
ML8TV;>IV:EM3VS:G[=1]G_<'G)^N8ZUU7I\6DVCD6C3=X4MYU^N32G,$>\P;
MDNM$)_3O0NVE<]0?7(?D'81I^W_T:VN;5_DPJU>I&PZR'O0MQB]S6)T8;S_/
ML^5)R4Z!<T-@LJ4HSEP2\E RH/-S-<G#R W;E?2RK<\'MS#>;'C3X,0J7 /@
MWNS[_>=X3MR!+LN2$/Z:EM*DOX4WZY@A#9)X@Y.K7/99V;GY"FA5V=\G B.I
MKG6!($K78(O!\\QS7"[DSK$HKH4Z>,;$]["5T/I_\G5.,M)E/+)+GK7IB&(R
M)Z&7KJ!QS]4N4ASG+T=G =Z"51P"6"=:4G0*#!,/)Z: +Z69P=;0(;F;\U/X
M"I"XL5WF*'W0XRQ;*^/73)';RKXAH^1KY1"[01&IF%WTE^*[8D_"+N TP \Z
M#)X%5SB?@"= =ANB)7(LH>N\= 8VSM0C'4#70^=DD6@:BY2/1D<5.LCO('L2
MYB@N(I*@8N KXNF\'LJ$;ZT?(YZCZ^DTB7=IC<8J2:FF$.R7SE3/8S9('RNO
M%!3+'I#M\;C\,Y$=- X(P;XX-X';4<;P=^'7^O<=:M'JNJF&*G&V^2NP43+7
M>(RQ0_)5;\S?*/M+FQX_1NZO'A>X1]%&ZIW_YY38^6%[X>Q.B_9-PC-M#+U)
M!#8S%0_$D0U1]-\2_]JY^0NE6<;K<1VR>AT0B"AFJ9XYBX"#Q+BU*@%UE6W[
M!*%M7XONCO!2UUJ%MZBEC:3GB1N;LO-TDI-U<^+\90N,ZP,3Y/W:D<Y4H)*<
MOM:"_W'#AS:C8/U:C2Y)F#G8*V\7S>@1T2Z*I[4OSULJ26C\$GM+NJX&"YPD
M3]2=<2X&%I.O!W0D4!G<!!,GJD^H#40DW57Z-WZ7J:"FX3C[>LY>?!DO)X:/
MO1?\]N=C9\2?'.G897EA_P9<S<YH;,!G<MZI]-@&GE!R#"OD?ZF&L/E"=<X4
M](G8)_HE>E#RT]\&/2#[YLA GP/+^S:B!R11#524*YV@A%$;Z6[Q >2%C%/5
MA>R7>V3G(^L4HZ.IR!K%4[];R%G@\?^HN=#(WC9D/F)3'PO?0RS)#'@],EIT
M&U;!#RMOPG+X=-9Q6 GOB_X+'H2W^0W"'^!A1P92#'?WP- A];NZ!*A1[4'D
M00)5G/ ,5*2,IWR'*&12U@2HELB- J%S>)Y?">R+Q3@RX/WH_.Y&<'/-EMI"
ML,;LA?- D5$L^ 32]4V40!#2;LH4@]O5QZ/F0M.4%_P<H3IBT_^H *RRZP9P
MHS6]IA,XU#P9VP:L:A +E@/=M9LJ&H!#IOL9G\&)AI&11T&&=I+O;VB"\J$C
M SJ.*[OB 9_>$S5C =NNW=AL8&S[2GZOXF>SOF(T8%M_(D, (.:/D73@@V&$
M[W6P67WY?Q2#4'0^5QQ8.]E<H]BRR@<U*@R]%_@+%;+.I>4&14]+2<8\8$R]
M,7(IH#)U^JX"([2R_U%69%1SA]&+\D(WI%]?S03OZ*BT\YP@;3C3L72)9C&[
M)O6NZAO/,OR[\IK@QC(^>5+\U.X/<45>UO1<3V?)M.]U5IR%X'3-1^YZ-JR^
MQ(\JD:OV"-ZEYBDWB':&-Y.K)3W+HHD=LJ/V5OA]P+-IGG:KZ)[FLZ96O!/P
M4@LE6M:@BB$M*3ZL9,BB4TZ3<GEDN!]1H\A:M@0_"*CLE^/CP#N-UAH;:*'Z
MFWHZ%*.P5TV&2I@WE-,A7O%,TATRI<03!=".L*=X#?32^Q?V"+:SS\7BX*H&
M7]5I98YZNO($>5$>0UXD79BCB"<$NP@@)N.;DF_AV?CHL$YL+9;J?1^S0.OL
MV>@@<J*>H3QI-*DJR N&?%DW<5?WFA&'?]%F%Y[#G=1[DO,Q0.44%H.^)(W>
M.U$9?MD>01=C(^J.DS\:NY3;R2GU?TL_$PMJY?1!?)EY8J$_QC/4)3U"S^OF
MAXU'5ZK-WMW(:_*.O0D9PB?7Q9 EG:C2FY"U/912<;3Y$MT"JVN "G:BEVNM
MDMAHM''/BAW(,5V\MQ:1JH;LVY$$_%WM:^+=8!!YDIC:^T3R#I_2^1]M )O5
MNJ$@ TUII"39(,=K9Z_ D3S#-F\6LE3C9C^(C""&](Y-HRGKD*7UYZLM!7FU
MEVEXY3WS<\:CW#'&5^R<^ 7Z!]PO(=W:LX(#'NWJ/>)[-F>4V^45.F.#E'D(
MKJECLTOY!VLDG%^5>285;S"GUF 25,<=TC6)$D.J-<V2#(\&58^LQ78JN0VP
MTCZMNRGLAX[4O!=I^-/-8\4<RK#13E*6\Y<^3,J(R]>6R<PA3FI0?M;#H.P#
MO&UCB4O@;NW2VAR@"'QA!H!.GH-Q%7"EXHO^,C@SFZ:;!!;'OM1$@WN"GZD@
MR-X#(0]! [8R8BKLI<FJF4N, IU,,?@ EV%0X%X5_KIMV*:L9YJ/V+)84AV'
M'@]>IVQ#<STDQ'?DM6T_7HE ZG7F:;HU &9,U@YQ3N@U&K"\7WM8[9U5I9F@
M?!P;_+_\NX)1\I__V1J+2,)'VY[ KJ*]:CM33)T;,-E06Z/G9.J.FSK+'30_
M#&CF*W6\KCSFIG*K)BHXB[11V7A0\%W$8]LG6"G6H=IIW-(**3H-(YL#V ]T
M7@UDV2Y-<6U-)JG:8&J- 90.^I[@!42O9L"C"(]0:FQ_82-PCHIJC.[I5$3K
M&SHWLV'MGC;OLCSUO::B3!^5:YTJ)H(<,FT*^D LTUWW2,*>J5[:34>W$(N0
MB.[)E +AEXZ JOTTVU:,9E5XNND0PY#J5G^'/6=E?<TM[FE_Q+A?L-9UM*Y!
M?-?JNIHMI\"[.G<Q?@G-;9]8+=2]+=Z<\$)Q(X7[)^55'<R_O9)NU@H?^@L,
MB&2BJZV6)1-8!ZA*@)FP7X>WH$+PH1479E"#FHZ+D@N^-HP2EZ5H:ETE-2M=
M3$G21_X%^@)YLNMR387BB;5>R0?;H<ZV;?(V05S++/F_U:I&JB*Q@%NW4;$M
M99[Y(^ 3<=_H IST#]9E@!S7%+44\K2^0O9#?Z QK6+T(']3TWU47?6N(12-
MR+]=:T"^)&\QW4!V1S0:G!&S_T(M#:&[%JJ&D%2;F<1G)!@$6R#U';Y/XP?U
MS"II?8K*.I]:TZVT2$XROB>71E3JPPA'_W&:)CS E:;\C(7;1!-E:#(XLWF]
MZ1_>\49G([-J4IU&?S9_A/F6;G+29Z.W)C;"3:=7*?U'J>^1QUUERCS\EPT7
M?X8% GN;ES0V\)H:.NM75]ZJ?5>;G'?,[&S:EK3+ !JLP]]JWVB;_:ZKL]1S
M7!'R%HG:U.($]@L FK9V./)R&EQ;!RL;:@5-^CS8-%AOE83JOYCWA1_7T@V5
M?H=5#[7S7%$25!ZV68_[XAW"5T.I%<_I*0./JD)+2GOYU)Y,B\[SC*6Q.UO?
MLO:%<AIO<,W>^VJ[!'K' \98\0U+:\U7>;E0M-J784.?WK^#N:O$K<>6S<[X
MTT'G1L8.M>#\B%!A@TS(]KY3DR+>ZS3.,%66:-FIO@6,%LX9W,.?3>OJBQ-,
M*;[1M4VX.&-3VR]11JRPV4:\+K2DWEWJZ?W*O%#VCU.$[HNBS6JBZB$("88'
M0J07: X]EV4KBG,Z$V4[,[);>^4IL6Z-MQ5_A0;5_E9<]7YK&@/L<>)J?X$'
MK:I5DZ!+@K"^+S! /=#=!%<7O>^8"Z>DOVGAPT$Q;QO^AL-#9]>\@XN]7QNG
MPJ13H]86WF>U39D%_^$_Z/VA7$IE=W639%%?^Q+B7'I?\_]V0\R&^D-X?LA7
M\Q]LA_=KPS+,TFFKAHH:K?XC]Z!C^+6]_GH3U:/SEDY41&]+URY.IS:M40_&
MB.N^JX)";IC#R1O>G_1B G>ZJ#Z&.UN[D:'H WY>3TOMT>H?G2$UUD7>K1M,
MMNE>3:/T7V(BZS*UYT*&3&O5&[R?Z!XK>YS>JU<09NL\XAK6PG?I\6R^4OVK
MXT3CWB*/5OOZ,>F+&TO-/V.":P>-DT.VFD;K?+R_Z(K5(N<QJIOD3FN ('$/
M^H3-URKH)3_7/Z\<RGJP9B=U2L+&05MZ6SC2X\+*]=>T/><FN8<V"@4,N[WF
M&^)+2[MUA?)26O.FC_2PDFOK+C).9UT=HK$T";OZ-W&DX>U=ZWEM_CM;A8)_
MW<F&:7\>_GD8MW)E26IZ2G1<8M2(41/$7'M'DT'F:.&G]51\IA5L)+B'2NJ&
M2WF[LX97?>3?2FCI\Q7ZA]=VAH@.^I]NF2.1N^^H.RY+L\>,%8ILB^T:%Y!"
MLUW_33*^)&7-+0F>53(HEBY,8/2<D-X+%[<_D)WW/]MT4?[(_4YM%S#5_HRA
M$"RP=% G0&NH+]?U@H$EBX=T8'B6VX 3F)G@TXV"DG!*VVKPB/\_C1LA=_>?
M-4W0*H=)>C'L9TFJ#/ IZO;A%KRB9,1J.?8M:U[_'$R1L+2+@_X.3VGM0IO\
M+S=L1!,]%I@WHK,<PG4;D:>6EY1OD4-4X]I3FH+B#ZLZU5#6U#Y/%3UA9J=.
M&16^LN4(Z>5_K?XAX>7A;WJ!1SKP=1.P<JO92@9:1V6O]3 M*GXW^-YP,FM:
MKTB_*&%*QREM5'A RW@UZG^V/E!YWB/<E$+Z.S1K87RM5:QR)!9.S5^SK[ZG
M^,M@>>V-K'D]U\WJA&D=#H9?X2'-U3K<_U9=G\;6(]%X5GG/88UV-O&W%9]<
MAYT]=(XZM?3^IGAZ<L7^KC2FK$JO/\1NH27)#G,/,V=5-0K&L]]G=(GXO(]A
MSZ66HA"/\0I7V:@#;RNC&/"&2]4G6%&=8^G.G'&Z+B;"/2/=PW[$;ZU<SZ,(
MX?3KPHEB("Q+_%FZR?V@/%01N-^I_+IXS'KK2J5X>WL#=;Z$J8VBMTG])":6
MIVPZ91/GJ>QG^@S^$?E_*\Z(G@$SW%%9)9BQEU:Z$<D;IE?@R-36EU5^\!GU
M'>HCN%&<SAB"917KV6:X.BV9UP/GK4@0?H4SW..E W#B[G/%-[3Z-4_+3FKR
M6GB4-K6=2EQ=I?PD\J"GD/^4[V%5$;M3V[@#>,?R&T)'C..^4/(;7;P++2JN
M7SLT5%I1V]2\LB+6S%1F5[D8@X5.-$_]M++G3(KF6<IOSAG5MN5"@80L</LH
M86/[=TH*W3H'5Z\O"6];WY14[MFL(1F5-@T9@@QJ>*U5F3^CQO@L!>#,UM4N
MM^$_4$]R.R_^0GCNV%00N9J]ZGUQ6;^^45>6T4TEUE 2V^WX;=6*IF>ES?0G
M=5TIX]B8R2WT-K]**W;;)JXE63N6Y?=O>KF*6W1HW:2&'Z7K5]TF9E;T]QKX
M4ZJN=ZPLM:2G-[U*[F*/JBT/K>']UAO=NL012LDVB+.^M'B@CV=?4=$PE]]1
M%8$?%\ZG3>)]%O4Q;I9\DL2QCR9[R6;PKH?L4,P5!;BZ@5S9O*WS6;/HLOYZ
M]C],;OT"KI"=CMWES^=Z\"P$Y_AS2H)%JX6SDSHEJ\3>(9FR%U*-ZQ@ 4OAM
M;J'O%[)[?S('156UZ]A"<2:JX49)HCD_^2[2Z.)X88 L/_&AF"&'@V])[RN.
MNMQ7#()^FR93-T ^/4SZWU!TC2-S$$I$HMDM4!K['G<C5%E4R7\)*1.#1$G0
MNF"!Y!-TS^6 _"D\>T-;U4O5@^XIM,FJA::+C 7*$.@/RYE,9]WEE!#L0A/O
M.-Z<T"W,PG8%SY/8H^=<!N1AR,GUG$JH!NY\6;W9=-^XAW;!.!_\ROBF#V*^
M9\=J"PJN<$^IH80% D39$G1,+"%,+D;99BQM'4K);?W6.;*JM1DV7*,>:C@.
M6M"_U;YGNK+*S',+_#F_#3[QP_Q3VJ @I>B1:I:+0A:,KQX^7R'M#^M(J3S0
M_<RPI/IU1R! I3NVE#(09G<#F=_#R:WIBH_@AQJ:@Y)%-$VF"T-Z@_AGN*3\
M[KH5[><K[5?_UANJX_O3%1=I>!>?_I4YJK4NWX=]O&%5W"/>(7-]T$31.%VX
M2XE42QY>K9*H2\>V_N]&5BS2?I6^JQHM?R@[1+U 7R$?9*S*8RGZV)VQ3X"]
MO ,!&Z$I(E\G$.Z7.:VBBV;0B!8+T6]&I^:V^#FK4_9 <H]33RN6ON8UY&Z1
MSQ5LCLU6E(K>!.0#CZ653GQHG<)K,(!_B?^FZ9;@@W"Q^K)HE"A8>DN\1)Q!
MA27)$EGN2.F =%O,=;F%_*^ F8IK"JD3%;P(+NB_R;T$.#>"_!F 6E4E6 G\
M(UDGA,")U4+1/3 MQT52 ?;'A,HF0B/]=\O?0G2G4G Z=*>OEF-#)C>$<J7$
M0Z47[RB1(=8(%N'KJ^J%C?BD;+XX"N-'[Y;.1J_Z"^56J*=3'D!#I+TDZ[BQ
MNMZ?XV;P(/VX&MUA40?OL]:O\H! K1[(NBA*4LV*3I"$D8"_OXR/'W7*4-Q$
MG_9L8*YK*J@K8ULV9!&5'++N+^$U[F^SOG(J?[5Q4E:4D-2A4>_%>O5C__'2
MN\JE3LF*"MRN9QKC<O>2VMVLE(Y(? =[>^LDH2?7I[&=PN.]J;/+W"-X;.J+
MJA6/TH_UNR.EJ'V=XA4C";_N 4;(ZO;:".;._C>X&WM1]V%!'Z>A/:?B,R^C
MZ6EF@2"GCAJU7*0UGO;KDX[1_'2*D6\AY[4]ASM*+A@/P_+R1\@^&*\\P[L)
M#U&[REGP70:4?A6Q9:,KFQ"8M\EG)SI6Y&__%3TB\V_]#L90]QLN@0SZ"W@_
MV,7\SOT7?,CYJVP0"N M3?>'!@29*VU@9]%:'P2^*PUWF(P<4SBWO%?8\U3Z
M?H6"?Q_:H_A':,_Y#GB+JDMO &O%6].:P7#IW(@=X >9R2<9NJAP=U@"/P%^
M-)^3^<E7Z"2R=?)+H%YNI4CDS)=W*0Z6SE:L  +3_E+\! Y$Y -7P'0?._ 1
M^-G!%;: !ILV2)JQ.UI :H?M FJEFS V>[HL%IM0$B\?@0ZF%LF?HHGA3Q5/
MD _+WH+SD%J'0$B$.#7N%R?K.!J=^*76H%@CP34\5J#41>U=K)5^5;Y.N2C[
M0*X*5RMF$,7+#@)5V$^'E>!C%&GX(PJONZX^(WI9ZRO_(-::HYA:R7*C?=$;
MZ5+=KY1<F:OF3'B$O%!E6-:G.$^Z."2"3&RH@2GDM4]3^XIL6H;D6:*CC7<9
M7\2*NFM%%1*J^6CR7:G),!CV7G91*UY&*K)4BQPRP GX0,-8P<W^L:J#PMKN
MN[++(L\.+X98]+ EJ/"+^&)#0+)..J;&.6Q(5F@8NRQ'_I]ZKT,>L(L0F9I4
M[TJ&<(EJ1OD&L5I)JVRDGB5O43GYS60Z(S<QBCC'IBTO(')X@YY/\%^B$-L!
M_+0LPGB:/$F=CFTFW>EAHAW$(+.8.I=P92OR_N"[N&L2+N"Y_._+I^&C14S/
M\]@%J:7M5>RPPLKP C_ 34.'\6S> >$5[)7 JCH$,PC1O"0L6/0A(0'])9&%
M[D+/R19Z_HT>D3^Q&XG>!&[KWZ#OI%RD%^V4N0L.HJFRZU5T=+Q<EMN,W%38
MQ1]##BKNAM*0'<"@9SMR&<3M'-"I$%_W'4E%4'@WL@"IYS^!'R)D90.\!2G.
M70S7(\'Q++@;L0H-A/<@$SWKX#_P9[MHI 2^IW.$%ZA-\%CHH^HS/P@ZK+*A
MO(#:E"XY3*B&=(][#ZTG D*>0L_Q,$\!G(CYV97!IU%++0PM-+.A?/"/R8Y7
M#UXVZ"C)X#;=P>P[X&[-VS@<?*&>%[(1\E(&>E9 FXD5=A(X%?/5? <SF^>"
M5\"(QL6\J>#\NAT5YX&O-3.SJ>!X8WG< C!1MR:$!?:K7WIF03[*"78:Z#6^
M5-,,'.XB0";P=_MM;CN@;AFH* 4J&A=G3P8$M>K8J\!!X]L0?]!-%^OI#UY6
M:>V:H';\+CY@;B\12/--$\LKF-6&M971):?U^52G]//:7PRKJ!.:5G9D8+#:
MGU?O%J)\(EINK2$WR!*P-\9UU;F2/884&L$XKA_)6%<2I=W!NI=>J6%P':)@
MM2V_/G">\I[(WBV>W"CY97V5:%/,P[ST^SASQ$]T.JZ9,4N;R9]0W*:Q$FC2
M[JO>B99&62M/B,\%/"<'I1UNJ42;O-5F(;X:V(^6:K^(UXO':VY)U'0/]3YI
M=M$G5;?,(2U3:9*/BCQ":N4? G82>L5'MPQ\$)QNDX5=@<*1.@T/\A2EJ:D0
MGX:K"J&6H@AE.K0^]0V9!!V/E!,,Z&- $VZ$K=WRL3-PH8T*LX1;X+OJ0'*=
M<%"UDDRD/E"N(/86[B(#B"FI,B("SXU,P*G8M@ 8&\;FNQ5ATU"^S494C1R'
M$U71AK^$OLIB_42JA,S7[B]<0:1HPE)^X=6J@RM?8#W*Y(!\]!UQSRT?Y>$Y
M-I?0B>@IZ+I27^\@.$BNK3531Q$#9K+@,MYD]$EIQ[;HGJ[482,UG0&6:+&J
MV"T/>4N.M'F']&%]$*P<V39;4$E:-S^N[B+F-<XL$.&C:Y^FI&"+30=7YJ \
M_4# :.2^QN26@:B55;9_(6EXEG192U6)$VM_DW?Y^/*##5:4%SE!=7]57TW@
MF(_0[Z[88&2RY_F ^O$\T.F%9HTHU'*-BBI+E1B;=E1UL:(;!JA'RY/KS/3_
MLA_6L%@A"=ZF99RN%6;]![ZK#Z1=);SG/$]-D]RTFJF,5DP1_]?P@/6 V5+W
MCE-9=JCF%?=]=JGI*K\F_I)ABS!^1:[.*';TX6LJI3;.(:IX>885BXP%^L7)
M]9;";XR'M>&B%V6CS)GBZUD7C=F22_%E^C3I_14SM0GR<3YYZDC%2N<L92+0
M9[6;8$&S1(.UJX 1C##S#:"LM-+X#=B2%6P8!_R*^Z.;#>8L/ZOQ (_XA*BB
MH5#G*I(-G;#ZC6^"\T6S:B#L)WVG:1]VKN2%X1&FR#RJ^X)-CVO13D77+.]5
M>Z!9/BY*"CK)642L1PY8^^*S$8FPS:S4G**O-%[63"J1Z'^I)V?FZ68KG\6%
M:OS(P\NK5=7$&A\7L@MO<U83$S#4N@*K1>G"$-,%,Y,^WNAD<BQ9H8\W"#.7
M:E-T8-P$-4=3N]Q-N5WUM\]H<BSYPKD>1XE)UFK,$?,5?#3%-5ZE'31T-HPO
M_JS;6=N:<4.STW0M]I+JNL%Z^22EG19>]H50JEX[M^$+R'3K0?02=HL5T<LI
MWE@A[>HO0_+RVZ]2*I*?MMRL+H],;.REJP(OU(6S'GI\-IWDT>S/Z1-$$1;C
MU!]EF<RA[I^5>RL6=_I4/\R;UI9*MTG^NSF2B4?Z-4SF3 R\7K.'=]!SL;%
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M,99>\A&])9)43$"'J1.JO-#J_#R:'K5.;&&Y("]6I//&(CN]NT5.B,XA1<9
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MJ#>RT:()G8QH\Y<1L:K8=)1P4+Z*E^&#R@D1)=@YXE-0.?J#F.K=C>;C22X
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MQR"SM 'J(QZ@[G#PBS:SF+N#ELF79IQ3I\^ZD'N/^6?7#\6(JKJ@*K'14-1
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M(_[DI\X1F/M^\;#;H:E)-Z)@<=<2$#%74M%1EV&8B$L(7/@E-#[L(I80>H%
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MOQJBT(9T[;60I[T-2G15H-)0X_M14]UW]=:FSQLQ-H^:<$ZWZLGDGG*FH+V
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MNT- 6]T?C'6Y8&5"!P<K3\#:>?S$8[#?*<Y.WYA8QZ]<-_LO0@_;SV*<]:=
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MUYDGAU<=?V2TL_RAE49VOZ-)PFU7Q[ ;!+RDC^HEN,+B>%_V$5)[)?[$WI
MCYX8&;8G+<2IIRC,L:<VS*'W3)C]I5MA#N?O1CAVW(V<",2LF@*%F]#]OV;*
MN[.+)MV]-U>I^]G:::TC>Q8=&]987_94?U_6$[,C\8]LS,(&G!PD#SW<!0_(
M).8])IUR3\ F]$OX;G=#A"YW8_T<[Z;[V_<726S[ZZ0V]\Y(;>[?D-C<' RP
M[1L,G BD+)\$%6LF?3NU0/GFY5E(][._E%O&ULZJ&]N]K.2E^I;,%WH'XT9-
M=4.?VYC[CSC9\T;<L?1A3SQIF$[&#?.\7(?%3*=A&<M^6,&U&4[A68WD"2Q&
M*GW,1QJ%9L/GA&8C#X3F0X,^$X&<Q4I0OT#IQKD92->UF<CI=_,GUXZO^ZMH
M?/>JC''U[;'C>JHAXV:Z_N-VIKQQ)QNO<3>,Y[@GUGW<R\-EG$-P'!=YVHT'
M4JS?A5,MW\1YF;].9YB]SF>:OJKP-GG5X&T\ULXR&NN:$)3]A=PX-0WI[)J&
MG+H] ZGYNG!JX=?U"]*^[ED3\TUCA_R[_D'Q#XLCW!^VAK0?&'/"3U=KMY]$
M>Z>?-(S##[:S[3<?K-57B9O%%[F[V><HG,FG!+SQQPR"T<=\HN&',D^#]_4D
M_?>-$[I];#)R_LQ4I.G25*3Z_@RE?%@\/04V+5* RAH9:&WS0[<_&\S4J6"M
MC0-'?2RX&CL"P<P.J!;6P+2R!)ZU.?C:FD* G3&$V!N"PD$?$ASU?J9C='_D
M.NG\*'76^5XQH0O-DY$3YR<CE3>F(+GOYB@GP_(94;!U83 <6"4"K4W>H+>3
M#,8J[F"IZ@3V&O;@<M@:<-H60-(U R]]$V 9& '?T #\C/0@P%@70DRT(<KT
M",2;'884<RW(MM""O DUM4Q"*GJ5D>Q[DY!$F*<<":NF!\'V>3ZP;RD#U-80
MX<A&5S#8Y@!F.VW =H\%.*F8@MM^(\ ?- "RJAYX'=(%EIHV\-4/@TA#"R2:
MFB#34H?PPVH0??@0)!U1A90)59Y'D.SK"!(WK(R$P7QE":R8PH6-LVBP8SX.
M5)8X@?H*6]!>;0%&ZTS <H,AV&W2 Z<M.N"Z]0C@MFF!YW8-H.Y0!\;.0\#>
MJ0J"70?!=_<!D.Y6 =F>?1"Q=Q]$30CH&R>#E\I,8!Y9!$*CU>!ON0TDCOM!
M['X8A!0CX+(LP=O/ >@AV)^4&-PWSQ3B%T(V^3.ND/;)HYS^T:V&\<&U@?D>
M>Y(U[M+!&G?N9K]SOLEY[3S(>>XRQ'F"?<:Y[SXRH?\W&C:@#?MF @MM$!FN
M!HGE5@APV \2-RWP(QD"W]L*V+Z.P)!A?] 4N&_D9,\OQ"S*)WR!UT>/,L8'
M]QKF>[<&UCCV%/N=2P?GG4L/]ZWS'>Y+ET?<9]@A[J#;,/>.^PCWCL?O 0-M
MH*,-7*U%(-9?!4'F6R'87@6"L.C+BV@((KH5< 6.P IT_4&/Q'^E))(^DS)H
M'PGYC ^X,N]QCQKV.[<&SCO74]RWV'.\-RZ7^:]<'O!'L(\%C]R>\N]Z/./W
MX88%$P$FVL! &_B:BT"JMPID9EL@Q%8%Y"Z:$(0W!'^:)0BXCL"1N'YGAA.^
MT.(IG\CI7A\\\YCCA%+V.UPU]ZU[ ^^-VVG!:]=.G]?8/I]1[(#PL=MCX3W<
M4Y]K^&?"'L)3T43 >_UD8.Z;!4*-11"DN^K7O9@(ZWT0[J0)(1X&$$BQ!%^6
M(_#]W+ZS0HA?Z#'4C]14QGM2+NL=L83[%E_-?^UQW.>5>XOPE6N7:,SUMN]3
MMT'?^[@GOM?Q0[Z]A"&_\YY/Q!,!%MK@C3;XJBT$N?9*B#3># JKO:!P5(<(
M-WV0>UJ E.$ 0A^W[[P@XF?O*.H'KV3F."6;\]:SF/^:4.WS"G=<-.9^QN^E
M6Z]XQ.V^^"'ND?@ZX8E_#_&QY+SG8^D9\B-IZP1^-;#VS@+_0PLA[,A*B#;<
M!'$6NR'.7@UBL+H003 'N9?]5PG7]9-00ASGAM/>>,=[CWEE<$<I!3XCGA6^
MSPC'Q$/XT_Z/<5V205R_]";QD;3'<S#@'&DPL)4R$-1$G1BPUTT&-MH0H+H
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MMN"TW1YH>RC@>!0[YP#4&U2@/L1>.P+U([;H"/CO7YR ^MX%'-^X+@T\M4G
M,/GQ9H0' BSX((0B"&%N$A#J*P^<,#4(2-0!WQQ#\*HP \\UEL#HM@;Z@"VX
MCMJ!RU8*..]R *=#5' Z[0BTJ]@#&M!>8A^P;[1O3O@K5Z"]H8/3"[>E_6<-
M'D9<X&?,#4%F?/]Y0Q3I*@$1/O(0&J(&G'A=8&<9@6^9&; :K,"SPP;<^^V
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M 3AQZ0*#6QN\N#6!S:,&H3PJ$,NK!&F\\E# )PLU?#+0QB\-&_BE8 N_).S
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MT/QL!=J8SL<E@#5> U4/S\<8AES@8<D-GE0^\/!8 >Z!HD"/D0275;) *U8
M:AW>^A95L.]1 [N-ZF WH@&V4YI@NU,+; YH@\U)[++V=YM[.@LV+W0^VWS0
M_FC[7?N]+>C,VX#NG WHO;$!_9^!K3X1G+2)P- F 5./"[S-N,''G@]\&"O
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MBCWK-,&>=]H2\-UI- "<-@>"TZ8E@*\T 4)Q[R7@[EZ%]R)7B?"I4(/XJMB
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M3$#NHS'(?S &A9^!.9YOB_O_QSN 'S\;0_OQ/HC"#8X,7J"REP$E2A#LTD3
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M !,](I@:$<'8@@1&5!(8>G*!/H<'=.-X03N+#[1*EX%F_7+0;!4 S=X5H#&
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M:A&?>*J/:W%J&<_\U&8)L]/'),Q.W>.9GG@K87+\BZ3),2(8S_JY $L7X1S
M^D]?!U"S!:!@-T#*08#(HP!^I^C@=EX4)E_F@<-E!;#_10?L_F<.DWZU YLK
M;I35%5_*\DH8;<)O<33SWS+H9E>+&297ZYE&5[N8!M<6LO2OK6/I73^(W&#I
M7GTAHG/E@ZC.KU_9XQE:B', \SLQOP[S"_< I!["?/1PWS/HX#]38'N%!99W
MN3#AK@R8WU4#LWL&8')_ AC?MP?#!ZY@\,"'TGL80ND^C*6T'Z73-!\5TS0>
M3Z.I/9Y)5WVRE*[\9#-=Z>DQY#9=\?%+NN*C#_]A .=_%]:_?BM T5[,/X+Y
MIP!\S@,X70:PN09@>IL&QB^Y8/A2"'JOE$#GE19HO38$C3<6H/YF$JB^=0+E
MMYZ@^"X0Y-]'4;+O4RGI/XLHJ0_3*.&'/DKP<1E-\N,HC?_I*'(=>?0?>M8"
M3,/^%V-^&M8^$OON_3. XQ4 RQL 1G< =%X":'T5 W7"!U4B TI$">2)!L@2
M/9 F)B DEB @]L G+L C/L E8< A2< F^2!*ZBD1TDLQR1**0=8C>R@Z.?8?
MFC"_%//3,3_J'.9CWZ=@WR?<!M"_!Z#^%$#E"X "86*F.&;R,4\*\^0Q3P7S
M-#%/#[-, "4=Z,0!@+@C@4@LDHU4(_@ (+CX" X\&?D/1->((@8&%#%$#$PH
MHC.11K2GT(BF-YVH1]")6@J#J!0PB'(UTL(DRMW('&201927L8C2*F2]"%':
M@NQ&#B%G18CR3>2)R&?EMR(?E+^RWJL0D??*1/2=,F'_"-'';"-=BI@@QF/W
M%M@>!QK1]Z03W5 ZT4YD$,U<!M&H8!*-1B91[V01]5G(@ A17X(,(VM%B?HF
M9 =R$#DE^EG]FN@']4>B[]3?B+[6^"+R2H.P7VH0L9?JA//'#Q C'8J8H>>:
MH_>;X[V%*5YM:<34G4Z,@^C$,(Y!]#.91*^4273K642W783H]")S1(G.0M&O
M.LO97W16LS_K;&!_TMG&_JBSC_VGSG'V.YTK[%<Z#]DO=%^SG^E^$7NB0SB/
M=0CW$?)0A_#&0TPQ>P)ZKJ4J1:SQW@;'QL::1JR<:62B'YU81#&(62J3F!2P
MOAI7BWPV;A;]:#2#_:?1+/9[H_EB[PR7B+TQ7"'VVG"$\\IPE//2<#?GA>%1
MSG.C2YS'1O<Y]XU><>X:?>;^;D0D;AL1_BWDIA&1' ^9,):M2!%;A6]G(5/T
M$!P/A\DT8H?C,2F4\<DZD?7>,D?D[<0RT5<3ZME_6+2)O;#HX3RSF,-Y:CXH
M_MA\F?@C\]7B#\TW<N^;[^3>,S_$O6-Q@7O3XI[X-8N7$K^:?Y:\;$X$%\V)
M\((YD3K_ W_EV\D"F8+.[:*$4QK'Q1WGINLDVF=G5_J[*0&,EPXQK&?VZ2*/
M[0K9#VVKQ.Y-:N+<L>D4_]VFCWO+>C[WIO5BWG7K%;RKUNLDKEAMX__/ZB#_
MLM59_@7K.Y)GK%\*3UI_DCYN362.6A/9(]9$[O /_)7O* 3BAGC* ?%10_2I
MC]X3J%=3)].>NGLQ'KB&L>ZX)(G>=,H1N^98*GYE2AWW\N16B9\=NO@7'&9+
MGK-?(#ACOTQXVGZUU$F[35+'[79+'[,[+G/$_IK,0?MGLOOL/\COMB<*N^R)
MXDYDQP^0R5) 7-&]O22!^.-]H")\"M*$EX'&U"-_&^IW7S?Z->] YB^>,:(7
M/-(X9]T+>*?<*OC'71L$1UW:I X[=TL?<NZ7.>@T*+O?:4ANK^.(_![';0J[
M'']2V.%X47&KTT/%S4[OE#<Z$97UR#IDY >(,V9[H/N/^7<PWH=)P^MP)7@8
MI@VW0LVI_P5/H9T+\F&># AG'_5+Y![RR>(?\"H2[/6LDMX]M5%FI\=TN>T>
MO?);W><JCKHO5MKDME)YH]LFE?5N>U1'W$ZKKG&[H[;2_;7ZL#M17^Y.-);A
M]4>(&V9[H_<&HW^'<^%#%!^>1$O!S2@EN!1E"*>C[&A'(Z8R#X8%L_>$Q'!W
M!J5*;@W(E1KU+Y7=Z%<CO]ZW66'$IU-IC7>?RBJO =457LO5ASQ'-)9[[M!<
MZGE4:['7#:V%7G]H+?#ZHCW?FVB-,>\'R%3,]D?O#1.%M]%L>!0G!G?CN' Y
M7AI.)>C"X7@KVKXX%^:.:#_VEL@(WL;P1,%(:*;TFI "N97!%0K#0?5*RP);
M598$=*LM\I^C,>BW6'/ ;Y7V/+]1G;E^/^GV^_VB.\OOJ>Y,_T^ZO?Y$MS>
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M$A_^KSH 7F/!7^,$>X-!;X[_0_FZ;V= ,=AW?\QV/('Y9P!T+P H_P(@=0V
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M5Y"_<"C_QAZ<@QNPOT.5 '.J<"T@-4A!#>;7HW<T H0W<R"X10H"6]7 O]4
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MP?X? ##%7*UC (J8*SP'P+T((/(+X.8?P5^'FW2 6VR VSR4 @' '5G<F*H
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M*#1"9U'NQSU&O;W-P :6W\M)#VGDSV6M]'WM]!T=&LCHU$=:ERE2NNT@Z_9
M4D\ $GHB$-^3(,3VI G1W;FBR.X2<7AWK3BT>[$DN&M0&M@UH1K0-:7FU_D8
MN:7FV_F>FE_'#VI^B_]6\VM7/.2B<B^LA>=#&^<B&2"+J5N[&"CJHO>F54OI
M5T'BTCF('YB'V$%KQ PZ(VK(!Y%#(8@8BD'8D$P(&<H2@H>*1(&#52+_P1:Q
M[^ 2B??@*HGGX X5CX'C4O>!&^0MJ?O2[Z3N_7\1A=2];X8SM$ '.[DNDS'2
M2]WF;GIO:N?2HJ4.TWLN!R+'M!"V8BY"5IHB>*4=@L;=$3CN#__Q</B-Q\-W
M/!7>XWF"UWB9X#'>*+B-]XA<QE>(G,>WBAU7'A$[K'R<O"YV&/M&[##ZI\1A
MN>(AQSNX+O5S7>X#AD@'CVL' #FU,T;I_<:!"%K6@/4J\-DP!UX;C>&YT1(>
M&QW@/ND)U\E N$Q&P'DR$4Z;,N"XJ0CVFVI@MVFQL&C3B&"S:5*PFCPH6$Y>
M%BPF[PF6&[\2+-;_+K)8IWC(P27 5EJP%8- /U^;1S@/J9U+[>2U[/]&(' +
MX$EO[CBE#OM=>K#=-1^+=EG!9K<CK'=[PFIW("QW1\)B=Q+,]V3#;$\I%NYI
MPH(]2V"R9P+S]NR!\9YS,-IS%T:[/X/1U"\PVJD0C&?9M8SKXAC/1]*Q@N?"
M:L[#=4 :;6'L-OK?*<!K+^!T + ^#"P\J@F38WJ8=VP>C(]9PNBX PR/>\#@
M> #F'H_"W!/)T#^1![T35= ]T0&=$V-D.[1/G(36B2>A=?Q]:!W[ =I'_R2*
M:;:LXOG(7/=-\%R@/2_=S'FX@V.P!PBCKL\1ZM,76Y^B!Z<W-S@O8,Y%#6A?
MTH76)2-H7C*'QB4[J%]R@]JE *A>CH+T<BHDEPLAOEP/D?*+F"XSH9?W\:)$
MOWV)1OX2C?/%[\DOTRB_DV>8EKQ]*U#%/N?QHS+V-^($X$=;[$Q/;GT1,+D"
MS+T&Z-P U&^I0/RD-HL./4+/?YN>_[8M<>,%, "XPX+@CO(_BO "]#1/NJ<Y
MN9YFYYX^2J[S?1KZ.Y^0;Z898[Y[E??AL,_R8QP#]C?Z//4O4?\J8,4_F?\$
MH'<;T'H:D#Y'O\^NX$55PCA>8APO&;$@-F4Q9,/"G$7R:_[ ZXSC=18B;W#!
M?X,G^IL<Z#=W$GK^?[+!?[U,WIVF?^_,?3BE_%4FM6/87W_J.O%CEM0U?@;0
MO0MHO B(7J'VZ^2?Y%_D+17@;4T6Y3K >W-I3N8#_V/)(EEI5GR!3UD@?ZK\
MPC(NQ)_SA/^<@_X%!_D+=O2+Q\E3T[0R/>7,>3;['4?M@%OL_QW @OTUHJX.
M=565NO\F[\[N@_QG]GX4Y7TAGPILFSGY4@OX2A?XQA#XCCGYT0[XF:;E%\;Q
M*R^,OW$Q_(TG_^^<&[\S\7\PZ7^<F4:AN0 *57I^*%E(E/L/GB2,))%<4CZ]
M_Z# 8KKW?OR!$?R.E?@5$_@%&_$SMN$G[,)][*?#/X;O<0;?TOM_0^__%;W_
MEPSV<_[F,_Q-%/\/"AWZ; UZ?L& /_$85L25!)$XDDG=8FK64*^%6MUL;0 _
M8#F^PSBUUE%K$[5V4&L/M0ZQW9-4O<!4/<&4O<C4?8CW^>GW&/U[;/'=6=Z9
M1:$[%PIM>GZI+A0BQ@(SXD!\222U4]B_?/:MG%H-U&K'%^BESB ^Q2@^QFIJ
MK:?*%FI-46L_VS^&MW"64^8:WL!S>&UZ)^1KO(+?<(^MODQ>>@2%WASF@IY?
MBVCJSXR+R(:_<6>.@]G/!&IF4D].K6KJ-%&G@ZWVXVT,<YJ,X4VLX53=2*UM
MU-E-C</L_2D\S_%X#G?P#"?QTVSE*6;R-EM^4E#@ENA_41AH,A=2HDYT& _'
M1,,,/TD=\*7$%_\11^)]<0K>EN3B34DI_B&IQ2N2%KRLTH4759;@>941W%59
MB6=5UN(9E4VXH[(3MU4.X);T!&Y*+^*&]#:NJ;V.Q]4_QV7-7W%12X$+_X7"
M6,(XZ/^-Q'QE''HZ^$''$)]I6>(]#5>\J1F$5[3B\*)6.NYJ%> 9[7+<T:['
M;>TVW-+NQA/:2W%#9QFNZZS"XSH;<%5G&R[K[,4EG6.X,.<"SLUY$F=U7\<I
MO2]Q0O]W'--7X.A<!8X\PO3C90MXVI O>7I_;"#%Q\S'OW6,<4_/%L_I>^/.
MW' \89"$ZP99N&HHQV7#2EPT;, %PS:<,^S!6:,!G#8:Q2FC-3AIM DGC*=P
MS/@PCLP[@\/S;N#@O'O8;_(I]IC\@ET+%,+4+#MG4?!4_H7+RF=<XMY=Q"7(
M4L"]!6IXWE@/MTTL<'VA"RZ;!N*\60S.F*7B,;-<G# KP3'S:APU;\1A\\4X
M9-Z+ ^9#V&^^ GLMUF&/Q3;LLMB/G18GA1V65X5MEL\+6ZP^$C99_R1LM%8(
M&\CZ1U#N WWI0'U7+K5<[I_E4ONDG1@WK+1QR=H$9Q;9XZ2M-X[:AN.070+V
MVV5@KUT!=MN58<JN!COMFK#=K@/;[/J%+78CPF:[U<*DW29A@_UN8;W],6&M
M_471A,,SHM4.[XO&'7\0K7!4B,;^B_OV7/8\@%>YM#[-9?XZ7R^YTWLZJ>.$
MLP$.NUAAOZL;=KL&8J=K-+:Y)6.+6S8VN19AHVLYUKO6">M<6X0)URYAC>N
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ML<3?#GW^'N@."$1G0"06!R2@+2 -K0&Y: Z0HS&@4F@(:!#J CJ$VH !477
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MRO\A\5GZ[7.7^4HS?_8#\CD:E??AC  9*S@&['/0).<@P[6E[D)^?"XUM4\
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M9O9?RIB/0L:2PY@R0E60$J8#69@A$L),$1>^"+'ASH@.]T)4>" B(R(1$9&
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MO4 #RF?!2"4U"TD&=1.S@(A<^B[:5I]">K]B>I]2,6S*M6!5H0?+BGDPK[2
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M,*K\#Z0LTJ\QCNLL0&Y$S'Q9V0T.]$T*W63C-PZ2R^09\D\4,=]I#"]Z-<>
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MB:[SE."Z1O&N>\'/P!^54/"U$@L6M N.]7 N*: =7,0!: .-O*X!Y;Q7 @I
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M0FP<0YL<D^&]&7$]1M?C_#H^O/9X:9Z86&/L1Z%_KGI?#0V$IW$O&(]9S<0
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M'T8?91GV[,,XU[,/8SDAO!8-O1F.$_%B/^%UB%JYQ;<'XWWP+\_>"^,,SA/
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MO@'E+H-1N0(LL ;*W@Q+Z2[X]S#0G.^R#/:=MM@M*A]";W^(W %UG__ [J#
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M-G@R,A0<L2'@C,3&OH8,CGT'M!X9-&07$C/D)!(]) V)&I(/DB$#8QV@!F1
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MYW\.AO_#ZP?V^C\8[/_.8O_OFNSA%OM_--C_L!?2I\\33SSY9%^P0?\!F!7
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MGP\8'!C#'&!X%1AV&(/"8S9_R7FG1YKL^X\X2*->0&K3\"E7%5S:30F;_I&
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MJ;-0RPLK?PA-VM1V/6Z?_^;P#$WM;+; MU;-MA\L95K/E159DMV%)IP7RT$
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M[M9O*U_8=Z-CQLG(M>E$6\WK'(5_DUK@.&3C6"^XL'L("@WX %U/"(+O'\X
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M+Y+LG%FVL?;7AB/Y:/Y/AF-F45^4<4'O],G^;RP]6*_PS-_O0="&:3S*$$-
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M/M=<QFEI+N2V-,((C.BJJ^--S(RU= TT$8F%>=S6AAS_MK-9O/;Z3%Y'W9^
MZ/^LXE&K)/5=D*EU%/)TE*! 7Q^*3*R_%6$([XML/28+'/U>Y%)"GF5XQ?V3
MS$N_$Q->>#TDL:K'/Z_QO&]=:RV[J;7$K[DEW_]<<S:OI2DSH+4Q/:"M(8W?
M=C:5WU[_)_YUB/O/(55M%V2K'X$"344HUM&%,@/,CW)3QX\55K2I<BQKO,Q9
M,%Q$CWJ8PTZYD1Q4<#$JIKHY**.YAE?17L1MZ,CA-;5E\,^=2Q.T-*4(6AN3
M ]L:D@+;SB8&MM?_"8A!'>)1AP34(5UU)^2J_GZ#30'*-+6A2M?\5XT1[F.=
M.?G-65O&BP9'OR>U;L$W2YA)%[-X!8T)X37ED4GG\D**SJ<'UG<F!S6V)P8W
MMR0$MS3'![<VQ@6W-L0%MYW]7T#L<A%(0!T248<,Y1V0KWP82E5.0Y6:)M1I
MF7QMT+>=.6?F_*K=ACITGL"XVTP+[*GR2FPNY.17I ?5Y"3$G4N*SNV,B:J_
M((QHZ!!&-+4*P\\U"\-;FH1AK8W"L+8&E+-_XO\<MDI"$NJ0I;@="L\<@@K%
MDU"KH@:-&@8?VW0Q;RZ8VK^X8NOXZ+*3^[4.BJ#]K$="=04K+R^?7YV8&74N
M(B7S?%!R[87@^(:.T)BFUK#HYG-APG/-X5$M31&1K8T1D6UG_P3$H0Z)J$/R
M\360H[ -3>,'H.JT'#0H*G]O4]-^UZ5C].J:J=G073N;V]<=Z%V77/AG6^EQ
M1?7>N:D5_I611>%- 7FI[;ZY59W<C(:.@.3&-D%"<TM0W+ESP;$M3<'1K0TA
MT6UG_P3$+Q.!)-0A178-Y)W<"F4G]D'=R6/0<EKATT5EU3?7M35''UIH/GQL
M97WU#H[:TDO@57118[+:&%DQC6@2K@DYRZQ,:G&O+&]C%*,?VNRF5DYZ\SG_
ME'/-O,36QH#XMK/\N/;Z/P$)J$,RZI"*.A3(;8%*V3W0>%SF:^<)N;?7%$^.
M/-0Y^?BYH6;?D*7EA4?VE+H[3G[YU\A1B=WNZ2&=K"+?MJ!JMY;$!G)+63/E
M;$NS>^FY9J_\EB9F5FNC;WI; R>EO=XON:/N3T BZI"R50+295=#\9&_H?;(
MSI]M,OMFKAP[-'I?X>##YRJG;[S4,;@X;&3?,&A)*WZ$Y:3=(X9'WJ(G^5]C
MYGKU!)72+L97N73FUQ([FVM)C>WUU,KV>K?B]GK/O(XZK^SSM=X9YVO^!"2A
M#FE;)"#[Z$HH/[0!&O=O^7AIWXX7=P]M?_!<]N"U5V>4.U^IF]:_U'4L&C'V
M2!VR](\<< CG]U,3?/M8&1Z]@?FNEV.*2=V99<3NJE+'2^<KG%LN5)+J+E11
M*BY4T8HO5-(++E;\"4A&$V@&ZO#[I&_UWC7?VW>N?]6W;=V#H=V;>U\=.=HQ
M?4JC[HT*IG!"BY#ZRM S:A3C+WCJ&,I^0(MAW&4ET_H$&2[7HW((O2EYCKV%
M^0Z]#?G8J]V%^,Z>8L?F[F)"77<QL>K/0"KJD(4ZE$@OA<9MRZ>OK%O^<'#M
MLM[7.W>TOS]\HO;#"9V"627KU'=:Q*A)8P_!2VL.9X@0Z#5 #Z<_9$:3^P,2
M"'?"DQUN)Z3A;F6GV_>59]C=:DVWZ>O-L+U\/<O^_+5L7,NUG#\!&4L0R-TL
M 55;I;YTKI)Z]'"Q>.^K-:O:/NS84_/MT*F";R?T4KXI6T=]U'$.G#*C<U[9
M^S!>$/SHS^E\\J!/"&& %^[P*#0*^S VVO9!6JSU_8(XJ_LU\9;W.^(L[_?%
M6?;=3;#JO9OX)R!K,0*%F\6A::78_6N+1'L'%DNV?EB[K@IV[L^'PPK)<%(W
M"M0P@5\,\)Q92Q>O*1R=.D%@D,9I+*<7WAS\"-???C@HP'8H*M#J66(09C K
MQ.)I<:C9TUJ4]E#3IS=#S 8&_@CD+4*@>I7(_8M2R)5;4DCKZ&*I2EBW(1=V
M[4^"(Z<BX;2F +2,.3]-K1E?K''4CSAGXBR1[#!-HV+?,MQL)]D>5A/\WV]!
M>)NC[9?I6 K+9"S'U^AE*=OP92W'\$4[Q^#%Y3\"10N01RWB2$^/)'*N?X%(
MQ?NEBW-@X\9$V+,W F3E^*"LS 8];0\P-:* E;G33ZP5[CO!SO:K*\[JLX>#
MQ2>FD]D'+L'D?1#1:#;2Q>!=/%E_)HVB-Y/KJCM=2M69KJ-I3YW[(X.U"'*Y
M0QQINBZ.E#V1$,V"%8OC8?.Z,-B_DP<G#C%!]00==,Z0P%C- 3!:=F"G9P6.
M!N;@8FP*=+3]8I@9@*^%'O P.K^"+;5_1EEK_DBPT?B>9JO^/==.[5NIO>JW
MJC_2VRR"-'6)(:5W19#T20G16%BY, 2VK>3"P4U>(+?3%13W.X'&$7O0/VX%
M9B?-P5K!&'"*!N"LK =D%6V@HQLL0UT#6!IJX*^I@L9898C4482XW\?Y=14@
M1T\!"O7_1'.;*%)R'4'2GB*($*1$@F"UA"]L6>(&TBN)(+,!"_);K$!YAQEH
M21N"P5X],#N@!=:'- ![6 T<952 =%0)J,?.@(?L:? Y?@HX<O+ /W$"0N7E
M0'A2%I)0TD[]B=)N!$F]CR#A+Q"$#XM$&+!,U 562>!A\T(KD%YJ"C)_&8#\
M&FU06J<.FAM40'^3(IAL5@#,EE-@LU4><-OEP&G'<7#9>0QHNXX"8[<,L*0/
M@_^>0Q"\]P!$[3L \7\$F&M$P6N;.#".+@%/]0W@:2(-/C:RX..D#%ZNNN#A
M;0YN/+L?U##'KY18ET\N*=0/Q"RW6>=\SW=.)5[3CI4^4PYUS"E<$^LMKMWW
M#;:;_<;^!F?2[A%G#/N,,X0;9C]R&&4_^ /_WW'8*@[>1Y<"0VT#>!OO 5]K
M66 [* .+H@=>GA;@R;7_[A;J_)D:0_E 2:+/NF1ZSA#SO*<)Q<RW3A6^;QSK
MV),.37Z3^ [N!*['?P+;YS^.?>P_C'_F/^#PG'O7:=C_]A\ %NK@C3KXH Y>
M:AN!9;@'_"R/ Q>O AP7?6"Y8WYY<7#?/(.(G]R$U/?41(\92KK7E$LNZPVQ
MF#U)J/";<*KU?^W8Q'OE<#[@%?XR_Q7NCF $/\!_XOB,?\]IB'_#>4APG3 _
MX+M:%'Q0!R;JX(TZ< SV_#LAXF-5@$<T (Z;Y2\F"__56T#ZZ!%)?T>/9TQ1
MTYAO*#GL29<B[FMB.>^5<RU_W*DY<,SQ?-"8P]7@E_C^X$''@>!^Y\&@FX2G
MP5>(3X,O_P%@KQ8!YA8Q8!U9"DS4@:>_!P+-CT.0O0H$$@P@@&;YD^/M\(45
M0'[O%>X^XQ'K_9:>PIZ@9G-?D0L#QDGE@2^)M<$OG)M#7CA="!MUO!;VW/%!
MV /"0%@?<2#\*NEQ>)?+X_ +?P XJ(,OZL!&'7Q5-X) =P^$FLE"N*T*A#D9
M0!#%Z@?/T_&SGQ]EEA7B.>45S9KT2.*^HF?RQUP+@EZ0RT)'2;7A(X1SD</.
M75'#3K>B'A$>1O61'D9=<7DHO$A^*&RG/!2V_0'P6R4"[,UBP$$=N,H;(41'
M&B)-9$%HK0)1> ,(=['Z$>SF^"G U_6=7R#C+2N2_=HK@3?FGA[T@I8?-N):
M%OG<I58X1&R)>4;HB7U"N!=[RZ4_]@JY/^Z":W]<&[4_KHG6']=(ZX^=#^"B
M#AS4P0]U"%#:"!%:TA!K= SB+94A#JL/,03+'Q%4QT_!7M29 )[7&[\PSBMF
MG. %(S5TV"TW<HA:&C-(KHM[2FI/>$*\GGB'?#?QBNN=I$[JG:06VIVD!OJ=
MI%JWNXDU?P#\5XJ W]]BP)59"D%G-D"TYFY(-#P*R>9*D&2C!PD.F)^Q9(=/
MD1ZN,\%L[\F (.X81Q@TXI,</N29$SU(+XU_0JE/>NQR(>6^RZW4J]2^M/.T
MOK1FM[ZT.O>^M"J/6ZGEGK=2RCQOSPOP4 <NZL!#'4(5-D \FKU_GQA*,SD#
M:1@=2+&W^)GHC/\<2Z7,1'I[308'<,=X$<'#O@E1@UY9<0-N)<F/7!O2'Y(O
M9UZCWL@\[W8]J]']>E:-Y_6L"L:-S!*O&QF%7C?3"[S[TN8# E '_TUB$( Z
M1)Q>#TEJ.R%=6P8R#10@RTP+,JW-(!V/_9),(K^+<V-,1K+]7@8%!_^>V#UE
M9B0^<B])OT=MRK[EVIO;Z=:;V^!Y-:^*<36OU+LWM]#G6DX>\WIV#O-&9C;S
M1L9\ /\O$>"A#GS407AR/:2J[( LC4.0JWL*\HPT( ]C_"/'SO9CEA-Q*M75
M_56\-WLX,B#H<5"D\+9?<G*O3UY6MT=-?J?[A<(&QN7""N_+A47,RX5YK"OY
MV;Y7\S)]>W/2V=>ST]C7L^;C7X< U$& .L3*KT.S]W;(53L(!5KR4&2@!D5F
M!I^+K*VF"_&.XWDDZO,,3Y\'B5S!C<B0Z.[ V)1VOXR<)F9I49UW2VD9\U)I
MOF]W23:[ISB#<[DPS>]*08K?U;PDOVLY2=QKV?,! M2!CSH$'EX&\2?60M:9
M;9"OLA^*-8Y#F9[RMW(3W=D*2[.)"JS]2#F)]$^!.^-&NJ^@*TX0W1(>F5HK
M2,XKXQ:4%'+.EN=PNLK3N5UE*?[=)4F\GJ($WN7">-[5_#A>;VX<[UK.?$ @
MZB! '8(/+X4DN;60<WH+%"GMA3*U8U"EK?"IUE#C;;V%X<L&.\S3.J+CK3*:
M9W>N-[\EA1M=$QN:5AP>GY\=E%V:RJ^N3.1?J(P7=)7'"BZ5Q@BZBZ,%EPNC
M!5<*A(+>W#_Q?PX;Q2#TT%)(0?-_WJG-4')&&BI59+[7:9Z<;=17?MUJKC5\
MWMZPO]G)X4HUQ:.]V#.@+ILM+$X.3,V,C<Y/C$PO%8:55X:'7:@*#[M8$1YZ
MJ2P\I+LD/.1R47CPE8+PX-X\E-SY@* 5(A"(.H0?6 +IQU9#@?PF*#^U"VH5
M#WYN4I-]VZY[ZN4E,Z6!2]8&-]L<\!?.NK@W5+KQR@J94=E9O-2$U(B\B(24
MTL#8XDI>;%L5/_IBA2#J4EE@9'=)4,3EHJ#P*P7!8;UY*+GS <&H0Q#J$+5_
M"62AN;?X^$:H.K']5\/IO>_;50Z][M8Y.GS#5/[>54O]RQ=QV)86HEM5/<T_
MK\(K,JG(+SDR-S2'GYE0S$XKJ/!..U?)2NXJY\1?*N7&=A?[1U\NY FOY =$
M]N;^"0A!'8)1AYB]BR'WZ%]0>FP=U,EN_MIZ8L?4)47IL3YMZ2?]!G(W;EKH
M=EZVMZOO=*85M;ARTLYZA@FKV(F"LL L5E%LH4=!;BFMH+',+?=2*2.]N\0G
MN:>(E7"EP#?N:CXGIC>7$W,M9SX@%'4(V2 &\;]/A\@LA\K#:Z!)9L.'"\?^
M?GWC]-]#CS4VWQW0D^VY9Z9][H:M3?D51TK611??N#:WX.!F9BS[+#_-O38Z
MEUR=74BH/EM$K+A<Y%IPN9">?:7 (_UJ/B.E-]<[\5JV3^+U>8&PY2(0ACHD
M[UH(10>60NV^O[ZU[UOUIO?@JF>/Y%?T#ZMNN3:D>Z1CP%2CMM_:,K\/3TKJ
M)7J']]#XW(O>D9[G Q(I[<)TI]:L;%Q;?0X6S=%.-;VYI)+>7$K^M1QJ]O5L
MMXP;F6[I\P/AJ$,$ZI"Q<P&4[5D$33N6O.O9MN3Y@UT+[PX?67UU3''7^5&M
MXV>?&VF4/+4T2_\'ZRB\Y^S.OTWE>-_T"J9>YT4Y]0KC[7NSDFUZZU.L>F^E
MV+7WI>'.WDQWK+R93BCI2W<IZ$MSR>M+G0^(7"8"4>O%('>[!-1LD_QR?KWD
MZ-U5XG>&MRR\/'%X0]OKT_OJQM5/%;W0TTD;,;$4/K=RX@_B:<PG9!_: ,/?
M^1$OR/Z1,-SJ47:4Q3]UT1:/^H28&_VQ5A?OQ=NVW$VT/WLW$5]U-]&A8GY
MB#K$KA6%8K27:EHC-G!]L>B=X66B/9-;EK9,']Q</25_N."-BF+JI(Z>\+6Q
MI>"5I0-S'$>AC1,]"&,>+-PHEVOS/()O^2PUR'RP)-CT:4N(Z>#]8/,[ V$6
M5QY%6%[X)]*ZY6&43?/\0,Q2!%+1O;-ZC<CC"PN1F[<6(MV3R\2;/V[YJ_+C
MP>WY'^2/I+Q748IZKZ,G>&]BP7IOA:6_QQ*(,R17_%L/-]L)#L-R/(1I_C*>
M;?HBQ\]XM(IK.'H>Y3'7Y-%SKNFMYP%F5YX)S'OF!Q*6()"W%'ER3A*YWKT
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M\OH0).$9@D3 4A$!;)1@P<XE=-B_B@!'-]C#R2T84-EA CK2!F"\3P<P!S3
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M2E'_V.CS[SM8,>^2'>FW/2C$/HX'[F:HC_7-9+;%S1(_T[X.KLG-$:YYU_,
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MB5/]W(E7^3SDH#[UQD%[]!U>Y\D[1]U[L\[S\2L90>Z7(\BE)K%_SR!4W)9
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MW@[,V^Q_F5[!_3!YB/]J,HZ?-9O"CV/>X0>M9AWN6;]WO&'ST>FRW4>G[GD
MQPVB@-TI!K:')( H(_7O',1;=0,P]7>"C\4A\,2> )J+,I"]M( 08  .D6:
M3?YO/EAJ_^]LT*+-X8?Y5:??,\'WYJ^<7V.FG)]9SQ#NV+XC]MK/DBYA9TGG
M<;.D]GD )]0!ASK@]DL Y9 4>,LM!X[2>N#J[  _TX/@:WL"O)R5@4[7!@K'
M" BA%N 0;PW8+/N?ML4.WZWKG+Y9MA._8*Z3/EH\=WEC.>$R9/O6Y8[]-.4*
M=MKU G[:M=5AVK7)<=JU81[ >;TH..P0 Z<]$N"V?P&PCRV#@#/K(%!K.P0:
M'X  :SGP<U "'XHVN'L;?7<58+Z0A.@*IN+?X_.=9^PK25.VS90W-CVNKZT'
MJ,.V$]0[V#?TR_@W;AV.D^[-3F_<ZYW?N%43WKA5$M[2YP((J(,CZD#:+0Z,
M/0N =V0IA"BLA7#-K1!NN ]",;(0B%/\[D_2^L3T,)IE<#%3]##["7*"TQ@A
MBS3J6.+Z''^6/HB]X#Z [?>XAYOPZ'%XS6AS>N750'CE54U\[55.>LTH<9GP
M+'*9\)@+(*+]M!/:3U/0OIZ%YHM F240>6HUQ*AOAE@#:8@V/_(UTN[T^Q!G
MC;<!-,-7;!9FU#L0^\PMVODQ)9723\IWN^U<Y7G#L=6[U_&ZSV7'E\Q6PABK
MCO2254$>8Q53QI@%KN,^N:ZOO'*HK^<$2.M$P!EUH&\31[.W!(0=7@RQ)U="
MHNI&2-;;^2W)]-#[>!OY-]$.JB_#*'I# F_SAQP>]K9W./&Z>SSM,C73LXM<
MXG.>=-:WC7B)<XXXZ%=#'O4K=1WU*Z"^X.307OIFTE^RTNGCS#2W<9^Y )>U
M(D#8)O;O+(:W0P*B#BZ$1/D5D*:R_F>&SK8/&4;[WJ1A9%\F8\\,QI*T^\/=
MS6\(V+C+?D&D"SY"MU;/%.\FMWS?.FH5M]JUG5?A>B^@B/:<ET,?]L]P'^&F
M>HQRDCU>L!,]7K(2/<?F!,C_.?S._P)T+6(.2$&JW#+(5EKS)5?C[^D\_=WC
MN6:'AK)MY?N3G;6NQ]#,N\-\<.T"GDN37[A[+2O>I\(KBU/L4<;+=V\6Y+A?
M#\ST>"9(\1SB)S*&>?%>(]PXKU%.C-<+=HS72]^Y0+=\$2"A:\#<* ;!6\4@
M ?UL9!Y?\BM/8>7[0M7U$R4ZVT9*C?<\*K \<3/#0;,[D6+6'LW -81R7*H$
MP>XE_M',/'8:-Y-9R$_UK@]*\KX<'.\S&!3+?":(9CX/B&(-^T>R1OPBF"\X
M*.RY  J:KRB_9T'H]T08ZI*\5Q)RCBWZ5B2_?+I,<?58E<;&P6K]77=*+.2N
MY.(T.M))9HT)[M@J(<NE*(SOGA,8R4KC)?DG^.4)HCG5P9'LBR'AG*?!89S!
MP%#.$#^4\YP7PAGAAK!'.2'L%^RY %?4@8KN6W[HYR,2W<?3I"6@X(C4QS+9
M)9,UIU:,-*BN?EBOO?-ZI=GQBT7VZLTY!-/J-)I]<8(W*3O:WSTE/)09&Q+O
M'QF8%1C"KP@1!'2$\OE/0OC\P2!^P#,!G_<\@.\_[,_W'_7C<U]PY@*HOV>D
MZ!KPUHA"-.J2N4OL5_%!R7=5,E+C#<<7#[:=7G&G26O[Y5K38VWEMFIUA4[&
MI=FN=CEI#&)*(L<M-C:(&1X5PPT,3Q=P0TM#V*&MH:RP?T)\0P:#.$'/!)S
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MJ?55"[1F=$'KM3YHCQB SA/#N0'S+:)@M%<,C&3$P>*()-B>D/KW?)"#WGK
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M"FBB%JBB 2BA*4,!;1BRZ,"01CY#$OT8XAC!$,%DIB 6,-DXC<G$#B8#!YB
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MRH?#:M0.A#9H[@MNT]D=W*VW,ZC78'O@D.'6P,W&FP,.FFP,N&2R/O"IZ=K
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M:CYNYP)+OYT;K,;L/&0]>N<+UJ-WW+4>M4W8CMPB[$9N%O8C-_V;:XW, >?
M'NIOH"5;RMCG;&(-Z$/+=P.YM&@)AX'HHQI$'K5#Q+$!"#OF@Y!CXZ6@8R&R
M2<=B%?['TE3CC^7K^AVKT!]SK,E@Y+%Y&I^C:XV&'SM@/.S8\\;#CGYC//3P
M7Z9##@KSP0>$Q>#]PO)9M/W(@ZS_%NJOI/Y<QMY,2U9%'UIP"$@Y#D2>H@<\
MK\2$"R88?\$!XYYSA]]S(^![T1^C+X9)(R_&RWPN9<F&7RI1#+W4H!Q\:8[*
M\](J'?=+>W4'7;ZB.^C25SH#+_RI/^"\,.A_5ACV/R,TSW)T/K"#^5]#_05;
M@-9=0#5M<N$Q()76,.H<,(E^=,PU&8:\I NO&R;PO-$''B\/A/O+/G"_.0&#
M;H5BP*U$]'\E!VZO5$@NK[1*SJ\ND3F^ND/6[[4+LGZO?B[K>^N1W.%EH7"X
M(91]7A*J9]E-_?747TS]F<Q]+6,O.@FDG6?\EQC_56 T[?+@FT#_UQ3H^XX^
M[-XWAMT'MK#]P VV'PZ%S4=^L/YH,JP_3H#5[5Q8?E(-BT]FP_S.6IA]>@2F
MG[T*TT]^ANG'0C+YB'P@9,^RD?I+J=^QIZ<'5<S8TQAWY#4@X$5@)+4]7P-<
MW@;LZ<DM;BMA_HT&IG?-87*O#XSON4'S[1!HOAL#P_M!4-^/@_[WN=#[H1:Z
M#^9"Y\?-4/YX%HH'GT/VX$_(OA>0?_=O5E!_SIZ>'M24L]2_ D10>P*UO5\'
M!KT#.%+;YA/ ]'/ Z <)A@_UH7YD!+T_+*#SAST4CUT@/?8 'H\D 80/PL<Y
MP)^\^3]FL1_SXGI\F=PC@C__-W.I/XWZ):Q[.F./I/9X:@_[#W/_$=#G#F/_
M M!\#>@_ '3_!)1"#IK\WOZ#*;$B?4E_,I2,Z]V#P8>AX#C$@M[> P,47Y''
M_^K#S.#<*V/M,ZY3_U7J,^ZAU';]%+#]$C"Y"QC<I^Z/X.__-\IG>B':L5@3
MQ]X^R&@22C((%P2"^1#,ASA#WB(?_XVP]H"P&4@&0%BX0Q@/@5"/DH1\DB00
M0S))&6DD,\E\LIRLYS"VDMWD$#E)GB,ODO^0K\A/Y$_R__G'COI]W"#L73F.
M_A!F')/&F^.8( G=2$DHTSB>8DG(:DDKZ2)+R&JR21+2#@AI/SE*SI)KY'6>
M^7/R@#S&8X[XL8S(B4)(CY7_1O2EOB,];C]'" =GYD4[#N;"Q$\2FE!)&"9)
M0ITG"?T*,IUTD 6$N=!?1[:2W>00.44NL3PWR2?X0_][_*;_"+^HA?2+@9!^
M-GR"[+\13M1WH=]WH<]UXM&![^VU]1D%81DH";-829BR'L8EI(XP%\;,A?%B
MLHIL)#ND/XWW2X^-CTF/C"](#TU>DGXQ^4AZ8/*==-_DH?2MJ9#=,Q.RNV9"
M_LW_0+A1=X UL81PT\+W;IP;SJQ'OPFL4X0D[%(D85,@_653*3VVGBX]M)XE
M_68]7_K5>IGTL_5:Z2?K+=(#F]W2#S:'9?=MSLJ^L[DNNVO[GNQ+VWO2IW8/
M99_8"?G']D+QD;U0?MC+!\\@!ME >)H1DQZ\M.^9"P\OB(%C.)Y@Z9%+O/2K
M<[;THU.I]+U3G>P[IQ;9/:=.V3=.BV1?.:V4?>&T4?:YTP[9ITX'9'><3\EN
M.U^5?>3\CNQ=E[OR-UP>*E]U%:I;KD+G95>A>T.+R[\17N:\I.F]A]'[>FL@
M?/C>AW49WA^/AGKCI\'^N.\9*7WCD2I]X5$@^]2C4G;;?9KL(_>9\O?=N^7O
MNB]5O.V^5O&F^U;%Z^Y[E:^Z'U/><K^HNNGQJNI%SZ]TKGG^IG?94^A?]!3J
M"Y["X+P6#V%P[AG$4,;N8P Q@KYSC!K"C^/QM<#OH_OB^Y'N^&K$:-SQ"<:'
M/O'2VS[9LM=]2N2O>-<H;GK/4-[PGJUZT7N!SO7ARW6O#5^O=V7X#KW+PP_J
M7QQ^1GUA^(OJ<]YWU*>\?S(\[BV,CI##WL+X$#G(U\\B?!C[*.K[R2 FJ"#\
MU7CD;X3OQEOB,S\GO#]V*-X8YX^;XZ)D+XY+E5\;FZ^\/+9<YZ)?O>YYOQ;]
ML[Z=ZM.^BPQ.^:XR/#%FD^;8F#U&1\8<-SXTYHK)P3'OF>SU_=YTEZ\PV^$K
MS+?SN(UL[<'T*6(4O;]?SQ:W7P+I_X-DN$,O_EF (=Z>:(.;@1ZX'NPG70X.
MD9T/2E"<"<Q2G9A4K'=L8I7Z\,1IA@<#VHWV!\PUWNN_Q'2W_UJS71.VF^^8
M<,ABVX3SEELFO&:YT?^NU7K_QU9K_875ZAXL5_D+BV<1OHQ]// P"/B"WO/#
M2'JN" 5>#]7#C5!S7(GHC_.1(Z53D8&RHQ'1RD/AJ;K[PO+T=X>6&>X,J37:
M'C+#9,OD#K--P?,M-@2OL%H7M,EZ3=!>FU5!IVU7!MVP6Q;TI=V2X(=VBX*%
M[<)@84.L%_1@]10Q3O:DO7V/^A_% *_'T^_$2[@>J\3E&!.<B7/"L83ATL%X
M?]G>^'#ESKA$W:TQ60:;HHN,-D15F*R-;#!?'=EJN3*BRWI9^!*;)>'K[!:%
M[>RS(.R80W?8\PYSPSYUZ S_S6%.N.@S.US8SXX0MCS:/(N8P,=I,'/ Q^W;
MB=2GY[F22L^5+,?I) V.I#A@?^I@:5?J6-G6E!#EQN0XO75):0:K$O.-5R24
MFBZ-K[%8%-=DM2"VP[8[9H%]5\PJASG1V_IV1!_N-S/ZLF-;]$>.+3$_]VN.
M$7U)'V)/[(CM4P0?]S_P\7:;\;]"[6OT/.?YR#W)XY%T-?9EVF)'MCLV9X^1
MK<\*5*[*C-9;GIYLL#@MVWA!:K%9=TJE95=R@_7LI#:[68ES^[0E+N_;DK#)
ML2GA@-.T^ O.C0G_<6Y(^-&I/E'T(WU)'V)/[)XB. ^_Y1QXG_[_)>I>I/<\
ME4]]>I]].;K8GF>%3?D#L+9@I&QE_D3EDKP(W84Y"0;SLC.,.[,*S#HRRRS;
M,VIM6M*;[6>DS7&8EKJD7T/J!J?:E+TNU2EG7:M2WG"M3/W!N2)5.)%^E:G"
M@?0A]D_1;CW]*I;SD/[_>>J?H_<\5@SL)SL*E=A49(ZU4URQ8HJW;''Q!,7\
MHE#=KL(X@XZ"-./V_%RSEKP2RZ;<:IO&G.GV]=D=#C59"QTK,]<ZEV?N=BW+
M..U:DOF*VY3,^RY3,H532:;H1_H2!]+G*0]9A\_HO5]E_B\7, <E]+UE]/YD
M4XF$-:4F6#[5"8O+ATK=4\<J.LN"=6:51JM;2Y*-9A1GFS46%5G6%U78U!0V
MVE<6M#M,S9_O6)*WVKDX=Z=K8>Y)M_S<F^1;U_Q<X4P<"W)%7^) ^CSEQW#.
M!=;A!G-P@;[O6#EK0.^UE:SAZV65QEA4W1?SJKVD.=6^\IE5@3K-E9'JZ>6)
MFOJIF:8U9046E:53K:>6U-F53&EU*)HRS[&@>*5S;M%VU^RBXVY912^Y91;=
M=<TL^LLYJT@X9A6*OMF%PN%9OH_B7$@'KC,'9Z?2\U4S!UP";J@%EG,)MJ#6
M$'/K[3&[P5UJ;Q@EGU$_4=58%ZY76QMO6%639E)>G6=>6E5J55Q98UM0,:-/
M;GEGOZRIRYTRRK:ZI)8==4TI>\$UN>QK'O]T3BD5CJFEHF]:J7!(*_F'>W$]
M/<DKS,')*LX#^M]MTY@#LJ !Z)RFQJPF:[3.&("F&3ZRAJ8)RIKI(;H5TV(,
MRAI3C(H;<LP*ZHLM<^LJ;;)JI]NGU\[NFUJSQ#&I>K-S0O5AE[CJY\E7+G%5
MCYWBJT2_^$K1-Z%2."14B#Y/^2*IIR?Y''-PE/'O;N(\:&$-Z(,[25NK#F:T
M6:"QW05U,X=)5>UC%5/;@G2FM$7I%[8F&N:U9)ID-Q>:9\PHMTIM:K!-FCZS
M3_ST17UCIFUPC)IVT"ERVE6GB,8OG"(:_G",;!!](^N%0U2=Z/,LMUF'%WD-
MG&$-#D[GM= &K)U)[TW:9G'=/UN&VCDFJ.KJA_(N+ZFD:[2LJ'.B,J\S7#=[
M3IPZ8W::)K4CSR2IH]0\?E:=5<S,-MO(]@7V8>WK'$+:]_>=W':Y7W#;9WV#
M6Q\Y3&X1#I.;19^0&<+^6=ZA%;G"N7><_GLO]3?1@R_O!+I(TUR@DDORTH6&
M*%YDB\)% Y&[V$?*6C1>GKYHLC)E8;1NXL)D==R";$WT_&+CB/G59J'=S9:3
MY\VS#IRWQG;BO+UV ?,NVOG/NV/GW_70SG^.L/.?+>P"9@O;@(Y_T/9%SW/^
M'6+^=\QA#N8Q!]2=25M2MYC>DWXT9X4N,E>9(WV5,U)7#T;2ZC%2_.I)\MA5
MX<JH5?$ZX:O2]4)6%A@$KZS03%HQW<1_19?9^.6K+,8NWVWIN_P"N6TY9NGO
M5F,6"ZLQB\C"?Z/M29[D'-C+^#=V,P>+F(.ES &URU<!N>N I(U [&8-8C;;
M(6K+ $1L\4;8EG%2R)9@6?"6:/FD+<G*@"TY.N,WE^J-W=R@'K-YMN&HS<LU
M(S;O-/+9?,[8>_-'1MX;?C,>OEZ8#E]+U@BS9[F@[4>R[MNHOWH)KX450/L:
MH&8]<[")_G,K_3]M6O >74S::XJ)>_O"?Y\[)NP;B?'[_3%V?ZCDNS].-GI_
MNGSD_B*%S_X:Y;#][:HA^Y?H>.W?INNY_[2>Q_[W=#WV_J+OOENH!^T4!H-V
M",-G.<$YL)OZZZF_9"4PF]J-FSD'=@!9NX&X_<#D0\!8>M(1)]3P/F&!X2<=
M,>RD!X:>&HDAI_PQ^'08O$XGP.-TMC3H]%1IX)DF6?\S"V2N9S;)7<X<ESN?
M>4/N?.IGA=,)H70\+E2.QX2.X]%_.,#Z;];NQ6+>NS:P!KT]H)P#0,(1(/0X
M/>@I>G!Z8O?GY'"Y8@"G*^9PNMH7CE<'H=\U;_2]-AX.SX>BS_5$V%_/@]T+
M-;!]839L7E@#ZQ</PNK%EV%U_8%D=4U(EE>%S/*RD#_+MB4]>Z&Z6?-FQEZY
MCW. VHDGJ4][.NX"]2\!@^C)G5X$;&XJ8/::/DS>,('Q&[8P?M,51F\.@>8M
M/S(9AER$&+Y= (-W&LD"J-_=#OUWGX/>>U]"_YV_H'Y+0/W&$Z2GK*7^0M:]
M;6=/#RB?<2>=!4(N,O^TZL/HQP>\!/2]!5B]3A].7V[P@1*Z'ZNANFT"Y6U;
M*#YQ@>R.%Z1/Q_ !R 71YUP,?<X+[@M.]B\YP;_<RX<S _CJ!^!K\7^QA/HS
M=_7T@ J8\Z3GJ'\5\'L!&/(RX/HJ8$^K;OX>H/D(T+L#R+Z@[_]&10R)"7"7
MGO\>/?]W]/S?CP0><%'R(\?Q$V]^/_&B_YF%_N4P\.MKP&\_$?$O9E._GO^Y
M\#20?%F[!PCPO0EX,69GQFSS(6/_A+%_!BB^HO9=\@OY67M4$C7/;43,@=_[
M (_Z<W'HW;L'(Z%W+T@[64N.]NZ[^(X\_)M&ZA<S]RF,/8QQ^U+;\UW D3%;
M?LK8OP1TM;K\8V J\?O_ZH5H]X48$./>/HAV;\H0,J%W+\C3<?"B%X=Z/P/S
M]M\(,_I;,U=Z?6)(WZ_RY&E]B#^)(NED"JDE+:2++":KR :RG>PEA\DI0N\/
M>G_<)M^2W___/1!+:EO2XYH[,@QG"'V."4/(6!)&DDD^J23320>93Y:1M60S
MV4D.D./D//["B_@3[^$/?(-'^!4/>T?R+ ^?0=A2W]:!*:3G-^-1P_?Z'A Z
MHR'D0?R-.))-2DD]:>W-Q2*RLC<7VZB[!X^9BT<X@]]PC5/F#?R$+_$C)XZV
M&_,#^?X9?G@&X:#M>]#OVUM!6%GWC,-D0$\_R(#UT(^$T$WCF I9IRK"7*AF
MX2]5-QZKEN*1:@U^5VW"KZJ=^%EU #^J3N 'Y25\IWP%]Y2?\_+A2'0%OM 7
M^%S]!.F_$8[4=32#Z$?_;6?*L=@R+RZLSV".QX_C"6&-$O!8DX.'FE+\JJG#
MSYH6_*B9@Q\T"W%?LP+?:=;AGF8K[FKVXFO-,7QI= %?&-W$'://\)'Q3WC/
M1$COF KI+3,AO6DF9&_\%\*5^J[T^RZ&$,[TX,[FG-;,1=^!'(\/'MI,Q,_6
M4?C>*@W?6A7B&ZM*?&DU#9];M>-3J[GXQ&H);ENMQD=6F_"!U2Z\9WT$[UB?
MPULV-_":[1WIIMU/TDOV0G:=7+,7\JO_ S& ^@/5$ /H?=UY=->^M\*?;D[X
MV=D+WSKZXLM^(?BT7P(^[I>-]QU+\(YC+=YTG"&]YM@AO>HT7[KEM$QZV6F=
M])+3-NE%Y_VRZ\XG9=><K\FNN'P@>\[UOOR<ZU^*TZY">9*<<!6J7I1/$1Z,
MWU,)X25!#.5QJ!I_#C;& W=K?#70%;<'#,>[ P+P^J HW')/Q4ON!=(+[N72
M-8]ZV16/%MDECSGRYSP6RB]XK)2?\]BH...Q2W':XXCRI,=%Y0G/UY5'/.^J
M#GK]H;//2^CN(;NU>/X;,5BWI[WKPUL=;[-W1\CPU7!=?#[8".]YV>'5H1YX
M:;@?KGF'X))/@G3>)TMVUJ=8=LJG4G["NU%QS+M-><2[2W78>['JH/<:G?W>
M6W7W>>_7V^-]1F^7]PW]'3Y?Z&_Q^5V]R4<8;.A!O?Z_$,-E/?I\W'PQ#OB0
MM[:WQBKPQD@]O#S* E?'N.'"V!$X/6Z2='Q<M'1D;*K\X-@\Q?ZQI<H]?C6J
M77Y-NCO]9NEM]^W6W^J[7+W9=X/!1M_=AAM\CVO6^3ZO6>/[B6:E[\]&R_V$
MT=(>-$O\A.&S:/6UK>6[_L!'0<!K?.R]Q.-U?R4N33#!F0!'')LT#(<")TC[
M L-DNP(3Y-LG92JW3"K4V32Q7'?#Q'K]=0$MZC4!<PQ7^2_2K/!?8[3,?[O)
M$O_#IHO]+YDN]'_/M-O_@>G< &':%2!,B'%G#T9/$:/X:!O;\\A]@[[O17KP
M2Q'TOJ$RG S6X'!('^P+\\3.<%]I:WBP;&-8C&)=6*IJ36BN[LJ0$OWE(54&
M2R=/TRR:/--H07"W27?P"M.Y09O-.X/V6\P..F?9$?2ZY<S@^Y9MP<*B-5B8
M$U-B\BS"%[C/1]R'U+\90]\;3Z]!CO/UP0@U=D?98%O,0&R,'2FMC9TH6Q43
MJ5@>DZA:$IVIMS"J4#T_<JKAW,@ZH\Z(%I/9$9UF,\.76+2%K[=L"=MC-2/L
MM'53V"WK:>'WK!O#_[)J"!<6Q)R8$=.G:/^JX6OFX.UHYI^/_//TO\=3@ -\
MO2M.!UOB+; ^T16KD[REY4D39(N30A4+$N-4\Q+2]#KC\]0=\26:F7'5QFVQ
MTTV;8V>9-\4LM&R,7F-='[W3IC;ZA&U-]$NV5=%?VU;&/+:NC!%6Q(*85T4+
MLZ?\PCGX>1B]/V._G$KOG\%U=B;UTX MR7*L2S'%RC0G+$T?*BU,'RN;EQZL
MZ$R+5LU*3=9K3\DV:$DITC0E5QA/2VHPJT]LLZA-[+:J3EAI4Y&PS79J_%&[
MLOCK=B4)7Y(_;$H2A!6Q)!:E"<+\*3^R#K?IO5]F_!>H?XR^:U\NO3]]\#KZ
MP!69QEB<W1?S<[S0E3-&UI$=J&C/CE2U9"7J-65FJ!LS"C3UZ67&->FU9I5I
MS1;EJ5U6I:G+;::D;+$K2CEL7Y!RU3X_Y3/RR#8_15@3JX(484',G_(]KX'W
M8UD'QGV6^H<+@)V%]/YYU.?[1;D:=.?;H[/ ';,*1DJM!0'R&?EAJL:\.-VZ
MO#1U36ZNIC*GQ'AJ=K59:7:317'6'*O"S"4V>9F;['(R#MIG9URVS\JX0WZW
MS<H0UL0J.T-8$HNGW OE_8"UO\K\GZ3^?BYYMI+57)(NXONYA0:876R#]BD#
MT%+B(TV?,EY>/R5$65,<HUM9E*(_M2C;L+2PR+BXH-*T('^:15[^+*OLO$4V
MF;D;[-)S]]NGYEZT3\F]37ZS3<T5-JDYPBHM1U@2BZ=\Q>OPU92>7IBV#[5G
M*CT?659*?8YE5JD>6J=:8$:Y*QK+ATEUY6-E5>5!BO*I43JE98EZQ669!@6E
M!49Y)5--LJ?4FV=,:;=,*UY@G5RTSC:Q:*]=0M$%^_BB#\FOMO&%PCJA4%@E
M% C+Q )A\91/>0W>R.CIA6G[4#NK@#657.]74)]>M+E2B<9J4]35.**Z9K!4
M43-&5E8S23&E.EQ56!VOFU>5ILZNS#/,J"PU3JNH-4LN;[5(*.^VBINZQB9F
MZF[;J*GG["*GOF<;6?:S352IL"96T27"DE@\Y2,N?9_/Z>F%[:?^UCKZ7OKP
MN61&#=?<?%_58(R*QCXHF^:.*=-&2H73)LCSIH4HLQMC=#(:DO72&K(-DNN+
M-0EU52:Q=3/,HFN[+"-J5UF%U>RT#JDY8S.YYFV;D.J?K$.JA%5HE; ,K106
M897"_"EO\7J\I.T',N[=]9R+TS@/&H$.TL#7%3. DF9#%+78(+_5#;EMPZ2L
MMK&R]+8@>6IKI#*I-4$GOB5#+[:YP""JN4(3/F.:2>B,.6;!3<LM INV6TYJ
M.F4YL>D-RXG3?[2<.$U83&P4YI,:2+TP>\JM+-:!M3_(N+=3;Q4MR;QFH)7'
MZE;Z#GKRG Y=9,XQ0WJG(U([O9#<.4I*Z R0Q76&RJ,[8Y61<U)UPN;DZH7,
M+E,'S6XPG-@QR\B_8ZG)^(ZMIF,[3ICY=;QJYC?S!U._=F$ZMHVTDA9A\I3G
MF8,3K,%>;1]J)K"4S";3J#UU#KTW/7'R @GQ"XT0N\@.T8OZ(VKQ<$0L'BN%
M+0Z4A2R.E <M3E1,6I2E#%A4K#-^48W>V(5MZC$+%QF,6KC9<.3"8YH1"V]J
M1BSX7N/3+30^<X613Y<P&M'Y#]I>V&'F? =UUW0"\[N8 U)-[<(%0"H]<?0*
M^K]5>@A>;8; U?TP:8T[)JX9 ?^U$S!A[61IW-H8F=_:5-F8M?GRD6LKE#YK
MFE7#U\S7&;IF@^[@-8=UO=;<T/5:_9VNUTJA[[F<+!-JSZ7_<))S;B\MT$;J
M+J/FG(5 XR*@E%8UB]KQM$8A&X )FX$Q6PTQ:IL51FYSPHCMGO#9/A+>V_TQ
M?$<8ANZ(EX;LR)2\=I1('CL:98-V=,D'[%@K[[_C@,)MQW6YV_9["M>M0NFZ
M6:A<-I&-0N<IVC[4-NJOHO:"94 +=2OIQ?.T/2#ZX?"M0  ]^:@]P.#]<@PZ
MJ,' @]88<,@9_0]YPNWP2+@>]H?+X3 X'TF$TY$\.!ZI0M\C,^%P=+ED?W2/
M9'?TLF1WY"O)[M!?,ML#0F:[7\AM]_W#;NJO8]Q+EO-:H"VMIVXQ==-V %'4
MG70 &$U/.O@8X'82<#BCA/4Y#:S.6<+J?#]8GA\$BPL^,+\P 6;/A<'TN612
M!).+C3"^.!_&E[9"<^DLN0.C"W_ Z+R \5DA/8MV+])RQM[)N*=M80WHPS/W
M [%'@,#CS#]U!Y\!7,\#?2X"%K2K1M>54-\PA-X-<^C>Z .=&_W),*A>'@?E
MRV%0W$R%_&8)9#=;(-UD<#?W ;=HZ&_2.-^D27Y90+KQ#ZM6\EI<S_N1M@>T
M%\AFS+'4#:3N:.IZ4=>9NG;7 ;,;@.$M^G!Z<^DM/3YH-%QX6 #O. #OTO._
MQ\7Q!]I%J?8OIO@0_%C[1<0=?# SP-L,Z./W>/R-B'^Q@/.M5=L#8NPYS'?<
M6>I3=]05P(.ZCB\!UM0UIJZ:5EWQ/KW^Q^03";C#<7S*<7QNQ@6Q'?"5"_#-
M8.">'_ =QW&?#X'[O/"_GPO\P +_P*!^^(SO'_(H_J9]1T\/*.\$KX$+0- U
M8"33-N@FT/<UYIZZ&NKJ:'4_)5]J>S"]O9!OR7TESVD /##FPM0*^*4?\+L[
M\ <7RG_RH?P7'\BB]IF]()?('?++W]0>[.D!)?(_!5-[%&,>] 9K_RYS_Q%@
M0%WY4]UO>_L@/_7V87[M[8D\(G_J\'R&O?M!M)^+&8">[P;1[@71CH,/ K&H
M=QS:[P1Y_6^$D4N/WU<[TNOS->@S,8R,(^$DA13\C_[#4K*&;"([R#YRE)PE
MSY,W>_>"_/RDS_%7;[_CK_^!,-'V/NAQ#?O0W_?E3YR)MA<SADPF"22'E#W3
M?^@D"\D*LHYL(;MXOH/X$R?Q&)?P!V[A(8OW.Q/W&W_R*W_CE_\'PD+;^Z#?
M-[9A+@CZ].9B!)E(HM'3#RHB54]R\1=F\:SS6((EU%E%G0W4V<;S[6741_$C
MSN$!7L3W^!#W6<#O^)OW^"?O_C\0UM2UM. XS%@3HN9X=%@3V9#>>FC[04DD
ME[IEU*NC5@MU9E-G/G6646<-E3939R>GS4%6X!2G[E5\CK>8B6]PAR/4=J<^
M^G\@[*AK2[]OJ>%TTL+Q&+$F!NX0>J,@5('X0QZ#WV3I^%%6B/NR2MR5->(K
M61N^E'?B<_E"?"I?@3OR];BMV(:/%/OP@>(XWE5>PCO*U_"FZBN\IOL[7M$7
MN*D6>-F@%_4_B+[4=U!S'#H0-CQ:FW \S(VI"QX9#\%/FG&X;QB*;PP2\85!
M#CXU*,''AC7XP+ )[QG.PCN&\_"6X1*\8;@&KVDVXU7-'MS2',/+FHNX8?0:
MKIM\@RNF#W'13.""F9#./\.Y7H23 82CHN?K=AR5'!/?VYO@5VM[?&LQ %^8
MC<!MTXEXSRP*;YJGXC6+?-RRG(J7+>OPDE4S7K":C>>MY^.:]7)<L5F/2S8[
M\)S-(5RP/8=SMB_CM-T7TG'[7Z6C?83L,#E$#OX7PDT%X8HG7_?S!V^W#USE
M^,%1C:_M3?&Q31^\9>>)6WW\\&+?$#S?+P&7';-PT:D8YYTJ<=:Y$6><6Z53
MSIW2">=%TG&75=)1E\W2$9>]LD,N)V4'7*_+]KG>ENUV^TF^PTW(MY&M;D*Q
MA<=G$0-[;B>_>O)6.X2W;]YJWW-7X!TG?;SB;(GK;OUQ:< (G!LT":?=HW#"
M(P5'/7*EPQXETD'/:FF_YW397L]VV1[/>;)=GDOE.SS7R;=[[E!L]3RBV.QY
M2;')\UW%>J_OE6N\A&K58*%:259X">6S" \\^;JCNSY\S/#V^CJY,0)X8; *
MESU-<':((XX/&XK#WN.PWR<4>WSBI5T^&=)VGP+95I^ILLT^M?)-/C,4&WPZ
M%.M\%BC7>J]2K?;>HEKI?4!GN<\YW64^K^DN]OE6=^&(OW3GCQ"ZW3WHS//Y
M!\&X?_3FHX"/F3?\J1W =39]\+DQ$DZ.T.#P:'OL]?7 3K\QV#8V")O&1DL;
MQJ;(UH[-D:\>6ZQ8Z5>I7.[7H%KJUZ:SQ*]+9Y'O4MT%OAOTNGWWZ,_U/:7N
M\KVAGNWWM7J6WQ_JF7Y"O[T'/:+[%.U'+K\=0\])[WLCF'XKA%Z#QR,<RX%Q
M^M@YP0I; _ICXT0?K)T4(*V:%"XMGY0@6S(Q0[YH8KYRP<1257= C<[<@";=
MSH ._=G^"]6S_-<8M/OO,&SU/Z9I\;^NF>'_N69ZP$/#:0'"H#% J'O1;_3O
MX5?F_4O&_?ID>D[ZOC.1U.=Q#\>R/5"%34%F6#O9&2M#AF%IZ#AI4>ADV?S0
M&/F\D!1%9TBV<G9(L<ZLR16Z[9,;]%N#V]3-P?,,IP>OT#0&;36J#SIL7!=T
MQ;@FZ!/CZN#?C*J"A888$@.BK@KJX2?6_Y-)7-Z$ \_1]QV/XQJ7/GPKQ[(A
M5,*J,!,LB^B'15%>F!\U1NJ*"I3-CHJ4SXI*5+1%9JA:(O-U9D24Z4V+J%4W
MA#<;U(5W:FK"EQI5A6TRJ0@[8#HU[*)I6=B'IJ7AOYB4A LCHBD)$X;$X"D_
MC.72ASEX(9K>G[[O<#+7^?3AZSF655%<9T9K,#_6'G/CW3$[?B1FQ@=(K?%A
M\AGQ<8KI<:FJQKA<W;K8*7HUL57JJICIAN4Q'49ET8N-2Z+7FQ9'[S,KC#YO
M5A#]KEE^]$^F^='"F!@134&4,"0&6K[E/'R+.;@:3^]/_[T_'=A,_[<JB?K\
M67>" >8DV6!6<G^TI7BC.66\-#UELKPA.5I1FYRLJD[*TJE(*M2;FEBN+DUL
M,"Q.:#<J3%A@DA^_UC0W?H]9=OQ9\ZSX-\TSXW\TRXP7)EGQPHAHLN*$X5.^
M8AU>90XN,OYC7'KMIO=;S^-2+@>[^;/9J?IH3[-$<[H+IF<,14.&GU2;$22K
MRHA45*0G*,O2,W1*TO/UBM/*U 6I=89YJ:U&.2G=)IDIJTW3DW>9IR6?-D])
M><T\)?D'LY1D89*:+(R))C5)&#[E,];A9>;]'#4/TW]OSV4.>%S(L<QF3EHS
M=="498;&'$?4Y7JA.G>T5)$[45:6$R8OR8E3%N6DZA1DY^KE99>HL[-J##,S
MFXW2,N>:I&2L-$W*V&&6D''2/#[C%7+?+#Y#F"2D"V.B24@3FL0T8:CE8];A
M!=;_-#4/Y+,.!?1;/,[-HS[',BU7CKI\$U07.*"BT!UE12.EDJ()LJ+"$'E!
M88PBMR!9E5V0K9N17Z2?EE]ID)+7I$G,FV,<G[O<-#9WFUET[G&SJ-R;Y#O3
MJ!QA0HRCLX6F%T,M[W'>767]CU-SSQ3ZG6)Z_R+Z'3*-XZGAL6**!F4E=IA2
M.@!%9=[(+QLKY98%R;)*(Q49I8G*U)(,G>22 KW$*>7JN"F-AC'%'4:1Q4N-
MPXNVF(85'34-*7J)W#,-*13&H87"*+1 :,(*A&%8?@_:O6G/:?=C46LG_>^J
M,OJ-4N: U)"I_%EQN0$**JV06^6"[*HAR*P:(Z57392E5(7)DZKB% F5J:K8
MRER=Z,I2O<B*.G58Q4S#D/)%1L'EFXP#RP^;3"I_P63BU+O&D\J$T:12H0DL
M%8:!)?^@[0F>90X.4'L+K<#22LZ#"F Z*>?K@AKZGCH=9-2;(JVA+U(:W9'4
M. ()C>.EN,;)LIC&*'E40Y(BO"%+&=I0K#.YOD8OL+Y5/;%N@8%_W0;-^+J#
MFG%USVO&UGVM&5?SI^&X:F$XKDH8C-=2V</SS,$)UF /]=?7:?<! 6VDCDSA
M<CQS&I \0T)\LP:Q+;:(:75#5.M01+3Y(KQMHA3:%B:;W!HO"VI-5TQL+5#Z
MMU:JQK?,T/5KF:<WIF6M_NB6_>J1+5?5(YN_5(]L>JP>.5VH1TX3^J,:_^$Y
MSK_#C'E'([!RFG8?$-!$*J<#^3.HWP9$SP+"9NMC\AQS!'?V0V"7.R9U^6!B
MUSCXSPV6)LR-DL9U)<O\NG+D8[K*%".[&I4^79VJX5VK=89U[M49TG5)9TCG
MYSI#9O^A.V26T!TRD[3_PRG6?"_CW=P*+&X!9I)ZOBZA=B:UXSJ!T&[ ?Z$,
M8Q=KX+O8&F.6.&/T$D^,6CH2(Y=.P(BE(?!>%HOAR]*EH<N*I,'+:F6>2V?)
MW9<NEP]:NDL^8.D%Q8"E=^3]%S]2]%\HE/T7D/G_<(0YWT'=-;,Y%VE/FTD%
M7^=U,0?4CJ UFKB,_GL5,&RM#KS6&<-SG2T\UKO ?;T7!FT8A8$;_#%@0QCZ
M;TR V\8<N&XLA_/&%LEIXV*IW\9M4M^-9R2'C1])#NM_ESFL%3*'-4+NL.H?
M]FH_$T?-9=2;/8_S@,?BA4!:;P\H: W@2U\\;#,](+VYTTX]]-UE H==MNBS
MVP7VNSUAMWLD;/?XPV9/.*SW),-J;R$LF5R+O7-AOG<CS/8=A^F^-V&Z^Q>8
M[1*2V8Y>MO>P;0ZOQ_F<B]1L7LIKD;K9J^E_UP.3J3MN.^"]B_K[Z,'I36V.
M *;'=&!TPAB:$U;$$88GW,D(&)STA_ID)/1/ID/O9!ET3[9"Y^1RJ$[NA?+D
M\SS>A<X) =WCY)B WM$>UM(.+V:N.ZA;2]T"ZB91-VPW,&$_X'.8^L>H3U]N
M?1HP.4<?_)P,JDMJR"Z90+IL UQV J[0:U_A8N0J%S]7^0"ZQAOO-5YLUSBA
MKC&1UWB":S3PUVB4KXI_L6PYKX6U/?MP2FB)TZD;Q5C]^4=\Z,<'TB+WO0!8
MTI<;7P7TK].'WZ#/ODG/?Y.>_Y8)\(HU<01>&\3%$!>F;W)1]A87(6_QQO,V
M+[BW.:G>9C+?N4)HX-_YDXB_F;>.U^)6H&P/KP/MY[!. @'4]:;N@,M GVN
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M-K%C-]A$C]UK$S7VHDW4LO=MHI::;:(6@T5FFV@K[C?V1"V@'>#:@CP<!PM
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MWDM-#4%J;(Q1?6.JZIIR5=M4JIJF6E4UM:BRJ==4WC3/5-HT9BINVF13V'3
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MVI_2H[I%E_'%@[QS/[6^CQ:YE]H9YZD,W',-S#86[F^-+FWMYF_* 4X/O:Q
M^&+@RJ >17!4ZXJ:*;^+:6I #V'' ]AQ'_ZX%SONUC;=I;VZDS:YI'/TSDNZ
M%4MNP>*;&4PW4L/S$SWW/V%</LQ,,7$1D)$1^<W$-# %_\V TQN^4+@2J4LV
M-I?"44N/:\73W;I-<^&8#\<2.%;"L8$R=^H&VN0,OC@UD1^YC]9Y&JM^1Z_]
M9&($';;BD!7?,I0_9LI_VSB0Z"P]PQ3S^%1C*K:#UQ7.V=0F$KX4N/+@*:>&
M]?2\-ITV]>BD:5 G;!;H>IME.F:[1D=LM^CPI+TZ..FX]D^^67LGWZ,]4Y[4
M[FFO:=?TC[7#SJSM]O^)+^#]RTRF(::3IUC^'O1D^6'JOX0MMT]UU"V3/75N
M:I!.3X_3";L,76]?J*,.53KLT*B#CAW:[SA'^QR'M<=QD:YS&M<NIXW:Z;1;
MVYV.:>N,&[7%^6YM<GY2&YW?T#J7S[3&U:S5_X6/X'^#9>;Y$)1P,-P!++78
M<Y;W3[M,TBDG9QUS]M4AEW#M=TW2'K<<[78KT4[W&FUW;]96CRYM\>C7)L_Y
MVNBY5.L]UVCMS.U:,_.05GG=H'&O.[7"^W$M]_ZUEOK\0TM\S5ILP.=[O OG
MJX0?3[#$_(#I_7R$= )[#O/^ 6S9/]-!UWEY:H=/D+;ZQFJ37[HVS"K0NED5
M6CN[7JMGMVJ5?X_&_0>UPG]48P'C6A:P64L"]VE1X"F-!E[4@J!'-3_H%<T+
M^KN&@\T:,A!D1:!9;X6Q',7C@T3I0@+\<7!C#^&9=F#+MH!IVA3@JO5!L[4F
M.%(K0Y*U(C1'8Z'%6A96K25A35H<WJG1\'XM#)^O!1%C&HE8K^&(ZS04>5QS
M(V]5?^1E]47^5'.B/E!/E%D]D=<@PJS76%*>)?2Y&YQ+H?Y&-@1[ML2BN;!E
M;82M5H4[:WFDCY9%A6IQ=+Q&8S*T,*9 \V/+-1);I^&X5@W%]6HP;E@#\4O4
M%[]&<^)WJ"?^J+KB;S9UQC]@ZDAXT=26\%=3:\)WIM9XLR809\&K\/V09?Y2
MIG22L&,O(="6-&+<)'0G?EF.7Y;$.6HTWE,+$@(U+S%:0TDI&DS*U4!RB?J3
MJ]67TJ3>E"[UI,Q55\JH.E-7JCUUFUI3#YM:4F\T-:7>9VI,?=[4D/JNJ3[U
M6V VU:=8D6PV_12^1W-I!Y;YHV!G-EH'F\:Q92F^681?YJ?8:3C537/39JL_
M/4)STA/5FY&E[HQ"=656J#.S0>V9[6K+ZE-+UGPU9ZU08]9F4WW6 5-=UCE3
M3=8]INJL9TU56>^8*K.^,55FFBW(,)NJP OP/5A 7V2)/PBV$A:OQJ9EV+(0
MO\P#<S.GJB_+13W9ONK*#E5G3IS:<]/5EINGEKPR->?5JBFO58UYO:K/GZ?:
M_&6JR=]HJLK?9ZK(/VLJS[_+5)K_M*DD_T^FDKRO@=E4DFM!:8[9]"R<]Q:C
MNPF%]X*-A6A.;!K%GF'\T@]Z\B:I,V^&VO.]U%H0I.;":#45IJBA*$?U1<6J
M*ZI6;7&3JHN[5%4\I(KB)2HO7F\J+=YC*BX^;2HJ_H&IH/@I4W[QV^ K4WZ1
MV91?:#85&"@PFWX$YYV$P"? +K"VA#8 (]C3CQW=?(Z\5TNQHQI+/%1?ZJ^Z
MT@C5E"6JNBQ35>6%JBRO4$5Y@\K*.U1:/J#BBD4JJEAC*JC8;<JK.&G*J;C#
ME%WQI"FKX@^FK/)_FK+*S*:L4K,IVT")V?0XO+<3_AXM9QR"56 4#);!CW_:
M^+R)UW45=JJI=%55I9\JJD)57A6GLNHTE5;GJ;BZ3$4UM2JL:5-!39_R:A8J
MIV:5LFMVFC)KCIO2:RZ:TFJ>,*76_-Z46OTE,)M2J\RFM$H+'JV4;D$6':R2
M-E59=N7,KS+R/^@=;&O@>0V?5]9,55FMLTKJO%54'Z3"^F@5-"0KOR%;>0W%
MRFFL4G9CL[(:>Y31.*+TQA5*;=RFY,9CIJ3&VTP)C5=,\8V_-<4W?&&*KS>;
M$NJLJ#6;'JIE7@![P3JP! R!;M (JNO1'$BFHB9;Y3<[*K?%0SDMLY75&J[,
MUGAEM*8KO2U?:6WE2FUK4');IY+:AY30/J;X]BV*;3^BZ/8+BFI_5)'M_Z/(
MML\5V6I65(O9%-4,FLRF>PF[3X&=8!5<"T%_@R4'5-<DE3>CNPB)LSNDC$X[
MI7:Y**7+1\G=04KJCE9B=[+B>[(5UU.LV)X:Q?2T*;JW7Y&]BQ71NT%AO0<5
MTGNS@GLO*ZCWEPKJ^51!W68%=X%.LT(ZS+I$^4>19%O &)@'>D +[U>UH3G@
MSNE&^_6B__LG*W; 2=$#'HJ:.TN1<T,5,3=.X8-I"AO,4^A@N8('&Q4TU*/
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ML,=? 3WA\N^)TZR>=/GU%LBWMTH^O:WRZAW0S-YE\NC=*O?>XW+KO5,NO<^
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MO^M2S7%=KQZWZ]3M=E*=;A?5[GY%;>Z_4:O'IVKQ,'\/=^;*(,NM*.>""4?
M5B/W$8CNQ*:EOL18V++8S4$+W=TUXC%;PY[A&O2,U\#,=/7/S-,<KU+U>E6K
MQ[M)7=Y=ZO2>JW:?16KS6:T6GYUJ\KU>C;ZWJM[W$=7YOJI:OW^HQL\\@5H#
MOF8]:YQ,(O0Y$6[9?[(^W)+[6$1X.!];YF'+D.\TS?5U49^?CWIG!:M[=K2Z
M9B>KPS]+[?Z%:@NH4$M O9H#VM48V*>&P 6J"QQ7;> V50<=4670+:H(>DCE
M03]36?!'*@TVJS3(K#(#@68]$44[1!-B@6TL]ZMX7,Q[\PA!YF)+'[;T!DU2
M=Z"3.H(\U1;LKY:0"#6')*@I-%T-H7FJ#RM575B-:L):5!W>H\KP>:H('U-9
M^&:51AQ2<<1-*HQX0 41/U5^Q(? /(&"< L>(12^D25^?[RT$8R!^;P>X/U>
M[.G"-^WXIB7<04T1;FJ(]%-=9*AJHV)4'96BJNAL5487J2*F4F4QC2J-Z5))
MS)"*8I>J(':C\F,/*#?VO')B[U-6[(O@?6"V(,:"!PB#SR9*U['$KP6+P1#H
MY;T.[$'*J1'4QTY73:R+JN*\51D?I/+X*)4E)*HT(4/%"?DJ2BQ786*]"A+;
ME9<XH-RDQ<I.6J_,I'W*2+I!:4GW*C6)63_IK\"LU$0K$LRZ.YF^D,(X) 1=
M"1: ?M#)>RU\UH"--=A3F3A%Y4DS5)KLJ>)D?Q6EA*L@)4[YJ6G*2\U5;FJ)
M<M)JE)76JLRT/J6GC2HM;8U2TO<H*?V,$M/O5GSZ<^ ]Q:=]IX14LP4I9MV1
M1M@-MB!-EEOWOQCYES;0P/O5V%*.325IMBI,=U1^AKOR,OR4DQFB[,P8964F
M*S,K2QE914K+JE)J5K-2LGN5E#U?"=FK%)^]6['9IQ63?9>BLI]59/9?%)7U
M+3 K.M.LF RS;H7S(.'OABS&(1@$75F6_$LM*./S(A[SD2TY.?;*RG%11JZW
MTG,#E987J92\!"7GI2LI/U^)^>5*R&]07'Z78@OF*;I@7)$%.Q11<%)A!7<J
MM.!IA12\HY#\;Q2:9U98K@4W4O;>'.8BPM^%H ^T@7I0"8I 3AZZ"\F25CA-
M*84SE%3DJ<2BV8HO#E5<<:QBBU,44Y*CZ)(21974*J*D0^&E@PHM'5-PZ38%
ME1Y70.DE^9?^2+-+_B3_DJ_E7VQ60)%9@85FG:'\G90_7B"-@![0#&J,_ _(
M*T1[(Q]32M%^9;:*+7=4=(6KHBI\%%D1I(C*2(57)BJT,E,AE84*KJI24%6K
M JH&Y%^U5+.J-LNWZJA\JFZ75]4/-;/J+7E5_DO>%6;YE%MPG+!["U@&SR#H
ML.: *D$1,BD;[M1R^"O1_]7HW]KI"JES5E"=IP+K9RF@/E3^]3&:79^J63C/
MKZ%</@V-\F[HU<R&47DV;)![PR&Y-=PJEX8KX$VYU/]3KG5$S[5$C> 0'.O+
MT/Z@#ZY64 O* ,VK=&128@W\2,<PI$I LZW\6AWDT^8B[S8OS6P+D&=;N#S:
M$N3>EBFW]B*YMM?*I;U3SNWS-:-]K9S:]\NQ_2;9MS\L^[9?@\_DT$KDVD(D
MWVS6==1O%3PCH!LT MRI8B,'!7<RW$P]8@I48!OZIU/RZ)DJESF.<I[C!GSD
M-"<(1,EQ3K(<YN3*?DZ%[.:T:-J<N9HZ9X4F(Z1LYYR5S9S[9=/[,OB[;'N(
MY+O-F@RVPK$,S 7MH Z4@[QZ^B#<<7"'(Y$"N^!'-GKTHP$';>4PSU[31IPU
M9<1#DT?\-&DD1#8CL3*-I%LV>(U0R$@/0$B/H'?G(9;GW24-HVN&T?Y#1'!#
M1)*#J)0FQD,S<T*3Y2Q8-2CB=29R.:$#_=\-/_+(9Z[D/@S_?,EAU*0I2PB^
MEA+P+"786.I%1=!3RYC4QYC4QAAL8^BJ,1PWALX<0TR/(:"7(9:7(MZ6(LB6
M8,-B\P16P#-,/;M (W]29N2 J',2=8X:D(*&X(?7?9'DA%RT0Z-/6D6PMP9=
MN8: :RUVK"/06._-)!/ HL-BMY$)=B.#:B.^V#@'\$<;K^/SF\$5OHLX7/<O
M_A8;UIBU&*Y^7-9N[,/A>0%U3AVD#XZ@OT?AA]<-V>ZT6IJV7K+9!#\:7=M-
M3/ $?#NQ8]<,%ASLV(,=>XU_"(JV[$G9;QS&I&+[%@#:8]]IZWZ4U_C^E__>
MCS(?/KJ.&D&)<0Z,K\<MD4+@]5D#_T;)<:LT92>\>\ !&8$F$[P5U^./X^C;
MD_CC%.URAG8YBQTWL/">8_([1\>^P;@>".>=1=R?1="?(8(_\[%T&AM.F35L
MG(4"E?@Z=XP^P%=#-]#_X'7=3=OOOR;_8N1>KN9")O:B6',BM^&3BP3E=Z#Y
M[T1KWXT=]Q*0W4O?N+?0>B['^+EL*G(/?WC/DWSG+P3QWTS<&CL'WOIQ^B'=
M)G4S?9"OS8+7C3HZG))LSUFY;K?F7.ZQYD+N!P]:<R(/6W,B5R9)3^"3)XU;
M2P@"GPVQ;-8UKI'_,?WB.1KTN6, W?_<+_CLDXE?S&FCSN6T;Q9=)H:N&W""
M_@>OXP7X[[!R/J#O]Z$8>U">L>+JF1PC)W)UK\;$61GC]E;:Y@W\\7O&RILL
M>G]@@GN+SOW6#NEM?/$V:NIM^N9;GZEN'_V0.B?AYU ^\KI$_\/,R4;^Y8J5
M\\=6GJLWMAK_*&ULS'_-F@^9.(OS7[F0]XU?\L6.S^BGG]-'OZ!-OF00_I,Q
M\A4=ZBOZQ3\I^)_&61A[?7_^X^K-G)9?!OG^5W.-7ZPU]H(8-X48OQICW)BZ
M5,9M(=^AIKY!^7R-LOL*)?:E3NIS.LRG--PG..\C%.2':.X/^(9Q*\?[UAR$
MD?]XWIJ#L.0^KFK_R=;\@W%C2: LOY)BW-!1K&]5 T<+'#VHM4'*7Z"/L>/O
MV/$!=OR- ?L> ^==U.>?4:5_I+.^1<?Y/6K]MRCYU_@KX^R+L??$V(/QM#4'
M\<C_D7\P\C+?HN^^DJ^^0.M^AB\^1F-^H#(XZBB_S7I+Z" ES]?K6D+9X_HE
M=KR*'3_37CB.T73GJ.<EFO$1^%Z>^-V8JV=/##QDS4'\X+]L,'X$^1-\\3<Y
MZ1UY4H] ZA&-)D_#_GS\5T'7J]<+V/%C['@&G?L4>OM)]/83J-<KJ,]'L>-A
M5/%#*/,'&,#WZ5ZXGM;=E&;<(VOD/>Z091_&S=8\Q/?Y%\L9E-_)L@?C)7SQ
M'+YX1J%TRW@X,BB_4)>QXP'L,/9AW//O?1CSJ/$BZSZ,];J YKY9!RG_#-ZX
MB'Y_E&>O,KU\-'&"RMAW8>S#,'YWZ*C5AB^LW?F7UN'V.+ZXC"_NHU_<)7\X
M(N%(HOPLIHHB>ERESF/'#=AQAGYZ2OV4.8]I;!&M,$ZY&YE*=V/%,73[S7CE
M/EKH.7KM7WCWZXG=3+NM,)[_4Y8+>7YFS7\\:)V*+N"+&_'%67EC?S"VQ\"1
M0ODYE%],^9647T_9+?3$+LKKI[QY>&")MFLU(V6K-C.Q;Z*$#92X'D^NHU6-
M^W:-$V;7PDAG_L*&NH.[3)8I\2PX@2^.,$8.R)UZS*(.87#$P9%&B^=J"W9L
MPHZ-V+$!?ZRC7=;2+JL9+RLUAC<V:#E_-49)2_'@$GJ)L8MH$2-I%-YK\0>6
MO6>8YN\!Y\$Q7N]GZK\.FW8R9VR5,_6928D!\$1@=X)6T3?&F3=6J 2.*BU3
M QQM</3",:2%/)N/-2-8/(SGAFB/07K1 '-%O_X*OIDX>7<5KS*U/\PR<PM+
MWC%P'<^WL!1O<&1YGV[2&EM[ZN4"GP]<P5IBBM8B4[(6VF1J@6V!1FS+-&]2
MC88G-6EP<J?F3AY0_^2%ZILRKMXI6]4S]9"ZIMZHSJGWJ7WJ\VJ;_J[:[+Y6
MJYUY FW@>0^6,./L#5/[7K"9YZL\"7L(!Y9@WV+'R5H\W5$+I[MKQ&Z6ANW"
M-&@?I[D.J>IWR%&?0Y'F.%:HQ[%>W8YMZG2<HPZG^6IS6J%6IRUJ=CJD1J<;
MU>!TO^J<7E2M\]_ M\#\;SSA:]G^>726Y9^#5O.XE-<+? C_L&?('3A/T]P9
MSNIS]E*O<Z"Z72+5Y9*H#M<,M;OFJ<VU5"VN-6IV:U:C6[<:W(95Y[Y,->X;
M5>V^7Y7N-ZC<XQZ5>3RG4H_W5.KY'3#SW(++A('GC="'Y7X#& NRY#[F\GX?
M]O1@2_=,&W5Y.*K=TUVMGK/4,C-435ZQ:O1*4;U7MNJ\BU3K7:%JGP95^72H
M@N"SW&>Q2GW7J=AWCXI\SZC ]R[E^SZC/+]WE.OW#8^L1+X6W!MLV8J[*Q0?
M&/D7,,CS7M[KQ)XV;&G!EF8_>S7ZN:INEH]J9P6I>G:DJF8GJM(_7>7^>2H+
M*%5I0*V* UI5%-"G@L"%R@]<K=S W<H./*7,P#N5$?24TH/^!+X&K$2!%MP)
MY_4L\5L)15> $= '.B+@YK-&;*S'EIJ@J:H*<E9%T$R5!_NK-"1,)2%Q*@I)
M46%HM@I"BY4?6J7<L&;EA/4H*VQ$F6$KE1Z^0ZGA)Y02SBP7_J02P]\&7RDI
MS#R!Y%"S;H/O4!1A;PS]  P1!G;SV,J2W\#[-=A2A2WEX9-4$NZHH@AW%4;X
M*3\R6'F1T<J-3%).5*:RHPJ4&56AC.@&I45W*35Z6,G1RY48O4T),=<K+N:B
M8F*>4'3,FSS^4S'19L5&67"SL2T;WK5QZ+UX8NQX2_ZED=<UH(+/2[&G$.3'
MV"LWQD79L=[*B@M49ER$TN/BE1:?IM3X/*7$ERHYODZ)").$A$'%)2Q33,(6
M124<563";0I/N**PA-^!+Q4>;U:$@3BS;H!G-Z'GJD3Z8I)E_TLKJ.-U!2CA
MLP)LRN$Q*W&ZTA.=E9;DJ=2DV4I.#E52<HP2DY.5D)*M^)1BQ:;4*":E35&I
M XI,7:+PU$T*33VLX-0+"DI]3(&IKRLPY0L%I9@5G R2S#H%S_9DRUZ@8=!%
M"-J8:LF_E(("D,7GZ3RFI$Y14IJ3$M+=%)_NJ[CT(,5F1"HZ(U%1&1F*S"Q0
M1&:EPC*;%9K9I^#,10K,8H;-.JC96;?(+^L1^6;^1GZ9GVM6AGD"L]/-.I9B
MN2%G"9)D +2#.E !BD .2,T@WLR4XK-L%)-MKZ@<%T7F>"DBUU]AN6$*S8U3
M2&ZJ@O-R%917IH"\!OGG]6A6_@+YYJ^53_Y^>>7?),_\R_+(^Z4\\S[5S%RS
MO'(L. C'.C@6PC''F@.J!J5&_@=D@B2D2ER>%(E\"RN<II B)P45N2NPR%<!
MQ<'R+X[2[.(D^15GR;>D6#XEM?(JZ=3,DA%YE*R66\E>N9:<ETO)@W(N>57.
MQ9_(I8C(%;@5FK4'>;HJQ[(7J LT@(JK.2"0!G<\W%%(Z= 2]&^9K695.,BW
MTD7>E3/E53E;,RO#Y%D9)X^J-+E7%<BMJDHN56URKAK2C*IQ.57MEF/563E4
MW2>[JI=D7_F!'"J(7,LMV ['6+YE+U ;J 6E(!]D$HXGP1U=2OW+X4>J^%5+
MGG53Y=;@)-<&-[DT>,NY(5 S&B+EU) HQX9L.3:6R;ZQ47:-?9K>N%13&[9J
M<L,)V3;\0#8-S\FV_CWPM2;7F36EUJR-<(P6,QZH8Q.H L6\SN$Q%>XXN,.K
MX$<V^M5+,QO1@"VV<FJWDWV'L^PZ/#2MPT]3.T(TI2-&DSO29-M1(%,'?]"!
M@.]88/SD+T PMJ/]VY^BLD1-;5\Q ,T3,,Z$S0.=%<R'/):# I#!ZP2X(VO1
M_T@DOV;JWRJY(%,<NVTT?<YT3>I#P_2QX/>QX/8SJ?<SX?8SB/MIX'X*Z4=G
M]B.J^Q&Q_8BI/B*D/L1:'V)H#C;TFB>P%-\.8')KC>4L6$FU)0>45$<;4.=@
MBO%KA[\;?B2C8[\TC6)MYA'HC!#TC!!LS&>A7X">6LABMY")=R&#;2&-N9 *
M+#1^AFDI0,@N1$0N0)S.1YC-)XH>P89Y*"9X>JAG$ZC"U_D\IE+GV#;T?R?Z
MER(\C?S/$!IX1)JRD$!O"5AJ*RU#5XX1["PGT!AGD5])(+"*!69UC&7SWZHR
MX^>P #ISE?%SQ"?Y#F)Y_%<L3I\#;%ANUB!?Z<#'#=2WA,=,?!U/G</ZX*>^
M'O Z+Y+LEDF35L!MY&#6@0T&L&,3=FS&'UNQ8QMV[,".G<9"S.2Z*]>R\6EG
MG^4G@78BJG<@I+?_A._^@[^Q[$7I@Z^-KE/)8RZ^3AJ@#\Z39H_"#Z\3?SI]
MK60R\B];9029!'RR[$?99^1$"(0/&O\ 1R!ZA'8YAAW'L>,D"]U)VN0DG?LD
M%3U!18[O O2)ZY_F>W\C<#)/H-<X"P6*\'4:73@*/_N/PP^OTV9IZ@YK_N6@
M->]R0I:]*&>L ;B1G[C1R(G@DPOXY#;:YJ*;99/RG2RZ=S+YW4DGNQ.2.W#@
M)03^)43]1?K$Q7].G,EIHZDJ,#&+.L<9]^!L9/S!ZT0]IQZV<IZQ\ER091^*
M(4",<SG&WI![K\F'&/F"1]'\5VB;'S)>GC(.KK,H/T7__!$-_2,J^"3.>_(2
MH#U^^)'TQ'>JH\X%QETTU#ETM^1-?9V/PW^#-?]B<-YES;U<W1/RA%40&;F)
MB?,X_YT+01B\2MO\!CO^A['RO[3):TQPK].Y?TM'^BV5>H/"WG@=?**R;<P%
M^#J:.L_"QZXWT?\N6O,O#UDYG[3F7:[>2_)S?7\WR;_/XOQ7+L0X'V/\M,5'
MM,O'!(>?L/!\RB#\C([V&82?WP:HQ.=&-F**=0_$9&L^Q-B#8=Q2:IR',>[C
MR 0ELNP%:06]LIR)62CC;I!O&2A?,TB^0N%]24>UW,EQ5A^CK(W[.-Y'H1NG
M4-[E&U=_(=;(01@W<OY(_]<=%#96.XQ<C'$>QKB/(WDB%_.-RM&F]?I,[?H'
M=OP=Y?0!NNYO*+GW4$%_P8X_8\<?&2Q_0)G^C@[T.IWF-[#\$F>]HD_^_<LH
MQAF4*]8<Q'^? ;%@"A;/H#XSJ4\0?+%HTG3K691*RF] N;;K?['CU]CQ"U3=
M*TQ:+V/'2]CQ(OKN.53J,PR>IW0KW>8!K'B>)GU/C^(U(^]B[/\P[L(P]E]<
M^"\;C',8[\M$?1STIMRHAQ]^"X,G 8XLRB_"LU64W4#9;93=0]D#E#M"=UV,
MY\<9(AL8*COA.,SPN4&7^/_M?/,V.LP%& S.6V39AW%&WY\!,?: ?&3M3L8>
MC!<TE>X^@^X_$XX .*+@2,9OV91=C(<K)_9AW$[_N!7=?P'E>O/$/HS%3!?C
M,&^D_.OPQ/4,[5OXOW$ZYB?H^/?_XQZ,_;+<NVOLP3!^&/IU6:[^N3(QW&W@
M<<!7KG#X4GZ(;E(,MJ?2VW(HNYBR*RF[GK);**]+A]1'"\RC-RQF2EN%!5NT
M:^(<R)F)W2E;&5S&Z:6K>S"N8A,P]L"\9AUZQC1C;(-C>.HTOC@N)S@\X)C-
M-!D&1QQVIVFW<O%V,>574GX=Y;=07B?E]=,2(RPG2[66_Z_&BI58.HZGEN/)
MY?2<L8G?/C;_&V,R3_Q U(^M4Y Q);&RZ<C$4F!#"?;T=!<XO. (Q,.1<"10
M?KK68,<J[!C'CA78L1P[EN&/I9J+)Q9JE$\64NOY6#]""PW32X;IFT/TS2'Z
MYJ#,$S!&^2M,K0]/M4SUUX,]/-]F+(?8L9XQLAI?K*1_+J=-QA0,1S0<25JD
M##CR&)TE<%32"O5PM%%N+U8,XY&EM,YZ7NVAYYY6-^W1R8S02:T[&.4=<!LP
M?I_:R,'<Z6A)_>\!&\$J7H\QQ2UE.5PL.^KD#)<G7+,I/0R>6$9#,CR9\.3#
M4PI/-3Q->**3LN<R>A?18]>H&6\VT7L:Z5T-C(]ZTQNJL_E,=;9FU4TR3SP^
MRK)_,]/Z0:;4S6 <+.+U".\/8\^@O:T&ISAH8)*+YMAZJV=2H+HG1ZAS2KPZ
MIJ2J;6JV6J<6J65JA9JGU:MQ6IL:IO>I;OH"U4Y?I6H[>HW=]:JPNUWE=E=4
M9O>:2NT_5:F#^=^XC^7^M"=ZCY!P#>'88AZ'9Q+R\5X/]G2Y *<IZG)P5+N#
MNUH=_-3L&*(FQV@U.":JWBE#=4YYJG4J5;53K:J<6E4Q8X[*9\Q7Z8R5*G;>
MH4(6P0+GVY7G_+ARG7^G7)<O@)GGS,#@#GB/$G)L99E=/HOZ@SZ>=_)>*Y\U
M8TL3MC2YV*G!V5EU+EZJ<0E0E6NX*EWC5.&6HG*W;)6Z%:G$K5+%[DTJ=.]6
MOONP\CR6*\=CJ[(\CBK#XU:E>SRF5(_7E.KYN=(\S1-(]V"NA._ ;/I?@''N
M!IT!ND +87(#[]=B2PVV5'M.4:6GD\IG>JATII]*O$)4Y!6E0J]$%7AG*-\[
M7[G>9<KQJ5>63X<R?0:5[KM4J;Z;E.Q[6$F^MRC!]Q'%^_Y*\7Z?\FCFM07G
MX+HNB!"44'0!8> <T 8:>%W-^Q785H9O2OUL5.SGH$(_5^7/\E;>K$#ES Y7
M]NPX9?FG*M,_1^G^)4KSKU%*0)N2 _J5&+!8\0$;%!MX4#&!-RDJ\+(B U\%
MGP"SH@+,B@:GX=G!\KZ"\&\8>= -FD&-D??@_1+L*<(O^2 W<+JR YV5&>2I
MC*#92@L.56IPM%)"DI0<DJFDD$(EA%0I/K19L:%S%!TZJJC0=8H(W:^PT!L5
M$OJ@@D-_#C[FN5FA(19<#\\6.)<:>W"BD$&@'E3RNH1PL(#/D-;*XGOI85.4
M&N:DE'!W)87[*C$B2 D1D8J/2%!L9+IB(O,5'5FNR,A&143U*"QJ@4*BUB@X
M:J\"H\[)/^H!S8YZ&7PD_TBS D!@!&L'/!O@7!1-7T06M( :4!9CR;WD@ P^
M3P5)T;9*B'907(R+8F.\%!/CKZC8,$7&QBHB-D7A<3D*BRM52%R]@N.Z%!@_
M(O_X59H5?YW\XL_*)_X^><6_)*^X#^4=9Y9OK 7[HRW;Y(V]0-U&#@A4@F*0
MQWN9( 4D@%C>BTZP4V2BL\(3/126Z*?0I&"%)$4I."E1@<F9"D@NDG]RC68E
MM\LW>4@^*>/R2MDESY0S<D^^1V[)+X(/>&Z61Y)9GHEF[:;L<<H>-O8!@;HD
M?  *>)X-TD BB$Z6(@A-0U.G*#C-48%IK@I(]Y9_>H!FIX=K5D:<?#/2Y).1
M+^^,2LW,;)5'YERY9X[)-7.'7#)/R3GS;CEEO #>EW,&46.Z62YI:'_*7P;G
M .6WIEAR0"4@%V2 9!";"G\ZV@^I$)!EHUG9]O+-<99WKH>\<OTT,S=8GKG1
M\LA+EGM>CESSRN22UR3GO#[-R%LJI[RM<L@[+ON\.V27][3L<O\L^]ROY9!C
MEF,VVM\XDY9FV0O4:,T!%8)L(P<$$D 4W*%(Z0"DFU\^^J-PBMR+'>5:["J7
M8B_@+^>2<,THB9=32:8<2XKE4%(G^Y)N3?__V'OK\"B/+O[[Q&UWLW%W5V*0
M( F!)$B0X.YN 8*[NY1"<7?W(L7=K4A;GK;42PO4J4.YW\_LWFG[/+_?'V_;
M?][K>ENN;W?WWGOGG#ES9N9\3V;F+NPC3H5CQ+'P9;$OV"2V!2?$KN #\*/8
MUR1RK*')"*AI3V2T)O1NJ.> \D .R 0IR(Y#=@0T);@F\J%N7K7LQ+VNJQB+
MW<50["UNQ4'B4APESL5)XE2<)0[%>6)?7%=LU8$BQ=V!>MPMW*9X'<X&6:@+
M":A+Y%A'LV!0-?HD,IKG<4O>GW) H(*>@XI"=D@1\FLCOUC$O;ZMN)6XB%,C
MH]@U9D)IS 33F$&U<:S5J1M3J<8JJ=)8/>Z']VI3 02J,<2P,=RF$5%3(W0H
MT2SHAXSV-?@*U ;Y*@<$,GB?6( /0-]#ZR ?RNC9$ Y(L6Y-;<2Q!8%&2R;^
M5DRPK9A06@=8!_DV#"QM<. V-%H;== PA+J-.N "PMP:KMD:8MCJ-OB>WVL6
M=*=^K4 #4(3J>7H.*(4ZQU#G4*B[?R/D-T4^IG5M+6+?C@"G@ST#BHM()X*-
MSNC1Q8>)GLFE6Y0UX=R-1NY69#WPMQM$OMMHOG\%0%*[7.<WWP%TZ 3W1TY3
MM0X'.EA ?2OS6@'UXTK@WTV0#U7U1*ZQO8@S9K7MBGR*E%YP_MX$87T(=OJB
M1REMTI])=B"32QEM4J8Z7)YUL<W CF P@_%< )'L#SDM)9+OIUG0!EF-N*T.
M]<WE-1-;)Z!Z>"OD4U\/Y!JZB3C"SPFH* /0O(2+0I#'9(<]1F"/4>@Q!GN,
M18_Q^,8$!N )=.H)V&(\!AS/C\=#Z,<1,8^%P(YY9#T7913<'WD-L7--7K.Y
M-9GFBT1M?^KK@5RW4A&[07_*OXP%$\!DH'(3T\!T6VL@.AO_F(L>+Z/' B;D
M!0SX"^A8"ZB@.@1F/@7,(VJ>!YE^B6AZSC, B]7W0E7%UA4ZXX/8.0 7\D"N
M*UW*5LF<I,N:K>="5.!-TUK6ABP1Z_H02SX$FZRA;=:[BVQ43]+!1S?3)IO5
M8_1:<FT@P3,%;-A!  F;6ON#93].0^3F8^O,WOA ?Y&@H>H,&NJOZEF>?U'R
M5.Y%Y5S4&A3+^A,]-['M3_D011#4>HV#SM8G"A]'C^-,N,<9Z([A9$<1=(3^
M<1@6<?@T> R>2RV:J3+J)5'GL/'T?^KKAER;17K=E,S-NIR].A$ZK$.1LN-_
MRH6<U\F:)0^"O]Y&CWOTV7M,C/?H\'=QLKLXTMT%(G<H[,Y=\)WDC61.HGVC
M9C &8&,C=K5;J]=QMRY3K74YH9.QB[J,_UI[(G\\Q:8\#Z+.3?T,/9[0+E_@
M&U\R9GS%(/,UMOB:QOUFC<BWC)G?WO\3[U9K,=1:$+4?1JW!4/MA$L3ZQ%IU
M-JI:"])(9R;JZ;G=84M]Y1G,YQ>8T,^PHA]A@$]AA-_B)%_!VI[ K3Z'I3^T
M[$3YV7(.AWI*2OD:C"-Z#N+_S#^4GTFJ]L.H)\:D(JLR<FK"W(OE.QC+5^CQ
M!#T>P=0>PK8^@>5]1,=YGT[S .?]#PSX#;CN;8QY4PXA\R:L^QM+[N6"GGLY
MH.<@MOU?='@&S_Q1C-3%2[[$%E](/+(RJ$=5RB^$']>3N["FU]'C!@SK&JSK
M"JSR(@/'>?0XBSU.P8J/PY:/RAK<9A=L]PRN^@E\_C?+,X5WBO4,C+5B?<[.
M'[*M^T#4.HAWQ1DY9IK:'QF1R$A"1A8EY>(6A91=C[(;4W8+RFZ'JW;&=7I2
M=G]8Y3"X^WC<>!9L>S$NO0E-#M&E;B/OJ67?B9*KUF"\HN<ARM=@J.5$=W67
M8X;'#8VXHQ>Z!Z-[##)2L9LZ"R.7L@LINYBR2RB[.>6VP?*=Z+X]*+L_;'\X
M5IA(^2_Q;Z7,P1:SY!Q=_7/+N1?JN<MJ_84Z85<]A_FI[L+7]6ZV5^\2Z[#%
M:G&G?%^&H##*CZ/\"NB>S1"52]D%E%V78:LA93:CS-:4V8FALR?E#F H'46K
M3),Q:*1."1E)K4;0DL,MSSVVKKT8+M9G(:DTXC6]NZO\QVJQIF;GT4]FBP&]
M/2D_@/(C*#^!\M.P=#;>ETOY!91?A_(;4%Y36J$UTTAGII/>]);!:#+>LCM&
M[=3I@S5[RV4\YTO+ZJH_XX[>_3?IP^Y<?5A6Z?$QV&(D?76X>%-^,.5'47(2
MY:=3?C96SZ7\ GIH'60TI/QF6*$MO;8K_TJE"[7M1 TZ4JOVU+"]G,1[/@'/
M@/8[U+"SG6EXJ1U#,\/]>*:?$?JT.!!;E&*+ON*!OG[("*7%8Y"1C(P,9.0@
M(Q<9!?34NI17@@8M\(X.])I>TA*-FULR1?/IT1OP8N7);X(?+"<@*ZC59RH'
MLT9M1W5C6F7:&\QK/Z:=7ESOCEY=Q0GK&I'C13T"D1.!G#BLGH*<3"161DYU
MY!31&O4HMPDC61NTZ48+#9#ZM%HQUJV+!ZM53;7QO-KRM>4DYMHZ=JHCP1C6
M)S/E#@5]05>&UPY<:\MW;5QLI;6]*W5R1Y8/<H*1$H6L!.14H 4J2@.;JE+?
MIH84V]:1NK8E4L>VI=2RZRQ%=J528#=*:MK-EGR[E5+=;H_DV5V67/O'DNOP
M7'(=-<D#ZBBPESQI>[7VQ-NZ[D/E/EIPK:D*5]&ED<%!&KD8I,3)0QHX^4D]
MYS"IZQPC=5R2I+9+NM1RR9%"USPI<"V2FJX-)-\-R[AUE%RWOE+-;:14,<R2
M',-*R3;LD8J&2^"15#3^!C2I9- L1\-/)Q0<1FC<VY_Z@Q:@$9\;<+V8[^NB
M2UV3D]0QFJ26T4L*C8%28(J0FJ9XR3>E2G531<ESKR:Y[@52U5Q/JIB;28ZY
M@U0R]Y4L\TC),,^2=/-*J6#>*RGF*Y+B\05@%@ 5S)HL88J?Q/1:IL)1E7\!
MC4%]/M<.A'.A3P&ZU/2RE1J>;I+O898\3S^IYADJ5;UBI(I7DN1X94BV5V6I
MY)TO6=YU)-.[L:1[MY,TGUZ2ZC-<DGUF2*+/<HGWV2UQ/I<DUN<QKQJ?F17!
M?.2,169IJ/5/E&KM24-0A\\%A*?Y?)?'/;GH4M7/22K[FB3'SULJ^05)1?](
MR?2/EPS_"I(>4$G2 G(E-:"6I 262%)@:TD,["'Q@4,D-G":1 <ND\C 71(1
M>$'" S_G]06?F17!W!#K.3"]";O:14))0#$HU/,>U<*)<= G![M4#+:7K&"C
M9 1[2EJ(OU0("9/4D!A)"4V6I-!,20RM*@EA!1(7UD!BPUI*=%@WB0P;).%A
M4R0L;(F$A.V0H+!SX#/P&Y^)$$(9NY$Q%)G=H06MHZ$],=;\2PW>5^-:#JC(
M]YG<EQ9N(ZD1KI(<89:D"!])C R6^,@HB8M,D-BH-(F)RI&HJ!H2&5TL$='-
M)2RZLX1$#Y2@Z$D2$+U(_**WBV_T&?&)_I37Y^(7180 IJKU2-'6?5 M5 X(
M0%\E#U3F6D60CDZIW)/$:T*,D\3%FB0FUDNBXP(D*BY<(N/B)"(^5<+C*TEH
M?)Z$Q->1H(2F$I#04?P3^HMOP@3Q3E@HG@E;Q2/AM'C$?P*>B5>\)MYQFDR@
MW/[(ZP@=: I-JYN(__%:%50"&5Q/!8D@EL_1B?82F620\"0/"4OVE9#D$ E.
MCI:@E"0)3,D4_Y1JXI=2)+ZIC<0[M;UXIO83C]1Q8DY=(*;4+6),.0'>![^(
M*9EH"8RA[#[(;:O6 >DYH.J@,LCB6@60!&+Y')E*W NE#4YSD<!TDP2D>XE?
M>J#X9D2(#\IZ9Z2)5T9E\<PL$(_,AF+.;"LF G9CYB@Q9+XDKIGKQ3GC"/@/
M^%Y<TS5Q \,IOP?TL!7E-]!S0-5X7PFDJ_P/2  TMX1E$/L3FOI5=!#O2@;Q
MS/80CVQ?$"+FG&AQSTD64TY%,>94%T-.L;CEM!27G.[BE#-,'')FB5W.&K')
M/@CNBFWVMV)721,',)CRNU!^,\L>+'P15 99H$*:RC_!?9$=CNR@2LB'RGI5
ML15S-1<QYIK$D.LE;KD!XIH;(2ZY">*<FRZ.>57%(:^6V.4U$9L\"$P>A"F/
MV3AW)8" Y,)OJGT#- O4OK3V:B]8%NT \K*L:X RN$;S2ASO(Y$=@FS_*B+>
MN2+FZK9BK.$L+@5&<2ST$+M"7[$M#+$F,PM3U&8N4 - 8 LAK840QD*B@4*(
M4L$> "FHB0XU-0MZ<7LK:%!]9!3DZ#D@KJ6!!-Y'58;_0QG]D>T%33'7A(,4
MV8AS;2>QJ\ND5M?=.J#74PEE.G ]'*P>%:O'#^I#XNO#\>I!7.M!&NLMY-Z=
M ')2%]Y=5[.@"W5KAHRZ(+^J=1U0)G*3>8VIA@]4AW]2):]"Y->&@U.L,[3-
MM@3^THA)OA%\NS$37Q,&]&8,9,VBK$E.=<A0LT+KYI9F$.AF$+EF\^A\1&M-
MB%J;?,GO- O:(:,$%(&\/-I!SP'%4>=PJ"I#KWC55?D?.&")B"-%$BR(M"38
M:460T=I-_7&!CL7$UI[)IX-*_*M-E^G60X?40Y\Z0*C5!H?V$-CV&QB0(89M
MG_ [S8(6J%H/6078N)J^#BBA2"2BCD@@U,Q+Y7^0Z]H<#@A')X"A/- )=$&/
MKHX,LMBC!WKT0H\^3+A]&?S[)E@3?GTIK&\+KO<!<+S>$.=>QT1Z?F99AR+=
MB:>05:>..@\(&V#KY&)\H %]H#'RD6M"KC/5L,&]"8WX+5#K4?J)=4T*?%D&
MT2Z#"<:&TB[#T6,4$]QH)IO1=+I1V&(4%1G9!4!N1Q Q#X?$#OV @/&Y93U*
M0^355N?Q\)J&K6.;,@9!C[UP9R-R'7OH,LOS+RH7,E*L:U%4;F*\'@!/QB;3
MU()D_'0V>KR$'B_13UZB<\TMM!X&/)M"9LTA<-W.?9#E:3^)3-6D06/K>3A9
MU#FA#7V@HW4/E!&Y#@-UF:-U62HG47XNB@K _S<?8ED?@DU6H<=:]-C I+]!
MG4^"@Z_#%FLI>"T*KX;8K\(G5L#LEFM2"UM7ILXIU#D"._OVMZZ!<1BMUV^Z
M+J]\'8I:$_+[^A.QYD,VRW^?V;J/8/@ OOH:>AQ1!^@Q^+Z&TQVFD@>IU %8
MQ(&#W/<1I.JY5*>-TWO3#S&3/]W'?;Q^!HRJXT)=YEJ=@)3OQU%K3RSY%OD_
M<R'E:T+4X0$W7:U/\;U#?[U-7WV=QKZ)@6]@R*LH? UV=>UKR:;+)$ H0B:(
M>-!UG.?K<M?II$_E>%0>Y,_K02[\24[YF23E>1"U'D2=$Z+^@*P6\C_&'D_H
M*X^9F!YCB\=TJL>CN+8,4(DG;_R)]ZLS,)S$N@]%K<%0ST11YW&HLU'5LUG4
MDW/5,V*:BMH3\QN=4YU-^BL,Z&><]4>8D3J;]%O8Y]<TW!<TV",,]Q #?0R3
M?Q^>J5:=J#48:B^(>BKJ7CT'\7];@U%^'H<&UU6YF&=PF9_@4T_A,5_#7+Y
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M'^[/U_GJ/!Y>$ZES>'WK'BPS<EV0:]-1E_F_:U&&ZH&ORH>H/(%E?0@^,IG
M;!I^.I, 9!83P2S\<R:VF$'C3>M!P#Y19 H^,0GR//$;@EATP,Y5D)O*+5%-
MZ8-T9S/4V*6;7D<E4_V1;X0><*N<A%J#HO(#:E].^=J0EW5BH'(4R_"15>BQ
MCKZRE@EG+9UM-0V[JJWU;))EW+0,SKT88K[HA53'UAG-U5G(^"!V]L"^+J6Z
MW/(\2/DZ%"5GH?RQ_F2E_'<NI'R?C"(+^_"1@^CQ&A/^8=KD$$Y^L!$DKH_(
M_IDB>[EQ]RWN_4&R&4J3.N,#ZASB@?B?JN\$O9ZJ?BK'4[X?I_P9.3OEC[4G
MO^_#D3_."U%Y$+4>Y)J^%N0VOO$Z_GF+1K]!XUX;![&$45T^*7+AD53 WE'(
M]AUI/0?&9K9N4T5ZUNLRR_?%E*\'88CY/1?RY_TQZJP0M2^F_-DQ:A'!Y]CC
M"7WV,9/N8P::1W2LSW"H3Q'R,17X^-[_Y![46I _[X=1YW$DB?79L'GZ7T0;
M6MC1<SKFK_"8GV%"/\(<U6F*W]%X7^,L7UK.)5TF#VF<C^%6[\L;J/43ZFF6
M',1^L9[!J=9 K)?_/H?SN05VO"]_/DR@_ ;'_$52D9$CW\ <OH _/$*/APP4
M']%AWX=]O4M'O4^GN4>'>1T];L!IKL+"+\%@SV'$TQCL!#RS//^Q45\#H<ZC
M6*3KH'(?WXOU+%"5AW@,M_H,?O<1O.I#^,R'<*K[\,O7+<]%R<?\M2FU <W1
ME.9O1?D=*+\;->X+=QQ,LXV!U<U ^B*8U4::\S7X_+LPSF>6LS>4W'EZ#D*M
MA5#Y#[4'Y3.]"6_I37Q&7"G?0XZ+/^5'4'XB96=0=A7*5JRM%F77I^S&E-V"
MKM&.\KM:5AFL0(]EL/7%,/B%?%I@V1ESB1923]&QYCU4#F*LGH=09U!\H+O3
M*?GC'(S-V&(]_&X=7'<M'',-W&X%OK$4/19ACU=@C/-A>/-@?B\Q><S!1V;A
M(S/08QKVF"+#8'B3D+4 ;38@2YU8\J$EYZ'67@P2ZQX0E8=XH+OU(;U[K]*'
M@)?@W+.QQ4S\<P9M,EU"0 QE)U-R!AP]Q[(.8S2,=B0^,@(?&8:/#$6/P>A1
M!GL?@%2U,Z8?G;L/UNLMUQEN?[2<]-M=K/L_U#Z0JWJW6Z=W2;4\;9(^/(W
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MHEF6@G9G6FG!D%Z/<*RF,R&;LS543>-:"B%),CHEB1WE.U&^&S !#^3X("<
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M:G*MK"9:],ASM6ZTK*$V7:J-AS'6 W_50:MJ<T$>?IE+_ZQ&Y%2%"+KRSQ@
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M_4D0AQB$B$'Z\_<PB*$8,=0@AA8#Y4\=YGIC779.C[I<B0/-'E'=E3ZR^L*
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M#BH0CS, 88#-1QX5_9K)]GT6Q@\:#1;31HBRR+N$-,Z0;U;T+:]\P4W/4M$
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ME?8I^0M#O?AGEI:\IXXN$8_=/8-'??W\1HA!7G=#0C%#X>'.MU@,^\$8ILV
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M&[-/<EN3CWGVYS^6.QA]:'8P^'#!\7=!VDS4C:HIJ(ZVJ:C::]-11=\6*67
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M% LJ*UU <YT=&&ZT!,LMR+#;CHRLG<C8V8T,CCWZ$+I7%R+W:4/T 2T0']2
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M(@:GO=/ X^!,\#X^%_#G%H.?_@KPMUD/>.PV\";M!1SC$'C$*@,FZ12@LU3
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MXZ$]\4>"AY(F@O:G' @\F;H_\,_4T:!G2<,A;Z('0J="^T(_^>\,^\S]'0C
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M0&AL#*%>W-];+B)4?8>(BD"<D 5RI$18)Q !:B(!H"?F#69+F&"[E 8N*ZC
M6.D,'#D'_"+,'L+7V$"\O!5D*%A"H:(Y5"N9PI9UQK!]O1&,K#>$B0T&< '[
M1_EW]HW@^1-X_AF$*F\BE/N,@-) @A #*XC!L):?"QL%F: E0@/#Q2Y@*>X
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M?P,8\Z\#"WX%L!60!T>!U> J( L>@C+ $5P. 4)+(5)("I*%)"%76 (_"4I
MH[ XM"P('#80P4:+#YPPU\T"0#,2 IJU*+A1Q('*D0*7\&7@G"H#3L6RX%"_
M"LA;UP!YISS8#Z\%^WT*8'=$$>S.8->4P.X!]FH=V'W$OF+P?U/Z80>*"_GO
M&NPT_KT/0M,6 (:A$#"L1('N(@XTEA2XABP':O)*H!2L N?:->#4MA8<MRN
MXQ#^;\>4P.'0.EQLZX%\&;N[ <@OL _*0)[#X+_FL6]DV#!'AO4+ 4>\!K+:
MO_<@&)H"P-03 I:%*#"=Q('A(07TH!5 2Y %M]S50*U:"Y0617#I7@<N_>O!
M><\&<#J@#$XG-H+3!15PO(T]4P7'*>S+)G"$33^PKXZ@^MD1-LXX@O)"P&D]
M$9Q4_[T'P53G!Z_-0N!M)@K>#N+ IDL#RV\%>,:N D:6/+B7*0*M<3VX=2B#
MZTX5H ZK F7?)J <40.7L^K@<D,#G!]K@O-;S>_.LUI?G>>U/CN#UHP+:$R[
M@-J4"Z@NY+]KH&PD@<?&?^^#\+0$P<]8%/SLQ('G)@T^7'S,(E<#.TT1F$7K
MP:-V(S"V; +W;>I &] $MSU:X'90!UQ/;9ZG7M']1KVO]X7R6G^&,F,P3?EA
M,$4%W7>NH//:#;1>NH'&0L!Y'1'<-I" O9X$/&5^"-00A!!#$0BQ%H=@RE((
M9*\$OQ!YX":M ^]<%6!7J,\SF[2^>W9L_L;8J3='WV7PQ7V?T6?:4>,9M_.F
M']WNF$VYOC!_X_K1XJ7;#[,7[F#\C X&CQF@^Y !.@L!%R4BT)5(X(W[*A!W
M7IB: $3JB4"4A1A$.DE#N(<LA 2LG0^,5?[FEZGVA5NL/<NIU?O(;C6:9G:;
M3GGV6[QC[+%Z0S]H\]I]TNXE[3KYJ=M3AT>T:?)]^G>;NQY@\3<33&^QP.@Z
M"PP6 A2\!N9:$OCBW@W#[1^#]R-^LS DF(E! ED:XFBRWZ*YBK/A$2K3P<E:
M[_WS]-_PRDU?>C=8/F.WVSYA;G=XY#'D_("^EW*7?LSU;_IEU_^X/W*[3I^B
M7//\YGB%#;:7.6!UG@-FISE@LA"@*A+!"W?OS_?>H_!:$G'[IVH)09KQ(DBS
MD?J:2I']E.2E^"XV>-/+B#C=IR$9)@_]"ZWO\JK(M[V;G?_D=%*OLWO=KK)V
MNU]F3M O,L\PSGO>\3CM^89QRFN.>M(''(]S\;,(#ZPF>&"Q$*"M)8(/GA_Z
ML[?6_/P=K7R0I2$ N0:BWW(MEWS,<5KY)L-3\5FRO]J#V$B#.Y')%C="<^RN
M!I8Z7?2OI9[CM=).<[L9)[T'/(]SQEA'.<?8A[VN>!WP>NHU[C/#&/<#ZCY_
M<!P- +O= 6"]$&#@:^"+YT?BWDK&:\G"9Z-@$_]\L:[P3(F9Q-MB\HJG^72%
M>UE<]9LIH097XN,MSD=EV$^&%S@?#ZEP.Q+80)_P;_<<]]O!WLL;YHSR#OKL
MYI[UV<6]SQWR^\ :"IQW'P@&2E\P..X,!KN%@">>&X#GQ^#N3<?=G:^ ^UN%
M;ZY"6_!]E?'BYU4VR^Z5N:V]6<!1NY059' Z)=KR>$(R^5!,CLMX9 EM+*S&
M8W=("VLHJ(LS$-C/[0W8R]OA?]*WQ_]/OVV!;[VWA7[S[ X#M\YP<.X(!X>%
M  O/#<;-'8][*PMW=[$\$2HWD#[5:0B\:C 0?=A@)76KFB)_J92E=CK?7_]H
M9KC%@=0$\EAB!F4XKL!](+K"LS>RP:LGO-VG*W0'KR-DMW];\)& UN K 2VA
M+WRW1,ZQ6Z. WAP%U*8H<%H(>.%]",6]F_2SO5?@YEM%^%ZK1)QJWL3W=,MF
MH7^VF$M>;7!><Z;*<]/1$I[^>%ZHQ9ZL6/)06BJE-SG'O2>AA-D96\-IBV[A
MMD1V^S5&# 741QP,J@T_'U03^22@-A9_)\?->]3$@1OFLA#PQG/#<>^E_FQO
M?#VJ9 E?&M<27K<IDQYV:0K\V6$J<:'%<?6).KKJP0H?O3W%0>:#>5'V.[.2
M*-WIF>[M*87,EJ1*3D-"([<VKL._*K8_L#QF7W!IS.G@DI@'064)GWS*D[XS
MRY* 5IH$E(4 %_=^%.Z]]"5X'Z1Q\ZT@?&I=17C>I4B\NT.5[VJWL?CI=O*J
MPTWN*GMK.+I#Y0'F.XLC[+ORXUW:<M+<FS+S/.O2RCA5*76\LJ1V_^+$G4$%
M":,A>0DG0W(2_@[)3YGF%:1]8Q6D AVC+@1\\3F(P;V7A;N[; GZV?]36V70
MXQVK"?_I4R9=W&$H=J+33G9\B]O&D4;VYMX:/[/N\C"[MN)8Y\:"%%I-;K9G
M178QIR2SAE>0WNJ?D]83E)FZ.R0]]5AH6NJMT(R,*=^LK*_LK,QY1E8FN"T$
M_/$YB,/=G8N[NU(2?6]9@MYT2Z'[ \O0'T/K26?[]!<?[K%9.=9!W3#0RM3I
M:>"9MM>$V#951#O7E";1RHLR/8L*"KWR\JJX63G-_FG9W4')6;M"$K..A,9G
M70]-RGWGEY+WU2LE;]XC-1?<%@*!^!PDXN[.QVK$T$R;&'JQ4PS='A%'ET:4
MB"<'=1<=Z+66&=Y&6;]SJX=61ZN/<7-CD$U-;:13>56"6U%%ND=N:;Y71G$Y
M-Z6HT2^AH#,P-G\P)"I_(C0R_TIH=-%K_[CB.4Y\T0^/^$*@+01"\%GXV;U%
MB]%L_2)TKTL8W>H70=='%Z.SHPK$(R,Z(F.#ELL'>IV5NK<Q-%L[O(WJM@18
ME3>'.Q0VQ+GFU*4RTJMSV4F5I3YQ%75^465; \-+^X-#2@^$!)=># DM?^D?
M43G'B:SXX1E9!K2%0#@^"^FB^"R(H$<M NA6CQ"Z-B2,+NX312?VKR$<V*LE
M/+S;?-GV(4>%]CYW]8;M7@8577X611VAY)RV&$I::[)[8E,6,Z:AF!-17\,+
MJ6OS#ZCM#?2KV1_$JST?Y%?WW"^PX0LGN.Z'9W MT!8"47@/LH71ARI^=+N-
M'UW=*8C.CPBBR8-"Z-"$'&'T@(9@WSY3J<X]9/FF83?5J@&6;E$OSRQG1[!M
MVK8HIX2N1+?HC@Q&6'LA*ZBMRMMO2RO/IW6G'Z=UKS^[]:R_UY:G/&[;9R_>
MEGD/WQ:@+03B\#7(YT?WZPFX??G0^0$!=&*4'QTZPH?V'EN!!H]NXM]VR$BR
M]8#MJII]5.7B44_MG!$?H]1=@5;Q@Q'DJ/YXE]#>-+> G?D>W.V5+$Y/"X?9
ML]W'HV>,R^@YPV5L?^+-W#[+9/< W:L;7!<"R8)HJA2A6[C_+VXGH1.[^-#!
M_20T>IP/#9Z61CVGE?G:3NJ+U1ZWEBD]XJR4,\%03SW T8O;[V\:N3?,.G@L
MENRW)]799W>N*WNDG.XQTNSA/MS#=!T>95&'SV!/F&[#LW3W87"E#X'+0B 3
MH?NX_Z]LQ?W?1T0'=Q/1[@DBZIOD1]V7Q%';)45BW04=D=)SYDMSSSBL29VD
M*<>=9&N&G_#5#SH68N)[-,:2<R3%EGDXUX%^N-S9[5 3E7*HQ\WYT!C-\= 9
M[ G^\RS%90*<* ?!82'O"Q&ZV8C[OP?W]Q ![=[[\V< 2*CCO !JO"F*:OY<
M12B]J2Z0<]U$(N6:G4SL5>K:L"O,C0&7N1K<2\&;V1>C##TN))O2+N184,^7
M6SN?;[9U.+_=WO[\&-GNPCGL&?[S9UO[<V!-/@M6"[E7B?>@':$CO0CMP?V]
M<P*A]DD2JK\JB,KN+D*%]U<1LNYOXD^ZIR\:?<]:*N2NRTJ_?QCRWG][KV?^
M':A"OQ.I[GHG2=OE3HZNXYUR??L[S8:V=[8;6_^]U\3JGW,F5G\_-;:Z\\G(
MZO:\D?5?8+B0:TT(G<#78'0(/_Y]>#[NW]H+)%1\2Q#EO)1$J2_EB7$O-_&'
MO]03"7AI+N[SDBS->NDFPWC!EG-[Z2=/>1FNZ/0R81WY9>8&NY<E*M8OZU4M
M7W6I6;P:43=[?5S=],W?ZJ:OWJN;OOBN;OH<U!9RNA.A??T(]>W!\W'_UIQ%
MJ. Z :7=%T )GZ10Y"=Y8M G%3[NI\U"[!E34?J,K3AUQGF)\PQ#VF'6>[G=
M;. *F]FHE9:SR7+FGW-7F7ZN7&/\N57>\,O.M09?]BGHSYU3T)M[K*#WY:."
MWN?O"QK?B5#_,)Y_$,^?1"C_*D+)?R,4/2N"@D&*P,/-S88-)#IH\E/!0,@1
M+$3L@+S(&JAB%N A;@H^$L80N,0 HJ3T(%EZ,^0MU8;J99K0MEP#^I>KP_@*
M-3BW8A,\Q-XO:' 0H0Z\!S4G$,J[A%#B;81"GR#D"\+("R01'60(%% @.H J
MGPUH\UN D8 )6 H:@KV0'E"$=8 NH@5>HNK@MV@3A"_:"(F+-T".V#JH%%."
M+>**L%-" <8DUL()[-J".D?Q_A_%C_\"GG\+H>!'"'E]0'BV ** &"*#-,$*
MY(BFH$0T!%62+FCS:8$!GSJ8\:N"-;\R. BL ZJ (G@(K@5OP=40*"0'T4(R
MD":\'(J%ET&#\%+H%)&& 6QL0?6'\/[C,Y!X \]_B!#S!4*4;PC/1L@21) Q
M2!#T8"E!"^0(:OAZ; 1EXCI0(RJ -FD-&)#DP)2T$JQ(RX',MQ0H?%+ X),$
M;WX<BOR+(8Y_$63RBT"I@ C4"PA#^X+ 7(4(YIHDL,'(.GS@8"@ 9"LAL',1
M!5LO,; .E03+9"FP*%P*YK7+P*QM!9AM7P&F@S)@.K823">P4RO!Y)(LF/R-
M/<>FL"^R8 K_-_SO@<R"+/ :+-5)8(\Y:O&!L[X .%D(@:.3*)!9XF 7+ DV
MB=)@G;<,K*I7@&6K#%AN6PD6_;)@L4<6S _(@?EQ[/PJ,+^%/<7>8Y]7@_D\
M_@K_L@"Y>0N07<A_UV"]B00.F_Z]%T/5%0!7,R&@."P"9P]Q< Q8 N2XI6"?
MO0+LRF7 MDD6;#KEP*9W%5@/KP;K?6O Z@AV1AZL_L >K06KM]@,]F/M#RM8
M^\T:Y+]:PYHY:UB]$+#<2 0[%1(X;R2!VR8^<-<6 +J)$-#M%X$;31RH/"EP
MB5X.SADRX%@B!PYUJX'<M@;L>]:"_: "V(TJ@MT$=DH)U^TZL+V'O5K_W?;3
M^CG;[^MG;6']C!TH?;(#Q8_VL'8A8*5,_.\]*=?U)& H\P%3@Q_8AD+ MED$
MGE0)8'"DP3UL!;@ERP(U?PU0JM:"2[,B.'>N Z?>]> XO $<]V^<=SBJ\L/A
MO,I7\FW5S^3GFSZ1IS=]('_;]-X!5-XZ@O(;1]CPV@G6O7;^7V"-U_#?>Q"*
M)&"O(X'/)G[@Z0D"SU(4?)PEP,MS*;""9, S;C4PLA3FW4O7?7>K5_[JVJ8R
M1^W9])DRH#[K,JKQR7E"\Z/SI/:TTQ\Z[YR>;'[E.+7YN=-7G:<NH/F$ FJ/
MJ*#ZT!4V+@3LUN%K@-N;B1N/B]L_0(4/@G0$(<A4% +)$N#GOA1XOK+?O2/E
MO[!3U\TP"S9^]*A4FZ(W:;ZC=>B\==NA^]IUE_Y+RC[#YY1CQL]<+ID\=GY@
M>M_EG<D_U#G#VVZ@>XL&VC?=0?,&'=1N,/X7."KB:[":"!S<G0&XP4,W\$&$
MI@!$&HE A(WXCS#JTB_!'+F/_B$*[WD)RJ^]L]1?L$MTGGK6ZC]FM!H]<.\R
MNT?KL_C';8_E;==#5K=<SUG?</W'YJKK&^M+M"_F%QE@?-X3],\Q8?-9%FB?
M88'6K\ %/WY/62+P9/#\GY]!P/L1I\8/"?I"/^(MQ69CG:2GHIARK\("E)X&
M1JD^\$W5^<<GS^ O3KG)#7:#^35FN]45SQZ;BXPAN_.,??9GZ<<=3M.O.9QT
M?^9PW&/&]B@++(YX@<EA#A@>\@;=B06 *[X&7C($","M&8G7DH#;/P7O1YJ.
MX&R:Z:+W*?92SQ/IL@]CN.ONA(>IW0A.V'PE(-/H@F^1^5ENE=6D=Y/M":\.
M\C'V3L?#K!'G">:$RP'F.<I^YGW*7M:4TQCGA^TH%RQ&>6"RVQ<,,8-? 4V6
M #YX?LC/WL)K2<7[D;6!-)>CR3^5:RCR/,=:\D&&Z\I;R5Y*5^."U,]'1NM.
MAJ48'P_.M3@<4&IST*^6O)_7ZCC&[7;9XSU '>;L=1OBG* -<&[2^KQ?N_;Q
MOCKT^8--7P!8[ P$$\SX5\# <WWQ_ C<O$FX?S/E")"O2/Q4M(GO58FNX,-B
M"[%;><XRES.92F>2_=2.QX?K'HI.,!F/R+ <"RVP&PFN<!@*;'#N]V^G[O3;
MX;;==\1]&^\PHXMWF='!>T;O"/CLTAD,]IVA8-T1"N9;0\'T5^")Y_KC^3_?
M:TW]>0]"AO"M6)[POF(#\4F5)O^=2M-%5XL=5YS-8R@>R^2J'4P)T1U+B#$9
MB4VQ&HS*L>N-*''<'EI#Z0II<=L:U.W>%CC(: DXX-D4<([9$/"0V1CRR;4I
M'!R;(_ S;"188A:_ A;N[B#<6G&X>3-Q=Q<N0[,5LH17M0J$^PVJI!NU1J+G
M*^R7'R]V5SB8Q]DTFAFHNRLUTJ0O,=&J)S[3OBNFP*D]JH+2&M%(:PSOH->%
M]GG6A.YE586<8E6$_,.NC)AVKXX"YYH8L*^.!6O,\E?@A1][B#B"1"P']W^I
M%)JN68Z>-LFAVZWKB9<;#40F:VR7'2IW6SM6Q-ZT*\]_<V]6N'%W6ISEUN0T
MN];$7*?&^%)J76PMK2JZC5$>M8-9$KF;711QS*L@\D^OHNCWC)*X'Y32!'#
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M+&WT9VM@&%L-X]G*F,E1Q.D<>6S@RN(\K@P.\4CC)AXI/$1^Y)'$Q_]E8!-
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M_>2&LM]#5U4&?:CG!LDQ?WX'(%*3A=&T'U&T'Q%NO!@:*/@Q.%;D;6"6Q,N
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M6I^%0?V+)*A\502EKQH@_TT?9+^9@S3:@R1.!7'T S&, !%, 2$L8H2P@1'
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M2'%3A$3^['B9G%EI"IF-N<JI#=/5DNIK-./KFG5B9O;H1]4N,XRH76\45GO
M.+3VAG%8[2O]B%K4CJQ%C:A:5)OL?CK #W06#],,QF?3#"A[Y5SJOEV43UV\
MI5L$&GN486:W$5,USXY3VN7&5]CI+Y0[-TPL:TZL5%I[BFQR6[9B0FNQ2FQ+
MM7ID\VRM\.9Y.B%-2_6F-:TS"&S:1_YE$#C[I>ZTV:@5/!LUB.ID-VD?3M.]
ML(_V8"M=_V@GP& /=4_JP<W] '4#@E ]( _E WI,R8 U.[_?A2=[@8] ^OQ@
MX92^*/&$WD3IV)Y,N:CN0L7P>94J(5V-:D%=G9K^G8NU?3O7ZOAT[M7U[KRJ
MZSWW#RV?N:CAVX%J?AVH,MDU^IETE.Z#G;3_ZRE_12_  &7/I1Y<OQ2@?!D7
MBH<DH6!($W*&S)B,98Z<E&6>O F#@0*Q2\.%HY;$BX<O3I,*69PG&[2H3-Y_
M8;V2S\(.%<^!16KN Z/J;@-[-*8.7-&8VO]"S6W!-Q6W!:CL/A^5)CLW,8-&
M.@<T_Q'*7S) _9^J2#/UX&JJ1KG4Q3/6B$#:J!(DCQHR":,VK)@UKIS(-;X\
M82,A_,$C,4*!JY-%_%;GB'NOFB[EL6JFC-O*=CF7E0,*3BO7*$Y9N5O)<>5E
M1<<5+Q0=EW]3<!Q"^2E#*#?9,;H7Q^D,K*/\(<I?0-?>/DS]EWIXR3KJ7]2%
M8[?P0=06*8C8J@EA6\V8X*V.K,"M'FS_+8%<GRT1O)Y;$OC=MV0(NFXN$G;>
M/$/4<7.KN/VF?DG;32-2-IMV25EOOB1EO?&%E-6&;U)6ZU'*:NR?]M(>;*(Z
MN)+R%P[2'M"U-U =*Z,>G+T5()ZZ:/ >!GSW"8///GGPVJ\+GOLMP7V_$S-U
MOS?CLC^8Y;0_FNVP/X5KMS^/QV9_)9_5_B9^B_U] F;[5PF:[M\I9'+@HJ#)
MON="QGN^"1OM1F&C72@RV38Z^R.4OX3RYU'^;+KVBLVT!]1#$_< A!Z@#GJ$
M :>3/&!W6@QL3RN"S1E=L#YC"59GG<#RK#>8GPUAS,[&,2;G,EA&YTI8!N?J
MV?KGNCFZYX8Y.N>W<[3/7^!HGWW.T3K]A4?S%/)JGORGM73^EE%^+^4WCP%4
MT;7G[0)(HNS0(Y1/-=GI#(#5#QPPO,H/.M=%0?NZ/&C?T :M&V:@^;,C\02-
M7X)!_=<X4/LU&U1N5H#RS59&Z=8B1N'6>D;^UC%&[N9#1NZ7#XS<S\B2O?%/
MRVG_YU-^Z]A?SZ#RZ=J3#E,^97M1MN,% '/JX_K7 =1O<D'ED0@H/Y(&Q<<J
M(/]8%^2>F(',$WN0_MT=I)X&@<336!!_E@5BSRO)'!!YL0Q$_M@&PG^<!Z$7
M3T'HV1<0^AW_88#RV\?^>@95L(_RCU$^97M2MCUEF_X$H/TK@/(= +FG+)!Y
M+PA2[\5!_(,LB'U0 9&/VB#\T1@$/UD#_V<7X/WL!YPO4<#^F@FL;Y4 7SL(
MW61?:'._7"+/R!?R]7]T4/[,B6=@^P&2Z=I#SP-X7 :PI6PCRM:@;/G[ ))/
M ,0^ 8@@#PBC$ B@&/"B%'!0 1A4 T!=8D8<B"?\^0$1Z0UYXC](].>S!UH'
MTJ#Q)+G_#_647TSY*?1;81<!W'\$L*%L@[L J@^ YDS9M'0ARN=' !["0@[]
ML_Q$F(@1*:) U(D^L2*N).C?WP6A-T1L)8L)'7K<_0^H1MU20_<OJ@8,RILQ
M*&'/H)@G@\)A# HE,RA0P$+^:M)$NACD[R>#9"592S8SR+>3'""GR(_D 7E)
M/@.UVK_P(_._TJ2NKTW]<H(FK4/9B$$Y:P:EW6@MP;26!!:*Y)(*TD#FD%ZR
MF"PG([36#60;V4N.DTOD-_*"^2;\B?DDC,Q'D?_X\!W4T0344_N+C@:@AAYM
MKP6#2BXTDP &96-8*)W!0LD24DM:2!<+)?K)(%E)UI+-9"<Y3,XQ7R5N,1\E
MGS%O)3\PKR61>45>2B+K#ZG_A@;4]8V4"/5M0V7:3IK'Q/,@;4?:'Q_:GW 6
M*J>P4)'V0Z&2-!*:A0+-0F$1ZZO"$.N+P@CKL\)ZUD>%[:P/"OM9[Q1.L5XK
M_,QZH?"$]53Q/>NQ(K(>*2+[H1*R'Y#[$Q3_ XTIVTP6T%R:7JESF],\S P
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M)7-B&M,HF8SR&N_'IYB#<\S_<>KOIP?O7PJL)>V+Z;LZ1=1V&J-JR7B4+W%
MR9)Y0N$2?UE>9[@\>W&\,F-QFG;:HER]Y(6E!@D+:PWC.A881W<L,XMLWV 1
MWK[',K3]E%5(^RVKX/9/K$+:?K<(;9/,0A=()F$+).-17BAA/; -#K6Q+7+Z
MO9,>>&,WT$U:214I76F HI5CD+]J&G)7N0A9J[S%])4ALM25,?*D[F1E?'>6
M=NR*(MVHY=7Z$<OG&X8N6VH<O&R]:>"R76;^72?-_98]9>[;==_<;^EOIGY+
M)1/_)9(Q,1KE#G-P@75P0KT.M8(YZ&$.UK =T LWT8^7K*?W6*^#S#XSI/?9
M(G6#(Y+ZW(6$O@ QMB]"%MT7+X]<GZX(6Y^O%;*N0B=P79.>?V^G@6]OKZ%W
M[TXCS]X3QAZ]3QJ[]WYDY+[F5R/WU9*A1\\PJE&NLQV>6<0<,-Z=J]D.J-N]
M@?6P":BA)<GK!Y*W"8C;9HC8[6,1O7T:(K<[(WR[MQ"Z/5@(WAXM!FY/EOEO
MRY;[;BM5>&VKU_(86*@];V"UKMO =CV7@>-ZS@/7]9T'/M";L_47O3E;)+TY
MF\FF?[G8SAPP_GV,?6L?_3]]>"=U&W>P#G;1?^^E_]L/A SJ('#0%/Z#$^ W
M.!.^!UWA?= 77@?#!(^#<<*\@^FBV\$"T>5@M6S.P3;YK,&5"L?!?J7#X%&E
M_>!5Y<S!]Y4S]_^B-6.?I#5CKZ0]8\^_J->A#E)_.V/OVTK_31\^?P_])W5S
M:<L2Z4=#CP/>M*QNI_3A<MH<SJ=M,>>T/6:==H/3D"\<A\+A,)0 ^Z$LS!@J
M$Z8--0M3AY8)DX<VBY.&#HEV9RZ+MF?>$6U/_22;>%*237Q,DD\X\2_'UHSL
M16+L*W>R#JA=<QC(IV[**2""?MSW<7K@"_3@3\@P^8H![*Z:P_;J1#(3$Z^Z
M8,(U'XR_%H9QUQ)A<ST78Z]78\SUA;"ZO@Z6-_;!XL9YF-UX%>;7?H#Y%4DP
MORP)9D](XBC[-JJ?1P-6[P86#0)UQX!":J=2-Y*ZOO3C+E>I3[ML2U\\YFD%
M3)_7@_%=$V(-H[M38/C"+*A>\"2A,'@A$0;W\J%_KQYZ]Y9!]UX_=.Z=@/:]
M.^0+:+_P)W2>E_X/ ]3OI7[G0:"!UKR8ECCM$O6IZTM=YYO ]#O A.< 2_IR
MXY?IP]]00/LM?2C?,H'B;6O(WYX,V3M.$-[Q -X-X81(_3]EU \"LJ-]?Q4'
M9C:L#WCA#^X!'W['XT,B_8?UK/NEAS1K0"7G@'1J1SX%^-P&YCP+3+T+C'L)
M,'L-4+T%Z+P'R#ZB[_]8BQ@ G]#S?SJ&$V([3H;H^;^<"WRMGIRI-X>R'-_R
MQO]N+=D'/&!B'S"(!U\#W__Z'Y:S[EN8^S+^.N,Z$,68O1GS+!9Y\BO V#<!
MDW<9^X> XF-J?TZ^'N%;!:^MQ^L8 3^8 S^-!WZ>QDFZ"_ ')ZH/.2C_R<'H
M+_6>%'8X?Q\ _CE/&)STP7]H5:]!,?>93P+1U/9^$7!BS'9O,_?O T;W&?MG
MU/N2?$.^)[^.\!OYG3S4TJS)_&W,:S(GTB0R2V-:AI_-4>])83FDWI$]*4RZ
M],1_D"PFT>O37YH0%7V_<B8DT.\B@,22;%).FLEBLI*L)UO)3K*?'"$GR3ER
ME3Q-WB"?XQ_\1/X97NOXB_SY/Y#&3F31Q[,LQ(CGNE,@R6?S-SXDBJ238E)/
MVLDRLF9D+6: [":#Y!@9HM8E7O<F'N(EINACINH'INPO_,S?JOGI?R"-H]>W
M&<-R$#-KYD*Z+]V/" K*BT^,"XV(#H&V#C.D[P!)QP.2(A22F,3OY9$JTC*2
MG6ZRCFQFS#NHN8^E.,Q2G,0OS,Y/N,ZR/,^*_ #?\;]O\ <;E'J=A@@2OOPO
MI(ET_Q/,6#)32);FS- X2*;3F2572 :L(7W6D$XF).U24H]_M-KPE]92-HH>
M_*[5AU^56_&3<A=^4![  ^4Q?*L\@Z^4E_&%\AE\IGP7GRB_P7WMA_A05\+[
M>A+>4Z,OX=U'D";1_4\R@F2K@C2>Q_%6+ ];C=4L9LJ++2<"?QFEX'?#?/QL
M6(D?#)OQ0+40WZJ6XVO5&GRIVHC/5=OPF6HO/E$=QGW5*7RHNHCW5;?QKNIM
MO&'T#5XQ?H@7322\8"()=\GSII+PG!H3#=(T0TC3]"%-T8$TU8!'YF,2:VSB
M=/QIXX9?Q@;B@54<OK+,Q&<6)?C8HA8?6K3B?8M.O&NQ$F]9K,,;%EOPFL5.
MO&)Y "]9'L<]JW.X:_4DGK=Z!4^/_4*X:?V[<,-:$J[92,)5&TF\HL;Z7R1[
MZMLKB R2(\OAP'S,,,=O4R?BNTF.^-S6$Q]-",<[$Y+Q^L0\O#RQ'/<F-N"N
M;1N>LUTJ/&.[2KACNUZX9;M5N&F[6WC2[I!PW>Z4<-7NLGAETG/BI4D?B^<F
M_RR>G2S)ALBI$4X^@C1+J;FYG=4/OHGXPUD;O\U2X6M["WPTS0YO3G/&2S,"
M\/S,6-R9F8&;,PN%&S.KA*LSFX3+,]O%2S.[Q(LS>\3S,_O$QV<.R,[.W"<;
MFGE,=LK^G/RD_2WY"?MWY$<<'L@/.?RC&'20Y <<)?E^-0[_HM%F1^?.CHD#
MP'WROIL6WG<RP,NSK/'L' ?<=/'"59=P7')-$LZ[9 MG74K$TRXUXDF79MD)
MYP[9<>=E\J/.J^6'G3<I#CKO4 XZ'U3N=SZMM=?YFM8>YY>U=KI\I;7=Y4^M
M 5=)J]]54F[5H!AE^.5'U/^*G=P'@<#KY$4_&5YPU\9M=W-<]9R*"UYS<<8[
M"">]8X5C7FGB8:]\V4'/,MD!SSKY/L_YBCT>BY2[/%9H[?#HU=KFOE5[P'VO
MSE;WX[J;W2_J;O)X3F^#QZ=ZZSU_T^WUE'36>DG:1.M1U/H_4/]C#H"O1=!]
M1 *WP^B" N1XPL\89P-L\5C@'!P)\L5@4(2P-S!)W!60)=L14"@?\*]4;/5O
M4&[V6Z"UT:]3N\]OE>YZWPUZO;X[]-?X'C+H\3UKL,KWEJK;[T/5<K^?#9;Y
M2WI$M\M?TND*D+1'D;PU ]^[U+[+SOYF/)TH7>F%" %#H2H<"[?!8(0#]D9X
M8D=$B# 0'BMN#DN3;0S+5:P/+5'VAE9KK0EITND)Z=!=&;Q,;T5PK_ZRX'[5
MTJ#]AIU!IXP6!]TP6AC\MG%'\ ^&[2&207NHI$=TB<XHOS 'GX5K5H6>3N;,
MGV[P/(^G69:CT7K8'V.%7;'3,1 [%YMC X2^F"BQ-R9)OCHZ4[$RJD"Y(JI<
M>UEDG<Z2R%:]Q1&=^@LC>E3MX9L,%X3O,6H-/V'2$G[%I#GB%=.FB.^,&R,E
M0V) ]$;05?,CZ__#:.!>$O-/)W@QD_ITYD=3.?M/U,*.1'-L39J,#4G.Z$WR
M%7H2P\3NA'CYLH0TQ9+X7.7BN!+MCKAJG;;8)KW6V Z#EI@5JJ:8/J.&F)TF
M=3%'36MC+IE5Q]PC7YM6Q_YM5!TGJ8@^T1OE.[:#=QGSLVG, 9W@X[F<>9/!
M+,[^4^78DFJ"OC1;K$F?A95I7L*RU&"Q,S5&MC E6=&>G*5L32[4;DDJUVE*
MJM=K2%Q@4)?895B3T&M<E;#-I"+AD%E9PGGSTH3GS4L2OS0K2?S3N#1),B0&
M1'^4K]@.7V<.;C/^)^C(3W/P/T+V\'PK/UN?:8356>.Q(LL!2[/<A459 6)[
M9J2L-2-!WIR>KFQ(S].J2RO5J4FKT:M*G6]0D=II6):RVK@DI=^T*&70K"#E
M<?/\E&<L\E(^-\]/?6B2GRH9%J1)*F) ]-5\SGIXF7E_DK&?YR3HL5+F@.PH
MYNR?G_7DJK \SQI+\F9@89Z;L"#/3VS.#9,UY,3)Z[)3%=79V5J5644ZY5E5
M>J6930;%F8L,"S-7&>=E;#;-S=AOEIUQQCPKXXY%9L:GYEF9?YAD94I&V9F2
MBAB,HEXE?('U?ZT .$OMHQ7 WDJZP'(Z(.9C6:$^%A=9H;UH*N87.:.IR%NH
M*PP1JPNBY94%R8JR_$RMDOP"[:*\"MV"O ;]O-P.54YNMW%F[B:3])R]9FDY
MI\U3<V]9I.1^S.-O)JFYDE%:KJ0B!J.\SWIX)@>XS+A/4_M0#1U(+1T(CRO*
M@,5E.EA09H[FLDEH*)^%VC(/H:HL4"POC925E"8JBDK2E?DE>=JYQ66ZV<5U
M^IE%;:KTHN5&*84;3)(*]Y@F%IXT3RA\RCR^\",>?S5)*)2,$@LE%3$8Y:U4
MS0K=!<9]@MH'&C2K,NMY[*1#7E"E0&.5"6JK)Z"JV@'EU?.$TFI_L:@J7)9?
M%2?/K4Q59E?F:&54E.BD5=3HI52T&B25=QG&EZ\WCBW;91I3=L(LJOP&>=\L
MJNP7D^@RR9"H8LHD@U%>R=2LT)VM9CW0$>^=KUF56<UC&\O10*H:#%'>8(/2
MQNDH:G1%?J./D-L8(F8UQ,@R&I(5:?59RN3Z(NW$NBK=^+IF_9C:):JHVEZC
MB-H=QF$UQTU":Z^9AM2^:Q):\[-Q:(UD&%8CJ<*J)8-1[K+]7V$;.$VM@]3>
MV:%9E>GFL64!]?E92:L^"A98(F_!9.2TS49FFZ>0WA8HIBZ(%),6),@36M,5
M<:WY6M'SR[4CYS?JAK<LT@]I6:T*:MEF&-ARU,B_Y0IYR\B_^2=#_V9)%=#$
M&5J3I#^*>K?:!=;!<<:]G]K]G9I5F:6D<0GU^7-.IS8R.DV1MF0B4I;8(VGI
M7"0L\17BEH2*,4MBQ:C.%%E$9XXBM+-4&;RX7CMP<8>.W^)5>CZ+^O6]%QTV
M\%STA,IS\1L&G@M_,/#LD/2)GF?[O]Q@#LXT X>IOXNZ&Y?3#7<#'2N!6I)/
M4E8*B%^E0NRJL8CIF8JHGMF(Z/%$>$^@$-H3*03W)(J!/9DR_U5%<I]5-0JO
M50N4'BN[M>>MW*+CMO*0KNO*2[HN*U_5=>G^7L=EA:3CLIPL^Y=+]>P3VC6[
M@_I7JI^.8@[6JG?&T VMIQOJ ^+HU,,VZB)XHRF"-DU P*:9\-_D"K]-/O#9
M% *O33&"YZ94P7U3GCAW4X7,=5.+S'GC,OGLC9L43AL'E8X;+R@=-KZL=-CP
M0&F_7E+:KR.]DM8H9UGGAZF_DV9U [57]OV[*E/0SQQL R)V 'X[!7CL4F'>
M+DO,W6T'U]T.<-GM!N?=OIBS.PRS]\3#:4\F'/<4"_9[&H09NSO%:;O[Q*F[
M]XF3=Y\3)^V^)T[:]9ULTHY_9';;);G=MG\YP?SOI?X6QKUF(^_'K6P'V]D.
M:)XSU*LR-(V!@\ \.F6G(PK,.&J(Z4>M,.V8':8><\"48VZ8?,P/DXZ%P^YX
M$FR/YV+B\4J,/]Z&<<?7P/KX+HP]/H0QQY_#F&/?"&.._"U8'99$JT/_<K '
MV,:<K]_,/G&;^NDHUL%^()N:\4>!X!. !PWC+#K5J33TX\\I,>:"(:PN6,+R
M@BTL+LR$^057F%WTA>G%")A<3(;)I4(87VJ T:5E,+S4#]6E$S"X= L&%S^'
MZOR?4)V3H'K\7W8R]QN9]V[FNTV],X?:N<>!1+KST#. YSGJTZ5/H6$==Q4P
MOT%G?%,)O3LJZ-XVA\[M\="^/1U:MYVAO.,#Q9T(D@;9G5*(=UHAW%D#W.&%
M;].!WZ&UO_V _$6D_["%N>_9J=F94\.X\ZF=]#CU+U+_,O-_#9A,EVY]"S!]
M&E#1K6O?$R"\I N\9$0L..B-!UZ9QHG0'$X(.3%[G8/Q&YR,O,&;[HV%ZC\5
M3@Z3Z^1#\A/YATC#K&6]+U:O"C'V L:=?(GZC->#NH[4M:/NF.<!XWN /L-0
MO$[W_PYY5P:\QW*\;\C)L!GPD0TGY9.!3YPX,?,$/F<YON!@^ 4[_"_9Z+X<
M((^1V^0^^9'\,LP2]:H0?U7$G*=<43\91?T[@ /CG4A="^H:OL'8U;H?J%=D
MR*<CJR-?")R0:W%":@!\:PP:,DZ0;8&?[(%?.5G^C9/$WSD8_,$!\"$[GH>L
M\(=,]$.*/'R;?#!,LWI5B%65RIR'4]N#,=N_!$QX#3#C/S/X8&1%9G1E1+U#
MA%5*8TTM\HMZA42DE@ZOIP+^-J598$ZDZ60N-&],93G4?[I+6C'RA,SQD2=C
MK@PC&4^DQQY/?TWD]/V81M0K$KXDFF20DO^?*Q*GR<61W2'WR'W\@^_Q-_[\
M/ZL@#_\+R8S^UF0L)!71YCG4Y7 DGB2<I) "4DWFD\Z1U1G-^H-ZE\H_V$N=
M0_@+)ZCQ./[ 5?R.9_$;WF6:OF&Z?A]>_?B1_$"^_R\D2WI]<POFPYRYL(2D
M&,=/IY.Y)(C$CZP0E9&&X5S\A2Z6OX=7[J/.5NKLQ,_83YTCU#C-ZU[$=[A)
M]5?Q%1O.E_P7G_.;GY%/_P?26'I]*V/FPPB2(8\&8R#I3F996!^"[\@*41IC
M+:1N-:_6PG@646<Y==909P.^1C]U=E-GD#HG\ ES<1_7\2%>P/MLQ._R&V\S
M4V^.K%N]+HP@:AA>][ Q8#[TF _Z?C/FPW@"ZV8F)#UW_*T=@M^5"?A9GHWO
MY*7X2EZ'SV2M^$3>B?OR;GPH7XOWY9OPGF([WE'LQ9N*(WA=,817%)?QDO)9
MW-/Z$'>U?\"SNA*>UI-P1U_"[?]"LM6'-)'^WT8&:9PN)&N6R8KU8S8)OQK/
MQ@.5+[Y21>)3@U1\9)"/]PPJ\)9! UXW:,.K!DOQLL$JO&BP'B^HMN)YU2X\
MISJ(9U0G<<?P$FX9/8.GC#[ ->,?<=E$PB53"1=,)>'\?R%-46H6&-5,9CEL
M=?'W.&/\,-8:7UA,PT=F;GC;- BOFL7AGGD&GC<OPC,65;AMT82;EAUXTK(+
M-ZQZ<,VJ#U>L!G!YS%Y<&G,4%\8\CG-CG\+C8]_ :>MOA<=L_A*.CY.$HR,<
M>83AVYC=[#\S>=N3SZ<)^-Q.!Y^,,\);UN/PXCA'/#O>&[<F1N#ZQ"1<L<W!
M)=L27+"KP3F[9IRU6X@ANV7":;O5PDF[C<*)23N$XY,&A:.33@F')UT1#DV^
M)QR8_(6X=\H?XNXIDKB+["0['D%R8!D<V?4XLZMU!=YV8;?O),,K4W3Q[!1+
M/#EM&B[/F(OS,X-PQCX6I^S3<,(^'\?LRX0C]G7"(?OYPJ#](N& _7)QGWVO
MN,=^B[C;?H^XT_Z8;+O]>=DVAZ=E_0[W99L=?Y%O=)1D&TB?$W'\%_7#AS]2
M]Q-V\6_XT/]SR'G: [@Y1X&K3L8X-]L6IYUGX[B+#PZ[1&#0)1'[7#*%/2Z%
MPDZ7"G&[2[VXS:55['?NE&UQ7BG;Y-PGW^B\7=[G?%"QSGE(T>ORE'*-R[O*
M'M<?E2M=)46W!OF*1_B+^E]3_]T ^JU@:I.K/+_H)>#,/!6.N]O@H(<]]GFZ
M8Y=7,+9[Q0C]GJG"9L\<<:-GL=CG625;Y]$H6^O1+E_MT:7H\5BC6.FQ1;G"
M8Z_6,H_'M+H\KF@O]7A5N]/S.^U%GO]H+?22E$3Q*#_/XQ#DSZ&7W?KM2,[S
MHX!S'/).!=%O^.IAOY\E=OE/Q4" *S8'^&%#0(2P+B!!6..?(?;XY\M6^I?)
M5OC5R)?YM2B6^BU2=OJNU%KDNT&[PW>G3KOO49T%OA=U6_U>T&WQ^TJWV?\O
M[69_28LHFQ[A!R\.A_3_=^E]K]-[GH\'3O)XF.79&ZR%[2%FV!)JA[[0V5@;
MYHV>T!"A.S166!::(BX-R98M#BF2+PRNE+<'-RC:@MN4K<%=VBU!O3I-0=MT
M&X(.Z=4'G=.O#7Y6OR;X<_V:D(>ZU2&2-M%ZE&_\@#<9]]/4OIP,#*4P?A[W
M\>=MD2(V1ABC-W(">J(<L"+:'5U1@4)G5*2P,#)1;(M,E[5&YLE;(DH531$U
MRH:(^5IUX9W:->&K=:K#M^I5AA_0+P\_8U 6?MN@-.(3\KM>:82D4QHI:?.H
M-<H7S/DK,<!3]+X7./5YC-..01YWLBR;8NEW8E58&6>-KK@9Z(QW0T>\G[ @
M+DR8'Q<G-L6FR!IBL^5U,46*FIA*955,HU9%S$+MLNB5NB71F_2*HO<:%$:?
M4A7$/*7*C_F(_*J?'ROI$AVB/<K'; <O,.9K:?2<6< Q>O!]9(!#?B_+U9VH
MCR5)5EB8- 5MR7/0DNR-IJ1@H3XI6JQ)3!*K$C-D%8GY\K*$<F5)0KU644*;
M=D'"<MW\^ WZN?&[#;+C'U-E)=Q092:\;YB9\(M^9J*DFY4HZ60E2-JC?,!Z
M?Y9:E]7K4/2>APKHM\CF7& 5R[4D51?M:>:8GV:'IG0GU*=YH"8M0*A,BQ#+
M4^/%TM0T67%JKKPPI421GU*CE9O2JIV=TJ6;F;)./R-EIT%:RG%5:LHUPY24
M=\A/!BDIDEYJBJ0S@K::=U@/MZEUD9J/%=+[E]#[D[XBSO6S.=?-4J(ERP0-
M61-0FVV/JNRY*,_R$TJRPH2BK%BQ(#-%EI>9+<_)+%)D958I,S):M-,RENBF
M9*S52\[8;I"8<4R5D'%%%9_Q)OG1("%#TB.Z1(=HJWDM@6V!.7B<L1\KY;U0
M3L_'Z?#:,F!1/OU&G@QU>4:HRK-!>?YTE.:[H"C?6RC(#Q;R\J+%[+PD659>
MICPCKT"1EENA3,EMTD[*7:R3D+-:+RYGFWY,SA&#Z-PG5%&YKY$?]*-S);WH
M'$F7Z!!M-2_R'KC&' PQ]L.5K =./S>3GFI@ 3^KHR^O*%:AI'@,"HNG(+]D
M-G)+/)%=$BADED2*Z<4)8FIQNBRY.$^>6%RFB"]JT(HMZM")+EJE&UG4KQ=>
M=$@_K.BB06C1R^2!?FBAI!M6*.F,H*WF.=X#3[ .3C+V YQV;F]@/30"RWEL
MYK2\@I\75>@AK\(<V96VR*QT1'K57*16^0DI56%"4F6LF%"9(HNKS)''5)8H
M(BMJE>$5;5JA%=TZP15;=(/*#^H%5%S0]Z]X4=^__#N]@'))-Z!,TB':@2/<
MYCUPGG5PC+'O;0*VSJ?O;&5;Y+&>92EA6;+KM9!>;XS4^G%(;IB.Q 87Q#=X
M(ZXQ6(AIB!*B&I+$B(9,65A#H3RDOEH15-^J#*A?KN57OTG;I^Z CE?].5VO
M^A=T/>N^T?&J_4?;JU;2]JJ1M$:YSAP,,=Y#U-_51M_70>]-:]1!:MKIN^C+
M4UL%Q+>J$+O "M$+)B.JS0D1;?,0WN:/T+9P(;@M3@AL2Q,#VO)%OP45,N\%
MS7+/!5T*]P4;E/,6[--R6W!6RW7!\UJNK5]KN<[_6\NU1=)R:Y&4;LT:+JF?
MU%,_I4;]@<7L$Y8 7;1%\[M8#SQFD002OD07(4M-$;1T/ *[9B"@RQG^75[P
M[0J"3U<4O+J2!(^N;&%>5ZGHUM4@<^GJE,U9NDX^>^D>N=/2(87CTF?(EW+'
MSK\4CHLEA>.B?SG+-G"$L>[J9 Z6L4_H5C^=Q'I8Q79 3YZR&H@B :M%>*U1
MP6.-)=S7VF'>6@?,7>L&U[4^<%D;"N?>.,SI3<>LWD+!<6VM8+^V0YBY=HTX
M?>U.<>K:4^*4M7?$*6N^$*>L_E,V996D8:6&QUCO!QA[/RU0+S6[UC('ZY@#
M^O%L6M7X3?3_F^E_Z<WG;-6&8[\Q'/K'PKY_,F;V.V)&_UQ,'_##M(%P3!U(
MQ)2!;$P:*(?=0"LF#JS$A(%MPKB!$X+-P$W!IO]3P6;+0\%ZLR18;Y+$40XS
M_IV,?0,M^LKU0/O&D3486M04VL,(>F*?W8#+'F#F/L#V@"XF'##&^ -C,6YP
M,FP&'6$].!=C!_TP9C 25H,IL#A8 /.#]3 [N!2F!S?#Y. 1&!^\#J/!^S#>
M_SN,]TDPWBL)H^RE_A;&OG8#T$GM!MK!8FJF4R^:?MS_$.!&VS[S*#WX"7IP
M^E.3TSHP&C(B5E -V1%[& RY$7_H#T5!;R@=ND-ET!Y: *VA-5 ,[87\]#GR
M$GD Q:E_H#PI_8<!YGT]\]W%N%L8<]E^().:L;2E <.[8NB!AQC_XX 5O;$Q
MK:K!%1FTKNE#=M4$PM4Q[.3L"+WV-7K<:YR$7>> >UV]190W_'56]#4&=^T8
MH=^^^@GYE4C_82/K>@5C7[ 7J&3,V=2..PT$GJ4^-6=>!"9>!BSIRXV>!/1N
M ?*GZ;6?I>=_EI[_61/@.9;C>9;C>9;C!3?@'LMQCX/QB^SL7V0G\R(;^8L,
M\$5>],5[Y&O^_G?RSS"K=FAVYE0? 7(9<_PYZC-6-]KR&=>!\2RZ^1U ]2R@
M?9?:+Y%7B7HMY TE)T#ZP%O&P#L6G)1. -ZG6?B0$_3[+,=]#D8?<_#[F)W>
M)TSX)ZS<3Y[@Y/$U\A7Y:9B%!X!:IBG_#/L!:@<Q7K>G-+MB;*AK^@*@_S)C
M5VN^3=XGZMTI]\DGZO40&4V)#O"EBI-CYN3;L30JDSE9GP/\S'+\S(G!+^R(
M?V&G]RLK_5<VK-\8X&_,QV\?#%//=E; NDYBOD-N G.9YVF,UYKQ&E-7=W3]
MY?[(^LOH#I%O1W:)_&<M1,[KZ0(/C8"_+$:>DG$:>5.(^HTEY2-/R&P=>5,J
M*UJZ/HQD8$.?;0W>J73$XPD]-YR(-XDDJ:2(U)#6_[G^\'^?DGE\9'?(L_3J
M[]%M?XN_Z-A'US[^^%]K($;T^@:6D)06_,EJI!SJ'2KS2 A))+FD@C22#M)%
M>D@?=;929^?P/HP_<80:I_ [+N)7W,3/>(4I^IS._]?AM8X'(VL>#T;X;@3)
MQ R2H0E]/H&:L60*-+MD_$G,R'I0,;5JJ#.?.HOP&Y;C%ZRAS@;J]+-*=O'Z
M!WC-8ZRJL_B*N?@"S[,$'[$*?\#'_/;'PZM#$C_1\.$(PVL?QBKFP@"2EB'K
MQ)R?3GQD/2B,FDG4RV4\Y=2I9W87X&O6R9=809VU^ P;J3- C3V\]B$VGY-X
ME[EX&[?Q!M[":RS5*[S*R[S:BR,K58\B6>JS'-K,A0*22@^2OC'+PEP(4YE?
M5\890,T8ZJ53JY ZE2Q[(V^/-KR#)53HIDXO;]=-U-A.C7UX@;EXGKEX%M=Q
MAS?S;9;T)NOC2>K=$"5<E_U?)&LERS'R\AM3EL.8^5"9X0_="?A>Z8#/9![X
M4!:*=V4)>$.>A5?DQ7A148V[BB8\IVC',XJEN*-8B=O*=;BIW(HGE;MP77D(
M5Y6G<5GK"BYIOX"+NI_BG-YO.&L@88B<5J.2<&J$X9</6VMXR%O[%PL%?F4Y
MOE:9X[Z>'=[4FX.7]'WQO$$DGC9(P2U5+IY4E>*ZJ@975<VX;-B!2X9=N&"T
M&N>--N!QH^TX8W0 IXT?PRGC)_"8\7,X9O(I#IO]AH/F$@Z0_?^%Q"Y6_1*B
M[R<!G[%K^9"W];MC%'C'2!\O&8_!,Z8S\)3Y/%RU",8ERUB<LTS#6:M\G+8J
MPTFK6IP8TX+C8Q;BZ)CE.#)V+0Z-W8S!L;MQP/H(]ED_CCTVM[';Y@-L'_>3
M,#!>$OK)U@F2L.41I*F:36^?.;(;G,6NG,?G^//3$[3QI(TIGAAOA\<GS,&I
MB3XX;AN.(W:).&27B0.3"K%O4@7V3JK#[DFMV#EI,79,ZL:VR>N%_LG;A*V3
M#PB;)Y\6-DZY+FR8\H:P;NH#8>TT25Q#5I,>#8*:AS/8[<T&WN.0]X([<&L>
MAS=GSK7M19R;HL+):>-P9(8]!F>Z8^_,(.RRC\9V^Q0,V&=CJWT1-MM7"AOM
M&X0^AP7">H>E0J_#:F&-PV9QM<,><97#<;';X0EQA>,]V3*GKV1+G?Z2+7&2
MQ,X1%H_P,[O33ZC[B@_]%CWX9?*X-W"*P]_167HX,,L2N^=,Q39G%VQU]L5&
MEW#TN<2CUR4=:UQRA1Z7$F&E2[70[=(D+'=9*':YK!"7N*R7=;ILERUR.2Q;
MZ').WN[RK+S-]3-YJ]L?\OENDJSEO_C>A3F@_G/TW]="@'.AG./R_! _VSM7
MB6US3;'9W19]'DY8Z^&!'H\@K/2(QG*/)*'+(U-8XE$@+/8H%Q=ZU(GM'JUB
MF\<26:O'&GF+QU9YL\<!1:/'D*+!XY:RSO.^LM;S-T6MER2OT2"K\=3PE8=F
M'\ZM<.!2%.,GAR. /<&<9_L*V.!MA+4^X[#*=R:6^[EAJ9\?%ON%8Z%?G-#N
MERHL\,L1YOL6B\V^56*C;Y.LWG>AK,YWI;S&=Y.BRG>OLM+WI++"[X96F=_[
MY!=EJ;^D(/)A_#1\RGA?9.S7HUD'<?0ZG'KLCU.O?W".R7*L#C# \L Q6!(T
M%8N"G=$>[(W6X&"T!$<+C<%)0GU0AE 7E"_6!)6)54%ULHJ@-GEYT#)%:=!Z
M97'0+JVBH.-:!4%7M?.#WR(_:>4'2\J\8$E!Y/DC?,@A_CGJ7:;V:0ZQAU.
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M/^MO(OV+DR2\[<KAV%NS!G."0]Q^LHU#?Y^G>OV#\SLG;;0[FJ#5:3R:9LU
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M'?0)UKU XZ'*Q7NE=! #@O?!0?=+K@=&R^&@D\8==->8 WX:?2!,-@=(A [
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M7R7^T.F!3H?'K;J>L<Z[O&!=$_*R=3[DU9'YD%'2'^VD/^.3MZF;=X*E]Q,
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M?(:OXC)"%),1I>C,1$5E9B@RJT 1694*SVY2&"0Y-&>V0G*6*RAWAP)S;U!
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M\F<@>QZM9P5WMF'=]6JQN:!FFP<T8=1OU33F,S6--?V(QXTYF B&L&AX+SC
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M..B^'DZ[NXAZ ,/P["'LF)%J60/20IS4ADIE 0XJ\G=3@;^/\OR#E1,0J>R
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M F,="FCC=37(@QHF@C ^]Z%*78 M-FH$BTD$%Y,(+B896^1N69.RB %N42S
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MO!;%V MT[3J4CK7TS2 ?)(%0[GFM)@;!&*!KL<H _EB)/U9BQTKL6$ELK&3
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MU\"4=L*DSL!<7_/XKJU;_UC88 _&CSK>S!H$<P[E(N]]K$K@I0$^!N!A087
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M)A@[.M"):@L)4FPN1[*F2B1EJDJ2ICHDT=R(Q)JW((X9C,P,7S)#I>8 S.;
M6.8 2^:((<V9ETD6(=]&.60P^T79X#\)/-.Z\O>A#$&.!M8/ [;NBBHZHMP=
MLMA#)Q:0PP#VHP&=*-N(DYR5'$E:*A&G%1Q\*TUFP8S9M -A(:@E(S2^;(48
MU@JQM!5F'RN "$N  4O$TY8W0?N!MP[#O!]I GB.[<[?AQ(;RK\ZHB<@>P ^
M[P!97#IA3 (JF4(GNFB>*NQ$P5F<I%H#RSA@<G& $[/'I&,/IV8/@[''P':
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MRJ"+,J"ZFX=$K#\P]X/4GX<Q A*Q!"YFGD9ZT3O$RPQ"JD+<_@).XCEB]Z?
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M'SWP,08?<_"QA&7:4P?(T1XU>N,O3U!X0$)FEXHK[-,%/>D,JW7$Z&D-BW?
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M/UUT>.=?M9T4/F[H\B,]XW5I\:Z%$^YOR9RXL/.#;=%NR=N?F86VB%PD?6.
MY_[.B<8IFP[M/_T\^19)S1JH>7-;J<+*>SVB^0*?.**PUS\^(,V,J)M&C?]S
M^Q<?.WGSBN2GZFS;O<\@L>;=L9BW4NNN#=AP:>*.8S5W3L^^_S(+Y68_U_]<
MYM)NPE*@Z9E3[A6^R9ER;KA 4,TIWG_R] :7=5I%H0@J.Z0^'O#STJY#RT8)
MG;1 LK4(7W/CS*_<J W#VZ3U<?<JF3GJXO5GIS/*+0\-+G;\Q41T?^T!),-.
M7SX]WZ/5Z?9O4K[_'!;Q?/Y'GP\I12,N%W=YVVOEC=:_7ZFB7W*YX%G(I_C(
M<9]?AM9D[GMY,36N?&O(VZL>AGJ\)2G]59<?/ M,WN(A__9Z_F>/@I51)R7/
MWWAV\M)GK2N%'MDYT=3ZTD*+#_;?]_F]Z;)7;72EF]:=C5\^SX^8\OWFV^7Y
ME\??Z'6YX/:/G[^ZIMZ)Z;$U_[#K_B-DE3-H^=VIBJ=V:/%WB8N/7L)9=#8A
M+B=F-<F9E'1)?^;A&5O)Z1/<ZFS%F(I[7!)7&+9M6X>P,6V+8B3W+5W_//_>
MST0WZ5WCWUS['@W0.%:OT^V?TSN7);A)]'S6K0/YY01'*">$*>]JSDDS2CJ9
M8K EBZR;E3KNW;5,1FS.MFM<YT^=\C;>'E[67'7^]4C 7MV:L_Y6TP:]+%P-
MVWM454O6\UK?5!H!L.*TM%?%S$'E3J\4KY[:KF][>,FV2^N.D'C[7<4#>L6E
M=AG6BJ_P>58.;ZY\FQLX9TPT:;^XM[YZ[?<VNS68Y9VTDF:KI@\Y8KNAZ,NO
M,8BL5#8OZUU3I?)2W;:SI8WG:<V*Q[M?Q@])UBGTF)/K5]"9R"IJR/*[-WT2
M]=[&W?>A_&TN ];=5MP2/.C3F]>/7707TOY['H=U>6B=T^'#YZ*$TRXA*\AZ
MGTO02HN15?HC )MN?WORX[7!9,>\+WGMEX?<7MIUSK=Q#RX75)#DI->EWY<M
M+CBZV</CS&HG)Z?JX]\Q1VD<WWY1;47H68MYQ-&4O3%_?\_,W5=>O?%T'=YR
M]H53;Q1M4_:[E0^G=45M?QQ867#TI;4>8'=OWP\IWSKL_/;]QSVKU'%=$^>Y
MC&@9OZ_L;4J6^#N[C'R]SWO,6NW5F&)\/=9S3DQ4X+;20X?"%X=$ARX-FCWA
M1N?+!?-@G9VTW:Y'_BII]7[8H+V/7KWO&G[GB0]S0^RDU^=/1^3[?1C./X4H
M.AP2JSBU)6CMVR6Y%5EDYV5B56->//]F3?Q8W3NE;X_%,([E1/S5A.#,!S<W
MW!PR4E/B1/+TW7L?#\^L.[?XNZ)KC!-[D1GG-2B+% </'#BYO?^X&L AB8F?
MMRV+Z_32I1]LPO9YI)6)>+'BP(DQZG&CIIJ?Z?IX-<P@[_O'GZ6.R^[=&#M@
M7L2=M0N>5#SAN:]E5\T]%18^'#5A,I',['OR:DGV426\><;9Q7?1UWDC)MWW
MDR&QXU_R<\^,[A,A.;+-JEFE&\^D%]FT+U"4'77@YR^>[^B>OJ+9W$^+[ARX
MW*-'9=<.^RN?'MGH\E/M@&/=.WC"MV<L[J^C96KP)HNDTKL/-'"?9J(5/N-P
M;O@J7MQ@Y3)DZ;U9!^]<"EN2_V#M6"+5*1,CQXI'7U\:-HLX*GH3^[T)_+5V
ME&_V9;_05:<9%SKL37>WJR$K>UM.3BPZL.)#Z.3R&JV!>WI/G81"@["RTR];
M7XMPZUNU<:?:E^,6!YQ63KY557V@?-B#RV]-/T_H@:%^ZL=8+Z_,I0<BK&87
M]GG[H(*HH\'#7O$+9X^[XS6:)[3H659+RBE\G%;ZB;<2Q)F^>-&]5@<\?.9J
MGN/=&:38:= 4IS4;#A[J(]:_;<?;=T?L]ZJ[M/FWLWC!S,G))7M6[?8FJ=V[
M=AU;8W;X9Q"FJ78U-R\ZKONLMP,:6ORQ0%.%4SYEUU%F?6%C7**#4MEUPV8E
M6761\+89USN4EVD,,GU=,:YGZZIK4>GN*#*8^KSL0_\OSVKIKN7YLDTIWN3X
MS23K^LXOB^Z<NP .78+/%W=(D)OJB-'NV*/EWH6)\YK??+;E7.3D^,L+?\A]
MO7L ,R[_?D;[TT6=WW:<5]&K.&?O_A\OES_X%%AY]0A_>AA25--W6DR?66D'
MB%,4^_3H1I>':D6?,EM7\Q]=J'>RC5C4<OYYT^'O1QWR^41BP5?B+WL/U9W?
MZCW,WWR+]I?6=Q9:O&<J$X_L,3JO<-H-.:T-!V-/GEG/?"8V^TG5A^._'M[R
M7QB7QE\3".A9'E4U>%Q-H><2(E^E88/B7X^Z:;*2#S-$!P V"D/VU-A\FWZ_
M'EJ(?ZSQ+KGJF;MD</KK(?^<OCFB]VI&GQHOWEH^XUNEQU>?_'[DSM8!MVXF
M##%\4]6_4+DZ[L%A6\S?+Q\S@;,"+W!65[8-6Z939FB8F#D97R"JSG#U4O/:
M^TT^ODK)\S274KPR,G<\V+^_ED9NK1Z\YO;"3W)?(PY>PJ#C3].G[K\V+=$X
M"^_GO&[GU5>);1GO5TL=W\RNP\>:6U9MN#7%Y\SIXM6<O:TDGN7.#?5\U<V(
M7ZC]&CZ_O_UPJZYGWOWZ6A+=<*#5S?]7?G[[55U+GB6\&4.W[[R(<WG,-!*&
M_R7F/QPU=LKMUZJ#,6"D)CU-/;6C],>\^_RW6#0",_;;;[Y66?S,8K11_60^
MV^:&G9/>H745N_Y)76'P_+3MH^X[XJ\-^YBXU/0#3W"Q^Q\^C]ESN?F^0E]>
MS/X^ RJ-UE*>NN^X0]K(.<['F 4<&-2EP;'QN5%EQBN_DM2IRM('JH%VR\^V
M(XJ_5*#^96TMM=GM],7WT\MRG<R[YZL3,&OUTM@_N&3;@>N=[BE<1:\<VA5L
MX?BZ[^G+)V?]O..587FMV&)XPF O_QUZV=E]Y 9D7G5;UXG?.LG-SU^D&L]-
MLG]3*>6=TBK7-37B[ON$S<HKHXY0AM2FJBMC9W:?)V/=*;O\7-#8_8]>O7MU
M;J;]NU'3M8K4-_B_OWB*.*O'#"S8FLR$F6TDUJPN6YEUR\F\QV,22+T.WVB]
M3RD-6)F)V!+,)SOE/9FJ6+R@#=&0FB*%ZL=QK?<XG?D'!X]X0-'EF9V?O!:7
MULX?;8WY:OU9L:IACJI:-[/CLT@\9.G<;)G^PX)Z)CZ7MER54\FQM;8<>K1H
MA?8Y;Y*(W'N[8$]&:I?)%<K/7SS[LE]O]=& //_O7;XCEHIWL[1JI1KQ]CI\
M47/#;4.O^7EU*P:_N,RV[_MQ]6_%6Y&&UFF71^U&Z.7Y)J1.;).7Z<WW3(/A
M5$PYZ)3/2UY=*_96-9E:/M8R(53V1AOB3"CL7%:@<;M\_GXC4O6;TO>.7FRH
M:UX6<71T"E<4.!WO/>W[<H\U%W[(6ARW^:Q G*F%NM)Y:KT_S]Z_FC/N0*'G
MQEIZ%.8W._O$L6L];YY>E7>)<_%;S2NOS"R]%S/ZO.R0M//\1 SUN',^PUZ.
MD_:WGAQ-AD=+,5HFS>^W&*/BIQ(S*CH]BHBW]/#HO-JI!4FE=']R."#/:/'V
M!R-1#:>?6_*E)^XV9N.+5LT1&'G:G^]N&)7,L2XLS%8/?7RX8/#'ZF^%RQ3N
MKWRP(K"RVX_+S/PTHD2W'R;OO.X.L)'!:8Z_+ODE;]'7T>BP_:3&HERYM\N(
MN">+M*N3K8?!^C <>XWXTF9C?,('I5NAM=3L7C1IJA4&O.EPX-$MO24\98K&
M$?(3=;=YSCS<?]0$S&@Q3\=-;#]R7-NU(\;]R!(;'&Y]9\#0)0ES*TC!Z7#/
M(K$2G[8I1+Q.39PHZ;"".%J*1?'EAHH+'D:3^'\I8($YV>>7*K=.M5\^T^^5
MS5S+]VE1JTIXDXY"\ION:3NM5MTJSNF,6$NJ*\)\V=',X"GQIC8/IHVYYR\]
MTLHP<?$](6\:?AB1AYZ6H>'VS-SO[W_>-1,;&7AFK6%JBSDDKW%G8^JCWEX[
M%QN4?TQQS>)/^H_5BSYE/'L\2FXQT;4^V0]":Z07A=><(++14AXV9="7!T:O
M,_.^57\CA>"W5WYJS^LCKS&BEN#:S!2E#WY2.IJO6J!.8B9A4L?OK8A^VZWX
M88M8I^>KG16[+!Q]A R4R[3>&+DH';NWQ1#HXXA8ERO%ASH,K9G./& 5]__@
MGQ9:&1@VM-4[.A.9&[;!SG],IG7>*X0F'](&;+?1"UWWB^FXSJD,-MS'PX;4
M80(/H/6M VB-()3A WKD71UU(?"=-W&4%!^^_+9)X=:I8))Z8>??JGM-:?:%
M+-)TKN@8Y>'E/[;[/ZU#2>S=Y^\_$Y9>-8]4.A>[JY;D'>)V*;=>^OT'(VKI
M^D7E-]H:+(QH=5 LQ"[BQK"/EWB!@>-2\WT]>D[?X'QI.]TJUXUXU.64VI@6
M1J1HW<7Z:<B:Z7UW;CG>[_KTJ)D6E1[/5GN3V/0G54E5$PI5J^U2\_0^[[B_
MP?#3^S($,+Q[F!K'GU(76LPWE/.?4WRT/5SC+[C&SRI&XZ]#;+VXU8'Y%_."
M-^[Y2A(I@S17[KW^.D.QFX#+C>]9R*T>X.:TNQ 3?&EE2'A&9[N[11VR*%/"
MT<;3\][W3K<J4[W)W#CQ[>O=);E^>0$D9G-MIFU4U8<"S2]P9F*_F"D D\KG
MA'&&S,JSQ-@--S?ON=YQBG3W?] [>V8:S-US[-3,+6)$@_>VC71\Z5[]NH(X
M"6:A6I=V7\N>DT6JOTHS+O(\+Y'/\<3PZD['![;I150N)3>P+;,TLIK$>]_N
MW2]XWH,,QE,:_8P?M*Q;S>Q;F.C\OY7-E,EZ<[QW-"../##3Y[U]?9:,CHC-
MN11W8?F+GLR+Q#6? SPK^,_-&=4A'R!#<6JWIQE6J]9H+1M/M,<C>^H@O3(]
MPS>C_*N?US1TR89SE>].[6<3Z5;=TN/*MJ_%[B&M]^E(Q[^TS8YBAKSD[F<O
M/E98A]N^>GFN6&Z3G<DVK2]>1G\U/%WR-(N2%[T9X*+[YSTII>F+RGN$FRZ,
M:+O?3%'JX">IH_D.!=HDWC%I^>"P.,^NB9M7D\+[#5T.3N]Z=%C?PT2%S7X:
MG'#8[NO9%]]>-$GLV]VM!_/*#AXAF>,77]U(VW[@1-!=IN(Y?7Q?=EL^/B<H
M#A7H;O8]%+LU\%7N,1Y3T>O(?;1OQ'WJ^U'M()<H_?DA]]C/[3I7'B&%0[L6
MVWL:NG[/(6+6Q3^N^?1V705),)&/;Z5=2,LCI#+\[J)#5]_=#M1$(YF%F\5?
MYG_!6+^9VK-7:/-]#_(Q-73V"K^]<4'&NE347OHKY=$Q([<=-_G/F\7GUMSI
M*A<7=&80G,:!Y;P(W\1B^%"/LR=_?=8[W*R65I6<'1^!T"9).;_'BX81=EGQ
M^[-?E_[<=R8BBIE*LL1E7HZXW+/E1\3V1\1'V2^?[3<LT#KI!3^L.S9DQ<@;
ML]=?NAKF'+4[\#7,]U3+D94_+YYZHV%#G(U%^H?S/RE;%7Z>!FFG&*94;BN\
M8A%:4=]34FMCN&WG>3A\[Q$N,,HZC8T:8MG7K[-1H39)C2A]LC)@<_3BO?>S
M:$!!TOS[4U\?W[$8,-EL.1U.K;)]\?FM'8G9JZ4Y159M!O!C#(G9=*-PV/II
MS=ZR^(F';I*2Q?,O!J-4C]XKEKV[H?H?])@?<SZ+KQMH&KXQBQR>G;^W_EOZ
ML\2.Q!GV9$'8I:G7#N?\8\,LHK=__^ I#_:B%H[QZT'/2H-U%]V280\S>%#&
M\?S(6;,O:2I ^:% JY.9!3,.AMTF9OTBX(R!67+E%5),ZFD2>6_ QB^)AQKZ
M2)F*"]OT1VS1?=5J-2EUJAKS/GYAE\1=3B-:1KY]7O:.%Q8?3P66GW</TU9E
M8N2^%O_%?MJPY5UXMMM\^6[ADP3Z*;Q?7%5"8%C%#2ZKGQ:CGZ9)_FT_B4>'
M3@^:W2+6X_GJ,8:8]:\MF,$)B16+B(\W^@<'U?]C[RNCZEBV=1MW@@678,'=
M@A,LN+L[P1V"DP1"@CL);L$EZ,(U0'!W=[?@FK=6DGWV/G+O.S_NN>_/JS$8
M3=?JKJJ>5?.;WYQ5U;UV+[(](S59 -;(NHI+.B%#WN3H?T^IV-[R2GWDCJFQ
M!X VXG>5VS0WC\?!M5(=%#0^2&5K$]3_DU(!T.5K^T[R]K-F\L7@/NJ0AX!#
M+P0<BFJOKW+5[=F1IR=3?".>_)KL49JIG;YW >V L<M].-\%[,?0IBFT,'(P
M2PHN(+L<A5X   'V6)%KS0%IFJHW27:?#__*1,'/3RW!2'VW<5'?+E6UHQ_^
MAPF&&'Y_U6U";9LB\-,OYNALC.K6ALU;*P'0'V]7UG/]KGZ_(93+2C](C1 %
MC)*M?P5!:+XQ%$5=:^<6^/P @",BD>J[N2IL4\T9 $/<$)=V)L),$E@''OJ,
MTW"G(&U_Q3+/  #S??),X:6^^OOTGV%9J,;IIMX<D#]^[5D&H&KH(Q!U5)N
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MZ1)+;/QM8'XT*#R.'AX7;IT$ 'W)+,ZQ&Z>?ZC  N)8894,^,H4;H?\R-@;
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MNNJ,Z]8)8@!D$D=L1&W&!X<UM&PW2.-&S&H:C3?TGA$+>PK:;:';'O9'6@'
M7 VN63TD^$._);ZW#*K0H8=L/\=QKO%_&X"D875I8G=MD\P. /A6/B7.<&DA
MKKM CZPVOR]TX]QA  "%==]GXYE-\F:5%GKG*Q5+EN$GP05 (.)(NY0XL_Q]
M]\%;*'RTZ!I; )MAI'3D(U0,KOG4QIKJA%"LU\U9WSBRX..=D:N;NW_L;-B&
ML[(*,!_B8<#,G4U#8'S<_:[&Z</EN;FEDYK.Q5X96%WD821T%>R\T9VY)C;7
M1%1':I+Q2SP.IL&.]#.P(^VUHVJ!]F+S'=>7W#N=*%CW"[M :^8&&4"F4K$!
MVZ%/;R9JV*^+=<7: K-5E<O^#6^#8-OOR)%LM\P<BWT13$4)H6_!LG/;_$L;
MBZM,?PT53QR)2OND"P!^Z4OV4]4G(XO#Z6TH^@>[Y87]K=T>#L'QO(;"NHZ6
M%SR+%EB&?0JOMS+OP?X^M-)-S#2%Z,W(@*/HEC=?*630C@-0:?A'KU1+3V=
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M+<^9>3%ISX,0Q Q['KT/,=MK+\/!7$.VV=T@V?5]]>CV%8S]E6;,3BSXAP
MV;E@Q.>VB7K'S=PR6@3^E6G3BD+#D,5B=-_,!7HV0_4\O!R_U!R?/0]"Q6M$
MNUMK\Y+YG'*C?XT>#._OM6=6UW5WF'Y^W@I*Z ?P[#;>V_5A;FMOAU)V&0"2
MF8/<ZV?>T2WE#12-UX00C$4F>O+]  1UO:V[69PV(.SK"_@^1=Z&*$,&?V81
MEY&(Y$GVY:^Z;NWS"7)YDG,2+R[-M$P@;WU:!U"_E4\]7[V\*59NU-C8<?-<
M$CWB]"[3GFG4AR:3N'$" %M=_#(O)T*H.1...:W6',>:X+=/ -2XZEC0,,-
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MU/!I=/P\+N4_5U^,5X-'GNJ9P:I65R@'*DP(?FI6=8V#H!6/*\K-'4(=1S,
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M8I'>Z*!?2>=1D@[)B7B6^&K?KG\MKL:JT^=@")(5<J'?;7(P[VD<&NE]MOO
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M28J+AU;>"+?'Q]D$3+F?0?2!<MUBK/Q^:'=!YJ\GXT5?^8L&7\LNDVVO_P,
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M1OLIG)%&_1V('K<L](F)GUIR*.Y8,]1&%>QKO;YP96A"7WY.;HSB5QGLSGX
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M17-MYC;FUL^<MM>_V\"2OYM YN*(Q)M-EC\/9']:2 [NWB5J_CFA]7(-+76
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MO)ZDU[1$&D1W?<N?8%LT"0GJIZIRX)PA/ T+/(,&C+XX+>@^00:6CARALII
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MO71%AE13>=4N'*SBN<F81!#<&!/I=:L>.Z$X)^W$2+PB%[<A_[N+7CK"NI7
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MM@A]5I^1ZF]M33ZL"-F6C*WJ(BP.(ZWT^]$BQ6AJ8CB/A7^X&Z0I(?FCE<*
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M/1(]<'6I8D );@]M\M4=;N$%5Z?/CQ7WB6$O+ ''JS[AYJ+O<<E9I$PXK71
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M4VI/;V<*/:E<#;!/#Z!J+KO(F'FT,0F--HN3VT'PSH"*;-Z_5I!'P(IRNK;
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M];6.K"!L"5ZH&)F"7V^BA@KI^M^D3V"Q_3W.X<MNCYOZVE-S-O;(T+Y?^>!
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MYHT_>5&5 ^7$*F6;B)YK5(5)QZWU]BB78H>FXP.9LJ81;EGF?CK5KA4X0&^
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M2!JWNYY8")6761R)LX "'02P"'D$L'Q)TGD.^IQUKN**/RH?7_$AUA7_V--
MFTNGXTJ"6%-K_L.V\X^QE@BI&KL(VQY=RJ328_D:)\0#K_8JUJFGHFEIJ6+.
M46Z\2)K.S_>$W@=!H^W\]:6ERB+CC/R$JYQK1!F4L2+PH[1^LU8]08,-GQ%[
M_1V6@0FCDB.ON+N7XP41"B'9G^1HX7CV4J&E6K)1@",=]!YG.QN;S'0#N9CF
MH\\@>"0H+"XI7V(G,B<AVE]>XB/&>+8<[?S\C+[M$]*<^(B"*M&1LO0%'NT&
MP^$$HDL:[81K>N;+)@$DNFS_ M0I&%H!W[8!^"UVIU*+4'9F259F46WO.'\5
M-A4,%8T,?3$;ZYU44YTK170%S +T"[6UXN#4_@A(-D@ZK QYF4&#EL&R[ED!
MIB?/ QH(J'*X(]PY'^*"/5Q+6L[MKA0><OL48W,0T8ENJN8OZ;N7CEV=%D=&
M73^S^,?O7KOS8?&QU+@7O+PK/XM]!+@,G:;\BK^B-ZQM?Y_ WMN/3;][6MI:
M+UA=63\L%0T].N8;G?GUF5*O6> ILY)M67H$Z,46?H!-PTKTP[4G,<JL?M8,
MC+B>EZ12[ YM+LXOY,UTSL3/DU5]W_G2J?)SB*/-[@?H$;!45=VKHDBD$J."
MN?C\V,*]L9#PVOW+DH&5G65\9JZ=9'%YQ_AQ%9N3$*0@?N(BK((A0=ZQ1F99
M0+ -/^J/%$,.=()9>BZZ4\;F2KBU5S:3(#R(\2Y3C2(17U8@1IH,-!="J%\4
ML89"YU2B0U27D$*Z79/,TC9P 9F[@+3N<RI_5'HNQP9$B@O$),Z4B9&NKBZI
MF4;BEF.A5#/W2342KK$N=1I(9F7;D2AEVU+4.J&D>((WT:&)9-.(-$WN0LX%
M8?DN0V/UG%)PWN>Z>+J@W[CA:-'S&KD0:\!L?4E<7MPC7X'[Z<XN6$4X<-%<
M,:"0;GFQ1$VJY.1$HHC6?WBXU^_W5FYK0.&@O?+(G/'M^Z]ME*0%%...V&N%
MN: F)Q O0@(G@9(&Y9LT@O2:A3;((\"PG-C1(?G6\2(2,Z;29.W5BB^,/$2U
MM ;:8NJ7HLZ+ZQ*D?P4]L[OC.Z>*B*],R2L9?UKZ*=_](XYQ(:]5O3OXLDGK
M4NN^6T3QU3RGWP>?6KIJS84?Q6EWXDGJGQGKY^9VW+[6U=4SY?]M!,D598F2
M/.V>+.Q49YE"ODU&HX,"4E"ES;@TG/W2AH_;!) (>#WF626-I;\\^Y*]UL=X
M'6UM62TW9K;S$GIM_X-)S112G(GL!#[LB/QWND\$JCK>V/HR=1^MI4W;RE'Q
M<F6L11C5_##L? 3\&)&6$[6@7'T$S%O<C/A\^/P]00W&=$X32LI&V[0;^&6@
M<'2 QYMB543$W2OE&+J_D->?JZQ-<KO_INOBT)J=3W1AR-YU@C65_/4)1FUU
MK5)I?"F+>/$_#*T;#+XMZ&DS@K%[=4 OH*%2T?;VES?DK[+M[&S<IJRD50QZ
MFE#K7],*Y"!3^:3N>C55I94Y.HBTZC?VS);_8Y:_S)?U=:;,YK8L>G/Z;/K<
MSMV*J4RD8^IBK)F=9;,05'[*^G (9<\I=:N/J*VF:K=.<-1N6Z,/17#DF'ZE
M=V6F=P&JGJJ@'_E?Y^2X>S_KPR%@"_GT". =ODQUE>/U*G,Q"G5-Y=DEJRF5
MM@8W/ )"@AX!4Z4N:$4YV*.OW\[>RCT"&BVR\^Q^,/Z>ZG/NK=N2P ZY=;,'
M%KHP/TZOB.:80T^75(!"C:L0[==Y)-M1KMXO\?4Q1/4)SV_(+1BD7'K/.YR*
M[S5CB(&J.W)D"CK<A'?;8XEOFSCNO1[R7;_VOC?SN/("PW>&OC Y)IE'36CB
M*9^1R0T1[9?1]^1VEUFD?)@U(0T.I3DV#09!^ D!2X-#&6FD<\3\%B$Q$E).
M/62)"7JH2$=93ZP1K*!QJGJ^ SHYGJ,,WJ[B->.\M352)_$A&8W.'7JI]"(X
M?:='.WF1\;FM2VXK.7*6:Y1:"Z:\XP=L[T)TPQ6PD/TO^AP\>Y2(TR,M+'U3
M_/2 N$0TZK*"/JTP?YI'0'\E3*<1]&2F8L_Z*.Z$</P&R=JFA:RJB]S2Y/;>
MK OM[FFUP1$YT+5>3U^IM3S>X.B^R/ZHKFC6]3],Y!&0!)UT?O_B:V";\HM-
M%,'1)4E'98_MR2/[RV:?5-NCH[U2&=WN 3@F\&=NJ?;'J6W#TT'ICO)CON_D
M%'WU"PM7S>#W?X,FZO[ OFH+B=&P!\78=YNPM#G>N=V7K^E[WB5T:7CNP/J&
M/>NGV<&)K<2*JB:BP!I^P_VZ.^5E^H^4\(CWJU:7S08&LM-35DJRJ[P/>#XG
M>N\N7Z\S/&PG_G7X"J9V+A[VMNR\[&["\0*:5D =E#JW>\)7.'P,A49J*:41
MBABZCMQ\UHXMY)"(Q2/1BY@T*/-<_)'7,AW55SER.:YAEUXVLP)/L4^9UF9/
M!E)N!E9%]'>3-\8N?S.][B-#1<-E:2WM\BP&7U(=;'NRQ,VAR!WM5+3Z3D*L
M9"*D5X18G_YR=1,M-YJX*/'!Q1PCRD9OA45!(EW+\(F)637R#Y0T<?YE.<5/
M<@*@DRFLNA]0MF[.R@I.U#03Q.1HF>(3=+^E1?5R#4]4#C\";D_OOKC:.<(-
MQ,+K.8#Z+1@TEKKZ=^ZFVNA262O;@T_CS37I0H90^QX!T90O2#[UY,2Y\N,8
MJIB>$^P,&2ZH$^L%5%VJD/$-OG"F%<R_.-G%BTQN:JQJ;DRA1IU+\*R8')#,
ML1=P0WRUH^NH\@;#_J25QKJ$G=:_]A'@#,.5S;3F<\PF9Q612P:QV[T@A:%D
MN3=S.&,FQ:XH9E_.)N+.U8SI/]'RJB30RMPQ#:>D_E2Q>#";7EL?TR8,6?G\
MC:)AN,BK1']PQG,A!2WP)>3PM7E+9PRO[X$;;E0T%BF$&FX,EW*V< STX3.+
M1>O&U:(Z85SP%DP""'96(J<CN^;D\X+L<BXS/*F5QI<LQ_ FU.MN<.5H(QW)
MZ@6"_+Y"5@Y)ZA4#$&#1EWRV-NNO5,Z<K%\6R'0/'S93J,0:*O<L#UA:@JJY
MR1) ^Z!8=>48V/:4H?8)]3&67TW7$-;S$W;I27!:%_' !OQ;9$"325XCR=93
M/3DD7 G4\=]+(H>DKQ\!S)6"3([A3(TU2'O$40R=6?"[X[A*H>O^; 4K/:^-
MV8/$GXJR8SJOU;N:^OX.]1.,N<V!>DZI..+Q"$@&N>)/BU!7!-_/HQQF_RCY
M8A]P-?&@+2,D%+QMS"P!KD04*R6(E8]BZ03_F/M36I.>BTY)V7? TG<Q20A
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M>0W76U]'H+-L@)OS+$'J&N?)%[*X*3OBO@Q]WHZ*$::2><[2$JWH\@K)>(A
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M3_ 'K2VQ)/WFT*T:KNC\Y 0QGNBX6TL@OJ0S%-C#ZL X,4!. #-I&&PO)/]
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M#>]=1L=QWJ/Y^<4G IE!I) P$D5%8E%55?3?S)Y\ME>4DSG#YXA( ]->3L=
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M4D*D8B:J7,L"W >2DQ9!?>@R06:O#TJ">0+7\G$;6#0J^?_U+=,!0#H$P&+
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M.N2L$V+:SZG5(^E/Y&A*U?):1*54S8K:,IO(_;F9(W&DCX-,8*^?R%>J)L]
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MFW*=(PSM=#4'.S&6-B7$$@.<:ZJ"K7WX+0J2&RJB]A6RWERRR$H^\T\RRRE
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MQ9\6!A/ !ZH1$3/\U,=P\D4JK_Q1;%A'?PN:O!_\RL_3S]H& ?T^5ON2VX7
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M!@>;MQ$/"$W>VZ;UH3Z\3^-+&RA%<GS#]+Q)O."J*6<]YPO"B36[#RJN>B0
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MB&1D/>#)G"CV&'YZDHH7?R4R+>NK<?%-%S[RG1@X&XV71J:0"&]<=/%_4MC
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MLZ[%';?[K=@E2)T0T] BE_X#<Q"@;P&ER &8J5NVYB?X80\*5D MTL!UWE_
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MN7!2BP3!#]169T+DKC-Z')$N>'LF'@&X(44Q8C%:RV>JDT9"9)>^TY>]'4N
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MFU1?)P-)OQ;98;:*-K8S14 >;].:E!5,WC0^9NK(_G$',^4F@=0(7=C*_@W
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M2I^=6X3SIN^O:=;+;A?44PC3P0BB'!-?<1Y;70)]M6\T8R8304TGHGZQ6RH
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M1379/45>"AE5"TXD:^W*##VX$.M9?-PL,Y@]H$9=FQY.82OR''E_H7KCS$T
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MV>'\1 .'HT4C]X<YS7-A1$ZTRR?M5E(BN:/T/WI1>E.;.1XC RD0IVCY=4]
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MJN;L3SJ0$1$3E^/733;39/MO5QC/&R?>_XJQCNJHP[]KIF M +@<H\&9=%"
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MQ(Y[NVQ:BJ1N9=HNS3;9MC](;<1PH^QXRE6Z(LDSEW+8R5-P!"_@\X\S\+^
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M/$Z&O[#S5*&:)K3A)?6;"L!=)@.:T\@KU6U.:_MU^0K[4OV=3;;@/^H<VM<
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MK PPH(%[AFOIYF!%1@[*Q%Y^3N_]BE'$J8G;+FM]D'?4M#*29.0YT0^M)/6
M,;'C M>Y3#FZK'%77G6"@>L,0DC3@@>4E8L!+SD@1CNE_R%7?T<0\T9 ;*++
M%LM(4G&BGT7_A>&"2Q\[I%1_&I;<=IV@(E$> S&?\E\SYOM=8J\ 5&RMZ>#D
M1P2]921XU!MR ]UXAUX62-+R$:-<R6Z%Y52^GC&<1=LS(SQHD8754=G =^]
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M^&1+HAZP]]=+O_O$V]5\*A<MCCMSYD)WTB0704:?U.-H;U6CN81=KI8Q4R6
M()9;S6B4\C/MMHIJ+YB++7+0=,_6)K_<]*9NCP/_HI;LEUF]ISEZ2,5]\K?F
MX'DHV2&N9'S*=-M/>3CN"P_@$XTW(_1\JEF&D31X12XOC$"\G&\!=IO:3,"(
MAXT.378UB75[L.Y>@?5,HL>)X%+-)./-F3&0$ANG&L]36E3-Z:%WGS_4>Y-?
MUU8=CEE-:-QN0^2,EQV[98R[EH&%7M[5>C] #3U^1;:&IHI!4V8:M)1;F'A
MS"*$D\@J#^-00J"T,I?"Y_U*YK@?^2,GP$1OJ\OC9'MB;2-0^0;B#*BWRL93
MIB](R%@2T'>-HGV7B5WP:#*S[X+M 4O9>ON+J!J)?J?!-\F391+7P%JFH.9*
M:+SP9?7G<4#FA\(%UCF3<P@-L<2;KH[.2 [Z6R42K^,JN[NXNC!1XCN_U&C
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M3E<C;(8$N]1L2KO:?\9FK6F3HUQ9)=DP9G]Z)%\3#AL57=4]*XL97XR2Y*&
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MW@7"O"/=LMFMGKH?-:1>LZ.A@!)BQ@K>"'_3T(_N%P)@#BUR-G0VE[[NC+:
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MC\NP0Y]95I@$=P =FZ]Q$2@^ (CE_V-V\]_MXSW40ZV,MKY8K/=!KX*?:9/
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MXCRR$8;Q-<M\P4 K(/3/B6.F<7>FQ6!&?/W-8+V\*]>$KP<+P&HU#X?8&X9
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MB%:B-A<!S8.BY)E=XC<S #P0M$Z]=?&*,[L"ED-?ITSY*^LC>5$]R(R_Z_&
M,HG_X=[_N[5$9!P@('$V48W7P%C;1\ \:&PSO\E(.?P249>"%36V93/JD1#6
MN28^3NFXUNG#?[W\JS.#&!S>98TWAH=@^75<7D<*]>98SO-,O;0.(/(4GA'W
M'?Y$^B$\^^S)]+8Z^<'I9M_JO7_8ELYXXS5C/5TC2&F^50Y?6?>W=8DZ;X5J
M,!>\ZTL5T\SPO/=E#M7\.+S@U#HF-P\CBE8;(\9#*TD2/$3!,_-@[,W:U9S2
MT55.RS@IAA>?6Y\IODLW%9<M!U^M3Q]S,H%:LM+EK4YDIP[)5RALY"DXH.._
MO$7[:AYN70:/76Y\"X32R[FR*[F,G_O_U\/QVE59U-YSS[GE(T.RYRL*2V$:
MN LP[>,&6DW[5MM"$JT*N".?^ZD/3^_I5P4X(E;%+^Z86,?!6CRWDG7\W0N,
M4,O8[L@WVDN37.^_-WC>8U=);RRG0E+0QDS)6O:R*=]J)?:A^!>""W<D&$_?
M4L/'^2$Y\RO6A=/$,I:=(2C(][+UB>S?$4.:M%!)^<R.6D^K;:(?UK@6)D4#
M^J>JW/[!&B6 .1VYTR_0((7D4_Z T8O_EB*':/8>K\HH'X YT?O2CT!QT)CL
M]-(83C^5#['_*]S_&=381KUC0N7+@A#J6A77,.I22Y$6,9?JDS(EA[&\[$W1
MVQ1/II 0T3% ^A+<$W')ZOW8ZF>7#KF@5=J[/R4I7"JPU+;UQ#\'_T!H/!.7
MUO\ >J=B&^'SO>"#U_\#,]R+0NRNL5,L,RXINKQH6:$"!?L^4!AU"=Z]I"8:
M_8V=EY8_  "$Q*H\:NDV2M8 P@GY?]HXYNPD< G;HG,NNM7]^:DC^=O 9C)=
M_!_>L\?'X^?O#[T$W?FY 3$45"%V=_F*UUJ1&XWO/TADK-)6&U0"#J*[1>VO
M"WPE3JGCKQ67OR+@<'_Z_*P$ CE79=*-4I><\=GQ=;0/D$>>F5^/QXNJ9#0F
MQ?YBVKY'GY(\SFT2$>Z?%+JVR9\G=(*WG\P C8'B*:F8?G^6K4UHV2I'T6Q8
MDDT%; Q!'J.HF>8_)?(P!DSU1K+IMR$"<A09UNN+[.1LUDTU-[%F/>)(I35
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MW )R/IL^YA9@QM1+*4V3NKF2STBC.('GQ<T?@;!]N1PN[) D0!P,V^MJ>!_
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M#HUX9]3#;MTTEZA[4*BQ]Z+G<$ETV@7?UI]O[?FH-ATQ)[!4O,:-U*##5I+
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ME<F'DO4*4'-66*N5+&->D;LT5_5% >FY_)YW$<JQM!'PI^-HW)[Z"C#*,S;
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M=UR+'8/37ZDR(K(4-9RLQ K7R<Y2[_9'X9!T;#L@<-Q(/?H3#;QS[#:NN.R
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MLYYD@.87+5+DG)68/J)T9OG-Z0?@C', @#CC7+4UXYCUITWUMA36:?<G631
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MTBZS97L9TH/E]+96TOJQNG&C7@"4F[7J^?&1XS&(PSSO*V3@0N%[SO=M,L;
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M,"2^)%$S/N>_?8=V=H-$>Y6C0!^!C$U^9M%G:CH+IUUV7$_(E%/1)$/$H<F
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MRQ=4IG!RO</31KBU:"3S0\FC9/>PHMAD^>\21DHURR%2M[E"7ZVM+J1R:M,
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MYCF3._CO0/BA8N NT8]2@%EZT\%6/X[B-'T]^[.#L4F;>>LW@UB;J2\ZZ.B
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M]CY9SWP*L6</)CKS,> G]K?<27ZH>8Q@F_(*#)07VW^BI[T$9[FC?V.,*HZ
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MYZN-(_5I^<\Z^MTN'9C,GK=U)K N3Y$%8E<X'^^@/?WY-K#'-<.E+!K\=)W
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M"WN068E!I\>&:CX@^A3T7M7/Y42:M0Z;WIFS=?"N]E/%->S0 +P99ML<]+W
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M-&^LMG%W'5@U_UPN6"./[:^B]I]O49349V=G!Q:4E;9'Y0MOU/3R,%N+/^8
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MC3G*9Z-SP[K7K?99.JP(@EOM)#M4WZ,OU'.4G#;'X/^+O?>.:ZI;UT5C15!
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M0GJ*RJ:$=&M=+T20+(R&ZK0[<3'.E=*FN^?RV_8V0_$/PMQ;[W=0_64)=UB
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MYM)$LHNS01:S%UC! JR "_0(P&?,4YC6AI,\Y\H;4OS.C%T.%H;KX&9?9VL
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M+T3"9#4+=C H7B-T =IE!"?5[Q/]) ESM30%7.VOLI7HRP)X.PHSO,JS&E#
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MZ62KQ.@;^?0AD*;ZU$8])NNWP$#KD("BP,MA.;_K\Z_&BKAP?= !G-YG:6&
M*/2N+5OF_\N[;==N_].C5?['RV%D+0'$1<T"2;0VG/HX*"!R--0M\3&;<1YP
ME'G* MR%/M8]-[%,D!Z8A>UZO9_4AN_)27$P-IU3#8+A]"3I;F&:L[@@N.T$
M?FJHR_,V:;M!0V8)G1G0\^-<\\F&T6D4FQ FGNTR#;M_.H))=[VT/7X33+!"
MCN%XJDEY: ?K*'#UJ:4[MX0'7'L!88=^^?QB"/=G'^6 B\X#W#+#R<9&)&]L
M(S'8G$]KH ZXXV#$1IP!:/D(VR\D$=6;8;HG:#N\>::'PU#P-/2&8#VA9WR<
ML$WY08<0Q&Y _(:*1Q7YD'FR^,21VF'>ITPAN@8Y<(X,>EQ>V.%39G8WTWV:
M+=K?N#-+?-\?8'2HSD,[[=-3\:KKR/U[);JII&7H-Q,6X-F<3#38 _IX2G:L
M!M5J*N*$FWVSZW6'-V_]:@15P.G-LW>W\\>+IS)"N5O-=ES#?U]"/O%UOD$$
M_\B;?E95O36NH&_B]T5-O2T5;*Q/7KGDZ+JSHDY<YW54>T<:(8Z/=]/WPW]6
MW5Y,.W<'PM@THE0]M4/1AJ'F->N&>2"FZ0V;A>C531.HF!2(5(L\MJ<;NUM(
MDZ$L4_W82)>>M)SR=0>'XIY:I^W&0 CF<90N:L7T5Z%Q(KII_4)$^<=G7FJZ
MU.<:X*A][^L,OY&^CZ:(-XA^S]5\2'\=7%*W APKOTV_9R)>"&G<,X\EHWF0
M$SB.;>]/RRGI[U_.KZL,9]EV]+:; FESZ#A<I<RC.DT"2)U0\NDPMF!*SN'6
MIX^FL#V/,[=XQ5*KE]M"$F<:^&Q/$K/C(^*MQLS\0F1K3=9=WQ5V?3R?@2FW
MAJ(FJY=PI%=P!R8_AGH5556,JVCHIJ _!D=T;6PF_&"^\>TQZ<=^QU.O(]@P
MS@FA2^/'1\!C> ^:T3B]92XXC3;*N#1PVA_[$>P.'-,RH;;E<@LXP(L1^EY"
M/@H=1_VSBSZAY^H;DC<=Q8B!!V(^;3:-1)=FP$8G%V6W;)@H!8S9L^N'81!A
MJX'$V3#M7Y\NS34X8;-D5/I'^[X26==RQ?3ECQTWU!/<Q*URL@ 'YZC&Y%O=
M1%!TD[9,20,T[+5FV6<D3EM"E!/<^FK-Y!,VZQX6<OZ[W_4D@562JJ/4;-F&
MEUM=NGMJQMUJY] H.") 2F-WK6Y@$JS21_H>1[N"'&$!/C+S.9X@M:B>*'[J
M78W8_CV[KHA[BS^=IBDL0,K#^&G ?AZO)1A[7I;/-^''CIH)@WGIY@GP%VO5
M?>N7!"?$J^,QKWC7S[KNE(S;]ZG ^!;]%I!G^KVQ126_Y[;E_CPJ:8G-EM]_
M9&^D$WP:/)U^^6[Z"_+.2@_1 Z%>V"3SAB=-8:!(JT,SZO9FX]2C-6?X#_D5
M<+F&36QY1]/M2R"FLY[S2\P.F_.OU3LL(& 4E-"#]]6(*>5CN-G!R8(VU$.4
MAV)/GV+>\(G_KC>$"IGBB%M4=[)#"T>[[CXR>R+E9?E\3M$,K,"=/&=U7^4W
M@+D(C^8B%/SF027LQ5A 5IX)E/N:[CW3BIQ*G+M;&(]16[!N6(C_78(U6%"S
MQ*ZCGKA3%>#O7V[3!15"37]@ 3CHO$7=[^ '6FP:SH<&R2FLJ,M[>[8^"+QF
ME=8>^F0L)-R K5;^Y4184<L[. O0HIXI&!K-*;A2)>_GF4-2_R)H=SCTY=CE
MQ$/^+,"'.H=M<'&8I6,*SMP+%4YG 7;ENID-)-0(LG#[B]_49#",J?40];-C
MH/R&PMJ9VL>*Q>[&=Y(/=$C>/^ET[<N99T<DZJU&Z*8$/)<'M@B>!RT=\)9@
M >P"4/[/VW'6#P'8Y'@9S8TV)\I2V-V\(WK?S3MQ5U<%IS'\N.D<8)G1H[I.
M)Z!S+5EJ[&[P9:G\>YOK%R)_1P<H.!L%T4*8P^#3:U!3QFM=CHJB"^/(B4IT
MF*3[)Z6/MA)[2ICBL$".QQJIHI"Q[ZF?\H:M[-^G,@]A)]+(5*8.(5X0ZL(U
M-99WS=(\!\,\D,NPUQW,A"O<#LU(2]28L>R1C-__0<Q8YBU6EII,\T5VX8]I
M=X;=()I5Y@:)&_WP/TNID@PXE+3C&986"3\(_(A?C2&OW1T$W\,FN#6/_E"V
M-86/))Q<;N43? R>5J#:%"'8\CO<"]F=>7ACC:Z7BX>GKUZ\GM[6QW>8$JM0
M8%2V5K*^XG/T6T#'S)M@[*>KEU'37T.+0^Q> \<=81F+J=,25WE71U)P5$7=
M#3:K2:>F,KF"9U@ ,4\S FYT8-JI>W: ?*R*_#7@$D<\(Q._AJ&*<O6P )%B
M;)YSFI$##B:K=_00$LZCZMUU%BJM]<=7*-D*6ZD<4PV=I)$G=(7I;E5_V!&X
M3XMI.:36*\]>\A*:R@60OXK>[E#L]/^ZL>>/V?R^[;[TNCQN8XAC+RW-+63>
M+L$DGQ$;F,MKF%V4FAF_&T2HHO-737=$'PO"\-$A!?!$P@/G(^,K@=TK5IQ)
MY$V._OJ=1B"'KB!=OE((SZL+7+0WZJS(+2NS2NZ@6;J$LCEC3$E*[.[$0(S?
MRB*NY(Z4RI[SO^U &B<_Z.#]&1-FRBVB.CR2RCRX#FJ5S8HE]?C_L[_9^5]1
MY$K;3I#+E5M+XB]^67YN]#G/0M^X\*(FD(]^D*I.K.\N1FCVCXZOF\)@/S7W
MRAV,Z<NSN#%URH,A),^2NWW?P2JD>'72<<>+G0Z7V.[5TF7+AP6PIYD4>IW2
M325R*X8).'R,7>I?DA!KJ^M,#M#1$R35V31J@OBG745N))P?;_>--6?DPF)!
MQ91)\4!UA1;B8GFBY<+J+N9U\C*P-*_)#$4$Q\V0[U\NJ@G,R)J4Z [R5AS-
MM/B2H*-T^=,,Q^FY6BSUMAX+<-2(J0\F&[, )6P?P'PQPM1A 6A@2$@7N>=Q
M70#M+'4!84#UWYBD>J[]GJK6?^E\+&0O#44QOAS1-+^.Y$LAF7NT_/@R%SQ\
M"L)MF)OW;;MT+#>E)#VPUMH;J&X**H[\4$ \LWMNNVI^(<S4P ]_K$&:"B7B
M(HEDH\BU'0E$E=":41I,6M-(#(V[JBG8.[)M+2P8W4Z8<7XR^$[*?SC_?=AK
M&:[GEG$U;*IK/?L?Y1,101W7/47E)>9%_R15M8*Y1I>&E?Q^3K8E1M.^M,P9
M_G+YNMLDX=4RFI('JC0P]W8!0HD\ER?^AIA34QFF9&SRY<49?4GO<WQS[8@V
M4=LPTP!L7_IN'),+3<JP(W<TK2IWC EF3X C87<3*;(C4MYN5G:2C3]7[\W(
M])D*-&)[ZS1[+MGRG'OWY(W;AYO>)B#;RH'9O@6,NF)!%WVY]77<T5</9A&.
MLGE/WR?%IR0:JW87#)4X>XN-)/?T_$H)6H#^V;* '<4368#53C)OXR?$2>HA
M_PW;A4>28^$Y\@I%ED)RHA#-Y@]CM*N$1Y8<@'V+F4"V$W.CWZ3&Y<O$@.^M
M/QN8F% '<>>4.IM%T'7]?Q[<.W1[T0E-YY\AJ)5-HR/V,.CM<:,JE*!SF]1+
M2\6C]LU%_-?%K[@E7M6Y*7?ZU%X@+N,S-N&2IGE83,M=4IZQG-U@O$2/G$KU
MN@RJ(B +_!YN&GYQ%,=+\-4<7!KRD2MX^+I:X@2CT\!A972I!TCUHAUA=J&.
M=04)H7B(0VLS'7NPIT"V"EH(O+CQ>.>(_(B"@L)]A<3O[6,:MV.N=IRX)O@[
M3R,/(%\6V_5I--,E;9#RJJ:?#85UXS1LU1>&_K[DV6HGD'M$]BDOVB?3]4H6
MX");4S]9_P]3I_[_N6 +/$("J_(@.9X4BXFQB7:73,ZDAS691\X,Q9YW%?FN
MJ&0#\9=.LG;O=-8DJ3_#W06+\3[%\60ZX+B=OO'/C1E*6;"G^@T0\ZO,[W!M
MQOH[W9,(,Q*N#76TC8@^.KEFN.NC,(%6FKK^\)D6$/GDH;S[S?ZM59@YYMK0
M2G9U175\A[: ]&R ]G$][*LZOVF8&/(+\C*0#RFF784\5?M2JKL\WB0KB?D>
MRD@T?TL*IN%3B1>I.-Y+#]MNWYE/-9MZ8%_#O:X!^LF\MZ4=8QCL.#&--5[#
MI78' RW[''=:0#$-PE0L 5YG00BM_X)7:*M],>?P]9E%A\MZ[S,#?]4]Y_^'
M;PCI?7U>ST1Q,?*$A</+/PR>[(R#*TZ'.GS@M\V]FFAT+LK&\J(>QP>)"MU8
M 8\(X^PY4!R89(J.8&H,NXT@]A$=>KCJ6U)3OHFZ5E=8!FM)7"B*T(E8%0/L
M1S_!_^6\(\.W1Q HHE>/H$YM=.PW!]?*BCN:HC/'NF9TXE9UCIQK>)/54,8(
M(>+S&3;+#W]6U/@YT /G68"OZ!<LP.^?P<LX^[W7FNO(NBHV%]@%;UBD4$CV
M5U(J/TI:_/98XIDJUX>WMP#LZ3V&,1#<\*[L*3&6NOM/3:OROT@1A/[1:"P\
M<?/;7T)L,A?,I(MZ4OZAL7D5H43-(*!BF<)Q;>+"M1,)&Q,.U>*N=:]F3P?J
M,H[\M/Z>G[LX-O5&]T7AJ)&?E]_)9W!ILV]+\#,1T$OP^<:IRXSG='_=<_3+
MP3YTU2!9TPP/D60#&<9U'$WRC=[TY@X.U'J;C!2_,QO;W-:CF%$W7>$O.O4
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M5S@/4%1T%]6!#%F]:+2C8+EA^A!/^;KS&THHFW%KYGX9T_#DG4+!N@_F+$"
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M:1NPOQ[Y$Z/;&]9;:75)<WDT!DUPB"0\!%WN&F)+!FS;0*D3N7GL021O&%[
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MQ(8&I(")NX"'!ONL"5%);G&:(0]"S/?H5^B>DGX2>.(2&OPS])_>QL$W@%4
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M1K7\]O/7G[N(%I#7/-9Q+%;5PRU U[,;(V%H94PZL!IFZC"8EAWP4\O0'Z_
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MCZ")$NR2-?5Q-3R FHFKIA1@"7;X,/7S]8*HZ^YS!8R5U\\:$0OWGXZ@ [R
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MQ0($9[X6$]H3>U<L8#GVI]@,8MYZ]F99J64D8W+X\D[.?GC^_^3/[U>,S\*
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M-'&WT$L"'_<'O7B';>3)?AVY+[RZ^:Y2_.721O5J^Y;/Y[/4CT/.!(>^7$E
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MJRY%X(573?-!F.8P1,],=;C'!*8[.OJJMK:I)-O+B1HEO ^3VI&F,"0ZJ:J
M ;&O*X!O6]PLK&NQFME>/<6ERXP?GLABH %GCG&1XER:*[' "$?"1P4+8D0R
MGHLHIU&:"D#SU>DE,-JG%_=D5;=&-PU9;;NPOL-OP^!2]^-]:ONZ7^],W>\O
M;=VO=Z3NUVOG'?8$\IH&"DJDKBAXIY_KS=E^KN_]_0%7X!_V=V"?J+'=LESS
MB K]V5_:SU[V+7W^%YVOU4Z7^U_:]]Y/R\I;+\K5S]ZR*P=?/9&5RHY4W54\
MMJ[4PU+4ME6\^M.+%LY5KL>[?)%!?\&T'$WGCW@7I'?\'>_#P84U+-=-9_+5
MV\?E,RD7LRA, S\) \3B6%HB&2L0B0H?^3D+LB#(!%4U9!85*7N$1H_.;=)Y
M_U/N\IJ5M+'I&^K D,1)M,RN.BXP@(;S+,6W+^XX(9OK4HU],N]3>'%"V)-E
M%*>>M]N\6CTT&31=?6/&?)'B-$(\81QARG3I9X!RD?I<9#Z+"E ;H$,2(V_8
MQDSK2C]M6FH?0<5L>UXF*VQC-F)V:6C.RSY/B^)H'QXA,.D./"W@_MX;>!+>
M(>%C:[]>+Q9K,F_FN<BCT@]SM=TR43!Y:8\B1/R$HD(DA/ LRH(4FW9&.$9@
M[&2REJ37T&RG!9FW03B*R?".<R$I;+\!A03U.AB2Q*K'P=$%)^MM,"1.OZ?!
MX'.68\GX2C5$UIT1&&>_O/U>JU;J*CVT21-0-:RZ@GN69C1)" L0UN.KLS!'
M!<]#A(,D3?.4T#2)(3T.S$F#MB.\]\'73P_>A^MO?_=^__;IHW?S5?Z_/SY]
M>[CY^JMW_>'AYH^;AQMH W0 K&8GY3A@P7:T[GS><:"ZP/VDF/#*Q<_>A@^O
M9>1-97IW/@%5+-#4;LG'-[5;#@>B@<%Q-2#-G/"T ]/ @!P,4(.O ,\UO7Y\
M7'UX6CS>+>K%'RKD^&W]_%R]J3M\O5H\%///R^KZ95[,_U&U0S<-TU'!"X]\
MX$M^*NUZ]SX\*9>$GF4EGU?'XR:(?DVE=E_/E8/>:RL>=6G4]7SNW?%%K6Z1
M=W+9NCU*]=;SE&2D>MOUVCZ8]S^W^P[#2FOT3P#36^^"OL-1K!?!:97Q"Z<V
M65*P-1#]O&'[12ZMDFFN15^EG.U%.<<%RT.1H)3D&&&19*B(Y7VF"!CQ<4Z2
M. E@\QQ.$X-L,:LI#+T2$;%)"2IMTZ6&4".<\"0G2*1J9*::FYN)"",5LHUH
M)$(*2S=S@YEMCMFK5D)L"YZ-$V8 +3,3TPT&P$OB5F9-],K;4AVCINB49,XK
MB@X(O5,]T2F!3U<3G7S#-MPA=X6T&>](R:11.8N$ST4:4)0S+N^.?N:C+/$S
ME,8A*XHT%#@5L"C'SOHC;U=]!7J1I+1M4+:TH2&-741,(QG6<D(#& TA3U%2
M$UB[6]P'\E+*N[6>X=(]=-5=YWHW/Y<1CJ,R.PML[*X^<3SCJ&B'88SCC]G[
M43_+NSB9_X.3ZK/\FWH6L2@)THPAGI!4[D>:(C6Z )$\DO>^-.$YCJ"NU#T:
M4WE3&[*>HNMIPG"/ZCXZYD[5"V2V]*N:BVOE6STAT$7NU?TU)_>PGA#JF)/U
MU*.6@<-.37[AI.;WJD7\K?B];D[;F:!Q$A=1A@(1$H03'B!ITLI-Z!-!4BIP
MAD$-TP:IC1U.W!P(<T7<JQ1U=<->UW:&[3!T9J>G,T!@>W6+A:9[Y6G*:"F0
MI-U8O XCD"8RN@I&#M*:-BYI(O9!B-+H);A'\W.3&*N2HN4%^NW37R_R]Z"]
M0K?BYOE%I4:7M&F*^[;MZ&3HU;1:?.S[:YL)W#&E#,8-6VK7[S-F[I6TP_*\
M9W)T&&$Z HR@69LQD'?Q(DBL/(QV%"?S,EX$2-_3>-E"EJ567>OA;8-8LN+'
MNB?.@@(7@4\IHEF0()P5"<HR/T>48D$IX=P/ DA,UYSTR#'=FVU'UI_:EJP_
M>T7KUU>)R)OVS+W>K9(U:%V6.=1FALHX ,(TDGGKZCLN5W#IJ8.+[ZI0RYSP
MM,5:8$ ."K;@*]C.L='>"J*)?20KTN4"<C^4-Q@1HB *0JED BHO-K[\8TIY
M',>Y*/P4-L?F.*&139V&M->C[2GB9U,)86"=]SBX@@"H%"REMYAA,RS:!3-L
M3BP\\0R;8?$.9]B<>=Z%/T*-L9JQK$B#-!4H2%*&, Y4#Y<D1T$L\CB*BCPF
MH)Y'AR0F]CRH67&7N!HT*C;^!:BL%SH5/@S)>:$;H2_**+X#3> ='09] 8>]
M!#M/6M0U?^0O%:>-Z=0V-K_G.N'D8;G?:7=&2)K%/ U1QG..<,$Q(DF8(I$0
MKB;!^4%F=&:"*8_MK.^QTLU*\*J&&55.?- '&E <"@)X>%^/"AO0W]]'K!N0
MT/+A/2R]2YJV@Q #5,..A9Q=,>N]XJ;6)<FJX)0T\W:6PF/0'Z/\1ZKV^TX!
MJ]NR51OH!JM.00M.5S1J(^=.S:?5 G;&DLH+6TME]VTI5M]))6]2*_G[*HMY
MXR]N<R*#E!'LJ_X1$9/7'")2E.5ACM*0I47H9TD<@+J4&U$=65UWM&%FE!E>
M9I:5<Q1@VK<C[W7T55Y[QT$3P7&8Z6DEM".SS(SFI)8:"(9]XPWV\J5YG9L6
M6G_G[)$WI0\J87[C?5GPNOZ5E(LOR[J>$1P2D44"91F+I'4G.,IQQ% 6Y#CV
MBS@+!*C+E24?(RL/U?;J2;&Q];8JZK9IC3"(S;3+!,!!K;V.H2NOUV-/,]65
MU#2IYSN,77F*->\GQ=SI?CH7)$Y:P>,\JQ+&Q3NE7%I!=3H?TVXY.WVF"AR^
MDF?>]EA(<<*(2%(4AU&*<*Q*VP.?HHP&3(2)O)^:.6Z/+S^R]E'$/$7-LO/$
M'A9F^L1>0IB:  @'WO3'97"TE_<6GW2+'A=L?^>=>,HR%/O\,E^^<?Z-5Z\E
MY<?[U'Q=ZJHZSG1+FEJ/XN[_NW(\?5VN_L%7*O[VN% 9N$TKFL_+JOTK]5PP
M"\*,$A80%)),#4K*8I0G28 "GO!4Q#%G,6C#3LO^R I!\>$MEBOOC3<7^8:5
MJ_8"KS.ZJRT[P$#PM!_:3!O]N)\/INTTXVBOZ]RVN9,N&FED:)K1-2YQ^;?-
MM[[O?>N[[;>^-_C6\ #VNT#N*@@^+?/3!M+?Y<,<!./?APL'0U%O%O?*\3IO
M.:_O>2W_B\]XRO) $-45@L8(DT*E+J<^2N(L*6(>!2PQJA^ $!WYH/CMP.TK
MKU:59L2K6TZ\JF'E@C&?IQ"-.,UBDA*$F9IV&%.&<E\:X2)D&6<$1[R(H1UI
M70)[<2_9PX&J!_AZR'M9/[^,B+)!_&>$7R/LW#L$ZF;A-3QX'1-7WOUH&%TP
M:=8!5HZ#/8?!G-.[^LHCM7I'K5 0N;[\1=9/7-H23/[FQYI&>P8ST!C:4VN]
MW_S9,](-#IX]]Z[=Y>R;:E5[4]=KSC[J<%YSB.I#N=;_N&D"RBM:RE-Z%HDT
M9#P)$2&"J!A/ADCL!Z@@F/HDP9@D>:>;S:Y8<"8LE#1,/V\H]=MVDZ:/XK^V
M3<#!';POP-WLOC,2EA??64YVU"[:CMK[=YOF$G/;M4[NV*UUYY+AGMG@&XL]
M:(YN'18,3'ISL =HW_J_8"4+"[Y)6IJ3NBZ%U*9JX=:72;.,\H@+E)(P5&8F
M1X2F*2(!%XGPLRACB;'-?I+,R%:ZINOM$@:Z>L_ 9& B.A$>IEC&EQM@]CF1
MW\[0L\,!9J&=%6_0)CO]]G16V%D)=NRN\T];Z*'C!0B[I23R+S]4TNA;;9H&
M?N4KW6=.V^\S@D62!CQ'$2URA(L@0D10@FB290$I0C^-?&.-Y8"AD76;*KBA
MFKQAM-P9T 8Z;V+X8-K1O'9)_4/#8Z]39<OEE=?P.3'X ,4[\4>P4]$3?0R8
M3G>(W*#V=T%GNG/"(2H[)XK+=>UN^??\E2_6_+.45Q6]J4J:_RI73Q_6]4HR
M5#7##;?UXR&/8Y[',8I$'B.<IPG*@T"@B!-&$Y\%OED_'#OR(Y\K+3-&H2\7
M8)I=V\>#"'9V=.BHK>%UG.@Q9E['R[BS3.V <'0-!Q*?] IN!\S^]=MR%4OG
MHKK4%^='$A7[(XEV70"JE>R-Y+5<U"75:6#!+*4LI2K&5N!(JJ@BSU"1!"&*
MTXCE?LJ2C!D-6Q^?U9'568^P-!(V77XW3#3)DT#GY'C?S=")^4-\C7=W=C8?
MU?13PKV>HZ/LRCLZ'J/3>E%'!_S VSH^Q0LGP.V:P5^7"\;96EK+DF);T70\
M0407)B=%5F#&$Q3@($(X2U2N7Q @EOD%3WR:^DD*2!-PRMPT>03:8]XI#LNQ
M<A=] C.%/AVB(WM,=CCN2E&OCBOU?G:>J^O[*("ZGI)W$4_O,U+/!8PGY^\Y
M6=Q!_MK?^5REQWTC<WY;-=D$LT"J2)Z''&$>% C'?HJR2*0H242$J9!F=F T
M1LR4X.1Y:RK-M98,>#JU6;%P09;0402CC.1Q05#B\QQA$JD^_#Q A(=%'(J0
M^X%OTC]L% 3A7<,.$ZX.$?20MQAHVVF'HX';W3$ZL$/B$!A%WI/T/<6 =UNU
M>6F.<;D@ ^U"?"[./CO,-WM2D!WY0;U'KMD .J \LV/KO%^.V8!4@_EE0^]9
M5@:7-9TOZW7%;\79Z=3UJ?'46T^JU+$^EE\")33*$&:,(Q*F\H\9"P*:LX!'
M(+>T8_Y&/MF^T2=I-<SUH"9M]1_S-;3F!+"\V/%W,KL2O"/Z,+V_951#;^#F
MJ0?]/-Z?S7"L4=SG(Z'JJHK9,7?35C>/ ^U!U?-(9&PCA_VKBPH;?../BHJN
MR*D?EA^6BWHY+]4YS:Z+6D<49D$J6(J+ H5)DLJ;!:<HB_T<%6'$PH %11&
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MU*R,X<\/U^:3?PE7A\!TC$][=DS^00Z.G.DYL ^8KJ5VW4R?[1H5)PGUPR!
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M8I-MG%-B]'?-R6<L["_6=)PC<^R'KQ_+FLZ7];KJN2U,3;)S"XV\7[;T/<G
M3Z\_>UL> #;;63@,S#B72  MNP$0O#^=.E9 DMI9@&=7G\XH-!5TQTXT?LG.
MV?SI^66^?./\&Z]>I2%Z/!+]=:D3.3EK.E3JCA?]?_^PK%=?EZM_\)4J2WE<
ME/_B;+M2\Y)N6/+P1!:W39AZEH413H(<HSP3\E@M&$<D"QCB"::$)EB$.("X
MI=]-DI%UTH9ECS0Y+/PO.E_KRI#E2^/^I))K;[%<>6^Z87O'^)5' *T*WQU'
M0]_VO\5W!GK!CR4L;;,_] 2W]C?0YC%]VOP&;MO?@))(/M?\!NY[OP'7Q7_O
MCK\C=_G[R3&I8_W=/]>^"_[]&;)PUF\J<G=*+'>+,.5?-KWFY#/-YOS*5RIO
M^(Y7:F*W&FU ,U5R$,?J^DBB !61O%+&<1APD0D<B[@K 1\^\YSQ9*33=NO
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M6%HEB B:H#S"(I-&;9 !>@>\BP@CJXZ.)X^W1(_,[.C^R7O1HRVMAG6\XV_
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M(I/>1(<%W;^%GGG:PCKZLEP\/O#J6?4OUA.K>XV"DC ,HD0(E,19@'"81*C
M?HQH+BAF/.$YIV;CY,^1@OQ6K<;(*]I($??N($V5SD)D8-0X$ANX13?R*K+M
MK'BC[DDP^0%VBB,<[ R3YAIQY<GC9EE)PV1!GM7OX%]2=_W$REHW0O_9D\;+
M<[E^UJJ-J8;>9=?06\]HNU)&S%PANU+(,HTL_ZN;[J;GQ.VV[OJ;*GJ6_ZP,
M[&*MUO,6RY4TB)[+E6XQ>:7^S)7?XZUIN%\L%ZSW1[I\?E9)EM)"FB^)RC=7
M?#^J'.3VSU+/R!W1E%HW'-5KJ228ZF'!6S&4/$L=(U1 Z0HH]?>N;"V#+SMH
M7 V]/YTU92#%COED\KQMCM-+*>TP]>M4";QK^6O[MA2K[Z3BU\W/5O_X@UGN
MLSPI.$/"9P7"+.(H\Y,098P(4@C.1$%A24UFA$?/8MJPH;NI*CZ\NF7DRB,]
M5J 92X; FME=8\ %= WVD.I8\+YMD+HV0<HB_P@FMK.$(T.R$V<8P< X3"D"
MOF_;RT">;7332J$=4*K.[$SX(>4Y4PG)*FLH#%#&6:"G!Q/.I:$G0 TV3U(:
M66GTZ:I3M4<9VFG@%%1F6L$) # UL"O[5R/9+2K_S\CEK*S_%)V):_;/B'M8
MD'_NA0O2_[3%.V]:T#5]>ON3X1Z6A_4\VVJ?>H;C* W2($0B#!G"' >H4$D!
M(DIB$:9Q*G(,V>.7LS2V,BCG:]TR@^O6,KJI;K_/N_) OI*Y=E1:MPAW\&',
M-,JT<,-43X^WKD-BVS!\?W3AYIM\VGR3,[W'72<P.H'096[C90Q-G_;H!,"C
M&9%N5KY@.H9-N:3RG*_>>NU7="KGPQ-9M(64ND/$IGIRQM-<C>H6*,\3O_6G
MT31 << HCS.&:>B#QS-,P/C(RKK1 D>&9Y#^& *N>?;*7@^DUJ4AV?:673G^
MH^9<!9;:BNO+)D!,\;/ $2Z"3!K?4>!+"]Q/I"WN<S6CDPL<<Y)$/C-SL_[(
M/PPKMZTFQ_\=/J+92?XC?AC8>6_4.J,8;)W1R++3S>QVNY,WC35^W>SD1B;'
MDT4F_ HNIY%,P?;T$TPF_!A'IYY,2?]',U(^+RO!53ABH\N"(, B2%.49U&&
MY/&4J6SR$!5)F,>,!RSG'-!'^AU$,-)_%W>7;LFN*SV[9:VF>:M;3=L"Y@<\
MLPX_]7L?6W9?[@<_N39"_7L=7B>_Q0]_?AUR_G_($7;RDTQWBIUFP?(@6TEM
M>[U@7^0O??Y _OK/=576K-2>4DW[-ZX4J1IF4*38]U' L$ I*P)49+Q I(AP
M%&:)'\>@N(0AW9'ONIH2\#@P!,Q0E;N' :B&%0,Z(T&SH+O(]YFX:E7JGPTC
M#KLE 45WI?4,J4ZKL6!0'&@;X.LP35%7J]D]5[-6M>;ZN'PFY6(F;4[,>):A
M*(X#A)G4#(4?<42+,"6^+P3+C'(=CJX^\JZ_YZ]EK4P-:1W>21U:M5:!]V=#
M_O2/W "8X7U_L;BPW6TOJ?%V'I1H:-/*%WL;5OYINUF/KSG)EAP4I]MXPP_!
M>P1\>%)V ;OCO/JU6JY?/B_ K0$&EA@[/:BA["G2GJ:M3.[E2F72F7<"&()@
M>$LYE!ZVN88$'Z'>WT!&JS+_H74GJ^XW$*Y?U&_RN*4]S.?R7Q]_Y0M>D;D:
M.<;4N''5,$U%2]L4[TT73)H3/Z(^1GGJJS)@7T63,$$D3A+FBQ@G#!3*AY$?
M.Q+4,'/E/3;L:#.1[#"TJ:_X#Z 5#8/9T)@>#3R@3=WA]FL/MUU>NA*-4?J0
MVN'@RL"&$9_6SK8"YL#<MEO%LEB+US7G)T;[MIZ#^N.:_X.3ZN'[<I8$G 0Y
M]A'-F;3+?6FA%['P44B)$ D/61B @MI ^B-K)/EK2X&57$#\S#3-B*C 5$W#
MB.I_?WI&=],-40V2O_(40Y[DR&%IF!T4KFK&@-2G+2:S@^:@RLQR&8MI0NQ_
M/RSO^%(Y+2WN("=>'UDG2*KK>J7C @]+[^[3[4XXP>8N<@J&\_<0!PC ]K^I
M\"/<1\[(:C=TZ,2:TPT=&A9J9^C0F4<O""P7YR,'Q8EA ;?K5;V2]J94%'OC
M >ZY\E+(O^_Z?*S)7!5,A3.68XY%P1#%%"-,XPQE292CE <<ATQ>;U+8)69Z
M&<:.$VPYZ@V1Z<:/5!U7JOJO8\M318D6D>:)OST@XOSC?M')(\^;V/+Q'T8W
M76@CG->3SGL8^F'8!:#?Y].X#$1/+,'T >GW^41' ]/OQ(KE@4B?.%O/^:U0
ME;T/.O]\8Y&%./()X2E*TY0A7'"JZN8P"@+"L!KEP8L<='(-$!O;V=:25J$:
M11QX= RA9*CC'<D.5,9[8DM#55>HC#(MUT1$5TIMB-2TVL= Z ,U8?+.CY8Y
MN9O@N:>>CDR*S:5]6R2X0")FJN%1&*(\HA1QG\:<^<SW [C9^R-(-K*F:JL
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MI1L?DR8/57NAS22#LC_YE6"KQ[)I5,I?JDV[Y+9'CR]/-:"'0==TZKWY?-$
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MRU(O0<T-FF:@$E\U#LHFC>K3JJX_B_6M?" _%I@$G&5Q 'FF$3,2+&&64'4
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ML^=)Q9D>/R]5A^T)M*^$AF)SZ>O1:(=%\G;^/$EDYB/HD*#'I]#!IQU38_5
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MEMHX?#\,PHE-9.99,S)QU,WOG'N*Q+W93/J/SM4CX;G;PWA<K4[FVSO+HY9
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ML7;4U"61?O+?<5''5Z43*<T6XFV-5 W:\-I-6VBC]+]1P:PR (^/.%D2X*A
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MV>!6V%@B[/"<HSS+4$H!A'$*8!PQ4*(R 3G&!<P+2O.2FU@X4P:F#JK3CH5
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MR+Q-S8=EHXPA6=6/JUJ94%4'\$YVR:J?WJTHFV=QD:0EPH#S,@$PC@A I(@
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M^J?/S/&$7*0CGV;^F(;]P-)QQK.QF+LX<3Y]P=GLPAZB#2G8X@"31JA%KQ2
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M@1B$8RPPE7UL%+_<6'@_1'2<'VTAT*XPL2VNWS)A1<BUK E"3 *4J7="T25
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M6.3?I[/91)EL;16(9YX1W3%!T(*!%BXJ3+S(1_LU' *6B[5[\'*: .,@878
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M'&@&3E"P4JM#F6:A\C(<Q@XZ$P?,83T?MHY21(^8VIEAEK.NS[Y D#! %6;
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M,I=I.ML.SKMJT>T*8H[DC 01"?2!06#9@?6>D:M28G&MNPGM1]G($Q.&P-,
M*NG D[O-U6]A-4T3C8*LI@D@DG:UGR0#[Z4"X14+F25E6>OWH/<2,FZH.83&
M?P"JIXN_0PR]G,[.Z92<6%2<":$@HJW2P0B>"TFA<Z%8!WF4MO6[B =(&3>R
M' %'AZB@ R3]'>OX-,PGWRB6.,5WYV<1E^_+G5?2ES++.<F$Q4,RVH/R,M1K
MT0Q,!6)01.=YZ\S84VD<>5K,$$?AH&KZB6"XM=8NAUB\)O.L32U2*P:BR 9L
M4JAU$L9AZ]NB)Q$X[B$Z+%8.!.;3%=<O*G>F_FXEB:(3(\M49T(I^J,0CTY%
MBHA+B=[HZ()MG85X(HGC'LL](+.)\CK YCVMZ2[:TET],RC&8,X66*Y>;9V+
MX4IMEQB%JLWI=#:MW<$]R-K/.OYD[_/;*J,#?-U,Y@2L*1N1P1JGB60C(4B^
M&<.A2DF8;/,*H*<GRP8[49NK]]'$V5-DW45=T#ZM,D_6Z^4TGJ_KY*?/BVV/
MJFM]\+3/-B<P+F%M5^8@EE"#<<%L\1B4'V1VTA$TCWN0#@W(9]5H!\;N,7Y?
MA-67U[/%[W_!?(I_#M-Y_>))H<4_8IJ%U6I:IFFC^>TM'(EF*XQ)R$QP96GG
MQEQJ@1\=)E$D8+62N?:?LK+Y /@A&!G7^#XO%I^P$9X'&/\TN^.*_>*]RI(7
MT,$E\NJ% T<JJH7]]!\E-+'9Y;YXVHX8S/K_$^R(P\#0Q2WR/M+_4(N6" SW
M*&%">S[$.J?0"4_G<BKU7(X!I$HA.D1C7&M7^DB2QRW4Z!;MK97=P27X(W[E
M1$=DT6N]R]VY8HD584";Y+C1G*0\0,>:A\@9%Y-#^]^M]-!_^^7K;5P^?7[_
MXM__\O[MRU<?/[WZ?__VYO/_OLG'<0UJ[OGT 5O2_(B7]JV8'VD'CC81%(6&
MHFRF,S;2&8MD 1G/AGENI.*M^WCN1=CQ P=VBWRN1G>2&:LC7 6$RIQRM:+.
ML5H;C$%FQ17:P5I.;RCHIKER(RS<G3EPL+P["&,NJ=]*I-K8Q9S^N3KY8[HB
M<YU*T:R67M8' =)DB+IPLMY")98YN0VMZV,?):@3+!V@Z8= <[38.\#0+1Y>
M+LXHRIDP1>Z=0 ,Y2$U,9!*4%^3EE613KN/)56OLW$M()Y@Y7M&WW]H<+?4.
MH'.M!^%?L=Y%3H33 2G^!8ZJSC:GOWF1-,A@&#=*QH #]H#<$C'R>[_C%?MP
MI\<#I-P!3!X8>+=CQAF4"I6!(B,Q$VV=6> <<%F\Y-$HE5M#YE&"1G[FUQP^
M[:3? 91N3QC;<8&9*+69$Q>U\JWVCG.U@H,"4J8T&J08LC&&[J=DW!B^/7@:
MR+L#U.PQ W''F&111A\<1%./=*88!(D!L'#&8V&2V&MMC/8E;MQV( ,8ID&T
MT@'<+KW&M[1U-I6*DY*RL\@"Q"1J89D2$+,UY"_2=HDJ)H_MAP;>IJ*3&38-
MXZ_#!-P!1 C>2PPK?(G;_[Z9W\UO?%S,9J\7R]_#,D^L949+2<<TBV7;72<4
MXM':A#IG$:5H?< ]D<1. K4#$7&W/G0P]72 OL=[QYN4LA18^U(0+X7706(U
MU@C,L\3] -._CV[C/V3APW! >%)'_R=HY6"$?<7E=)%I+RW7C0[".Y,VI<G<
M$[T0'&U-%8F%X.M1'NA4]\&@:]X@^<"1IT.^UGTV3!VI@;Z0M)V9\O)\21OB
MPW:!S3ZY*'K$7%U(\A\WJMRTCIY8Q=#XZ*$X5* HHH6@F -B$KE-011LGP,_
MC-;1NW<_+RJ'UF8'Y^P#?&[&DSW&9O:6PFG%0<AZSZZ](M>%&([D*[L218ZY
M>>/<PT@=O2GXV)AMJLL.('N2_\_Y:ET]Z=7GQ0.IPPV[\3:['Y'DO9JN<3?+
M82N?6J9\.M]\RD94$U,BN=]"0_)5'B)S<"I$X#&5P*-3.37O.SXP3Z/WV'RV
M3= 5.KHH%'GT*'MU]G6V^(ZXG4]YODQ?2"P?9F&^FL1B,[=,@90B@5*J@'>6
M@U6&.R>-3*YU7>6!I([>]G-L$]]4EUV =N]M?.=,NU\*R\7I,IS]<(M/I- V
MT*:&F.K47^D8N)(EH&*<"\V=\JV=\9%8';UC7W]'PHA8ZL"OVC#Y$;_NV,PG
M<^)F/5W>9VHF22O,: 48%D@?=;"L4T6!S8XI@P:3:EUE]13Z1N\'^+PGPA!:
M.[;LX_,S W/KG7$O9#&E@/.UN;I+ J+,&3AJ5824Z%CKHM8GD#=Z]\'.8/ET
MG76$RLV6JH<(R>MS^./OT_67*DIBCKYP_WDR<=D)BAL"8.;$:E":6"T)''(M
MA4PA^>:7K ?0.7Y;P^<#ZM!J[*)\[IH+]!$W[QD^+_9E-C)4EC$#R28%RM?[
MRCKMBQ?/D@U&)]6Z</0(<L=O0S:&7SNH4KM \+$U@1J9D<4ZT%$R<GTP0N!:
M@RXY96N-5K'YM*1G*  =M&//LR'Y.97;0:1UL_,,BY&51.(R&4EPBD6(V]'"
MWC@M?%*^]8.^ [K\_%/<ZATN^ Y0\^CC"Z%UTD9E8 8S*,DT^) +,)%8= IE
M3JWS5L<_B?FGN'5KII8C7S*\FK<Y:.]YC^&,D!R%!*-U;=(G#/BB&*2(6*3A
M/OG69^>!+V+X/\4=UI$J: JD9ZE!?W'RZ2^OW[[_^Z>;+!Q7>G[UH0-6G#]
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MGN]),[R<KM)LL3I?XJ7L>/;>92^!!W2@DJCYC2B(WYBB*46RU#HI>2S-XW:
M&M0C>S95=@'=S1N13;^J/%T3)ZLWVS+S_-OY^MUB_;]Q8\@G)C#%,#@PH0ZL
M=(Q!],5M,G*2\<Q$;/TH=U_:QCU2GQ<Q=^ Z@/J:P;+I[*K?PFJZ6I0/USXL
MS/.[4)E>E%V]Y&*^NLG%?B.L]O[L!I.L#N.CT4"K]\O3,-^UZGQ!BRQFT[S=
M*?-\G:++-IYA=FEJK[WIC700)ZW)CTNU\42BH]ZE#!*%]44IQ.8/])L0?JRQ
MW*CN?=F5D-?Y@CZY'$66(+.*M'>=@2@P@>=><<EME*)UAYX[1(QK_IX?4;=M
MX'%:Z=/8?3H_.PO+[XOR:7HZGY9IJG4_EPQ^("&G>H]W@*G;\Y,;&+I#>&AD
MYNXN<Q6F1*ZMI_ S$T1 "7(3?:0C46 .1M 9:4WS:>H/4G-T.NTQR7XF8?XV
MJV^/C%*6"VL@\%(?^R+M,X84D"M-W_(^Q-SZEF(_RD:>]],&)7=2:>V5TJ>1
MNJB\?K$XBV3;#_>^[ON<%I[6#^EK9&[N68A.OTVAW*: <SLJXJI=B)/,)2DH
M( V>#CM9:Y6D!S2J..5X3+)UT]RG47BTGW1WM:NXYVH',%F<,3$ S\J"BJYF
MC(R ;',*UC"3F_?WVH^R<<W2@&BZXSJU5U2?INHC?L/Y.1YBG2Y^M8%!NI>*
M1C9H]]FU&SH=/S<0$HSV+GD+.62^K8UTTB(DA;E$)E)H_A;W86J.+U3;?')]
M2$CAQN8CZ_O5%^>K]>(,EU>@]<B59YQB"*8*J$#A0-08P7*=DV'<RN9!ZKZT
MC6M?&B'E;B': (KITYK<Z9!R@%FYO\O*<?;E<;J.-#2;#BFW5[A$#M8>I$(6
M"*CI%$)C(6B*NUTVT7@NC+U]EC_0CN:A%8YJIW/G0VMN8MM2X[[S+J-+)A@/
MK&A"J(_D_;-4,PF!"8<R8C2',?/HNN.8A79ZO=%+9T"1]VD4+K@+U[O6'& 8
M[OV<!L;AQ_0U\D0>;%9S"2I7/ '),%":(RE;6O"Z./ YEF12E,H-4*7[.%$-
MRDWN7^ ^M)-C;HO6&43!FN[$VLE1&7*M,13%<E+-A]D_A;YQ_9.V^+FG$F48
M/?5IE?Z\6.3?IS-B-M\9J'B <7KLXQK8J+VI;62J+M8[N;O>/1>UH6CE3;84
M7W,%RF:$(.G(TL6(J*60)K2>6OTD H^>3KO/8E>;0ZE$&@B:CNQ- M.EVF!1
M 5/92>^LX,TSZ4^C<%PS-ARV[@RF'4YO?1JU6M9_B/7:_%X#,W5W_4;VJ'[P
M/>! %D7RQ4,IG@Z]I"4$1QZR])*.(&1,V];]=NZGY/A!A_'><U8'<OU#[6RM
MC09%0 0?K:XC:S%[E-R;UM62#Y RKLUHH/^[HPF/%WFO5F Y_19J2\++EP5O
MYB2Q\\W3 G(A_H+Y]&;=ZT$VX\FK-+$PQ_'6S!Y=D'%M]9-[5K\'M,[6AA>U
M88#P6'M-U>%(J4#QP=.91I#VK?.O1Y![O&5[\M)7>Y$C133:!@@IUJ"F*' V
M*C#!V)08YGP[WS2&J+JQD<^#R;N&])DTW*>UO?9$_Q S>OW7&]C'!ZEI9/@N
M/_\>$$GK>2VN RS2@8K"@O<6(4H3H[8&T;6N@W^$G&;E+O?!-D4K$A.FAB'$
M*C,5P+5I41'12)6-5ZTCWL?H&7UL41-,/%C\<JP&^C0<M0G6='WAM]2K0;*6
M.#_T_>)C']? L.Q-;2-#<VV]DUOKW0.SS(OWQ@L*!*0%)80$%W0MCF() ^/6
MZM:#X)]$X-'5*/LL=K4YZ/#$>@-%XK 9%'H%D0<)FC%+D,&<V"CBZ,1@#8>M
M.V4HP^FM3Z/VMG9!.<A^[7ZS@:FZCX9&5FG[T5=N<XY.>%DS!#57(&JN("D&
M26J?G%4^R-8-)F]2<*Q=>5OG ^'5C+_-AU_SSIE066$FANJSEU(*1,TTQ*(T
M1IY99JV[83Q.T;AVXPCMWS8,#07?0;'D+3[>E\K>8GFOWY8<$R&1W\:BH4@S
M& A*!- J!2>0A5!:>\[[4S=N07E#> VDD#[/G >ZEQYP!CW6!_7(FI\]:&R5
MF[Q4\J;1[N5BN\ZFFW;/&W)B)>>B[^G55-FB4U:J  ^,?)# "OB@.4A)+HB6
MP?'0/#UY%,5'9RCW7?VWZZM?CT2YX)MGH8'725-2@\=0@$F/BDN? V]]2!Y)
M\LAYRN?#YYU4Y3.JND];>5'8\ E/*V_7^I4<4Z!TSZ<U+%/Z$:V-[.9NF8_X
M=;'<]"FX;+*:I)-1*S YU.$+ID#@+ )#E80I-EC>NI;Y(5J.KHN\];GWOCAU
M5EJG&<C"1!WN;<CM-+69&I=)832VM+YSWH.LD=M#M<#&G7K(QLKHT^*\(D.R
M^([X&\ZQ3->;_M9A-US^$)OSZ.<UL#K[T]LNTWEY$&W:&JZG2[SY\/*J'4"2
MM=2,SKW,$BC/<VU48@ ]1QV\)X>]=?3T!/*.?BI,ZVQ7V4C[ QW'R\OE=OJX
M-V\6#7KCE:)(F=O:UR!!$#)32*-T]K13,FL^4^9 6D?/? Z"M3N/B9]#DWW:
MN_VZ.PS?J>+Y.U:,U;FBB)B39QYXK!-7549PQ2J0@G$E C/*M3:*PW6NN-$J
M9O/AWZ]VAW5&UZ<8D%U]Y!^8!.<< EJ3K45B.+7.-S]&3[==*IZ"B+M7-HT4
MT$%>]K:'N67G-E-&A5(;(X,GN8"2VH./14&]W=*8%)G[YEU0]B%LW&SL0/!J
MKY(.</:W.M3KU6H]I? <5Q,CZFQASR FP4%I+!!%*6"1<^>2-;QY\Z^;%(P[
MU6\@Y!PAY X@<E_/F2WJ)SY+F83T( GVM>Y=@*M^IPW9<L>L]:;UN[&'J1EW
MULE T&DD_ Y@M.O]?WL8RVWSJ5/VF4YH8:T&52>E!F$1@@TQ>T\GN&WN)^U#
MV+A31H9RF)JKI .<_:!IQVWN2HK&2,M AI#K^VF2G]6)Q,E+IM!-MW^H_C0*
MQYT3,A#R!E12!Q#<7MEO+_!OL\)T5ES+#)AM 47>( 2%#EST14J=4+#6(>\C
MY(P[^F,@<+42?P=(^KP,&2]R<3MQK3YB0C+6<88[3P"EBY99!W$S6R 9!\$G
M#4'+DIE)R%/KKG-[$39N0_V!T-5>)1W@K+9XG]./W EGM1,Q)H90C,EUD)B'
M6$1EADPNC\I:;/VFY"%:]D*3_\G0U$3P(P+HWL9(MWGAC!5F4P&6HR=>Z""/
M+@5@B3.%T;,2;CGU>S:?.BBKR7X2B#07;0=VYL%6-7?3M8DL)<^0E:P=]8BO
M8#7)+_%<E"LYZ]9NTKZT[8>RGRUY/HAF.D#<(YU$+KZU.[*-\5[K%,$)).EI
MK< E*X'5$I*"GLGFE4A[$[<?YGZVC/HPNND;=+?_O6.0@@]?BN5@I:I)%H<0
MB2DP3'@,T2@=6]_D/)G(_4#XLR7GA]55!V#<#53:#31Y7S;##.=AMGDSNV/)
MH97$38$D!7F;/*9:OB8 M9<R6Z:9:MV.9P^R]@/<SY;2;ZV/#B#VYNQKF"XW
MP^MJI<K7Q2K,WI>WB_GIV^DWS-=WSS77-4CR)#S2OLFTC4KM#X8&(>="07,V
M0F'KN\9#Z-P/A#];ZG]PC76 RFVEWOUY0*MS1N8%&!M"[1B7(4K% )VOZ664
MWK8&WR/D[(>QGRW)WTK^8Z<W[G:7KZ;Z?=E]_39KWD85331@;7U]27L&@O$,
M; Z:!<]T"+=>X3^0[7C:NOMAZ&?)Y0\M^ [,TXO%/&&]^]K4,4U7_WA!-$S7
M]6\3J17GL1@P)K#Z@M="K$53'*W-GB>IFY?R/4+.?M#ZV1+YK>3? 90N^^W<
MWA)*9BE-46!=E4\JFLPL1O")6\=CR!Y;5S@^1,M^(/KY\O<-)#_V ?=Y26?T
M^?+[IS51_L"S1I0%M;0UR*TW\(Z#P\W0!.Z16-+B=K^,!PZU'Z^UW^/1GRJ+
MWUC '5B<^ZOBWW_=E:>\V9A6BB0V15B[H%8PZZ4BR05OR.=S@OY6$D43)%.=
M+"_:M,[I'T#F?O#[V=+[0^NK TB^W"W[@E@]O1MQQ!09%@HQ(BI>LW8,0LXD
M3)Y]B%%'ETMC]#U.T7Y ^]ER^@VUT &F7H7EG"2T^H#+S0ZZS4Z2QM<!'9!"
M[;ZJ24C1,P.*Y3J9V:926K\>_ %)^Z'J9TO2M]1#!["Z:KQ[9X,(M-XQ*4&K
M4AM5% N.$SO"9YDX*B5T^[[Q#U&S'YA^M@1\(^EW@*/78;K\CS [QVNCZ*^U
M<MZ=X]:8%)-(@&1=004AP 42F Z*Y,09#[SU:*:]"-L/73];9KV]3CH VCO\
M_9JXEHLY_37A-8;NY.(R13.1<4">:[FE-!3^6@D2O54Z2%5BZSJ.I]*X'_Q^
MMJ3[H)KZF>OV;[L0G^MKW0&K^!]8[]EJ^O?A]QDJ_)4P')&@K%&!2LR2OV\B
MH/?2"AE5,*WOV8:K\/^4OF ^G]5BSEO"I<AZFBB.?CF=G:\Q;V1]M<7(=0A2
MBPP4--,6X^28>ED0,C=!.I%J3-0Z\7$8J?WV!7@"CN[D/IY!;7U:QONJ1P^W
M>X]\6L.><3^BM9'-NF<Y L+FW<-)^L_SZ>KF&'%;G'&> DP*-$/M;A,I,*A#
MJWA045E1A&H=Z#^-PG:V;7?=^E^8W^2:%"S3B_<@FV4)V$3&VVF(T]EF. Q]
MCUS;VYO'<HDH=0#/L@4E _TM^@+6.IV*"RF*YJTIVK(PKBT<$)\/V\?G5WV?
M=G/WP.!P4WGS QI8QT<H:F00[SZVN!K6)Q-&"@_ :Y?H(,P2G!!T^)J(=!@:
M"E!:^R\/4].@:7 X/5WBZ>[YY77)7IOG$)-R)EDP6=+9GZ.&J J'G%F4I&<=
M16J=AMN'L'&-4B.,W-/<M[%*.DB97%G5BR+1=XLUKMXNPKQ.%-GEAN:G5Z6C
MU]+9P:&3+ !J5\B:$[_!D%B3T5P&(Y7,K0MZCR!WW&Y/ V'RN=37YP%XN^SP
M\)/P@4]J<"3N0^.19^.])9A7'805TXC6 28?ZPS;"-X7!=E%75N*&VW#C\3S
MZ I'/>JY O"]@KI6:2Q+Y!@<%+4)<PFMSB@+%&ZG*+D6VL6]V-AWQ7'.L':Z
MO/&T9Q Q]VD4+DI$P[7JT,,-PR.?UL X[$MK(^?YP>K9J^$'42 3"J&DA*!L
MC<VB%Q =ALQ9"*IYJ\8?$C58-?<5Z@GB15EOH?"<*184"HAA6ZN9+ JM>6C>
M7NG'5(WK1+?%RMYUW(?II$]+=%&S&>[6;!YND'[\H0WLTA,I;V2>'JEQO6_R
M*YU31M276;:>A5(BQ*()?A$C4Y8EPF+C/?LD MM%9A?+7NT-9#D1ZPRBKOVA
MC,S@PB;(E(ZA+K&$YA-#'B9G7$,U'&H>#K:.T\C8#^E?A.7R>QTR<E8CQIJO
M3>G\['PSHHB^MEQ?%?WN\JMUS]]K"*Y=0Q62:TX1K.:<!)#K01 ,G0LQ9BFL
M<U[NY9\/0=VXL?_P".U#K1VELQ;U5=-TC9LRX=LLOCY?5X%?$\FK/^IC\]NI
M/(GHF,H*RJ89N](U,6,D&,]SXLA3:-[WOR7]XS:I?GZS_.PZ[]/K?(GQB'CW
MVF\W\",?HJ75)$KZ^'O Y*W11I'ZI*^WC'0B@T?N(2C+F;11Y]#:,[R?DG8N
M( F]CA3<E'Z^#FEWL7GM13!S*.J&(3W6P=ZUA(\1=JV,4DAKC<76CV?W)F[D
M:9#'8^1A/["E6CHZ/=^7OP8REQMFMNTV/N/R['(S7^^RAD9GYB :7VJK#5<G
M2#LP0O&4O72N^?SNI](XKNLW*/H&4%)7(+R'EYRS82$6*,Q*4(P9")C(3TC:
M<RV3+:'U*(?'Z!G7Q1H47$<*OU??Z**FYKZBAS#/?\%\6D.H1#^SM>5'>%('
MKM7$[VK!9S,O[8*8:S2<W$/#?5AVC$<FR D/HG94S'4<#2,$QIQ*M5\EM;Z/
M.(+<EJ;O'B+>S#\1%#95$M>J=CXLMH_L+BMZKE7KIRAS=@B<2XJJ*,("VKZL
M#G=5(F2NM1GN17<3%L;V'9\'N8]9X>?&05<>0)WY\GJV^+T*'(GO-#O/-;:_
MEMG:-+BOW0*6^*4.!:V2JLU.WBY6MW-9BJ%Q3')@L99-<A8@2.?!I92X32*A
M:CYX>AA6QG9JQ]X6X^&B3[_FLK_/,0[+W0]IX(G\@+)&+L;E*O<A3JM4,%M@
MAGQ5)7.!8 AV(B9A@\&H;/O9$ ^2T\XV;A?Y#<MBB5<+TG]6ZTVUT&OZ^O1T
M?@OKQO&2M17@D'E0@M/^XS) *1EM1(:2MVX??B3)X[H K9#UL"T;7H]]'>ED
MDA?S>F)<L$[L[G+QN\'=MU]4ZY)*80RT,QQ45@BUSP$477(*1@D*:(<[MI]*
M[KA'\_!P'59_74'U52F8UI>> _'YD3R+^H1[7E.]&Z7>?CYIDO;)!B O)X-2
M(I-[8Q($5VI947)>M6[?= R]X^:OA@?KP!KL"JT7/O&G\Z_D[%6?/,RN!'O;
MYV7<1^V9!BP^@K5*0=!. O<\>D:>K[*M[\@.)'7<@;G/8% 'TUM7\+SHN$:B
MW-5JWJC1O,4F%QF#5@Q,X :4XYH<'2D!C>3,<DW_W[HQRX&DCCMR=WAX#J>W
M/D/I;2/XPZ/H&[_?((!^F)Y&L?-V@:M7W:%P+C&#+YP""\_H_&/&@I!.\.R3
M,Z7UP7"3@N/G*="GU0[LMZ 9959!^PS21MH.MK8ZULJ#2%%*ZQ)/IG7D^P I
MXT:T1^C[[NB$XT7=P2&UG0#Q_BO6)NOSTPU7%R;N^^Z2_?N=KBNHR+P5H*V/
MH%A,X%%&,!$%FL@#-G]P<P"9XP:C39$VK(HZ0.$MYNH?%Z?[S><<T9=-@^-$
M"*$ Q3MBRW&(5I=:_R=1M<YG[DG:N-%D0[0-H8JQ'_V_PW6=XKM:UPCCS?Q3
M('_B,_WB-?_B>J-:(2*J LR67/M81>)),N#:%>%J;9<S/W*$GKSJN(%> _@,
M*^<.3-1V9/W-W?$A?-_<_WU>_(;;+@.8'S#(G-<F&$621Y 5J!!#C5TU_4T;
M)5Q43K=.CAU'\;BQ7>/C\YD4UV=4=_]@@2.::S[V>2V:9^Y-;ZM'6I?Y@VV*
M_V+)C[BY3=],?=P0%2M1%]BY!*<6PCCN%!B!I4Z^E>"#]34#P&-DUF71VAT^
MCN(&_9DN5[]?62?+99B?;GO:_O;]ZF=VE)S\'I;Y6G_;R+CD24'F:,B5H#,A
M1(&@';>,"\&5:?V2NC$+(S_5>C[\WM,7:C0H=. 4O%MLW!W,'^G/Y331WS8#
MA#9LKG:/@6Z?*":%C!2&09)U_D'.]43)GKP?8MRJPCRV=@4.H7/D=U;C87IP
MI78 W/OWZ@=<EL7R+,P3[IBMN_-O.W$\P'D1QGC+/,A<3'W59NH,H@A92JY-
M+NCE\\R,.H3ZD8L8Q@/Y2 #H ?J7USOWR^ 5^<"+[XC;27#GR_2E!@RS,']H
MYT<;O>,)4E U2B@6 H\>#/,BZ>"BD<.UT6W"PKC)AS$WP8A0^ EVPH;M[0"Z
MAXZ]*#CS+CO0G <Z]@P=>R4$.O:L]\$K$<UP=]6'4CUN:J-CO#=6>*<0OQYY
M7.>X%HYL45![9G^]:F]_+>F=M='1"4AL4TY:!'@T$D)022$) M-P510M.-@+
M^H,-U.D,^L\$A#ZS@A?=ZS_AZ39;OW'\CLL,_O S&PZAV(_N1AG"W6(?\6OM
MH3(_O=:[)<<<BMX6 ZN""#%J!SDE&8J51MGF30 >H*6AJ;RUPC49__9]]\UK
M)X)+QO"L0&B+)((4:%>Z#)R);&W!(O5PKRF?1.JX6;HF&'K$K VFM$[M5UA-
M5XORX=J'A7E^5R]Q<%%VUSUDN%_B.DQGAYFS)R[1PKH=PU4C8_=^>1KFNT91
M+VBMQ6R:+Z:;7"?L6OWM94WNU6'MLN6:*P'6,0V*<P:.V0).L9"$X4F+UMTJ
MFA#>SHQ^6"[R>;IS0DV4LL(%$DH),8(R2=?+S @F9"V=9]+?;DK>T& ^0-2X
MIO'Y$?>P'6VAM1$#G]5R/=FQ\'[Y"9??I@E/_IBN)JE$YEBQP-#5FQ4?:_%Q
M;5L<M(B.&9?VBM1I@6N(HW]=H>VAM4<^=]NJ=M%0SGW@I+YJWW&P>KDX"]/Y
MQ--2)5&0Y5%2?*6Y@2"R!RM\CCY$GO->/MU^8+E+P#B(::/3NP Y4L!COYX[
M.8NUK<!B^?T#1<.KO^)9Q.7$I"*ST!E\3!0!6YO >^_ U3F0.EJIRWX];^_]
M^-$!<*S.%DT%.+*A^%AO\#<[@27CB;  VM6^]YH$X9UT8#C]G[0U,]CB%+E<
M<-Q+Z.&.CL,DV@,,=NA5#F7FP@'%BJX^,#<0N0K @E4R"">TVNO6:Q\@C&T2
M#E36;74?(+F1%?[7Z7QZ=GZV(UQXF203'+R4M;=>)DL820):)*&*QZ#VJX[Z
M@<IO+#JRT@]1V:*%_#JX.J% +)&,M@F'C]/5/W[[_AO.TY>SL/S'9C-PQJ(K
MJ;[8+K09I.;@ D8*NAPFYASSKO4(O!_1-.YSCF&.BT'TT26^+KC9^5O%)^E+
M4>"-4/6ZAY/7S06$P*U6.G)K6E^V_8BF<2/9M@CX(;R.4$<7\%JMM\-*5KO=
M^'8ZOS#H7)"$N$KU)C&1H!2O3CT#%U74VCJO0NMZV,?HZ0U6QVC^#JP:J:$+
M2-W9?[6Z:;/UG''6))_ DD\ *A@+=8PH>(Y&;A($O'6Z^Q%RQGW1]>SGX$%:
MZ!%0E9'=IN.!U2X\C*13R^,RTMX05H!A2C-O0E)R<._JBIS>+-2!*O\1E Z4
M?P=0VG30F=:NG[=8VIG:R(ID160(V4I015<Q!7(-ZOQEH0Q2[-KZTNEQDCJ#
MU*&JOWV1U% //<#J\K'4Y@@_F>=WBSE>/(O=Y4<_+\-\%=+NJ<%. )O-J9@0
MPFD-@=<QV]S6-CSDGT:&Q4M5$L?FSV..HGC<IZ'#'IS/J,N?$+D7O.YL (H4
M,O,9?(J^#@Y)X"5MUAA=5IX,@]/-'S8?1?'(EZS/B*TC87V$HL>^B?MT-EU_
M6>VFF+^9I]V9XDA R((''9VJDY9T??- QY<(F82G<M*W)J(^-![^WL__N9!U
MC'H7;67=@16\>X[4\/O-&L_(<_:V&%[ST<4YBKZCJ'5;!A*Y)VB-=7C[!O=H
M$_<(.>.^3!_VY&VEA;'MS[OSN@?JP*VT?88XD11P8<XDE5RC+\41(CH+F!2/
M/I#(I-O+]-SYZ-$GP+?1V**9^#JP)G>"F@^XK%\(I\@ILM$V,*>!B4#VT+$(
MM0LG6"NTE2BBDNUSJ@_3,^[+@=;X::Z!/A]U?SH_.PO+[XOR:7HZGQ8Z>N?K
MDY3J3.?I_/3#8C9-4UR]"\LJ@&]XQ-ON U=JT=ZF 8^-7GK?7?;R,6V1RA55
MD_PFUCR%KSE_G0%#5"(B?>NV83]Z-S],S3.7MFS.>Z9-,<(9",$%4+6^/6:)
M0%*70CM)GF3K_.L!9(Y[2C;"SY%%+4]65P_/J#9A;TP";4F^]C*GX"1'BDL"
M$2V"1>-MCF2RG_TUW3,\Q!Y(K?>^KWN*C'L QB[.#-I;78?:<%X*J. +.&L-
MU"PQ\:V(^A:/K3I[7_<D93WPONXIDNOJ?1TW6@BE%4@M-/F%TD#4J0!WJ(.(
MUB?3XDEEA^_KGJ2R!]_7/45^8RL^_'&-\%)4R=QG<(9S4-%;<)P[B-)[EI1%
M6KV%XJ\O.DYXU$SQ!\NO@RB:8L.ON%Q_KXUDUB?S_.H_SZ=?ZY%W[59;B$@B
M20J<#*;>0TKP(A:H4QDQ&6/1MYY>NP=9O;S&']9_&$I//4/OVNVWS598ES4D
M81SM21O!H]9@BV>%#N!,SOQS0:^7!RC-H; OU [4R]B)XNO9<TQ?YHO9XO3[
MIT59_T[BOK#:&)3'%"#;0!&BB1Z"-P@IR!*UDD7?;H/Y0.IXC\4Z1<^AVET,
M*.H.K%1M#71.'W<IIQT;F5L5I3*U1P8Y>-[D.O<3H3#F4LG,6FT:6Z8'2!D]
MN3P(GEK*OP,8O:;H8(UO:V_W-Z2=^>F4/(+M'*_?OO\U_)_%\L4LK%8;XZV]
M*YR"!S"^]F!)@=5B3 3R'DR6WI&T6O?D?0)YO92U/(_?-93>^H;D%6/OPMG%
M+E;"*V\+;3$7:<<59L!I14&2%%:)H$(TSPC+^T@<]V0=#"K[0_)HO8WMJWWX
M\GTU3=-0FZV\.%^M%V>XW#3DJS?47Z:7]>K,Q!)]3,!,R*!0D*>KG0">78R"
M-KM5^\W%V7/!;I%UO,87 XN_ TMWX4-<>**WA'B1LLNF!!TB&!L9J)QJS$3'
M1$HF1"<4E\U[A^]%V+C^W7-@;S@]=0"^O\V_AC4)&O-52+3C1/- QX A;U@9
M.@70&XC%))"\&$9N,4DP-4;<P]2,Z]<])\P:::0#;+U;U&EX7W&-)Z=+W+8@
MNZCMD-%8;Q7%7#5(2L13<"0ES;0,C+AAI?6;B8>I&;<$\#FQU4@C'6#K9+Z>
MYNGLO+[[^82ICB.;XNK5'VEV3H'3:Y+RUESOFN&]"LLY16&K#V2^-Z^DO]__
M 1OWUR<M+7<4LCM%)CS6') 0FZ:C)!+:8Y:U?L\R(#N]%+@^3T3<"RZZW2+7
M+$DPY Y+ID '\E)4# 5B<AR$L34_I8WB>[VI.1KGO<3(W8!G+U ?J,D.D'EC
M6,BVD_R%]YPR$8\>BC=T"DG:^IX;"5I'9CR/TK#6E[D/$M,C%@_5^6((!72
MI$<.E;>7K\A3R+$@(X\I&"2W.5F2E&<0+6TZALX&V_HR9!^Z>BF@?9Z#N;FF
M.D#?197*EJDJHAV7JXG I'3"#$6I!$IP#=%;!CP:P[+@+C6_@'N8FKZZ^1^O
M^=M131LUC)U=OF#CLG'WF_EJ/5V?;^N?E(\\<1E!2&1U!K@&%RP'2;M.)B^2
M3+=>N?Z@?.S>949^MC044AK+MP/3<W-(]YL:UF-U3I?X!><K\AFV7WI5JU]6
M-:/P=KI:3W@Q/)![ %[6[9!X?4287;7BG.0JDL;6 _@.(G3D6]RA#=;PRNL
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MLV+J!"UT *<#GL2;;XUT+'HC4 HHM6";/%(//HL,DH+:H&P(CJO&J'J*IJ/
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MG"L&F%/,E:*8L4?U+M-/O84-^K?ON/CA@_.^Z+;R5<;+L ?%W\Q,(A,6+$?
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MT09(*JM<1R;$V+KN:1B%?;[GMK9,C33T'%*+OX;+J\TN ;<NMVL3FR47G_I
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MAE6[3O%;[MZ-E74HK63<T;&H10 "#3@N*0A(6E@Z.4RF*8LVAEQP9W^1/ 5
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M OAH9!"(S$V*_:<H/.H$F/\] 1/K?OYS,.+FV\U<V@G>2E3 >:+CSI(#9X(
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M$>F=O",V+@"90Z\=^*_'N.Q//?!?LZP+&!TH['19@8O1 <84#.=!Z-#:EVU
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M)G8,#XT2L758YL5Z>[7!W\OMC[_#BVHWZM:@[8Z\6,F[N8R_%P1[)A0+]3F
M(GXEI8; R)K5QT#!HE3!MWZM/8WBD\U?^HCYZH*^_;#27I#.5A]V^S.V/WW]
M_G?V=+SX,VSROD1 265$)JE91?]()D#,2D%"R8W#[(-OGBEH1?R\*=TS8O:>
M@9U%_1W$7M>4UYNE%M*QXE(HF4,*/H'2+H'3FD3(4) \I22F6K^2WB9@7OS-
M!(*[KZFC-=(!G,8+[CO;J_SV(M M^0GWY7O>IZR)54@NU-4OEGPH)BUPK6T@
M]]J7YE7_4_ Q+[A/@-6]'7(SZ[@#G/]"CN;Z*^(?E^OTS]]WJ]3V!:$\!AVK
M*)FU I32%EQ(%H0DMY^IF$)LW6QVD)B9S>GL.%E/H;0.T/<.R>59)O*)=JSL
MF1"&V=H@ \YG"C"=%A1J6@,,(PNI9*9EZ_69#Q(R[_-I=Z@[75D=(.XM;LIZ
M\^FZYX^$M]VS896)L2Z,S)'1/8+* /V; 1Z"+J:$(+!U*<L!4N9]W^P.=2T4
MU@'N?C#9>Q8,0\NL)&-=^P)51@_$"[' A99UG6C[)M 'R)CWZ;$[O)VJJ ZP
M]N]DJ)>K#SO_6"N?G$@!+/,95.09/&:$[%#;C(5SWWJMYZW/SWR#=A$&C]5&
M/T#:GRICA46.";(0=8@/UQ"M#H#"RESSTLRVOB)_(&#>(&"T&A^&PPB9SMYU
M=^^ ?#\_]=T0,_'UZW*U_'3UJ=8E;3^N+_+>@B9EK;2>0>9UEU:6&ARCVQJU
MB3*C=??>A0]UX8TGH@O\C-'[>@8E] RV%R1J_/((GZFX)%""B(+XK/-?G @%
MZF_7WD;#PW'+74\@8MZ;[PQ@:ZF$#JZZ&P]R9]\%U]YG)*]1%EF7\5%LP5+>
M[41.60D>FL]9NOW]F2/ +KRFT?KH"$O[X\=,-B8'0X?.,**YMEHSGD SX5(6
MW(G<NHF@IWS]>$T>@,0(L<Y]F[T@#?%?_OMJ>?GU]:KN^UQ^P<K.WE96$4AK
M/'!6:NEV$>"-J[OT1*BE-CSZ?-2%]?AW^L#!&/6MIY%E![#@ZC KWEG4*,E@
MNNQ!H4C@>8D0E"U9%L,S.VY\UN/?F==5:0B+5K*<$1;;S>7B7;U>=];2)NFL
M4!X<MW7?"-VBGAL+PF0M4K9:XE$SJ^FGWKHUZ-^^WQ@_?'#F5."LCL=XR?<
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M[[*%9"T/BFF7V9-]1E,0UGEMW330GEW#O5CVT>SO'[:N6>>+*$,6LF2@^"^
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M/6& %CP )Q%S2$H.LW> .<M![9V$8.^@]BZ(5"!.QS-NSP!)&Z#C7CA@A*:
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MA/G4N(Q'_''TWXC4*OI!A [HRK<C\0,]P5^5)>A3GL_:$7AZY=Z"<5HR!&4
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MK"[P5W"A\+0O#A5*8$($""YUG]3, "VQ RR>&SIZ8M"HW-FZLVR U4D(]C;
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M@\U/[[_,&_OWIW\F49.^CKZE)@/OOGRZ?+R?=S_2+_VU90H'HT.J8?* "DM
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MMYI?LOAWS>1^X%035BS+/W(ITX;Z&\+4!\?JZ%SO3<!4!0L\<190ABW0A D
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MO$%0JZ@"+/M ]J,V6KB"MG^AZQN\"HS7E[MOW\8C/UOUZ[E6DG-NO01:BVB
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M"A>L2C=Y[:\2SJM/Z;I=EK".1.'22KG3<9*@_*55@>I%-]'*[3W8D53-@51
M5BG0]O;A^07,"C?"#0SK)N)95&6SQG>N5;G.X5B\]<')9L B5BL%ZET-AXC4
M2]32^=&R;+1:@H(HZT6%@LZ@7L;$K#:\QA).K%*DW-1T!^SAPVJ 2@,NK@<G
M!GF_*_U(PN]0I)^<G=FG7)<!!<.M7,,DR\*G'MU'+'0M\?>RL,%P[_[UC\.5
M@>P'X:_[E]9'],",8+5FL<338.OR$GXD^IBO <./00\$)6,&VYQOHNNBO"W@
MWN LK&:8P'B@9/BC=ED=WHC;LLF!#^!E )4E8NJ')\%\^E6A0"\#/638!S$%
M^R!-,]RF$6IAN@%6UEK"*&!C&3! 4G8W\.]Z20Q1% ]D[9ELGK&/\O@6.$G5
MY,AMX"B;/!8M!K8R!^T-?Z2!@:9PR('XXNU=E" U"K*T@,7"#),EF%(@=.*<
M^"A+K30#U5!G1@_L56B^^/SYMR_1DKZ!":;,S_P?DIJ)=-(^2R4OH4<U3;ZE
MI@*_DYG!1&%N(,]PQF9ZH&VIR,P1/]\RP\'0RL-]+EW/V]7T_!S^/90E]9/_
M*P5K ).1[(P:1:.G=2#IXJ$OLUE6 _5\\Q)D\CX1A*%#/&*FQ+G_)"C:=!4,
M8Q.R!'8$TXR1RHH#YD8!GS(^ERX3-,82TS"\=&^V+\Z$'.@4=0H@KR0O-2A5
M3%\=/@JT3-2HB>76QHE!\_3]%D,3U5?9^G%-5-SO 6[*&EC)(]ON'S'#LO&-
MC\$Z//7-'JN?D,0BOO2@V9MY^S$W(SQ?L*5UHSI1.//4K*SK<O7BB7LDGNDR
M;^KN(W<$[OA_EY49>1TOU,&L4O'U03P'1ODBSF_CC0Y?__N#A8]S6;YZ^<7G
M1U\]Z?G?'QKRWZ#.L,63#-_>Z3=F78P=/-XH::F<GS?P#31@-*]0&)#H:\CH
M0!LWA7>@%LT*>E:FY"Q018*?TDMP+BF*2M*@EBP#42;N4N+9E*17/WV&1B:^
M&4^9O0<M;=UJZB+45#H@=]Y[G3+PZVTRN:G9%/6/AV=GK7/</9;=@^&X[[4+
MXT+?PI$[5V99&87<)P%_)[J;-NI$-&P$2X(8P;9&39&CDT6O59+-P4K)86/C
M!JR+"A9&[HJT!.OQ<. $=@7'K\CG4I21>I>HM=W"VQ@X-B^;K)*UF&WJ!G0\
MM(T#%R)=6ZU@VPJ%[J>X(@;$H=R,C+@]X]+#NUXHWJ4J1C-F519JP^YWL>!!
MGYW;V(L"GK( ;K'9']"-?:AV\&9\-;F8CE]'IV>G!^=O?P %(0 2[+&]XW^V
M/Y2U;C/S.ZP'Z.0.>P1.\"UNBF_>M\RCT> 48[.F1S896@(-Q:G_$=W!. )E
M!R\0^TUN@"GB92;W4IY=JYQ<K:SK9:MU6:&;&:TUH-J,F./M4I$:@)B 9L..
MAQ%YE\L\-6[Q<=^[$WK+3"'N  Q(ON' /M'I$8M:L0D=[,"ILT2-[$NSFD0U
MJ8'LTR[4@I1'F,C2C&]6 &\P1T,>:V1FY)>+9H3-.L"]M(X@9C!L.\,ZS9-9
MO6$+&.XLC##RO\#19F"2@Z1$=4.>)O0;J$L42%FBYSLQGOJL2IH5OC!1XNO.
M4+.J@6>JFSAO3)!8X=XE!,8P<J.V&A>..5.%FF?TFF56I!J7,R#NMX-0!W1O
M3RT+^@AN[C+6XBD$8K$Z:@2"#[U)<&_%;[B*JVM5K_,X44 0$[I>75]-1P.&
MZT<!EZIL%DM1AD'&HD_1([NWAY>'T:7CQTC!DW?),BX6%%%>9>QX&IQ#YW)R
M_-B8 ZM0&Y=T"4K0K$PI)K:N4%\$2U@A:(?Q5WP&*Z5J=P@QJ#X;+>R$O(+X
MX-#UR'&>=PD:,0&PW*J+%C+8 @L6 FK&.#1R_IK11OFFS[1IX+O HNT8=3 *
M\LG+#!885_EF%,Q+HEVIS,A%J$4XO;?%.XI +4[+KNE+.R&QHHTB22LWFH5%
M[I@"!NIVKQ\6=M&L"(*4DNUA'R_$@TP4!3^@H*RLTFID66CO:!9C8+[@E^2I
M1GDT,M.-81WT+?X.I&"F';JC+/JG]_BD.(0Y_,RN>GOPZ,4@C *!$3#Z3KI#
M CN^*"MQOO09I>I=O%KG_'WG?MT:=8B#F4C5O6X2)E=0H&9(\F3KU: +KC+6
MT-HWQ*(B'NX%')IKH >" :8L\&6TV,5/\"MKJL[:!'[;Y+7F:*!V?R(G8X!K
M3DXI^&_V6P,Z<[WQ6+]FQN.-%Q@_'_5VGALR9JN?:86U? 'G&!,_!GZ,#AC$
M"ZL$]D/HF75^#<RQ-G]4RL2]](C1E36PG#4-[/C9FA \!(-4%4G+P<<[W\^E
M)^9$)Y(,G$0," D"&QN(':MP)$"+$JQ.@!PS]*:.G(1M"F!'*2(]Z@Q!4J/H
MUS*#E=\P9@H$E2*SG#:8#@((OZZ:I!;?+2J90.HBT5#<-EH;9Q$8:25(+0G"
M5QRFK,I%1?*2?,WH'R+J\!U'9%\I')\\)75\K8J/^P#A!42;B @FSR F2I'Z
MK&53T@:M1?+.5S=98A#<BQB^AD^1N9!Q&0XAB@8])]K%R&,[J_A7E/ID&I!B
MPJ_\R!G.L=LX>$N\8'N9B1_18A_Y\L:$I76'#'>B8;D$9AKFUB%*#UAEMA#V
MB6B/!J\U_(0Q++0A[.:17WT"U\>!L]R.6,48OL4;9("KY$89S)H?ZA3>AF?Y
M.YPZ'(HUJ$[*NS&X-LZ8HJA:6<VR-%4"E^1DV/ZH7!\R9LZ!V PX^RT.?P.,
M #9Y1%*434(!"Z&2BF\0E,:6=X J8*)4!$:T?QF_DR D66R 6"X8G6@5#8-=
MM'E?Q&U,UI?X--FBT&Q2B)'C6Q1S,&J*5'OZ1ZQUF2!.&!7K->*!63$(@Y(V
M.M"*37-8 .A:(L5B[%>2L@3Z8B8^V;XP,>QDSC$HW.V;K/3A@IRYP,D@2X4@
MS"0I&S@$\WL#.IQM\+<=Q+.G_,,\04?B_"WZJ<4]#UU0]>S:"C0.W!,@OYI,
M)#B;8X'XJT(K@RE&*KLI,R0*H%[0X2@U''X(&F=BW *O8!_%EOWXK<J3DNA=
M5&#0?6_!R+E1>;FFW,J1^(\X&H)J.FK<M>HU\ GD248..72UM:!4#NH^9P@@
M(@>Y[(A4\KBA] >XB%F%;C/2'^-W&$HS!M2&!\.@"I ^$KC@D%%E6((=FPY&
M8/Z> UB@.;HFC5A<88K]=V%Z'ALH97'@/O 4C*+7S_8I; ](:;"^I<B">)=[
MO4,M"B1NKQ,,F,$^KH2*A,$A(56J!O9^H^CK3V*K8+'5YGWV*B/IJ=ZM*50#
M$RT&GR5QE\F%/.(>6U&*B*.J'S,%7RCC\+]1_!7K#^1**$O&TZ2\W_PCC[H0
M D_I34Q?<?H)T5:YO@]I4<*J@;XTF(R O^2<3 JH4_P(I8D)/J,? #T(NOS(
M26XZ]_8'+?LX*[8HN*C*<:T"3GS P/Q\Q!ED#AY BB,B'328T2DZQH.DB10=
M6R (AB,%'VHVGI]=34ZO$$QT?#%],SV%?V!VQ/'T7]/7T>NI25.%S[[X_-G7
M+\\NJ$S)]/PU_/0"/J<Z%D->_&??'QU&KT%GSPB%@9?# )2O6!UW&O4')N9S
M+Y]I?E>FQ\A,6U.V:Y@$E%1@,17R> *6 V'>3'!8P3<<@G>YK-EJ7<%]9Z\/
M;HHJ%O%"+(X'I?1&!!6B/#2N/($WB-)',8\M5^EB6\;'EG11#GEQG1$;_/:1
M+7"QL>Q-Q2!?-'C5'$9%5R@*5HH7-&#P<B()6LJDS=)?H.5Q"E@8! MS3_@1
MPN/(L;33;LB<1M"35IX_*;=D5@:&L'.N"M9!G(Z4A<6L6EM\QYQW<![#(:*E
M'U\K'X@% ZXI>@IL_(9==F%&6U WPA+-H!G49]\_;=]1<4T\VMT,+AN=]BPP
M_?'^E&O5PJ[.-KYC9(_SV$%Z^,G'%-,:&N8%[L5:J<>&O<#NP/U;>2S$@9?N
MFWE;5CW#K-!;5BE.%4ACBTP690C%.E ;?\KX!P8I]*&?8HM=Z-37Z>&.AX@E
MC"XGQP3*8HZ1 @^I@"LZQDQ(:,,]S:(=<X!/4H[^5R4B^3CS%WY9&PDF+Y$*
M/A0-5>],L C9CRL_,RW2!K26373AN.M8N.L&]<5(EVN,;://!>9*&7Q568"I
MHIOJ1F5Y3I5 :I4LBPRQ\K@?39&0NM_B1@-G.U\>1C82?0*[GJWA-P@X'_.%
M?C3V,[$.!A1([&=404ZO+3OCJ0&IOP3F2<:%1!4RV-<*_U5YML@\;CMO,'(;
MK>-*(N9BHO:0-I;^JFDL%'IPMQAPA==.5:B$F"1G]I$P# @IT&>DE4*X,//#
M+?C505/.+HWZ8G)\]D9*X_WX=GHR 55Y<LGYN=$5ZM@_8M47N*UO+Z97T\EE
MD);\\_3TY.SGZ'QR,3T[N1S*'FR3D1@LI(,+E0[G'@O+O&TM1H:0!& @314O
MR#O\4WF+E86(G4E6"6$(,I&SCO,3%T3EE]+6[ZIZ]C"B^CMT]F&Y\3%+^I]!
MA2]OHW-*[QL\4/T*.1A!I;T2:P*"#@N%[4I3^:.+ =E:0%(:@FV,5GFY_M)>
M0<FC/[M(CTW%  VY0M@*J3;P)07FQ:O^,',4:R!(EB@!63E+=*; N"W,ARG*
M(DKOQ+_R6-?T$4JM&(0E+P1,Z$K7!*# ?VL$^OW6@(@T*8^XAJQH)'3;3ASU
M4+2"U7;CM@""7" &%4T9GX;'&@K>0HZ>'< <-4MQ39(75E89++]DKYHEQ$6!
M<(>-BJMH+SM4AZ/H1"5T4-'1U_5R_\]: ;]QD*4%>]C+WP4*=F+Q!:* &/*P
M_ X:-%(T)PUXCGH'-Y$3K@P[0^G=1A[L-I]$Q_0N=3?MFR@1;R:"U<J*,[G,
MN^FBR#.L_\84*H#K_/S)?QDJMNINP2@Z3I1*I,(L!V2$B)U7R03UC;^F4K64
MPB5-N 4FE>R$H'0M[D?#SAQTX[B2028[SOF7"8I9T1J)"<Z)-<#4X'J"/F3
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M@Z6Y6@6ILFBR^UL7,/5)[.W6GIP='3.J+?*YO?&L.7>OBM,DZ)92E'>S;SU
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MV[MW*X(2P?*9W"RR;6I\@X)?'9.WS/OUV?Q]:.F_'G\ 4$L#!!0    ( /&
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MN-8RE^-_+I+GZX[^J!3,]VNL*F)_4/#J_UNG;YS&^?B&ZT %?/$>E7>[L2(
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M1W8(6R FFI4ZPUW,^]':"_9]WYJ0FGVD)I7&,$@&D@-,/9B;N4<:464/*&P
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M (+BEX+@OE,5WA\Q*THGVKVLUON[IC]"B>_+KEH&!UKWI@#,)ZUS]Z(Z#[<
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M].5_ %!+ 0(4 Q0    ( /& 6URG_E-U*%8" *&/&@ 1              "
M 0    !I;F9U+3(P,C4Q,C,Q+FAT;5!+ 0(4 Q0    ( /& 6US)[6#H&14
M %O^   1              "  5=6 @!I;F9U+3(P,C4Q,C,Q+GAS9%!+ 0(4
M Q0    ( /& 6UPG?''Q'3,  *T8 @ 5              "  9]K @!I;F9U
M+3(P,C4Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #Q@%M<''-4WY%I  #RX 0
M%0              @ 'OG@( :6YF=2TR,#(U,3(S,5]D968N>&UL4$L! A0#
M%     @ \8!;7(052W/8LP@ NM\+ !0              ( !LP@# &EN9G4M
M,C R-3$R,S%?9S$N:G!G4$L! A0#%     @ \8!;7.& ]H/TX   G4,! !0
M             ( !O;P+ &EN9G4M,C R-3$R,S%?9S(N:G!G4$L! A0#%
M  @ \8!;7%*6"M2'5@$ )V<- !4              ( !XYT, &EN9G4M,C R
M-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( /& 6USQ8<2J#,8  $)X"0 5
M          "  9WT#0!I;F9U+3(P,C4Q,C,Q7W!R92YX;6Q02P$"% ,4
M" #Q@%M<\:>?\9@P  "!! $ &               @ '<N@X :6YF=2TR,#(U
M,3(S,7AE>'@Q.3$N:'1M4$L! A0#%     @ \8!;7$C.1@_X @  _!   !@
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M,2YH=&U02P$"% ,4    " #Q@%M<V=+2@SD$  !_$   &
M@ $I!P\ :6YF=2TR,#(U,3(S,7AE>'@S,C(N:'1M4$L! A0#%     @ \8!;
M7.&^G>!&&@  BI\  !X              ( !F L/ &EN9G4M,C R-3$R,S%X
F97AX.3<Q9F]R;65R+FAT;5!+!08     $  0 $0$   :)@\    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>infu-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:infu="http://infusystem.com/20251231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="infu-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <instant>2026-02-25</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:AmbulatoryPumpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">infu:SmithsMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">infu:InformationTechnologySoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UnpatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-31</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">infu:ApolloMedicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:DirectPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">infu:ThirdPartyPayerRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesAndDeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">infu:PhysicianAndCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-05</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-05</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-05</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-25</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-26</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:TermBenchmarkLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">infu:The2021CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">infu:ABRLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:GA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:MI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="infu:LeaseClassificationAxis">infu:SalesTypeLeaseNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="infu:LeaseClassificationAxis">infu:SalesTypeLeaseNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-18</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-04-23</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-19</startDate>
            <endDate>2018-07-19</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-15</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">infu:ShareBasedPaymentArrangementAchievingMinimumThresholdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">infu:ShareBasedPaymentArrangementExceedingMinimumThresholdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2014EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">infu:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <instant>2024-05-16</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <startDate>2024-05-16</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:PatientServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">infu:DeviceSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">infu:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001337013</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="location">
        <measure>infu:location</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>infu:segment</measure>
    </unit>
    <unit id="financial_institution">
        <measure>infu:financial_institution</measure>
    </unit>
    <unit id="network">
        <measure>infu:network</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0001337013</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-35">false</dei:AmendmentFlag>
    <us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList contextRef="c-1" id="f-302">http://fasb.org/us-gaap/2025#Revenues</us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList contextRef="c-1" id="f-303">http://fasb.org/us-gaap/2025#Revenues</us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-31" id="f-316">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-32" id="f-318">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-34" id="f-322">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-36" id="f-324">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-36" id="f-330">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-31" id="f-342">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LessorOperatingLeaseRenewalTerm contextRef="c-31" id="f-371">P7D</us-gaap:LessorOperatingLeaseRenewalTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-35020</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">INFUSYSTEM HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">20-3341405</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">3851 West Hamlin Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Rochester Hills</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">48309</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">(248)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">291-1210</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">INFU</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">122267022</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">20215159</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for its 2026 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-36">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize the critical importance of cybersecurity in safeguarding sensitive information, maintaining operational integrity, and ensuring the safety and efficacy of our medical devices. Our cybersecurity risk management program, which is based on recognized cybersecurity frameworks established by the National Institute of Standards and Technology ("NIST")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and led by our Chief Information Officer (CIO), is fully integrated into our overall enterprise risk management program, and shares common reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, operational and financial risk areas. We are dedicated to maintaining the highest standards of cybersecurity to protect our customers and stakeholders. We will continue to adapt to evolving threats and regulations to ensure the safety and security of our products and information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see the Item 1A. Risk Factor above entitled "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;" for more information regarding cybersecurity incident risks associated with InfuSystem.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-37">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-38">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cybersecurity Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Risk Assessment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: We conduct regular risk assessments and penetration tests, leveraging AI-driven threat detection and continuous monitoring tools to identify vulnerabilities impacting confidentiality, integrity, and availability of systems and data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Policies and Procedures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: InfuSystem has established and maintains cybersecurity policies and procedures that align with industry best practices and regulatory requirements. These policies address areas such as data protection, access control, incident response, and vulnerability management.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Training and Awareness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: We provide ongoing cybersecurity training and awareness programs to our employees and contractors, emphasizing the importance of their role in safeguarding sensitive information and reporting security incidents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Use of Third-Parties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: InfuSystem works with a third-party Cybersecurity risk partner whose systems ingest information regarding the current state of the Company&#x2019;s information and technology environment and using specialized algorithms provide assessments of the company&#x2019;s Cybersecurity risk exposure as well as providing targeted advice to mitigate any risks identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Third-Party Risk Management&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: InfuSystem evaluates the cybersecurity practices of third-party vendors and suppliers, ensuring that they meet our cybersecurity standards and pose no undue risk to our medical devices and data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Incident Response Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: We maintain a robust incident response plan that outlines the steps to be taken in the event of a cybersecurity incident. This plan includes procedures for reporting incidents, containing threats, and notifying affected parties as required by law.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-41">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;InfuSystem is committed to continuous improvement in our cybersecurity risk management practices. In the coming fiscal year, we will focus on:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Enhancing our threat detection and monitoring capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Conducting regular tabletop exercises to improve incident response readiness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Staying abreast of emerging threats and adjusting our cybersecurity posture accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Collaborating with industry partners and regulatory authorities to enhance overall cybersecurity resilience in the medical device industry.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-42">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;InfuSystem maintains a dedicated cybersecurity governance framework. While senior management is primarily responsible for assessing and managing our exposure to risk, our Board of Directors oversees our ERM, including cybersecurity risk management, and ultimately approves ERM policies and procedures. Our Board conducts much of its risk oversight activities, including cybersecurity risk oversight, through our Audit Committee. Given the ever-increasing volume of cyber &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;threats and the magnitude of a potential breach, cybersecurity is a standing topic for the Board of Directors and Audit Committee.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-43">Our Board conducts much of its risk oversight activities, including cybersecurity risk oversight, through our Audit Committee.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-44">As noted above, our CIO leads our cybersecurity risk management program.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-45">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-46">Our CIO has over a decade of executive-level experience managing information systems and cybersecurity programs in the healthcare industry. The CIO serves as an Executive Officer who reports directly to senior management and, at least quarterly, makes reports to the Audit Committee.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">CIO has over a decade of executive-level experience managing information systems and cybersecurity programs in the healthcare industry. The CIO serves as an Executive Officer who reports directly to senior management and, at least quarterly, makes reports to the Audit Committee. Senior management reports to the full Board of Directors with respect to cybersecurity matters on at least a quarterly basis.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-48">The CIO serves as an Executive Officer who reports directly to senior management and, at least quarterly, makes reports to the Audit Committee. Senior management reports to the full Board of Directors with respect to cybersecurity matters on at least a quarterly basis.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-49">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-50">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-51">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-52">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-53">Detroit, Michigan</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">3186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">527000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">22901000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">21155000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">5391000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">6528000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">4858000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">3955000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">36336000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">32165000</us-gaap:AssetsCurrent>
    <infu:MedicalEquipmentHeldForSaleOrRental contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">4589000</infu:MedicalEquipmentHeldForSaleOrRental>
    <infu:MedicalEquipmentHeldForSaleOrRental contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">3157000</infu:MedicalEquipmentHeldForSaleOrRental>
    <infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">34456000</infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation>
    <infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">39175000</infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">3359000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">4030000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">3710000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">3710000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">6866000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">6456000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">4178000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">5374000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">4640000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">7188000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">748000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">1481000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">1678000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">878000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">100560000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">103614000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">10821000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">9848000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">9361000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">7813000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">20182000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">17661000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">19625000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">23864000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">3427000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">4560000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">43234000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">46085000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-96"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-98" unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-99" unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-100" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-101" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-104"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-105"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-106" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-107" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-108" unitRef="shares">20209636</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-109" unitRef="shares">20209636</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-110" unitRef="shares">21272351</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-111" unitRef="shares">21272351</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">117461000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">113868000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">565000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">1119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-118" unitRef="usd">-60702000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">-57460000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">57326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">57529000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-122" unitRef="usd">100560000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">103614000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">143436000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">134861000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">63140000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">64458000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">80296000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">70403000</us-gaap:GrossProfit>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">920000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">991000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingAndMarketingExpense contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">10487000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">11312000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">56969000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">51209000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">68376000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">63512000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">11920000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">6891000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">1299000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">1777000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">-55000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">10623000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">5059000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">3996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">2714000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">6627000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">2345000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-154" unitRef="shares">20657877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-155" unitRef="shares">21271608</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-156" unitRef="shares">21097323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-157" unitRef="shares">21707151</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">6627000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">2345000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">-733000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="c-6" decimals="-3" id="f-161" unitRef="usd">40000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-179000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">-554000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-165" unitRef="usd">31000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">6073000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-167" unitRef="usd">2376000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="-3" id="f-168" unitRef="shares">21197000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-169" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-170" unitRef="usd">109837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-171" unitRef="usd">-58625000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-172" unitRef="usd">1088000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-173" unitRef="usd">52302000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="c-12" decimals="-3" id="f-174" unitRef="shares">303000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c-13" decimals="-3" id="f-175" unitRef="usd">45000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c-6" decimals="-3" id="f-176" unitRef="usd">45000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-177" unitRef="usd">4460000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-178" unitRef="usd">4460000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-12" decimals="-3" id="f-179" unitRef="shares">53000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-13" decimals="-3" id="f-180" unitRef="usd">342000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-6" decimals="-3" id="f-181" unitRef="usd">342000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-12" decimals="-3" id="f-182" unitRef="shares">172000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-14" decimals="-3" id="f-183" unitRef="usd">1180000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-6" decimals="-3" id="f-184" unitRef="usd">1180000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-12" decimals="-3" id="f-185" unitRef="shares">109000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-3" id="f-186" unitRef="usd">816000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-187" unitRef="usd">816000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-188" unitRef="usd">31000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-189" unitRef="usd">31000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-190" unitRef="usd">2345000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-191" unitRef="usd">2345000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="-3" id="f-192" unitRef="shares">21272000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-193" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-194" unitRef="usd">113868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-195" unitRef="usd">-57460000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-196" unitRef="usd">1119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-197" unitRef="usd">57529000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="c-20" decimals="-3" id="f-198" unitRef="shares">336000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c-21" decimals="-3" id="f-199" unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="-3" id="f-201" unitRef="usd">4363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">4363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-20" decimals="-3" id="f-203" unitRef="shares">62000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-21" decimals="-3" id="f-204" unitRef="usd">280000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">280000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-20" decimals="-3" id="f-206" unitRef="shares">1327000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-22" decimals="-3" id="f-207" unitRef="usd">9869000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">9869000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-20" decimals="-3" id="f-209" unitRef="shares">133000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-21" decimals="-3" id="f-210" unitRef="usd">1105000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">1105000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-23" decimals="-3" id="f-212" unitRef="usd">-554000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-554000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-214" unitRef="usd">6627000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">6627000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-24" decimals="-3" id="f-216" unitRef="shares">20210000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-217" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-218" unitRef="usd">117461000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-219" unitRef="usd">-60702000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-220" unitRef="usd">565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-221" unitRef="usd">57326000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">6627000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-223" unitRef="usd">2345000</us-gaap:NetIncomeLoss>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">200000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-6" decimals="-3" id="f-225" unitRef="usd">-167000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">12374000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-227" unitRef="usd">11508000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">519000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-6" decimals="-3" id="f-229" unitRef="usd">942000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">3308000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-6" decimals="-3" id="f-231" unitRef="usd">2268000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">920000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-233" unitRef="usd">991000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">81000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">78000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">4363000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-237" unitRef="usd">4460000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">2726000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-239" unitRef="usd">1918000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">-263000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">701000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">-1140000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">126000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">903000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-6" decimals="-3" id="f-245" unitRef="usd">-202000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">-114000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">-1953000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">-708000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="c-6" decimals="-3" id="f-249" unitRef="usd">-676000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">24408000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-251" unitRef="usd">20459000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">1412000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
    <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="c-6" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">8126000</infu:PaymentsToAcquireMedicalEquipment>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-6" decimals="-3" id="f-255" unitRef="usd">16741000</infu:PaymentsToAcquireMedicalEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">560000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-257" unitRef="usd">1092000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">3308000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-6" decimals="-3" id="f-259" unitRef="usd">4594000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">-6790000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-261" unitRef="usd">-13239000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">52349000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities contextRef="c-6" decimals="-3" id="f-263" unitRef="usd">56113000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">48226000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-6" decimals="-3" id="f-265" unitRef="usd">50798000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">197000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-6" decimals="-3" id="f-267" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">9869000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-6" decimals="-3" id="f-269" unitRef="usd">1180000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">1105000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-271" unitRef="usd">816000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">335000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-6" decimals="-3" id="f-273" unitRef="usd">387000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">-14959000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-275" unitRef="usd">-6924000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">2659000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-277" unitRef="usd">296000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-278" unitRef="usd">527000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-279" unitRef="usd">231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-280" unitRef="usd">3186000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-281" unitRef="usd">527000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">1243000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-6" decimals="-3" id="f-283" unitRef="usd">1749000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">543000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-6" decimals="-3" id="f-285" unitRef="usd">753000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">3094000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-6" decimals="-3" id="f-287" unitRef="usd">1383000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BasisOfAccounting contextRef="c-1" id="f-288">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"&gt;Basis of Presentation and Nature of Operations&lt;/span&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;InfuSystem Holdings, Inc. and its consolidated subsidiaries (collectively, the &#x201c;Company&#x201d;) are a leading national provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from seven locations in the United States ("U.S.") and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site healthcare providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem, Inc. is the operating subsidiary of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s core service is supplying electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company&#x2019;s pumps are electronic infusion pumps. ICU Medical, Inc. supplied approximately 60% of the ambulatory pumps purchased by the Company in 2025. The Company has a supply agreement in place with this supplier. Certain &#x201c;spot&#x201d; purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (&#x201c;NPWT&#x201d;) medical equipment, as well as related disposables and ancillary supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company&#x2019;s ambulatory infusion pump management service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <infu:NumberOfLocations
      contextRef="c-1"
      decimals="INF"
      id="f-289"
      unitRef="location">7</infu:NumberOfLocations>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-28"
      decimals="INF"
      id="f-290"
      unitRef="number">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-291">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in two reportable segments, Patient Services and Device Solutions based on management's view of its business for purpose of evaluating performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company&#x2019;s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker ("CODM"), reviews segment financial information. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i13594bbbfc1e4b049c5f01f53e10e953_142" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 14&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for segment disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions.  For intangible assets, the Company typically uses the income approach to determine their estimated fair values. Key estimates and assumptions in that approach include the amount and timing of projected future cash flow, the discount rate selected to measure the risks inherent in those cash flows and the assessment of the asset's useful life. Initial purchase price allocations are subject to revision within the measurement period, not to exceed one year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains substantially all of its cash and cash equivalents primarily with two financial institutions that are insured with the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits. Accounts at banks with an aggregate excess of the amount of outstanding checks over the cash balances are included in accounts payable in current liabilities in the consolidated balance sheet. At December&#160;31, 2025, and 2024, the Company did not have any cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenues from multiple sources including from the sale and rental of our products as well as service contracts. Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") stipulates revenue recognition at the time and in an amount that reflects the consideration expected to be entitled for the performance obligations that have been provided. ASC 606 defines contracts as creating enforceable rights and may be established through written contracts, oral agreements and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three separate and distinct performance obligations offered to its customers: a rental service performance obligation, a product sale performance obligation and a service performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial payers, government insurance payers, medical facilities and patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates a significant amount of its revenues that are accounted for under ASC 606 from the rental service of infusion pumps to its customers and the remainder of its revenue from product sales and services. For the rental service performance obligation revenue is based on its standalone price, determined using reimbursement rates established by third-party payer or other contracts. Revenue is recognized over the contract term in the period in which the related performance obligation is satisfied. The Company&#x2019;s revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms, or when the customer uses the products in the case of when our products are stored at a customer's location. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products. The Company's revenues related to services are recognized as the service work is completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and product performance obligations. These judgments include, among others, the estimation of variable consideration. The Company allocates variable consideration using standalone selling price when appropriate and available. When an appropriate standalone selling price is not available, the Company allocates based on a best estimate approach using the relative fair market value. Variable factors include differences in transaction price and changes in the expected total volume of services during the contract period.  In calculating the variable amount of revenue for these performance obligations, variable consideration is estimated as price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other customer concessions. The contract period starts at contract inception and typically extends 30 days past the end of each reporting period representing the non-cancelable period of each agreement.  These estimates for variable consideration are based on historical service volumes with our customers and prices with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn&#x2019;t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that is expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the components of variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as changes in volume and actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer&#x2019;s ability to pay are recorded as an adjustment to the allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also generates its revenues from the rental of infusion pumps to its customers as leases. Under Accounting Standards Codification Topic 842, "Leases" ("ASC 842"), leases may be classified as either financing, sales-type, or operating, and the Company is required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition and classification within the statement of operations. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient for all qualifying non-lease components. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial insurance payers, government insurance payers, medical facilities and patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily participates in operating leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. The Company&#x2019;s operating leases are primarily for medical equipment under operating lease arrangements that expire at various dates over the next twelve months. The Company&#x2019;s leases do not contain any restrictive covenants. Most of the Company&#x2019;s equipment leases do not contain any material residual value guarantees. For the agreements that have guarantees, the residual value reflects management's best estimate of the expected sales price for the equipment at lease termination based on sales history adjusted for recent trends in the expected exit markets. The Company&#x2019;s equipment leases may contain renewal options which range from one week to one year. Lease payments receivable reflect contractual lease payments adjusted for renewal or termination options that the Company believe the customer is reasonably certain to exercise. As of December&#160;31, 2025, the Company did not have any operating leases that contained renewal options with increasing rental amounts. Many of the Company's leases allow the customer to extend the lease at prevailing market terms. The Company's operating leased assets are not protected against casualty loss through third-party insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates, including management's assessment of probability of collection, are required to record revenue and accounts receivable at their net realizable values, otherwise, if probability of collection is not met, the Company records revenue for such leases on a cash basis. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in variable lease payments that require adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. The Company adjusts revenue for historical trends on revenue adjustments due to timely filings, deaths, and other types of analyzable adjustments on a monthly basis to record rental revenue at the expected collectible amounts. Consistent with Accounting Standards Codification Topic 450, "Contingencies", for contracts where collection is considered probable, accounts receivable is reduced by an allowance for credit losses which provides for those accounts from which payment is not expected to be received although product was delivered and revenue was earned. The Company records an allowance for credit losses based upon an analysis of historical collections. The Company has elected to record the adjustments to accounts receivables in net revenues on the &lt;span style="-sec-ix-hidden:f-302"&gt;&lt;span style="-sec-ix-hidden:f-303"&gt;Consolidated Statements of Operations and Comprehensive Income&lt;/span&gt;&lt;/span&gt;. The determination that an account is uncollectible, and the ultimate write-off of that account occurs once collection is considered to be highly unlikely, and it is written-off and charged to the allowance at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also participates in sales-type leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. In a sales-type lease, lessors are required to recognize a lease receivable, selling profit, initial indirect costs, and residual asset values for all of these types of leases, and to disclose key information about leasing arrangements. The Company&#x2019;s sales-type leases are primarily for medical equipment under sales-type lease arrangements that expire at various dates over the next three years. The Company&#x2019;s leases do not contain any restrictive covenants. The Company&#x2019;s equipment leases do not contain any material residual value guarantees or renewal options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease revenue for leased assets is recognized in net revenue. The Company further recognizes any variable lease payments that are not included in the net investment in the lease as income in profit or loss in the period when the changes in facts and circumstances on which the variable lease payments are based occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses, and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts billed that have not yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;realizable value, inclusive of adjustments for variable consideration. These adjustments reflect the amounts expected to be collected from payers based on an analysis of historical collections. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for credit losses, and contingencies, is established as a result of an adverse change in the Company&#x2019;s payers&#x2019; ability to pay outstanding billings. The allowance for credit losses was $0.3 million and $0.2 million as of December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (first-in, first-out basis) or net realizable value. Cost primarily represents the purchase price paid for the items on hand. The Company periodically performs an analysis of slow-moving inventory and records an adjustment to reflect the recoverable amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medical Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment (&#x201c;Equipment&#x201d;) consists of equipment that the Company purchases from third-parties and is (1) held for sale or rent, and (2) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically seven years. The Company does not depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a gain or loss is recorded in the current period. The Company periodically performs an analysis to identify potentially missing Equipment and records a reserve equal to the underlying net book value, which was $2.7 million and $2.5 million as of December&#160;31, 2025 and 2024, respectively. This amount approximates the accelerated depreciation the Company would recognize over the remaining useful lives of the assets determined to be missing. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than $0.1 million as of both December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Medical Equipment in the Consolidated Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (&#x201c;Unallocated Assets&#x201d;). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its two primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from &lt;span style="-sec-ix-hidden:f-316"&gt;three&lt;/span&gt; to seven years. Externally purchased information technology software and hardware are depreciated over &lt;span style="-sec-ix-hidden:f-318"&gt;three&lt;/span&gt; and five years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are expensed to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment annually or more frequently when certain events or circumstances trigger a review. Management has the option to first assess qualitative factors such as current performance and overall economic conditions to determine whether or not it is necessary to perform a quantitative goodwill impairment test. If the Company chooses that option, then the Company would not be required to perform a quantitative goodwill impairment test unless the Company determines that, based on a qualitative assessment, it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines that an impairment is more likely than not, or if the Company chooses not to perform a qualitative assessment, the Company will then proceed with the quantitative assessment. Under the quantitative test, if the fair value of a reporting unit exceeds its carrying amount, then goodwill of the reporting unit is considered to not be impaired. If the carrying amount of the reporting unit exceeds its fair value, then an impairment loss is recognized in an amount equal to the excess, up to the value of the goodwill. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that there was no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of trade names, physician and customer relationships, unpatented technology, non-competition agreements and software. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from &lt;span style="-sec-ix-hidden:f-322"&gt;fifteen&lt;/span&gt; to twenty years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others. The useful lives of these relationships are based on the expected attrition rates. Acquired software is amortized on a straight-line basis over the period of expected benefit, which ranges from &lt;span style="-sec-ix-hidden:f-324"&gt;three&lt;/span&gt; to five years. Acquired unpatented technology arose from recent acquisitions and is amortized on a straight-line basis over the period of expected benefit, which is seven years. This asset represents acquired knowledge of repair solutions that will be leveraged into opportunities into the acute care market. The non-competition agreements arose from recent acquisitions and are amortized on a straight-line basis over the terms of the agreements, which is five years. Trade names associated with the original acquisition of InfuSystem are not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. Management has the option of first performing the impairment test for intangible assets with indefinite lives on a qualitative basis, by evaluating factors to determine whether it is more likely than not that an impairment exists. If it is more likely than not that an impairment exists, or if the Company chooses not to perform a qualitative assessment, then a quantitative impairment test is performed. Impairment exists when the carrying amount of the intangible asset exceeds its fair value. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization and Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of &lt;span style="-sec-ix-hidden:f-330"&gt;three&lt;/span&gt; to five years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The Company did not capitalize any internal-use software for the year ended December&#160;31, 2025, and 2024. Amortization expense for capitalized software was $0.1 million as of both December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. For the year ended December&#160;31, 2025, the Company assessed the impairment indicators and found none to be present.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value may not be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management&#x2019;s best estimates, appropriate assumptions and projections at the time. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group. For the years ended December&#160;31, 2025 and 2024, respectively, the Company assessed the impairment indicators and found none to be present.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For policies related to the Company acting as a lessor, refer to the "Lease Arrangements" policy section above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the policies related to the Company as lessee, under ASC 842, lessees are required to recognize a lease liability and right-of-use asset (&#x201c;ROU asset&#x201d;) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 842 provides practical expedients for an entity&#x2019;s ongoing accounting. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient. The company also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did not recognize ROU assets and lease liabilities for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In adopting ASC 842, the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company&#x2019;s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next seven years. The Company&#x2019;s leases do not contain any restrictive covenants. The Company&#x2019;s office leases generally contain renewal options for periods ranging from &lt;span style="-sec-ix-hidden:f-342"&gt;one&lt;/span&gt; to five years. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company&#x2019;s office leases do not contain any material residual value guarantees. The Company&#x2019;s equipment leases generally do not contain renewal options. The Company is not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company&#x2019;s office leases, the implicit rate is typically not available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments due under the Company&#x2019;s operating leases include fixed payments as well as variable payments. For the Company&#x2019;s office leases, variable payments include amounts for the Company&#x2019;s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company&#x2019;s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues include the costs of servicing and maintaining pumps, products and services sold, shipping, depreciation of medical equipment, and other direct and indirect costs related to net revenues, and these expenses are expensed as incurred. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025 and 2024, the Company had contracts with nearly 840 and 835 third-party payer networks, respectively. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless the Company or the contracted payer elect not to renew. The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of its Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of the Company's net revenue in 2025 or 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred&#160;income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all of any deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities.&#160;Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows a two-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-not that the position will be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sustained upon examination. Second, for positions that are determined are more-likely-than-not to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than 50% likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which may include open market transactions or privately negotiated transactions and may be made under a Rule 10b5-1 plan, or in targeted stock purchase agreements approved by the Board. Treasury stock is accounted for using the par value method. As of December&#160;31, 2025 and 2024, respectively, the Company did not have any shares being held in treasury.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, &#x201c;Share-Based Awards&#x201d;) on the date of grant using either the grant date price of the Company's common stock or option-pricing models which are affected by the Company&#x2019;s stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company&#x2019;s expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company&#x2019;s stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. Forfeitures are recognized as they occur. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company also determines the fair value of performance-based restricted stock units (&#x201c;PSUs&#x201d;) based upon the type of performance measure. These awards typically vest after the Company&#x2019;s achievement of either a specific Company performance metric or when the market value of the Company&#x2019;s stock meets a specific metric such as when the closing price of the Company's stock reaches a target value for a minimum number of consecutive trading days. Under FASB Accounting Standards Codification Topic 718, "Compensation: Stock Compensation", the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A third-party valuation expert was engaged to prepare a &#x201c;Monte Carlo simulation&#x201d; to account for the market condition to assist management in its conclusion of fair value. That simulation takes into account the beginning stock price of the Company&#x2019;s common stock, the expected volatilities for the Company&#x2019;s stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. Compensation costs are accelerated if the market condition is satisfied prior to the end of the service period derived under the Monte Carlo simulation. The grant date fair value of the other PSUs is calculated as the closing price of the Company&#x2019;s common stock on the grant date multiplied by the number of shares estimated to be delivered subject to the award terms. Company performance measure goals are considered a performance condition and the timing and amount of compensation cost for those PSUs corresponds with management&#x2019;s expectation of the probable outcome of the performance conditions as of the grant date and during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized debt issuance costs as of December&#160;31, 2025 and 2024 relate to the Company&#x2019;s credit facility. The costs related to the agreement are netted against current and non-current debt and is recognized in Interest expense. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports its earnings per share which includes the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the 2014 and 2021 stock incentive plans. Anti-dilutive stock awards are comprised of stock options and unvested &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method. In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Numerator (in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,657,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,271,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive effect of common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;439,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;435,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,097,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,707,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options of 2,072,460 and 1,950,403 shares were not included in the calculation for the years ended December&#160;31, 2025 and 2024, respectively, because they would have an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company&#x2019;s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (&#x201c;AOCI&#x201d;) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s derivative financial instruments are categorized as Level II of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the consolidated balance sheets as of December&#160;31, 2025 and 2024 for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company&#x2019;s long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted Accounting Standards Codification Topic 820, "Fair Value Measurement", which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;quoted prices in active markets for identical instruments;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level III&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements and Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#x201c;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#x201d; (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 enhances existing income tax disclosures primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments in this ASU require public entities to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. Public entities are also required to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes and also disaggregated by individual jurisdictions. The Company adopted the standard on January 1, 2025.  Because the ASU affects disclosure requirements only, adoption did not impact the Company's consolidated financial position, results of operations, or cash flows.  See Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which reflects the expanded disclosures required under the amended guidance.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2024, the FASB issued Accounting Standards Update 2024-03, &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d; (&#x201c;ASU 2024-03&#x201d;), which requires disclosures, in the notes to the financial statements, about the types of expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2025, the FASB issued Accounting Standards Update 2025-05, &#x201c;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&#x201d; (&#x201c;ASU 2025-05&#x201d;), which provides a practical expedient election that assumes current conditions as of the balance sheet date remain unchanged when developing forecasts for estimating expected credit losses. ASU 2025-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2025, with early adoption permitted.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is currently evaluating the impact of ASU 2025-05 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;n September 2025, the FASB issued Accounting Standards Update 2025-06, &#x201c;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), Targeted improvements to the Accounting for Internal-Use Software&#x201d; (&#x201c;ASU 2025-06&#x201d;), to update accounting for software costs that are accounted for under Subtopic 350-40. The ASU 2025-06 removes all references to prescriptive and sequential software development stages throughout Subtopic 350-40. The amendments in ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company&#x2019;s project to replace its enterprise resource planning application is expected to be completed prior to the required adoption period. The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;n December 2025, the FASB issued Accounting Standards Update 2025-09, "Derivatives and Hedging (Topic 815): Hedge Accounting Improvements" ("ASU 2025-09"), which provides clarifications to certain hedge accounting requirements.  The amendments are intended to improve consistency in the application of hedge effectiveness and related disclosures.  The standard is effective for fiscal years beginning after December 15, 2026.  The Company is currently evaluating the impact of ASU 2025-09 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-292">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-293">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in two reportable segments, Patient Services and Device Solutions based on management's view of its business for purpose of evaluating performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company&#x2019;s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker ("CODM"), reviews segment financial information. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i13594bbbfc1e4b049c5f01f53e10e953_142" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 14&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for segment disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-294"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-295">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-296">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions.  For intangible assets, the Company typically uses the income approach to determine their estimated fair values. Key estimates and assumptions in that approach include the amount and timing of projected future cash flow, the discount rate selected to measure the risks inherent in those cash flows and the assessment of the asset's useful life. Initial purchase price allocations are subject to revision within the measurement period, not to exceed one year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-297">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains substantially all of its cash and cash equivalents primarily with two financial institutions that are insured with the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits. Accounts at banks with an aggregate excess of the amount of outstanding checks over the cash balances are included in accounts payable in current liabilities in the consolidated balance sheet. At December&#160;31, 2025, and 2024, the Company did not have any cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <infu:NumberOfFinancialInstitutions
      contextRef="c-4"
      decimals="INF"
      id="f-298"
      unitRef="financial_institution">2</infu:NumberOfFinancialInstitutions>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-299">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenues from multiple sources including from the sale and rental of our products as well as service contracts. Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") stipulates revenue recognition at the time and in an amount that reflects the consideration expected to be entitled for the performance obligations that have been provided. ASC 606 defines contracts as creating enforceable rights and may be established through written contracts, oral agreements and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three separate and distinct performance obligations offered to its customers: a rental service performance obligation, a product sale performance obligation and a service performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial payers, government insurance payers, medical facilities and patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates a significant amount of its revenues that are accounted for under ASC 606 from the rental service of infusion pumps to its customers and the remainder of its revenue from product sales and services. For the rental service performance obligation revenue is based on its standalone price, determined using reimbursement rates established by third-party payer or other contracts. Revenue is recognized over the contract term in the period in which the related performance obligation is satisfied. The Company&#x2019;s revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms, or when the customer uses the products in the case of when our products are stored at a customer's location. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products. The Company's revenues related to services are recognized as the service work is completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and product performance obligations. These judgments include, among others, the estimation of variable consideration. The Company allocates variable consideration using standalone selling price when appropriate and available. When an appropriate standalone selling price is not available, the Company allocates based on a best estimate approach using the relative fair market value. Variable factors include differences in transaction price and changes in the expected total volume of services during the contract period.  In calculating the variable amount of revenue for these performance obligations, variable consideration is estimated as price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other customer concessions. The contract period starts at contract inception and typically extends 30 days past the end of each reporting period representing the non-cancelable period of each agreement.  These estimates for variable consideration are based on historical service volumes with our customers and prices with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn&#x2019;t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that is expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the components of variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as changes in volume and actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer&#x2019;s ability to pay are recorded as an adjustment to the allowance for credit losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="c-1" id="f-300">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also generates its revenues from the rental of infusion pumps to its customers as leases. Under Accounting Standards Codification Topic 842, "Leases" ("ASC 842"), leases may be classified as either financing, sales-type, or operating, and the Company is required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition and classification within the statement of operations. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient for all qualifying non-lease components. The Company's customers include medical facilities or patients, depending on the arrangement, and payments are received from different sources which include commercial insurance payers, government insurance payers, medical facilities and patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily participates in operating leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. The Company&#x2019;s operating leases are primarily for medical equipment under operating lease arrangements that expire at various dates over the next twelve months. The Company&#x2019;s leases do not contain any restrictive covenants. Most of the Company&#x2019;s equipment leases do not contain any material residual value guarantees. For the agreements that have guarantees, the residual value reflects management's best estimate of the expected sales price for the equipment at lease termination based on sales history adjusted for recent trends in the expected exit markets. The Company&#x2019;s equipment leases may contain renewal options which range from one week to one year. Lease payments receivable reflect contractual lease payments adjusted for renewal or termination options that the Company believe the customer is reasonably certain to exercise. As of December&#160;31, 2025, the Company did not have any operating leases that contained renewal options with increasing rental amounts. Many of the Company's leases allow the customer to extend the lease at prevailing market terms. The Company's operating leased assets are not protected against casualty loss through third-party insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates, including management's assessment of probability of collection, are required to record revenue and accounts receivable at their net realizable values, otherwise, if probability of collection is not met, the Company records revenue for such leases on a cash basis. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in variable lease payments that require adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. The Company adjusts revenue for historical trends on revenue adjustments due to timely filings, deaths, and other types of analyzable adjustments on a monthly basis to record rental revenue at the expected collectible amounts. Consistent with Accounting Standards Codification Topic 450, "Contingencies", for contracts where collection is considered probable, accounts receivable is reduced by an allowance for credit losses which provides for those accounts from which payment is not expected to be received although product was delivered and revenue was earned. The Company records an allowance for credit losses based upon an analysis of historical collections. The Company has elected to record the adjustments to accounts receivables in net revenues on the &lt;span style="-sec-ix-hidden:f-302"&gt;&lt;span style="-sec-ix-hidden:f-303"&gt;Consolidated Statements of Operations and Comprehensive Income&lt;/span&gt;&lt;/span&gt;. The determination that an account is uncollectible, and the ultimate write-off of that account occurs once collection is considered to be highly unlikely, and it is written-off and charged to the allowance at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also participates in sales-type leases as a lessor, and determined, and will continue to determine, whether an arrangement is a lease at inception. In a sales-type lease, lessors are required to recognize a lease receivable, selling profit, initial indirect costs, and residual asset values for all of these types of leases, and to disclose key information about leasing arrangements. The Company&#x2019;s sales-type leases are primarily for medical equipment under sales-type lease arrangements that expire at various dates over the next three years. The Company&#x2019;s leases do not contain any restrictive covenants. The Company&#x2019;s equipment leases do not contain any material residual value guarantees or renewal options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease revenue for leased assets is recognized in net revenue. The Company further recognizes any variable lease payments that are not included in the net investment in the lease as income in profit or loss in the period when the changes in facts and circumstances on which the variable lease payments are based occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:LessorOperatingLeaseRenewalTerm contextRef="c-29" id="f-301">P1Y</us-gaap:LessorOperatingLeaseRenewalTerm>
    <us-gaap:LessorSalesTypeLeaseTermOfContract1 contextRef="c-4" id="f-304">P3Y</us-gaap:LessorSalesTypeLeaseTermOfContract1>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-305">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses, and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts billed that have not yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at net &lt;/span&gt;&lt;/div&gt;realizable value, inclusive of adjustments for variable consideration. These adjustments reflect the amounts expected to be collected from payers based on an analysis of historical collections. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for credit losses, and contingencies, is established as a result of an adverse change in the Company&#x2019;s payers&#x2019; ability to pay outstanding billings.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-5" id="f-306" unitRef="usd">300000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-5" id="f-307" unitRef="usd">200000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (first-in, first-out basis) or net realizable value. Cost primarily represents the purchase price paid for the items on hand. The Company periodically performs an analysis of slow-moving inventory and records an adjustment to reflect the recoverable amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <infu:MedicalEquipmentPolicyTextBlock contextRef="c-1" id="f-309">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medical Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment (&#x201c;Equipment&#x201d;) consists of equipment that the Company purchases from third-parties and is (1) held for sale or rent, and (2) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically seven years. The Company does not depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a gain or loss is recorded in the current period. The Company periodically performs an analysis to identify potentially missing Equipment and records a reserve equal to the underlying net book value, which was $2.7 million and $2.5 million as of December&#160;31, 2025 and 2024, respectively. This amount approximates the accelerated depreciation the Company would recognize over the remaining useful lives of the assets determined to be missing. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than $0.1 million as of both December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Medical Equipment in the Consolidated Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (&#x201c;Unallocated Assets&#x201d;). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its two primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.&lt;/span&gt;&lt;/div&gt;</infu:MedicalEquipmentPolicyTextBlock>
    <infu:MedicalEquipmentInRentalServicesUsefulLife contextRef="c-1" id="f-310">P7Y</infu:MedicalEquipmentInRentalServicesUsefulLife>
    <infu:MedicalEquipmentInRentalServicesReserve contextRef="c-4" decimals="-5" id="f-311" unitRef="usd">2700000</infu:MedicalEquipmentInRentalServicesReserve>
    <infu:MedicalEquipmentInRentalServicesReserve contextRef="c-5" decimals="-5" id="f-312" unitRef="usd">2500000</infu:MedicalEquipmentInRentalServicesReserve>
    <infu:MedicalEquipmentHeldForSaleOrRentalReserve contextRef="c-29" decimals="-5" id="f-313" unitRef="usd">100000</infu:MedicalEquipmentHeldForSaleOrRentalReserve>
    <infu:MedicalEquipmentHeldForSaleOrRentalReserve contextRef="c-30" decimals="-5" id="f-314" unitRef="usd">100000</infu:MedicalEquipmentHeldForSaleOrRentalReserve>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-315">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from &lt;span style="-sec-ix-hidden:f-316"&gt;three&lt;/span&gt; to seven years. Externally purchased information technology software and hardware are depreciated over &lt;span style="-sec-ix-hidden:f-318"&gt;three&lt;/span&gt; and five years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are expensed to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-29" id="f-317">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-33" id="f-319">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-320">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;Goodwill is tested for impairment annually or more frequently when certain events or circumstances trigger a review. Management has the option to first assess qualitative factors such as current performance and overall economic conditions to determine whether or not it is necessary to perform a quantitative goodwill impairment test. If the Company chooses that option, then the Company would not be required to perform a quantitative goodwill impairment test unless the Company determines that, based on a qualitative assessment, it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines that an impairment is more likely than not, or if the Company chooses not to perform a qualitative assessment, the Company will then proceed with the quantitative assessment. Under the quantitative test, if the fair value of a reporting unit exceeds its carrying amount, then goodwill of the reporting unit is considered to not be impaired. If the carrying amount of the reporting unit exceeds its fair value, then an impairment loss is recognized in an amount equal to the excess, up to the value of the goodwill. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that there was no impairment.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-321">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of trade names, physician and customer relationships, unpatented technology, non-competition agreements and software. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from &lt;span style="-sec-ix-hidden:f-322"&gt;fifteen&lt;/span&gt; to twenty years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others. The useful lives of these relationships are based on the expected attrition rates. Acquired software is amortized on a straight-line basis over the period of expected benefit, which ranges from &lt;span style="-sec-ix-hidden:f-324"&gt;three&lt;/span&gt; to five years. Acquired unpatented technology arose from recent acquisitions and is amortized on a straight-line basis over the period of expected benefit, which is seven years. This asset represents acquired knowledge of repair solutions that will be leveraged into opportunities into the acute care market. The non-competition agreements arose from recent acquisitions and are amortized on a straight-line basis over the terms of the agreements, which is five years. Trade names associated with the original acquisition of InfuSystem are not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. Management has the option of first performing the impairment test for intangible assets with indefinite lives on a qualitative basis, by evaluating factors to determine whether it is more likely than not that an impairment exists. If it is more likely than not that an impairment exists, or if the Company chooses not to perform a qualitative assessment, then a quantitative impairment test is performed. Impairment exists when the carrying amount of the intangible asset exceeds its fair value. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company performed its annual impairment analysis by using a quantitative assessment as of October&#160;31, 2025 and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in no impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-35" id="f-323">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-37" id="f-325">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-38" id="f-326">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-39" id="f-327">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-40" decimals="INF" id="f-328" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:CapitalizationOfInternalCostsPolicy contextRef="c-1" id="f-329">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization and Depreciation&lt;/span&gt;&lt;/div&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of &lt;span style="-sec-ix-hidden:f-330"&gt;three&lt;/span&gt; to five years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred.</us-gaap:CapitalizationOfInternalCostsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-37" id="f-331">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="c-5" decimals="INF" id="f-332" unitRef="usd">0</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="c-4" decimals="INF" id="f-333" unitRef="usd">0</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareAmortization1 contextRef="c-6" decimals="-5" id="f-334" unitRef="usd">100000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1 contextRef="c-1" decimals="-5" id="f-335" unitRef="usd">100000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-41" decimals="INF" id="f-336" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value may not be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management&#x2019;s best estimates, appropriate assumptions and projections at the time. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-41" decimals="INF" id="f-338" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-42" decimals="INF" id="f-339" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-340">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For policies related to the Company acting as a lessor, refer to the "Lease Arrangements" policy section above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the policies related to the Company as lessee, under ASC 842, lessees are required to recognize a lease liability and right-of-use asset (&#x201c;ROU asset&#x201d;) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 842 provides practical expedients for an entity&#x2019;s ongoing accounting. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient. The company also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did not recognize ROU assets and lease liabilities for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In adopting ASC 842, the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company&#x2019;s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next seven years. The Company&#x2019;s leases do not contain any restrictive covenants. The Company&#x2019;s office leases generally contain renewal options for periods ranging from &lt;span style="-sec-ix-hidden:f-342"&gt;one&lt;/span&gt; to five years. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company&#x2019;s office leases do not contain any material residual value guarantees. The Company&#x2019;s equipment leases generally do not contain renewal options. The Company is not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company&#x2019;s office leases, the implicit rate is typically not available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments due under the Company&#x2019;s operating leases include fixed payments as well as variable payments. For the Company&#x2019;s office leases, variable payments include amounts for the Company&#x2019;s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company&#x2019;s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-4" id="f-341">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-29" id="f-343">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <infu:RevenueRecognitionCostOfRevenuePolicyTextBlock contextRef="c-1" id="f-344">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues include the costs of servicing and maintaining pumps, products and services sold, shipping, depreciation of medical equipment, and other direct and indirect costs related to net revenues, and these expenses are expensed as incurred. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.&lt;/span&gt;&lt;/div&gt;</infu:RevenueRecognitionCostOfRevenuePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-345">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025 and 2024, the Company had contracts with nearly 840 and 835 third-party payer networks, respectively. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless the Company or the contracted payer elect not to renew. The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of its Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of the Company's net revenue in 2025 or 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <infu:NumberOfContractsWithThirdParties contextRef="c-4" decimals="0" id="f-346" unitRef="network">840</infu:NumberOfContractsWithThirdParties>
    <infu:NumberOfContractsWithThirdParties contextRef="c-5" decimals="0" id="f-347" unitRef="network">835</infu:NumberOfContractsWithThirdParties>
    <infu:TermOfContract contextRef="c-1" id="f-348">P1Y</infu:TermOfContract>
    <infu:TermOfRenewal contextRef="c-1" id="f-349">P1Y</infu:TermOfRenewal>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred&#160;income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all of any deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities.&#160;Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows a two-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-not that the position will be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sustained upon examination. Second, for positions that are determined are more-likely-than-not to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than 50% likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <infu:TreasuryStockPolicyPolicyTextBlock contextRef="c-1" id="f-351">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which may include open market transactions or privately negotiated transactions and may be made under a Rule 10b5-1 plan, or in targeted stock purchase agreements approved by the Board. Treasury stock is accounted for using the par value method.</infu:TreasuryStockPolicyPolicyTextBlock>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-6" decimals="0" id="f-352" unitRef="shares">0</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-1" decimals="0" id="f-353" unitRef="shares">0</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-354">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, &#x201c;Share-Based Awards&#x201d;) on the date of grant using either the grant date price of the Company's common stock or option-pricing models which are affected by the Company&#x2019;s stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company&#x2019;s expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company&#x2019;s stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. Forfeitures are recognized as they occur. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company also determines the fair value of performance-based restricted stock units (&#x201c;PSUs&#x201d;) based upon the type of performance measure. These awards typically vest after the Company&#x2019;s achievement of either a specific Company performance metric or when the market value of the Company&#x2019;s stock meets a specific metric such as when the closing price of the Company's stock reaches a target value for a minimum number of consecutive trading days. Under FASB Accounting Standards Codification Topic 718, "Compensation: Stock Compensation", the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A third-party valuation expert was engaged to prepare a &#x201c;Monte Carlo simulation&#x201d; to account for the market condition to assist management in its conclusion of fair value. That simulation takes into account the beginning stock price of the Company&#x2019;s common stock, the expected volatilities for the Company&#x2019;s stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. Compensation costs are accelerated if the market condition is satisfied prior to the end of the service period derived under the Monte Carlo simulation. The grant date fair value of the other PSUs is calculated as the closing price of the Company&#x2019;s common stock on the grant date multiplied by the number of shares estimated to be delivered subject to the award terms. Company performance measure goals are considered a performance condition and the timing and amount of compensation cost for those PSUs corresponds with management&#x2019;s expectation of the probable outcome of the performance conditions as of the grant date and during the vesting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c-1" id="f-355">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized debt issuance costs as of December&#160;31, 2025 and 2024 relate to the Company&#x2019;s credit facility. The costs related to the agreement are netted against current and non-current debt and is recognized in Interest expense. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-356">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports its earnings per share which includes the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the 2014 and 2021 stock incentive plans. Anti-dilutive stock awards are comprised of stock options and unvested &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method. In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-357">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Numerator (in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,657,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,271,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive effect of common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;439,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;435,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,097,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,707,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">6627000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-359" unitRef="usd">2345000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-360" unitRef="shares">20657877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-361" unitRef="shares">21271608</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="0" id="f-362" unitRef="shares">439446</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-6" decimals="0" id="f-363" unitRef="shares">435543</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-364" unitRef="shares">21097323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-365" unitRef="shares">21707151</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-43" decimals="0" id="f-366" unitRef="shares">2072460</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-44" decimals="0" id="f-367" unitRef="shares">1950403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-368">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company&#x2019;s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (&#x201c;AOCI&#x201d;) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s derivative financial instruments are categorized as Level II of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-369">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the consolidated balance sheets as of December&#160;31, 2025 and 2024 for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company&#x2019;s long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted Accounting Standards Codification Topic 820, "Fair Value Measurement", which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;quoted prices in active markets for identical instruments;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level III&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-370">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements and Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#x201c;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#x201d; (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 enhances existing income tax disclosures primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments in this ASU require public entities to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. Public entities are also required to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes and also disaggregated by individual jurisdictions. The Company adopted the standard on January 1, 2025.  Because the ASU affects disclosure requirements only, adoption did not impact the Company's consolidated financial position, results of operations, or cash flows.  See Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which reflects the expanded disclosures required under the amended guidance.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2024, the FASB issued Accounting Standards Update 2024-03, &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d; (&#x201c;ASU 2024-03&#x201d;), which requires disclosures, in the notes to the financial statements, about the types of expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2025, the FASB issued Accounting Standards Update 2025-05, &#x201c;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&#x201d; (&#x201c;ASU 2025-05&#x201d;), which provides a practical expedient election that assumes current conditions as of the balance sheet date remain unchanged when developing forecasts for estimating expected credit losses. ASU 2025-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2025, with early adoption permitted.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is currently evaluating the impact of ASU 2025-05 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;n September 2025, the FASB issued Accounting Standards Update 2025-06, &#x201c;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), Targeted improvements to the Accounting for Internal-Use Software&#x201d; (&#x201c;ASU 2025-06&#x201d;), to update accounting for software costs that are accounted for under Subtopic 350-40. The ASU 2025-06 removes all references to prescriptive and sequential software development stages throughout Subtopic 350-40. The amendments in ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company&#x2019;s project to replace its enterprise resource planning application is expected to be completed prior to the required adoption period. The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;n December 2025, the FASB issued Accounting Standards Update 2025-09, "Derivatives and Hedging (Topic 815): Hedge Accounting Improvements" ("ASU 2025-09"), which provides clarifications to certain hedge accounting requirements.  The amendments are intended to improve consistency in the application of hedge effectiveness and related disclosures.  The standard is effective for fiscal years beginning after December 15, 2026.  The Company is currently evaluating the impact of ASU 2025-09 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-372">Business Combinations&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions Accounted for Using the Purchase Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;30, 2025 (the &#x201c;Closing Date&#x201d;), the Company acquired certain assets of Apollo Medical Supply (&#x201c;Apollo&#x201d;), a privately-held wound care service company based in Florida. As part of the Company&#x2019;s Patient Services segment, this acquisition supplements the Company&#x2019;s existing wound care business by providing access to an advanced patient service fulfillment know-how and software platform that the Company plans to integrate into its existing operations. Apollo&#x2019;s results of operation are included in the Company&#x2019;s consolidated statements of operations and comprehensive income since the Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Price Allocation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805, &#x201c;Business Combinations,&#x201d; the purchase price for the acquisition was allocated to the assets acquired and liabilities assumed based upon their estimated fair values as of the respective acquisition date. The preliminary purchase price allocation was primarily based upon a valuation using &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;management&#x2019;s estimates and assumptions. Upon completion of the final purchase price allocation, the Company expects to specifically identify intangible assets and allocate the excess of the purchase price over the net assets to goodwill, if any. The preliminary allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Apollo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2025, the Company updated the valuation of Apollo with immaterial changes in accounts receivable, intangible assets and other liabilities. As the amounts are immaterial, the unaudited pro forma financial information has not been presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-373">The preliminary allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Apollo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-45" decimals="-3" id="f-374" unitRef="usd">140000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-45" decimals="-3" id="f-375" unitRef="usd">6000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-45" decimals="-3" id="f-376" unitRef="usd">1330000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-45" decimals="-3" id="f-377" unitRef="usd">64000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-45" decimals="-3" id="f-378" unitRef="usd">1412000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-379">Revenue&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregated Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s disaggregated revenue by offering type (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;% of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;% of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Services revenue recognized at a point in time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Third-Party Payer products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Services revenue recognized over time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct rental services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Third-Party Payer rental services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Patient Services accounted for under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Device Solutions revenue recognized at a point in time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Device Solutions revenue recognized over time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Device Solutions accounted for under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue Accounted for under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Services Lease Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Device Solutions Lease Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue accounted for under ASC 842&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Change in 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in contract assets during the fiscal year ended December&#160;31, 2025 was mainly due to $8.7 million of contract assets reclassified to accounts receivable as our right to consideration for these contract assets became unconditional, partially offset by $9.4 million of revenue recognized for which the payment is subject to conditions other than the passage of time. Contract assets are included in other current assets on the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-380">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s disaggregated revenue by offering type (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;% of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;% of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total Net&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Services revenue recognized at a point in time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Third-Party Payer products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Services revenue recognized over time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct rental services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Third-Party Payer rental services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Patient Services accounted for under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Device Solutions revenue recognized at a point in time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Device Solutions revenue recognized over time:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Device Solutions accounted for under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue Accounted for under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Services Lease Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Device Solutions Lease Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue accounted for under ASC 842&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-46" decimals="-3" id="f-381" unitRef="usd">2591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-47" decimals="3" id="f-382" unitRef="number">0.018</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-48" decimals="-3" id="f-383" unitRef="usd">2706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-49" decimals="3" id="f-384" unitRef="number">0.020</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-50" decimals="-3" id="f-385" unitRef="usd">17750000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-51" decimals="3" id="f-386" unitRef="number">0.124</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-52" decimals="-3" id="f-387" unitRef="usd">15023000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-53" decimals="3" id="f-388" unitRef="number">0.111</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-54" decimals="-3" id="f-389" unitRef="usd">7755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-55" decimals="3" id="f-390" unitRef="number">0.054</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-3" id="f-391" unitRef="usd">7683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-57" decimals="3" id="f-392" unitRef="number">0.057</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-58" decimals="-3" id="f-393" unitRef="usd">50091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-59" decimals="3" id="f-394" unitRef="number">0.349</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-60" decimals="-3" id="f-395" unitRef="usd">47394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-61" decimals="3" id="f-396" unitRef="number">0.351</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-62" decimals="-3" id="f-397" unitRef="usd">78187000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="3" id="f-398" unitRef="number">0.545</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-64" decimals="-3" id="f-399" unitRef="usd">72806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-65" decimals="3" id="f-400" unitRef="number">0.539</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-66" decimals="-3" id="f-401" unitRef="usd">17274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-67" decimals="3" id="f-402" unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-68" decimals="-3" id="f-403" unitRef="usd">16552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="3" id="f-404" unitRef="number">0.123</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="-3" id="f-405" unitRef="usd">11829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="3" id="f-406" unitRef="number">0.082</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="-3" id="f-407" unitRef="usd">8861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="3" id="f-408" unitRef="number">0.066</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="-3" id="f-409" unitRef="usd">5790000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="3" id="f-410" unitRef="number">0.040</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-3" id="f-411" unitRef="usd">8082000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="3" id="f-412" unitRef="number">0.060</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-413" unitRef="usd">34893000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-79" decimals="3" id="f-414" unitRef="number">0.243</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-415" unitRef="usd">33495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="3" id="f-416" unitRef="number">0.249</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-417" unitRef="usd">113080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-83" decimals="3" id="f-418" unitRef="number">0.788</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-419" unitRef="usd">106301000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-85" decimals="3" id="f-420" unitRef="number">0.788</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LeaseIncome contextRef="c-62" decimals="-3" id="f-421" unitRef="usd">8345000</us-gaap:LeaseIncome>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="3" id="f-422" unitRef="number">0.058</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LeaseIncome contextRef="c-64" decimals="-3" id="f-423" unitRef="usd">7572000</us-gaap:LeaseIncome>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-87" decimals="3" id="f-424" unitRef="number">0.056</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LeaseIncome contextRef="c-88" decimals="-3" id="f-425" unitRef="usd">22011000</us-gaap:LeaseIncome>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-89" decimals="3" id="f-426" unitRef="number">0.153</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LeaseIncome contextRef="c-90" decimals="-3" id="f-427" unitRef="usd">20988000</us-gaap:LeaseIncome>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-91" decimals="3" id="f-428" unitRef="number">0.156</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LeaseIncome contextRef="c-82" decimals="-3" id="f-429" unitRef="usd">30356000</us-gaap:LeaseIncome>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="3" id="f-430" unitRef="number">0.212</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LeaseIncome contextRef="c-84" decimals="-3" id="f-431" unitRef="usd">28560000</us-gaap:LeaseIncome>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-93" decimals="3" id="f-432" unitRef="number">0.212</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-433" unitRef="usd">143436000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-94" decimals="3" id="f-434" unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-435" unitRef="usd">134861000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-95" decimals="3" id="f-436" unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-437">&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Change in 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-438" unitRef="usd">22901000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-439" unitRef="usd">21155000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-96" decimals="-3" id="f-440" unitRef="usd">1746000</us-gaap:AccountsReceivableNetCurrent>
    <infu:ContractAssets contextRef="c-4" decimals="-3" id="f-441" unitRef="usd">1244000</infu:ContractAssets>
    <infu:ContractAssets contextRef="c-5" decimals="-3" id="f-442" unitRef="usd">570000</infu:ContractAssets>
    <infu:ContractAssets contextRef="c-96" decimals="-3" id="f-443" unitRef="usd">674000</infu:ContractAssets>
    <infu:ContractLiabilities contextRef="c-4" decimals="-3" id="f-444" unitRef="usd">109000</infu:ContractLiabilities>
    <infu:ContractLiabilities contextRef="c-5" decimals="-3" id="f-445" unitRef="usd">0</infu:ContractLiabilities>
    <infu:ContractLiabilities contextRef="c-96" decimals="-3" id="f-446" unitRef="usd">109000</infu:ContractLiabilities>
    <infu:ContractAssetsRevenuePartiallyOffsetAmount contextRef="c-1" decimals="-5" id="f-447" unitRef="usd">8700000</infu:ContractAssetsRevenuePartiallyOffsetAmount>
    <infu:ContractAssetsRevenueRecognized contextRef="c-1" decimals="-5" id="f-448" unitRef="usd">9400000</infu:ContractAssetsRevenueRecognized>
    <infu:MedicalEquipmentAndPropertyDisclosureTextBlock contextRef="c-1" id="f-449">Medical Equipment&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment for sale or rental&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment for sale or rental - pump reserve&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment for sale or rental - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment in rental service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment in rental service - pump reserve&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(71,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(65,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment in rental service - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for medical equipment for the years ended December&#160;31, 2025 and 2024 was $11.1 million and $10.2 million, respectively, which were recorded in &#x201c;cost of revenues&#x201d; for each period. The pump reserve for medical equipment in rental service represents an estimate for medical equipment that is considered to be missing. The reserve calculated is equal to the net book value of assets that have not returned from the field within a certain timeframe. Sales of the Company's medical equipment are included in net revenue.&lt;/span&gt;&lt;/div&gt;</infu:MedicalEquipmentAndPropertyDisclosureTextBlock>
    <infu:ScheduleOfMedicalEquipmentTableTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment for sale or rental&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment for sale or rental - pump reserve&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment for sale or rental - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment in rental service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment in rental service - pump reserve&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(71,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(65,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Equipment in rental service - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</infu:ScheduleOfMedicalEquipmentTableTextBlock>
    <infu:MedicalEquipmentHeldForSaleOrRentalGross contextRef="c-4" decimals="-3" id="f-451" unitRef="usd">4600000</infu:MedicalEquipmentHeldForSaleOrRentalGross>
    <infu:MedicalEquipmentHeldForSaleOrRentalGross contextRef="c-5" decimals="-3" id="f-452" unitRef="usd">3182000</infu:MedicalEquipmentHeldForSaleOrRentalGross>
    <infu:MedicalEquipmentHeldForSaleOrRentalReserve contextRef="c-4" decimals="-3" id="f-453" unitRef="usd">11000</infu:MedicalEquipmentHeldForSaleOrRentalReserve>
    <infu:MedicalEquipmentHeldForSaleOrRentalReserve contextRef="c-5" decimals="-3" id="f-454" unitRef="usd">25000</infu:MedicalEquipmentHeldForSaleOrRentalReserve>
    <infu:MedicalEquipmentHeldForSaleOrRental contextRef="c-4" decimals="-3" id="f-455" unitRef="usd">4589000</infu:MedicalEquipmentHeldForSaleOrRental>
    <infu:MedicalEquipmentHeldForSaleOrRental contextRef="c-5" decimals="-3" id="f-456" unitRef="usd">3157000</infu:MedicalEquipmentHeldForSaleOrRental>
    <infu:MedicalEquipmentInRentalServicesGross contextRef="c-4" decimals="-3" id="f-457" unitRef="usd">109060000</infu:MedicalEquipmentInRentalServicesGross>
    <infu:MedicalEquipmentInRentalServicesGross contextRef="c-5" decimals="-3" id="f-458" unitRef="usd">107028000</infu:MedicalEquipmentInRentalServicesGross>
    <infu:MedicalEquipmentInRentalServicesReserve contextRef="c-4" decimals="-3" id="f-459" unitRef="usd">2727000</infu:MedicalEquipmentInRentalServicesReserve>
    <infu:MedicalEquipmentInRentalServicesReserve contextRef="c-5" decimals="-3" id="f-460" unitRef="usd">2530000</infu:MedicalEquipmentInRentalServicesReserve>
    <infu:MedicalEquipmentInRentalServicesAccumulatedDepreciation contextRef="c-4" decimals="-3" id="f-461" unitRef="usd">71877000</infu:MedicalEquipmentInRentalServicesAccumulatedDepreciation>
    <infu:MedicalEquipmentInRentalServicesAccumulatedDepreciation contextRef="c-5" decimals="-3" id="f-462" unitRef="usd">65323000</infu:MedicalEquipmentInRentalServicesAccumulatedDepreciation>
    <infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation contextRef="c-4" decimals="-3" id="f-463" unitRef="usd">34456000</infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation>
    <infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation contextRef="c-5" decimals="-3" id="f-464" unitRef="usd">39175000</infu:MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation>
    <infu:MedicalEquipmentNet contextRef="c-4" decimals="-3" id="f-465" unitRef="usd">39045000</infu:MedicalEquipmentNet>
    <infu:MedicalEquipmentNet contextRef="c-5" decimals="-3" id="f-466" unitRef="usd">42332000</infu:MedicalEquipmentNet>
    <infu:DepreciationExpenseRelatedToMedicalEquipment contextRef="c-1" decimals="-5" id="f-467" unitRef="usd">11100000</infu:DepreciationExpenseRelatedToMedicalEquipment>
    <infu:DepreciationExpenseRelatedToMedicalEquipment contextRef="c-6" decimals="-5" id="f-468" unitRef="usd">10200000</infu:DepreciationExpenseRelatedToMedicalEquipment>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-469">Property and Equipment&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for property and equipment for each of the years ended December&#160;31, 2025 and 2024 was $1.2 million and $1.3 million, respectively. This expense was recorded in &#x201c;general and administrative expenses&#x201d; for each period.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-97" decimals="-3" id="f-471" unitRef="usd">6358000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-97" decimals="-3" id="f-472" unitRef="usd">5032000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-97" decimals="-3" id="f-473" unitRef="usd">1326000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-98" decimals="-3" id="f-474" unitRef="usd">6180000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-98" decimals="-3" id="f-475" unitRef="usd">4588000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-98" decimals="-3" id="f-476" unitRef="usd">1592000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-99" decimals="-3" id="f-477" unitRef="usd">66000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-99" decimals="-3" id="f-478" unitRef="usd">66000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-99" decimals="-3" id="f-479" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-100" decimals="-3" id="f-480" unitRef="usd">87000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-100" decimals="-3" id="f-481" unitRef="usd">87000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-100" decimals="-3" id="f-482" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-101" decimals="-3" id="f-483" unitRef="usd">5099000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-101" decimals="-3" id="f-484" unitRef="usd">3066000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-101" decimals="-3" id="f-485" unitRef="usd">2033000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-102" decimals="-3" id="f-486" unitRef="usd">4911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-102" decimals="-3" id="f-487" unitRef="usd">2473000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-102" decimals="-3" id="f-488" unitRef="usd">2438000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-489" unitRef="usd">11523000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-490" unitRef="usd">8164000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-491" unitRef="usd">3359000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-492" unitRef="usd">11178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-493" unitRef="usd">7148000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-494" unitRef="usd">4030000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationNonproduction contextRef="c-1" decimals="-5" id="f-495" unitRef="usd">1200000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c-6" decimals="-5" id="f-496" unitRef="usd">1300000</us-gaap:DepreciationNonproduction>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-497">Goodwill and Intangible Assets&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying value of goodwill by segment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Device Solutions (a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(a) The Patient Services segment has no recorded goodwill. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and accumulated amortization of intangible assets were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonamortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician and customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(34,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unpatented technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-competition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total nonamortizable and amortizable intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for intangible assets for the years ended December&#160;31, 2025 and 2024 was $0.9&#160;million and $1.0 million, respectively, which was recorded in "amortization of intangibles expenses" for each period. Expected remaining annual amortization expense for the next five years for intangible assets recorded as of December&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2031 and &lt;br/&gt;thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-498">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying value of goodwill by segment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Device Solutions (a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(a) The Patient Services segment has no recorded goodwill. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-103" decimals="-3" id="f-499" unitRef="usd">3710000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-88" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill contextRef="c-104" decimals="-3" id="f-501" unitRef="usd">3710000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-105" decimals="INF" id="f-502" unitRef="usd">0</us-gaap:Goodwill>
    <infu:CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock contextRef="c-1" id="f-503">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and accumulated amortization of intangible assets were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonamortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician and customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(34,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unpatented technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-competition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total nonamortizable and amortizable intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</infu:CarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-504" unitRef="usd">2000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-505" unitRef="usd">2000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-506" unitRef="usd">2000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-507" unitRef="usd">2000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-106" decimals="-3" id="f-508" unitRef="usd">23000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-106" decimals="-3" id="f-509" unitRef="usd">23000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-106" decimals="-3" id="f-510" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-107" decimals="-3" id="f-511" unitRef="usd">23000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-107" decimals="-3" id="f-512" unitRef="usd">23000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-107" decimals="-3" id="f-513" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-108" decimals="-3" id="f-514" unitRef="usd">40164000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-108" decimals="-3" id="f-515" unitRef="usd">35627000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-108" decimals="-3" id="f-516" unitRef="usd">4537000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-109" decimals="-3" id="f-517" unitRef="usd">38834000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-109" decimals="-3" id="f-518" unitRef="usd">34996000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-109" decimals="-3" id="f-519" unitRef="usd">3838000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-110" decimals="-3" id="f-520" unitRef="usd">943000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-110" decimals="-3" id="f-521" unitRef="usd">662000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-110" decimals="-3" id="f-522" unitRef="usd">281000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-111" decimals="-3" id="f-523" unitRef="usd">943000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-111" decimals="-3" id="f-524" unitRef="usd">528000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-111" decimals="-3" id="f-525" unitRef="usd">415000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-39" decimals="-3" id="f-526" unitRef="usd">472000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-39" decimals="-3" id="f-527" unitRef="usd">444000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-39" decimals="-3" id="f-528" unitRef="usd">28000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-112" decimals="-3" id="f-529" unitRef="usd">472000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-112" decimals="-3" id="f-530" unitRef="usd">349000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-112" decimals="-3" id="f-531" unitRef="usd">123000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-113" decimals="-3" id="f-532" unitRef="usd">10300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-113" decimals="-3" id="f-533" unitRef="usd">10280000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-113" decimals="-3" id="f-534" unitRef="usd">20000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-114" decimals="-3" id="f-535" unitRef="usd">10300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-114" decimals="-3" id="f-536" unitRef="usd">10220000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-114" decimals="-3" id="f-537" unitRef="usd">80000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-3" id="f-538" unitRef="usd">53902000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-539" unitRef="usd">47036000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-540" unitRef="usd">6866000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-3" id="f-541" unitRef="usd">52572000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-542" unitRef="usd">46116000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-543" unitRef="usd">6456000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-544" unitRef="usd">900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-5" id="f-545" unitRef="usd">1000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-546">Expected remaining annual amortization expense for the next five years for intangible assets recorded as of December&#160;31, 2025 is as follows (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2031 and &lt;br/&gt;thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-547" unitRef="usd">715000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-548" unitRef="usd">661000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">538000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-550" unitRef="usd">527000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-551" unitRef="usd">527000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-3" id="f-552" unitRef="usd">1898000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-553">Debt&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;February&#160;5, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company entered into a Credit Agreement (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 Credit Agreement&#x201d;) with JPMorgan Chase Bank, N.A., as administrative agent (the &#x201c;Agent&#x201d;), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the 2021 Credit Agreement are InfuSystem Holdings, Inc. and its subsidiaries (collectively, the &#x201c;Borrowers&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Credit Agreement provides for a revolving credit facility (the &#x201c;Revolving Facility&#x201d;) of $75.0 million. The Revolving Facility may be increased by $25.0 million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7.0 million in letters of credit subject to the satisfaction of certain conditions. The 2021 Credit Agreement has customary representations and warranties. The ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Credit Agreement includes customary events of default. The occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder. Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 26, 2023, the Company entered into a First Amendment to the 2021 Credit Agreement (the &#x201c;First Amendment&#x201d;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things: (i) an extension of the maturity date for the 2021 Credit Agreement to April 26, 2028, (ii) the replacement of London Interbank Offered Rate with Adjusted Term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) as a benchmark interest rate, and (iii) an increase of the maximum dollar amount of incremental revolving loans from $25&#160;million to $35&#160;million. Incremental revolving loans continue to be subject to certain conditions, including the consent of the Agent and obtaining necessary commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2025, the Company entered into a Second Amendment to the 2021 Credit Agreement (the &#x201c;Second Amendment&#x201d;) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things, an extension of the maturity date for the 2021 Credit Agreement to July 15, 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The First Amendment and Second Amendment were accounted for as debt modifications. As of December&#160;31, 2025, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement, as amended&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving Facility:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross availability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding draws&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Availability on Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had future maturities of its long-term debt as of December&#160;31, 2025 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2031 and &lt;br/&gt;thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a breakdown of the Company&#x2019;s current and long-term debt (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Term&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Term&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized value of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement, as amended, bear interest at a variable rate equal to, at the Company&#x2019;s election, Adjusted Term SOFR for Term Benchmark loans or an Alternative Base Rate for ABR loans, as defined by the Second Amendment, plus a spread that will vary depending &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upon the Company&#x2019;s leverage ratio. The spread ranges from 2.05% to 3.05% for Term Benchmark Loans and 1.05% to 2.05% for base rate loans. The weighted-average Term Benchmark loan rate at December&#160;31, 2025 was 5.83% (Adjusted Term SOFR of 3.78% plus 2.05%). The actual ABR loan rate at December&#160;31, 2025 was 7.80% (lender&#x2019;s prime rate of 6.75% plus 1.05%).&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-115" decimals="INF" id="f-554" unitRef="usd">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions contextRef="c-115" decimals="-5" id="f-555" unitRef="usd">25000000.0</infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-116" decimals="INF" id="f-556" unitRef="usd">7000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <infu:PercentageOfTotalDepreciationExpense
      contextRef="c-117"
      decimals="INF"
      id="f-557"
      unitRef="number">0.50</infu:PercentageOfTotalDepreciationExpense>
    <infu:DebtInstrumentCovenantMinimumFixedCoverageRatio
      contextRef="c-118"
      decimals="INF"
      id="f-558"
      unitRef="number">1.20</infu:DebtInstrumentCovenantMinimumFixedCoverageRatio>
    <infu:DebtInstrumentCovenantMaximumLeverageRatio
      contextRef="c-118"
      decimals="INF"
      id="f-559"
      unitRef="number">3.50</infu:DebtInstrumentCovenantMaximumLeverageRatio>
    <infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions contextRef="c-119" decimals="-6" id="f-560" unitRef="usd">25000000</infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions>
    <infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions contextRef="c-120" decimals="-6" id="f-561" unitRef="usd">35000000</infu:LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c-1" id="f-562">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving Facility:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross availability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding draws&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Availability on Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c-121" decimals="-3" id="f-563" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c-122" decimals="-3" id="f-564" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCredit contextRef="c-121" decimals="-3" id="f-565" unitRef="usd">20000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c-122" decimals="-3" id="f-566" unitRef="usd">24124000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-121" decimals="-3" id="f-567" unitRef="usd">55000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-122" decimals="-3" id="f-568" unitRef="usd">50876000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-569">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had future maturities of its long-term debt as of December&#160;31, 2025 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2031 and &lt;br/&gt;thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-121" decimals="-3" id="f-570" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-121" decimals="-3" id="f-571" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-121" decimals="-3" id="f-572" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-121" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-121" decimals="-3" id="f-574" unitRef="usd">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-121" decimals="-3" id="f-575" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-121" decimals="-3" id="f-576" unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-4" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-4" decimals="-3" id="f-578" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-4" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-4" decimals="-3" id="f-580" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-4" decimals="-3" id="f-581" unitRef="usd">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-4" decimals="-3" id="f-582" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="-3" id="f-583" unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a breakdown of the Company&#x2019;s current and long-term debt (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Term&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Term&lt;br/&gt;Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized value of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <infu:LongTermDebtGrossCurrent contextRef="c-121" decimals="-3" id="f-585" unitRef="usd">0</infu:LongTermDebtGrossCurrent>
    <infu:LongTermDebtGrossNoncurrent contextRef="c-121" decimals="-3" id="f-586" unitRef="usd">20000000</infu:LongTermDebtGrossNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-121" decimals="-3" id="f-587" unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <infu:LongTermDebtGrossCurrent contextRef="c-122" decimals="-3" id="f-588" unitRef="usd">0</infu:LongTermDebtGrossCurrent>
    <infu:LongTermDebtGrossNoncurrent contextRef="c-122" decimals="-3" id="f-589" unitRef="usd">24124000</infu:LongTermDebtGrossNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-122" decimals="-3" id="f-590" unitRef="usd">24124000</us-gaap:DebtInstrumentCarryingAmount>
    <infu:UnamortizedDebtIssuanceExpenseCurrent contextRef="c-4" decimals="-3" id="f-591" unitRef="usd">0</infu:UnamortizedDebtIssuanceExpenseCurrent>
    <infu:UnamortizedDebtIssuanceExpenseNoncurrent contextRef="c-4" decimals="-3" id="f-592" unitRef="usd">375000</infu:UnamortizedDebtIssuanceExpenseNoncurrent>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-4" decimals="-3" id="f-593" unitRef="usd">375000</us-gaap:UnamortizedDebtIssuanceExpense>
    <infu:UnamortizedDebtIssuanceExpenseCurrent contextRef="c-5" decimals="-3" id="f-594" unitRef="usd">0</infu:UnamortizedDebtIssuanceExpenseCurrent>
    <infu:UnamortizedDebtIssuanceExpenseNoncurrent contextRef="c-5" decimals="-3" id="f-595" unitRef="usd">260000</infu:UnamortizedDebtIssuanceExpenseNoncurrent>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-5" decimals="-3" id="f-596" unitRef="usd">260000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-597" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-598" unitRef="usd">19625000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-599" unitRef="usd">19625000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-600" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-601" unitRef="usd">23864000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt contextRef="c-5" decimals="-3" id="f-602" unitRef="usd">23864000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-123"
      decimals="INF"
      id="f-603"
      unitRef="number">0.0205</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-124"
      decimals="INF"
      id="f-604"
      unitRef="number">0.0305</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-125"
      decimals="INF"
      id="f-605"
      unitRef="number">0.0105</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-126"
      decimals="INF"
      id="f-606"
      unitRef="number">0.0205</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-127" decimals="4" id="f-607" unitRef="number">0.0583</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-128"
      decimals="INF"
      id="f-608"
      unitRef="number">0.0378</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-129"
      decimals="INF"
      id="f-609"
      unitRef="number">0.0205</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-130" decimals="4" id="f-610" unitRef="number">0.0780</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-131"
      decimals="INF"
      id="f-611"
      unitRef="number">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-132"
      decimals="INF"
      id="f-612"
      unitRef="number">0.0105</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-613">Derivative Financial Instruments and Hedging Activities&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows a derivative investment policy which provides guidelines and objectives related to managing financial and operational exposures arising from market changes in short term interest rates. In accordance with this policy, the Company can enter into interest rate swaps or similar instruments, will endeavor to evaluate all the risks inherent in a transaction before entering into a derivative financial instrument and will not enter into derivative financial instruments for speculative or trading purposes. Hedging relationships are formally documented at the inception of the hedge and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 Credit Agreement. The Company uses an interest rate swap agreement to manage exposure arising from this risk.  The swap has a constant notional amount over a five-year term that ends on April 26, 2028. The agreement pays the Company 30-day SOFR on the notional amount and the Company pays a fixed rate of interest equal to 1.74%. The Company does not have any other derivative financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Fair Value Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="21" style="padding:0 1pt"&gt;&lt;div style="margin-top:12pt;padding-left:40.57pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Fair Value Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="21" style="padding:0 1pt"&gt;&lt;div style="margin-top:12pt;padding-left:40.57pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Gain on cash flow hedges - interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,088&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unrealized gain recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amounts reclassified to interest expense (a)(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;179&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;565&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(a) Negative amounts represent interest income and positive amounts represent interest expense. Interest expense as presented in the consolidated statement of operations for the years ended December&#160;31, 2025 and 2024 was $1.3 million and $1.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(b) As of December&#160;31, 2025, $0.3 million of income is expected to be reclassified into earnings within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not incur any hedge ineffectiveness during the years ended December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeTermOfContract contextRef="c-133" id="f-614">P5Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeFixedInterestRate contextRef="c-134" decimals="4" id="f-615" unitRef="number">0.0174</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-616">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Fair Value Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="21" style="padding:0 1pt"&gt;&lt;div style="margin-top:12pt;padding-left:40.57pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.28pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Fair Value Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 41.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="21" style="padding:0 1pt"&gt;&lt;div style="margin-top:12pt;padding-left:40.57pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-134" decimals="-3" id="f-617" unitRef="usd">20000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-134" decimals="-3" id="f-618" unitRef="usd">748000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-135" decimals="-3" id="f-619" unitRef="usd">20000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-135" decimals="-3" id="f-620" unitRef="usd">1481000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-621">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Gain on cash flow hedges - interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,088&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unrealized gain recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amounts reclassified to interest expense (a)(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;179&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;565&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(a) Negative amounts represent interest income and positive amounts represent interest expense. Interest expense as presented in the consolidated statement of operations for the years ended December&#160;31, 2025 and 2024 was $1.3 million and $1.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(b) As of December&#160;31, 2025, $0.3 million of income is expected to be reclassified into earnings within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-136" decimals="-3" id="f-622" unitRef="usd">1119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-137" decimals="-3" id="f-623" unitRef="usd">1088000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-138" decimals="-3" id="f-624" unitRef="usd">-227000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-139" decimals="-3" id="f-625" unitRef="usd">734000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-138" decimals="-3" id="f-626" unitRef="usd">506000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-139" decimals="-3" id="f-627" unitRef="usd">694000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-138" decimals="-3" id="f-628" unitRef="usd">-179000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-139" decimals="-3" id="f-629" unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity contextRef="c-140" decimals="-3" id="f-630" unitRef="usd">565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-136" decimals="-3" id="f-631" unitRef="usd">1119000</us-gaap:StockholdersEquity>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-5" id="f-632" unitRef="usd">1300000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-6" decimals="-5" id="f-633" unitRef="usd">1800000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths contextRef="c-133" decimals="-5" id="f-634" unitRef="usd">300000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss contextRef="c-133" decimals="INF" id="f-635" unitRef="usd">0</us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss>
    <us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss contextRef="c-141" decimals="INF" id="f-636" unitRef="usd">0</us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-637">Income Taxes&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2025, U.S. Congress enacted the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;), which included significant provisions modifying the U.S. tax framework. While the Company continues to evaluate the impact of OBBBA, these legislative changes did not and are not expected to have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s income before income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s components of the consolidated provision for income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Federal income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. Federal income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total state and local income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a reconciliation of the Company&#x2019;s income tax (expense) benefit from the effective income tax rate to the U.S. federal statutory rate (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Pretax Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Pretax Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense at the statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,231)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,062)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax expense, net of federal income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Meals and Entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-deductible Officer's Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Income for Canada Disregarded Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Tax Effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciling Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit at effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,996)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,714)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During 2025, state and local taxes in California, Kansas, Michigan, and Texas comprised the majority of the state and local income taxes, net of federal effect category.  During 2024, state and local taxes in Texas, Michigan, Kansas, Illinois, and New York comprised the majority of the state and local income taxes, net of federal effect category&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;The following table illustrates incomes taxes paid by jurisdiction (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Florida&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Georgia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Illinois&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michigan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;New York&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pennsylvania&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Texas&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a) The amount of income taxes paid during the year does not meet the 5% disaggregation threshold and is included in other.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Federal, state and local tax assets &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debt reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research &amp;amp; development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred Federal, state and local tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Federal, state and local tax liabilities &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and asset basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred Federal, state and local tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) At December&#160;31, 2025 and 2024, this includes state and local net operating losses of $0.2 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. federal net operating loss carryforward for tax purposes was $5.8 million at December&#160;31, 2025, resulting in a federal deferred tax asset of $1.2 million; such net operating loss carryforwards have an indefinite life. The Company&#x2019;s state net operating loss carryforward of approximately $0.2 million is comprised of various jurisdictions. These state net operating losses can be used for a period of 5 to 20 years and vary by state, and if unused, begin to expire in 2026, though a substantial portion expires beyond 2026. Approximately less than $0.1 million of the state net operating loss carryforwards have an indefinite life. Tax benefits of operating loss and tax credit carryforwards are evaluated on an ongoing basis, including a review of historical and projected future operating results, the eligible carryforward period, and other circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor shifts in past ownership (as defined under Section 382 of the Code).  The Company had no uncertain tax positions for the years ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation for Federal and various state jurisdictions in the U.S. and Canada. The Federal income tax returns of the Company for the years 2022 through 2025 are open to examination by the Internal Revenue Service. The state income tax returns and other state tax filings of the Company are subject to examination by the state taxing authorities, for various periods generally up to four years after they are filed. Canadian income tax returns of the Company for the years 2020 through 2025 are subject to examination by the Canada Revenue Agency.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-638">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s income before income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-639" unitRef="usd">9322000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-6" decimals="-3" id="f-640" unitRef="usd">3938000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-641" unitRef="usd">1301000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-6" decimals="-3" id="f-642" unitRef="usd">1121000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-643" unitRef="usd">10623000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-644" unitRef="usd">5059000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-645">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s components of the consolidated provision for income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Federal income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. Federal income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total state and local income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-646" unitRef="usd">5000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-648" unitRef="usd">2496000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-649" unitRef="usd">1673000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="c-1" decimals="-3" id="f-650" unitRef="usd">2501000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="c-6" decimals="-3" id="f-651" unitRef="usd">1673000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-652" unitRef="usd">750000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-653" unitRef="usd">488000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-654" unitRef="usd">232000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-655" unitRef="usd">245000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="c-1" decimals="-3" id="f-656" unitRef="usd">982000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="c-6" decimals="-3" id="f-657" unitRef="usd">733000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-658" unitRef="usd">513000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-659" unitRef="usd">308000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-660" unitRef="usd">3996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-661" unitRef="usd">2714000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-662">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a reconciliation of the Company&#x2019;s income tax (expense) benefit from the effective income tax rate to the U.S. federal statutory rate (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Pretax Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Pretax Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense at the statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,231)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,062)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax expense, net of federal income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Meals and Entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-deductible Officer's Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Income for Canada Disregarded Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Tax Effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciling Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit at effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,996)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,714)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-663" unitRef="usd">2231000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-664" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="-3" id="f-665" unitRef="usd">1062000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="3" id="f-666" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-667" unitRef="usd">776000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-668" unitRef="number">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="-3" id="f-669" unitRef="usd">579000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="3" id="f-670" unitRef="number">0.114</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-1" decimals="-3" id="f-671" unitRef="usd">127000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-1" decimals="3" id="f-672" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-6" decimals="-3" id="f-673" unitRef="usd">124000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-6" decimals="3" id="f-674" unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-676" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-677" unitRef="usd">471000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="3" id="f-678" unitRef="number">0.093</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount contextRef="c-1" decimals="-3" id="f-679" unitRef="usd">491000</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent contextRef="c-1" decimals="3" id="f-680" unitRef="number">0.046</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount contextRef="c-6" decimals="-3" id="f-681" unitRef="usd">153000</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent contextRef="c-6" decimals="3" id="f-682" unitRef="number">0.030</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount contextRef="c-1" decimals="-3" id="f-683" unitRef="usd">165000</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent contextRef="c-1" decimals="3" id="f-684" unitRef="number">0.016</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount contextRef="c-6" decimals="-3" id="f-685" unitRef="usd">171000</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityAmount>
    <infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent contextRef="c-6" decimals="3" id="f-686" unitRef="number">0.034</infu:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIncomeForDisregardedEntityPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-3" id="f-687" unitRef="usd">-34000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-688" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-6" decimals="-3" id="f-689" unitRef="usd">2000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-6" decimals="3" id="f-690" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount contextRef="c-1" decimals="-3" id="f-691" unitRef="usd">0</infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount>
    <infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent contextRef="c-1" decimals="3" id="f-692" unitRef="number">0</infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent>
    <infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount contextRef="c-6" decimals="-3" id="f-693" unitRef="usd">-78000</infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingAmount>
    <infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent contextRef="c-6" decimals="3" id="f-694" unitRef="number">-0.016</infu:EffectiveIncomeTaxRateReconciliationTaxCreditIncludingNettingPercent>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-695" unitRef="usd">240000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-696" unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-6" decimals="-3" id="f-697" unitRef="usd">72000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-6" decimals="3" id="f-698" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-699" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-700" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-6" decimals="-3" id="f-701" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-6" decimals="3" id="f-702" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-703" unitRef="usd">3996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-704" unitRef="number">0.376</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-705" unitRef="usd">2714000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-706" unitRef="number">0.536</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c-1" id="f-707">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;The following table illustrates incomes taxes paid by jurisdiction (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Florida&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Georgia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Illinois&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michigan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;New York&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pennsylvania&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Texas&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a) The amount of income taxes paid during the year does not meet the 5% disaggregation threshold and is included in other.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived contextRef="c-1" decimals="-3" id="f-708" unitRef="usd">0</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived contextRef="c-6" decimals="-3" id="f-709" unitRef="usd">0</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-142" decimals="-3" id="f-710" unitRef="usd">28000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-143" decimals="-3" id="f-711" unitRef="usd">81000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-144" decimals="-3" id="f-712" unitRef="usd">51000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-145" decimals="-3" id="f-713" unitRef="usd">51000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-146" decimals="-3" id="f-714" unitRef="usd">65000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-147" decimals="-3" id="f-715" unitRef="usd">47000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-148" decimals="-3" id="f-716" unitRef="usd">61000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-149" decimals="-3" id="f-717" unitRef="usd">94000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-150" decimals="-3" id="f-718" unitRef="usd">50000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-151" decimals="-3" id="f-719" unitRef="usd">180000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-152" decimals="-3" id="f-720" unitRef="usd">255000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-1" decimals="-3" id="f-721" unitRef="usd">349000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-6" decimals="-3" id="f-722" unitRef="usd">614000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidForeignAfterRefundReceived contextRef="c-1" decimals="-3" id="f-723" unitRef="usd">194000</us-gaap:IncomeTaxPaidForeignAfterRefundReceived>
    <us-gaap:IncomeTaxPaidForeignAfterRefundReceived contextRef="c-6" decimals="-3" id="f-724" unitRef="usd">139000</us-gaap:IncomeTaxPaidForeignAfterRefundReceived>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-725" unitRef="usd">543000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-6" decimals="-3" id="f-726" unitRef="usd">753000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-727">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Federal, state and local tax assets &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debt reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research &amp;amp; development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred Federal, state and local tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Federal, state and local tax liabilities &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and asset basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred Federal, state and local tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) At December&#160;31, 2025 and 2024, this includes state and local net operating losses of $0.2 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-4" decimals="-3" id="f-728" unitRef="usd">5673000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-5" decimals="-3" id="f-729" unitRef="usd">4448000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-730" unitRef="usd">2343000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-731" unitRef="usd">1806000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-732" unitRef="usd">1385000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-733" unitRef="usd">3434000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <infu:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-4" decimals="-3" id="f-734" unitRef="usd">1248000</infu:DeferredTaxAssetsOperatingLeaseLiabilities>
    <infu:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-5" decimals="-3" id="f-735" unitRef="usd">1548000</infu:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-4" decimals="-3" id="f-736" unitRef="usd">1067000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-5" decimals="-3" id="f-737" unitRef="usd">801000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-4" decimals="-3" id="f-738" unitRef="usd">763000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-5" decimals="-3" id="f-739" unitRef="usd">713000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-740" unitRef="usd">517000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-741" unitRef="usd">555000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c-4" decimals="-3" id="f-742" unitRef="usd">23000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c-5" decimals="-3" id="f-743" unitRef="usd">23000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-744" unitRef="usd">120000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-745" unitRef="usd">1128000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-746" unitRef="usd">13139000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-747" unitRef="usd">14456000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-748" unitRef="usd">6502000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-749" unitRef="usd">4792000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets contextRef="c-4" decimals="-3" id="f-750" unitRef="usd">731000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-751" unitRef="usd">737000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <infu:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-4" decimals="-3" id="f-752" unitRef="usd">1083000</infu:DeferredTaxLiabilitiesRightOfUseAssets>
    <infu:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-5" decimals="-3" id="f-753" unitRef="usd">1377000</infu:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c-4" decimals="-3" id="f-754" unitRef="usd">183000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c-5" decimals="-3" id="f-755" unitRef="usd">362000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-756" unitRef="usd">8499000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-757" unitRef="usd">7268000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-758" unitRef="usd">4640000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-759" unitRef="usd">7188000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-153" decimals="-5" id="f-760" unitRef="usd">200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-154" decimals="-5" id="f-761" unitRef="usd">400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-155" decimals="-5" id="f-762" unitRef="usd">5800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-155" decimals="-5" id="f-763" unitRef="usd">1200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-153" decimals="-5" id="f-764" unitRef="usd">200000</us-gaap:OperatingLossCarryforwards>
    <infu:OperatingLossCarryforwardsExpirationPeriods contextRef="c-156" id="f-765">P5Y</infu:OperatingLossCarryforwardsExpirationPeriods>
    <infu:OperatingLossCarryforwardsExpirationPeriods contextRef="c-157" id="f-766">P20Y</infu:OperatingLossCarryforwardsExpirationPeriods>
    <infu:OperatingLossCarryforwardsWithADefiniteLife contextRef="c-153" decimals="-5" id="f-767" unitRef="usd">100000</infu:OperatingLossCarryforwardsWithADefiniteLife>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-768" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-769" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-770">Commitments and Contingencies&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time in the ordinary course of its business, the Company may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not at this time involved in any proceedings that the Company currently believes could have a material effect on the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c-1" id="f-772">Leases&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;As Lessee:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s operating lease costs consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs for the years ended December&#160;31, 2025 and 2024 of approximately $2.4 million and $2.3 million, respectively, were recorded to G&amp;amp;A expenses. Expense related to short-term leases, which are not recorded on the Company's consolidated balance sheets, was $0.8 million and nil for the fiscal years ended December&#160;31, 2025, and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to the Company&#x2019;s leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities and right of use assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases to right of use assets resulting from lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates for the Company&#x2019;s operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The long-term portion of the lease liabilities included in the amounts above is $3.4 million with the remainder included in other current liabilities in the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;As Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient for all qualifying non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s lease revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our net investment in sales-type leases as of December&#160;31, 2025 and 2024 were (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment in leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December&#160;31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of sales-type leases as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sales-Type Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-771">Leases&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;As Lessee:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s operating lease costs consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs for the years ended December&#160;31, 2025 and 2024 of approximately $2.4 million and $2.3 million, respectively, were recorded to G&amp;amp;A expenses. Expense related to short-term leases, which are not recorded on the Company's consolidated balance sheets, was $0.8 million and nil for the fiscal years ended December&#160;31, 2025, and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to the Company&#x2019;s leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities and right of use assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases to right of use assets resulting from lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates for the Company&#x2019;s operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The long-term portion of the lease liabilities included in the amounts above is $3.4 million with the remainder included in other current liabilities in the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;As Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient for all qualifying non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s lease revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our net investment in sales-type leases as of December&#160;31, 2025 and 2024 were (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment in leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December&#160;31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of sales-type leases as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sales-Type Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-773">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s operating lease costs consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to the Company&#x2019;s leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities and right of use assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases to right of use assets resulting from lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates for the Company&#x2019;s operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-774" unitRef="usd">1989000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-3" id="f-775" unitRef="usd">1910000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-776" unitRef="usd">460000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-3" id="f-777" unitRef="usd">359000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-778" unitRef="usd">2449000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-6" decimals="-3" id="f-779" unitRef="usd">2269000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-158" decimals="-5" id="f-780" unitRef="usd">2400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-159" decimals="-5" id="f-781" unitRef="usd">2300000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeasePayments contextRef="c-1" decimals="-5" id="f-782" unitRef="usd">800000</us-gaap:ShortTermLeasePayments>
    <us-gaap:ShortTermLeasePayments contextRef="c-6" decimals="INF" id="f-783" unitRef="usd">0</us-gaap:ShortTermLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-784" unitRef="usd">2025000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-785" unitRef="usd">1863000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-786" unitRef="usd">37000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-787" unitRef="usd">250000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <infu:IncreasesToRightOfUseAssetsResultingFromLeaseModifications contextRef="c-1" decimals="-3" id="f-788" unitRef="usd">344000</infu:IncreasesToRightOfUseAssetsResultingFromLeaseModifications>
    <infu:IncreasesToRightOfUseAssetsResultingFromLeaseModifications contextRef="c-6" decimals="-3" id="f-789" unitRef="usd">0</infu:IncreasesToRightOfUseAssetsResultingFromLeaseModifications>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-790">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-791">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-792" unitRef="number">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-793" unitRef="number">0.079</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-794">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-795" unitRef="usd">1903000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-796" unitRef="usd">1627000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-797" unitRef="usd">1504000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-798" unitRef="usd">1396000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-799" unitRef="usd">818000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-800" unitRef="usd">273000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-801" unitRef="usd">7521000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-802" unitRef="usd">2706000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-803" unitRef="usd">4815000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-5" id="f-804" unitRef="usd">3400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c-1" id="f-805">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s lease revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-1" decimals="-3" id="f-806" unitRef="usd">30006000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-6" decimals="-3" id="f-807" unitRef="usd">27843000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:SalesTypeLeaseLeaseIncome contextRef="c-1" decimals="-3" id="f-808" unitRef="usd">350000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:SalesTypeLeaseLeaseIncome contextRef="c-6" decimals="-3" id="f-809" unitRef="usd">717000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:LeaseIncome contextRef="c-1" decimals="-3" id="f-810" unitRef="usd">30356000</us-gaap:LeaseIncome>
    <us-gaap:LeaseIncome contextRef="c-6" decimals="-3" id="f-811" unitRef="usd">28560000</us-gaap:LeaseIncome>
    <infu:NetInvestmentInSalesTypeLeasesTableTextBlock contextRef="c-1" id="f-812">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our net investment in sales-type leases as of December&#160;31, 2025 and 2024 were (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment in leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December&#160;31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</infu:NetInvestmentInSalesTypeLeasesTableTextBlock>
    <us-gaap:SalesTypeLeaseLeaseReceivable contextRef="c-4" decimals="-3" id="f-813" unitRef="usd">1905000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable contextRef="c-5" decimals="-3" id="f-814" unitRef="usd">1934000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease contextRef="c-4" decimals="-3" id="f-815" unitRef="usd">1905000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease contextRef="c-5" decimals="-3" id="f-816" unitRef="usd">1934000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-160" decimals="-3" id="f-817" unitRef="usd">563000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-161" decimals="-3" id="f-818" unitRef="usd">1207000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:OtherAssets contextRef="c-160" decimals="-3" id="f-819" unitRef="usd">1342000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-161" decimals="-3" id="f-820" unitRef="usd">727000</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="c-160" decimals="-3" id="f-821" unitRef="usd">1905000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-161" decimals="-3" id="f-822" unitRef="usd">1934000</us-gaap:Assets>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock contextRef="c-1" id="f-823">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of sales-type leases as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sales-Type Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths contextRef="c-4" decimals="-3" id="f-824" unitRef="usd">807000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears contextRef="c-4" decimals="-3" id="f-825" unitRef="usd">658000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears contextRef="c-4" decimals="-3" id="f-826" unitRef="usd">562000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears contextRef="c-4" decimals="-3" id="f-827" unitRef="usd">408000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived contextRef="c-4" decimals="-3" id="f-828" unitRef="usd">2435000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-829" unitRef="usd">530000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivable contextRef="c-4" decimals="-3" id="f-830" unitRef="usd">1905000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivable>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-831">Share-Based Compensation&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has various stock option and stock-based incentive plans and agreements whereby equity based awards are granted to certain employees, directors and others approved by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) or Compensation Committee. Grants may be made in the form of stock options, restricted stock awards ("RSUs" or "RSAs"), performance-based restricted stock units ("PSU's), unrestricted common stock in addition to other award types. Stock options are granted with an exercise price at, or above, fair market value on the date of grant, generally expire in 5 to 10 years from the grant date and generally become exercisable over a period of up to 3 years. RSUs generally become vested over a period of up to three years. PSUs generally become vested over a period of up to three years based on the performance of a specific achievement. Awards typically vest and are issued only if the participants remain employed by the Company through the vesting date. Common stock issued under these awards is issued from shares reserved under the Company&#x2019;s plan described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 18, 2021, the Company&#x2019;s Board adopted the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan was approved by the Company&#x2019;s shareholders at the 2021 Annual Meeting on May 18, 2021 and became effective at that time. The 2021 plan supersedes the 2014 Amended and Restated Stock Incentive Plan (the "2014 Plan"). The 2021 Plan provided for the issuance of a maximum of 2,500,000 shares of common stock in connection with the grant of stock-based or stock-denominated awards, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan, which as of December 31, 2025 totaled 428,067. On May 16, 2023 at the 2023 Annual Meeting, the Company's shareholders approved the First Amendment (the "First Amendment") to the 2021 Plan. The First Amendment increased the maximum number of shares of the Company's common stock reserved for issuance under the 2021 Plan by 2,500,000 shares to 5,000,000 shares, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan. On May 15, 2025 at the 2025 Annual Meeting, the Company's shareholders approved the Second Amendment (the "Second Amendment") to the 2021 Plan. The Second Amendment increased the maximum number of shares of the Company's common stock reserved for issuance under the 2021 Plan by 1,000,000 shares to 6,000,000 shares, plus the number of shares of the Company's common stock underlying any outstanding award granted under the 2014 Plan that expires or is cancelled, forfeited, or terminated under the terms of the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reductions in the available share limit associated with these grants are based on a fungible ratio of 1:1 for stock options and stock appreciation rights and 2:1 for all other types of awards. Any shares subject to an award that expires or is cancelled, forfeited, or terminated without issuance of the full number of shares of stock to which the award related again become available for issuance under the limit. As of December&#160;31, 2025, a total of 639,308 common shares remained available for future grant under the 2021 Plan. This amount reflects reductions from the original limit for grants reflective of the respective fungible ratios. The available amount also reflects the maximum potential share issuance potential in the case of performance grants that provide for variable share payouts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 23, 2014, the Company&#x2019;s Board adopted the 2014 Plan. The 2014 Plan was approved by the Company&#x2019;s shareholders at the 2014 Annual Meeting and became effective as of the date it was adopted by the Board of Directors. The 2014 Plan provided for the issuance of a maximum of 2,000,000 shares of common stock in connection with the grant of stock-based or stock-denominated awards. On July 19, 2018, the Company&#x2019;s stockholders approved the reservation of an additional 1,000,000 shares to be issued under the 2014 Plan. On May 15, 2019, the Company&#x2019;s stockholders approved the reservation of an additional 1,000,000 shares to be issued under the 2014 Plan. The 2021 Plan replaced and superseded the 2014 Plan, so as of the adoption date of the 2021 Plan, no common shares remained available for future grant under the 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock option awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted share expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shares Forgone to Satisfy Minimum Statutory Withholdings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2025 and 2024, shares of common stock were issued to employees and directors as their restricted stock awards vested or stock options were exercised. Under the terms of the Company&#x2019;s stock plans, at the election of each employee, the Company can authorize a net settlement of distributable shares to employees in order to satisfy an individual employees' tax withholding obligations. For the years ended December&#160;31, 2025 and 2024 the Company received 132,909 shares and 108,607 shares, respectively, from employees for tax withholding obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards entitle the holder to receive, upon meeting certain time-based vesting criteria, a specified number of shares of the Company&#x2019;s common stock. Stock-based compensation cost of restricted stock awards is measured by the market value of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted share activity, excluding the Company&#x2019;s employee stock purchase plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant&lt;br/&gt;date fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value of awards granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there was $1.3 million of pre-tax total unrecognized compensation cost related to non-vested restricted stock awards, which will be adjusted for future forfeitures, if any. The Company expects to recognize such cost over a weighted average period of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2025, the Company granted approximately 364,905 PSUs and during the year ended December&#160;31, 2024, the Company granted approximately 117,582 PSUs. PSUs entitle the holder to receive, upon meeting certain performance-based vesting criteria, a specified number of shares of the Company&#x2019;s common stock. These market-based awards vest after the Company&#x2019;s achievement of either a specified trading price metric of the Company&#x2019;s stock, such as when the trading price reaches a target value for a minimum number of consecutive trading days, or after an attainment of total shareholder return ("TSR") metric relative to a TSR for a benchmark group of other companies. In the case of the awards having a trading price metric, awards are paid in stock either immediately upon achievement of the performance condition or expire without any payment after the third anniversary of the grant date. In the case of the awards having a TSR metric, awards can be earned at an amount of 50% of the target number of shares for achieving a minimum threshold below the target or up to 200% of the target number of shares for exceeding the target, with a linear adjustment between the threshold and target or between target and maximum performance achievement. The TSR awards also have a time-based vesting criteria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s PSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant &lt;br/&gt;date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value of awards granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there was $1.5 million of pre-tax total unrecognized compensation cost related to non-vested PSUs, which will be adjusted for changes to management&#x2019;s expectations of the probable outcomes of the performance conditions, if any. The Company expects to recognize such cost over a weighted average period of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At the 2023 Annual Meeting of Stockholders held on May 16, 2023, the Company's stockholders approved the InfuSystem Holdings, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP"), which was previously approved by the Company's Board.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the adoption of the 2023 ESPP, the Company's Board terminated the InfuSystem Holdings, Inc. Employee Stock Purchase Plan (the "Original ESPP").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following termination of the Original ESPP, all rights the Company intends to grant under an "employee stock purchase plan" as such term is defined in section 423 of the Internal Revenue Code of 1986, as amended, will be granted under the 2023 ESPP.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The 2023 ESPP provides that a maximum of 300,000 shares of Common Stock, plus any shares remaining under the Original ESPP after the close of its final offering period, are available for sale under the 2023 ESPP.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The terms of the 2023 ESPP provides eligible participants electing to participate in the plan with an option to acquire shares of Common Stock during specified offering periods.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The per share option exercise price at which shares of Common Stock will be sold under the 2023 ESPP will be equal to the lesser of (i) 85% of the closing price of a share of Common Stock on the NYSE American (or such other exchange on which the shares of Common Stock are traded) on the first day of an offering period or (ii) 85% of the closing price of a share of Common Stock on the purchase date.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No employee may purchase more than $25,000 worth of fair market value shares in any calendar year. As allowed under the 2023 ESPP, a participant may elect to withdraw from the plan, effective for the purchase period in progress at the time of the election with all accumulated payroll deductions returned to the participant at the time of withdrawal. The 2023 ESPP is administered by the Board's Compensation Committee.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eligible participants under the plan include all full-time employees and certain part-time employees of the Company who meet certain eligibility requirements set forth in the 2023 ESPP.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Participation in the 2023 ESPP for any eligible employee is voluntary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2025, there were 209,321 shares remaining available for future issuance. The following table summarizes the activity relating to the Company&#x2019;s ESPP program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of stock sold to employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value per ESPP award&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the fair value of stock option awards using the Black-Scholes option pricing model, which incorporates various assumptions including volatility, expected term, risk-free interest rates and dividend yields. The expected volatility assumption is based on historical volatility of the Company&#x2019;s common stock over the most recent period commensurate with the expected life of the stock option granted. The Company uses historical volatility because management believes such volatility is representative of prospective trends. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the stock option awarded. The Company uses historical exercise data to determine the expected lives. Dividend yields have not been a factor in determining fair value of stock options granted as the Company has never issued cash dividends and does not anticipate issuing cash dividends in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables detail the various stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2014 Plan (Options)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Authorized&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares tendered for cashless exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Plan (Options)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Authorized&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cashless exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,888,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock Options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46% to 57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46% to 51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.56% to 4.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.22% to 4.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected lives at date of grant (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2024, our Board of Directors approved a stock repurchase program (the "Share Repurchase Program") that authorizes the Company to repurchase up to $20.0 million of the Company's outstanding common stock through June 30, 2026. The Share Repurchase Program supersedes the previous authorization, which was set to expire on June 30, 2024. Repurchases under the Share Repurchase Program are subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's existing credit agreement. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company had repurchased and retired approximately $11.0 million, or 1,498,376 shares, of the Company's outstanding common stock under the Share Repurchase Program. The Company had repurchased and retired approximately $6.2 million, or 553,149 shares under the previous authorization.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-162" id="f-832">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-163" id="f-833">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod contextRef="c-164" id="f-834">P3Y</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisablePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-165" id="f-835">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-166" id="f-836">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-167"
      decimals="INF"
      id="f-837"
      unitRef="shares">2500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-168"
      decimals="INF"
      id="f-838"
      unitRef="shares">428067</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c-169"
      decimals="INF"
      id="f-839"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-170"
      decimals="INF"
      id="f-840"
      unitRef="shares">5000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c-171"
      decimals="INF"
      id="f-841"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-172"
      decimals="INF"
      id="f-842"
      unitRef="shares">6000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio contextRef="c-1" decimals="INF" id="f-843" unitRef="number">1</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio contextRef="c-1" decimals="INF" id="f-844" unitRef="number">2</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-168"
      decimals="INF"
      id="f-845"
      unitRef="shares">639308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-173"
      decimals="INF"
      id="f-846"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-174"
      decimals="INF"
      id="f-847"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-175"
      decimals="INF"
      id="f-848"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-849">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted share expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:RestrictedStockExpense contextRef="c-1" decimals="-3" id="f-850" unitRef="usd">2384000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="c-6" decimals="-3" id="f-851" unitRef="usd">2384000</us-gaap:RestrictedStockExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c-1" decimals="-3" id="f-852" unitRef="usd">1979000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c-6" decimals="-3" id="f-853" unitRef="usd">2076000</us-gaap:StockOptionPlanExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-854" unitRef="usd">4363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-855" unitRef="usd">4460000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-3" id="f-856" unitRef="usd">766000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-6" decimals="-3" id="f-857" unitRef="usd">475000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="0" id="f-858" unitRef="shares">132909</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="0" id="f-859" unitRef="shares">108607</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-860">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted share activity, excluding the Company&#x2019;s employee stock purchase plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant&lt;br/&gt;date fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value of awards granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-176"
      decimals="INF"
      id="f-861"
      unitRef="shares">503894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-176"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">8.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-177"
      decimals="INF"
      id="f-863"
      unitRef="shares">228539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-177"
      decimals="2"
      id="f-864"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-177"
      decimals="INF"
      id="f-865"
      unitRef="shares">110286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-177"
      decimals="2"
      id="f-866"
      unitRef="usdPerShare">9.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod
      contextRef="c-177"
      decimals="INF"
      id="f-867"
      unitRef="shares">65989</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue
      contextRef="c-177"
      decimals="2"
      id="f-868"
      unitRef="usdPerShare">9.36</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-177"
      decimals="INF"
      id="f-869"
      unitRef="shares">75279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-177"
      decimals="2"
      id="f-870"
      unitRef="usdPerShare">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-178"
      decimals="INF"
      id="f-871"
      unitRef="shares">480879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-178"
      decimals="2"
      id="f-872"
      unitRef="usdPerShare">7.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-177"
      decimals="2"
      id="f-873"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-179"
      decimals="2"
      id="f-874"
      unitRef="usdPerShare">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-177" decimals="0" id="f-875" unitRef="usd">824800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-179" decimals="0" id="f-876" unitRef="usd">1122749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue contextRef="c-177" decimals="0" id="f-877" unitRef="usd">493515</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue contextRef="c-179" decimals="0" id="f-878" unitRef="usd">651469</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-178" decimals="-5" id="f-879" unitRef="usd">1300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-880">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-180" decimals="0" id="f-881" unitRef="shares">364905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-181" decimals="0" id="f-882" unitRef="shares">117582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned contextRef="c-182" decimals="2" id="f-883" unitRef="number">0.50</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned contextRef="c-183" decimals="2" id="f-884" unitRef="number">2</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeEarned>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-885">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s PSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant &lt;br/&gt;date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value of awards granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-184"
      decimals="INF"
      id="f-886"
      unitRef="shares">189221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-184"
      decimals="2"
      id="f-887"
      unitRef="usdPerShare">7.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-180"
      decimals="INF"
      id="f-888"
      unitRef="shares">364905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="2"
      id="f-889"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-180"
      decimals="INF"
      id="f-890"
      unitRef="shares">30325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="2"
      id="f-891"
      unitRef="usdPerShare">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone
      contextRef="c-180"
      decimals="INF"
      id="f-892"
      unitRef="shares">19675</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgone>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="2"
      id="f-893"
      unitRef="usdPerShare">3.19</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedSharesForgoneWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-180"
      decimals="INF"
      id="f-894"
      unitRef="shares">121324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="2"
      id="f-895"
      unitRef="usdPerShare">9.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-185"
      decimals="INF"
      id="f-896"
      unitRef="shares">382802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-897"
      unitRef="usdPerShare">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="2"
      id="f-898"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-181"
      decimals="2"
      id="f-899"
      unitRef="usdPerShare">5.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-180" decimals="0" id="f-900" unitRef="usd">309921</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-181" decimals="0" id="f-901" unitRef="usd">83862</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue contextRef="c-180" decimals="0" id="f-902" unitRef="shares">201079</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue contextRef="c-181" decimals="0" id="f-903" unitRef="shares">67137</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueSharesForgoneFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-185" decimals="-5" id="f-904" unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-180" id="f-905">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP contextRef="c-1" decimals="INF" id="f-906" unitRef="shares">300000</us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-186"
      decimals="INF"
      id="f-907"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-186"
      decimals="INF"
      id="f-908"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <infu:EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum contextRef="c-1" decimals="INF" id="f-909" unitRef="usd">25000</infu:EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum>
    <infu:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance contextRef="c-4" decimals="INF" id="f-910" unitRef="shares">209321</infu:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock contextRef="c-1" id="f-911">The following table summarizes the activity relating to the Company&#x2019;s ESPP program:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of stock sold to employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value per ESPP award&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="c-1" decimals="0" id="f-912" unitRef="usd">139140</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="c-6" decimals="0" id="f-913" unitRef="usd">93523</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-1" decimals="0" id="f-914" unitRef="shares">61470</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-6" decimals="0" id="f-915" unitRef="shares">52965</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <infu:EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="c-1"
      decimals="2"
      id="f-916"
      unitRef="usdPerShare">6.00</infu:EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased>
    <infu:EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="c-6"
      decimals="2"
      id="f-917"
      unitRef="usdPerShare">9.21</infu:EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-918">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables detail the various stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2014 Plan (Options)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Authorized&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares tendered for cashless exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Plan (Options)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Authorized&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised shares forgone to satisfy minimum statutory withholding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cashless exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,888,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-187"
      decimals="INF"
      id="f-919"
      unitRef="shares">535667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-187"
      decimals="2"
      id="f-920"
      unitRef="usdPerShare">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-188" id="f-921">P3Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-187" decimals="0" id="f-922" unitRef="usd">1588137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-189"
      decimals="INF"
      id="f-923"
      unitRef="shares">49259</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-189"
      decimals="2"
      id="f-924"
      unitRef="usdPerShare">2.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-189"
      decimals="INF"
      id="f-925"
      unitRef="shares">32889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-189"
      decimals="2"
      id="f-926"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod
      contextRef="c-189"
      decimals="INF"
      id="f-927"
      unitRef="shares">27852</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-189"
      decimals="2"
      id="f-928"
      unitRef="usdPerShare">2.50</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-189"
      decimals="INF"
      id="f-929"
      unitRef="shares">75750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-189"
      decimals="2"
      id="f-930"
      unitRef="usdPerShare">8.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-190"
      decimals="INF"
      id="f-931"
      unitRef="shares">349917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-190"
      decimals="2"
      id="f-932"
      unitRef="usdPerShare">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-189" id="f-933">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-190" decimals="0" id="f-934" unitRef="usd">960120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-190"
      decimals="INF"
      id="f-935"
      unitRef="shares">349917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-190"
      decimals="2"
      id="f-936"
      unitRef="usdPerShare">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-189" id="f-937">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-190" decimals="0" id="f-938" unitRef="usd">960120</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-191"
      decimals="INF"
      id="f-939"
      unitRef="shares">1840786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-191"
      decimals="2"
      id="f-940"
      unitRef="usdPerShare">8.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-192" id="f-941">P8Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-191" decimals="0" id="f-942" unitRef="usd">1504894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-193"
      decimals="INF"
      id="f-943"
      unitRef="shares">889421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-944"
      unitRef="usdPerShare">6.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-193"
      decimals="INF"
      id="f-945"
      unitRef="shares">12549</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-946"
      unitRef="usdPerShare">8.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-193"
      decimals="INF"
      id="f-947"
      unitRef="shares">14356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-948"
      unitRef="usdPerShare">7.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod
      contextRef="c-193"
      decimals="INF"
      id="f-949"
      unitRef="shares">177214</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod>
    <infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-950"
      unitRef="usdPerShare">8.39</infu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-193"
      decimals="INF"
      id="f-951"
      unitRef="shares">236755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-952"
      unitRef="usdPerShare">8.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-168"
      decimals="INF"
      id="f-953"
      unitRef="shares">2289333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-168"
      decimals="2"
      id="f-954"
      unitRef="usdPerShare">8.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-193" id="f-955">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-168" decimals="0" id="f-956" unitRef="usd">3888088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-168"
      decimals="INF"
      id="f-957"
      unitRef="shares">911118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-168"
      decimals="2"
      id="f-958"
      unitRef="usdPerShare">9.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-193" id="f-959">P7Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-168" decimals="0" id="f-960" unitRef="usd">729868</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-961">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock Options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46% to 57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46% to 51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.56% to 4.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.22% to 4.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected lives at date of grant (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-164" decimals="2" id="f-962" unitRef="number">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-164" decimals="2" id="f-963" unitRef="number">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-194" decimals="2" id="f-964" unitRef="number">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-194" decimals="2" id="f-965" unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-164" decimals="4" id="f-966" unitRef="number">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-164" decimals="4" id="f-967" unitRef="number">0.0401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-194" decimals="4" id="f-968" unitRef="number">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-194" decimals="4" id="f-969" unitRef="number">0.0460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-164" id="f-970">P4Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-194" id="f-971">P4Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-195"
      decimals="2"
      id="f-972"
      unitRef="usdPerShare">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-196"
      decimals="2"
      id="f-973"
      unitRef="usdPerShare">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-164" decimals="0" id="f-974" unitRef="usd">926116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-194" decimals="0" id="f-975" unitRef="usd">322797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-197" decimals="INF" id="f-976" unitRef="usd">20000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-198" decimals="-5" id="f-977" unitRef="usd">11000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-198" decimals="0" id="f-978" unitRef="shares">1498376</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-199" decimals="-5" id="f-979" unitRef="usd">6200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-199" decimals="0" id="f-980" unitRef="shares">553149</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-981">Business Segment Information&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s reportable segments are organized based on service platforms, with the Patient Services segment reflecting higher margin rental revenues that generally include payments made by third-party and direct payers and the Device Solutions segment reflecting lower margin product sales, direct payer rental and services revenues. Resources are allocated and performance is assessed for these segments by the Company&#x2019;s Chief Executive Officer, whom the Company has determined to be its CODM. The CODM uses gross profit for each segment predominantly in the annual budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making operating and capital resource allocation decisions among each segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial information summarized below is presented by reportable segment:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patient Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Device Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate/&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - external&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - internal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant Segment Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and material costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patient Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Device Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate/&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - external&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - internal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant Segment Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and material costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-982">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial information summarized below is presented by reportable segment:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patient Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Device Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate/&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - external&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - internal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant Segment Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and material costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patient Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Device Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate/&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - external&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues - internal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant Segment Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and material costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Other segment items included in Segment gross profit include estimates for medical equipment that is considered to be missing and other miscellaneous shop expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <infu:NetRevenuesExternal contextRef="c-200" decimals="-3" id="f-983" unitRef="usd">86532000</infu:NetRevenuesExternal>
    <infu:NetRevenuesExternal contextRef="c-201" decimals="-3" id="f-984" unitRef="usd">56904000</infu:NetRevenuesExternal>
    <infu:NetRevenuesExternal contextRef="c-202" decimals="-3" id="f-985" unitRef="usd">0</infu:NetRevenuesExternal>
    <infu:NetRevenuesExternal contextRef="c-1" decimals="-3" id="f-986" unitRef="usd">143436000</infu:NetRevenuesExternal>
    <infu:NetRevenuesInternal contextRef="c-200" decimals="-3" id="f-987" unitRef="usd">0</infu:NetRevenuesInternal>
    <infu:NetRevenuesInternal contextRef="c-201" decimals="-3" id="f-988" unitRef="usd">7192000</infu:NetRevenuesInternal>
    <infu:NetRevenuesInternal contextRef="c-202" decimals="-3" id="f-989" unitRef="usd">-7192000</infu:NetRevenuesInternal>
    <infu:NetRevenuesInternal contextRef="c-1" decimals="-3" id="f-990" unitRef="usd">0</infu:NetRevenuesInternal>
    <us-gaap:Revenues contextRef="c-200" decimals="-3" id="f-991" unitRef="usd">86532000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-201" decimals="-3" id="f-992" unitRef="usd">64096000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-202" decimals="-3" id="f-993" unitRef="usd">-7192000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-994" unitRef="usd">143436000</us-gaap:Revenues>
    <us-gaap:SuppliesExpense contextRef="c-200" decimals="-3" id="f-995" unitRef="usd">23478000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="c-201" decimals="-3" id="f-996" unitRef="usd">18932000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="c-202" decimals="-3" id="f-997" unitRef="usd">-7192000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="c-1" decimals="-3" id="f-998" unitRef="usd">35218000</us-gaap:SuppliesExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-200" decimals="-3" id="f-999" unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-201" decimals="-3" id="f-1000" unitRef="usd">16328000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-202" decimals="-3" id="f-1001" unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-1" decimals="-3" id="f-1002" unitRef="usd">16328000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-200" decimals="-3" id="f-1003" unitRef="usd">7357000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-201" decimals="-3" id="f-1004" unitRef="usd">3787000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-202" decimals="-3" id="f-1005" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-1" decimals="-3" id="f-1006" unitRef="usd">11144000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-200" decimals="-3" id="f-1007" unitRef="usd">324000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-201" decimals="-3" id="f-1008" unitRef="usd">126000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-202" decimals="-3" id="f-1009" unitRef="usd">0</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-1" decimals="-3" id="f-1010" unitRef="usd">450000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:GrossProfit contextRef="c-200" decimals="-3" id="f-1011" unitRef="usd">55373000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-201" decimals="-3" id="f-1012" unitRef="usd">24923000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-202" decimals="-3" id="f-1013" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-1014" unitRef="usd">80296000</us-gaap:GrossProfit>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-1015" unitRef="usd">68376000</us-gaap:OperatingExpenses>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-1016" unitRef="usd">1299000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-1017" unitRef="usd">2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1018" unitRef="usd">10623000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets contextRef="c-203" decimals="-3" id="f-1019" unitRef="usd">53518000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-204" decimals="-3" id="f-1020" unitRef="usd">45042000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-205" decimals="-3" id="f-1021" unitRef="usd">2000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-1022" unitRef="usd">100560000</us-gaap:Assets>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-200" decimals="-3" id="f-1023" unitRef="usd">4560000</infu:PaymentsToAcquireMedicalEquipment>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-201" decimals="-3" id="f-1024" unitRef="usd">3566000</infu:PaymentsToAcquireMedicalEquipment>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-202" decimals="-3" id="f-1025" unitRef="usd">0</infu:PaymentsToAcquireMedicalEquipment>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-1" decimals="-3" id="f-1026" unitRef="usd">8126000</infu:PaymentsToAcquireMedicalEquipment>
    <us-gaap:DepreciationAndAmortization contextRef="c-200" decimals="-3" id="f-1027" unitRef="usd">8492000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-201" decimals="-3" id="f-1028" unitRef="usd">4802000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-202" decimals="-3" id="f-1029" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-1030" unitRef="usd">13294000</us-gaap:DepreciationAndAmortization>
    <infu:NetRevenuesExternal contextRef="c-206" decimals="-3" id="f-1031" unitRef="usd">80378000</infu:NetRevenuesExternal>
    <infu:NetRevenuesExternal contextRef="c-207" decimals="-3" id="f-1032" unitRef="usd">54483000</infu:NetRevenuesExternal>
    <infu:NetRevenuesExternal contextRef="c-208" decimals="-3" id="f-1033" unitRef="usd">0</infu:NetRevenuesExternal>
    <infu:NetRevenuesExternal contextRef="c-6" decimals="-3" id="f-1034" unitRef="usd">134861000</infu:NetRevenuesExternal>
    <infu:NetRevenuesInternal contextRef="c-206" decimals="-3" id="f-1035" unitRef="usd">0</infu:NetRevenuesInternal>
    <infu:NetRevenuesInternal contextRef="c-207" decimals="-3" id="f-1036" unitRef="usd">7254000</infu:NetRevenuesInternal>
    <infu:NetRevenuesInternal contextRef="c-208" decimals="-3" id="f-1037" unitRef="usd">-7254000</infu:NetRevenuesInternal>
    <infu:NetRevenuesInternal contextRef="c-6" decimals="-3" id="f-1038" unitRef="usd">0</infu:NetRevenuesInternal>
    <us-gaap:Revenues contextRef="c-206" decimals="-3" id="f-1039" unitRef="usd">80378000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-207" decimals="-3" id="f-1040" unitRef="usd">61737000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-208" decimals="-3" id="f-1041" unitRef="usd">-7254000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-1042" unitRef="usd">134861000</us-gaap:Revenues>
    <us-gaap:SuppliesExpense contextRef="c-206" decimals="-3" id="f-1043" unitRef="usd">20255000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="c-207" decimals="-3" id="f-1044" unitRef="usd">21948000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="c-208" decimals="-3" id="f-1045" unitRef="usd">-7254000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="c-6" decimals="-3" id="f-1046" unitRef="usd">34949000</us-gaap:SuppliesExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-206" decimals="-3" id="f-1047" unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-207" decimals="-3" id="f-1048" unitRef="usd">18573000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-208" decimals="-3" id="f-1049" unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-6" decimals="-3" id="f-1050" unitRef="usd">18573000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-206" decimals="-3" id="f-1051" unitRef="usd">6788000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-207" decimals="-3" id="f-1052" unitRef="usd">3454000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-208" decimals="-3" id="f-1053" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c-6" decimals="-3" id="f-1054" unitRef="usd">10242000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-206" decimals="-3" id="f-1055" unitRef="usd">493000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-207" decimals="-3" id="f-1056" unitRef="usd">201000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-208" decimals="-3" id="f-1057" unitRef="usd">0</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-6" decimals="-3" id="f-1058" unitRef="usd">694000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:GrossProfit contextRef="c-206" decimals="-3" id="f-1059" unitRef="usd">52842000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-207" decimals="-3" id="f-1060" unitRef="usd">17561000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-208" decimals="-3" id="f-1061" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-6" decimals="-3" id="f-1062" unitRef="usd">70403000</us-gaap:GrossProfit>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-1063" unitRef="usd">63512000</us-gaap:OperatingExpenses>
    <us-gaap:InterestExpenseNonoperating contextRef="c-6" decimals="-3" id="f-1064" unitRef="usd">1777000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-1065" unitRef="usd">-55000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-1066" unitRef="usd">5059000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets contextRef="c-209" decimals="-3" id="f-1067" unitRef="usd">54203000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-210" decimals="-3" id="f-1068" unitRef="usd">47411000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-211" decimals="-3" id="f-1069" unitRef="usd">2000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-1070" unitRef="usd">103614000</us-gaap:Assets>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-206" decimals="-3" id="f-1071" unitRef="usd">6679000</infu:PaymentsToAcquireMedicalEquipment>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-207" decimals="-3" id="f-1072" unitRef="usd">10062000</infu:PaymentsToAcquireMedicalEquipment>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-208" decimals="-3" id="f-1073" unitRef="usd">0</infu:PaymentsToAcquireMedicalEquipment>
    <infu:PaymentsToAcquireMedicalEquipment contextRef="c-6" decimals="-3" id="f-1074" unitRef="usd">16741000</infu:PaymentsToAcquireMedicalEquipment>
    <us-gaap:DepreciationAndAmortization contextRef="c-206" decimals="-3" id="f-1075" unitRef="usd">7891000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-207" decimals="-3" id="f-1076" unitRef="usd">4608000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-208" decimals="-3" id="f-1077" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-1078" unitRef="usd">12499000</us-gaap:DepreciationAndAmortization>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1079">Employee Benefit Plans and Other&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a defined contribution plan in which the Company makes discretionary matching contributions for a certain percentage of employee contributions.  For the years ended December&#160;31, 2025 and 2024, the Company&#x2019;s matching contributions was $1.4 million and $1.3 million, respectively.   The Company does not provide other post-retirement or post-employment benefits to its employees. As of December&#160;31, 2025 and 2024, accrued payroll liabilities included in Other current liabilities were $5.5 million and $4.8 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-1" decimals="-5" id="f-1080" unitRef="usd">1400000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-6" decimals="-5" id="f-1081" unitRef="usd">1300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-1082" unitRef="usd">5500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-1083" unitRef="usd">4800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-212" id="f-1084">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-212" id="f-1085">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-212" id="f-1086">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-212" id="f-1087">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1088">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-286"
          xlink:label="f-286"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-287"
          xlink:label="f-287"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts consist of current liabilities for medical equipment and property that have not been included in investing activities. These amounts have not been paid for as of December 31, 2025 and 2024, respectively, but will be included as a cash outflow from investing activities for purchases of medical equipment and property when paid.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-286"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-287"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
